=== PAGE 1 ===

GARIS PANDUAN
KAUNSELING UBAT-UBATAN
EDISI KEEMPAT 2025
BORANG PENILAIAN
KEMAHIRAN
KAUNSELING
PEGAWAI FARMASI
2 0 2 52 0 2 5
VER. 2/2025

=== PAGE 2 ===

 
CONTENTS
 
 
(PART
 
A
 
:
 
DRUG
 
CLASS/ACTIVE
 
INGREDIENTS)
 
 
Abacavir
..................................................................................................................................
5
 
Abacavir/Lamivudine
.............................................................................................................
8
 
Acetylsalicyclic
 
Acid
 
(Aspirin)
............................................................................................
10
 
Acyclovir,
 
Topical
.................................................................................................................
13
 
Adapalene
.............................................................................................................................
15
 
Amiodarone
..........................................................................................................................
17
 
Amitriptyline
.........................................................................................................................
20
 
Amlodipine
............................................................................................................................
23
 
Amorolfine
............................................................................................................................
25
 
Anticholinesterases
 
/
 
N-methyl-D-aspartate
 
(NMDA)
 
Receptor
 
Antagonist
...................
27
 
Antipsychotics,
 
First
 
Generation
........................................................................................
31
 
Antipsychotics,
 
Injectables
.................................................................................................
35
 
Antipsychotics,
 
Second
 
Generation
..................................................................................
39
 
Apixaban
...............................................................................................................................
48
 
Atazanavir
.............................................................................................................................
50
 
Azelaic
 
Acid,
 
Topical
............................................................................................................
54
 
Benzodiazepines
..................................................................................................................
56
 
Benzoyl
 
Peroxide,
 
Topical
...................................................................................................
60
 
Beta-Blockers
.......................................................................................................................
62
 
Benzyl
 
Benzoate,
 
Emulsion
 
(EBB)
.....................................................................................
65
 
Bisphosphonates
.................................................................................................................
67
 
Buprenorphine,
 
Transdermal
 
Patch
...................................................................................
71
 
Calcium
 
Carbonate
..............................................................................................................
76
 
Carbamazepine
.....................................................................................................................
78
 
Cetrimide,
 
Lotion
..................................................................................................................
80
 
Clarithromycin
......................................................................................................................
82
 
Clofazimine
...........................................................................................................................
84
 
Clopidogrel
...........................................................................................................................
86
 
Clotrimazole,
 
Topical
...........................................................................................................
88
 
Clozapine
..............................................................................................................................
90
 
Corticosteroids,
 
Topical
......................................................................................................
94
 
Crotamiton,
 
Topical
..............................................................................................................
97
 
Dabigatran
..........................................................................................................................
100
 
Dapsone
..............................................................................................................................
103
 
Darbepoetin
 
Alfa
................................................................................................................
105
 
Darunavir
............................................................................................................................
108
 
Deferasirox
 
and
 
Deferiprone
.............................................................................................
111
 
Desferrioxamine
 
B
 
Methanesulphonate
...........................................................................
116
 
Digoxin
................................................................................................................................
121
 
Diltiazem
.............................................................................................................................
124
 
1
 

=== PAGE 3 ===

 
Direct-Acting
 
Antiviral
 
(DAA)
............................................................................................
127
 
Dolutegravir
........................................................................................................................
130
 
Dolutegravir
 
/Lamivudine/Tenofovir
 
Disoproxil
 
Fumarate
.............................................
132
 
Edoxaban
............................................................................................................................
135
 
Efavirenz
.............................................................................................................................
138
 
Enoxaparin
..........................................................................................................................
141
 
Entecavir
.............................................................................................................................
145
 
Erythropoietin
 
Human
 
Recombinant
 
(Alfa/Beta)
.............................................................
147
 
Everolimus
..........................................................................................................................
151
 
Evolocumab
........................................................................................................................
154
 
Felodipine
...........................................................................................................................
157
 
Fentanyl,
 
Transdermal
 
Patch
............................................................................................
159
 
Flecainide
 
Acetate
..............................................................................................................
163
 
Follitropin
 
Alpha
 
(Recombinant
 
Human
 
FSH)
.................................................................
166
 
Follitropin
 
Beta
 
(Recombinant
 
Human
 
FSH)
...................................................................
169
 
Fondaparinux
.....................................................................................................................
172
 
Fusidic
 
Acid,
 
Topical
..........................................................................................................
175
 
Gamma
 
Benzene
 
Hexachloride,
 
Topical
..........................................................................
177
 
Ganirelix
..............................................................................................................................
179
 
Gentamicin,
 
Topical
...........................................................................................................
181
 
Glucagon
 
like
 
peptide-1
 
Receptor
 
Agonist
 
(GLP-1
 
RA)
.................................................
183
 
Glyceryl
 
Trinitrate
 
(GTN)
 
Sublingual
 
Spray
.....................................................................
191
 
Glyceryl
 
Trinitrate
 
(GTN)
 
Sublingual
 
Tablet
.....................................................................
193
 
Gonadotropin-Releasing
 
Hormone
 
Antagonists
 
/
 
Gonadotropins
................................
195
 
Gonadotropin-Releasing
 
Hormone
 
(GnRH)
 
Antagonists
 
:
.............................................
195
 
Heparin
 
Sodium
..................................................................................................................
199
 
Imiquimod
...........................................................................................................................
202
 
Insulin
..................................................................................................................................
205
 
Iron
 
Supplements,
 
Oral
......................................................................................................
213
 
Isosorbide
 
Dinitrate/
 
Isosorbide
 
Mononitrate
..................................................................
216
 
Ivabradine
...........................................................................................................................
218
 
Ketoconazole
 
/
 
Selenium
 
Sulfide
 
Lotion/Shampoo
........................................................
221
 
Lamivudine
.........................................................................................................................
223
 
Lamotrigine
.........................................................................................................................
225
 
Lanthanum
 
Carbonate
.......................................................................................................
227
 
Levofloxacin
.......................................................................................................................
229
 
Lignocaine
 
(Lidocaine),
 
Medicated
 
Plaster
.....................................................................
232
 
Lithium
................................................................................................................................
234
 
Loop
 
Diuretics
....................................................................................................................
237
 
Lopinavir/Ritonavir
............................................................................................................
240
 
Methadone
..........................................................................................................................
243
 
Methoxy
 
Polyethylene-glycol
 
Epoetin
 
Beta
.....................................................................
252
 
Methylphenidate
.................................................................................................................
256
 
Miconazole,
 
Topical
............................................................................................................
259
 
2
 

=== PAGE 4 ===

 
Minocycline
.........................................................................................................................
261
 
Mirtazapine
.........................................................................................................................
264
 
Moxifloxacin
.......................................................................................................................
267
 
Mupirocin,
 
Topical
..............................................................................................................
270
 
Mycophenolate
 
Mofetil/Mycophenolate
 
Sodium
.............................................................
272
 
Neomycin,
 
Topical
..............................................................................................................
275
 
Nevirapine
...........................................................................................................................
277
 
Nifedipine
............................................................................................................................
280
 
Non-steroidal
 
Anti-inflammatory
 
Drugs
 
(NSAIDs)
 
/
 
COX-2
 
Inhibitors
...........................
282
 
Nystatin,
 
Topical
.................................................................................................................
285
 
Nystatin
 
Oral
 
Suspension
.................................................................................................
287
 
Ofloxacin
.............................................................................................................................
289
 
Opioids,
 
Short
 
Acting
 
Strong
............................................................................................
291
 
Opioids,
 
Sustained-Release
 
Strong
.................................................................................
295
 
Opioids,
 
Weak
.....................................................................................................................
298
 
Paracetamol
........................................................................................................................
301
 
Permethrin,
 
Lotion
.............................................................................................................
303
 
Podophyllum
 
Paint
.............................................................................................................
305
 
Ranolazine
..........................................................................................................................
307
 
Renin-angiotensin
 
aldosterone
 
system
 
inhibitor
 
(RAASi)
.............................................
309
 
Ribavirin
..............................................................................................................................
312
 
Rifampicin
...........................................................................................................................
315
 
Rilpivirine
............................................................................................................................
317
 
Rivaroxaban
........................................................................................................................
320
 
Salicylic
 
Acid,
 
Topical
........................................................................................................
323
 
Selective
 
Norepinephrine
 
Reuptake
 
Inhibitor
 
(SNRI)
.....................................................
325
 
Selective
 
Serotonin
 
Reuptake
 
Inhibitors
 
(SSRIs)
 
/
 
Multimodal
 
Serotonin
 
Modulator
.
330
 
Sevelamer
...........................................................................................................................
336
 
Sodium-Glucose
 
Cotransporter
 
2
 
(SGLT2)
 
Inhibitor
 
(SGLT2-i)
......................................
338
 
Sodium
 
Valproate
...............................................................................................................
342
 
Spironolactone
...................................................................................................................
346
 
Statin
...................................................................................................................................
350
 
Sulphur
 
in
 
calamine/
 
petrolatum
......................................................................................
353
 
Tacrolimus
..........................................................................................................................
355
 
Tar,
 
Topical
..........................................................................................................................
358
 
Tenofovir
 
Alafenamide
.......................................................................................................
360
 
Tenofovir
 
Disoproxil
 
Fumarate
 
(TDF)
...............................................................................
362
 
Tenofovir
 
Disoproxil
 
Fumarate
 
/
 
Emtricitabine
................................................................
365
 
Ticagrelor
............................................................................................................................
367
 
Ticlopidine
..........................................................................................................................
369
 
Tretinoin,
 
Topical
................................................................................................................
371
 
Trimetazidine/Trimetazidine
 
Modified
 
Release
 
(MR)
.......................................................
375
 
Verapamil
............................................................................................................................
377
 
Vitamin
 
D
 
Analogues
.........................................................................................................
380
 
3
 

=== PAGE 5 ===

 
Warfarin
...............................................................................................................................
384
 
Zidovudine
 
/
 
Lamivudine
...................................................................................................
387
 
 
 
4
 

=== PAGE 6 ===

 
Abacavir
 
 
Name
 
:
 
 
Unit
 
:
 
 
●
 
Please
 
tick
 
(
✔
)
 
Yes
 
for
 
correct
 
instruction.
 
●
 
Please
 
tick
 
(
✔
)
 
No
 
for
 
incorrect
 
instruction.
 
Yes
 
No
 
Remarks
 
Pharmacological
 
Group
 
Nucleoside
 
reverse
 
transcriptase
 
inhibitor
 
 
 
 
 
Indications
 
and
 
Dosage
 
1.
 
Indication:
 
Antiretroviral
 
combination
 
therapy
 
for
 
the
 
treatment
 
of
 
HIV
 
infection
 
in
 
adults,
 
adolescents
 
and
 
children
 
weighing
 
at
 
least
 
25
 
kg.
 
a)
 
 
Adult
 
Dosage:
 
300mg
 
BD
 
or
 
600mg
 
OD
 
 
 
 
Method
 
of
 
Administration*
 
1.
 
May
 
be
 
administered
 
with
 
or
 
without
 
food.
 
 
Missed
 
dose
 
management
 
:
 
 
1.
 
To
 
take
 
medication
 
consistently
 
at
 
the
 
same
 
time
 
everyday .
 
Any
 
missed
 
dose
 
to
 
be
 
taken
 
as
 
soon
 
as
 
possible.
 
2.
 
For
 
twice
 
daily
 
dosing
 
of
 
abacavir ,
 
if
 
the
 
gap
 
is
 
more
 
than
 
6
 
hours,
 
to
 
skip
 
and
 
continue
 
with
 
a
 
regular
 
dosing
 
schedule.
 
Do
 
not
 
double
 
the
 
dose
 
on
 
the
 
next
 
administration
 
time.
 
3.
 
For
 
once
 
daily
 
dosing
 
of
 
abacavir ,
 
if
 
the
 
gap
 
is
 
more
 
than
 
12
 
hours,
 
to
 
skip
 
and
 
continue
 
with
 
a
 
regular
 
dosing
 
schedule.
 
 
Do
 
not
 
stop
 
taking
 
your
 
medication
 
unless
 
advised
 
to
 
do
 
so
 
by
 
your
 
prescriber
 
 
 
 
Special
 
Considerations
 
Pregnancy
 
 
 
 
1.
 
Patients
 
who
 
become
 
pregnant
 
while
 
taking
 
abacavir
  
may
 
continue
 
if
 
viral
 
suppression
 
is
 
effective
 
and
 
the
 
regimen
 
is
 
well
 
tolerated.
 
 
 
 
 
Breastfeeding
 
 
 
 
1.
 
Abacavir
 
is
  
present
 
in
 
breast
 
milk.
 
 
2.
 
It
 
is
 
recommended
 
that
 
HIV
 
infected
 
women
 
do
 
not
 
breast-feed
 
their
 
infants
 
under
 
any
 
circumstances
 
in
 
order
 
to
 
avoid
 
transmission
 
of
 
HIV.
 
 
 
 
 
Elderly
 
 
 
 
1.
 
No
 
pharmacokinetic
 
data
 
are
 
currently
 
available
 
in
 
patients
 
over
 
65
 
years
 
of
 
age.
 
Special
 
care
 
is
 
advised
 
in
 
this
 
age
 
group
 
due
 
to
 
age
 
associated
 
changes
 
such
 
as
 
decrease
 
in
 
hepatic,
 
renal
 
and
 
cardiac
 
function,
 
and
 
concomitant
 
disease
 
or
 
other
 
drug
 
therapy .
 
 
 
 
Paediatric
 
 
 
 
Children
 
weighing
 
14
 
to
 
<
 
20
 
kg:
 
one-half
 
of
 
a
 
scored
 
abacavir
 
tablet
 
twice
 
daily.
 
 
Children
 
weighing
 
≥
 
20
 
kg
 
to
 
<
 
25
 
kg:
 
one-half
 
of
 
a
 
scored
 
abacavir
 
tablet
 
taken
 
in
 
the
 
morning
 
and
 
one
 
whole
 
tablet
 
taken
 
in
 
the
 
evening.
 
For
 
adolescents
 
and
 
children
 
who
 
weigh
 
less
 
than
 
25kg,
 
commercial
 
oral
 
solution
 
is
 
available.
 
Alternatively ,
 
the
 
tablets
 
 
 
 
5
 

=== PAGE 7 ===

 
may
 
be
 
crushed.
 
1,2
 
Fasting
 
 
 
 
To
 
be
 
discussed
 
with
 
infectious
 
disease
 
consultant
 
 
 
 
Hepatic
 
impairment
 
 
 
 
 
1.
 
Abacavir
 
is
 
primarily
 
metabolised
 
by
 
the
 
liver.
 
In
 
patients
 
with
 
mild
 
hepatic
 
impairment
 
(
Child-Pugh
 
Class
 
A)
 
,
 
200mg
 
twice
 
daily
 
is
 
recommended.
 
 
2.
 
Hepatic
 
impairment
 
with
 
Child-Pugh
 
Class
 
B
 
or
 
C:
 
Contraindicated
 
3.
 
Abacavir
 
oral
 
solution
 
should
 
be
 
used
 
for
 
dose
 
reduction.
 
In
 
patients
 
with
 
moderate
 
or
 
severe
 
hepatic
 
impairment,
  
the
 
use
 
of
 
abacavir
 
is
 
not
 
recommended
 
unless
 
judged
 
necessary .
 
 
 
 
Renal
 
impairment
 
 
 
 
1.
 
No
 
dosage
 
adjustment
 
necessary
 
for
 
any
 
degree
 
of
 
kidney
 
dysfunction.
 
 
 
 
 
Side
 
Effects
 
and
 
their
 
Management*
 
1.
 
Abacavir
 
is
 
associated
 
with
 
a
 
risk
 
for
 
hypersensitivity
 
reactions.
Patients
 
who
 
test
 
positive
 
for
 
HLA-B*5701
 
are
 
at
 
the
 
highest
 
risk
 
of
 
experiencing
 
HSRs.
 
HLA
 
screening
 
should
 
be
 
done
 
before
 
initiating
 
ABC.
 
 
2.
 
Symptoms
 
usually
 
appeared
 
within
 
the
 
first
 
six
 
weeks
 
of
 
initiation
 
of
 
treatment
 
with
 
abacavir ,
 
although
 
these
 
reactions
 
may
 
occur
 
at
 
any
 
time
 
during
 
therapy .
 
These
 
reactions
 
usually
 
include
 
signs
 
or
 
symptoms
 
from
 
two
 
or
 
more
 
of
 
the
 
following:
 
fever ,
 
skin
 
rash,
 
constitutional
 
symptoms
 
(malaise,
 
fatigue,
 
aches),
 
respiratory
 
symptoms
 
(eg,
 
pharyngitis,
 
dyspnea,
 
cough),
 
and
 
GI
 
symptoms
 
(eg,
 
abdominal
 
pain,
 
diarrhea,
 
nausea,
 
vomiting).
 
3.
 
Abacavir/Lamivudine
 
must
 
be
 
stopped
 
without
 
delay ,
 
even
 
in
 
the
 
absence
 
of
 
the
 
HLA-B*5701
 
allele,
 
if
 
an
 
HSR
 
is
 
suspected.
 
Delay
 
in
 
stopping
 
treatment
 
with
 
abacavir/lamivudine
 
after
 
the
 
onset
 
of
 
hypersensitivity
 
may
 
result
 
in
 
a
 
life-threatening
 
reaction.
 
4.
 
Do
 
not
 
restart
 
abacavir/lamivudine
 
as
 
it
  
can
 
result
 
in
 
a
 
prompt
 
return
 
of
 
symptoms
 
within
 
hours.
 
This
 
recurrence
 
is
 
usually
 
more
 
severe
 
than
 
on
 
initial
 
presentation,
 
and
 
may
 
include
 
life-threatening
 
hypotension
 
and
 
death
 
 
 
 
Storage*
 
Store
 
in
 
a
 
dry
 
place
 
below
 
30
 
C.
 
Store
 
in
 
the
 
original
 
container .
 
 
 
 
Others
 
Precautions
 
1.
 
Abacavir
 
should
 
not
 
be
 
used
 
in
 
patients
 
known
 
to
 
carry
 
the
 
HLA-B*5701
 
allele
 
or
 
in
 
patients
 
with
 
a
 
prior
 
hypersensitivity
 
reaction
 
to
 
abacavir .
 
 
 
 
6
 

=== PAGE 8 ===

 
Before
 
ending
 
this
 
peer
 
review
 
session,
 
the
 
reviewee
 
should
 
be
 
informed
 
of
 
the
 
step(s)
 
that
 
he/
 
she
 
missed
 
out
 
in
 
order
 
to
 
ensure
 
all
 
the
 
counselling
 
points
 
are
 
being
 
covered.
 
 
Remarks:
 
 
 
 
 
Reviewed
 
by:
 
Name
 
&
 
Signature
                                                                   
Date:
 
 
 
 
 
*Mandatory
 
for
 
validation
 
/
 
peer
 
review
 
References:
 
 
1.
 
Kivexa.
 
(n.d.).
 
In
 
UpToDate.
 
Retrieved
 
October
 
28,
 
2024,
 
from
 
https://www .uptodate.com/contents/abacavir-and-lamivudine-drug-information?search=kivexa&source=p
anel_search_result&selectedT itle=1%7E20&usage_type=panel&kp_tab=drug_general&display_rank=1
 
2.
 
Panel
 
on
 
Antiretroviral
 
Guidelines
 
for
 
Adults
 
and
 
Adolescents.
 
(n.d.).
 
Guidelines
 
for
 
the
 
use
 
of
 
antiretroviral
 
agents
 
in
 
adults
 
and
 
adolescents
 
with
 
HIV.
 
Department
 
of
 
Health
 
and
 
Human
 
Services.
 
Retrieved
 
January
 
20,
 
2025,
 
from
 
https://clinicalinfo.hiv .gov/en/guidelines/adult-and-adolescent-arv
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
7
 

=== PAGE 9 ===

 
Abacavir/Lamivudine
 
 
Name
 
:
 
 
Unit
 
:
 
 
●
 
Please
 
tick
 
(
✔
)
 
Yes
 
for
 
correct
 
instruction.
 
●
 
Please
 
tick
 
(
✔
)
 
No
 
for
 
incorrect
 
instruction.
 
Yes
 
No
 
Remarks
 
Pharmacological
 
Group
 
Nucleoside
 
reverse
 
transcriptase
 
inhibitor
 
 
 
 
 
Indications
 
and
 
Dosage
 
1.
 
Indications:
 
Antiretroviral
 
combination
 
therapy
 
for
 
the
 
treatment
 
of
 
HIV
 
infection
 
in
 
adults,
 
adolescents
 
and
 
children
 
weighing
 
at
 
least
 
25
 
kg
 
 
              
Dosage:
 
1
 
tablet
 
once
 
daily
 
 
 
 
Method
 
of
 
Administration*
 
1.
 
May
 
be
 
administered
 
with
 
or
 
without
 
food.
 
 
Missed
 
dose
 
management
 
 
1.
 
To
 
take
 
medication
 
consistently
 
at
 
the
 
same
 
time
 
everyday .
 
Any
 
missed
 
dose
 
to
 
be
 
taken
 
as
 
soon
 
as
 
possible.
 
2.
 
However
 
if
 
the
 
gap
 
is
 
more
 
than
 
12
 
hours,
 
to
 
skip
 
and
 
continue
 
with
 
a
 
regular
 
dosing
 
schedule.
 
Do
 
not
 
double
 
the
 
dose
 
on
 
the
 
next
 
administration
 
time.
 
 
Do
 
not
 
stop
 
taking
 
your
 
medication
 
unless
 
advised
 
to
 
do
 
so
 
by
 
your
 
prescriber
 
 
 
 
Special
 
Considerations
 
Pregnancy
 
 
 
 
1.
 
Patients
 
who
 
become
 
pregnant
 
while
 
taking
 
abacavir/lamivudine
 
may
 
continue
 
if
 
viral
 
suppression
 
is
 
effective
 
and
 
the
 
regimen
 
is
 
well
 
tolerated.
 
 
 
 
 
Breastfeeding
 
 
 
 
1.
 
Abacavir
 
and
 
lamivudine
 
are
 
present
 
in
 
breast
 
milk.
 
2.
 
 
It
 
is
 
recommended
 
that
 
HIV
 
infected
 
women
 
do
 
not
 
breast-feed
 
their
 
infants
 
under
 
any
 
circumstances
 
in
 
order
 
to
 
avoid
 
transmission
 
of
 
HIV.
 
 
 
 
Elderly
 
 
 
 
1.
 
No
 
pharmacokinetic
 
data
 
are
 
currently
 
available
 
in
 
patients
 
over
 
65
 
years
 
of
 
age.
 
Special
 
care
 
is
 
advised
 
in
 
this
 
age
 
group
 
due
 
to
 
age
 
associated
 
changes
 
such
 
as
 
the
 
decrease
 
in
 
renal
 
function
 
and
 
alteration
 
of
 
haematological
 
parameters.
 
 
 
 
Paediatric
 
 
 
 
1.
 
Abacavir/Lamivudine
 
should
 
not
 
be
 
administered
 
to
 
children
 
who
 
weigh
 
less
 
than
 
25
 
kg
 
because
 
it
 
is
 
a
 
fixed-dose
 
tablet
 
that
 
cannot
 
be
 
dose
 
reduced.
 
 
 
 
Fasting
 
 
 
 
1.
 
To
 
be
 
discussed
 
with
 
infectious
 
disease
 
consultant
 
 
 
 
Hepatic
 
impairment
 
 
 
 
 
8
 

=== PAGE 10 ===

 
1.
 
In
 
patients
 
with
 
moderate
 
or
 
severe
 
hepatic
 
impairment,
  
the
 
use
 
of
 
abacavir/lamivudine
 
is
 
not
 
recommended
 
unless
 
judged
 
necessary .
 
 
 
 
 
Renal
 
impairment
 
 
 
 
1.
 
It
 
is
 
not
 
recommended
 
for
 
use
 
in
 
patients
 
with
 
a
 
creatinine
 
clearance
 
<
 
30
 
ml/min.
 
(
 
use
 
dose-adjusted
 
individual
 
components)
 
 
 
 
Side
 
Effects
 
and
 
their
 
Management*
 
1.
 
Abacavir
 
is
 
associated
 
with
 
a
 
risk
 
for
 
hypersensitivity
 
reactions.
Patients
 
who
 
test
 
positive
 
for
 
HLA-B*5701
 
are
 
at
 
the
 
highest
 
risk
 
of
 
experiencing
 
HSRs.
 
HLA
 
screening
 
should
 
be
 
done
 
before
 
initiating
 
ABC.
 
 
2.
 
Symptoms
 
usually
 
appeared
 
within
 
the
 
first
 
six
 
weeks
 
of
 
initiation
 
of
 
treatment
 
with
 
abacavir ,
 
although
 
these
 
reactions
 
may
 
occur
 
at
 
any
 
time
 
during
 
therapy .
 
These
 
reactions
 
usually
 
include
 
signs
 
or
 
symptoms
 
from
 
two
 
or
 
more
 
of
 
the
 
following:
 
fever ,
 
skin
 
rash,
 
constitutional
 
symptoms
 
(malaise,
 
fatigue,
 
aches),
 
respiratory
 
symptoms
 
(eg,
 
pharyngitis,
 
dyspnea,
 
cough),
 
and
 
GI
 
symptoms
 
(eg,
 
abdominal
 
pain,
 
diarrhea,
 
nausea,
 
vomiting).
 
3.
 
Abacavir/Lamivudine
 
must
 
be
 
stopped
 
without
 
delay ,
 
even
 
in
 
the
 
absence
 
of
 
the
 
HLA-B*5701
 
allele,
 
if
 
an
 
HSR
 
is
 
suspected.
 
Delay
 
in
 
stopping
 
treatment
 
with
 
abacavir/lamivudine
 
after
 
the
 
onset
 
of
 
hypersensitivity
 
may
 
result
 
in
 
a
 
life-threatening
 
reaction.
 
4.
 
Do
 
not
 
restart
 
abacavir/lamivudine
 
as
 
it
  
can
 
result
 
in
 
a
 
prompt
 
return
 
of
 
symptoms
 
within
 
hours.
 
This
 
recurrence
 
is
 
usually
 
more
 
severe
 
than
 
on
 
initial
 
presentation,
 
and
 
may
 
include
 
life-threatening
 
hypotension
 
and
 
death.
 
 
 
 
Storage*
 
1.
 
Store
 
in
 
a
 
dry
 
place
 
below
 
30
 
C.
 
Store
 
in
 
the
 
original
 
container .
 
 
 
 
Others
 
Precautions
 
1.
 
Abacavir
 
should
 
not
 
be
 
used
 
in
 
patients
 
known
 
to
 
carry
 
the
 
HLA-B*5701
 
allele
 
or
 
in
 
patients
 
with
 
a
 
prior
 
hypersensitivity
 
reaction
 
to
 
abacavir .
 
 
 
 
 
Before
 
ending
 
this
 
peer
 
review
 
session,
 
the
 
reviewee
 
should
 
be
 
informed
 
of
 
the
 
step(s)
 
that
 
he/
 
she
 
missed
 
out
 
in
 
order
 
to
 
ensure
 
all
 
the
 
counselling
 
points
 
are
 
being
 
covered.
 
 
Remarks:
 
 
 
Reviewed
 
by:
 
Name
 
&
 
Signature
                                                                   
Date:
 
 
 
*Mandatory
 
for
 
validation
 
/
 
peer
 
review
 
References:
 
 
1.
 
Kivexa.
 
(n.d.).
 
In
 
UpToDate.
 
Retrieved
 
October
 
28,
 
2024,
 
from
 
https://www .uptodate.com/contents/abacavir-and-lamivudine-drug-information?search=kivexa&source=p
anel_search_result&selectedT itle=1%7E20&usage_type=panel&kp_tab=drug_general&display_rank=1
 
2.
 
ViiV
 
Healthcare.
 
(2022).
 
Kivexa
 
product
 
leaflet.
 
Retrieved
 
October
 
28,
 
2024,
 
from
 
https://quest3plus.bpfk.gov .my/front-end/attachment/724/pharma/21 1036/V_80853_20240412_150431_
D3.pdf
 
3.
 
Panel
 
on
 
Antiretroviral
 
Guidelines
 
for
 
Adults
 
and
 
Adolescents.
 
(n.d.).
 
Guidelines
 
for
 
the
 
use
 
of
 
antiretroviral
 
agents
 
in
 
adults
 
and
 
adolescents
 
with
 
HIV.
 
Department
 
of
 
Health
 
and
 
Human
 
Services.
 
Retrieved
 
January
 
20,
 
2025,
 
from
 
https://clinicalinfo.hiv .gov/en/guidelines/adult-and-adolescent-arv
 
9
 

=== PAGE 11 ===

 
Acetylsalicyclic
 
Acid
 
(Aspirin)
 
Name
 
:
 
 
Unit
 
:
 
 
●
 
Please
 
tick
 
(
✔
)
 
Yes
 
for
 
correct
 
instruction.
 
●
 
Please
 
tick
 
(
✔
)
 
No
 
for
 
incorrect
 
instruction.
 
Yes
 
No
 
Remarks
 
Pharmacological
 
Group
 
Antiplatelet
 
agent
 
 
Non-steroidal
 
anti-inflammatory
 
drug
 
(NSAID)
 
 
 
 
Indications
 
and
 
Dosage
 
1.
 
i)
 
Prevention
 
of
 
myocardial
 
infarct,
 
stroke,
 
vascular
 
occlusion
 
and
 
deep
 
vein
 
thrombosis.
 
ii)
 
Transient
 
ischaemic
 
attacks
 
a.
 
Acetylsalicylic
 
Acid
 
100
 
mg
 
&
 
Glycine
 
45
 
mg
 
Tablet
 
 
2.
 
Initial
 
treatment
 
of
 
cardiovascular
 
disorders
 
such
 
as
 
angina
 
pectoris
 
and
 
myocardial
 
infarction
 
and
 
for
 
the
 
prevention
 
of
 
cardiovascular
 
events
 
in
 
patients
 
at
 
risk.
 
Other
 
such
 
uses
 
include
 
the
 
treatment
 
and
 
prevention
 
of
 
cerebrovascular
 
disorders
 
such
 
as
 
stroke
 
a.
 
Acetylsalicylic
 
Acid
 
300
 
mg
 
Soluble
 
Tablet
 
b.
 
Acetylsalicylic
 
Acid
 
150mg
 
Dispersible
 
Tablet
 
c.
 
Acetylsalicylic
 
Acid
 
75mg
 
Dispersible
 
Tablet
 
Or
 
 
To
 
counsel
 
based
 
on
 
specific
 
medication’ s
 
indication
 
and
 
dosage
 
as
 
prescribed
 
by
 
the
 
doctor
 
 
 
 
Method
 
of
 
Administration*
 
1.
 
Aspirin
 
may
 
be
 
taken
 
after
 
food
 
to
 
reduce
 
stomach
 
discomfort.
 
 
2.
 
Acetylsalicylic
 
Acid
 
100
 
mg
 
&
 
Glycine
 
45
 
mg
 
Tablet
 
may
 
be
 
swallowed
 
whole
 
or
 
place
 
on
 
the
 
tongue
 
to
 
dissolve
 
for
 
rapid
 
absorption
 
 
3.
 
Dispersible
 
tablet
 
formulations
 
can
 
be
 
dispersed
 
in
 
water
 
immediately
 
before
 
use
 
or
 
swallowed
 
whole.
 
 
 
Missed
 
dose
 
management:
 
Take
 
aspirin
 
as
 
soon
 
as
 
you
 
remember
 
if
 
you
 
forget
 
to
 
take
 
it.
 
However ,
 
if
 
it
 
is
 
almost
 
time
 
for
 
your
 
next
 
dose,
 
skip
 
the
 
dose
 
you
 
missed
 
and
 
take
 
your
 
next
 
dose
 
when
 
you
 
are
 
meant
 
to.
 
Do
 
not
 
take
 
a
 
double
 
dose
 
to
 
make
 
up
 
for
 
the
 
dose
 
that
 
you
 
missed.
 
 
Inform
 
all
 
treating
 
doctors,
 
dentists,
 
and
 
pharmacists
 
that
 
you
 
are
 
taking
 
aspirin
 
 
Do
 
not
 
stop
 
taking
 
your
 
medication
 
unless
 
advised
 
to
 
do
 
so
 
by
 
your
 
prescriber
 
 
 
 
Special
 
Considerations
 
Pregnancy
 
 
 
 
1.
 
Do
 
not
 
use
 
aspirin
 
if
 
you
 
are
 
pregnant
 
or
 
trying
 
for
 
a
 
baby
 
unless
 
directed
 
by
 
your
 
doctor .
 
Aspirin
 
can
 
prolong
 
labour
 
and
 
affect
 
blood
 
clotting
 
in
 
the
 
mother
 
or
 
baby .
 
 
 
2.
 
Aspirin
 
should
 
be
 
avoided
 
1
 
week
 
prior
 
to
 
and
 
during
 
labor
 
and
 
delivery
 
because
 
it
 
can
 
result
 
in
 
excessive
 
blood
 
loss
 
at
 
delivery .
 
Prolonged
 
gestation
 
and
 
prolonged
 
labor
 
due
 
to
 
prostaglandin
 
inhibition
 
have
 
been
 
reported.
 
 
 
 
10
 

=== PAGE 12 ===

 
Breastfeeding
 
 
 
 
1.
 
Nursing
 
mothers
 
should
 
avoid
 
using
 
aspirin
 
because
 
salicylate
 
is
 
excreted
 
in
 
breast
 
milk.
 
Use
 
of
 
high
 
doses
 
may
 
lead
 
to
 
rashes,
 
platelet
 
abnormalities,
 
and
 
bleeding
 
in
 
nursing
 
infants.
 
 
 
 
Elderly
 
 
 
 
Beers
 
Criteria:
 
 
a.
 
Avoid
 
initiating
 
aspirin
 
for
 
primary
 
prevention
 
of
 
cardiovascular
 
disease.
 
Consider
 
deprescribing
 
aspirin
 
in
 
older
 
adults
 
already
 
taking
 
it
 
for
 
primary
 
prevention
.
 
Risk
 
of
 
major
 
bleeding
 
from
 
aspirin
 
increases
 
markedly
 
in
 
older
 
age.
 
Studies
 
suggest
 
lack
 
of
 
net
 
benefit
 
and
 
potential
 
for
 
net
 
harm
 
when
 
initiated
 
for
 
primary
 
prevention
 
in
 
older
 
adults.
 
There
 
is
 
less
 
evidence
 
about
 
stopping
 
aspirin
 
among
 
long-term
 
users,
 
although
 
similar
 
principles
 
as
 
for
 
initiation
 
may
 
apply .
 
 
Note:
 
Aspirin
 
is
 
generally
 
indicated
 
for
 
secondary
 
prevention
 
in
 
older
 
adults
 
with
 
established
 
cardiovascular
 
disease
.
 
 
b.
 
Avoid
 
in
 
patients
 
with
 
a
 
history
 
of
 
gastric
 
or
 
duodenal
 
ulcers
 
unless
 
other
 
alternatives
 
are
 
not
 
effective
 
and
 
patients
 
can
 
take
 
gastroprotective
 
agents
 
(i.e.,
 
proton-pump
 
inhibitor
 
or
 
misoprostol).
 
May
 
exacerbate
 
existing
 
ulcers
 
or
 
cause
 
new/
 
additional
 
ulcers
 
 
 
 
Paediatric
 
 
 
 
1.
 
There
 
is
 
a
 
possible
 
association
 
between
 
aspirin
 
and
 
Reye's
 
syndrome
 
when
 
given
 
to
 
children.
 
Reye’ s
 
syndrome
 
typically
 
occurs
 
after
 
a
 
viral
 
infection
 
such
 
as
 
chickenpox
 
or
 
influenza.
 
 
 
 
 
Fasting
 
 
 
 
1.
 
Not
 
applicable
 
To
 
refer
 
to
 
the
 
latest
 
advisory
 
by
 
religious
 
authority
 
 
 
 
Others
 
 
 
 
 
1.
 
Do
 
not
 
use
 
aspirin
 
continuously
 
for
 
more
 
than
 
10
 
days
 
for
 
pain
 
or
 
more
 
than
 
3
 
days
 
for
 
fever
 
without
 
consulting
 
a
 
doctor .
 
 
 
 
Side
 
Effects
 
and
 
their
 
Management*
 
1.
 
Aspirin
 
may
 
cause
 
allergic
 
reactions
 
involving
 
severe
 
urticaria,
 
angioedema,
 
or
 
bronchospasm
 
(asthma).
 
 
2.
 
Aspirin
 
may
 
cause
 
dizziness
 
or
 
light-headedness
 
in
 
some
 
people.
 
Make
 
sure
 
patients
 
know
 
how
 
they
 
react
 
to
 
aspirin
 
before
 
they
 
drive
 
a
 
car,
 
operate
 
machinery ,
 
or
 
do
 
anything
 
else
 
that
 
could
 
be
 
dangerous
 
if
 
they
 
are
 
dizzy
 
or
 
lightheaded.
 
 
3.
 
These
 
possible
 
side-ef fects
 
may
 
go
 
away
 
during
 
treatment
 
as
 
your
 
body
 
adjusts
 
to
 
the
 
medicine.
 
If
 
they
 
continue,
 
are
 
severe
 
or
 
bother
 
you,
 
tell
 
your
 
doctor
 
or
 
pharmacist.
 
a.
 
stomach
 
pain
 
or
 
discomfort,
 
indigestion
 
or
 
heartburn.
 
 
b.
 
nausea
 
or
 
vomiting.
 
 
 
 
 
11
 

=== PAGE 13 ===

 
4.
 
Although
 
the
 
following
 
side
 
effects
 
are
 
less
 
common,
 
if
 
they
 
do
 
occur ,
 
they
 
need
 
medical
 
attention.
 
Contact
 
your
 
doctor
 
as
 
soon
 
as
 
possible
 
if
 
you
 
notice:
 
 
a.
 
unusual
 
bleeding
 
or
 
bruising
 
 
b.
 
black
 
stools
 
 
c.
 
vomiting
 
blood
 
 
d.
 
chest
 
tightness
 
and
 
difficulty
 
in
 
breathing,
 
and
 
may
 
provoke
 
asthma
 
attack
 
in
 
susceptible
 
individuals'
 
Storage*
 
1.
 
Store
 
below
 
30
o
C.
 
 
2.
 
Protect
 
from
 
light
 
and
 
moisture.
 
 
3.
 
Keep
 
out
 
of
 
the
 
reach
 
and
 
sight
 
of
 
children
 
 
4.
 
Keep
 
aspirin
 
in
 
the
 
original
 
bottle
 
or
 
blister
 
package
 
to
 
keep
 
it
 
dry
 
(protect
 
the
 
tablets
 
from
 
moisture).
 
 
 
 
 
Others
 
1.
 
Discuss
 
with
 
your
 
doctor
 
or
 
pharmacists
 
if
 
you:
 
 
a.
 
are
 
allergic
 
(hypersensitive)
 
to
 
aspirin,
 
salicylates
 
or
 
NSAIDs
 
or
 
other
 
ingredients
 
in
 
the
 
product
 
b.
 
have
 
the
 
syndrome
 
of
 
asthma,
 
rhinitis,
 
and
 
nasal
 
polyps.
 
c.
 
are
 
prone
 
to
 
indigestion
 
or
 
known
 
to
 
have
 
a
 
stomach
 
or
 
small
 
intestine
 
ulcer
 
 
d.
 
have
 
severe
 
kidney ,
 
heart
 
or
 
liver
 
problem
 
 
e.
 
are
 
receiving
 
anticoagulant
 
(medicine
 
used
 
to
 
prevent
 
blood
 
clot)
 
f.
 
have
 
haemophilia
 
or
 
other
 
bleeding
 
disorders
 
 
g.
 
have
 
gout
 
 
 
 
 
Before
 
ending
 
this
 
peer
 
review
 
session,
 
the
 
reviewee
 
should
 
be
 
informed
 
of
 
the
 
step(s)
 
that
 
he/
 
she
 
missed
 
out
 
in
 
order
 
to
 
ensure
 
all
 
the
 
counselling
 
points
 
are
 
being
 
covered.
 
 
Remarks:
 
 
 
 
 
Reviewed
 
by:
 
Name
 
&
 
Signature
                                                                   
Date:
 
 
 
 
 
*Mandatory
 
for
 
validation
 
/
 
peer
 
review
 
 
References:
 
 
1.
 
Product
 
information
 
leaflet
 
Cardiprin®
 
100mg.
 
(2019)
 
Reckitt
 
Benckiser
 
(RB)
 
Health
 
Malaysia
 
Sdn
 
Bhd.
 
Retrieved
 
from
 
Quest
 
3+
 
Search
 
on
 
1
st
 
January
 
2025
 
2.
 
Product
 
information
 
leaflet
 
Glyprin
 
(2021)
 
Duopharma
 
Manufacturing
 
(Bangi)
 
Sdn.
 
Bhd.
 
.
 
Retrieved
 
from
 
Quest
 
3+
 
Search
 
on
 
1
st
 
January
 
2025
 
3.
 
Product
 
information
 
leaflet
 
Millispirin
 
(2022)
 
Unimed
 
Sdn
 
Bhd
 
Retrieved
 
from
 
Quest
 
3+
 
Search
 
on
 
1
st
 
January
 
2025
 
4.
 
Formulari
 
Ubat
 
KKM
 
Acetylsalicylic
 
acid.
 
Accessed
 
on
 
1
st
 
January
 
2025
 
5.
 
2023
 
American
 
Geriatrics
 
Society
 
Beers
 
Criteria®
 
Update
 
Expert
 
Panel.
 
(2023).
 
American
 
Geriatrics
 
Society
 
2023
 
updated
 
AGS
 
Beers
 
Criteria®
 
for
 
potentially
 
inappropriate
 
medication
 
use
 
in
 
older
 
adults.
 
Journal
 
of
 
the
 
American
 
Geriatrics
 
Society ,
 
71(7),
 
2052-2081.
 
 
 
12
 

=== PAGE 14 ===

 
Acyclovir,
 
Topical
 
Name
 
:
 
 
Unit
 
:
 
 
●
 
Please
 
tick
 
(
✔
)
 
Yes
 
for
 
correct
 
instruction.
 
●
 
Please
 
tick
 
(
✔
)
 
No
 
for
 
incorrect
 
instruction.
 
Yes
 
No
 
Remarks
 
Pharmacological
 
Group
 
Antiviral
 
Agent,
 
Topical
 
 
 
 
Indications
 
and
 
Dosage
 
Indication:
 
Herpes
 
simplex
 
infections
 
of
 
the
 
skin,
 
including
 
initial
 
and
 
recurrent
 
labial
 
and
 
genital
 
herpes
 
simplex
 
infections
 
 
Dosage:
 
Apply
 
6
 
times
 
daily
 
(every
 
≈
 
3
 
hours),
 
omitted
 
night
 
sleep
 
time,
 
for
 
5-10
 
days
 
 
To
 
counsel
 
based
 
on
 
specific
 
medication’ s
 
indication
 
and
 
dosage
 
as
 
prescribed
 
by
 
the
 
doctor
 
 
 
 
Method
 
of
 
Administration*
 
1.
 
Apply
 
as
 
early
 
as
 
possible
 
following
 
the onset
 
of
 
prodromal
 
symptoms
 
or
 
when
 
lesions
 
appear
 
2.
 
Wash
 
your
 
hands
 
with
 
soap
 
and
 
water
 
prior
 
to
 
application
 
and
 
after
 
application
 
3.
 
Ensure
 
application
 
sites
 
are
 
clean
 
and
 
dry
 
4.
 
A
 
finger
 
cot
 
or
 
rubber
 
glove
 
should
 
be
 
used
 
while
 
applying
 
the
 
cream
 
to
 
prevent
 
autoinoculation
 
of
 
other
 
body
 
sites
 
or
 
transmission
 
of
 
infection
 
to
 
another
 
person
 
5.
 
Apply
 
sufficient
 
amount
 
to
 
cover
 
all
 
lesions,
 
including
 
the
 
outer
 
margin
 
6.
 
Avoid
 
unnecessary
 
rubbing
 
of
 
the
 
affected
 
area
 
7.
 
Do
 
not
 
apply
 
to
 
mucous
 
membranes
 
e.g.
 
in
 
the
 
mouth,
 
eyes
 
or
 
vagina
 
as
 
it
 
may
 
be
 
irritant
 
8.
 
To
 
help
 
clear
 
up
 
the
 
herpes
 
infection,
 
continue
 
using
 
the
 
medicine
 
for
 
the
 
full
 
course
 
of
 
treatment,
 
even
 
if
 
the
 
symptoms
 
or
 
lesions
 
begin
 
to
 
clear
 
up
 
after
 
a
 
few
 
days
 
Do
 
not
 
stop
 
taking
 
your
 
medication
 
unless
 
advised
 
to
 
do
 
so
 
by
 
your
 
prescriber
 
 
 
 
Special
 
Considerations
 
Pregnancy
 
 
 
 
1.
 
Compatible
 
 
 
 
Breastfeeding
 
 
 
 
Compatible.
 
The
 
decision
 
to
 
breastfeed
 
during
 
therapy
 
should
 
consider
 
the
 
risk
 
of
 
infant
 
exposure,
 
the
 
benefits
 
of
 
breastfeeding
 
to
 
the
 
infant,
 
and
 
the
 
benefits
 
of
 
treatment
 
to
 
the
 
mother .
 
Patients
 
with
 
herpetic
 
lesions
 
near
 
or
 
on
 
the
 
breast
 
should
 
avoid
 
breastfeeding
 
to
 
prevent
 
direct
 
viral
 
transmission
 
to
 
the
 
infant.
 
 
 
 
Elderly
 
 
 
 
Minimal
 
systemic
 
absorption
 
occurs
 
with
 
topical
 
acyclovir ,
 
making
 
it
 
generally
 
safe
 
for
 
elderly
 
patients.
 
 
 
 
Paediatric
 
 
 
 
1.
 
The
 
dosage
 
is
 
the
 
same
 
as
 
in
 
adults
 
for
 
adolescents
 
12
 
years
 
of
 
age
 
and
 
older .
 
2.
 
Safety
 
and
 
effectiveness
 
in
 
pediatric
 
patients
 
less
 
than
 
 
 
 
13
 

=== PAGE 15 ===

 
12
 
years
 
of
 
age
 
have
 
not
 
been
 
established.
 
 
Others:
 
 
 
 
 
Dosage
 
adjustment
 
is
 
unlikely
 
for
 
renal
 
and
 
kidney
 
impairment
 
due
 
to
 
low
 
systemic
 
absorption.
 
 
 
 
Side
 
Effects
 
and
 
their
 
Management*
 
May
 
be
 
irritating
 
and
 
cause
 
contact
 
sensitization.
 
Do
 
not
 
apply
 
to
 
mucous
 
membranes
 
e.g.
 
in
 
the
 
mouth,
 
eyes
 
or
 
vagina.
 
 
 
 
Storage*
 
Store
 
under
 
room
 
temperature,
 
below
 
30°C.
 
 
 
 
 
Others
 
1.
 
Women
 
with
 
herpes
 
genitalis
 
may
 
have
 
an
 
increased
 
risk
 
of
 
cervical
 
cancer ,
 
an
 
annual
 
Pap
 
test
 
may
 
be
 
recommended.
 
2.
 
Kindly
 
seek
 
medical
 
attention
 
if
 
no
 
improvement
 
after
 
a
 
few
 
days
 
of
 
treatment.
 
3.
 
Use
 
of
 
acyclovir
 
has
 
not
 
been
 
shown
 
to
 
prevent
 
transmission
 
of
 
herpes
 
simplex
 
virus
 
to
 
sexual
 
partners.
 
 
 
 
Before
 
ending
 
this
 
peer
 
review
 
session,
 
the
 
reviewee
 
should
 
be
 
informed
 
of
 
the
 
step(s)
 
that
 
he/
 
she
 
missed
 
out
 
in
 
order
 
to
 
ensure
 
all
 
the
 
counselling
 
points
 
are
 
being
 
covered.
 
 
Remarks:
 
 
 
 
 
Reviewed
 
by:
 
Name
 
&
 
Signature
                                                                   
Date:
 
 
 
 
 
*Mandatory
 
for
 
validation
 
/
 
peer
 
review
 
 
References
 
:
 
 
1.
 
Briggs,
 
G.G.
 
(2015),
 
Drugs
 
in
 
pregnancy
 
and
 
lactation
 
10
th
 
Edition,
 
Wolters
 
Kluwer
 
2.
 
Formulari
 
Ubat
 
KKM
 
(n.d.).
 
Ministry
 
of
 
Health
 
Malaysia.
 
Retrieved
 
December
 
20,
 
2024,
 
from
 
https://pharmacy .moh.gov .my/ms/apps/fukkm
 
3.
 
HOVID
 
Bhd
 
(2014).
 
VIREST
 
cream
 
5%,
 
acyclovir
 
[Product
 
Insert]
 
4.
 
UptoDate:
 
Acyclovir
 
(topical)
 
(2024).
 
UpToDate
 
[Drug
 
information].
 
Retrieved
 
November
 
8,
 
2024,
 
from
 
https://www .uptodate.com
 
 
 
 
 
 
 
 
 
 
 
 
 
14
 

=== PAGE 16 ===

 
Adapalene
 
 
Name
 
:
 
 
Unit
 
:
 
 
●
 
Please
 
tick
 
(
✔
)
 
Yes
 
for
 
correct
 
instruction.
 
●
 
Please
 
tick
 
(
✔
)
 
No
 
for
 
incorrect
 
instruction.
 
Yes
 
No
 
Remarks
 
Pharmacological
 
Group
 
Topical
 
retinoid
 
 
 
 
Indications
 
and
 
Dosage
 
Treatment
 
for
 
acne
 
vulgaris
 
where
 
comedones,
 
papules
 
and
 
pustules
 
predominate.
 
 
Apply
 
a
 
thin
 
layer
 
once
 
daily,
 
at
 
bedtime.
 
 
Or
 
 
To
 
counsel
 
based
 
on
 
specific
 
medication’ s
 
indication
 
and
 
dosage
 
as
 
prescribed
 
by
 
the
 
doctor
 
 
 
 
Method
 
of
 
Administration*
 
1.
 
Wash
 
face
 
with
 
a
 
gentle,
 
non-medicated
 
cleanser
 
and
 
allow
 
the
 
face
 
to
 
dry
 
thoroughly .
 
 
2.
 
Dispense
 
a
 
small
 
amount
 
of
 
the
 
medication
 
onto
 
fingertips
 
and
 
spread
 
a
 
thin
 
layer
 
to
 
the
 
entire
 
face
 
and
 
any
 
other
 
affected
 
areas
 
of
 
the
 
skin
 
once
 
daily
 
at
 
bedtime.
 
 
3.
 
Avoid
 
application
 
to
 
eyelids,
 
lips
 
and
 
mucous
 
membranes.
 
 
Do
 
not
 
stop
 
taking
 
your
 
medication
 
unless
 
advised
 
to
 
do
 
so
 
by
 
your
 
prescriber
 
 
 
 
Special
 
Considerations
 
Pregnancy
 
 
 
 
1.
 
To
 
be
 
avoided
 
in
 
pregnancy
 
especially
 
the
 
first
 
trimester .
 
Use
 
in
 
pregnancy
 
only
 
if
 
the
 
potential
 
benefits
 
justifies
 
the
 
potential
 
risk
 
to
 
the
 
fetus.
 
 
 
 
 
Breastfeeding
 
 
 
 
1.
 
Caution
 
should
 
be
 
exercised
 
to
 
nursing
 
women.
 
Risk
 
to
 
the
 
nursing
 
infant
 
is
 
considered
 
low,
 
as
 
only
 
a
 
negligible
 
amount
 
is
 
absorbed
 
after
 
topical
 
application.
 
Do
 
not
 
apply
 
at
 
the
 
nipple
 
area
 
and
 
ensure
 
the
 
infant's
 
skin
 
does
 
not
 
come
 
into
 
direct
 
contact
 
with
 
treated
 
skin
 
areas.
 
 
 
 
 
Elderly
 
 
 
 
1.
 
Not
 
applicable.
 
Refer
 
to
 
the
 
usual
 
adult
 
dose.
 
 
 
 
 
Paediatric
 
 
 
 
1.
 
The
 
safety
 
and
 
efficacy
 
of
 
topical
 
Adapalene
 
in
 
paediatric
 
patients
 
below
 
12
 
years
 
old
 
have
 
not
 
been
 
established.
 
 
 
 
Fasting
 
 
 
 
To
 
refer
 
to
 
the
 
latest
 
advisory
 
by
 
religious
 
authority
 
 
 
 
Others
  
 
 
 
 
15
 

=== PAGE 17 ===

 
NA
 
 
 
 
Side
 
Effects
 
and
 
their
 
Management*
 
Skin
 
dryness,
 
erythema,
 
scaling,
 
stinging/burning
 
 
May
 
use
 
gentle
 
moisturizers
 
not
 
containing
 
alpha
 
hydroxy
 
or
 
glycolic
 
acids
 
to
 
relieve
 
dry
 
skin.
 
 
Caution
 
should
 
be
 
exercised
 
when
 
using
 
products
 
containing
 
sulfur ,
 
resorcinol,
 
salicylic
 
acid,
 
preparations
 
that
 
may
 
dry/irritate
 
the
 
skin
 
such
 
as
 
those
 
with
 
astringents,
 
spices
 
and
 
with
 
high
 
concentration
 
of
 
alcohol.
 
 
 
 
Storage*
 
Store
 
at
 
room
 
temperature
 
below
 
30
o
C
 
 
 
 
Others
 
Should
 
not
 
be
 
applied
 
to
 
cuts,
 
abrasions,
 
eczematous
 
or
 
sunburned
 
skin.
 
 
Avoid
 
excessive
 
exposure
 
to
 
sunlight
 
and
 
sunlamps.
 
Wear
 
sunscreen
 
and
 
protective
 
clothing
 
over
 
treated
 
areas
 
when
 
sun
 
exposure
 
cannot
 
be
 
avoided.
 
 
Avoid
 
extreme
 
weather
 
such
 
as
 
wind
 
and
 
cold.
 
 
 
 
Before
 
ending
 
this
 
peer
 
review
 
session,
 
the
 
reviewee
 
should
 
be
 
informed
 
of
 
the
 
step(s)
 
that
 
he/
 
she
 
missed
 
out
 
in
 
order
 
to
 
ensure
 
all
 
the
 
counselling
 
points
 
are
 
being
 
covered.
 
 
Remarks:
 
 
 
 
 
Reviewed
 
by:
 
Name
 
&
 
Signature
                                                                   
Date:
 
 
 
 
 
*Mandatory
 
for
 
validation
 
/
 
peer
 
review
 
References:
 
 
1.
 
Formulari
 
Ubat
 
Kementerian
 
Kesihatan
 
Malaysia
 
Bil
 
2/2024.
 
2.
 
Differin
 
(adapalene)
 
Gel
 
Label.
 
(2018).
 
Topical
 
preparations
 
counseling
 
guide
 
for
 
pharmacists
 
(1st
 
ed.).
 
Retrieved
 
November
 
11,
 
2024,
 
from
 
https://www .accessdata.fda.gov
 
3.
 
T3
 
Ada
 
Gel
 
0.1%
 
Product
 
Insert.
 
(2019).
 
Revision
 
date:
 
October
 
2019.
 
4.
 
Tolaymat,
 
L.,
 
Dearborn,
 
H.,
 
&
 
Zito,
 
P.
 
M.
 
(2023,
 
June
 
26).
 
Adapalene.
 
In
 
StatPearls
 
[Internet].
 
StatPearls
 
Publishing.
 
Available
 
from
 
https://www .ncbi.nlm.nih.gov/books/NBK482509/
 
 
  
 
 
 
 
 
 
 
 
16
 

=== PAGE 18 ===

 
Amiodarone
 
 
Name
 
:
 
 
Unit
 
:
 
 
●
 
Please
 
tick
 
(
✔
)
 
Yes
 
for
 
correct
 
instruction.
 
●
 
Please
 
tick
 
(
✔
)
 
No
 
for
 
incorrect
 
instruction.
 
Yes
 
No
 
Remarks
 
Pharmacological
 
Group
 
Antiarrhythmic
 
agent,
 
Class
 
III
 
C01BD01
 
 
 
 
Indications
 
and
 
Dosage
 
1.
 
Arrhythmias
 
Loading
 
dose:
 
400mg
 
every
 
8
 
to
 
24
 
hours
 
for
 
a
 
total
 
loading
 
dose
 
of
 
6
 
to
 
10g
 
(total
 
of
 
intravenous
 
and
 
oral
 
doses),
 
then
 
change
 
to
 
a
 
maintenance
 
dose.
 
Maintenance
 
dose:
 
100
 
to
 
200mg
 
once
 
daily
 
 
 
 
Method
 
of
 
Administration*
 
1.
 
May
 
be
 
taken
 
with
 
or
 
without
 
food.
 
2.
 
Take
 
with
 
meals
 
if
 
high
 
dose
 
or
 
to
 
reduce
 
GI
 
discomfort.
 
3.
 
Swallow
 
whole
 
with
 
sufficient
 
amount
 
of
 
water
 
 
Missed
 
dose
 
management
:
 
Take
 
a
 
missed
 
dose
 
as
 
soon
 
as
 
remembered.
 
If
 
it
 
is
 
close
 
to
 
the
 
time
 
for
 
the
 
next
 
dose,skip
 
and
 
go
 
back
 
to
 
normal
 
time.
 
Do
 
not
 
take
 
2
 
doses
 
at
 
the
 
same
 
time
 
 
Do
 
not
 
stop
 
taking
 
your
 
medication
 
unless
 
advised
 
to
 
do
 
so
 
by
 
your
 
prescriber
 
 
 
 
Special
 
Considerations
 
Pregnancy
 
 
 
 
May
 
cause
 
fetal
 
harm
 
(including
 
neonatal
 
bradycardia,
 
QT
 
prolongation,
 
and
 
periodic
 
ventricular
 
extrasystoles;
 
neonatal
 
hypothyroidism
 
and
 
hyperthyroxinemia)
 
when
 
administered
 
to
 
pregnant
 
women.
 
Amiodarone
 
should
 
only
 
be
 
used
 
in
 
pregnancy
 
when
 
other
 
treatments
 
are
 
contraindicated.
 
 
 
 
Breastfeeding
 
 
 
 
Breast
 
feeding
 
could
 
expose
 
nursing
 
infants
 
to
 
significant
 
doses
 
of
 
the
 
drug;
 
risk
 
of
 
exposing
 
infants
 
to
 
amiodarone
 
must
 
be
 
weighed
 
against
 
potential
 
benefit
 
of
 
arrhythmia
 
suppression
 
in
 
mother .
 
There
 
are
 
cases
 
of
 
hypothyroidism
 
and
 
bradycardia
 
in
 
breastfed
 
infants
 
 
 
 
Elderly
 
 
 
 
MALPIP:
 
May
 
increase
 
the
 
risk
 
of
 
bradycardia,
 
orthostatic
 
hypotension,
 
urinary
 
retention,
 
and
 
falls.
 
Examine
 
drug-drug
 
interactions.
 
Tailor
 
regimen
 
according
 
to
 
the
 
patient's
 
physiology
 
and
 
medication
 
profile.
 
Routine
 
blood
 
test
 
and
 
ECG
 
warranted.
 
 
Beers
 
Criteria:
 
Avoid
 
as
 
first
 
line
 
therapy
 
for
 
atrial
 
fibrillation
 
unless
 
the
 
patient
 
has
 
heart
 
failure
 
or
 
substantial
 
left
 
ventricular
 
hypertrophy .
 
Initial
 
dose
 
selection
 
should
 
be
 
at
 
the
 
low
 
end
 
of
 
dosage
 
range,
 
and
 
titration
 
should
 
be
 
slower
 
to
 
evaluate
 
response.
 
A
 
maintenance
 
dose
 
of
 
100mg
 
daily
 
is
 
commonly
 
used,
 
especially
 
for
 
elderly
 
patients
 
with
 
low
 
body
 
mass.
 
 
 
 
17
 

=== PAGE 19 ===

 
Paediatric
 
 
 
 
Given
 
its
 
extensive
 
side
 
effect
 
profile,
 
amiodarone
 
is
 
typically
 
used
 
in
 
refractory
 
cases.
 
 
 
 
Fasting
 
 
 
 
To
 
refer
 
to
 
the
 
latest
 
advisory
 
by
 
religious
 
authority
 
 
 
 
Others
  
 
 
 
 
1.
 
Renal
 
impairment:
 
No
 
dosage
 
adjustment
 
necessary
 
 
2.
 
Hepatic
 
impairment
 
If
 
hepatic
 
enzymes
 
exceed
 
three
 
times
 
normal
 
or
 
double
 
in
 
a
 
patient
 
with
 
an
 
elevated
 
baseline,
 
consider
 
decreasing
 
the
 
dose
 
or
 
discontinuing
 
amiodarone
 
 
 
 
Side
 
Effects
 
and
 
their
 
Management*
 
1.
 
Endocrine
 
disorders:
 
Hypothyroidism
 
or
 
hyperthyroidism
 
2.
 
Nervous
 
system
 
disorders:
 
Extrapyramidal
 
tremors,
 
nightmare,
 
dyssomia,
 
sensory ,
 
motor
 
and
 
mixed
 
peripheral
 
neuropathy
 
3.
 
Eye
 
disorders:
 
Cornea
 
verticillate
 
4.
 
Cardiac
 
disorders:
 
Bradycardia
 
5.
 
Respiratory:
 
Hypersensitivity
 
pneumonitis
 
(result
 
of
 
pulmonary
 
toxicity
 
of
 
amiodarone)
 
6.
 
Gastrointestinal
 
disorders:
 
Nausea,
 
vomiting,
 
taste
 
disturbance
 
at
 
the
 
beginning
 
of
 
treatment
 
7.
 
Hepatobiliary
 
disorders:
 
Isolated
 
elevation
 
of
 
serum
 
transaminases
 
at
 
the
 
beginning
 
of
 
therapy
 
(1.5
 
to
 
3
 
fold
 
the
 
normal
 
value).
 
Value
 
normalizes
 
spontaneously
 
or
 
with
 
dose
 
reduction.
 
8.
 
Skin
 
and
 
subcutaneous
 
tissue
 
disorders:
 
Photosensitisation
 
with
 
increased
 
tendency
 
to
 
sunburn,
 
Eczema.
 
 
 
 
Storage*
 
 
Do
 
not
 
store
 
above
 
30
0
C
 
 
 
 
Others
 
Precautions
 
Use
 
with
 
caution
 
in
 
patients
 
with
 
underlying
 
thyroid
 
disorder ,
 
hepatic
 
impairment,
 
cardiac
 
disorder
 
(bradycardia),
 
skin
 
disorders
 
(eczema)
 
 
Special
 
monitoring
 
parameters
 
 
Thyroid
 
levels,
 
liver
 
function
 
test,
 
heart
 
rate
 
 
Significant
 
drug-drug
 
/
 
drug-food
 
interactions
 
(if
 
applicable)
 
1.
 
Avoid
 
using
 
with
 
medications
 
that
 
induces
 
torsade
 
de
 
pointes
 
and
 
prolongs
 
QT
 
interval
 
(fluroquinolones)
 
2.
 
Use
 
with
 
caution
 
with
 
medications
 
that
 
may
 
induce
 
hypokalemia
 
(diuretics,
 
systemic
 
corticosteroids,
 
intravenous
 
amphotericin)
 
3.
 
Raises
 
plasma
 
concentration
 
of
  
Warfarin
 
and
 
Phenytoin
 
through
 
inhibition
 
of
 
CYP2C9
 
4.
 
Raises
 
plasma
 
levels
 
of
 
Flecainide
 
thorough
 
inhibition
 
of
 
CY2D6
 
 
Significant
 
drug-food
 
interactions
 
1.
 
Grapefruit
 
increases
 
plasma
 
concentration
 
of
 
amiodarone
 
by
 
inhibition
 
of
 
CYP3A4
 
 
 
 
18
 

=== PAGE 20 ===

 
Before
 
ending
 
this
 
peer
 
review
 
session,
 
the
 
reviewee
 
should
 
be
 
informed
 
of
 
the
 
step(s)
 
that
 
he/
 
she
 
missed
 
out
 
in
 
order
 
to
 
ensure
 
all
 
the
 
counselling
 
points
 
are
 
being
 
covered.
 
 
Remarks:
 
 
 
 
 
Reviewed
 
by:
 
Name
 
&
 
Signature
                                                                   
Date:
 
 
 
 
 
*Mandatory
 
for
 
validation/peer
 
review
 
 
References
 
:
 
 
1.
 
Amiohexal
 
200
 
(May
 
2018).
 
Product
 
leaflet.
 
Salutas
 
Pharma
 
GmbH.
 
2.
 
Joglar
 
JA
 
(2023).
 
ACC/AHA/ACCP/HRS
 
guideline
 
for
 
the
 
diagnosis
 
and
 
management
 
of
 
atrial
 
fibrillation:
 
a
 
report
 
of
 
the
 
American
 
College
 
of
 
Cardiology/American
 
Heart
 
Association
 
joint
 
committee
 
on
 
clinical
 
practice
 
guidelines.
 
Circulation.
 
3.
 
Skrifvars
 
et
 
al
 
(2004).
 
The
 
use
 
of
 
undiluted
 
amiodarone
 
in
 
the
 
management
 
of
 
out-of-hospital
 
cardiac
 
arrest.
 
Acta
 
Anaesthesiology
 
Scand.
 
4.
 
Denorfia
 
MT
 
et
 
al(2014).
 
Diagnosis
 
and
 
treatment
 
of
 
fetal
 
cardiac
 
disease:
 
a
 
scientific
 
statement
 
from
 
American
 
Heart
 
Association.
 
Circulation.
 
5.
 
Ito
 
S
 
(2000).
 
Drug
 
therapy
 
for
 
breast
 
feeding
 
women.
 
New
 
England
 
Journal
 
Medical.
 
6.
 
 
2023
 
American
 
Geriatrics
 
Society
 
Beers
 
Criteria®
 
Update
 
Expert
 
Panel.
 
(2023).
 
American
 
Geriatrics
 
Society
 
2023
 
updated
 
AGS
 
Beers
 
Criteria®
 
for
 
potentially
 
inappropriate
 
medication
 
use
 
in
 
older
 
adults.
 
Journal
 
of
 
the
 
American
 
Geriatrics
 
Society
,
 
71
(7),
 
2052-2081.
 
7.
 
 
Paul
 
T
 
et
 
al
 
(1994).
 
New
 
Antiarrhythmic
 
Drugs
 
in
 
Paediatric
 
Use:
 
Amiodarone).
 
Paediatric
 
Cardiology .
 
8.
 
 
Shenoi
 
RP
 
et
 
al
 
(2020).
 
Drugs
 
used
 
to
 
treat
 
paediatric
 
emergencies.
 
Paediatrics.
 
9.
 
Ujhelyi
 
MR
 
(1996).
 
Disposition
 
of
 
intravenous
 
amiodarone
 
in
 
subjects
 
with
 
normal
 
and
 
impaired
 
renal
 
function.
 
Journal
 
Clinical
 
Pharmacology .
 
10.
 
Amidorane
 
(2024).
 
Interactions.
 
Medscape
 
(online).
 
11.
 
Chang,
 
C.
 
T.,
 
Chan,
 
H.
 
K.,
 
Cheah,
 
W.
 
K.,
 
Tan,
 
M.
 
P.,
 
Ch’ng,
 
A.
 
S.
 
H.,
 
Thiam,
 
C.
 
N.,
 
...
 
&
 
Lee,
 
S.
 
W.
 
H.
 
(2023).
 
Development
 
of
 
a
 
Malaysian
 
potentially
 
inappropriate
 
prescribing
 
screening
 
tool
 
in
 
older
 
adults
 
(MALPIP):
 
a
 
Delphi
 
study .
 
Journal
 
of
 
Pharmaceutical
 
Policy
 
and
 
Practice
,
 
16
(1),
 
122.
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
19
 

=== PAGE 21 ===

 
Amitriptyline
 
Name
 
:
 
 
Unit
 
:
 
 
●
 
Please
 
tick
 
(
✔
)
 
Yes
 
for
 
correct
 
instruction.
 
●
 
Please
 
tick
 
(
✔
)
 
No
 
for
 
incorrect
 
instruction.
 
Yes
 
No
 
Remarks
 
Pharmacological
 
Group
 
Tricyclic
 
antidepressant
 
(TCA)
 
 
 
 
 
Indications
 
and
 
Dosage
 
Depression:
 
Adult:
 
25-150
 
mg/day
 
in
 
divided
 
doses
  
(max:
 
300mg/day)
 
Or
 
 
To
 
counsel
 
based
 
on
 
specific
 
medication’ s
 
indication
 
and
 
dosage
 
as
 
prescribed
 
by
 
the
 
doctor
 
 
 
 
Method
 
of
 
Administration*
 
May
 
be
 
taken
 
with
 
or
 
without
 
food
 
 
Do
 
not
 
stop
 
taking
 
your
 
medication
 
unless
 
advised
 
to
 
do
 
so
 
by
 
your
 
prescriber
 
 
 
 
Special
 
Considerations
 
Pregnancy
 
 
 
 
May
 
be
 
used
 
if
 
other
 
agents
 
are
 
ineffective
 
or
 
contraindicated,
 
considering
 
the
 
risks
 
and
 
benefits
 
of
 
use.
 
 
 
 
Breastfeeding
 
 
 
 
1.
 
Very
 
small
 
amounts
 
of
 
amitriptyline
 
can
 
be
 
detected
 
in
 
the
 
plasma
 
of
 
infants.
 
2.
 
I
nfants
 
exposed
 
to
 
amitriptyline
 
via
 
breast
 
milk
 
for
 
adverse
 
effects
 
(eg,
 
over
 
sedation,
 
poor
 
feeding)
 
 
 
 
Elderly
 
 
 
 
Beers
 
Criteria:
 
1.
 
Avoid.
TCAs
 
increase
 
the
 
risk
 
of
 
orthostatic
 
hypotension
 
(OH).
 
Avoid
 
TCAs
 
in
 
elderly
 
whose
 
syncope
 
may
 
be
 
due
 
to
 
OH.
 
 
2.
 
TCAs
 
are
 
highly
 
anticholinergic
 
and
 
sedating,
 
which
 
may
 
increase
 
the
 
risk
 
of
 
cognitive
 
impairment,
 
delirium,
 
falls,
 
fractures
 
in
 
older
 
adults.
 
3.
 
Use
 
with
 
caution,
 
may
 
exacerbate
 
or
 
cause
 
SIADH
 
or
 
hyponatremia;
 
monitor
 
sodium
 
levels
 
closely
 
when
 
starting
 
or
 
changing
 
dosages
 
in
 
older
 
adults.
 
4.
 
Avoid
 
concomitant
 
use
 
of
 
3
 
or
 
more
 
CNS
 
active
 
agents
 
in
 
any
 
combination
 
due
 
to
 
increased
 
risk
 
of
 
falls
 
and
 
fracture.
 
STOPP/Start
 
Criteria:
 
1.
 
Avoid
 
initiation
 
of
 
TCA
 
as
 
first-line
 
treatment
 
for
 
major
 
depression
 
(higher
 
risk
 
of
 
adverse
 
drug
 
reactions
 
with
 
TCA
  
than
 
with
 
SSRIs
 
or
 
SNRIs).
 
2.
 
Avoid
 
TCA
 
in
 
patients
 
with
 
dementia,
 
narrow
 
angle
 
glaucoma,
 
cardiac
 
conduction
 
abnormalities,
 
prostatism,
 
chronic
 
constipation,
 
recent
 
falls,
 
prior
 
history
 
of
 
urinary
 
retention
 
or
 
orthostatic
 
hypotension
 
(risk
 
of
 
worsening
 
these
 
conditions).
 
 
 
 
Paediatric
 
 
 
 
1.
 
Safety
 
and
 
efficacy
 
of
 
Amitriptyline
  
in
 
pediatrics
 
patients
 
below
 
12
 
years
 
of
 
age
 
have
 
not
 
been
 
 
 
 
20
 

=== PAGE 22 ===

 
established.
 
Renal
 
Impairment
 
 
 
 
1.
 
Dose
 
adjustments
 
may
 
be
 
required
 
in
 
pre-existing
 
or
 
newly
 
developed
 
renal
 
or
 
hepatic
 
impairment.
 
Please
 
contact
 
your
 
prescriber .
  
 
2.
 
 
Monitor
 
patient
 
for
 
urinary
 
retention,
 
confusion,
 
sedation
 
and
 
postural
 
hypotension
 
 
 
 
Hepatic
 
Impairment
 
 
 
 
1.
 
Liver
 
impairment
 
may
 
lead
 
to
 
increased
 
drug
 
exposure
 
and
 
may
 
cause
 
increased
 
propensity
 
to
 
cause
 
side
 
effects
 
such
 
as
 
sedation
 
and
 
constipation.
 
Inform
 
your
 
prescriber
 
if
 
you
 
have
 
increased
 
or
 
intolerable
 
side
 
effects.
 
 
 
 
Fasting
 
 
 
 
Administer
 
during
 
Sahur
 
or
 
after
 
Iftar.
 
 
Kindly
 
refer
 
to
 
the
 
latest
 
advisory
 
by
 
religious
 
authority
 
 
 
 
Side
 
Effects
 
and
 
their
 
Management*
 
1.
 
Anticholinergic:
 
 
a.
 
Blurred
 
vision,
 
constipation,
 
urinary
 
retention
 
and
 
dry
 
mouth
 
b.
 
Constipation
 
can
 
be
 
managed
 
by
 
physical
 
activity ,
 
fluid
 
and
 
fibre
 
intake
 
or
 
laxatives.
 
2.
 
Gastrointestinal:
 
a.
 
Nausea
 
&
 
vomiting:
 
consider
 
taking
 
doses
 
with
 
food
 
b.
 
Heartburn,
 
anorexia,
 
diarrhea,
 
abdominal
 
discomfort
 
such
 
as
 
gastric
 
or
 
bloatedness
 
c.
 
Weight
 
Gain:
 
advise
 
on
 
nutritional
 
counselling
 
(avoid
 
low-volume,
 
high-calorie
 
foods)
 
and
 
emphasize
 
need
 
for
 
physical
 
exercise.
 
3.
 
Neurologic:
 
 
a.
 
Anxiety:
 
Contact
 
your
 
prescriber
 
if
 
intolerable
 
b.
 
Headache,
 
dizziness,
 
fatigue,
 
weakness,
 
insomnia,
 
agitation,
 
nervousness,
 
restlessness.
 
May
 
require
 
dosage
 
adjustment.
 
Inform
 
prescriber
 
at
 
next
 
appointment
 
c.
 
Sedation:
 
Avoid
 
activity
 
requiring
 
mental
 
alertness
 
or
 
coordination.
 
Do
 
not
 
drink
 
alcohol
 
during
 
treatment
 
with
 
this
 
medicine
 
as
 
it
 
might
 
increase
 
the
 
sedative
 
effect.
 
Do
 
not
 
drive
 
or
 
work
 
with
 
tools
 
or
 
machinery
 
if
 
affected
 
4.
 
Sexual
 
dysfunction:
 
impotence,
 
change
 
in
 
libido
 
a.
 
Inform
 
your
 
prescriber
 
at
 
next
 
appointment
 
5.
 
Cardiac:
 
 
a.
 
Increase
 
heart
 
rate,
 
prolong
 
QT
 
interval,
 
slows
 
cardiac
 
conduction
 
b.
 
Postural
 
hypotension:
 
Rise
 
slowly
 
when
 
getting
 
up
 
or
 
from
 
lying
 
down.
 
 
●
 
Most
 
side
 
effects
 
are
 
immediate
 
but
 
often
 
go
 
away
 
with
 
time. 
 
●
 
It
 
may
 
take
 
a
 
few
 
weeks
 
before
 
the
 
patient
 
feels
 
any
 
improvement.
 
Therefore,
 
advise
 
patients
 
not
 
to
 
change
 
the
 
dose
 
of
 
the
 
medicine
 
or
 
stop
 
taking
 
the
 
medicine
 
without
 
consulting
 
the
 
doctor
 
first. 
 
●
 
Instruct
 
patient
 
to
 
immediately
 
report
 
worsening
 
depression,
 
suicidal
 
ideation,
 
especially
 
at
 
initiation
 
of
 
 
 
 
21
 

=== PAGE 23 ===

 
therapy
 
(children
 
and
 
adolescents
 
are
 
at
 
higher
 
risk
 
for
 
these
 
effects
 
during
 
the
 
first
 
few
 
months
 
of
 
therapy). 
 
Storage*
 
Store
 
at
 
temperatures
 
below
 
30°C
 
 
 
 
Others
 
1.
 
Significant
 
Pharmacodynamic
 
Interactions
 
a.
 
Risk
 
of
 
life-threatening
 
Serotonin
 
syndrome
 
when
 
SSRIs
 
co-prescribed
 
with
 
serotonergic
 
drugs.
 
(e.g.
 
tramadol,
 
ondansetron,
 
sumatriptan,
 
MAOI)
 
 
Signs
 
and
 
Symptoms
 
i.
 
Mild:
 
Insomnia,
 
anxiety ,
 
nausea,
 
diarrhea,
 
hypertension,
 
tachycardia,
 
hyper-reflexia
 
ii.
 
Moderate:Agitation,
 
myoclonus,
 
tremor ,
 
mydriasis,
 
flushing,
 
diaphoresis,
 
low
 
fever
 
(<38.5°C)
 
iii.
 
Severe:
 
Severe
 
hyperthermia,
 
confusion,rigidity ,
 
respiratory
 
failure,
 
coma,
 
death
 
Management:
 
Seek
 
immediate
 
medical
 
attention
 
if
 
you
 
experience
 
any
 
of
 
the
 
symptoms
 
mentioned
 
above.
 
b.
 
Increase
 
risk
 
of
 
upper
 
GI
 
bleeding
 
if
 
SSRIs
 
are
 
used
 
together
 
with
 
Aspirin
 
and
 
NSAID
 
due
 
to
 
inhibition
 
of
 
platelet
 
aggregation.
 
Watch
 
out
 
for
 
black
 
or
 
tarry
 
stools,
 
easily
 
bleeding
 
gums
 
or
 
spontaneous
 
bruises
 
c.
 
Risk
 
of
 
hyponatremia
 
especially
 
if
 
SSRIs
 
are
 
used
 
with
 
drugs
 
such
 
as
 
diuretics.
 
 
2.
 
Discontinuation
 
Syndrome
 
a.
 
TCA
  
should
 
not
 
be
 
stopped
 
abruptly
 
as
 
this
 
may
 
cause
 
discontinuation/
 
withdrawal
 
symptoms.
 
The
 
symptoms
 
are
 
usually
 
mild
 
and
 
selflimiting,
 
but
 
can
 
occasionally
 
be
 
severe
 
and
 
prolonged.
 
b.
 
The
 
patients
 
must
 
inform
 
prescribers
 
if
 
they
 
wish
 
to
 
change
 
or
 
stop
 
medications
 
 
 
 
Before
 
ending
 
this
 
peer
 
review
 
session,
 
the
 
reviewee
 
should
 
be
 
informed
 
of
 
the
 
step(s)
 
that
 
he/
 
she
 
missed
 
out
 
in
 
order
 
to
 
ensure
 
all
 
the
 
counselling
 
points
 
are
 
being
 
covered.
 
 
Remarks:
 
 
 
Reviewed
 
by:
 
Name
 
&
 
Signature
                                                                   
Date:
 
 
*Mandatory
 
for
 
validation
 
/
 
peer
 
review
 
References
 
:
 
 
1.
 
Apotex
 
International
 
(2017).
 
Product
 
Information
 
Leaflet:
 
Amitriptyline.
 
Retrieved
 
from
 
Quest
 
3+
 
Search
 
on
 
January
 
20,
 
2025
 
2.
 
Formulari
 
Ubat
 
KKM.
 
(2025,
 
January
 
1).
 
Accessed
 
on
 
January
 
20,
 
2025.
 
3.
 
Stahl,
 
S.
 
M.
 
(2017).
 
Stahl’s
 
Essential
 
Psychopharmacology
 
Prescriber’s
 
Guide.
 
In
 
Australian
 
Prescriber
 
(6th
 
ed.,
 
Issue
 
1).
 
Cambridge
 
university
 
ress.
 
https://doi.org/10.18773/austprescr.2016.001
 
 
4.
 
Visvalingam
 
U,
 
et.
 
al.
 
CPG
 
Management
 
of
 
Major
 
Depressive
 
Disorder
 
(2019).
 
Accessed
 
on
 
January
 
20,
 
2025.
 
Available
 
from:
 
CPG
 
Management
 
of
 
Major
 
Depressive
 
Disorder
 
(Second
 
Edition).pdf
 
5.
 
Krishnasamy
 
A.
 
et.
 
al.
 
Medication
 
Counseling
 
for
 
Pharmacists.
 
(First
 
Edition
 
2021).
 
Perak
 
State
 
Health
 
Department,
 
Pharmaceutical
 
Services
 
Division.
 
6.
 
Taylor,
 
D.,
 
Barnes,
 
T.
 
R.
 
E.,
 
&
 
Young,
 
A.
 
H.
 
(2021).
 
The
 
Maudsley
 
prescribing
 
guidelines
 
in
 
psychiatry
 
(14th
 
ed.).
 
Wiley-Blackwell.
 
 
7.
 
2023
 
American
 
Geriatrics
 
Society
 
Beers
 
Criteria®
 
Update
 
Expert
 
Panel.
 
(2023).
 
American
 
Geriatrics
 
Society
 
2023
 
updated
 
AGS
 
Beers
 
Criteria®
 
for
 
potentially
 
inappropriate
 
medication
 
use
 
in
 
older
 
adults.
 
Journal
 
of
 
the
 
American
 
Geriatrics
 
Society,
 
71(7),
 
2052-2081
 
8.
 
O’Mahony,
 
D.,
 
Cherubini,
 
A.,
 
Guiteras,
 
A.
 
R.,
 
Denkinger,
 
M.,
 
Beuscart,
 
J.
 
B.,
 
Onder,
 
G.,
 
...
 
&
 
Curtin,
 
D.
 
(2023).
 
STOPP/START
 
criteria
 
for
 
potentially
 
inappropriate
 
prescribing
 
in
 
older
 
people:
 
version
 
3.
 
European
 
geriatric
 
medicine,
 
14(4),
 
625-632.
 
22
 

=== PAGE 24 ===

 
Amlodipine
 
Name
 
:
 
 
Unit
 
:
 
 
●
 
Please
 
tick
 
(
✔
)
 
Yes
 
for
 
correct
 
instruction.
 
●
 
Please
 
tick
 
(
✔
)
 
No
 
for
 
incorrect
 
instruction.
 
Yes
 
No
 
Remarks
 
Pharmacological
 
Group
 
Dihydropyridine
 
Calcium
 
Antagonist
 
-
 
Antihypertensive
 
 
 
 
Indications
 
and
 
Dosage
 
Hypertension
 
Initial
 
5mg
 
OD,
 
may
 
titrate
 
to
 
maximum
 
dose
 
10mg
 
OD
 
 
 
 
Method
 
of
 
Administration*
 
Amlodipine
 
can
 
be
 
taken
 
with
 
or
 
without
 
food
 
and
 
at
 
any
 
time
 
of
 
the
 
day,
 
try
 
to
 
make
 
sure
 
it's
 
around
 
the
 
same
 
time
 
every
 
day.
 
Swallow
 
amlodipine
 
tablets
 
whole.
 
In
 
general,
 
amlodipine
 
tablets
 
may
 
be
 
cut
 
or
 
crushed.
 
 
Missed
 
dose
 
management:
 
If
 
a
 
dose
 
of
 
amlodipine
 
is
 
not
 
taken
 
at
 
the
 
scheduled
 
time,
 
the
 
dose
 
should
 
be
 
taken
 
as
 
soon
 
as
 
possible
 
on
 
the
 
same
 
day.
 
If
 
the
 
dose
 
was
 
missed
 
for
 
the
 
whole
 
day,
 
skip
 
the
 
missed
 
dose
 
and
 
take
 
the
 
usual
 
dose
 
the
 
next
 
day
 
at
 
the
 
usual
 
time.
 
Never
 
take
 
2
 
doses
 
at
 
once
 
to
 
make
 
up
 
for
 
a
 
forgotten
 
one.
 
 
Do
 
not
 
stop
 
taking
 
your
 
medication
 
unless
 
advised
 
to
 
do
 
so
 
by
 
your
 
prescriber
 
 
 
 
Special
 
Considerations
 
Pregnancy
 
 
 
 
1.
 
Limited
 
data.
 
No
 
evidence
 
of
 
teratogenicity
 
or
 
other
 
embryo/fetal
 
toxicity
 
was
 
found
 
in
 
animal
 
studies.
 
 
2.
 
Amlodipine
 
should
 
be
 
used
 
during
 
pregnancy
 
only
 
if
 
the
 
potential
 
benefit
 
justifies
 
the
 
potential
 
risk
 
to
 
the
 
fetus
 
 
 
 
Breastfeeding
 
 
 
 
1.
 
No
 
data
 
available.
 
It
 
is
 
recommended
 
nursing
 
be
 
discontinued
 
while
 
on
 
amlodipine
 
 
 
 
Elderly
 
 
 
 
MALPIP
 
Increased
 
risk
 
of
 
ankle
 
oedema,
 
to
 
consider
 
dosage
 
adjustment,
 
switching
 
CCB
 
or
 
switching
 
to
 
other
 
classes
 
if
 
necessary .
 
 
 
 
 
Paediatric
 
 
 
 
1.
 
Limited
 
data
 
available
 
for
 
children
 
<6
 
years
 
old.
 
 
 
 
Fasting
 
 
 
 
1.
 
Not
 
applicable
 
 
 
 
 
Others
  
 
 
 
 
1.
 
Amlodipine
 
may
 
be
 
used
 
in
 
patients
 
with
 
renal
 
impairment
 
at
 
normal
 
doses.
 
Amlodipine
 
is
 
not
 
dialyzable.
 
2.
 
Amlodipine
 
half-life
 
is
 
prolonged
 
in
 
patients
 
with
 
 
 
 
23
 

=== PAGE 25 ===

 
impaired
 
liver
 
function
 
and
 
dosage
 
recommendations
 
have
 
not
 
been
 
established,
 
thus
 
amlodipine
 
should
 
be
 
administered
 
with
 
caution
 
in
 
these
 
patients
 
Side
 
Effects
 
and
 
their
 
Management*
 
1.
 
Most
 
common
 
side
 
effects
 
include:
 
a.
 
Flushing
 
b.
 
Fatigue
 
c.
 
Edema
 
d.
 
Dizziness,headache
 
e.
 
Abdominal
 
pain,nausea
 
f.
 
Palpitation
 
g.
 
Somnolence
 
 
2.
 
If
 
pedal
 
edema
 
occurs,
 
may
 
consider
 
to
 
elevate
 
feet
 
using
 
a
 
stool
 
or
 
pillow ,
 
and
 
avoid
 
prolonged
 
sitting
 
or
 
standing
 
 
 
 
 
Storage*
 
Store
 
below
 
30
0
C
 
 
 
 
Others
 
Monitor
 
blood
 
pressure
 
and
 
heart
 
rate
 
periodically ,
 
as
 
advised.
 
 
 
 
Before
 
ending
 
this
 
peer
 
review
 
session,
 
the
 
reviewee
 
should
 
be
 
informed
 
of
 
the
 
step(s)
 
that
 
he/
 
she
 
missed
 
out
 
in
 
order
 
to
 
ensure
 
all
 
the
 
counselling
 
points
 
are
 
being
 
covered.
 
 
Remarks:
 
 
 
 
 
Reviewed
 
by:
 
Name
 
&
 
Signature
                                                                   
Date:
 
 
 
 
 
*Mandatory
 
for
 
validation/peer
 
review
 
 
References:
 
 
1.
 
Briggs,
 
G.
 
G.,
 
Towers,
 
C.
 
V.,
 
&
 
Forinash,
 
A.
 
B.
 
(2022). Briggs
 
drugs
 
in
 
pregnancy
 
and
 
lactation:
 
a
 
reference
 
guide
 
to
 
fetal
 
and
 
neonatal
 
risk,
 
12e.
 
Lippincott
 
Williams
 
&
 
Wilkins,
 
a
 
Wolters
 
Kluwer
 
business. https://apn.lwwhealthlibrary .com/book.aspx?bookid=3077&sectionid=0
 
 
2.
 
Formulari
 
Ubat
 
KKM.
 
(2025).
 
Accessed
 
on
 
January
 
20,
 
2025.
 
3.
 
Hovid
 
Bhd.
 
(2019)
 
Product
 
information
 
leaflet:
 
Hovasc.
 
Retrieved
 
from
 
Quest
 
3+
 
Product
 
Search
 
on
 
January
 
20,
 
2025.
 
4.
 
Ch
ang,
 
C.
 
T.,
 
Chan,
 
H.
 
K.,
 
Cheah,
 
W.
 
K.,
 
Tan,
 
M.
 
P.,
 
Ch’ng,
 
A.
 
S.
 
H.,
 
Thiam,
 
C.
 
N.,
 
...
 
&
 
Lee,
 
S.
 
W.
 
H.
 
(2023).
 
Development
 
of
 
a
 
Malaysian
 
potentially
 
inappropriate
 
prescribing
 
screening
 
tool
 
in
 
older
 
adults
 
(MALPIP):
 
a
 
Delphi
 
study . Journal
 
of
 
Pharmaceutical
 
Policy
 
and
 
Practice, 16(1),
 
122.
 
 
 
 
 
 
 
 
 
 
24
 

=== PAGE 26 ===

 
Amorolfine
 
 
Name
 
:
 
 
Unit
 
:
 
 
●
 
Please
 
tick
 
(
✔
)
 
Yes
 
for
 
correct
 
instruction.
 
●
 
Please
 
tick
 
(
✔
)
 
No
 
for
 
incorrect
 
instruction.
 
Yes
 
No
 
Remarks
 
Pharmacological
 
Group
 
Topical
 
Antifungal
 
 
 
 
Indications
 
and
 
Dosage
 
Fungal
 
nail
 
infections
 
(onychomycosis):
 
 
Use
 
1
 
or
 
2
 
applications
 
weekly .
 
Treat
 
fingernails
 
for
 
6
 
months,
 
toenails
 
for
 
9-12
 
months
 
(review
 
at
 
interval
 
of
 
3
 
months).
 
 
To
 
counsel
 
based
 
on
 
specific
 
medication’ s
 
indication
 
and
 
dosage
 
as
 
prescribed
 
by
 
the
 
doctor
 
 
 
 
Method
 
of
 
Administration*
 
i.
 
Before
 
the
 
first
 
application,
 
file
 
down
 
the
 
infected
 
areas
 
of
 
the
 
nail,
 
including
 
the
 
nail
 
surface,
 
as
 
much
 
as
 
possible
 
using
 
the
 
nail
 
file
 
provided.
 
CAUTION:
 Do
 
not
 
use
 
nail
 
files
 
used
 
for
 
infected
 
nails
 
on
 
healthy
 
nails,
 
otherwise
 
you
 
may
 
spread
 
the
 
infection.
 
ii.
 
Use
 
one
 
of
 
the
 
swabs
 
provided
 
to
 
clean
 
the
 
nail
 
surface.
 
Repeat
 
steps
 
1
 
and
 
2
 
for
 
each
 
affected
 
nail.
 
iii.
 
Dip
 
the
 
applicator
 
into
 
the
 
bottle
 
of
 
nail
 
lacquer .
 
The
 
lacquer
 
must
 
not
 
be
 
wiped
 
off
 
on
 
the
 
edge
 
of
 
the
 
bottle
 
before
 
it
 
is
 
applied.
 
iv.
 
Apply
 
the
 
nail
 
lacquer
 
evenly
 
over
 
the
 
entire
 
surface
 
of
 
the
 
nail.
 
Repeat
 
steps
 
3
 
and
 
4
 
for
 
each
 
affected
 
nail.
 
v.
 
Let
 
the
 
treated
 
nail(s)
 
dry
 
for
 
approximately
 
3
 
minutes.
 
Wait
 
at
 
least
 
10
 
minutes
 
before
 
applying
 
cosmetic
 
nail
 
varnish.
 
vi.
 
The
 
applicator
 
provided
 
is
 
re-usable.
 
However ,
 
it
 
is
 
important
 
to
 
clean
 
it
 
thoroughly
 
after
 
completing
 
each
 
treatment
 
procedure,
 
using
 
the
 
same
 
swab
 
you
 
used
 
for
 
nail
 
cleansing.
 
Avoid
 
touching
 
newly
 
treated
 
nails
 
with
 
the
 
swab.
 
Close
 
the
 
nail
 
lacquer
 
bottle
 
tightly .
 
Dispose
 
of
 
the
 
swab
 
carefully
 
as
 
it
 
is
 
inflammable.
 
 
     
REMINDER:
 
a)
 
Before
 
using
 
this
 
again,
 
first
 
remove
 
the
 
old
 
lacquer
 
and
 
any
 
nail
 
varnish
 
from
 
your
 
nails
 
using
 
a
 
swab,
 
then
 
file
 
down
 
the
 
nails
 
again
 
if
 
necessary .
 
 
b)
 
Re-apply
 
the
 
lacquer
 
as
 
described
 
above.
 
 
c)
 
When
 
dried,
 
the
 
nail
 
lacquer
 
is
 
unaffected
 
by
 
soap
 
and
 
water ,
 
so
 
you
 
may
 
wash
 
your
 
hands
 
and
 
feet
 
as
 
normal.
 
When
 
working
 
with
 
organic
 
solvents
 
(thinners
 
or
 
white
 
spirit),
 
wear
 
impermeable
 
(waterproof)
 
gloves
 
to
 
protect
 
the
 
lacquer
 
on
 
your
 
fingernails.
 
d)
 
It
 
is
 
important
 
to
 
continue
 
the
 
treatment
 
without
 
interruption
 
until
 
the
 
nail
 
is
 
regenerated
 
and
 
the
 
affected
 
areas
 
are
 
cured.
 
In
 
general,
 
this
 
usually
 
takes
 
6
 
months
 
for
 
finger
 
nails
 
and
 
9
 
to
 
12
 
months
 
for
 
toe
 
nails.
 
 
Do
 
not
 
stop
 
taking
 
your
 
medication
 
unless
 
advised
 
to
 
do
 
so
 
by
 
your
 
prescriber
 
 
 
 
Special
 
Considerations
 
Pregnancy
 
 
 
 
 
No
 
clinical
 
experience
 
exists
 
with
 
pregnancy ,
 
its
 
use
 
should
 
be
 
avoided.
 
 
 
 
25
 

=== PAGE 27 ===

 
Breastfeeding
 
 
 
 
No
 
clinical
 
experience
 
exists
 
with
 
nursing,
 
its
 
use
 
should
 
be
 
avoided.
 
 
 
 
Elderly
 
 
 
 
None
 
specifically
 
to
 
those
 
products.
 
 
 
 
Paediatric
 
 
 
 
The
 
safety
 
and
 
efficacy
 
of
 
Amorolfine
 
Nail
 
Lacquer
 
in
 
paediatric
 
patients
 
below
 
age
 
18
 
have
 
not
 
been
 
established.
 
 
 
 
 
Fasting
 
 
 
 
To
 
refer
 
to
 
the
 
latest
 
advisory
 
by
 
religious
 
authority
 
 
 
 
Others
  
 
 
 
 
NA
 
 
 
 
Side
 
Effects
 
and
 
their
 
Management*
 
1.
 
Burning
 
sensation
 
and
 
contact
 
dermatitis
 
may
 
occur
 
 
2.
 
Nail
 
disorders
 
(eg.
 
nail
 
discolouration,
 
brittle
 
or
 
broken
 
nails)
 
have
 
been
 
reported
 
in
 
rare
 
cases.
 
However ,
 
these
 
reactions
 
can
 
also
 
be
 
linked
 
to
 
the
 
onychomycosis
 
itself.
 
 
 
 
Storage*
 
1.
 
Store
 
in
 
a
 
cool
 
dry
 
place
 
below
 
30
 
degrees
 
Celsius.
 
2.
 
Protect
 
from
 
light
 
and
 
heat.
 
3.
 
Keep
 
out
 
of
 
reach
 
of
 
children.
 
 
 
 
Others
 
Nail
 
files
 
for
 
affected
 
nails
 
must
 
not
 
be
 
reused
 
on
 
healthy
 
nails.
 
Use
 
of
 
cosmetic
 
lacquer
 
or
 
artificial
 
nails
 
should
 
be
 
avoided
 
during
 
the
 
treatment.
 
Avoid
 
contact
 
with
 
the
 
eyes,
 
ears
 
and
 
mucous
 
membranes.
 
The
 
lacquer
 
should
 
not
 
be
 
applied
 
on
 
the
 
skin
 
around
 
the
 
nail.
 
 
 
 
Before
 
ending
 
this
 
peer
 
review
 
session,
 
the
 
reviewee
 
should
 
be
 
informed
 
of
 
the
 
step(s)
 
that
 
he/
 
she
 
missed
 
out
 
in
 
order
 
to
 
ensure
 
all
 
the
 
counselling
 
points
 
are
 
being
 
covered.
 
 
Remarks:
 
 
 
 
 
Reviewed
 
by:
 
Name
 
&
 
Signature
                                                                   
Date:
 
 
 
 
 
*Mandatory
 
for
 
validation/peer
 
review
 
 
References:
 
 
1.
 
Ministry
 
of
 
Health
 
Malaysia.
 
(n.d.).
 
FUKKM
 
list.
 
Retrieved
 
November
 
11,
 
2024,
 
from
 
https://i.pharmacy .gov.my/fukkm
 
2.
 
Zuellig
 
Pharma.
 
(2024).
 
Loceryl
 
Nail
 
Lacquer
 
5%
 
Solution:
 
Summary
 
of
 
product
 
characteristics.
 
Retrieved
 
November
 
11,
 
2024.
 
3.
 
Product
 
information
 
Oflomil
 
Amorolfine
 
hydrochloride
 
Nail
 
Lacquer
 
5%
 
w/v
 
(2021).
 
Retrieved
 
from
 
https://quest3plus.bpfk.gov .my/front-end/attachment/4272/pharma/532052/532052_20210301_142325_. 
pdf
 
4.
 
Product
 
Infomation
 
Mycofine
 
5%
 
w/v
 
Nail
 
Lacquer
 
(2023).
 
Retrieved
 
from
 
https://quest3plus.bpfk.gov .my/front-end/attachment/627/pharma/77127/V_75639_20230420_154829_D 
3.pdf
 
26
 

=== PAGE 28 ===

 
Anticholinesterases
 
/
 
N-methyl-D-aspartate
 
(
NMDA)
 
Receptor
 
Antagonist
 
Name
 
:
 
 
Unit
 
:
 
 
●
 
Please
 
tick
 
(
✔
)
 
Yes
 
for
 
correct
 
instruction.
 
●
 
Please
 
tick
 
(
✔
)
 
No
 
for
 
incorrect
 
instruction.
 
Yes
 
No
 
Remarks
 
Pharmacological
 
Group
 
Anticholinesterases
 
 
Donepezil
 
 
Rivastigmine
  
 
NMDA
 
receptor
 
antagonist
 
Memantine
 
 
 
 
 
Indications
 
and
 
Dosage
 
1.
 
Donepezil
 
a.
 
Dementia
 
in
 
Alzheimer's
 
disease:
 
Tablet
 
&
 
Orodispersible
 
tablet:
 
5-10mg/day
 
(as
 
single
 
daily
 
dose)
 
2.
 
Rivastigmine
 
Oral
 
&
 
patch:
 
a.
 
Dementia
 
in
 
Alzheimer's
 
disease
 
&
 
Dementia
 
associated
 
with
 
Parkinson's
 
disease:
 
b.
 
Oral:
 
Initial
 
dose
 
1.5
 
mg
 
BD,
 
increased
 
every
 
two
 
weeks
 
to
 
6-12mg/day
 
(in
 
2
 
divided
 
doses)
 
c.
 
Transdermal
 
patch:
 
Initial:
 
4.6mg/24
 
hours
 
daily,
 
then
 
increased
 
after
 
4
 
weeks
 
to
 
9.6mg/24hours
 
-13.3mg/24hours
 
(applied
 
once
 
daily)
 
1.
 
Memantine
 
d.
 
Moderate
 
to
 
severe
 
Alzheimer's
 
disease.
 
Oral:Initial
 
5mg/day ,
 
then
 
increased
 
at
 
weekly
 
intervals
 
to
 
maximum
 
of
 
20mg/day
 
(in
 
1
 
or
 
2
 
divided
 
doses)
 
 
*Used
 
to
 
slow
 
down
 
the
 
progression
 
of
 
the
 
disease
 
&
 
manage
 
symptoms
 
but
 
NOT
 
cure
 
or
 
reverse
 
the
 
condition
 
Or
 
 
To
 
counsel
 
based
 
on
 
specific
 
medication’ s
 
indication
 
and
 
dosage
 
as
 
prescribed
 
by
 
the
 
doctor
 
 
 
 
Method
 
of
 
Administration*
 
Donepezil:
 
1.
 
Tablet:
 
May
 
be
 
taken
 
with
 
or
 
without
 
food
 
2.
 
Orodispersible
 
Tablet:
 
 
a.
 
Tablet
 
should
 
be
 
taken
 
orally
 
immediately
 
after
 
removal
 
b.
 
Placed
 
the
 
tablet
 
on
 
the
 
tongue
 
and
 
allowed
 
it
 
to
 
disintegrate
 
before
 
swallowing
 
with
 
or
 
without
 
water
 
Rivastigmine:
 
1.
 
Capsule/
 
Oral
 
Solution:
 
May
 
be
 
taken
 
with
 
or
 
without
 
food
 
2.
 
Transdermal
  
Patch:
 
 
Steps
 
to
 
apply
 
patch
 
a.
 
Open
 
the
 
pouch
 
only
 
when
 
you
 
are
 
ready
 
to
 
apply
 
the
 
patch
 
b.
 
Cut
 
the
 
pouch
 
carefully
 
along
 
the
 
dotted
 
line.
 
Not
 
to
 
cut
 
the
 
patch
 
inside.
 
Then,
 
remove
 
the
 
patch
 
from
 
the
 
pouch
 
c.
 
Bend
 
the
 
patch
 
slightly
 
to
 
raise
 
the
 
edge
 
of
 
one
 
half
 
of
 
the
 
release
 
liner
 
covering
 
the
 
 
 
 
27
 

=== PAGE 29 ===

 
patch.
 
Then,
 
peel
 
off
 
that
 
side
 
of
 
the
 
liner
 
and
 
avoid
 
touching
 
the
 
sticky
 
part
 
of
 
the
 
patch
 
d.
 
Patch
 
should
 
be
 
applied
 
once
 
a
 
day
 
to
 
clean,
 
dry,
 
hairless
 
skin
 
with
 
no
 
cuts
 
or
 
sores.
 
e.
 
Put
 
the
 
sticky
 
side
 
of
 
the
 
patch
 
on
 
the
 
skin
 
(on
 
the
 
upper
 
or
 
lower
 
back,
 
upper
 
arm
 
or
 
chest)
 
in
 
a
 
place
 
which
 
not
 
be
 
rubbed
 
by
 
tight
 
clothing
 
f.
 
Peel
 
off
 
the
 
second
 
side
 
of
 
the
 
release
 
liner
 
and
 
firmly
 
press
 
down
 
on
 
the
 
patch
 
g.
 
The
 
previous
 
day’s
 
patch
 
must
 
be
 
removed
 
before
 
applying
 
a
 
new
 
one
 
h.
 
The
 
patch
 
should
 
be
 
replaced
 
by
 
a
 
new
 
one
 
after
 
24
 
hours.
 
Only
 
ONE
 
patch
 
should
 
be
 
worn
 
at
 
a
 
time
 
i.
 
The
 
patch
 
should
 
not
 
be
 
applied
 
to
 
skin
 
that
 
is
 
red,
 
irritated
 
or
 
cut.
 
It
 
is
 
recommended
 
to
 
change
 
the
 
application
 
site
 
daily
 
(
 
not
 
using
 
the
 
same
 
spot
 
for
 
at
 
least
 
14
 
days)
 
to
 
avoid
 
potential
 
irritation
 
j.
 
If
 
the
 
patch
 
falls
 
off,
 
a
 
new
 
patch
 
should
 
be
 
applied
 
to
 
the
 
same
 
site
 
for
 
the
 
rest
 
of
 
the
 
24
 
hours,
 
and
 
it
 
should
 
be
 
replaced
 
at
 
the
 
same
 
time
 
as
 
usual
 
the
 
next
 
day
 
k.
 
The
 
patch
 
can
 
be
 
used
 
in
 
everyday
 
situations,
 
including
 
bathing
 
and
 
during
 
hot
 
weather
 
l.
 
The
 
patch
 
should
 
not
 
be
 
exposed
 
to
 
any
 
external
 
heat
 
sources
 
(e.g.
 
Excessive
 
sunlight,
 
saunas)
 
for
 
long
 
periods
 
of
 
time
 
m.
 
The
 
patch
 
should
 
not
 
be
 
cut
 
into
 
pieces
 
Steps
 
to
 
remove
 
patch
 
e.
 
Gently
 
pull
 
at
 
one
 
edge
 
of
 
the
 
patch
 
to
 
remove
 
it
 
slowly
 
from
 
the
 
skin.
 
Fold
 
the
 
used
 
patch
 
in
 
half
 
(with
 
the
 
sticky
 
sides
 
together).
 
In
 
case
 
the
 
adhesive
 
residue
 
is
 
left
 
over
 
on
 
your
 
skin,
 
gently
 
soak
 
the
 
area
 
with
 
warm
 
water
 
and
 
mild
 
soap
 
or
 
use
 
baby
 
oil
 
to
 
remove
 
it.
 
Alcohol
 
or
 
other
 
dissolving
 
liquids
 
(nail
 
polish
 
remover
 
or
 
other
 
solvents)
 
should
 
not
 
be
 
used
 
f.
 
Wash
 
your
 
hands
 
with
 
soap
 
and
 
water
 
after
 
removing
 
the
 
patch.
 
In
 
case
 
of
 
contact
 
with
 
eyes
 
or
 
if
 
the
 
eyes
 
become
 
red
 
after
 
handling
 
the
 
patch,
 
rinse
 
immediately
 
with
 
plenty
 
of
 
water
 
and
 
seek
 
medical
 
advice
 
if
 
symptoms
 
do
 
not
 
resolve
 
Memantine:
 
1.
 
Tablet:
 
May
 
be
 
taken
 
with
 
or
 
without
 
food.
 
Missed
 
dose
 
management:
 
1.
 
Take
 
the
 
missed
 
dose
 
as
 
soon
 
as
 
you
 
remember .
 
If
 
it’s
 
nearly
 
time
 
for
 
your
 
next
 
dose,
 
skip
 
the
 
missed
 
one
 
and
 
take
 
only
 
the
 
next
 
dose.
 
Do
 
not
 
take
 
two
 
doses
 
at
 
once.
 
2.
 
Rivastigmine
 
patch
 
a.
 
If
 
you
 
miss
 
more
 
than
 
3
 
doses
 
of
 
applying
 
rivastigmine
 
patch,
 
contact
 
the
 
prescriber
 
before
 
putting
 
on
 
a
 
new
 
patch.
 
Do
 
not
 
stop
 
taking
 
your
 
medication
 
unless
 
advised
 
to
 
do
 
so
 
by
 
your
 
prescriber .
 
Special
 
Considerations
 
Pregnancy
 
 
 
 
28
 

=== PAGE 30 ===

 
 
Should
 
not
 
be
 
used
 
during
 
pregnancy
 
 
 
 
 
Breastfeeding
 
 
 
 
Women
 
taking
 
these
 
medications
 
should
 
not
 
breast-feed.
 
 
 
 
Elderly
 
 
 
 
Beers
 
Criteria:
 
For
 
anticholinesterase
 
(Donepezil,
 
Rivastigmine):
 
1)
 
Avoid
 
use
 
in
 
older
 
adults
 
with
 
syncope
 
as
 
it
 
may
 
increase
 
the
 
risk
 
of
 
bradycardia.
 
 
2)
 
ECG
 
must
 
be
 
performed
 
at
 
baseline
 
and
 
post
 
initiation
 
of
 
the
 
drug.
 
To
 
suggest
 
regular
 
monitoring
 
of
 
BP/HR
 
at
 
home.
 
STOPP/ST ART
 
Criteria:
 
1)
 
Acetylcholinesterase
 
inhibitors
 
with
 
a
 
known
 
history
 
of
 
persistent
 
bradycardia
 
(<
 
60
 
beats/min.),
 
heart
 
block
 
or
 
recurrent
 
unexplained
 
syncope
 
(risk
 
of
 
cardiac
 
conduction
 
failure,
 
syncope
 
and
 
injury).
 
2)
 
Acetylcholinesterase
 
inhibitors
 
with
 
concurrent
 
treatment
 
with
 
drugs
 
that
 
induce
 
persistent
 
bradycardia
 
(<
 
60
 
beats/min.)
 
such
 
as
 
beta-blockers,
 
digoxin,
 
diltiazem,
 
verapamil
 
(risk
 
of
 
cardiac
 
conduction
 
failure,
 
syncope
 
and
 
injury).
 
 
3)
 
Memantine
 
with
 
known
 
current
 
or
 
previous
 
seizure
 
disorder
 
(increased
 
risk
 
of
 
seizures).
 
 
 
 
Paediatric
 
 
 
 
1.
 
The
 
safety
 
and
 
efficacy
 
of
 
Rivastigmine
   
in
 
pediatric
 
patients
 
have
 
not
 
been
 
established.
 
2.
 
The
 
safety
 
and
 
efficacy
 
of
 
Memantine
 
and
 
Donepezil
  
in
 
pediatric
 
patients
 
younger
 
than
 
6
 
years
 
of
 
age
 
have
 
not
 
been
 
established.
 
3.
 
The
 
safety
 
and
 
efficacy
 
of
 
extended-release
 
Memantine
 
and
 
Donepezil
  
in
 
pediatric
 
patients
 
have
 
not
 
been
 
established.
 
 
 
 
Fasting
 
 
 
 
Administer
 
during
 
Sahur
 
or
 
after
 
Iftar.
 
 
Kindly
 
refer
 
to
 
the
 
latest
 
advisory
 
by
 
religious
 
authority
 
 
 
 
Renal
 
Impairment
 
 
 
 
 
Anticholinesterase
  
(Donepezil
 
&
 
Rivastigmine)
 
1.
 
Dose
 
adjustment
 
not
 
necessary;
 
titrate
 
to
 
point
 
of
 
tolerability
 
 
NMDA
 
receptor
 
antagonist
 
(Memantine)
 
1.
 
No
 
dose
 
adjustment
 
required
 
in
 
mild
 
or
 
moderate
 
impairment
 
 
2.
 
If
 
CrClr
 
<30ml/min,
 
dose
 
should
 
not
 
exceed
 
10mg/day
 
 
 
 
Hepatic
 
Impairment
 
 
 
 
 
Anticholinesterase
  
(Donepezil
 
&
 
Rivastigmine)
 
1.
 
Mild
 
to
 
moderate:
 
Dose
 
adjustment
 
not
 
necessary
 
2.
 
Severe:
 
Caution
 
should
 
be
 
exercised.
 
NMDA
 
receptor
 
antagonist
 
(Memantine)
 
1.
 
Does
 
not
 
require
 
dose
 
adjustment
 
 
 
 
 
Cardiac
 
Impairment
 
 
 
 
 
29
 

=== PAGE 31 ===

 
Anticholinesterase
  
(Donepezil
 
&
 
Rivastigmine)
 
1.
 
Should
 
be
 
used
 
with
 
caution
 
 
2.
 
Syncopal
 
episodes
 
have
 
been
 
reported
 
 
NMDA
 
receptor
 
antagonist
 
(Memantine)
 
1.
 
Not
 
likely
 
to
 
require
 
dosage
 
adjustment
 
 
 
 
Side
 
Effects
 
and
 
their
 
Management*
 
Anticholinesterase
  
(Donepezil
 
&
 
Rivastigmine)
 
1.
 
Nausea,
 
diarrhea,
 
vomiting,
 
appetite
 
loss,
 
increased
 
gastric
 
acid
 
secretion,
 
weight
 
loss
 
(take
 
with
 
meals
 
to
 
reduce
 
GI
 
effects),
 
insomnia,
 
headache,
 
dizziness,
 
fatigue,
 
abnormal
 
dreams
 
2.
 
Rivastigmine
 
patch:
 
application
 
site
 
reactions
 
with
 
transdermal
 
patch.(other
 
s/e
 
may
 
differ
 
from
 
capsule
 
formulation)
 
NMDA
 
receptor
 
antagonist
 
(Memantine)
 
1.
 
Dizziness,
 
headache
 
(take
 
before
 
sleep
 
to
 
lower
 
the
 
side
 
effects)
 
2.
 
Constipation
 
(ensure
 
adequate
 
hydration
 
and
 
increase
 
fibre
 
intake)
 
 
 
 
Storage*
 
Store
 
at
 
a
 
temperature
 
below
 
30°C.
 
Keep
 
rivastigmine
 
patch
 
and
 
orodispersible
 
donepezil
 
sealed
 
until
 
ready
 
to
 
use.
 
 
 
 
Before
 
ending
 
this
 
peer
 
review
 
session,
 
the
 
reviewee
 
should
 
be
 
informed
 
of
 
the
 
step(s)
 
that
 
he/
 
she
 
missed
 
out
 
in
 
order
 
to
 
ensure
 
all
 
the
 
counselling
 
points
 
are
 
being
 
covered.
 
 
Remarks:
 
 
 
Reviewed
 
by:
 
Name
 
&
 
Signature
                                                                   
Date:
 
 
 
*mandatory
 
for
 
validation/peer
 
review
 
References
 
:
 
 
1.
 
Eisai
 
(Malaysia)
 
Sdn.
 
Bhd.
 
(2022).
 
Product
 
Information
 
Leaflet:
 
Aricept
 
®
 
EVESS
 
5mg,
 
10mg,
 
Donepezil
 
5mg,
 
10mg.
 
Retrieved
 
from
 
Quest
 
3+
 
Search
 
on
 
January
 
20,
 
2025
 
2.
 
Lundbeck
 
Malaysia
 
Sdn.
 
Bhd.
 
(2024).
 
Product
 
Information
 
Leaflet:
 
Ebixa
 
10mg
 
and
 
20mg
 
tablet
 
Memantine
 
hydrochloride.
 
Retrieved
 
from
 
Quest
 
3+
 
Search
 
on
 
January
 
20,
 
2025
 
3.
 
Novartis
 
(2022).
 
Product
 
Information
 
Leaflet:
 
Rivastigmine
 
Capsule.Retrieved
 
from
 
Quest
 
3+
 
Search
 
on
 
January
 
20,
 
2025
 
4.
 
Novartis
 
(2022).
 
Product
 
Information
 
Leafelet:
 
Rivastigmine
 
Patch.
 
Retrieved
 
from
 
Quest
 
3+
 
Search
 
on
 
January
 
20,
 
2025
 
5.
 
Formulari
 
Ubat
 
KKM.
 
(2025,
 
January
 
1).
 
Accessed
 
on
 
January
 
20,
 
2025
.
 
6.
 
Chan
 
YF.
 
et.
 
al.
 
(2021).
 
CPG
 
Management
 
of
 
Dementia
 
(Third
 
Edition).
 
Accessed
 
on
 
January
 
20,
 
2025.
 
7.
 
Available
 
from:
 
CPG
 
Management
 
of
 
Dementia
 
(3rd
 
Edition)
 
2021 1201.pdf
 
8.
 
Stahl,
 
S.
 
M.
 
(2017).
 
Stahl’ s
 
Essential
 
Psychopharmacology
 
Prescriber ’s
 
Guide.
 
In
 
Australian
 
Prescriber
 
(6th
 
ed.,
 
Issue
 
1).
 
Cambridge
 
University
 
Press.
 
https://doi.org/10.18773/austprescr .2016.001
 
 
9.
 
Krishnasamy
 
A.
 
et.
 
al.
 
Medication
 
Counseling
 
for
 
Pharmacists.
 
(First
 
Edition
 
2021).
 
Perak
 
State
 
Health
 
Department,
 
Pharmaceutical
 
Services
 
Division.
 
10.
 
Taylor ,
 
D.,
 
Barnes,
 
T.
 
R.
 
E.,
 
&
 
Young,
 
A.
 
H.
 
(2021).
 
The
 
Maudsley
 
prescribing
 
guidelines
 
in
 
psychiatry
 
(14th
 
ed.).
 
Wiley-Blackwell.
 
 
11.
 
2023
 
American
 
Geriatrics
 
Society
 
Beers
 
Criteria®
 
Update
 
Expert
 
Panel.
 
(2023).
 
American
 
Geriatrics
 
Society
 
2023
 
updated
 
AGS
 
Beers
 
Criteria®
 
for
 
potentially
 
inappropriate
 
medication
 
use
 
in
 
older
 
adults.
 
Journal
 
of
 
the
 
American
 
Geriatrics
 
Society ,
 
71(7),
 
2052-2081.
 
12.
 
O’Mahony ,
 
D.,
 
Cherubini,
 
A.,
 
Guiteras,
 
A.
 
R.,
 
Denkinger ,
 
M.,
 
Beuscart,
 
J.
 
B.,
 
Onder ,
 
G.,
 
...
 
&
 
Curtin,
 
D.
 
(2023).
 
STOPP/ST ART
 
criteria
 
for
 
potentially
 
inappropriate
 
prescribing
 
in
 
older
 
people:
 
version
 
3.
 
European
 
geriatric
 
medicine,
 
14(4),
 
625-632.
 
30
 

=== PAGE 32 ===

 
Antipsychotics,
 
First
 
Generation
 
 
Name
 
: 
 
Unit
 
: 
 
●
 
Please
 
tick
 
(
✔
)
 
Yes
 
for
 
correct
 
instruction.
 
●
 
Please
 
tick
 
(
✔
)
 
No
 
for
 
incorrect
 
instruction.
 
Yes
 
No
 
Remarks
 
Pharmacological
 
Group
 
First
 
Generation
 
Antipsychotics
 
 
Chlorpromazine
 
Haloperidol
 
 
Perphenazine
 
Trifluoperazine
 
Sulpiride
 
 
 
 
 
Indications
 
and
 
Dosage
 
I
ndication:
 
Treatment
 
of
 
psychotic
 
disorders
 
Dosage:
 
1.
 
Chlorpromazine:
 
25
 
–
 
50
 
mg
 
BD/TDS,
 
up
 
to
 
100
 
mg
 
BD/TDS
 
2.
 
Haloperidol
 
tablet:
 
0.5
 
–
 
2
 
mg
 
BD/TDS
 
up
 
to
 
5
 
mg
 
TDS
 
(
doses
 
>30
 
mg/day
 
are
 
not
 
recommended)
 
3.
 
Perphenazine:
 
4
 
mg
 
TDS
 
(max
 
24
 
mg/day)
 
4.
 
Trifluoperazine:
 
5mg
 
BD
 
(max
 
40mg/day)
 
5.
 
Sulpiride:
 
200
 
–
 
1000
 
mg/day
 
(max
 
2.4g/day)
 
Or 
 
To
 
counsel
 
based
 
on
 
specific
 
medication’ s
 
indication
 
and
 
dosage
 
as
 
prescribed
 
by
 
the
 
doctor
 
 
 
 
Method
 
of
 
Administration*
 
1.
 
May
 
be
 
taken
 
with
 
or
 
without
 
food
 
2.
 
Trifluoperazine:
 
do
 
not
 
take
 
within
 
2
 
hours
 
of
 
any
 
antacids
 
3.
 
Chlorpromazine:
 
brown
 
precipitate
 
may
 
occur
 
when
 
chlorpromazine
 
is
 
mixed
 
with
 
caffeine-containing
 
liquids.
 
 
Do
 
not
 
stop
 
taking
 
your
 
medication
 
abruptly
 
unless
 
advised
 
to
 
do
 
so
 
by
 
your
 
prescriber .
 
 
 
 
 
Special
 
Considerations
 
Pregnancy
 
 
 
 
Risk
 
of
 
treatment
 
to
 
the
 
child
 
must
 
be
 
weighed
 
against
 
the
 
risk
 
of
 
no
 
treatment
 
to
 
the
 
mother
 
and
 
child.
 
Inform
 
your
 
doctor
 
if
 
you
 
are
 
planning
 
for
 
pregnancy
 
or
 
become
 
pregnant
 
while
 
taking
 
antipsychotics.
 
 
 
 
Breastfeeding
 
 
 
 
1.
 
Lactating
 
mother
 
are
 
advised
 
not
 
to
 
breastfeed
 
while
 
on
 
treatment.For
 
those
 
who
 
do
 
not
 
wish
 
to
 
continue
 
lactating,
 
formula
 
milk
 
supplementation
 
should
 
be
 
offered
 
to
 
the
 
infants
 
 
 
 
Elderly
 
 
 
 
31
 

=== PAGE 33 ===

 
Beers
 
Criteria:
 
 
1)
 
Use
 
in
 
caution
 
for
 
approved
 
FDA
 
indications
 
such
 
as
 
schizophrenia,
 
bipolar
 
disorder ,
 
Parkinson
 
disease
 
psychosis.
 
Avoid
 
use
 
as
 
adjunctive
 
treatment
 
of
 
major
 
depressive
 
disorder ,
 
or
 
for
 
short-term
 
use
 
as
 
antiemetic.
 
 
2)
 
Increased
 
risk
 
of
 
stroke
 
and
 
greater
 
rate
 
of
 
cognitive
 
decline
 
and
 
mortality
 
in
 
persons
 
with
 
dementia.
 
Additional
 
evidence
 
suggests
 
association
 
of
 
increased
 
risk
 
between
 
antipsychotic
 
medication
 
and
 
mortality
 
independent
 
of
 
dementia.
 
Avoid
 
antipsychotics
 
for
 
behavioral
 
problems
 
of
 
dementia
 
or
 
delirium
 
unless
 
documented
 
nonpharmacologic
 
options
 
(e.g.,
 
behavioral
 
interventions)
 
have
 
failed
 
and/or
 
the
 
patient
 
is
 
threatening
 
substantial
 
harm
 
to
 
self
 
or
 
others.
 
In
 
these
 
circumstances,
 
periodic
 
deprescribing
 
attempts
 
should
 
be
 
considered
 
to
 
assess
 
ongoing
 
need
 
and/or
 
lowest
 
effective
 
dose.
 
STOPP/Start
 
Criteria:
 
1)
 
Antipsychotics
 
(i.e.,
 
other
 
than
 
clozapine
 
or
 
quetiapine)
 
in
 
those
 
with
 
parkinsonism
 
or
 
Dementia
 
with
 
Lewy
 
Bodies
 
(risk
 
of
 
severe
 
extra-pyramidal
 
symptoms).
 
 
2)
 
Antipsychotics
 
prescribed
 
for
 
behavioural
 
and
 
psychological
 
symptoms
 
of
 
dementia
 
(BPSD)
 
an
 
unchanged
 
dose
 
for
 
>
 
3
 
months
 
without
 
medication
 
review
 
(increased
 
risk
 
of
 
extrapyramidal
 
side-ef fects
 
and
 
chronic
 
worsening
 
of
 
cognition,
 
increased
 
risk
 
of
 
major
 
cardiovascular
 
morbidity
 
and
 
mortality).
 
3)
 
Antipsychotics
 
in
 
patients
 
with
 
behavioural
 
and
 
psychological
 
symptoms
 
of
 
dementia
 
(BPSD)
 
for
 
longer
 
than
 
12
 
weeks
 
unless
 
BPSD
 
symptoms
 
are
 
severe
 
and
 
other
 
nonpharmacological
 
treatments
 
have
 
failed
 
(increased
 
risk
 
of
 
stroke,
 
myocardial
 
infarction).
 
4)
 
Antipsychotics
 
with
 
moderate-marked
 
antimuscarinic/anticholinergic
 
effects
 
(acepromazine,
 
chlorpromazine,
 
clozapine,
 
flupenthixol,
 
fluphenzine,
 
levomepromazine,
 
olanzapine,
 
pipothiazine,
 
promazine,
 
thioridazine)
 
with
 
a
 
history
 
of
 
lower
 
urinary
 
tract
 
symptoms
 
associated
 
with
 
benign
 
prostatic
 
hyperplasia
 
or
 
previous
 
urinary
 
retention
 
(high
 
risk
 
of
 
urinary
 
retention).
 
5)
 
Antipsychotics
 
as
 
hypnotics,
 
unless
 
sleep
 
disorder
 
is
 
due
 
to
 
psychosis
 
or
 
BPSD
 
effects
 
of
 
dementia
 
(not
 
recommended
 
in
 
summary
 
of
 
product
 
characteristics;
 
increased
 
risk
 
of
 
confusion,
 
hypotension,
 
extra-pyramidal
 
side
 
effects,
 
falls).
 
6)
 
Antipsychotics
 
with
 
dysphagia
 
(increased
 
risk
 
of
 
aspiration
 
pneumonia)
 
7)
 
Antipsychotic
 
drugs
 
in
 
patients
 
with
 
recurrent
 
falls
 
(may
 
cause
 
Parkinsonism).
 
 
 
 
Paediatrics
 
 
 
 
1)
 
Chlorpromazine:
 
The
 
safety
 
and
 
efficacy
 
in
 
pediatric
 
patients
 
younger
 
than
 
6
 
months
 
of
 
age
 
have
 
not
 
been
 
established
 
2)
 
Haloperidol:
 
The
 
safety
 
and
 
efficacy
 
in
 
pediatric
 
patients
 
younger
 
than
 
3
 
years
 
of
 
age
 
have
 
not
 
been
 
established
 
3)
 
Perphenazine:
 
The
 
safety
 
and
 
efficacy
 
in
 
pediatric
 
patients
 
younger
 
than
 
12
 
years
 
of
 
age
 
have
 
not
 
been
 
established
 
 
 
 
32
 

=== PAGE 34 ===

 
4)
 
Trifluoperazine:
 
The
 
safety
 
and
 
efficacy
 
in
 
pediatric
 
patients
 
younger
 
than
 
6
 
years
 
of
 
age
 
have
 
not
 
been
 
established
 
5)
 
Sulpiride:
 
Clinical
 
experience
 
in
 
children
 
under
 
 
14
 
years
 
of
 
age
 
is
 
insuf ficient
 
to
 
permit
 
specific
 
recommendations.
 
Fasting
 
 
 
 
Administer
 
during
 
Sahur
 
or
 
after
 
Iftar.
 
 
To
 
refer
 
to
 
the
 
latest
 
advisory
 
by
 
religious
 
authority
 
 
 
 
Renal
 
Impairment
 
 
 
 
1.
 
Watch
 
for
 
signs
 
of
 
kidney
 
problems,
 
like
 
reduced
 
urination,
 
swelling
 
in
 
your
 
hands
 
or
 
feet,
 
feeling
 
very
 
tired,
 
shortness
 
of
 
breath,
 
or
 
changes
 
in
 
your
 
blood
 
pressure.
 
If
 
you
 
notice
 
these
 
symptoms,
 
contact
 
your
 
prescriber
 
immediately
 
2.
 
No
 
agent
 
clearly
 
preferred
 
to
 
another;
 
however ,
 
in
 
general
 
 
a.
 
avoid
 
sulpiride
 
and
 
amisulpride
 
b.
 
avoid
 
highly
 
anticholinergic
 
agents
 
because
 
they
 
can
 
contribute
 
to
 
urinary
 
retention
 
c.
 
May
 
consider
 
haloperidol
 
2-6
 
mg
 
a
 
day
 
 
 
 
Hepatic
 
Impairment
 
 
 
 
1.
 
Watch
 
out
 
for
 
signs
 
of
 
liver
 
problems
 
such
 
as
 
yellowing
 
of
 
your
 
skin
 
or
 
eyes,
 
dark
 
urine,
 
severe
 
tiredness,
 
nausea,
 
or
 
pain
 
on
 
the
 
right
 
side
 
of
 
your
 
abdomen.
 
If
 
you
 
notice
 
any
 
of
 
these
 
symptoms,
 
contact
 
your
 
prescriber
 
immediately
 
2.
 
In
 
general:
 
 
Sulpiride:
 
no
 
dosage
 
reduction
 
required
 
if
 
renal
 
function
 
is
 
normal
 
Paliperidone:
 
if
 
depot
 
required
 
 
 
 
 
Side
 
Effects
 
and
 
their
 
Management*
 
Common
 
adverse
 
drugs
 
reactions
 
are
 
as
 
below:
 
 
●
 
Extrapyramidal
 
side
 
effects
 
Inform
 
your
 
prescriber
 
if
 
you
 
have
 
symptoms
 
like
 
tremor ,
 
rigidity ,
 
reduced
 
arm
 
swing,
 
drooling
 
of
 
saliva,
 
slurred
 
speech,
 
uprolling
 
eyeball
 
(oculogyric
 
crisis)
  
 
●
 
Tachycardia
 
(palpitation)
 
–
 
Contact
 
your
 
prescriber
 
if
 
intolerable.
 
●
 
Weight
 
gain
 
and
 
metabolic
 
syndrome
 
–
 
advise
 
on
 
nutritional
 
counselling
 
(avoid
 
low-volume,
 
high-calorie
 
foods)
 
and
 
emphasize
 
need
 
for
 
physical
 
exercise.
 
●
 
Postural
 
hypotension
 
(dizziness)
 
–
 
change
 
of
 
position
 
should
 
be
 
done
 
slowly
 
and
 
gradually
 
and
 
any
 
sudden
 
change
 
of
 
position
 
should
 
be
 
avoided.
 
●
 
Anticholinergic
 
effects
 
such
 
as
 
constipation,
 
dry
 
mouth,
 
blurred
 
vision
 
or
 
urinary
 
retention
 
Staying
 
well-hydrated,
 
taking
 
a
 
high-fiber
 
diet
 
and
 
being
 
physically
 
active
 
may
 
help
 
with
 
constipation.
 
Immediately
 
contact
 
prescriber
 
if
 
unable
 
to
 
pass
 
flatus
 
or
 
if
 
there
 
is
 
abdominal
 
pain
 
●
 
Drowsiness
 
and
 
lethargy
:
 
usually
 
occur
 
only
 
during
 
the
 
initial
 
stage
 
of
 
medication
 
therapy .
 
Avoid
 
activity
 
requiring
 
mental
 
alertness
 
or
 
coordination.
 
Do
 
not
 
drink
 
alcohol
 
during
 
treatment
 
with
 
this
 
medicine
 
as
 
it
 
might
 
increase
 
the
 
sedative
 
effect.
 
Do
 
not
 
drive
 
or
 
 
 
 
33
 

=== PAGE 35 ===

 
work
 
with
 
tools
 
or
 
machinery
 
if
 
affected.
 
Inform
 
prescriber
 
at
 
next
 
appointment
 
●
 
Sexual
 
dysfunction
:
 
inform
 
physicians/pharmacists
 
if
 
you
 
experience
 
problems
 
with
 
libido
 
and
 
arousal
 
●
 
Hyperprolactinemia
:
 
female
 
patients
 
may
 
experience
 
menstrual
 
disturbance
 
or
 
excessive
 
production
 
of
 
breast
 
milk
 
despite
 
not
 
breastfeeding,
 
whereas
 
male
 
patients
 
may
 
experience
 
growth
 
of
 
breast
 
tissue.
 
Inform
 
physicians/pharmacists
 
if
 
it
 
occurs.
 
●
 
Sun-sensitivity
:
 
advise
 
patients
 
to
 
use
 
sunscreen
 
and
 
avoid
 
excessive
 
exposure
 
to
 
sunlight
 
Storage*
 
Store
 
at
 
a
 
temperature
 
below
 
30°C.
 
 
 
 
Before
 
ending
 
this
 
peer
 
review
 
session,
 
the
 
reviewee
 
should
 
be
 
informed
 
of
 
the
 
step(s)
 
that
 
he/
 
she
 
missed
 
out
 
in
 
order
 
to
 
ensure
 
all
 
the
 
counselling
 
points
 
are
 
being
 
covered.
 
 
Remarks:
 
 
Reviewed
 
by:
 
Name
 
&
 
Signature
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Date:
 
 
*Mandatory
 
for
 
validation/peer
 
review
 
 
References
 
: 
 
1.
 
Babu,
 
G.
 
N.,
 
Desai,
 
G.,
 
&
 
Chandra,
 
P.
 
S.
 
(2015).
 
Antipsychotics
 
in
 
pregnancy
 
and
 
lactation.
 
Indian
 
journal
 
of
 
psychiatry ,
 
57(Suppl
 
2),
 
S303–S307. 
https://doi.org/10.4103/0019-5545.161497
 
 
2.
 
Chokhawala
 
K,
 
Stevens
 
L.
 
Antipsychotic
 
Medications.
 
[Updated
 
2023
 
Feb
 
26].
 
In:
 
StatPearls
 
[Internet].
 
Treasure
 
Island
 
(FL):
 
StatPearls
 
Publishing;
 
2024
 
Jan-.
 
Available
 
from: 
https://www .ncbi.nlm.nih.gov/books/NBK519503/
 
3.
 
Galbally ,
 
M.,
 
Snellen,
 
M.,
 
&
 
Power ,
 
J.
 
(2014).
 
Antipsychotic
 
drugs
 
in
 
pregnancy:
 
a
 
review
 
of
 
their
 
maternal
 
and
 
fetal
 
effects.
 
Therapeutic
 
advances
 
in
 
drug
 
safety ,
 
5(2),
 
100–109. 
https://doi.org/10.1 177/2042098614522682
 
 
4.
 
Merative
 
L.
 
P.
 
(2024).
 
Micromedex
 
Drug
 
Reference
 
(Version
 
3.0.6)
 
[Mobile
 
App].
 
App
 
Store.
 
https://apps.apple.com/us/app/micromedex-drug-reference/id666520138
 
5.
 
UpToDate,
 
Inc.
 
(2025).
 
Trifluoperazine,
 
Haloperidol,
 
Sulpiride,
 
Chlorpromazine
 
and
 
Pherpenazine:
 
Drug
 
information
 
(Version
 
3.68.3)
 
[Mobile
 
application].
 
UpToDate,
 
Inc.
 
6.
 
Stahl,
 
S.
 
M.
 
(2017).
 
Stahl’ s
 
Essential
 
Psychopharmacology
 
Prescriber ’s
 
Guide.
 
In
 
Australian
 
Prescriber
 
(6th
 
ed.,
 
Issue
 
1).
 
Cambridge
 
university
 
press.
 
https://doi.org/10.18773/austprescr .2016.001
 
 
7.
 
Krishnasamy
 
A.
 
et.
 
al.
 
Medication
 
Counseling
 
for
 
Pharmacists.
 
(First
 
Edition
 
2021).
 
Perak
 
State
 
Health
 
Department,
 
Pharmaceutical
 
Services
 
Division.
 
8.
 
Taylor ,
 
D.,
 
Barnes,
 
T.
 
R.
 
E.,
 
&
 
Young,
 
A.
 
H.
 
(2021).
 
The
 
Maudsley
 
prescribing
 
guidelines
 
in
 
psychiatry
 
(14th
 
ed.).
 
Wiley-Blackwell.
 
 
9.
 
2023
 
American
 
Geriatrics
 
Society
 
Beers
 
Criteria®
 
Update
 
Expert
 
Panel.
 
(2023).
 
American
 
Geriatrics
 
Society
 
2023
 
updated
 
AGS
 
Beers
 
Criteria®
 
for
 
potentially
 
inappropriate
 
medication
 
use
 
in
 
older
 
adults.
 
Journal
 
of
 
the
 
American
 
Geriatrics
 
Society
,
 
71
(7),
 
2052-2081.
 
10.
 
O’Mahony ,
 
D.,
 
Cherubini,
 
A.,
 
Guiteras,
 
A.
 
R.,
 
Denkinger ,
 
M.,
 
Beuscart,
 
J.
 
B.,
 
Onder ,
 
G.,
 
...
 
&
 
Curtin,
 
D.
 
(2023).
 
STOPP/ST ART
 
criteria
 
for
 
potentially
 
inappropriate
 
prescribing
 
in
 
older
 
people:
 
version
 
3.
 
European
 
geriatric
 
medicine
,
 
14
(4),
 
625-632.
 
 
 
 
 
 
34
 

=== PAGE 36 ===

 
Antipsychotics,
 
Injectables
 
Name
 
:
 
 
Unit
 
:
 
 
●
 
Please
 
tick
 
(
✔
)
 
Yes
 
for
 
correct
 
instruction.
 
●
 
Please
 
tick
 
(
✔
)
 
No
 
for
 
incorrect
 
instruction.
 
Yes
 
No
 
Remarks
 
Pharmacological
 
Group
 
First
 
Generation
 
Antipsychotics
 
Flupentixol
 
 
Fluphenazine
 
 
Zuclopenthixol
 
 
 
Second
 
Generation
 
Antipsychotics
 
Aripiprazole
 
 
Paliperidone
 
 
 
 
 
Indications
 
and
 
Dosage
 
Indication:
 
 
Maintenance
 
treatment
 
of
 
schizophrenia
 
 
Dosage:
 
 
First
 
Generation
 
Antipsychotics
 
Drug
 
Dose
 
Dosing
 
Interval
 
Flupentixol
 
Decanoate
 
 
50mg
 
-
 
400mg
 
 
2-4
 
weeks
 
 
Fluphenazine
 
Decanoate
 
12.5mg
 
-
 
100mg
 
2-5
 
weeks
 
Zuclopenthixol
 
Decanoate
 
200
 
-
 
600mg
 
1-4
 
weeks
 
 
 
Second
 
Generation
 
Antipsychotics
 
Drug
 
Dose
 
Dosing
 
Interval
 
Aripiprazole
 
LAI
 
300
 
-
 
400mg
 
Every
 
month
 
Paliperidone
 
Palmitate
 
LAI
 
1-month
 
50-150mg
 
Every
 
month
 
Paliperidone
 
Palmitate
 
LAI
 
3-month
 
175
 
–
 
525mg
 
Every
 
3
 
months
 
 
Or
 
 
 
To
 
counsel
 
based
 
on
 
specific
 
medication’ s
 
indication
 
and
 
dosage
 
as
 
prescribed
 
by
 
the
 
doctor
 
 
 
 
Method
 
of
 
Administration*
 
Test
 
dose
 
and
 
Injection
 
Site
 
 
First
 
Generation
 
Antipsychotics
 
Drug
 
Test
 
Dose
 
Injection
 
Site
 
Fluphenazine
 
Decanoate
 
12.5mg*
 
Gluteal
 
region
 
Flupenthixol
 
20mg*
 
Gluteal
 
region
 
 
 
 
35
 

=== PAGE 37 ===

 
Decanoate
 
Zuclopenthixol
 
Decanoate
 
100mg*
 
Gluteal
 
region,
 
Lateral
 
thigh
 
*balance
 
of
 
the
 
doses
 
should
 
be
 
given
 
7
 
days
 
after
 
the
 
initial
 
dose
 
(may
 
be
 
between
 
4
 
-
 
7
 
days
 
for
 
certain
 
products)
 
 
Second
 
Generation
 
Antipsychotics
 
Do
 
not
 
require
 
a
 
test
 
dose
 
but
 
tolerability
 
and
 
response
 
to
 
oral
 
preparation
 
should
 
be
 
established
 
before
 
administering
 
the
 
injections.
 
 
 
Drug
 
Test
 
Dose
 
Injection
 
Site
 
Aripiprazole
 
LAI
 
Tolerability
 
to
 
the
 
oral
 
preparation
 
should
 
be
 
established
 
first.
 
Deltoid
 
or
 
gluteal
 
Paliperidone
 
Palmitate
 
LAI
 
1-month
 
First
 
and
 
second
 
initiation
 
doses
 
are
 
administered
 
in
 
the
 
deltoid
 
muscle.
 
Following
 
monthly
 
maintenance
 
doses
 
can
 
be
 
administered
 
in
 
either
 
the
 
deltoid
 
or
 
gluteal
 
muscle.
 
Paliperidone
 
Palmitate
 
LAI
 
3-month
 
After
 
4
 
months
 
treatment
 
with
 
Paliperidone
 
Palmitate
 
LAI
 
1-month.
 
The
 
last
 
2
 
doses
 
of
 
Paliperidone
 
Palmitate
 
LAI
 
1-month
 
must
 
be
 
the
 
same
 
dosage
 
strength
 
before
 
starting
 
Paliperidone
 
Palmitate
 
LAI
 
3-month
 
in
 
order
 
to
 
establish
 
a
 
consistent
 
maintenance
 
dose.
 
 
Missed
 
dose
 
management:
 
 
If
 
a
 
dose
 
is
 
missed,
 
ask
 
the
 
patient
 
to
 
contact
 
the
 
healthcare
 
provider
 
right
 
away
 
to
 
discuss
 
what
 
should
 
be
 
done
 
next.
 
 
Do
 
not
 
stop
 
taking
 
your
 
medication
 
unless
 
advised
 
to
 
do
 
so
 
by
 
your
 
prescriber .
 
Special
 
Considerations
 
Pregnancy
 
 
 
 
Use
 
of
 
LAI
 
during
 
pregnancy
 
should
 
be
 
avoided
 
in
 
order
 
to
 
limit
 
the
 
duration
 
of
 
any
 
possible
 
toxic
 
effect
 
to
 
the
 
foetus.
 
 
 
 
Breastfeeding
 
 
 
 
All
 
antipsychotics
 
that
 
have
 
been
 
studied
 
to
 
date
 
cross
 
the
 
placenta,
 
are
 
present
 
in
 
amniotic
 
fluid
 
and
 
excreted
 
in
 
breast
 
milk.
 
Decisions
 
about
 
breastfeeding
 
on
 
exposure
 
to
 
antipsychotics
 
in
 
infants
 
and
 
associated
 
benefits
 
and
 
harms
 
should
 
be
 
discussed
 
with
 
all
 
women.
 
For
 
those
 
who
 
do
 
not
 
wish
 
to
 
continue
 
lactating,
 
formula
 
milk
 
supplementation
 
should
 
be
 
offered
 
to
 
the
 
infants.
 
 
 
 
36
 

=== PAGE 38 ===

 
Elderly
 
 
 
 
All
 
LAIs
 
are
 
not
 
licensed
 
for
 
the
 
treatment
 
of
 
dementia-related
 
psychosis
 
or
 
behavioural
 
disturbances.
 
 
Parenteral
 
haloperidol
 
has
 
been
 
listed
 
in
 
Malaysian
 
Society
 
of
 
Geriatric
 
Medicines
 
position
 
statement
 
as
 
one
 
of
 
the
 
options
 
in
 
an
 
emergency
,
 
when
 
oral
 
medication
 
is
 
refused.
 
 
Haloperidol
 
carries
 
the
 
same
 
risk
 
as
 
the
 
other
 
antipsychotic.
 
Used
 
in
 
elderly
 
have
 
been
 
associated
 
with
 
an
 
increased
 
risk
 
of
 
cardiovascular
 
events
 
and
 
stroke
 
in
 
elderly
 
with
 
dementia.
 
 
Use
 
is
 
associated
 
with
 
fall
 
risk.
 
To
 
advise
 
on
 
fall
 
precautions.
 
 
 
 
Paediatric
 
 
 
 
SAIs
 
are
 
only
 
used
 
in
 
an
 
acute
 
state
 
for
 
a
 
short
 
term.
 
 
All
 
LAIs
 
are
 
not
 
indicated
 
for
 
children
 
and
 
adolescents.
 
 
If
 
use
 
is
 
required,
 
to
 
monitor
 
side
 
effects.
 
 
 
 
 
Fasting
 
 
 
 
Not
 
applicable
 
 
 
 
Side
 
Effects
 
and
 
their
 
Management*
 
1.
 
Side
 
effects
 
for
 
LAIs
 
are
 
the
 
same
 
or
 
less
 
when
 
compared
 
with
 
oral
 
medications
 
(e.g.
 
EPS,
 
anticholinergic
 
effects),
 
except
 
injection
 
site
 
reactions
 
such
 
as
 
pain,
 
oedema,
 
pruritus
 
and
 
sometimes
 
a
 
palpable
 
mass.
 
The
 
physical
 
discomfort
 
of
 
regular
 
injections
 
can
 
also
 
be
 
reduced
 
by
 
alternating
 
the
 
injection
 
site
 
each
 
time.
 
 
 
 
Storage*
 
Not
 
applicable.
 
Not
 
intended
 
to
 
be
 
kept
 
by
 
patient
 
 
 
 
Others
 
1.
 
Advantages
 
and
 
Disadvantages
 
These
 
drugs
 
are
 
administered
 
via
 
deep
 
intramuscular
 
injection
 
and
 
are
 
gradually
 
released
 
from
 
the
 
injection
 
site,
 
resulting
 
in
 
relatively
 
stable
 
plasma
 
drug
 
levels
 
over
 
extended
 
periods,
 
allowing
 
the
 
injections
 
to
 
be
 
given
 
every
 
few
 
weeks.
 
Advantages
 
of
 
LAI:
 
1.
 
Given
 
once
 
a
 
week
 
to
 
once
 
a
 
month,
 
compared
 
to
 
oral
 
medication,
 
which
 
must
 
be
 
taken
 
every
 
day.
 
 
2.
 
Reduced
 
likelihood
 
of
 
forgetting
 
to
 
take
 
the
 
medication,
 
which
 
consequently
 
decreases
 
the
 
risk
 
of
 
becoming
 
ill
 
Disadvantages
 
of
 
LAI
 
1.
 
Some
 
people
 
feel
 
uncomfortable
 
about
 
having
 
injections,
 
such
 
as
 
anxiety
 
about
 
needles.
 
2.
 
Some
 
people
 
experience
 
pain
 
from
 
the
 
injection
 
which
 
can
 
last
 
for
 
a
 
few
 
days
 
but
 
this
 
is
 
usually
 
mild.
 
 
2.
    
Dosing
 
window
 
Advise
 
patients
 
not
 
to
 
miss
 
doses.
 
If
 
necessary ,
 
patients
 
may
 
receive
 
injection:
 
 
1.
 
Aripiprazole:
 
 
No
 
sooner
 
than
 
26
 
days
 
after
 
the
 
previous
 
injection.
 
The
 
injection
 
should
 
be
 
administered
 
as
 
soon
 
as
 
possible
 
within
 
7
 
days
 
of
 
the
 
monthly
 
time
 
point.
 
 
 
2.
 
Paliperidone
 
Palmitate
 
LAI
 
1-month:
 
 
 
 
 
37
 

=== PAGE 39 ===

 
The
 
second
 
initiation
 
dose
 
can
 
be
 
administered
 
up
 
to
 
4
 
days
 
before
 
or
 
after
 
the
 
1-week
 
time
 
point.
 
Monthly
 
maintenance
 
dose
 
can
 
be
 
administered
 
up
 
to
 
7
 
days
 
before
 
or
 
after
 
the
 
monthly
 
time
 
point.
 
 
3.
 
Paliperidone
 
Palmitate
 
LAI
 
3-month:
 
 
Up
 
to
 
2
 
weeks
 
before
 
or
 
after
 
the
 
3-month
 
time
 
point.
 
Before
 
ending
 
this
 
peer
 
review
 
session,
 
the
 
reviewee
 
should
 
be
 
informed
 
of
 
the
 
step(s)
 
that
 
he/
 
she
 
missed
 
out
 
in
 
order
 
to
 
ensure
 
all
 
the
 
counselling
 
points
 
are
 
being
 
covered.
 
 
Remarks:
 
 
 
 
Reviewed
 
by:
 
Name
 
&
 
Signature
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Date:
 
*Mandatory
 
for
 
validation
 
/
 
peer
 
review
 
References:
 
 
1.
 
Lundbeck
 
Canada.
 
(2020)
 
Product
 
Information
 
Leaflet:
 
PrCLOPIXOL®
 
DEPOT
 
(200
 
mg/mL
 
Zuclopenthixol
 
Intramuscular
 
Injection).
 
Retrieved
 
from
 
Quest
 
3+
 
Search
 
on
 
January
 
21,
 
2025
 
2.
 
Janssen
 
Pharmaceuticals,
 
Inc.
 
(2024).Product
 
Information
 
Leaflet:
 
INVEGA
 
SUSTENNA®
 
(paliperidone
 
palmitate)
 
extended-release
 
injectable
 
suspension.
 
Retrieved
 
from
 
Quest
 
3+
 
Search
 
on
 
January
 
21,
 
2025
 
3.
 
Otsuka
 
Pharmaceutical
 
Co.(2020).
 
Product
 
Information
 
Leaflet:
 
ABILIFY
 
MAINTENA®
 
(aripiprazole)
 
for
 
extended-release
 
injectable
 
suspension,
 
for
 
intramuscular
 
use.
 
Retrieved
 
from
 
Quest
 
3+
 
Search
 
on
 
January
 
21,
 
2025
 
4.
 
Janssen
 
Pharmaceuticals,
 
Inc.(2024).Product
 
Information
 
Leaflet:
 
INVEGA
 
TRINZA®
 
(paliperidone
 
palmitate)extended-release
 
injectable
 
suspension.
 
Retrieved
 
from
 
Quest
 
3+
 
Search
 
on
 
January
 
21,
 
2025
 
5.
 
Ahmad
 
S.N.A.
 
et.
 
al.
 
CPG
 
Management
 
of
 
Schizophrenia
 
(Second
 
Edition,
 
2021).
 
Accessed
 
on
 
January
 
21,
 
2025.
 
Available
 
from:
 
CPG
 
Management
 
of
 
Schizophrenia
 
(Second
 
Edition)
 
v20221219.pdf
 
6.
 
National
 
Institute
 
for
 
Health
 
and
 
Care
 
Excellence.
 
(2021).
 
Psychosis
 
and
 
schizophrenia
 
in
 
adults.
 
Treatment
 
and
 
management.
 
 
7.
 
College
 
of
 
Mental
 
Health
 
Pharmacy
 
(CMHP).
 
(2017).
 
Practice
 
Leaflet
 
for
 
Community
 
Pharmacists
 
-
 
Antipsychotics.
 
8.
 
Formulari
 
Ubat
 
KKM.
 
(2025,
 
January
 
1).
 
Accessed
 
on
 
January
 
21,
 
2025.
 
9.
 
Taylor ,
 
D.,
 
Barnes,
 
T.
 
R.
 
E.,
 
&
 
Young,
 
A.
 
H.
 
(2021).
 
The
 
Maudsley
 
prescribing
 
guidelines
 
in
 
psychiatry
 
(14th
 
ed.).
 
Wiley-Blackwell.
 
 
10.
 
Malaysian
 
Society
 
of
 
Geriatric
 
Medicine
 
Position
 
Statement
 
on
 
Delirium.
 
(2017).
 
 
 
 
 
 
 
 
 
 
 
 
 
38
 

=== PAGE 40 ===

 
Antipsychotics,
 
Second
 
Generation
 
Name
 
: 
 
Unit
 
: 
 
●
 
Please
 
tick
 
(
✔
)
 
Yes
 
for
 
correct
 
instruction.
 
●
 
Please
 
tick
 
(
✔
)
 
No
 
for
 
incorrect
 
instruction.
 
Yes
 
No
 
Remarks
 
Pharmacological
 
Group
 
Second
 
Generation
 
Antipsychotics
 
Amisulpride
 
Aripiprazole
 
Asenapine
 
 
Olanzapine
 
Paliperidone
 
Quetiapine
 
Risperidone
 
 
 
 
 
Indications
 
and
 
Dosage
 
Indication:
 
Treatment
 
of
 
psychotic
 
disorder .
 
Dosage:
 
1.
 
Amisulpride:
 
300-600
 
mg
 
/day
 
in
 
2
 
divided
 
doses
  
(max
 
1200
 
mg/day)
 
2.
 
Aripiprazole:
 
10-15mg
 
/day
 
as
 
single
 
daily
 
dose
 
(max
 
30
 
mg/day)
 
3.
 
Asenapine:
 
5-10mg
 
/day
 
in
 
2
 
divided
 
doses
 
(max
 
20
 
mg/day)
 
4.
 
Clozapine:
 
max
 
900
 
mg/day
 
(refer
 
to
 
clozapine
 
section)
 
5.
 
Olanzapine:
 
5-20mg
 
/
 
day
 
as
 
single
 
daily
 
dose
 
(max
 
20
 
mg/day)
 
6.
 
Paliperidone:
 
3-6
 
mg
 
/day
 
as
 
single
 
daily
 
dose
 
(max
 
12
 
mg/day)
 
7.
 
Quetiapine:
 
300-600
 
mg
 
/day
 
(IR
 
in
 
divided
 
does;
 
XR
 
as
 
single
 
daily
 
dose)
  
(max
 
800
 
mg/day)
 
8.
 
Risperidone:
 
2mg-
 
8mg
 
/day
 
in
 
single
 
or
 
divided
 
doses
 
(max
 
16
 
mg/day)
 
 
Or
 
 
To
 
counsel
 
based
 
on
 
specific
 
medication’ s
 
indication
 
and
 
dosage
 
as
 
prescribed
 
by
 
the
 
doctor
 
 
 
 
Method
 
of
 
Administration*
 
 
Drugs/
 
Formulation
 
Special
 
Counselling
 
Amisulpride
 
Tablet
 
1.
 
It
 
must
 
be
 
swallowed
 
whole
 
tablets
 
with
 
the
 
aid
 
of
 
liquids
 
before
 
meals.
 
Aripiprazole
 
Tablet
 
1.
 
To
 
be
 
taken
 
in
 
the
 
morning
 
before
 
or
 
after
 
as
 
sedation
 
is
 
unusual,
 
and
 
to
 
prevent
 
sleeping
 
difficulty
 
as
 
it
 
can
 
cause
 
akathisia
 
and
 
activation.
 
Asenapine
 
Sublingual
 
Tablet
 
1.
 
Place
 
the
 
whole
 
tablet
 
under
 
the
 
tongue
 
and
 
allow
 
it
 
to
 
dissolve
 
completely;
 
do
 
not
 
split,
 
crush,
 
chew ,
 
or
 
swallow
 
the
 
tablet.
 
 
2.
 
Do
 
not
 
eat
 
or
 
drink
 
for
 
10
 
minutes
 
after
 
administration
 
as
 
it
 
can
 
reduce
 
the
 
absorption
 
of
 
drugs.
 
3.
 
Do
 
not
 
remove
 
the
 
tablet
 
from
 
the
 
original
 
package
 
until
 
ready
 
to
 
administer .
 
 
 
 
39
 

=== PAGE 41 ===

 
Clozapine
 
Tablet
 
Refer
 
Clozapine
 
section
 
Olanzapine
 
Tablet
 
/
 
Orodispersible
 
Tablet
 
1.
 
It
 
must
 
be
 
swallowed
 
whole
 
with
 
the
 
aid
 
of
 
liquids
 
before
 
or
 
after
 
a
 
meal.
 
2.
 
Orosdispersible
 
tablet
 
should
 
be
 
placed
 
in
 
the
 
mouth,
 
where
 
it
 
will
 
rapidly
 
disperse
 
in
 
saliva,
 
so
 
it
 
can
 
be
 
easily
 
swallowed
 
with
 
or
 
without
 
liquid.
 
Alternatively ,
 
it
 
may
 
be
 
dispersed
 
in
 
a
 
full
 
glass
 
of
 
water
 
or
 
other
 
suitable
 
beverage
 
(orange
 
juice,
 
apple
 
juice,
 
milk
 
or
 
coffee)
 
immediately
 
before
 
administration.
 
Do
 
not
 
remove
 
the
 
tablet
 
from
 
the
 
original
 
package
 
until
 
ready
 
to
 
administer .
 
Paliperidone
 
Extended
 
Release
 
Tablet
 
1.
 
To
 
be
 
taken
 
in
 
the
 
morning
 
before
 
or
 
after
 
a
 
meal.
 
It
 
must
 
be
 
swallowed
 
whole
 
with
 
the
 
aid
 
of
 
liquids,
 
and
 
must
 
not
 
be
 
chewed,
 
divided
 
or
 
crushed.
 
2.
 
The
 
medication
 
is
 
contained
 
within
 
a
 
nonabsorbable
 
shell
 
designed
 
to
 
release
 
the
 
drug
 
at
 
a
 
controlled
 
rate.
 
The
 
tablet
 
shell
 
is
 
eliminated
 
from
 
the
 
body
 
and
 
the
 
patient
 
should
 
not
 
be
 
concerned
 
if
 
it
 
appears
 
in
 
the
 
stool.
 
 
Quetiapine
 
Immediate
 
Release
 
Tablet
 
1.
 
It
 
must
 
be
 
swallowed
 
whole
 
with
 
the
 
aid
 
of
 
liquids
 
before
 
a
 
meal
 
or
 
with
 
a
 
light
 
meal
 
(≤300
 
calories).
 
Quetiapine
 
Extended
 
Release
 
Tablet
 
1.
 
It
 
must
 
be
 
swallowed
 
whole
 
and
 
not
 
split,
 
chewed
 
or
 
crushed
 
before
 
a
 
meal
 
or
 
with
 
a
 
light
 
meal
 
(≤300
 
calories).
 
2.
 
Preferably
 
administered
 
once
 
daily,
 
in
 
the
 
evening
 
3.
 
Taking
 
high
 
fat
 
or
 
calorie
 
meals
 
with
 
this
 
medication
 
should
 
be
 
avoided.
 
Risperidone
 
Tablet/Syrup
 
 
1.
 
It
 
must
 
be
 
swallowed
 
whole
 
with
 
the
 
aid
 
of
 
liquids
 
before
 
or
 
after
 
meal.
 
2.
 
It
 
can
 
be
 
mixed
 
with
 
water
 
or
 
orange
 
juice
 
and
 
consumed
 
immediately .
 
3.
 
Syrup
 
is
 
Incompatible
 
with
 
most
 
types
 
of
 
cola
 
and
 
tea
 
including
 
black
 
tea.
 
 
Do
 
not
 
stop
 
taking
 
your
 
medication
 
unless
 
advised
 
to
 
do
 
so
 
by
 
your
 
prescriber
 
Special
 
Considerations
 
Pregnancy
 
 
 
 
1.
 
All
 
APs
 
that
 
have
 
been
 
studied
 
to
 
date
 
cross
 
the
 
placenta,
 
are
 
present
 
in
 
amniotic
 
fluid
 
and
 
excreted
 
in
 
breast
 
milk.
 
Hence
 
APs
 
withdrawal
 
can
 
occur
 
in
 
newborns
 
when
 
they
 
are
 
used
 
in
 
the
 
third
 
trimester .
 
The
 
symptoms
 
are
 
crying,
 
agitation,
 
increased
 
suckling,
 
abnormal
 
increase
 
in
 
tone,
 
tremors,
 
sleepiness,
 
difficulty
 
in
 
feeding
 
and
 
breathing
 
which
 
alleviate
 
within
 
hours
 
or
 
days
 
and
 
do
 
not
 
require
 
 
 
 
40
 

=== PAGE 42 ===

 
specific
 
treatment.
 
However
 
the
 
benefit
 
of
 
treatment
 
for
 
mothers
 
and
 
newborns
 
superseded
 
the
 
harm
 
of
 
discontinuing
 
APs
 
and
 
generally
 
favours
 
continuation
 
of
 
APs.
 
 
Breastfeeding
 
 
 
 
In
 
general,
 
a
 
relative
 
infant
 
dose
 
(RID)
 
below
 
10%
 
of
 
the
 
average
 
maternal
 
level
 
of
 
an
 
antidepressant
 
is
 
considered
 
safe.
 
Drug
 
Lactation
 
Risk
 
RID
 
(%)
 
Amisulpride
 
NA
 
4.7%-10.7%
 
Aripiprazole
 
NA
 
0.9-8.3%
 
Asenapine
 
NA
 
No
 
published
 
data
 
Olanzapine
 
L2
 
1.0-1.6%
 
Paliperidone
 
NA
 
No
 
specific
 
data.
 
Refer
 
risperidone
 
Quetiapine
 
L4
 
0.09-0.1%
 
Risperidone
 
L3
 
2.8-9.1%
 
American
 
College
 
of
 
Obstetricians
 
and
 
Gynecologist
 
lactation
 
risk
 
categories:
 
L1=Safest,
 
L2=Safer,
 
L3=Moderately
 
Safe,
 
Possibly
 
Hazardous,
 
L5=Contraindicated.
 
 
 
Low
 
RID
 
value
 
(Olanzapine,
 
Quetiapine)
 
and
 
moderate
 
RID
 
values
 
(Risperidone/Paliperidone,
 
Aripiprazole)
 
are
 
more
 
widely
 
studied
 
compared
 
to
 
other
 
second-generation
 
antipsychotics
 
and
 
they
 
are
 
considered
 
relatively
 
safe.
 
 
Breastfeeding
 
is
 
not
 
recommended
 
while
 
on
 
treatment
 
with
 
Clozapine.
 
For
 
those
 
who
 
do
 
not
 
wish
 
to
 
continue
 
lactating,
 
formula
 
milk
 
supplementation
 
should
 
be
 
offered
 
to
 
the
 
infants
 
 
 
 
Elderly
 
 
 
 
Beers
 
Criteria:
 
1)
 
All
 
antipsychotics
 
(including
 
second
 
generation)
 
have
 
increased
 
risk
 
of
 
death
 
in
 
elderly
 
patients
 
with
 
dementia-related
 
psychosis.
 
Start
 
with
 
a
 
low
 
dose
 
and
 
increase
 
slowly .
 
2)
 
Avoid
 
use
 
as
 
adjunctive
 
treatment
 
of
 
major
 
depressive
 
disorder ,
 
or
 
for
 
short-term
 
use
 
as
 
antiemetic.
 
 
3)
 
Use
 
in
 
caution
 
for
 
approved
 
FDA
 
indications
 
such
 
as
 
schizophrenia,
 
bipolar
 
disorder ,
 
Parkinson
 
disease
 
psychosis.
 
4)
 
Avoid
 
 
in
 
PD
 
patients
 
(except
 
Clozapine
 
and
 
Quetiapine).
 
Antipsychotics
 
may
 
precipitate
 
the
 
worsening
 
of
 
Parkinson
 
disease.
 
5)
 
Use
 
is
 
associated
 
with
 
fall
 
risk.
 
To
 
advise
 
on
 
fall
 
precautions.
 
Strong
 
anticholinergic
 
properties
 
which
 
may
 
be
 
detrimental
 
in
 
older
 
adults
 
(e.g.,
 
ataxia,
 
impaired
 
psychomotor
 
function,
 
syncope,
 
or
 
additional
 
falls).
 
 
STOPP/Start
 
Criteria:
 
1)
 
Antipsychotics
 
(i.e.,
 
other
 
than
 
clozapine
 
or
 
quetiapine)
 
in
 
those
 
with
 
parkinsonism
 
or
 
Dementia
 
with
 
Lewy
 
 
 
 
41
 

=== PAGE 43 ===

 
Bodies
 
(risk
 
of
 
severe
 
extra-pyramidal
 
symptoms).
 
 
2)
 
Antipsychotics
 
prescribed
 
for
 
behavioural
 
and
 
psychological
 
symptoms
 
of
 
dementia
 
(BPSD)
 
an
 
unchanged
 
dose
 
for
 
>
 
3
 
months
 
without
 
medication
 
review
 
(increased
 
risk
 
of
 
extrapyramidal
 
side-ef fects
 
and
 
chronic
 
worsening
 
of
 
cognition,
 
increased
 
risk
 
of
 
major
 
cardiovascular
 
morbidity
 
and
 
mortality).
 
3)
 
Antipsychotics
 
in
 
patients
 
with
 
behavioural
 
and
 
psychological
 
symptoms
 
of
 
dementia
 
(BPSD)
 
for
 
longer
 
than
 
12
 
weeks
 
unless
 
BPSD
 
symptoms
 
are
 
severe
 
and
 
other
 
nonpharmacological
 
treatments
 
have
 
failed
 
(increased
 
risk
 
of
 
stroke,
 
myocardial
 
infarction).
 
4)
 
Antipsychotics
 
with
 
moderate-marked
 
antimuscarinic/anticholinergic
 
effects
 
(acepromazine,
 
chlorpromazine,
 
clozapine,
 
flupenthixol,
 
fluphenzine,
 
levomepromazine,
 
olanzapine,
 
pipothiazine,
 
promazine,
 
thioridazine)
 
with
 
a
 
history
 
of
 
lower
 
urinary
 
tract
 
symptoms
 
associated
 
with
 
benign
 
prostatic
 
hyperplasia
 
or
 
previous
 
urinary
 
retention
 
(high
 
risk
 
of
 
urinary
 
retention).
 
5)
 
Antipsychotics
 
as
 
hypnotics,
 
unless
 
sleep
 
disorder
 
is
 
due
 
to
 
psychosis
 
or
 
BPSD
 
effects
 
of
 
dementia
 
(not
 
recommended
 
in
 
summary
 
of
 
product
 
characteristics;
 
increased
 
risk
 
of
 
confusion,
 
hypotension,
 
extra-pyramidal
 
side
 
effects,
 
falls).
 
6)
 
Antipsychotics
 
with
 
dysphagia
 
(increased
 
risk
 
of
 
aspiration
 
pneumonia)
 
7)
 
Antipsychotic
 
drugs
 
in
 
patients
 
with
 
recurrent
 
falls
 
(may
 
cause
 
Parkinsonism).
 
Paediatric
 
1)
 
The
 
safety
 
and
 
efficacy
 
of
 
Aripiprazole
 
(Oral
 
/
 
Depot)
 
in
 
pediatric
 
patients
 
younger
 
than
 
6
 
years
 
of
 
age
 
have
 
not
 
been
 
established.
 
2)
 
The
 
safety
 
and
 
efficacy
 
of
 
Asenapine
 
(Oral)
 
in
 
pediatric
 
patients
 
have
 
not
 
been
 
established.
 
3)
 
The
 
safety
 
and
 
efficacy
 
of
 
Clozapine
 
(Oral)
 
in
 
pediatric
 
patients
 
have
 
not
 
been
 
established.
 
 
4)
 
The
 
safety
 
and
 
efficacy
 
of
 
Olanzapine
 
(Oral)
 
in
 
pediatric
 
patients
 
younger
 
than
 
13
 
years
 
of
 
age
 
have
 
not
 
been
 
established.
 
5)
 
The
 
safety
 
and
 
efficacy
 
of
 
Paliperidone
 
(Oral
 
/
 
Depot)
 
in
 
pediatric
 
patients
 
have
 
not
 
been
 
established.
 
6)
 
The
 
safety
 
and
 
efficacy
 
of
 
Quetiapine(Oral)
 
in
 
pediatric
 
patients
 
younger
 
than
 
10
 
years
 
of
 
age
 
have
 
not
 
been
 
established.
 
7)
 
The
 
safety
 
and
 
efficacy
 
of
 
Risperidone
 
(Oral)
 
in
 
pediatric
 
patients
 
younger
 
than
 
5
 
years
 
of
 
age
 
have
 
not
 
been
 
established.
 
 
 
 
Fasting
 
 
 
 
Administer
 
during
 
Sahur
 
or
 
after
 
Iftar.
 
 
To
 
refer
 
to
 
the
 
latest
 
advisory
 
by
 
religious
 
authority
 
 
 
 
Renal
 
Impairment
 
 
 
 
1.
 
Watch
 
for
 
signs
 
of
 
kidney
 
problems,
 
like
 
reduced
 
urination,
 
swelling
 
in
 
your
 
hands
 
or
 
feet,
 
feeling
 
very
 
tired,
 
shortness
 
of
 
breath,
 
or
 
changes
 
in
 
your
 
blood
 
pressure.
 
If
 
you
 
notice
 
these
 
symptoms,
 
contact
 
your
 
prescriber
 
immediately
 
2.
 
No
 
agent
 
clearly
 
preferred
 
to
 
another;
 
however ,
 
in
 
general
 
 
 
 
 
42
 

=== PAGE 44 ===

 
a.
 
avoid
 
sulpiride
 
and
 
amisulpride
 
b.
 
avoid
 
highly
 
anticholinergic
 
agents
 
because
 
they
 
can
 
contribute
 
to
 
urinary
 
retention
 
c.
 
May
 
consider
 
olanzapine
 
5mg
 
a
 
day
 
Hepatic
 
Impairment
 
 
 
 
1.
 
Watch
 
out
 
for
 
signs
 
of
 
liver
 
problems
 
such
 
as
 
yellowing
 
of
 
your
 
skin
 
or
 
eyes,
 
dark
 
urine,
 
severe
 
tiredness,
 
nausea,
 
or
 
pain
 
on
 
the
 
right
 
side
 
of
 
your
 
abdomen.
 
If
 
you
 
notice
 
any
 
of
 
these
 
symptoms,
 
contact
 
your
 
prescriber
 
immediately
 
2.
 
In
 
general:
 
 
Sulpiride/Amisulpride:
 
no
 
dosage
 
reduction
 
required
 
if
 
renal
 
function
 
is
 
normal
 
Paliperidone:
 
if
 
depot
 
required
 
 
 
 
Side
 
Effects
 
and
 
their
 
Management*
 
Side
 
Effects
 
 
 
Drugs
 
High
 
Incidence
 
Moderate
 
Incidence
 
Low
 
incidence
 
Amisulpride
 
Prolactin
 
elevation
 
QT
 
prolongation,
 
constipation
 
Weight
 
gain,
 
akathisia,
 
parkinsonism,
 
tardive
 
dyskinesia
 
Aripiprazole
 
-
 
-
 
Constipation,
 
akathisia,
 
tardive
 
dyskinesia,
 
QT
 
prolongation
 
Asenapine
 
-
 
-
 
Constipation,
 
sedation,
 
weight
 
gain,
 
akathisia,
 
tardive
 
dyskinesia,
 
QT
 
prolongation,
 
prolactin
 
elevation
 
Clozapine
 
Refer
 
clozapine
 
section
 
Olanzapine
 
Weight
 
gain
 
Constipation,
 
sedation,
 
 
Tardive
 
dyskinesia,
 
anticholinergic,
 
hypotension,
 
QT
 
prolongation,
 
prolactin
 
elevation
 
Paliperidone
 
Prolactin
 
elevation
 
Constipation,
 
weight
 
gain,
 
hypotension
 
Sedation,
 
akathisia,
 
parkinsonism,
 
tardive
 
dyskinesia,
 
anticholinergic,
 
QT
 
prolongation
 
 
 
 
43
 

=== PAGE 45 ===

 
Quetiapine
 
-
 
Constipation,
 
sedation,
 
weight
 
gain,
 
hypotension,
 
QT
 
prolongation,
 
 
Tardive
 
dyskinesia,
 
anticholinergic
 
Risperidone
 
Prolactin
 
elevation
 
Constipation,
 
weight
 
gain,
 
akathisia,
 
hypotension,
 
 
Sedation,
 
parkinsonism,
 
tardive
 
dyskinesia,
 
anticholinergic,
 
QT
 
prolongation
 
Side
 
Effects
 
and
 
Management
 
Strategies
 
 
 
Side
 
Effects
 
Onset
 
Management
 
Strategies
 
Constipation
 
First
 
four
 
months
 
of
 
AP
  
administration
 
1.
 
Ensure
 
adequate
 
fiber,
 
fluid
 
and
 
exercise
 
2.
 
May
 
require
 
additional
 
medication,
 
consult
 
your
 
prescriber
 
3.
 
Immediately
 
Contact
 
prescriber
 
if
 
unable
 
to
 
pass
 
flatus
 
or
 
if
 
there
 
is
 
abdominal
 
pain
 
EPS:
 
Dystonia
 
Within
 
hours
 
to
 
days
 
of
 
AP
 
administration
 
or
 
dose
 
increase
 
1.
 
May
 
require
 
a
 
change
 
in
 
dose
 
of
 
medication.
 
Inform
 
prescriber
 
at
 
next
 
visit
 
2.
 
Contact
 
immediately
 
if
 
if
 
you
 
are
 
having
 
repeated
 
uncontrolled
 
movements,
 
pain
 
or
 
severe
 
muscle
 
stiffness
 
EPS:
 
Pseudoparkinso
nism
 
Day
 
to
 
weeks
 
after
 
AP
 
administration
 
or
 
dose
 
increase
 
1.
 
May
 
require
 
a
 
change
 
in
 
dose
 
of
 
medication.
 
Inform
 
prescriber
 
at
 
next
 
visit
 
if
 
you
 
are
 
having
 
symptoms
 
of
 
tremor ,
 
rigidity ,
 
bradykinesia
 
Akathisia
 
Within
 
hours
 
to
 
weeks
 
of
 
AP
 
1.
 
May
 
require
 
a
 
change
 
in
 
dose
 
44
 

=== PAGE 46 ===

 
administration
 
or
 
dose
 
increase
 
of
 
medication.
 
Inform
 
your
 
prescriber
 
if
 
you
 
feel
 
like
 
you
 
can't
 
sit
 
still
 
or
 
constantly
 
need
 
to
 
move,
 
such
 
as
 
pacing,
 
tapping
 
your
 
feet,
 
or
 
shifting
 
in
 
your
 
seat.
 
 
Tardive
 
dyskinesia
 
After
 
months
 
to
 
years
 
of
 
AP
 
administration
 
1.
 
May
 
require
 
a
 
change
 
in
 
dose
 
of
 
medication.
 
Inform
 
prescriber
 
at
 
next
 
visit
 
if
 
you
 
are
 
having
 
repetitive
 
movements,
 
often
 
around
 
the
 
face,
 
mouth,
 
or
 
tongue,
 
like
 
lip
 
smacking,
 
blinking,
 
or
 
chewing
 
motions.
 
 
Sedation
 
Within
 
hours
 
to
 
days
 
of
 
AP
 
administration
 
 
1.
 
Avoid
 
activity
 
requiring
 
mental
 
alertness
 
or
 
coordination.
 
 
2.
 
Do
 
not
 
drink
 
alcohol
 
during
 
treatment
 
with
 
this
 
medicine
 
as
 
it
 
might
 
increase
 
the
 
sedative
 
effect.
 
Do
 
not
 
drive
 
or
 
work
 
with
 
tools
 
or
 
machinery
 
if
 
affected.
 
 
3.
 
Inform
 
prescriber
 
at
 
next
 
appointment.
 
You
 
may
 
require
 
a
 
change
 
in
 
dose
 
or
 
medication.
 
Weight
 
Gain
 
Within
 
three
 
months
 
of
 
AP
 
administration
 
1.
 
Advise
 
on
 
nutritional
 
counselling
 
(avoid
 
low-volume,
 
high-calorie
 
foods)
 
and
 
emphasize
 
need
 
for
 
physical
 
exercise
 
Hyperprolactina
emia
 
Within
 
hours
 
to
 
months
 
of
 
AP
 
administration
 
 
1.
 
May
 
require
 
a
 
change
 
in
 
dose
 
or
 
medication.
 
Inform
 
doctor
 
/
 
pharmacist
 
if
 
any
 
signs
 
of
 
irregular
 
or
 
no
 
menses
 
and
 
galactorrhoea
 
(milky
 
nipple
 
45
 

=== PAGE 47 ===

 
discharge)
 
in
 
women
 
Orthostatic
 
hypotension
 
Within
 
hours
 
to
 
days
 
of
 
AP
 
administration
 
or
 
dose
 
increase
 
1.
 
Advice
 
to
 
patients,
 
eg.
 
sitting
 
on
 
the
 
edge
 
of
 
the
 
bed
 
for
 
several
 
minutes
 
before
 
attempting
 
to
 
stand
 
in
 
the
 
morning
 
and
 
slowly
 
rising
 
from
 
a
 
seated
 
position
 
ECG
 
changes
 
-
 
QT
 
prolongation
 
After
 
2-4
 
weeks
 
of
 
AP
 
administration
 
 
1.
 
May
 
be
 
asymptomatic.
 
However ,
 
immediately
 
visit
 
the
 
prescriber
 
if
 
you
 
have
 
chest
 
pain
 
or
 
discomfort.
 
2.
 
You
 
may
 
have
 
more
 
frequent
 
monitoring
 
of
 
heart
 
(ECT)
 
and
 
salt
 
levels
 
in
 
your
 
blood
 
 
Storage*
 
Store
 
at
 
a
 
temperature
 
below
 
30°C.
 
 
 
 
Others
 
Monitoring
 
Parameters
 
 
Parameter
/
 
Test
 
Suggested
 
Frequency
 
Drugs
 
with
 
precautions
 
Drugs
 
which
  
do
 
not
 
require
 
monitoring
 
Blood
 
Pressure
 
Baseline,
 
during
 
dose
 
titration
 
and
 
dose
 
changes
 
Clozapine
 
and
 
Quetiapine
 
Amisulpride,
 
Aripiprazole
 
Weight
 
(include
 
waist
 
size
 
and
 
BMI)
 
Baseline,
 
frequently
 
for
 
three
 
months
 
then
 
yearly
 
Clozapine,
 
Olanzapine
 
Aripiprazole
 
Full
 
blood
 
count
 
Baseline
 
and
 
yearly
 
Clozapine
 
None
 
Plasma
 
glucose
 
Baseline,
 
at
 
4-6
 
month,
 
then
 
yearly
 
Clozapine,
 
Olanzapine
 
All
 
patients
 
should
 
be
 
monitored.
 
Urea
 
and
 
electrolyte
s
 
including
 
creatinine
 
Baseline,
 
at
 
4-6
 
month,
 
then
 
yearly
 
Amisulpride
 
None
 
 
 
 
46
 

=== PAGE 48 ===

 
Blood
 
lipids
 
Baseline,
 
three
 
months,
 
then
 
yearly
 
Clozapine,
 
Olanzapine
 
All
 
patients
 
should
 
be
 
monitored.
 
Liver
 
Function
 
Test
 
(LFT)
 
Baseline
 
and
 
yearly
 
to
 
detect
 
chronic
 
AP
 
induced
 
changes
 
(rare)
 
Clozapine
 
Amisulpride
 
Prolactin
 
Baseline,
 
then
 
at
 
6
 
months,
 
then
 
yearly
 
Amisulpride,
 
Risperidone,
 
Paliperidone
 
Asenapine,
 
Aripiprazole,
 
Clozapine,
 
Quetiapine,
 
Olanzapine
 
(<20mg).
 
Measure
 
if
 
symptoms
 
arise.
 
Creatinine
 
phosphoki
nase
 
 
Baseline,
 
then
 
if
 
NMS
 
is
 
suspected
 
NMS
 
is
 
more
 
likely
 
with
 
FGAs
 
None
 
ECG
 
Baseline
 
None
 
Risk
 
of
 
sudden
 
cardiac
 
death
 
increased
 
with
 
most
 
APs.
 
All
 
patients
 
should
 
be
 
offered
 
an
 
ECG
 
at
 
least
 
yearly .
 
 
Before
 
ending
 
this
 
peer
 
review
 
session,
 
the
 
reviewee
 
should
 
be
 
informed
 
of
 
the
 
step(s)
 
that
 
he/
 
she
 
missed
 
out
 
in
 
order
 
to
 
ensure
 
all
 
the
 
counselling
 
points
 
are
 
being
 
covered.
 
 
Remarks:
 
 
 
 
Reviewed
 
by:
 
Name
 
&
 
Signature
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Date:
 
 
 
 
*Mandatory
 
for
 
validation
 
/
 
peer
 
review
 
 
References
 
:  
1.
 
Alomi
 
YA.
 
et
 
al
 
(2019).
 
Antipsychotic
 
medication
 
therapy
 
during
 
the
 
holy
 
month
 
of
 
Ramadan:
 
a
 
literature
 
review .
 
Pharmacology ,
 
Toxicology
 
and
 
Biomedical
 
Reports.
 
Vol
 
5,
 
Issue
 
2,
 
May-Aug,
 
2019
 
2.
 
Horowitz
 
M.A
 
et
 
al
 
(2021).
 
A
 
Method
 
for
 
Tapering
 
Antipsychotic
 
Treatment
 
That
 
May
 
Minimize
 
the
 
Risk
 
of
 
Relapse.
 
Schizophrenia
 
Bulletin
 
Vol.
 
47
 
no.
 
4
 
pp.
 
1116–1 129,
 
2021
 
47
 

=== PAGE 49 ===

 
3.
 
Formulari
 
Ubat
 
KKM.
 
(2025,
 
January
 
1).
 
Accessed
 
on
 
January
 
21,
 
2025.
 
4.
 
UpToDate,
 
Inc.
 
(2024).
 
Methylphenidate:
 
Drug
 
information
 
(Version
 
3.68.3)
 
[Mobile
 
application].
 
UpToDate,
 
Inc.
 
5.
 
Ahmad
 
S.N.A.
 
et.
 
al.
 
CPG
 
Management
 
of
 
Schizophrenia
 
(Second
 
Edition,
 
2021).
 
Accessed
 
on
 
January
 
21,
 
2025.
 
Available
 
from:
 
CPG
 
Management
 
of
 
Schizophrenia
 
(Second
 
Edition)
 
v20221219.pdf
 
6.
 
Stahl,
 
S.
 
M.
 
(2017).
 
Stahl’ s
 
Essential
 
Psychopharmacology
 
Prescriber ’s
 
Guide.
 
In
 
Australian
 
Prescriber
 
(6th
 
ed.,
 
Issue
 
1).
 
Cambridge
 
University
 
press.
 
https://doi.org/10.18773/austprescr .2016.001
 
7.
 
Krishnasamy
 
A.
 
et.
 
al.
 
Medication
 
Counseling
 
for
 
Pharmacists.
 
(First
 
Edition
 
2021).
 
Perak
 
State
 
Health
 
Department,
 
Pharmaceutical
 
Services
 
Division.
 
8.
 
Taylor ,
 
D.,
 
Barnes,
 
T.
 
R.
 
E.,
 
&
 
Young,
 
A.
 
H.
 
(2021).
 
The
 
Maudsley
 
prescribing
 
guidelines
 
in
 
psychiatry
 
(14th
 
ed.).
 
Wiley-Blackwell.
 
 
9.
 
2023
 
American
 
Geriatrics
 
Society
 
Beers
 
Criteria®
 
Update
 
Expert
 
Panel.
 
(2023).
 
American
 
Geriatrics
 
Society
 
2023
 
updated
 
AGS
 
Beers
 
Criteria®
 
for
 
potentially
 
inappropriate
 
medication
 
use
 
in
 
older
 
adults.
 
Journal
 
of
 
the
 
American
 
Geriatrics
 
Society ,
 
71(7),
 
2052-2081.
 
10.
 
O’Mahony ,
 
D.,
 
Cherubini,
 
A.,
 
Guiteras,
 
A.
 
R.,
 
Denkinger ,
 
M.,
 
Beuscart,
 
J.
 
B.,
 
Onder ,
 
G.,
 
...
 
&
 
Curtin,
 
D.
 
(2023).
 
STOPP/ST ART
 
criteria
 
for
 
potentially
 
inappropriate
 
prescribing
 
in
 
older
 
people:
 
version
 
3.
 
European
 
geriatric
 
medicine,
 
14(4),
 
625-632.
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Apixaban
 
Name
 
:
 
 
Unit
 
:
 
 
●
 
Please
 
tick
 
(
✔
)
 
Yes
 
for
 
correct
 
instruction
 
or
 
sequence.
 
Yes
 
No
 
Remarks
 
48
 

=== PAGE 50 ===

 
●
 
Please
 
tick
 
(
✔
)
 
No
 
for
 
incorrect
 
instruction
 
or
 
sequence.
 
Pharmacological
 
Group
 
Factor
 
Xa
 
inhibitors
 
 
 
 
 
Indications
 
and
 
Dosage
 
1.
 
Prophylaxis
 
of
 
venous
 
thromboembolic
 
events
 
following
 
hip
 
and
 
knee
 
replacement
 
surgery
 
Dosage:
 
2.5
 
mg
 
twice
 
daily,
 
starting
 
12-24
 
hours
 
after
 
surgery .
 
Duration
 
of
 
treatment:
 
10-14
 
days
 
(knee
 
replacement);
 
32-38
 
days
 
(hip
 
replacement)
 
2.
 
Prophylaxis
 
of
 
stroke
 
and
 
systemic
 
embolism
 
in
 
adult
 
patients
 
with
 
non-valvular
 
atrial
 
fibrillation
 
with
 
one
 
or
 
more
 
risk
 
factors,
 
such
 
as
 
prior
 
stroke
 
or
 
TIA,
 
age
 
≥75
 
years,
 
hypertension,
 
diabetes
 
mellitus,
 
symptomatic
 
heart
 
failure
 
(NYHA
 
Class
 
≥II)
 
3.
 
Dosage:
 
5
 
mg
 
twice
 
daily.
 
Dose
 
reduction
 
in
 
patients
 
with
 
at
 
least
 
2
 
of
 
the
 
following
 
criteria:
 
≥80
 
years
 
old,
 
body
 
weight
 
≤60
 
kg,
 
serum
 
creatinine
 
≥1.5
 
mg/dL
 
(133
 
micromole/L):
 
2.5
 
mg
 
twice
 
daily
 
4.
 
Deep
 
vein
 
thrombosis,
 
Pulmonary
 
embolism
 
5.
 
Dosage:
 
Treatment
 
:10
 
mg
 
bid
 
for
 
7
 
days
 
followed
 
by
 
5
 
mg
 
bid.
 
Prophylaxis
 
of
 
recurrent
 
cases:
 
2.5
 
mg
 
bid
 
following
 
completion
 
of
 
≥6
 
months
 
of
 
anticoagulant
 
treatment
 
 
 
 
Method
 
of
 
Administration*
 
1.
 
May
 
be
 
taken
 
with
 
or
 
without
 
food.
 
2.
 
May
 
be
 
crushed
 
&
 
suspended
 
in
 
water/D5W/apple
 
juice
 
or
 
mixed
 
with
 
apple
 
puree.
 
Take
 
the
 
mixture
 
immediately
 
or
 
within
 
4
 
hours.
 
 
Missed
 
dose
 
management:
 
Take
 
the
 
missed
 
dose
 
as
 
soon
 
as
 
remembered.
 
If
 
it
 
is
 
close
 
to
 
the
 
time
 
for
 
the
 
next
 
dose,
 
skip
 
and
 
go
 
back
 
to
 
normal
 
time.
 
Do
 
not
 
take
 
2
 
doses
 
at
 
the
 
same
 
time
 
 
 
 
Special
 
Considerations
 
Pregnancy
 
 
 
 
Preferable
 
to
 
avoid
 
the
 
use
 
of
 
apixaban
 
during
 
pregnancy
 
 
 
 
Breastfeeding
 
 
 
 
It
 
is
 
unknown
 
whether
 
apixaban
 
or
 
its
 
metabolites
 
are
 
excreted
 
in
 
human
 
milk.
 
Available
 
data
 
in
 
animals
 
have
 
shown
 
excretion
 
of
 
apixaban
 
in
 
milk.
 
A
 
decision
 
must
 
be
 
made
 
whether
 
to
 
discontinue
 
breast-feeding
 
or
 
to
 
discontinue/abstain
 
from
 
apixaban
 
therapy
 
taking
 
into
 
account
 
the
 
benefit
 
of
 
breast-feeding
 
for
 
the
 
child
 
and
 
the
 
benefit
 
of
 
therapy
 
for
 
the
 
woman.
 
 
 
 
Paediatric
 
 
 
 
Not
 
recommended
 
in
 
children
 
and
 
adolescents
 
under
 
18
 
years
 
of
 
age.
 
 
 
 
Elderly
 
 
 
 
MALPIP:
 
Increased
 
risk
 
of
 
gastrointestinal
 
bleeding.
 
Increased
 
serum
 
concentrations
 
may
 
occur
 
with
 
renal
 
impairment
 
and
 
dose
 
adjustment
 
may
 
be
 
indicated.
 
Assess
 
renal
 
profile
 
before
 
initiation.
 
 
 
 
Others
  
 
 
 
 
49
 

=== PAGE 51 ===

 
1.
 
Hepatic
 
Impairment:
 
Severe
 
(Child-Pugh
 
class
 
C):
 
Not
 
recommended.
 
2.
 
Renal
 
impairment:
 
Patients
 
undergoing
 
dialysis:
 
Not
 
recommended.
 
 
 
 
Side
  
Effects
 
and
 
their
 
Management*
 
1.
 
Blood
 
and
 
lymphatic
 
system
 
disorders:
 
Anaemia,
 
thrombocytopenia.
 
 
2.
 
Haemorrhagic
 
risk.
 
Apixaban
 
should
 
be
 
discontinued
 
if
 
severe
 
haemorrhage
 
occurs.
 
 
 
 
Storage*
 
Store
 
between
 
15-30°C.
 
 
 
 
Others
 
1.
 
Monitoring
 
Parameters:
 
Monitor
 
CBC,
 
aPTT ,
 
prothrombin
 
time,
 
serum
 
creatinine,
 
and
 
liver
 
function
 
prior
 
to
 
initiation,
 
when
 
clinically
 
indicated,
 
and
 
at
 
least
 
annually
 
thereafter .
 
Observe
 
closely
 
for
 
signs
 
and
 
symptoms
 
of
 
blood
 
loss.
 
2.
 
Interactions
 
below
 
lead
 
to
 
an
 
increased
 
bleeding
 
risk-
 
patients
 
should
 
be
 
monitored
 
closely
 
for
 
signs
 
of
 
bleeding
 
and
 
anaemia.
  
 
a.
 
Concomitant
 
use
 
of
 
systemic
 
azole
 
antimycotics
 
e.g.
 
ketoconazole,
 
itraconazole,
 
voriconazole,
 
posaconazole
 
 
b.
 
HIV
 
protease
 
inhibitors
 
 
c.
 
Other
 
anticoagulants
  
 
d.
 
NSAIDs
 
and
 
platelet
 
aggregation
 
inhibitors(e.g.
 
clopidogrel)
 
 
3.
 
Interactions
 
below
 
lead
 
to
 
a
 
decrease
 
in
 
anticoagulant
 
concentration
 
therefore
 
treatment
 
may
 
be
 
suboptimal
 
a.
 
Concomitant
 
use
 
strong
 
CYP3A4
 
inducers
 
e.g.
 
phenytoin,
 
carbamazepine,
 
phenobarbital,
 
St.
 
John’ s
 
Wort
 
4.
 
Decreased
 
plasma
 
concentration
 
with
 
St.
 
John's
 
wort.
 
 
 
 
Before
 
ending
 
this
 
peer
 
review
 
session,
 
the
 
reviewee
 
should
 
be
 
informed
 
of
 
the
 
step(s)
 
that
 
he/
 
she
 
missed
 
out
 
in
 
order
 
to
 
ensure
 
all
 
the
 
counselling
 
points
 
are
 
being
 
covered.
 
 
Remarks:
 
 
 
Reviewed
 
by:
 
Name
 
&
 
Signature
                                                                   
Date:
 
 
*Mandatory
 
for
 
validation/peer
 
review
 
 
References:
 
1.
 
MIMS
 
Malaysia.
 
(2024).
 
Apixaban.
 
In
 
MIMS
 
Online.
 
Retrieved
 
26
 
November ,
 
2024,
 
from
 
https://www .mims.com/malaysia/drug/info/apixaban?mtype=generic
 
2.
 
MIMS
 
Malaysia.
 
(2024).
 
Eliquis.
 
In
 
MIMS
 
Online.
 
Retrieved
 
26
 
November ,
 
2024,
 
from
 
https://www .mims.com/malaysia/drug/info/eliqu
is
 
3.
 
Formulari
 
Ubat
 
KKM
 
(FUKKM)
 
-
 
Apixaban
 
4.
 
Chang,
 
C.
 
T.,
 
Chan,
 
H.
 
K.,
 
Cheah,
 
W.
 
K.,
 
Tan,
 
M.
 
P.,
 
Ch’ng,
 
A.
 
S.
 
H.,
 
Thiam,
 
C.
 
N.,
 
...
 
&
 
Lee,
 
S.
 
W.
 
H.
 
(2023).
 
Development
 
of
 
a
 
Malaysian
 
potentially
 
inappropriate
 
prescribing
 
screening
 
tool
 
in
 
older
 
adults
 
(MALPIP):
 
a
 
Delphi
 
study .
 
Journal
 
of
 
Pharmaceutical
 
Policy
 
and
 
Practice,
 
16(1),
 
122.
 
Atazanavir
 
 
Name
 
:
 
 
Unit
 
:
 
 
50
 

=== PAGE 52 ===

 
●
 
Please
 
tick
 
(
✔
)
 
Yes
 
for
 
correct
 
instruction.
 
●
 
Please
 
tick
 
(
✔
)
 
No
 
for
 
incorrect
 
instruction.
 
Yes
 
No
 
Remarks
 
Pharmacological
 
Group
 
Protease
 
inhibitors
 
(PIs)
 
 
 
 
Indications
 
and
 
Dosage
 
Treatment
 
of
 
HIV-1
 
infected,
 
antiretroviral
 
treatment
 
experienced
 
adults,
 
in
 
combination
 
with
 
other
 
antiretroviral
 
medicinal
 
products
 
a.
 
The
 
recommended
 
dose
 
is
 
300
 
mg
 
once
 
daily
 
taken
 
with
 
ritonavir
 
100
 
mg
 
once
 
daily
 
and
 
with
 
food.
 
Ritonavir
 
is
 
used
 
as
 
a
 
booster
 
of
 
atazanavir
 
pharmacokinetics.
 
 
Atazanavir
 
is
 
not
 
approved
 
for
 
use
 
in
 
neonates
 
and
 
infants
 
aged
 
<3
 
months.
 
Atazanavir
 
should
 
not
 
be
 
administered
 
to
 
neonates
 
because
 
of
 
risks
 
associated
 
with
 
hyperbilirubinemia.
 
Because
 
Ritonavir
 
oral
 
solution
 
is
 
no
 
longer
 
commercially
 
available,
 
use
 
of
 
Atazanavir/Ritonavir
 
is
 
limited
 
to
 
children
 
weighing
 
≥15
 
kg
 
who
 
can
 
use
 
the
 
Ritonavir
 
100
 
mg
 
powder
 
packet
 
or
 
100
 
mg
 
tablet.
 
a.
 
15
 
kg
 
to
 
<35
 
kg
 
-
 
ATV/r
 
200
 
mg/100
 
mg,
 
both
 
with
 
food
 
b.
 
≥35
 
kg
 
-
 
ATV/r
 
300
 
mg/100
 
mg,
 
both
 
with
 
food
 
 
 
 
Method
 
of
 
Administration*
 
Atazanavir
 
should
 
be
 
taken
 
with
 
food,
 
the
 
capsule
 
should
 
be
 
swallowed
 
whole
 
with
 
a
 
drink
 
such
 
as
 
a
 
glass
 
of
 
water
 
or
 
fruit
 
juice.
 
 
It
 
is
 
recommended
 
that
 
you
 
take
 
your
 
medicine
 
at
 
about
 
the
 
same
 
time
 
each
 
day.
 
Taking
 
it
 
at
 
the
 
same
 
time
 
each
 
day
 
will
 
have
 
the
 
best
 
effect.
 
It
 
will
 
also
 
help
 
you
 
remember
 
when
 
to
 
take
 
it.
 
 
Missed
 
dose
 
management:
 
If
 
you
 
forget
 
to
 
take
 
it,
 
and
 
if
 
it
 
is
 
almost
 
time
 
for
 
your
 
next
 
dose,
 
skip
 
the
 
dose
 
you
 
missed
 
and
 
take
 
the
 
next
 
dose
 
when
 
you
 
are
 
meant
 
to
 
take
 
it.
 
Otherwise,
 
take
 
it
 
as
 
soon
 
as
 
you
 
remember ,
 
and
 
then
 
go
 
back
 
to
 
take
 
your
 
medicine
 
as
 
you
 
would
 
normally .
 
 
Do
 
not
 
stop
 
taking
 
your
 
medication
 
unless
 
advised
 
to
 
do
 
so
 
by
 
your
 
prescriber
 
 
 
 
Special
 
Considerations
 
Pregnancy
 
 
 
 
1.
 
Unboosted
 
Atazanavir
 
is
 
not
 
recommended
 
during
 
pregnancy .
 
Ritonavir-boosted
 
Atazanavir
 
(ATV/r)
 
is
 
an
 
alternative
 
protease
 
inhibitor
 
for
 
pregnant
 
patients
 
with
 
HIV
 
who
 
are
 
antiretroviral-naive
 
(initial
 
therapy),
 
who
 
have
 
had
 
ART
 
therapy
 
in
 
the
 
past
 
but
 
are
 
restarting,
 
or
 
who
 
require
 
a
 
new
 
ART
 
regimen
 
(due
 
to
 
poor
 
tolerance
 
or
 
poor
 
virologic
 
response
 
of
 
current
 
regimen).
 
Patients
 
who
 
become
 
pregnant
 
while
 
taking
 
Atazanavir
 
boosted
 
with
 
Ritonavir
 
may
 
continue
 
if
 
viral
 
suppression
 
is
 
effective
 
and
 
the
 
regimen
 
is
 
well
 
tolerated.
 
 
 
 
Breastfeeding
 
 
 
 
1.
 
It
 
is
 
not
 
known
 
whether
 
Atazanavir
 
passes
 
into
 
breast
 
milk.
 
Therefore,
 
to
 
avoid
 
possible
 
side
 
effects
 
in
 
the
 
nursing
 
infant,
 
mothers
 
should
 
stop
 
breastfeeding
 
if
 
they
 
are
 
taking
 
Atazanavir .
 
2.
 
It
 
is
 
recommended
 
that
 
HIV
 
infected
 
women
 
do
 
not
 
breastfeed
 
their
 
infants
 
under
 
any
 
circumstances
 
to
 
 
 
 
51
 

=== PAGE 53 ===

 
avoid
 
transmission
 
to
 
the
 
infant
.
 
Elderly
 
 
 
 
A
 
dose
 
adjustment
 
for
 
age
 
is
 
not
 
recommended.
 
 
 
 
Paediatric
 
 
 
 
Do
 
not
 
use
 
it
 
in
 
children
 
below
 
three
 
months
 
of
 
age
 
due
 
to
 
potential
 
for
 
kernicterus.
 
 
 
 
Fasting
 
 
 
 
To
 
refer
 
to
 
the
 
latest
 
advisory
 
by
 
religious
 
authority
 
 
 
 
Renal
 
impairment
 
 
 
 
No
 
dosage
 
adjustment
 
is
 
needed.
 
However ,
 
Atazanavir
 
with
 
Ritonavir
 
is
 
not
  
recommended
 
in
 
treatment-experienced
 
patients
 
undergoing
 
hemodialysis.
 
 
 
 
Hepatic
 
impairment
 
 
 
 
No
 
dose
 
adjustment
 
in
 
patients
 
with
 
mild
 
impairment
 
(Child-Pugh
 
Class
 
A).
 
Otherwise;
 
 
Moderate
 
(Child-Pugh
 
Class
 
B):
 
300mg
 
once
 
daily
 
(unboosted)
 
for
 
ARV-naive
 
patients
 
only.
 
Severe
 
(Child-Pugh
 
Class
 
C):
 
Not
 
recommended
 
 
 
 
Side
 
Effects
 
and
 
their
 
Management*
 
1.
 
Rashes:
 
usually
 
mild
 
to
 
moderate
 
skin
 
eruptions
 
that
 
occur
 
within
 
3
 
weeks
 
of
 
starting
 
Atazanavir .
 
Patients
 
should
 
be
 
advised
 
of
 
signs
 
and
 
symptoms
 
and
 
monitored
 
closely
 
for
 
skin
 
reactions.
 
Atazanavir
 
should
 
be
 
discontinued
 
if
 
severe
 
rashes
 
develop.
 
2.
 
Hyperbilirubinemia:
 
Most
 
patients
 
experience
 
asymptomatic
 
increases
 
in
 
indirect
 
bilirubin,
 
which
 
is
 
reversible
 
upon
 
discontinuation;
 
do
 
not
 
reduce;
 
if
 
concomitant
 
transaminase
 
increase
 
occurs,
 
evaluate
 
for
 
alternative
 
etiologies.
 
3.
 
Fat
 
redistribution:
 
Central
 
obesity ,
 
buffalo
 
hump,
 
peripheral
 
wasting,
 
facial
 
wasting,
 
breast
 
enlargement,
 
and
 
“cushingoid
 
appearance”.
 
Clinical
 
examination
 
should
 
include
 
evaluation
 
for
 
physical
 
signs
 
of
 
fat
 
redistribution.
 
4.
 
Metabolic
 
disorders:
 
Dyslipidemia,
 
new
 
onset
 
diabetes
 
mellitus,
 
hyperglycemia,
 
and
 
exacerbation
 
of
 
existing
 
diabetes
 
mellitus.
 
Standard
 
guidelines
 
for
 
management
 
of
 
dyslipidemia
 
and
 
diabetes
 
mellitus.
 
 
 
 
Storage*
 
1.
 
Store
 
below
 
25°C.
 
 
 
 
Others
 
Beware
 
of
 
Atazanavir/ritonavir-drug
 
interactions.
 
Kindly
 
refer
 
to
 
Liverpool
 
HIV
 
Interactions
 
website
 
for
 
further
 
information.
 
 
1.
 
Atazanavir/Ritonavir
 
is
 
an
 
inhibitor
 
of
 
the
 
P450
 
isoform
 
CYP3A.
 
Co-administration
 
of
 
Atazanavir/Ritonavir
 
and
 
drugs
 
primarily
 
metabolised
 
by
 
CYP3A
  
may
 
result
 
in
 
increased
 
plasma
 
concentrations
 
of
 
the
 
other
 
drugs
 
(e.g.
 
HMG
 
CoA
 
reductase,
 
dihydropyridine
 
calcium
 
channel
 
blockers,
 
immunosuppressant
 
etc).
 
2.
 
Overdoses
 
with
 
Atazanavir/Ritonavir
 
have
 
been
 
reported
 
in
 
association
 
with
 
jaundice
 
due
 
to
 
indirect
 
(unconjugated)
 
hyperbilirubinemia
 
or
 
PR
 
interval
 
prolongations.
 
Treatment
 
of
 
overdose
 
should
 
consist
 
of
 
general
 
supportive
 
measures
 
including
 
monitoring
 
of
 
 
 
 
52
 

=== PAGE 54 ===

 
vital
 
signs
 
and
 
ECG,
 
and
 
observations
 
of
 
the
 
clinical
 
status
 
of
 
patients.
 
Before
 
ending
 
this
 
peer
 
review
 
session,
 
the
 
reviewee
 
should
 
be
 
informed
 
of
 
the
 
step(s)
 
that
 
he/
 
she
 
missed
 
out
 
in
 
order
 
to
 
ensure
 
all
 
the
 
counselling
 
points
 
are
 
being
 
covered.
 
 
Remarks:
 
 
 
 
 
Reviewed
 
by:
 
Name
 
&
 
Signature
                                                                   
Date:
 
 
 
 
 
*Mandatory
 
for
 
validation/peer
 
review
 
 
References:
 
 
1.
 
Ministry
 
of
 
Health
 
Malaysia
 
(2022).
 
Malaysian
 
Consensus
 
Guidelines
 
on
 
Antiretroviral
 
Therapy .
 
2.
 
Atazar-300
 
Product
 
leaflet
 
(2020).
 
3.
 
Atazanavir
 
Mylan
 
Consumer
 
Medicine
 
Information,
 
2019.
 
4.
 
Wolter
 
Kluwer
 
(2024).
 
UpToDate
 
-
 
Atazanavir/Ritonavir .
 
UpToDate,Inc.
 
5.
 
Guidelines
 
for
 
the
 
Use
 
of
 
Antiretroviral
 
Agents
 
in
 
Pediatric
 
HIV
 
Infection.
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
53
 

=== PAGE 55 ===

 
Azelaic
 
Acid,
 
Topical
 
Name
 
:
 
 
Unit
 
:
 
 
●
 
Please
 
tick
 
(
✔
)
 
Yes
 
for
 
correct
 
instruction.
 
●
 
Please
 
tick
 
(
✔
)
 
No
 
for
 
incorrect
 
instruction.
 
Yes
 
No
 
Remarks
 
Pharmacological
 
Group
 
1.
 
Anti
 
microbial
 
 
Inhibits
 
the
 
growth
 
of
 
susceptible
 
organisms
 
(Propionibacterium
 
acnes)
 
on
 
the
 
skin
 
surface
 
and
 
inhibits
 
follicular
 
keratinisation.
 
This
 
restricts
 
the
 
development
 
of
 
comedone.
 
 
 
 
Indications
 
and
 
Dosage
 
1.
 
Treatment
 
of
 
Acne
 
Vulgaris
 
 
Apply
 
twice
 
daily
 
(for
 
sensitive
 
skin,
 
once
 
daily
 
during
 
the
 
1st
 
week)
.
 
Treatment
 
should
 
not
 
exceed
 
6
 
months.
 
(12
 
months
 
based
 
on
 
product
 
insert)
 
 
 
 
Method
 
of
 
Administration*
 
1.
 
Wash
 
face
 
with
 
a
 
gentle,
 
non-medicated
 
cleanser
 
and
 
allow
 
the
 
face
 
to
 
dry
 
thoroughly .
 
 
2.
 
Put
 
a
 
thin
 
layer
 
to
 
the
 
affected
 
skin
 
and
 
rub
 
in
 
gently ,
 
twice
 
daily
 
(morning
 
and
 
evening).
 
 
3.
 
Avoid
 
application
 
to
 
eyelids,
 
lips
 
and
 
mucous
 
membranes.
 
4.
 
A
 
daily
 
dose
 
of
 
approximately
 
2.5cm/1
 
inch
 
of
 
cream
 
is
 
sufficient
 
for
 
the
 
entire
 
facial
 
area.
 
Excessive
 
amounts
 
must
 
be
 
avoided.
 
 
Do
 
not
 
stop
 
taking
 
your
 
medication
 
unless
 
advised
 
to
 
do
 
so
 
by
 
your
 
prescriber
 
 
 
 
Special
 
Considerations
 
Pregnancy
 
 
 
 
Use
 
is
 
not
 
recommended
 
during
 
pregnancy
 
unless
 
the
 
benefit
 
outweighs
 
the
 
risk.
 
 
 
 
Breastfeeding
 
 
 
 
Use
 
is
 
not
 
recommended
 
during
 
breastfeeding
 
unless
 
the
 
benefit
 
outweighs
 
the
 
risk.
 
 
 
 
Elderly
 
 
 
 
No
 
elderly-specific
 
problems
 
have
 
been
 
documented
 
to
 
date.
 
Refer
 
to
 
the
 
usual
 
adult
 
dosage
 
guide.
 
 
 
 
Paediatric
 
 
 
 
The
 
safety
 
and
 
efficacy
 
of
 
topical
 
Azelaic
 
acid
 
in
 
paediatric
 
patients
 
below
 
12
 
years
 
old
 
have
 
not
 
been
 
established.
 
 
 
 
 
Fasting
 
 
 
 
To
 
refer
 
to
 
the
 
latest
 
advisory
 
by
 
religious
 
authority
 
 
 
 
 
Side
 
Effects
 
and
 
their
 
Management*
 
1.
 
Local
 
skin
 
irritation
 
(erythema,
 
scaling,
 
burning,
 
itching)
 
2.
 
Photosensitivity
 
 
 
If
 
excessive
 
skin
 
irritation
 
occurs,
 
consider
 
the
 
following
 
until
 
the
 
 
 
 
54
 

=== PAGE 56 ===

 
irritation
 
ceases:
 
i)
 
reduce
 
the
 
frequency
 
of
 
application
 
to
 
once
 
daily
 
or
 
ii)
 
reduce
 
the
 
amount
 
of
 
cream,
 
 
or
  
 
iii)
 
temporarily
 
withhold
 
the
 
treatment
 
for
 
a
 
few
 
days.
 
Use
 
a
 
gentle
 
moisturizer
 
to
 
reduce
 
dryness.
 
Storage*
 
1.
 
Keep
 
the
 
container
 
tightly
 
closed.
 
2.
 
Store
 
at
 
room
 
temperature.
 
3.
 
Protect
 
from
 
light,
 
heat
 
and
 
moisture.
 
4.
 
Keep
 
medicine
 
out
 
of
 
reach
 
of
 
children.
 
 
 
 
Others
 
1.
 
Prolonged
 
and
 
repeated
 
administration
 
may
 
lead
 
to
 
hypersensitivity .
 
Excessive
 
use
 
should
 
be
 
avoided.
 
 
2.
 
If
 
severe
 
irritation
 
or
 
allergic
 
reactions
 
occur ,
 
discontinue
 
use
 
and
 
consult
 
a
 
healthcare
 
provider .
 
3.
 
Avoid
 
contact
 
with
 
eyes,
 
mouth
 
and
 
other
 
mucous
 
surfaces.
 
4.
 
Avoid
 
occlusive
 
dressings/wrappings.
 
5.
 
For
 
external
 
use
 
only.
 
6.
 
Dispose
 
of
 
any
 
remaining
 
product
 
in
 
the
 
tube
 
after
 
completing
 
your
 
course
 
of
 
treatment
 
or
 
once
 
the
 
product
 
has
 
expired.
 
 
 
 
Before
 
ending
 
this
 
peer
 
review
 
session,
 
the
 
reviewee
 
should
 
be
 
informed
 
of
 
the
 
step(s)
 
that
 
he/
 
she
 
missed
 
out
 
in
 
order
 
to
 
ensure
 
all
 
the
 
counselling
 
points
 
are
 
being
 
covered.
 
 
Remarks:
 
 
 
 
 
Reviewed
 
by:
 
Name
 
&
 
Signature
                                                                   
Date:
 
 
 
 
 
 
*Mandatory
 
for
 
validation/peer
 
review
 
 
References:
 
 
1.
 
Product
 
leaflet
 
Skinoren
 
2.
 
Formulari
 
Ubat
 
Kementerian
 
Kesihatan
 
Malaysia
 
Bil
 
2/2024.
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
55
 

=== PAGE 57 ===

 
Benzodiazepines
 
Name
 
:
 
 
Unit
 
:
 
 
●
 
Please
 
tick
 
(
✔
)
 
Yes
 
for
 
correct
 
instruction.
 
●
 
Please
 
tick
 
(
✔
)
 
No
 
for
 
incorrect
 
instruction.
 
Yes
 
No
 
Remarks
 
Pharmacological
 
Group
 
Benzodiazepines
 
Diazepam
  
 
Lorazepam
 
 
 
 
 
 
 
 
Bromazepam
 
 
 
Alprazolam
 
 
 
 
Clonazepam
 
 
Midazolam
 
 
 
 
 
Indications
 
and
 
Dosage
 
1.
 
Diazepam:
 
 
Anxiety
 
disorder:
 
Oral:
 
2
 
mg
 
3
 
times
 
daily,
 
increased
 
in
 
severe
 
anxiety
 
to
 
15
 
-
 
30
 
mg
 
daily
 
in
 
divided
 
doses
 
2.
 
Lorazepam:
 
 
Severe
 
anxiety:
 
1-10mg
 
daily
 
in
 
divided
 
doses
 
Insomnia:
 
1-2mg
 
on
 
night
 
3.
 
Bromazepam:
 
 
Anxiety
 
disorder:
 
6-18mg
 
daily
 
initially
 
in
 
divided
 
doses.
 
(max
 
dose:
 
60mg)
 
4.
 
Alprazolam:
 
 
Anxiety
 
disorder:
 
0.25mg-0.5mg
 
3
 
times
 
daily.
 
(max:
 
3mg/day)
 
5.
 
Clonazepam:
 
 
Anxiety:
 
0.5
 
mg/day
 
to
 
4
 
mg/day
 
in
 
2
 
to
 
4
 
divided
 
doses
 
(max
 
of
 
8
 
mg/day)
 
6.
 
Midazolam:
 
 
Insomnia:
 
Oral:
 
7.5mg
 
-
 
15mg/day
 
 
Benzodiazepines
 
are
 
usually
 
used
 
as
 
an
 
adjunct
 
therapy
 
in
 
psychiatric
 
disorders
 
such
 
as
 
mood
 
disorder
 
(e.g.
 
anxiety
 
disorder
 
&
 
major
 
depressive
 
disorder),
 
schizophrenia
  
and
 
sleep
 
disorders.
 
 
Benzodiazepines
 
are
 
usually
 
used
 
as
 
short
 
term
 
therapy
 
of
 
no
 
more
 
than
 
2
 
to
 
4
 
weeks
 
together
 
with
 
first
 
line
 
medications.
 
 
Or
 
 
 
To
 
counsel
 
based
 
on
 
specific
 
medication’ s
 
indication
 
and
 
dosage
 
as
 
prescribed
 
by
 
the
 
doctor
 
 
 
 
Method
 
of
 
Administration*
 
1.
 
Tablets
 
should
 
be
 
swallowed
 
whole
 
or
 
crushed.
 
2.
 
Benzodiazepines
 
provide
 
symptomatic
 
relief
 
but
 
do
 
not
 
treat
 
the
 
underlying
 
psychological
 
problem,
 
duration
 
of
 
the
 
therapy
 
is
 
usually
 
short
 
term
 
or
 
take
 
it
 
only
 
when
 
necessary .
 
3.
 
Tolerance
 
and
 
dependence
 
may
 
occur
 
after
 
prolonged
 
use.Use
 
ONLY
 
as
 
instructed,
 
DO
 
NOT
 
take
 
more
 
than
 
prescribed.
 
Inform
 
your
 
prescriber
 
if
 
your
 
usage
 
increases.
 
 
Do
 
not
 
stop
 
taking
 
your
 
medication
 
unless
 
advised
 
to
 
do
 
so
 
by
 
your
 
prescriber .
 
 
 
 
Special
 
Considerations
 
Pregnancy
 
 
 
 
1.
 
Possible
 
increased
 
risk
 
of
 
birth
 
defects
 
with
 
 
 
 
56
 

=== PAGE 58 ===

 
benzodiazepines
 
taken
 
during
 
pregnancy .
 
Not
 
recommended
 
during
 
pregnancy
 
especially
 
during
 
the
 
1st
 
trimester .
 
 
2.
 
The
 
drug
 
should
 
be
 
tapered
 
if
 
discontinued.
 
Infants
 
whose
 
mothers
 
received
 
a
 
benzodiazepine
 
late
 
in
 
pregnancy
 
may
 
experience
 
withdrawal
 
symptoms.
 
Neonatal
 
flaccidity
 
has
 
been
 
reported
 
in
 
infants
 
whose
 
mothers
 
took
 
a
 
benzodiazepine
 
during
 
pregnancy .
 
Seizures,
 
even
 
mild
 
ones,
 
may
 
cause
 
harm
 
to
 
the
 
embryo/foetus.
 
Breastfeeding
 
 
 
 
Not
 
recommended
 
 
 
 
Elderly
 
 
 
 
Beers
 
Criteria:
 
 
1.
 
Avoid
 
use
 
of
 
benzodiazepines;
 
expose
 
users
 
to
 
risks
 
of
 
abuse,
 
misuse,
 
and
 
addiction.
 
Concomitant
 
use
 
with
 
opioids
 
may
 
result
 
in
 
profound
 
sedation,
 
respiratory
 
depression,
 
coma,
 
and
 
death.
 
Older
 
adults
 
have
 
increased
 
sensitivity
 
to
 
benzodiazepines
 
and
 
decreased
 
metabolism
 
of
 
long-acting
 
agents;
 
the
 
continued
 
use
 
of
 
benzodiazepines
 
may
 
lead
 
to
 
clinically
 
significant
 
physical
 
dependence.
 
2.
 
In
 
general,
 
all
 
benzodiazepines
 
increase
 
risk
 
of
 
cognitive
 
impairment,
 
delirium,
 
falls,
 
fractures,
 
and
 
motor
 
vehicle
 
crashes
 
in
 
older
 
adults.
 
May
 
be
 
appropriate
 
for
 
seizure
 
disorders,
 
rapid
 
eye
 
movement
 
sleep
 
behavior
 
disorder ,
 
benzodiazepine
 
withdrawal,
 
ethanol
 
withdrawal,
 
severe
 
generalized
 
anxiety
 
disorder ,
 
and
 
periprocedural
 
anesthesia.
 
 
STOPP/Start
 
Criteria:
 
 
1)
 
Use
 
as
 
short
 
a
 
term
 
as
 
possible
 
(not
 
exceeding
 
4
 
weeks).
 
2)
 
Use
 
for
 
agitated
 
behaviour
 
or
 
psychotic
 
symptoms
 
of
 
dementia
 
(no
 
evidence
 
of
 
efficacy).
 
3)
 
Use
 
for
 
insomnia
 
for
 
≥
 
2
 
weeks
 
(high
 
risk
 
of
 
dependency ,
 
increased
 
risk
 
of
 
falls,
 
fractures
 
and
 
road
 
traffic
 
accidents).
 
 
 
 
Paediatric
 
 
 
 
1.
 
Safety
 
and
 
efficacy
 
of
 
Benzodiazepines
 
remain
 
unapproved
 
for
 
pediatric
 
use
 
outside
 
of
 
epilepsy
 
and
 
seizures
.
 
Use
 
with
 
caution.
 
 
 
 
Fasting
 
 
 
 
1.
 
Administer
 
during
 
Sahur
 
or
 
after
 
Iftar.
 
 
Kindly
 
refer
 
to
 
the
 
latest
 
advisory
 
by
 
religious
 
authority
 
 
 
 
Renal
 
Impairment
 
 
 
 
1.
 
No
 
agent
 
clearly
 
preferred
 
to
 
another;
 
however ,
 
excessive
 
sedation
 
is
 
more
 
likely
 
to
 
occur
 
in
 
patients
 
with
 
renal
 
impairment.
 
Advise
 
patients
 
to
 
monitor
 
for
 
signs
 
&
 
symptoms
 
of
 
toxicity .
 
 
 
 
Hepatic
 
Impairment
 
 
 
 
 
57
 

=== PAGE 59 ===

 
1.
 
Prolonged
 
duration
 
of
 
effect
 
particularly
 
for
 
drugs
 
with
 
active
 
metabolites
 
(diazepam,
 
midazolam,
 
clonazepam).
 
Lorazepam
 
does
 
not
 
have
 
active
 
metabolites
 
and
 
are
 
preferred.
 
Use
 
low
 
doses
 
with
 
caution,
 
as
 
sedative
 
drugs
 
used
 
in
 
severe
 
disease
 
can
 
precipitate
 
hepatic
 
encephalopathy
 
.
 
 
 
Side
 
Effects
 
and
 
their
 
Management*
 
 
Side
 
effects
 
Management
 
Common
 
Being
 
very
 
unsteady
 
on
 
your
 
feet.
 
Inform
 
your
 
prescriber
 
at
 
next
 
visit
 
Feeling
 
light
 
headed,
 
faint
 
or
 
as
 
if
 
head
 
is
 
spinning.
 
 
Stand
 
up
 
slower .
 
Try
 
to
 
sit
 
or
 
lie
 
down
 
when
 
symptoms
 
occur ..
 
Do
 
not
 
drive.
 
Feeling
 
sleepy
 
or
 
sluggish.
 
Possible
 
to
 
lead
 
to
 
falls.
 
“Hangover”
 
the
 
next
 
morning.
 
 
Do
 
not
 
drive
 
or
 
operate
 
heavy
 
machinery .
 
Ask
 
your
 
prescriber
 
if
 
adjustments
 
in
 
medication,
 
dose
 
or
 
timing
 
is
 
required
 
Rare
 
You
 
may
 
feel
 
like
 
fainting
 
when
 
standing
 
up.
 
A
 
low
 
blood
 
pressure.
 
Rise
 
slowly
 
when
 
getting
 
up
 
or
 
from
 
lying
 
down.
 
Do
 
not
 
drive
 
if
 
you
 
feel
 
dizzy .
 
Loss
 
of
 
memory
 
or
 
difficulty
 
in
 
remembering.
 
 
Inform
 
your
 
prescriber
 
at
 
next
 
visit
 
Headaches
 
May
 
take
 
analgesics.
 
Inform
 
your
 
prescriber
 
if
  
too
 
frequent.
 
Rare
 
-
 
significant
 
concern
 
You
 
may
 
be
 
too
 
talkative,
 
excited
 
or
 
unfriendly .
 
Immediately
 
contact
 
your
 
prescriber .
 
Change
 
in
 
mediation
 
will
 
likely
 
be
 
required
 
Confusion,
 
disorientated
 
Inform
 
your
 
prescriber
 
at
 
next
 
visit
 
Rashes,
 
skin
 
redness,
 
trouble
 
breathing
 
Stop
 
taking
 
and
 
immediately
 
see
 
your
 
prescriber
 
 
 
 
 
Storage*
 
Store
 
at
 
a
 
temperature
 
below
 
30°C.
 
 
 
 
Others
 
1.
 
Do
 
not
 
combine
 
with
 
alcohol
 
or
 
other
 
CNS
 
depressants
 
because
 
it
 
can
 
intensify
 
side
 
effects.
 
2.
 
Educate
 
patients
 
with
 
sleep
 
problems
 
on
 
sleep
 
hygiene.
 
3.
 
You
 
may
 
experience
 
these
 
effects
 
upon
 
stopping
 
the
 
medication:
 
Common
 
symptoms:
 
anxiety ,
 
insomnia,
 
restlessness,muscle
 
tension,
 
irritability .
 
Immediately
 
contact
 
your
 
prescriber
 
if
 
intolerable.
 
 
 
 
58
 

=== PAGE 60 ===

 
Before
 
ending
 
this
 
peer
 
review
 
session,
 
the
 
reviewee
 
should
 
be
 
informed
 
of
 
the
 
step(s)
 
that
 
he/
 
she
 
missed
 
out
 
in
 
order
 
to
 
ensure
 
all
 
the
 
counselling
 
points
 
are
 
being
 
covered.
 
 
Remarks:
 
 
 
 
 
Reviewed
 
by:
 
Name
 
&
 
Signature
                                                                   
Date:
 
 
 
 
 
*Mandatory
 
for
 
validation
 
/
 
peer
 
review
 
 
References
 
:
 
 
 
1.
 
UpToDate,
 
Inc.
 
(2025).
 
Clonazepam,
 
Lorazepam,
 
Alprazolam,
 
Diazepam:
 
Drug
 
information
 
(Version
 
3.68.3)
 
[Mobile
 
application].
 
UpToDate,
 
Inc.
 
2.
 
CHEPLAPHARM
 
Arzneimittel
 
GmbH
 
(2020
).
 
Product
 
Information
 
Leaflet:
 
Dormicum.
 
Retrieved
 
from
 
Quest
 
3+
 
Search
 
on
 
January
 
21,
 
2025
 
3.
 
Pharmaceutical
 
Services
 
Programme,
 
Ministry
 
of
 
Health
 
Malaysia.
 
(2025).
 
Formulari
 
Ubat
 
KKM
 
(FUKKM).
 
Retrieved
 
from
 
https://pharmacy .moh.gov .my/ms/apps/fukkm
 
4.
 
Stahl,
 
S.
 
M.
 
(2017).
 
Stahl’ s
 
Essential
 
Psychopharmacology
 
Prescriber ’s
 
Guide.
 
In
 
Australian
 
Prescriber
 
(6th
 
ed.,
 
Issue
 
1).
 
Cambridge
 
University
 
Press.
 
https://doi.org/10.18773/austprescr .2016.001
 
5.
 
Krishnasamy
 
A.
 
et.
 
al.
 
Medication
 
Counseling
 
for
 
Pharmacists.
 
(First
 
Edition
 
2021).
 
Perak
 
State
 
Health
 
Department,
 
Pharmaceutical
 
Services
 
Division.
 
6.
 
Taylor ,
 
D.,
 
Barnes,
 
T.
 
E.,
 
&
 
Young,
 
A.
 
H.
 
(2021).
 
The
 
Maudsley
 
prescribing
 
guidelines
 
in
 
psychiatry
 
(14th
 
ed.).
 
Wiley-Blackwell.
 
7.
 
2023
 
American
 
Geriatrics
 
Society
 
Beers
 
Criteria®
 
Update
 
Expert
 
Panel.
 
(2023).
 
American
 
Geriatrics
 
Society
 
2023
 
updated
 
AGS
 
Beers
 
Criteria®
 
for
 
potentially
 
inappropriate
 
medication
 
use
 
in
 
older
 
adults.
 
Journal
 
of
 
the
 
American
 
Geriatrics
 
Society ,
 
71(7),
 
2052-2081.
 
8.
 
O’Mahony ,
 
D.,
 
Cherubini,
 
A.,
 
Guiteras,
 
A.
 
R.,
 
Denkinger ,
 
M.,
 
Beuscart,
 
J.
 
B.,
 
Onder ,
 
G.,
 
...
 
&
 
Curtin,
 
D.
 
(2023).
 
STOPP/ST ART
 
criteria
 
for
 
potentially
 
inappropriate
 
prescribing
 
in
 
older
 
people:
 
version
 
3.
 
European
 
geriatric
 
medicine,
 
14(4),
 
625-632.
 
 
 
 
 
 
 
 
 
 
 
 
 
59
 

=== PAGE 61 ===

 
Benzoyl
 
Peroxide,
 
Topical
 
 
Name
 
:
 
 
Unit
 
:
 
 
●
 
Please
 
tick
 
(
✔
)
 
Yes
 
for
 
correct
 
instruction.
 
●
 
Please
 
tick
 
(
✔
)
 
No
 
for
 
incorrect
 
instruction.
 
Yes
 
No
 
Remarks
 
Pharmacological
 
Group
 
Antibacterial
 
and
 
anti-inflammatory
 
agent
 
 
 
 
Indications
 
and
 
Dosage
 
Treatment
 
for
 
acne
 
vulgaris.
 
 
To
 
be
 
applied
 
on
 
acne
 
spots
 
once
 
or
 
twice
 
daily.
 
 
To
 
counsel
 
based
 
on
 
specific
 
medication’ s
 
indication
 
and
 
dosage
 
as
 
prescribed
 
by
 
the
 
doctor
 
 
 
 
Method
 
of
 
Administration*
 
Wash
 
the
 
affected
 
area
 
with
 
a
 
mild
 
skin
 
cleanser
 
and
 
water
 
and
 
pat
 
skin
 
dry.
 
 
Apply
 
a
 
thin
 
film
 
of
 
medication
 
to
 
the
 
affected
 
area
 
once
 
daily.
 
Start
 
at
 
night
 
for
 
a
 
week,
 
if
 
there
 
is
 
no
 
skin
 
irritation/redness/peeling,
 
can
 
apply
 
twice
 
daily
 
if
 
needed.
 
 
Do
 
not
 
stop
 
taking
 
your
 
medication
 
unless
 
advised
 
to
 
do
 
so
 
by
 
your
 
prescriber
 
 
 
 
Special
 
Considerations
 
Pregnancy
 
 
 
 
Use
 
in
 
pregnancy
 
only
 
if
 
clearly
 
needed.
 
 
 
 
Breastfeeding
 
 
 
 
Caution
 
should
 
be
 
exercised
 
to
 
nursing
 
women.
 
Should
 
not
 
be
 
used
 
on
 
the
 
chest
 
in
 
a
 
breastfeeding
 
woman
 
to
 
avoid
 
accidental
 
transfer
 
to
 
the
 
infant.
 
 
 
 
Elderly
 
 
 
 
Not
 
applicable.
 
 
 
 
 
Paediatric
 
 
 
 
The
 
safety
 
and
 
efficacy
 
of
 
topical
 
Benzoyl
 
peroxide
 
in
 
paediatric
 
patients
 
below
 
12
 
years
 
old
 
have
 
not
 
been
 
established.
 
 
 
 
 
Fasting
 
 
 
 
To
 
refer
 
to
 
the
 
latest
 
advisory
 
by
 
religious
 
authority
 
 
 
 
Others
 
 
 
 
 
Not
 
applicable.
 
 
 
 
 
Side
 
Effects
 
and
 
their
 
Management*
 
Skin
 
dryness,
 
skin
 
redness,
 
peeling
 
of
 
the
 
skin,
 
burning
 
sensation
 
of
 
the
 
skin,
 
itching
 
of
 
the
 
skin.
 
 
Avoid
 
products
 
that
 
may
 
dry
 
or
 
irritate
 
skin
 
such
 
as
 
products
 
containing
 
alcohol,
 
harsh
 
skin
 
cleaners
 
and
 
medicated
 
soap.
 
 
 
 
Storage*
 
Store
 
at
 
room
 
temperature
 
below
 
25
o
C
 
 
 
 
60
 

=== PAGE 62 ===

 
Others
 
Avoid
 
areas
 
of
 
skin
 
around
 
eyes,
 
lips,
 
mouth,
 
angles
 
of
 
nose,
 
mucous
 
membrane
 
and
 
sensitive
 
area
 
of
 
the
 
neck.
 
 
Should
 
not
 
be
 
applied
 
to
 
damaged/broken
 
skin.
 
 
If
 
excessive
 
stinging
 
or
 
burning
 
occurs,
 
remove
 
with
 
mild
 
soap
 
and
 
water ,
 
resume
 
use
 
the
 
next
 
day.
 
 
Avoid
 
excessive
 
exposure
 
to
 
sunlight
 
or
 
other
 
sources
 
of
 
ultraviolet
 
light.
 
Wear
 
sunscreen
 
when
 
sun
 
protection
 
is
 
needed.
 
 
May
 
bleach
 
or
 
discolour
 
fabrics
 
such
 
as
 
clothing,
 
towel,
 
bed
 
linen)
 
 
 
 
Before
 
ending
 
this
 
peer
 
review
 
session,
 
the
 
reviewee
 
should
 
be
 
informed
 
of
 
the
 
step(s)
 
that
 
he/
 
she
 
missed
 
out
 
in
 
order
 
to
 
ensure
 
all
 
the
 
counselling
 
points
 
are
 
being
 
covered.
 
 
Remarks:
 
 
 
 
 
Reviewed
 
by:
 
Name
 
&
 
Signature
                                                                   
Date:
 
 
 
 
 
*Mandatory
 
for
 
validation/peer
 
review
 
 
References:
 
 
1.
 
Kementerian
 
Kesihatan
 
Malaysia.
 
(2024).
 
Formulari
 
Ubat
 
Kementerian
 
Kesihatan
 
Malaysia
 
Bil
 
2/2024.
 
Kementerian
 
Kesihatan
 
Malaysia.
 
Retrieved
 
from:
  
https://pharmacy .moh.gov .my/sites/default/files/document-upload/fukkm-bil-2-2024_0.pdf
 
2.
 
Medsafe.Benzac
 
AC
 
consumer
 
medicine
 
information.
 
Medsafe.
 
Retrieved
 
November
 
11,
 
2024,
 
from
  
https://www .medsafe.govt.nz
 
3.
 
Pharmaceutical
 
Services
 
Programme,
 
Ministry
 
of
 
Health
 
Malaysia.
 
(2018).
 
Topical
 
preparations
 
counseling
 
guide
 
for
 
pharmacists
 
(1st
 
ed.)
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
61
 

=== PAGE 63 ===

 
Beta-Blockers
 
Name
 
:
 
 
Unit
 
:
 
 
●
 
Please
 
tick
 
(
✔
)
 
Yes
 
for
 
correct
 
instruction.
 
●
 
Please
 
tick
 
(
✔
)
 
No
 
for
 
incorrect
 
instruction.
 
Yes
 
No
 
Remarks
 
Pharmacological
 
Group
 
Beta-blockers
 
 
 
 
Indications
 
and
 
Dosage
 
 
 
Hypertension
 
 
Drug
 
Initial
 
Dose
 
Maximum
 
Dose
 
Atenolol
 
50mg
 
OD
 
100mg
 
OD
 
Bisoprolol
 
5mg
 
OD
 
20mg/day
 
Labetalol
 
100mg
 
BD
 
2400mg/day
 
Metoprolol
 
50mg
 
BD
 
200mg
 
BD
 
Propranolol
 
40mg
 
BD
 
320mg
 
BD
 
 
Heart
 
Failure
 
 
Drug
 
Initial
 
Dose
 
Target
 
Dose
 
Bisoprolol
 
1.25mg
 
OD
 
10mg
 
OD
 
Carvedilol
 
3.125mg
 
BD
 
25mg
 
BD
 
 
 
Arrythmias
 
 
 
Drug
 
Initial
 
Dose
 
Maximum
 
Dose
 
Sotalol
 
80mg
 
BD
 
480
 
-
 
640mg
 
in
 
divided
 
doses
 
 
To
 
counsel
 
based
 
on
 
specific
 
medication’ s
 
indication
 
and
 
dosage
 
as
 
prescribed
 
by
 
the
 
doctor
 
 
 
 
Method
 
of
 
Administration
*
 
 
 
1.
 
Can
 
take
 
without
 
regards
 
to
 
meal:
 
 
a.
 
Atenolol
 
b.
 
Bisoprolol
 
 
2.
 
Recommended
 
to
 
administer
 
on
 
empty
 
stomach:
 
 
a.
 
Propranolol
 
 
3.
 
Recommended
 
to
 
administer
 
with
 
food:
 
 
a.
 
Carvedilol:
 
to
 
minimise
 
orthostatic
 
hypotension
 
b.
 
Metoprolol
 
 
 
Missed
 
dose
 
management:
 
1.
 
Single
 
daily
 
dosing
 
regime:
 
missed
 
dose
 
taken
 
up
 
to
 
until
 
12
 
h
 
after
 
the
 
scheduled
 
dosing
 
 
2.
 
Twice
 
daily
 
dosing
 
regime:
 
missed
 
dose
 
taken
 
up
 
until
 
 
 
 
62
 

=== PAGE 64 ===

 
6
 
h
 
after
 
the
 
scheduled
 
intake
 
 
 
Do
 
not
 
stop
 
taking
 
your
 
medication
 
unless
 
advised
 
to
 
do
 
so
 
by
 
your
 
prescriber
 
Special
 
Considerations
 
 
 
 
 
Pregnancy
 
 
 
 
1.
 
Exposure
 
to
 
beta-blockers
 
during
 
pregnancy
 
may
 
increase
 
the
 
risk
 
for
 
adverse
 
events
 
in
 
neonates.
 
 
 
2.
 
If
 
maternal
 
use
 
of
 
a
 
beta-blocker
 
is
 
needed,
 
monitor
 
fetal
 
growth
 
during
 
pregnancy;
 
monitor
 
the
 
newborn
 
for
 
48
 
hours
 
after
 
delivery
 
for
 
bradycardia,
 
hypoglycemia,
 
and
 
respiratory
 
depression.
 
 
 
 
Breastfeeding
 
 
 
 
1.
 
Present
 
in
 
breast
 
milk:
 
atenolol,
 
propranolol,
 
metoprolol.
 
2.
 
Not
 
known
 
(if
 
present
 
in
 
breast
 
milk):
 
bisoprolol,
 
carvedilol.
 
3.
 
The
 
manufacturer
 
recommends
 
that
 
caution
 
be
 
exercised
 
when
 
administering
 
beta-blockers
 
to
 
patients
 
who
 
are
 
breastfeeding.
 
4.
 
Bradycardia
 
has
 
been
 
observed
 
in
 
some
 
breastfeeding
 
infants
 
and
 
neonates
 
may
 
also
 
be
 
at
 
risk
 
for
 
hypoglycemia.
 
Adverse
 
events
 
may
 
be
 
more
 
likely
 
in
 
premature
 
infants
 
or
 
infants
 
with
 
impaired
 
renal
 
function.
 
 
 
 
Elderly
 
 
 
 
Refer
 
to
 
adult
 
dosing.
 
Consider
 
lower
 
initial
 
doses
 
and
 
titrate
 
to
 
response.
 
 
 
 
Paediatric
 
 
 
 
Dose
 
should
 
be
 
individualized
 
based
 
on
 
patient
 
response.
 
 
 
 
Fasting
 
 
 
 
Not
 
applicable
 
 
 
 
Renal
 
Impairment
 
 
 
 
1.
 
No
 
dosage
 
adjustment
 
necessary:
 
 
a.
 
Metoprolol,
 
carvedilol,
 
propranolol.
 
 
2.
 
Renal
 
dose
 
required:
 
Atenolol,
 
Bisoprolol.
 
 
 
 
Liver
 
Impairment
 
 
 
 
1.
 
There
 
are
 
no
 
specific
 
dosage
 
adjustments
 
provided
 
in
 
the
 
manufacturer ’s
 
labelling.
 
 
2.
 
Consider
 
initiating
 
with
 
reduced
 
doses
 
and
 
gradual
 
dosage
 
titration.
 
 
 
 
Side
 
Effects
 
and
 
their
 
Management
*
 
1.
 
Worsening
 
symptoms
 
or
 
signs
 
(e.g.
 
increasing
 
dyspnoea,
 
fatigue,
 
oedema,
 
weight
 
gain):
 
○
 
If
 
increasing
 
congestion,
 
increase
 
a
 
dose
 
of
 
diuretic
 
or
 
halve
 
a
 
dose
 
of
 
beta-blocker
 
(if
 
increasing
 
diuretic
 
dose
 
does
 
not
 
work).
 
○
 
If
 
serious
 
deterioration,
 
halve
 
the
 
dose
 
of
 
beta-blocker
 
or
 
stop
 
this
 
treatment
 
(rarely
 
 
 
 
63
 

=== PAGE 65 ===

 
necessary);
 
seek
 
specialist
 
advice.
 
2.
 
Low
 
heart
 
rate:
 
○
 
If
 
<50
 
b.p.m.
 
and
 
worsening
 
symptoms,
 
halve
 
the
 
dose
 
of
 
beta-blocker ,
 
or,
 
if
 
severe
 
deterioration,
 
stop
 
beta-blocker
 
(rarely
 
necessary).
 
○
 
Review
 
need
 
for
 
other
 
heart
 
rate-slowing
 
drugs
 
(e.g.
 
digoxin,
 
ivabradine,
 
amiodarone,
 
diltiazem,
 
or
 
verapamil).
 
○
 
Arrange
 
ECG
 
to
 
exclude
 
heart
 
block.
 
3.
 
Asymptomatic
 
low
 
blood
 
pressure:
 
○
 
Does
 
not
 
usually
 
require
 
any
 
change
 
in
 
therapy .
 
4.
 
Symptomatic
 
hypotension:
 
○
 
If
 
dizziness,
 
light-headedness,
 
or
 
confusion
 
and
 
a
 
low
 
blood
 
pressure,
 
reconsider
 
the
 
need
 
for
 
nitrates,
 
calcium-channel
 
blockers
 
and
 
other
 
vasodilators
 
and
 
reduce/stop,
 
if
 
possible.
 
○
 
If
 
there
 
are
 
no
 
signs
 
or
 
symptoms
 
of
 
congestion,
 
consider
 
reducing
 
diuretic
 
dose.
 
Storage*
 
Store
 
it
 
at
 
room
 
temperature
 
and
 
away
 
from
 
excess
 
heat
 
and
 
moisture.
 
 
 
 
Others
 
Monitoring
 
parameters:
 
Heart
 
rate,
 
blood
 
pressure,
 
serum
 
glucose
 
(in
 
diabetic
 
patients),
 
ECG.
 
 
 
 
Before
 
ending
 
this
 
peer
 
review
 
session,
 
the
 
reviewee
 
should
 
be
 
informed
 
of
 
the
 
step(s)
 
that
 
he/
 
she
 
missed
 
out
 
in
 
order
 
to
 
ensure
 
all
 
the
 
counselling
 
points
 
are
 
being
 
covered.
 
 
Remarks:
 
 
 
 
 
Reviewed
 
by:
 
Name
 
&
 
Signature
                                                                   
Date:
 
 
 
 
 
*Mandatory
 
for
 
validation/peer
 
review
 
 
References:
 
 
1.
 
Lexicomp.
 
(2023).
 
Lexicomp
 
online.
 
Wolters
 
Kluwer .
 
https://www .lexicomp.com/
 
2.
 
Regitz-Zagrosek,
 
V.,
 
et
 
al.
 
(2018).
 
2018
 
ESC
 
guidelines
 
for
 
the
 
management
 
of
 
cardiovascular
 
diseases
 
during
 
pregnancy .
 
European
 
Society
 
of
 
Cardiology .
 
3.
 
Cífková,
 
R.,
 
et
 
al.
 
(2020).
 
2020
 
ESC
 
guidelines
 
on
 
cardiovascular
 
disease
 
prevention
 
in
 
clinical
 
practice.
 
European
 
Society
 
of
 
Cardiology .
 
4.
 
Aronow ,
 
W.
 
S.,
 
Fleg,
 
J.
 
L.,
 
Pepine,
 
C.
 
J.,
 
et
 
al.;
 
ACCF
 
Task
 
Force.
 
(2011).
 
ACCF/AHA
 
2011
 
expert
 
consensus
 
document
 
on
 
hypertension
 
in
 
the
 
elderly:
 
A
 
report
 
of
 
the
 
American
 
College
 
of
 
Cardiology
 
Foundation
 
Task
 
Force
 
on
 
Clinical
 
Expert
 
Consensus
 
Documents.
 
Circulation,
 
123(21),
 
2434-2506.
 
https://doi.org/10.1 161/CIR.0b013e31821a1034
 
5.
 
European
 
Society
 
of
 
Cardiology .
 
(2021).
 
Supplementary
 
data
 
for
 
the
 
management
 
of
 
heart
 
failure.
 
European
 
Heart
 
Journal,
 
00,
 
142.
 
https://doi.org/10.1093/eurheartj/ehab368
 
6.
 
Malaysian
 
Clinical
 
Practice
 
Guidelines:
 
Management
 
of
 
Heart
 
Failure
 
2023
 
(5
th
 
Edition)
 
7.
 
Malaysian
 
Clinical
 
Practice
 
Guidelines
 
Management
 
of
 
Hypertension
 
2018
 
(3
rd
 
Edition)
 
8.
 
Formulari
 
Ubat
 
KKM.
 
Database
 
version:241 115.0002
 
 
64
 

=== PAGE 66 ===

 
Benzyl
 
Benzoate,
 
Emulsion
 
(EBB)
 
Name
 
:
 
 
Unit
 
:
 
 
●
 
Please
 
tick
 
(
✔
)
 
Yes
 
for
 
correct
 
instruction.
 
●
 
Please
 
tick
 
(
✔
)
 
No
 
for
 
incorrect
 
instruction.
 
Yes
 
No
 
Remarks
 
Pharmacological
 
Group
 
Scabicide
 
 
 
 
Indications
 
and
 
Dosage
 
1.
 
For
 
the
 
treatment
 
of
 
scabies
 
 
a.
 
12.5%:
 
2
 
years
 
old
 
to
 
12
 
years
 
old
 
b.
 
25%:
 
More
 
than
 
12
 
years
 
old
 
 
To
 
counsel
 
based
 
on
 
specific
 
medication’ s
 
indication
 
and
 
dosage
 
as
 
prescribed
 
by
 
the
 
doctor
 
 
 
 
Method
 
of
 
Administration*
 
1.
 
Individuals
 
to
 
be
 
treated
 
should
 
have
 
a
 
shower
 
or
 
bath
 
with
 
soap,
 
and
 
dry
 
their
 
body
 
thoroughly
 
prior
 
to
 
treatment.
 
 
2.
 
The
 
emulsion
 
should
 
be
 
shaken
 
well
 
before
 
use.
 
3.
 
Apply
 
from
 
neck
 
to
 
soles,
 
paying
 
particular
 
attention
 
to
 
all
 
skin
 
folds
 
such
 
as
 
between
 
fingers
 
and
 
toes,
 
underarms
 
and
 
groin.
 
Avoid
 
head,
 
face
 
and
 
private
 
areas.
 
4.
 
Allow
 
the
 
emulsion
 
to
 
dry
 
(usually
 
takes
 
about
 
10min)
 
and
 
then
 
put
 
on
 
clean
 
clothes.
 
Do
 
not
 
wash
 
your
 
hands.
 
5.
 
Leave
 
the
 
emulsion
 
on
 
the
 
body .
 
Do
 
not
 
bath,
 
shower
 
or
 
change
 
clothes
 
before
 
the
 
second
 
application.
 
6.
 
Apply
 
on
 
the
 
skin
 
surface
 
continuously
 
for
 
24
 
hours
 
for
 
2-3
 
days.
 
7.
 
Rinse
 
off
 
after
 
24
 
hours
 
and
 
then
 
reapply ,
 
with
 
a
 
bath
 
taken
 
in
 
between
 
each
 
application.
 
 
8.
 
A
 
third
 
application
 
may
 
be
 
required
 
in
 
some
 
cases
 
i.e.
 
HIV/
 
immunocompromised
 
patients.
 
9.
 
Wash
 
off
 
thoroughly
 
after
 
the
 
recommended
 
time
 
period.
 
 
10.
 
Alternatively ,
 
may
 
do
 
3
 
applications
 
within
 
a
 
12
 
hour
 
interval.
 
Missed
 
dose
 
management
:
 
If
 
a
 
dose
 
is
 
missed,
 
use
 
it
 
as
 
soon
 
as
 
possible.
 
If
 
it
 
is
 
almost
 
time
 
for
 
the
 
next
 
dose,
 
use
 
only
 
that
 
dose.
 
Do
 
not
 
use
 
double
 
or
 
extra
 
doses.
 
 
Do
 
not
 
stop
 
your
 
medication
 
unless
 
advised
 
to
 
do
 
so
 
by
 
your
 
prescriber
 
 
 
 
Special
 
Considerations
 
Pregnancy
 
 
 
 
Use
 
of
 
EBB
 
is
 
contraindicated
 
in
 
pregnancy .
 
 
 
 
Breastfeeding
 
 
 
 
Use
 
of
 
EBB
 
is
 
contraindicated
 
in
 
breast
 
feeding
 
women.
 
 
 
 
Elderly
 
 
 
 
The
 
xerosis
 
of
 
the
 
skin
 
makes
 
the
 
skin
 
more
 
susceptible
 
to
 
the
 
drying
 
effects
 
of
 
benzyl
 
benzoate
 
and
 
irritation
 
may
 
be
 
worse
 
in
 
this
 
group
 
of
 
patients.
 
Alternative
 
treatment
 
in
 
the
 
elderly
 
should
 
 
 
 
65
 

=== PAGE 67 ===

 
be
 
used.
 
Paediatric
 
 
 
 
Use
 
of
 
EBB
 
is
 
contraindicated
 
in
 
infants
 
of
 
<2
 
years
 
old.
 
 
 
 
Fasting
 
 
 
 
N/A
 
 
 
 
Others
  
 
 
 
 
1.
 
Should
 
NOT
 
be
 
used
 
on
 
the
 
face
 
due
 
to
 
its
 
irritant
 
effect
 
on
 
the
 
skin,
 
and
 
should
 
NOT
 
be
 
used
 
on
 
broken,
 
irritated
 
or
 
inflamed
 
skin.
 
 
 
 
Side
 
Effects
 
and
 
their
 
Management*
 
1.
 
Burning
 
sensation,
 
rashes,
 
skin
 
irritation.
 
2.
 
Irritation
 
of
 
the
 
skin,
 
eyes
 
and
 
mucous
 
membranes.
 
3.
 
If
 
incorrectly
 
used
 
for
 
long
 
periods
 
of
 
time
 
it
 
will
 
induce
 
both
 
irritant
 
and
 
allergic
 
dermatitis
 
reactions.
 
 
 
 
Storage*
 
1.
 
Store
 
at
 
room
 
temperature
 
below
 
25C.
 
2.
 
Discard
 
any
 
unused
 
medicine
 
after
 
the
 
expired
 
date.
 
 
 
 
Others
 
1.
 
Patients
 
with
 
scabies
 
and
 
their
 
close
 
physical
 
contacts,
 
even
 
without
 
symptoms,
 
should
 
receive
 
treatment
 
at
 
the
 
same
 
time.
 
 
2.
 
Avoid
 
contact
 
with
 
eyes
 
or
 
mucous
 
membranes
 
or
 
the
 
area
 
around
 
the
 
mouth.
 
3.
 
If
 
the
 
treatment
 
is
 
applied
 
by
 
someone
 
without
 
scabies,
 
this
 
person
 
should
 
wear
 
medical
 
gloves
 
during
 
application.
 
4.
 
After
 
completion
 
of
 
treatment,
 
patients
 
should
 
use
 
fresh,
 
clean
 
bedding
 
and
 
clothing.
 
 
5.
 
Itching
 
and
 
rash
 
may
 
continue
 
for
 
up
 
to
 
4
 
weeks
 
after
 
treatment,
 
but
 
this
 
is
 
usually
 
a
 
temporary
 
reaction.
 
6.
 
Wash
 
all
 
toys
 
in
 
very
 
hot
 
soapy
 
water
 
for
 
5-10min
 
or
 
seal
 
in
 
an
 
airtight
 
plastic
 
bag
 
for
 
2
 
weeks.
 
This
 
is
 
especially
 
important
 
for
 
stuffed
 
toys
 
used
 
on
 
the
 
bed.
 
 
 
 
Before
 
ending
 
this
 
peer
 
review
 
session,
 
the
 
reviewee
 
should
 
be
 
informed
 
of
 
the
 
step(s)
 
that
 
he/
 
she
 
missed
 
out
 
in
 
order
 
to
 
ensure
 
all
 
the
 
counselling
 
points
 
are
 
being
 
covered.
 
 
Remarks:
 
 
 
 
Reviewed
 
by:
 
Name
 
&
 
Signature
                                                                   
Date:
 
 
 
 
*Mandatory
 
for
 
validation
 
/
 
peer
 
review
 
References:
 
 
1.
 
Hospital
 
Authority
 
(2021).
 
Benzyl
 
benzoate
 
emulsion
 
(for
 
scabies).
 
COC-Grade
 
(Pharmaceutical
 
Services)
 
[online
 
leaflet]
 
Retrieved
 
from:
 
www .ha.org.hk/hadf/Portals/0/Docs/Leaflets/Eng/Benzyl_benzoate_emulsion_for_scabies.pdf
 
2.
 
Idaman
 
Pharma
 
Sdn
 
Bhd
 
(2018).
 
Emulsion
 
benzyl
 
benzoate.
 
[RiMUP]
 
3.
 
MIMS
 
Malaysia
 
(2025).
 
Benzyl
 
benzoate.
 
Retrieved
 
from:
 
https://www .mims.com/malaysia/drug/info/benzyl-benzoate?mtype=generic
.
 
Accessed
 
on
 
January
 
21,
 
2025.
 
4.
 
Formulari
 
Ubat
 
KKM.
 
(2025,
 
January
 
1).
 
Accessed
 
on
 
January
 
1,
 
2025.
 
5.
 
Strong,
 
M.,
 
&
 
Johnstone,
 
P.
 
(2007).
 
Interventions
 
for
 
treating
 
scabies.
 
Cochrane
 
Database
 
of
 
Systematic
 
Reviews,
 
(3).
 
66
 

=== PAGE 68 ===

 
Bisphosphonates
 
Name
 
:
 
 
Unit
 
:
 
 
●
 
Please
 
tick
 
(
✔
)
 
Yes
 
for
 
correct
 
instruction.
 
●
 
Please
 
tick
 
(
✔
)
 
No
 
for
 
incorrect
 
instruction.
 
Yes
 
No
 
Remarks
 
Pharmacological
 
Group
 
Bisphosphonate
 
 
 
 
 
Indications
 
and
 
Dosage
 
1.
 
Alendronate
 
sodium
 
70mg
 
tablet
 
 
i)
 
Treatment
 
of
 
osteoporosis
 
in
 
high-risk
 
postmenopausal
 
women:
 
70
 
mg
 
once
 
weekly .
 
ii)
 
Male
 
Osteoporosis:
 
70
 
mg
 
once
 
weekly .
 
2.
 
Alendronate
 
sodium
 
70mg
 
+
 
Cholecalciferol
 
5600
 
IU
 
tablet
 
 
i)
 
Osteoporosis
 
in
 
postmenopausal
 
women
 
with
 
a
 
history
 
of
 
vertebral
 
fracture
 
and
 
whom
 
oestrogen
 
replacement
 
therapy
 
is
 
contraindicated:
 
1
 
tablet
 
once
 
weekly
 
[70mg/5600
 
IU]
 
ii)
 
Male
 
Osteoporosis
 
Dosage:
 
1
 
tablet
 
once
 
weekly
 
[70mg/5600
 
IU]
 
3.
 
Ibandronic
 
150mg
 
i)
 
Treatment
 
of
 
postmenopausal
 
osteoporosis
 
to
 
reduce
 
the
 
risk
 
of
 
fracture:
 
150mg
 
once
 
monthly
 
 
 
 
Method
 
of
 
Administration*
 
1.
   
Alendronate
 
sodium
 
70mg
 
tablet
 
 
2.
 
Alendronate
 
sodium
 
70mg
 
+
 
Cholecalciferol
 
5600
 
IU
 
tablet
 
 
 
ADMINISTRA TION
 
1.
 
Take
 
1
 
dose
 
every
 
week
 
on
 
the
 
chosen
 
day
 
after
 
getting
 
up
 
for
 
the
 
day
 
and
 
before
 
taking
 
first
 
food,
 
drink,
 
or
 
other
 
medicine
 
while
 
sitting
 
or
 
standing
 
up.
 
2.
 
Swallow
 
one
 
tablet
 
with
 
a
 
full
 
glass
 
of
 
plain
 
water
 
(not
 
mineral
 
water ,
  
coffee,
 
tea
 
or
 
juice).
 
Do
 
not
 
chew
 
or
 
suck.
 
3.
 
After
 
taking,
 
wait
 
at
 
least
 
30
 
minutes
:
 
 
a.
 
Before
 
lying
 
down.
 
May
 
sit,
 
stand
 
or
 
walk,
 
and
 
do
 
normal
 
activities
 
like
 
reading.
 
 
b.
 
Before
 
taking
 
the
 
first
 
food
 
or
 
drink
 
except
 
for
 
plain
 
water .
 
 
c.
 
Before
 
taking
 
other
 
medicines,
 
including
 
antacids,
 
calcium,
 
and
  
other
 
supplements
 
and
 
vitamins.
 
MISSED
 
DOSE
 
1.
 
If
 
you
 
miss
 
a
 
dose,
 
take
 
only
 
1
 
dose
 
in
 
the
 
morning
 
after
 
remembering.
 
 
2.
 
Do
 
not
 
take
 
2
 
doses
 
on
 
the
 
same
 
day.
 
 
3.
 
Continue
 
the
 
usual
 
schedule
 
of
 
1
 
dose
 
once
 
a
 
week
 
on
 
the
 
chosen
 
day.
 
OVERDOSE
 
1.
 
If
 
taken
 
more
 
than
 
the
 
prescribed
 
dose,
 
drink
 
a
 
full
 
glass
 
of
 
milk
 
and
 
visit
 
the
 
doctor
 
right
 
away .
 
 
2.
 
Do
 
not
 
try
 
to
 
vomit.
 
 
3.
 
Do
 
not
 
lie
 
down.
 
 
3.
 
Ibrandronic
 
Acid
 
150mg
 
Tablet
 
 
1.
 
One
 
tablet
 
once
 
a
 
month.
 
Choose
 
the
 
day
 
of
 
the
 
month
 
that
 
best
 
fits
 
your
 
schedule.
 
Can
 
choose
  
either
 
the
 
same
 
date
 
(such
 
as
 
the
 
1st
 
of
 
each
 
month)
 
or
 
the
 
same
 
day
 
(such
 
as
 
the
 
first
  
Sunday
 
of
 
each
 
month)
 
to
 
take
 
the
 
tablet.
 
 
2.
 
Take
 
the
 
tablet
 
at
 
least
 
6
 
hours
 
after
 
having
 
eaten
 
or
 
drank
 
anything
 
except
 
water .
 
 
 
  
 
67
 

=== PAGE 69 ===

 
3.
 
Swallow
 
one
 
tablet
 
with
 
a
 
full
 
glass
 
of
 
plain
 
water
 
(not
 
mineral
 
water ,
  
coffee,
 
tea
 
or
 
juice).
 
Do
 
not
 
chew
 
or
 
suck.
 
4.
 
After
 
taking,
 
wait
 
at
 
least
 
60
 
minutes
:
 
 
a.
 
Before
 
lying
 
down.
 
May
 
sit,
 
stand
 
or
 
walk,
 
and
 
do
 
normal
 
activities
 
like
 
reading.
 
 
b.
 
Before
 
taking
 
the
 
first
 
food
 
or
 
drink
 
except
 
for
 
plain
 
water .
 
 
c.
 
Before
 
taking
 
other
 
medicines,
 
including
 
antacids,
 
calcium,
 
and
  
other
 
supplements
 
and
 
vitamins.
 
 
M
ISSED
 
DOSE
 
1.
 
If
 
forgotten
 
to
 
take
 
the
 
tablet
 
on
 
the
 
morning
 
of
 
the
 
chosen
 
day,
 
do
 
not
 
take
 
a
 
tablet
 
later
 
in
 
the
 
day.
 
Instead,
 
consult
 
the
 
calendar
 
and
 
find
 
out
  
when
 
the
 
next
 
scheduled
 
dose
 
is:
 
 
2.
 
If
 
the
 
next
 
scheduled
 
dose
 
is
 
only
 
1
 
to
 
7
 
days
 
away
 
 
a.
 
Should
 
wait
 
until
 
the
 
next
 
scheduled
 
dose
 
is
 
due
 
and
 
take
 
it
 
as
 
normal;
 
then,
 
continue
 
taking
 
one
 
tablet
 
once
 
a
 
month
 
on
 
the
 
scheduled
 
days
 
marked
 
on
 
the
 
calendar .
 
 
3.
 
If
 
the
 
next
 
scheduled
 
dose
 
is
 
more
 
than
 
7
 
days
 
away
.
 
 
a.
 
Should
 
take
 
one
 
tablet
 
the
 
next
 
morning
 
after
 
the
 
day
 
the
 
patient
  
remembers;
 
then,
 
continue
 
taking
 
one
 
tablet
 
once
 
a
 
month
 
on
 
the
 
scheduled
 
days
 
marked
 
on
 
the
 
calendar .
 
 
4.
 
Never
 
take
 
two
 
doses
 
within
 
the
 
same
 
week.
 
 
OVERDOSE
 
If
 
taken
 
more
 
than
 
the
 
prescribed
 
dose,
 
drink
 
a
 
full
 
glass
 
of
 
milk
 
and
 
visit
 
the
 
doctor
 
right
 
away .
 
Do
 
not
 
try
 
to
 
vomit.
 
Do
 
not
 
lie
 
down
 
 
Do
 
not
 
stop
 
taking
 
your
 
medication
 
unless
 
advised
 
to
 
do
 
so
 
by
 
your
 
prescriber
 
Special
 
Considerations
 
Pregnancy
 
 
 
 
May
 
cause
 
fetal
 
harm.
 
Limited
 
human
 
data-
 
animal
 
data
 
suggest
 
risk.
 
 
 
 
Breastfeeding
 
 
 
 
Infant
 
risk
 
cannot
 
be
 
ruled
 
out.
 
No
 
human
 
data-
 
probably
 
compatible.
 
 
 
 
Elderly
 
 
 
 
1.
 
Swallowing
 
difficulties
 
(dysphagia):
 
Older
 
adults
 
with
 
swallowing
 
issues
 
or
 
esophageal
 
abnormalities
 
may
 
not
 
tolerate
 
alendronate
 
tablets
 
well
 
and
 
may
 
benefit
 
from
 
alternative
 
formulations.
 
2.
 
Osteonecrosis
 
of
 
the
 
Jaw
 
(ONJ)
 
:
 
with
 
prolonged
 
use,
 
poor
 
dental
 
health,
 
or
 
invasive
 
dental
 
procedures.
 
Dental
 
assessments
 
and
 
preventive
 
care
 
are
 
essential.
 
3.
 
Atypical
 
Femur
 
Fractures
 
(AFF):
 
Long-term
 
use
 
may
 
increase
 
the
 
risk
 
of
 
atypical
 
femoral
 
fractures
 
4.
 
Hypocalcemia:Preexisting
 
vitamin
 
D
 
deficiency
 
or
 
low
 
calcium
 
levels
 
are
 
more
 
common
 
in
 
the
 
elderly
 
and
 
must
 
be
 
corrected
 
before
 
starting
 
alendronate.
 
 
STOPP/ST ART
 
Criteria:
 
 
 
 
68
 

=== PAGE 70 ===

 
1.
 
Avoid
 
use
 
of
 
oral
 
bisphosphonate
 
in
 
patient
 
with
 
current
 
or
 
recent
 
history
 
of
 
upper
 
gastrointestinal
 
disease
 
(
 
eg
 
esophagitis,
 
gastritis,
 
duodenitis,
 
or
 
peptic
 
ulcer
 
disease
 
)
 
Paediatric
 
 
 
 
Not
 
indicated
 
for
 
use
 
in
 
paediatric
 
patients
.
 
The
 
safety
 
and
 
efficacy
 
of
 
biphosphonate
 
in
 
paediatric
 
patients
 
below
 
age
 
18
 
have
 
not
 
been
 
established
.
 
 
 
 
Fasting
 
 
 
 
Refer
 
to
 
the
 
latest
 
advisory
 
by
 
religious
 
authority .
 
 
 
 
Others
 
 
 
 
 
1.
 
Contraindicated
 
in
 
patient
 
with:
 
a.
 
esophageal
 
abnormalities
 
b.
 
hypocalcemia
 
c.
 
inability
 
to
 
stand
 
or
 
sit
 
upright
 
for
 
30
 
minutes
 
(alendronate
 
and
 
alendronate/cholecalciferol)
 
and
 
for
 
60
 
minutes
 
(ibandronate).
 
2.
 
Renal
 
impairment
:use
 
not
 
recommended
 
in
 
patient
 
with:
 
a.
 
CrCl
 
<
 
35ml/min
  
(alendronate
 
and
 
alendronate/cholecalciferol)
 
b.
 
CrCl
 
<
 
30ml/min
 
(ibandronate)
 
3.
 
Hepatic
 
impairment
:
 
No
 
adjustments
 
necessary
 
4.
 
Musculoskeletal
 
pain
 
(severe)
:
 
Discontinue
 
use
 
5.
 
Upper
 
gastrointestinal
 
adverse
 
effects
:
 
Discontinue
 
use
 
and
 
evaluate
 
6.
 
Special
 
populations
:
 
Use
 
cautiously
 
in
 
patient
 
with:
 
a.
 
restricted
 
sodium
 
intake
 
b.
 
effervescent
 
tablet
 
contains
 
sodium
 
 
 
 
 
Side
 
Effects
 
and
 
their
 
Management*
 
1.
 
May
 
cause
 
problems
 
in
 
the
 
oesophagus
 
including
 
irritation,
 
inflammation
 
or
 
ulcers
 
which
 
may
 
sometimes
 
bleed.
 
 
●
 
This
 
may
 
occur
 
especially
 
if
 
patients
 
do
 
not
 
drink
 
a
 
full
 
glass
 
of
 
water
 
with
 
the
 
medication
 
or
 
if
 
lying
 
down
 
in
 
less
 
than
 
30
 
minutes
 
(alendronate
 
and
 
alendronate/cholecalciferol)
 
and
 
less
 
than
 
60
 
minutes
 
(ibandronate)
 
or
 
before
 
the
 
first
 
food
 
of
 
the
 
day.
  
 
2.
 
Mouth
 
sores
 
(ulcers)
 
may
 
occur
 
if
 
the
 
medication
 
is
 
chewed
 
or
 
dissolved
 
in
 
the
 
mouth.
  
 
3.
 
May
 
get
 
flu-like
 
symptoms,
 
typically
 
at
 
the
 
start
 
of
 
treatment.
  
 
4.
 
May
 
get
 
allergic
 
reactions,
 
such
 
as
 
hives
 
or,
 
in
 
rare
 
cases,
 
swelling
 
of
 
the
 
face,
 
lips,
 
tongue,
 
or
 
throat.
  
 
5.
 
May
 
cause
 
jaw-bone
 
problems
 
in
 
some
 
people.
 
Jaw-bone
 
problems
 
may
 
include
 
infection,
 
and
 
delayed
 
healing
 
after
 
teeth
 
are
 
pulled.
  
 
6.
 
Stop
 
taking
 
the
 
medication
 
and
 
call
 
the
 
doctor
 
right
 
away
 
if
 
there
 
are
 
any
 
of
 
these
 
signs
 
of
 
possible
 
serious
 
problems
 
of
 
the
 
oesophagus:
  
 
●
 
Chest
 
pain
 
 
●
 
New
 
or
 
worsening
 
heartburn
  
 
●
 
Trouble
 
or
 
pain
 
when
 
swallowing.
 
7.
 
The
 
most
 
common
 
side
 
effect
 
is
 
stomach
 
area
 
(abdominal)
 
pain.
 
Less
 
common
 
side
 
effects
 
are
 
nausea,
 
vomiting,
 
a
 
full
 
or
 
bloated
 
feeling
 
in
 
the
 
stomach,
 
constipation,
 
diarrhoea,
 
black
 
or
 
bloody
 
stools
 
(bowel
 
movements),
 
gas,
 
eye
 
pain,
 
rash
 
that
 
 
 
 
69
 

=== PAGE 71 ===

 
may
 
be
 
made
 
worse
 
by
 
sunlight,
 
hair
 
loss,
 
headache,
 
dizziness,
 
a
 
changed
 
sense
 
of
 
taste,
 
joint
 
swelling
 
or
 
swelling
 
in
 
the
 
hands
 
or
 
legs,
 
and
 
bone,
 
muscle,
 
or
 
joint
 
pain.
 
 
Storage*
 
1.
 
Store
 
your
 
tablets
 
in
 
the
 
original
 
blister
 
pack
 
at
 
or
 
below
 
30°C.
 
 
2.
 
Protect
 
from
 
moisture
 
and
 
light
 
 
 
 
Others
 
1.
 
Drug
 
interaction
 
with
 
Parathyroid
 
hormone
 
2.
 
All
 
food
 
and
 
beverages
 
(including
 
mineral
 
water)
 
calcium
 
supplements,
 
antacids,may
 
decrease
 
absorption
 
of
 
this
 
drug.
 
 
 
 
Before
 
ending
 
this
 
peer
 
review
 
session,
 
the
 
reviewee
 
should
 
be
 
informed
 
of
 
the
 
step(s)
 
that
 
he/
 
she
 
missed
 
out
 
in
 
order
 
to
 
ensure
 
all
 
the
 
counselling
 
points
 
are
 
being
 
covered.
 
 
Remarks:
 
 
 
 
 
Reviewed
 
by:
 
Name
 
&
 
Signature
                                                                   
Date:
 
 
 
*Mandatory
 
for
 
validation/peer
 
review
 
 
References:
 
1.
 
Sterling,
 
A.,
 
M
 
Zand,
 
Jonathan.
 
Alendronate:
 
Drug
 
Information.
 
UpToDate.
 
(2024)
 
UpToDate
 
(
Version
 
3.68.3)
 
[Mobile
 
App]
 
Mobile
 
Clinical
 
Decision
 
Support
 
App
 
|
 
UpToDate
 
|
 
Wolters
 
Kluwer
 
2.
 
Formulari
 
Ubat
 
KKM
 
(FUKKM).
 
(Version
 
241030.001
)
 
Retrieved
 
from
 
https://i.pharmacy .gov.my/fukkm/1668
,
 
https://i.pharmacy .gov.my/fukkm/1801
 
and
 
https://i.pharmacy .gov.my/fukkm/1590
 
3.
 
Frishauf,
 
Peter .
 
Alendronate.
 
Medscape.
 
(2024)
 
Medscape
 
(Version
 
12.2.1)
 
[Mobile
 
App]
 
Point-of-Care
 
Medical
 
Reference
 
App
 
For
 
Doctors
 
|
 
Medscape
 
4.
 
Merative,
 
L.P.
 
Alendronate
 
Sodium.
 
Micromedex.
 
(2024)
 
Micromedex
 
(Version
 
4.6.0)
 
[Mobile
 
App]
 
https://play .google.com/store/apps/details?id=com.truven.druginfonative.customer
 
5.
 
Hovid.
 
(2022).
 
Alendronate
 
70mg
 
tablet
 
[Product
 
Insert].
 
Retrieved
 
from
 
Alendronate
 
(VIALE06-var)
 
MY
 
(PengHooi)2
 
(bpfk.gov .my)
 
6.
 
Roche.
 
(2015).
 
Ibandronate
 
150mg
 
tablet
 
[Product
 
Insert].
 
https://www .accessdata.fda.gov/drugsatfda_docs/label/2015/021455s019lbl.pdf
 
7.
 
O’Mahony ,
 
D.,
 
et.al.
 
(2023).
 
STOPP-ST ART
 
v.3
 
Screening
 
Tool
 
of
 
Older
 
People’ s
 
Prescriptions
 
(STOPP)
 
Screening
 
Tool
 
to
 
Alert
 
to
 
Right
 
Treatment
 
(START).
 
https://www .cgakit.com/_files/ugd/2a1cfa_94280508e6014f3db06594abd0193994.pdf
 
8.
 
American
 
Geriatrics
 
Society
 
Beers
 
Criteria®
 
Update
 
Expert
 
Panel.
 
(2023).
 
American
 
Geriatrics
 
Society
 
2023
 
updated
 
AGS
 
Beers
 
Criteria®
 
for
 
Potentially
 
Inappropriate
 
Medication
 
Use
 
in
 
Older
 
Adults.
 
Journal
 
of
 
the
 
American
 
Geriatrics
 
Society
,
 
71
(7),
 
2052-2081.
 
9.
 
Sterling,
 
A.,
 
M
 
Zand,
 
Jonathan.
 
Ibandronate:
 
Drug
 
Information.
 
UpToDate.
 
(2024)
 
UpToDate
 
(
Version
 
3.68.3)
 
[Mobile
 
App]
 
Mobile
 
Clinical
 
Decision
 
Support
 
App
 
|
 
UpToDate
 
|
 
Wolters
 
Kluwer
 
10.
 
Frishauf,
 
Peter .
 
Ibandronate.
 
Medscape.
 
(2024)
 
Medscape
 
(Version
 
12.2.1)
 
[Mobile
 
App]
 
Point-of-Care
 
Medical
 
Reference
 
App
 
For
 
Doctors
 
|
 
Medscape
 
11.
 
Merative,
 
L.P.
 
Alendronate
 
Sodium/Cholecalciferol.
 
Micromedex.
 
(2024)
 
Micromedex
 
(Version
 
4.6.0)
 
[Mobile
 
App]
 
https://play .google.com/store/apps/details?id=com.truven.druginfonative.customer
 
12.
 
12.
 
Merative,
 
L.P.
 
Ibandronate
 
Sodium.
 
Micromedex.
 
(2024)
 
Micromedex
 
(Version
 
4.6.0)
 
[Mobile
 
App]
 
https://play .google.com/store/apps/details?id=com.truven.druginfonative.customer
 
13.
 
Chiu,
 
W.
 
Y.,
 
Lee,
 
J.
 
J.,
 
&
 
Tsai,
 
K.
 
S.
 
(2013).
 
Atypical
 
femoral
 
fractures
 
shortly
 
after
 
osteonecrosis
 
of
 
the
 
jaw
 
in
 
a
 
postmenopausal
 
woman
 
taking
 
alendronate
 
for
 
osteoporosis.
 
The
 
Journal
 
of
 
clinical
 
endocrinology
 
and
 
metabolism
,
 
98
(4),
 
E723–E726.
 
https://doi.org/10.1210/jc.2012-4144
 
14.
 
Bauer ,
 
D.
 
C.,
 
Black,
 
D.,
 
Ensrud,
 
K.,
 
Thompson,
 
D.,
 
Hochberg,
 
M.,
 
Nevitt,
 
M.,
 
...
 
&
 
Fracture
 
Intervention
 
Trial
 
Research
 
Group.
 
(2000).
 
Upper
 
gastrointestinal
 
tract
 
safety
 
profile
 
of
 
alendronate:
 
the
 
fracture
 
intervention
 
trial.
 
Archives
 
of
 
internal
 
medicine
,
 
160
(4),
 
517-525.7
 
15.
 
Khosla,
 
S.,
 
Burr,
 
D.,
 
Cauley ,
 
J.,
 
Dempster ,
 
D.
 
W.,
 
Ebeling,
 
P.
 
R.,
 
Felsenberg,
 
D.,
 
...
 
&
 
Shane,
 
E.
 
(2007).
 
Bisphosphonate
‐
associated
 
osteonecrosis
 
of
 
the
 
jaw:
 
report
 
of
 
a
 
task
 
force
 
of
 
the
 
American
 
Society
 
for
 
Bone
 
and
 
Mineral
 
Research.
 
Journal
 
of
 
bone
 
and
 
mineral
 
research
,
 
22
(10),
 
1479-1491.
 
70
 

=== PAGE 72 ===

 
Buprenorphine,
 
Transdermal
 
Patch
 
Name
 
:
 
 
Unit
 
:
 
 
●
 
Please
 
tick
 
(
✔
)
 
Yes
 
for
 
correct
 
instruction.
 
●
 
Please
 
tick
 
(
✔
)
 
No
 
for
 
incorrect
 
instruction.
 
Yes
 
No
 
Remarks
 
Pharmacological
 
Group
 
Opioid
 
Analgesic
 
 
 
 
Indications
 
and
 
Dosage
 
Treatment
 
of
 
non-malignant
 
pain
 
of
 
moderate
 
intensity
 
when
 
an
 
opioid
 
is
 
necessary
 
for
 
obtaining
 
adequate
 
analgesia.
 
Not
 
suitable
 
for
 
the
 
treatment
 
of
 
acute
 
pain.
 
 
For
 
elderly
 
patients
 
or
 
patients
 
with
 
comorbidities/
 
difficulties
 
to
 
swallow .
 
 
Once
 
weekly
 
transdermal
 
patch/for
 
hospital
 
use
 
only.
 
Patients
 
aged
 
18
 
years
 
and
 
over.
 
Initial
 
dose:
 
5
 
mcg/hr .
 
 
Renal
 
impairment:
 
No
 
special
 
dose
 
adjustments
 
necessary
 
in
 
patients
 
with
 
renal
 
impairment.
 
 
 
Hepatic
 
impairment:
 
Patients
 
with
 
hepatic
 
insuf ficiency
 
should
 
be
 
carefully
 
monitored
 
during
 
the
 
treatment
 
with
 
buprenorphine
 
patch.
 
Alternate
 
therapy
 
should
 
be
 
considered.
 
Patch
 
should
 
be
 
used
 
with
 
cautions
 
in
 
severe
 
hepatic
 
impairment
 
patients.
 
 
 
To
 
counsel
 
based
 
on
 
specific
 
medication’ s
 
indication
 
and
 
dosage
 
as
 
prescribed
 
by
 
the
 
doctor
 
 
 
 
Method
 
of
 
Administration*
 
Step
 
1:
 
Preparing
 
the
 
skin
 
a.
 
Make
 
sure
 
the
 
skin
 
is
 
completely
 
dry,
 
clean
 
and
 
cool
 
before
 
putting
 
the
 
patch
 
on.
 
b.
 
Sites
 
of
 
application
 
are
 
chest,
 
back
 
and
 
upper
 
arms
 
Step
 
2:
 
Open
 
the
 
sachet
 
a.
 
Each
 
patch
 
is
 
sealed
 
in
 
its
 
own
 
sachet
 
b.
 
Tear
 
or
 
cut
 
open
 
the
 
sachet
 
at
 
the
 
notch,
 
shown
 
by
 
the
 
arrow
 
Step
 
3:
 
Peel
 
and
 
press
 
a.
 
Carefully
 
peel
 
one
 
half
 
of
 
the
 
shiny
 
plastic
 
backing
 
away
 
from
 
the
 
centre
 
of
 
the
 
patch.
 
Try
 
not
 
to
 
touch
 
the
 
sticky
 
side
 
of
 
the
 
patch
 
b.
 
Press
 
the
 
sticky
 
part
 
of
 
the
 
patch
 
onto
 
the
 
skin
 
c.
 
Remove
 
the
 
other
 
part
 
of
 
the
 
backing
 
and
 
press
 
the
 
whole
 
patch
 
onto
 
the
 
skin
 
with
 
the
 
palm
 
of
 
your
 
hand.
 
d.
 
Hold
 
for
 
at
 
least
 
30
 
seconds.
 
Make
 
sure
 
it
 
sticks
 
well,
 
especially
 
the
 
edges
 
e.
 
The
 
date
 
and
 
time
 
of
 
application
 
and/or
 
renewal
 
should
 
be
 
written
 
on
 
the
 
patch.
 
Step
 
4:
 
Disposing
 
of
 
the
 
patch
 
a.
 
As
 
soon
 
as
 
take
 
a
 
patch
 
off,
 
fold
 
it
 
firmly
 
in
 
half
 
so
 
that
 
the
 
sticky
 
side
 
sticks
 
to
 
itself
 
b.
 
Put
 
it
 
back
 
in
 
its
 
original
 
sachet
 
and
 
dispose
 
of
 
the
 
sachet
 
as
 
instructed
 
Step
 
5:
 
Wash
 
a.
 
Always
 
wash
 
the
 
hands
 
after
 
handling
 
the
 
patch
 
using
 
clean
 
water
 
only
 
Step
 
6:
 
Change
 
of
 
patch
 
a.
 
Change
 
patch
 
every
 
7
 
days
 
at
 
the
 
same
 
time
 
b.
 
If
 
the
 
patch
 
falls
 
off
 
before
 
the
 
scheduled
 
change
 
date
 
(7
 
days),
 
discard
 
it
 
and
 
apply
 
a
 
new
 
patch
 
to
 
a
 
different
 
skin
 
site.
 
 
 
 
71
 

=== PAGE 73 ===

 
c.
 
Rotate
 
the
 
site
 
after
 
each
 
patch
 
removal
 
and
 
wait
 
for
 
at
 
least
 
3-4
 
weeks
 
before
 
reapplying
 
to
 
the
 
same
 
site
 
 
Missed
 
dose
 
management:
 
1.
 
Apply
 
a
 
new
 
patch
 
as
 
soon
 
as
 
you
 
remember
 
 
2.
 
Do
 
not
 
apply
 
twice
 
the
 
number
 
of
 
patches
 
to
 
make
 
up
 
for
 
the
 
patch
 
that
 
you
 
missed.
 
 
3.
 
This
 
will
 
increase
 
the
 
chance
 
of
 
you
 
getting
 
unwanted
 
side-ef fects
 
 
Do
 
not
 
stop
 
taking
 
your
 
medication
 
unless
 
advised
 
to
 
do
 
so
 
by
 
your
 
prescriber
 
Special
 
Considerations
 
Pregnancy
 
 
 
 
1.
 
May
 
need
 
dose
 
adjustment;
 
depends
 
on
 
withdrawal
 
signs
 
and
 
symptoms
 
need
 
to
 
be
 
monitored.
 
 
2.
 
Use
 
of
 
an
 
extended
 
period
 
of
 
time
 
may
 
expose
 
in
 
the
 
neonatal
 
opioids
 
withdrawal
 
syndrome
 
3.
 
Advice
 
of
 
the
 
risk
 
of
 
neonatal
 
opioids
 
withdrawal
 
syndrome
 
and
 
ensure
 
that
 
management
 
by
 
neonatology
 
experts
 
will
 
be
 
available
 
at
 
delivery
 
 
 
 
 
Breastfeeding
 
 
 
 
1.
 
Infant
 
risk
 
cannot
 
be
 
ruled
 
out.
 
 
 
 
Elderly
 
 
 
 
1.
 
Increased
 
sensitivity
 
to
 
weak
 
opioids
  
in
 
elderly
 
patients
 
can
 
result
 
in
 
excessive
 
sedation,
 
dizziness,
 
confusion,
 
and
 
an
 
elevated
 
risk
 
of
 
delirium
 
and
 
lead
 
to
 
falls.
 
2.
 
Use
 
with
 
caution
 
in
 
the
 
elderly ,
 
debilitated
 
or
 
cachectic
 
patients
 
have
 
an
 
increased
 
risk
 
for
 
respiratory
 
depression.
 
3.
 
Use
 
in
 
elderly
 
patients
 
carry
 
risks
 
of
  
constipation
 
that
 
lead
 
to
  
delirium
 
and
 
increased
 
risk
 
of
 
falls.
 
4.
 
Avoid
 
in
 
patients
 
with
 
a
 
history
 
of
 
fractures
 
or
 
falls,
 
it
 
may
 
contribute
 
to
 
additional
 
fall.
 
 
 
 
Paediatric
 
 
 
 
1.
 
The
 
safety
 
and
 
efficacy
 
in
 
pediatric
 
patients
 
have
 
not
 
been
 
established.
 
 
 
 
Others
 
 
 
 
 
1.
 
Addiction:
 
abuse,
 
misuse,
 
or
 
opioid
 
addiction
 
may
 
occur .
 
Use
 
cautiously
 
in
 
patients
 
with
 
a
 
history
 
of
 
substance
 
abuse
 
or
 
mental
 
illness.
 
2.
 
Fever
 
with
 
increased
 
core
 
body
 
temperature
 
might
 
increase
 
adverse
 
effects;
 
adjust
 
dose
 
if
 
necessary
 
 
3.
 
Heat
 
exposure:
 
Avoid
 
heat
 
exposure
 
to
 
application
 
site
 
or
 
surrounding
 
areas
 
(e.g:
 
heating
 
pads,
 
electric
 
blankets,
 
heating
 
lamps,
 
sauna,
 
hot
 
water
 
or
 
direct
 
sunlight)
 
4.
 
Concomitant
 
use
 
with
 
others:
 
Benzodiazepines
 
or
 
Central
 
Nervous
 
System(CNS)
 
depressants
 
including
 
alcohol
 
may
 
result
 
in
 
profound
 
sedation,
 
respiratory
 
depression,
 
coma,
 
and
 
death.
 
 
 
 
Side
 
Effects
 
and
 
their
 
Management*
 
1.
 
Opioid-induced
 
constipation
 
a.
 
A
 
common
 
side
 
effect
 
b.
 
Tolerance
 
does
 
not
 
develop,
 
hence
 
laxatives
 
 
 
 
72
 

=== PAGE 74 ===

 
must
 
be
 
taken
 
regularly 
 
c.
 
Use
 
combination
 
of
 
stimulant
 
(e.g.
 
bisacodyl)
 
+
 
softener
 
(e.g.
 
lactulose)
 
d.
 
Increase
 
fluid
 
and
 
dietary
 
fibre
 
intake,
 
maintain
 
good
 
physical
 
activity ,
 
and
 
try
 
to
 
establish
 
a
 
toilet
 
routine
 
 
2.
 
Opioid-induced
 
sedation
 
/
 
impaired
 
alertness
 
a.
 
May
 
occur
 
upon
 
initiation
 
of
 
opioids
 
b.
 
Avoid
 
driving
 
and
 
other
 
activities
 
that
 
require
 
mental
 
alertness
 
until
 
it
 
is
 
clear
 
how
 
morphine/
 
Oxycodone
 
affects
 
the
 
patient
 
c.
 
Tolerance
 
develops
 
after
 
5
 
-
 
10
 
days
 
 
3.
 
Opioid-induced
 
neurotoxicity
 
(delirium,
 
confusion)
 
a.
 
May
 
occur ,
 
but
 
usually
 
transient
 
b.
 
May
 
consider
 
use
 
of
 
haloperidol
 
for
 
delirium
 
 
4.
 
Opioid-induced
 
nausea
 
and
 
vomiting
 
a.
 
May
 
occur
 
upon
 
initiation
 
of
 
opioids
 
b.
 
Tolerance
 
develops
 
5
 
-
 
10
 
days
 
after
 
starting
 
c.
 
May
 
use
 
antiemetics
 
(e.g.
 
metoclopramide,
 
haloperidol
 
or
 
prochlorperazine)
 
d.
 
Be
 
consistent
 
when
 
taking
 
morphine
 
with
 
or
 
without
 
meals
 
 
5.
 
Opioid-induced
 
dry
 
mouth 
 
a.
 
Sip
 
water
 
often,
 
let
 
small
 
ice
 
chips
 
melt
 
in
 
your
 
mouth
 
b.
 
Minimise
 
intake
 
of
 
caffeinated
 
drinks,
 
such
 
as
 
coffee,
 
tea,
 
and
 
some
 
sodas
 
as
 
well
 
as
 
use
 
of
 
tobacco
 
and
 
alcohol
 
c.
 
Chew
 
sugarless
 
gum
 
or
 
suck
 
on
 
sugarless
 
hard
 
candy
 
to
 
stimulate
 
saliva
 
flow
 
 
6.
 
Dermatologic:
 
 
a.
 
Severe
 
application
 
site
 
reactions
 
may
 
occur .
 
Onset
 
ranged
 
from
 
days
 
to
 
months
 
after
 
initiation.
 
Storage*
 
1.
 
Store
 
your
 
medication
 
in
 
a
 
cool,
 
dry
 
place
 
away
 
from
 
heat,
 
moisture
 
and
 
direct
 
sunlight
 
2.
 
Disposal:
 
FOLD
 
used
 
patches
 
so
 
that
 
the
 
adhesive
 
side
 
adheres
 
to
 
itself.
 
 
 
 
Others
 
1.
 
Do
 
not
 
shave
 
the
 
skin
 
if
 
it
 
is
 
hairy .
 
Instead,
 
clip
 
the
 
hair
 
as
 
close
 
to
 
the
 
skin
 
as
 
possible
 
2.
 
If
 
Opioids-induce
 
hyperalgesia
 
and
 
allodynia
 
(OIH)
 
reported,carefully
 
decreasing
 
dose
 
of
 
current
 
opioids
 
or
 
rotation
 
to
 
a
 
different
 
opioids
 
moiety
 
3.
 
Serotonin
 
Syndrome
 
is
 
rare
 
but
 
potentially
 
life-threatening
 
resulting
 
from
 
concomitant
 
administration
 
of
 
serotonergic
 
drugs
 
like
 
Selective
 
Serotonin
 
Reuptake
 
Inhibitors
 
(SSRIs)
 
4.
 
When
 
discontinuing
 
patch,
 
taper
 
dose
 
as
 
part
 
of
 
comprehensive
 
treatment
 
plan;
 
consider
 
use
 
of
 
immediate-release
 
opioids
 
analgesics.
 
 
 
 
 
73
 

=== PAGE 75 ===

 
Before
 
ending
 
this
 
peer
 
review
 
session,
 
the
 
reviewee
 
should
 
be
 
informed
 
of
 
the
 
step(s)
 
that
 
he/
 
she
 
missed
 
out
 
in
 
order
 
to
 
ensure
 
all
 
the
 
counselling
 
points
 
are
 
being
 
covered.
 
 
Remarks:
 
 
 
 
 
Reviewed
 
by:
 
Name
 
&
 
Signature
                                                                   
Date:
 
 
 
 
 
*Mandatory
 
for
 
validation
 
/
 
peer
 
review
 
References:
 
 
1.
 
Burprenorphine
 
(2025).
 
MEDSCAPE
 
Drug
 
Reference
 
version
 
v1158.0.
 
Retrieved
 
January
 
20,
 
2025
 
from
 
https://reference.medscape.com/drug/buprenex-buprenorphine-343326
 
2.
 
Buprenorphine
 
(2025).
 
Micromedex
 
(electronic
 
version).
 
Retrieved
 
January
 
20,
 
2025
 
from
 
http://www .micromedexsolutions.com/
 
 
3.
 
Formulari
 
Ubat
 
KKM
 
(2025).
 
Ministry
 
of
 
Health
 
Malaysia.
 
Retrieved
 
January
 
20,
 
2025
 
from
 
https://pharmacy .moh.gov .my/ms/apps/fukkm?generic=buprenorphine&category=&indications=
 
4.
 
Mundipharma
 
New
 
Zealand
 
Limited.
 
(2020).
 
Norspan
 
patch
 
[Data
 
sheet].
 
Medsafe.
 
Retrieved
 
January
 
20,
 
2025,
 
from
 
https://www .medsafe.govt.nz/profs/Datasheet/n/Norspanpatch.pd
 
5.
 
2023
 
American
 
Geriatrics
 
Society
 
Beers
 
Criteria®
 
Update
 
Expert
 
Panel.
 
(2023).
 
American
 
Geriatrics
 
Society
 
2023
 
updated
 
AGS
 
Beers
 
Criteria®
 
for
 
potentially
 
inappropriate
 
medication
 
use
 
in
 
older
 
adults.
 
Journal
 
of
 
the
 
American
 
Geriatrics
 
Society ,
 
71(7),
 
2052-2081
.
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
74
 

=== PAGE 76 ===

 
Calcium
 
Carbonate
 
Name
 
:
 
 
Unit
 
:
 
 
●
 
Please
 
tick
 
(
✔
)
 
Yes
 
for
 
correct
 
instruction.
 
●
 
Please
 
tick
 
(
✔
)
 
No
 
for
 
incorrect
 
instruction.
 
Yes
 
No
 
Remarks
 
Pharmacological
 
Group
 
Calcium
 
Calcium
 
Carbonate
 
 
 
 
 
Indications
 
and
 
Dosage
 
1.
 
Hyperphosphatemia
 
(phosphate
 
binder)
 
in
 
chronic
 
kidney
 
disease
 
patients
 
a.
 
Total
 
dose
 
of
 
elemental
 
calcium
 
from
 
calcium-based
 
phosphate
 
binder
 
not
 
to
 
exceed
 
1,500
 
mg/day .Dosing
 
is
 
individualised
 
based
 
on
 
serum
 
phosphate
 
level
 
and
 
according
 
to
 
product
 
insert/protocol
 
2.
 
Calcium
 
supplementation
 
a.
 
500
 
mg
 
to
 
4g
 
per
 
day
 
as
 
calcium
 
carbonate
 
in
 
1-3
 
divided
 
doses
 
(500mg
 
capsule
 
contains
 
200mg
 
elemental
 
calcium).Dosing
 
is
 
individualised
 
based
 
on
 
serum
 
calcium
 
level
 
and
 
according
 
to
 
product
 
insert/protocol
 
To
 
counsel
 
based
 
on
 
specific
 
medication’ s
 
indication
 
and
 
dosage
 
as
 
prescribed
 
by
 
the
 
doctor
 
 
 
 
Method
 
of
 
Administration*
 
1.
 
Hyperphosphatemia
 
 
Tablet
 
1.
 
To
 
chew
 
/
 
crush
 
and
 
take
 
WITH
 
meals
 
/
 
snacks
 
 
2.
 
Can
 
be
 
crushed
 
and
 
served
 
through
 
Ryle’ s
 
tube
 
 
Capsule
 
1.
 
To
 
swallow
 
WITH
 
meals
 
/
 
snacks
 
OR
 
to
 
open
 
the
 
capsule
 
and
 
sprinkle
 
the
 
powder
 
on
 
the
 
meal
 
 
2.
 
Calcium
 
Supplements
 
1.
 
To
 
swallow
 
the
 
whole
 
tablet
 
/
 
capsule
 
with
 
food.
 
2.
 
Post
 
parathyroidectomy ,
 
to
 
swallow
 
the
 
whole
 
tablet
 
/
 
capsule
 
on
 
empty
 
stomach
 
to
 
minimise
 
the
 
phosphate
 
binding
 
effects.
 
Missed
 
dose
 
management:
 
In
 
case
 
of
 
a
 
missed
 
dose,
 
take
 
it
 
during
 
the
 
meal
 
or
 
immediately
 
after
 
the
 
meal.
 
Omit
 
the
 
dose
 
if
 
totally
 
forgotten
 
and
 
remember
 
to
 
take
 
as
 
per
 
instructed
 
during
 
the
 
next
 
meal.
 
 
 
Do
 
not
 
stop
 
taking
 
your
 
medication
 
unless
 
advised
 
to
 
do
 
so
 
by
 
your
 
prescriber
 
 
 
 
Special
 
Considerations
 
Pregnancy
 
 
 
 
1.
 
Calcium
 
crosses
 
the
 
placenta.
 
 
2.
 
Calcium
 
carbonate
 
is
 
generally
 
considered
 
safe
 
for
 
use
 
during
 
pregnancy .
 
 
 
 
 
Breastfeeding
 
 
 
 
1.
 
Calcium
 
is
 
found
 
in
 
breast
 
milk
 
2.
 
Calcium
 
carbonate
 
is
 
unlikely
 
to
 
be
 
harmful
 
to
 
a
 
nursing
 
baby
 
if
 
used
 
as
 
directed.
 
 
 
 
 
Elderly
 
 
 
 
Monitor
 
for
 
hypercalcemia,
 
especially
 
in
 
the
 
elderly
 
who
 
are
 
more
 
prone
 
to
 
decreased
 
renal
 
function.
 
 
 
 
75
 

=== PAGE 77 ===

 
Paediatric
 
 
 
 
1.
 
Can
 
be
 
used
 
for
 
children
 
with
 
CKD
 
for
 
phosphate
 
binding
 
/
 
calcium
 
supplements.
 
2.
 
Monitor
 
serum
 
calcium
 
level
 
regularly .
 
 
 
 
Fasting
 
 
 
 
1.
 
Adjust
 
the
 
timing
 
of
 
administration
 
according
 
to
 
the
 
fasting
 
schedule
 
during
 
Ramadhan.
 
To
 
take
 
during
 
Sahur
 
(before
 
fasting)
 
and
 
Iftar
 
(breaking
 
fast).
 
2.
 
If
 
more
 
than
 
two
 
doses
 
have
 
been
 
prescribed,
 
consult
 
with
 
the
 
healthcare
 
provider
 
to
 
adjust
 
your
 
phosphate
 
binder
 
administration.
  
 
 
 
 
Others
  
 
 
 
 
No
 
dosage
 
adjustment
 
was
 
provided
 
in
 
the
 
manufacturer ’s
 
labelling.
 
 
 
 
Side
 
Effects
 
and
 
their
 
Management*
 
1.
 
Generally ,
 
well
 
tolerated.
 
2.
 
Gastrointestinal:
 
Abdominal
 
pain,
 
anorexia,
 
constipation,
 
flatulence,
 
nausea,
 
vomiting
 
3.
 
Endocrine/metabolic:
 
Hypercalcemia
 
 
 
 
 
Storage*
 
1.
 
Store
 
at
 
room
 
temperature.
 
2.
 
Store
 
in
 
a
 
dry
 
place
 
and
 
protect
 
from
 
moisture.
 
3.
 
Keep
 
out
 
of
 
reach
 
of
 
children.
 
 
 
 
Others
 
1.
 
Monitor
 
serum
 
calcium
 
/
 
phosphate
 
regularly .
 
2.
 
Significant
 
drug-drug
 
interactions:
 
a.
 
Calcium
 
carbonate
 
reduces
 
the
 
absorption
 
of
 
 
iron
 
supplements,
 
bisphosphonates,
 
thyroid
 
hormones,
 
fluoroquinolones
 
–
 
space
 
out
 
1
 
hour
  
or
 
2
 
hours
 
from
 
calcium
 
supplements
 
b.
 
Concurrent
 
use
 
of
 
calcium
 
carbonate
 
with
 
a
 
proton
 
pump
 
inhibitor
 
may
 
reduce
 
the
 
effectiveness
 
of
 
calcium
 
carbonate.
 
 
c.
 
Calcium
 
carbonate
 
increases
 
the
 
absorption
 
of
 
Vitamin
 
D
 
Analogs.
 
3.
 
Contraindications
 
Hypersensitivity ,
 
hypercalcemia
 
 
 
 
Before
 
ending
 
this
 
peer
 
review
 
session,
 
the
 
reviewee
 
should
 
be
 
informed
 
of
 
the
 
step(s)
 
that
 
he/
 
she
 
missed
 
out
 
in
 
order
 
to
 
ensure
 
all
 
the
 
counselling
 
points
 
are
 
being
 
covered.
 
 
Remarks:
 
 
 
Reviewed
 
by:
 
Name
 
&
 
Signature
                                                                   
Date:
 
 
 
*Mandatory
 
for
 
validation/peer
 
review
 
 
References:
 
 
1.
 
MPI
 
Pharmaceutical
 
(2011).
 
Product
 
information
 
leaflet:
 
Calcium
 
Carbonate.
 
Retrieved
 
from
 
Quest
 
3+
 
Product
 
Search
 
on
 
January
 
1,
 
2025.
 
2.
 
IOM
 
(Institu
te
 
of
 
Medicine)
 
(2011).
 
Dietary
 
Reference
 
Intakes
 
for
 
Calcium
 
and
 
Vitamin
 
D.
 
The
 
National
 
Academies
 
Press.Retrieved
 
from
 
doi.org/10.17226/13050
 
3.
 
Prenticce
 
A.
 
(2000).
 
Calcium
 
in
 
pregnancy
 
and
 
lactation.
 
Annu
 
Rev
 
Nutr.
 
20:249-272.
 
Retrieved
 
from
 
doi:10.1 146/annurev .nutr.20.1.249
 
4.
 
Fritz
 
K
 
et
 
al.
 
(2023)
 
Calcium
 
Carbonate.
 
StatPearls.
 
Retrieved
 
from
 
https://www .ncbi.nlm.nih.gov/books/NBK562303/
 
5.
 
Formulari
 
Ubat
 
KKM.
 
(2025,
 
January
 
1).
 
Accessed
 
on
 
January
 
1,
 
2025.
 
76
 

=== PAGE 78 ===

 
Carbamazepine
 
Name
 
:
 
 
Unit
 
:
 
 
●
 
Please
 
tick
 
(
✔
)
 
Yes
 
for
 
correct
 
instruction.
 
●
 
Please
 
tick
 
(
✔
)
 
No
 
for
 
incorrect
 
instruction.
 
Yes
 
No
 
Remarks
 
Pharmacological
 
Group
 
Antiepileptic
 
drugs/
 
Anticonvulsants
 
drugs
 
 
 
 
 
Indications
 
and
 
Dosage
 
1.
 
 
Epilepsy
 
 
a.
 
100-200
 
mg
 
1-3
 
times
 
daily
 
increased
 
gradually
 
to
 
the
 
usual
 
dose
 
of
 
0.8-1.2
 
g
 
daily
 
in
 
divided
 
doses.
 
 
2.
 
Trigeminal
 
neuralgia
 
a.
 
Initial
 
dose
 
200-
 
400
 
mg
 
should
 
be
 
slowly
 
raised
 
daily
 
until
 
freedom
 
from
 
pain
 
is
 
achieved.
 
Or
 
 
 
To
 
counsel
 
based
 
on
 
specific
 
medication’ s
 
indication
 
and
 
dosage
 
as
 
prescribed
 
by
 
the
 
doctor
 
 
 
 
Method
 
of
 
Administration*
 
1.
 
Should
 
be
 
taken
 
with
 
food.
 
2.
 
Try
 
to
 
take
 
it
 
at
 
the
 
same
 
time
 
each
 
day.
 
3.
 
Avoid
 
grapefruit
 
juice.
 
 
Missed
 
dose
 
management:
 
 
1.
 
If
 
you
 
forget
 
to
 
take
 
a
 
dose,
 
take
 
it
 
as
 
soon
 
as
 
you
 
remember .
 
Do
 
not
 
take
 
two
 
doses
 
at
 
once.
 
 
Do
 
not
 
stop
 
taking
 
your
 
medication
 
unless
 
advised
 
to
 
do
 
so
 
by
 
your
 
prescriber
 
 
 
 
Special
 
Considerations
 
Pregnancy
 
 
 
 
1.
 
Associated
 
with
 
increased
 
risk
 
of
 
major
 
congenital
 
malformations.
 
Use
 
only
 
when
 
benefits
 
outweigh
 
risks.
  
 
 
 
 
Breastfeeding
 
 
 
 
1.
 
Excreted
 
in
 
human
 
milk
 
with
 
concentration
 
ranging
 
from
 
1%
 
–
 
10%
 
of
 
maternal
 
serum
 
levels.
 
 
 
 
Elderly
 
 
 
 
1.
 
Initiate
 
at
 
lower
 
dose
 
and
 
increase
 
slowly .
 
Initial
 
dose
 
of
 
100mg
 
twice
 
daily
 
is
 
recommended.
 
2.
 
Precaution
 
with
 
falls
 
as
 
associated
 
with
 
ataxia,
 
dizziness,
 
hypotension,
 
3.
 
May
 
exacerbate
 
or
 
cause
 
SIADH
 
or
 
hyponatremia;
 
monitor
 
sodium
 
levels
 
closely
 
when
 
starting
 
or
 
changing
 
dosages
 
in
 
older
 
adults.
 
 
 
 
Paediatric
 
 
 
 
1.
 
HLA-B*15:02
 
allele
 
screening
 
in
 
patients
 
with
 
risk
 
of
 
genetic
 
variant
 
prior
 
to
  
initiation.
 
 
 
 
 
Fasting
 
 
 
 
77
 

=== PAGE 79 ===

 
To
 
refer
 
to
 
the
 
latest
 
advisory
 
by
 
religious
 
authority
 
 
 
 
Others
  
 
 
 
 
Hepatic
 
Impairment:
 
Special
 
precaution
 
 
 
 
Side
 
Effects
 
and
 
their
 
Management*
 
1.
 
Sedation,
 
Nausea,
 
dizziness,
 
tremor ,
 
Hypotension
 
or
 
hypertension.
  
 
2.
 
This
 
drug
 
may
 
cause
 
drowsiness
 
or
 
blurred
 
vision,
 
do
 
not
 
drive
 
or
 
operate
 
machinery .
 
 
3.
 
Women
 
of
 
childbearing
 
potential
 
must
 
use
 
highly
 
effective
 
birth
 
control
 
methods
 
without
 
interruption
 
during
 
therapy .
 
 
 
 
 
Storage*
 
Store
 
between
 
15
 
–
 
30º
 
c.
 
Protect
 
from
 
light
 
and
 
moisture.
 
 
 
 
Others
 
1.
 
Special
 
precaution:
 
Mixed
 
seizure
 
disorder ,
 
preexisting
 
cardiac
 
damage
 
or
 
underlying
 
ECG
 
abnormalities.
 
 
 
2.
 
Drug
 
interactions:
 
 
a.
 
Increased
 
plasma
 
level
 
with
 
erythromycin
 
and
 
olanzapine.
 
b.
 
Decreased
 
plasma
 
level
 
with
 
phenobarbital
 
and
 
valproic
 
acid.
 
 
c.
 
May
 
potentiate
 
the
 
CNS
 
depressants
 
effect
 
of
 
alcohol.
 
d.
 
Plasma
 
concentration
 
may
 
be
 
decreased
 
with
 
St
 
John’ s
 
wort.
 
 
 
 
 
Before
 
ending
 
this
 
peer
 
review
 
session,
 
the
 
reviewee
 
should
 
be
 
informed
 
of
 
the
 
step(s)
 
that
 
he/
 
she
 
missed
 
out
 
in
 
order
 
to
 
ensure
 
all
 
the
 
counselling
 
points
 
are
 
being
 
covered.
 
 
Remarks:
 
 
 
 
 
Reviewed
 
by:
 
Name
 
&
 
Signature
                                                                   
Date:
 
 
 
 
 
*Mandatory
 
for
 
validation/
 
peer
 
review
 
 
References:
 
 
1.
 
Ministry
 
of
 
Health
 
Malaysia.
 
(2024).
 
Formulari
 
Ubat
 
Kementerian
 
Kesihatan
 
Malaysia.
 
2.
 
Novartis
 
Corporation
 
(Malaysia)
 
Sdn.
 
Bhd.(2024)
 
Product
 
information
 
leaflet:
 
Pradaxa.
 
Retrieved
 
from
 
Quest
 
3+
 
Product
 
Search
 
on
 
January
 
1,
 
2025.
 
3.
 
Amstutz,
 
U.,
 
Shear ,
 
N.
 
H.,
 
Rieder ,
 
M.
 
J.,
 
Hwang,
 
S.,
 
Fung,
 
V.,
 
Nakamura,
 
H.,
 
Connolly ,
 
M.
 
B.,
 
Ito,
 
S.,
 
&
 
Carleton,
 
B.
 
C.
 
(2014).
 
Recommendations
 
for
 
HLA
‐
B*15:02
 
and
 
HLA
‐
A*31:01
 
genetic
 
testing
 
to
 
reduce
 
the
 
risk
 
of
 
carbamazepine
‐
induced
 
hypersensitivity
 
reactions.
 
Epilepsia,
 
55(4),
 
496–506.
 
https://doi.org/10.1 111/epi.12564
 
4.
 
2023
 
American
 
Geriatrics
 
Society
 
Beers
 
Criteria®
 
Update
 
Expert
 
Panel.
 
(2023).
 
American
 
Geriatrics
 
Society
 
2023
 
updated
 
AGS
 
Beers
 
Criteria®
 
for
 
potentially
 
inappropriate
 
medication
 
use
 
in
 
older
 
adults.
 
Journal
 
of
 
the
 
American
 
Geriatrics
 
Society ,
 
71(7),
 
2052-2081.
 
 
 
 
 
 
 
78
 

=== PAGE 80 ===

 
Cetrimide,
 
Lotion
 
Name
 
:
 
 
Unit
 
:
 
 
●
 
Please
 
tick
 
(
✔
)
 
Yes
 
for
 
correct
 
instruction.
 
●
 
Please
 
tick
 
(
✔
)
 
No
 
for
 
incorrect
 
instruction.
 
Yes
 
No
 
Remarks
 
Pharmacological
 
Group
 
1.
 
Antiseptic
 
 
2.
 
Bactericidal
 
activity
 
against
 
gram-positive
 
bacteria
 
 
 
 
Indications
 
and
 
Dosage
 
1.
 
Treatment
 
of
 
Acne
 
Vulgaris
 
2.
 
General
 
antiseptic
 
and
 
skin
 
disinfectant
 
for
 
wounds,
 
cuts
 
and
 
insect
 
bites.
 
 
 
Apply
 
to
 
the
 
affected
 
area
 
as
 
required
 
or
 
as
 
directed
 
by
 
the
 
physician.
 
 
 
 
Method
 
of
 
Administration*
 
1.
 
Apply
 
solution
 
onto
 
the
 
face
 
twice
 
daily
 
.
 
2.
 
Cetrimide
 
mix
 
with
 
water
 
on
 
palms,
 
rub
 
hand
 
together
 
until
 
froth
 
 
3.
 
Apply
 
froth
 
on
 
face
 
 
4.
 
Then
 
rinse
 
off
 
with
 
water
 
 
5.
 
Dap
 
dry
 
 
Do
 
not
 
stop
 
taking
 
your
 
medication
 
unless
 
advised
 
to
 
do
 
so
 
by
 
your
 
prescriber
 
 
 
 
Special
 
Considerations
 
Pregnancy
 
 
 
 
1.
 
Should
 
be
 
used
 
during
 
pregnancy
 
only
 
if
 
the
 
potential
 
benefits
 
justify
 
the
 
potential
 
risks
 
to
 
the
 
fetus.
 
 
 
 
Breastfeeding
 
 
 
 
1.
 
Generally
 
considered
 
safe
 
for
 
use
 
during
 
breastfeeding
 
when
 
applied
 
topically .
 
2.
 
Avoid
 
applying
 
it
 
to
 
the
 
breast
 
area
 
to
 
prevent
 
accidental
 
ingestion
 
by
 
the
 
infant.
 
 
 
 
Elderly
 
 
 
 
1.
 
Not
 
applicable.
 
Refer
 
to
 
the
 
usual
 
adult
 
dose.
 
 
 
 
Paediatric
 
 
 
 
1.
 
Generally
 
considered
 
efficacious
 
in
 
paediatric
 
patients
 
for
 
antiseptic
 
and
 
disinfectant
 
use.
 
 
2.
 
Safety
 
depends
 
on
 
different
 
concentrations
 
and
 
skin
 
conditions.
 
 
 
 
Fasting
 
 
 
 
1.
 
To
 
refer
 
to
 
the
 
latest
 
advisory
 
by
 
religious
 
authority
 
 
 
 
Side
 
Effects
 
and
 
their
 
Management*
 
1.
 
Burning
 
sensation
 
 
Prolonged
 
and
 
repeated
 
administration
 
may
 
lead
 
to
 
hypersensitivity .
 
If
 
this
 
occurs,
 
stop
 
using
 
the
 
lotion
 
and
 
consult
 
your
 
physician.
 
 
 
 
 
Storage*
 
1.
 
Keep
 
the
 
container
 
tightly
 
closed.
 
 
 
 
79
 

=== PAGE 81 ===

 
2.
 
Store
 
at
 
room
 
temperature.
 
3.
 
Protect
 
from
 
light,
 
heat
 
and
 
moisture.
 
4.
 
Keep
 
medicine
 
out
 
of
 
reach
 
of
 
children.
 
5.
 
Dispose
 
of
 
any
 
remaining
 
product
 
in
 
the
 
tube
 
after
 
completing
 
your
 
course
 
of
 
treatment
 
or
 
once
 
the
 
product
 
has
 
expired.
 
Others
 
1.
 
Do
 
not
 
use
 
it
 
if
 
the
 
skin
 
is
 
weeping
 
or
 
badly
 
inflamed.
 
2.
 
Avoid
 
contact
 
with
 
eyes
 
and
 
middle
 
ear.
 
3.
 
It
 
should
 
not
 
be
 
used
 
in
 
body
 
cavities
 
(eg:mouth
 
&
 
ears)
 
4.
 
For
 
external
 
use
 
only.
 
 
 
 
Before
 
ending
 
this
 
peer
 
review
 
session,
 
the
 
reviewee
 
should
 
be
 
informed
 
of
 
the
 
step(s)
 
that
 
he/
 
she
 
missed
 
out
 
in
 
order
 
to
 
ensure
 
all
 
the
 
counselling
 
points
 
are
 
being
 
covered.
 
 
Remarks:
 
 
 
 
 
Reviewed
 
by:
 
Name
 
&
 
Signature
                                                                   
Date:
 
 
 
 
 
*Mandatory
 
for
 
validation/peer
 
review
 
 
References:
 
 
1.
 
Xorix
 
SDN
 
BHD.(Feb
 
2023).
 
Xortrim
 
2
 
Cetrimide
 
2%
 
W/V
 
lotion
 
product
 
insert.
 
Retrieved
 
from
 
V_76558_20230222_102504_D4.pdf
 
2.
 
Xorix
 
SDN
 
BHD.(Feb
 
2023).
 
Xortrim
 
1
 
Cetrimide
 
1%
 
W/V
 
lotion
 
product
 
insert.
 
Retrieved
 
from
 
V_76564_20230222_1 14648_D4.pdf
 
3.
 
Formulari
 
Ubat
 
Kementerian
 
Kesihatan
 
Malaysia
 
Bil
 
2/2024.
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
80
 

=== PAGE 82 ===

 
Clarithromycin
 
 
Name
 
:
 
 
Unit
 
:
 
 
●
 
Please
 
tick
 
(
✔
)
 
Yes
 
for
 
correct
 
instruction.
 
●
 
Please
 
tick
 
(
✔
)
 
No
 
for
 
incorrect
 
instruction.
 
Yes
 
No
 
Remarks
 
Pharmacological
 
Group
 
Macrolide
 
 
 
 
Indications
 
and
 
Dosage
 
1.
 
Second-line
 
treatment
 
for
 
leprosy
  
 
2.
 
Drug-resistant
 
leprosy
 
 
Adult
 
:
 
500mg
 
once
 
daily
 
(in
 
combination
 
with
 
other
 
anti-leprosy
 
drugs)
 
 
 
 
Method
 
of
 
Administration*
 
Food:
 
Administered
 
with
 
or
 
without
 
food
 
 
RT
 
administration:
 
No
 
specific
 
data
 
on
 
enteral
 
tube
 
administration
 
are
 
available
 
for
 
this
 
formulation.
 
Alternative
 
route
 
available:
 
parenteral
 
route.
 
 
Missed
 
dose:
 
Take
 
the
 
missed
 
dose
 
as
 
soon
 
as
 
possible
 
 
Do
 
not
 
stop
 
taking
 
your
 
medication
 
unless
 
advised
 
to
 
do
 
so
 
by
 
your
 
prescriber
 
 
 
 
Special
 
Considerations
 
Pregnancy
 
 
 
 
Avoid
 
unless
 
benefits
 
outweigh
 
risks
 
 
 
 
 
Breastfeeding
 
 
 
 
Avoid
 
 
 
 
Elderly
 
 
 
 
Adverse
 
effects
 
may
 
be
 
increased
 
in
 
older
 
patients
 
 
 
 
Paediatric
 
 
 
 
NA
 
 
 
 
Fasting
 
 
 
 
NA
 
 
 
 
Others
:
 
1.
 
Renal
 
impairment
 
(CrCl
<
30
 
mL/min):
 
No
 
dose
 
adjustment
 
required
 
at
 
doses
 
used
 
in
 
leprosy
 
 
2.
 
Liver
 
Impairment:
 
No
 
dose
 
adjustment
 
required
 
at
 
doses
 
used
 
for
 
leprosy
 
 
 
 
Side
 
Effects
 
and
 
their
 
Management*
 
Gastrointestinal
 
Disturbance:
 
Dysgeusia,
 
diarrhea,
 
vomiting,
 
nausea
 
 
Taste
 
Alteration:
 
metallic
 
taste,
 
loss
 
of
 
taste
 
sensation
 
Central
 
nervous
 
System:
 
Headache,
 
dizziness,
 
insomnia
 
 
Cardiovascular
:
 
QT
 
prolongation
 
Ototoxicity:
 
Hearing
 
loss
 
and
 
tinnitus
 
reported
 
in
 
association
 
 
 
 
81
 

=== PAGE 83 ===

 
with
 
long-term
 
use.
 
Storage*
 
Store
 
at
 
room
 
temperature
 
(do
 
not
 
refrigerate)
 
and
 
protect
 
from
 
light
 
 
 
 
Others
 
Precautions:
 
1.
 
Myasthenia
 
Gravis:
 
Macrolides
 
may
 
aggravate
 
myasthenia
 
gravis.
 
2.
 
Cardiovascular
 
Disease:
 
Due
 
to
 
the
 
risk
 
for
 
QT
 
prolongation,
 
clarithromycin
 
should
 
be
 
used
 
with
 
caution
 
in
 
patients
 
with
 
coronary
 
artery
 
disease,
 
severe
 
cardiac
 
insuf ficiency ,
 
hypomagnesaemia,
 
bradycardia
 
(<50
 
bpm),
 
or
 
when
 
co-administered
 
with
 
other
 
medicinal
 
products
 
associated
 
with
 
QT
 
prolongation.
 
 
Significant
 
drug-drug
 
/
 
drug-food
 
interactions:
 
1.
 
Avoid
 
alcohol
 
as
 
it
 
may
 
worsen
 
dizziness
 
or
 
other
 
CNS
 
side
 
effects
 
2.
 
Avoid
 
driving
 
or
 
operating
 
machinery
 
if
 
feeling
 
dizzy
 
or
 
light-headed
 
3.
 
Ticagrelol:increase
 
the
 
risk
 
of
 
serious
 
life
 
threatening
 
bleeding
 
complication
 
4.
 
Simvastatin:
 
Increase
 
risk
 
of
 
side
 
effect
 
such
 
as
 
liver
 
damage
 
and
 
rhabdomyolysis
 
5.
 
Colchicine:
 
Increase
 
blood
 
level
 
of
 
colchicine
 
to
 
dangerous
 
level,
 
and
 
can
 
affect
 
muscles,
 
blood
 
cells
 
and
 
nervous
 
system
 
 
 
 
Before
 
ending
 
this
 
peer
 
review
 
session,
 
the
 
reviewee
 
should
 
be
 
informed
 
of
 
the
 
step(s)
 
that
 
he/
 
she
 
missed
 
out
 
in
 
order
 
to
 
ensure
 
all
 
the
 
counselling
 
points
 
are
 
being
 
covered.
 
 
Remarks:
 
 
 
 
 
Reviewed
 
by:
 
Name
 
&
 
Signature
                                                                   
Date:
 
 
 
 
 
*Mandatory
 
for
 
validation/peer
 
review
 
 
References:
 
 
1.
 
World
 
Health
 
Organization.
 
Guidelines
 
for
 
the
 
diagnosis,
 
treatment
 
and
 
prevention
 
of
 
leprosy .
 
2018
 
2.
 
World
 
Health
 
Organization.
 
WHO
 
model
 
prescribing
 
information:
 
drugs
 
used
 
in
 
leprosy .
 
In
 
WHO
 
model
 
prescribing
 
information:
 
drugs
 
used
 
in
 
leprosy
 
1998
 
3.
 
TB
 
Drug
 
Monographs.
 
Clarithromycin.
 
https://www .tbdrugmonographs.co.uk/ofloxacin.html
 
4.
 
WHO
 
Expert
 
Committee
 
on
 
Leprosy .
 
WHO
 
Expert
 
Committee
 
on
 
Leprosy:
 
Eighth
 
Report.
 
World
 
Health
 
Organization.
 
2010
 
5.
 
Critical
 
Care
 
Pharmacy
 
Handbook.
 
Pharmaceutical
 
Services
 
Programme.
 
Second
 
edition.
 
2020
 
6.
 
Manual
 
Pengurusan
 
Kusta
 
Edisi
 
Ke-3.
 
MOH.
 
2023
 
7.
 
Protocol
 
on
 
Drug
 
Administration
 
Via
 
Enteral
 
Feeding
 
Tubes.
 
First
 
edition.
 
MOH.
 
2022
 
 
 
 
 
82
 

=== PAGE 84 ===

 
Clofazimine
 
 
Name
 
:
 
 
Unit
 
:
 
 
●
 
Please
 
tick
 
(
✔
)
 
Yes
 
for
 
correct
 
instruction.
 
●
 
Please
 
tick
 
(
✔
)
 
No
 
for
 
incorrect
 
instruction.
 
Yes
 
No
 
Remarks
 
Pharmacological
 
Group
 
Iminophenazine
 
 
 
 
Indications
 
and
 
Dosage
 
1.
 
First-line
 
treatment
 
for
 
leprosy
 
(Paucibacillary
  
&
 
Multibacillary)
 
(to
 
be
 
used
 
in
 
combination
 
with
 
other
 
anti-leprosy
 
agents)
 
              
a.
   
Adult:
 
300mg
 
once
 
a
 
month
 
&
 
50mg
 
once
 
daily
 
              
b.
  
Children:
 
i)
 
10-14
 
years
 
old
 
:
 
150mg
 
once
 
a
 
month
 
&
 
50mg
 
on
 
alternate
 
day
 
ii)
 
<10
 
years
 
old
 
or
 
<40kg:
 
6mg/kg
 
once
 
a
 
month
 
&
 
1mg/kg
 
once
 
daily
 
 
              
C.
 
Duration:
 
Paucibacillary:
 
6
 
month
 
              
Multibacillary:
 
12
 
mont
h
 
 
2.
 
Drug-resistant
 
leprosy
 
 
              
Adult
 
:
 
50mg
 
once
 
daily
 
(in
 
combination
 
with
 
other
  
anti-leprosy
 
drugs)
 
 
 
 
 
Method
 
of
 
Administration*
 
Oral;
 
not
 
available
 
parenterally
 
 
Food
 
1.
 
To
 
be
 
taken
 
with
 
food
 
to
 
avoid
 
stomach
 
upset
 
and
 
improve
 
absorption
 
(including
 
enteral
 
feeding).
 
 
RT
 
administration
 
1.
 
Capsules
 
containing
 
powdered
 
therapeutic
 
substances
 
can
 
be
 
administered
 
enterally
 
 
Do
 
not
 
stop
 
taking
 
your
 
medication
 
unless
 
advised
 
to
 
do
 
so
 
by
 
your
 
prescriber
 
 
 
 
Special
 
Considerations
 
Pregnancy
 
 
 
 
Not
 
recommended
 
due
 
to
 
limited
 
data
 
(some
 
reports
 
of
 
normal
 
outcomes,
 
some
 
reports
 
of
 
neonatal
 
deaths)
 
 
 
 
Breastfeeding
 
 
 
 
Avoided
 
with
 
breastfeeding
 
due
 
to
 
pigmentation
 
of
 
the
 
infant
 
 
 
 
Elderly
 
 
 
 
NA
 
 
 
 
Paediatric
 
 
 
 
The
 
100
 
mg
 
soft
 
gel
 
capsule
 
is
 
difficult
 
to
 
swallow
 
for
 
young
 
children
 
and
 
therefore
 
countries
 
are
 
strongly
 
encouraged
 
to
 
make
 
the
 
50
 
mg
 
tablet
 
formulation
 
available.
 
[WHO
 
WEIGHT
 
BAND]
 
 
 
 
Fasting
 
 
 
 
To
 
refer
 
to
 
the
 
latest
 
advisory
 
by
 
religious
 
authority
 
 
 
 
83
 

=== PAGE 85 ===

 
Others
 
 
 
 
 
Use
 
in
 
renal
 
disease:
 
No
 
dosage
 
adjustment
 
required
 
Use
 
in
 
hepatic
 
disease:
 
Avoid
 
in
 
patients
 
with
 
liver
 
impairment
 
(Child-Pugh
 
classes
 
A,
 
B,
 
and
 
C)
 
unless
 
benefit
 
outweighs
 
risk.
 
 
 
 
Side
 
Effects
 
and
 
their
 
Management*
 
1.
 
Orange-pink,
 
red,
 
or
 
brownish-black
 
discoloration
 
of
 
skin,
 
conjunctiva,
 
cornea,
 
and
 
body
 
fluids.
 
2.
 
Gastrointestinal
 
intolerance
 
3.
 
Photosensitivity
 
4.
 
QT
 
prolongation
 
(risk
 
for
 
torsades
 
de
 
pointes)
 
 
Advise
 
patients
 
to
 
inform
 
their
 
healthcare
 
providers
 
if
 
they
 
experience
 
any
 
side
 
effects.
 
 
Inform
 
pt
  
discoloration
 
effect
 
goes
 
away
 
after
 
stopping
 
the
 
medicine
 
but
 
may
 
take
 
a
 
long
 
time
 
to
 
do
 
so
 
(months
 
to
 
years).
 
Patients
 
should
 
avoid
 
the
 
sun
 
and
 
use
 
strong
 
sunscreens.
 
 
 
 
Storage*
 
Room
 
temperature
 
 
 
 
Others
 
Monitoring
 
parameters:
 
 
-
 
ECG
 
monitoring
 
required
 
*if
 
other
 
QT-prolonging
 
drugs
 
are
 
taken
 
concurrently
 
 
Drug-drug
 
interactions:
 
 
Drugs
 
prolong
 
the
 
QT
 
interval
 
 
Examples:
 
-
 
fluoroquinolones,bedaquiline
 
and
 
delamanid
 
 
-
 
ancillary
 
and
 
common
 
drugs
 
(azoles,
 
macrolides,
 
metoclopramide,
 
efavirenz,
 
furosemide,
 
hydrochlorothiazide,
 
SSRIs
 
and
 
TCAs:
 
citalopram,
 
escitalopram,
 
methadone,
 
antiarrhythmics
 
and
 
others).
 
 
 
 
 
Before
 
ending
 
this
 
peer
 
review
 
session,
 
the
 
reviewee
 
should
 
be
 
informed
 
of
 
the
 
step(s)
 
that
 
he/
 
she
 
missed
 
out
 
in
 
order
 
to
 
ensure
 
all
 
the
 
counselling
 
points
 
are
 
being
 
covered.
 
 
Remarks:
 
 
 
 
Reviewed
 
by:
 
Name
 
&
 
Signature
                                                                   
Date:
 
 
*Mandatory
 
for
 
validation/peer
 
review
 
 
References:
 
 
1.
 
World
 
Health
 
Organization.
 
Guidelines
 
for
 
the
 
diagnosis,
 
treatment
 
and
 
prevention
 
of
 
leprosy .
 
2018
 
2.
 
World
 
Health
 
Organization.
 
WHO
 
model
 
prescribing
 
information:
 
drugs
 
used
 
in
 
leprosy .
 
In
 
WHO
 
model
 
prescribing
 
information:
 
drugs
 
used
 
in
 
leprosy
 
1998
 
3.
 
TB
 
Drug
 
Monographs.
 
Clofazimine.
 
https://www .tbdrugmonographs.co.uk/ofloxacin.html
 
4.
 
WHO
 
Expert
 
Committee
 
on
 
Leprosy .
 
WHO
 
Expert
 
Committee
 
on
 
Leprosy:
 
Eighth
 
Report.
 
World
 
Health
 
Organization.
 
2010
 
5.
 
Critical
 
Care
 
Pharmacy
 
Handbook.
 
Pharmaceutical
 
Services
 
Programme.
 
Second
 
edition.
 
2020
 
6.
 
Manual
 
Pengurusan
 
Kusta
 
Edisi
 
Ke-3.
 
MOH.
 
2023
 
7.
 
Protocol
 
on
 
Drug
 
Administration
 
Via
 
Enteral
 
Feeding
 
Tubes.
 
First
 
edition.
 
MOH.
 
2022
 
8.
 
UpToDate
 
Inc.
 
9.
 
World
 
Health
 
Organization.
 
(2022).
 
WHO
 
operational
 
handbook
 
on
 
tuberculosis.
 
Module
 
4:
 
treatment-drug-resistant
 
tuberculosis
 
treatment,
 
2022
 
update.
 
World
 
Health
 
Organization
 
10.
 
Pharmaceutical
 
Services
 
Division
 
Negeri
 
Sembilan
 
State
 
Health
 
Department.
 
(2022).
 
Protocol
 
on
 
Drug
 
Administration
 
Via
 
Enteral
 
Feeding
 
Tubes.
 
First
 
Edition
 
84
 

=== PAGE 86 ===

 
Clopidogrel
 
 
Name
 
:
 
 
Unit
 
:
 
 
●
 
Please
 
tick
 
(
✔
)
 
Yes
 
for
 
correct
 
instruction.
 
●
 
Please
 
tick
 
(
✔
)
 
No
 
for
 
incorrect
 
instruction.
 
Yes
 
No
 
Remarks
 
Pharmacological
 
Group
 
Antiplatelet-Thienopyridine
 
P2Y12
 
Antagonist
 
 
 
 
Indications
 
and
 
Dosage
 
1.
 
Indication
 
1
:Non-ST
 
segment
  
elevation
 
acute
 
coronary
 
syndrome(unstable
 
angina
 
or
 
non-Q-wave
 
myocardial
 
infarction)
 
including
 
patients
 
undergoing
 
a
 
stent
 
placement
 
following
 
percutaneous
 
coronary
 
intervention
 
a.
 
Dosage
 
for
 
indication
 
1:
 
75mg
 
od
 
 
2.
 
Indication
 
2:
 
ST
 
segment
 
elevation
 
acute
 
myocardial
 
infarction,in
 
combination
 
with
 
acetylsalicylic
 
acid
 
(ASA)
 
in
 
medically
 
treated
 
patients
 
eligible
 
for
 
thrombolytic
 
therapy
 
a.
 
Dosage
 
for
 
indication
 
2:
 
75mg
 
od
 
 
3.
 
Indication
 
3:
 
Ischaemic
 
stroke
 
                     
a.
 
Dosage
 
for
 
indication
 
3:
 
75mg
 
od
 
 
 
 
 
Method
 
of
 
Administration*
 
Take
  
with
 
or
 
without
 
food.
 
Can
 
be
 
crushed
 
to
 
administer
 
through
 
an
 
NG
 
tube
 
 
Missed
 
dose
 
management:
 
Take
 
a
 
missed
 
dose
 
as
 
soon
 
as
 
remembered.If
 
it
 
is
 
close
 
to
 
the
 
time
 
for
 
the
 
next
 
dose,
 
skip
 
and
 
go
 
back
 
to
 
normal
 
time.
 
Do
 
not
 
take
 
2
 
doses
 
at
 
the
 
same
 
time.
 
 
Do
 
not
 
stop
 
taking
 
your
 
medication
 
unless
 
advised
 
to
 
do
 
so
 
by
 
your
 
prescriber
 
 
 
 
Special
 
Considerations
 
Pregnancy
 
 
 
 
No
 
clinical
 
data
 
on
 
exposure
 
to
 
clopidogrel
 
during
 
pregnancy
 
are
 
available
 
 
 
 
Breastfeeding
 
 
 
 
Limited
 
data
 
 
 
 
Elderly
 
 
 
 
Safe
 
in
 
elderly
 
 
 
 
Paediatric
 
 
 
 
Should
 
not
 
be
 
used
 
in
 
children
 
 
 
 
Fasting
 
 
 
 
Not
 
applicable
 
 
 
 
Others
  
 
 
 
 
1.
 
Experience
 
is
 
limited
 
in
 
patients
 
with
 
moderate
 
hepatic
 
 
 
 
85
 

=== PAGE 87 ===

 
disease
 
who
 
may
 
have
 
bleeding
 
diathesis.
 
2.
 
Experience
 
is
 
limited
 
in
 
patients
 
with
 
severe
 
and
 
 
moderate
 
renal
 
impairment.
 
Side
 
Effects
 
and
 
their
 
Management*
 
1.
 
Haematoma,Epistaxis,Gastro-intestinal
 
haemorrhage,diarrhoea,abdominal
 
pain,dyspepsia,bruising
 
 
 
 
Storage*
 
1.
 
Store
 
below
 
30°C.
 
Protected
 
from
 
light
 
 
 
 
Others
 
1.
 
Concomitant
 
use
 
of
 
Omeprazole
 
or
 
Esomeprazole
 
with
 
Clopidogrel
 
should
 
be
 
discouraged.
 
        
2.
   
Bleeding
 
risk
 
is
 
increased
 
with
 
concomi tant
 
use
 
of
  
 
               
other
 
drugs
 
that
 
increase
 
bleeding
 
(eg
 
anticoagulants,
   
 
              
antiplatelet
 
agents,
 
and
 
chronic
 
use
 
of
 
NSAIDs.
 
        
3.
   
Interrupt
 
use
 
5
 
days
 
prior
 
to
 
elective
 
surgery
 
with
 
major
    
              
risk
 
of
 
bleeding,
 
when
 
possible.
 
        
 
 
 
 
Before
 
ending
 
this
 
peer
 
review
 
session,
 
the
 
reviewee
 
should
 
be
 
informed
 
of
 
the
 
step(s)
 
that
 
he/
 
she
 
missed
 
out
 
in
 
order
 
to
 
ensure
 
all
 
the
 
counselling
 
points
 
are
 
being
 
covered.
 
 
Remarks:
 
 
 
 
 
Reviewed
 
by:
 
Name
 
&
 
Signature
                                                                   
Date:
 
 
 
 
 
*Mandatory
 
for
 
validation/peer
 
review
 
 
References:
 
 
1.
 
 
Troikaa
 
Pharmaceuticals
 
Ltd.
 
Clopidogrel
 
75mg
 
(AntiPlatt)
 
Product
   
Leaflet.Revised:
 
August
 
2022
 
2.
 
 
MIMS
 
Gateway
 
Online.Release
 
version:
 
October
 
2024
 
3.
 
 
Formulari
 
Ubat
 
KKM.
 
Database
 
version:241 115.0002
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
86
 

=== PAGE 88 ===

 
Clotrimazole,
 
Topical
 
Name
 
:
 
 
Unit
 
:
 
 
●
 
Please
 
tick
 
(
✔
)
 
Yes
 
for
 
correct
 
instruction.
 
●
 
Please
 
tick
 
(
✔
)
 
No
 
for
 
incorrect
 
instruction.
 
Yes
 
No
 
Remarks
 
Pharmacological
 
Group
 
Antifungal
 
agent:
 
Imidazole
 
Derivatives
 
 
 
 
Indications
 
and
 
Dosage
 
Adult
 
 
Candidal
 
balanitis
 
1.
 
Apply
 
2
 
or
 
3
 
times
 
onto
 
male
 
sexual
 
partner ’s
 
genital
 
organ,
 
for
 
up
 
to
 
2
 
weeks.
 
 
Skin
 
fungal
 
infections
 
1.
 
Apply
 
thinly
 
to
 
the
 
affected
 
area(s)
 
2
 
or
 
3
 
times
 
per
 
day.
 
Continue
 
treatment
 
for
 
at
 
least
 
4
 
weeks
 
(dermatophyte
 
infections)
 
or
 
at
 
least
 
2
 
weeks
 
(candida
 
infections)
 
 
Paediatric
 
 
Tinea
 
Cruris
 
1.
 
Apply
 
twice
 
daily
 
(morning
 
&
 
night)
 
up
 
to
 
2
 
weeks.
 
 
Tinea
 
Corporis
 
and
 
Tinea
 
Pedis
 
1.
 
Apply
 
twice
 
daily
 
(morning
 
&
 
night)
 
up
 
to
 
4
 
weeks
 
 
To
 
counsel
 
based
 
on
 
specific
 
medication’ s
 
indication
 
and
 
dosage
 
as
 
prescribed
 
by
 
the
 
doctor
 
 
 
 
Method
 
of
 
Administration*
 
Adult
 
1.
 
For
 
external
 
use
 
only
 
2.
 
Avoid
 
contact
 
with
 
eyes
 
and
 
application
 
to
 
severely
 
cracked
 
or
 
irritated
 
areas
 
of
 
the
 
skin.
 
Apply
 
a
 
thin
 
layer
 
to
 
the
 
affected
 
area.
 
3.
 
Athlete’ s
 
foot;
 
pay
 
special
 
attention
 
to
 
spaces
 
between
 
the
 
toes;
 
wear
 
well-fitting,
 
ventilated
 
shoes
 
and
 
change
 
shoes
 
and
 
socks
 
at
 
least
 
once
 
a
 
day.
 
 
Paediatric
 
1.
 
For
 
external
 
use
 
only
 
2.
 
Apply
 
sparingly
 
and
 
rub
 
gently
 
into
 
the
 
cleansed,
 
affected
 
area.
 
3.
 
Do
 
not
 
apply
 
to
 
the
 
eye.
 
4.
 
Tinea
 
pedis:
 
apply
 
to
 
spaces
 
between
 
toes
 
 
Do
 
not
 
stop
 
taking
 
your
 
medication
 
unless
 
advised
 
to
 
do
 
so
 
by
 
your
 
prescriber
 
 
 
 
Special
 
Considerations
 
Pregnancy
 
 
 
 
1.
 
Minimally
 
absorbed
 
following
 
topical
 
or
 
vaginal
 
administration.
 
Pregnancy
 
category
 
(USFDA):
 
C
 
 
 
 
Breastfeeding
 
 
 
 
1.
 
Presence
 
in
 
breast
 
milk
 
is
 
unknown
 
 
 
 
Elderly
 
 
 
 
1.
 
Refer
 
to
 
adult
 
dosing
 
2.
 
Patients
 
who
 
use
 
topical
 
oils,
 
creams,
 
and
 
ointments
 
have
 
potential
 
fall
 
risk
 
.Patients
 
may
 
be
 
advised
 
to
 
 
 
 
87
 

=== PAGE 89 ===

 
wear
 
nonslip
 
socks
 
if
 
applying
 
topical
 
medications
 
to
 
feet.
 
Patients
 
should
 
be
 
advised
 
to
 
apply
 
cream
 
while
 
seated
 
or
 
standing
 
on
 
non-slip
 
surfaces.
 
Paediatric
 
 
 
 
Children
 
under
 
12
 
years
 
old
 
should
 
be
 
supervised
 
during
 
use.
 
 
 
 
Others
 
 
 
 
 
No
 
dosage
 
adjustments
 
in
 
kidney
 
impairment
 
and
 
liver
 
impairment
 
as
 
well
 
as
 
paediatric
 
populations
 
 
 
 
Side
 
Effects
 
and
 
their
 
Management*
 
1.
 
General
 
disorders
 
and
 
administration
 
site
 
conditions: Application
 
site
 
reactions
 
may
 
include.
 
peeling/exfoliation,
 
stinging
 
sensation,
 
pain,
 
discomfort
 
2.
 
Skin
 
and
 
subcutaneous
 
tissue
 
disorders: Rash,
 
urticaria,
 
pruritus.
 
3.
 
Local
 
irritation:If
 
irritation
 
or
 
sensitivity
 
develops,
 
discontinue
 
therapy
 
immediately .
 
Consult
 
a
 
healthcare
 
provider
 
for
 
appropriate
 
alternative
 
therapy .
 
 
 
 
Storage*
 
1.
 
Protect
 
from
 
light.
 
2.
 
Store
 
below
 
25°C
 
/
 
30°C
 
 
 
 
Others
 
1.
 
Topical
 
cream
 
therapy
 
may
 
not
 
be
 
effective
 
for
 
treating
 
infection
 
of
  
the
  
scalp
 
or
 
nails.
 
2.
 
Monitor
 
the
 
application
 
site
 
for
 
signs
 
of
 
severe
 
skin
 
irritation
 
(e.g.
 
redness,
 
itching,
 
burning,
 
blistering,
 
swelling,
 
oozing).
 
3.
 
Hypersensitivity
 
reactions,
 
such
 
as
 
rash
 
or
 
swelling,
 
may
 
also
 
occur .
 
If
 
such
 
reactions
 
are
 
noticed,
 
the
 
use
 
of
 
the
 
product
 
should
 
be
 
stopped
 
immediately ,
 
and
 
medical
 
advice
 
should
 
be
 
sought.
 
 
 
 
Before
 
ending
 
this
 
peer
 
review
 
session,
 
the
 
reviewee
 
should
 
be
 
informed
 
of
 
the
 
step(s)
 
that
 
he/
 
she
 
missed
 
out
 
in
 
order
 
to
 
ensure
 
all
 
the
 
counselling
 
points
 
are
 
being
 
covered.
 
 
Remarks:
 
 
 
 
 
Reviewed
 
by:
 
Name
 
&
 
Signature
                                                                   
Date:
 
 
 
 
 
*Mandatory
 
for
 
validation
 
/
 
peer
 
review
 
References:
 
 
1.
 
Clotimazole
 
(topical)
 
Adult
 
&
 
Paediatric
 
(2024).
 
UptoDate
 
[Drug
 
information].
 
Retrieved
 
November
 
16,
 
2024,
 
from
 
https://www .uptodate.com
 
2.
 
Formulari
 
Ubat
 
KKM
 
(n.d.).
 
Ministry
 
of
 
Health
 
Malaysia.
 
Retrieved
 
December
 
20,
 
2024,
 
from
 
https://pharmacy .moh.gov .my/ms/apps/fukk
 
3.
 
Glenmark
 
Pharmaceuticals
 
LTD
 
(2020).
 
Candid
 
Cream
 
1%
 
w/w
 
[Product
 
insert
 
4.
 
HOE
 
Pharmaceuticals
 
Sdn.
 
Bhd.
 
(2023).
 
Candazole
 
Cream
 
1%
 
w/w
 
[Product
 
insert]
 
5.
 
Malaysian
 
Pharmaceutical
 
Industries
 
Sdn
 
Bhd
 
(2021).
 
Canezin
 
Cream
 
1%
 
w/w
 
[Product
 
insert]
 
6.
 
MIMS
 
Pte
 
Ltd
 
(n.d.).
 
Clotrimazole.
 
Retrieved
 
January
 
21,
 
2025,
 
from
 
https://online1.mimsgateway .com.my/Malaysia/home/index?redir=%2F%2Fdrug%2Finfo%2FClotrimazol 
e%2FClotrimazole%3Ftype%3Dbrief%26mtype%3Dgeneric
 
7.
 
Price
 
KN,
 
Grinnell
 
M,
 
Butler
 
D,
 
Shah
 
A.
 
Art
 
of
 
prevention:
 
Practical
 
tips
 
for
 
improving
 
adherence
 
to
 
treatments
 
for
 
older
 
patients
 
in
 
dermatology .
 
Int
 
J
 
Womens
 
Dermatol.
 
2021
 
Mar
 
18;7(4):478-481.
 
 
88
 

=== PAGE 90 ===

 
Clozapine
 
Name:
 
 
Unit
 
:
 
 
●
 
Please
 
tick
 
(
✔
)
 
Yes
 
for
 
correct
 
instruction.
 
●
 
Please
 
tick
 
(
✔
)
 
No
 
for
 
incorrect
 
instruction.
 
Yes
 
No
 
Remarks
 
Pharmacological
 
Group
 
Atypical
 
Antipsychotic
s
 
 
 
 
Indications
 
and
 
Dosage
 
Treatment-resistant
 
schizophrenia
 
1.
 
Suggested
 
starting
 
dose
 
:
 
12.5mg
 
once
 
or
 
twice
 
on
 
the
 
first
 
day,
 
followed
  
by
 
25
 
or
 
50mg
 
on
 
the
 
second
 
day.
 
If
 
well
 
tolerated,
 
the
 
dose
 
may
 
then
 
be
 
increased
 
in
 
increments
 
of
 
25-50mg/day
 
in
 
order
 
to
 
achieve
 
a
 
daily
 
dose
 
of
 
300mg
 
within
 
2-3
 
weeks.
 
Thereafter ,
 
may
 
be
 
further
 
increased
 
in
 
50-100mg
 
increments
 
at
 
half
 
or
 
weekly
 
intervals.
 
2.
 
Speed
 
&
 
dose
 
titration
 
depends
 
if
 
pt
 
is
 
naive
 
and
 
care
 
setting
 
e.g.
 
inpatient
 
vs
 
outpatient)
 
3.
 
Therapeutic
 
dose
 
range
 
(usually
 
given
 
in
 
two
 
divided
 
doses):
 
 
i.
 
Female
 
250mg/day
 
[smokers,
 
450mg/day]
 
ii.
 
Male
 
350mg/day
 
[smokers,
 
550mg/day]
 
4.
 
Maximum
 
dose
 
:
 
900mg/day .
 
 
Or
 
 
 
To
 
counsel
 
based
 
on
 
specific
 
medication’ s
 
indication
 
and
 
dosage
 
as
 
prescribed
 
by
 
the
 
doctor
 
 
 
 
Method
 
of
 
Administration*
 
1.
 
Take
 
Clozapine
 
at
 
the
 
same
 
time
 
every
 
day
 
with
 
water
 
or
 
a
 
cool
 
drink
 
2.
 
This
 
medication
 
can
 
be
 
taken
 
with
 
or
 
without
 
food.
 
 
 
Missed
 
dose
 
management:
 
1.
 
Take
 
as
 
soon
 
as
 
you
 
remember ,
 
omit
 
If
 
it
 
is
 
almost
 
time
 
for
 
next
 
dose
 
2.
 
Take
 
the
 
next
 
dose
 
as
 
usual.
 
Do
 
not
 
double
 
the
 
dose.
 
3.
 
If
 
you
 
miss
 
2
 
or
 
more
 
days
 
of
 
Clozapine
 
doses,
 
talk
 
to
 
your
 
doctor
 
before
 
you
 
start
 
taking
 
it
 
again.
 
You
 
might
 
have
 
to
 
restart
 
the
 
medicine
 
at
 
a
 
lower
 
dose.
 
4.
 
Treatment
 
interruption
 
may
 
lead
 
to
 
changes
 
to
 
the
 
blood
 
monitoring
 
schedule
 
 
Do
 
not
 
stop
 
taking
 
your
 
medication
 
unless
 
advised
 
to
 
do
 
so
 
by
 
your
 
prescriber .
 
 
 
 
Special
 
Considerations
 
Pregnancy
 
 
 
 
Animal-reproduction
 
studies
 
have
 
not
 
demonstrated
 
a
 
foetal
 
risk
 
but
 
there
 
is
 
no
 
controlled
 
study
 
in
 
humans.
 
 
Inform
 
your
 
doctor
 
if
 
you
 
are
 
planning
 
for
 
pregnancy
 
or
 
become
 
pregnant
 
while
 
taking
 
clozapine.
 
 
 
 
Breastfeeding
 
 
 
 
1.
 
Lactating
 
mothers
 
on
 
clozapine
 
are
 
advised
 
not
 
to
 
breastfeed
 
while
 
on
 
treatment.
  
For
 
those
 
who
 
do
 
not
 
wish
 
to
 
continue
 
lactating,
 
formula
 
milk
 
supplementation
 
should
 
be
 
offered
 
to
 
the
 
infants
 
 
 
 
89
 

=== PAGE 91 ===

 
Elderly
 
 
 
 
In
 
older
 
patients
 
(
≧
60
 
years)
 
initiation
 
of
 
treatment
 
at
 
a
 
particularly
 
low
 
dose
 
is
 
recommended
 
(12.5mg
 
given
 
once
 
on
 
the
 
first
 
day),
 
with
 
subsequent
 
dose
 
increment
 
restricted
 
to
 
25mg/day .
 
 
Beers
 
Criteria:
 
1)
 
Avoid
 
in
 
adjunctive
 
treatment
 
of
 
MDD
 
or
 
for
 
short
 
term
 
use
 
as
 
antiemetic,
 
except
 
in
 
FDA
 
approved
 
indications
 
(e.g
 
Schizophrenia,
 
bipolar
 
disorder ,
 
Parkinson
 
disease
 
psychosis).
 
Increase
 
risk
 
of
 
death,
 
metabolic
 
effects,
 
orthostatic
 
hypotension
 
and
 
cardiac
 
arrhythmias.
 
2)
 
Use
 
is
 
associated
 
with
 
fall
 
risk.
 
To
 
advise
 
on
 
fall
 
precautions.
 
 
Micromedex:
 
Black
 
Box
 
Warning
 
:Avoid
 
for
 
behavioral
 
problems
 
related
 
psychosis
 
of
 
dementia
 
or
 
delirium
 
 
 
 
Paediatric
 
 
 
 
Safety
 
and
 
effectiveness
 
in
 
pediatric
 
patients
 
have
 
not
 
been
 
established
 
 
 
 
Fasting
 
 
 
 
1.
 
Administer
 
during
 
Sahur
 
or
 
after
 
Iftar.
 
 
To
 
refer
 
to
 
the
 
latest
 
advisory
 
by
 
religious
 
authority
.
 
 
 
 
Pre-Operative
 
 
 
 
1.
 
If
 
clozapine
 
was
 
withheld
 
before
 
surgery
 
and
 
discontinued
 
for
 
more
 
than
 
48
 
hours,
 
treatment
 
should
 
be
 
re-initiated.
 
Changes
 
to
 
blood
 
monitoring
 
schedule
 
may
 
be
 
required.
 
Contact
 
your
 
prescriber .
 
 
 
 
Renal
 
Impairment
 
 
 
 
 
1.
 
Mild
 
to
 
moderate
 
renal
 
impairment:
 
low
 
starting
 
dose
 
(12.5mg
 
on
 
the
 
first
 
day)and
 
increased
 
slowly
 
in
 
small
 
increments.
 
 
2.
 
Contraindicated
 
in
 
severe
 
renal
 
impairment.
 
 
 
 
Hepatic
 
Impairment
 
 
 
 
 
1.
 
Contraindicated
 
in
 
active
 
liver
 
disease
 
associated
 
with
 
nausea,
 
anorexia
 
or
 
jaundice;
 
progressive
 
liver
 
disease,
 
hepatic
 
failure.
 
2.
 
If
 
you
 
develop
 
symptoms
 
of
 
possible
 
liver
 
dysfunction
 
such
 
as
 
yellowing
 
of
 
the
 
skin,
 
abdominal
 
pain,
 
nausea,
 
vomiting
 
and/or
 
anorexia
 
during
 
clozapine
 
treatment,
 
Immediately
 
contact
 
your
 
prescriber
 
 
 
 
Dietary
 
and
 
lifestyle
 
considerations
 
●
 
Adopt
 
healthy
 
lifestyle
 
which
 
includes
 
well
 
balanced
 
diet,
 
adequate
 
hydration
 
and
 
exercise
 
●
 
Cleaning
 
teeth
 
morning
 
and
 
night
 
(this
 
also
 
helps
 
keep
 
white
 
cell
 
counts
 
up)
 
●
 
Reduce
 
or
 
quit
 
smoking.
 
Plan
 
this
 
with
 
the
 
doctor .
 
 
 
 
Side
 
Effects
 
and
 
their
 
Management*
 
Common
 
side
 
effects:
 
1.
 
Sedation:
 
may
 
improve
 
with
 
time.
 
Avoid
 
activity
 
requiring
 
mental
 
alertness
 
or
 
coordination.
 
Do
 
not
 
drink
 
 
 
 
90
 

=== PAGE 92 ===

 
alcohol
 
during
 
treatment
 
with
 
this
 
medicine
 
as
 
it
 
might
 
increase
 
the
 
sedative
 
effect.
 
Do
 
not
 
drive
 
or
 
work
 
with
 
tools
 
or
 
machinery
 
if
 
affected.
 
Inform
 
prescriber
 
at
 
next
 
appointment
 
(to
 
consider
 
night-time
 
dosing
 
only)
 
2.
 
Constipation:
 
bowel
 
habit
 
monitoring,
  
increase
 
your
 
physical
 
activity ,
 
fluid
 
and
 
fibre
 
intake.
 
May
 
require
 
medications.
  
Contact
 
prescriber
 
if
 
unable
 
to
 
pass
 
flatus
 
or
 
if
 
there
 
is
 
abdominal
 
pain/discomfort
 
(warning
 
sign)
 
3.
 
Tachycardia:
 
contact
 
your
 
prescriber
 
if
 
you
 
experience
 
persistent
 
palpitation
 
4.
 
Weight
 
gain:
 
Advise
 
on
 
nutritional
 
counselling
 
(avoid
 
low-volume,
 
high-calorie
 
foods)
 
and
 
emphasize
 
need
 
for
 
physical
 
exercise.
 
5.
 
Hypersalivation:
 
often
 
improves
 
over
 
time.
 
If
 
persistent,
 
inform
 
your
 
prescriber
 
at
 
the
 
next
 
appointment.
 
Use
 
a
 
towel
 
on
 
the
 
pillow
 
while
 
sleeping
 
and
 
make
 
sure
 
to
 
bring
 
towel/tissue
 
along.
 
6.
 
Blood
 
pressure
 
changes:
 
clozapine
 
can
 
cause
 
both
 
hypotension
 
and
 
hypertension
 
7.
 
Hyperglycaemia:
 
watch
 
out
 
for
 
symptoms
 
of
 
increased
 
sugar
 
levels
 
such
 
as
 
frequent
 
urination,
 
increased
 
thirst
 
and
 
delay
 
in
 
wound
 
healing
 
 
Rare
 
but
 
serious
 
side
 
effects
 
:
 
1.
 
Severe
 
infection
 
(due
 
to
 
drop
 
in
 
white
 
cells
 
-
 
a
 
condition
 
called
 
Neutropenia):
 
advise
 
to
 
seek
 
urgent
 
medical
 
assessment
 
it
 
patient
 
develop
 
flu-like
 
symptoms
 
2.
 
Clozapine
 
lowers
 
the
 
seizure
 
threshold.
 
Higher
 
risk
 
with
 
higher
 
doses.
 
Immediately
 
contact
 
your
 
prescriber
 
in
 
an
 
event
 
of
 
seizure.
 
3.
 
Cardiac
 
complications
 
including
 
myocarditis
 
and
 
cardiomyopathy .
  
In
 
cases
 
where
 
tachycardia
 
persists
 
at
 
rest
 
and
 
is
 
associated
 
with
 
fever ,
 
hypotension
 
or
 
chest
 
pain,
 
it
 
may
 
indicate
 
myocarditis.
 
Immediately
 
contact
 
your
 
prescriber .
 
 
Storage*
 
Store
 
at
 
a
 
temperature
 
below
 
30°C.
 
 
 
 
Others
 
Drug-lifestyle
 
interactions
 
●
 
Cigarette
 
smoking
 
can
 
decrease
 
clozapine
 
levels.
 
May
 
require
 
a
 
decrease
 
clozapine
 
dose
 
during
 
periods
 
of
 
smoking
 
cessation,
 
please
 
inform
 
your
 
prescriber
 
 
Blood
 
regular
 
monitoring
 
●
 
During
 
the
 
first
 
18
 
weeks
 
of
 
administration,
 
patients
 
are
 
required
 
to
 
have
 
their
 
full
 
blood
 
count
 
checked
 
weekly .
 
This
 
changes
 
to
 
fortnightly
 
after
 
18
 
weeks
 
and
 
then
 
monthly
 
after
 
one
 
year.
 
 
 
 
Before
 
ending
 
this
 
peer
 
review
 
session,
 
the
 
reviewee
 
should
 
be
 
informed
 
of
 
the
 
step(s)
 
that
 
he/
 
she
 
missed
 
out
 
in
 
order
 
to
 
ensure
 
all
 
the
 
counselling
 
points
 
are
 
being
 
covered.
 
 
Remarks:
 
 
 
 
 
Reviewed
 
by:
 
Name
 
&
 
Signature
                                                                   
Date:
 
 
 
 
 
*Mandatory
 
for
 
validation
 
/
 
peer
 
review
 
91
 

=== PAGE 93 ===

 
References:
 
 
     
 
1.
 
UpToDate,
 
Inc.
 
(2024).
 
Clozapine:
 
Drug
 
information
 
(Version
 
3.68.1)
 
[Mobile
 
application].
 
UpToDate,
 
Inc.
 
2.
 
MADAUS
 
GmbH.(2023).
 
Product
 
Information
 
Leaflet:
 
Cloz
aril
 
.Retrieved
 
from
 
Quest
 
3+
 
Search
 
on
 
January
 
21,
 
2025
 
3.
 
Sullivan,
 
C.
 
(2023,
 
November
 
3).
 
Clozapine
 
counselling
 
–
 
OSCE
 
guide.
 
Geeky
 
Medic.
 
https://geekymedics.com/clozapine-counselling-osce-guide/
 
4.
 
Ahmad
 
S.N.A.
 
et.
 
al.
 
CPG
 
Management
 
of
 
Schizophrenia
 
(Second
 
Edition,
 
2021).
 
Accessed
 
on
 
January
 
21,
 
2025.
 
Available
 
from:
 
CPG
 
Management
 
of
 
Schizophrenia
 
(Second
 
Edition)
 
v20221219.pdf
 
5.
 
Krishnasamy
 
A.
 
et.
 
al.
 
Medication
 
Counseling
 
for
 
Pharmacists.
 
(First
 
Edition
 
2021).
 
Perak
 
State
 
Health
 
Department,
 
Pharmaceutical
 
Services
 
Division.
 
6.
 
Pharmaceutical
 
Services
 
Programme,
 
Ministry
 
of
 
Health
 
Malaysia.
 
(2025).
 
Formulari
 
Ubat
 
KKM
 
(FUKKM).
 
Retrieved
 
from
 
https://pharmacy .moh.gov .my/ms/apps/fukkm
 
7.
 
Taylor ,
 
D.,
 
Barnes,
 
T.
 
R.
 
E.,
 
&
 
Young,
 
A.
 
H.
 
(2021).
 
The
 
Maudsley
 
prescribing
 
guidelines
 
in
 
psychiatry
 
(14th
 
ed.).
 
Wiley-Blackwell.
 
 
8.
 
2023
 
American
 
Geriatrics
 
Society
 
Beers
 
Criteria®
 
Update
 
Expert
 
Panel.
 
(2023).
 
American
 
Geriatrics
 
Society
 
2023
 
updated
 
AGS
 
Beers
 
Criteria®
 
for
 
potentially
 
inappropriate
 
medication
 
use
 
in
 
older
 
adults.
 
Journal
 
of
 
the
 
American
 
Geriatrics
 
Society ,
 
71(7),
 
2052-2081.
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
92
 

=== PAGE 94 ===

 
Corticosteroids,
 
Topical
 
Name
 
:
 
 
Unit
 
:
 
 
●
 
Please
 
tick
 
(
✔
)
 
Yes
 
for
 
correct
 
instruction.
 
●
 
Please
 
tick
 
(
✔
)
 
No
 
for
 
incorrect
 
instruction.
 
Yes
 
No
 
Remarks
 
Pharmacological
 
Group
 
TOPICAL
 
CORTICOSTEROIDS
 
 
1.
 
Very
 
Potent
 
(Class
 
I)
 
Clobetasol
 
propionate
 
0.05%
 
cream/ointment
 
 
2.
 
Potent
 
(Class
 
II)
 
Betamethasone
 
dipropionate
 
0.05%
 
cream/ointment
 
Betamethasone
 
valerate
 
0.1%
 
cream/ointment
 
Mometasone
 
furoate
 
0.1%
 
cream/ointment
 
 
3.
 
Moderate
 
Potent
 
(Class
 
III)
 
Betamethasone
 
valerate
 
0.05%
 
cream/ointment
 
(1:2)
 
Betamethasone
 
valerate
 
0.025%
 
cream/ointment
 
(1:4)
 
Clobetasone
 
butyrate
 
0.05%
 
cream/ointment
 
 
4.
 
Mild
 
Potent
 
(Class
 
IV)
 
Betamethasone
 
valerate
 
0.0125%
 
cream/ointment
 
(1:8)
 
Hydrocortisone
 
acetate
 
0.5-1%
 
cream/ointment
 
 
*Based
 
on
 
UK
 
classification:
 
Creams
 
are
 
generally
 
less
 
potent
 
than
 
ointments
 
of
 
the
 
same
 
medication.
 
 
 
 
Indications
 
and
 
Dosage
 
For
 
the
 
relief
 
of
 
inflammatory
 
and
 
pruritic
 
manifestations
 
associated
 
with
 
steroid
 
responsive
 
dermatoses.
 
For
 
disease:
 
 
●
 
eczema
 
–
 
such
 
as
 
atopic
 
eczema
 
●
 
contact
 
dermatitis
 
–
 
which
 
causes
 
symptoms
 
such
 
as
 
dandruf f
 
and
 
scaly
 
patches
 
on
 
the
 
skin
 
●
 
psoriasis
 
Apply
 
as
 
directed
 
by
 
the
 
prescribing
 
doctor .
 
 
 
 
 
Method
 
of
 
Administration*
 
1.
 
The
 
medicine
 
should
 
only
 
be
 
applied
 
to
 
affected
 
areas
 
of
 
skin.
 
Gently
 
smooth
 
a
 
thin
 
layer
 
onto
 
your
 
skin
 
in
 
the
 
direction
 
the
 
hair
 
grows.
 
Wash
 
your
 
hands
 
before
 
and
 
after
 
you've
 
applied
 
the
 
medicine,
 
unless
 
you
 
are
 
treating
 
an
 
area
 
on
 
your
 
hands.
 
 
2.
 
If
 
you're
 
using
 
both
 
topical
 
corticosteroids
 
and
 
emollients,
 
topical
 
corticosteroids
 
should
 
be
 
applied
 
20-
 
30
 
minutes
 
after
 
the
 
application
 
of
 
emollient
 
 
 
3.
 
Sometimes,
 
the
 
amount
 
of
 
medicine
 
you're
 
advised
 
to
 
use
 
will
 
be
 
given
 
in
 
fingertip
 
units
 
(FTUs).
 
 
4.
 
A
 
FTU
 
(about
 
500mg
 
of
 
cream/ointment
 
or
 
2%
 
Body
 
Surface
 
Area)
 
is
 
the
 
amount
 
needed
 
to
 
squeeze
 
a
 
line
 
from
 
the
 
tip
 
of
 
an
 
adult
 
finger
 
to
 
the
 
first
 
crease
 
of
 
the
 
finger .
 
It
 
should
 
be
 
enough
 
to
 
treat
 
an
 
area
 
of
 
skin
 
double
 
the
 
size
 
of
 
your
 
palm
 
with
 
your
 
fingers
 
together .
 
 
5.
 
Duration
 
of
 
usage:
 
 
a)
 
short-term
 
therapy
 
with
 
potent
 
and
 
very
 
potent
 
topical
 
corticosteroids
 
may
 
be
 
used
 
to
 
gain
 
rapid
 
clearance
 
in
 
psoriasis
 
patients
 
with
 
limited
 
 
 
 
93
 

=== PAGE 95 ===

 
plaques.
 
These
 
preparations
 
should
 
be
 
avoided
 
on
 
the
 
face,
 
genitalia
 
and
 
body
 
folds.
 
 
b)
 
Limit
 
use
 
of
 
super
 
potent
 
corticosteroids
 
to
 
less
 
than
 
30g/week.
 
 
c)
 
Limit
 
use
 
of
 
potent
 
corticosteroids
 
to
 
less
 
than
 
60g/week.
 
 
d)
 
Continuous
 
use
 
of
 
potent
 
corticosteroids
 
should
 
not
 
exceed
 
four
 
weeks.
 
e)
 
Continuous
 
use
 
of
 
super
 
potent
 
corticosteroids
 
should
 
not
 
exceed
 
two
 
weeks.
 
 
f)
 
Mild
 
potency
 
corticosteroids
 
may
 
be
 
used
 
for
 
face,
 
genitalia
 
and
 
body
 
folds.
 
 
g)
 
Do
 
not
 
abruptly
 
discontinue
 
using
 
topical
 
steroids
 
as
 
it
 
can
 
cause
 
the
 
disease
 
to
 
flare
 
up.
 
Apply
 
the
 
principle
 
of
 
Step
 
down
 
and
 
Step
 
up
 
and
 
not
 
PRN
 
basis.
 
 
Do
 
not
 
stop
 
taking
 
your
 
medication
 
unless
 
advised
 
to
 
do
 
so
 
by
 
your
 
prescriber
 
Special
 
Considerations
 
Pregnancy
 
 
 
 
Overall
 
topical
 
corticosteroids
 
appear
 
to
 
be
 
safe
 
during
 
pregnancy .
 
High-potency
 
topical
 
corticosteroids
 
should
 
be
 
avoided
 
if
 
possible
 
and
 
when
 
they
 
must
 
be
 
used
 
they
 
should
 
be
 
used
 
only
 
for
 
a
 
short
 
time,
 
the
 
amount
 
used
 
should
 
be
 
kept
 
to
 
a
 
minimum
 
and
 
fetal
 
growth
 
should
 
be
 
monitored.
 
 
 
 
Breastfeeding
 
 
 
 
There
 
are
 
no
 
studies
 
assessing
 
the
 
safety
 
of
 
topical
 
corticosteroid
 
use
 
during
 
lactation.
 
It
 
is
 
recommended
 
that
 
the
 
topical
 
treatment
 
in
 
the
 
nipple
 
region
 
be
 
applied
 
after
 
nursing
 
the
 
child,
 
to
 
allow
 
the
 
drug
 
to
 
be
 
absorbed
 
before
 
the
 
next
 
feeding,
 
and
 
that
 
the
 
nipple
 
area
 
be
 
gently
 
cleaned
 
of
 
the
 
remaining
 
drug
 
before
 
nursing.
 
 
 
 
Elderly
 
 
 
 
NA
 
 
 
 
Paediatric
 
 
 
 
Safety
 
and
 
efficacy
 
of
 
topical
 
steroids
 
are
 
established
 
in
 
pediatric
 
patients.
 
 
Follow
 
the
 
specific
 
instructed
 
duration,
 
use
 
different
 
potencies
 
on
 
different
 
areas,
 
avoid
 
sensitive
 
areas
 
and
 
occlusion
 
unless
 
directed,
 
and
 
monitor
 
for
 
side
 
effects
 
such
 
as
 
skin
 
atrophy
 
or
 
systemic
 
absorption.
 
 
 
 
 
Fasting
 
 
 
 
NA
 
 
 
 
Others
 
 
 
 
 
NA
 
 
 
 
Side
 
Effects
 
and
 
their
 
Management*
 
1.
 
When
 
used
 
correctly ,
 
topical
 
corticosteroids
 
rarely
 
cause
 
serious
 
side
 
effects.
 
The
 
most
 
common
 
side
 
effect
 
is
 
a
 
burning
 
or
 
stinging
 
sensation,
 
which
 
typically
 
improves
 
with
 
continued
 
use.
 
2.
 
Less
 
common
 
side
 
effects
 
can
 
include:
 
3.
 
Skin
 
issues:
 
Thinning,
 
striae
 
formation,
 
contact
 
 
 
 
94
 

=== PAGE 96 ===

 
dermatitis,
 
acne,
 
rosacea,
 
changes
 
in
 
skin
 
color
 
(more
 
noticeable
 
in
 
dark
 
skin),
 
and
 
excessive
 
hair
 
growth.
 
4.
 
Infections:
 
Worsening
 
or
 
spreading
 
of
 
existing
 
infections
 
and
 
inflamed
 
hair
 
follicles
 
(folliculitis).
 
5.
 
Risks
 
are
 
higher
 
with
 
more
 
potent
 
steroids,
 
prolonged
 
use,
 
large
 
application
 
areas,
 
and
 
in
 
vulnerable
 
groups
 
like
 
the
 
elderly
 
and
 
young
 
children.
 
Prolonged
 
use
 
of
 
high-potency
 
steroids
 
can
 
lead
 
to
 
systemic
 
effects
 
like
 
Cushing's
 
syndrome
 
or
 
growth
 
suppression
 
in
 
children.
 
6.
 
For
 
detailed
 
side
 
effect
 
information,
 
consult
 
the
 
medicine
 
leaflet.
 
Storage*
 
Keep
 
the
 
jar
 
tightly
 
closed.
 
Store
 
below
 
30°C
 
and
 
protect
 
from
 
heat,
 
moisture,
 
and
 
light.
 
Do
 
not
 
freeze.
 
Keep
 
out
 
of
 
reach
 
of
 
children.
 
 
 
 
Others
 
●
 
Unless
 
the
 
medication
 
is
 
formulated
 
for
 
the
 
eye
 
area,
 
Do
 
not
  
use
 
steroids
 
on,
 
in
 
or
 
around
 
the
 
eyes
 
as
 
it
 
can
 
cause
 
cataracts
 
and
 
glaucoma.
 
 
 
 
 
Before
 
ending
 
this
 
peer
 
review
 
session,
 
the
 
reviewee
 
should
 
be
 
informed
 
of
 
the
 
step(s)
 
that
 
he/
 
she
 
missed
 
out
 
in
 
order
 
to
 
ensure
 
all
 
the
 
counselling
 
points
 
are
 
being
 
covered.
 
 
Remarks:
 
 
 
 
 
Reviewed
 
by:
 
Name
 
&
 
Signature
                                                                   
Date:
 
*Mandatory
 
for
 
validation
 
/
 
peer
 
review
 
References:
 
 
1.
 
Alabdulrazzaq,
 
F.,
 
&
 
Koren,
 
G.
 
(2012).
 
Topical
 
corticosteroid
 
use
 
during
 
pregnancy .
 
Canadian
 
Family
 
Physician,
 
58(6),
 
643–644.
 
PMCID:
 
PMC3374684,
 
PMID:
 
22700732.
 
 
2.
 
National
 
Health
 
Service.
 
(2023).
 
Topical
 
steroids.
 
NHS.
 
Retrieved
 
December
 
19,
 
2024,
 
from
 
https://www .nhs.uk/conditions/topical-steroids/
 
 
3.
 
Ministry
 
of
 
Health
 
Malaysia.
 
(2013).
 
Management
 
of
 
psoriasis
 
vulgaris.
 
Ministry
 
of
 
Health
 
Malaysia.
 
Retrieved
 
December
 
18,
 
2024,
 
from
 
https://www .moh.gov .my/moh/attachments/9004.pdf
 
 
4.
 
Vestergaard,
 
C.,
 
Wollenberg,
 
A.,
 
Barbarot,
 
S.,
 
et
 
al.
 
(2019).
 
European
 
task
 
force
 
on
 
atopic
 
dermatitis
 
position
 
paper:
 
Treatment
 
of
 
parental
 
atopic
 
dermatitis
 
during
 
preconception,
 
pregnancy
 
and
 
lactation
 
period.
 
Journal
 
of
 
the
 
European
 
Academy
 
of
 
Dermatology
 
and
 
Venereology ,
 
33(8),
 
1644.
 
5.
 
Academy
 
of
 
Medicine
 
Malaysia.
 
(2018).
 
Management
 
of
 
atopic
 
eczema.
 
https://www .acadmed.org.my/CPGdl/CPG%20Management%20of%20Atopic%20Eczema.pdf
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
95
 

=== PAGE 97 ===

 
Crotamiton,
 
Topical
 
Name
 
:
 
 
Unit
 
:
 
 
●
 
Please
 
tick
 
(
✔
)
 
Yes
 
for
 
correct
 
instruction.
 
●
 
Please
 
tick
 
(
✔
)
 
No
 
for
 
incorrect
 
instruction.
 
Yes
 
No
 
Remarks
 
Pharmacological
 
Group
 
Scabicide
 
Antipruritic
 
agent
 
 
 
 
Indications
 
and
 
Dosage
 
1.
 
Scabies
 
for
 
infant
 
<2yo
 
2.
 
Pruritus
 
3.
 
Insect
 
bite
 
reaction
 
 
Or
 
 
To
 
counsel
 
based
 
on
 
specific
 
medication’ s
 
indication
 
and
 
dosage
 
as
 
prescribed
 
by
 
the
 
doctor
 
 
 
 
Method
 
of
 
Administration*
 
1.
 
Scabies
 
a.
 
Bath
 
and
 
dab
 
dry
 
before
 
applying
 
the
 
cream.
 
b.
 
Apply
 
the
 
cream
 
by
 
massaging
 
into
 
the
 
skin
 
from
 
the
 
chin
 
to
 
the
 
toes
 
including
 
skin
 
folds
 
and
 
creases.
 
Special
 
attention
 
should
 
be
 
paid
 
to
 
sites
 
that
 
are
 
particularly
 
susceptible
 
to
 
infestation
 
by
 
the
 
mites
 
(interdigital
 
space,
 
wrist,
 
axillae
 
and
 
genitalia).
 
c.
 
Cut
 
fingernails
 
short
 
and
 
make
 
sure
 
to
 
apply
 
under
 
fingernails
 
too.
 
d.
 
DO
 
NOT
 
apply
 
the
 
cream
 
in
 
the
 
eyes
 
or
 
mouth.
 
e.
 
DO
 
NOT
 
apply
 
to
 
raw,
 
weeping,
 
or
 
inflamed
 
skin.
 
f.
 
Areas
 
where
 
there
 
is
 
pus
 
formation
 
should
 
be
 
covered
 
with
 
a
 
dressing
 
impregnated
 
with
 
crotamiton.
 
g.
 
The
 
application
 
should
 
be
 
repeated
 
once
 
daily,
 
preferably
 
in
 
the
 
evening,
 
for
 
a
 
total
 
of
 
3-5
 
days
 
depending
 
on
 
the
 
response.
 
h.
 
For
 
nodular
 
scabies,
 
apply
 
to
 
the
 
nodules
 
3
 
times
 
a
 
day
 
for
 
7-14
 
days.
 
i.
 
Finish
 
the
 
full
 
course
 
prescribed
 
by
 
your
 
doctor
 
even
 
if
 
you
 
think
 
your
 
condition
 
is
 
better .
 
2.
 
Pruritus
 
and
 
Insect
 
bite
 
reaction
 
a.
 
Massage
 
the
 
cream
 
into
 
itchy
 
patches
 
until
 
the
 
medication
 
is
 
absorbed
 
into
 
the
 
skin
 
2-3
 
times
 
a
 
day
 
until
 
itching
 
has
 
subsided.
 
b.
 
DO
 
NOT
 
apply
 
the
 
cream
 
in
 
the
 
eyes
 
or
 
mouth.
 
c.
 
DO
 
NOT
 
apply
 
to
 
raw,
 
weeping,
 
or
 
inflamed
 
skin.
 
Miss
 
dose
 
management
:
 
If
 
a
 
dose
 
is
 
missed,
 
use
 
it
 
as
 
soon
 
as
 
possible.
 
If
 
it
 
is
 
almost
 
time
 
for
 
the
 
next
 
dose,
 
use
 
only
 
that
 
dose.
 
Do
 
not
 
use
 
double
 
or
 
extra
 
doses.
 
 
Do
 
not
 
stop
 
taking
 
your
 
medication
 
unless
 
advised
 
to
 
do
 
so
 
by
 
your
 
prescriber
 
 
 
 
Special
 
Considerations
 
Pregnancy
 
 
 
 
Use
 
during
 
pregnancy ,
 
particularly
 
during
 
the
 
first
 
trimester
 
is
 
NOT
 
ADVISED.
 
 
 
 
96
 

=== PAGE 98 ===

 
Breastfeeding
 
 
 
 
No
 
data
 
on
 
the
 
harmful
 
effect
 
on
 
breastfeeding
 
women.
 
Nursing
  
mothers
 
should,
 
in
 
all
 
events,
 
avoid
 
applying
 
crotamiton
 
in
 
the
 
area
 
of
 
the
 
nipples.
 
 
 
 
Elderly
 
 
 
 
None
 
specifically
 
to
 
the
 
product
 
 
 
 
Paediatric
 
 
 
 
Dosing
 
and
 
treatment
 
recommendations
 
may
 
vary
 
among
 
individual
 
products
 
or
 
between
 
countries.
 
 
 
 
 
Fasting
 
 
 
 
To
 
refer
 
to
 
the
 
latest
 
advisory
 
by
 
religious
 
authority
 
 
 
 
Others
  
 
 
 
 
N/A
 
 
 
 
Side
 
Effects
 
and
 
their
 
Management*
 
1.
 
Burning,
 
itching,
 
rash,
 
redness,
 
stinging,
 
swelling,
 
numbness
 
2.
 
Discontinue
 
use
 
if
 
severe
 
irritation
 
or
 
sensitization
 
occurs.
 
 
 
 
Storage*
 
1.
 
Store
 
at
 
room
 
temperature
 
below
 
25C.
 
2.
 
Protect
 
from
 
light
 
3.
 
Discard
 
any
 
unused
 
medicine
 
after
 
the
 
expired
 
date
 
 
 
 
Others
 
1.
 
Patients
 
with
 
scabies
 
and
 
their
 
close
 
physical
 
contacts,
 
even
 
without
 
symptoms,
 
should
 
receive
 
treatment
 
at
 
the
 
same
 
time.
 
 
2.
 
Wash
 
clothing
 
and
 
bedding
 
in
 
hot
 
water
 
or
 
by
 
dry
 
cleaning.
 
Clothing
 
that
 
cannot
 
be
 
washed
 
may
 
be
 
stored
 
in
 
a
 
sealed
 
plastic
 
bag
 
for
 
three
 
days.
 
3.
 
If
 
the
 
treatment
 
is
 
applied
 
by
 
someone
 
without
 
scabies,
 
this
 
person
 
should
 
wear
 
medical
 
gloves
 
during
 
application
 
4.
 
Avoid
 
application
 
to
 
the
 
face,
 
eyes,
 
mouth
 
or
 
an
 
acutely
 
inflamed,
 
denuded
 
or
 
weeping
 
skin.
 
5.
 
After
 
completion
 
of
 
treatment,
 
patients
 
should
 
use
 
fresh,
 
clean
 
bedding
 
and
 
clothing.
 
 
6.
 
To
 
prevent
 
re-infestation,
 
put
 
freshly
 
washed
 
or
 
dry-cleaned
 
clothing
 
and
 
change
 
bedding.
 
 
 
 
Before
 
ending
 
this
 
peer
 
review
 
session,
 
the
 
reviewee
 
should
 
be
 
informed
 
of
 
the
 
step(s)
 
that
 
he/
 
she
 
missed
 
out
 
in
 
order
 
to
 
ensure
 
all
 
the
 
counselling
 
points
 
are
 
being
 
covered.
 
 
Remarks:
 
 
 
 
 
Reviewed
 
by:
 
Name
 
&
 
Signature
                                                                   
Date:
 
 
 
 
 
*Mandatory
 
for
 
validation
 
/
 
peer
 
review
 
 
97
 

=== PAGE 99 ===

 
References:
 
 
1.
 
MIMS
 
Malaysia
 
Online.
 
Crotamiton
 
(Available
 
at
    
 
https://www .mims.com/malaysia/drug/info/crotamiton?mtype=generic
).
 
Accessed
 
on
 
January
 
20,
 
2025.
 
 
2.
 
Formulari
 
Ubat
 
KKM.
 
(2025,
 
January
 
1).
 
Accessed
 
on
 
January
 
20,
 
2025.
 
3.
 
Cleveland
 
Clinic.
 
Crotamiton
 
topical
 
cream
 
or
 
lotion
 
(Available
 
at
 
https://my .clevelandclinic.org/health/drugs/18703-crotamiton-topical-cream-or-lotion
).
 
Accessed
 
on
 
January
 
20,
 
2025
 
4.
 
UpToDate
 
Online.
 
Crotamiton:
 
Drug
 
information.(A vailable
 
at
 
 
https://www .uptodateonline.ir/contents/UTD.htm?12/45/1301 1?source=see_link
)
 
Accessed
 
on
 
January
 
20,
 
2025
 
Ismail,
 
H.I.H.M.,
 
Ibrahim,
 
H.M.,
 
Ng,
 
H.P.,
 
Kesihatan,
 
M.K.
 
and
 
Thomas,
 
T.
 
(2019)
 
Paediatric
 
Protocols
 
for
    
Malaysian
 
Hospitals.
 
4th
 
Edition,
 
Ministry
 
of
 
Health,
 
Putrajaya.
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
98
 

=== PAGE 100 ===

 
Dabigatran
 
Name
 
:
 
 
Unit
 
:
 
 
●
 
Please
 
tick
 
(
✔
)
 
Yes
 
for
 
correct
 
instruction.
 
●
 
Please
 
tick
 
(
✔
)
 
No
 
for
 
incorrect
 
instruction.
 
Yes
 
No
 
Remarks
 
Pharmacological
 
Group
 
Direct
 
Oral
 
Anticoagulant
 
-
 
Direct
 
Thrombin
 
Inhibitor
 
 
 
 
Indications
 
and
 
Dosage
 
1.
 
Prevention
 
of
 
venous
 
thromboembolic
 
events
 
in
 
patients
 
who
 
have
 
undergone
 
total
 
knee
 
replacement
 
or
 
total
 
hip
 
replacement
 
surgery .
 
a.
 
Following
 
total
 
knee
 
replacement:
 
Initially
 
ADUL T
 
110mg
 
(ELDERL Y,
 
75
 
mg)
 
within
 
1-
 
4
 
hours
 
after
 
surgery ,
 
then
 
220
 
mg
 
(ELDERL Y,
 
150
 
mg)
 
once
 
daily
 
thereafter
 
for
 
6-10
 
days
 
Following
 
total
 
hip
 
replacement:
 
Initially
 
ADUL T
 
110
 
mg
 
(ELDERL Y,
 
75
 
mg)
 
within
 
1-
 
4
 
hours
 
after
 
surgery ,
 
then
 
220
 
mg
 
(ELDERL Y,
 
150
 
mg)
 
once
 
daily
 
thereafter
 
for
 
28-35
 
days
 
 
2.
 
Reduction
 
of
 
the
 
risk
 
of
 
stroke
 
and
 
systemic
 
embolism
 
in
 
patients
 
with
 
non-valvular
 
atrial
 
fibrillation
 
(AF)
 
a.
 
Recommended
 
daily
 
dose
 
is
 
300mg
 
taken
 
orally
 
as
 
150mg
 
hard
 
capsule
 
twice
 
daily.
 
Therapy
 
should
 
be
 
continued
 
lifelong.
 
b.
 
For
 
the
 
following
 
groups,
 
the
 
recommended
 
daily
 
dose
 
is
 
220
 
mg
 
taken
 
as
 
one
 
110mg
 
capsule
 
twice
 
daily:
 
-
 
Patients
 
aged
 
80
 
years
 
or
 
above
 
-Patients
 
who
 
receive
 
concomitant
 
verapamil
 
Special
 
patient
 
population
 
for
 
renal
 
impairment:
 
Renal
 
function
 
should
 
be
 
assessed
 
by
 
calculating
 
the
 
creatinine
 
clearance
 
(CrCl)
 
prior
 
to
 
initiation
 
of
 
treatment
 
with
 
Dabigatran
 
to
 
exclude
 
patients
 
for
 
treatment
 
with
 
severe
 
renal
 
impairment
 
(i.e.
 
CrCl
 
<
 
30
 
ml/min).
 
 
3.
 
Treatment
 
of
 
deep
 
vein
 
thrombosis
 
(DVT)
 
and
 
pulmonary
 
embolism
 
(PE)
 
and
 
prevention
 
of
 
recurrent
 
DVT
 
and
 
PE
 
in
 
adults.
 
a.
 
Recommended
 
daily
 
dose
 
is
 
300mg
 
taken
 
as
 
one
 
150mg
 
capsule
 
BD
 
following
 
treatment
 
with
 
a
 
parenteral
 
anticoagulant
 
for
 
at
 
least
 
5
 
days.
 
The
 
duration
 
of
 
therapy
 
should
 
be
 
individualized
 
after
 
careful
 
assessment
 
of
 
the
 
treatment
 
benefit
 
against
 
the
 
risk
 
for
 
bleeding.
 
b.
 
Same
 
as
 
2b
 
 
 
 
Method
 
of
 
Administration*
 
1.
 
The
 
capsules
 
should
 
be
 
swallowed
 
whole.
 
2.
 
Breaking,
 
chewing,
 
or
 
emptying
 
the
 
contents
 
of
 
the
 
capsule
 
can
 
result
 
in
 
increased
 
exposure.The
 
oral
 
bioavailability
 
of
 
dabigatran
 
etexilate
 
increases
 
by
 
75%
 
when
 
the
 
pellets
 
are
 
taken
 
without
 
the
 
capsule
 
shell
 
compared
 
to
 
the
 
intact
 
capsule
 
formulation.
 
3.
 
Dabigatran
 
can
 
be
 
taken
 
with
 
or
 
without
 
food.
 
 
Missed
 
dose
 
management
 
:
 
 
1.
 
If
 
a
 
dose
 
of
 
dabigatran
 
is
 
not
 
taken
 
at
 
the
 
scheduled
 
time,
 
the
 
dose
 
should
 
be
 
taken
 
as
 
soon
 
as
 
possible
 
on
 
the
 
same
 
day;
 
the
 
missed
 
dose
 
should
 
be
 
skipped
 
if
 
it
 
cannot
 
be
 
taken
 
at
 
least
 
6
 
hours
 
before
 
the
 
next
 
 
 
 
99
 

=== PAGE 101 ===

 
scheduled
 
dose.
 
The
 
dose
 
of
 
dabigatran
 
should
 
not
 
be
 
doubled
 
to
 
make
 
up
 
for
 
a
 
missed
 
dose.
 
 
Do
 
not
 
stop
 
taking
 
your
 
medication
 
unless
 
advised
 
to
 
do
 
so
 
by
 
your
 
prescriber
 
Special
 
Considerations
 
Pregnancy
 
 
 
 
1.
 
There
 
are
 
no
 
adequate
 
and
 
well-controlled
 
studies
 
in
 
pregnant
 
women.
 
 
2.
 
Safety
 
and
 
effectiveness
 
of
 
dabigatran
 
during
 
labor
 
and
 
delivery
 
have
 
not
 
been
 
studied
 
in
 
clinical
 
trials.
 
 
 
 
Breastfeeding
 
 
 
 
1.
 
It
 
is
 
not
 
known
 
whether
 
dabigatran
 
is
 
excreted
 
in
 
human
 
milk.
 
 
 
 
Elderly
 
 
 
 
1.
 
Dose
 
reductions
 
may
 
be
 
required
 
as
 
per
 
‘Indications
 
and
 
Dosage’
 
MALPIP:
 
 
Increased
 
risk
 
of
 
gastrointestinal
 
bleeding;
 
haemorrhagic
 
stroke
 
and
 
haemorrhage.
 
Avoid
 
use
 
in
 
elderly
 
patients
 
with
 
CrCl
 
less
 
than
 
30
 
mL/min
 
 
Beers
 
Criteria:
 
Use
 
caution
 
in
 
selecting
 
dabigatran
 
over
 
other
 
DOACs
 
(e.g.,
 
apixaban)
 
for
 
long-term
 
treatment
 
of
 
nonvalvular
 
atrial
 
fibrillation
 
or
 
VTE.
 
Increased
 
risk
 
of
 
GI
 
bleeding
 
compared
 
with
 
warfarin
 
(based
 
on
 
head-to-head
 
clinical
 
trials)
 
and
 
of
 
GI
 
bleeding
 
and
 
major
 
bleeding
 
compared
 
with
 
apixaban
 
(based
 
on
 
observational
 
studies
 
and
 
meta-analyses)
 
in
 
older
 
adults
 
when
 
used
 
for
 
long-term
 
treatment
 
of
 
nonvalvular
 
atrial
 
fibrillation
 
or
 
VTE.
 
 
*
 
When
 
selecting
 
among
 
DOACs
 
and
 
choosing
 
a
 
dosage,
 
pay
 
special
 
consideration
 
to
 
kidney
 
function,indication,
 
and
 
body
 
weight
 
&
 
swallowing
 
status
 
(dysphagia)
 
 
 
 
Paediatric
 
 
 
 
Dosing
 
is
 
based
 
on
 
weight
 
and
 
age.
 
 
 
 
Fasting
 
 
 
 
Not
 
applicable
 
 
 
 
Others
 
 
 
 
1.
 
No
 
dose
 
adjustment
 
of
 
dabigatran
 
is
 
recommended
 
in
 
patients
 
with
 
mild
 
or
 
moderate
 
renal
 
impairment
 
2.
 
Reduce
 
the
 
dose
 
of
 
dabigatran
 
in
 
patients
 
with
 
severe
 
renal
 
impairment
 
(CrCl
 
15-30
 
mL/min).
 
The
 
recommended
 
dose
 
is
 
75
 
mg
 
twice
 
daily
 
3.
 
Dosing
 
recommendations
 
for
 
patients
 
with
 
a
 
CrCl
 
<15mls/min
 
or
 
on
 
dialysis
 
cannot
 
be
 
provided.
 
4.
 
For
 
patients
 
with
 
liver
 
disease
 
that
 
is
 
associated
 
with
 
changes
 
in
 
the
 
blood
 
tests,
 
the
 
use
 
of
 
dabigatran
 
is
 
not
 
recommended.
 
 
 
 
Side
 
Effects
 
and
 
their
 
1.
 
In
 
some
 
people,
 
dabigatran
 
can
 
cause
 
symptoms
 
of
 
an
 
allergic
 
reaction,
 
including
 
hives,
 
rash,
 
and
 
itching.
 
 
 
 
 
100
 

=== PAGE 102 ===

 
Management*
 
2.
 
To
 
seek
 
medical
 
assistance
 
right
 
away
 
if
 
you
 
have
 
any
 
of
 
the
 
following
 
symptoms
 
of
 
a
 
serious
 
allergic
 
reaction
 
with
 
dabigatran:
 
 
a.
 
chest
 
pain
 
or
 
chest
 
tightness
 
 
b.
 
swelling
 
of
 
your
 
face
 
or
 
tongue
 
 
c.
 
trouble
 
breathing
 
or
 
wheezing
 
 
d.
 
feeling
 
dizzy
 
or
 
faint
 
 
3.
 
To
 
seek
 
emergency
 
care
 
right
 
away
 
if
 
there
 
are
 
signs
 
or
 
symptoms
 
of
 
unusual
 
or
 
serious
 
bleeding
 
from
 
any
 
parts
 
of
 
the
 
body .
 
4.
 
Common
 
side
 
effects
 
of
 
dabigatran
 
include:
 
 
a.
 
indigestion,
 
upset
 
stomach,
 
or
 
burning
 
b.
 
stomach
 
pain
 
 
Storage*
 
1.
 
Store
 
dabigatran
 
at
 
room
 
temperature
 
between
 
15°C
 
to
 
30°C.
 
 
2.
 
Keep
 
dabigatran
 
in
 
the
 
original
 
blister
 
package
 
to
 
keep
 
it
 
dry
 
(protect
 
the
 
capsules
 
from
 
moisture).
 
 
3.
 
Do
 
not
 
put
 
dabigatran
 
in
 
pill
 
boxes
 
or
 
pill
 
organizers.
 
 
 
 
 
Others
 
1.
 
Monitoring
 
parameters
 
a.
 
Serum
 
creatinine
 
b.
 
Hemoglobin
 
level
 
(Frequency
 
of
 
monitoring
 
depends
 
on
 
the
 
baseline
 
level)
 
2.
 
Drug
 
interactions
 
a.
 
P-gp
 
Inducers
 
Rifampin
 
-
 
Avoid
 
b.
 
P-gp
 
Inhibitors:
 
Dronedarone
 
ketoconazole,
 
amiodarone,
 
verapamil,
 
and
 
quinidine
 
Consider
 
reducing
 
the
 
dose
 
of
 
dabigatran
 
to
 
75
 
mg
 
twice
 
daily
 
when
 
dronedarone
 
or
 
systemic
 
ketoconazole
 
is
 
coadministered
 
with
 
dabigatran
 
in
 
patients
 
with
 
moderate
 
renal
 
impairment
 
(CrCl30-50
 
ml/min).
 
The
 
use
 
of
 
dabigatran
 
and
 
P-gp
 
inhibitors
 
in
 
patients
 
with
 
severe
 
renal
 
impairment
 
(CrCl
 
15-30
 
mL/min)
 
should
 
be
 
avoided.
 
 
 
 
Before
 
ending
 
this
 
peer
 
review
 
session,
 
the
 
reviewee
 
should
 
be
 
informed
 
of
 
the
 
step(s)
 
that
 
he/
 
she
 
missed
 
out
 
in
 
order
 
to
 
ensure
 
all
 
the
 
counselling
 
points
 
are
 
being
 
covered.
 
 
Remarks:
 
 
 
Reviewed
 
by:
 
Name
 
&
 
Signature
                                                                   
Date:
 
 
 
*Mandatory
 
for
 
validation
 
/
 
peer
 
review
 
 
References:
 
 
1.
 
Boehringer
 
Ingelheim
 
Pharmaceuticals,
 
Inc.
 
(2011).
 
Product
 
information
 
leaflet:
 
Pradaxa.
 
Retrieved
 
from
 
Quest
 
3+
 
Product
 
Search
 
on
 
January
 
1,
 
2025.
 
2.
 
Formulari
 
Ubat
 
KKM.
 
(2025,
 
January
 
1).
 
Accessed
 
on
 
January
 
1,
 
2025.
 
3.
 
Sandoz
 
Products
 
Malaysia
 
Sdn.
 
Bhd.
 
(2024).
 
Product
 
information
 
leaflet:
 
Dabigatran
 
Sandoz.
 
Retrieved
 
from
 
Quest
 
3+
 
Search
 
on
 
January
 
1,
 
2025.
 
4.
 
Chang,
 
C.
 
T.,
 
Chan,
 
H.
 
K.,
 
Cheah,
 
W.
 
K.,
 
Tan,
 
M.
 
P.,
 
Ch’ng,
 
A.
 
S.
 
H.,
 
Thiam,
 
C.
 
N.,
 
...
 
&
 
Lee,
 
S.
 
W.
 
H.
 
(2023).
 
Development
 
of
 
a
 
Malaysian
 
potentially
 
inappropriate
 
prescribing
 
screening
 
tool
 
in
 
older
 
adults
 
(MALPIP):
 
a
 
Delphi
 
study .
 
Journal
 
of
 
Pharmaceutical
 
Policy
 
and
 
Practice,
 
16(1),
 
122.
 
5.
 
2023
 
American
 
Geriatrics
 
Society
 
Beers
 
Criteria®
 
Update
 
Expert
 
Panel.
 
(2023).
 
American
 
Geriatrics
 
Society
 
2023
 
updated
 
AGS
 
Beers
 
Criteria®
 
for
 
potentially
 
inappropriate
 
medication
 
use
 
in
 
older
 
adults.
 
Journal
 
of
 
the
 
American
 
Geriatrics
 
Society ,
 
71(7),
 
2052-2081.
 
101
 

=== PAGE 103 ===

 
Dapsone
 
 
Name
 
:
 
 
Unit
 
:
 
 
●
 
Please
 
tick
 
(
✔
)
 
Yes
 
for
 
correct
 
instruction.
 
●
 
Please
 
tick
 
(
✔
)
 
No
 
for
 
incorrect
 
instruction.
 
Yes
 
No
 
Remarks
 
Pharmacological
 
Group
 
Sulfone
 
antibiotic
 
 
 
 
Indications
 
and
 
Dosage
 
First-line
 
treatment
 
for
 
leprosy
 
(Paucibacillary
 
&
 
Multibacillary)
 
(to
 
be
 
used
 
in
 
combination
 
with
 
other
 
anti-leprosy
 
agents)
 
a.
 
Adult:
 
100mg
 
daily
 
b.
 
Children:
 
i)
 
10-14
 
years
 
old
 
:
 
50mg
 
daily
 
ii)
 
<10
 
years
 
old
 
or
 
<40kg:
 
2mg/kg
 
daily
 
 
 
 
Method
 
of
 
Administration*
 
Food
 
To
 
be
 
taken
 
with
 
meals
 
if
 
GI
 
upset
 
occurs
 
 
 
RT
 
administration
 
Tablet
 
can
 
be
 
crushed,
 
mixed
 
with
 
water
 
and
 
administered
 
through
 
Ryles
 
Tube
 
 
Missed
 
dose
 
Take
 
as
 
soon
 
as
 
remembered,
 
skip
 
if
 
near
 
next
 
dose;
 
do
 
not
 
double
 
dose
 
 
Do
 
not
 
stop
 
taking
 
your
 
medication
 
unless
 
advised
 
to
 
do
 
so
 
by
 
your
 
prescriber
 
 
 
 
Special
 
Considerations
 
Pregnancy
 
 
 
 
Safe
 
in
 
pregnancy
 
 
 
 
Breastfeeding
 
 
 
 
Safe
 
to
 
be
 
used
 
in
 
breastfeeding,
 
but
 
avoid
 
for
 
infants
 
with
 
G6PD
 
deficiency .
 
 
 
 
Elderly
 
 
 
 
NA
 
 
 
 
Paediatric
 
 
 
 
Dapsone
 
syrup
 
2mg/ml
 
can
 
be
 
prepared
 
 
 
 
 
Fasting
 
 
 
 
NA
 
 
 
 
Others
 
 
Use
 
in
 
renal
 
disease:
 
 
Can
 
be
 
used
 
without
 
dose
 
adjustment
 
 
Use
 
in
 
hepatic
 
disease:
 
No
 
recommended
 
dose
 
adjustment,
 
use
 
with
 
caution
 
 
 
 
Side
 
Effects
 
and
 
their
 
Management*
 
1.
 
GI
 
disorders:
 
nausea
 
and
 
vomiting
 
2.
 
Headache
 
3.
 
Haematologic:
 
haemolytic
 
anaemia,
 
haemolysis,
 
 
 
 
102
 

=== PAGE 104 ===

 
methaemoglobinaemia
 
4.
 
Hypersensitivity
 
reaction,
 
including
 
SJS,
 
TEN
 
5.
 
Hepatitis,
 
transaminitis
 
 
Advise
 
patients
 
to
 
inform
 
their
 
healthcare
 
providers
 
if
 
they
 
experience
 
any
 
side
 
effects.
 
Storage*
 
1.
 
Tablet
 
should
 
be
 
kept
 
at
 
room
 
temperature
 
2.
 
Suspension
 
should
 
be
 
refrigerated
 
and
 
protected
 
from
 
light;
 
stable
 
for
 
91
 
days
 
(Extemp
 
formulation
 
2015)
 
 
 
 
Others
 
Avoid
 
use
 
in
 
individuals
 
with
 
G6PD-deficiency .
 
 
 
 
Before
 
ending
 
this
 
peer
 
review
 
session,
 
the
 
reviewee
 
should
 
be
 
informed
 
of
 
the
 
step(s)
 
that
 
he/
 
she
 
missed
 
out
 
in
 
order
 
to
 
ensure
 
all
 
the
 
counselling
 
points
 
are
 
being
 
covered.
 
 
Remarks:
 
 
 
 
 
Reviewed
 
by:
 
Name
 
&
 
Signature
                                                                   
Date:
 
 
 
 
 
*Mandatory
 
for
 
validation
 
/
 
peer
 
review
 
References:
 
 
1.
 
Manual
 
Pengurusan
 
Kusta
 
Kebangsaan,
 
Edisi
 
3.
 
(2023).
 
Kementerian
 
Kesihatan
 
Malaysia.
 
2.
 
Extemporaneous
 
Formulation.
 
(2015).
 
Kementerian
 
Kesihatan
 
Malaysia.
 
3.
 
Senarai
 
Ubat
 
Galenikal
 
dan
 
Ekstemporaneous
 
(GAEX)
 
Dalam
 
PhIS,
 
updated
 
on
 
5
 
Dec
 
2024
 
4.
 
X-Temp
 
Oral
 
Suspension
 
Master
 
Formulation
 
Sheets.
 
(2023).
 
Pharm-D.
 
5.
 
Dapsone
 
(systemic):
 
Drug
 
information.
 
UpToDate
 
Inc.
 
Accessed
 
March
 
2025.
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
103
 

=== PAGE 105 ===

 
Darbepoetin
 
Alfa
 
Name
 
:
 
 
Unit
 
:
 
 
●
 
Please
 
tick
 
(
✔
)
 
Yes
 
for
 
correct
 
instruction.
 
●
 
Please
 
tick
 
(
✔
)
 
No
 
for
 
incorrect
 
instruction.
 
Yes
 
No
 
Remarks
 
Pharmacological
 
Group
 
Other
 
antianemic
 
preparations
 
Darbepoetin
 
Alfa
 
 
 
 
Indications
 
and
 
Dosage
 
1.
 
Treatment
 
of
 
anaemia
 
associated
 
with
 
chronic
 
kidney
 
failure,
 
including
 
patients
 
on
 
dialysis
 
and
 
patients
 
not
 
on
 
dialysis
 
a.
 
CKD
 
ON
 
dialysis:
 
 
IV/SC:
 
0.45
 
mcg/kg
 
once
 
weekly
 
or
 
0.75
 
mcg/kg
 
once
 
every
 
2
 
weeks
 
b.
 
CKD
 
NOT
 
on
 
dialysis:
 
SC:
  
0.45
 
mcg/kg
 
once
 
every
 
2
 
to
 
4
 
weeks
 
 
Dose
 
may
 
be
 
increased
 
or
 
decreased
 
by
 
25%
 
once
 
every
 
4
 
weeks,
 
according
 
to
 
Hb
 
level.
 
The
 
dose
 
should
 
not
 
exceed
 
180mcg
 
per
 
single
 
injection.
 
 
2.
 
Anemia
 
with
 
myelodysplastic
 
syndrome
 
a.
 
240
 
mcg
 
as
 
a
 
single
 
subcutaneous
 
injection
 
once
 
weekly .
 
 
The
 
dose
 
should
 
be
 
decreased
 
in
 
view
 
of
 
the
 
degree
 
of
 
anemic
 
symptoms
 
and
 
the
 
patient’ s
 
age.
 
 
Dosing
 
is
 
according
 
to
 
product
 
insert
.
 
 
To
 
counsel
 
based
 
on
 
specific
 
medication’ s
 
indication
 
and
 
dosage
 
as
 
prescribed
 
by
 
the
 
doctor
 
 
 
 
Method
 
of
 
Administration*
 
Route
 
of
 
Administration:
 
Intravenous
 
(IV)
 
or
 
Subcutaneous
 
(SC):
 
 
 
Site
 
of
 
administration
 
for
 
SC:
 
Lower
 
part
 
of
 
abdomen,
 
thigh
 
or
 
arm
 
 
Injection
 
technique
 
for
 
SC
 
(for
 
self-administered)
 
1.
 
Take
 
one
 
syringe
 
out
 
of
 
the
 
package
 
and
 
check
 
that
 
the
 
solution
 
is
 
clear ,
 
colourless
 
and
 
free
 
from
 
visible
 
particles
.
 
2.
 
Allow
 
the
 
syringe
 
to
 
reach
 
room
 
temperature.
 
3.
 
Wash
 
your
 
hands..
 
 
4.
 
Unscrew
 
the
 
cap
 
from
 
the
 
syringe.
 
5.
 
Remove
 
the
 
needle
 
from
 
the
 
pack,
 
fix
 
it
 
on
 
the
 
syringe
 
and
 
remove
 
the
 
protective
 
cap
 
from
 
the
 
needle.
 
 
6.
 
Clean
 
the
 
skin
 
at
 
the
 
site
 
of
 
injection
 
using
 
an
 
alcohol
 
swab.
 
7.
 
Form
 
a
 
skin
 
fold
 
by
 
pinching
 
the
 
skin
 
between
 
thumb
 
and
 
forefinger .
 
8.
 
Fully
 
insert
 
the
 
needle
 
45
0
 
or
 
90
0
 
angle
 
into
 
the
 
skin
 
fold
 
with
 
a
 
quick,
 
short
 
motion.
 
Once
 
the
 
needle
 
is
 
inserted,
 
release
 
the
 
pinch.
 
9.
 
Slowly
 
inject
 
the
 
darbepoetin
 
solution.
 
 
10.
 
Withdraw
 
the
 
needle
 
and
 
apply
 
pressure
 
over
 
the
 
injection
 
site
 
with
 
a
 
dry
 
and
 
sterile
 
pad.
 
11.
 
Dispose
 
the
 
empty
 
syringe
 
in
 
a
 
special
 
waste
 
container
 
12.
 
Tear
 
off
 
the
 
medication
 
label
 
on
 
the
 
syringe
 
and
 
stick
 
into
 
the
 
booklet/diary
 
(e.g.,
 
CAPD
 
book)
 
after
 
the
 
injection
 
for
 
the
 
administration
 
record,
 
if
 
available.
 
 
 
 
 
 
 
104
 

=== PAGE 106 ===

 
Consideration:
 
1.
 
Blood
 
pressure
 
(BP)
 
cutof f
 
for
 
administering
 
Erythropoietin
 
Stimulating
 
Agent
 
(ESA)
 
is
 
individualised.
 
Generally ,
 
ESA
 
is
 
not
 
given
 
if
 
BP
 
exceeds
 
160/100
 
mmHg.
 
Patients
 
need
 
to
 
be
 
informed
 
about
 
their
 
specific
 
BP
 
cutof f
 
whether
 
to
 
continue
 
or
 
hold
 
ESA
 
at
 
home.
 
2.
 
The
 
site
 
of
 
SC
 
injection
 
should
 
be
 
rotated.
 
 
 
Missed
 
dose
 
management:
 
The
 
missed
 
dose
 
should
 
be
 
administered
 
as
 
soon
 
as
 
possible
 
and
 
administration
 
of
 
Darbepoetin
 
Alfa
 
is
 
to
 
be
 
restarted
 
at
 
the
 
prescribed
 
dosing
 
frequency .
 
 
Do
 
not
 
stop
 
taking
 
your
 
medication
 
unless
 
advised
 
to
 
do
 
so
 
by
 
your
 
prescriber
 
Special
 
Considerations
 
Pregnancy
 
 
 
 
1.
 
Not
 
recommended.
 
 
2.
 
When
 
use
 
is
 
necessary ,
 
should
 
be
 
limited
 
to
 
cases
 
where
 
expected
 
therapeutic
 
benefits
 
outweigh
 
possible
 
risks
 
 
 
 
Breastfeeding
 
 
 
 
1.
 
Not
 
recommended.
 
2.
 
When
 
necessary ,patients
 
should
 
avoid
 
lactation
 
during
 
the
 
treatment.Safety
 
has
 
not
 
been
 
established.
 
 
 
 
Elderly
 
 
 
 
1.
 
Parameters
 
such
 
as
 
the
 
blood
 
pressure,
 
haemoglobin
 
concentration
 
and
 
hematocrit
 
level
 
should
 
be
 
frequently
 
measured,
 
elderly
 
generally
 
have
 
reduced
 
physiological
 
function
 
and
 
are
 
likely
 
to
 
have
 
cardiovascular
 
complications
 
such
 
as
 
hypertension
 
 
 
 
 
Paediatric
 
 
 
 
Safe
 
to
 
be
 
used
 
in
 
children.
 
The
 
recommended
 
dosing
 
schedule
 
should
 
be
 
individualized.
 
 
 
 
Fasting
 
 
 
 
Administer
 
as
 
usual
 
 
 
 
Others
 
 
 
 
 
No
 
dosage
 
adjustment
 
was
 
provided
 
in
 
the
 
manufacturer ’s
 
labelling.
 
 
 
 
Side
 
Effects
 
and
 
their
 
management*
 
1.
 
Common
 
side
 
effects,
 
generally
 
not
 
serious:
 
headache,
 
increased
 
blood
 
pressure,
 
irritation
 
or
 
pain
 
at
 
the
 
injection
 
site.
 
Note:
 
●
 
To
 
advise
 
on
 
the
 
importance
 
of
 
compliance
 
with
 
antihypertensive
 
medications
 
and
 
dietary
 
restrictions
 
for
 
BP
 
control.
 
●
 
If
 
side
 
effects
 
persist,
 
please
 
consult
 
a
 
healthcare
 
professional
 
 
2.
 
Uncommon/rare:
 
Pure
 
red
 
cell
 
aplasia
 
(PRCA)
 
 
 
 
Storage*
 
1.
 
Transport
 
of
 
ESA
 
is
 
only
 
allowed
 
in
 
a
 
cool
 
box
 
with
 
ice
 
 
 
 
105
 

=== PAGE 107 ===

 
packs.
 
2.
 
Preferably
 
to
 
return
 
home
 
immediately
 
after
 
getting
 
ESA
 
from
 
the
 
pharmacy
 
to
 
facilitate
 
fast
 
storage.
 
3.
 
ESA
 
is
 
very
 
sensitive
 
to
 
light
 
and
 
temperature.
 
4.
 
Protect
 
ESA
 
from
 
light
 
5.
 
Store
 
ESA
 
in
 
the
 
refrigerator ,
 
do
 
not
 
freeze.
 
Keep
 
at
 
2-8°C.
 
 
6.
 
Avoid
 
fridge
 
doors,
 
and
 
vegetable
 
compartments.
 
Ensure
 
there
 
is
 
proper
 
air
 
circulation
 
around
 
your
 
ESA.
 
7.
 
If
 
you're
 
travelling,
 
try
 
to
 
keep
 
your
 
medication
 
in
 
a
 
cooler
 
with
 
ice
 
packs,
 
and
 
avoid
 
storing
 
it
 
in
 
any
 
place
 
where
 
it
 
might
 
get
 
too
 
hot,
 
like
 
in
 
a
 
car.
 
8.
 
According
 
to
 
the
 
stability
 
data
 
for
 
NESP
 
Injection,
 
the
 
syringe
 
remains
 
stable
 
for
 
up
 
to
 
3
 
months
 
when
 
stored
 
in
 
its
 
box
 
or
 
a
 
dark
 
place
 
at
 
25°C.
 
 
Handling
 
of
 
disposal:
 
1.
 
Needles
 
and
 
syringes
 
should
 
never
 
be
 
reused.
  
 
2.
 
Place
 
all
 
used
 
needles
 
and
 
syringes
 
into
 
a
 
sharps
 
container
 
(puncture-proof
 
disposable
 
container).
 
3.
 
Keep
 
the
 
sharp
 
container
 
out
 
of
 
the
 
reach
 
of
 
children.
  
 
4.
 
Avoid
 
disposing
 
of
 
used
 
sharps
 
containers
 
in
 
household
 
waste.
 
5.
 
Dispose
 
of
 
full
 
sharps
 
containers
 
according
 
to
 
local
 
regulations
 
or
 
at
 
designated
 
facilities.
 
Others
 
Precautions:
 
1.
 
Hypertension.
 
2.
 
Cardiovascular
 
disease
 
including
 
recent
 
myocardia
 
infarction
 
(MI)
 
and
 
venous
 
thromboembolism
 
3.
 
Malignant
 
disease
 
4.
 
Patients
 
with
 
epilepsy ,
 
history
 
of
 
seizures,
 
or
 
medical
 
conditions
 
associated
 
with
 
a
 
predisposition
 
to
 
seizure
 
activity
 
such
 
as
 
CNS
 
infections
 
and
 
brain
 
metastases.
 
Monitoring
 
parameters:
 
1.
 
Blood
 
pressure
 
particularly
 
at
 
the
 
start
 
of
 
therapy
 
2.
 
Monitor
 
haemoglobin
 
at
 
least
 
monthly
 
during
 
the
 
initiation
 
phase.
 
 
3.
 
Monitor
 
iron
 
status
 
at
 
least
 
every
 
3
 
months
 
during
 
ESA
 
therapy .
 
Contraindications:
 
1.
 
Known
 
hypersensitivity
 
to
 
the
 
active
 
substance
 
or
 
to
 
any
 
of
 
the
 
excipients
 
2.
 
Uncontrolled
 
hypertension.
 
3.
 
Pure
 
red
 
cell
 
aplasia
 
(PRCA)
 
that
 
begins
 
after
 
treatment
 
with
 
other
 
erythropoietin
 
stimulating
 
agents
 
(ESAs).
 
 
 
 
Before
 
ending
 
this
 
peer
 
review
 
session,
 
the
 
reviewee
 
should
 
be
 
informed
 
of
 
the
 
step(s)
 
that
 
he/
 
she
 
missed
 
out
 
in
 
order
 
to
 
ensure
 
all
 
the
 
counselling
 
points
 
are
 
being
 
covered.
 
 
Remarks:
 
 
 
Reviewed
 
by:
 
Name
 
&
 
Signature
                                                                   
Date:
 
 
*Mandatory
 
for
 
validation
 
/
 
peer
 
review
 
References
 
:
 
 
1.
 
Formulari
 
Ubat
 
KKM.
 
(2025,
 
January
 
1).
 
Accessed
 
on
 
January
 
1,
 
2025.
 
 
2.
 
Bak
 
Leong,
 
G.,
 
Sunita,
 
B.,
 
Rosnawati,
 
Y.,
 
&
 
Lily,
 
M.
 
(2023).
 
Handbook
 
of
 
kidney
 
replacement
 
therapy
 
(5th
 
ed.).
 
Ministry
 
of
 
Health
 
Malaysia.
 
3.
 
Kyowa
 
Kirin
 
(2019).
 
Product
 
information
 
leaflet:
 
NESP®
.
 
Retrieved
 
from
 
Quest
 
3+
 
Product
 
Search
 
on
 
January
 
1,
 
2025.
 
106
 

=== PAGE 108 ===

 
Darunavir
 
Name
 
:
 
Darunavir
 
600mg
 
Tablet
 
Unit
 
:
 
 
●
 
Please
 
tick
 
(
✔
)
 
Yes
 
for
 
correct
 
instruction.
 
●
 
Please
 
tick
 
(
✔
)
 
No
 
for
 
incorrect
 
instruction.
 
Ye
s
 
No
 
Remarks
 
Pharmacological
 
Group
 
Protease
 
Inhibitors
 
 
 
 
 
Indications
 
and
 
Dosage
 
HIV
 
Infection
 
in
 
combination
 
with
 
other
 
antiretroviral
 
agents.
 
 
 
Adult:
 
 
Darunavir
 
600mg
 
twice
 
daily
 
to
 
be
 
taken
 
together
 
with
 
100mg
 
Ritonavir
 
twice
 
daily
          
 
 
Children
 
≥
 
12
 
years
 
old
 
or
 
adolescents
 
weighing
 
≥
 
40kg:
 
Darunavir
 
600mg
 
together
 
with
 
100mg
 
Ritonavir
 
twice
 
daily
 
 
 
 
Method
 
of
 
Administration*
 
Take
 
Darunavir
 
always
 
together
 
with
 
Ritonavir
 
Should
 
take
 
Darunavir
 
with
 
food
 
(increase
 
bioavailability)
 
 
To
 
take
 
medication
 
consistently
 
at
 
the
 
same
 
time
 
everyday
 
 
Enteral
 
feeding/enteral
 
tube:
 
No
 
data.
 
Oral
 
suspension
 
formulation
 
is
 
available.
 
 
Do
 
not
 
stop
 
taking
 
your
 
medication
 
unless
 
advised
 
to
 
do
 
so
 
by
 
your
 
prescriber
 
 
 
 
Special
 
Considerations
 
Pregnancy
 
 
 
 
There
 
are
 
no
 
adequate
 
and
 
well-controlled
 
studies
 
on
 
pregnancy
 
outcome
 
with
 
darunavir
 
in
 
pregnant
 
women.
 
Studies
 
in
 
animals
 
have
 
not
 
shown
 
evidence
 
of
 
development
 
toxicity
 
or
 
effect
 
on
 
reproductive
 
function
 
and
 
fertility .
 
Darunavir
 
should
 
be
 
used
 
during
 
pregnancy
 
only
 
if
 
the
 
potential
 
benefit
 
justifies
 
the
 
potential
 
risk.No
 
dose
 
adjustment
 
is
 
required
 
for
 
darunavir
 
during
 
pregnancy
 
and
 
postpartum
.
 
 
 
 
Breastfeeding
 
 
 
 
It
 
is
 
not
 
known
 
whether
 
darunavir
 
is
 
excreted
 
in
 
human
 
milk.
 
Studies
 
in
 
rats
 
have
 
demonstrated
 
that
 
Darunavir
 
is
 
excreted
 
in
 
milk.
 
Because
 
of
 
both
 
the
 
potential
 
for
 
HIV
 
transmission
 
and
 
the
 
potential
 
for
 
serious
 
adverse
 
events
 
in
 
nursing
 
infants,
 
mothers
 
should
 
be
 
instructed
 
not
 
to
 
breastfeed
 
if
 
they
 
are
 
receiving
 
Darunavir .
 
 
 
 
Elderly
 
 
 
 
N/A
 
 
 
 
Paediatric
 
 
 
 
Darunavir
 
is
 
not
 
recommended
 
in
 
children
 
below
 
3
 
years
 
old
 
and
 
less
 
than
 
10kg.
 
 
 
 
Fasting
 
 
 
 
Time
 
of
 
administration
 
for
 
this
 
medication
 
may
 
be
 
adjusted
 
accordingly
 
when
 
fasting.
 
 
 
 
 
107
 

=== PAGE 109 ===

 
Others
  
 
 
 
 
Adult:
 
 
1.
 
Renal
 
impairment
 
:
 
 
No
 
dosage
 
adjustment
 
needed
 
2.
 
Hepatic
 
impairment
 
:
 
 
              
Mild
 
to
 
moderate
 
impairment
 
-
 
No
 
dosage
 
adjustment
 
              
needed
 
              
Severe
 
impairment
 
-
 
Use
 
is
 
not
 
recommended
 
 
 
 
Side
 
Effects
 
and
 
their
 
Management*
 
1.
 
Very
 
common
 
side
 
effects
 
 
(may
 
affect
 
more
 
than
 
1
 
in
 
10
 
people)
 
-
 
diarrhoea
 
 
2.
 
Common
 
side
 
effects
 
 
(may
 
affect
 
up
 
to
 
1
 
in
 
10
 
people)
 
-
 
vomiting,
 
nausea,
 
abdominal
 
pain
 
or
 
distension,
 
dyspepsia,
 
flatulence
 
headache,
 
tiredness,
 
dizziness,
 
drowsiness,
 
numbness,
 
tingling
 
or
 
pain
 
in
 
hands
 
or
 
feet,
 
loss
 
of
 
strength,
 
difficulty
 
falling
 
asleep.
 
 
 
 
Storage*
 
Do
 
not
 
store
 
above
 
30°C.
 
 
 
 
Others
 
Contraindications
 
 
Coadministration
 
with
 
alfuzosin,
 
dihydroergotamine,
 
ergonovine,
 
ergotamine,
 
methylergonovine,
 
cisapride,
 
pimozide,
 
oral
 
midazolam,
 
triazolam,
 
St.
 
John’ s
 
Wort,
 
lovastatin,
 
simvastatin,
 
rifampin
 
and
 
sildenafil
 
(for
 
treatment
 
of
 
pulmonary
 
arterial
 
hypertension)
 
 
 
 
Before
 
ending
 
this
 
peer
 
review
 
session,
 
the
 
reviewee
 
should
 
be
 
informed
 
of
 
the
 
step(s)
 
that
 
he/
 
she
 
missed
 
out
 
in
 
order
 
to
 
ensure
 
all
 
the
 
counselling
 
points
 
are
 
being
 
covered.
 
 
Remarks:
 
 
 
 
 
Reviewed
 
by:
 
Name
 
&
 
Signature
                                                                   
Date:
 
 
 
 
 
*Mandatory
 
for
 
validation
 
/
 
peer
 
review
 
References:
 
 
1.
 
Wolter
 
Kluwer .
 
2024
 
.
 
UpToDate
 
-
 
Darunavir .
 
UpToDate,Inc.
 
 
2.
 
Janssen
 
Pharmaceuticals
 
Inc
 
(2006).
 
PREZIST A
 
600MG
 
TABLET
 
(Consumer
 
Medication
 
Information
 
Leaflet
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
108
 

=== PAGE 110 ===

 
 
Deferasirox
 
and
 
Deferiprone
 
Name
 
:
 
 
Unit
 
:
 
 
●
 
Please
 
tick
 
(
✔
)
 
Yes
 
for
 
correct
 
instruction.
 
●
 
Please
 
tick
 
(
✔
)
 
No
 
for
 
incorrect
 
instruction.
 
Yes
 
No
 
Remarks
 
Pharmacological
 
Group
 
ORAL
 
IRON
 
CHELA TORS
 
 
DEFERIPRONE
 
(DFP)
 
Tab
 
Deferiprone
 
(DFP)
 
500mg
 
Immediate
 
Release
 
(IR)
 
Tab
 
Deferiprone
 
(DFP)
 
1000mg
 
Delayed
 
Release
 
(DR)
 
Syrup
 
Deferiprone
 
100mg/ml
 
 
DEFERASIROX
 
(DFX)
 
Tab
 
Deferasirox
 
(DFX)
 
Film-Coated
 
90mg,
 
180mg,
 
360mg
 
 
Can
 
be
 
used
 
as
 
monotherapy
 
or
 
in
 
combination
 
with
 
other
 
oral
 
iron
 
chelating
 
agents.
 
 
 
 
 
Indications
 
and
 
Dosage
 
To
 
remove
 
excessive
 
iron
 
in
 
the
 
body
 
due
 
to
 
regular
 
blood
 
transfusion
 
in
 
thalassemia
 
patients.
 
 
The
 
goal
 
is
 
to
 
maintain
 
a
 
safe
 
level
 
of
 
body
 
iron
 
at
 
all
 
times,
 
to
 
prevent
 
iron
 
overload
 
from
 
transfusion
 
therapy .
 
 
DFP
 
50-100mg/kg/day
 
Tablet:
 
Not
 
recommended
 
for
 
children
 
below
 
6
 
years
 
of
 
age.
 
 
Syrup:
 
Not
 
recommended
 
for
 
children
 
below
 
3
 
years
 
of
 
age.
 
 
 
DFX
 
14-28mg/kg/day
 
Not
 
recommended
 
for
 
children
 
below
 
2
 
years
 
of
 
age.
 
Tablets
 
may
 
be
 
halved
 
for
 
necessary
 
dose
 
rounding.
 
 
 
To
 
counsel
 
based
 
on
 
specific
 
medication’ s
 
indication
 
and
 
dosage
 
as
 
prescribed
 
by
 
the
 
doctor
 
 
 
 
Method
 
of
 
Administration*
 
DFP
 
 
DFP
 
is
 
available
 
as:
 
 
i)
  
Syrup
 
100mg/ml
 
form,
 
 
ii)
  
Tablet
 
500mg
 
immediate-release
 
(three-times-a-day)
 
 
iii)
 
Tablet
 
1000mg
 
delayed
 
release
  
(twice-a-day)
 
 
 
Always
 
verify
 
formulation
 
prior
 
to
 
dispensing.
 
 
Administration:
 
To
 
be
 
taken
 
orally .
 
 
Oral
 
solution
 
100mg/ml:
 
Administer
 
in
 
three
 
divided
 
dosing
 
(in
 
the
 
morning,
 
at
 
midday ,
 
and
 
in
 
the
 
evening).
 
Measure
 
dose
 
accurately .
 
After
 
dose
 
administration,
 
add
 
10mL
 
to
 
15mL
 
of
 
water
 
to
 
the
 
cup,
 
swirl
 
around
 
to
 
mix
 
any
 
remaining
 
medication
 
and
 
consume.
 
 
500mg
 
IR
 
tablet:
 
Administer
 
in
 
three
 
divided
 
dosing
 
(in
 
the
 
morning,
 
at
 
midday ,
 
and
 
in
 
the
 
evening).
 
 
 
1000mg
 
DR
 
tablet
 
ONLY:
 
Administer
 
in
 
two
 
divided
 
doses
,
 
approximately
 
every
 
12
 
hourly .
 
 
May
 
be
 
taken
 
before
 
or
 
after
 
a
 
meal,
 
but
 
taking
 
it
 
after
 
a
 
meal
 
may
 
reduce
 
nausea.
 
 
 
 
109
 

=== PAGE 111 ===

 
The
 
tablets
 
are
 
scored
 
and
 
breakable
 
in
 
half.
 
 
Missed
 
dose
 
management
 
:
 
 
If
 
a
 
dose
 
is
 
missed,
 
take
 
it
 
as
 
soon
 
as
 
possible.
 
If
 
it
 
is
 
almost
 
time
 
for
 
the
 
next
 
dose,
 
skip
 
the
 
missed
 
dose;
 
do
 
not
 
catch-up
 
or
 
double
 
doses
 
to
 
make
 
up
 
for
 
the
 
missed
 
dose.
 
 
DFX
 
 
DFX
 
is
 
available
 
as
 
a
 
film-coated
 
90mg,
 
180mg,
 
360mg
 
tablet.
 
 
 
Administration:
 
To
 
be
 
taken
 
orally .
 
Swallow
 
it
 
whole
 
with
 
a
 
full
 
glass
 
of
 
water .
 
 
 
Take
 
it
 
on
 
an
 
empty
 
stomach
 
(30
 
minutes
 
before
 
eating)
 
or
 
with
 
a
 
light
 
meal
 
(low
 
in
 
fat),
 
if
 
necessary
 
for
 
better
 
tolerability .
 
 
 
Take
 
it
 
in
 
the
 
evening
 
before
 
dinner ,
 
and
 
to
 
be
 
administered
 
consistently
 
at
 
the
 
same
 
time.
 
 
 
Can
 
also
 
be
 
crushed
 
and
 
sprinkled
 
on
 
to
 
soft
 
food
 
e.g.
 
yoghurt
 
or
 
apple
 
puree
 
immediately
 
prior
 
to
 
administration.
 
 
 
(Does
 
not
 
require
 
to
 
be
 
dissolved
 
in
 
water ,
 
compared
 
to
 
previous
 
effervescent
 
tablet
 
form)
 
 
Missed
 
dose
 
management
 
:
 
 
If
 
a
 
dose
 
is
 
missed,
 
take
 
it
 
as
 
soon
 
as
 
possible.
 
If
 
it
 
is
 
almost
 
time
 
for
 
the
 
next
 
dose,
 
skip
 
the
 
missed
 
dose;
 
do
 
not
 
catch-up
 
or
 
double
 
doses
 
to
 
make
 
up
 
for
 
the
 
missed
 
dose.
 
 
These
 
oral
 
iron
 
chelators
 
can
 
be
 
taken
 
in
 
combinations
 
of
 
the
 
following
 
regimens
 
including
 
parenteral
 
deferoxamine
 
(DFO)
 
&
 
DFX,
 
DFO
 
&
 
DFP
 
or
 
DFP
 
&
 
DFX).
 
 
Combination
 
use
 
of
 
DFP
 
with
 
DFO
 
has
 
synergistic
 
effect
 
and
 
has
 
been
 
shown
 
to
 
improve
 
outcome
 
in
 
patients
 
with
 
severe
 
iron
 
load
 
in
 
the
 
heart.
 
 
Do
 
not
 
stop
 
taking
 
your
 
medication
 
unless
 
advised
 
to
 
do
 
so
 
by
 
your
 
prescriber .
 
Special
 
Considerations
 
Pregnancy
 
 
 
 
All
 
oral
 
iron
 
chelators
 
(DFP ,
 
DFX)
 
should
 
be
 
discontinued
 
3
 
months
 
prior
 
to
 
planned
 
conception
 
AND/OR
 
once
 
pregnancy
 
is
 
confirmed
 
in
 
thalassaemic
 
patients.
 
 
 
Pregnant
 
patients
 
should
 
be
 
immediately
 
referred
 
to
 
haematologists
 
for
 
further
 
management.
 
 
 
 
Breastfeeding
 
 
 
 
 
Breastfeeding
 
should
 
be
 
encouraged
 
unless
 
the
 
patient
 
is
 
HIV
 
positive.
 
 
Both
 
oral
 
iron
 
chelators
 
should
 
be
 
withheld
 
as
 
long
 
as
 
the
 
patient
 
is
 
still
 
breastfeeding,
 
due
 
to
 
lack
 
of
 
safety
 
data
 
in
 
breastfeeding
 
patients.
 
 
Resume
 
oral
 
iron
 
chelators
 
after
 
cessation
 
of
 
breastfeeding
 
 
 
 
Elderly
 
 
 
 
DFP
 
 
 
 
110
 

=== PAGE 112 ===

 
Limited
 
data
 
on
 
the
 
use
 
in
 
elderly .
 
Other
 
reported
 
clinical
 
experience
 
has
 
not
 
identified
 
differences
 
in
 
responses
 
between
 
the
 
elderly
 
and
 
younger
 
patients.
 
 
DFX
 
Use
 
with
 
caution
 
due
 
to
 
the
 
higher
 
incidence
 
of
 
adverse
 
drug
 
reaction
 
or
 
toxicity
 
(eg:
 
hepatotoxicity)
 
and
 
fatal
 
reactions
 
during
 
use;
 
monitor
 
closely .
 
May
 
require
 
dose
 
adjustment.
 
 
Paediatric
 
 
 
 
DFP
 
 
1.
 
Syrup
 
:
 
For
 
3
 
years
 
old
 
and
 
above
 
2.
 
Tablet:
 
For
 
6
 
years
 
old
 
and
 
above
 
(European
 
Licensing);
 
for
 
8
 
years
 
old
 
and
 
above
 
(USA
 
Licensing)
 
3.
 
Due
 
to
 
risk
 
of
 
agranulocytosis,
 
monitoring
 
of
 
absolute
 
neutrophil
 
count
 
(ANC)
 
is
 
needed
 
as
 
below:
 
 
●
 
Baseline
 
 
●
 
First
 
6
 
months
 
:
 
every
 
week
 
 
●
 
Subsequent
 
6
 
months:
 
every
 
2
 
weeks
 
 
●
 
After
 
1
 
year:
 
every
 
2-4weeks
 
 
 
DFX
 
1.
 
For
 
2
 
years
 
old
 
and
 
above
 
 
 
 
Fasting
 
 
 
 
 
To
 
refer
 
to
 
the
 
latest
 
advisory
 
by
 
religious
 
authority
 
 
 
 
Others
  
 
 
 
 
Dosing
 
adjustment/treatment
 
cessation
 
DFP
  
 
The
 
dosing
 
of
 
DFP
 
remains
 
unchanged
 
for
 
patients
 
with
 
renal
 
or
 
liver
 
impairment
 
(refer
 
to
 
standard
 
dose
 
adjustment
 
guide).
 
 
 
Treatment
 
may
 
be
 
interrupted/ceased
 
if
 
a
 
patient
 
shows
 
toxicity
 
(persistent
 
increase
 
in
 
liver
 
enzyme
 
serum
 
transaminase
 
level,
 
neutropenia,
 
agranulocytosis).
 
 
DFX
 
The
 
dosing
 
of
 
DFX
 
may
 
be
 
adjusted
 
in
 
patients
 
with
 
renal
 
or
 
liver
 
impairment
 
(refer
 
to
 
standard
 
dose
 
adjustment
 
guide).
 
 
 
Treatment
 
may
 
be
 
interrupted
 
/ceased
 
if
 
a
 
patient
 
showing
 
toxicity
 
(auditory ,
 
vision,
 
bone
 
marrow
 
suppression,
 
severe
 
rashes,
 
gastrointestinal
 
ulceration)
 
 
 
 
Side
 
Effects
 
and
 
their
 
Management*
 
DFP
 
Common
 
adverse
 
drug
 
reactions
 
:
 
 
Dry
 
skin
 
(if
 
associated
 
with
 
zinc
 
deficiency),
 
gastrointestinal
 
disturbances
 
which
 
include
 
abdominal
 
pain,
 
nausea
 
&vomiting,
 
dyspepsia;
 
increased
 
liver
 
enzyme,
 
joint
 
pain
 
&
 
stiffness
 
(10%),
 
red
 
coloring
 
of
 
urine
 
(desirable
 
side
 
effect
 
as
 
it
 
shows
 
iron
 
is
 
being
 
excreted
 
through
 
the
 
urine).
 
 
Serious
 
adverse
 
drug
 
reactions:
  
very
 
low
 
white
 
blood
 
cell
 
count
 
i.e
 
agranulocytosis
 
(2%),
 
neutropenia
 
(6%)
 
 
Deferiprone
 
can
 
cause
 
serious
 
side
 
effects,
 
including
 
a
 
very
 
low
 
white
 
blood
 
cell
 
count.
 
One
 
type
 
of
 
white
 
blood
 
cell
 
that
 
is
 
important
 
for
 
fighting
 
infection
 
is
 
called
 
a
 
neutrophil.
 
If
 
the
 
neutrophil
 
count
 
is
 
low
 
(neutropenia)
 
or
 
severely
 
low
 
(agranulocytosis),
 
patients
 
can
 
be
 
at
 
risk
 
of
 
developing
 
a
 
serious
 
infection
 
that
 
may
 
be
 
life-threatening.
 
 
 
 
 
111
 

=== PAGE 113 ===

 
 
The
 
healthcare
 
provider
 
will
 
do
 
a
 
blood
 
test
 
before
 
starting
 
deferiprone
 
and
 
regularly
 
during
 
treatment
 
to
 
check
 
the
 
neutrophil
 
count.
 
 
 
DFX:
 
Common
 
adverse
 
drug
 
reactions:
 
rash,
 
protein
 
in
 
the
 
urine
 
(frothy
 
urine),
 
renal
 
impairment,
 
neurotoxicity
 
(visual
 
and
 
auditory)
 
 
Refer
 
to
 
dosage
 
adjustment/cessation
 
for
 
management
 
of
 
these
 
adverse
 
effects.
 
 
 
The
 
doctor
 
will
 
monitor
 
these
 
side
 
effects
 
closely .
 
Remind
 
patients
 
to
 
attend
 
clinic
 
appointments
 
as
 
scheduled
 
and
 
inform
 
their
 
healthcare
 
providers
 
if
 
they
 
experience
 
any
 
of
 
the
 
above
 
undesirable
 
side
 
effects.
 
Diet
 
&
 
Lifestyle
 
Advice
 
 
Diet
 
1.
 
Restrict
 
iron
 
rich
 
food
 
intake
 
(i.e
 
beef,
 
oyster ,
 
liver,
 
spinach,
 
pucuk
 
paku
,
 
chickpeas,
 
chocolate,
 
egg
 
yolk,
 
iron
 
-fortified
 
cereals)
 
2.
 
Take
 
a
 
high
 
calcium
 
diet
 
i.e
 
milk,
 
cheese,
 
oily
 
fish,
 
with
 
calcium
 
and
 
vit
 
D
 
supplementation.
 
 
3.
 
High
 
calorie,
 
nutrient
 
dense
 
diet
 
to
 
promote
 
growth
 
in
 
children.
 
 
 
Lifestyle
 
1.
 
Weight-bearing
 
exercise
 
to
 
strengthen
 
bone
 
(i.e
 
walking,
 
jogging,
 
light
 
weights
 
lifting)
 
2.
 
Avoidance
 
of
 
smoking
 
and
 
excessive
 
alcohol
 
consumption.
 
Refer
 
to
 
the
 
smoking
 
cessation
 
clinic,
 
if
 
applicable.
  
 
 
Supplementations
 
1.
 
Doctors
 
may
 
also
 
prescribe
 
zinc
 
supplement
 
(if
 
deficient),
 
vitamin
 
D
 
and
 
calcium
 
supplement
 
for
 
healthy
 
bone.
 
2.
 
Ascorbic
 
acid
 
(less
 
than
 
or
 
equal
 
to
 
100mg)
 
may
 
also
 
be
 
prescribed
 
for
 
those
 
with
 
vitamin
 
C
 
deficiency .
 
The
 
dosage
 
may
 
not
 
exceed
 
100mg/day .
 
  
 
 
 
 
Storage*
 
1.
 
DFP
 
:
 
Store
 
below
 
30°C.
 
Protect
 
from
 
moisture
 
and
 
light.
 
2.
 
Syrup
 
DFP
 
:
 
stable
 
for
 
35
 
days
 
once
 
opened.
 
3.
 
DFX:
 
Store
 
your
 
tablets
 
in
 
the
 
original
 
blister
 
pack
 
at
 
or
 
below
 
30°C.
 
Protect
 
from
 
moisture
 
and
 
light.
 
 
 
 
Others
 
Only
 
a
 
small
 
fraction
 
of
 
body
 
iron
 
is
 
available
 
for
 
iron
 
chelation
 
at
 
any
 
moment
 
of
 
time.
 
Therefore,
 
it
 
is
 
important
 
to
 
adhere
 
to
 
the
 
regimen
 
prescribed
 
by
 
the
 
doctor .
 
Speak
 
to
 
the
 
doctor/pharmacist
 
if
 
a
 
patient
 
encounters
 
difficulties
 
in
 
taking
 
the
 
medications
 
as
 
prescribed.
 
 
To
 
monitor
 
the
 
effectiveness
 
of
 
the
 
medications,
 
the
 
doctor
 
will
 
order
 
tests
 
such
 
as
 
serum
 
ferritin
 
every
 
3
 
to
 
6
 
monthly
 
and/or
 
MRI
 
T2*
 
for
 
heart
 
and
 
liver
 
every
 
1
 
to
 
2
 
yearly .
 
(depending
 
on
 
facilities)
 
 
Due
 
to
 
an
 
unknown
 
mechanism
 
of
 
deferiprone-induced
 
neutropenia,
 
patients
 
must
 
avoid
 
taking
 
medicinal
 
products
 
known
 
to
 
be
 
associated
 
with
 
neutropenia
 
or
 
those
 
that
 
can
 
cause
 
agranulocytosis.
 
 
Ensure
 
at
 
least
 
a
 
4
 
hours
 
gap
 
between
 
oral
 
iron
 
chelators
 
and
 
any
 
aluminium/magnesium
 
containing
 
antacids,
 
calcium
 
 
 
 
112
 

=== PAGE 114 ===

 
supplements,
 
thyroid
 
medications
 
or
 
any
 
other
 
multivitamins,
 
for
 
best
 
absorption.
 
 
Sick
 
Day
 
Management
 
It
 
is
 
important
 
to
 
advise
 
if
 
the
 
patient
 
has
 
fever
 
or
 
shows
 
signs
 
of
 
infections
 
such
 
as
 
sore
 
throat,
 
mouth
 
ulcers
 
or
 
flu-like
 
symptoms,
 
advise
 
patient
 
to
 
STOP
 
taking
 
the
 
iron
 
chelators
 
temporarily
 
and
 
seek
 
medical
 
attention
 
immediately
 
(within
 
24
 
hours).
 
 
Diet
 
&
 
Lifestyle
 
 
1.
 
Restrict
 
iron
 
rich
 
food
 
intake
 
(i.e
 
beef,
 
oyster ,
 
liver,
 
spinach,
 
pucuk
 
paku
,
 
chickpeas,
 
chocolate,
 
egg
 
yolk,
 
iron
 
-fortified
 
cereals)
 
2.
 
Take
 
a
 
high
 
calcium
 
diet
 
i.e
 
milk,
 
cheese,
 
oily
 
fish,
 
with
 
calcium
 
and
 
vit
 
D
 
supplementation.
 
 
3.
 
High
 
calorie,
 
nutrient
 
dense
 
diet
 
to
 
promote
 
growth
 
in
 
children.
 
 
4.
 
Weight-bearing
 
exercise
 
to
 
strengthen
 
bone
 
(i.e
 
walking,
 
jogging,
 
light
 
weights
 
lifting)
 
5.
 
Avoidance
 
of
 
smoking
 
and
 
excessive
 
alcohol
 
consumption.
 
Refer
 
to
 
the
 
smoking
 
cessation
 
clinic,
 
if
 
applicable.
  
 
6.
 
Doctors
 
may
 
also
 
prescribe
 
zinc
 
supplement
 
(if
 
deficient),
 
vitamin
 
D
 
and
 
calcium
 
supplement
 
for
 
healthy
 
bone.
 
7.
 
Ascorbic
 
acid
 
(less
 
than
 
or
 
equal
 
to
 
100mg)
 
may
 
also
 
be
 
prescribed
 
for
 
those
 
with
 
vitamin
 
C
 
deficiency .
 
The
 
dosage
 
may
 
not
 
exceed
 
100mg/day .
 
Before
 
ending
 
this
 
peer
 
review
 
session,
 
the
 
reviewee
 
should
 
be
 
informed
 
of
 
the
 
step(s)
 
that
 
he/
 
she
 
missed
 
out
 
in
 
order
 
to
 
ensure
 
all
 
the
 
counselling
 
points
 
are
 
being
 
covered.
 
 
Remarks:
 
 
 
 
 
Reviewed
 
by:
 
Name
 
&
 
Signature
                                                                   
Date:
 
 
 
 
 
*Mandatory
 
for
 
validation
 
/
 
peer
 
review
 
References:
 
 
1.
 
Product
 
Insert.
 
Ferriprox®
 
Deferiprone
 
delayed-release
 
enteric
 
coated
 
tablets
 
1000mg.
 
Chiesi.
 
Updated
 
02/2023.
 
2.
 
European
 
Medicines
 
Agency .
 
Ferriprox:
 
EPAR-
 
Product
 
Information.
 
(Available
 
at:
 
https://www .ema.europa.eu/en/documents/product-information/ferriprox-epar-product-information_en.
 
pdf).
 
3.
 
Uptodate
 
2024
 
Medical
 
Apps
 
Application.
 
Wolters
 
Kluwer .
 
Assessed
 
6
 
January
 
2025.
 
4.
 
Novartis
 
Pharma
 
AG.
 
Understanding
 
EXJADE®
 
(deferasirox)
 
Film-Coated
 
Tablets-
 
A
 
physician
 
guide
 
to
 
dosing
 
and
 
administration.
 
Basel:
 
Novartis:
 
2017.
 
5.
 
MSN
 
Laboratories
 
Private
 
Limited,
 
India.
 
Prescribing
 
information
 
.
 
Jedoxred
 
®
 
(defarasirox)
 
Dispersible
 
Tablet
 
(Revised
 
February
 
2020).
 
6.
 
Thalassemia
 
International
 
Federation.
 
(2022).
 
Management
 
of
 
transfusion
 
dependent
 
thalassemia:
 
A
 
short
 
guide
 
(2nd
 
ed.).
 
Retrieved
 
from
 
https://thalassaemia.org.cy/publications/tif-publications/a-short-guide-for-the-management-of-transfusion
-dependent-thalassaemia-2022/convef
 
7.
 
European
 
Medicines
 
Agency .
 
Ferriprox:
 
EPAR
 
Product
 
Information
 
(updated
 
2022).
 
Available
 
at:
 
https://www .ema.europa.eu/en/medicines/human/EP AR/ferriprox
 
 
 
 
113
 

=== PAGE 115 ===

 
Desferrioxamine
 
B
 
Methanesulphonate
 
 
Name
 
:
 
 
Unit
 
:
 
 
●
 
Please
 
tick
 
(
✔
)
 
Yes
 
for
 
correct
 
instruction.
 
●
 
Please
 
tick
 
(
✔
)
 
No
 
for
 
incorrect
 
instruction.
 
Yes
 
No
 
Remarks
 
Pharmacological
 
Group
 
Iron
 
Chelating
 
Agent
 
 
 
 
Indications
 
and
 
Dosage
 
Subcutaneous:
 
Usually
 
slowly
 
infused
 
over
 
8
 
-
 
12
 
hours
 
(or
 
in
 
some
 
patients,
 
over
 
24
 
hr)
 
using
 
a
 
small
 
portable
 
pump
 
for
  
5
 
to
 
7
 
days
 
per
 
week.
 
 
 
The
 
longer
 
the
 
infusion
 
time,
 
the
 
more
 
iron
 
can
 
be
 
removed
 
due
 
to
 
desferal’ s
 
short
 
half
 
lives.
 
 
Chronic
 
iron
 
overload
 
or
 
toxicity
 
 
Adult:
 
Monotherapy
 
 
Usual
 
average
 
daily
 
dose
 
of
 
40-60
 
mg/kg
 
daily.
 
 
Administer
 
5
 
-7
 
times
 
a
 
week,
 
depending
 
on
 
the
 
extent
 
of
 
iron
 
overload.
 
 
 
Combination
 
therapy
 
(added
 
with
 
oral
 
iron
 
chelator)
 
Usual
 
average
 
daily
 
dose
 
of
 
40-50
 
mg/kg
 
daily.
 
 
Administer
 
2
 
-
 
5
 
times
 
a
 
week
 
 
 
Guy’s
 
and
 
St
 
Thomas’
 
(NHS)
 
Guidelines
 
for
 
iron
 
chelation
 
in
 
adults
 
with
 
a
 
haemoglobinopathy
 
or
 
other
 
inherited
 
anaemia
 
diagnosis.
 
(2016)
 
:
 
 
 
Ferritin
 
Desferrioxamine
 
Dose
 
(7
 
nights)
 
Desferrioxamine
 
Dose
 
(5
 
nights)
 
<2000
 
25mg/kg/day
 
35mg/kg/day
 
2000-3000
 
35mg/kg/day
 
49mg/kg/day
 
>3000
 
Up
 
to
 
50mg/kg/day
 
70mg/kg/day
 
Note
 
:
 
ensure
 
dose
 
within
 
therapeutic
 
index
 
 
Pediatrics:
 
Usual
 
average
 
daily
 
dose
 
of
 
20-40
 
mg/kg
 
daily.
 
 
Administer
 
5
 
-7
 
times
 
a
 
week
 
depending
 
on
 
the
 
extent
 
of
 
iron
 
overload.
 
 
Aim
 
for
 
therapeutic
 
index
 
<0.025
 
at
 
all
 
times
 
Therapeutic
 
index
 
=
 
Mean
 
daily
 
dose
 
(mg/kg)
 
/
 
ferritin
 
(ng/mL).
 
 
 
Combination
 
or
 
sequential
 
dosing
 
of
 
desferrioxamine
 
with
 
oral
 
chelators
 
is
 
indicated
 
when
 
monotherapy
 
fails.
 
 
 
To
 
counsel
 
based
 
on
 
specific
 
medication’ s
 
indication
 
and
 
dosage
 
as
 
prescribed
 
by
 
the
 
doctor
 
 
 
 
Method
 
of
 
Administration*
 
1.
 
Choose
 
a
 
clean
 
and
 
well-lit
 
area.
 
2.
 
Gather
 
all
 
necessary
 
items
 
for
 
the
 
Desferrioxamine
 
infusion:
 
Desferrioxamine
 
vials,
 
syringe,
 
sterile
 
needle,
 
extension
 
tube,
 
butterfly
 
needle
 
set/Thalaset,
 
and
 
a
 
sharps
 
bin.
 
 
 
 
114
 

=== PAGE 116 ===

 
3.
 
Wash
 
your
 
hands
 
thoroughly
 
and
 
dry
 
them
 
with
 
a
 
clean
 
towel.
 
4.
 
Unwrap
 
a
 
sterile
 
syringe
 
and
 
attach
 
a
 
new
 
sterile
 
needle.
 
5.
 
Break
 
the
 
top
 
off
 
an
 
ampoule
 
of
 
sterile
 
Water
 
for
 
Injections
 
(WFI).
 
6.
 
Draw
 
the
 
required
 
amount
 
of
 
WFI
 
into
 
the
 
syringe:
 
○
 
For
 
each
 
500
 
mg
 
vial,
 
use
 
5
 
mL
 
of
 
WFI
 
to
 
dissolve
 
the
 
powder .
 
○
 
For
 
a
 
2
 
g
 
vial,
 
use
 
20
 
mL
 
of
 
WFI.
 
7.
 
Clean
 
the
 
rubber
 
stopper
 
of
 
the
 
Desferal
 
vial
 
with
 
an
 
alcohol
 
wipe.
 
8.
 
Inject
 
the
 
WFI
 
from
 
the
 
syringe
 
into
 
the
 
vial
 
through
 
the
 
rubber
 
stopper .
 
9.
 
Shake
 
the
 
vial
 
well
 
to
 
dissolve
 
the
 
powder .
 
The
 
solution
 
should
 
become
 
clear ,
 
colorless,
 
or
 
slightly
 
yellowish.
 
Do
 
not
 
use
 
if
 
the
 
solution
 
is
 
cloudy
 
or
 
if
 
you
 
cannot
 
see
 
through
 
it.
 
10.
 
Clean
 
the
 
stopper
 
of
 
the
 
vial
 
again
 
with
 
an
 
alcohol
 
wipe,
 
then
 
draw
 
the
 
diluted
 
Desferal
 
solution
 
back
 
into
 
the
 
syringe.
 
Preparing
 
the
 
Portable
 
Pump
 
1.
 
Attach
 
the
 
extension
 
tube
 
to
 
the
 
syringe.
 
2.
 
Connect
 
the
 
extension
 
tube
 
to
 
the
 
butterfly
 
needle
 
(or
 
Thalaset).
 
3.
 
Fill
 
the
 
extension
 
tube
 
with
 
the
 
solution
 
from
 
the
 
syringe.
 
4.
 
Place
 
the
 
syringe
 
in
 
the
 
infusion
 
pump
 
and
 
secure
 
it
 
with
 
the
 
strap.
 
5.
 
Follow
 
the
 
instructions
 
provided
 
by
 
your
 
healthcare
 
provider
 
or
 
the
 
pump
 
manufacturer
 
for
 
setting
 
up
 
the
 
pump.
 
 
Infusion
 
Sites
 
&
 
Administration
 
1.
 
Clean
 
the
 
injection
 
site
 
with
 
an
 
alcohol
 
swab.
 
2.
 
Insert
 
the
 
needle
 
at
 
a
 
45-degree
 
angle
 
underneath
 
the
 
skin.
 
3.
 
Secure
 
the
 
needle
 
with
 
a
 
plaster .
 
4.
 
Place
 
the
 
pump
 
in
 
a
 
pouch.
 
5.
 
The
 
pump
 
can
 
be
 
worn
 
on
 
a
 
belt
 
or
 
in
 
a
 
shoulder
 
holster ,
 
allowing
 
you
 
to
 
move
 
about
 
while
 
the
 
infusion
 
is
 
ongoing
 
(e.g.,
 
over
 
8-12
 
hours).
 
6.
 
Rotate
 
the
 
infusion
 
sites
 
regularly
 
to
 
ensure
 
proper
 
absorption
 
of
 
the
 
medication
 
and
 
to
 
reduce
 
the
 
risk
 
of
 
skin
 
breakdown
 
or
 
scar
 
tissue
 
formation.
 
 
Needle
 
Disposal
 
1.
 
Remove
 
the
 
needle
 
from
 
the
 
syringe
 
and
 
immediately
 
place
 
it
 
in
 
a
 
proper
 
sharps
 
disposal
 
container .
 
 
2.
 
If
 
a
 
designated
 
container
 
is
 
unavailable,
 
a
 
sturdy ,
 
empty
 
hard
 
plastic
 
detergent
 
bottle
 
or
 
a
 
similar
 
container
 
can
 
be
 
used
 
as
 
a
 
temporary
 
solution.
 
3.
 
Ensure
 
that
 
the
 
container
 
is
 
tightly
 
sealed
 
and
 
cannot
 
be
 
accessed
 
by
 
others.
 
4.
 
Always
 
refer
 
to
 
your
 
local
 
disposal
 
regulations
 
for
 
proper
 
disposal
 
guidelines.
 
 
Do
 
not
 
stop
 
taking
 
your
 
medication
 
unless
 
advised
 
to
 
do
 
so
 
by
 
your
 
prescriber
 
Special
 
Considerations
 
Pregnancy
 
 
 
 
1.
 
Consider
 
the
 
benefits
 
and
 
risks
 
of
 
Desferrioxamine
 
for
 
the
 
mother
 
and
 
possible
 
risks
 
to
 
the
 
fetus
 
when
 
 
 
 
115
 

=== PAGE 117 ===

 
prescribing
 
Desferrioxamine
 
to
 
a
 
pregnant
 
woman.
 
 
Breastfeeding
 
 
 
 
1.
 
Breastfeeding
 
can
 
be
 
recommenced
 
after
 
delivery
 
as
 
its
 
concentration
 
is
 
very
 
low
 
in
 
breastmilk
 
and
 
not
 
orally
 
absorbed.
 
 
 
 
Elderly
 
 
 
 
1.
 
Dose
 
selection
 
for
 
an
 
elderly
 
patient
 
should
 
be
 
cautious,
 
usually
 
starting
 
at
 
the
 
low
 
end
 
of
 
the
 
dosing
  
range,
 
reflecting
 
the
 
greater
 
frequency
 
of
 
decreased
 
hepatic,
 
renal,
 
or
 
cardiac
 
function,
 
and
 
of
 
concomitant
 
disease
 
or
 
other
 
drug
 
therapy
 
2.
 
Elderly
 
patients
 
are
 
at
 
increased
 
risk
 
for
 
hearing
 
loss.
 
 
 
 
Paediatric
 
 
 
 
1.
 
Desferrioxamine
 
is
 
licensed
 
for
 
patients
 
3
 
years
 
and
 
above.
 
2.
 
High
 
doses
 
of
 
Desferrioxamine
 
and
 
concomitant
 
low
 
ferritin
 
levels
 
have
 
been
 
associated
 
with
 
growth
 
suppression
 
in
 
pediatric
 
patients.
 
Monitor
 
growth
 
in
 
paediatric
 
patients
 
receiving
 
Desferrioxamine
 
every
 
3
 
months.
 
 
 
 
Fasting
 
 
 
 
1.
 
Not
 
applicable.
 
 
 
To
 
refer
 
to
 
the
 
latest
 
advisory
 
by
 
religious
 
authority
 
 
 
 
Others
 
 
 
 
 
 
1.
 
The
 
dosing
 
of
 
desferrioxamine
 
may
 
be
 
adjusted
 
in
 
patients
 
with
 
renal
 
impairment
 
(refer
 
to
 
standard
 
dose
 
adjustment
 
guide).
 
 
2.
 
Advise
 
patients
 
to
 
temporarily
 
discontinue
 
desferrioxamine
 
and
 
seek
 
immediate
 
medical
 
attention
 
if
 
showing
 
signs
 
and
 
symptoms
 
of
 
infections.
 
 
 
 
 
Side
 
Effects
 
and
 
their
 
Management*
 
Adverse
 
events
 
associated
 
with
 
desferrioxamine:
 
●
 
injection
 
site
 
reactions
 
●
 
neurotoxicity
 
(visual,
 
auditory)
 
●
 
retinopathy
 
●
 
hypersensitive
 
reactions
 
●
 
growth
 
disturbance
 
●
 
Yersinia
 
and
 
Mucor
 
infections
 
 
Management
 
of
 
adverse
 
effects:
 
1.
 
Hypersensitivity
 
reactions,
 
including
 
anaphylaxis,
 
have
 
occurred
 
in
 
patients
 
treated
 
with
 
desferrioxamine
.
 
These
 
reactions
 
have
 
included
 
skin
 
flushing,
 
urticaria,
 
hypotension,
 
and
 
shock.
 
They
 
typically
 
occur
 
if
 
desferrioxamine
 
is
 
administered
 
via
 
rapid
 
intravenous
 
injection;
 
administered
 
by
 
slow
 
IV
 
infusion.
 
2.
 
If
 
the
 
patient
 
shows
 
signs
 
or
 
symptoms
 
of
 
Yersinia
 
infections
 
(such
 
as
 
fever ,
 
diarrhea,
 
or
 
abdominal
 
pain),
 
advise
 
them
 
to
 
temporarily
 
discontinue
 
desferrioxamine
 
and
 
seek
 
immediate
 
medical
 
attention.
 
3.
 
Local
 
Skin
 
Reactions
 
 
 
 
116
 

=== PAGE 118 ===

 
i)
 
Ensure
 
proper
 
dilution
 
(10%),
 
appropriate
 
infusion
   
rate,
 
and
 
check
 
for
 
potential
 
dressing
 
allergies.
 
ii)
 
Rotate
 
injection
 
sites
 
to
 
prevent
 
persistent
 
local
 
skin
 
reactions.
 
iii)
 
For
 
doses
 
greater
 
than
 
2g,
 
consider
 
dividing
 
the
 
infusion
 
into
 
two
 
parts
 
to
 
reduce
 
the
 
risk
 
of
 
local
 
skin
 
reactions(e.g.,
 
divide
 
3g/24hr
 
dose
 
into
 
1.5g/12hrs
 
x2)
 
 
iv)
 
In
 
severe
 
cases,
 
your
 
doctor
 
may
 
recommend
 
adding
 
mild
 
steroids
 
i.e.
 
5–10
 
mg
 
of
 
hydrocortisone
 
to
 
the
 
infusion
 
mixture.
 
Alternatively ,
 
applying
 
a
 
topical
 
low-potency
 
corticosteroid
 
cream
 
after
 
injection
 
may
 
help
 
reduce
 
local
 
reactions.
 
v)
 
If
 
skin
 
ulceration
 
occurs,
 
ensure
 
proper
 
needle
 
depth
 
to
 
avoid
 
excessive
 
skin
 
trauma.
 
 
Other
 
considerations:
 
1.
 
Desferrioxamine
 
may
 
cause
 
dizziness,
 
which
 
can
 
impair
 
the
 
ability
 
to
 
drive
 
or
 
operate
 
machinery .
 
 
2.
 
Careful
 
monitoring
 
of
 
the
 
eyes,
 
ears,
 
bones,
 
and
 
growth
 
(in
 
children)
 
is
 
necessary
 
to
 
detect
 
any
 
drug-related
 
toxicity .
 
3.
 
Urine
 
discoloration:
 
urine
 
may
 
have
 
a
 
pink,
 
reddish
 
or
 
orange
 
discoloration
 
(vin
 
rose
 
discoloration).
 
Storage*
 
1.
 
Before
 
reconstitution,
 
store
 
below
 
25°C
 
(77°F).
 
2.
 
After
 
reconstitution,
 
may
 
store
 
at
 
room
 
temperature
 
up
 
to
 
7
 
days.
 
 
3.
 
Protect
 
from
 
light.
 
4.
 
Do
 
not
 
refrigerate
 
the
 
reconstituted
 
solution.
 
 
 
 
Others
 
Incompatibility
 
-
 
Incompatible
 
with
 
heparin.
 
 
Contraindications
 
-
 
Severe
 
renal
 
disease
 
or
 
anuria.
 
 
Drug
 
Interaction
 
-
 
Increased
 
risk
 
of
 
neurological
 
symptoms
 
when
 
used
 
concurrently
 
with
 
phenothiazines.
 
 
-
 
May
 
affect
 
imaging
 
results
 
if
 
given
 
together
 
with
 
gallium-67
 
 
Ascorbic
 
Acid
 
-
 
Ascorbic
 
acid,
 
when
 
given
 
to
 
enhance
 
iron
 
excretion,
 
should
 
not
 
exceed
 
a
 
dose
 
of
 
2–3
 
mg/kg/day .
 
-
 
It
 
should
 
be
 
administered
 
1
 
hour
 
after
 
the
 
start
 
of
 
the
 
desferrioxamine
 
infusion,
 
ideally
 
beginning
 
only
 
after
 
at
 
least
 
1
 
month
 
of
 
regular
 
desferrioxamine
 
therapy .
 
The
 
maximum
 
recommended
 
doses
 
are:
 
●
 
200
 
mg/day
 
(in
 
divided
 
doses)
 
for
 
adults
 
●
 
50
 
mg/day
 
for
 
pediatric
 
patients
 
under
 
10
 
years
 
old
 
●
 
100
 
mg/day
 
for
 
pediatric
 
patients
 
older
 
than
 
10
 
years
 
●
 
Do
 
not
 
administer
 
desferrioxamine
 
in
 
combination
 
with
 
ascorbic
 
acid
 
in
 
patients
 
with
 
pre-existing
 
cardiac
 
failure.
 
Monitoring
 
-
 
To
 
monitor
 
the
 
effectiveness
 
of
 
the
 
medication,
 
the
 
doctor
 
will
 
order
 
tests
 
such
 
as
 
serum
 
ferritin
 
every
 
3
 
to
 
6
 
months
 
and/or
 
MRI
 
T2*
 
scans
 
of
 
the
 
heart
 
and
 
liver
 
every
 
1
 
to
 
2
 
years
 
(depending
 
on
 
available
 
facilities).
 
 
 
 
117
 

=== PAGE 119 ===

 
Before
 
ending
 
this
 
peer
 
review
 
session,
 
the
 
reviewee
 
should
 
be
 
informed
 
of
 
the
 
step(s)
 
that
 
he/
 
she
 
missed
 
out
 
in
 
order
 
to
 
ensure
 
all
 
the
 
counselling
 
points
 
are
 
being
 
covered.
 
 
Remarks:
 
 
 
 
 
Reviewed
 
by:
 
Name
 
&
 
Signature
                                                                   
Date:
 
 
 
 
 
*Mandatory
 
for
 
validation
 
/
 
peer
 
review
 
References:
 
 
1.
 
MIMS
 
Malaysia.
 
(2025).
 
Desferal.
 
In
 
MIMS
 
Online.
 
https://www .mims.com/malaysia
 
2.
 
Novartis
 
Pharmaceuticals
 
Corporation.
 
(Revised
 
09/2022)
 
Full
 
Prescribing
 
Information:
 
DESFERAL®
 
(deferoxamine
 
mesylate)
 
for
 
injection.
 
Novartis
 
Pharmaceuticals
 
Corporation
 
East
 
Hanover ,
 
New
 
Jersey
 
07936.
 
T2022-57.
 
3.
 
NOV ARTIS
 
Pharmaceuticals
 
Australia
 
Pty
 
Limited.(Nov
 
2011).
 
Consumer
 
Medicine
 
Information:
 
Desferal
 
500
 
mg
 
vial
 
AUST
 
R
 
11030,
 
Desferal
 
2
 
g
 
vial
 
AUST
 
R
 
72343.
 
 
4.
 
Novartis
 
Pharma
 
AG,
 
Basel,
 
Switzerland.
 
(Revised
 
07/2021)
 
Approved
 
Package
 
Leaflet:
 
Desferal
 
®
 
(deferoxamine
 
mesylate)
 
for
 
injection.
 
 
5.
 
Desferrioxamine
 
chelation
 
in
 
patients
 
with
 
haemoglobin
 
disorders:
 
Clinical
 
guideline.
 
Wessex
 
and
 
Thames
 
Valley
 
Haemoglobinopathy
 
Coordinating
 
Centre
 
(HCC)
 
Network.
 
S7.3.
 
V3.0.
 
https://nssg.oxford-haematology .org.uk/red-cell/documents/iron-overload-and-chelation/S7-3-desferrioxa
mine-chelaton.pdf
 
6.
 
Guy’s
 
and
 
St
 
Thomas’
 
NHS
 
Foundation
 
Trust
 
(2016)
 
Guidelines
 
for
 
iron
 
chelation
 
in
 
adults
 
with
 
a
 
haemoglobinopathy
 
or
 
other
 
inherited
 
anaemia
 
diagnosis.
 
7.
 
Thalassemia
 
International
 
Federation.
 
(2022).
 
Management
 
of
 
transfusion
 
dependent
 
thalassemia:
 
A
 
short
 
guide
 
(2nd
 
ed.).
 
Retrieved
 
from
 
https://thalassaemia.org.cy/publications/tif-publications/a-short-guide-for-the-management-of-transfusion
-dependent-thalassaemia-2022/convef
 
8.
 
Micromidex
 
Paediatric
 
Reference.
 
Deferoxamine
 
(2025).
 
 
9.
 
Malaysian
 
Health
 
Technology
 
Assessment
 
Section.
 
(2024)
 
Clinical
 
Practice
 
Guidelines:
 
Management
 
of
 
Thalassaemia.(2nd
 
ed.)
 
10.
 
Uptodate
 
2024
 
Medical
 
Apps
 
Application.
 
Wolters
 
Kluwer .
 
Accessed
 
on
 
January
 
22,
 
2025.
 
 
 
 
 
 
 
 
 
 
 
 
 
118
 

=== PAGE 120 ===

 
Digoxin
 
 
Name
 
:
 
 
Unit
 
:
 
 
●
 
Please
 
tick
 
(
✔
)
 
Yes
 
for
 
correct
 
instruction.
 
●
 
Please
 
tick
 
(
✔
)
 
No
 
for
 
incorrect
 
instruction.
 
Yes
 
No
 
Remarks
 
Pharmacological
 
Group
 
Cardiac
 
glycoside
 
 
C01AA05
 
 
 
 
Indications
 
and
 
Dosage
 
1.
 
Heart
 
failure
 
(reserve
 
for
 
use
 
in
 
patients
 
with
 
persistent
 
NYHA
 
class
 
III
 
or
 
IV
 
symptoms
 
despite
 
optimal
 
guideline-directed
 
medical
 
therapy)
 
 
a)
 
Loading
 
dose
 
not
 
recommended
 
 
b)
 
Maintenance
 
dose:
 
0.125mg
 
to
 
0.25mg
 
od
 
 
2.Supraventricular
 
arrhythmias
 
(particularly
 
atrial
 
fibrillation)
 
 
a)
 
May
 
initiate
 
with
 
a
 
loading
 
dose
 
followed
 
by
 
maintenance
 
dosing
 
if
 
rapid
 
titration
 
if
 
desired
 
or
 
initiate
 
with
 
maintenance
 
dosing
 
without
 
a
 
loading
 
dose.
 
0.25mg
 
to
 
0.5mg
 
once,
 
repeat
 
doses
 
of
 
0.25mg
 
every
 
6
 
hours
 
to
 
a
 
maximum
 
of
 
1.5mg
 
over
 
24
 
hours
 
 
 
b)
 
Maintenance
 
dose:
 
0.0625
 
mg
 
to
 
0.25mg
 
od
 
 
 
 
 
Method
 
of
 
Administration*
 
May
 
be
 
taken
 
with
 
or
 
without
 
food
 
 
Missed
 
dose
 
management:
 
If
 
missed
 
dose,
 
to
 
take
 
as
 
soon
 
as
 
possible,
 
however ,
 
if
 
near
 
to
 
next
 
dose,
 
skip
 
the
 
missed
 
dose
 
and
 
go
 
back
 
to
 
your
 
regular
 
dosing
 
schedule
 
 
 
Do
 
not
 
stop
 
taking
 
your
 
medication
 
unless
 
advised
 
to
 
do
 
so
 
by
 
your
 
prescriber
 
 
 
 
Special
 
Considerations
 
Pregnancy
 
 
 
 
The
 
use
 
of
 
digoxin
 
in
 
pregnancy
 
is
 
not
 
contraindicated.
 
Use
 
should
 
be
 
considered
 
only
 
when
 
the
 
expected
 
clinical
 
benefit
 
treatment
 
to
 
mother
 
outweighs
 
any
 
possible
 
risk
 
to
 
developing
 
fetus
 
 
 
 
 
Breastfeeding
 
 
 
 
Digoxin
 
is
 
excreted
 
in
 
breast
 
milk,
 
but
 
quantities
 
are
 
minute
 
and
 
breastfeeding
 
is
 
not
 
contraindicated
 
 
 
 
 
Elderly
 
 
 
 
119
 

=== PAGE 121 ===

 
Beers
 
Criteria:
 
Avoid
 
this
 
rate
 
control
 
agent
 
as
 
first-line
 
therapy
 
for
 
atrial
 
fibrillation.
 
Avoid
 
first-line
 
therapy
 
for
 
heart
 
failure.
 
See
 
rationale
 
for
 
caution
 
about
 
withdrawal
 
in
 
long-term
 
users
 
with
 
HFrEF .
 
If
 
used
 
for
 
atrial
 
fibrillation
 
or
 
heart
 
failure,
 
avoid
 
dosages
 
>0.125
 
mg/day .
 
 
Use
 
in
 
atrial
 
fibrillation:
 
should
 
not
 
be
 
used
 
as
 
a
 
first-line
 
agent
 
because
 
there
 
are
 
safer
 
and
 
more
 
effective
 
alternatives
 
for
 
rate
 
control.
 
Use
 
in
 
heart
 
failure:
 
evidence
 
for
 
benefits
 
and
 
harms
 
of
 
digoxin
 
is
 
conflicting
 
and
 
of
 
lower
 
quality;
 
most
 
(but
 
not
 
all)
 
evidence
 
concerns
 
use
 
in
 
HFrEF .
 
There
 
is
 
strong
 
evidence
 
for
 
other
 
agents
 
as
 
first-line
 
therapy
 
to
 
reduce
 
hospitalizations
 
and
 
mortality
 
in
 
adults
 
with
 
HFrEF .
 
In
 
heart
 
failure,
 
higher
 
dosages
 
are
 
not
 
associated
 
with
 
additional
 
benefit
 
and
 
may
 
increase
 
risk
 
of
 
toxicity .
 
Use
 
caution
 
in
 
discontinuing
 
digoxin
 
among
 
current
 
users
 
with
 
HFrEF ,
 
given
 
limited
 
evidence
 
suggesting
 
worse
 
clinical
 
outcomes
 
after
 
discontinuation.
 
Decreased
 
renal
 
clearance
 
of
 
digoxin
 
may
 
lead
 
to
 
increased
 
risk
 
of
 
toxic
 
effects;
 
further
 
dose
 
reduction
 
may
 
be
 
necessary
 
in
 
those
 
with
 
Stage
 
4
 
or
 
5
 
chronic
 
kidney
 
disease.
 
 
 
 
Paediatric
 
 
 
 
Dose
 
calculated
 
based
 
on
 
body
 
weight.
 
 
 
 
Fasting
 
Not
 
applicable
 
 
 
 
To
 
refer
 
to
 
the
 
latest
 
advisory
 
by
 
religious
 
authority
 
 
 
 
Others
  
 
 
 
 
1.
 
Renal
 
impairment:
 
dosing
 
recommendations
 
should
 
be
 
considered
 
as
 
renal
 
clearance
 
of
 
digoxin
 
is
 
reduced
 
 
2.
 
Liver
 
impairment:
 
no
 
dosage
 
adjustment
 
necessary
 
 
 
 
 
Side
 
Effects
 
and
 
their
 
Management*
 
1.
 
Digoxin
 
toxicity
 
is
 
typically
 
associated
 
with
 
level
 
>
 
2ng/ml,
 
however ,
 
due
 
to
 
its
 
narrow
 
therapeutic
 
window ,
 
digoxin
 
toxicity
 
is
 
possible
 
at
 
therapeutic
 
levels.
 
 
2.
 
Symptoms
 
of
 
digoxin
 
toxicity:
 
nausea,
 
vomiting,
 
visual
 
disturbances
 
(halos,
 
yellow
 
or
 
blurred
 
vision),
 
lethargy ,
 
life
 
threatening
 
arrhythmias
 
(paroxysmal
 
atrial
 
tachycardia,
 
atrioventricular
 
block,
 
ventricular
 
premature
 
contractions,
 
ventricular
 
tachycardia,
 
ventricular
 
fibrillation)
 
 
3.
 
Management:
 
digoxin
 
immune
 
fab
 
 
 
 
Storage*
 
Store
 
below
 
30
℃
 
 
 
 
Others
 
Monitoring
 
 
 
1.
 
Serum
 
digoxin
 
concentration
 
monitoring
 
if
 
suspect
 
digoxin
 
toxicity ,
 
digoxin
 
serum
 
concentration
 
should
 
be
 
drawn
 
at
 
least
 
6
 
to
 
8
 
hours
 
after
 
last
 
dose
 
2.
 
Digoxin
 
therapeutic
 
serum
 
concentration:
 
 
                    
Heart
 
failure:
 
0.5
 
-
 
0.9ng/ml
 
                    
Atrial
 
fibrillation:
 
0.8
 
-
 
2ng/ml
 
 
3.
 
Monitor
 
serum
 
electrolytes
 
(serum,
 
potassium,
 
magnesium,
 
calcium)
 
and
 
renal
 
function
 
 
 
 
 
120
 

=== PAGE 122 ===

 
Before
 
ending
 
this
 
peer
 
review
 
session,
 
the
 
reviewee
 
should
 
be
 
informed
 
of
 
the
 
step(s)
 
that
 
he/
 
she
 
missed
 
out
 
in
 
order
 
to
 
ensure
 
all
 
the
 
counselling
 
points
 
are
 
being
 
covered.
 
 
Remarks:
 
 
 
 
 
Reviewed
 
by:
 
Name
 
&
 
Signature
                                                                   
Date:
 
 
 
 
 
*Mandatory
 
for
 
validation/peer
 
review
 
 
References:
 
 
1.
 
Lanoxin-PG
 
Digoxin
 
Tablet
 
BP
 
62.5mcg
 
Product
 
leaflet
 
(revised
 
15
 
June
 
2020).
 
Aspen.Zuellig
 
Pharma
 
2.
 
Digoxin
  
(2024).
 
MIMS
 
(online)
 
3.
 
2023
 
American
 
Geriatrics
 
Society
 
Beers
 
Criteria®
 
Update
 
Expert
 
Panel.
 
(2023).
 
American
 
Geriatrics
 
Society
 
2023
 
updated
 
AGS
 
Beers
 
Criteria®
 
for
 
potentially
 
inappropriate
 
medication
 
use
 
in
 
older
 
adults.
 
Journal
 
of
 
the
 
American
 
Geriatrics
 
Society ,
 
71(7),
 
2052-2081.
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
121
 

=== PAGE 123 ===

 
Diltiazem
 
Name
 
:
 
 
Unit
 
:
 
 
●
 
Please
 
tick
 
(
✔
)
 
Yes
 
for
 
correct
 
instruction.
 
●
 
Please
 
tick
 
(
✔
)
 
No
 
for
 
incorrect
 
instruction.
 
Yes
 
No
 
Remarks
 
Pharmacological
 
Group
 
Non
 
dihydropyridine
 
calcium-channel
 
blocker
 
 
 
 
 
Indications
 
and
 
Dosage
 
1.
 
Treatment
 
for
 
angina
 
a.
 
Immediate
 
release:
 
Initial
 
dose:
 
30mg
 
four
 
times
 
daily,
 
may
 
be
 
increased
 
gradually
 
at
 
one
 
to
 
two
 
day
 
intervals
 
until
 
optimum
 
response
 
is
 
achieved.
 
Usual
 
dose
 
range:
 
180
 
to
 
360mg
 
daily.
 
b.
 
Sustained
 
release:
 
Initial
 
dose:
 
60mg
 
twice
 
daily,
 
may
 
be
 
increased
 
to
 
360mg
 
daily
 
if
 
necessary .
 
Max
 
dose:
 
480mg
 
daily
 
 
2.
 
Hypertension
 
a.
 
Immediate
 
release:
 
Initial
 
dose:
 
30
 
to
 
60mg
 
thrice
 
daily
 
(90
 
to
 
180mg
 
daily).
 
b.
 
 
Sustained
 
release:
 
Initial
 
dose:
 
60
 
to
 
120mg
 
twice
 
daily,
 
increase
 
dose
 
as
 
needed
 
after
 
7
 
to
 
14
 
days;
 
usual
 
dose:
 
120
 
to
 
360mg
 
once
 
daily
 
 
To
 
counsel
 
based
 
on
 
specific
 
medication’ s
 
indication
 
and
 
dosage
 
as
 
prescribed
 
by
 
the
 
doctor
 
 
 
 
Method
 
of
 
Administration*
 
May
 
be
 
taken
 
with
 
or
 
without
 
food.
 
Swallow
 
tablet,do
 
not
 
chew
 
 
Missed
 
dose
 
management:
 
Take
 
the
 
missed
 
dose
 
as
 
soon
 
as
 
remembered.
 
If
 
it
 
is
 
close
 
to
 
the
 
time
 
for
 
the
 
next
 
dose,
 
skip
 
and
 
go
 
back
 
to
 
normal
 
time.
 
Do
 
not
 
take
 
2
 
doses
 
at
 
the
 
same
 
time
 
 
Do
 
not
 
stop
 
taking
 
your
 
medication
 
unless
 
advised
 
to
 
do
 
so
 
by
 
your
 
prescriber
 
 
 
 
Special
 
Considerations
 
Pregnancy
 
 
 
 
1.
 
Should
 
not
 
be
 
administered
 
to
 
pregnant
 
women
 
or
 
women
 
who
 
may
 
possibly
 
be
 
pregnant.
 
 
 
 
Breastfeeding
 
 
 
 
1.
 
Use
 
not
 
recommended
 
in
 
women
 
who
 
are
 
breast
 
feeding
 
 
 
 
Elderly
 
 
 
 
1.
 
Consider
 
lower
 
initial
 
doses
 
(eg
 
120mg
 
once
 
daily
 
using
 
extended-release
 
capsule)
 
 
MALPIP:
 
May
 
increase
 
the
 
risk
 
of
 
bradycardia
 
and
 
interact
 
with
 
digoxin,
 
beta-blockers
 
 
Beers
 
Criteria:
 
Potential
 
to
 
promote
 
fluid
 
retention
 
and/
 
or
 
exacerbate
 
heart
 
failure
 
(NSAIDs
 
and
 
COX-2
 
inhibitors,
 
non-dihydropyridine
 
CCBs,
 
thiazolidinediones)
 
 
 
 
122
 

=== PAGE 124 ===

 
Paediatric
 
 
 
 
1.
 
Hypertension
 
a.
 
Infants
 
and
 
children
 
Immediate
 
release:
 
Initial
 
dose
 
1.5
 
to
 
2
 
mg/kg/day
 
in
 
3
 
to
 
4
 
divided
 
doses,
 
increase
 
gradually
 
at
 
1
 
to
 
2
 
day
 
intervals
 
until
 
optimum
 
response
 
is
 
obtained;
 
Max:
 
3.5mg/kg/day
 
Sustained
 
release:
 
Total
 
daily
 
dose
 
of
 
immediate
 
release
 
dose
  
converted
 
to
 
extended
 
release
 
dose
 
with
 
appropriate
 
interval
 
(once
 
or
 
twice
 
daily)
 
in
 
children
 
able
 
to
 
swallow
 
capsules
 
whole
 
b.
 
Adolescents:
 
Immediate
 
release:
 
Initial
 
dose:
 
30
 
to
 
120mg
 
/dose
 
administered
 
3
 
to
 
4
 
times
 
daily;
 
usual
 
daily
 
dosage
 
range:180
 
to
 
360mg/day .
 
Sustained
 
release:
 
120mg
 
to
 
300mg
 
once
 
daily
 
 
 
 
Fasting
 
 
 
 
1.
 
Take
 
single
 
dose
 
of
 
sustained
 
release
 
at
 
night
 
(10pm)
 
after
 
breaking
 
fast
 
2.
 
Take
 
immediate
 
release
 
before
 
fasting
 
(morning)
 
and
 
after
 
breaking
 
fast.
 
May
 
omit
 
afternoon
 
dose.
 
 
 
 
Others
  
 
 
 
 
1.
 
Renal
 
impairment:
 
No
 
dosage
 
adjustment.
 
 
2.
 
Liver
 
impairment:
 
No
 
dosage
 
adjustment.
 
Use
 
with
 
caution
 
as
 
Diltiazem
 
is
 
extensively
 
metabolized
 
by
  
liver,
 
half-life
 
is
 
increased
 
in
 
patients
 
with
 
cirrhosis
 
 
 
 
Side
 
Effects
 
and
 
their
 
Management*
 
1.
 
Bradyarrhythmia.
 
May
 
cause
 
first-degree
 
atrioventricular
 
(AV)
 
block,
 
second-degree
 
AV
 
block,
 
complete
 
AV
 
block.
 
Reversal
 
of
 
symptoms
 
is
 
possible
 
after
 
discontinuation
 
2.
 
Bradycardia
 
3.
 
Peripheral
 
edema
 
 
 
 
Storage*
 
Store
 
between
 
15
 
to
 
30
0
C.
 
Protect
 
from
 
light.
 
Avoid
 
storing
 
in
 
excessive
 
heat
 
and
 
humidity
 
 
 
 
Others
 
Precautions
 
1.
 
Use
 
with
 
caution
 
in
 
patients
 
with
 
hepatic
 
impairment,
 
reduced
 
left
 
ventricular
 
function,
 
bradycardia,
 
1
st
 
degree
 
AV
 
block,
 
prolonged
 
PR
 
interval
 
(detected
 
on
 
ECG
 
 
Monitoring
 
parameters
 
1.
 
Blood
 
pressure,
 
ECG,
 
heart
 
rate,
 
liver
 
function
 
test
 
(ALT)
 
 
Significant
 
drug-drug
 
interactions
 
1.
 
Ivabradine:
 
Exacerbate
 
bradycardia
 
and
 
conduction
 
disturbances
 
–
 
potentially
 
fatal
 
2.
 
Amiodarone,
 
Digoxin,
 
beta
 
blockers:
 
Increase
 
depression
 
of
 
cardiac
 
conduction
 
–
 
increasing
 
risk
 
of
 
bradycardia.
 
3.
 
Clonidine:
 
concomitant
 
use
 
may
 
lead
 
to
 
sinus
 
bradycardia
 
leading
 
to
 
hospitalization
 
and
 
insertion
 
of
 
pacemaker
 
4.
 
Lithium:
 
May
 
increase
 
risk
 
of
 
lithium
 
induced
 
nephrotoxicity
 
5.
 
Atorvastatin,
 
Fluvastatin,
 
Simvastatin:
 
May
 
increase
 
risk
 
 
 
 
123
 

=== PAGE 125 ===

 
of
 
myopathy
 
and
 
rhabdomyolysis
 
 
Significant
 
drug-food
 
interactions
 
1.
 
Grapefruit
 
juice:
 
Increase
 
serum
 
concentration
 
of
 
diltiazem
 
Before
 
ending
 
this
 
peer
 
review
 
session,
 
the
 
reviewee
 
should
 
be
 
informed
 
of
 
the
 
step(s)
 
that
 
he/
 
she
 
missed
 
out
 
in
 
order
 
to
 
ensure
 
all
 
the
 
counselling
 
points
 
are
 
being
 
covered.
 
 
Remarks:
 
 
 
 
Reviewed
 
by:
 
Name
 
&
 
Signature
                                                                   
Date:
 
 
 
 
*Mandatory
 
for
 
validation/peer
 
review
 
 
References:
 
 
1.
 
Herbesser
 
Tablet
 
30mg,
 
60mg.
 
Product
 
leaflet
 
(updated
 
July
 
2023).
 
Mitsubishi
 
Tanabe
 
Pharma.
 
2.
 
Virani
 
SS
 
et
 
al
 
(2023).
 
AHA/ACC/ACCP/ASPC/NLA/PCNA
 
guideline
 
for
 
the
 
management
 
of
 
patients
 
with
 
chronic
 
coronary
 
disease:
 
a
 
report
 
of
 
the
 
American
 
Heart
 
Association/American
 
College
 
of
 
Cardiology
 
Joint
 
Committee
 
on
 
Clinical
 
Practice
 
Guidelines.
 
Circulation.
 
3.
 
Kannam
 
JP
 
et
 
al
 
(2019).
 
Calcium
 
channel
 
blockers
 
in
 
the
 
management
 
of
 
stable
 
angina
 
pectoris.
 
Post
 
TW.
 
4.
 
Weiner
 
DA
 
et
 
al
 
(1986).
 
Efficacy
 
and
 
safety
 
of
 
sustained-
 
released
 
diltiazem
 
in
 
stable
 
angina
 
pectoris.
 
Am
 
H
 
Cardiol.
 
5.
 
Whelton
 
PK
 
et
 
al
 
(2017).
 
ACC/AHA/AAP A/ABC/ACPM/AGS/APhA/ACH/ASPC/NMA/PCNA
 
guideline
 
for
 
prevention,
 
detection,
 
evaluation,
 
and
 
management
 
of
 
high
 
blood
 
pressure
 
in
 
adults:
 
a
 
report
 
of
 
American
 
College
 
of
 
Cardiology/American
 
Heart
 
Association
 
Task
 
Force
 
on
 
Clinical
 
Practice
 
Guidelines.
 
Hypertension.
 
6.
 
Rodgers
 
SK
 
et
 
al
 
(2019).
 
American
 
College
 
of
 
Obstetricians
 
and
 
Gynecologists.
 
Obstetrics
 
&
  
Gynecology
 
144(6).
 
7.
 
 
Okada
 
M
 
(1985).
 
Excretion
 
of
 
diltiazem
 
in
 
human
 
milk.
 
N
 
Engl
 
J
 
Med.
 
8.
 
Aronow
 
WS
 
et
 
al
 
(2016).
 
ACCF/AHA
 
2011
 
expert
 
consensus
 
document
 
on
 
hypertension
 
in
 
the
 
elderly:
 
a
 
report
 
of
 
the
 
American
 
College
 
of
 
Cardiology
 
Foundation
 
Task
 
Force
 
on
 
Clinical
 
Expert
 
Consensus
 
Documents.
 
Circulation.
 
9.
 
Pass
 
RH
 
et
 
al
 
(2000).
 
Continuous
 
Intravenous
 
Diltiazem
 
Infusion
 
for
 
Short
 
Term
 
Ventricular
 
Rate
 
Control
 
in
 
Children.
 
Am
 
J
 
Cardiology .
 
10.
 
Flynn
 
JT
 
et
 
al
 
(2000).
 
Calcium
 
channel
 
blockers:
 
Pharmacology
 
and
 
place
 
in
 
therapy
 
of
 
pediatric
 
hypertension.
 
Pediatric
 
Nephrology .
 
11.
 
Echizen
 
H
 
et
 
al
 
(1986).
 
Clinical
 
pharmacokinetics
 
of
 
verapamil,
 
nifedipine
 
and
 
diltiazem.
 
Clinical
 
Pharmacokinetics.
 
12.
 
Inamura
 
T
 
et
 
al
 
(1986).
 
Sinoatrial
 
block
 
induced
 
by
 
oral
 
diltiazem.
 
Clinical
 
Cardiology .
 
13.
 
Diltiazem
 
(2024).
 
MIMS
 
(online).
 
14.
 
Chang,
 
C.
 
T.,
 
Chan,
 
H.
 
K.,
 
Cheah,
 
W.
 
K.,
 
Tan,
 
M.
 
P.,
 
Ch’ng,
 
A.
 
S.
 
H.,
 
Thiam,
 
C.
 
N.,
 
...
 
&
 
Lee,
 
S.
 
W.
 
H.
 
(2023).
 
Development
 
of
 
a
 
Malaysian
 
potentially
 
inappropriate
 
prescribing
 
screening
 
tool
 
in
 
older
 
adults
 
(MALPIP):
 
a
 
Delphi
 
study .
 
Journal
 
of
 
Pharmaceutical
 
Policy
 
and
 
Practice,
 
16(1),
 
122.
 
15.
 
2023
 
American
 
Geriatrics
 
Society
 
Beers
 
Criteria®
 
Update
 
Expert
 
Panel.
 
(2023).
 
American
 
Geriatrics
 
Society
 
2023
 
updated
 
AGS
 
Beers
 
Criteria®
 
for
 
potentially
 
inappropriate
 
medication
 
use
 
in
 
older
 
adults.
 
Journal
 
of
 
the
 
American
 
Geriatrics
 
Society ,
 
71(7),
 
2052-2081.
 
 
 
 
 
 
 
124
 

=== PAGE 126 ===

 
Direct-Acting
 
Antiviral
 
(DAA)
 
 
Name
 
:
 
 
Unit
 
:
 
 
●
 
Please
 
tick
 
(
✔
)
 
Yes
 
for
 
correct
 
instruction.
 
●
 
Please
 
tick
 
(
✔
)
 
No
 
for
 
incorrect
 
instruction.
 
Yes
 
No
 
Remarks
 
Pharmacological
 
Group
 
NS5B
 
polymerase
 
inhibitor
 
1.
 
Tab
 
Sofosbuvir
 
400mg
 
NS5A
 
inhibitors
 
1.
 
Tab
 
Daclatasvir
 
30mg/
 
60mg
 
 
2.
 
Tab
 
Ravidasvir
 
200mg
 
 
NS5B
 
polymerase
 
inhibitor/NS5A
 
inhibitors
 
1.
 
Tab
 
Sofosbuvir
 
400mg
 
&
 
Velpatasvir
 
100mg
 
 
 
 
 
Indications
 
and
 
Dosage
 
For
 
the
 
treatment
 
of
 
chronic
 
hepatitis
 
C
 
virus
 
(HCV)
 
infection
 
in
 
adults
 
 
●
 
DAAs
 
must
 
be
 
used
 
in
 
combination
 
as
 
per
 
relevant
 
guidelines.
 
 
●
 
The
 
choice
 
of
 
DAA
 
regimen,
 
dosage
 
and
 
treatment
 
duration
 
is
 
individualized
 
and
 
depends
 
on
 
the
 
stage
 
of
 
liver
 
disease.
 
 
Or
 
To
 
counsel
 
based
 
on
 
specific
 
medication’ s
 
indication
 
and
 
dosage
 
as
 
prescribed
 
by
 
the
 
doctor
 
 
 
 
Method
 
of
 
Administration*
 
●
 
Must
 
be
 
taken
 
orally
 
at
 
the
 
same
 
time
 
everyday ,
 
with
 
or
 
without
 
food,
 
according
 
to
 
prescribed
 
treatment
 
regimen
 
as
 
instructed.
 
●
 
Tablets
 
should
 
be
 
swallowed
 
whole
 
and
 
should
 
not
 
be
 
chewed
 
or
 
crushed
 
(to
 
avoid
 
bitter
 
aftertaste).
 
●
 
Patients
 
must
 
complete
 
the
 
prescribed
 
treatment
 
regimen.
 
This
 
is
 
to
 
ensur e
 
treatment
 
effectiv eness
 
and
 
prevent
 
resistance.
 
●
 
DO
 
NOT
 
RUN
 
OUT
 
OF
 
MEDICA TION
.
 
Reﬁll
 
the
 
prescription
 
befor e
 
it
 
ﬁnishes.
 
 
Missed
 
dose
 
management:
 
●
 
If
 
you
 
miss
 
a
 
dose
 
and
 
it
 
is
 
less
 
than
 
18
 
hours
 
past
 
your
 
usual
 
time,
 
take
 
the
 
missed
 
dose
 
as
 
soon
 
as
 
possible.
 
●
 
If
 
more
 
than
 
18
 
hours
 
have
 
passed
 
since
 
your
 
usual
 
dose,
 
skip
 
the
 
missed
 
dose
 
and
 
take
 
your
 
next
 
dose
 
at
 
the
 
usual
 
time.
 
●
 
DO
 
NOT
 
take
 
two
 
doses
 
at
 
the
 
same
 
time
 
to
 
make
 
up
 
for
 
the
 
missed
 
dose.
 
 
Do
 
not
 
stop
 
taking
 
your
 
medication
 
unless
 
advised
 
to
 
do
 
so
 
by
 
your
 
prescriber .
 
 
 
 
Special
 
Considerations
 
Pregnancy
 
 
 
 
●
 
Limited
 
outcome
 
data.
 
Hence,
 
it
 
is
 
preferable
 
to
 
avoid
 
DAAs
 
during
 
pregnancy .
 
●
 
Use
 
is
 
not
 
currently
 
recommended
 
for
 
the
 
purpose
 
of
 
reducing
 
mother
 
to
 
child
 
transmission
 
of
 
HCV
 
due
 
to
 
lack
 
of
 
safety
 
and
 
efficacy
 
data.
 
●
 
The
 
decision
 
to
 
continue
 
treatment
 
in
 
a
 
patient
 
who
 
becomes
 
pregnant
 
while
 
taking
 
DAAs
 
should
 
be
 
individualized
 
after
 
considering
  
potential
 
risks
 
and
 
benefits
 
of
 
therapy .
 
 
 
 
125
 

=== PAGE 127 ===

 
Breastfeeding
 
 
 
 
It
 
is
 
unknown
 
whether
 
sofosbuvir
 
and
 
its
 
metabolites
 
are
 
excreted
 
in
 
human
 
milk.
 
A
 
risk
 
to
 
new-borns/infants
 
cannot
 
be
  
excluded.
 
 
 
 
Elderly
 
 
 
 
No
 
significant
 
precaution
 
in
 
elderly .
 
 
 
 
 
Paediatric
 
 
 
 
●
 
Adolescents
 
aged
 
≥
 
12
 
years
 
can
 
be
 
treated
 
with
 
regimens
 
approved
 
for
 
adults,
 
with
 
caution
 
pending
 
on
 
more
 
safety
 
data
 
in
 
this
 
population.
 
●
 
In
 
children
 
younger
 
than
 
12
 
years,
 
treatment
 
should
 
be
 
deferred
 
until
 
DAAs
 
are
 
approved
 
for
 
this
 
age
 
group.
 
 
 
 
 
Fasting
 
 
 
 
To
 
take
 
once
 
daily
 
during
 
Sahur
 
or
 
Iftar
.
 
 
 
 
Renal
 
impairment
 
 
 
 
●
 
Renal
 
impairment
 
(eGFR
 
<30
 
ml/min/1.73
 
m2)
 
or
 
those
 
with
 
end
 
stage
 
renal
 
disease
 
on
 
dialysis:
 
Sofosbuvir-free
 
regime
 
is
 
preferred.
 
If
 
there
 
is
 
no
 
alternative,
 
a
 
sofosbuvir-based
 
regime
 
may
 
be
 
used
 
with
 
close
 
monitoring
 
and
 
treatment
 
should
 
be
 
interrupted
 
if
 
renal
 
function
 
deteriorates.
 
●
 
Hemodialysis:
 
When
 
a
 
scheduled
 
dose
 
falls
 
on
 
hemodialysis
 
day,
 
DAAs
 
should
 
be
 
taken
 
after
 
hemodialysis.
 
 
 
 
 
Side
 
Effects
 
and
 
their
 
Management*
 
●
 
Side
 
effects
 
may
 
include
 
fatigue,
 
headache,
 
nausea
 
and
 
diarrhoea.
 
 
●
 
If
 
patients
 
experience
 
any
 
allergic
 
reaction
 
(e.g.
 
rashes,
 
breathlessness,
 
swollen
 
eyes),
 
they
 
should
 
stop
 
the
 
medication
 
immediately
 
and
 
seek
 
immediate
 
medical
 
assistance.
 
 
 
 
Storage*
 
●
 
Store
 
below
 
30
°
C.
 
 
●
 
Keep
 
medication
 
in
 
its
 
original
 
container ,
 
tightly
 
sealed
 
to
 
protect
 
from
 
moisture
 
and
 
light.
 
 
●
 
Keep
 
out
 
of
 
reach
 
and
 
sight
 
of
 
children.
 
 
 
 
Others
 
Drug-drug/
 
Drug-food
 
Interactions:
 
●
 
Patients
 
should
 
report
 
all
 
prescribed
 
medications,
 
over-the-counter
 
medications,
 
traditional
 
medicines
 
or
 
drinks,
 
and
 
health
 
supplements,
 
both
 
before
 
starting
 
therapy
 
and
 
during
 
treatment.
 
 
●
 
They
 
must
 
stop
 
taking
 
any
 
traditional
 
or
 
herbal
 
medications,
 
health
 
supplements,
 
or
 
health
 
drinks
 
during
 
treatment
 
and
 
should
 
consult
 
prescribers
 
before
 
starting
 
any
 
new
 
medications.
 
 
Vomiting
 
Management:
 
●
 
If
 
vomiting
 
occurs
 
within
 
2
 
hours
 
of
 
dosing,
 
an
 
additional
 
tablet
 
should
 
be
 
taken.
 
 
●
 
If
 
vomiting
 
occurs
 
more
 
than
 
2
 
hours
 
after
 
dosing,
 
no
 
additional
 
dose
 
is
 
needed.
 
 
 
 
126
 

=== PAGE 128 ===

 
Before
 
ending
 
this
 
peer
 
review
 
session,
 
the
 
reviewee
 
should
 
be
 
informed
 
of
 
the
 
step(s)
 
that
 
he/
 
she
 
missed
 
out
 
in
 
order
 
to
 
ensure
 
all
 
the
 
counselling
 
points
 
are
 
being
 
covered.
 
 
Remarks:
 
 
 
 
 
Reviewed
 
by:
 
Name
 
&
 
Signature
                                                                   
Date:
 
 
 
 
 
*Mandatory
 
for
 
validation
 
/
 
peer
 
review
 
References:
 
 
1.
 
Formulari
 
Ubat
 
KKM.
 
(2025,
 
January
 
1).
 
Accessed
 
on
 
January
 
21,
 
2025.
 
2.
 
Strides
 
Pharma
 
Science
 
Limited.
 
(2019).
 
Product
 
information
 
leaflet:
 
Virso.
 
Retrieved
 
from
 
Quest
 
3+
 
Product
 
Search
 
on
 
January
 
21,
 
2025.
 
3.
 
Hetero
 
Labs
 
Limited.
 
(2019).
 
Product
 
information
 
leaflet:
 
Dasvir .
 
Retrieved
 
from
 
Quest
 
3+
 
Product
 
Search
 
on
 
January
 
21,
 
2025.
 
4.
 
Mylan
 
Laboratories
 
Limited.
 
(2023).
 
Product
 
information
 
leaflet:
 
MyHep
 
ALL.
 
Retrieved
 
from
 
Quest
 
3+
 
Product
 
Search
 
on
 
January
 
21,
 
2025.
 
5.
 
European
 
Egyptian
 
Pharmaceutical
 
Industries
 
Co.
 
(2024).
 
Product
 
information
 
leaflet:
 
RAVIDA.
 
Retrieved
 
from
 
Quest
 
3+
 
Product
 
Search
 
on
 
January
 
21,
 
2025.
 
6.
 
American
 
Association
 
of
 
the
 
Study
 
of
 
Liver
 
Diseases/
 
Infectious
 
Diseases
 
Society
 
of
 
America
 
(AASLD/IDSA).
 
Recommendations
 
for
 
testing,
 
managing,
 
and
 
treating
 
hepatitis
 
C.
 
www .hcvguidelines.org.
 
Accessed
 
on
 
January
 
20,
 
2025.
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
127
 

=== PAGE 129 ===

 
Dolutegravir
 
 
Name
 
:
 
 
Unit
 
:
 
 
●
 
Please
 
tick
 
(
✔
)
 
Yes
 
for
 
correct
 
instruction.
 
●
 
Please
 
tick
 
(
✔
)
 
No
 
for
 
incorrect
 
instruction.
 
Yes
 
No
 
Remarks
 
Pharmacological
 
Group
 
Integrase
 
Inhibitor
 
 
 
 
Indications
 
and
 
Dosage
 
Dolutegravir
 
50mg
 
tablets
 
are
 
used
 
in
 
treatment
 
of
 
HIV-1
 
infected,
 
antiretroviral
 
treatment
 
naive
 
or
 
experienced
 
adults,
 
in
 
combination
 
with
 
other
 
antiretroviral
 
medicinal
 
products.
 
 
a.
 
50
 
mg
 
OD
 
for
 
patients
 
without
 
documented
 
or
 
clinically
 
suspected
 
resistance
 
to
 
the
 
integrase
 
class
 
 
 
b.
 
50
 
mg
 
BD
 
for
 
patients
 
with
 
resistance
 
to
 
the
 
integrase
 
class
 
 
Dolutegravir
 
tablets
 
for
 
oral
 
suspension
 
are
 
used
 
in
 
pediatric
 
patients
 
(treatment-naïve
 
or
 
-experienced
 
but
 
INSTI
 
naïve)
 
aged
 
at
 
least
 
4
 
weeks
 
and
 
weighing
 
at
 
least
 
3
 
kg.
 
 
a.
 
3
 
kg
 
to
 
<
 
6
 
kg
  
-
 
5
 
mg
 
once
 
daily
 
(one-half
 
tablet)
 
b.
 
6
 
kg
 
to
 
<
 
10
 
kg
 
-
  
15
 
mg
 
once
 
daily
 
(1
 
and
 
one-half
 
tablets)
 
 
c.
 
10
 
kg
 
to
 
<14
 
kg
 
-
  
20
 
mg
 
once
 
daily
 
(2
 
tablets)
 
d.
 
14
 
kg
 
to
 
<20
 
kg
 
-
  
25
 
mg
 
once
 
daily
 
(2
 
and
 
one-half
 
tablets)
 
 
e.
 
20
 
kg
 
and
 
greater
  
-
 
30
 
mg
 
once
 
daily
 
(3
 
tablets)
 
 
Dolutegravir
 
tablets
 
and
 
dolutegravir
 
tablets
 
for
 
oral
 
suspension
 
are
 
not
 
bioequivalent
 
and
 
are
 
not
 
interchangeable
 
on
 
a
 
milligram-per-milligram
 
basis
 
 
 
 
 
Method
 
of
 
Administration*
 
Can
 
be
 
taken
 
with
 
or
 
without
 
food.
 
 
Dolutegravir
 
50
 
mg
 
tablet
 
is
 
ideally
 
to
 
be
 
swallowed
 
whole.
 
The
 
tablet
 
may
 
also
 
be
 
split
 
into
 
halves
 
followed
 
by
 
immediate
 
ingestion
 
OR
 
it
 
may
 
be
 
crushed
 
and
 
added
 
to
 
a
 
small
 
amount
 
of
 
semi-solid
 
food
 
or
 
liquid
 
and
 
to
 
be
 
consumed
 
immediately .
 
 
Do
 
not
 
stop
 
taking
 
your
 
medication
 
unless
 
advised
 
to
 
do
 
so
 
by
 
your
 
prescriber
 
 
 
 
Special
 
Considerations
 
Pregnancy
 
 
 
 
1.
 
A
 
small
 
increase
 
of
 
neural
 
tube
 
defects
 
(0.05-0.1%)
 
occurs
 
within
 
the
 
first
 
4
 
weeks
 
of
 
embryonic
 
development
 
after
 
conception
 
(~
 
6
 
weeks
 
after
 
the
 
last
 
menstrual
 
period).
 
The
 
benefits
 
and
 
risks
 
of
 
continuing
 
dolutegravir
 
versus
 
switching
 
to
 
another
 
regimen
 
should
 
be
 
discussed
 
with
 
the
 
patient.
 
2.
 
Dolutegravir
 
may
 
be
 
used
 
during
 
the
 
second
 
and
 
third
 
trimester
 
of
 
pregnancy
 
when
 
the
 
expected
 
benefits
 
justify
 
the
 
potential
 
risk
 
to
 
the
 
fetus.
 
 
 
 
Breastfeeding
 
 
 
 
Dolutegravir
 
is
 
excreted
 
in
 
human
 
milk
 
in
 
small
 
amounts.
 
There
 
is
 
insuf ficient
 
information
 
on
 
its
 
effects
 
in
 
neonates/infants.
 
However ,
 
it
 
is
 
recommended
 
HIV
 
infected
 
women
 
do
 
not
 
 
 
 
128
 

=== PAGE 130 ===

 
breast-feed
 
their
 
infants
 
in
 
order
 
to
 
avoid
 
HIV
 
transmission.
 
Elderly
 
 
 
 
Limited
 
data
 
is
 
available
 
for
 
patients
 
aged
 
more
 
than
 
65
 
years
 
old.
 
However ,
 
there
 
is
 
no
 
evidence
 
that
 
elderly
 
require
 
different
 
doses
 
compared
 
to
 
younger
 
adult
 
patients.
 
 
 
 
Paediatric
 
 
 
 
Dolutegravir
 
dispersible
 
tablet
 
for
 
oral
 
suspension
 
is
 
available
 
for
 
treatment-naive
 
or
 
treatment-experienced
 
INSTI-naive
 
patients
 
aged
 
at
 
least
 
4
 
weeks
 
and
 
weighing
 
at
 
least
 
3
 
kg.
 
Film
 
coated
 
50
 
mg
 
tablets
 
are
 
not
 
bioequivalent
 
to
 
dispersible
 
tablets.
 
 
 
 
 
Fasting
 
 
 
 
To
 
refer
 
to
 
the
 
latest
 
advisory
 
by
 
religious
 
authority
 
 
 
 
Others
 
 
 
 
 
No
 
data
 
are
 
available
 
in
 
patients
 
with
 
severe
 
hepatic
 
impairment
 
(Child-Pugh
 
Grade
 
C).
 
Use
 
with
 
caution
 
in
 
these
 
patients.
 
 
 
 
Side
 
Effects
 
and
 
their
 
Management*
 
Common
 
side
 
effects
 
are
 
nausea,
 
headache
 
and
 
insomnia.
 
 
Changing
 
the
 
administration
 
time
 
of
 
dolutegravir
 
to
 
morning
 
time
 
may
 
help
 
to
 
reduce
 
the
 
incidence
 
of
 
insomnia
 
 
 
 
Storage*
 
Store
 
below
 
30
 
degree
 
celsius
 
 
 
 
 
Others
 
Beware
 
of
 
dolutegravir-drug
 
interactions.
 
Kindly
 
refer
 
to
 
Liverpool
 
HIV
 
Interactions
 
website
 
for
 
further
 
information.
 
 
1.
 
Hepatic
 
enzyme
 
inducers
 
such
 
as
 
rifampicin,
 
phenytoin:
     
 
    
Increase
 
dolutegravir
 
dose
 
to
 
50
 
mg
 
BD
 
 
 
2.
 
Polyvalent
 
cation
 
such
 
as
 
multivitamin,
 
calcium
 
and
 
ferrous
  
 
    
containing
 
medications:
 
Administer
 
dolutegravir
 
at
 
least
 
2
  
 
    
hours
 
before
 
or
 
at
 
least
 
6
 
hours
 
after
 
these
 
medications
 
 
 
 
 
Before
 
ending
 
this
 
peer
 
review
 
session,
 
the
 
reviewee
 
should
 
be
 
informed
 
of
 
the
 
step(s)
 
that
 
he/
 
she
 
missed
 
out
 
in
 
order
 
to
 
ensure
 
all
 
the
 
counselling
 
points
 
are
 
being
 
covered.
 
 
Remarks:
 
 
 
 
 
Reviewed
 
by:
 
Name
 
&
 
Signature
                                                                   
Date:
 
 
 
 
 
*Mandatory
 
for
 
validation
 
/
 
peer
 
review
 
References:
 
 
1.
 
Capetti
 
AF
 
et.al
  
(2017).
 
Morning
 
Dosing
 
for
 
Dolutegravir-related
 
Insomnia
 
and
 
Sleep
 
Disorders.
 
HIV
 
Medicine.
 
2.
 
Ministry
 
of
 
Health
 
Malaysia
 
(2022).
 
Malaysian
 
Consensus
 
Guidelines
 
on
 
Antiretroviral
 
Therapy
 
3.
 
Myltega
 
Product
 
Leaflet
 
4.
 
Tseng
 
A
 
et.al
 
(2024).
 
Oral
 
Antiretroviral/HCV
 
DAA
 
Administration:
 
Information
 
on
 
Crushing
 
and
 
Liquid
 
Drug
 
Formulations.
 
Available
 
at
 
https://hivclinic.ca/
 
(Assessed
 
on
 
November
 
5,
  
2024)
 
5.
 
Dolutegravir
 
Tablets
 
for
 
oral
 
suspension
 
product
 
leaflet
 
129
 

=== PAGE 131 ===

 
Dolutegravir
 
/Lamivudine/Tenofovir
 
Disoproxil
 
Fumarate
 
 
Name
 
:
 
 
Unit
 
:
 
 
●
 
Please
 
tick
 
(
✔
)
 
Yes
 
for
 
correct
 
instruction.
 
●
 
Please
 
tick
 
(
✔
)
 
No
 
for
 
incorrect
 
instruction.
 
Yes
 
No
 
Remarks
 
Pharmacological
 
Group
 
Antiretroviral:
 
Combination
 
of
 
two
 
Nucleoside
 
Reverse
 
Transcriptase
 
Inhibitors
 
(NRTIs):
 
Lamivudine
 
and
 
Tenofovir
 
disoproxil
 
fumarate)
 
with
 
Integrase
 
Inhibitor
 
(INSTI):
 
Dolutegravir
 
 
 
 
Indications
 
and
 
Dosage
 
Indication:
 
A
 
complete
 
regimen
 
for
 
the
 
treatment
 
of
 
human
 
immunodeficiency
 
virus
 
type
 
1
 
(HIV-1)
 
infection
 
in
 
adults
 
and
 
adolescents
 
above
 
12
 
years
 
of
 
age
 
and
 
weighing
 
40
 
kg
 
or
 
greater .
 
 
Dosage:
 
One
 
tablet
 
once
 
daily.
 
 
 
 
Method
 
of
 
Administration*
 
May
 
be
 
administered
 
orally
 
with
 
or
 
without
 
food.
 
 
Do
 
not
 
stop
 
taking
 
your
 
medication
 
unless
 
advised
 
to
 
do
 
so
 
by
 
your
 
prescriber
 
 
 
 
Special
 
Considerations
 
Pregnancy
 
 
 
 
1.
 
Safe
 
to
 
be
 
used
 
in
 
pregnancy .
 
 
 
 
Breastfeeding
 
 
 
 
Studies
 
found
 
that
 
all
 
Dolutegravir ,
 
Lamivudine,
 
and
 
Tenofovir
 
disoproxil
 
fumarate
 
are
 
excreted
 
in
 
breast
 
milk.
 
It
 
is
 
recommended
 
that
 
HIV-1
 
infected
 
mothers
 
not
 
to
 
breastfeed
 
their
 
infants
 
to
 
avoid
 
risking
 
postnatal
 
transmission
 
of
 
HIV-1
 
infection
 
and
 
potential
 
of
 
serious
 
adverse
 
reactions
 
in
 
nursing
 
infants.
 
 
 
 
Elderly
 
 
 
 
Generally
 
safe
 
to
 
be
 
used
 
among
 
elderly
 
patients,
 
however
 
monitoring
 
on
 
renal
 
function
 
is
 
required
 
as
 
this
 
preparation
 
contains
 
Tenofovir
 
disoproxil
 
fumarate
 
that
 
may
 
induce
 
renal
 
toxicity .
 
 
 
 
 
Paediatric
 
 
 
 
Dolutegravir ,
 
Lamivudine,
 
Tenofovir
 
disoproxil
 
fumarate
 
should
 
not
 
be
 
administered
 
to
 
children
 
less
 
than
 
12
 
years
 
of
 
age
 
and
 
those
 
who
 
weigh
 
less
 
than
 
35
 
kg.
 
 
 
 
 
Fasting
 
 
 
 
Time
 
of
 
administration
 
for
 
this
 
medication
 
may
 
be
 
adjusted
 
accordingly
 
when
 
fasting.
 
 
 
 
Others
 
 
 
 
 
1.
 
Hepatic
 
impairment
 
No
 
dosage
 
adjustment
 
is
 
necessary
 
for
 
patients
 
with
 
mild
 
to
 
moderate
 
hepatic
 
impairment
 
(Child-Pugh
 
Score
 
A
 
or
 
B).
 
The
 
effect
 
of
 
severe
 
hepatic
 
impairment
 
(Child-Pugh
 
Score
 
C)
 
on
 
the
 
pharmacokinetics
 
of
 
dolutegravir
 
has
 
not
 
 
 
 
130
 

=== PAGE 132 ===

 
been
 
studied.
 
Therefore,
 
dolutegravir
 
is
 
not
 
recommended
 
for
 
use
 
in
 
patients
 
with
 
severe
 
hepatic
 
impairment.
 
2.
 
Renal
 
impairment
 
Dolutegravir ,
 
Lamivudine,
 
Tenofovir
 
disoproxil
 
fumarate
 
is
 
a
 
fixed-dose
 
tablet,
 
thus
 
it
 
is
 
not
 
recommended
 
to
 
be
 
used
 
among
 
patients
 
requiring
 
renal-dose
 
adjustment.
 
Side
 
Effects
 
and
 
their
 
Management*
 
1.
 
Hypersensitivity
 
reaction:
 
Discontinue
 
Dolutegravir ,
 
Lamivudine,
 
Tenofovir
 
disoproxil
 
immediately .
 
Delay
 
in
 
action
 
may
 
result
 
in
 
life-threatening
 
reactions.
 
2.
 
Renal
 
toxicity ,
 
including
 
cases
 
of
 
acute
 
renal
 
failure
 
and
 
Fanconi
 
syndrome:
 
Assess
 
renal
 
function
 
prior
 
to
 
initiation
 
of
 
this
 
medication.
 
Avoid
 
concomitant
 
use
 
with
 
nephrotoxic
 
agents
 
such
 
as
 
high
 
dose
 
NSAIDs.
 
3.
 
Hepatotoxicity:
 
Avoid
 
use
 
in
 
severe
 
liver
 
disease.
 
 
4.
 
Bone
 
effects
 
of
 
Tenofovir
 
disoproxil
 
fumarate:
 
Supplementation
 
with
 
calcium
 
and
 
Vitamin
 
D
 
may
 
be
 
beneficial.
 
Assessment
 
on
 
bone
 
health
 
should
 
be
 
monitored
 
accordingly .
 
5.
 
Insomnia
 
effects
 
of
 
Dolutegravir:
 
Adjust
 
administration
 
time
 
accordingly
 
to
 
ensure
 
good
 
quality
 
of
 
sleep
 
thus
 
not
 
affecting
 
daily
 
activities.
 
6.
 
Others:
 
TELDY
 
may
 
cause
 
dizziness
 
and
 
reduce
 
alertness.
 
It
 
is
 
advisable
 
for
 
patients
 
not
 
to
 
drive
 
or
 
operate
 
machinery .
 
 
 
 
Storage*
 
1.
 
Store
 
below
 
30°C.
 
2.
 
Protect
 
from
 
light
 
and
 
moisture.
 
 
 
 
Others
 
Special
 
monitoring
 
parameter(s):
 
a.
 
Drug-drug
 
interaction
 
especially
 
involving
 
Dolutegravir
 
can
 
lead
 
to
 
loss
 
of
 
virologic
 
response
 
and
 
adverse
 
drug
 
reactions.
 
Always
 
review
 
concomitant
 
medications
 
during
 
therapy
 
with
 
Dolutegravir .
 
b.
 
Severe
 
hypophosphatemia
 
can
 
be
 
an
 
indicator
 
of
 
renal
 
impairment
 
due
 
to
 
proximal
 
renal
 
tubulopathy
 
which
 
is
 
also
 
associated
 
with
 
worsening
 
bone
 
or
 
muscle
 
symptoms
 
related
 
to
 
Tenofovir
 
disoproxil
 
fumarate.
 
 
Significant
 
drug-drug
 
/
 
drug-food
 
interaction(s):
 
a.
 
Medications
 
containing
 
polyvalent
 
cations
 
(eg.
 
Mg
 
or
 
Al),
 
oral
 
calcium
 
or
 
iron
 
can
 
reduce
 
concentration
 
of
 
Dolutegravir:
 
 
Administer
 
doletugravir/lamivudine/tenofovir
 
disoproxil
 
fumarate
 
at
 
least
 
2 hours
 
before
 
or
 
at
 
least
 
6
 
hours
 
after
 
these
 
medications.
 
b.
 
Metformin:
 
Dolutegravir
 
may
 
increase
 
concentration
 
of
 
Metformin.
 
Limit
 
the
 
total
 
daily
 
dose
 
of
 
Metformin
 
to
 
1000mg
 
and
 
monitor
 
blood
 
sugar
 
accordingly .
 
c.
 
Hepatic
 
enzyme
 
inducers
 
such
 
as
 
Rifampin,
 
Carbamazepine,
 
and
 
Phenytoin
 
will
 
reduce
 
the
 
concentration
 
of
 
Dolutegravir:
 
Additional
 
dose
 
of
 
Dolutegravir
 
50mg
 
should
 
be
 
taken
 
after
 
12
 
hours
 
of
 
doletugravir/lamivudine/tenofovir
 
disoproxil
 
fumarate.
 
 
Contraindication(s):
 
Prior
 
hypersensitivity
 
reaction
 
to
 
dolutegravir ,
 
lamivudine,
 
or
 
tenofovir
 
disoproxil
 
fumarate.
 
 
 
 
 
131
 

=== PAGE 133 ===

 
Before
 
ending
 
this
 
peer
 
review
 
session,
 
the
 
reviewee
 
should
 
be
 
informed
 
of
 
the
 
step(s)
 
that
 
he/
 
she
 
missed
 
out
 
in
 
order
 
to
 
ensure
 
all
 
the
 
counselling
 
points
 
are
 
being
 
covered.
 
 
Remarks:
 
 
 
 
 
Reviewed
 
by:
 
Name
 
&
 
Signature
                                                                   
Date:
 
 
 
 
 
*Mandatory
 
for
 
validation
 
/
 
peer
 
review
 
References:
 
 
1.
 
HETERO
 
LABS
 
LIMITED.
 
(2022).
 
TELDY
 
(Dolutegravir
 
50
 
mg
 
/
 
Lamivudine
 
300
 
mg
 
/
 
Tenofovir
 
Disproxil
 
Fumarate
 
300
 
mg)
 
Film-coated
 
Tablets
 
Product
 
Insert.
 
2.
 
Ministry
 
of
 
Health
 
Malaysia
 
(2022).
 
Malaysian
 
Consensus
 
Guidelines
 
on
 
Antiretroviral
 
Therapy .
 
https://www .mashm.net/.
 
 
  
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
132
 

=== PAGE 134 ===

 
Edoxaban
 
 
Name
 
:
 
 
Unit
 
:
 
 
●
 
Please
 
tick
 
(
✔
)
 
Yes
 
for
 
correct
 
instruction
 
or
 
sequence.
 
●
 
Please
 
tick
 
(
✔
)
 
No
 
for
 
incorrect
 
instruction
 
or
 
sequence.
 
Yes
 
No
 
Remarks
 
Pharmacological
 
Group
 
Direct
 
Oral
 
Anticoagulant
 
-
 
Factor
 
Xa
 
inhibitor
 
 
 
 
 
Indications
 
and
 
Dosage
 
1.
 
Prevention
 
of
 
stroke
 
and
 
systemic
 
embolism
 
in
 
adult
 
patients
 
with
 
nonvalvular
 
atrial
 
fibrillation
 
(NVAF)
 
with
 
one
 
or
 
more
 
risk
 
factors,
 
such
 
as
 
congestive
 
heart
 
failure,
 
hypertension,
 
and
 
age
 
≥
 
75
 
years,
 
diabetes
 
mellitus,
 
prior
 
stroke
 
or
 
transient
 
ischaemic
 
attack
 
(TIA).
 
a.
 
The
 
recommended
 
dose
 
is
 
60
 
mg
 
edoxaban
 
once
 
daily
 
for
 
life-long.
 
b.
 
The
 
recommended
 
dose
 
is
 
30
 
mg
 
once
 
daily
 
in
 
patients
 
with
 
one
 
or
 
more
 
of
 
the
 
following
 
clinical
 
factors:
 
-
 
Moderate
 
or
 
severe
 
renal
 
impairment
 
(creatinine
 
clearance
 
(CrCL)
 
15
 
-
 
50
 
mL/min)
 
-
 
Low
 
body
 
weight
 
≤
 
60
 
kg
 
-
 
Concomitant
 
use
 
of
 
the
 
following
 
P-glycoprotein
 
(P-gp)
 
inhibitors:
 
ciclosporin,
 
dronedarone,
 
erythromycin,
 
or
 
ketoconazole.
 
 
 
 
 
Method
 
of
 
Administration*
 
1.
 
Swallow
 
the
 
tablet,
 
preferably
 
with
 
water .
 
 
2.
 
Edoxaban
 
may
 
be
 
taken
 
with
 
or
 
without
 
food.
 
3.
 
The
 
tablet
 
may
 
be
 
crushed
 
and
 
mixed
 
with
 
water
 
or
 
apple
 
puree
 
immediately
 
before
 
administration.
 
 
Missed
 
dose
 
management:
 
If
 
a
 
dose
 
of
 
edoxaban
 
is
 
missed,
 
the
 
dose
 
should
 
be
 
taken
 
immediately
 
and
 
then
 
be
 
continued
 
the
 
following
 
day
 
with
 
the
 
once-daily
 
intake
 
as
 
recommended.
 
The
 
prescribed
 
dose
 
should
 
not
 
take
 
doubled
 
on
 
the
 
same
 
day
 
to
 
make
 
up
 
for
 
a
 
missed
 
dose.
 
 
Do
 
not
 
stop
 
taking
 
your
 
medication
 
unless
 
advised
 
to
 
do
 
so
 
by
 
your
 
prescriber
 
 
 
 
Special
 
Considerations
 
Pregnancy
 
 
 
 
Contraindicated
 
during
 
pregnancy
 
 
 
 
Breastfeeding
 
 
 
 
Contraindicated
 
during
 
breastfeeding
 
 
 
 
Elderly
 
 
 
 
1.
 
No
 
dose
 
reduction
 
is
 
required
 
(
After
 
taking
 
renal
 
function
 
and
 
body
 
weight
 
into
 
account,
 
age
 
had
 
no
 
additional
 
clinically
 
significant
 
effect
 
on
 
edoxaban
 
pharmacokinetics
 
in
 
a
 
population
 
pharmacokinetic
 
analysis
 
of
 
the
 
pivotal
 
Phase
 
3
 
study
 
in
 
NVAF
 
(ENGAGE
 
AF-TIMI
 
48).
 
2.
 
The
 
co-administration
 
with
 
ASA
 
in
 
elderly
 
patients
 
should
 
be
 
used
 
cautiously
 
because
 
of
 
a
 
potentially
 
higher
 
bleeding
 
risk
 
 
 
 
133
 

=== PAGE 135 ===

 
 
MALPIP
 
1.
 
Use
 
with
 
caution
 
and
 
monitor
 
bleeding
 
risk
 
2.
 
Increased
 
serum
 
concentration
 
may
 
occur
 
with
 
renal
 
impairment
 
and
 
dose
 
adjustment
 
may
 
be
 
indicated.
 
Assess
 
renal
 
profile
 
before
 
initiation.
 
 
 
START/ST OPP
 
criteria
 
1.
 
No
 
added
 
benefit
 
for
 
anti-platelet
 
combination
 
therapy
 
with
 
factor
 
Xa
 
inhibitor
 
in
 
patients
 
with
 
chronic
 
atrial
 
fibrillation
 
unless
 
there
 
is
 
concurrent
 
coronary
 
artery
 
stent
 
or
 
presence
 
of
 
high
 
grade
 
(>50%)
 
coronary
 
artery
 
stenosis.
 
 
2.
 
No
 
added
 
benefit
 
for
 
anti-platelet
 
combination
 
therapy
 
with
 
factor
 
Xa
 
inhibitor
 
in
 
patients
 
with
 
stable
 
coronary ,
 
cerebrovascular/peripheral
 
arterial
 
disease.
 
 
3.
 
Concomitant
 
use
 
with
 
P-glycoprotein
 
(P-gp)
 
inhibitors
 
increased
 
risk
 
of
 
bleeding.
 
4.
 
Concomitant
  
use
 
with
 
NSAID
 
or
 
SSRI
 
leads
 
to
 
risk
 
of
 
major
 
gastrointestinal
 
bleeding
 
and
 
increased
 
bleeding
 
risk
 
respectively .
 
 
5.
 
Avoid
 
factor
 
Xa
 
inhibitor
 
use
 
in
 
patients
 
with
 
concurrent
 
significant
 
bleeding
 
risk.
 
Pediatric
 
 
 
 
The
 
safety
 
and
 
efficacy
 
of
 
edoxaban
 
in
 
children
 
and
 
adolescents
 
less
 
than
 
18
 
years
 
of
 
age
 
have
 
not
 
been
 
established.
 
No
 
data
 
available.
 
 
 
 
Fasting:
 
 
 
 
Not
 
applicable
 
 
 
 
Others
 
 
 
 
1.
 
The
 
recommended
 
dose
 
in
 
patients
 
with
 
renal
 
impairment
 
 
a.
 
Mild
 
(CrCl
 
>
 
50
 
–
 
80
 
mL/min):
 
60
 
mg
 
once
 
daily.
 
 
b.
 
moderate
 
or
 
severe
 
(CrCl
 
15
 
–
 
50
 
mL/min):
 
30
 
mg
 
once
 
daily
 
 
c.
 
end
 
stage
 
renal
 
disease
 
(ESRD)
 
(CrCl
 
<
 
15
 
mL/min)
 
or
 
on
 
dialysis:
 
Not
 
recommended
 
2.
 
The
 
recommended
 
dose
 
in
 
patients
 
with
 
liver
 
impairment
 
a.
 
Mild
 
to
 
moderate:
 
60
 
mg
 
once
 
daily
 
b.
 
Elevated
 
liver
 
enzymes
 
(alanine
 
aminotransferase
 
(ALT)
 
or
 
aspartate
 
transaminase
 
(AST)
 
6
 
>
 
2
 
x
 
upper
 
limit
 
of
 
normal
 
(ULN)
 
or
 
total
 
bilirubin
 
≥
 
1.5
 
x
 
ULN:
 
Use
 
with
 
caution
 
because
 
these
 
patients
 
were
 
excluded
 
from
 
studies
 
c.
 
Severe:
 
Not
 
recommended
 
d.
 
Hepatic
 
disease
 
associated
 
with
 
coagulopathy
 
and
 
clinically
 
relevant
 
bleeding
 
risk:
 
Contraindicated
 
 
 
 
 
Side
 
effects
 
and
 
their
 
Management*
 
1.
 
To
 
seek
 
emergency
 
care
 
right
 
away
 
if
 
there
 
are
 
signs
 
or
 
symptoms
 
of
 
unusual
 
or
 
serious
 
bleeding
 
from
 
any
 
parts
 
of
 
the
 
body .
 
2.
 
Common
 
side
 
effects
 
of
 
edoxaban
 
include:
 
a.
 
Stomach
 
pain
 
b.
 
Dizziness
 
&
 
tiredness
 
 
 
 
134
 

=== PAGE 136 ===

 
Storage*
 
1.
 
Store
 
between
 
20-25
°C
 
2.
 
Do
 
not
 
use
 
this
 
medicine
 
after
 
the
 
expiry
 
date
 
which
 
is
 
stated
 
on
 
the
 
carton
 
and
 
on
 
each
 
blister
 
(after
 
EXP).
 
The
 
expiry
 
date
 
refers
 
to
 
the
 
last
 
day
 
of
 
that
 
month.
 
 
 
 
Others
 
1.
 
Monitoring
 
parameters
 
a.
 
Renal
 
profile
 
b.
 
Liver
 
profile
 
 
2.
 
Drug
 
interactions:
 
a.
 
P-gp
 
inhibitors
 
(ciclosporin,
 
dronedarone,
 
erythromycin,
 
ketoconazole):
  
dose
 
reduction
 
to
 
30
 
mg
 
once
 
daily.
 
b.
 
P-gp
 
inducers
 
(phenytoin,
 
carbamazepine
 
or
 
phenobarbital):
 
A
void
 
c.
 
Anticoagulants,
 
antiplatelets,
 
NSAIDs
 
and
 
SSRIs/SNRIs:
 
Use
 
with
 
caution
 
due
 
to
 
increased
 
risk
 
of
 
bleeding
 
 
 
 
Before
 
ending
 
this
 
peer
 
review
 
session,
 
the
 
reviewee
 
should
 
be
 
informed
 
of
 
the
 
step(s)
 
that
 
he/
 
she
 
missed
 
out
 
in
 
order
 
to
 
ensure
 
all
 
the
 
counselling
 
points
 
are
 
being
 
covered.
 
 
Remarks:
 
 
 
 
 
Reviewed
 
by:
 
Name
 
&
 
Signature
                                                                   
Date:
 
 
 
 
 
*Mandatory
 
for
 
validation
 
/
 
peer
 
review
 
 
References:
 
1.
 
A.Menarani
 
Singapore
 
Pte
 
Ltd.
 
(2023)
 
Product
 
information
 
leaflet:
 
Lixiana.
 
Retrieved
 
from
 
Quest
 
3+
 
Product
 
Search
 
on
 
January
 
20,
 
2025.
 
2.
 
Formulari
 
Ubat
 
KKM.
 
(2025).
 
Accessed
 
on
 
January
 
20,
 
2025.
 
3.
 
MIMS
 
Malaysia.
 
(2024).
 
Edoxaban.
 
In
 
MIMS
 
Online.
 
Retrieved
 
26
 
November ,
 
2024,
 
from
 
https://www .mims.com/malaysia/drug/info/edoxaban
 
4.
 
MIMS
 
Malaysia.
 
(2024).
 
Lixiana.
 
In
 
MIMS
 
Online.
 
Retrieved
 
26
 
November ,
 
2024,
 
from
 
https://www .mims.com/malaysia/drug/info/lixiana?type=full
 
5.
 
Chang,
 
C.
 
T.,
 
Chan,
 
H.
 
K.,
 
Cheah,
 
W.
 
K.,
 
Tan,
 
M.
 
P.,
 
Ch’ng,
 
A.
 
S.
 
H.,
 
Thiam,
 
C.
 
N.,
 
...
 
&
 
Lee,
 
S.
 
W.
 
H.
 
(2023).
 
Development
 
of
 
a
 
Malaysian
 
potentially
 
inappropriate
 
prescribing
 
screening
 
tool
 
in
 
older
 
adults
 
(MALPIP):
 
a
 
Delphi
 
study .
 
Journal
 
of
 
Pharmaceutical
 
Policy
 
and
 
Practice,
 
16(1),
 
122.
 
6.
 
O’Mahony ,
 
D.,
 
Cherubini,
 
A.,
 
Guiteras,
 
A.
 
R.,
 
Denkinger ,
 
M.,
 
Beuscart,
 
J.
 
B.,
 
Onder ,
 
G.,
 
...
 
&
 
Curtin,
 
D.
 
(2023).
 
STOPP/ST ART
 
criteria
 
for
 
potentially
 
inappropriate
 
prescribing
 
in
 
older
 
people:
 
version
 
3.
 
European
 
geriatric
 
medicine,
 
14(4),
 
625-632
 
 
 
 
 
 
 
 
 
 
 
135
 

=== PAGE 137 ===

 
Efavirenz
 
 
Name
 
:
 
 
Unit
 
:
 
 
●
 
Please
 
tick
 
(
✔
)
 
Yes
 
for
 
correct
 
instruction.
 
●
 
Please
 
tick
 
(
✔
)
 
No
 
for
 
incorrect
 
instruction.
 
Yes
 
No
 
Remarks
 
Pharmacological
 
Group
 
Non-Nucleoside
 
Reverse
 
Transcriptase
 
Inhibitors
 
(NNR TIs)
 
 
 
 
Indications
 
and
 
Dosage
 
1.
 
Treatment
 
for
 
HIV-1
 
infections
 
in
 
combination
 
with
 
other
 
antiretroviral
 
agents
 
indicated
 
 
a)
 
Adults
 
:
 
600
 
mg
 
or
 
400mg
 
PO
 
once
 
daily
 
on
 
an
 
empty
 
stomach,
 
preferably
 
at
 
or
 
before
 
bedtime
  
 
 
b)
 
Children
 
aged
 
>3
 
years
 
weighing
 
>10
 
kg
 
:
 
 
                      
13-15kg
 
200mg
 
once
 
daily
 
                      
15-20kg
 
250mg
 
once
 
daily
 
                      
20-25kg
 
300mg
 
once
 
daily
 
                      
25-32kg
 
350mg
 
once
 
daily
 
                      
33-40kg
 
400mg
 
once
 
daily
 
                      
>40kg
 
600mg
 
once
 
daily
      
                 
 
 
 
 
Method
 
of
 
Administration*
 
1.
 
Efavirenz
 
may
 
be
 
taken
 
with
 
or
 
without
 
food.
 
It
 
is
 
recommended
 
that
 
efavirenz
 
be
 
taken
 
on
 
an
 
empty
 
stomach.
 
The
 
increased
 
efavirenz
 
concentrations
 
observed
 
following
 
administration
 
of
 
efavirenz
 
with
 
food
 
may
 
lead
 
to
 
an
 
increase
 
in
 
frequency
 
of
 
adverse
 
reactions.
 
 
2.
 
In
 
order
 
to
 
improve
 
the
 
tolerability
 
of
 
central
 
nervous
 
system
 
side
 
effects,
 
bedtime
 
dosing
 
is
 
recommended
 
and
 
in
 
patients
 
who
 
continue
 
to
 
experience
 
these
 
symptoms.
 
 
3.
 
Efavirenz
 
200mg/600mg
 
tablet
 
is
 
ideally
 
to
 
be
 
swallowed
 
whole.
 
 
 
Missed
 
dose
 
management
 
 
 
1.
 
To
 
take
 
medication
 
consistently
 
at
 
the
 
same
 
time
 
everyday .
 
Any
 
missed
 
dose
 
to
 
be
 
taken
 
as
 
soon
 
as
 
possible.
 
2.
 
However
 
if
 
the
 
gap
 
is
 
more
 
than
 
12
 
hours,
 
to
 
skip
 
and
 
continue
 
with
 
a
 
regular
 
dosing
 
schedule.
 
Do
 
not
 
double
 
the
 
dose
 
on
 
the
 
next
 
administration
 
time.
 
 
Do
 
not
 
stop
 
taking
 
your
 
medication
 
unless
 
advised
 
to
 
do
 
so
 
by
 
your
 
prescriber .
 
 
 
 
Special
 
Considerations
 
Pregnancy
 
 
 
 
1.
 
Efavirenz
 
has
 
a
 
moderate
 
level
 
of
 
transfer
 
across
 
the
 
human
 
placenta.
 
 
2.
 
Based
 
on
 
data
 
from
 
the
 
Antiretroviral
 
Pregnancy
 
Registry ,
 
an
 
increased
 
risk
 
of
 
overall
 
teratogenic
 
effects
 
has
 
not
 
been
 
observed
 
following
 
first
 
trimester
 
exposure
 
to
 
efavirenz.
 
Neural
 
tube
 
and
 
other
 
CNS
 
defects
 
have
 
been
 
reported;
 
however ,
 
data
 
collected
 
by
 
the
 
registry
 
has
 
shown
 
that
 
the
 
risk
 
for
 
neural
 
tube
 
defects
 
after
 
efavirenz
 
exposure
 
in
 
the
 
first
 
trimester
 
 
 
 
136
 

=== PAGE 138 ===

 
are
 
not
 
greater
 
than
 
those
 
in
 
the
 
general
 
population.
 
 
3.
 
Patients
 
who
 
become
 
pregnant
 
while
 
taking
 
efavirenz
 
may
 
continue
 
if
 
viral
 
suppression
 
is
 
effective
 
and
 
the
 
regimen
 
is
 
well
 
tolerated.
 
 
4.
 
Although
 
not
 
recommended
 
by
 
the
 
manufacturer ,
 
available
 
guidelines
 
do
 
not
 
restrict
 
the
 
use
 
of
 
efavirenz
 
in
 
the
 
first
 
trimester .
 
Breastfeeding
 
 
 
 
1.
 
Efavirenz
 
is
 
present
 
in
 
breast
 
milk.
 
2.
 
It
 
is
 
recommended
 
that
 
HIV
 
infected
 
women
 
do
 
not
 
breastfeed
 
their
 
infants
 
under
 
any
 
circumstances
 
to
 
avoid
 
transmission
 
to
 
the
 
infant.
 
 
 
 
 
Elderly
 
 
 
 
1.
 
Insuf ficient
 
data
 
to
 
determine
 
whether
 
they
 
respond
 
differently
 
than
 
younger
 
patients
 
2.
 
In
 
general,
 
dose
 
selection
 
for
 
an
 
elderly
 
patient
 
should
 
be
 
cautious,
 
reflecting
 
the
 
greater
 
frequency
 
of
 
decreased
 
hepatic,
 
renal,
 
or
 
cardiac
 
function
 
and
 
of
 
concomitant
 
disease
 
or
 
other
 
therapy .
 
3.
 
May
 
cause
 
changes
 
in
 
lipid
 
profiles,
 
including
 
increased
 
LDL
 
and
 
triglycerides,
 
which
 
is
 
particularly
 
relevant
 
for
 
elderly
 
patients
 
with
 
cardiovascular
 
risk
 
factors.
 
 
 
 
Paediatric
 
 
 
 
Use
 
of
 
efavirenz
 
tablets
 
in
 
patients
 
younger
 
than
 
3
 
months
 
of
 
age
 
OR
 
less
 
than
 
3.5
 
kg
 
body
 
weight
 
is
 
not
 
recommended
 
because
 
the
 
safety ,
 
pharmacokinetics,
 
and
 
antiviral
 
activity
 
of
 
efavirenz
 
tablets
 
have
 
not
 
been
 
evaluated
 
in
 
this
 
age
 
group
 
and
 
there
 
is
 
a
 
risk
 
of
 
developing
 
HIV
 
resistance
 
if
 
efavirenz
 
tablets
 
are
 
underdosed.
 
 
 
 
Fasting
 
 
 
 
To
 
be
 
discussed
 
with
 
the
 
infectious
 
disease
 
consultant.
 
 
 
 
Others
  
 
 
 
 
1.
 
Efavirenz
 
tablets
 
are
 
not
 
recommended
 
for
 
patients
 
with
 
moderate
 
or
 
severe
 
hepatic
 
impairment
 
because
 
there
 
is
 
insuf ficient
 
data
 
to
 
determine
 
whether
 
dose
 
adjustment
 
is
 
necessary .
 
Patients
 
with
 
mild
 
hepatic
 
impairment
 
may
 
be
 
treated
 
with
 
efavirenz
 
without
 
any
 
adjustment
 
in
 
dose.
 
Because
 
of
 
the
 
extensive
 
cytochrome
 
P450-mediated
 
metabolism
 
of
 
efavirenz
 
and
 
limited
 
clinical
 
experience
 
in
 
patients
 
with
 
hepatic
 
impairment,
 
caution
 
should
 
be
 
exercised
 
in
 
administering
 
efavirenz
 
tablets
 
to
 
these
 
patients.
 
 
2.
 
EFV
 
400mg
 
daily
 
was
 
found
 
to
 
be
 
better
 
tolerated
 
than
 
standard
 
dose
 
of
 
EFV
 
600mg
 
daily
 
and
 
is
 
comparable
 
to
 
EFV
 
600mg
 
in
 
terms
 
of
 
viral
 
suppression
 
and
 
mortality .
 
 
 
3.
 
EFV
 
400mg
 
can
 
be
 
co-administered
 
with
 
rifampicin-
 
containing
 
anti-TB
 
treatment
 
 
4.
 
The
 
impact
 
of
 
renal
 
impairment
 
on
 
efavirenz
 
 
 
 
137
 

=== PAGE 139 ===

 
elimination
 
should
 
be
 
minimal.
 
Side
 
Effects
 
and
 
their
 
Management*
 
1.
 
Nervous
 
system
 
symptoms:
 
a)
 
The
 
frequently
 
reported
 
undesirable
 
effects
 
are
 
dizziness,
 
insomnia,
 
somnolence,
 
impaired
 
concentration
 
and
 
abnormal
 
dreams.
 
b)
 
Nervous
 
system
 
symptoms
 
usually
 
begin
 
during
 
the
 
first
 
one
 
or
 
two
 
days
 
of
 
therapy
 
and
 
generally
 
resolve
 
after
 
the
 
first
 
2-4
 
weeks.
 
c)
 
These
 
symptoms
 
may
 
occur
 
more
 
frequently
 
when
 
efavirenz
 
is
 
taken
 
concomitantly
 
with
 
meals
 
possibly
 
due
 
to
 
increased
 
plasma
 
levels.
 
d)
 
Dosing
 
at
 
bedtime
 
seems
 
to
 
improve
 
tolerability
 
and
 
can
 
be
 
recommended.
 
 
2.
 
Psychiatric
 
disorder
 
such
 
as
 
anxiety
 
and
 
depression
 
 
3.
 
Hepatic
 
disorder:Increased
 
liver
 
enzymes
 
(incidence
 
higher
 
with
 
hepatitis
 
B
 
and/or
 
C
 
coinfection)
 
 
4.
 
Gastrointestinal
 
disorder:Abdominal
 
pain,
 
diarrhea,
 
nausea,
 
vomiting
 
 
5.
 
Metabolic
 
disorder:Increased
 
serum
 
cholesterol,
 
increased
 
HDL,
 
increased
 
triglycerides
 
 
6.
 
Hypersensitivity
 
reactions:Rash
 
 
 
 
Storage*
 
1.
 
Do
 
not
 
store
 
above
 
30
℃
.
 
 
 
 
Others
 
1.
 
Efavirenz
 
plasma
 
concentrations
 
may
 
be
 
altered
 
by
 
substrates,
 
inhibitors,
 
or
 
inducers
 
of
 
CYP3A.
 
Important
 
to
 
screen
 
for
 
drug
 
interactions.
 
 
 
 
Before
 
ending
 
this
 
peer
 
review
 
session,
 
the
 
reviewee
 
should
 
be
 
informed
 
of
 
the
 
step(s)
 
that
 
he/
 
she
 
missed
 
out
 
in
 
order
 
to
 
ensure
 
all
 
the
 
counselling
 
points
 
are
 
being
 
covered.
 
 
Remarks:
 
 
 
 
 
Reviewed
 
by:
 
Name
 
&
 
Signature
                                                                   
Date:
 
 
 
 
 
*Mandatory
 
for
 
validation
 
/
 
peer
 
review
 
References:
 
1.
 
Panel
 
on
 
Antiretroviral
 
Therapy
 
and
 
Medical
 
Management
 
of
 
Children
 
Living
 
with
 
HIV.
 
(2024).
 
Guidelines
 
for
 
the
 
use
 
of
 
antiretroviral
 
agents
 
in
 
pediatric
 
HIV
 
infection.
 
Department
 
of
 
Health
 
and
 
Human
 
Services.
 
Retrieved
 
December
 
2,
 
2024,
 
from
 
https://clinicalinfo.hiv .gov/en/guidelines/pediatric-arv
 
2.
 
European
 
AIDS
 
Clinical
 
Society
 
(EACS).
 
(2022).
 
EACS
 
guidelines
 
(Version
 
11.1,
 
October
 
2022).
 
3.
 
Efavirenz.
 
(2024).
 
In
 
UpToDate
 
Lexi-Drugs.
 
4.
 
Panel
 
on
 
Antiretroviral
 
Guidelines
 
for
 
Adults
 
and
 
Adolescents.
 
(2024).
 
Guidelines
 
for
 
the
 
use
 
of
 
antiretroviral
 
agents
 
in
 
adults
 
and
 
adolescents
 
with
 
HIV.
 
Department
 
of
 
Health
 
and
 
Human
 
Services.
 
Retrieved
 
December
 
2,
 
2024,
 
from
 
https://clinicalinfo.hiv .gov/en/guidelines/adult-and-adolescent-arv
 
5.
 
Malaysian
 
Society
 
for
 
HIV
 
Medicine.
 
(2022).
 
Malaysian
 
consensus
 
guidelines
 
on
 
antiretroviral
 
therapy
 
2022.
 
 
138
 

=== PAGE 140 ===

 
Enoxaparin
 
Name
 
:
 
 
Unit
 
:
 
 
●
 
Please
 
tick
 
(
✔
)
 
Yes
 
for
 
correct
 
instruction
 
or
 
sequence.
 
●
 
Please
 
tick
 
(
✔
)
 
No
 
for
 
incorrect
 
instruction
 
or
 
sequence.
 
Yes
 
No
 
Remarks
 
Pharmacological
 
Group
 
Antithrombotic
 
Agent
 
-
 
Low
 
Molecular
 
Weight
 
Heparin
 
(LMWH)
 
 
 
 
Indications
 
and
 
Dosage
 
1.
 
Prophylaxis
 
of
 
venous
 
thromboembolism
 
(VTE)
 
in
 
surgical
 
patients
 
a.
 
moderate
 
risk
 
-
 
20mg
 
or
 
40mg
 
once
 
daily
 
b.
 
high
 
risk
 
-
 
40mg
 
once
 
daily
 
 
2.
 
Prophylaxis
 
of
 
venous
 
thromboembolism
 
(VTE)
 
in
 
medical
 
patients
 
a.
 
40mg
 
once
 
daily
 
 
3.
 
Treatment
 
of
 
deep
 
vein
 
thrombosis
 
(DVT)
 
and
 
pulmonary
 
embolism
 
(PE)
 
a.
 
1mg/kg
 
twice
 
daily
 
(recommended),
 
or
 
b.
 
1.5mg/kg
 
once
 
daily
 
 
4.
 
Prevention
 
of
 
extra
 
corporeal
 
thrombus
 
during
 
hemodialysis
 
a.
 
1mg/kg
 
b.
 
high
 
risk
 
of
 
hemorrhage
 
-
 
0.5
 
mg/kg
 
for
 
double
 
vascular
 
access
 
or
 
0.75
 
mg/kg
 
for
 
single
 
vascular
 
access
 
 
5.
 
Treatment
 
of
 
unstable
 
angina
 
and
 
non-Q-wave
 
myocardial
 
infarction
 
(NSTEMI)
 
a.
 
1mg/kg
 
twice
 
daily
 
 
6.
 
Treatment
 
of
 
acute
 
ST-segment
 
Elevation
 
Myocardial
 
Infarction
 
(STEMI)
 
including
 
patients
 
to
 
be
 
managed
 
medically
 
or
 
with
 
subsequent
 
Percutaneous
 
Coronary
 
Intervention
 
(PCI)
 
a.
 
single
 
IV
 
bolus
 
of
 
30
 
mg
 
plus
 
a
 
1
 
mg/kg
 
SC
 
dose,
 
followed
 
by
 
1
 
mg/kg
 
twice
 
daily
 
 
7.
 
Prevention
 
of
 
DVT
 
in
 
antenatal
 
and/or
 
postnatal
 
women
 
with
 
VTE
 
risk
 
scoring
 
of
 
3
 
or
 
more.
 
a.
 
<50
 
kg:
 
20mg
 
OD
 
b.
 
50-90
 
kg:
 
40mg
 
OD
 
c.
 
91-130
 
kg:
 
60mg
 
OD
 
d.
 
131-170
 
kg:
 
80mg
 
OD
 
e.
 
>170
 
kg:
 
0.6mg/kg/day
 
 
To
 
counsel
 
based
 
on
 
specific
 
medication’ s
 
indication
 
and
 
dosage
 
as
 
prescribed
 
as
 
doctor
 
 
 
 
Method
 
of
 
Administration*
 
1.
 
Subcutaneous
 
(SC)
 
injection
:
  
prevention
 
of
 
VTE,
 
treatment
 
of
 
DVT
 
and
 
PE,
 
treatment
 
of
 
unstable
 
angina
 
NSTEMI
 
and
 
acute
 
STEMI.
 
2.
 
IV
 
bolus
 
injection
:
 
single
 
IV
 
bolus
 
injection
 
immediately
 
followed
 
by
 
a
 
subcutaneous
 
injection,
 
for
 
treatment
 
of
 
acute
 
STEMI.
 
3.
 
Arterial
 
line
 
injection
:
 
administered
 
through
 
the
 
arterial
 
line
 
of
 
a
 
dialysis
 
circuit
 
for
 
the
 
prevention
 
of
 
thrombus
 
formation
 
in
 
the
 
extra-corporeal
 
circulation
 
during
 
haemodialysis
 
 
 
 
139
 

=== PAGE 141 ===

 
4.
 
Should
 
NOT
 
be
 
administered
 
by
 
intramuscular
 
route.
 
Subcutaneous
 
Injection
 
Technique
 
 
Preparation
 
1.
 
Prior
 
to
 
injection,
 
wash
 
your
 
hands
 
thoroughly
 
with
 
soap
 
and
 
water .
 
Towel
 
dry.
 
2.
 
Adjust
 
the
 
dose
 
to
 
be
 
injected
 
(if
 
necessary):
 
Hold
 
the
 
syringe
 
pointing
 
down
 
(to
 
keep
 
the
 
air
 
bubble
 
in
 
the
 
syringe)
 
and
 
expel
 
the
 
excess
 
medicine
 
into
 
an
 
appropriate
 
container .
 
3.
 
When
 
there
 
is
 
no
 
need
 
to
 
adjust
 
the
 
dose,
 
the
 
prefilled
 
syringe
 
is
 
ready
 
to
 
use.
 
Do
 
not
 
expel
 
any
 
air
 
from
 
the
 
syringe
 
before
 
administering
 
the
 
injection.
 
You
 
may
 
lose
 
some
 
of
 
the
 
medicine
 
if
 
you
 
do.
 
4.
 
Sit
 
in
 
a
 
comfortable
 
position
 
so
 
you
 
can
 
easily
 
see
 
the
 
area
 
of
 
their
 
stomach
 
where
 
you
 
will
 
be
 
injecting.
 
A
 
lounge
 
chair ,
 
recliner ,or
 
bed
 
(propped
 
up
 
with
 
pillows)
 
is
 
ideal.
 
Inspection
 
5.
 
Check
 
the
 
expiry
 
date
 
on
 
the
 
syringe.
 
Do
 
not
 
use
 
if
 
the
 
date
 
has
 
passed.
 
 
6.
 
Check
 
the
 
syringe
 
is
 
not
 
damaged
 
and
 
the
 
medicine
 
in
 
it
 
is
 
a
 
clear
 
solution
 
without
 
particles.
 
If
 
the
 
syringe
 
is
 
damaged
 
or
 
the
 
medicine
 
is
 
not
 
clear ,
 
use
 
another
 
syringe.
 
Injection
 
site
 
7.
 
Choose
 
an
 
area
 
on
 
the
 
right
 
or
 
left
 
side
 
of
 
your
 
stomach.
 
This
 
should
 
be
 
at
 
least
 
5
 
centimetres
 
away
 
from
 
your
 
belly
 
button
 
and
 
out
 
towards
 
your
 
sides.
 
 
8.
 
Change
 
the
 
place
 
where
 
you
 
inject
 
between
 
the
 
left
 
and
 
right
 
sides
 
of
 
your
 
stomach,
 
depending
 
on
 
the
 
area
 
you
 
were
 
last
 
injected.
 
This
 
is
 
to
 
prevent
 
scarring
 
which
 
will
 
make
 
it
 
harder
 
to
 
inject
 
the
 
area
 
and
 
also
 
affect
 
how
 
the
 
medication
 
is
 
released
 
into
 
your
 
body .
 
Avoid
 
injecting
 
on
 
scars
 
and
 
bruises.
 
 
Injection
 
technique
 
9.
 
Cleanse
 
(do
 
not
 
rub)
 
the
 
selected
 
site
 
for
 
injection
 
with
 
an
 
alcohol
 
swab.
 
 
10.
 
Remove
 
the
 
protective
 
cap
 
off
 
the
 
needle,
 
do
 
not
 
allow
 
the
 
needle
 
to
 
touch
 
anything
 
to
 
make
 
sure
 
it
 
stays
 
clean.
 
11.
 
Hold
 
the
 
syringe
 
in
 
the
 
hand
 
you
 
write
 
with
 
(like
 
a
 
pencil)
 
and
 
with
 
your
 
other
 
hand,
 
gently
 
pinch
 
the
 
cleaned
 
area
 
of
 
your
 
abdomen
 
between
 
your
 
forefinger
 
and
 
thumb
 
to
 
make
 
a
 
fold
 
in
 
the
 
skin.
 
Make
 
sure
 
you
 
hold
 
the
 
skin
 
fold
 
throughout
 
the
 
injection.
 
12.
 
Hold
 
the
 
syringe
 
with
 
the
 
needle
 
pointing
 
downwards
 
(vertically
 
at
 
90
 
degree
 
angle)
 
and
 
inject
 
a
 
full
 
length
 
needle
 
into
 
the
 
skin
 
fold.
 
Inject
 
at
 
45°
 
angle
 
for
 
needle
 
length
 
≥8
 
mm
 
or
 
if
 
the
 
patient
 
is
 
thin.
 
13.
 
Press
 
down
 
plunger
 
with
 
your
 
finger
 
(thumb).
 
Complete
 
the
 
injection
 
using
 
all
 
of
 
the
 
medicine
 
in
 
the
 
syringe.
 
Hold
 
for
 
10
 
seconds.
 
14.
 
Remove
 
the
 
needle
 
by
 
pulling
 
it
 
straight
 
out.
 
Let
 
go
 
of
 
the
 
skin
 
fold.
 
15.
 
To
 
avoid
 
bruising,
 
do
 
not
 
rub
 
the
 
injection
 
site.
 
16.
 
Drop
 
the
 
used
 
syringe
 
into
 
a
 
hard,
 
puncture-proof
 
container .
 
Close
 
the
 
container
 
lid
 
tightly
 
and
 
place
 
the
 
container
 
out
 
of
 
reach
 
of
 
children.
 
17.
 
When
 
the
 
container
 
is
 
full,
 
dispose
 
of
 
it
 
safely .
 
 
 
 
Missed
 
dose
 
management
 
If
 
you
 
miss
 
a
 
dose
 
of
 
Enoxaparin,
 
inject
 
it
 
as
 
soon
 
as
 
you
 
remember .
 
If
 
it
 
is
 
too
 
near
 
the
 
next
 
dose,
 
skip
 
the
 
missed
 
dose
 
and
 
go
 
back
 
to
 
your
 
usual
 
dosing
 
times.
 
Do
 
not
 
double
 
dose.
 
 
 
 
140
 

=== PAGE 142 ===

 
 
Do
 
not
 
stop
 
taking
 
your
 
medication
 
unless
 
advised
 
to
 
do
 
so
 
by
 
your
 
prescriber
 
Special
 
Considerations
 
Pregnancy
 
 
 
 
Safe
 
to
 
use
 
 
 
 
Breastfeeding
 
 
 
 
Safe
 
to
 
use
 
 
 
 
Elderly
 
 
 
 
1.
 
For
 
treatment
 
of
 
STEMI
 
In
 
patients
 
≥
 
75
 
years
 
of
 
age,
 
do
 
not
 
use
 
an
 
initial
 
IV
 
bolus.
 
Initiate
 
dosing
 
with
 
0.75
 
mg/kg
 
SC
 
every
 
12
 
hours
 
(maximum
 
75
 
mg
 
for
 
each
 
of
 
the
 
first
 
two
 
SC
 
doses
 
only,
 
followed
 
by
 
0.75
 
mg/kg
 
SC
 
dosing
 
for
 
the
 
remaining
 
doses).
 
2.
 
Increased
 
incidence
 
of
 
bleeding
 
with
 
doses
 
of
 
1.5mg/kg/day
 
or
 
1mg/kg
 
every
 
12
 
hours
 
(therapeutic
 
dosage
 
range).
 
 
3.
 
Careful
 
clinical
 
monitoring
 
is
 
advised,
 
particularly
  
elderly
 
<
 
45kg.
 
 
 
 
Paediatric
 
 
 
 
Dosing
 
based
 
on
 
age
 
and
 
body
 
weight
 
 
 
 
Others
 
 
 
 
1.
 
Renal
 
impairment
 
a.
 
Not
 
recommended
 
for
 
patients
 
with
 
end
 
stage
 
renal
 
disease
 
(creatinine
 
clearance
 
<
 
15ml/min)
 
due
 
to
 
limited
 
clinical
 
data
 
b.
 
Severe
 
renal
 
impairment
 
(creatinine
 
clearance
 
15-30
 
ml/min)
 
prophylactic
 
dose
 
-
 
20mg
 
once
 
daily
 
c.
 
Severe
 
renal
 
impairment
 
(creatinine
 
clearance
 
15-30
 
ml/min)
 
treatment
 
dose
 
-
 
1mg/kg
 
once
 
daily
 
2.
 
Hepatic
 
impairment
 
-
 
Use
 
with
 
caution
 
 
 
 
Side
 
effects
 
and
 
their
 
Management*
 
1.
 
May
 
develop
 
hematoma
 
at
 
the
 
injection
 
site
 
(a
 
localised
 
swelling
 
that
 
is
 
filled
 
with
 
blood).
 
2.
 
Symptoms
 
of
 
bleeding
 
such
 
as
 
bruises
 
with
 
unknown
 
cause,
 
blood
 
in
 
urine/dark
 
coloured
 
urine,
 
black
 
stools,
 
gum
 
bleeding
 
or
 
heavy
 
menstrual
 
bleeding
 
3.
 
Seek
 
medical
 
attention
 
if
 
any
 
sign
 
or
 
symptom
 
of
 
bleeding
 
occurs
 
 
 
 
Storage*
 
Do
 
not
 
store
 
above
 
30°C,
 
do
 
not
 
freeze.
 
 
 
 
Others
 
1.
 
Enoxaparin
 
is
 
derived
 
from
 
animal
 
sources
 
(mainly
 
porcine).
 
Please
 
confirm
 
the
 
source
 
and
 
disclose
 
it
 
to
 
the
 
patient,
 
if
 
needed.
 
2.
 
Inform
 
healthcare
 
professionals
 
(dentist,
 
surgeon,
 
doctor ,
 
pharmacist)
 
if
 
the
 
patient
 
is
 
planning
 
to
 
get
 
a
 
tooth
 
extraction,
 
or
 
when
 
consulting
 
for
 
medication,
 
supplement
 
or
 
herbal
 
remedies
 
3.
 
Monitoring
 
parameters
 
a.
 
Full
 
blood
 
count
 
b.
 
Renal
 
function
 
 
 
 
141
 

=== PAGE 143 ===

 
Before
 
ending
 
this
 
peer
 
review
 
session,
 
the
 
reviewee
 
should
 
be
 
informed
 
of
 
the
 
step(s)
 
that
 
he/
 
she
 
missed
 
out
 
in
 
order
 
to
 
ensure
 
all
 
the
 
counselling
 
points
 
are
 
being
 
covered.
 
 
Remarks:
 
 
 
 
 
Reviewed
 
by:
 
Name
 
&
 
Signature
                                                                   
Date:
 
 
 
 
 
*Mandatory
 
for
 
validation
 
/
 
peer
 
review
 
References:
 
1.
 
Aamani
 
Jupalli; Arshad
 
Muhammad
 
Iqbal.
 
Enoxaparin.
 
NIH.
 
Last
 
Update: August
 
28,
 
2023.
 
2.
 
Formulari
 
Ubat
 
KKM.
 
(2025).
 
Accessed
 
on
 
January
 
20,
 
2025.
 
3.
 
Medispec
 
M
 
Sdn
 
Bhd
 
(2021)
 
Product
 
information
 
leaflet:
 
Inhixa.
 
Retrieved
 
from
 
Quest
 
3+
 
Product
 
Search
 
on
 
January
 
20,
 
2025.
 
4.
 
UpToDate.
 
(2024)
 
UpToDate
 
(Version
 
3.70.4)
 
[Mobile
 
App]
 
Mobile
 
Clinical
 
Decision
 
Support
 
App
 
|
 
UpToDate
 
|
 
Wolters
 
KluwerW olters
 
Kluwer
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
142
 

=== PAGE 144 ===

 
Entecavir
 
 
Name
 
:
 
 
Unit
 
:
 
 
●
 
Please
 
tick
 
(
✔
)
 
Yes
 
for
 
correct
 
instruction.
 
●
 
Please
 
tick
 
(
✔
)
 
No
 
for
 
incorrect
 
instruction.
 
Yes
 
No
 
Remarks
 
Pharmacological
 
Group
 
Nucleoside
 
reverse
 
transcriptase
 
inhibitors
 
 
 
 
Indications
 
and
 
Dosage
 
First
 
line
 
treatment
 
of
 
Chronic
 
Hepatitis
 
B
 
in
 
patients
 
who
 
satisfy
 
the
 
criteria
 
for
 
treatment
 
and
 
require
 
long-term
 
therapy
 
or
 
have
 
a
 
very
 
high
 
baseline
 
viral
 
load
 
 
Dosage:
 
0.5-1mg
 
once
 
daily.
 
 
Or
 
To
 
counsel
 
based
 
on
 
specific
 
medication’ s
 
indication
 
and
 
dosage
 
as
 
prescribed
 
by
 
the
 
doctor
 
 
 
 
Method
 
of
 
Administration*
 
●
 
Should
 
be
 
taken
 
orally
 
on
 
an
 
EMPTY
 
STOMACH
 
(2
 
hours
 
before
 
or
 
after
 
a
 
meal)
 
●
 
Must
 
be
 
taken
 
at
 
the
 
same
 
time
 
every
 
day
 
as
 
instructed
 
for
 
it
 
to
 
be
 
effective.
 
●
 
Continue
 
taking
 
this
 
medicine
 
as
 
prescribed,
 
even
 
if
 
you
 
feel
 
better .
 
This
 
medication
 
does
 
not
 
cure
 
hepatitis
 
B;
 
it
 
helps
 
to
 
suppress
 
the
 
virus
 
and
 
prevent
 
relapse.
 
●
 
DO
 
NOT
 
RUN
 
OUT
 
OF
 
MEDICA TION
.
 
Reﬁll
 
the
 
prescription
 
befor e
 
it
 
ﬁnishes.
 
 
Missed
 
dose
 
management
 
●
 
Take
 
the
 
missed
 
dose
 
as
 
soon
 
as
 
you
 
remember ,
 
on
 
an
 
empty
 
stomach
 
●
 
If
 
the
 
missed
 
dose
 
is
 
close
 
to
 
your
 
next
 
dose,
 
skip
 
the
 
missed
 
dose
 
and
 
take
 
the
 
next
 
dose
 
at
 
the
 
usual
 
time.
 
 
●
 
DO
 
NOT
 
take
 
two
 
doses
 
at
 
the
 
same
 
time
 
to
 
make
 
up
 
for
 
the
 
missed
 
dose.
 
 
Do
 
not
 
stop
 
taking
 
your
 
medication
 
unless
 
advised
 
to
 
do
 
so
 
by
 
your
 
prescriber
 
 
 
 
 
 
 
Special
 
Considerations
 
Pregnancy
 
 
 
 
●
 
Agents
 
other
 
than
 
entecavir
 
are
 
recommended
 
when
 
hepatitis
 
B
 
treatment
 
is
 
needed
 
in
 
pregnant
 
patients.
 
 
●
 
Patients
 
who
 
become
 
pregnant
 
while
 
taking
 
entecavir
 
should
 
be
 
switched
 
to
 
the
 
preferred
 
agent.
 
 
 
 
Breastfeeding
 
 
 
 
●
 
It
 
is
 
not
 
known
 
if
 
entecavir
 
is
 
present
 
in
 
breast
 
milk.
 
The
 
effect
 
of
 
this
 
exposure
 
on
 
a
 
nursing
 
infant
 
is
 
unknown.
 
 
●
 
Patients
 
requiring
 
antivirals
 
for
 
hepatitis
 
B
 
may
 
breastfeed
 
if
 
the
 
infant
 
received
 
immunoprophylaxis
 
(hepatitis
 
B
 
immune
 
globulin
 
at
 
birth
 
&
 
hepatitis
 
B
 
vaccine
 
series
 
soon
 
after
 
birth)
 
 
 
 
Elderly
 
 
 
 
No
 
significant
 
precaution
 
for
 
elderly .
 
 
 
 
Paediatric
 
 
 
 
143
 

=== PAGE 145 ===

 
For
 
children
 
≥
 
2
 
years
 
with
 
weighing
 
≥10kg
 
 
 
 
Fasting
 
 
 
 
To
 
refer
 
to
 
the
 
latest
 
advisory
 
by
 
religious
 
authority
 
 
 
 
Renal
 
Impairment
 
 
 
 
1.
 
CrCl
 
>
 
50
 
mL/min:
 
No
 
dosage
 
adjustment
 
required
 
2.
 
CrCl
 
30
 
-
 
49
 
mL/min:
 
administer
 
the
 
usual
 
indication-specific
 
dose
 
every
 
48
 
hours
 
3.
 
CrCl
 
10
 
-
 
29
 
mL/min:
 
administer
 
the
 
usual
 
indication-specific
 
dose
 
every
 
72
 
hours
 
4.
 
CrCl
 
<10
 
mL/min,
 
hemodialysis,
 
or
 
CAPD:
 
administer
 
the
 
usual
 
indication-specific
 
dose
 
every
 
7
 
days.
 
5.
 
When
 
a
 
scheduled
 
dose
 
falls
 
on
 
hemodialysis
 
day,
 
entecavir
 
should
 
be
 
taken
 
after
 
hemodialysis.
 
 
 
 
 
Side
 
Effects
 
and
 
their
 
Management*
 
1.
 
Side
 
effects
 
may
 
include
 
nausea,
 
dizziness,
 
headache
 
and
 
fatigue.
 
2.
 
Advise
 
patients
 
to
 
report
 
symptoms
 
of
 
lactic
 
acidosis
 
(nausea,
 
vomiting,
 
abdominal
 
pain,
 
tachypnea)
 
and
 
liver
 
problems
 
(dark
 
urine,
 
light-coloured
 
stools,
 
or
 
yellow
 
skin
 
or
 
eyes)
 
 
 
 
Storage*
 
1.
 
Store
 
below
 
30
°
C.
 
 
2.
 
Keep
 
medication
 
in
 
its
 
original
 
container ,
 
tightly
 
sealed
 
to
 
protect
 
from
 
moisture
 
and
 
light.
 
 
3.
 
Keep
 
out
 
of
 
reach
 
and
 
sight
 
of
 
children.
 
 
 
 
Others
 
1.
 
Advise
 
patients
 
against
 
sudden
 
discontinuation
 
of
 
the
 
drug
 
due
 
to
 
potential
 
exacerbation
 
of
 
hepatitis
 
B.
 
2.
 
Advise
 
patients
 
to
 
practise
 
safe
 
sex
 
and
 
ensure
 
to
 
take
 
proper
 
precautions
 
to
 
avoid
 
transmission.
 
This
 
drug
 
does
 
not
 
prevent
 
disease
 
transmission.
 
 
 
 
Before
 
ending
 
this
 
peer
 
review
 
session,
 
the
 
reviewee
 
should
 
be
 
informed
 
of
 
the
 
step(s)
 
that
 
he/
 
she
 
missed
 
out
 
in
 
order
 
to
 
ensure
 
all
 
the
 
counselling
 
points
 
are
 
being
 
covered.
 
Remarks:
 
 
 
Reviewed
 
by:
 
Name
 
&
 
Signature
                                                                   
Date:
 
 
*Mandatory
 
for
 
validation
 
/
 
peer
 
review
 
 
References:
 
 
1.
 
Formulari
 
Ubat
 
KKM.
 
(2025,
 
January
 
1).
 
Accessed
 
on
 
January
 
21,
 
2025.
 
2.
 
Entecavir .
 
(2024).
 
MimsGateway .
 
Retrieved
 
January
 
21,
 
2025,
 
from
 
https://online1.mimsgateway .com.my/
 
3.
 
Y.S.P.
 
Industries
 
(M)
 
Sdn.
 
Bhd.
 
(2024).
 
Product
 
information
 
leaflet:
 
Hebecavir .
 
Retrieved
 
from
 
Quest
 
3+
 
Product
 
Search
 
on
 
January
 
21,
 
2025.
 
4.
 
European
 
Association
 
for
 
the
 
Study
 
of
 
the
 
Liver
 
(2017).
 
EASL
 
2017
 
Clinical
 
Practice
 
Guidelines
 
on
 
the
 
management
 
of
 
hepatitis
 
B
 
virus
 
infection.
 
Journal
 
of
 
Hepatology ,
 
67(2),
 
370–398.
 
https://doi.org/10.1016/j.jhep.2017.03.021
 
5.
 
Terrault,
 
N.
 
A.,
 
Lok,
 
A.
 
S.
 
F.,
 
McMahon,
 
B.
 
J.,
 
Chang,
 
K.
 
M.,
 
Hwang,
 
J.
 
P.,
 
Jonas,
 
M.
 
M.,
 
Brown,
 
R.
 
S.,
 
Jr,
 
Bzowej,
 
N.
 
H.,
 
&
 
Wong,
 
J.
 
B.
 
(2018).
 
Update
 
on
 
prevention,
 
diagnosis,
 
and
 
treatment
 
of
 
chronic
 
hepatitis
 
B:
 
AASLD
 
2018
 
hepatitis
 
B
 
guidance.
 
Hepatology
 
(Baltimore,
 
Md.),
 
67(4),
 
1560–1599.
 
https://doi.org/10.1002/hep.29800
 
6.
 
Shanks,
 
A.
 
(2015).
 
Drugs
 
in
 
Pregnancy
 
and
 
Lactation:
 
A
 
Reference
 
Guide
 
to
 
Fetal
 
and
 
Neonatal
 
Risk,
 
10th
 
edition.
 
American
 
Journal
 
of
 
Health-System
 
Pharmacy ,
 
72(14),
 
1239–1240.
 
https://doi.org/10.1093/ajhp/72.14.1239
 
144
 

=== PAGE 146 ===

 
Erythropoietin
 
Human
 
Recombinant
 
(Alfa/Beta
)
 
 
Name
 
:
 
 
Unit
 
:
 
 
●
 
Please
 
tick
 
(
✔
)
 
Yes
 
for
 
correct
 
instruction.
 
●
 
Please
 
tick
 
(
✔
)
 
No
 
for
 
incorrect
 
instruction.
 
Yes
 
No
 
Remarks
 
Pharmacological
 
Group
 
Other
 
antianemic
 
preparations
 
Erythropoietin
 
 
 
Product
 
available:
 
Erythropoietin
 
alfa
 
-
 
Erysaa
 
®,
 
Eprex
 
®,
 
Binocrit
 
®
 
 
Erythropoietin
 
beta
 
-
 
Recormon
 
®
 
 
 
 
Indications
 
and
 
Dosage
 
1.
 
Treatment
 
of
 
anaemia
 
associated
 
with
 
chronic
 
renal
 
failure.
 
Dialysis
 
patients
 
who
 
have
 
haemoglobin
 
less
 
than
 
10
 
g/dL
 
or
 
are
 
exhibiting
 
symptoms
 
of
 
anaemia
 
although
 
haemoglobin
 
more
 
than
 
10
 
g/dL
 
and
 
pre-transplant
 
cases.
 
a.
 
Initiation
:
 
50
 
IU/kg
 
three
 
times
 
per
 
week,
 
with
 
dose
 
adjustments
 
should
 
be
 
made
 
in
 
increments
 
of
 
25
 
IU/kg
 
three
 
times
 
per
 
week
 
at
 
intervals
 
of
 
at
 
least
 
4
 
weeks.
 
b.
 
Maintenance
:
 
Total
 
weekly
 
dose
 
is
 
between
 
75
 
to
 
300
 
IU/kg.
 
 
2.
 
Anaemia
 
in
 
cancer
 
(non-myeloid
 
malignancies)
 
with
 
concomitant
 
chemotherapy
 
 
a.
 
EPO
 
Alfa:
 
Initiation:
 
150
 
IU/kg
 
three
 
times
 
weekly
 
or
 
40,000
 
IU
 
once
 
weekly .
 
May
 
increase
 
to
 
60,000
 
IU
 
once
 
weekly
 
units
 
after
 
4
 
weeks
 
if
 
necessary .
 
b.
 
EPO
 
Beta:
 
 
Initiation::
 
450
 
IU/kg
 
once
 
weekly
 
or
 
30,000
 
IU
 
once
 
weekly .
 
Max:
 
60,000
 
IU/week.
 
 
Dosing
 
is
 
according
 
to
 
product
 
insert
.
 
 
To
 
counsel
 
based
 
on
 
specific
 
medication’ s
 
indication
 
and
 
dosage
 
as
 
prescribed
 
by
 
the
 
doctor
 
 
 
 
Method
 
of
 
Administration*
 
Route
 
of
 
Administration:
 
Intravenous
 
(IV)
 
or
 
Subcutaneous
 
(SC):
 
 
Erythropoietin
 
alfa
 
(Eprex®,
 
Binocrit
 
®)
 
and
 
Erythropoietin
 
beta
 
(Recormon
 
®)
 
 
Intravenous
 
(IV)
 
ONLY
 
for
 
Erythropoietin
 
alfa
 
(Erysaa
 
®)
 
 
Site
 
of
 
administration
 
for
 
SC:
 
Lower
 
part
 
of
 
abdomen,
 
thigh
 
or
 
arm
 
 
Injection
 
technique
 
for
 
SC
 
(for
 
self-administered):
 
1.
 
Take
 
one
 
syringe
 
out
 
of
 
the
 
package
 
and
 
check
 
that
 
the
 
solution
 
is
 
clear ,
 
colourless
 
and
 
free
 
from
 
visible
 
particles
.
 
2.
 
Allow
 
the
 
syringe
 
to
 
reach
 
room
 
temperature.
 
3.
 
Wash
 
your
 
hands.
 
4.
 
Remove
 
the
 
rubber
 
cap
 
from
 
the
 
syringe.
 
5.
 
Remove
 
the
 
needle
 
from
 
the
 
pack,
 
fix
 
it
 
on
 
the
 
syringe
 
and
 
remove
 
the
 
protective
 
cap
 
from
 
the
 
needle.
 
6.
 
Expel
 
air
 
from
 
the
 
syringe
 
and
 
needle
 
by
 
holding
 
the
 
syringe
 
vertically
 
and
 
gently
 
pressing
 
the
 
plunger
 
upwards.
 
7.
 
Clean
 
the
 
skin
 
at
 
the
 
site
 
of
 
injection
 
using
 
an
 
alcohol
 
swab.
 
8.
 
Form
 
a
 
skin
 
fold
 
by
 
pinching
 
the
 
skin
 
between
 
thumb
 
and
 
forefinger .
 
 
 
 
145
 

=== PAGE 147 ===

 
9.
 
Fully
 
insert
 
the
 
needle
 
45
0
 
or
 
90
0
 
angle
 
into
 
the
 
skin
 
fold
 
with
 
a
 
quick,
 
firm
 
action.
 
10.
 
Inject
 
erythropoietin
 
solution.
 
11.
 
Withdraw
 
the
 
needle
 
quickly
 
and
 
apply
 
pressure
 
over
 
the
 
injection
 
site
 
with
 
a
 
dry,
 
sterile
 
pad
.
 
12.
 
Dispose
 
the
 
empty
 
syringe
 
in
 
a
 
special
 
waste
 
container
 
13.
 
Tear
 
off
 
the
 
medication
 
label
 
on
 
the
 
syringe
 
and
 
stick
 
into
 
the
 
booklet/diary
 
(e.g.,
 
CAPD
 
book)
 
after
 
the
 
injection
 
for
 
the
 
administration
 
record,
 
if
 
available.
 
 
Consideration:
 
1.
 
Blood
 
pressure
 
(BP)
 
cutof f
 
for
 
administering
 
Erythropoetin
 
Stimulating
 
Agent
 
(ESA)
 
is
 
individualised.
 
Generally ,
 
ESA
 
is
 
not
 
given
 
if
 
BP
 
exceeds
 
160/100
 
mmHg.
 
Patients
 
need
 
to
 
be
 
informed
 
about
 
their
 
specific
 
BP
 
cutof f
 
whether
 
to
 
continue
 
or
 
hold
 
ESA
 
at
 
home.
 
2.
 
Site
 
of
 
SC
 
injection
 
should
 
be
 
rotated
 
 
Missed
 
dose
 
management:
 
The
 
missed
 
dose
 
should
 
be
 
administered
 
as
 
soon
 
as
 
possible
 
and
 
administration
 
of
 
Erythropoietin
 
is
 
to
 
be
 
restarted
 
at
 
the
 
prescribed
 
dosing
 
frequency .
 
 
Do
 
not
 
stop
 
taking
 
your
 
medication
 
unless
 
advised
 
to
 
do
 
so
 
by
 
your
 
prescriber
 
Special
 
Considerations
 
Pregnancy
 
 
 
 
Safety
 
information
 
is
 
based
 
on
 
post-marketing
 
experience.
 
Consult
 
the
 
prescriber
 
if
 
pregnant.
 
 
 
 
Breastfeeding
 
 
 
 
Unknown
 
risk
 
to
 
the
 
infant.
 
The
 
decision
 
to
 
continue
 
should
 
be
 
based
 
on
 
the
 
benefits
 
outweigh
 
the
 
risks.
 
 
 
 
Elderly
 
 
 
 
No
 
dosage
 
adjustment
 
provided
 
in
 
the
 
manufacturer ’s
 
labelling.
 
 
 
 
Paediatric
 
 
 
 
Safe
 
to
 
be
 
used
 
in
 
children.
 
The
 
younger
 
the
 
patients,
 
the
 
higher
 
erythropoietin
 
doses
 
required.
 
However ,
 
the
 
recommended
 
dosing
 
schedule
 
should
 
be
 
individualized.
 
 
 
 
Fasting
 
 
 
 
Administer
 
as
 
usual
 
 
 
 
Others
  
 
 
 
 
No
 
dosage
 
adjustment
 
was
 
provided
 
in
 
the
 
manufacturer ’s
 
labelling.
 
 
 
 
Side
 
Effects
 
and
 
their
 
management*
 
1.
 
Common
 
side
 
effects,
 
generally
 
not
 
serious:
 
headache,
 
increased
 
blood
 
pressure,
 
irritation
 
or
 
pain
 
at
 
the
 
injection
 
site.
 
 
Note:
 
●
 
To
 
advise
 
on
 
the
 
importance
 
of
 
compliance
 
with
 
antihypertensive
 
medications
 
and
 
dietary
 
restrictions
 
for
 
BP
 
control.
 
●
 
If
 
side
 
effects
 
persist,
 
please
 
consult
 
a
 
healthcare
 
professional
 
 
2.
 
Uncommon/rare:
 
Pure
 
red
 
cell
 
aplasia
 
(PRCA).
 
 
 
 
146
 

=== PAGE 148 ===

 
Storage*
 
1.
 
Transport
 
of
 
ESA
 
is
 
only
 
allowed
 
in
 
cool
 
box
 
with
 
ice
 
packs.
 
2.
 
Preferably
 
to
 
return
 
home
 
immediately
 
after
 
getting
 
ESA
 
from
 
the
 
pharmacy
 
to
 
facilitate
 
fast
 
storage.
 
3.
 
ESA
 
is
 
very
 
sensitive
 
to
 
light
 
and
 
temperature.
 
4.
 
Protect
 
ESA
 
from
 
light
 
5.
 
Store
 
ESA
 
in
 
the
 
refrigerator ,
 
do
 
not
 
freeze.
 
Keep
 
at
 
2-8°C.
 
 
6.
 
Avoid
 
fridge
 
doors,
 
and
 
vegetable
 
compartments.
 
Ensure
 
there
 
is
 
proper
 
air
 
circulation
 
around
 
your
 
ESA.
 
7.
 
If
 
you're
 
travelling,
 
try
 
to
 
keep
 
your
 
medication
 
in
 
a
 
cooler
 
with
 
ice
 
packs,
 
and
 
avoid
 
storing
 
it
 
in
 
any
 
place
 
where
 
it
 
might
 
get
 
too
 
hot,
 
like
 
in
 
a
 
car.
 
 
Do
 
not
 
take
 
out
 
the
 
ESA
 
from
 
the
 
fridge
 
unless
 
it
 
is
 
time
 
for
 
use.
 
If
 
the
 
ESA
 
is
 
accidentally
 
left
 
outside
 
the
 
fridge,
 
it
 
should
 
be
 
used
 
as
 
soon
 
as
 
possible
 
to
 
prevent
 
damage.
 
Below
 
is
 
the
 
expiry
 
period
 
following
 
a
 
break
 
in
 
the
 
cold
 
chain:
 
Product
 
Expiry
 
period
 
after
 
break
 
of
 
cold
 
chain
 
Recormon
 
 
3
 
Days
 
Erysaa
 
7
 
days
 
Eprex
 
7
 
days
 
Binocrit
 
3
 
Days
 
 
Handling
 
of
 
disposal:
 
●
 
Needles
 
and
 
syringes
 
should
 
never
 
be
 
reused.
  
 
●
 
Place
 
all
 
used
 
needles
 
and
 
syringes
 
into
 
a
 
sharps
 
container
 
(puncture-proof
 
disposable
 
container).
 
●
 
Keep
 
the
 
sharp
 
container
 
out
 
of
 
the
 
reach
 
of
 
children.
  
 
●
 
Avoid
 
disposing
 
of
 
used
 
sharps
 
containers
 
in
 
household
 
waste.
 
●
 
Dispose
 
of
 
full
 
sharps
 
containers
 
according
 
to
 
local
 
regulations
 
or
 
at
 
designated
 
facilities.
 
 
 
 
Others
 
Precautions:
 
1.
 
Hypertension.
 
2.
 
Cardiovascular
 
disease
 
including
 
recent
 
myocardia
 
infarction
 
(MI)
 
and
 
venous
 
thromboembolism
 
3.
 
Malignant
 
disease
 
4.
 
Patients
 
with
 
epilepsy ,
 
history
 
of
 
seizures,
 
or
 
medical
 
conditions
 
associated
 
with
 
a
 
predisposition
 
to
 
seizure
 
activity
 
such
 
as
 
CNS
 
infections
 
and
 
brain
 
metastases.
 
 
Monitoring
 
parameters:
 
1.
 
Blood
 
pressure
 
particularly
 
at
 
the
 
start
 
of
 
therapy
 
2.
 
Monitor
 
haemoglobin
 
at
 
least
 
monthly
 
during
 
the
 
initiation
 
phase.
 
 
3.
 
Monitor
 
iron
 
status
 
at
 
least
 
every
 
3
 
months
 
during
 
ESA
 
therapy .
 
 
Contraindications
 
:
 
1.
 
Known
 
hypersensitivity
 
to
 
the
 
active
 
substance
 
or
 
to
 
any
 
of
 
the
 
excipients
 
2.
 
Uncontrolled
 
hypertension.
 
3.
 
Pure
 
red
 
cell
 
aplasia
 
(PRCA)
 
that
 
begins
 
after
 
treatment
 
with
 
other
 
erythropoietin
 
stimulating
 
agents
 
(ESAs).
 
 
 
 
 
 
147
 

=== PAGE 149 ===

 
Before
 
ending
 
this
 
peer
 
review
 
session,
 
the
 
reviewee
 
should
 
be
 
informed
 
of
 
the
 
step(s)
 
that
 
he/
 
she
 
missed
 
out
 
in
 
order
 
to
 
ensure
 
all
 
the
 
counselling
 
points
 
are
 
being
 
covered.
 
Remarks:
 
 
 
 
Reviewed
 
by:
 
Name
 
&
 
Signature
                                                                   
Date:
 
 
 
 
 
*Mandatory
 
for
 
validation
 
/
 
peer
 
review
 
 
References:
 
 
1.
 
Formulari
 
Ubat
 
KKM.
 
(2025,
 
January
 
1).
 
Accessed
 
on
 
January
 
1,
 
2025.
 
 
2.
 
Kidney
 
Disease:
 
Improving
 
Global
 
Outcomes
 
(KDIGO)
 
Anemia
 
Work
 
Group.
 
(2012).
 
KDIGO
 
clinical
 
practice
 
guideline
 
for
 
anemia
 
in
 
chronic
 
kidney
 
disease.
 
Kidney
 
International
 
Supplements,
 
2(4),
 
279–335.
 
3.
 
Roche
 
(2022).
 
Product
 
information
 
leaflet:
 
Recormon®
.
 
Retrieved
 
from
 
Quest
 
3+
 
Product
 
Search
 
on
 
January
 
1,
 
2025.
 
4.
 
Duopharma
 
(2018).
 
Product
 
information
 
leaflet:
 
Erysaa®
.
 
Retrieved
 
from
 
Quest
 
3+
 
Product
 
Search
 
on
 
January
 
1,
 
2025.
 
5.
 
Johnson
 
&
 
Johnson
 
(2022).
 
Product
 
information
 
leaflet:
 
Eprex®
.
 
Retrieved
 
from
 
Quest
 
3+
 
Product
 
Search
 
on
 
January
 
1,
 
2025.
 
6.
 
Sandoz
 
GMBH
 
(2024).
 
Product
 
information
 
leaflet:
 
Binocrit®
.
 
Retrieved
 
from
 
Quest
 
3+
 
Product
 
Search
 
on
 
January
 
1,
 
2025.
 
7.
 
Bahagian
 
Perkhidmatan
 
Farmasi,
 
Kementerian
 
Kesihatan
 
Malaysia.
 
(2016).
 
Garis
 
panduan
 
pemantauan
 
keselamatan
 
produk
 
erythropoietin
 
stimulating
 
agents
 
(ESAs)
 
dan
 
pelaporan
 
kesan
 
advers
 
pure
 
red
 
cell
 
aplasia
 
(PRCA).
 
 
 
 
 
 
 
 
 
 
 
 
 
148
 

=== PAGE 150 ===

 
Everolimus
 
Name
 
: 
 
Unit
 
: 
 
●
 
Please
 
tick
 
(
✔
)
 
Yes
 
for
 
correct
 
instruction.
 
●
 
Please
 
tick
 
(
✔
)
 
No
 
for
 
incorrect
 
instruction.
 
Yes
 
N
o
 
Remark
s
 
Pharmacological
 
Group
 
Mammalian
 
target
 
of
 
rapamycin
 
(mTOR)
 
kinase
 
inhibitors
 
Everolimus
 
 
 
 
Indications
 
and
 
Dosage
 
1.
 
Prophylaxis
 
of
 
organ
 
rejection
 
in
 
adult
 
patients
 
at
 
low
 
to
 
moderate
 
immunological
 
risk
 
receiving
 
an
 
allogeneic
 
renal
 
or
 
cardiac
 
transplant
 
in
 
combination
 
with
 
ciclosporin
 
for
 
microemulsion
 
and
 
corticosteroids.
 
 
Product
 
available
 
-
 
Certican
 
®:
 
 
Tablet
 
dosage
 
form
 
available
 
in
 
two
 
strength:
 
0.25mg
 
and
 
0.75mg
 
:
 
 
             
Dose
 
is
 
adjusted
 
based
 
on
 
therapeutic
 
drug
 
monitoring.
 
 
 
To
 
counsel
 
based
 
on
 
specific
 
medication’ s
 
indication
 
and
 
dosage
 
as
 
prescribed
 
by
 
the
 
doctor
 
 
 
 
Method
 
of
 
Administration*
 
To
 
be
 
swallowed
 
whole
 
twice
 
daily,
 
12
 
hours
 
apart. 
 
 
Do
 
not
 
chew
 
or
 
crush
 
the
 
tablets.
 
 
Must
 
be
 
taken
 
at
 
the
 
same
 
time
 
every
 
day
 
either
 
with
 
or
 
without
 
food,
 
but
 
advisable
 
to
 
be
 
taken
 
on
 
empty
 
stomach.
 
 
To
 
ensure
 
the
 
accuracy
 
of
 
everolimus
 
levels,
 
it
 
is
 
important
 
to
 
take
 
the
 
everolimus
 
after
 
the
 
blood
 
is
 
drawn
 
for
 
therapeutic
 
drug
 
monitoring.
 
 
Missed
 
dose
 
management:
 
1.
 
If
 
the
 
everolimus
 
dose
 
is
 
missed,
 
patients
 
should
 
take
 
it
 
as
 
soon
 
as
 
possible
 
within
 
six
 
hours
 
after
 
regular
 
dose.
 
2.
 
If
 
it
 
is
 
more
 
than
 
6
 
hours,
 
skip
 
the
 
missed
 
dose
 
and
 
return
 
to
 
normal
 
dosing
 
schedule.
 
 
3.
 
Do
 
not
 
double
 
a
 
dose
 
under
 
any
 
circumstances.
 
 
Do
 
not
 
stop
 
taking
 
your
 
medication
 
unless
 
advised
 
to
 
do
 
so
 
by
 
your
 
prescriber
 
 
 
 
Special
 
Considerations
 
Pregnancy
 
 
 
 
1.
 
The
 
potential
 
risk
 
to
 
humans
 
is
 
unknown.
 
There
 
is
 
no
 
adequate
 
data
 
from
 
the
 
use
 
of
 
Certican
 
in
 
pregnant
 
women.
 
 
2.
 
Everolimus
 
should
 
not
 
be
 
given
 
to
 
pregnant
 
women
 
unless
 
the
 
potential
 
benefit
 
outweighs
 
the
 
potential
 
risk
 
to
 
the
 
fetus
 
 
3.
 
To
 
inform
 
specialist
 
if
 
you
 
want
 
to
 
get
 
pregnant
 
/
 
pregnant
 
 
 
 
 
Breastfeeding
 
 
 
 
1.
 
Everolimus
 
is
 
excreted
 
into
 
breast
 
milk,
 
thus
 
breastfeeding
 
is
 
not
 
recommended
 
 
 
 
Elderly
 
 
 
 
149
 

=== PAGE 151 ===

 
1.
 
Dose
 
selection
 
for
 
an
 
elderly
 
patient
 
should
 
be
 
cautious,
 
usually
 
starting
 
at
 
the
 
low
 
end
 
of
 
the
 
dosing
 
range.
 
 
 
 
Paediatric
 
 
 
 
1.
 
There
 
are
 
limited
 
data
 
on
 
the
 
use
 
of
 
Everolimus
 
in
 
children
 
and
 
adolescents
 
however ,
 
Everolimus
 
can
 
be
 
used
 
in
 
renal
 
transplant
 
pediatric
 
patients
 
 
 
 
Fasting
 
 
 
 
1.
 
Transplant
 
patients
 
should
 
consult
 
with
 
transplant
 
specialists
 
to
 
assess
 
their
 
conditions
 
and
 
determine
 
whether
 
fasting
 
is
 
safe
 
for
 
them.
 
2.
 
If
 
fasting
 
is
 
permissible,tacrolimus
 
can
 
be
 
taken
 
on
 
an
 
empty
 
stomach
 
during
 
Sahur
 
and
 
Iftar.
 
It's
 
important
 
to
 
stay
 
hydrated
 
throughout
 
the
 
night.
 
If
 
you
 
miss
 
a
 
dose
 
during
 
Sahur ,
 
you
 
must
 
break
 
your
 
fast
 
that
 
day
 
to
 
take
 
the
 
missed
 
dose.
 
 
 
 
Others
 
 
 
 
 
 
1.
 
Mild
 
hepatic
 
impairment
 
(Child-Pugh
 
Class
 
A),
 
reduce
 
the
 
dose
 
to
 
2/3
 
of
 
the
 
normal
 
dose.
 
 
2.
 
Moderate
 
hepatic
 
impairment
 
(Child-Pugh
 
B)
 
reduce
 
the
 
dose
 
to
 
½
 
of
 
the
 
normal
 
dose.
 
3.
 
Severe
 
hepatic
 
impairment
 
(Child-Pugh
 
C)
 
reduce
 
the
 
dose
 
to
 
1/3
 
of
 
the
 
normal
 
dose
 
 
Further
 
dose
 
titration
 
should
 
be
 
based
 
on
 
therapeutic
 
drug
 
monitoring
 
 
 
 
Side
 
Effects
 
and
 
their
 
Management*
 
1.
 
Metabolic
 
abnormalities:
 
Diabetes
 
mellitus,
 
Hyperlipidaemia,
 
hypokalemia
 
2.
 
Delayed
 
wound
 
healing
 
3.
 
Increased
 
risk
 
of
 
infection.
 
Seek
 
healthcare
 
advice
 
if
 
have
 
any
 
symptoms
 
of
 
infections
 
such
 
as
 
fever ,
 
chills,
 
or flu-like
 
symptoms. 
 
4.
 
GI
 
disorder:
 
Nausea,
 
diarrhea,
 
vomiting,
 
dry
 
mouth,
 
mouth
 
ulcer ,
 
mucositis
 
5.
 
Hypertension
 
6.
 
Nephrotoxicity
 
 
 
 
Storage*
 
1.
 
Store
 
at
 
room
 
temperature.
 
 
2.
 
Store
 
in
 
the
 
original
 
package
 
in
 
order
 
to
 
protect
 
from
 
light
 
and
 
moisture.
 
3.
 
The
 
tablet
 
should
 
remain
 
in
 
the
 
blister
 
when
 
kept
 
in
 
the
 
pillbox.
 
 
 
 
Others
 
1.
 
Avoid
 
live-attenuated
 
vaccination. 
 
2.
 
Concomitant
 
use
 
with
 
strong
 
CYP3A4
 
inhibitors
 
such
 
as
 
ritonavir ,
 
ketoconazole,
 
erythromycin,
 
verapamil,
 
diltiazem
 
may
 
increase
 
everolimus
 
level.
 
3.
 
Concomitant
 
use
 
with
 
strong
 
CYP3A4
 
inducers
 
such
 
as
 
rifampicin,
 
phenytoin,
 
carbamazepine
 
may
 
decrease
 
everolimus
 
level,
 
potentially
 
increasing
 
the
 
risk
 
of
 
rejection.
 
 
4.
 
Avoid
 
the
 
fruit
 
and
 
juice
 
of
 
grapefruit,
 
pomelo
 
and
 
pomegranate
 
as
 
it
 
may
 
increase
 
the
 
everolimus
 
level.
 
 
 
 
 
 
150
 

=== PAGE 152 ===

 
Before
 
ending
 
this
 
peer
 
review
 
session,
 
the
 
reviewee
 
should
 
be
 
informed
 
of
 
the
 
step(s)
 
that
 
he/
 
she
 
missed
 
out
 
in
 
order
 
to
 
ensure
 
all
 
the
 
counselling
 
points
 
are
 
being
 
covered.
 
 
Remarks:
 
 
 
 
Reviewed
 
by:
 
Name
 
&
 
Signature
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Date:
 
 
 
 
*Mandatory
 
for
 
validation
 
/
 
peer
 
review
 
References: 
 
1.
 
Formulari
 
Ubat
 
KKM.
 
(2025,
 
January
 
1).
 
Accessed
 
on
 
January
 
1,
 
2025.
 
2.
 
Novartis
 
(2022).
 
Product
 
information
 
leaflet:
 
Certican.
 
Retrieved
 
from
 
Quest
 
3+
 
Product
 
Search
 
on
 
January
 
1,
 
2025.
 
3.
 
MIMS
 
GATEW AY
 
(2025).
 
Everolimus.
 
MIMS.
 
Retrieved
 
January
 
20,
 
2025,
 
from
 
 
https:// 
www .mims.com/malaysia/drug/info/everolimus
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
151
 

=== PAGE 153 ===

 
Evolocumab
 
Name
 
:
 
 
Unit
 
:
 
 
●
 
Please
 
tick
 
(
✔
)
 
Yes
 
for
 
correct
 
instruction
 
or
 
sequence.
 
●
 
Please
 
tick
 
(
✔
)
 
No
 
for
 
incorrect
 
instruction
 
or
 
sequence.
 
Yes
 
No
 
Remarks
 
Pharmacological
 
Group
 
Lipid
 
modifying
 
agent
 
-
 
PCSK9
 
inhibitors
 
 
 
 
Indications
 
and
 
Dosage
 
1.
 
Prevention
 
of
 
cardiovascular
 
events
 
a.
 
140mg
 
every
 
2
 
weeks
 
b.
 
420mg
 
monthly
 
 
2.
 
Primary
 
hyperlipidemia
 
(including
 
heterozygous
 
familial
 
hypercholesterolemia
 
HeFH)
 
a.
 
140mg
 
every
 
2
 
weeks
 
b.
 
420mg
 
monthly
 
 
3.
 
Homozygous
 
familial
 
hypercholesterolemia
 
HoFH
 
a.
 
420mg
 
monthly
 
 
 
 
When
 
switching
 
dosing
 
regimen,
 
administer
 
the
 
first
 
dose
 
of
 
the
 
new
 
regimen
 
on
 
the
 
next
 
scheduled
 
date
 
of
 
the
 
prior
 
regimen.
 
Method
 
of
 
Administration*
 
1.
 
Evolocumab
 
is
 
administered
 
under
 
the
 
skin
 
(subcutaneously),
 
every
 
2
 
weeks
 
or
 
1
 
time
 
each
 
month.
 
2.
 
420mg
 
dose
 
can
 
be
 
administered
 
by
 
giving
 
3
 
injections
 
consecutively
 
within
 
30
 
minutes
 
at
 
different
 
injection
 
sites.
 
 
 
 
Preparation
 
1.
 
Remove
 
the
 
pre-filled
 
pen
 
from
 
the
 
original
 
package
 
carefully .
 
Return
 
the
 
original
 
package
 
with
 
unused
 
pre-filled
 
pen
 
to
 
the
 
refrigerator .
 
2.
 
Wait
 
for
 
at
 
least
 
30
 
minutes
 
for
 
the
 
pre-filled
 
pen
 
to
 
reach
 
room
 
temperature
 
before
 
injecting.
 
This
 
will
 
minimise
 
pain
 
at
 
the
 
injection
 
site.
 
Do
 
not
 
warm
 
or
 
expose
 
to
 
direct
 
sunlight
 
to
 
warm
 
the
 
pre-filled
 
pen.
 
3.
 
Do
 
not
 
shake
 
the
 
pre-filled
 
pen.
 
Inspection
 
4.
 
Check
 
the
 
solution
 
in
 
the
 
window .
 
It
 
should
 
be
 
clear
 
and
 
colourless
 
to
 
slightly
 
yellow .
 
5.
 
Do
 
not
 
use
 
if
 
●
 
The
 
solution
 
is
 
cloudy
 
or
 
discoloured
 
or
 
contains
 
large
 
lumps.
 
●
 
Any
 
part
 
of
 
the
 
pre-filled
 
pen
 
appears
 
cracked
 
or
 
broken.
 
●
 
If
 
the
 
pre-filled
 
pen
 
has
 
been
 
dropped.
 
●
 
The
 
orange
 
cap
 
is
 
missing
 
or
 
not
 
securely
 
attached.
 
●
 
The
 
expiration
 
date
 
has
 
passed.
 
Injection
 
Site
 
6.
 
Only
 
inject
 
at
 
these
 
injection
 
sites:
 
●
 
Thigh
 
●
 
Abdomen,
 
except
 
2
 
inches
 
(5
 
cm)
 
area
 
around
 
belly
 
button.
 
●
 
Outer
 
area
 
of
 
upper
 
arm
 
(not
 
for
 
self-injection).
 
7.
 
Rotate
 
injection
 
site.
 
If
 
you
 
need
 
to
 
use
 
the
 
same
 
injection
 
site,
 
make
 
sure
 
it
 
is
 
not
 
the
 
same
 
spot
 
on
 
the
 
site
 
you
 
used
 
in
 
the
 
previous
 
injection.
 
8.
 
Do
 
not
 
inject
 
into
 
areas
 
where
 
the
 
skin
 
is
 
tender ,
 
152
 

=== PAGE 154 ===

 
bruised,
 
red
 
or
 
hard.
 
Avoid
 
injecting
 
into
 
areas
 
with
 
scars
 
or
 
stretch
 
marks.
 
9.
 
Do
 
not
 
co-administer
 
with
 
other
 
injectable
 
drugs
 
at
 
the
 
same
 
administration
 
site.
 
 
Injection
 
Technique
 
10.
 
Clean
 
the
 
injection
 
site
 
with
 
alcohol
 
wipe.
 
Let
 
the
 
skin
 
dry
 
before
 
injection.
 
Do
 
not
 
touch
 
this
 
area
 
again
 
before
 
injecting.
 
11.
 
Pull
 
the
 
orange
 
cap
 
straight
 
off.
 
 
●
 
Do
 
not
 
twist,
 
bend
 
or
 
wiggle
 
the
 
orange
 
cap.
 
 
●
 
Do
 
not
 
put
 
the
 
orange
 
cap
 
back
 
onto
 
the
 
pre-filled
 
pen.
 
●
 
Do
 
not
 
leave
 
the
 
orange
 
cap
 
off
 
for
 
more
 
than
 
5
 
minutes
 
as
 
this
 
can
 
dry
 
out
 
the
 
medicine.
 
12.
 
It
 
is
 
normal
 
to
 
see
 
a
 
drop
 
of
 
liquid
 
at
 
the
 
end
 
of
 
the
 
needle
 
or
 
yellow
 
safety
 
guard.
 
Do
 
not
 
put
 
fingers
 
into
 
the
 
yellow
 
safety
 
guard.
 
13.
 
Create
 
a
 
firm
 
surface
 
at
 
the
 
selected
 
injection
 
site
 
by
 
using
 
either
 
stretch
 
method
 
or
 
pinch
 
method.
 
●
 
Stretch
 
method:
 
stretch
 
the
 
skin
 
firmly
 
by
 
moving
 
your
 
thumb
 
and
 
fingers
 
in
 
the
 
opposite
 
direction,
 
creating
 
an
 
area
 
about
 
2
 
inches
 
(5
 
cm)
 
wide.
 
●
 
Pinch
 
method:
 
pinch
 
the
 
skin
 
firmly
 
between
 
your
 
thumb
 
and
 
fingers,
 
creating
 
an
 
area
 
about
 
2
 
inches
 
(5
 
cm)
 
wide.
 
It
 
is
 
important
 
to
 
keep
 
skin
 
stretched
 
or
 
pinched
 
while
 
injecting.
 
14.
 
Keep
 
holding
 
the
 
stretched
 
or
 
pinched
 
skin.
 
With
 
the
 
orange
 
cap
 
off,
 
put
 
the
 
yellow
 
safety
 
guard
 
on
 
your
 
skin
 
at
 
90
 
degrees.
 
The
 
needle
 
is
 
inside
 
the
 
yellow
 
safety
 
guard.
 
Do
 
not
 
touch
 
the
 
grey
 
button
 
yet.
 
15.
 
Firmly
 
push
 
down
 
the
 
pre-filled
 
pen
 
onto
 
the
 
skin
 
until
 
it
 
stops
 
moving.
 
16.
 
When
 
you
 
are
 
ready
 
to
 
inject,
 
press
 
the
 
grey
 
start
 
button.
 
You
 
will
 
hear
 
a
 
click.
 
17.
 
Keep
 
pushing
 
down
 
on
 
the
 
skin.
 
Window
 
on
 
the
 
pre-filled
 
pen
 
turns
 
from
 
clear
 
to
 
yellow
 
when
 
the
 
injection
 
is
 
done.
 
You
 
may
 
hear
 
a
 
second
 
click.
 
Your
 
injection
 
could
 
take
 
about
 
15
 
seconds.
 
18.
 
Lift
 
your
 
thumb
 
while
 
still
 
holding
 
the
 
pre-filled
 
pen
 
on
 
your
 
skin.
 
19.
 
Remove
 
the
 
pre-filled
 
pen
 
from
 
your
 
skin.
 
The
 
needle
 
will
 
be
 
automatically
 
covered.
 
Do
 
not
 
recap
 
the
 
pre-filled
 
pen
 
or
 
put
 
fingers
 
into
 
yellow
 
safety
 
guard.
 
20.
 
Discard
 
the
 
used
 
pre-filled
 
pen
 
and
 
orange
 
cap
 
in
 
a
 
hard,
 
puncture-proof
 
disposal
 
container .
 
21.
 
If
 
there
 
is
 
blood
 
at
 
injection
 
site,
 
press
 
a
 
cotton
 
ball
 
or
 
gauze
 
pad
 
on
 
your
 
injection
 
site.
 
Do
 
not
 
rub
 
the
 
injection
 
site.
 
Apply
 
a
 
plaster
 
if
 
needed.
 
Missed
 
dose
 
management
 
1.
 
If
 
a
 
dose
 
is
 
missed
 
and
 
administer
 
within
 
7
 
days
 
from
 
the
 
missed
 
dose,
 
you
 
can
 
resume
 
the
 
original
 
schedule.
 
2.
 
If
 
a
 
2-weekly
 
dose
 
is
 
not
 
administered
 
within
 
7
 
days,
 
wait
 
until
 
the
 
next
 
dose
 
of
 
the
 
original
 
schedule
 
and
 
inject.
 
3.
 
If
 
a
 
monthly
 
dose
 
is
 
not
 
administered
 
within
 
7
 
days,
 
administer
 
the
 
dose
 
and
 
start
 
a
 
new
 
schedule
 
based
 
on
 
the
 
new
 
injection
 
date.
 
 
Do
 
not
 
stop
 
taking
 
your
 
medication
 
unless
 
advised
 
to
 
do
 
so
 
by
 
your
 
prescriber
 
 
 
 
 
153
 

=== PAGE 155 ===

 
Special
 
Considerations
 
Pregnancy
 
 
 
 
1.
 
No
 
data
 
on
 
use
 
of
 
evolocumab
 
to
 
inform
 
a
 
drug-associated
 
risk.
 
 
 
 
Breastfeeding
 
 
 
 
1.
 
No
 
data
 
on
 
the
 
presence
 
of
 
evolocumab
 
in
 
human
 
milk.
 
 
 
 
Elderly
 
 
 
 
1.
 
No
 
differences
 
in
 
safety
 
or
 
effectiveness
 
were
 
observed
 
between
 
the
 
elderly
 
(≥
 
65
 
or
 
≥
 
75
 
years
 
old)
 
and
 
younger
 
patients,
 
but
 
greater
 
sensitivity
 
of
 
some
 
older
 
individuals
 
cannot
 
be
 
ruled
 
out.
 
 
 
 
Pediatric
 
 
 
 
1.
 
Safety
 
and
 
effectiveness
 
have
 
not
 
been
 
established
 
in
 
pediatric
 
patients
 
with
 
primary
 
hyperlipidemia
 
or
 
 
HeFH;
 
and
 
HoFH
 
who
 
are
 
younger
 
than
 
10
 
years
 
old
 
 
 
 
Others
 
 
 
 
1.
 
Renal
 
Impairment
 
-
 
No
 
dose
 
adjustment
 
is
 
needed.
 
2.
 
Hepatic
 
impairment
 
a.
 
No
 
dose
 
adjustment
 
for
 
mild
 
to
 
moderate
 
hepatic
 
impairment
 
(Child-Pugh
 
A
 
or
 
B).
 
b.
 
No
 
data
 
for
 
severe
 
hepatic
 
impairment.
 
(Child-Pugh
 
C).
 
Use
 
with
 
caution
 
 
 
 
Side
 
effects
 
and
 
their
 
Management*
 
Hypersensitivity
 
reaction
 
(e.g.
 
rash,
 
urticaria).
 
Inj.
 
evolocumab
 
is
 
contraindicated
 
in
 
patients
 
with
 
a
 
history
 
of
 
serious
 
hypersensitivity
 
reaction.
 
 
 
 
Storage*
 
1.
 
Store
 
in
 
a
 
refrigerator
 
(2
 
-
 
8
o
C).
 
Do
 
not
 
freeze
 
or
 
use
 
the
 
pre-filled
 
pen
 
if
 
it
 
has
 
been
 
frozen.
 
2.
 
May
 
be
 
stored
 
at
 
room
 
temperature
 
(25
o
C)
 
and
 
used
 
within
 
1
 
month.
 
3.
 
Protected
 
from
 
light.
 
 
 
 
Others
 
Drug
 
-
 
drug
 
interaction
 
with
 
statin
 
 
Approximately
 
20%
 
increase
 
in
 
clearance
 
of
 
evolocumab:
 
No
 
statin
 
dose
 
adjustment
 
is
 
necessary
 
when
 
used
 
concomitantly
 
with
 
evolocumab
 
 
 
 
Before
 
ending
 
this
 
peer
 
review
 
session,
 
the
 
reviewee
 
should
 
be
 
informed
 
of
 
the
 
step(s)
 
that
 
he/
 
she
 
missed
 
out
 
in
 
order
 
to
 
ensure
 
all
 
the
 
counselling
 
points
 
are
 
being
 
covered.
 
 
Remarks:
 
 
 
Reviewed
 
by:
 
Name
 
&
 
Signature
                                                                   
Date:
 
 
 
*Mandatory
 
for
 
validation
 
/
 
peer
 
review
 
Reference:
 
1.
 
Amgen
 
Biopharmaceuticals
 
Malaysia
 
Sdn
 
Bhd
 
(2024)
 
Product
 
information
 
leaflet:
 
Repatha.
 
Retrieved
 
from
 
Quest
 
3+
 
Product
 
Search
 
on
 
January
 
20,
 
2025.
 
154
 

=== PAGE 156 ===

 
Felodipine
 
Name
 
:
 
 
Unit
 
:
 
 
●
 
Please
 
tick
 
(
✔
)
 
Yes
 
for
 
correct
 
instruction.
 
●
 
Please
 
tick
 
(
✔
)
 
No
 
for
 
incorrect
 
instruction.
 
Yes
 
No
 
Remarks
 
Pharmacological
 
Group
 
Dihydropyridine
 
Calcium
 
Antagonist
 
-
 
Antihypertensive
 
 
 
 
Indications
 
and
 
Dosage
 
1.
 
Hypertension
 
a.
 
Initial
 
5mg
 
OD,
 
may
 
titrate
 
to
 
maximum
 
dose
 
20mg/day
 
 
 
 
Method
 
of
 
Administration*
 
1.
 
Felodipine
 
should
 
preferably
 
be
 
taken
 
in
 
the
 
morning
 
on
 
an
 
empty
 
stomach
 
or
 
following
 
a
 
light,
 
low
 
fat
 
or
 
carbohydrate
 
meal.
 
2.
 
Felodipine
 
tablets
 
must
 
be
 
swallowed
 
with
 
water
 
and
 
not
 
be
 
divided,
 
crushed
 
or
 
chewed
 
 
Missed
 
medication
 
management
 
 
If
 
you
 
forgot
 
to
 
take
 
a
 
dose
 
of
 
felodipine,
 
take
 
it
 
as
 
soon
 
as
 
you
 
remember
 
it.
 
However ,
 
if
 
it
 
is
 
almost
 
time
 
for
 
your
 
next
 
dose,
 
skip
 
the
 
missed
 
dose.
 
Do
 
not
 
take
 
a
 
double
 
dose
 
(two
 
doses
 
at
 
the
 
same
 
time)
 
to
 
make
 
up
 
for
 
a
 
forgotten
 
dose.
 
 
Do
 
not
 
stop
 
taking
 
your
 
medication
 
unless
 
advised
 
to
 
do
 
so
 
by
 
your
 
prescriber
 
 
 
 
Special
 
Considerations
 
Pregnancy
 
 
 
 
1.
 
Avoid
 
use
 
in
 
pregnant
 
women
 
as
 
there
 
is
 
a
 
risk
 
of
 
harm
 
to
 
the
 
foetus.
 
 
 
 
Breastfeeding
 
 
 
 
1.
 
Although
 
detected
 
in
 
breast
 
milk.
 
when
 
taken
 
in
 
therapeutic
 
dose
 
felodipine
 
is
 
unlikely
 
to
 
affect
 
the
 
infant
 
 
 
 
Elderly
 
 
 
 
1.
 
Initial
 
treatment
 
with
 
lowest
 
available
 
dose
 
should
 
be
 
considered,
 
and
 
titrate
 
at
 
no
 
less
 
than
 
2
 
week
 
intervals
 
to
 
response.
 
 
2.
 
Prolonged-
 
release
 
tablets
 
must
 
not
 
be
 
divided,
 
crushed
 
or
 
chewed.
 
Consideration
 
should
 
be
 
given
 
in
 
elderly
 
with
 
dysphagia
 
or
 
requiring
 
enteral
 
tube
 
feeding.
 
 
 
MALPIP
 
1.
 
Increased
 
risk
 
of
 
ankle
 
oedema,
 
to
 
consider
 
dosage
 
adjustment,
 
switching
 
CCB
 
or
 
switching
 
to
 
other
 
classes
 
if
 
necessary
 
 
 
 
Paediatric
 
 
 
 
Limited
 
data
 
 
 
 
Fasting
 
 
 
 
Not
 
applicable
 
 
 
 
155
 

=== PAGE 157 ===

 
Others
 
 
 
 
 
1.
 
No
 
dose
 
adjustment
 
is
 
required.
 
However ,
 
Plendil
  
should
 
be
 
used
 
with
 
caution
 
in
 
patients
 
with
 
severely
 
impaired
 
renal
 
function
 
2.
 
Patients
 
with
 
impaired
 
hepatic
 
function
 
may
 
have
 
elevated
 
plasma
 
concentrations
 
of
 
felodipine
 
and
 
may
 
respond
 
to
 
treatment
 
at
 
lower
 
doses
 
 
 
 
 
Side
 
Effects
 
and
 
their
 
Management*
 
1.
 
Most
 
of
 
reactions
 
are
 
dose
 
dependent
 
&
 
appear
 
at
 
the
     
start
 
of
 
treatment
 
or
 
after
 
dose
 
increment
 
such
 
as
 
flushing,headache,palpitations,
 
dizziness
 
and
 
fatigue
 
 
2.
 
Dose-dependant
 
ankle
 
swelling,results
 
from
 
precapillary
 
vasodilation
 
and
 
not
 
related
 
to
 
fluid
 
retention
 
 
If
 
pedal
 
edema
 
occurs,
 
may
 
consider
 
to
 
elevate
 
feet
 
using
 
a
 
stool
 
or
 
pillow ,
 
and
 
avoid
 
prolonged
 
sitting
 
or
 
standing
 
 
3.
 
Mild
 
gingival
 
enlargement
 
with
 
pronounced
 
gingivitis/peridontitis
 
 
 
 
 
Storage*
 
Do
 
not
 
store
 
above
 
30
0
C
 
 
 
 
Others
 
1.
 
Drug-drug
 
interaction
 
a.
 
Enzyme
 
inhibitor
 
of
 
cytochrome
 
P450
 
(Erythromycin,
 
Itraconazole,
 
Ketoconazole,
 
grapefruit
 
juice)
 
has
 
been
 
shown
 
to
 
cause
 
increase
 
in
 
Felodipine
 
plasma
 
concentrations
 
b.
 
Enzyme
 
inducer
 
of
 
cytochrome
 
P450
 
(phenytoin,
 
carbamazepine,
 
rifampicin,
 
barbiturates
 
&
 
St.
 
John’ s
 
wort)
 
may
 
cause
 
decrease
 
in
 
Felodipine
 
plasma
 
concentrations
 
4.
 
Avoid
 
for
 
patients
 
with
 
hereditary
 
galactose
 
intolerance
 
or
 
glucose-galactose
 
malabsorption
 
as
 
Felodipine
 
contains
 
lactose.
 
 
 
 
Before
 
ending
 
this
 
peer
 
review
 
session,
 
the
 
reviewee
 
should
 
be
 
informed
 
of
 
the
 
step(s)
 
that
 
he/
 
she
 
missed
 
out
 
in
 
order
 
to
 
ensure
 
all
 
the
 
counselling
 
points
 
are
 
being
 
covered.
 
Remarks:
 
 
 
 
Reviewed
 
by:
 
Name
 
&
 
Signature
                                                                   
Date:
 
 
*Mandatory
 
for
 
validation
 
/
 
peer
 
review
 
References:
 
 
1.
 
AstraZeneca
 
Pharmaceutical
 
Co.,
 
Ltd.,
 
(2024)
 
Product
 
Information
 
Leaflet.
 
Plendil
 
Retrieved
 
from
 
Quest
 
3+
 
Product
 
Search
 
on
 
January
 
20,
 
2025.
 
2.
 
Formulari
 
Ubat
 
KKM.
 
(2025).
 
Accessed
 
on
 
January
 
20,
 
2025.
 
3.
 
Lexi-Comp,
 
I.
 
and
 
Lexicomp
 
(2013).
 
Drug
 
Information
 
Handbook:
 
A
 
Comprehensive
 
Resource
 
for
 
All
 
Clinicians
 
and
 
Healthcare
 
Professionals,
 
Lexi-Comp.
 
4.
 
 
UpToDate.
 
(2024)
 
UpToDate
 
(Version
 
3.70.4)
 
[Mobile
 
App]
 
Mobile
 
Clinical
 
Decision
 
Support
 
App
 
|
 
UpToDate
 
|
 
 
5.
 
Chang,
 
C.
 
T.,
 
Chan,
 
H.
 
K.,
 
Cheah,
 
W.
 
K.,
 
Tan,
 
M.
 
P.,
 
Ch’ng,
 
A.
 
S.
 
H.,
 
Thiam,
 
C.
 
N.,
 
...
 
&
 
Lee,
 
S.
 
W.
 
H.
 
(2023).
 
Development
 
of
 
a
 
Malaysian
 
potentially
 
inappropriate
 
prescribing
 
screening
 
tool
 
in
 
older
 
adults
 
(MALPIP):
 
a
 
Delphi
 
study . Journal
 
of
 
Pharmaceutical
 
Policy
 
and
 
Practice, 16(1),
 
122.
 
156
 

=== PAGE 158 ===

 
Fentanyl,
 
Transdermal
 
Patch
 
Name
 
:
 
 
Unit
 
:
 
 
●
 
Please
 
tick
 
(
✔
)
 
Yes
 
for
 
correct
 
instruction.
 
●
 
Please
 
tick
 
(
✔
)
 
No
 
for
 
incorrect
 
instruction.
 
Yes
 
No
 
Remarks
 
Pharmacological
 
Group
 
Opioid
 
analgesic
 
 
 
 
Indications
 
and
 
Dosage
 
1.
 
As
 
a
 
second
 
line
 
drug
 
in
 
the
 
management
 
of
 
opioid
 
responsive,
 
moderate
 
to
 
severe
 
chronic
 
cancer
 
pain.
 
 
2.
 
It
 
should
 
only
 
be
 
considered
 
in
 
patients
 
with
 
stable
 
opioid
 
requirements
 
who
 
have
 
difficulties
 
in
 
swallowing
 
and
 
intractable
 
nausea
 
and
 
vomiting.
 
 
a.
 
Dose
 
requirement
 
is
 
established
 
using
 
short-acting
 
preparations
 
before
 
switching
 
to
 
transdermal
 
formulation.
 
b.
 
Dose
 
is
 
individualised
 
based
 
on
 
patient-specific
 
factors
 
and
 
severity
 
of
 
pain,
 
and
 
is
 
given
 
every
 
72
 
hours.
 
c.
 
Subsequently ,
 
dose
 
is
 
adjusted
 
according
 
to
 
patient
 
response,
 
taking
 
into
 
account
 
the
 
amount
 
of
 
rescue
 
medication
 
used,
 
pain
 
score,
 
functional
 
assessment
 
and
 
side
 
effects.
 
 
To
 
counsel
 
based
 
on
 
specific
 
medication’ s
 
indication
 
and
 
dosage
 
as
 
prescribed
 
by
 
the
 
doctor
 
 
 
 
Method
 
of
 
Administration*
 
Step
 
1:
 
Preparing
 
the
 
Skin
 
a.
 
Make
 
sure
 
the
 
skin
 
is
 
completely
 
dry,
 
clean
 
and
 
cool
 
before
 
putting
 
the
 
patch
 
on.
 
b.
 
Sites
 
of
 
application
 
are
 
chest,
 
back
 
and
 
upper
 
arms
 
Step
 
2:
 
Open
 
the
 
sachet
 
a.
 
Each
 
patch
 
is
 
sealed
 
in
 
its
 
own
 
sachet
 
b.
 
Tear
 
or
 
cut
 
open
 
the
 
sachet
 
at
 
the
 
notch,
 
shown
 
by
 
the
 
arrow
 
Step
 
3:
 
Peel
 
and
 
press
 
a.
 
Carefully
 
peel
 
one
 
half
 
of
 
the
 
shiny
 
plastic
 
backing
 
away
 
from
 
the
 
centre
 
of
 
the
 
patch.
 
Try
 
not
 
to
 
touch
 
the
 
sticky
 
side
 
of
 
the
 
patch
 
b.
 
Press
 
the
 
sticky
 
part
 
of
 
the
 
patch
 
onto
 
the
 
skin
 
c.
 
Remove
 
the
 
other
 
part
 
of
 
the
 
backing
 
and
 
press
 
the
 
whole
 
patch
 
onto
 
the
 
skin
 
with
 
the
 
palm
 
of
 
your
 
hand.
 
d.
 
Hold
 
for
 
at
 
least
 
30
 
seconds.
 
Make
 
sure
 
it
 
sticks
 
well,
 
especially
 
the
 
edges
 
e.
 
The
 
date
 
and
 
time
 
of
 
application
 
and/or
 
renewal
 
should
 
be
 
written
 
on
 
the
 
patch.
 
Step
 
4:
 
Disposing
 
of
 
the
 
patch
 
a.
 
As
 
soon
 
as
 
take
 
a
 
patch
 
off,
 
fold
 
it
 
firmly
 
in
 
half
 
so
 
that
 
the
 
sticky
 
side
 
sticks
 
to
 
itself
 
b.
 
Put
 
it
 
back
 
in
 
its
 
original
 
sachet
 
and
 
dispose
 
of
 
the
 
sachet
 
as
 
instructed
 
Step
 
5:
 
Wash
 
a.
 
Always
 
wash
 
the
 
hands
 
after
 
handling
 
the
 
patch
 
using
 
clean
 
water
 
only
 
Step
 
6:
 
Change
 
of
 
patch
 
a.
 
Change
 
patch
 
every
 
3
 
days
 
at
 
the
 
same
 
time
 
of
 
day
 
b.
 
If
 
the
 
patch
 
falls
 
off
 
before
 
the
 
scheduled
 
change
 
date
 
(3
 
days),
 
discard
 
it
 
and
 
apply
 
a
 
new
 
patch
 
to
 
a
 
different
 
skin
 
site.
 
 
 
 
157
 

=== PAGE 159 ===

 
c.
 
Rotate
 
the
 
site
 
after
 
each
 
patch
 
removal
 
and
 
wait
 
for
 
at
 
least
 
3
 
days
 
before
 
reapplying
 
to
 
the
 
same
 
site.
 
 
Missed
 
dose
 
management:
 
1.
 
Apply
 
a
 
new
 
patch
 
as
 
soon
 
as
 
you
 
remember
 
 
2.
 
Do
 
not
 
apply
 
twice
 
the
 
number
 
of
 
patches
 
to
 
make
 
up
 
for
 
the
 
patch
 
that
 
you
 
missed.
 
 
3.
 
This
 
will
 
increase
 
the
 
chance
 
of
 
you
 
getting
 
unwanted
 
side-ef fects
 
 
 
Do
 
not
 
stop
 
taking
 
your
 
medication
 
unless
 
advised
 
to
 
do
 
so
 
by
 
your
 
prescriber
 
Special
 
Considerations
 
Pregnancy
 
 
 
 
1.
 
Prolonged
 
use
 
of
 
opioid
 
analgesics
 
during
 
pregnancy
 
may
 
cause
 
neonatal
 
opioid
 
withdrawal
 
syndrome
 
 
 
 
Breastfeeding
 
 
 
 
1.
 
Fentanyl
 
is
 
excreted
 
in
 
human
 
milk;
 
therefore,
 
it
 
is
 
not
 
recommended
 
for
 
use
 
in
 
nursing
 
women
 
because
 
of
 
the
 
possibility
 
of
 
effects
 
in
 
their
 
infants.
 
 
 
 
Elderly
 
 
 
 
1.
 
Increased
 
sensitivity
 
to
 
weak
 
opioids
  
in
 
elderly
 
patients
 
can
 
result
 
in
 
excessive
 
sedation,
 
dizziness,
 
confusion,
 
and
 
an
 
elevated
 
risk
 
of
 
delirium
 
and
 
lead
 
to
 
falls.
 
2.
 
Use
 
with
 
caution
 
in
 
the
 
elderly ,
 
debilitated
 
or
 
cachectic
 
patients
 
have
 
an
 
increased
 
risk
 
for
 
respiratory
 
depression.
 
3.
 
Use
 
in
 
elderly
 
patients
 
carry
 
risks
 
of
  
constipation
 
that
 
lead
 
to
  
delirium
 
and
 
increased
 
risk
 
of
 
falls.
 
4.
 
Avoid
 
in
 
patients
 
with
 
a
 
history
 
of
 
fractures
 
or
 
falls,
 
it
 
may
 
contribute
 
to
 
additional
 
fall.
 
5.
 
Use
 
caution
 
in
 
elderly
 
patients.
 
Starts
 
at
 
lower
 
dosage
 
in
 
this
 
population.
 
6.
 
Avoid
 
in
 
patients
 
with
 
very
 
low
 
BMI
 
(<
 
18.5kg/m2)
 
due
 
to
 
concern
 
about
 
absorption
 
variability .
 
 
7.
 
Caution
 
in
 
patient
 
with
 
thin,
 
fragile
 
skin
 
:
 
a.
 
it
 
may
 
reduce
 
the
 
patch
 
adhesion
 
to
 
the
 
skin
  
 
b.
 
reduce
  
absorption
 
due
 
to
 
inadequate
  
subcutaneous
 
fat
  
 
 
 
 
Paediatric
 
 
 
 
1.
 
Use
 
with
 
caution
 
in
 
paediatric
 
patients.
 
Starts
 
at
 
lower
 
dosage
 
in
 
this
 
population.
 
 
 
 
Others
 
 
 
 
 
1.
 
Addiction:
 
abuse,
 
misuse,
 
or
 
opioid
 
addiction
 
may
 
occur .
 
Use
 
cautiously
 
in
 
patients
 
with
 
a
 
history
 
of
 
substance
 
abuse
 
or
 
mental
 
illness.
 
2.
 
Heat
 
exposure:
 
Avoid
 
heat
 
exposure
 
to
 
application
 
site
 
or
 
surrounding
 
areas
 
(e.g:
 
heating
 
pads,
 
electric
 
blankets,
 
heating
 
lamps,
 
sauna,
 
hot
 
water
 
or
 
direct
 
sunlight)
 
3.
 
Concomitant
 
use
 
with
 
others:
 
Benzodiazepines
 
or
 
Central
 
Nervous
 
System(CNS)
 
depressants
 
including
 
alcohol
 
may
 
result
 
in
 
profound
 
sedation,
 
respiratory
 
depression,
 
coma,
 
and
 
death
 
 
 
 
158
 

=== PAGE 160 ===

 
Side
 
Effects
 
and
 
their
 
Management*
 
1.
 
Opioid-induced
 
constipation
 
a.
 
A
 
common
 
side
 
effect
 
b.
 
Tolerance
 
does
 
not
 
develop,
 
hence
 
laxatives
 
must
 
be
 
taken
 
regularly 
 
c.
 
Use
 
combination
 
of
 
stimulant
 
(e.g.
 
bisacodyl)
 
+
 
softener
 
(e.g.
 
lactulose)
 
d.
 
Increase
 
fluid
 
and
 
dietary
 
fibre
 
intake,
 
maintain
 
good
 
physical
 
activity ,
 
and
 
try
 
to
 
establish
 
a
 
toilet
 
routine
 
 
2.
 
Opioid-induced
 
sedation
 
/
 
impaired
 
alertness
 
a.
 
May
 
occur
 
upon
 
initiation
 
of
 
opioids
 
b.
 
Avoid
 
driving
 
and
 
other
 
activities
 
that
 
require
 
mental
 
alertness
 
until
 
it
 
is
 
clear
 
how
 
morphine/
 
Oxycodone
 
affects
 
the
 
patient
 
c.
 
Tolerance
 
develops
 
after
 
5
 
-
 
10
 
days
 
 
3.
 
Opioid-induced
 
neurotoxicity
 
(delirium,
 
confusion)
 
a.
 
May
 
occur ,
 
but
 
usually
 
transient
 
b.
 
May
 
consider
 
use
 
of
 
haloperidol
 
for
 
delirium
 
 
4.
 
Opioid-induced
 
nausea
 
and
 
vomiting
 
a.
 
May
 
occur
 
upon
 
initiation
 
of
 
opioids
 
b.
 
Tolerance
 
develops
 
5
 
-
 
10
 
days
 
after
 
starting
 
c.
 
May
 
use
 
antiemetics
 
(e.g.
 
metoclopramide,
 
haloperidol
 
or
 
prochlorperazine)
 
d.
 
Be
 
consistent
 
when
 
taking
 
morphine
 
with
 
or
 
without
 
meals
 
 
5.
 
Opioid-induced
 
dry
 
mouth 
 
a.
 
Sip
 
water
 
often,
 
let
 
small
 
ice
 
chips
 
melt
 
in
 
your
 
mouth
 
b.
 
Minimise
 
intake
 
of
 
caffeinated
 
drinks,
 
such
 
as
 
coffee,
 
tea,
 
and
 
some
 
sodas
 
as
 
well
 
as
 
use
 
of
 
tobacco
 
and
 
alcohol
 
c.
 
Chew
 
sugarless
 
gum
 
or
 
suck
 
on
 
sugarless
 
hard
 
candy
 
to
 
stimulate
 
saliva
 
flow
 
 
6.
 
Dermatologic:
 
 
a.
 
Severe
 
application
 
site
 
reactions
 
may
 
occur .
 
Onset
 
ranged
 
from
 
days
 
to
 
months
 
after
 
initiation.
 
 
 
 
Storage*
 
1.
 
Store
 
your
 
medication
 
in
 
a
 
cool,
 
dry
 
place
 
away
 
from
 
heat,
 
moisture
 
and
 
direct
 
sunlight.
 
 
2.
 
Disposal:
 
FOLD
 
used
 
patches
 
so
 
that
 
the
 
adhesive
 
side
 
adheres
 
to
 
itself.
 
 
 
 
Others
 
1.
 
Do
 
not
 
drink
 
alcohol
 
while
 
using
 
Transdermal
 
Fentanyl
 
Patch
 
2.
 
Do
 
not
 
drive
 
or
 
use
 
any
 
tools
 
or
 
machines
 
if
 
patient
 
complaints
 
of
 
sleepy
 
or
 
dizzy
 
3.
 
Do
 
not
 
shave
 
the
 
skin
 
if
 
it
 
is
 
hairy .
 
Instead,
 
clip
 
the
 
hair
 
as
 
close
 
to
 
the
 
skin
 
as
 
possible
 
4.
 
Overdosage:
 
Patient
 
can
 
present
 
with
 
respiratory
 
depression,
 
somnolence
 
progressing
 
to
 
stupor
 
or
 
coma,
 
skeletal
 
muscle
 
flaccidity ,
 
cold
 
and
 
clammy
 
skin,
 
constricted
 
pupils,
 
and
 
in
 
some
 
cases,
 
pulmonary
 
edema,
 
bradycardia,
 
hypotension,
 
partial
 
or
 
complete
 
airway
 
obstruction,
 
atypical
 
snoring,
 
and
 
death.
 
 
 
 
159
 

=== PAGE 161 ===

 
Before
 
ending
 
this
 
peer
 
review
 
session,
 
the
 
reviewee
 
should
 
be
 
informed
 
of
 
the
 
step(s)
 
that
 
he/
 
she
 
missed
 
out
 
in
 
order
 
to
 
ensure
 
all
 
the
 
counselling
 
points
 
are
 
being
 
covered.
 
 
Remarks:
 
 
 
 
 
Reviewed
 
by:
 
Name
 
&
 
Signature
                                                                   
Date:
 
 
 
 
*Mandatory
 
for
 
validation
 
/
 
peer
 
review
 
 
References:
 
 
1.
 
Clinical
 
Practice
 
Guidelines
 
Management
 
of
 
Cancer
 
Pain
 
(Second
 
Edition)
 
(2023)
 
Ministry
 
of
 
Health
 
Malaysia.
 
2.
 
Fentanyl
 
(2025).
 
MEDSCAPE
 
Drug
 
Reference
 
version
 
v1158.0.
 
Retrieved
 
January
 
20,
 
2025
 
from
 
https://reference.medscape.com/drug/duragesic-fentanyl-transdermal-999646
 
3.
 
Fentanyl
  
(2025).
 
Micromedex
 
(electronic
 
version).
 
Retrieved
 
January
 
20,
 
2025
 
from
 
http://www .micromedexsolutions.com/
 
4.
 
Formulari
 
Ubat
 
KKM
 
(2025).
 
Ministry
 
of
 
Health
 
Malaysia.
 
Retrieved
 
January
 
20,
 
2025
 
from
 
https://pharmacy .moh.gov .my/ms/apps/fukkm?generic=fentanyl&category=&indications=
 
5.
 
Janssen
 
Pharmaceutica
 
NV.
 
(2023).
 
Durogesic®
 
DTrans®
 
[Data
 
sheet].
 
Medsafe.
 
Retrieved
 
January
 
20,
 
2025,
 
from
 
https://www .medicines.org.uk/emc/files/pil.6941.pdf
 
6.
 
Tan
 
Tock
 
Seng
 
Hospital
 
Pharmacy
 
Drug
 
Information
 
Fentanyl
 
Patch
 
(2019).
 
Singapore.
 
7.
 
2023
 
American
 
Geriatrics
 
Society
 
Beers
 
Criteria®
 
Update
 
Expert
 
Panel.
 
(2023).
 
American
 
Geriatrics
 
Society
 
2023
 
updated
 
AGS
 
Beers
 
Criteria®
 
for
 
potentially
 
inappropriate
 
medication
 
use
 
in
 
older
 
adults.
 
Journal
 
of
 
the
 
American
 
Geriatrics
 
Society ,
 
71(7),
 
2052-2081.
 
8.
 
Heiskanen,
 
T.,
 
Mätzke,
 
S.,
 
Haakana,
 
S.,
 
Gergov ,
 
M.,
 
Vuori,
 
E.,
 
&
 
Kalso,
 
E.
 
(2009).
 
Transdermal
 
fentanyl
 
in
 
cachectic
 
cancer
 
patients.
 
Pain,
 
144(1),
 
218-222.
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
160
 

=== PAGE 162 ===

 
Flecainide
 
Acetate
 
Name
 
:
 
 
Unit
 
:
 
 
●
 
Please
 
tick
 
(
✔
)
 
Yes
 
for
 
correct
 
instruction.
 
●
 
Please
 
tick
 
(
✔
)
 
No
 
for
 
incorrect
 
instruction.
 
Yes
 
No
 
Remarks
 
Pharmacological
 
Group
 
Antiarrhythmic,
 
Class
 
1C
 
 
 
 
 
Indications
 
and
 
Dosage
 
1.
 
Sustained
 
monomorphic
 
ventricular
 
tachycardias
 
a.
 
Initial
 
dose:
 
50
 
to
 
100mg
 
twice
 
daily
 
for
 
3
 
to
 
5
 
days.
 
Reduced
 
to
 
the
 
lowest
 
dose
 
that
 
controls
 
the
 
arrhythmias.
 
Max:
 
400mg
 
daily
 
 
2.
 
Pre
 
excited
 
atrial
 
fibrillation
 
or
 
Syndrome
 
Reciprocating
 
Atrio-V entricular
 
tachycardias
 
(AVT)
 
associated
 
with
 
Wolff
 
Parkinson
 
White
 
Syndrome
 
a.
 
Initial
 
dose:
 
50mg
 
every
 
12
 
hours;
 
increase
 
by
 
50mg
 
twice
 
daily
 
at
 
4-day
 
intervals.
 
Max:
 
300mg/day
 
 
3.
 
Supraventricular
 
tachycardias
 
due
 
to
 
Intra-Atrio
 
Ventricular
 
Nodal
 
Reentry
 
a.
 
Initial
 
dose:
 
50mg
 
twice
 
daily.
 
Max:
 
300mg
 
daily
 
 
 
 
Method
 
of
 
Administration*
 
May
 
be
 
taken
 
with
 
or
 
without
 
food
 
Take
 
flecainide
 
at
 
about
 
the
 
same
 
time
 
each
 
day.
 
 
Missed
 
dose
 
management
 
If
 
you
 
miss
 
a
 
dose,
 
take
 
it
 
as
 
soon
 
as
 
you
 
remember .
 
If
 
it
 
is
 
near
 
to
 
the
 
next
 
dosing
 
time,
 
do
 
not
 
take
 
a
 
double
 
dose
 
to
 
replace
 
it.
 
Just
 
take
 
the
 
dose
 
as
 
usual.
 
 
Do
 
not
 
stop
 
taking
 
your
 
medication
 
unless
 
advised
 
to
 
do
 
so
 
by
 
your
 
prescriber
 
 
 
 
Special
 
Considerations
 
Pregnancy
 
 
 
 
1.
 
Maybe
 
considered
 
in
 
sustained
 
fetal
 
tachycardia
 
(maternal/transplacental
 
administration):
 
a.
 
Initial
 
dose:
 
100
 
to
 
300mg/day
 
in
 
divided
 
doses
 
administered
 
every
 
8
 
to
 
12
 
hours.
 
Dose
 
adjusted
 
to
 
fetal
 
response.
 
Maximum
 
dose:
 
450mg/day .
 
Avoid
 
use
 
during
 
the
 
first
 
trimester .
 
There
 
is
 
no
 
evidence
 
as
 
to
 
drug
 
safety
 
in
 
human
 
pregnancy .
 
Data
 
have
 
shown
 
that
 
Flecainide
 
crosses
 
the
 
placenta
 
to
 
the
 
foetus
 
in
 
patients
 
taking
 
Flecainide
 
during
 
pregnancy .
 
 
 
 
Breastfeeding
 
 
 
 
1.
 
Flecainide
 
is
 
excreted
 
in
 
human
 
milk
 
and
 
appears
 
in
 
concentrations
 
which
 
reflect
 
those
 
in
 
maternal
 
blood.
 
Relative
 
infant
 
dose
 
(RID)
 
of
 
flecainide
 
is
 
8%
 
when
 
calculated
 
using
 
the
 
highest
 
average
 
breast
 
milk
 
concentration
 
located
 
and
 
compared
 
to
 
a
 
weight
 
-adjusted
 
maternal
 
dose
 
of
 
200mg/day .
 
Breast
 
feeding
 
is
 
considered
 
acceptable
 
when
 
the
 
RID
 
of
 
a
 
medication
 
is
 
<
 
10%.
 
2.
 
The
 
risk
 
of
 
adverse
 
effects
 
to
 
the
 
nursing
 
infant
 
is
 
very
 
 
 
 
161
 

=== PAGE 163 ===

 
small.
 
The
 
benefit
 
of
 
Tambocor®
 
Tablet
 
100mg
 
during
 
lactation
 
should
 
therefore
 
be
 
weighed
 
against
 
the
 
possible
 
effects
 
on
 
the
 
child.
 
Elderly
 
 
 
 
1.
 
The
 
dose
 
for
 
elderly
 
patients
 
should
 
not
 
exceed
 
300
 
mg
 
per
 
day
 
(or
 
150
 
mg
 
twice
 
daily).
 
 
MALPIP
 
 
1.
 
May
 
increase
 
risk
 
of
 
bradycardia,
 
orthostatic
 
hypotension,
 
urinary
 
retention,
 
and
 
falls.
 
 
2.
 
Examine
 
drug-drug
 
interactions,
 
tailor
 
regime
 
according
 
to
 
patient’ s
 
physiology
 
and
 
medication
 
profile.
 
3.
 
Routine
 
blood
 
test
 
and
 
ECG
 
warranted.
 
 
 
 
 
Paediatric
 
 
 
 
1.
 
Tambocor
 
Tablet
 
100mg
 
is
 
not
 
recommended
 
for
 
children
 
under
 
12
 
years
 
of
 
age,
 
as
 
there
 
is
 
insuf ficient
 
evidence
 
of
 
its
 
use
 
in
 
this
 
age
 
group
 
2.
 
Children
 
are
 
particularly
 
susceptible
 
to
 
flecainide
 
toxicity
 
given
 
its
 
narrow
 
therapeutic
 
window
 
and
 
the
 
frequent
 
need
 
among
 
younger
 
patients
 
for
 
extemporaneous
 
compounding
 
of
 
a
 
liquid
 
formulation,increasing
 
the
 
risk
 
for
 
medication
 
dosing
 
errors.
 
 
 
 
Fasting
 
 
 
 
Not
 
applicable
 
 
 
 
Others
  
 
 
 
 
1.
 
Renal
 
impairment
 
CrCl
 
≤
 
35
 
ml/min:
 
Max
 
initial
 
dose:
 
100mg
 
daily.
 
Dose
 
may
 
be
 
adjusted
 
after
 
6-7
 
days
 
as
 
tolerated.
 
2.
 
Hepatic
 
impairment
 
Max
 
dose:
 
100mg
 
daily
 
3.
 
Patients
 
with
 
permanent
 
pacemaker;
 
Patients
 
receiving
 
cimetidine
 
or
 
amiodarone
 
Max
 
dose:
 
100mg
 
daily
 
 
 
 
Side
 
Effects
 
and
 
their
 
Management*
 
Common
 
side
 
effects:
 
1.
 
Heartbeat
 
changes,
 
it
 
starts
 
to
 
pound,
 
or
 
it
 
gets
 
faster
 
or
 
slower
 
 
2.
 
Skin
 
problems
 
associated
 
with
 
exposure
 
to
 
sunlight
 
 
3.
 
Nausea
 
and
 
vomiting
 
 
4.
 
Increased
 
in
 
liver
 
enzyme
 
or
 
jaundice
 
 
5.
 
Giddiness,
 
dizziness,
 
and
 
light-headedness.
 
 
6.
 
Numb
 
and
 
tingling
 
hand
 
or
 
feet
 
 
7.
 
Unsteady
 
walking
 
or
 
uncontrolled
 
movement
 
 
8.
 
Small
 
cloudy
 
spot
 
on
 
the
 
eyeball
 
 
9.
 
Double
 
vision
 
and
 
blurring
 
of
 
vision
 
 
10.
 
Certain
 
lungs
 
disease
 
(pulmonary
 
fibrosis)
 
or
 
inflammation
 
of
 
the
 
lungs
 
(pneumonitis)
 
 
 
 
Storage*
 
Store
 
between
 
20
 
to
 
25
0
C
 
 
 
 
Others
 
Precautions
 
1.
 
May
 
cause
 
dizziness
 
and
 
visual
 
disturbance,
 
not
 
to
 
drive
 
or
 
operate
 
machinery
 
Special
 
monitoring
 
parameters
 
1.
 
Monitor
 
ECG,
 
BP,
 
and
 
respiratory
 
functions
 
 
 
 
162
 

=== PAGE 164 ===

 
Significant
 
drug-drug
 
/
 
drug-food
 
interactions
 
(if
 
applicable)
 
1.
 
Drug-drug
 
interaction
 
a.
 
Amiodarone
 
-may
 
enhance
 
QTc
 
prolonging
 
effect
 
of
 
Flecainide.
 
Decrease
 
Flecainide
 
dose
 
by
 
50%
 
when
 
using
 
commitantly
 
b.
 
Haloperidol,
 
Risperidone,
 
Quinolone
 
antibiotics
 
–
 
enhance
 
QTc
 
prolonging
 
effect
 
of
 
Flecainide
 
Before
 
ending
 
this
 
peer
 
review
 
session,
 
the
 
reviewee
 
should
 
be
 
informed
 
of
 
the
 
step(s)
 
that
 
he/
 
she
 
missed
 
out
 
in
 
order
 
to
 
ensure
 
all
 
the
 
counselling
 
points
 
are
 
being
 
covered.
 
 
Remarks:
 
 
 
 
 
Reviewed
 
by:
 
Name
 
&
 
Signature
                                                                   
Date:
 
 
 
 
 
*Mandatory
 
for
 
validation
 
/
 
peer
 
review
 
 
References:
 
 
1.
 
Anderson
 
PO
 
et
 
al(2016).
 
Modeling
 
drug
 
passage
 
into
 
human
 
milk.
 
Clinical
 
Pharmacology
 
Therapy .
 
2.
 
Flecainide.
 
(2024).
 
MIMS
 
(online).
 
3.
 
Flecainide.
 
(2024).
 
Drug
 
Interaction
 
Checker .
 
Medscape
 
(online).
 
4.
 
Formulari
 
Ubat
 
KKM.
 
(2025).
 
Accessed
 
on
 
January
 
20,
 
2025
 
5.
 
Geanacopoulos,
 
A.
 
T.,
 
Zielonka,
 
B.,
 
Fox,
 
M.
 
T.,
 
Kerr,
 
S.,
 
Chambers,
 
K.
 
D.,
 
Przybylski,
 
R.,
 
&
 
Burns,
 
M.
 
M.
 
(2024).
 
Pediatric
 
antiarrhythmics
 
and
 
toxicity:
 
A
 
clinical
 
review .
 
Journal
 
of
 
the
 
American
 
College
 
of
 
Emergency
 
Physicians
 
Open,
 
5(1),
 
e13090.
 
6.
 
iNova
 
Pharmaceuticals
 
(Singapore)
 
Pte
 
Ltd
 
(incorporated
 
In
 
Singapore)
 
Malaysia
 
Branch
 
(2022)
 
Product
 
Information
 
Leaflet.
 
Tambacor
 
Retrieved
 
from
 
Quest
 
3+
 
Product
 
Search
 
on
 
January
 
21,
 
2025.
 
7.
 
Chang,
 
C.
 
T.,
 
Chan,
 
H.
 
K.,
 
Cheah,
 
W.
 
K.,
 
Tan,
 
M.
 
P.,
 
Ch’ng,
 
A.
 
S.
 
H.,
 
Thiam,
 
C.
 
N.,
 
...
 
&
 
Lee,
 
S.
 
W.
 
H.
 
(2023).
 
Development
 
of
 
a
 
Malaysian
 
potentially
 
inappropriate
 
prescribing
 
screening
 
tool
 
in
 
older
 
adults
 
(MALPIP):
 
a
 
Delphi
 
study . Journal
 
of
 
Pharmaceutical
 
Policy
 
and
 
Practice, 16(1),
 
12
2.
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
163
 

=== PAGE 165 ===

 
Follitropin
 
Alpha
 
(Recombinant
 
Human
 
FSH)
 
 
Name
 
:
 
 
Unit
 
:
 
 
●
 
Please
 
tick
 
(
✔
)
 
Yes
 
for
 
correct
 
instruction.
 
●
 
Please
 
tick
 
(
✔
)
 
No
 
for
 
incorrect
 
instruction.
 
Yes
 
No
 
Remarks
 
Pharmacological
 
Group
 
Recombinant
 
Human
 
Follicle-Stimulating
 
Hormone
 
(FSH)
 
 
 
 
Indications
 
and
 
Dosage
 
Indication
 
Anovulation,
 
including
 
polycystic
 
ovarian
 
syndrome
 
(PCOS),
 
in
 
women
 
who
 
have
 
been
 
unresponsive
 
to
 
treatment
 
with
 
clomiphene
 
citrate.
 
 
Dosage
 
:
 
 
75
 
-
 
150
 
IU
 
daily,
 
should
 
commence
 
within
 
the
 
first
 
7
 
days
 
of
 
the
 
menstrual
 
cycle
 
and
 
increase
 
by
 
37.5
 
IU
 
or
 
75
 
IU
 
at
 
7-
 
or
 
14-days
 
intervals.
 
 
Max
 
daily
 
dose
 
225
 
IU
 
 
Indication
 
Controlled
 
ovarian
 
hyperstimulation
 
to
 
induce
 
the
 
development
 
of
 
multiple
 
follicles
 
for
 
assisted
 
reproductive
 
technologies
 
(ART).
 
 
  
Dosage
 
:
 
 
 
150
 
-
 
225
 
IU
 
daily
 
commencing
 
on
 
days
 
2
 
or
 
3
 
of
 
the
 
cycle.
 
 
  
Max
 
daily
 
dose
 
450
 
IU.
 
 
Dosing
 
is
 
individualised
 
and
 
according
 
to
 
product
 
insert/protocol.
 
 
 
 
Site
 
&
  
Method
 
of
 
Administration*
 
Site
 
of
 
administration
 
or
 
injection:
 
●
 
 
Abdomen
 
(preferably)
 
●
 
 
Buttock
 
 
Method
 
of
 
administration:
 
a)
 
Wash
 
your
 
hands
 
with
 
soap
 
and
 
water .
 
 
b)
 
Check
 
that
 
the
 
-
 
The
 
expiry
 
had
 
not
 
passed
 
-
 
The
 
solution
 
is
 
clear
 
and
 
colourless
 
and
 
does
 
not
 
contain
 
particle
 
-
 
The
 
pre-filled
 
pen
 
is
 
not
 
damaged
 
 
c)
 
Sit
 
in
 
a
 
comfortable
 
position
 
so
 
you
 
can
 
easily
 
see
 
the
 
area
 
of
 
their
 
stomach
 
where
 
you
 
will
 
be
 
injecting.
 
 
d)
 
Select
 
an
 
area
 
on
 
the
 
right
 
or
 
left
 
side
 
of
 
your
 
stomach,
 
at
 
least
 
2
 
inches
 
from
 
your
 
navel.
 
Alternate
 
left
 
and
 
right
 
side
 
of
 
the
 
lower
 
abdominal
 
area
 
at
 
each
 
injection.
 
Do
 
not
 
inject
 
yourself
 
within
 
about
 
2
 
inches
 
of
 
your
 
navel,
 
near
 
scars,
 
bruises
 
or
 
stretch
 
marks.
 
 
e)
 
Clean
 
the
 
area
 
you
 
have
 
selected
 
for
 
your
 
injection
 
with
 
an
 
alcohol
 
swab
 
and
 
allow
 
the
 
area
 
to
 
dry.
 
 
f)
  
Remove
 
the
 
protective
 
cap.
 
 
g)
 
Screw
 
a
 
new
 
needle
 
to
 
the
 
pen.
 
Remove
 
the
 
inner
 
and
 
outer
 
cap.
 
 
h)
 
Prime
 
the
 
Gonal-F
 
pen
 
with
 
the
 
needle
 
pointing
 
upwards
 
for
 
 
 
 
164
 

=== PAGE 166 ===

 
when
 
you
 
use
 
a
 
new
 
cartridge.
 
(Observe
 
at
 
least
 
a
 
drop
 
of
 
medication
 
at
 
the
 
needle
 
tip
 
before
 
injecting.)
 
 
i)
 
Dial
 
the
 
dose
 
knob
 
to
 
the
 
desired
 
dose
 
by
 
turning
 
the
 
dose
 
knob.
 
 
j)
 
If
 
by
 
mistake
 
you
 
dial
 
past
 
the
 
correct
 
number ,
 
turn
 
the
 
dose
 
setting
 
knob
 
backward
 
to
 
correct
 
the
 
dose.
 
 
k)
 
Once
 
you
 
have
 
set
 
the
 
correct
 
dose,
 
swab
 
the
 
site
 
of
 
injection
 
with
 
an
 
alcohol
 
swab
 
and
 
pinch
 
the
 
area
 
with
 
two
 
fingers.
 
 
l)
 
Insert
 
the
 
pen
 
needle
 
into
 
the
 
skin
 
at
 
an
 
angle
 
of
 
90°
 
and
 
push
 
the
 
end
 
of
 
the
 
dose
 
knob
 
until
 
the
 
figure
 
in
 
the
 
dose
 
window
 
returns
 
to
 
0.
 
 
m)
 
Count
 
to
 
10
 
slowly
 
before
 
withdrawing
 
the
 
needle
 
from
 
the
 
skin.
 
Counting
 
past
 
10
 
may
 
be
 
necessary
 
for
 
higher
 
doses.
 
This
 
is
 
to
 
ensure
 
full
 
dose
 
delivery
 
and
 
prevent
 
leakage.
 
 
n)
 
Recap
 
the
 
used
 
pen
 
needle
 
using
 
the
 
outer
 
needle
 
cap
 
on
 
and
 
unscrew
 
the
 
needle.
 
 
o)
  
Replace
 
the
 
pen
 
cap.
 
 
p)
 
Immediately
 
discard
 
the
 
used
 
needle
 
into
 
a
 
designated
 
disposal
 
bin.
 
 
q)
  
Do
 
not
 
rub
 
the
 
injection
 
site
 
after
 
administration
 
 
Do
 
not
 
stop
 
taking
 
your
 
medication
 
unless
 
advised
 
to
 
do
 
so
 
by
 
your
 
prescriber
 
 
Missed
 
dose
 
:
 
 
 
Administer
 
as
 
soon
 
as
 
you
 
remember .
 
 
If
 
it
 
is
 
close
 
to
 
the
 
next
 
dose,
 
omit
 
the
 
current
 
dose
 
and
 
administer
 
the
 
current
 
dose.
 
 
DO
 
NOT
 
DOUBLE
 
THE
 
DOSE
 
Administer
 
as
 
soon
 
as
 
you
 
remember .
 
 
If
 
it
 
is
 
close
 
to
 
the
 
next
 
dose,
 
omit
 
the
 
current
 
dose
 
and
 
administer
 
the
 
current
 
dose.
 
 
DO
 
NOT
 
DOUBLE
 
THE
 
DOSE
 
 
 
 
Special
 
Considerations
 
Pregnancy
 
 
 
 
Contraindicated
 
 
 
 
Breastfeeding
 
 
 
 
Contraindicated
 
 
 
 
Elderly
 
 
 
 
NA
 
 
 
 
Paediatric
 
 
 
 
The
 
safety
 
and
 
efficacy
 
of
 
Follitropin
 
Alpha
  
in
 
paediatric
 
patients
 
below
 
age
 
18
 
have
 
not
 
been
 
established
.
 
 
 
 
Fasting
 
 
 
 
165
 

=== PAGE 167 ===

 
To
 
refer
 
to
 
the
 
latest
 
advisory
 
by
 
religious
 
authority
 
 
 
 
Others
 
 
 
 
NA
 
 
 
 
Side
 
Effects
 
and
 
their
 
Management*
 
1.
 
Bloating
 
2.
 
Nausea
 
&
 
vomiting
 
3.
 
Breast
 
tenderness
 
4.
 
Injection
 
site
 
reaction
 
(bruising,
 
pain,
 
redness)
 
 
*Note
 
for
 
IVF
:
 
Ovarian
 
Hyperstimulation
 
Syndrome
 
(OHSS)
 
warning
 
signs
 
and
 
symptoms:
 
Severe
 
abdominal
 
pain,
 
severe
 
nausea
 
and
 
vomiting,
 
difficulty
 
in
 
breathing
 
 
Seek
 
help
 
from
 
doctor
 
if
 
symptoms
 
worsen
 
 
 
 
Storage*
 
●
 
Store
 
at
 
2-8
 
°C
 
(in
 
a
 
refrigerator).
 
●
 
DO
 
NOT
 
FREEZE.
 
 
●
 
Avoid
 
storage
 
at
 
the
 
door
 
of
 
the
 
fridge
 
and
 
vegetable
 
compartment,
 
ensure
 
there
 
is
 
proper
 
air
 
circulation
 
around
 
medication.
 
●
 
TRANSPOR T
 
of
 
medication
 
is
 
only
 
allowed
 
in
 
a
 
COOL
 
BOX
 
WITH
 
ICE/ICE
 
PACKS
 
●
 
Preferable
 
return
 
home
 
immediately
 
after
 
getting
 
medication
 
from
 
pharmacy
 
to
 
facilitate
 
proper
 
storage
 
 
 
 
Others
 
Administration
 
timing
 
and
 
importance
 
of
 
compliance
 
 
●
 
Always
 
inject
 
at
 
the
 
same
 
specified
 
time
 
of
 
the
 
day
 
for
 
adequate
 
follicular
 
response
 
●
 
Importance
 
of
 
rotation
 
of
 
side
 
of
 
administration
 
 
Disposal
 
of
 
sharps
 
(syringe,
 
needles,
 
vial,
 
ampoule)
 
 
●
 
Dispose
 
sharps
 
in
 
a
 
container
 
before
 
disposal
 
●
 
Collect
 
sharps
 
in
 
a
 
container
 
and
 
return
 
to
 
the
 
pharmacy
 
or
 
healthcare
 
facility
 
for
 
proper
 
disposal
 
into
 
a
 
sharp
 
bin.
 
 
 
 
 
Before
 
ending
 
this
 
peer
 
review
 
session,
 
the
 
reviewee
 
should
 
be
 
informed
 
of
 
the
 
step(s)
 
that
 
he/
 
she
 
missed
 
out
 
in
 
order
 
to
 
ensure
 
all
 
the
 
counselling
 
points
 
are
 
being
 
covered.
 
 
Remarks:
 
 
 
 
Reviewed
 
by:
 
Name
 
&
 
Signature
                                                                   
Date:
 
 
 
 
 
*Mandatory
 
for
 
peer
 
review/validation
 
 
References:
 
1.
 
Hospital
 
Tunku
 
Azizah,
 
(2023),
 
Fertility
 
Pharmacy
 
Services,
 
Pharmacy
 
Department
 
of
 
Hospital
 
Tunku
 
Azizah.
 
2.
 
Merck
 
KGaA
 
(2017),
 
Gonal-F
 
Pen
 
Product
 
Monograph,
 
Follitropin
 
alpha
 
For
 
Injection,
 
Retrieved
 
from
 
https://pdf.hres.ca/dpd_pm/00039076.PDF
 
3.
 
Ministry
 
of
 
Health
 
(2024),
 
Formulari
 
Ubat
 
KKM
 
(FUKKM),
 
Retrieved
 
from
 
https://i.pharmacy .gov.my/fukkm/1669
 
166
 

=== PAGE 168 ===

 
Follitropin
 
Beta
 
(Recombinant
 
Human
 
FSH)
 
Name
 
:
 
 
Unit
 
:
 
 
●
 
Please
 
tick
 
(
✔
)
 
Yes
 
for
 
correct
 
instruction.
 
●
 
Please
 
tick
 
(
✔
)
 
No
 
for
 
incorrect
 
instruction.
 
Yes
 
No
 
Remarks
 
Pharmacological
 
Group
 
Recombinant
 
Human
 
Follicle-Stimulating
 
Hormone
 
(FSH)
 
 
 
 
Indications
 
and
 
Dosage
 
Indication
 
Anovulation,
 
including
 
polycystic
 
ovarian
 
syndrome
 
(PCOS),
 
in
 
women
 
who
 
have
 
been
 
unresponsive
 
to
 
treatment
 
with
 
clomiphene
 
citrate.
 
 
Dosage
 
:
 
50
 
IU
 
daily,
 
maintaining
 
the
 
starting
 
dose
 
for
 
at
 
least
 
7
 
days.
 
 
Indication
 
Controlled
 
ovarian
 
hyperstimulation
 
to
 
induce
 
the
 
development
 
of
 
multiple
 
follicles
 
for
 
assisted
 
reproductive
 
technologies
 
(ART).
 
 
  
Dosage
 
:
 
100-225
 
IU
 
daily,
 
maintaining
 
the
 
starting
 
dose
 
for
 
at
 
least
 
the
 
first
 
4
 
days.
 
 
Dosing
 
is
 
individualised
 
and
 
according
 
to
 
product
 
insert/protocol.
 
 
 
  
 
Site
 
&
  
Method
 
of
 
Administration*
 
Site
 
of
 
administration
 
or
 
injection:
 
●
 
 
Abdomen
 
(preferably)
 
●
 
 
Buttock
 
 
Method
 
of
 
administration:
 
 
a)
 
Wash
 
your
 
hands
 
with
 
soap
 
and
 
water .
 
 
b)
 
Check
 
that
 
-
 
The
 
expiry
 
had
 
not
 
passed
 
-
 
The
 
cartridge
 
solution
 
is
 
clear
 
and
 
colourless
 
and
 
does
 
not
 
contain
 
particle
 
-
 
The
 
puregon
 
pen
 
is
 
not
 
damaged
 
 
c)
 
Sit
 
in
 
a
 
comfortable
 
position
 
so
 
you
 
can
 
easily
 
see
 
the
 
area
 
of
 
their
 
stomach
 
where
 
you
 
will
 
be
 
injecting.
 
 
d)
 
Select
 
an
 
area
 
on
 
the
 
right
 
or
 
left
 
side
 
of
 
your
 
stomach,
 
at
 
least
 
2
 
inches
 
from
 
your
 
navel.
 
Alternate
 
left
 
and
 
right
 
side
 
of
 
the
 
lower
 
abdominal
 
area
 
at
 
each
 
injection.
 
Do
 
not
 
inject
 
yourself
 
within
 
about
 
2
 
inches
 
of
 
your
 
navel,
 
near
 
scars,
 
bruises
 
or
 
stretch
 
marks.
 
 
e)
 
Clean
 
the
 
area
 
you
 
have
 
selected
 
for
 
your
 
injection
 
with
 
alcohol
 
swab
 
and
 
allow
 
the
 
area
 
to
 
dry.
 
 
f)
  
Remove
 
the
 
protective
 
cap
 
and
 
unscrew
 
the
 
cartridge
 
holder .
 
 
g)
 
Insert
 
the
 
cartridge
 
into
 
the
 
cartridge
 
holder .
 
Screw
 
the
 
cartridge
 
holder
 
to
 
the
 
pen
 
body
 
tightly .
 
 
h)
 
Screw
 
a
 
new
 
needle
 
to
 
the
 
pen.
 
Remove
 
the
 
inner
 
and
 
outer
 
cap.
 
 
i)
 
Prime
 
the
 
Puregon
 
pen
 
with
 
the
 
needle
 
pointing
 
upwards
 
for
 
when
 
you
 
use
 
a
 
new
 
cartridge.
 
(Observe
 
at
 
least
 
a
 
drop
 
of
 
medication
 
at
 
the
 
needle
 
tip
 
before
 
injecting.)
 
 
 
 
167
 

=== PAGE 169 ===

 
 
j)
 
Dial
 
the
 
dose
 
knob
 
to
 
the
 
desired
 
dose
 
by
 
turning
 
the
 
dose
 
knob.
 
 
k)
 
If
 
by
 
mistake
 
you
 
dial
 
past
 
the
 
correct
 
number ,
 
DO
 
NOT
 
try
 
to
 
turn
 
the
 
knob
 
backward
 
to
 
fix
 
the
 
mistake.
 
Continue
 
to
 
turn
 
the
 
dosage
 
knob
 
in
 
the
 
same
 
direction
 
past
 
the
 
450iu
 
mark,
 
as
 
far
 
as
 
it
 
will
 
turn.
 
The
 
dosage
 
scale
 
must
 
move
 
freely .
 
Push
 
the
 
injection
 
button
 
all
 
the
 
way.
 
Start
 
to
 
dial
 
again
 
starting
 
from
 
0
 
upwards.
 
 
l)
 
Once
 
you
 
have
 
set
 
the
 
correct
 
dose,
 
swab
 
the
 
site
 
of
 
injection
 
with
 
an
 
alcohol
 
swab
 
and
 
pinch
 
the
 
area
 
with
 
two
 
fingers.
 
 
m)
 
Insert
 
pen
 
needle
 
into
 
the
 
skin
 
at
 
an
 
angle
 
of
 
90°
 
and
 
push
 
the
 
end
 
of
 
the
 
dose
 
knob
 
until
 
the
 
figure
 
in
 
the
 
dose
 
window
 
returns
 
to
 
0.
 
 
n)
 
Count
 
to
 
10
 
slowly
 
before
 
withdrawing
 
the
 
needle
 
from
 
the
 
skin.
 
Counting
 
past
 
10
 
may
 
be
 
necessary
 
for
 
higher
 
doses.
 
This
 
is
 
to
 
ensure
 
full
 
dose
 
delivery
 
and
 
prevent
 
leakage.
 
 
o)
 
Recap
 
the
 
used
 
pen
 
needle
 
using
 
the
 
outer
 
needle
 
cap
 
on
 
and
 
unscrew
 
the
 
needle.
 
 
p)
 
Replace
 
the
 
pen
 
cap.
 
 
q)
 
Immediately
 
discard
 
the
 
used
 
needle
 
into
 
a
 
designated
 
disposal
 
bin.
 
 
r)
 
Do
 
not
 
rub
 
the
 
injection
 
site
 
after
 
administration
 
 
Do
 
not
 
stop
 
taking
 
your
 
medication
 
unless
 
advised
 
to
 
do
 
so
 
by
 
your
 
prescriber
 
 
Missed
 
Dose
 
:
 
 
Administer
 
as
 
soon
 
as
 
you
 
remember .
 
If
 
it
 
is
 
close
 
to
 
the
 
next
 
dose,
 
omit
 
the
 
current
 
dose
 
and
 
administer
 
the
 
current
 
dose.
 
 
 
DO
 
NOT
 
DOUBLE
 
THE
 
DOSE
 
Special
 
Considerations
 
Pregnancy
 
 
 
 
Contraindicated
 
 
 
 
Breastfeeding
 
 
 
 
No
 
information
 
available
 
from
 
clinical
 
or
 
animal
 
studies.
 
 
 
 
Elderly
 
 
 
 
NA
 
 
 
 
Paediatric
 
 
 
 
The
 
safety
 
and
 
efficacy
 
of
 
Follitropin
 
Beta
 
in
 
paediatric
 
patients
 
below
 
age
 
18
 
have
 
not
 
been
 
established
.
 
 
 
 
Fasting
 
 
 
 
To
 
refer
 
to
 
the
 
latest
 
advisory
 
by
 
religious
 
authority
 
 
 
 
Others
 
 
 
 
168
 

=== PAGE 170 ===

 
NA
 
 
 
 
Side
 
Effects
 
and
 
their
 
Management*
 
1.
 
Bloating
 
2.
 
Nausea
 
&
 
vomiting
 
3.
 
Breast
 
tenderness
 
4.
 
Injection
 
site
 
reaction
 
(bruising,
 
pain,
 
redness)
 
 
 
*Note
 
for
 
IVF
:
 
Ovarian
 
Hyperstimulation
 
Syndrome
 
(OHSS)
 
warning
 
signs
 
and
 
symptoms
 
:
 
Severe
 
abdominal
 
pain,
 
severe
 
nausea
 
and
 
vomiting,
 
difficulty
 
in
 
breathing
 
 
Seek
 
help
 
from
 
doctor
 
if
 
symptoms
 
worsen
 
 
 
 
Storage*
 
●
 
Store
 
at
 
2-8
 
°C
 
(in
 
a
 
refrigerator).
 
DO
 
NOT
 
FREEZE.
 
Avoid
 
storage
 
at
 
the
 
door
 
of
 
the
 
fridge
 
and
 
vegetable
 
compartment,
 
ensure
 
there
 
is
 
proper
 
air
 
circulation
 
around
 
medication.
 
●
 
TRANSPOR T
 
of
 
medication
 
is
 
only
 
allowed
 
in
 
a
 
COOL
 
BOX
 
WITH
 
ICE/ICE
 
PACKS
 
●
 
Preferable
 
return
 
home
 
immediately
 
after
 
getting
 
medication
 
from
 
pharmacy
 
to
 
facilitate
 
proper
 
storage
 
 
 
 
 
Others
 
Administration
 
timing
 
and
 
importance
 
of
 
compliance
 
 
●
 
Always
 
inject
 
at
 
the
 
same
 
specified
 
time
 
of
 
the
 
day
 
for
 
adequate
 
follicular
 
response
 
●
 
Importance
 
of
 
rotation
 
of
 
side
 
of
 
administration
 
 
Disposal
 
of
 
sharps
 
(syringe,
 
needles,
 
vial,
 
ampoule)
 
 
●
 
Dispose
 
sharps
 
in
 
a
 
container
 
before
 
disposal
 
●
 
Collect
 
sharps
 
in
 
a
 
container
 
and
 
return
 
to
 
the
 
pharmacy
 
or
 
healthcare
 
facility
 
for
 
proper
 
disposal
 
into
 
a
 
sharp
 
bin.
 
 
 
 
 
Before
 
ending
 
this
 
peer
 
review
 
session,
 
the
 
reviewee
 
should
 
be
 
informed
 
of
 
the
 
step(s)
 
that
 
he/
 
she
 
missed
 
out
 
in
 
order
 
to
 
ensure
 
all
 
the
 
counselling
 
points
 
are
 
being
 
covered.
 
 
Remarks:
 
 
 
 
 
Reviewed
 
by:
 
Name
 
&
 
Signature
                                                                   
Date:
 
 
 
 
 
*Mandatory
 
for
 
peer
 
review/validation
 
 
References:
 
1.
 
Hospital
 
Tunku
 
Azizah,
 
(2023),
 
Fertility
 
Pharmacy
 
Services,
 
Pharmacy
 
Department
 
of
 
Hospital
 
Tunku
 
Azizah.
 
2.
 
Ministry
 
of
 
Health
 
(2024),
 
Formulari
 
Ubat
 
KKM
 
(FUKKM),
 
Retrieved
 
from
 
https://i.pharmacy .gov.my/fukkm/1458
 
3.
 
Vetter
 
Pharma-Fertigung
 
GmbH
 
&
 
Co.
 
KG,
 
Germany
 
(2024),
 
Package
 
Insert,
 
Retrieved
 
from
 
https://quest3plus.bpfk.gov .my/front-end/attachment/638/pharma/209914/V_88585_20240108_164306_ 
D3.pdf
 
 
169
 

=== PAGE 171 ===

 
Fondaparinux
 
Name
 
:
 
Unit
 
:
 
 
●
 
Please
 
tick
 
(
✔
)
 
Yes
 
for
 
correct
 
instruction
 
or
 
sequence.
 
●
 
Please
 
tick
 
(
✔
)
 
No
 
for
 
incorrect
 
instruction
 
or
 
sequence.
 
Yes
 
No
 
Remarks
 
Pharmacological
 
Group
 
Antithrombotic
 
Agent
 
 
-
 
Synthetic
 
and
 
Selective
 
Inhibitor
 
of
 
activated
 
Factor
 
X
 
(Xa)
 
 
 
 
Indications
 
and
 
Dosage
 
1.
 
Prophylaxis
 
of
 
venous
 
thromboembolism
 
(VTE)
 
in
 
surgical
 
patients
 
a.
 
2.5mg
 
once
 
daily
 
 
2.
 
Prophylaxis
 
of
 
venous
 
thromboembolism
 
(VTE)
 
in
 
medical
 
patients
 
a.
 
2.5mg
 
once
 
daily
 
 
3.
 
Treatment
 
of
 
deep
 
vein
 
thrombosis
 
(DVT)
 
and
 
pulmonary
 
embolism
 
(PE),
 
dose
 
depends
 
on
 
body
 
weight
 
a.
 
<50kg:
 
5mg
 
once
 
daily
 
b.
 
50-100kg:
 
7.5mg
 
once
 
daily
 
c.
 
>100kg:
 
10mg
 
once
 
daily
 
 
4.
 
Treatment
 
of
 
unstable
 
angina
 
and
 
non-Q-wave
 
myocardial
 
infarction
 
(NSTEMI)
 
a.
 
2.5mg
 
once
 
daily
 
 
5.
 
Treatment
 
of
 
acute
 
ST-segment
 
Elevation
 
Myocardial
 
Infarction
 
(STEMI)
 
a.
 
2.5mg
 
once
 
daily,
 
first
 
dose
 
administered
 
intravenously
 
and
 
subsequent
 
doses
 
administered
 
by
 
subcutaneous
 
injection
 
 
 
 
Method
 
of
 
Administration*
 
1.
 
Subcutaneous
 
(SC)
 
injection
:
  
prevention
 
of
 
VTE,
 
treatment
 
of
 
DVT
 
and
 
PE,
 
treatment
 
of
 
unstable
 
angina
 
NSTEMI
 
and
 
acute
 
STEMI.
 
2.
 
IV
 
bolus
 
injection
:
 
first
 
dose
 
in
 
treatment
 
of
 
acute
 
STEMI.
 
3.
 
Should
 
NOT
 
be
 
administered
 
by
 
intramuscular
 
route.
 
 
 
 
Subcutaneous
 
Injection
 
Technique
 
:
 
 
 
Preparation
 
1.
 
Prior
 
to
 
injection,
 
wash
 
your
 
hands
 
thoroughly
 
with
 
soap
 
and
 
water .
 
Towel
 
dry.
 
2.
 
Sit
 
in
 
a
 
comfortable
 
position
 
so
 
you
 
can
 
easily
 
see
 
the
 
area
 
of
 
their
 
stomach
 
where
 
you
 
will
 
be
 
injecting.
 
A
 
lounge
 
chair ,
 
recliner ,
 
or
 
bed
 
(propped
 
up
 
with
 
pillows)
 
is
 
ideal.
 
 
Inspection
 
1.
 
Check
 
the
 
expiry
 
date
 
on
 
the
 
syringe.
 
Do
 
not
 
use
 
it
 
if
 
the
 
date
 
has
 
passed.
 
 
2.
 
Check
 
the
 
syringe
 
is
 
not
 
damaged
 
and
 
the
 
medicine
 
in
 
it
 
is
 
a
 
clear
 
solution
 
without
 
particles.
 
If
 
the
 
syringe
 
is
 
damaged
 
or
 
the
 
medicine
 
is
 
not
 
clear ,
 
use
 
another
 
syringe.
 
3.
 
Do
 
not
 
expel
 
any
 
air
 
from
 
the
 
syringe
 
before
 
administering
 
the
 
injection.
 
You
 
may
 
lose
 
some
 
of
 
the
 
medicine
 
if
 
you
 
do.
 
 
 
 
 
170
 

=== PAGE 172 ===

 
Injection
 
Site
 
1.
 
Only
 
inject
 
at
 
these
 
injection
 
sites:
 
●
 
Thigh
 
●
 
Abdomen,
 
except
 
2
 
inches
 
(5
 
cm)
 
area
 
around
 
belly
 
button.
 
●
 
Outer
 
area
 
of
 
upper
 
arm
 
(not
 
for
 
self-injection).
 
2.
 
Choose
 
an
 
area
 
on
 
the
 
right
 
or
 
left
 
side
 
of
 
your
 
stomach.
 
This
 
should
 
be
 
at
 
least
 
5
 
centimetres
 
away
 
from
 
your
 
belly
 
button
 
and
 
out
 
towards
 
your
 
sides.
 
 
3.
 
Rotate
 
injection
 
site.
 
Change
 
the
 
place
 
where
 
you
 
inject
 
between
 
the
 
left
 
and
 
right
 
sides
 
of
 
your
 
stomach,
 
depending
 
on
 
the
 
area
 
you
 
were
 
last
 
injected.
 
This
 
is
 
to
 
prevent
 
scarring
 
which
 
will
 
make
 
it
 
harder
 
to
 
inject
 
the
 
area
 
and
 
also
 
affect
 
how
 
the
 
medication
 
is
 
released
 
into
 
your
 
body .
 
Avoid
 
injecting
 
on
 
scars
 
and
 
bruises.
 
 
4.
 
Do
 
not
 
co-administer
 
with
 
other
 
injectable
 
drugs
 
at
 
the
 
same
 
administration
 
site.
 
 
Injection
 
Technique
 
1.
 
Clean
 
(do
 
not
 
rub)
 
the
 
injection
 
site
 
with
 
alcohol
 
wipe.
 
Let
 
the
 
skin
 
dry
 
before
 
injection.
 
Do
 
not
 
touch
 
this
 
area
 
again
 
before
 
injecting.
 
2.
 
Hold
 
the
 
syringe
 
in
 
the
 
hand
 
you
 
write
 
with
 
(like
 
a
 
pencil)
 
and
 
with
 
your
 
other
 
hand,
 
gently
 
pinch
 
the
 
cleaned
 
area
 
of
 
your
 
abdomen
 
between
 
your
 
forefinger
 
and
 
thumb
 
to
 
make
 
a
 
fold
 
in
 
the
 
skin.
 
Make
 
sure
 
you
 
hold
 
the
 
skin
 
fold
 
throughout
 
the
 
injection
 
3.
 
Hold
 
the
 
syringe
 
with
 
the
 
needle
 
pointing
 
downwards
 
(vertically
 
at
 
90
 
degree
 
angle)
 
and
 
inject
 
a
 
full
 
length
 
needle
 
into
 
the
 
skin
 
fold.
 
Inject
 
at
 
45°
 
angle
 
for
 
needle
 
length
 
≥8
 
mm
 
or
 
if
 
the
 
patient
 
is
 
thin.
 
4.
 
Press
 
down
 
plunger
 
with
 
your
 
finger
 
(thumb).
 
Complete
 
the
 
injection
 
using
 
all
 
of
 
the
 
medicine
 
in
 
the
 
syringe.
 
Hold
 
for
 
10
 
seconds.
 
5.
 
Release
 
the
 
plunger
 
and
 
the
 
needle
 
will
 
withdraw
 
automatically
 
from
 
the
 
skin
 
and
 
retract
 
into
 
the
 
security
 
sleeve
 
where
 
it
 
will
 
be
 
locked
 
permanently .
 
Let
 
go
 
of
 
the
 
skin
 
fold.
 
6.
 
To
 
avoid
 
bruising,
 
do
 
not
 
rub
 
the
 
injection
 
site.
 
7.
 
Drop
 
the
 
used
 
syringe
 
into
 
a
 
hard,
 
puncture-proof
 
container .
 
Close
 
the
 
container
 
lid
 
tightly
 
and
 
place
 
the
 
container
 
out
 
of
 
reach
 
of
 
children.
 
8.
 
When
 
the
 
container
 
is
 
full,
 
dispose
 
of
 
it
 
safely .
 
9.
 
If
 
there
 
is
 
blood
 
at
 
the
 
injection
 
site,
 
press
 
a
 
cotton
 
ball
 
or
 
gauze
 
pad
 
on
 
your
 
injection
 
site.
 
Do
 
not
 
rub
 
the
 
injection
 
site.
 
Apply
 
a
 
plaster
 
if
 
needed.
 
10.
 
Do
 
not
 
stop
 
taking
 
your
 
medication
 
unless
 
advised
 
to
 
do
 
so
 
by
 
your
 
prescriber .
 
Missed
 
dose
 
management
 
If
 
you
 
forget
 
to
 
take
 
a
 
dose,
 
inject
 
it
 
as
 
soon
 
as
 
you
 
remember .
 
Do
 
not
 
inject
 
a
 
double
 
dose
 
to
 
make
 
up
 
for
 
a
 
forgotten
 
dose
 
 
Do
 
not
 
stop
 
taking
 
your
 
medication
 
unless
 
advised
 
to
 
do
 
so
 
by
 
your
 
prescriber
 
 
 
 
Special
 
Considerations
 
Pregnancy
 
 
 
 
1.
 
Not
 
recommended
 
unless
 
potential
 
benefit
 
outweighs
 
risk
 
 
 
 
Breastfeeding
 
 
 
 
1.
 
Not
 
recommended
 
 
 
 
171
 

=== PAGE 173 ===

 
Elderly
 
 
 
 
 
1.
 
Used
 
with
 
caution
 
in
 
older
 
adults
 
(from
 
75
 
years
 
age
 
and
 
above)
 
due
 
to
 
the
 
risk
 
of
 
hemorrhage.
 
 
 
MALPIP
 
1.
 
Use
 
caution
 
and
 
monitor
 
bleeding
 
risk.
 
 
 
 
 
Paediatric
 
 
 
 
1.
 
The
 
safety
 
and
 
efficacy
 
of
 
fondaparinux
 
in
 
patients
 
under
 
the
 
age
 
of
 
17
 
has
 
not
 
been
 
established
 
 
 
 
Others
 
1.
 
Renal
 
impairment
 
-
 
Not
 
recommended
 
in
 
severe
 
renal
 
impairment
 
(creatinine
 
clearance
 
<30
 
ml/min)
 
2.
 
Liver
 
impairment
 
-
 
no
 
dose
 
adjustment
 
3.
 
Body
 
weight
 
below
 
50
 
kg
 
are
 
at
 
increased
 
risk
 
of
 
bleeding
 
 
 
 
Side
 
Effects
 
and
 
their
 
Management*
 
1.
 
May
 
develop
 
hematoma
 
at
 
the
 
injection
 
site
 
(a
 
localised
 
swelling
 
that
 
is
 
filled
 
with
 
blood).
 
2.
 
Educate
 
patient
 
on
 
symptoms
 
of
 
bleeding
 
such
 
as
 
bruises
 
with
 
unknown
 
cause,
 
blood
 
in
 
urine/dark
 
coloured
 
urine,
 
black
 
stools,
 
gum
 
bleeding
 
or
 
heavy
 
menstrual
 
bleeding
 
3.
 
Seek
 
immediate
 
medical
 
attention
 
if
 
any
 
sign
 
or
 
symptom
 
of
 
bleeding
 
occurs
 
 
 
 
Storage*
 
1.
 
Store
 
below
 
25°C,
 
do
 
not
 
freeze.
 
 
 
 
Others
 
1.
 
To
 
inform
 
healthcare
 
professionals
 
(dentist,
 
surgeon,
 
doctor ,
 
pharmacist)
 
if
 
the
 
patient
 
is
 
planning
 
to
 
get
 
a
 
tooth
 
extraction,
 
or
 
when
 
consulting
 
for
 
medication,
 
supplement
 
or
 
herbal
 
remedies
 
2.
 
Monitoring
 
parameters
 
a.
 
Full
 
blood
 
count
 
b.
 
Renal
 
function
 
 
 
 
Before
 
ending
 
this
 
peer
 
review
 
session,
 
the
 
reviewee
 
should
 
be
 
informed
 
of
 
the
 
step(s)
 
that
 
he/
 
she
 
missed
 
out
 
in
 
order
 
to
 
ensure
 
all
 
the
 
counselling
 
points
 
are
 
being
 
covered.
 
 
Remarks:
 
 
 
 
Reviewed
 
by:
 
Name
 
&
 
Signature
                                                                   
Date:
 
 
 
 
*Mandatory
 
for
 
validation
 
/
 
peer
 
review
 
 
References:
 
1.
 
Formulari
 
Ubat
 
KKM.
 
(2025).
 
Accessed
 
on
 
January
 
21,
 
2025.
 
2.
 
Aspen
 
Medical
 
Products
 
Malaysia
 
Sdn
 
Bhd
 
(2019)
 
Product
 
information
 
leaflet:
 
Arixtra.
 
Retrieved
 
from
 
Quest
 
3+
 
Product
 
Search
 
on
 
January
 
21,
 
2025.
 
3.
 
Robert-Ebadi,
 
H.,
 
Le
 
Gal,
 
G.,
 
&
 
Righini,
 
M.
 
(2009).
 
Use
 
of
 
anticoagulants
 
in
 
elderly
 
patients:
 
practical
 
recommendations.
 
Clinical
 
interventions
 
in
 
aging,
 
165-177.
 
4.
 
Chang,
 
C.
 
T.,
 
Chan,
 
H.
 
K.,
 
Cheah,
 
W.
 
K.,
 
Tan,
 
M.
 
P.,
 
Ch’ng,
 
A.
 
S.
 
H.,
 
Thiam,
 
C.
 
N.,
 
...
 
&
 
Lee,
 
S.
 
W.
 
H.
 
(2023).
 
Development
 
of
 
a
 
Malaysian
 
potentially
 
inappropriate
 
prescribing
 
screening
 
tool
 
in
 
older
 
adults
 
(MALPIP):
 
a
 
Delphi
 
study . Journal
 
of
 
Pharmaceutical
 
Policy
 
and
 
Practice, 16(1),
 
122.
 
 
172
 

=== PAGE 174 ===

 
Fusidic
 
Acid,
 
Topical
 
Name
 
:
 
Fusidic
 
acid
 
2%
 
w/w
 
Unit
 
:
 
15gram
 
tubes
 
●
 
Please
 
tick
 
(
✔
)
 
Yes
 
for
 
correct
 
instruction.
 
●
 
Please
 
tick
 
(
✔
)
 
No
 
for
 
incorrect
 
instruction.
 
Yes
 
No
 
Remarks
 
Pharmacological
 
Group
 
Fusidic
 
acid
 
cream
 
is
 
a
 
topical
 
antibiotic
 
(Group:
 
Fusidanes)
 
used
 
to
 
treat
 
bacterial
 
skin
 
infections.
 
 
 
 
 
Indications
 
and
 
Dosage
 
Fusidic
 
acid
 
is
 
indicated
 
for
 
the
 
treatment
 
of
 
mild
 
to
 
moderately
 
severe
 
skin
 
and
 
soft-tissue
 
infections
 
which
 
include
 
impetigo,
 
folliculitis,
 
erythrasma,
 
furunculosis,
 
abscesses
 
and
 
infected
 
traumatic
 
wounds
 
and
 
infected
 
eczema
 
 
Fusidic
 
acid
 
is
 
particularly
 
effective
 
against
 
Gram-positive
 
organisms
,
 
with
 
Staphylococcus
 
aureus
,
 
including
 
methicillin-resistant
 
Staphylococcus
 
aureus
 
(MRSA)
,
 
being
 
one
 
of
 
its
 
most
 
notable
 
targets.
 
 
Dosage
 
Apply
 
to
 
the
 
affected
 
area
 
2
 
-
 
3
 
times
 
daily
 
for
 
a
 
duration
 
of
 
7
 
days.
 
Do
 
not
 
use
 
it
 
for
 
more
 
than
 
2
 
weeks.
 
 
To
 
counsel
 
based
 
on
 
specific
 
medication’ s
 
indication
 
and
 
dosage
 
as
 
prescribed
 
by
 
the
 
doctor
 
 
 
 
Method
 
of
 
Administration*
 
1.
 
Apply
 
a
 
thin
 
layer
 
of
 
fusidic
 
acid
 
cream
 
to
 
the
 
affected
 
area
 
2
 
to
 
3
 
times
 
a
 
day,
 
or
 
as
 
directed
 
by
 
a
 
healthcare
 
provider .
 
 
2.
 
Clean
 
the
 
affected
 
area
 
gently
 
before
 
application
 
to
 
remove
 
any
 
dirt
 
or
 
debris.
 
 
3.
 
Treatment
 
duration
 
generally
 
lasts
 
7
 
to
 
14
 
days,
 
depending
 
on
 
the
 
severity
 
of
 
the
 
infection,
 
or
 
as
 
prescribed
 
by
 
a
 
healthcare
 
provider .
 
Do
 
not
 
discontinue
 
treatment
 
prematurely ,
 
even
 
if
 
symptoms
 
improve,
 
unless
 
advised
 
by
 
your
 
healthcare
 
provider .
 
 
Do
 
not
 
stop
 
taking
 
your
 
medication
 
unless
 
advised
 
to
 
do
 
so
 
by
 
your
 
prescriber
 
 
 
 
Special
 
Considerations
 
Pregnancy
 
 
 
 
1.
 
No
 
effects
 
during
 
pregnancy
 
are
 
anticipated.
 
2.
 
Topical
 
fusidic
 
acid
 
cream/ointment
 
can
 
be
 
used
 
during
 
pregnancy .
 
However ,
  
if
 
administration
 
is
 
necessary ,
 
its
 
potential
 
benefits
 
should
 
be
 
weighed
 
against
 
possible
 
hazards
 
to
 
the
 
fetus.
 
 
 
 
 
Breastfeeding
 
 
 
 
1.
 
No
 
effects
 
on
 
the
 
breast-fed
 
new-born/infant
 
are
 
anticipated
 
since
 
systemic
 
exposure
 
of
 
topically
 
applied
 
fusidic
 
acid/sodium
 
fusidate
 
to
 
the
 
breast-feeding
 
woman
 
is
 
negligible.
 
2.
 
Topical
 
fusidic
 
cream
 
can
 
be
 
used
 
during
 
breast-feeding
 
but
 
it
 
is
 
recommended
 
to
 
avoid
 
applying
 
on
 
the
 
breast.
 
 
 
 
Elderly
 
 
 
 
173
 

=== PAGE 175 ===

 
1.
 
Patients
 
who
 
use
 
topical
 
oils,
 
creams,
 
and
 
ointments
 
have
 
potential
 
fall
 
risk
 
.Patients
 
may
 
be
 
advised
 
to
 
wear
 
nonslip
 
socks
 
if
 
applying
 
topical
 
medications
 
to
 
feet.
 
Patients
 
should
 
be
 
advised
 
to
 
apply
 
cream
 
while
 
seated
 
or
 
standing
 
on
 
non-slip
 
surfaces.
 
 
 
 
Paediatric
 
 
 
 
1.
 
The
 
frequency ,
 
type
 
and
 
severity
 
of
 
adverse
 
reactions
 
in
 
children
 
are
 
expected
 
to
 
be
 
the
 
same
 
as
 
in
 
adults.
 
 
 
 
Side
 
Effects
 
and
 
their
 
Management*
 
1.
 
Various
 
skin
 
reactions
 
such
 
as
 
pruritus
 
and
 
rash
 
2.
 
Application
 
site
 
reactions
 
such
 
as
 
pain
 
and
 
irritation.
 
3.
 
Hypersensitivity
 
and
 
angioedema.
 
 
 
 
Storage*
 
1.
 
Keep
 
out
 
of
 
reach
 
of
 
children.
 
2.
 
Keep
 
the
 
container
 
tightly
 
closed.
 
3.
 
Store
 
in
 
a
 
dry
 
place
 
below
 
30°C.
 
4.
 
Protect
 
from
 
light.
 
 
 
 
 
Others
 
1.
 
Overdose
 
is
 
unlikely
 
to
 
occur .
 
2.
 
Unless
 
hypersensitivity
 
to
 
fusidic
 
acid
 
or
 
any
 
of
 
the
 
excipients
 
exists,
 
accidental
 
ingestion
 
of
 
fusidic
 
acid
 
and
 
the
 
concentration
 
of
 
the
 
excipients
 
is
 
too
 
low
 
to
 
constitute
 
a
 
safety
 
risk.
 
3.
 
Avoid
 
prolonged
 
use
 
as
 
it
 
may
 
lead
 
to
 
antibiotic
 
resistance.
 
4.
 
Do
 
not
 
apply
 
to
 
the
 
eyes,
 
mouth,
 
or
 
mucous
 
membrane.
 
5.
 
Avoid
 
using
 
under
 
occlusive
 
dressings
 
unless
 
directed
 
by
 
a
 
physician.
 
 
 
 
Before
 
ending
 
this
 
peer
 
review
 
session,
 
the
 
reviewee
 
should
 
be
 
informed
 
of
 
the
 
step(s)
 
that
 
he/
 
she
 
missed
 
out
 
in
 
order
 
to
 
ensure
 
all
 
the
 
counselling
 
points
 
are
 
being
 
covered.
 
 
Remarks:
 
 
 
 
 
Reviewed
 
by:
 
Name
 
&
 
Signature
                                                                   
Date:
 
 
 
 
 
*Mandatory
 
for
 
validation
 
/
 
peer
 
review
 
References:
 
 
1.
 
Dynapharm
 
(M)
 
SDN
 
BHD
 
(2022).
 
Dyna
 
fusidic
 
cream
 
2%
 
[product
 
insert]
,
 
Revision:
 
Feb
 
2022.
 
2.
 
J.
 
D.,
 
Wilkinson
 
(1998).
 
Fusidic
 
acid
 
in
 
dermatology
.
 
Br
 
J
 
Dermatol.
 
1998
 
Dec;139
 
Suppl
 
53:37-40.
 
3.
 
Price
 
KN,
 
Grinnell
 
M,
 
Butler
 
D,
 
Shah
 
A.
 
Art
 
of
 
prevention:
 
Practical
 
tips
 
for
 
improving
 
adherence
 
to
 
treatments
 
for
 
older
 
patients
 
in
 
dermatology .
 
Int
 
J
 
Womens
 
Dermatol.
 
2021
 
Mar
 
18;7(4):478-481.
 
 
 
 
 
 
174
 

=== PAGE 176 ===

 
Gamma
 
Benzene
 
Hexachloride,
 
Topical
 
Name
 
:
 
 
Unit
 
:
 
 
●
 
Please
 
tick
 
(
✔
)
 
Yes
 
for
 
correct
 
instruction.
 
●
 
Please
 
tick
 
(
✔
)
 
No
 
for
 
incorrect
 
instruction.
 
Yes
 
No
 
Remarks
 
Pharmacological
 
Group
 
Topical
 
insecticide
 
 
 
 
Indications
 
and
 
Dosage
 
1.
 
For
 
topical
 
treatment
 
of
 
head
 
lice
 
(Second-line
 
treatment)
 
Risk
 
of
 
neurologic
 
toxicity .
 
Should
 
only
 
be
 
used
 
in
 
patients
 
who
 
cannot
 
tolerate
 
or
 
have
 
failed
 
first-line
 
treatment
 
with
 
safer
 
medications
 
for
 
the
 
treatment
 
of
 
scabies.
 
 
To
 
counsel
 
based
 
on
 
specific
 
medication’ s
 
indication
 
and
 
dosage
 
as
 
prescribed
 
by
 
the
 
doctor
 
 
 
 
Method
 
of
 
Administration*
 
1.
 
Before
 
applying,
 
wash
 
hair
 
with
 
shampoo
 
for
 
at
 
least
 
1
 
hour
 
and
 
dry
 
it
 
thoroughly .
 
Do
 
not
 
use
 
any
 
creams,
 
oils,
 
or
 
conditioners.
 
2.
 
Shake
 
the
 
lotion
 
well.
 
Apply
 
just
 
enough
 
lotion
 
to
 
make
 
hair,
 
scalp,
 
and
 
the
 
small
 
hairs
 
on
 
the
 
back
 
of
 
neck
 
wet.
 
3.
 
Leave
 
the
 
shampoo
 
on
 
your
 
hair
 
for
 
exactly
 
4
 
minutes.
 
Keep
 
hair
 
uncovered
 
during
 
this
 
time.
 
4.
 
At
 
the
 
end
 
of
 
4
 
minutes,
 
use
 
a
 
small
 
amount
 
of
 
warm
 
water
 
to
 
lather
 
the
 
shampoo.
 
Do
 
not
 
use
 
hot
 
water .
 
5.
 
Wash
 
all
 
of
 
the
 
shampoo
 
off
 
of
 
hair
 
and
 
skin
 
with
 
warm
 
water .
 
6.
 
Dry
 
hair
 
with
 
a
 
clean
 
towel.
 
7.
 
Comb
 
hair
 
with
 
a
 
fine
 
tooth
 
comb
 
(nit
 
comb)
 
or
 
use
 
tweezers
 
to
 
remove
 
nits
 
(empty
 
egg
 
shells
).
 
 
8.
 
 
Missed
 
dose
 
management
:
 
If
 
a
 
dose
 
is
 
missed,
 
use
 
it
 
as
 
soon
 
as
 
possible.
 
If
 
it
 
is
 
almost
 
time
 
for
 
the
 
next
 
dose,
 
use
 
only
 
that
 
dose.
 
Do
 
not
 
use
 
double
 
or
 
extra
 
doses.
 
 
Do
 
not
 
stop
 
your
 
medication
 
unless
 
advised
 
to
 
do
 
so
 
by
 
your
 
prescriber
 
 
 
 
Special
 
Considerations
 
Pregnancy
 
 
 
 
1.
 
There
 
are
 
no
 
adequate
 
and
 
well-controlled
 
studies
 
of
 
gamma
 
benzene
 
hexachloride
 
in
 
pregnant
 
women.
 
A
nother
 
safer
 
agent
 
should
 
be
 
used.
 
 
 
 
Breastfeeding
 
 
 
 
1.
 
Topical
 
application
 
may
 
increase
 
drug
 
milk
 
levels
 
for
 
at
 
least
 
several
 
days.
 
Because
 
it
 
is
 
potentially
 
toxic
 
in
 
infants,
 
is
 
a
 
persistent
 
environmental
 
contaminant,
 
and
 
possibly
 
has
 
estrogenic
 
effects
 
that
 
could
 
decrease
 
lactation
 
as
 
well
 
as
 
affect
 
the
 
nursing
 
infant,
 
another
 
agent
 
should
 
be
 
used
 
.
 
 
 
 
Elderly
 
 
 
 
1.
 
Use
 
with
 
caution
 
due
 
to
 
increased
 
systemic
 
absorption
 
and
 
neurotoxicity .
 
 
 
 
175
 

=== PAGE 177 ===

 
Paediatric
 
 
 
 
1.
 
Use
 
with
 
caution
 
due
 
to
 
increased
 
systemic
 
absorption
 
and
 
neurotoxicity .
 
2.
 
Contraindicated
 
for
 
premature
 
infants
 
because
 
their
 
skin
 
may
 
be
 
more
 
permeable
 
than
 
that
 
of
 
full
 
term
 
infants
 
and
 
their
 
liver
 
enzymes
 
may
 
not
 
be
 
sufficiently
 
developed
 
to
 
metabolize
 
gamma
 
benzene
 
hexachloride
.
 
 
 
 
Fasting
 
 
 
 
N/A
 
 
 
 
Others
  
 
 
 
 
1.
 
Cotraindicated
 
in
 
individuals
 
with
 
known
 
uncontrolled
 
seizure
 
disorders.
 
2.
 
Increased
 
systemic
 
absorption
 
and
 
neurotoxicity
 
for
 
people
 
weighing
 
less
 
than
 
50
 
kg
 
and
 
d
 
individuals
 
with
 
other
 
skin
 
conditions
 
(eg,
 
atopic
 
dermatitis,
 
psoriasis).
 
 
 
 
Side
 
Effects
 
and
 
their
 
Management*
 
1.
 
 
If
 
irritation,
 
sensitization,
 
drowsiness,
 
headache,
 
dizziness,
 
seizure
 
occurs,
 
the
 
patient
 
should
 
be
 
advised
 
to
 
consult
 
a
 
physician.
 
 
 
 
Storage*
 
1.
 
Store
 
below
 
30
 
degrees.
 
2.
 
Keep
 
out
 
of
 
reach
 
of
 
children.
 
3.
 
For
 
external
 
use
 
only.
 
 
 
 
Others
 
1.
 
 
Cleaning
 
of
 
items
 
in
 
prolonged
 
or
 
intimate
 
contact
 
with
 
the
 
head
 
(eg,
 
hats,
 
pillowcases,
 
brushes
 
and
 
combs)
 
may
 
be
 
warranted.
 
Washing
 
the
 
item
 
in
 
hot
 
water
 
(66°C),
 
drying
 
it
 
in
 
a
 
hot
 
dryer
 
for
 
15
 
min
 
or
 
storing
 
it
 
in
 
an
 
occlusive
 
plastic
 
bag
 
for
 
two
 
weeks
 
can
 
kill
 
lice
 
and
 
nits.
 
 
 
 
Before
 
ending
 
this
 
peer
 
review
 
session,
 
the
 
reviewee
 
should
 
be
 
informed
 
of
 
the
 
step(s)
 
that
 
he/
 
she
 
missed
 
out
 
in
 
order
 
to
 
ensure
 
all
 
the
 
counselling
 
points
 
are
 
being
 
covered.
 
 
Remarks:
 
 
 
 
 
Reviewed
 
by:
 
Name
 
&
 
Signature
                                                                   
Date:
 
 
 
 
 
*Mandatory
 
for
 
validation
 
/
 
peer
 
review
 
References:
 
 
1.
 
National
 
Institute
 
of
 
Health
 
(2024).
 
Lindane.
 
MedlinePlus.
 
Retrieved
 
from:
 
https://medlineplus.gov/druginfo/meds/a682651.html
 
2.
 
Formulari
 
Ubat
 
KKM
 
(2025).
 
Accessed
 
on
 
January
 
21,
 
2025.
 
3.
 
Lindane
 
Lotion
 
USP,
 
%
 
(2025).
 
Retrieved
 
from:
 
https://www .accessdata.fda.gov/drugsatfda_docs/label/2003/006309lotionlbl.pdf
.
 
Accessed
 
on
 
January
 
21.
 
2025.
 
4.
 
Lidane.
 
Drug
 
and
 
Lactation
 
Database.
 
Retrieved
 
from:
 
https://www .ncbi.nlm.nih.gov/books/NBK501378/
.
 
Accessed
 
on
 
January
  
21.
 
2025.
 
 
 
176
 

=== PAGE 178 ===

 
Ganirelix
 
 
Name
 
:
 
 
Unit
 
:
 
 
●
 
Please
 
tick
 
(
✔
)
 
Yes
 
for
 
correct
 
instruction.
 
●
 
Please
 
tick
 
(
✔
)
 
No
 
for
 
incorrect
 
instruction.
 
Yes
 
No
 
Remarks
 
Pharmacological
 
Group
 
Gonadotropin-releasing
 
hormone
 
(GnRH)
 
antagonist
 
 
 
 
Indications
 
and
 
Dosage
 
Indication
 
Prevention
 
of
 
premature
 
luteinizing
 
hormone
 
surges
 
in
 
women
 
undergoing
 
controlled
 
ovarian
 
hyperstimulation
 
for
 
assisted
 
reproduction
 
technique
 
Dose
 
Given
 
by
 
SC
 
0.25
 
mg
 
once
 
daily,
 
starting
 
on
 
day
 
6
 
of
 
ovarian
 
stimulation
 
and
 
continued
 
until
 
ovulation
 
induction
 
 
 
 
Method
 
of
 
Administration*
 
Site
 
of
 
administration
 
or
 
injection:
 
●
 
 
Upper
 
leg
 
(preferably)
 
●
 
 
Abdomen
 
●
 
 
Buttock
 
Method
 
of
 
administration:
 
a)
 
Wash
 
hands
 
with
 
soap
 
and
 
water .
 
Dry
 
your
 
hands
 
 
b)
 
Check
 
that
 
the
 
 
-
 
The
 
expiry
 
had
 
not
 
passed
 
 
-
 
The
 
solution
 
is
 
clear
 
and
 
colourless
 
and
 
does
 
not
 
contain
 
particle
 
-
 
The
 
syringe
 
had
 
not
 
been
 
opened
 
or
 
damaged
 
 
c)
 
Sit
 
in
 
a
 
comfortable
 
position
 
so
 
you
 
can
 
easily
 
see
 
the
 
area
 
of
 
site
 
of
 
injection
 
d)
 
Do
 
not
 
inject
 
within
 
2
 
inches
 
of
 
your
 
navel
 
area,
 
near
 
scars,
 
bruises
 
or
 
stretch
 
marks.
 
Use
 
alternate
 
site
 
for
 
the
 
next
 
dose
 
e)
 
Clean
 
the
 
area
 
you
 
have
 
selected
 
for
 
your
 
injection
 
with
 
alcohol
 
swab
 
and
 
allow
  
the
 
area
 
to
 
dry
 
for
 
at
 
least
 
1
 
minute
 
f)
 
Remove
 
the
 
cap
 
to
 
expose
 
the
 
needle.
 
To
 
prevent
 
infection,
 
do
 
not
 
touch
 
the
 
needle
 
or
 
let
 
it
 
come
 
in
 
contact
 
with
 
any
 
surface
 
before
 
injection.
  
 
g)
 
Do
 
not
 
press
 
on
 
the
 
plunger
 
to
 
get
 
rid
 
of
 
air
 
bubbles.
 
This
 
can
 
lead
 
to
 
a
 
loss
 
of
 
the
 
medicine.
  
 
h)
 
Hold
 
the
 
syringe
 
with
 
the
 
dominant
 
hand
 
and
 
with
 
the
 
other
 
hand,
 
gently
 
pinch
 
the
 
cleaned
 
area
 
of
 
the
 
injection
 
site
 
between
 
the
 
forefinger
 
and
 
thumb
 
to
 
make
 
a
 
fold
 
in
 
the
 
skin.
 
Make
 
sure
 
to
 
hold
 
the
 
skin
 
folded
 
throughout
 
the
 
injection.
 
 
i)
 
Insert
 
the
 
full
 
length
 
of
 
the
 
needle
 
into
 
the
 
skin
 
fold
 
at
 
an
 
angle
 
of
 
45-90
 
degree
 
and
 
press
 
down
 
the
 
plunger
 
fully.
 
 
j)
 
Hold
 
for
 
10
 
seconds
 
before
 
removing
 
the
 
needle
 
by
 
pulling
 
it
 
straight
 
out,
 
then
 
let
 
go
 
of
 
the
 
skin
 
fold.
 
 
k)
 
Immediately
 
discard
 
the
 
used
 
needle
 
into
 
a
 
designated
 
disposal
 
bin
 
l)
 
Do
 
not
 
rub
 
the
 
injection
 
site
 
after
 
administration
 
 
Do
 
not
 
stop
 
taking
 
your
 
medication
 
unless
 
advised
 
to
 
do
 
so
 
by
 
your
 
prescriber
 
 
Missed
 
dose
 
management:
 
 
I
f
 
you
 
realize
 
that
 
you
 
forgot
 
a
 
dose,
 
administer
 
it
 
as
 
soon
 
as
 
possible.
 
Do
 
not
 
inject
 
a
 
double
 
dose
 
to
 
make
 
up
 
for
 
a
 
missed
 
dose.
 
If
 
you
 
are
 
more
 
than
 
6
 
hours
 
late
 
(so
 
the
 
time
 
between
 
two
 
injections
 
is
 
longer
 
than
 
30
 
hours)
 
administer
 
the
 
dose
 
as
 
 
 
 
177
 

=== PAGE 179 ===

 
soon
 
as
 
possible,
 
and
 
contact
 
your
 
doctor
 
for
 
further
 
advice.
 
Special
 
Considerations
 
Pregnancy
 
 
 
 
Contraindicated
 
 
 
 
Breastfeeding
 
 
 
 
Contraindicated
 
 
 
 
Elderly
 
 
 
 
NA
 
 
 
 
Paediatric
 
 
 
 
The
 
safety
 
and
 
efficacy
 
of
 
Ganirelix
 
in
 
paediatric
 
patients
 
below
 
age
 
18
 
have
 
not
 
been
 
established
.
 
 
 
 
Fasting
 
 
 
 
To
 
refer
 
to
 
the
 
latest
 
advisory
 
by
 
religious
 
authority
 
 
 
 
Others
 
 
 
 
NA
 
 
 
 
Side
 
Effects
 
and
 
their
 
Management*
 
Redness,
 
swelling
 
of
 
skin
 
at
 
the
 
injection
 
site.
 
 
Headache,
  
Nausea,
 
Dizziness.
 
 
Tiredness
 
and
 
malaise
 
(general
 
feeling
 
of
 
being
 
unwell)
  
Abdominal
 
pain,
 
Hot
 
flushes,
 
Vaginal
 
bleeding.
 
 
Seek
 
help
 
from
 
doctor
 
if
 
symptoms
 
worsen
 
 
 
 
Storage*
 
●
 
Keep
 
out
 
of
 
reach
 
and
 
sight
 
of
 
children.
 
 
●
 
Store
 
at
 
room
 
temperature
 
between
 
15°C
 
and
 
30°C.
 
 
●
 
Store
 
in
 
the
 
original
 
package
 
in
 
order
 
to
 
protect
 
from
 
light
 
 
 
 
Others
 
Administration
 
timing
 
and
 
importance
 
of
 
compliance
 
●
 
Always
 
inject
 
at
 
the
 
same
 
specified
 
time
 
of
 
the
 
day
 
●
 
Importance
 
of
 
rotation
 
of
 
side
 
of
 
administration
 
 
Disposal
 
of
 
sharps
 
(syringe,
 
needles,
 
vial,
 
ampoule)
 
●
 
Dispose
 
sharps
 
in
 
a
 
container
 
before
 
disposal
 
●
 
Collect
 
sharps
 
in
 
a
 
container
 
and
 
return
 
to
 
the
 
pharmacy
 
or
 
healthcare
 
facility
 
for
 
proper
 
disposal
 
into
 
a
 
sharp
 
bin.
 
 
 
 
Before
 
ending
 
this
 
peer
 
review
 
session,
 
the
 
reviewee
 
should
 
be
 
informed
 
of
 
the
 
step(s)
 
that
 
he/
 
she
 
missed
 
out
 
in
 
order
 
to
 
ensure
 
all
 
the
 
counselling
 
points
 
are
 
being
 
covered.
 
 
Remarks:
 
 
 
Reviewed
 
by:
 
Name
 
&
 
Signature
                                                                   
Date:
 
 
 
*Mandatory
 
for
 
validation
 
/
 
peer
 
review
 
References:
 
1.
 
Fertility
 
Pharmacy
 
Services
 
Hospital
 
Tunku
 
Azizah
 
Protocol
 
2023
 
2.
 
Formulari
 
Ubat
 
KKM
 
(FUKKM).
 
(Version
 
241030.001
)
  
Retrieved
 
from
 
https://i.pharmacy .gov.my/fukkm
 
3.
 
Product
 
Insert
 
Orgalutran
 
178
 

=== PAGE 180 ===

 
Gentamicin,
 
Topical
 
Name
 
:
 
 
Unit
 
:
 
 
●
 
Please
 
tick
 
(
✔
)
 
Yes
 
for
 
correct
 
instruction.
 
●
 
Please
 
tick
 
(
✔
)
 
No
 
for
 
incorrect
 
instruction.
 
Yes
 
No
 
Remarks
 
Pharmacological
 
Group
 
Antibiotic,
 
Topical
 
 
 
 
Indications
 
and
 
Dosage
 
Indication:
 
For
 
the
 
treatment
 
of
 
primary
 
and
 
secondary
 
skin
 
infections
 
caused
 
by
 
susceptible
 
bacteria.
 
 
Dosage:
 
Apply
 
2
 
-
 
4
 
times
 
daily
 
to
 
affected
 
area
 
 
To
 
counsel
 
based
 
on
 
specific
 
medication’ s
 
indication
 
and
 
dosage
 
as
 
prescribed
 
by
 
the
 
doctor
 
 
 
 
Method
 
of
 
Administration*
 
1.
 
Clean
 
the
 
affected
 
area
 
and
 
remove
 
any
 
crusts
 
(e.g.,
 
in
 
cases
 
of
 
impetigo
 
contagiosa)
 
if
 
necessary
 
2.
 
Apply
 
a
 
small
 
amount
 
of
 
cream/ointment
 
gently
 
to
 
the
 
affected
 
area.
 
3.
 
The
 
treated
 
area
 
may
 
be
 
covered
 
with
 
a
 
sterile
 
gauze
 
dressing,
 
if
 
needed,
 
to
 
protect
 
the
 
application
 
site.
 
 
Do
 
not
 
stop
 
taking
 
your
 
medication
 
unless
 
advised
 
to
 
do
 
so
 
by
 
your
 
prescriber
 
 
 
 
Special
 
Considerations
 
Pregnancy
 
 
 
 
1.
 
When
 
gentamicin
 
is
 
applied
 
topically
 
to
 
large,
 
denuded
 
areas
 
of
 
skin,
 
there
 
is
 
a
 
potential
 
risk
 
of
 
fetal
 
ototoxicity ,
 
as
 
systemic
 
absorption
 
may
 
occur .
 
2.
 
Use
 
during
 
pregnancy
 
should
 
be
 
considered
 
only
 
if
 
the
 
potential
 
benefits
 
outweigh
 
the
 
risks,
 
and
 
under
 
the
 
guidance
 
of
 
a
 
healthcare
 
provider .
 
 
 
 
 
 
 
 
 
Breastfeeding
 
 
 
 
1.
 
While
 
systemic
 
absorption
 
of
 
topical
 
gentamicin
 
is
 
generally
 
low,
 
caution
 
should
 
be
 
exercised
 
if
 
applied
 
to
 
large,
 
denuded
 
areas
 
of
 
skin,
 
as
 
this
 
may
 
increase
 
the
 
risk
 
of
 
systemic
 
absorption
 
and
 
potential
 
ototoxicity
 
in
 
the
 
breastfeeding
 
infant.
 
2.
 
Avoid
 
applying
 
gentamicin
 
to
 
the
 
breast
 
area
 
to
 
prevent
 
accidental
 
ingestion
 
by
 
the
 
infant.
 
 
 
 
Elderly
 
 
 
 
1.
 
Refer
 
to
 
adult
 
dosing
 
May
 
consider:
 
-
 
Systemic
 
absorption
 
of
 
gentamicin
 
from
 
topical
 
application
 
is
 
usually
 
minimal;
 
however ,
 
caution
 
is
 
advised
 
in
 
elderly
 
patients,
 
particularly
 
when
 
applied
 
to
 
large
 
or
 
denuded
 
areas
 
of
 
skin,
 
as
 
absorption
 
may
 
be
 
increased
 
due
 
to
 
age-related
 
changes
 
in
 
skin
 
integrity .
 
-
 
Elderly
 
patients
 
may
 
also
 
have
 
an
 
increased
 
risk
 
of
 
nephrotoxicity
 
and
 
ototoxicity
 
if
 
systemic
 
absorption
 
occurs,
 
especially
 
in
 
those
 
with
 
pre-existing
 
renal
 
impairment.
 
-
 
Close
 
monitoring
 
is
 
recommended
 
for
 
prolonged
 
use
 
or
 
extensive
 
application.
 
-
 
Patients
 
who
 
use
 
topical
 
oils,
 
creams,
 
and
 
ointments
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
179
 

=== PAGE 181 ===

 
have
 
potential
 
fall
 
risk
 
.Patients
 
may
 
be
 
advised
 
to
 
wear
 
nonslip
 
socks
 
if
 
applying
 
topical
 
medications
 
to
 
feet.
 
Patients
 
should
 
be
 
advised
 
to
 
apply
 
cream
 
while
 
seated
 
or
 
standing
 
on
 
non-slip
 
surfaces.
 
 
 
Paediatric
 
 
 
 
1.
 
Apply
 
a
 
small
 
amount
 
gently
 
to
 
the
 
cleansed
 
affected
 
area.
 
May
 
cover
 
with
 
gauze
 
dressing.
 
 
 
 
Others
 
 
 
 
 
1.
 
Hepatic
 
and
 
renal
 
impairment:
 
There
 
are
 
no
 
dosage
 
adjustments
 
provided
 
in
 
the
 
manufacturer's
 
labelling
 
for
 
kidney
 
and
 
liver
 
impairment.
 
However ,
 
dosage
 
adjustment
 
is
 
unlikely
 
due
 
to
 
low
 
systemic
 
absorption.
 
2.
 
Contraindication:
 
Hypersensitivity
 
to
 
g
е
ո
tami
ϲ
i
ո
 
or
 
any
 
component
 
of
 
the
 
formulation
 
 
 
 
Side
 
Effects
 
and
 
their
 
Management*
 
1.
 
Hypersensitivity
 
reactions:
 
Topical
 
use
 
has
 
been
 
associated
 
with
 
itching,
 
redness,
 
swelling
 
and
 
other
 
signs
 
of
 
irritation
 
that
 
are
 
not
 
present
 
before
 
therapy .
 
Discontinuation
 
of
 
therapy
 
normally
 
brings
 
relief
 
to
 
the
 
symptoms.
 
2.
 
Superinfection:
 
Prolonged
 
use
 
may
 
result
 
in
 
fungal
 
or
 
bacterial
 
superinfection;
 
discontinue
 
if
 
superinfection
 
is
 
noted.
 
 
 
 
Storage*
 
1.
    
Store
 
under
 
room
 
temperature,
 
below
 
30
o
C
 
 
 
 
Others
 
1.
 
For
 
external
 
use
 
only;
 
not
 
for
 
ophthalmic
 
use.
 
2.
 
Long-term
 
use:
 
Not
 
intended
 
for
 
long-term
 
therapy .
 
 
 
 
Before
 
ending
 
this
 
peer
 
review
 
session,
 
the
 
reviewee
 
should
 
be
 
informed
 
of
 
the
 
step(s)
 
that
 
he/
 
she
 
missed
 
out
 
in
 
order
 
to
 
ensure
 
all
 
the
 
counselling
 
points
 
are
 
being
 
covered.
 
 
Remarks:
 
 
 
 
 
Reviewed
 
by:
 
Name
 
&
 
Signature
                                                                   
Date:
 
 
 
 
 
*Mandatory
 
for
 
validation
 
/
 
peer
 
review
 
References:
 
 
1.
 
Gentamicin
 
(topical)
 
(2024).
 
UpToDate
 
[Drug
 
information]
 
Retrieved
 
November
 
14,
 
2024,
 
from
 
https://www .uptodate.com
 
2.
 
Hovid
 
BHD
 
(2021).
 
Gentamicin
 
cream
 
0.1%
 
[product
 
Insert]
 
3.
 
MIMS
 
Malaysia.
 
(n.d.)
 
Gentamicin.
 
MIMS
 
Pte
 
Ltd.
 
Retrieved
 
November
 
13,
 
2024,
 
from
 
https://www .mims.com/malaysia/drug/info/gentamicin?mtype=generic
.
 
4.
 
Price
 
KN,
 
Grinnell
 
M,
 
Butler
 
D,
 
Shah
 
A.
 
Art
 
of
 
prevention:
 
Practical
 
tips
 
for
 
improving
 
adherence
 
to
 
treatments
 
for
 
older
 
patients
 
in
 
dermatology .
 
Int
 
J
 
Womens
 
Dermatol.
 
2021
 
Mar
 
18;7(4):478-481.
 
 
 
 
 
180
 

=== PAGE 182 ===

 
Glucagon
 
like
 
peptide-1
 
Receptor
 
Agonist
 
(GLP-1
 
RA)
 
Name
 
:
 
 
Unit
 
:
 
 
●
 
Please
 
tick
 
(
✔
)
 
Yes
 
for
 
correct
 
instruction.
 
●
 
Please
 
tick
 
(
✔
)
 
No
 
for
 
incorrect
 
instruction.
 
Yes
 
No
 
Remarks
 
Pharmacological
 
Group
 
GLP-1
 
receptor
 
agonist
 
(GLP-1
 
RA)
 
1.
 
Currently
 
available
 
in
 
Malaysia:
 
 
a.
 
Liraglutide
 
(daily
 
injection)
 
b.
 
Dulaglutide
 
(weekly
 
injection)
 
c.
 
Semaglutide
 
(weekly
 
injection
 
and
 
oral
 
tablet)
 
d.
 
combination
 
of
 
insulin
 
Glargine
 
with
 
Lixisenatide
 
(daily
 
injection)
 
 
 
 
Indications
 
and
 
Dosage
 
1.
 
Treatment
 
for
 
T2DM.
 
   
Dosage:
 
titration
 
and
 
maintenance
 
dose
 
depending
 
on
    
   
agent
 
a.
 
Liraglutide:
 
 
i.
 
Initiate
 
at
 
0.6
 
mg
 
injected
 
subcutaneously
 
once
 
daily
 
for
 
one
 
week
 
then
 
increase
 
to
 
1.2
 
mg
 
daily.
 
 
ii.
 
If
 
additional
 
glycemic
 
control
 
is
 
required,
 
increase
 
the
 
dose
 
to
 
1.8
 
mg
 
daily
 
after
 
one
 
week
 
of
 
treatment
 
with
 
the
 
1.2
 
mg
 
daily
 
dose.
 
 
b.
 
Dulaglutide:
 
 
i.
 
Recommended
 
starting
 
dosage
 
is
 
0.75
 
mg
 
injected
 
subcutaneously
 
once
 
weekly .
 
 
ii.
 
After
 
4
 
weeks,
 
the
 
dosage
 
may
 
be
 
increased
 
to
 
1.5
 
mg
 
once
 
weekly
 
for
 
additional
 
glycemic
 
control.
 
 
iii.
 
If
 
additional
 
glycemic
 
control
 
is
 
needed,
 
increase
 
the
 
dosage
 
in
 
1.5
 
mg
 
increments
 
after
 
at
 
least
 
4
 
weeks
 
on
 
the
 
current
 
dosage.
 
iv.
 
The
 
maximum
 
recommended
 
dosage
 
is
 
4.5
 
mg
 
injected
 
subcutaneously
 
once
 
weekly
 
 
c.
 
Semaglutide
 
(injection):
 
 
i.
 
Start
 
at
 
0.25
 
mg
 
once
 
weekly .
 
 
ii.
 
After
 
4
 
weeks,
 
increase
 
the
 
dosage
 
to
 
0.5
 
mg
 
once
 
weekly .
 
 
iii.
 
If
 
additional
 
glycemic
 
control
 
is
 
needed,
 
increase
 
the
 
dosage
 
to
 
1
 
mg
 
once
 
weekly
 
after
 
at
 
least
 
4
 
weeks
 
on
 
the
 
0.5
 
mg
 
dose.
 
 
iv.
 
If
 
additional
 
glycemic
 
control
 
is
 
needed,
 
increase
 
the
 
dosage
 
to
 
2
 
mg
 
once
 
weekly
 
after
 
at
 
least
 
4
 
weeks
 
on
 
the
 
1
 
mg
 
dosage
 
 
d.
 
Semaglutide
 
(oral
 
tablet):
 
 
i.
 
Day
 
1
 
to
 
30:
 
The
 
recommended
 
starting
 
dosage
 
is
 
3
 
mg
 
orally
 
once
 
daily
 
for
 
30
 
days
 
(this
 
dosage
 
is
 
not
 
effective
 
for
 
glycemic
 
control)
 
 
ii.
 
Days
 
31
 
to
 
60:
 
Increase
 
the
 
dosage
 
to
 
7
 
mg
 
orally
 
once
 
daily.
 
 
iii.
 
On
 
Day
 
61
 
or
 
thereafter ,
 
if:
 
No
 
additional
 
glycemic
 
control
 
is
 
needed,
 
maintain
 
the
 
dosage
 
at
 
7
 
mg
 
orally
 
once
 
daily.
 
Additional
 
 
 
 
181
 

=== PAGE 183 ===

 
glycemic
 
control
 
is
 
needed,
 
increasing
 
the
 
dosage
 
to
 
14
 
mg
 
orally
 
once
 
daily.
 
 
e.
 
Lixisenatide
 
(in
 
combination
 
with
 
insulin
 
Glargine):
 
i.
 
Discontinue
 
therapy
 
with
 
basal
 
insulin
 
or
 
a
 
GLP-1
 
RA
 
prior
 
to
 
initiation
 
of
 
insulin
 
glargine
 
+
 
lixisenatide.
 
ii.
 
In
 
patients
 
inadequately
 
controlled
 
on
 
less
 
than
 
30
 
units
 
of
 
basal
 
insulin
 
or
 
on
 
lixisenatide,
 
the
 
starting
 
dosage
 
is
 
15
 
units
 
(15
 
units
 
insulin
 
glargine/5
 
mcg
 
lixisenatide)
 
given
 
subcutaneously
 
once
 
daily.
 
iii.
 
In
 
patients
 
inadequately
 
controlled
 
on
 
30
 
to
 
60
 
units
 
of
 
basal
 
insulin,
 
the
 
starting
 
dosage
 
is
 
30
 
units
 
(30
 
units
 
insulin
 
glargine/10
 
mcg
 
lixisenatide)
 
given
 
subcutaneously
 
once
 
daily.
 
 
iv.
 
Titrate
 
the
 
dosage
 
upwards
 
or
 
downwards
 
by
 
two
 
to
 
four
 
units
 
every
 
week
 
based
 
on
 
the
 
patient’ s
 
metabolic
 
needs,
 
blood
 
glucose
 
monitoring
 
results,
 
and
 
glycemic
 
control
 
goal
 
until
 
the
 
desired
 
fasting
 
plasma
 
glucose
 
is
 
achieved.
 
 
v.
 
Maximum
 
daily
 
dosage
 
is
 
60
 
units
 
(60
 
units
 
of
 
insulin
 
glargine
 
and
 
20
 
mcg
 
of
 
lixisenatide).
 
 
2.
 
Treatment
 
for
 
obesity
 
 
a.
 
Liraglutide:
 
Doses
 
up
 
to
 
3
 
mg
 
daily
 
are
 
approved
 
for
 
obesity
 
management.
 
b.
 
Semaglutide:
 
Higher
 
doses
 
(e.g.,
 
2.4
 
mg
 
weekly
 
SC)
 
have
 
been
 
approved
 
for
 
weight
 
management
 
in
 
obesity .
 
Method
 
of
 
Administration*
 
Injection
 
 
Administration
 
and
 
missed
 
dose
 
management
 
 
A.
 
Liraglutide
 
(Victoza
®
)
 
1.
 
Administer
 
subcutaneously
 
(SC)
 
in
 
the
 
abdomen,
 
thigh,
 
or
 
upper
 
arm
 
once
 
daily
 
at
 
any
 
time
 
of
 
the
 
day,
 
with
 
or
 
without
 
meals.
 
 
2.
 
Rotate
 
injection
 
sites
 
to
 
reduce
 
irritation.
 
3.
 
When
 
using
 
injection
 
of
 
Liraglutide
 
with
 
insulin,
 
administer
 
as
 
separate
 
injections.
 
It
 
is
 
acceptable
 
to
 
inject
 
Liraglutide
 
and
 
insulin
 
in
 
the
 
same
 
body
 
region
 
but
 
the
 
injections
 
should
 
not
 
be
 
adjacent
 
to
 
each
 
other .
 
4.
 
If
 
a
 
dose
 
is
 
missed
 
less
 
than
 
12
 
hours,
 
administer
 
the
 
dose
 
as
 
soon
 
as
 
possible.
 
If
 
more
 
than
 
12
 
hours
 
have
 
passed,
 
skip
 
the
 
dose
 
and
 
resume
 
the
 
once-daily
 
dosage
 
regimen
 
as
 
prescribed
 
with
 
the
 
next
 
scheduled
 
dose.
 
Do
 
not
 
administer
 
an
 
extra
 
dose
 
or
 
increase
 
the
 
dose
 
to
 
make
 
up
 
for
 
the
 
missed
 
dose.
 
5.
 
If
 
more
 
than
 
3
 
days
 
elapsed
 
since
 
the
 
last
 
dose,
 
initiate
 
therapy
 
at
 
0.6
 
mg/day
 
to
 
avoid
 
GI
 
symptoms.
 
 
B.
 
Dulaglutide
 
(Trulicity
®
)
 
 
 
 
182
 

=== PAGE 184 ===

 
1.
 
Administer
 
subcutaneously
 
(SC)
 
in
 
the
 
abdomen,
 
thigh,
 
or
 
upper
 
arm
 
once
 
weekly
 
on
 
the
 
same
 
day
 
each
 
week
 
at
 
any
 
time
 
of
 
the
 
day,
 
with
 
or
 
without
 
food.
 
2.
 
Rotate
 
injection
 
sites
 
to
 
reduce
 
irritation.
 
3.
 
When
 
using
 
injection
 
Dulaglutide
 
with
 
insulin,
 
administer
 
as
 
separate
 
injections.
 
It
 
is
 
acceptable
 
to
 
inject
 
Dulaglutide
 
and
 
insulin
 
in
 
the
 
same
 
body
 
region
 
but
 
the
 
injections
 
should
 
not
 
be
 
adjacent
 
to
 
each
 
other .
 
4.
 
If
 
a
 
dose
 
is
 
missed,
 
administer
 
as
 
soon
 
as
 
possible
 
within
 
4
 
days
 
after
 
the
 
missed
 
dose.
 
If
 
less
 
than
 
3
 
days
 
remain
 
before
 
the
 
next
 
scheduled
 
dose,
 
skip
 
the
 
missed
 
dose
 
and
 
administer
 
the
 
next
 
dose
 
on
 
the
 
regularly
 
scheduled
 
day.
 
5.
 
The
 
day
 
of
 
weekly
 
administration
 
can
 
be
 
changed,
 
if
 
necessary ,
 
as
 
long
 
as
 
the
 
last
 
dose
 
was
 
administered
 
3
 
or
 
more
 
days
 
before
 
the
 
new
 
day
 
of
 
administration.
 
 
 
C.
 
Semaglutide
 
(Ozempic
®
)
 
1.
 
Administer
 
subcutaneously
 
(SC)
 
in
 
the
 
abdomen,
 
thigh,
 
or
 
upper
 
arm
 
once
 
weekly
 
at
 
any
 
time
 
of
 
day,
 
with
 
or
 
without
 
meals.
 
 
2.
 
Rotate
 
injection
 
sites
 
to
 
reduce
 
irritation.
 
3.
 
When
 
using
 
injection
 
Semaglutide
 
with
 
insulin,
 
administer
 
as
 
separate
 
injections.
 
It
 
is
 
acceptable
 
to
 
inject
 
Semaglutide
 
and
 
insulin
 
in
 
the
 
same
 
body
 
region
 
but
 
the
 
injections
 
should
 
not
 
be
 
adjacent
 
to
 
each
 
other .
 
4.
 
If
 
a
 
dose
 
is
 
missed,
 
administer
 
it
 
as
 
soon
 
as
 
possible
 
within
 
5
 
days
 
after
 
the
 
missed
 
dose.
 
If
 
more
 
than
 
5
 
days
 
have
 
passed,
 
skip
 
the
 
missed
 
dose
 
and
 
administer
 
the
 
next
 
dose
 
on
 
the
 
regularly
 
scheduled
 
day.
 
In
 
each
 
case,
 
patients
 
can
 
then
 
resume
 
their
 
regular
 
once-weekly
 
dosing
 
schedule.
 
5.
 
The
 
day
 
of
 
weekly
 
administration
 
can
 
be
 
changed
 
if
 
necessary
 
as
 
long
 
as
 
the
 
time
 
between
 
two
 
doses
 
is
 
at
 
least
 
2
 
days
 
(>48
 
hours).
 
 
D.
 
Lixisenatide/
 
insulin
 
Glargine
 
(
Soliqua
®
)
 
1.
 
Administer
 
subcutaneously
 
(SC)
 
in
 
the
 
abdomen,
 
thigh,
 
or
 
upper
 
arm
 
once
 
daily,
 
60
 
minutes
 
before
 
the
 
first
 
meal
 
of
 
the
 
day.
 
 
2.
 
Rotate
 
injection
 
sites
 
to
 
reduce
 
irritation.
 
3.
 
If
 
a
 
dose
 
is
 
missed,
 
resume
 
the
 
once-daily
 
regimen
 
as
 
prescribed
 
with
 
the
 
next
 
scheduled
 
dose.
 
 
Injection
 
technique
 
 
Dulaglutide
 
(Trulicity
®
)
 
1.
 
Before
 
removing
 
the
 
cap,
 
make
 
sure
 
the
 
pen
 
is
 
locked.
 
Pull
 
off
 
the
 
grey
 
base
 
cap.
 
Do
 
not
 
put
 
the
 
base
 
cap
 
back
 
on
 
because
 
this
 
could
 
damage
 
the
 
needle.
 
2.
 
Place
 
the
 
clear
 
base
 
flat
 
and
 
firmly
 
against
 
the
 
skin
 
at
 
the
 
injection
 
site.
 
Unlock
 
by
 
turning
 
the
 
lock
 
ring.
 
3.
 
Press
 
and
 
hold
 
the
 
green
 
injection
 
button.
 
Listen
 
for
 
the
 
first
 
click
 
to
 
indicate
 
injection
 
start.
 
4.
 
Hold
 
in
 
place
 
until
 
the
 
second
 
click
 
(5–10
 
seconds),
 
which
 
signals
 
needle
 
retraction.
 
183
 

=== PAGE 185 ===

 
5.
 
Remove
 
the
 
pen
 
from
 
the
 
skin.
 
The
 
injection
 
is
 
complete
 
when
 
the
 
grey
 
part
 
is
 
visible.
 
6.
 
Remove
 
the
 
needle
 
from
 
the
 
skin,
 
recap
 
it
 
with
 
the
 
outer
 
cap,
 
and
 
unscrew
 
it
 
carefully .
 
Replace
 
the
 
pen
 
cap.
 
 
Semaglutide
 
(Ozempic
®
)
 
and
  
Liraglutide
 
(Victoza
®
)
 
1.
 
Remove
 
the
 
protective
 
tab
 
from
 
the
 
outer
 
needle
 
cap.
 
2.
 
Remove
 
the
 
paper
 
tab,
 
screw
 
the
 
needle
 
to
 
the
 
pen
 
and
 
remove
 
the
 
inner
 
and
 
outer
 
cap
 
(do
 
not
 
keep
 
the
 
inner
 
cap).
 
3.
 
Prime
 
only
 
before
 
the
 
first
 
use
 
of
 
a
 
new
 
pen.
 
To
 
prime,
 
turn
 
the
 
dose
 
knob
 
until
 
the
 
flow
 
check
 
symbol.
 
Hold
 
the
 
pen
 
with
 
the
 
needle
 
pointing
 
up,
 
and
 
tap
 
the
 
cartridge
 
gently
 
with
 
your
 
finger
 
a
 
few
 
times
 
to
 
bring
 
any
 
air
 
bubbles
 
to
 
the
 
top
 
of
 
the
 
cartridge.
 
4.
 
Keep
 
the
 
needle
 
pointing
 
up
 
and
 
press
 
the
 
dose
 
button
 
until
 
0
 
mg
 
aligns
 
with
 
the
 
pointer
 
and
 
until
 
a
 
drop
 
can
 
be
 
seen
 
at
 
the
 
needle
 
tip.
 
5.
 
Turn
 
the
 
dose
 
knob
 
until
 
the
 
needed
 
dose
 
aligns
 
with
 
the
 
pointer .
 
6.
 
If
 
mistakenly
 
select
 
a
 
wrong
 
dose,
 
change
 
it
 
by
 
turning
 
the
 
dose
 
knob
 
backwards
 
or
 
forwards
 
until
 
the
 
correct
 
dose
 
aligns
 
with
 
the
 
pointer .
 
Be
 
careful
 
not
 
to
 
press
 
the
 
dose
 
button
 
when
 
turning
 
the
 
dose
 
knob.
 
 
7.
 
Inject
 
by
 
pressing
 
the
 
dose
 
button
 
until
 
0
 
mg
 
aligns
 
with
 
the
 
pointer .
 
Hold
 
in
 
place
 
for
 
at
 
least
 
6
 
seconds.
 
8.
 
Remove
 
the
 
needle
 
from
 
the
 
skin,
 
recap
 
it
 
with
 
the
 
outer
 
cap,
 
and
 
unscrew
 
it
 
carefully .
 
Replace
 
the
 
pen
 
cap.
 
 
Lixisenatide/
 
insulin
 
Glargine
 
(
Soliqua
®
)
 
1.
 
Remove
 
the
 
protective
 
tab
 
from
 
the
 
outer
 
needle
 
cap.
 
2.
 
Remove
 
the
 
paper
 
tab,
 
screw
 
the
 
needle
 
to
 
the
 
pen
 
and
 
remove
 
the
 
inner
 
and
 
outer
 
cap
 
(do
 
not
 
keep
 
the
 
inner
 
cap).
 
3.
 
Prime
 
before
 
each
 
injection.
 
To
 
prime,
 
select
 
2
 
units
 
by
 
turning
 
the
 
dose
 
selector
 
until
 
the
 
dose
 
pointer
 
is
 
at
 
the
 
2
 
mark.
 
4.
 
Keep
 
the
 
needle
 
pointing
 
up
 
and
 
press
 
the
 
injection
 
button
 
all
 
the
 
way
 
in.
 
5.
 
Turn
 
the
 
dose
 
knob
 
until
 
the
 
needed
 
dose
 
aligns
 
with
 
the
 
pointer .
 
6.
 
If
 
mistakenly
 
select
 
a
 
wrong
 
dose,
 
change
 
it
 
by
 
turning
 
the
 
dose
 
knob
 
backwards
 
or
 
forwards
 
until
 
the
 
correct
 
dose
 
aligns
 
with
 
the
 
pointer .
 
Be
 
careful
 
not
 
to
 
press
 
the
 
dose
 
button
 
when
 
turning
 
the
 
dose
 
knob.
 
 
7.
 
Inject
 
by
 
placing
 
the
 
thumb
 
on
 
the
 
injection
 
button.
 
Then
 
press
 
all
 
the
 
way
 
in
 
and
 
hold
 
for
 
10
 
seconds.
 
8.
 
Remove
 
the
 
needle
 
from
 
the
 
skin,
 
recap
 
it
 
with
 
the
 
outer
 
cap,
 
and
 
unscrew
 
it
 
carefully .
 
Replace
 
the
 
pen
 
cap.
 
Oral
 
 
 
Semaglutide
 
tablet
 
(
Rybelsus
®
)
 
1.
 
Should
 
be
 
taken
 
on
 
an
 
empty
 
stomach
 
upon
 
waking
 
up.
 
2.
 
The
 
tablet
 
should
 
not
 
be
 
split,
 
crushed
 
or
 
chewed.
 
 
3.
 
It
 
should
 
be
 
swallowed
 
whole
 
with
 
a
 
sip
 
of
 
plain
 
water
 
(up
 
to
 
half
 
a
 
glass
 
of
 
plain
 
water
 
equivalent
 
to
 
120
 
ml).
 
Taking
 
the
 
tablet
 
with
 
more
 
than
 
120ml
 
of
 
water
 
may
 
result
 
in
 
adverse
 
absorption
 
of
 
the
 
drug.
 
184
 

=== PAGE 186 ===

 
4.
 
Wait
 
at
 
least
 
30
 
minutes
 
to
 
2
 
hours
 
before
 
eating
 
or
 
drinking.
 
Taking
 
semaglutide
 
with
 
food
 
or
 
less
 
than
 
30
 
minutes
 
before
 
food,
 
beverages
 
or
 
other
 
oral
 
drugs
 
may
 
decrease
 
the
 
absorption
 
of
 
the
 
drug.
 
5.
 
If
 
a
 
dose
 
is
 
missed,
 
skip
 
the
 
dose
 
for
 
that
 
day
 
and
 
take
 
the
 
next
 
dose
 
on
 
the
 
following
 
day.
 
6.
 
Do
 
not
 
place
 
tablets
 
in
 
pill
 
boxes,
 
keep
 
in
 
original
 
blister
 
packs
 
until
 
use.
 
 
Do
 
not
 
stop
 
taking
 
your
 
medication
 
unless
 
advised
 
to
 
do
 
so
 
by
 
your
 
prescriber
 
Special
 
Considerations
 
Pregnancy
 
 
 
 
Should
 
be
 
avoided
 
in
 
pregnancy .
 
Discontinue
 
agents
 
at
 
least
 
2
 
months
 
before
 
trying
 
to
 
conceive.
 
 
 
 
Breastfeeding
 
 
 
 
Should
 
be
 
avoided
 
in
 
breastfeeding.
 
 
 
 
Elderly
 
 
 
 
Limited
 
experience
 
in
 
patients
 
aged
 
>75
 
years.
 
Use
 
with
 
caution,
 
particularly
 
in
 
underweight
 
elderly
 
patients
 
which
 
can
 
cause
 
undernutrition
 
and
 
lead
 
to
 
osteopenia
 
and
 
osteoporosis.
 
 
 
 
 
Paediatric
 
 
 
 
1.
 
Lixisenatide,
 
Semaglutide:
 
Safety
 
and
 
efficacy
 
not
 
established
 
in
 
individuals
 
under
 
18
 
years.
  
 
 
2.
 
Liraglutide
 
and
 
Dulaglutide:
 
Safety
 
and
 
efficacy
 
not
 
established
 
in
 
children
 
under
 
10
 
years.
 
 
 
 
 
Fasting
 
 
 
 
GLP-1
 
RA
 
can
 
be
 
safely
 
used
 
during
 
fasting
 
(e.g.,
 
Ramadan)
 
if
 
dose
 
titration
 
is
 
completed
 
2–4
 
weeks
 
prior.
 
No
 
further
 
modifications
 
are
 
needed.
 
 
 
 
Others
  
 
 
 
 
1.
 
GLP-1
 
RA
 
is
 
not
 
a
 
substitute
 
for
 
insulin.
 
2.
 
GLP-1
 
RA
 
cannot
 
be
 
used
 
for
 
patients
 
with
 
T1DM.
 
3.
 
GLP-1
 
RA
 
can
 
be
 
used
 
as
 
an
 
adjunct
 
to
 
oral
 
glucose-lowering
 
drugs
 
and
 
with
 
insulin
 
therapy .
 
4.
 
GLP-1
 
RA
 
should
 
not
 
be
 
used
 
in
 
patients
 
with
 
a
 
history
 
of
 
pancreatitis.
 
 
5.
 
GLP-1
 
RA
 
should
 
not
 
be
 
used
 
in
 
patients
 
with
 
a
 
history
 
of
 
or
 
a
 
family
 
history
 
of
 
MEN
 
2A
 
or
 
2B
 
or
 
medullary
 
thyroid
 
cancer .
 
6.
 
Lixisenatide
 
should
 
not
 
be
 
used
 
in
 
patients
 
with
 
gastroparesis.
 
7.
 
For
 
Semaglutide,
 
patients
 
with
 
a
 
history
 
of
 
diabetic
 
retinopathy
 
should
 
be
 
monitored
 
for
 
progression
 
of
 
retinopathy
 
and
 
slower
 
dose
 
titration
 
may
 
be
 
warranted.
 
8.
 
Use
 
with
 
caution
 
in
 
patients
 
at
 
risk
 
of
 
kidney
 
injury
 
due
 
to
 
dehydration
 
or
 
volume
 
contraction
 
(e.g.,
 
polyuria,
 
polydipsia,
 
or
 
those
 
on
 
renin-angiotensin
 
system
 
inhibitors).
 
 
 
 
Side
 
Effects
 
and
 
their
 
1.
 
Gastrointestinal
 
symptoms
 
-
 
The
 
most
 
common
 
side
 
effects
 
are
 
usually
 
mild
 
to
 
 
 
 
185
 

=== PAGE 187 ===

 
Management*
 
moderate
 
but
 
some
 
patients
 
may
 
experience
 
severe
 
symptoms
 
that
 
can
 
increase
 
the
 
risk
 
of
 
acute
 
kidney
 
injury
 
due
 
to
 
volume
 
contraction.
 
-
 
Usually
 
started
 
with
 
a
 
low
 
dose
 
of
 
GLP-1
 
RA
 
and
 
increased
 
slowly
 
to
 
reduce
 
the
 
likelihood
 
of
 
GI
 
side
 
effects.
 
-
 
General
 
advice
 
to
 
reduce
 
the
 
likelihood
 
of
 
GI
 
side
 
effects:
 
1.
 
Improve
 
eating
 
habits:
 
 
-
 
Eat
 
slowly
 
-
 
Eat
 
when
 
hungry
 
and
 
stop
 
at
 
the
 
first
 
sign
 
of
 
fullness
 
-
 
Eat
 
smaller ,
 
more
 
frequent
 
meals.
 
-
 
Choose
 
easy-to-digest
 
food
 
(ie.
 
bland
 
options)
 
-
 
Drink
 
in
 
small
 
sips
 
throughout
 
the
 
day
 
-
 
Avoid
 
lying
 
down
 
after
 
having
 
a
 
meal
 
-
 
Try
 
not
 
to
 
be
 
too
 
active
 
after
 
eating
 
-
 
Avoid
 
eating
 
too
 
close
 
to
 
bedtime
 
 
2.
 
Get
 
some
 
fresh
 
air
 
and
 
do
 
some
 
light
 
exercise
 
 
3.
 
Keeping
 
a
 
food
 
diary
 
may
 
be
 
useful
 
in
 
identifying
 
foods
 
and
 
meal
 
timing
 
that
 
worsen
 
GI
 
side
 
effects
 
 
 
-
 
Additional
 
advice
 
for
 
managing
 
GI
 
side
 
effects:
 
 
a.
 
Nausea
 
-
 
avoid
 
strong
 
smells
 
-
 
eat
 
crackers,
 
mint,
 
or
 
ginger-based
 
food
 
or
 
drinks
 
about
 
half
 
an
 
hour
 
after
 
taking
 
a
 
GLP-1
 
RA.
 
 
b.
 
Vomiting
 
-
 
stay
 
well
 
hydrated
 
-
 
have
 
more
 
frequent
 
meals
 
in
 
smaller
 
amounts.
 
 
c.
 
Diarrhea
 
-
 
drink
 
plenty
 
of
 
water
 
-
 
avoid
 
dairy
 
products
 
and
 
high-fiber
 
foods
 
until
 
symptoms
 
resolve
 
-
 
Eat
 
chicken
 
broth,
 
rice,
 
carrots,
 
very
 
ripe
 
fruit
 
without
 
skin
 
 
d.
 
Constipation
 
-
 
Drink
 
generous
 
amounts
 
of
 
water
 
or
 
other
 
sugar-free
 
liquids
 
-
 
Ensure
 
adequate
 
intake
 
of
 
fibre
 
in
 
diet
 
-
 
Increase
 
physical
 
activity
 
 
 
-
 
In
 
case
 
of
 
persistence
 
of
 
nausea
 
and/or
 
vomiting,
 
avoid
 
drinks
 
during
 
meals,
 
rather
 
have
 
them
 
between
 
30
 
and
 
60
 
min
 
before
 
and/or
 
after
 
meals
 
 
2.
 
Skin
 
side
 
effects
 
-
 
Injection
 
site
 
reactions
 
(rash,
 
erythema
 
or
 
itching)
 
-
 
Usually
 
mild,
 
often
 
transient
 
in
 
nature
 
-
 
Management:
 
rotate
 
injection
 
sites
 
and
 
use
 
proper
 
injection
 
techniques.
 
Cold
 
compresses
 
can
 
help
 
reduce
 
pain.
 
 
3.
 
Small
 
increase
 
in
 
heart
 
rate,
 
clinically
 
not
 
significant
 
 
4.
 
Infections
 
(Upper
 
respiratory
 
tract
 
infections
 
and
 
nasopharyngitis)
 
 
5.
 
Headache
 
186
 

=== PAGE 188 ===

 
-
 
Monitor
 
and
 
manage
 
symptomatically .
 
Storage*
 
A.
 
Liraglutide
 
(Victoza
®
)
 
-
 
Store
 
new,
 
unused
 
pens
 
in
 
the
 
refrigerator
 
at
 
2°C
 
to
 
8°C.
 
Do
 
not
 
freeze.
 
 
-
 
After
 
first
 
use,
 
the
 
pen
 
can
 
be
 
stored
 
for
 
30
 
days
 
at
 
controlled
 
room
 
temperature
 
(15°C
 
to
 
30°C)
 
or
 
in
 
a
 
refrigerator
 
(2°C
 
to
 
8°C).
 
 
-
 
Keep
 
the
 
pen
 
cap
 
on
 
when
 
not
 
in
 
use.
 
Protect
 
the
 
pen
 
from
 
excessive
 
heat
 
and
 
sunlight.
 
 
-
 
Always
 
remove
 
the
 
needle
 
after
 
each
 
injection
 
and
 
store
 
the
 
pen
 
without
 
the
 
needle
 
attached.
 
This
 
reduces
 
the
 
risk
 
of
 
contamination,
 
infection,
 
leakage
 
and
 
inaccurate
 
dosing.
 
 
B.
 
Dulaglutide
 
(Trulicity®)
 
-
 
Store
 
new,
 
unused
 
pens
 
in
 
the
 
refrigerator
 
at
 
2°C
 
to
 
8°C.
 
Do
 
not
 
freeze
 
 
-
 
If
 
needed,
 
each
 
single-dose
 
pen
 
can
 
be
 
kept
 
at
 
room
 
temperature,
 
not
 
to
 
exceed
 
30°C
 
for
 
a
 
total
 
of
 
14
 
days.
 
 
-
 
Keep
 
the
 
pen
 
cap
 
on
 
when
 
not
 
in
 
use.
 
Protect
 
the
 
pen
 
from
 
excessive
 
heat
 
and
 
sunlight.
 
 
-
 
Storage
 
in
 
the
 
original
 
carton
 
is
 
recommended
 
until
 
the
 
time
 
of
 
administration.
 
 
 
C.
 
Semaglutide
 
(Ozempic
®
)
 
 
-
 
Store
 
new,
 
unused
 
pens
 
in
 
the
 
refrigerator
 
at
 
2°C
 
to
 
8°C.
 
Do
 
not
 
freeze
 
-
 
After
 
the
 
first
 
use,
 
pens
 
can
 
be
 
stored
 
at
 
room
 
temperature
 
(15°C
 
to
 
30°C)
 
or
 
refrigerated
 
(2°C
 
to
 
8°C)
 
and
 
used
 
within
 
56
 
days.
 
 
-
 
Keep
 
the
 
pen
 
cap
 
on
 
when
 
not
 
in
 
use.
 
Protect
 
the
 
pen
 
from
 
excessive
 
heat
 
and
 
sunlight.
 
 
-
 
Always
 
remove
 
and
 
safely
 
discard
 
the
 
needle
 
after
 
each
 
injection
 
and
 
store
 
the
 
pen
 
without
 
an
 
injection
 
needle
 
attached.
 
D.
 
Lixisenatide/
 
insulin
 
Glargine
 
(
Soliqua
®
)
 
-
 
Store
 
new,
 
unused
 
pens
 
in
 
the
 
refrigerator
 
at
 
2°C
 
to
 
8°C.
 
Protect
 
the
 
pen
 
from
 
light.
 
Do
 
not
 
freeze
 
the
 
pen
 
and
 
do
 
not
 
use
 
it
 
if
 
it
 
has
 
been
 
frozen.
 
-
 
After
 
first
 
use,
 
store
 
the
 
pen
 
at
 
room
 
temperature
 
no
 
higher
 
than
 
25°C.
 
Use
 
the
 
pen
 
for
 
up
 
to
 
28
 
days.
 
-
 
Replace
 
the
 
pen
 
cap
 
after
 
each
 
use
 
to
 
protect
 
it
 
from
 
light.
 
 
-
 
Remove
 
the
 
needle
 
after
 
each
 
injection
 
and
 
store
 
the
 
pen
 
without
 
a
 
needle
 
attached.
 
 
 
 
Others
 
1.
 
Risk
 
of
 
hypoglycaemia
 
in
 
patients
 
taking
 
concurrent
 
insulin
 
or
 
sulfonylurea.
 
Consider
 
reducing
 
the
 
dose
 
of
 
insulin
 
or
 
sulfonylurea
 
when
 
starting
 
GLP-1
 
RA.
 
2.
 
Combination
 
therapy
 
with
 
GLP-1
 
receptor
 
agonists
 
and
 
dipeptidyl
 
peptidase-4
 
inhibitors
 
is
 
not
 
recommended
 
due
 
to
 
minimal
 
additional
 
glycemic
 
benefits
 
observed
 
in
 
studies,
 
alongside
 
an
 
increased
 
risk
 
of
 
adverse
 
effects
 
such
 
as
 
enhanced
 
hypoglycemia.
 
Both
 
drug
 
classes
 
work
 
on
 
the
 
incretin
 
pathway ,
 
making
 
their
 
combined
 
use
 
redundant
 
3.
 
Concurrent
 
administration
 
of
 
GLP-1
 
RA
 
with
 
warfarin
 
may
 
alter
 
the
 
absorption
 
of
 
warfarin
 
as
 
GLP-1
 
RA
 
delays
 
gastric
 
motility .
 
Regular
 
INR
 
monitoring
 
is
 
recommended
 
in
 
patients
 
taking
 
concomitant
 
GLP-1
 
 
 
 
187
 

=== PAGE 189 ===

 
RA
 
and
 
warfarin.
 
4.
 
Several
 
drugs
 
(paracetamol,
 
digoxin,
 
oral
 
contraceptive
 
pills,
 
statin,
 
ACE
 
inhibitor)
 
have
 
been
 
reported
 
to
 
interact
 
with
 
GLP-1
 
RA
 
resulting
 
in
 
delayed
 
absorption
 
with
 
no
 
significant
 
clinical
 
outcome.
 
To
 
avoid
 
delayed
 
absorption
 
of
 
interacting
 
drugs,
 
administer
 
at
 
least
 
one
 
hour
 
before
 
GLP-1
 
RA.
 
5.
 
Risk
 
of
 
developing
 
pancreatitis
 
especially
 
in
 
patients
 
with
 
risk
 
factors.
 
GLP-1
 
RA
 
should
 
be
 
discontinued
 
in
 
patients
 
who
 
develop
 
acute
 
pancreatitis.
 
Before
 
ending
 
this
 
peer
 
review
 
session,
 
the
 
reviewee
 
should
 
be
 
informed
 
of
 
the
 
step(s)
 
that
 
he/
 
she
 
missed
 
out
 
in
 
order
 
to
 
ensure
 
all
 
the
 
counselling
 
points
 
are
 
being
 
covered.
 
 
Remarks:
 
 
 
 
 
Reviewed
 
by:
 
Name
 
&
 
Signature
                                                                   
Date:
 
 
 
 
 
*Mandatory
 
for
 
validation
 
/
 
peer
 
review
 
References:
 
 
1.
 
Bækdal
 
T.A.,
 
Breitschaft
 
A.,
 
Donsmark
  
M.,
 
Maarbjerg
 
S.J.,
 
Søndergaard
 
F.L.
 
&
 
Borregaard
 
J.
 
(2021).
 
Effect
 
of
 
various
 
dosing
 
conditions
 
on
 
the
 
pharmacokinetics
 
of
 
oral
 
semaglutide,
 
a
 
human
 
Glucagon-Like
 
Peptide-1
 
analogue
 
in
 
a
 
tablet
 
formulation.
 
Diabetes
 
Therapy ,
 
12,
 
1915–1927
 
2.
 
Collins
 
L.
 
&
 
Costello
 
R.A.
 
(2024).
 
Glucagon-Like
 
Peptide-1
 
Receptor
 
Agonists.
 
National
 
Library
 
of
 
Medicine.
  
https://www .ncbi.nlm.nih.gov/books/NBK551568/
 
3.
 
Isaacs
 
D.M.,
 
Kruger
 
D.F.
 
&
 
Spollet
 
G.R.
 
(2021).
 
Optimizing
 
Therapeutic
 
outcomes
 
with
 
oral
 
semaglutide:
 
A
 
patient
 
centered
 
approach.
 
Diabetes
 
Spectrum,
 
34(1),7–19.
 
https://doi.org/10.2337/ds20-0016
 
4.
 
Eli
 
Lilly.
 
(2024).
 
Trulicity
 
(Dulaglutide)
 
injection
 
prescribing
 
information.
 
Retrieved
 
from
 
https://products.sanofi.us/soliqua100-33/soliqua100-33.pdf
 
 
5.
 
Filippatos
 
T.D.,
 
Panagiotopoulou
 
T.V.
 
&
 
Elisaf
 
M.S.(2014).
 
Adverse
 
Effects
 
of
 
GLP-1
 
Receptor
 
Agonists.
 
Review
 
of
 
Diabetic
 
Studies,
 
11(3),
 
202–230.
 
https://pmc.ncbi.nlm.nih.gov/articles/PMC5397288/
 
 
6.
 
Gorgojo-Martínez
  
J.J.,
 
Mezquita-Raya
 
P.,
 
Carretero-Gómez
 
J.,
 
Castro
 
A.;
 
Cebrián-Cuenca
 
A.,
 
de
 
Torres-Sánchez
 
A.,
 
García-de-Lucas
 
M.D.,
 
Núñez
 
J.,
 
Obaya
 
J.C.,
 
Soler ,
 
M.J.,
 
Gorriz
 
J.L
 
&
 
Rubio-Herrera
 
M.A.
 
(2022).
 
Clinical
 
Recommendations
 
to
 
Manage
 
Gastrointestinal
 
Adverse
 
Events
 
in
 
Patients
 
Treated
 
with
 
Glp-1
 
Receptor
 
Agonists:
 
A
 
Multidisciplinary
 
Expert
 
Consensus.
 
Journal
 
of
 
Clinical
 
Medicine,
 
12(1),
 
145.
 
https://doi.org/10.3390/jcm1201014
5
 
 
7.
 
Hassanein,
 
Mohamed
 
et
 
al.
 
(2022).
 
Diabetes
 
and
 
Ramadan:
 
Practical
 
guidelines
 
2021.
 
Diabetes
 
Research
 
and
 
Clinical
 
Practice,
 
185,
 
109185.
 
https://www .diabetesresearchclinicalpractice.com/article/S0168-8227(21)00545-3/fulltext
 
 
8.
 
Henney ,
 
A.
 
E.,
 
Wilding,
 
J.
 
P.,
 
Alam,
 
U.,
 
&
 
Cuthbertson,
 
D.
 
J.
 
(2024).
 
Obesity
 
pharmacotherapy
 
in
 
older
 
adults:
 
a
 
narrative
 
review
 
of
 
evidence.
 
International
 
Journal
 
of
 
Obesity ,
 
1-12
 
9.
 
Maideen
 
N.M.P .
 
(2019).
 
Pharmacologically
 
relevant
 
drug
 
interactions
 
of
 
Glucagon-like
 
peptide-1
 
receptor
 
agonists.
 
Journal
 
of
 
Analytical
 
&
 
Pharmaceutical
 
Research,
 
8(2),
 
51-53.
 
https://medcraveonline.com/JAPLR/JAPLR-08-0031 1.pdf
 
 
10.
 
Ministry
 
of
 
Health
 
Malaysia.
 
(2020).
 
Clinical
 
practice
 
guidelines
 
on
 
the
 
management
 
of
 
Type
 
2
 
Diabetes
 
Mellitus
 
(6th
 
edition).
 
 
11.
 
Ministry
 
of
 
Health
 
Malaysia.
 
(2023).
 
Clinical
 
practice
 
guidelines
 
on
 
the
 
management
 
of
 
obesity
 
(2nd
 
edition).
 
12.
 
Novo
 
Nordisk.
 
(2024).
 
Ozempic
 
(Semaglutide)
 
injection
 
prescribing
 
information.
 
Retrieved
 
from
 
www .novo-pi.com/ozempic.pdf
 
13.
 
Novo
 
Nordisk.
 
(2024).
 
Rybelsus
 
(Semaglutide)
 
tablet
 
prescribing
 
information.
 
Retrieved
 
from
 
https://www .novo-pi.com/rybelsus.pdf
 
14.
 
Novo
 
Nordisk.
 
(2024).
 
Victoza
 
(Liraglutide)
 
injection
 
prescribing
 
information.
 
Retrieved
 
from
 
https://www .novo-pi.com/victoza.pdf
 
 
15.
 
Sanofi-A ventis.
 
(2024).
 
Soliqua
 
(Insulin
 
Glargine
 
and
 
Lixisenatide)
 
injection
 
prescribing
 
information.
 
Retrieved
 
from
 
https://products.sanofi.us/soliqua100-33/soliqua100-33.pdf
 
.
 
188
 

=== PAGE 190 ===

 
Glyceryl
 
Trinitrate
 
(GTN)
 
Sublingual
 
Spray
 
Name
 
:
 
 
Unit
 
:
 
 
●
 
Please
 
tick
 
(
✔
)
 
Yes
 
for
 
correct
 
instruction.
 
●
 
Please
 
tick
 
(
✔
)
 
No
 
for
 
incorrect
 
instruction.
 
Yes
 
No
 
Remarks
 
Pharmacological
 
Group
 
Nitrate;
 
Antianginal
 
agent
 
 
 
 
Indications
 
and
 
Dosage
 
1.
 
Angina
 
pectoris
 
2.
 
Variant
 
angina
 
 
Dosage:
 
1-2
 
metered
 
sprays
 
sublingual
 
every
 
5
 
minutes
 
as
 
required
 
or
 
5-10minutes
 
prior
 
to
 
activities
 
that
 
might
 
precipitate
 
an
 
acute
 
attack.
 
 
Dosing
 
is
 
according
 
to
 
product
 
insert
 
or
 
protocol.
 
 
 
 
Method
 
of
 
Administration*
 
1.
 
Priming:
 
Before
 
using
 
GTN
 
spray
 
for
 
the
 
first
 
time,
 
check
 
that
 
the
 
spray
 
is
 
working
 
by
 
pressing
 
the
 
spray
 
button
 
a
 
few
 
times
 
until
 
it
 
produces
 
a
 
fine
 
mist
 
of
 
liquid.
 
2.
 
During
 
application
 
the
 
patient
 
should
 
rest,
 
ideally
 
in
 
the
 
sitting
 
position.
 
Advise
 
patients
 
to
 
hold
 
breath
 
prior
 
to
 
spray .
 
3.
 
The
 
canister
 
should
 
be
 
held
 
vertically
 
with
 
the
 
valve
 
head
 
uppermost
 
and
 
the
 
spray
 
orifice
 
as
 
close
 
to
 
the
 
mouth
 
as
 
possible.
 
Press
 
down
 
the
 
button
 
firmly .
 
4.
 
The
 
spray
 
should
 
not
 
be
 
inhaled.
 
5.
 
A
 
spray
 
may
 
be
 
repeated
 
approximately
 
every
 
5
 
minutes
 
as
 
needed.
 
6.
 
If
 
chest
 
pain
 
persists
 
after
 
a
 
total
 
of
 
3
 
sprays,
 
prompt
 
medical
 
attention
 
is
 
recommended.
 
7.
 
Patients
 
should
 
be
 
instructed
 
to
 
familiarise
 
themselves
 
with
 
the
 
position
 
of
 
the
 
spray
 
orifice,
 
which
 
can
 
be
 
identified
 
by
 
the
 
finger
 
rest
 
on
 
top
 
of
 
the
 
valve,
 
in
 
order
 
to
 
facilitate
 
orientation,
 
for
 
administration
 
at
 
night.
 
 
Do
 
not
 
stop
 
taking
 
your
 
medication
 
unless
 
advised
 
to
 
do
 
so
 
by
 
your
 
prescriber .
 
 
 
 
Special
 
Considerations
 
Pregnancy
 
 
 
 
●
 
There
 
is
 
no,
 
or
 
inadequate,
 
evidence
 
of
 
safety
 
of
 
nitrates
 
in
 
human
 
pregnancy .
 
●
 
Nitrates
 
should
 
not
 
be
 
administered
 
in
 
pregnancy
 
unless
 
considered
 
essential.
 
●
 
To
 
inform
 
the
 
prescriber
 
if
 
you
 
are
 
pregnant.
 
 
 
 
Breastfeeding
 
 
 
 
●
 
It
 
is
 
unknown
 
if
 
the
 
drug
 
is
 
present
 
in
 
breast
 
milk.
 
Related
 
data
 
is
 
limited.
 
 
●
 
There
 
is
 
no,
 
or
 
inadequate,
 
evidence
 
of
 
safety
 
of
 
nitrates
 
in
 
lactation;
 
nitrates
 
should
 
not
 
be
 
administered
 
in
 
lactation
 
unless
 
considered
 
essential.
 
●
 
To
 
inform
 
the
 
prescriber
 
if
 
you
 
are
 
breastfeeding.
 
 
 
 
Elderly
 
 
 
 
1.
 
Nitroglycerin
 
can
 
be
 
used
 
safely
 
in
 
elderly
 
patients
 
with
 
careful
 
dose
 
management,
 
monitoring
 
for
 
side
 
effects,
 
and
 
patient
 
education
 
to
 
mitigate
 
risks
 
like
 
 
 
 
189
 

=== PAGE 191 ===

 
hypotension,
 
falls,
 
and
 
tolerance.
 
Paediatric
 
 
 
 
1.
 
No
 
data
 
 
 
 
Fasting
 
 
 
 
To
 
refer
 
to
 
the
 
latest
 
advisory
 
by
 
religious
 
authority
 
 
 
 
Others
 
 
 
 
 
NA
 
 
 
 
Side
 
Effects
 
and
 
their
 
Management*
 
Side
 
effects
 
may
 
include
 
severe
 
headache,
 
blurred
 
vision,
 
dry
 
mouth,
 
dizziness
 
or
 
flushing.
 
If
 
affected,
 
do
 
not
 
drive
 
or
 
operate
 
machinery . 
 
 
 
 
Storage*
 
1.
 
Store
 
below
 
30°C.
 
2.
 
Do
 
not
 
refrigerate
 
or
 
freeze.
 
 
3.
 
Do
 
not
 
use
 
GTN
 
Spray
 
if
 
you
 
are
 
near
 
a
 
naked
 
flame,
 
e.g.
 
a
 
cigarette.
 
 
 
 
Others
 
1.
 
Continuous
 
use
 
may
 
result
 
in
 
a
 
tolerance
 
to
 
GTN
 
spray ,
 
reducing
 
its
 
effectiveness.
 
2.
 
Inability
 
to
 
relieve
 
chest
 
pain
 
after
 
3
 
doses
 
may
 
signal
 
acute
 
myocardial
 
infarction
 
necessitating
 
emergency
 
management. 
 
 
 
 
Before
 
ending
 
this
 
peer
 
review
 
session,
 
the
 
reviewee
 
should
 
be
 
informed
 
of
 
the
 
step(s)
 
that
 
he/
 
she
 
missed
 
out
 
in
 
order
 
to
 
ensure
 
all
 
the
 
counselling
 
points
 
are
 
being
 
covered.
 
 
Remarks:
 
 
 
 
 
Reviewed
 
by:
 
Name
 
&
 
Signature
                                                                   
Date:
 
 
 
 
 
*Mandatory
 
for
 
validation
 
/
 
peer
 
review
 
 
References:
 
 
1.
 
Formulari
 
Ubat
 
KKM.
 
(2025,
 
January
 
1).
 
Accessed
 
on
 
January
 
21,
 
2025.
 
2.
 
Beximco
 
Pharmaceuticals
 
Ltd.
 
(2024).
 
Product
 
information
 
leaflet:
 
NITROSOL.
 
Retrieved
 
from
 
Quest
 
3+
 
Product
 
Search
 
on
 
January
 
21,
 
2025.
 
3.
 
Glyceryl
 
trinitrate.
 
(2024).
 
MimsGateway .
 
Retrieved
 
January
 
21,
 
2025,
 
from
 
https://online1.mimsgateway .com.my/
 
4.
 
FDA
 
Prescribing
 
Information
 
for
 
Nitroglycerin;
 
Retrieved
 
January ,
 
24
 
2025
 
from
 
https://www .accessdata.fda.gov/drugsatfda_docs/label/2017/021 134s009lbl.pdf
 
 
 
 
 
 
 
190
 

=== PAGE 192 ===

 
Glyceryl
 
Trinitrate
 
(GTN)
 
Sublingual
 
Tablet
 
Name
 
:
 
 
Unit
 
:
 
 
●
 
Please
 
tick
 
(
✔
)
 
Yes
 
for
 
correct
 
instruction.
 
●
 
Please
 
tick
 
(
✔
)
 
No
 
for
 
incorrect
 
instruction.
 
Yes
 
No
 
Remarks
 
Pharmacological
 
Group
 
Nitrate;
 
Antianginal
 
agent
 
 
 
 
Indications
 
and
 
Dosage
 
Prophylaxis
 
and
 
treatment
 
of
 
angina
 
and
 
left
 
ventricular
 
failure
 
 
Dosage:
 
0.5-1
 
mg
 
sublingually
 
may
 
be
 
repeated
 
every
 
5
 
minutes
 
until
 
relief
 
is
 
obtained.
 
 
 
 
 
Method
 
of
 
Administration*
 
Treatment
 
of
 
angina
 
1.
 
During
 
an
 
acute
 
angina
 
attack,
 
the
 
patient
 
should
 
rest,
 
preferably
 
in
 
a
 
sitting
 
position.
 
2.
 
Place
 
one
 
tablet
 
under
 
the
 
tongue,
 
allowing
 
it
 
to
 
dissolve.
 
Do
 
not
 
swallow
 
or
 
chew
 
the
 
tablet.
 
3.
 
If
 
pain
 
remains,
 
remove
 
the
 
undissolved
 
tablet
 
and
 
place
 
a
 
new
 
tablet
 
under
 
the
 
tongue.
 
The
 
dose
 
may
 
be
 
repeated
 
every
 
5
 
minutes
 
for
 
a
 
maximum
 
of
 
3
 
times.
 
 
4.
 
If
 
pain
 
persists
 
or
 
becomes
 
more
 
intense
 
after
 
a
 
total
 
dose
 
of
 
3
 
times
 
in
 
15
 
minutes,
 
patient
 
should
 
call
 
the
 
ambulance
 
or
 
go
 
to
 
the
 
hospital.
 
 
Prophylaxis
 
of
 
angina
 
1.
 
Take
 
1
 
tablet
 
5
 
to
 
10
 
minutes
 
before
 
exercise
 
or
 
exertion
 
to
 
prevent
 
an
 
attack.
 
 
Do
 
not
 
stop
 
taking
 
your
 
medication
 
unless
 
advised
 
to
 
do
 
so
 
by
 
your
 
prescriber .
 
 
 
 
Special
 
Considerations
 
Pregnancy
 
 
 
 
1.
 
There
 
is
 
no,
 
or
 
inadequate,
 
evidence
 
of
 
safety
 
of
 
nitrates
 
in
 
human
 
pregnancy .
 
2.
 
Nitrates
 
should
 
not
 
be
 
administered
 
in
 
pregnancy
 
unless
 
considered
 
essential.
 
3.
 
To
 
inform
 
the
 
prescriber
 
if
 
you
 
are
 
pregnant.
 
 
 
 
Breastfeeding
 
 
 
 
1.
 
It
 
is
 
unknown
 
if
 
the
 
drug
 
is
 
present
 
in
 
breast
 
milk.
 
Related
 
data
 
is
 
limited.
 
 
2.
 
There
 
is
 
no,
 
or
 
inadequate,
 
evidence
 
of
 
safety
 
of
 
nitrates
 
in
 
lactation;
 
nitrates
 
should
 
not
 
be
 
administered
 
in
 
lactation
 
unless
 
considered
 
essential.
 
3.
 
To
 
inform
 
the
 
prescriber
 
if
 
you
 
are
 
breastfeeding.
 
 
 
 
Elderly
 
 
 
 
Nitroglycerin
 
can
 
be
 
used
 
safely
 
in
 
elderly
 
patients
 
with
 
careful
 
dose
 
management,
 
monitoring
 
for
 
side
 
effects,
 
and
 
patient
 
education
 
to
 
mitigate
 
risks
 
like
 
hypotension,
 
falls,
 
and
 
tolerance.
 
 
 
 
Paediatric
 
 
 
 
No
 
data
 
 
 
 
Fasting
 
 
 
 
191
 

=== PAGE 193 ===

 
To
 
refer
 
to
 
the
 
latest
 
advisory
 
by
 
religious
 
authority
 
 
 
 
Others
 
 
 
 
NA
 
 
 
 
Side
 
Effects
 
and
 
their
 
Management*
 
Side
 
effects
 
may
 
include
 
severe
 
headache,
 
blurred
 
vision,
 
dry
 
mouth,
 
dizziness
 
or
 
flushing.
 
If
 
affected,
 
do
 
not
 
drive
 
or
 
operate
 
machinery . 
 
 
 
 
Storage*
 
1.
 
Store
 
the
 
tablets
 
below
 
25°C
 
in
 
a
 
cool,
 
dry
 
place,
 
protected
 
from
 
direct
 
sunlight.
 
2.
 
Discard
 
the
 
tablets
 
2
 
months
 
after
 
first
 
opening
 
of
 
the
 
bottle
 
(mark
 
the
 
date
 
on
 
the
 
bottle).
 
 
3.
 
Do
 
not
 
put
 
cotton
 
wool,
 
other
 
medicines,
 
or
 
anything
 
else
 
in
 
the
 
bottle
 
with
 
the
 
tablets.
 
4.
 
Do
 
not
 
expose
 
the
 
opened
 
bottle
 
or
 
keep
 
the
 
bottle
 
in
 
a
 
humid
 
condition/area.
 
5.
 
Keep
 
out
 
of
 
reach
 
and
 
sight
 
of
 
children
 
 
 
 
Others
 
Inability
 
to
 
relieve
 
chest
 
pain
 
after
 
3
 
doses
 
may
 
signal
 
acute
 
myocardial
 
infarction
 
necessitating
 
emergency
 
management. 
 
 
 
 
Before
 
ending
 
this
 
peer
 
review
 
session,
 
the
 
reviewee
 
should
 
be
 
informed
 
of
 
the
 
step(s)
 
that
 
he/
 
she
 
missed
 
out
 
in
 
order
 
to
 
ensure
 
all
 
the
 
counselling
 
points
 
are
 
being
 
covered.
 
 
Remarks:
 
 
 
 
 
Reviewed
 
by:
 
Name
 
&
 
Signature
                                                                   
Date:
 
 
 
 
 
*Mandatory
 
for
 
validation
 
/
 
peer
 
review
 
References:
 
 
1.
 
Formulari
 
Ubat
 
KKM.
 
(2025,
 
January
 
1).
 
Accessed
 
on
 
January
 
21,
 
2025.
 
2.
 
Troikaa
 
Pharmaceuticals
 
Ltd.
 
(2023).
 
Product
 
information
 
leaflet:
 
Virso.
 
Retrieved
 
from
 
Quest
 
3+
 
Product
 
Search
 
on
 
January
 
21,
 
2025.
 
3.
 
Glyceryl
 
trinitrate.
 
(2024).
 
MimsGateway .
 
Retrieved
 
January
 
21,
 
2025,
 
from
 
https://online1.mimsgateway .com.my/
 
4.
 
FDA
 
Prescribing
 
Information
 
for
 
Nitroglycerin;
 
Retrieved
 
January ,
 
24
 
2025
 
from
 
https://www .accessdata.fda.gov/drugsatfda_docs/label/2017/021 134s009lbl.pdf
 
 
 
 
 
 
 
 
 
 
 
192
 

=== PAGE 194 ===

 
Gonadotropin-Releasing
 
Hormone
 
Antagonists
 
/
 
Gonadotropins
 
Name
 
:
 
 
Unit
 
:
 
 
●
 
Please
 
tick
 
(
✔
)
 
Yes
 
for
 
correct
 
instruction.
 
●
 
Please
 
tick
 
(
✔
)
 
No
 
for
 
incorrect
 
instruction.
 
Yes
 
No
 
Remarks
 
Pharmacological
 
Group
 
Gonadotropin-Releasing
 
Hormone
 
(GnRH)
 
Antagonists
 
:
 
 
1.
 
Cetrorelix
 
(Asporelix)
 
0.25
 
mg
 
Injection
 
 
2.
 
Cetrorelix
 
(Cetrotide)
 
0.25mg
 
Injection
 
 
 
 
Gonadotropins
 
:
 
 
1.
 
Human
 
Chorionic
 
Gonadotrophin
 
(Hucog)
 
5000IU
 
Injection
 
 
2.
 
Menotrophin,
 
Highly
 
Purified
 
(Humog)
 
75iu
 
Injection
 
3.
 
Urofollitropin
 
(Folliculin)
 
75iu,
 
150iu
 
Injection
 
 
 
 
Indications
 
and
 
Dosage
 
To
 
counsel
 
based
 
on
 
specific
 
medication’ s
 
indication
 
and
 
dosage
 
as
 
prescribed
 
by
 
the
 
doctor
 
 
 
 
Preparation
 
and
 
Reconstitution
 
of
 
Medicine
 
[For
 
preparation
 
of
 
Cetrorelix
 
-
 
see
 
Preparation
 
and
 
Administration
 
of
 
Cetrorelix
 
Injection
 
]
 
 
 
Preparation
 
and
 
Administration
 
:
 
 
Preparation
 
of
 
medication
 
and
 
disposables
 
required
 
for
 
administration
 
of
 
medication
 
 
●
 
Medication
 
(powder
 
in
 
vial)
 
and
 
diluent
 
(ampoule)
 
 
●
 
Syringe
 
3cc
 
●
 
Needle
 
(23G
 
x
 
25mm)
 
●
 
Needle
 
(26G
 
x
 
12mm)
 
●
 
Alcohol
 
swab
 
 
Reconstitution
 
of
 
medication:
 
a)
 
Wash
 
hands
 
with
 
soap
 
and
 
water .
 
Dry
 
your
 
hands
 
b)
 
Check
 
that
 
the
 
-
 
The
 
expiry
 
had
 
not
 
passed
 
-
 
The
 
correct
 
drug
 
and
 
strength
 
-
 
The
 
vial
 
and
 
ampoule
 
is
 
not
 
damaged
 
c)
 
Attach
 
needle
 
to
 
syringe
 
for
 
mixing
 
(23G
 
x
 
25mm),
 
twist
 
to
 
tighten.
 
Set
 
aside.
 
d)
 
Hold
 
the
 
glass
 
ampoule
 
base
 
upright.
 
Tap
 
the
 
ampoule
 
gently
 
to
 
ensure
 
all
 
solution
 
is
 
at
 
the
 
base.
 
Look
 
for
 
a
 
scoring/line
 
at
 
the
 
neck
 
of
 
the
 
ampoule.
 
Hold
 
the
 
top
 
and
 
base
 
firmly .
 
e)
 
For
 
safety ,
 
use
 
a
 
piece
 
of
 
paper/cloth
 
to
 
hold
 
the
 
top.
 
Apply
 
pressure
 
at
 
90°,
 
turn
 
and
 
snap
 
the
 
top
 
off.
 
The
 
ampoule
 
should
 
break
 
at
 
the
 
neck
 
only.
 
f)
 
Insert
 
needles
 
that
 
were
 
set
 
aside
 
in
 
(a)
 
and
 
draw
 
out
 
all
 
the
 
solution
 
from
 
the
 
ampoule.
 
g)
 
Remove
 
the
 
cap
 
from
 
the
 
vial
 
and
 
wipe
 
the
 
top
 
of
 
the
 
vial
 
with
 
an
 
alcohol
 
swab.
 
h)
 
Insert
 
the
 
needle
 
at
 
an
 
angle
 
through
 
the
 
grey
 
rubber
 
circle.
 
Point
 
the
 
needle
 
tip
 
to
 
the
 
wall
 
of
 
the
 
vial
 
and
 
gently
 
empty
 
the
 
solution
 
into
 
it.
 
i)
 
Swirl
 
the
 
bottle
 
to
 
solubilise
 
the
 
powder
 
inside
 
the
 
vial
 
while
 
keeping
 
the
 
needle
 
inside
 
until
 
the
 
solution
 
becomes
 
a
 
clear
 
solution.
 
j)
 
Invert
 
the
 
vial
 
upside
 
down.
 
Inject
 
air
 
into
 
the
 
vial
 
to
 
put
 
more
 
pressure
 
into
 
the
 
vial.
 
k)
 
Gently
 
pull
 
back
 
the
 
tip
 
of
 
the
 
needle
 
to
 
the
 
same
 
level
 
as
 
the
 
rubber
 
stopper
 
of
 
the
 
vial.
 
l)
 
Release
 
the
 
plunger
 
of
 
the
 
syringe
 
and
 
the
 
solution
 
will
 
enter
 
 
 
 
193
 

=== PAGE 195 ===

 
the
 
syringe
 
automatically .
 
m)
 
Repeat
 
step
 
(b)
 
to
 
(j)
 
until
 
you
 
have
 
reached
 
the
 
prescribed
 
dose.
 
n)
 
Remove
 
the
 
needle
 
from
 
the
 
syringe
 
while
 
it
 
is
 
still
 
in
 
the
 
vial
 
for
 
safety .
 
o)
 
Attached
 
the
 
smaller
 
needle
 
(26G
 
x
 
12mm).
 
p)
 
Turn
 
the
 
syringe
 
upside
 
down,
 
slowly
 
tap
 
the
 
syringe
 
to
 
remove
 
air
 
bubbles.
 
Depress
 
plunger
 
to
 
expel
 
air
 
out
 
of
 
the
 
syringe
 
through
 
the
 
needle
 
slowly
 
until
 
a
 
tiny
 
drop
 
of
 
solution
 
appears
 
at
 
the
 
tip
 
of
 
the
 
needle.
 
The
 
solution
 
is
 
now
 
ready
 
to
 
be
 
injected.
 
 
Preparation
 
and
 
Administration
 
of
 
Cetrorelix
 
Injection
 
:
 
 
Preparation
 
of
 
medication
 
and
 
disposables
 
required
 
for
 
administration
 
of
 
medication
 
●
 
Medication
 
(powder
 
in
 
vial)
 
and
 
prefilled
 
syringe
 
with
 
diluent
 
●
 
Needle
 
(20G
 
x
 
40mm)
 
●
 
Needle
 
(27G
 
x
 
19mm)
 
●
 
Alcohol
 
swab
 
 
Reconstitution
 
of
 
medication:
 
a)
 
Wash
 
hands
 
with
 
soap
 
and
 
water .
 
Dry
 
your
 
hands
 
b)
 
Check
 
that
 
the
 
 
    
-
 
The
 
expiry
 
had
 
not
 
passed
 
    
-
 
The
 
solution
 
in
 
the
 
syringe
 
is
 
clear
 
and
 
colourless
 
and
 
does
   
not
 
contain
 
particle
 
    
-
 
The
 
vial
 
is
 
not
 
opened
 
or
 
damaged
 
c)
 
Attach
 
the
 
pre-filled
 
syringe
 
to
 
the
 
marked
 
yellow
 
needle,
 
twist
 
to
 
tighten.
 
d)
 
Remove
 
the
 
cap
 
from
 
the
 
vial
 
and
 
wipe
 
the
 
top
 
of
 
the
 
vial
 
with
 
an
 
alcohol
 
swab.
 
e)
 
Insert
 
the
 
needle
 
at
 
an
 
angle
 
through
 
the
 
grey
 
rubber
 
circle.
 
Point
 
the
 
needle
 
tip
 
to
 
the
 
wall
 
of
 
the
 
vial
 
and
 
gently
 
empty
 
the
 
solution
 
into
 
it.
 
f)
 
Swirl
 
the
 
bottle
 
to
 
solubilise
 
the
 
powder
 
inside
 
the
 
vial
 
while
 
keeping
 
the
 
needle
 
inside
 
until
 
the
 
solution
 
becomes
 
a
 
clear
 
solution.
 
g)
 
Invert
 
the
 
vial
 
upside
 
down.
 
Inject
 
air
 
into
 
the
 
vial
 
to
 
put
 
more
 
pressure
 
into
 
the
 
vial.
 
h)
 
Gently
 
pull
 
back
 
the
 
tip
 
of
 
the
 
needle
 
to
 
the
 
same
 
level
 
as
 
the
 
rubber
 
stopper
 
of
 
the
 
vial.
 
i)
 
Release
 
the
 
plunger
 
of
 
the
 
syringe
 
and
 
the
 
solution
 
will
 
enter
 
the
 
syringe
 
automatically .
 
Repeat
 
until
 
all
 
dissolved
 
solution
 
is
 
transferred
 
into
 
the
 
syringe.
 
j)
 
Remove
 
the
 
needle
 
from
 
the
 
syringe
 
while
 
it
 
is
 
still
 
in
 
the
 
vial
 
for
 
safety .
 
k)
 
Attached
 
the
 
marked
 
grey
 
needle
 
to
 
the
 
syringe
 
with
 
the
 
dissolved
 
medicine
 
inside,
 
twist
 
to
 
tighten.
 
l)
 
Turn
 
the
 
syringe
 
upside
 
down,
 
slowly
 
tap
 
the
 
syringe
 
to
 
remove
 
air
 
bubbles.
 
Depress
 
plunger
 
to
 
expel
 
air
 
out
 
of
 
the
 
syringe
 
through
 
the
 
needle
 
slowly
 
until
 
a
 
tiny
 
drop
 
of
 
solution
 
appears
 
at
 
the
 
tip
 
of
 
the
 
needle.
 
The
 
solution
 
is
 
now
 
ready
 
to
 
be
 
injected.
 
 
Method
 
of
 
Administration*
 
Site
 
of
 
administration
 
or
 
injection:
 
●
 
 
Abdomen
 
(preferably)
 
●
 
 
Buttock
 
 
Method
 
of
 
administration:
 
 
a)
 
Sit
 
in
 
a
 
comfortable
 
position
 
so
 
you
 
can
 
easily
 
see
 
the
 
area
 
of
 
their
 
stomach
 
where
 
you
 
will
 
be
 
injecting.
 
b)
 
Select
 
an
 
area
 
on
 
the
 
right
 
or
 
left
 
side
 
of
 
your
 
stomach,
 
at
 
least
 
2
 
inches
 
from
 
your
 
navel.
 
Alternate
 
left
 
and
 
right
 
side
 
of
 
 
 
 
194
 

=== PAGE 196 ===

 
the
 
lower
 
abdominal
 
area
 
at
 
each
 
injection.
 
Do
 
not
 
inject
 
yourself
 
within
 
about
 
2
 
inches
 
of
 
your
 
navel,
 
near
 
scars,
 
bruises
 
or
 
stretch
 
marks.
 
c)
 
Clean
 
the
 
area
 
you
 
have
 
selected
 
for
 
your
 
injection
 
with
 
alcohol
 
swab
 
and
 
allow
 
the
 
area
 
to
 
dry
 
d)
 
Remove
 
the
 
protective
 
needle
 
cap.
 
e)
 
Insert
 
needle
 
into
 
the
 
skin
 
at
 
an
 
angle
 
of
 
90°
 
and
 
push
 
the
 
entire
 
length
 
of
 
the
 
needle
 
into
 
the
 
subcutaneous
 
tissue.
 
Push
 
all
 
the
 
solution
 
into
 
the
 
tissue.
 
f)
 
Count
 
to
 
10
 
slowly
 
before
 
withdrawing
 
the
 
needle
 
from
 
the
 
skin
 
at
 
the
 
same
 
angle
 
it
 
was
 
inserted.
 
This
 
is
 
to
 
ensure
 
full
 
dose
 
delivery
 
and
 
prevent
 
leakage.
 
g)
 
Immediately
 
discard
 
the
 
used
 
needle
 
into
 
a
 
designated
 
disposal
 
bin.
 
 
h)
 
Do
 
not
 
rub
 
the
 
injection
 
site
 
after
 
administration
 
 
Missed
 
Dose
 
Administer
 
as
 
soon
 
as
 
you
 
remember .
 
If
 
it
 
is
 
close
 
to
 
the
 
next
 
dose,
 
omit
 
the
 
current
 
dose
 
and
 
administer
 
the
 
current
 
dose.
 
DO
 
NOT
 
DOUBLE
 
THE
 
DOSE
 
 
Do
 
not
 
stop
 
taking
 
your
 
medication
 
unless
 
advised
 
to
 
do
 
so
 
by
 
your
 
prescriber
 
Special
 
Considerations
 
Pregnancy
 
 
 
 
Contraindicated
 
 
 
 
Breastfeeding
 
 
 
 
Contraindicated
 
 
 
 
Elderly
 
 
 
 
NA
 
 
 
 
Paediatric
 
 
 
 
NA
 
 
 
 
Fasting
 
 
 
 
To
 
refer
 
to
 
the
 
latest
 
advisory
 
by
 
religious
 
authority
 
 
 
 
Others
 
 
 
 
NA
 
 
 
 
Side
 
Effects
 
and
 
their
 
Management*
 
1.
 
Injection
 
site
 
reaction
 
(bruising,
 
pain,
 
redness)
 
2.
 
Headache
 
Seek
 
help
 
from
 
doctor
 
if
 
symptoms
 
worsen
 
 
 
 
Storage*
 
1.
 
Store
 
at
 
2-8
 
°C
 
(in
 
a
 
refrigerator).
 
DO
 
NOT
 
FREEZE.
 
Avoid
 
storage
 
at
 
the
 
door
 
of
 
the
 
fridge
 
and
 
vegetable
 
compartment,
 
ensure
 
there
 
is
 
proper
 
air
 
circulation
 
around
 
medication.
 
2.
 
TRANSPOR T
 
of
 
medication
 
is
 
only
 
allowed
 
in
 
a
 
COOL
 
BOX
 
WITH
 
ICE/ICE
 
PACKS
 
3.
 
Preferable
 
return
 
home
 
immediately
 
after
 
getting
 
medication
 
from
 
pharmacy
 
to
 
facilitate
 
proper
 
storage
 
 
 
 
Others
 
Administration
 
timing
 
and
 
importance
 
of
 
compliance
 
3.
 
Always
 
inject
 
at
 
the
 
same
 
specified
 
time
 
of
 
the
 
day
 
for
 
adequate
 
follicular
 
response
 
 
 
 
195
 

=== PAGE 197 ===

 
4.
 
Importance
 
of
 
rotation
 
of
 
side
 
of
 
administration
 
 
Disposal
 
of
 
sharps
 
(syringe,
 
needles,
 
vial,
 
ampoule)
 
1.
 
Dispose
 
sharps
 
in
 
a
 
container
 
before
 
disposal
 
2.
 
Collect
 
sharps
 
in
 
a
 
container
 
and
 
return
 
to
 
the
 
pharmacy
 
or
 
healthcare
 
facility
 
for
 
proper
 
disposal
 
into
 
a
 
sharp
 
bin.
 
Before
 
ending
 
this
 
peer
 
review
 
session,
 
the
 
reviewee
 
should
 
be
 
informed
 
of
 
the
 
step(s)
 
that
 
he/
 
she
 
missed
 
out
 
in
 
order
 
to
 
ensure
 
all
 
the
 
counselling
 
points
 
are
 
being
 
covered.
 
 
Remarks:
 
 
 
 
 
Reviewed
 
by:
 
Name
 
&
 
Signature
                                                                   
Date:
 
 
 
 
 
*Mandatory
 
for
 
validation
 
/
 
peer
 
review
 
References:
 
1.
 
Fertility
 
Pharmacy
 
Services
 
Hospital
 
Tunku
 
Azizah
 
Protocol
 
2023
 
2.
 
Formulari
 
Ubat
 
KKM
 
(FUKKM)
 
3.
 
Product
 
leaflet
 
Cetrotide
 
0.25mg
 
(2025
 
January ,
 
21).
 
Retrieved
 
from
 
https://quest3plus.bpfk.gov .my/front-end/attachment/514/pharma/71265/V_62743_20220202_172544_D
3.pdf
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
196
 

=== PAGE 198 ===

 
Heparin
 
Sodium
 
 
Name
 
:
 
 
Unit
 
:
 
 
●
 
Please
 
tick
 
(
✔
)
 
Yes
 
for
 
correct
 
instruction.
 
●
 
Please
 
tick
 
(
✔
)
 
No
 
for
 
incorrect
 
instruction.
 
Yes
 
No
 
Remarks
 
Pharmacological
 
Group
 
Antithrombotic
 
agent
 
 
 
 
 
Indications
 
and
 
Dosage
 
1.
 
Prophylaxis
 
and
 
treatment
 
of
 
venous
 
thrombosis
 
and
 
pulmonary
 
embolism.
 
       
a.
 
By
 
intravenous
 
injection,
 
loading
 
dose
 
of
 
5000
 
units
 
(10,000
 
units
 
in
 
severe
 
pulmonary
 
embolism)
 
followed
 
by
 
continuous
 
infusion
 
of
 
15-25
 
units/kg/hr .
 
By
 
subcutaneous
 
injection
 
(for
 
DVT)
 
of
 
15,000
 
units
 
every
 
12
 
hours
 
(laboratory
 
monitoring
 
on
 
daily
 
basis
 
essential
 
to
 
adjust
 
dose).
 
2.
 
Treatment
 
of
 
myocardial
 
infarction
 
and
 
arterial
 
embolism.
 
a.
 
Same
 
as
 
1
 
a.
 
3.
 
Prevention
 
of
 
clotting
 
in
 
arterial
 
and
 
heart
 
surgery
 
and
 
for
 
prevention
 
of
 
cerebral
 
thrombosis
 
 
a.
 
Prophylaxis
 
in
 
general
 
surgery ,by
 
subcutaneous
 
injection
 
5000
 
units
 
2
 
hr
 
before
 
surgery ,
 
then
 
every
 
8-12
 
hrs
 
for
 
7
 
days
 
or
 
until
 
patient
 
is
 
ambulant.During
 
pregnancy
 
(with
 
monitoring),
 
5000-10000
 
units
 
every
 
12
 
hours.An
 
adjusted
 
dose
 
regimen
 
may
 
be
 
used
 
for
 
major
 
orthopaedic
 
surgery
 
or
 
low
 
molecular
 
weight
 
heparin
 
may
 
be
 
selected.
 
To
 
counsel
 
based
 
on
 
specific
 
medication’ s
 
indication
 
and
 
dosage
 
as
 
prescribed
 
as
 
doctor
 
 
 
 
Method
 
of
 
Administration*
 
1.
 
Administer
 
only
 
by
 
intermittent
 
IV
 
injection,
 
IV
 
infusion,
 
or
 
deep
 
subQ
 
injection;
 
avoid
 
IM
 
administration
 
 
 
 
Preparation
 
1.
 
Prior
 
to
 
injection,
 
wash
 
your
 
hands
 
thoroughly
 
with
 
soap
 
and
 
water .
 
Towel
 
dry.
 
2.
 
Sit
 
in
 
a
 
comfortable
 
position
 
so
 
you
 
can
 
easily
 
see
 
the
 
area
 
of
 
their
 
stomach
 
where
 
you
 
will
 
be
 
injecting.
 
A
 
lounge
 
chair ,
 
recliner ,or
 
bed
 
(propped
 
up
 
with
 
pillows)
 
is
 
ideal.
 
Inspection
 
1.
 
Check
 
the
 
expiry
 
date
 
on
 
the
 
syringe.
 
Do
 
not
 
use
 
it
 
if
 
the
 
date
 
has
 
passed.
 
 
2.
 
Check
 
the
 
syringe
 
is
 
not
 
damaged
 
and
 
the
 
medicine
 
in
 
it
 
is
 
a
 
clear
 
solution
 
without
 
particles.
 
If
 
the
 
syringe
 
is
 
damaged
 
or
 
the
 
medicine
 
is
 
not
 
clear ,
 
use
 
another
 
syringe.
 
Injection
 
site
 
1.
 
Choose
 
an
 
area
 
on
 
the
 
right
 
or
 
left
 
side
 
of
 
your
 
stomach.
 
This
 
should
 
be
 
at
 
least
 
5
 
centimetres
 
away
 
from
 
your
 
belly
 
button
 
and
 
out
 
towards
 
your
 
sides.
 
 
2.
 
Change
 
the
 
place
 
where
 
you
 
inject
 
between
 
the
 
left
 
and
 
right
 
sides
 
of
 
your
 
stomach,
 
depending
 
on
 
the
 
area
 
you
 
were
 
last
 
injected.
 
This
 
is
 
to
 
prevent
 
scarring
 
which
 
will
 
make
 
it
 
harder
 
to
 
inject
 
the
 
area
 
and
 
also
 
affect
 
how
 
the
 
medication
 
is
 
released
 
into
 
your
 
body .Avoid
 
injecting
 
on
 
scars
 
and
 
bruises.
 
 
Dose
 
preparation
 
1.
 
Wipe
 
the
 
top
 
of
 
the
 
heparin
 
vial
 
with
 
an
 
alcohol
 
swab.
 
 
 
 
197
 

=== PAGE 199 ===

 
2.
 
Remove
 
the
 
cap
 
from
 
the
 
plunger .
 
3.
 
Attach
 
a
 
long
 
needle
 
(21G)
 
and
 
remove
 
the
 
shield
 
from
 
the
 
needle
 
to
 
withdraw
 
heparin.
 
4.
 
Pull
 
the
 
plunger
 
back
 
to
 
draw
 
air
 
into
 
the
 
syringe
 
equal
 
to
 
the
 
dose
 
of
 
heparin
 
to
 
be
 
injected.
 
5.
 
Insert
 
the
 
needle
 
into
 
the
 
rubber
 
stopper
 
of
 
the
 
heparin
 
vial
 
at
 
a
 
45°
 
angle.
 
6.
 
Press
 
down
 
the
 
plunger
 
to
 
inject
 
air
 
into
 
the
 
vial.
 
7.
 
Turn
 
the
 
vial
 
upside
 
down.
 
8.
 
Pull
 
the
 
plunger
 
back
 
to
 
draw
 
the
 
desired
 
dose
 
into
 
the
 
syringe.
 
9.
 
To
 
remove
 
air
 
bubbles
 
(if
 
present)
 
in
 
the
 
syringe,
 
draw
 
up
 
several
 
more
 
units
 
of
 
heparin,
 
tap
 
the
 
barrel
 
to
 
move
 
them
 
to
 
the
 
top
 
then
 
expel
 
them
 
by
 
pushing
 
the
 
plunger
 
10.
 
Remove
 
the
 
needle
 
straight
 
out
 
of
 
the
 
vial
 
and
 
change
 
to
 
a
 
shorter
 
needle
 
(26G)
 
for
 
injection
 
purposes
 
Injection
 
technique
 
1.
 
Cleanse
 
(do
 
not
 
rub)
 
the
 
selected
 
site
 
for
 
injection
 
with
 
an
 
alcohol
 
swab.
 
 
2.
 
Remove
 
the
 
protective
 
cap
 
off
 
the
 
needle,
 
do
 
not
 
allow
 
the
 
needle
 
to
 
touch
 
anything
 
to
 
make
 
sure
 
it
 
stays
 
clean.
 
3.
 
Hold
 
the
 
syringe
 
in
 
the
 
hand
 
you
 
write
 
with
 
(like
 
a
 
pencil)
 
and
 
with
 
your
 
other
 
hand,
 
gently
 
pinch
 
the
 
cleaned
 
area
 
of
 
your
 
abdomen
 
between
 
your
 
forefinger
 
and
 
thumb
 
to
 
make
 
a
 
fold
 
in
 
the
 
skin.
 
Make
 
sure
 
you
 
hold
 
the
 
skin
 
fold
 
throughout
 
the
 
injection
 
4.
 
Hold
 
the
 
syringe
 
with
 
the
 
needle
 
pointing
 
downwards
 
(vertically
 
at
 
90
 
degree
 
angle)
 
and
 
inject
 
a
 
full
 
length
 
needle
 
into
 
the
 
skin
 
fold.
 
Inject
 
at
 
45°
 
angle
 
for
 
needle
 
length
 
≥8
 
mm
 
or
 
if
 
the
 
patient
 
is
 
thin.
 
5.
 
Press
 
down
 
plunger
 
with
 
your
 
finger
 
(thumb).
 
Complete
 
the
 
injection
 
using
 
all
 
of
 
the
 
medicine
 
in
 
the
 
syringe.
 
Hold
 
for
 
10
 
seconds
 
6.
 
Remove
 
the
 
needle
 
by
 
pulling
 
it
 
straight
 
out.
 
Let
 
go
 
of
 
the
 
skin
 
fold
 
7.
 
To
 
avoid
 
bruising,
 
do
 
not
 
rub
 
the
 
injection
 
site.
 
8.
 
Drop
 
the
 
used
 
syringe
 
into
 
a
 
hard,
 
puncture-proof
 
container .
 
Close
 
the
 
container
 
lid
 
tightly
 
and
 
place
 
the
 
container
 
out
 
of
 
reach
 
of
 
children.
 
9.
 
When
 
the
 
container
 
is
 
full,
 
dispose
 
of
 
it
 
safely .
 
Missed
 
dose
 
management
 
If
 
you
 
miss
 
a
 
dose
 
of
 
heparin,
 
inject
 
it
 
as
 
soon
 
as
 
you
 
remember .
 
If
 
it
 
is
 
too
 
near
 
the
 
next
 
dose,
 
skip
 
the
 
missed
 
dose
 
and
 
go
 
back
 
to
 
your
 
usual
 
dosing
 
times.
 
Do
 
not
 
double
 
dose.
 
 
Do
 
not
 
stop
 
taking
 
your
 
medication
 
unless
 
advised
 
to
 
do
 
so
 
by
 
your
 
prescriber
 
 
 
 
Special
 
Considerations
 
Pregnancy
 
 
 
 
1.
 
Available
 
evidence
 
is
 
inconclusive
 
or
 
inadequate
 
for
 
determining
 
fetal
 
risk
 
when
 
used
 
in
 
pregnant
 
women.
 
 
 
 
Breastfeeding
 
 
 
 
 
1.
 
Heparin
 
is
 
not
 
distributed
 
in
 
milk
 
 
 
 
Elderly
 
 
 
 
1.
 
Older
 
adults
 
>60
 
years
 
of
 
age,
 
especially
 
women
 
may
 
have
 
higher
 
serum
 
levels
 
and
 
clinical
 
response
 
(longer
 
aPTT s)
 
as
 
compared
 
to
 
younger
 
patients
 
receiving
 
 
 
 
198
 

=== PAGE 200 ===

 
similar
 
dosages.
 
 
2.
 
Dosage
 
reduction
 
and
 
monitoring
 
of
 
APTT
 
may
 
be
 
advisable.
 
 
Paediatric
 
 
 
 
As
 
some
 
heparin
 
preparations
 
may
 
contain
 
benzyl
 
alcohol,
 
its
 
use
 
should
 
be
 
avoided
 
in
 
children
 
under
 
two
 
years
 
of
 
age.
 
Not
 
to
 
be
 
used
 
in
 
neonates.
 
 
 
 
 
Fasting
 
 
 
 
Not
 
applicable
 
 
 
 
Others
  
 
 
 
 
No
 
dosage
 
adjustment
 
required
 
in
 
both
 
hepatic
 
and
 
renal
 
impairment
 
 
 
 
Side
 
Effects
 
and
 
their
 
Management*
 
1.
 
May
 
develop
 
hematoma
 
at
 
the
 
injection
 
site
 
(a
 
localised
 
swelling
 
that
 
is
 
filled
 
with
 
blood).
 
2.
 
Symptoms
 
of
 
bleeding
 
such
 
as
 
bruises
 
with
 
unknown
 
cause,
 
blood
 
in
 
urine/dark
 
coloured
 
urine,
 
black
 
stools,
 
gum
 
bleeding
 
or
 
heavy
 
menstrual
 
bleeding
 
3.
 
Seek
 
medical
 
attention
 
if
 
any
 
sign
 
or
 
symptom
 
of
 
bleeding
 
occurs
 
 
 
 
Storage*
 
1.
 
Do
 
not
 
store
 
above
 
30ºC.Do
 
not
 
refrigerate.
 
2.
 
Stable
 
for
 
28
 
days
 
if
 
aseptic
 
technique
 
is
 
used.
 
 
 
 
Others
 
1.
 
Heparin
 
is
 
derived
 
from
 
animal
 
sources
 
(mainly
 
bovine).
 
Please
 
confirm
 
the
 
source
 
and
 
disclose
 
it
 
to
 
the
 
patient,
 
if
 
needed.
 
2.
 
Drug
 
-
 
drug
 
interactions
 
a.
 
Enhanced
 
anticoagulant
 
effect
 
with
 
other
 
drugs
 
affecting
 
platelet
 
function
 
or
 
the
 
coagulation
 
system
 
(aspirin,
 
clopidogrel,
 
warfarin,
 
NSAIDs)
 
b.
 
Potassium
 
level
 
may
 
be
 
increased
 
when
 
co-administrated
 
with
 
drugs
 
that
 
may
 
cause
 
elevated
 
potassium
 
levels
 
(ACEi//
 
ARB)
 
3.
 
Monitor
 
parameters
 
a.
 
Full
 
blood
 
count
 
b.
 
Coagulation
 
profile
 
 
 
 
Before
 
ending
 
this
 
peer
 
review
 
session,
 
the
 
reviewee
 
should
 
be
 
informed
 
of
 
the
 
step(s)
 
that
 
he/
 
she
 
missed
 
out
 
in
 
order
 
to
 
ensure
 
all
 
the
 
counselling
 
points
 
are
 
being
 
covered.
 
 
Remarks:
 
 
 
Reviewed
 
by:
 
Name
 
&
 
Signature
                                                                   
Date:
 
 
  
*Mandatory
 
for
 
validation
 
/
 
peer
 
review
 
 
References:
 
 
1.
 
Formulari
 
Ubat
 
KKM.
 
(2025).
 
Accessed
 
on
 
January
 
21,
 
2025.
 
2.
 
Ain
 
Medicare
 
Sdn
 
Bhd
 
(2020)
 
Product
 
information
 
leaflet:
 
Heparinol.
 
Retrieved
 
from
 
Quest
 
3+
 
Product
 
Search
 
on
 
January
 
21,
 
2025.
 
3.
 
UpToDate.
 
(2024)
 
UpToDate
 
(Version
 
3.70.4)
 
[Mobile
 
App]
 
Mobile
 
Clinical
 
Decision
 
Support
 
App
 
|
 
UpToDate
 
|
 
Wolters
 
Kluwer
 
4.
 
Duopharma
 
(M)
 
Sdn
 
Bhd
 
(2019)
 
Product
 
information
 
leaflet:
 
Unihepa.
 
Retrieved
 
from
 
product
 
insert
 
on
 
22/1/25
 
199
 

=== PAGE 201 ===

 
Imiquimod
 
 
Name
 
:
 
 
Unit
 
:
 
 
●
 
Please
 
tick
 
(
✔
)
 
Yes
 
for
 
correct
 
instruction.
 
●
 
Please
 
tick
 
(
✔
)
 
No
 
for
 
incorrect
 
instruction.
 
Yes
 
No
 
Remarks
 
Pharmacological
 
Group
 
Immune
 
response
 
modifier
 
 
 
 
 
Indications
 
and
 
Dosage
 
External
 
Genital/Perianal
 
Warts
 
 
To
 
counsel
 
based
 
on
 
specific
 
medication’ s
 
indication
 
and
 
dosage
 
as
 
prescribed
 
by
 
the
 
doctor
 
 
 
 
Method
 
of
 
Administration*
 
Apply
 
Imiquimod
 
exactly
 
as
 
directed
 
by
 
your
 
doctor
 
or
 
according
 
to
 
the
 
instructions
 
on
 
the
 
label.
 
Do
 
not
 
use
 
it
 
more
 
often
 
or
 
over
 
a
 
larger
 
area
 
than
 
instructed
 
by
 
the
 
doctor .
 
1.
 
Wash
 
your
 
hands.
 
2.
 
Clean
 
and
 
thoroughly
 
dry
 
the
 
affected
 
area
 
before
 
application,
 
usually
 
before
 
bedtime.
 
3.
 
Open
 
the
 
sachet
 
and
 
squeeze
 
some
 
cream
 
onto
 
your
 
fingertip.
 
4.
 
Apply
 
a
 
thin
 
layer
 
on
 
the
 
affected
 
area
 
and
 
rub
 
the
 
cream
 
gently
 
on
 
the
 
skin
 
until
 
it
 
disappears.
 
Do
 
not
 
cover ,
 
wrap
 
or
 
bandage
 
the
 
area
 
unless
 
instructed
 
by
 
the
 
doctor .
 
5.
 
Leave
 
the
 
cream
 
on
 
the
 
affected
 
area
 
for
 
a
 
certain
 
time
 
as
 
prescribed
 
by
 
the
 
doctor .
 
Do
 
not
 
bathe,
 
shower
 
or
 
swim
 
after
 
applying
 
the
 
cream.
 
6.
 
After
 
the
 
prescribed
 
treatment
 
time,
 
wash
 
the
 
affected
 
area
 
with
 
mild
 
soap
 
and
 
water .
 
7.
 
Wash
 
your
 
hands
 
carefully
 
after
 
application.
 
8.
 
Cream
 
sachets
 
should
 
not
 
be
 
reused
 
once
 
opened.
 
Open
 
a
 
new
 
sachet
 
each
 
time
 
you
 
use
 
the
 
cream.
 
Throw
 
away
 
the
 
opened
 
sachet
 
according
 
to
 
your
 
doctor
 
or
 
pharmacist's
 
instructions
 
even
 
if
 
all
 
the
 
cream
 
was
 
not
 
completely
 
used.
 
 
MISSED
 
DOSE
 
:
 
Apply
 
cream
 
as
 
soon
 
as
 
you
 
remember
 
and
 
then
 
continue
 
in
 
your
 
regular
 
schedule.
 
Do
 
not
 
apply
 
the
 
cream
 
more
 
than
 
once
 
per
 
day.
 
 
Do
 
not
 
stop
 
taking
 
your
 
medication
 
unless
 
advised
 
to
 
do
 
so
 
by
 
your
 
prescriber
 
 
 
 
Special
 
Considerations
 
Pregnancy
 
 
 
 
Drugs
 
should
 
be
 
given
 
only
 
if
 
the
 
potential
 
benefit
 
justifies
 
the
 
potential
 
risk
 
to
 
the
 
fetus.
 
 
 
 
Breastfeeding
 
 
 
 
Not
 
known
 
 
 
 
Elderly
 
 
 
 
No
 
overall
 
differences
 
in
 
safety
 
or
 
effectiveness
 
were
 
observed
 
between
 
elderly
 
and
 
younger
 
patients.
 
 
 
 
200
 

=== PAGE 202 ===

 
Paediatric
 
 
 
 
The
 
safety
 
and
 
efficacy
 
in
 
paediatric
 
patients
 
below
 
age
 
12
 
have
 
not
 
been
 
established.
 
 
 
 
Fasting
 
 
 
 
 
N/A
 
 
 
 
Others
  
 
 
 
 
 
N/A
 
 
 
 
Side
 
Effects
 
and
 
their
 
Management*
 
1.
 
Wart
 
Site
 
–
 
very
 
common:
 
erythema,
 
erosion,
 
excoriation/flaking,
 
oedema,
 
itching,
 
burning
 
 
2.
 
Remote
 
Site
 
–
 
common:
 
bleeding,
 
burning,
 
itching,
 
pain,
 
tenderness,
 
tinea
 
cruris
 
 
 
 
 
Storage*
 
1.
 
Store
 
at
 
below
 
25°C.
 
2.
 
Store
 
in
 
a
 
place
 
that
 
is
 
not
 
exposed
 
to
 
heat
 
and
 
moisture.
 
3.
 
Do
 
not
 
freeze.
 
4.
 
Keep
 
this
 
medication
 
in
 
the
 
original
 
container ,
 
tightly
 
closed
 
and
 
out
 
of
 
reach
 
of
 
children.
 
 
 
 
Others
 
Special
 
precautions
 
for:
 
 
1.
 
Patient
 
with
 
pre-existing
 
autoimmune
 
disorders,
 
inherent
 
sensitivity
 
to
 
sunlight
 
or
 
potential
 
for
 
considerable
 
sun
 
exposure
 
(e.g.
 
occupational
 
reasons);
 
2.
 
Reduced
 
haematologic
 
reserve.
 
3.
 
Immunocompromised
 
patients,
 
including
 
organ
 
transplant
 
patients.
 
 
4.
 
Not
 
indicated
 
for
 
urethral,
 
cervical,
 
rectal,
 
intravaginal,
 
or
 
intra-anal
 
HPV
 
disease.
 
 
5.
 
Not
 
recommended
 
to
 
be
 
used
 
until
 
the
 
skin
 
has
 
healed
 
from
 
any
 
previous
 
sunburn,
 
drug
 
or
 
surgical
 
treatment.
 
 
6.
 
Not
 
intended
 
for
 
oral,
 
nasal,
 
or
 
ophthalmic
 
use.
 
 
7.
 
Avoid
 
contact
 
of
 
Imiquimod
 
with
 
your
 
eyes,
 
lips,
 
or
 
nostrils.
 
Rinse
 
immediately
 
with
 
water
 
if
 
this
 
medicine
 
gets
 
into
 
your
 
eyes,
 
lips,
 
or
 
nostrils.
 
Alert
 
your
 
doctor
 
if
 
you
 
start
 
to
 
have
 
any
 
problems
 
with
 
your
 
eyes.
 
8.
 
Do
 
not
 
apply
 
on
 
broken
 
or
 
sunburned
 
skin.
 
9.
 
If
 
you
 
are
 
using
 
Imiquimod
 
for
 
genital
 
or
 
anal
 
warts,
 
avoid
 
getting
 
this
 
medicine
 
into
 
your
 
anus.
 
Females
 
must
 
take
 
special
 
care
 
when
 
applying
 
near
 
the
 
vaginal
 
opening
 
to
 
avoid
 
getting
 
it
 
into
 
the
 
vagina.
 
Uncircumcised
 
males
 
treating
 
warts
 
under
 
their
 
penis
 
foreskin
 
must
 
pull
 
their
 
foreskin
 
back
 
and
 
clean
 
the
 
area
 
daily
 
before
 
each
 
treatment.
 
10.
 
Avoid
 
or
 
minimize
 
exposure
 
to
 
sunlight,
 
UV
 
lights,
 
and
 
tanning
 
beds;
 
use
 
protective
 
clothing
 
during
 
therapy .
 
 
11.
 
Avoid
 
the
 
use
 
of
 
excessive
 
amounts
 
of
 
cream
 
or
 
occlusive
 
dressing.
 
 
12.
 
Avoid
 
sexual
 
contact
 
while
 
the
 
cream
 
is
 
on
 
the
 
skin
 
as
 
it
 
may
 
weaken
 
condoms
 
and
 
diaphragms
 
(when
 
used
 
for
 
external
 
genital
 
or
 
perianal
 
warts).
 
 
Monitoring
 
parameters;
 
Monitor
 
for
 
local
 
skin
 
reactions
 
and
 
signs
 
and
 
symptoms
 
of
 
hypersensitivity .
 
 
Significant
 
drug-drug
 
/
 
drug-food
 
interactions
 
 
 
 
201
 

=== PAGE 203 ===

 
Due
 
to
 
its
 
immunostimulating
 
properties,
 
Imiquimod
 
cream
 
should
 
be
 
used
 
with
 
caution
 
in
 
patients
 
who
 
are
 
receiving
 
immunosuppressive
 
medication.
 
Before
 
ending
 
this
 
peer
 
review
 
session,
 
the
 
reviewee
 
should
 
be
 
informed
 
of
 
the
 
step(s)
 
that
 
he/
 
she
 
missed
 
out
 
in
 
order
 
to
 
ensure
 
all
 
the
 
counselling
 
points
 
are
 
being
 
covered.
 
 
Remarks:
 
 
 
 
 
Reviewed
 
by:
 
Name
 
&
 
Signature
                                                                   
Date:
 
 
 
 
 
  
*Mandatory
 
for
 
validation
 
/
 
peer
 
review
 
 
References:
 
 
1.
 
Mims
 
Gateway .
 
Imiquimod
 
5%
 
w/w
 
cream.
 
Retrieved
 
November
 
13,
 
2024,
 
from
 
h
ttps://online1.mimsgateway .com.my/
 
2.
 
Medline
 
Plus.
  
What
 
should
 
I
 
know
 
about
 
storage
 
and
 
disposal
 
of
 
this
 
medication?
 
Retrieved
 
November
 
13,
 
2024,
 
from
 
https://medlineplus.gov/druginfo/meds/a698010.html#storage-conditions
 
3.
 
Product
 
Leaflet
  
Imiquimod
 
Cream
 
USP
 
5%
 
w/w
 
.
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
202
 

=== PAGE 204 ===

 
Insulin
 
Name
 
:
 
 
Unit
 
:
 
 
●
 
Please
 
tick
 
(
✔
)
 
Yes
 
for
 
correct
 
instruction.
 
●
 
Please
 
tick
 
(
✔
)
 
No
 
for
 
incorrect
 
instruction.
 
Yes
 
No
 
Remarks
 
Pharmacological
 
Group
 
A.
 
BOLUS
 
1.
 
Short-acting
 
regular
 
human
 
insulin:
 
E.g:
 
●
 
Actrapid
®
 
●
 
Insugen
®
R
 
2.
 
Rapid-acting
 
analogue
 
insulin:
 
 
a.
 
Aspart
 
(Novorapid
®
)
 
b.
 
Lispro
 
(Humalog
®
)
 
c.
 
Glulisine
 
(Apidra
®
)
 
 
B.
 
BASAL
 
1.
 
Intermediate-acting
 
or
 
NPH
 
insulin.
 
E.g:
 
●
 
Insulatard
®
 
●
 
Insugen
®
N
 
2.
 
Long-acting
 
analogue
 
insulin:
 
 
a.
 
Glargine
 
U100
 
(Basalog
®
,
 
Lantus
®
 
Solostar)
 
b.
 
Detemir
 
(Levemir
®
)
 
c.
 
Glargine
 
U300
 
(Toujeo
®
 
Solostar)
 
d.
 
Degludec
 
(Tresiba
®
)
 
 
C.
 
PREMIXED
 
1.
 
Premixed
 
human
 
insulin:
 
a.
 
(30%
 
regular
 
insulin
 
+
 
70%
 
NPH):
 
●
 
Mixtard
®
30
 
●
 
Insugen
®
30/70
 
2.
 
Premixed
 
analogue
 
insulin:
 
a.
 
30%
 
insulin
 
aspart
 
+
 
70%
 
insulin
 
aspart
 
protamine
 
(Novomix
®
30)
 
b.
 
25%
 
insulin
 
lispro
 
+
 
75%
 
insulin
 
lispro
 
protamine
 
(HumalogMix
®
25
TM
)
 
c.
 
50%
 
insulin
 
lispro
 
+
 
50%
 
insulin
 
lispro
 
protamine
 
(HumalogMix
®
50
TM
)
 
 
D.
 
CO-FORMULA TION
 
1.
 
70%
 
insulin
 
degludec
 
+
 
30%
 
insulin
 
aspart;
 
iDegAsp
 
(Ryzodeg®
 
70/30)
 
 
2.
 
Insulin
 
glargine
 
+
 
lixisenatide
 
(Soliqua
TM
)
 
 
 
 
 
Indications
 
and
 
Dosage
 
A.
 
Bolus
 
insulin
 
–
 
administered
 
pre-meal
 
due
 
to
 
its
 
short
 
or
 
rapid
 
onset
 
of
 
action.
 
It
 
is
 
used
 
to
 
control
 
the
 
post-meal
 
glucose
 
excursion
 
and
 
can
 
be
 
used
 
with
 
an
 
insulin
 
pump
 
 
B.
 
Basal
 
insulin
 
–
 
administered
 
once
 
or
 
twice
 
daily
 
due
 
to
 
its
 
intermediate
 
or
 
long-acting
 
profile.
 
It
 
covers
 
the
 
basal
 
insulin
 
requirements
 
between
 
meals
 
and
 
overnight
 
secondary
 
to
 
endogenous
 
hepatic
 
glucose
 
production
 
 
C.
 
Premixed
 
insulin
 
–
 
biphasic
 
insulin
 
incorporating
 
a
 
combination
 
of
 
short
 
or
 
rapid-acting
 
insulin
 
with
 
its
 
intermediate-acting
 
counterpart
 
into
 
a
 
single
 
formulation.
 
It
 
covers
 
both
 
post-prandial
 
glucose
 
excursions
 
as
 
well
 
as
 
basal
 
insulin
 
requirements
 
simultaneously
 
D.
 
Co-formulations
 
–
 
a
 
combination
 
of
 
two
 
types
 
of
 
insulin
 
or
 
insulin
 
with
 
a
 
glucagon
 
like
 
peptide-1
 
receptor
 
analogue
 
(GLP1-RA)
 
such
 
as:
 
 
 
 
 
203
 

=== PAGE 205 ===

 
1.
 
Insulin
 
Degludec-Aspart
 
(iDegAsp)
 
–
 
a
 
combination
 
of
 
a
 
rapid-acting
 
(insulin
 
aspart)
 
and
 
an
 
ultra-long-acting
 
(insulin
 
degludec)
 
insulin
 
in
 
a
 
single
 
formulation,
 
which
 
can
 
be
 
injected
 
once
 
a
 
day
 
to
 
provide
 
both
 
bolus
 
and
 
basal
 
insulin
 
coverage
 
 
2.
 
Insulin
 
glargine/lixisenatide
 
–
 
a
 
combination
 
of
 
long-acting
 
insulin
 
and
 
a
 
GLP1RA
 
in
 
a
 
single
 
formulation.
 
Insulin
 
glargine
 
provides
 
basal
 
insulin
 
while
 
lixisenatide
 
stimulates
 
endogenous
 
insulin
 
secretion
 
to
 
cover
 
for
 
bolus
 
insulin
 
requirement.
 
 
 
Insulin
 
dosage
 
is
 
individualised
 
and
 
dose
 
adjustments
 
are
 
typically
 
made
 
weekly
 
based
 
on
 
the
 
patient’ s
 
metabolic
 
needs,
 
blood
 
glucose
 
monitoring
 
results,
 
and
 
glycemic
 
control
 
goal
 
until
 
the
 
desired
 
glycaemic
 
control
 
is
 
achieved.
 
 
 
Counsel
 
based
 
on
 
specific
 
medication
 
indications
 
and
 
dosages
 
as
 
prescribed
 
by
 
the
 
doctor .
 
Administration
 
time
 
1.
 
Short-acting
 
regular
 
human
 
insulin:
 
 
●
 
30
 
minutes
 
before
 
meals
 
2.
 
Rapid-acting
 
analogue
 
insulin:
 
 
●
 
Inject
 
immediately
 
before
 
meals
 
or
 
when
 
necessary ,
 
0-15
 
minutes
 
before
 
or
 
after
 
meals
 
3.
 
Intermediate-acting
 
regular
 
human
 
insulin:
 
 
●
 
For
 
daily
 
dosing,
 
usually
 
inject
 
before
 
sleep
 
(1
 
hour
 
before
 
bed)
 
●
 
For
 
twice
 
daily
 
dosing,
 
inject
 
pre-breakfast
 
and
 
pre-bed
 
4.
 
Long-acting
 
analogue
 
insulin:
 
 
●
 
Inject
 
once
 
daily
 
at
 
any
 
time
 
of
 
the
 
day,
 
preferably
 
at
 
the
 
same
 
time
 
every
 
day
 
●
 
Insulin
 
Detemir:
 
Administer
 
once-daily
 
doses
 
with
 
the
 
evening
 
meal
 
or
 
at
 
bedtime.
 
For
 
twice-daily
 
dosing,
 
administer
 
the
 
evening
 
dose
 
with
 
the
 
evening
 
meal,
 
at
 
bedtime,
 
or
 
12
 
hours
 
after
 
the
 
morning
 
dose.
 
5.
 
Premixed
 
human
 
insulin:
 
 
●
 
Once
 
daily
 
doses:
 
30
 
minutes
 
before
 
dinner
 
●
 
Twice
 
daily
 
doses:
 
30
 
minutes
 
before
 
breakfast
 
and
 
dinner
 
6.
 
Premixed
 
analogue
 
insulin:
 
●
 
Inject
 
immediately
 
before
 
meals
 
or
 
when
 
necessary ,
 
0-15
 
minutes
 
before
 
or
 
after
 
meals
 
7.
 
Co-formulation:
 
 
●
 
Ryzodeg®
 
-
 
Can
 
be
 
administered
 
once
 
or
 
twice
 
daily
 
with
 
the
 
main
 
meal(s).
 
When
 
needed,
 
the
 
time
 
of
 
administration
 
can
 
be
 
changed,
 
as
 
long
 
as
 
it
 
is
 
dosed
 
with
 
the
 
main
 
meal
 
when
 
taken
 
once
 
daily
 
●
 
Soliqua
TM
 
-
 
Once
 
a
 
day
 
within
 
the
 
hour
 
before
 
the
 
first
 
meal
 
of
 
the
 
day
 
 
 
 
 
Method
 
of
 
Administration*
 
1.
 
Gently
 
roll
 
refrigerated
 
insulin
 
between
 
the
 
palms
 
10
 
times
 
to
 
warm
 
the
 
insulin.
 
2.
 
Pull
 
off
 
the
 
pen
 
cap.
 
3.
 
Inserting
 
a
 
new
 
cartridge
 
(Only
 
for
 
non-prefilled
 
insulin
 
pen):
 
 
i.
 
Detach
 
the
 
cartridge
 
holder
 
by
 
twisting
 
&
 
pulling
 
gently
 
away
 
from
 
the
 
pen
 
with
 
a
 
click.
 
 
ii.
 
Reset
 
the
 
plunger
 
rod
 
by
 
pushing
 
the
 
plunger
 
rod
 
gently
 
back
 
into
 
the
 
pen
 
body .
 
 
 
 
204
 

=== PAGE 206 ===

 
iii.
 
Insert
 
the
 
insulin
 
cartridge
 
into
 
the
 
cartridge
 
holder
 
of
 
the
 
insulin
 
pen
 
and
 
screw
 
the
 
cartridge
 
holder
 
to
 
the
 
pen
 
body
 
tightly .
 
4.
 
Mixing
 
/
 
Resuspending
 
the
 
insulin
 
pen
 
(only
 
for
 
cloudy
 
insulin
 
eg
 
NPH,
 
and
 
premixed
 
insulin).
 
i.
 
Gently
 
tip
 
cloudy
 
insulin
 
up
 
and
 
down
 
for
 
10
 
cycles
 
or
 
until
 
uniformly
 
cloudy .
 
Vigorous
 
shaking
 
should
 
be
 
avoided
 
since
 
this
 
produces
 
bubbles
 
which
 
reduce
 
dose
 
accuracy
 
 
ii.
 
Visually
 
check
 
for
 
milky
 
white
 
appearance.
 
●
 
Inadequate
 
resuspension
 
of
 
cloudy
 
insulin
 
before
 
injection
 
may
 
lead
 
to
 
varying
 
concentrations
 
of
 
medication
 
dosage
 
that
 
can
 
cause
 
unpredictable
 
clinical
 
responses
 
5.
 
Fix
 
the
 
needle
 
to
 
the
 
insulin
 
pen.
 
i.
 
Remove
 
the
 
paper
 
tab
 
of
 
a
 
new
 
needle,
 
screw
 
the
 
needle
 
to
 
the
 
pen
 
and
 
remove
 
the
 
inner
 
and
 
outer
 
cap
 
(do
 
not
 
keep
 
the
 
inner
 
cap).
 
●
 
Shorter
 
needles
 
(4,
 
5,
 
6
 
mm)
 
provide
 
equal
 
efficacy
 
and
 
safety
 
when
 
compared
 
with
 
the
 
longer
 
needle
 
(8
 
mm)
 
and
 
are
 
suitable
 
for
 
all
 
patients
 
regardless
 
of
 
BMI.
 
●
 
8
 
mm
 
needles
 
should
 
be
 
discouraged
 
to
 
prevent
 
the
 
risk
 
of
 
intramuscular
 
injection
 
ii.
 
Using
 
a
 
new
 
needle
 
each
 
time
 
may
 
reduce
 
the
 
risk
 
of
 
needle
 
breakage
 
in
 
the
 
skin,
 
clogging
 
of
 
the
 
needle,
 
inaccurate
 
dosing
 
and
 
complications
 
associated
 
with
 
using
 
blunt
 
needles
 
(e.g.
 
lipohypertrophy ,
 
abscess)
 
6.
 
Priming
 
the
 
insulin
 
pen
 
i.
 
Priming
 
should
 
be
 
done
 
when
 
changing
 
to
 
new
 
insulin
 
cartridge/
 
prefilled
 
pen
 
and
 
before
 
each
 
injection.
 
ii.
 
To
 
prime,
 
turn
 
the
 
dose
 
selector
 
to
 
select
 
2
 
units
 
and
 
hold
 
the
 
insulin
 
pen
 
with
 
the
 
needle
 
pointing
 
up.
 
iii.
 
Tap
 
the
 
top
 
of
 
the
 
pen
 
gently
 
a
 
few
 
times
 
to
 
let
 
any
 
air
 
bubbles
 
rise
 
to
 
the
 
top.
 
iv.
 
Press
 
and
 
hold
 
in
 
the
 
dose
 
button
 
until
 
the
 
dose
 
counter
 
shows
 
“0”.
 
The
 
“0”
 
must
 
line
 
up
 
with
 
the
 
dose
 
pointer .
 
A
 
drop
 
of
 
insulin
 
should
 
be
 
seen
 
at
 
the
 
needle
 
tip
 
v.
 
 
If
 
you
 
do
 
not
 
see
 
a
 
drop
 
of
 
insulin,
 
repeat
 
steps
 
ii
 
-
 
iv.
 
7.
 
Dial
 
the
 
correct
 
dose
 
–
 
Check
 
the
 
dose
 
indicator
 
to
 
ensure
 
the
 
correct
 
dose
 
is
 
selected.
 
8.
 
Identify
 
proper
 
injection
 
site/rotation.
 
●
 
For
 
ease
 
of
 
self-injection,
 
the
 
abdomen
 
and
 
thighs
 
are
 
the
 
two
 
main
 
recommended
 
injection
 
sites
 
for
 
adults.
 
a.
 
Abdomen
 
–
 
inject
 
at
 
any
 
place
 
between
 
the
 
bottom
 
of
 
the
 
ribs
 
and
 
the
 
pubic
 
area,
 
3
 
fingers
 
width
 
away
 
from
 
the
 
navel.
 
 
b.
 
Thighs
 
–
 
inject
 
in
 
the
 
top
 
and
 
outer
 
part
 
of
 
the
 
thigh,
 
between
 
5
 
fingers
 
width
 
away
 
from
 
the
 
knee
 
and
 
5
 
fingers
 
width
 
away
 
from
 
the
 
groin.
 
Avoid
 
the
 
inner
 
thigh.
 
c.
 
Buttocks
 
and
 
flanks
 
–
 
Inject
 
into
 
the
 
upper ,
 
outer
 
area
 
of
 
the
 
buttocks.
 
This
 
site
 
can
 
be
 
very
 
difficult
 
to
 
use
 
for
 
self-injection
 
and
 
may
 
require
 
another
 
person
 
for
 
administration.
 
 
d.
 
Arm
 
–
 
inject
 
at
 
the
 
back
 
of
 
the
 
arm,
 
between
 
4
 
fingers
 
width
 
away
 
from
 
the
 
205
 

=== PAGE 207 ===

 
shoulder
 
and
 
4
 
fingers
 
width
 
away
 
from
 
the
 
elbow .
 
●
 
Injection
 
site
 
rotation
 
within
 
any
 
quadrant
 
or
 
half
 
should
 
be
 
done
 
systematically
 
with
 
spacing
 
of
 
at
 
least
 
1
 
cm
 
apart
 
from
 
each
 
injection
 
to
 
prevent
 
repeat
 
tissue
 
trauma.
 
●
 
Advise
 
to
 
rotate
 
injection
 
sites
 
within
 
the
 
same
 
part
 
of
 
the
 
body ,
 
not
 
to
 
change
 
the
 
injection
 
part
 
of
 
the
 
body
 
too
 
frequently
 
due
 
to
 
different
 
absorption
 
of
 
insulin
 
at
 
different
 
parts
 
of
 
the
 
body .
 
 
●
 
Do
 
not
 
inject
 
where
 
the
 
skin
 
has
 
pits,
 
is
 
thickened,
 
or
 
has
 
lumps.
 
Do
 
not
 
inject
 
where
 
the
 
skin
 
is
 
tender ,
 
bruised,
 
scaly
 
or
 
hard,
 
or
 
into
 
scars
 
or
 
damaged
 
skin.
 
 
9.
 
Inject
 
the
 
insulin
 
on
 
clean
 
skin.
 
i.
 
Insert
 
the
 
needle
 
into
 
the
 
skin
 
at
 
90°.
 
●
 
For
 
extremely
 
thin
 
adults
 
with
 
diabetes
 
(BMI
 
<19),
 
the
 
proper
 
injection
 
technique
 
is
 
to
 
use
 
the
 
4
 
mm
 
needle
 
accompanied
 
by
 
the
 
lifting
 
of
 
the
 
skin
 
fold
 
when
 
injecting
 
to
 
avoid
 
the
 
intramuscular
 
injection
 
●
 
Individuals
 
who
 
have
 
to
 
continue
 
using
 
≥8
 
mm
 
needles
 
should
 
always
 
lift
 
a
 
skin
 
fold
 
and/or
 
inject
 
at
 
45
⁰
 
to
 
avoid
 
intramuscular
 
injections
 
ii.
 
Press
 
the
 
injection
 
button
 
until
 
the
 
figure
 
in
 
the
 
dose
 
window
 
returns
 
to
 
0.
 
 
iii.
 
Count
 
to
 
10
 
slowly
 
before
 
withdrawing
 
the
 
needle
 
from
 
the
 
skin
 
iv.
 
Counting
 
past
 
10
 
may
 
be
 
necessary
 
for
 
higher
 
insulin
 
doses.
 
This
 
is
 
to
 
ensure
 
full
 
dose
 
delivery
 
and
 
prevent
 
insulin
 
leakage
 
10.
 
Disposal
 
of
 
used
 
needle
 
i.
 
Recap
 
the
 
used
 
insulin
 
needle
 
using
 
the
 
outer
 
cap.
 
ii.
 
Always
 
remove
 
and
 
safely
 
discard
 
the
 
needle
 
after
 
each
 
injection
 
and
 
store
 
the
 
pen
 
without
 
an
 
injection
 
needle
 
attached.
 
This
 
reduces
 
the
 
risk
 
of
 
contamination,
 
infection,
 
leakage
 
and
 
inaccurate
 
dosing.
 
11.
 
Keep
 
the
 
insulin
 
pen
 
in
 
its
 
case
 
at
 
room
 
temperature,
 
away
 
from
 
heat
 
and
 
light
 
Special
 
 
Considerations
 
Pregnancy
 
 
 
 
Insulin
 
is
 
considered
 
the
 
“gold
 
standard”
 
treatment
 
in
 
managing
 
gestational
 
diabetes
 
mellitus
 
(GDM)
 
and
 
T2DM
 
during
 
pregnancy .
 
●
 
Short-acting
 
regular
 
human
 
insulin
 
and
 
intermediate-acting
 
regular
 
human
 
insulin
 
are
 
generally
 
considered
 
safe
 
and
 
labelled
 
Category
 
B
 
by
 
the
 
US
 
FDA.
 
●
 
Several
 
insulin
 
analogues
 
(insulin
 
aspart,
 
insulin
 
lispro
 
and
 
insulin
 
detemir)
 
are
 
also
 
classified
 
as
 
Category
 
B
 
 
●
 
Insulin
 
glargine
 
can
 
be
 
given
 
when
 
the
 
potential
 
benefits
 
outweigh
 
the
 
potential
 
risk.
 
Although
 
there
 
is
 
no
 
randomised
 
controlled
 
trial
 
on
 
its
 
use
 
in
 
pregnancy ,
 
many
 
case
 
reports
 
and
 
observational
 
studies
 
did
 
not
 
find
 
any
 
association
 
with
 
adverse
 
maternal
 
or
 
neonatal
 
outcome.
 
 
 
 
 
Breastfeeding
 
 
 
 
Exogenous
 
insulin
 
has
 
been
 
detected
 
in
 
human
 
milk,
 
including
 
 
 
 
206
 

=== PAGE 208 ===

 
biosynthetic
 
insulin.
 
Insulin
 
is
 
not
 
absorbed
 
by
 
the
 
infant
 
but
 
may
 
have
 
beneficial
 
local
 
activity
 
in
 
the
 
gastrointestinal
 
tract.
 
Elderly
 
 
 
 
1.
 
Cautions
 
in
 
elderly
 
with
 
cognitive
 
impairment;
  
they
 
may
 
have
 
difficulty
 
recognising
 
or
 
responding
 
appropriately
 
to
 
the
 
symptoms
 
of
 
hypoglycaemia.
 
2.
 
Consider
 
patient-related
 
factors
 
such
 
as
 
manual
 
dexterity ,
 
hand
 
strength,
 
tremors,
 
vision,
 
comorbidities,
 
cognition
 
and
 
others.
 
3.
 
Hypoglycemia
 
in
 
elderly
 
significantly
 
increases
 
the
 
risk
 
of
 
falls.
 
 
 
 
Paediatric
 
 
 
 
1.
 
The
 
safety
 
and
 
effectiveness
 
of
 
insulin
 
Glargine
 
and
 
insulin
 
Glulisine
 
in
 
paediatric
 
patients
 
below
 
6
 
years
 
old
 
have
 
not
 
been
 
established
 
2.
 
The
 
safety
 
and
 
effectiveness
 
of
 
insulin
 
Lispro
 
in
 
paediatric
 
patients
 
below
 
3
 
years
 
old
 
have
 
not
 
been
 
established
 
3.
 
The
 
safety
 
and
 
effectiveness
 
of
 
insulin
 
Detemir
 
and
 
insulin
 
Aspart
 
in
 
paediatric
 
patients
 
below
 
2
 
years
 
old
 
have
 
not
 
been
 
established
 
4.
 
Treatment
 
recommendations
 
may
 
vary
 
among
 
individual
 
products
 
and
 
countries,
 
refer
 
to
 
local
 
treatment
 
guidelines
 
 
 
 
Fasting
 
 
 
 
Appropriate
 
adjustments
 
of
 
dose
 
and
 
time
 
of
 
administration
 
of
 
insulin
 
should
 
be
 
made
 
for
 
patients
 
who
 
are
 
eligible
 
to
 
fast
 
to
 
reduce
 
risk
 
of
 
hypoglycaemia
 
and
 
other
 
complications
 
during
 
fasting.
 
 
 
 
 
Others
 
 
 
 
 
NA
 
 
 
 
Side
 
Effects
 
and
 
their
 
Management*
 
1.
 
Hypoglycaemia
 
(Plasma
 
glucose
 
level
 
below
 
3.9
 
mmol/L)
 
●
 
It
 
may
 
happen
 
if
 
the
 
patient
 
 
a.
 
did
 
not
 
take
 
a
 
meal
 
after
 
the
 
injection
 
b.
 
if
 
he/she
 
has
 
a
 
sudden
 
change
 
in
 
diet
 
c.
 
alcohol
 
consumption
 
with
 
no
 
carbohydrate
 
intake
 
d.
 
excessive
 
physical
 
activity
 
e.
 
excessive
 
dose
 
f.
 
sick
 
day
 
or
 
poor
 
appetite
 
g.
 
inject
 
the
 
wrong
 
type
 
of
 
insulin
 
 
●
 
Recognition
 
of
 
hypoglycaemia
 
symptoms
 
 
a.
 
Shivering
 
b.
 
Palpitation
 
c.
 
Sweating
 
d.
 
Dizziness
 
e.
 
Hunger
 
pangs
 
f.
 
Tingling
 
or
 
numbness
 
 
●
 
Treatment
 
of
 
hypoglycaemia
 
(Rule
 
of
 
15)
 
i.
 
Check
 
plasma
 
glucose
 
level
 
to
 
confirm
 
that
 
the
 
plasma
 
glucose
 
level
 
is
 
below
 
4.0
 
mmol/L
 
(or
 
70
 
mg/dL)
 
if
 
possible
 
ii.
 
In
 
adult
 
patients,
 
consume
 
15
 
grams
 
of
 
simple
 
 
 
 
207
 

=== PAGE 209 ===

 
carbohydrate
 
e.g:
 
●
 
1
 
tablespoon
 
of
 
honey ,
 
●
 
150-200
 
ml
 
of
 
fruit
 
juice
 
such
 
as
 
orange
 
juice
 
or
 
regular
 
soft
 
drink;
 
or
 
●
 
3
 
teaspoons
 
of
 
table
 
sugar
 
dissolved
 
in
 
water
 
iii.
 
In
 
children
,
 
give
 
0.3g/kg
 
of
 
simple
            
carbohydrates.
 
iv.
 
After
 
consuming
 
the
 
CHO,
 
wait
 
for
 
15
 
minutes
 
to
 
allow
 
the
 
glucose
 
to
 
be
 
absorbed
 
and
 
the
 
plasma
 
glucose
 
to
 
rise
 
v.
 
Recheck
 
plasma
 
glucose.
 
If
  
plasma
 
glucose
 
remains
 
below
 
4.0
 
mmol/L,
 
repeat
 
step
 
ii.
 
vi.
 
Once
 
hypoglycaemia
 
has
 
been
 
reversed
 
(BG
 
>
 
4.0
 
mmol/L),
 
the
 
patient
 
should
 
have
 
the
 
usual
 
meal
 
that
 
is
 
due
 
at
 
that
 
time
 
of
 
the
 
day
 
or
 
15g
 
of
 
complex
 
carbohydrate
 
to
 
prevent
 
recurrent
 
hypoglycaemia.
 
E.g:
 
●
 
3
 
pieces
 
of
 
crackers
 
 
●
 
1
 
piece
 
of
 
bread
 
 
2.
 
Weight
 
gain
 
●
 
Insulin-related
 
weight
 
gain
 
may
 
be
 
a
 
consequence
 
of
 
several
 
factors:
 
a.
 
Improving
 
metabolic
 
control
 
reduces
 
glycosuria
 
resulting
 
in
 
fewer
 
calories
 
lost
 
in
 
this
 
manner
 
b.
 
The
 
fear
 
of
 
hypoglycaemia
 
might
 
induce
 
increased
 
snacking
 
between
 
meals,
 
increasing
 
calorie
 
intake.
 
c.
 
The
 
anabolic
 
nature
 
of
 
insulin
 
can
 
increase
 
lean
 
body
 
mass.
 
d.
 
Using
 
insulin
 
can
 
also
 
cause
 
salt
 
and
 
water
 
retention
 
●
 
Educate
 
patient
 
on
 
steps
 
to
 
counter
 
weight
 
gain:
 
a.
 
Advise
 
restricting
 
calories
 
and
 
using
 
portion
 
control,
 
particularly
 
for
 
carbohydrates
 
and
 
fats.
 
b.
 
Advise
 
patients
 
to
 
keep
 
physically
 
active
 
and
 
practice
 
regular
 
exercise.
 
c.
 
Avoiding
 
high
 
doses
 
of
 
insulin
 
by
 
reducing
 
carbohydrate
 
intake
 
and
 
being
 
physically
 
active
 
(reduces
 
insulin
 
requirement).
 
d.
 
Preventing
 
hypoglycaemia
 
as
 
it
 
can
 
lead
 
to
 
defensive
 
eating/snacking
 
Storage*
 
A.
 
New
 
insulin
 
cartridges
 
and
 
prefilled
 
pen
 
●
 
Unopened
 
insulin
 
should
 
be
 
kept
 
at
 
a
 
refrigerated
 
temperature
 
between
 
2°C–8°C.
 
 
●
 
Do
 
not
 
keep
 
the
 
insulin
 
at
 
the
 
side
 
of
 
the
 
fridge
 
door
 
and
 
do
 
not
 
put
 
it
 
inside
 
the
 
freezer .
 
 
●
 
Do
 
not
 
use
 
insulin
 
that
 
has
 
been
 
frozen.
 
●
 
Check
 
the
 
manufacturer ’s
 
storage
 
instructions
 
as
 
there
 
may
 
be
 
possible
 
differences
 
from
 
one
 
manufacturer
 
to
 
the
 
other
 
 
B.
 
In-use
 
insulin
 
cartridges
 
and
 
prefilled
 
pen
 
●
 
In-use
 
insulin
 
pens
 
can
 
be
 
stored
 
at
 
room
 
temperature
 
(15
 
-30°C).
 
 
●
 
Do
 
not
 
remove
 
cartridges
 
from
 
non-prefilled
 
insulin
 
pen
 
between
 
use
 
and
 
never
 
refrigerate
 
non-prefilled
 
insulin
 
pen.
 
●
 
Write
 
the
 
date
 
of
 
opening
 
on
 
insulin
 
cartridges
 
or
 
prefilled
 
insulin
 
pens.
 
Most
 
insulins
 
can
 
be
 
used
 
within
 
28
 
-
 
42
 
days
 
once
 
opened.
 
 
●
 
Please
 
refer
 
to
 
the
 
individual
 
product
 
information
 
for
 
further
 
details.
 
 
 
 
208
 

=== PAGE 210 ===

 
Others
 
1.
 
Supply
 
of
 
insulin
 
cartridges,
 
insulin
 
pens
 
and
 
needles
 
●
 
Insulin
 
cartridges
 
will
 
be
 
supplied
 
to
 
the
 
patient
 
by
 
the
 
pharmacy
 
●
 
Non-prefilled
 
insulin
 
pens
 
will
 
be
 
given
 
free
 
for
 
first-time
 
users
 
●
 
If
 
the
 
pen
 
is
 
damaged
 
after
 
the
 
first
 
supply ,
 
patients
 
have
 
to
 
acquire
 
their
 
own
 
replacement
 
pen
 
 
●
 
Change
 
the
 
needle
 
after
 
each
 
use
 
(using
 
a
 
needle
 
more
 
than
 
once
 
is
 
at
 
the
 
patient’ s
 
own
 
risk)
 
●
 
Needles
 
can
 
be
 
bought
 
from
 
retail
 
pharmacies
 
●
 
Dispose
 
the
 
needles
 
safely
 
(e.g.
 
inside
 
the
 
puncture-proof
 
container)
 
before
 
being
 
discarded.
 
 
2.
 
Sick
 
day
 
management
 
●
 
ALWAYS
 
TAKE
 
your
 
diabetes
 
pills
 
unless
 
you
 
are
 
vomiting
 
●
 
ALWAYS
 
TAKE
 
your
 
insulin.
 
Your
 
insulin
 
dose
 
may
 
be
 
decreased
 
or
 
increased.
 
Seek
 
advice
 
from
 
your
 
doctor/pharmacist
 
for
 
insulin
 
dose
 
adjustment
 
●
 
Test
 
your
 
blood
 
sugar
 
level
 
more
 
often.
 
Test
 
before
 
and
 
two
 
hours
 
after
 
each
 
meal.
 
If
 
you
 
are
 
not
 
able
 
to
 
eat
 
your
 
regular
 
meals,
 
you
 
should
 
check
 
your
 
blood
 
sugar
 
levels
 
every
 
2-4
 
hours.
 
Record
 
readings
 
with
 
date
 
and
 
time
 
●
 
Try
 
to
 
eat
 
the
 
same
 
amount
 
of
 
food
 
as
 
usual
 
●
 
Drink
 
plenty
 
of
 
fluids:
 
drink
 
at
 
least
 
every
 
hour
 
or
 
take
 
small
 
sips
 
every
 
10-15
 
minutes
 
 
3.
 
Encourage
 
home
 
glucose
 
monitoring
 
using
 
a
 
glucometer
 
●
 
Record
 
glucose
 
readings
 
and
 
meals
 
in
 
a
 
diary
 
for
 
review
 
by
 
the
 
healthcare
 
provider .
 
 
 
 
Before
 
ending
 
this
 
peer
 
review
 
session,
 
the
 
reviewee
 
should
 
be
 
informed
 
of
 
the
 
step(s)
 
that
 
he/
 
she
 
missed
 
out
 
in
 
order
 
to
 
ensure
 
all
 
the
 
counselling
 
points
 
are
 
being
 
covered.
 
 
Remarks:
 
 
 
 
 
Reviewed
 
by:
 
Name
 
&
 
Signature
                                                                   
Date:
 
 
 
 
 
*Mandatory
 
for
 
validation
 
/
 
peer
 
review
 
References:
 
 
1.
 
American
 
Geriatrics
 
Society .
 
(2023).
 
American
 
Geriatrics
 
Society
 
2023
 
updated
 
AGS
 
Beers
 
Criteria®
 
for
 
potentially
 
inappropriate
 
medication
 
use
 
in
 
older
 
adults.
 
Journal
 
of
 
the
 
American
 
Geriatrics
 
Society ,
 
71(7),
 
2052-2081.
 
2.
 
Biocon.
 
(n.d).
 
Insupen
 
Pro
 
IFU.
 
Retrieved
 
from
 
https://www .biocon.com/docs/domestic-market-pi/metabolics/INSUPen%20Pro%20IFU.pdf
 
 
3.
 
Malaysian
 
Diabetes
 
Educators
 
Society .
 
(2017).
 
Forum
 
for
 
Injection
 
Technique
 
Malaysia
 
(FIT-My):
 
Recommendations
 
for
 
Best
 
Practice
 
in
 
Injection
 
Technique.
 
4.
 
Malaysian
 
Endocrine
 
and
 
Metabolic
 
Society .
 
(2024).
 
Practical
 
Guide
 
to
 
Insulin
 
Therapy
 
in
 
Type
 
2
 
Diabetes
 
Mellitus
 
(2nd
 
edition).
 
5.
 
National
 
Institute
 
of
 
Child
 
Health
 
and
 
Human
 
Development.
 
(updated
 
2024
 
November
 
15).
 
Insulin.
 
Drugs
 
and
 
Lactation
 
Database
 
(LactMed)
 
(Internet).
 
Retrieved
 
from
 
https://www .ncbi.nlm.nih.gov/books/NBK500991/
 
 
6.
 
Novo
 
Nordisk.
 
(2021).
 
Novorapid
 
(insulin
 
aspart)
 
injection
 
prescribing
 
information.
 
Retrieved
 
from
 
https://quest3plus.bpfk.gov .my/front-end/attachment/519/pharma/601 10/V_58375_20210930_145028_D
3.pdf
 
209
 

=== PAGE 211 ===

 
7.
 
Novo
 
Nordisk.
 
(2022).
 
Levemir
 
(insulin
 
detemir)
 
injection
 
prescribing
 
information.
 
Retrieved
 
from
 
https://www .novo-pi.com/levemir .pdf
 
8.
 
Novo
 
Nordisk.
 
(2022).
 
Ryzodeg
 
(insulin
 
degludec
 
and
 
insulin
 
aspart)
 
injection
 
prescribing
 
information.
 
Retrieved
 
from
 
https://www .novo-pi.com/ryzodeg7030.pdf
 
9.
 
Sanofi-A ventis.
 
(2023).
 
Lantus
 
(insulin
 
glargine)
 
injection
 
prescribing
 
information.
 
Retrieved
 
from
 
https://products.sanofi.us/lantus/lantus.pdf
 
10.
 
Sanofi-A ventis.
 
(2024).
 
Soliqua
 
(Insulin
 
Glargine
 
and
 
Lixisenatide)
 
injection
 
prescribing
 
information.
 
Retrieved
 
from
 
https://products.sanofi.us/soliqua100-33/soliqua100-33.pdf
 
 
11.
 
Sanofi-A ventis.
 
(2024).
 
Toujeo
 
(insulin
 
glargine)
 
injection
 
prescribing
 
information.
 
Retrieved
 
from
 
https://products.sanofi.us/toujeo/toujeo.pdf
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
210
 

=== PAGE 212 ===

 
Iron
 
Supplements,
 
Oral
 
Name
 
:
 
 
Unit
 
:
 
 
●
 
Please
 
tick
 
(
✔
)
 
Yes
 
for
 
correct
 
instruction.
 
●
 
Please
 
tick
 
(
✔
)
 
No
 
for
 
incorrect
 
instruction.
 
Yes
 
No
 
Remarks
 
Pharmacological
 
Group
 
Iron
 
bivalent,
 
oral
 
preparations
 
ferrous
 
fumarate
 
 
ferrous
 
sulfate
 
 
 
Iron
 
trivalent,
 
oral
 
preparations
 
ferric
 
oxide
 
polymaltose
 
complexes
 
 
 
 
Indications
 
and
 
Dosage
 
1.
 
Prevention
 
and
 
treatment
 
of
 
iron
 
deficiency
 
anaemia
 
 
Tablet
 
formulations:
 
a.
 
Ferrous
 
fumarate
 
200
 
mg
 
tablet
 
(66
 
mg
 
elemental
 
iron
 
per
 
tablet)
 
 
b.
 
Zincofer
Ⓡ
 
capsule
 
(Ferrous
 
fumarate
 
salt
 
providing
 
115
 
mg
 
elemental
 
iron
 
per
 
capsule)
 
c.
 
Iberet
Ⓡ
 
 
Folic
 
500
 
tablet
 
(Ferrous
 
sulfate
 
salt
 
providing
 
105
 
mg
 
elemental
 
iron
 
per
 
tablet)
 
d.
 
New
 
Obimin
Ⓡ
 
tablet
 
(Ferrous
 
fumarate
 
salt
 
providing
 
30
 
mg
 
elemental
 
iron
 
per
 
tablet)
 
e.
 
Maltofer
Ⓡ
 
(Iron
 
(III)
 
hydroxide
 
polymaltose
 
complex
 
providing
 
100
 
mg
 
elemental
 
iron
 
per
 
tablet)
 
 
                 
Syrup
 
formulations:
 
a.
 
Ferric
 
ammonium
 
citrate
 
solution
 
(providing
 
17.2
 
mg/ml
 
elemental
 
iron)
 
b.
 
Maltofer
Ⓡ
 
syrup
 
(Iron
 
(III)
 
hydroxide
 
polymaltose
 
complex
 
providing
 
10
 
mg/ml
 
elemental
 
iron)
 
 
To
 
counsel
 
based
 
on
 
specific
 
medication’ s
 
indication
 
and
 
dosage
 
as
 
prescribed
 
by
 
the
 
doctor
 
 
 
 
Method
 
of
 
Administration*
 
1.
 
Ferrous
 
fumarate
 
tablets
 
should
 
be
 
taken
 
on
 
an
 
empty
 
stomach
 
(1
 
hour
 
before
 
or
 
2
 
hours
 
after
 
meals)
 
for
 
better
 
absorption.
 
However ,
 
may
 
take
 
with
 
meals
 
to
 
minimise
 
gastrointestinal
 
(GI)
 
irritation.
 
It
 
can
 
be
 
crushed
 
and
 
administered
 
via
 
Ryle’ s
 
tube.
 
 
2.
 
Zincofer
Ⓡ
 
capsule
 
should
 
be
 
taken
 
with
 
meal.
 
 
3.
 
Iberet
Ⓡ
 
 
Folic
 
to
 
be
 
swallowed
 
whole
 
with
 
or
 
without
 
meals.
 
Do
 
not
 
chew
 
or
 
crush
 
as
 
Iberet
 
is
 
formulated
 
with
 
a
 
controlled-release
 
vehicle.
 
4.
 
Maltofer
Ⓡ
 
may
 
be
 
chewed
 
or
 
swallowed
 
whole
 
during
 
or
 
immediately
 
after
 
meals.
 
 
5.
 
New
 
Obimin
Ⓡ
 
tablet
 
to
 
be
 
taken
 
with/
 
without
 
meal.
 
May
 
be
 
taken
 
with
 
meals
 
for
 
better
 
absorption
 
or
 
if
 
GI
 
discomfort
 
occurs.
 
 
 
Missed
 
dose
 
management:
 
In
 
case
 
of
 
a
 
missed
 
dose,
 
take
 
it
 
immediately .
 
Omit
 
the
 
dose
 
if
 
totally
 
forgotten
 
and
 
remember
 
to
 
take
 
as
 
per
 
instructed
 
during
 
the
 
next
 
dose.
 
 
 
Do
 
not
 
stop
 
taking
 
your
 
medication
 
unless
 
advised
 
to
 
do
 
so
 
by
 
your
 
prescriber
 
 
 
 
 
 
211
 

=== PAGE 213 ===

 
Special
 
Considerations
 
Pregnancy
 
 
 
 
Iron
 
supplements
 
are
 
safe
 
to
 
be
 
taken
 
in
 
pregnancy .
 
 
 
 
Breastfeeding
 
 
 
 
Iron
 
supplements
 
are
 
safe
 
to
 
be
 
taken
 
while
 
breastfeeding.
 
 
 
 
Elderly
 
 
 
 
Lower
 
doses
 
of
 
iron
 
may
 
have
 
similar
 
clinical
 
efficacy
 
but
 
with
 
less
 
gastrointestinal
 
side
 
effects
 
compared
 
to
 
higher
 
doses.
 
 
 
 
Paediatric
 
 
 
 
Dosage
 
range:
 
3
 
-
 
6
 
mg
 
elemental
 
iron/kg/day .
 
Milk
 
and/or
 
dairy
 
products
 
should
 
be
 
avoided
 
for
 
approximately
 
one
 
hour
 
before
 
and
 
two
 
hours
 
after
 
each
 
dose
 
because
 
such
 
products
 
limit
 
iron
 
absorption.
 
 
 
 
Fasting
 
 
 
 
To
 
take
 
at
 
either
 
Sahur
 
(before
 
fasting)
 
or
 
Iftar
 
(breakfast).
 
 
 
 
Others
  
 
 
 
 
No
 
dosage
 
adjustment
 
necessary
 
 
 
 
Side
 
Effects
 
and
 
their
 
Management*
 
1.
 
Gastrointestinal
 
side
 
effects
 
e.g.
 
metallic
 
taste,
 
nausea,
 
vomiting,
 
darkening
 
of
 
stools,
 
constipation,
 
stomach
 
cramps.
 
2.
 
Increase
 
fluid
 
and
 
fibre
 
intake
 
to
 
ease
 
constipation.
 
If
 
constipation
 
persists,
 
the
 
use
 
of
 
stool
 
softeners
 
or
 
laxatives
 
may
 
be
 
considered.
 
 
 
 
 
Storage*
 
1.
 
Store
 
in
 
room
 
temperature
 
and
 
dry
 
place.
 
2.
 
Keep
 
out
 
of
 
reach
 
of
 
children.
 
3.
 
Keep
 
Maltofer
 
tablets
 
in
 
original
 
packaging
 
in
 
order
 
to
 
protect
 
from
 
light.
 
 
 
 
Others
 
1.
 
May
 
take
 
with
 
ascorbic
 
acid
 
to
 
enhance
 
iron
 
absorption.
 
2.
 
Take
 
oral
 
iron
 
one
 
hour
 
before
 
or
 
two
 
hours
 
after
 
calcium
 
tablets.
 
3.
 
Take
 
iron
 
tablets
 
two
 
hours
 
before
 
or
 
four
 
hours
 
after
 
ingestion
 
of
 
antacids
 
as
 
antacids
 
impair
 
iron
 
absorption.
 
4.
 
Absorption
 
of
 
tetracycline
 
and
 
fluoroquinolone
 
antibiotics
 
is
 
reduced
 
with
 
concurrent
 
iron
 
intake.
 
Space
 
two
 
to
 
three
 
hours
 
between
 
these
 
drugs.
 
 
5.
 
Do
 
not
 
take
 
levothyroxine
 
within
 
four
 
hours
 
of
 
iron
 
tablets.
 
Absorption
 
of
 
levothyroxine
 
is
 
affected
 
by
 
oral
 
iron.
 
6.
 
Do
 
not
 
take
 
with
 
caffeinated
 
drinks
 
(tea,
 
coffee
 
and
 
cola)
 
or
 
calcium-containing
 
foods
 
and
 
beverages
 
as
 
it
 
may
 
interfere
 
with
 
iron
 
absorption.
 
 
7.
 
Oral
 
and
 
parenteral
 
iron
 
therapy
 
should
 
not
 
be
 
used
 
concurrently .
 
 
 
 
212
 

=== PAGE 214 ===

 
Before
 
ending
 
this
 
peer
 
review
 
session,
 
the
 
reviewee
 
should
 
be
 
informed
 
of
 
the
 
step(s)
 
that
 
he/
 
she
 
missed
 
out
 
in
 
order
 
to
 
ensure
 
all
 
the
 
counselling
 
points
 
are
 
being
 
covered.
 
 
Remarks:
 
 
 
 
 
Reviewed
 
by:
 
Name
 
&
 
Signature
                                                                   
Date:
 
 
 
 
 
*Mandatory
 
for
 
validation
 
/
 
peer
 
review
 
References:
 
 
1.
 
Pharmaceutical
 
Services
 
Programme
 
(2019). Garis
 
Panduan
 
Kaunseling
 
Ubat-ubatan (Edisi
 
Ketiga).
 
Pharmaceutical
 
Services
 
Programme,
 
Ministry
 
of
 
Health
 
Malaysia.
 
2.
 
Bak
 
Leong,
 
G.,
 
Sunita,
 
B.,
 
Rosnawati,
 
Y.,
 
&
 
Lily,
 
M.
 
(2023).
 
Handbook
 
of
 
kidney
 
replacement
 
therapy
 
(5th
 
ed.).
 
Ministry
 
of
 
Health
 
Malaysia.
 
3.
 
Lee,
 
S.
 
W.,
 
Subramaniam,
 
M.
 
D.,
 
Ibrahim
 
N.,
 
&
 
Zainol
 
Abidin,
 
R.N.
 
(2018).
 
Renal
 
Pharmacy
 
Handbook
 
-
 
A
 
Practical
 
Guide
 
to
 
Drug
 
Therapy
 
(Third
 
Edition).
 
Malaysian
 
Pharmacists
 
Society .
 
4.
 
Vaughn,
 
C.
 
J.
 
(2012).
 
Drugs
 
and
 
lactation
 
database:
 
LactMed.
 
Journal
 
of
 
electronic
 
resources
 
in
 
medical
 
libraries,
 
9(4),
 
272-277.
 
5.
 
Auerbach,
 
M.,
 
&
 
DeLoughery ,
 
T.
 
G.
 
(2024).
 
Treatment
 
of
 
iron
 
deficiency
 
anemia
 
in
 
adults.
 
UpToDate.
 
Retrieved
 
4
th
 
October
 
2024
 
from:
 
https://www .uptodate.com/contents/treatment-of-iron-deficiency-anemia-in-adults
 
6.
 
Warady ,
 
B.A.,
 
Weidemann,
 
D.K.,
 
&
 
Srivastava,
 
T.
 
(2024).
 
Chronic
 
kidney
 
disease
 
in
 
children:
 
complications.
 
UpToDate.
 
Retrieved
 
4
th
 
October
 
2024
 
from:
 
https://www .uptodate.com/contents/chronic-kidney-disease-in-children-complications
 
 
7.
 
Ismail,
 
H.IH.M.,
 
Ibrahim,
 
H.M.,
 
Ng,
 
H.P.,
 
&
 
Thomas,
 
T.
 
(2019)
 
Paediatric
 
Protocols
 
for
 
Malaysian
 
Hospitals.
 
4th
 
Edition,
 
Ministry
 
of
 
Health,
 
Putrajaya.
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
213
 

=== PAGE 215 ===

 
Isosorbide
 
Dinitrate/
 
Isosorbide
 
Mononitrate
 
Name
 
:
 
 
Unit
 
:
 
 
●
 
Please
 
tick
 
(
✔
)
 
Yes
 
for
 
correct
 
instruction.
 
●
 
Please
 
tick
 
(
✔
)
 
No
 
for
 
incorrect
 
instruction.
 
Yes
 
No
 
Remarks
 
Pharmacological
 
Group
 
Nitrate;
 
Antianginal
 
agent
 
●
 
Isosorbide
 
dinitrate
 
(ISDN)
 
●
 
Isosorbide
 
mononitrate
 
(ISMN)
 
 
 
 
Indications
 
and
 
Dosage
 
1.
 
Prophylaxis
 
and
 
treatment
 
of
 
angina
 
pectoris
 
a.
 
Isosorbide
 
dinitrate
 
5-20mg
 
2-3
 
times
 
daily
 
(up
 
to
 
120mg
 
per
 
day). 
 
b.
 
Isosorbide
 
mononitrate
 
30
 
to
 
120mg
 
daily
 
(up
 
to
 
240mg
 
per
 
day)
 
2.
 
Heart
 
failure
 
a.
 
Isosorbide
 
dinitrate
 
20-40mg
 
tds;
 
trials
 
were
 
done
 
in
 
combination
 
with
 
hydralazine.
 
 
To
 
counsel
 
based
 
on
 
specific
 
medication’ s
 
indication
 
and
 
dosage
 
as
 
prescribed
 
by
 
the
 
doctor
 
 
 
 
Method
 
of
 
Administration*
 
1.
 
ISDN
 
&
 
ISMN
 
should
 
be
 
taken
 
without
 
food,
 
preferably
 
first
 
thing
 
in
 
the
 
morning,
 
and
 
same
 
time
 
everyday ,
 
as
 
advised
 
2.
 
Swallow
 
controlled
 
release
 
tablets
 
whole
 
because
 
if
 
they
 
are
 
crushed
 
or
 
chewed
 
they
 
won't
 
work
 
properly .
 
3.
 
In
 
general,
 
immediate
 
release
 
tablets
 
may
 
be
 
cut
 
or
 
crushed.
 
4.
 
Allow
 
nitrate-free
 
intervals
 
of
 
10-12
 
hours
 
to
 
prevent
 
development
 
of
 
tolerance. 
 
5.
 
Isosorbide
 
dinitrate
 
 
a.
 
For
 
twice
 
daily
 
dosing,
 
consider
 
administering
 
at
 
8am
 
and
 
1pm
 
b.
 
For
 
3-times-daily
 
dosing,
 
consider
 
8am,
 
1pm,
 
and
 
6pm. 
 
6.
 
Isosorbide
 
mononitrate,
 
 
a.
 
consider
 
once
 
daily
 
dosing
 
at
 
the
 
same
 
time
 
everyday . 
 
b.
 
For
 
twice
 
daily
 
dosing,
 
consider
 
administering
 
at
 
8am
 
and
 
1pm
 
Missed
 
dose
 
management
 
If
 
you
 
miss
 
a
 
dose
 
of
 
this
 
medicine,
 
take
 
it
 
as
 
soon
 
as
 
possible.
 
However ,
 
if
 
it
 
is
 
almost
 
time
 
for
 
the
 
next
 
dose,
 
skip
 
the
 
missed
 
dose
 
and
 
go
 
back
 
to
 
the
 
regular
 
dosing
 
schedule.
 
Do
 
not
 
double
 
doses.
 
 
Do
 
not
 
stop
 
taking
 
your
 
medi
cation
 
unless
 
advised
 
to
 
do
 
so
 
by
 
your
 
prescriber
 
 
 
 
Special
 
Considerations
 
Pregnancy
 
 
 
 
Use
 
with
 
caution
 
if
 
benefits
 
outweigh
 
risks.
 
 
 
 
Breastfeeding
 
 
 
 
It
 
is
 
unknown
 
if
 
the
 
drug
 
is
 
distributed
 
into
 
breast
 
milk.T o
 
inform
 
the
 
doctor
 
if
 
you
 
are
 
breastfeeding.
 
 
 
 
Elderly
 
 
 
 
1.
 
Use
 
with
 
caution
 
2.
 
Administer
 
the
 
lowest
 
recommended
 
adult
 
daily
 
dose
 
 
 
 
214
 

=== PAGE 216 ===

 
initially
 
and
 
titrate
 
upward.
 
 
3.
 
Isosorbide
 
Mononitrate
:
 
Prolonged-
 
release
 
tablets
 
must
 
not
 
be
 
divided,
 
crushed
 
or
 
chewed.
 
Consideration
 
should
 
be
 
given
 
in
 
elderly
 
with
 
dysphagia
 
or
 
requiring
 
enteral
 
tube
 
feeding.
 
 
MALPIP
 
 
1.
 
Increased
 
risk
 
of
 
orthostatic
 
hypotension.
 
START/ST OPP
 
criteria
 
 
1.
 
Avoid
 
use
 
in
 
patients
 
with
 
recurrent
 
falls
 
with
 
persistent
 
postural
 
hypotension,
 
due
 
to
 
increased
 
risk
 
of
 
syncope
 
and
 
falls.
 
 
2.
 
Aim
 
to
 
carefully
 
reduce
 
and
 
discontinue
 
these
 
drugs
 
in
 
patients
 
who
 
have
 
had
 
no
 
reported
 
anginal
 
symptoms
 
in
 
previous
 
12
 
months
 
AND
 
who
 
have
 
no
 
proven
 
or
 
objective
 
evidence
 
of
 
coronary
 
artery
 
disease.
 
 
Paediatric
 
 
 
 
The
 
safety
 
and
 
effectiveness
 
of
 
isosorbide
 
dinitrate
 
in
 
children
 
has
 
not
 
been
 
established.
 
 
 
 
Fasting
 
 
 
 
Not
 
applicable
 
 
 
 
Side
 
Effects
 
and
 
their
 
Management*
 
1.
 
Report
 
these
 
symptoms
 
to
 
the
 
physician:
 
Severe
 
headache,
 
blurred
 
vision,
 
dizziness
 
or
 
flushing. 
 
2.
 
If
 
affected,
 
do
 
not
 
drive
 
or
 
operate
 
machinery . 
 
 
 
 
Storage*
 
1.
 
Store
 
under
 
room
 
temperature.
 
Protect
 
from
 
moisture.
 
 
 
 
Others
 
Drug-drug
 
interactions:
 
Avoid
 
use
 
with
 
Phosphodiesterase-5
 
(PDE-5)
 
inhibitors
 
(e.g.
 
avanafil,
 
sildenafil,
 
tadalafil,
 
vardenafil)
 
as
 
it
 
may
 
cause
 
severe
 
hypotension.  
 
 
 
 
Before
 
ending
 
this
 
peer
 
review
 
session,
 
the
 
reviewee
 
should
 
be
 
informed
 
of
 
the
 
step(s)
 
that
 
he/
 
she
 
missed
 
out
 
in
 
order
 
to
 
ensure
 
all
 
the
 
counselling
 
points
 
are
 
being
 
covered.
 
 
Remarks:
 
 
 
 
Reviewed
 
by:
 
Name
 
&
 
Signature
                                                                   
Date:
 
 
 
 
*Mandatory
 
for
 
validation
 
/
 
peer
 
review
 
References:
 
 
1.
 
Formulari
 
Ubat
 
KKM.
 
(2025).
 
Accessed
 
on
 
January
 
21,
 
2025.
 
2.
 
SM
 
Pharmaceuticals
 
Sdn
 
Bhd
 
(2023
 
)
 
Product
 
information
 
leaflet:
 
Solbid.
 
Retrieved
 
from
 
Quest
 
3+
 
Product
 
Search
 
on
 
January
 
20,
 
2025.
 
3.
 
Duopharma
 
Marketing
 
Sdn.
 
Bhd
 
(2020)
 
Product
 
information
 
leaflet:
 
Index
 
CR.
 
Retrieved
 
from
 
Quest
 
3+
 
Product
 
Search
 
on
 
January
 
20,
 
2025.
 
4.
 
UpToDate.
 
(2024)
 
UpToDate
 
(Version
 
3.70.4)
 
[Mobile
 
App]
 
Mobile
 
Clinical
 
Decision
 
Support
 
App
 
|
 
UpToDate
 
|
 
Wolters
 
KluwerW olters
 
Kluwer
 
5.
 
Chang,
 
C.
 
T.,
 
Chan,
 
H.
 
K.,
 
Cheah,
 
W.
 
K.,
 
Tan,
 
M.
 
P.,
 
Ch’ng,
 
A.
 
S.
 
H.,
 
Thiam,
 
C.
 
N.,
 
...
 
&
 
Lee,
 
S.
 
W.
 
H.
 
(2023).
 
Development
 
of
 
a
 
Malaysian
 
potentially
 
inappropriate
 
prescribing
 
screening
 
tool
 
in
 
older
 
adults
 
(MALPIP):
 
a
 
Delphi
 
study . Journal
 
of
 
Pharmaceutical
 
Policy
 
and
 
Practice, 16(1),
 
122.
 
6.
 
2023
 
American
 
Geriatrics
 
Society
 
Beers
 
Criteria®
 
Update
 
Expert
 
Panel.
 
(2023).
 
American
 
Geriatrics
 
Society
 
2023
 
updated
 
AGS
 
Beers
 
Criteria®
 
for
 
potentially
 
inappropriate
 
medication
 
use
 
in
 
older
 
adults. Journal
 
of
 
the
 
American
 
Geriatrics
 
Society , 71(7),
 
2052-2081.
 
215
 

=== PAGE 217 ===

 
Ivabradine
 
 
Name
 
:
 
 
Unit
 
:
 
 
●
 
Please
 
tick
 
(
✔
)
 
Yes
 
for
 
correct
 
instruction.
 
●
 
Please
 
tick
 
(
✔
)
 
No
 
for
 
incorrect
 
instruction.
 
Yes
 
No
 
Remarks
 
Pharmacological
 
Group
 
I
f
 
current
 
inhibitors
 
 
Other
 
cardiac
 
preparations
 
Ivabradine
 
 
 
 
Indications
 
and
 
Dosage
 
1.
 
Symptomatic
 
treatment
 
of
 
chronic
 
stable
 
angina
 
pectoris
 
in
 
coronary
 
artery
 
disease
 
adults
 
with
 
normal
 
sinus
 
rhythm
 
and
 
heart
 
rate
 
≥
 
70
 
bpm
 
a.
 
Dosage
 
adjustment
 
based
 
on
 
resting
 
heart
 
rate:
 
Initial:
 
5mg
 
twice
 
daily
 
or
 
2.5mg
 
twice
 
daily
 
(patients
 
with
 
history
 
of
 
conduction
 
defects/hemodynamic
 
compromise
 
due
 
to
 
bradycardia)
 
If
 
heart
 
rate
 
>
 
60bpm:
 
Increase
 
dose
 
by
 
2.5mg
 
twice
 
daily;
 
maximum
 
dose:
 
7.5mg
 
twice
 
daily.
 
If
 
heart
 
rate
 
50
 
to
 
60
 
bpm:
 
Maintain
 
dose.
 
If
 
heart
 
rate
 
<50bpm
 
or
 
signs
 
and
 
symptoms
 
of
 
bradycardia:
 
Decrease
 
dose
 
by
 
2.5mg
 
twice
 
daily;
 
if
 
current
 
dose
 
is
 
2.5mg
 
twice
 
daily,
 
discontinue
 
therapy .
 
 
2.
 
Treatment
 
of
 
chronic
 
heart
 
failure
 
NYHA
 
II
 
to
 
IV
 
class
 
with
 
systolic
 
dysfunction,
 
in
 
patients
 
in
 
sinus
 
rhythm
 
and
 
whose
 
heart
 
rate
 
is
 
≥
 
70
 
bpm
 
a.
 
Initial:
 
2.5mg
 
to
 
5mg
 
twice
 
daily;
 
titrate
 
up
 
in
 
increments
 
of
 
2.5mg
 
after
 
3
 
to
 
4
 
weeks
 
if
 
symptoms
 
persists
 
and
 
heart
 
rate
 
is
 
>60
 
bpm;
 
maximum
 
dose:
 
7.5mg
 
twice
 
daily
 
 
 
 
Method
 
of
 
Administration*
 
Taken
 
twice
 
daily
 
orally
 
i.e.
 
once
 
in
 
the
 
morning
 
and
 
once
 
in
 
the
 
evening
 
with
 
food
 
 
Do
 
not
 
stop
 
taking
 
your
 
medication
 
unless
 
advised
 
to
 
do
 
so
 
by
 
your
 
prescriber
 
 
 
 
 
 
Special
 
Considerations
 
Pregnancy
 
 
 
 
Contraindicated
 
during
 
pregnancy .
 
Animal
 
studies
 
data
 
have
 
shown
 
embryotoxic
 
and
 
teratogenic
 
effects.
 
 
 
 
Breastfeeding
 
 
 
 
Contraindicated
 
during
 
breast
 
feeding.
 
Animal
 
studies
 
indicate
 
that
 
Ivabradine
 
is
 
excreted
 
in
 
milk
 
 
 
 
Elderly
 
 
 
 
1.
 
In
 
patients
 
aged
 
75
 
years
 
or
 
more,
 
a
 
lower
 
starting
 
dose
 
should
 
be
 
considered
 
(2.5mg
 
twice
 
daily
 
i.e.
 
one
 
half
 
5mg
 
tablet
 
twice
 
daily)
 
before
 
up
 
titration
 
if
 
necessary .
 
 
2.
 
Risk
 
of
 
bradycardia,
 
especially
 
in
 
elderly
 
patients
 
or
 
those
 
with
 
concomitant
 
conditions
 
that
 
lower
 
heart
 
rate.
 
 
 
 
Paediatric
 
 
 
 
1.
 
Data
 
available
 
for
 
use
 
in
 
6
 
months
 
old
 
and
 
older .
 
 
 
 
216
 

=== PAGE 218 ===

 
Fasting
 
 
 
 
To
 
refer
 
to
 
the
 
latest
 
advisory
 
by
 
religious
 
authority
 
 
 
 
Others
  
 
 
 
 
1.
 
Renal
 
impairment
 
●
 
No
 
dose
 
adjustment
 
is
 
required
 
in
 
patients
 
with
 
renal
 
insuf ficiency
 
and
 
creatinine
 
clearance
 
(CrCl)
 
above
 
15
 
ml/min.
 
No
 
data
 
are
 
available
 
in
 
patients
 
with
 
CrCl
 
less
 
than
 
15
 
ml/min.
 
Ivabradine
 
should
 
be
 
therefore
 
be
 
used
 
with
 
precaution
 
2.
 
Hepatic
 
impairment
 
●
 
No
 
dose
 
adjustment
 
is
 
required
 
in
 
patients
 
with
 
mild
 
hepatic
 
impairment.
 
Caution
 
should
 
be
 
exercised
 
when
 
using
 
Ivabradine
 
in
 
patients
 
with
 
moderate
 
hepatic
 
impairment.
 
Ivabradine
 
is
 
contraindicated
 
for
 
use
 
in
 
patients
 
with
 
severe
 
hepatic
 
insuf ficiency ,
 
since
 
it
 
has
 
not
 
been
 
studied
 
in
 
this
 
population.
 
 
 
 
Side
 
Effects
 
and
 
their
 
Management*
 
Common
 
side
 
effects
 
include:
 
 
1.
 
Nervous
 
system
 
disorders:
 
Headache
 
(generally
 
during
 
first
 
month
 
of
 
treatment),
 
dizziness
 
(related
 
to
 
bradycardia)
 
2.
 
Eye
 
disorders:
 
Blurred
 
vision
 
3.
 
Cardiac
 
disorders:
 
Bradycardia,
 
AV
 
1st
 
degree
 
block,
 
Atrial
 
fibrillation
 
4.
 
Vascular
 
disorders:
 
Uncontrolled
 
blood
 
pressure
 
 
 
 
Storage*
 
Store
 
below
 
30
0
C
 
 
 
 
Others
 
Significant
 
drug-drug
 
/
 
drug-food
 
interactions
 
(if
 
applicable)
 
1.
 
Concomitant
 
use
 
of
 
the
 
below
 
medications/food
 
with
 
ivabradine
 
is
 
not
 
recommended:
 
●
 
Cardiovascular
 
QT
 
prolonging
 
medicinal
 
products
 
(e.g
 
quinidine,
 
amiodarone)
 
●
 
Non
 
cardiovascular
 
QT
 
prolonging
 
medicinal
 
products
 
(e.g
 
pentamidine,
 
intravenous
 
erythromycin)
 
●
 
Concomitant
 
use
 
of
 
potent
 
CYP3A4
 
(e.g
 
azole
 
antifungals,
 
macrolide
 
antibiotics,
 
HIV
 
protease
 
inhibitors)
 
is
 
contraindicated
 
●
 
Concomitant
 
use
 
with
 
grape
 
juice
 
is
 
contraindicated
 
as
 
ivabradine
 
exposure
 
will
 
be
 
increased
 
by
 
2-fold
 
following
 
co
 
administration
 
with
 
grapefruit
 
juice
 
2.
 
Concomitant
 
use
 
with
 
caution
 
●
 
Potassium
 
depleting
 
diuretics
 
(thiazide
 
diuretics
 
and
 
loop
 
diuretics).
 
As
 
ivabradine
 
may
 
cause
 
bradycardia,
 
combination
 
of
 
hypokalaemia
 
and
 
bradycardia
 
is
 
a
 
predisposed
 
factor
 
to
 
the
 
onset
 
of
 
severe
 
arrhythmias.
 
 
 
 
217
 

=== PAGE 219 ===

 
Before
 
ending
 
this
 
peer
 
review
 
session,
 
the
 
reviewee
 
should
 
be
 
informed
 
of
 
the
 
step(s)
 
that
 
he/
 
she
 
missed
 
out
 
in
 
order
 
to
 
ensure
 
all
 
the
 
counselling
 
points
 
are
 
being
 
covered.
 
 
Remarks:
 
 
 
 
 
Reviewed
 
by:
 
Name
 
&
 
Signature
                                                                   
Date:
 
 
 
 
 
*Mandatory
 
for
 
validation
 
/
 
peer
 
review
 
References:
 
 
1.
 
Montalescot
 
G
 
et
 
al.
 
(2013).
 
ESC
 
guidelines
 
on
 
the
 
management
 
of
 
stable
 
coronary
 
artery
 
disease:
 
the
 
Task
 
Force
 
on
 
the
 
management
 
of
 
stable
 
coronary
 
artery
 
disease
 
of
 
the
 
European
 
Society
 
of
 
Cardiology .
 
Eur
 
Heart
 
J.
 
2.
 
Swedberg
 
K
 
et
 
al.
 
(2010).
 
SHIFT
 
Investigators.
 
Ivabradine
 
and
 
outcomes
 
in
 
chronic
 
heart
 
failure
 
(SHIFT);
 
a
 
randomised
 
placebo-controlled
 
study .
 
Lancet.
 
3.
 
Maddow
 
TM
 
et
 
al.
 
(2021).
 
Writing
 
Committee.
 
2021
 
update
 
to
 
the
 
2017
 
ACC
 
expert
 
consensus
 
decision
 
pathway
 
for
 
optimization
 
of
 
heart
 
failure
 
treatment:
 
answers
 
to
 
10
 
pivotal
 
issues
 
about
 
heart
 
failure
 
with
 
reduced
 
ejection
 
fraction:
 
a
 
report
 
of
 
the
 
American
 
College
 
of
 
Cardiology
 
Solution
 
Set
 
Oversight
 
Committee.
 
J
 
Am
 
Coll
 
Cardiol.
 
4.
 
Ivaswift
 
5
 
(Ivabradine
 
Tablets
 
5mg);
 
Ivaswift
 
7.5
 
(Ivabradine
 
Tablets
 
7.5mg)(2019).
 
Product
 
Information
 
Sheet.
 
Ind-Swift
 
Limited.
 
5.
 
Heidenreich
 
PA
 
et
 
al.
 
(2022).
 
AHA/ACC/HFSA
 
guideline
 
for
 
the
 
management
 
of
 
heart
 
failure:
 
a
 
report
 
of
 
the
 
American
 
College
 
of
 
Cardiology/American
 
Heart
 
Association
 
Joint
 
Committee
 
on
 
Clinical
 
Practice
 
Guidelines.
 
Circulation.
 
6.
 
Sag
 
S
 
et
 
al.(2016).
 
Inappropriate
 
sinus
 
tachycardia-induced
 
cardiomyopathy
 
during
 
pregnancy
 
and
 
successful
 
treatment
 
with
 
ivabradine.
 
Anatol
 
J
 
Cardiol.
 
7.
 
Ivabradine.
 
(2024).
 
MIMS
 
(online).
 
8.
 
Ivabradine.
 
(2024).
 
Drug
 
Interaction
 
Checker .
 
Medscape
 
(online).
 
 
9.
 
McDonagh,
 
T.
 
A.,
 
Metra,
 
M.,
 
Adamo,
 
M.,
 
Gardner ,
 
R.
 
S.,
 
Baumbach,
 
A.,
 
Böhm,
 
M.,
 
...
 
&
 
Kathrine
 
Skibelund,
 
A.
 
(2021).
 
2021
 
ESC
 
Guidelines
 
for
 
the
 
diagnosis
 
and
 
treatment
 
of
 
acute
 
and
 
chronic
 
heart
 
failure:
 
Developed
 
by
 
the
 
Task
 
Force
 
for
 
the
 
diagnosis
 
and
 
treatment
 
of
 
acute
 
and
 
chronic
 
heart
 
failure
 
of
 
the
 
European
 
Society
 
of
 
Cardiology
 
(ESC)
 
With
 
the
 
special
 
contribution
 
of
 
the
 
Heart
 
Failure
 
Association
 
(HFA)
 
of
 
the
 
ESC.
 
European
 
heart
 
journal
,
 
42
(36),
 
3599-3726.
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
218
 

=== PAGE 220 ===

 
Ketoconazole
 
/
 
Selenium
 
Sulfide
 
Lotion/Shampoo
 
Name
 
:
 
 
Unit
 
:
 
 
●
 
Please
 
tick
 
(
✔
)
 
Yes
 
for
 
correct
 
instruction.
 
●
 
Please
 
tick
 
(
✔
)
 
No
 
for
 
incorrect
 
instruction.
 
Yes
 
No
 
Remarks
 
Pharmacological
 
Group
 
Imidazole
 
Antimycotic
 
and
 
Topical
 
Antifungal
 
 
 
 
Indications
 
and
 
Dosage
 
A)
 
Ketoconazole
 
2%
 
Shampoo
 
1.
 
Seborrhoeic
 
dermatitis
 
&
 
dandruf f
 
a)
 
Apply
 
twice
 
weekly
 
for
 
2
 
to
 
4
 
weeks.
 
2.
 
Pityriasis
 
versicolor
 
a)
 
 
Apply
 
once
 
daily
 
for
 
up
 
to
 
5
 
days.
 
 
3.
 
Prophylaxis
 
a)
  
Once
 
every
 
1
 
or
 
2
 
weeks.
 
 
B)
 
Selenium
 
Sulfide
 
2.5%
 
Lotion/Shampoo
 
1.
 
Dandruf f
 
&
 
seborrheic
 
dermatitis
 
of
 
scalp
 
a)
 
Use
 
twice
 
weekly
 
at
 
first,
 
then
 
as
 
necessary
 
as
 
directed
 
by
 
the
 
physician.
 
2.
 
Pityriasis
 
versicolor
 
a)
 
Apply
 
daily
 
for
 
1
 
week,
 
then
 
apply
 
2-3
 
times
 
per
 
week..
 
 
To
 
counsel
 
based
 
on
 
specific
 
medication’ s
 
indication
 
and
 
dosage
 
as
 
prescribed
 
by
 
the
 
doctor
 
 
 
 
Method
 
of
 
Administration*
 
A)
 
Ketoconazole
 
2%
 
Shampoo:
 
Apply
 
onto
 
skin/hair
 
and
 
leave
 
it
 
for
 
3-5
 
minutes
 
before
 
rinsing.
 
B)
 
Selenium
 
Sulfide
 
2.5%
 
Lotion/Shampoo:
 
i)
 
Dandruf f
 
&
 
seborrheic
 
dermatitis
 
of
 
scalp:
 
Apply
 
onto
 
wet
 
hair,
 
lather
 
and
 
leave
 
on
 
scalp
 
for
 
3
 
minutes.
 
Rinse
 
and
 
repeat
 
application,
 
then
 
rinse
 
thoroughly .
 
ii)
 
Pityriasis
 
versicolor:
 
Apply
 
to
 
affected
 
areas
 
and
 
lather
 
with
 
small
 
amounts
 
of
 
water
 
for
 
10-15
 
minutes,
 
then
 
rinse
 
thoroughly .
 
Do
 
not
 
stop
 
taking
 
your
 
medication
 
unless
 
advised
 
to
 
do
 
so
 
by
 
your
 
prescriber
 
 
 
 
Special
 
Considerations
 
Pregnancy
 
 
 
 
 
A)
 
Ketoconazole
 
2%
 
Shampoo:
 
 
There
 
are
 
no
 
adequate
 
and
 
well-controlled
 
studies
 
in
 
pregnant
 
women.
 
There
 
are
 
no
 
known
 
risks
 
associated
 
with
 
its
 
use
 
in
 
pregnancy .
 
B)
 
Selenium
 
Sulfide
 
2.5%
 
Lotion/Shampoo:
 
Should
 
only
 
use
 
it
 
on
 
the
 
scalp,
 
and
 
not
 
on
 
the
 
body
 
to
 
treat
 
skin
 
infections. Risks
 
and
 
benefits
 
should
 
be
 
discussed
 
with
 
the
 
doctor
 
before
 
use.
 
 
 
 
Breastfeeding
 
 
 
 
A)
 
Ketoconazole
 
2%
 
Shampoo:
 
 
There
 
are
 
no
 
adequate
 
and
 
well-controlled
 
studies
 
in
 
lactating
 
women.
 
There
 
are
 
no
 
known
 
risks
 
associated
 
with
 
its
 
use
 
in
 
lactation.
 
B)
 
Selenium
 
Sulfide
 
2.5%
 
Lotion/Shampoo:
 
 
It
 
is
 
not
 
known
 
whether
 
or
 
not
 
this
 
drug
 
is
 
secreted
 
in
 
human
 
milk.
 
Caution
 
should
 
be
 
exercised
 
when
 
this
 
product
 
is
 
administered
 
to
 
a
 
nursing
 
woman.
 
 
 
 
Elderly
 
 
 
 
219
 

=== PAGE 221 ===

 
None
 
specifically
 
to
 
those
 
products.
 
 
 
 
Paediatric
 
 
 
 
The
 
safety
 
and
 
efficacy
 
of
 
Ketoconazole
 
Shampoo
 
in
 
paediatric
 
patients
 
below
 
age
 
12
 
have
 
not
 
been
 
established.
 
 
 
The
 
safety
 
and
 
efficacy
 
of
 
Selenium
 
Sulfide
 
in
 
paediatric
 
patients
 
below
 
age
 
5
 
have
 
not
 
been
 
established.
 
 
 
 
Fasting
 
 
 
 
To
 
refer
 
to
 
the
 
latest
 
advisory
 
by
 
religious
 
authority
 
 
 
 
Others
 
 
 
 
 
NA
 
 
 
 
Side
 
Effects
 
and
 
their
 
Management*
 
Burning
 
sensation
 
and
 
contact
 
dermatitis
 
may
 
occur
 
with
 
all
 
the
 
above
 
preparations.
 
 
 
 
Storage*
 
1.
 
Store
 
in
 
a
 
cool
 
dry
 
place
 
below
 
30
 
degrees
 
Celsius.
 
2.
 
Protect
 
from
 
light
 
and
 
heat.
 
3.
 
Keep
 
out
 
of
 
reach
 
of
 
children.
 
 
 
 
Others
 
A)
 
Ketoconazole
 
2%
 
Shampoo:
  
 
Avoid
 
contact
 
with
 
the
 
eyes
 
and
 
other
 
mucous
 
membranes.
 
If
 
hypersensitivity
 
or
 
irritation
 
occurs,
 
discontinue
 
use
 
and
 
contact
 
healthcare
 
providers.
 
 
B)
 
Selenium
 
Sulfide
 
2.5%
 
Lotion/Shampoo:
 
 
Avoid
 
contact
 
with
 
the
 
eyes.
 
If
 
contact
 
with
 
the
 
eyes
 
occurs,
 
rinse
 
thoroughly
 
with
 
water .
 
When
 
treating
 
tinea
 
versicolor
 
of
 
genital
 
areas
 
or
 
skin
 
folds,
 
the
 
areas
 
should
 
be
 
rinsed
 
thoroughly
 
following
 
application
 
to
 
minimise
 
irritation.
 
Remove
 
jewellery
 
before
 
application,
 
as
 
it
 
may
 
get
 
damaged.
 
Avoid
 
using
 
this
 
48
 
hours
 
before
 
or
 
after
 
permanent
 
waving,
 
tinting
 
or
 
bleaching.
 
 
 
 
 
Before
 
ending
 
this
 
peer
 
review
 
session,
 
the
 
reviewee
 
should
 
be
 
informed
 
of
 
the
 
step(s)
 
that
 
he/
 
she
 
missed
 
out
 
in
 
order
 
to
 
ensure
 
all
 
the
 
counselling
 
points
 
are
 
being
 
covered.
 
 
Remarks:
 
 
 
 
Reviewed
 
by:
 
Name
 
&
 
Signature
                                                                   
Date:
 
 
 
 
*Mandatory
 
for
 
validation
 
/
 
peer
 
review
 
References:
 
 
1.
 
Ministry
 
of
 
Health
 
Malaysia.
 
(n.d.).
 
FUKKM
 
list.
 
Retrieved
 
November
 
11,
 
2024,
 
from
 
https://i.pharmacy .gov.my/fukkm
 
2.
 
Imeks
 
Pharma
 
Sdn
 
Bhd.
 
(2024).
 
Selfide
 
Lotion:
 
Summary
 
of
 
product
 
characteristics.
 
Retrieved
 
November
 
11,
 
2024.
 
3.
 
SPG
 
Pharma
 
Malaysia
 
Sdn
 
Bhd.
 
(2024).
 
Ketazon
 
Shampoo
 
2%:
 
Summary
 
of
 
product
 
characteristics.
 
Retrieved
 
November
 
11,
 
2024.
 
4.
 
MIMS
 
Malaysia
 
(2025).
 
Selenium
 
Sulfide.
 
Retrieved
 
from
 
https://www .mims.com/malaysia/drug/info/selenium-sulfide.
 
 
220
 

=== PAGE 222 ===

 
Lamivudine
 
 
Name
 
:
 
Lamivudine
 
150
 
mg
 
Tablet
 
 
Unit
 
:
 
 
●
 
Please
 
tick
 
(
✔
)
 
Yes
 
for
 
correct
 
instruction.
 
●
 
Please
 
tick
 
(
✔
)
 
No
 
for
 
incorrect
 
instruction.
 
Yes
 
No
 
Remarks
 
Pharmacological
 
Group
 
Nucleoside
 
or
 
Nucleotide
 
Reverse
 
Transcriptase
 
Inhibitors
 
(NRTI)
 
 
 
 
 
Indications
 
and
 
Dosage
 
1.
 
Indication
 
:
 
HIV
 
Infection
 
in
 
combination
 
with
 
other
 
antiretroviral
 
agents.
 
 
a.
 
Dosage
 
for
 
indication
 
:
 
ADUL T
 
150
 
mg
 
BD
 
or
 
300
 
mg
 
OD.
 
 
b.
 
Dosage
 
for
 
indication
 
Neonates
 
and
 
Children
 
:
 
>
 
32
 
weeks
 
Gestation
 
at
 
Birth,
  
Birth
 
to
 
age
 
4
 
weeks
 
:
 
2
 
mg/kg
 
BD.
 
Age
 
>
 
4
 
weeks
 
and
 
Child
 
3
 
months
 
or
 
over
 
:
 
4mg/kg
 
BD.
 
(Maximum
 
300
 
mg
 
daily)
 
 
 
 
 
Method
 
of
 
Administration*
 
1.
 
May
 
be
 
administered
 
without
 
regard
 
to
 
meals.
 
 
2.
 
Crushability:
 
Not
 
to
 
be
 
cut.
 
For
 
patients
 
who
 
are
 
unable
 
to
 
swallow
 
tablets,
 
the
 
tablet
 
is
 
crushed
 
and
 
added
 
to
 
a
 
small
 
amount
 
of
 
semi-solid
 
or
 
liquid
 
and
 
immediately
 
consumed.
 
Missed
 
dose
 
management
 
 
1.
 
To
 
take
 
medication
 
consistently
 
at
 
the
 
same
 
time
 
everyday .
 
Any
 
missed
 
dose
 
to
 
be
 
taken
 
as
 
soon
 
as
 
possible.
 
2.
 
For
 
lamivudine
 
prescribed
 
twice
 
daily
 
dosing,
 
if
 
the
 
gap
 
is
 
more
 
than
 
6
 
hours,
 
to
 
skip
 
and
 
continue
 
with
 
a
 
regular
 
dosing
 
schedule.
 
Do
 
not
 
double
 
the
 
dose
 
on
 
the
 
next
 
administration
 
time.
 
 
3.
 
For
 
lamivudine
 
prescribed
 
once
 
daily
 
dosing,
 
if
 
the
 
gap
 
is
 
more
 
than
 
12
 
hours,
 
to
 
skip
 
and
 
continue
 
with
 
the
 
regular
 
dosing
 
schedule.
 
Do
 
not
 
stop
 
taking
 
your
 
medication
 
unless
 
advised
 
to
 
do
 
so
 
by
 
your
 
prescriber
 
 
 
 
Special
 
Considerations
 
Pregnancy
 
 
 
 
1.
 
First-trimester
 
exposure
 
to
 
lamivudine
 
is
 
not
 
associated
 
with
 
increased
 
risk
 
of
 
congenital
 
anomalies.
 
2.
 
Lamivudine
 
use
 
during
 
pregnancy
 
has
 
not
 
been
 
associated
 
with
 
adverse
 
maternal,
 
obstetric,
 
or
 
infant
 
outcomes.
 
 
 
 
Breastfeeding
 
 
 
 
1.
 
Lamivudine
 
is
 
detected
 
in
 
breastmilk.
 
The
 
lack
 
of
 
long-term
 
safety
 
data
 
with
 
long-term,
 
low-level
 
infant
 
exposure
 
should
 
be
 
discussed
 
with
 
the
 
mother .
 
 
2.
 
It
 
is
 
recommended
 
that
 
HIV
 
infected
 
women
 
do
 
not
 
breastfeed
 
their
 
infants
 
under
 
any
 
circumstances
 
in
 
order
 
to
 
avoid
 
transmission
 
of
 
HIV.
 
 
 
 
Elderly
 
 
 
 
None
 
specifically
 
to
 
Lamivudine.
 
 
 
 
 
Paediatric
 
 
 
 
Use
 
extra
 
caution
 
during
 
calculations
 
to
 
ensure
 
accurate
 
mg
 
of
 
 
 
 
221
 

=== PAGE 223 ===

 
lamivudine
 
administered.
 
Fasting
 
 
 
 
To
 
be
 
discussed
 
with
 
infectious
 
disease
 
consultant
 
 
 
 
Renal
 
Impairment
 
 
 
 
1.
 
Dose
 
adjustment
 
required
 
for
 
CrCl
 
(ml/min)
 
:
 
 
a)
 
30-49
 
:
 
150mg
 
OD
 
b)
 
15-29
 
:
 
1
 
x
 
150mg,
 
then
 
100mg
 
OD,
 
or
 
150mg
 
OD
 
c)
 
15
   
:
 
1
 
x
 
150mg,
 
then
 
50mg
 
OD,
 
or
 
75mg
 
OD
 
d)
 
Haemodialysis
 
:
 
1
 
x
 
50mg,
 
then
 
25-50mg
 
OD,
 
or
 
75mg
 
OD
 
 
*Note
 
-
 
Intermittent
 
HD
 
or
 
PD
 
:
 
No
 
additional
 
doses
 
are
 
required,
 
negligible
 
amounts
 
are
 
removed
 
by
 
4
 
hour
 
HD
 
or
 
PD.
 
 
 
 
 
Hepatic
 
Impairment
 
 
 
 
1.
 
Adult
 
:
 
No
 
dosage
 
adjustment
 
necessary .
 
However ,
 
it
 
has
 
not
 
been
 
studied
 
in
 
the
 
setting
 
of
 
decompensated
 
liver
 
disease
 
2.
 
Paediatrics
 
:
 
No
 
dose
 
adjustment
 
is
 
req
uired.
 
Safety
  
and
 
efficacy
 
have
 
not
 
been
 
established
 
in
 
patients
 
with
 
decompensated
 
liver
 
disease.
 
 
 
 
Side
 
Effects
 
and
 
their
 
Management*
 
1.
 
Minimal
 
toxicity
 
2.
 
Severe
 
acute
 
hepatitis
 
flare
 
may
 
occur
 
in
 
HBV
 
co-infected
 
patients
 
who
 
discontinue
 
lamivudine.
 
 
 
 
Storage*
 
1.
 
Suggest
 
to
 
refer
 
to
 
product
 
leaflet
 
(in
 
respect
 
to
 
brand
 
purchased)
 
 
2.
 
General
 
recommendation
 
is
 
to
 
store
 
below
 
30ºC
 
and
 
protect
 
from
 
light
 
&
 
moisture.
 
 
 
 
Before
 
ending
 
this
 
peer
 
review
 
session,
 
the
 
reviewee
 
should
 
be
 
informed
 
of
 
the
 
step(s)
 
that
 
he/
 
she
 
missed
 
out
 
in
 
order
 
to
 
ensure
 
all
 
the
 
counselling
 
points
 
are
 
being
 
covered.
 
Remarks:
 
 
Reviewed
 
by:
 
Name
 
&
 
Signature
                                                                   
Date:
 
*Mandatory
 
for
 
validation/
 
peer
 
review
 
 
References:
 
1.
 
Ministry
 
of
 
Health
 
Malaysia,
 
&
 
Malaysian
 
Society
 
for
 
HIV
 
Medicine.
 
(2022).
 
Malaysian
 
Consensus
 
Guideline
 
on
 
Antiretroviral
 
Therapy
 
2022.
 
The
 
Malaysian
 
Society
 
for
 
HIV
 
Medicine.
 
2.
 
Pharmaceutical
 
Services
 
Programme,
 
Ministry
 
of
 
Health
 
Malaysia.
 
(2023).
 
Formulari
 
Ubat
 
Kementerian
 
Kesihatan
 
Malaysia
 
(Blue
 
Book).
 
Ministry
 
of
 
Health
 
Malaysia.
 
3.
 
HHS
 
Panel
 
on
 
Antiretroviral
 
Therapy
 
and
 
Medical
 
Management
 
of
 
Children
 
Living
 
with
 
HIV.
 
(2024).
 
Guidelines
 
for
 
the
 
Use
 
of
 
Antiretroviral
 
Agents
 
in
 
Paediatric
 
HIV
 
Infection.
 
4.
 
Y.S.P
 
Industries
 
(M)
 
Sdn.
 
Bhd.
 
(2016).
 
VALFIX
 
Film
 
Coated
 
Tablet
 
150mg
 
(Consumer
 
Medication
 
Information
 
Leaflet
 
(RiMUP).
 
Y.S.P
 
Industries
 
(M)
 
Sdn.
 
Bhd.
 
5.
 
Pharmaceutical
 
Services
 
Division,
 
Negeri
 
Sembilan
 
State
 
Health
 
Department.
 
(2022).
 
Protocol
 
on
 
Drug
 
Administration
 
Via
 
Enteral
 
Feeding
 
Tubes.
 
Pharmaceutical
 
Services
 
Division,
 
Negeri
 
Sembilan
 
State
 
Health
 
Department.
 
6.
 
Clinical
 
Info
 
HIV
 
Gov.
 
(2024).
 
Recommendations
 
for
 
the
 
use
 
of
 
antiretroviral
 
drugs
 
during
 
pregnancy
 
and
 
interventions
 
to
 
reduce
 
perinatal
 
HIV
 
transmission
 
in
 
the
 
United
 
States.
 
HIVinfo.NIH.gov .
 
7.
 
National
 
Library
 
of
 
Medicine.
 
(2024).
 
Drugs
 
and
 
Lactation
 
(LactMed)
 
-
 
Lamivudine.
 
National
 
Library
 
of
 
Medicine.
 
222
 

=== PAGE 224 ===

 
Lamotrigine
 
 
Name
 
:
 
Unit
 
:
 
 
●
 
Please
 
tick
 
(
✔
)
 
Yes
 
for
 
correct
 
instruction.
 
●
 
Please
 
tick
 
(
✔
)
 
No
 
for
 
incorrect
 
instruction.
 
Yes
 
No
 
Remarks
 
Pharmacological
 
Group
 
Antiepileptic
 
drugs/
 
Anticonvulsants
 
drugs
 
 
 
 
 
Indications
 
and
 
Dosage
 
1.
 
Adjunct
 
or
 
monotherapy
 
for
 
partial
 
seizure
 
and
 
generalised
 
tonic
 
clonic
 
seizures
 
a.
 
up
 
to
 
200
 
mg
 
daily
 
in
 
single
 
or
 
divided
 
dose
 
 
2.
 
Prevention
 
of
 
mood
 
episodes
 
a.
 
25-200
 
mg
 
daily
 
 
 
Or
 
 
 
To
 
counsel
 
based
 
on
 
specific
 
medication’ s
 
indication
 
and
 
dosage
 
as
 
prescribed
 
by
 
the
 
doctor
 
 
 
 
Method
 
of
 
Administration*
 
1.
 
May
 
be
 
taken
 
with
 
or
 
without
 
food
 
2.
 
Try
 
to
 
take
 
lamotrigine
 
at
 
the
 
same
 
time
 
each
 
day
 
 
Missed
 
dose
 
management
 
(if
 
applicable):
 
1.
 
If
 
you
 
forget
 
to
 
take
 
a
 
dose,
 
take
 
it
 
as
 
soon
 
as
 
you
 
remember .
 
 
2.
 
Do
 
not
 
take
 
two
 
doses
 
at
 
once.
 
 
Do
 
not
 
stop
 
taking
 
your
 
medication
 
unless
 
advised
 
to
 
do
 
so
 
by
 
your
 
prescriber
 
 
 
 
Special
 
Considerations
 
Pregnancy
 
 
 
 
Possible
 
risk
 
but
 
likely
 
to
 
be
 
low
 
 
 
 
Breastfeeding
 
 
 
 
Passes
 
in
 
uncertain
 
levels
 
into
 
breast
 
milk,
 
not
 
known
 
to
 
cause
 
harm
 
to
 
infant
 
 
 
 
 
Elderly
 
 
 
 
1.
 
Beers
 
criteria:avoid
 
use
 
in
 
elderly
  
with
 
history
 
of
 
falls
 
or
 
fractures
 
(
 
unless
 
used
 
for
 
seizure
 
or
 
mood
 
disorders)
 
and
 
unless
 
safer
 
alternatives
 
are
 
not
 
available,
 
syncope
 
,
 
impaired
 
psychomotor
 
function,
 
or
 
ataxia
 
may
 
occur
 
2.
 
Avoid
 
concomitant
 
use
 
of
 
3
 
or
 
more
 
CNS
 
active
 
agents
 
in
 
any
 
combination
 
due
 
to
 
increased
 
risk
 
of
 
falls.
 
 
 
 
Paediatric
 
 
 
 
1.
 
To
 
adhere
 
strictly
 
to
 
recommended
 
initial
 
dose,
 
titration
 
schedules
 
and
 
adjustments
 
to
 
reduce
 
the
 
risk
 
of
 
severe
 
reaction.
 
2.
 
With
 
valproic
 
acid:
 
The
 
safety
 
and
 
efficacy
 
of
 
Lamotrigine
 
in
 
patients
 
below
 
age
 
2
 
have
 
not
 
been
 
established.
 
 
 
 
Fasting
 
 
 
 
223
 

=== PAGE 225 ===

 
To
 
refer
 
to
 
the
 
latest
 
advisory
 
by
 
religious
 
authority
 
 
 
 
Others
  
 
 
 
 
1.
 
Hepatic:
 
Doses
 
should
 
generally
 
be
 
reduced
 
by
 
50%
 
in
 
moderate
 
impairment
 
and
 
by
 
75%
 
in
 
severe
 
hepatic
 
impairment
 
 
2.
 
Renal:
 
In
 
end-stage
 
renal
 
failure,
 
initial
 
doses
 
of
 
lamotrigine
 
should
 
be
 
based
 
on
 
patients'
 
concomitant
 
medicinal
 
products;
 
reduced
 
maintenance
 
doses
 
may
 
be
 
effective
 
in
 
significant
 
renal
 
impairment
 
 
 
 
Side
 
Effects
 
and
 
their
 
Management*
 
1.
 
Sleepiness,
 
nausea
 
and
 
vomiting,
 
general
 
aches
 
–
 
including
 
joint
 
point
 
and
 
back
 
ache,
 
headache,
 
tremor ,
 
dizziness,
 
aggression
 
or
 
irritability ,
 
rash
 
2.
 
It
 
is
 
recommended
 
that
 
people
 
taking
 
lamotrigine
 
should
 
avoid
 
alcohol.
 
This
 
is
 
because
 
both
 
can
 
cause
 
drowsiness
 
and
 
if
 
the
 
two
 
are
 
taken
 
together ,
 
severe
  
drowsiness
 
can
 
result.
 
 
 
 
Storage*
 
1.
 
Store
 
lamotrigine
 
as
 
directed
 
by
 
the
 
manufacturers
 
information,
 
it
 
does
 
not
 
usually
 
require
 
any
 
special
 
storage
 
conditions.
 
 
 
 
Others
 
1.
 
Precaution:
 
Patient
 
should
 
report
 
if
 
any
 
sign
 
and
 
symptoms
 
of
 
fever ,
 
sore
 
throat
 
or
 
any
 
unusual
 
bleeding,
 
facial
 
swelling
 
2.
 
Avoid
 
excessive
 
exposure
 
to
 
sunlight
 
or
 
UV
 
lights;
 
use
 
protective
 
clothing
 
and
 
sunscreen
 
when
 
going
 
outdoor
 
3.
 
Drug-drug
 
interaction:
 
a.
 
Valproate
 
increased
 
concentration
 
of
 
lamotrigine
 
 
b.
 
 
Carbamazepine,
 
phenytoin,
 
phenobarbitone
 
reduces
 
the
 
concentration
 
of
 
lamotrigine
 
 
 
4.
 
Monitoring
 
parameters:
 
 
a.
 
Serum
 
level
 
of
 
concomitant
 
anticonvulsants
 
b.
 
Liver
 
function
 
test,
  
renal
 
function
 
c.
 
ECG
 
 
 
 
Before
 
ending
 
this
 
peer
 
review
 
session,
 
the
 
reviewee
 
should
 
be
 
informed
 
of
 
the
 
step(s)
 
that
 
he/
 
she
 
missed
 
out
 
in
 
order
 
to
 
ensure
 
all
 
the
 
counselling
 
points
 
are
 
being
 
covered.
 
 
Remarks:
 
 
 
 
Reviewed
 
by:
 
Name
 
&
 
Signature
                                                                   
Date:
 
 
 
*Mandatory
 
for
 
validation/
 
peer
 
review
 
 
References:
 
 
1.
 
Ministry
 
of
 
Health
 
Malaysia.
 
(2024).
 
Formulari
 
Ubat
 
Kementerian
 
Kesihatan
 
Malaysia.
 
2.
 
GlaxoSmithKline
 
UK.
 
Summary
 
of
 
Product
 
Characteristics:
 
Lamictal
 
Tablets.February
 
28,
 
2022.
 
Available
 
at:
 
https://www .medicines.org.uk/emc/product/8052/smpc
  
 
3.
 
2023
 
American
 
Geriatrics
 
Society
 
Beers
 
Criteria®
 
Update
 
Expert
 
Panel.
 
(2023).
 
American
 
Geriatrics
 
Society
 
2023
 
updated
 
AGS
 
Beers
 
Criteria®
 
for
 
potentially
 
inappropriate
 
medication
 
use
 
in
 
older
 
adults.
 
Journal
 
of
 
the
 
American
 
Geriatrics
 
Society ,
 
71(7),
 
2052-2081.
 
224
 

=== PAGE 226 ===

 
Lanthanum
 
Carbonate
 
Name
 
:
 
 
Unit
 
:
 
 
●
 
Please
 
tick
 
(
✔
)
 
Yes
 
for
 
correct
 
instruction.
 
●
 
Please
 
tick
 
(
✔
)
 
No
 
for
 
incorrect
 
instruction.
 
Yes
 
No
 
Remarks
 
Pharmacological
 
Group
 
Drugs
 
for
 
treatment
 
of
 
hyperkalemia
 
and
 
hyperphosphatemia
 
Lanthanum
 
carbonate
 
 
 
 
 
Indications
 
and
 
Dosage
 
1.
 
Phosphate
 
binding
 
agent
 
for
 
the
 
treatment
 
of
 
hyperphosphataemia
 
in
 
dialysis
 
patients
 
with
 
sustained
 
hypercalcaemia
 
of
 
more
 
than
 
three
 
months
 
and
 
secondary
 
hyperparathyroidism
 
a.
 
Initial:
 
750
 
to
 
1500
 
mg/day
 
in
 
divided
 
doses
 
with
 
meals,
 
then
 
titrate
 
in
 
increments
 
of
 
750
 
mg/day
 
at
 
intervals
 
of
 
2
 
to
 
3
 
weeks.
 
b.
 
Maintenance:
 
1500-3000
 
mg/day
 
in
 
divided
 
doses.
 
Max:
 
3750
 
g/day
 
To
 
counsel
 
based
 
on
 
specific
 
medication’ s
 
indication
 
and
 
dosage
 
as
 
prescribed
 
by
 
the
 
doctor
 
 
 
 
Method
 
of
 
Administration*
 
1.
 
To
 
chew
 
/
 
crush
 
and
 
take
 
WITH
 
meals
 
/
 
snacks
 
or
 
IMMEDIA TELY
 
after
 
meals.
 
2.
 
Do
 
not
 
swallow
 
intact
 
tablets.
 
 
3.
 
Consider
 
crushing
 
tablets
 
completely
 
for
 
patients
 
with
 
poor
 
dentition.
 
Missed
 
dose
 
management:
 
In
 
case
 
of
 
a
 
missed
 
dose,
 
take
 
it
 
during
 
the
 
meal
 
or
 
immediately
 
after
 
the
 
meal.
 
Omit
 
the
 
dose
 
if
 
totally
 
forgotten
 
and
 
remember
 
to
 
take
 
as
 
per
 
instructed
 
during
 
the
 
next
 
meal.
 
 
Do
 
not
 
stop
 
taking
 
your
 
medication
 
unless
 
advised
 
to
 
do
 
so
 
by
 
your
 
prescriber
 
 
 
 
Special
 
Considerations
 
Pregnancy
 
 
 
 
Not
 
recommended
 
(Lanthanum
 
may
 
cross
 
the
 
placenta)
 
 
 
 
Breastfeeding
 
 
 
 
There
 
is
 
no
 
data
 
on
 
the
 
presence
 
of
 
lanthanum
 
carbonate
 
in
 
human
 
milk,
 
the
 
effects
 
on
 
the
 
breastfed
 
infant,
 
or
 
the
 
effects
 
on
 
milk
 
production.
 
 
 
 
Elderly
 
 
 
 
NA
 
 
 
 
Paediatric
 
 
 
 
Not
 
recommended
 
 
 
 
Fasting
 
 
 
 
1.
 
Adjust
 
the
 
timing
 
of
 
administration
 
according
 
to
 
the
 
fasting
 
schedule
 
during
 
Ramadhan.
 
To
 
take
 
during
 
Sahur
 
(before
 
fasting)
 
and
 
Iftar
 
(breaking
 
fast).
 
2.
 
If
 
more
 
than
 
two
 
doses
 
have
 
been
 
prescribed,
 
consult
 
with
 
the
 
healthcare
 
provider
 
to
 
adjust
 
your
 
phosphate
 
binder
 
administration.
  
 
 
 
 
Others
  
 
 
 
 
225
 

=== PAGE 227 ===

 
NA
 
 
 
 
Side
 
Effects
 
and
 
their
 
Management*
 
1.
 
Significant:
 
 
a.
 
Gastrointestinal:
 
nausea,
 
vomiting,
 
abdominal
 
pain,
 
constipation,
 
dyspepsia.
 
,metallic
 
taste
 
2.
 
Others:
 
a.
 
Endocrine:
 
hyperparathyroidism,
 
hyperglycemia
 
b.
 
Dermatologic:
 
alopecia,
 
sweating
 
c.
 
Musculoskeletal:
 
bone
 
deposition,
 
myalgia,
 
arthralgia,
 
osteoporosis
 
Advise
 
patients
 
to
 
chew
 
or
 
crush
 
the
 
tablet
 
completely
 
to
 
reduce
 
the
 
risk
 
of
 
serious
 
adverse
 
gastrointestinal
 
events.
 
 
 
 
 
Storage*
 
1.
 
Store
 
at
 
room
 
temperature.
 
2.
 
Store
 
in
 
a
 
dry
 
place
 
and
 
protect
 
from
 
moisture.
 
3.
 
Keep
 
out
 
of
 
reach
 
of
 
children.
 
 
 
 
Others
 
1.
 
Serious
 
cases
 
of
 
gastrointestinal
 
obstruction,
 
ileus,
 
subileus,
 
gastrointestinal
 
perforation,
 
and
 
faecal
 
impaction
 
have
 
been
 
reported.
 
 
2.
 
Significant
 
drug-drug
 
interactions:
 
a.
 
Drug
 
binding
 
to
 
Antacids
:
 
There
 
is
 
a
 
potential
 
for
 
lanthanum
 
carbonate
 
to
 
interact
  
with
 
compounds
 
that
 
bind
 
to
 
cationic
 
antacids
 
(i.e.,
 
aluminium-,
 
magnesium-,
 
or
 
calcium-based)
 
-space
 
out
 
1
 
hour
  
or
 
2
 
hours
 
from
 
lanthanum
 
carbonate
 
b.
 
Quinolone
 
antibiotics
:
 
Oral
 
quinolone
 
antibiotics
 
must
 
be
 
taken
 
at
 
least
 
1
 
hour
 
before
 
or
 
4
 
hours
 
after
 
Lanthanum
 
Carbonate.
 
c.
 
Levothyroxine
:
 
Do
 
not
 
take
 
thyroid
 
hormone
 
replacement
 
therapy
 
within
 
2
 
hours
 
of
 
dosing
 
with
 
Lanthanum
 
Carbonate.
 
Monitoring
 
of
 
TSH
 
levels
 
is
 
recommended
 
in
 
patients
 
receiving
 
both
 
medicinal
 
agents.
 
3.
 
Contraindications:
 
Hypersensitivity
 
to
 
Lanthanum
 
Carbonate
 
or
 
to
 
any
 
ingredient
 
in
 
the
 
formulation,
 
bowel
 
obstruction,
 
ileus,
 
and
 
faecal
 
impaction.
 
4.
 
Advise
 
patients
 
to
 
notify
 
their
 
physician
 
that
 
they
 
are
 
taking
 
Lanthanum
 
Carbonate
 
prior
 
to
 
an
 
abdominal
 
X-ray
 
(as
 
Lanthanum
 
Carbonate
 
is
 
considered
 
radiopaque)
 
or
 
if
 
they
 
have
 
a
 
history
 
of
 
gastrointestinal
 
disease.
 
 
 
 
Before
 
ending
 
this
 
peer
 
review
 
session,
 
the
 
reviewee
 
should
 
be
 
informed
 
of
 
the
 
step(s)
 
that
 
he/
 
she
 
missed
 
out
 
in
 
order
 
to
 
ensure
 
all
 
the
 
counselling
 
points
 
are
 
being
 
covered.
 
 
Remarks:
 
 
 
Reviewed
 
by:
 
Name
 
&
 
Signature
                                                                   
Date:
 
 
 
*Mandatory
 
for
 
validation
 
/
 
peer
 
review
 
References:
 
 
1.
 
MPI
 
Pharmaceutical
 
(2019).
 
Product
 
information
 
leaflet:
 
Lanthanum
 
Carbonate.
 
Retrieved
 
from
 
Quest
 
3+
 
Product
 
Search
 
on
 
January
 
1,
 
2025.
 
2.
 
Formulari
 
Ubat
 
KKM.
 
(2025,
 
January
 
1).
 
Accessed
 
on
 
January
 
1,
 
2025.
 
3.
 
MIMS
 
GATEW AY
 
(2025).
 
Lanthanum
 
Carbonate.
 
MIMS.
 
Retrieved
 
January
 
20,
 
2025,
 
from
 
https://online.mimsgateway .com.my/
 
226
 

=== PAGE 228 ===

 
Levofloxacin
 
 
Name
 
:
 
Levofloxacin
 
Unit
 
:
 
 
Please
 
tick
 
(
✔
)
 
Yes
 
for
 
correct
 
instruction.
 
Please
 
tick
 
(
✔
)
 
No
 
for
 
incorrect
 
instruction.
 
Yes
 
No
 
Remarks
 
Pharmacological
 
Group
 
Fluoroquinolone
 
 
 
 
Indications
 
and
 
Dosage
 
Indication:
 
Secondary-line
 
leprosy
 
treatment
 
 
Dosage
 
:
 
500mg
 
daily
 
f
or
 
6-18
 
months
 
(in
 
combination
 
with
 
other
 
anti-leprosy
 
agents)
 
 
 
 
Method
 
of
 
Administration*
 
Food:
 
Can
 
be
 
administered
 
with
 
or
 
without
 
food.
 
Should
 
not
 
be
 
administered
 
by
 
mouth
 
within
 
2
 
hours
 
of
 
ingestion
 
of
 
milk-based
 
products,
 
antacids,
 
or
 
other
 
medications
 
containing
 
divalent
 
cations
 
(iron,
 
magnesium,
 
calcium,
 
zinc,
 
vitamins,
 
didanosine,
 
sucralfate).
 
 
RT
 
administration:
 
1.
 
Tablets
 
do
 
not
 
disperse
 
readily
 
in
 
water .
 
 
2.
 
The
 
tablet
 
can
 
be
 
crushed,
 
but
 
the
 
flaky
 
coating
 
makes
 
crushing
 
difficult.
 
It
 
takes
 
a
 
few
 
minutes
 
for
 
the
 
coating
 
to
 
dissolve
 
when
 
mixed
 
with
 
water .
 
 
3.
 
Use
 
an
 
8Fr
 
NG
 
tube
 
to
 
ease
 
administration/minimize
 
blockage.
 
 
 
Suggestion:
 
1.
 
As
 
the
 
tablets
 
do
 
not
 
disperse
 
readily
 
in
 
water ,
 
consider
 
changing
 
to
 
an
 
alternative
 
antibiotic
 
available
 
in
 
a
 
liquid
 
or
 
dispersible
 
tablet
 
formulation.
 
 
2.
 
When
 
continued
 
therapy
 
with
 
oral
 
levofloxacin
 
is
 
essential
 
use
 
the
 
extemporaneous
 
preparation;
 
consider
 
using
 
the
 
higher
 
end
 
of
 
the
 
dose
 
range.
 
 
3.
 
Stop
 
feed
 
1
 
hour
 
before
 
dose
 
and
 
restart
 
feed
 
2
 
hours
 
after
 
dose
 
 
 
Missed
 
dose:
 
Administer
 
as
 
soon
 
as
 
possible
 
if
 
≥8
 
hours
 
until
 
next
 
scheduled
 
dose;
 
otherwise,
 
wait
 
until
 
next
 
scheduled
 
dose.
 
 
Do
 
not
 
stop
 
taking
 
your
 
medication
 
unless
 
advised
 
to
 
do
 
so
 
by
 
your
 
prescriber
 
 
 
 
Special
 
Considerations
 
Pregnancy
 
 
 
 
1.
 
US
 
FDA
 
Category
 
C
 
(PO)
 
2.
 
Levofloxacin
 
crosses
 
the
 
placenta
 
and
 
can
 
be
 
detected
 
in
 
the
 
amniotic
 
fluid
 
and
 
cord
 
blood.
 
3.
 
Based
 
on
 
available
 
data,
 
use
 
of
 
levofloxacin
 
in
 
pregnancy
 
does
 
not
 
increase
 
risk
 
of
 
major
 
birth
 
defects,
 
miscarriage
 
or
 
other
 
adverse
 
fetal
 
outcomes
 
4.
 
There
 
is
 
limited
 
data
 
on
 
the
 
use
 
of
 
levofloxacin
 
in
 
pregnant
 
women.
 
Nonclinical
 
studies
 
suggest
 
a
 
risk
 
of
 
damage
 
by
 
fluoroquinolones
 
to
 
the
 
weight-bearing
 
cartilage
 
of
 
the
 
growing
 
organism.
 
Consider
 
alternate
 
inhalation
 
therapy
 
to
 
levofloxacin
 
during
 
pregnancy .
 
 
 
 
227
 

=== PAGE 229 ===

 
Breastfeeding
 
 
 
 
Based
 
on
 
data
 
on
 
other
 
fluoroquinolones
 
and
 
very
 
limited
 
data
 
on
 
levofloxacin
 
it
 
can
 
be
 
presumed
 
that
 
levofloxacin
 
will
 
be
 
excreted
 
in
 
human
 
milk.
 
Because
 
of
 
the
 
potential
 
for
 
serious
 
adverse
 
reactions
 
from
 
levofloxacin
 
in
 
nursing
 
infants,
 
a
 
decision
 
should
 
be
 
made
 
whether
 
to
 
discontinue
 
nursing
 
or
 
to
 
discontinue
 
the
 
drug,
 
taking
 
into
 
account
 
the
 
importance
 
of
 
the
 
drug
 
to
 
the
 
mother
 
 
 
 
Elderly
 
 
 
 
Geriatric
 
patients
 
are
 
at
 
increased
 
risk
 
for
 
developing
 
severe
 
tendon
 
disorders
 
including
 
tendon
 
rupture
 
when
 
being
 
treated
 
with
 
a
 
fluoroquinolone.
 
This
 
risk
 
is
 
further
 
increased
 
in
 
patients
 
receiving
 
concomitant
 
corticosteroid
 
therapy
 
 
 
 
Paediatric
 
 
 
 
Quinolones,
 
including
 
levofloxacin,
 
cause
 
arthropathy
 
and
  
osteochondrosis
 
in
 
juvenile
 
animals
 
of
 
several
 
species.
 
 
 
 
Fasting
 
 
 
 
N/A
 
To
 
refer
 
to
 
the
 
latest
 
advisory
 
by
 
religious
 
authority
 
 
 
 
Others
:
 
1.
 
Renal
 
impairment
 
(If
 
usual
 
recommended
 
dose
 
is
 
500mg
 
daily)
 
-
 
CrCl
 
͕͕≥50ml/min:
 
no
 
dosage
 
adjustment
 
-
 
CrCl
 
20
 
-
 
<50ml/min:
 
500mg
 
initial
 
dose,
 
then
 
250mg
 
daily
 
-
 
CrCl
 
<20ml/min:
 
500mg
 
initial
 
dose,
 
then
 
250mg
 
every
 
48H
 
-
 
HD,
 
intermittent
 
(3x/week)
 
/
 
PD:
 
500mg
 
initial
 
dose,
 
then
 
250mg
 
every
 
48H
 
or
 
125mg
 
daily
 
 
-
 
Administer
 
dose
 
after
 
HD
 
after
 
on
 
dialysis
 
days
 
-
 
CRR T:
 
500mg
 
initial
 
dose,
 
then
 
250mg
 
daily
 
or
 
500mg
 
48H
 
-
 
PIRR T:
 
500mg
 
initial
 
dose,
 
then
 
250mg
 
daily
 
(after
 
PIRR T
 
treatment
 
when
 
possible)
 
-
 
Moxifloxacin
 
may
 
be
 
preferred
 
in
 
renal
 
failure
 
 
2.
 
Liver
 
impairment
 
 
The
 
pharmacokinetics
 
of
 
levofloxacin
 
are
 
not
 
expected
 
to
 
be
 
affected
 
by
 
hepatic
 
impairment.
 
 
3.
 
Obesity
 
Patients
 
with
 
BMI
 
͕͕≥40kg/m2
 
and
 
CrCl
 
>110ml/min;
 
consider
 
use
 
TDM
 
(if
 
available)
 
or
 
alternative
 
treatment
 
options
 
 
 
 
 
 
 
Side
 
Effects
 
and
 
their
 
Management*
 
1.
 
Tendon
 
Effects
 
 
2.
 
Hypersensitivity
 
reactions
 
3.
 
Hepatotoxicity
 
4.
 
Central
 
nervous
 
system
 
effects
 
 
5.
 
Clostridium
 
difficile-associated
 
diarrhea
 
 
6.
 
Peripheral
 
neuropathy
 
7.
 
Prolongation
 
of
 
the
 
QT
 
interval
 
8.
 
Blood
 
glucose
 
dDisturbances
 
 
9.
 
Photosensitivity
 
/
 
Phototoxicity
 
 
 
 
Storage*
 
Store
 
at
 
room
 
temperature
 
(do
 
not
 
refrigerate)
 
and
 
protect
 
from
 
light.
 
 
 
 
228
 

=== PAGE 230 ===

 
Others
 
Precautions:
 
1.
 
Long
 
QT
 
syndrome
 
2.
 
Hypokalaemia,
 
malnutrition,
 
hypothyroidism
 
in
 
those
 
aged
 
>60
 
years,
 
multiple
 
QT-prolonging
 
drugs
 
3.
 
Increased
 
risk
 
of
 
QTc
 
prolongation
 
4.
 
Diabetes
:
 
Increased
 
risk
 
of
 
hypoglycaemia.
 
5.
 
May
 
cause
 
sun
 
sensitivity:
 
use
 
sunscreen
 
 
6.
 
May
 
induce
 
convulsions
 
in
 
patients
 
with
 
or
 
without
 
history
 
of
 
convulsions,
 
use
 
with
 
caution
 
if
 
epileptic
 
or
 
conditions
 
predisposing
 
seizures
 
 
Significant
 
drug-drug
 
/
 
drug-food
 
interactions:
 
1.
 
Chelation
 
Agents:
 
Antacids,
 
Sucralfate,
 
Metal
 
Cations,
 
Multivitamins:
 
may
 
interfere
 
with
 
the
 
gastrointestinal
 
absorption
 
of
 
levofloxacin,
 
resulting
 
in
 
systemic
 
levels
 
considerably
 
lower
 
than
 
desired
 
2.
 
Warfarin:
 
levofloxacin
 
will
 
enhance
 
the
 
anticoagulant
 
effect
 
of
 
warfarin
 
3.
 
Antidiabetic:
 
disturbance
 
of
 
blood
 
glucose
 
(including
 
hypoglycemia
 
and
 
hyperglycemia)
 
4.
 
Theophylline:
 
concomitant
 
administration
 
of
 
other
 
fluoroquinolones
 
with
 
theophylline
 
has
 
resulted
 
in
 
prolonged
 
elimination
 
half-life,
 
elevated
 
serum
 
theophylline
 
levels,
 
and
 
a
 
subsequent
 
increase
 
in
 
the
 
risk
 
of
 
theophylline-related
 
adverse
 
reactions
 
in
 
the
 
patient
 
population
 
5.
 
Cyclosporin:
 
elevated
 
serum
 
levels
 
of
 
cyclosporine
 
have
 
been
 
reported
 
in
 
the
 
patient
 
population
 
when
 
co-administered
 
with
 
some
 
other
 
fluoroquinolones
 
 
 
 
Before
 
ending
 
this
 
peer
 
review
 
session,
 
the
 
reviewee
 
should
 
be
 
informed
 
of
 
the
 
step(s)
 
that
 
he/
 
she
 
missed
 
out
 
in
 
order
 
to
 
ensure
 
all
 
the
 
counselling
 
points
 
are
 
being
 
covered.
 
 
Remarks:
 
 
 
Reviewed
 
by:
 
Name
 
&
 
Signature
                                                                   
Date:
 
 
*Mandatory
 
for
 
validation
 
/
 
peer
 
review
 
References:
 
 
1.
 
Cooreman/Leprosy ,
 
E.
 
A.
 
(Ed.).
 
(2018).
 
Guidelines
 
for
 
the
 
Diagnosis,
 
Treatment
 
and
 
Prevention
 
of
 
Leprosy .
 
World
 
Health
 
Organization.
 
https://iris.who.int/bitstream/handle/10665/274127/9789290226383-eng.pdf
 
2.
 
White,
 
R.,
 
&
 
Bradnam,
 
V.
 
(2015).
 
Handbook
 
of
 
drug
 
administration
 
via
 
enteral
 
feeding
 
tubes
 
(3rd
 
ed.).
 
Pharmaceutical
 
Press.
 
3.
 
TB
 
Drug
 
Monographs.
 
(n.d.).
 
Levofloxacin.
 
TB
 
Drug
 
Monographs.
 
Retrieved
 
January
 
14,
 
2025,
 
from
 
https://www .tbdrugmonographs.co.uk/levofloxacin.html
 
4.
 
Sowinski
 
KM,
 
Lucksiri
 
A,
 
Kays
 
MB,
 
Scott
 
MK,
 
Mueller
 
BA,
 
Hamburger
 
RJ.
 
Levofloxacin
 
pharmacokinetics
 
in
 
ESRD
 
and
 
removal
 
by
 
the
 
cellulose
 
acetate
 
high
 
performance-210
 
hemodialyzer .
 
Am
 
J
 
Kidney
 
Dis.
 
2003;42(2):342-349.
 
5.
 
Vossen
 
MG,
 
Thalhammer
 
F.
 
Effects
 
of
 
renal
 
replacement
 
therapy
 
on
 
antimicrobial
 
therapy .
 
Curr
 
Clin
 
Pharmacol.
 
2013;8(1):39-45.
 
6.
 
Trotman
 
RL,
 
Williamson
 
JC,
 
Shoemaker
 
DM,
 
Salzer
 
WL.
 
Antibiotic
 
dosing
 
in
 
critically
 
ill
 
adult
 
patients
 
receiving
 
continuous
 
renal
 
replacement
 
therapy .
 
Clin
 
Infect
 
Dis.
 
2005;41(8):1 159-1 166
 
7.
 
Hoff
 
BM,
 
Maker
 
JH,
 
Dager
 
WE,
 
Heintz
 
BH.
 
Antibiotic
 
dosing
 
for
 
critically
 
ill
 
adult
 
patients
 
receiving
 
intermittent
 
hemodialysis,
 
prolonged
 
intermittent
 
renal
 
replacement
 
therapy ,
 
and
 
continuous
 
renal
 
replacement
 
therapy:
 
an
 
update.
 
Ann
 
Pharmacother .
 
2020;54(1):43-55.
 
doi:10.1 177/1060028019865873
 
 
8.
 
Pai
 
MP,
 
Cojutti
 
P,
 
Pea
 
F.
 
Levofloxacin
 
dosing
 
regimen
 
in
 
severely
 
morbidly
 
obese
 
patients
 
(BMI
 
≥40
 
kg/m(2))
 
should
 
be
 
guided
 
by
 
creatinine
 
clearance
 
estimates
 
based
 
on
 
ideal
 
body
 
weight
 
and
 
optimized
 
by
 
therapeutic
 
drug
 
monitoring.
 
Clin
 
Pharmacokinet.
 
2014;53(8):753-762.
 
doi:10.1007/s40262-014-0154-1
 
229
 

=== PAGE 231 ===

 
Lignocaine
 
(Lidocaine),
 
Medicated
 
Plaster
 
 
Name
 
:
 
 
Unit
 
:
 
 
●
 
Please
 
tick
 
(
✔
)
 
Yes
 
for
 
correct
 
instruction.
 
●
 
Please
 
tick
 
(
✔
)
 
No
 
for
 
incorrect
 
instruction.
 
Yes
 
No
 
Remarks
 
Pharmacological
 
Group
 
Local
 
Anaesthetic,
 
Topical
 
 
 
 
Indications
 
and
 
Dosage
 
Symptomatic
 
relief
 
of
 
neuropathic
 
pain
 
associated
 
with
 
previous
 
herpes
 
zoster
 
infection
 
(post-herpetic
 
neuralgia,
 
PHN)
 
a.
 
1
 
plaster
 
once
 
daily.
 
Cover
 
the
 
painful
 
area
 
for
 
up
 
to
 
12
 
hours
 
within
 
a
 
24-hour
 
period.
 
Not
 
more
 
than
 
3
 
plasters
 
should
 
be
 
applied
 
at
 
the
 
same
 
time.
 
b.
 
Renal
 
impairment:
 
No
 
special
 
dose
 
adjustments
 
necessary
 
in
 
patients
 
with
 
renal
 
impairment.
 
 
c.
 
Hepatic
 
impairment:
 
No
 
special
 
dose
 
adjustments
 
necessary
 
in
 
patients
 
with
 
hepatic
 
impairment.
 
 
To
 
counsel
 
based
 
on
 
specific
 
medication’ s
 
indication
 
and
 
dosage
 
as
 
prescribed
 
by
 
the
 
doctor
 
 
 
 
Method
 
of
 
Administration*
 
Step
 
1:
 
Preparing
 
the
 
skin
 
a.
 
The
 
plaster
 
must
 
be
 
applied
 
to
 
the
 
most
 
painful
 
area.
 
The
 
area
 
must
 
be
 
intact,
 
dry,
 
non-irritated
 
skin.
 
Step
 
2:
 
Cut
 
the
 
plaster
 
a.
 
The
 
plaster
 
may
 
be
 
cut
 
into
 
smaller
 
sizes
 
with
 
scissors
 
prior
 
to
 
removal
 
of
 
the
 
release
 
liner.
 
 
Step
 
3:
 
Apply
 
the
 
plaster
 
a.
 
The
 
plaster
 
must
 
be
 
applied
 
to
 
the
 
skin
 
immediately
 
after
 
removal
 
from
 
the
 
sachet
 
and
 
following
 
removal
 
of
 
the
 
release
 
liner
 
from
 
the
 
gel
 
surface.
 
b.
 
Leave
 
the
 
plaster
 
on
 
for
 
12
 
hours
 
only.
 
c.
 
If
 
your
 
pain
 
is
 
worse
 
during
 
the
 
day,
 
apply
 
the
 
plaster
 
in
 
the
 
morning
 
and
 
remove
 
it
 
after
 
12
 
hours
 
in
 
the
 
evening.
 
Step
 
4:
 
Disposing
 
of
 
the
 
plaster
 
a.
 
To
 
remove
 
previous
 
plaster ,
 
use
 
your
 
finger
 
to
 
peel
 
off
 
slowly .
 
Fold
 
the
 
plaster
 
into
 
half
 
and
 
press
 
firmly
 
to
 
seal
 
it
 
shut.
 
Discard
 
properly .
 
b.
 
Remove
 
immediately
 
if
 
a
 
burning
 
sensation
 
occurs.
 
 
Missed
 
dose
 
management:
 
a.
 
Apply
 
a
 
new
 
plaster
 
as
 
soon
 
as
 
you
 
remember
 
 
b.
 
Do
 
not
 
apply
 
twice
 
the
 
number
 
of
 
plasters
 
to
 
make
 
up
 
for
 
the
 
plaster
 
that
 
you
 
missed.
 
 
c.
 
This
 
will
 
increase
 
the
 
chance
 
of
 
you
 
getting
 
unwanted
 
side-ef fects
 
 
Do
 
not
 
stop
 
taking
 
your
 
medication
 
unless
 
advised
 
to
 
do
 
so
 
by
 
your
 
prescriber
 
 
 
 
Special
 
Considerations
 
Pregnancy
 
 
 
 
1.
 
Lignocaine
 
crosses
 
the
 
placenta.
 
However ,
 
the
 
potential
 
risk
 
of
 
human
 
is
 
unknown.
 
Therefore,
 
it
 
should
 
not
 
be
 
used
 
during
 
pregnancy
 
unless
 
clearly
 
necessary .
 
 
 
 
Breastfeeding
 
 
 
 
1.
 
Lignocaine
 
is
 
excreted
 
in
 
breast
 
milk.
 
However ,
 
there
 
 
 
 
230
 

=== PAGE 232 ===

 
are
 
no
 
studies
 
of
 
the
 
plaster
 
in
 
breast-feeding
 
women.
 
The
 
metabolism
 
of
 
lidocaine
 
occurs
 
relatively
 
fast
 
and
 
almost
 
in
 
the
 
liver,
 
only
 
very
 
low
 
levels
 
of
 
lidocaine
 
to
 
be
 
excreted
 
into
 
human
 
milk.
 
 
Paediatric
 
 
 
 
1.
 
The
 
safety
 
and
 
efficacy
 
in
 
paediatric
 
patients
 
below
 
18
 
years
 
old
 
have
 
not
 
been
 
established.
 
 
 
 
Others
 
 
 
 
1.
 
The
 
plaster
 
should
 
be
 
used
 
caution
 
in
 
patients
 
with
 
severe
 
cardiac
 
impairment,
 
severe
 
renal
 
impairment
 
or
 
severe
 
hepatic
 
impairment
 
 
 
 
Side
 
Effects
 
and
 
their
 
Management*
 
Rash,
 
skin
 
irritation,
 
burning,
 
dermatitis
 
erythema,
 
pruritus.
 
 
 
 
Storage*
 
1.
 
Store
 
your
 
medication
 
in
 
a
 
cool,
 
dry
 
place
 
(below
 
30°C)
 
away
 
from
 
heat,
 
moisture
 
and
 
direct
 
sunlight
 
2.
 
After
 
first
 
opening,
 
keep
 
the
 
sachet
 
tightly
 
closed.
 
The
 
plaster
 
contains
 
water
 
and
 
will
 
dry
 
out
 
if
 
the
 
sachet
 
is
 
not
 
closed
 
properly .
 
 
 
 
Others
 
1.
 
Do
 
not
 
shave
 
the
 
skin
 
if
 
it
 
is
 
hairy .
 
Instead,
 
clip
 
the
 
hair
 
as
 
close
 
to
 
the
 
skin
 
as
 
possible.
 
 
 
 
Before
 
ending
 
this
 
peer
 
review
 
session,
 
the
 
reviewee
 
should
 
be
 
informed
 
of
 
the
 
step(s)
 
that
 
he/
 
she
 
missed
 
out
 
in
 
order
 
to
 
ensure
 
all
 
the
 
counselling
 
points
 
are
 
being
 
covered.
 
 
Remarks:
 
 
 
 
 
Reviewed
 
by:
 
Name
 
&
 
Signature
                                                                   
Date:
 
 
 
 
 
*Mandatory
 
for
 
validation
 
/
 
peer
 
review
 
References
 
:
 
 
1.
 
Comer ,
 
A.
 
M.,
 
&
 
Lamb,
 
H.
 
M.
 
(2012).
 
Lidocaine
 
patch
 
5%.
 
SpringerLink.
 
2.
 
Davies,
 
P.
 
S.,
 
&
 
Galer ,
 
B.
 
S.
 
(2012).
 
Review
 
of
 
lidocaine
 
patch
 
5%
 
studies
 
in
 
the
 
treatment
 
of
 
postherpetic
 
neuralgia.
 
SpringerLink.
 
3.
 
Lidocaine
 
(2025).
 
Micromedex
 
(electronic
 
version).
 
Retrieved
 
January
 
20,
 
2025,
 
from
 
http://www .micromedexsolutions.com/
 
 
4.
 
Lidocaine
 
(local
 
and
 
regional
 
anesthetic).
 
(2024).
 
UpToDate.
 
Retrieved
 
October
 
1,
 
2024
 
from
 
https://www .uptodate.com/
 
5.
 
Mundipharma
 
Pharmaceutical
 
(2012).
 
Lignopad®
 
5%
 
medicated
 
plaster
 
[Patient
 
Information].
 
Retrieved
 
January
 
20,
 
from
 
https://www .npra.gov .my/index.php/en/consumer-medication-information-leaflets-rimup/item/lignopad-m
edicated-plaster .html
 
 
231
 

=== PAGE 233 ===

 
Lithium
 
Name:
 
 
Unit
 
:
 
 
●
 
Please
 
tick
 
(
✔
)
 
Yes
 
for
 
correct
 
instruction.
 
●
 
Please
 
tick
 
(
✔
)
 
No
 
for
 
incorrect
 
instruction.
 
Yes
 
No
 
Remarks
 
Pharmacological
 
Group
 
Mood
 
stabiliser
 
 
 
 
Indications
 
and
 
Dosage
 
1.
 
Indication:
 
 
a.
 
Prophylaxis
 
and
 
treatment
 
of
 
acute
 
mania
 
b.
 
Prophylaxis
 
and
 
treatment
 
of
 
acute
 
hypomania
 
c.
 
Prophylaxis
 
of
 
manic
 
depression
 
in
 
bipolar
 
illness
 
or
 
bipolar
 
depression
 
and
 
recurrent
 
depression
 
2.
 
Dosage:
 
a.
 
Acute
 
Mania:
 
600
 
-
 
1800
 
mg/day
 
in
 
divided
 
dose.
 
(Therapeutic
 
range:
 
0.8
 
to
 
1.2
 
mEq/L
 
(SI:
 
0.8
 
to
 
1.2
 
mmol/L)
 
b.
 
Usual
 
Maintenance
 
dose:
 
300
 
-
 
1800
 
mg/day .
 
May
 
be
 
given
 
as
 
a
 
single
 
dose
 
at
 
night.
 
(Therapeutic
 
range
 
0.8
 
to
 
1
 
mEq/L
 
(SI:
 
0.6
 
to
 
1
 
mmol/L)
 
3.
 
Blood
 
levels
 
can
 
be
 
drawn
 
to
 
make
 
sure
 
you
 
are
 
in
 
the
 
right
 
range
 
to
 
get
 
the
 
most
 
benefit
 
with
 
the
 
least
 
side
 
effects.Encourage
 
patients
 
to
 
learn
 
their
 
own
 
blood
 
levels.
 
a.
 
Blood
 
sampling
 
should
 
be
 
done
 
5
 
-
 
7
 
days
 
after
 
initiation
 
or
 
after
 
a
 
dose/formulation
 
change
 
or
 
after
 
introduction
 
of
 
interacting
 
medication,
 
&
 
weekly
 
until
 
levels
 
are
 
stable.
 
 
b.
 
A
 
12-hour
 
trough
 
level
 
is
 
preferred,
 
but
 
in
 
some
 
circumstances
 
it
 
may
 
be
 
drawn
 
8
 
to12
 
hours
 
post
 
dose
 
(I,e,
 
TDS
 
dose).
 
Or
 
 
To
 
counsel
 
based
 
on
 
specific
 
medication’ s
 
indication
 
and
 
dosage
 
as
 
prescribed
 
by
 
the
 
doctor
 
 
 
 
Method
 
of
 
Administration*
 
1.
 
Administration
 
instruction
 
a.
 
Take
 
each
 
dose
 
at
 
the
 
same
 
time
 
every
 
day
 
with
 
water
 
or
 
a
 
cool
 
drink
 
b.
 
This
 
medication
 
can
 
be
 
taken
 
with
 
or
 
without
 
food.
 
2.
 
Missed
 
dose
 
management:
 
a.
 
Take
 
the
 
missed
 
dose
 
as
 
soon
 
as
 
you
 
remember .
 
If
 
it’s
 
nearly
 
time
 
for
 
your
 
next
 
dose,
 
skip
 
the
 
missed
 
one
 
and
 
take
 
only
 
the
 
next
 
dose.
 
Do
 
not
 
take
 
two
 
doses
 
at
 
once.
 
 
Do
 
not
 
stop
 
taking
 
your
 
medication
 
unless
 
advised
 
to
 
do
 
so
 
by
 
your
 
prescriber
 
 
 
 
Special
 
Considerations
 
Pregnancy
 
 
 
 
1.
 
Inform
 
your
 
doctors
 
if
 
you
 
are
 
planning
 
to
 
become
 
pregnant
 
2.
 
Seek
 
immediate
 
medical
 
advice
 
if
 
you
 
become
 
pregnant
 
while
 
taking
 
Lithium
 
 
 
 
Breastfeeding
 
 
 
 
232
 

=== PAGE 234 ===

 
Breastfeeding
 
should
 
be
 
avoided
 
during
 
maternal
 
use
 
of
 
lithium
 
 
 
 
Elderly
 
 
 
 
Clearance
 
is
 
decreased
 
in
 
elderly
 
patients
 
secondary
 
to
 
age-related
 
decreases
 
in
 
renal
 
function.
 
Monitor
 
closely
 
for
 
emergence
 
of
 
adverse
 
reactions
 
or
 
toxicity
 
●
 
Beers
 
Criteria:
 
Avoid
 
using
 
with
 
ACEi,
 
ARB,
 
ARNI,
 
Loop
 
diuretics.
 
Interaction
 
with
 
the
 
listed
 
class
 
of
 
drug
 
increased
 
risk
 
of
 
toxicity .
 
Monitor
 
lithium
 
concentration.
 
●
 
STOPP/Start
 
Criteria:
 
Monitor
 
ECG
 
in
 
view
 
of
 
predictably
 
for
 
prolonged
 
QTc
 
interval
 
●
 
MALPIP:
 
May
 
affect
 
cognitive
 
function,
 
cause
 
hypothyroidism,
 
impair
 
renal
 
functions.
 
 
 
 
Paediatric
 
 
 
 
1.
 
The
 
safety
 
and
 
efficacy
 
of
 
Lithium
 
for
 
the
 
treatment
 
of
 
acute
 
manic
 
and
 
mixed
 
episodes
 
in
 
bipolar
 
disorder
 
have
 
not
 
been
 
established
 
in
 
patients
 
younger
 
than
 
7
 
years
 
of
 
age.
 
2.
 
The
 
safety
 
and
 
efficacy
 
of
 
sustained
 
-release
 
(SR)
 
Lithium
 
for
 
the
 
treatment
 
of
 
acute
 
manic
 
and
 
mixed
 
episodes
 
in
 
bipolar
 
disorder
 
have
 
not
 
been
 
established
 
in
 
patients
 
younger
 
than
 
12
 
years
 
of
 
age.
 
 
 
 
 
Fasting
 
 
 
 
Administer
 
during
 
Sahur
 
or
 
after
 
Iftar.
 
 
Kindly
 
refer
 
to
 
the
 
latest
 
advisory
 
by
 
religious
 
authority
 
 
 
 
Pre-Operative
 
 
 
 
Inform
 
your
 
prescriber
 
if
 
you're
 
planned
 
for
 
surgery
 
Lithium
 
should
 
be
 
withheld
 
24
 
hours
 
before
 
minor
 
surgery
 
and
 
up
 
to
 
72
 
hours
 
prior
 
to
 
major
 
surgery .
 
 
 
 
Renal
 
Impairment
 
 
 
 
1.
 
Mild
 
to
 
moderate
 
(30
 
–
 
89
 
ml/min)
 
:
 
Initiate
 
lower
 
doses
 
and
 
titrate
 
more
 
slowly .
 
 
2.
 
Use
 
is
 
not
 
recommended
 
when
 
CrCl
 
is
 
less
 
than
 
30
 
ml/min.
 
 
 
 
Hepatic
 
Impairment
 
 
 
 
 
No
 
dose
 
adjustment
 
 
 
 
Side
 
Effects
 
and
 
their
 
Management*
 
1.
 
Possible
 
side
 
effects
 
a.
 
Dry
 
mouth
 
and
 
/
 
or
 
metallic
 
taste,
 
sedation,
 
mild
 
diarrhoea,
 
mild
 
shaking
 
or
 
tremor
 
of
 
your
 
hands,
 
thirst,
 
Gastrointestinal
 
discomforts
 
(e.g.
 
nausea),
 
weight
 
gain,
 
low
 
thyroid
 
activity
 
(tiredness,
 
easily
 
feel
 
cold),
 
excessive
 
thirst
 
and
 
frequent
 
urination
 
2.
 
Signs
 
and
 
symptoms
 
of
 
toxicity
 
(when
 
there
 
is
 
too
 
much
 
lithium
 
in
 
your
 
body)
 
a.
 
Severe
 
hand
 
shakes
 
(tremor),
 
blurred
 
vision,
 
being
 
unsteady
 
on
 
your
 
feet,
 
clumsiness,
 
confusion,
 
feeling
 
unusually
 
sleepy ,
 
difficulty
 
 
 
 
233
 

=== PAGE 235 ===

 
in
 
speaking
 
or
 
slurring
 
of
 
words,
 
muscle
 
twitches
 
or
 
weakness,
 
stomach-ache
 
along
 
with
 
feeling
 
sick
 
and
 
having
 
diarrhoea
 
3.
 
Dietary
 
and
 
lifestyle
 
considerations
 
to
 
ensure
 
stable
 
blood
 
medication
 
levels
 
a.
 
Adequate
 
hydration
 
(2
 
-
 
3
 
L
 
of
 
water
 
everyday)
 
b.
 
Keep
 
salt
 
intake
 
about
 
the
 
same
 
(avoid
 
drastic
 
changes
 
in
 
salt
 
intake)
 
c.
 
Avoid
 
alcohol
 
if
 
possible
 
OR
 
avoid
 
alcohol
 
in
 
the
 
first
 
month
 
or
 
two,
 
then
 
drink
 
in
 
moderation
 
i.e.
 
up
 
to
 
1
 
-
 
2
 
drinks
 
3
 
times
 
a
 
week
 
d.
 
Avoid
 
excessive
 
use
 
and
 
keep
 
caffeine
 
intake
 
(e.g.
 
coffee,
 
tea,
 
cola,
 
other
 
soft
 
drinks)
 
about
 
the
 
same
 
e.
 
Seek
 
doctor ’s
 
review
 
if
 
you
 
fall
 
sick
 
(e.g.
 
fever ,
 
sore
 
throat,
 
flu-like
 
symptoms)
 
or
 
have
 
diarrhoea
 
more
 
than
 
a
 
day
 
Storage*
 
Store
 
at
 
a
 
temperature
 
below
 
30°C.
 
 
 
 
Others
 
Drug-drug
 
interactions
 
1.
 
Always
 
inform
 
your
 
other
 
doctor ,
 
pharmacist
 
or
 
healthcare
 
professional
 
that
 
you
 
are
 
taking
 
lithium
 
2.
 
Should
 
not
 
be
 
taken
 
with
 
NSAIDs,
 
diuretics,
 
ACE-Inhibitors,
 
SLGT2
 
inhibitors,
 
sodium-containing
 
antacids
 
(seek
 
medical
 
advice
 
first)
 
 
 
 
Before
 
ending
 
this
 
peer
 
review
 
session,
 
the
 
reviewee
 
should
 
be
 
informed
 
of
 
the
 
step(s)
 
that
 
he/
 
she
 
missed
 
out
 
in
 
order
 
to
 
ensure
 
all
 
the
 
counselling
 
points
 
are
 
being
 
covered.
 
Remarks:
 
 
 
Reviewed
 
by:
 
Name
 
&
 
Signature
                                                                   
Date:
 
 
 
 
*Mandatory
 
for
 
validation
 
/
 
peer
 
review
 
References:
 
 
1.
 
UpToDate,
 
Inc.
 
(2024).
 
Lithium:
 
Drug
 
information
 
(Version
 
3.68.3)
 
[Mobile
 
application].
 
UpToDate,
 
Inc.
 
2.
 
IBM
 
Corporation.
 
(2024).
 
Lithium
 
drug
 
information
 
(Version
 
4.6.0
 
(900))
 
[Mobile
 
application].
 
IBM
 
Micromedex.
 
3.
 
Tees
 
Esk
 
and
 
Wear
 
Valley
 
NHS
 
Foundation
 
Trust.
 
(2021,
 
March
 
25).
 
Guidelines
 
on
 
safe
 
lithium
 
prescribing
 
and
 
shared
 
care.
 
https://www.tewv.nhs.uk/wp-content/uploads/2022/01/Lithium-Shared-Care-Guidelines.pdf
 
4.
 
Alimuddin
 
AS.
 
et.
 
al.
 
CPG
 
Management
 
of
 
Bipolar
 
Disorder
 
(Second
 
Edition,
 
2024).
 
Accessed
 
on
 
January
 
21,
 
2025.
 
Available
 
from:
 
acadmed.org.my/CPGdl/CPG
 
Management
 
of
 
Bipolar
 
Disorder
 
(2nd
 
Edition).pdf
 
5.
 
National
 
Institute
 
for
 
Health
 
and
 
Care
 
Excellence
 
(NICE).
 
(2014).
 
Bipolar
 
disorder:
 
Assessment
 
and
 
management
 
(NICE
 
Clinical
 
Guideline
 
CG185).
 
https://www.nice.org.uk/guidance/cg185
 
6.
 
Stahl,
 
S.
 
M.
 
(2017).
 
Stahl’s
 
Essential
 
Psychopharmacology
 
Prescriber’s
 
Guide.
 
In
 
Australian
 
Prescriber
 
(6th
 
ed.,
 
Issue
 
1).
 
Cambridge
 
University
 
Press.
 
https://doi.org/10.18773/austprescr.2016.001
 
7.
 
Krishnasamy
 
A.
 
et.
 
al.
 
Medication
 
Counseling
 
for
 
Pharmacists.
 
(First
 
Edition
 
2021).
 
Perak
 
State
 
Health
 
Department,
 
Pharmaceutical
 
Services
 
Division.
 
8.
 
Taylor,
 
D.,
 
Barnes,
 
T.
 
E.,
 
&
 
Young,
 
A.
 
H.
 
(2021).
 
The
 
Maudsley
 
prescribing
 
guidelines
 
in
 
psychiatry
 
(14th
 
ed.).
 
Wiley-Blackwell.
 
9.
 
2023
 
American
 
Geriatrics
 
Society
 
Beers
 
Criteria®
 
Update
 
Expert
 
Panel.
 
(2023).
 
American
 
Geriatrics
 
Society
 
2023
 
updated
 
AGS
 
Beers
 
Criteria®
 
for
 
potentially
 
inappropriate
 
medication
 
use
 
in
 
older
 
adults.
 
Journal
 
of
 
the
 
American
 
Geriatrics
 
Society,
 
71(7),
 
2052-2081.
 
10.
 
Chang,
 
C.
 
T.,
 
Chan,
 
H.
 
K.,
 
Cheah,
 
W.
 
K.,
 
Tan,
 
M.
 
P.,
 
Ch’ng,
 
A.
 
S.
 
H.,
 
Thiam,
 
C.
 
N.,
 
...
 
&
 
Lee,
 
S.
 
W.
 
H.
 
(2023).
 
Development
 
of
 
a
 
Malaysian
 
potentially
 
inappropriate
 
prescribing
 
screening
 
tool
 
in
 
older
 
adults
 
(MALPIP):
 
a
 
Delphi
 
study.
 
Journal
 
of
 
Pharmaceutical
 
Policy
 
and
 
Practice,
 
16(1),
 
122.
 
11.
 
 
O’Mahony,
 
D.,
 
Cherubini,
 
A.,
 
Guiteras,
 
A.
 
R.,
 
Denkinger,
 
M.,
 
Beuscart,
 
J.
 
B.,
 
Onder,
 
G.,
 
...
 
&
 
Curtin,
 
D.
 
(2023).
 
STOPP/START
 
criteria
 
for
 
potentially
 
inappropriate
 
prescribing
 
in
 
older
 
people:
 
version
 
3.
 
European
 
geriatric
 
medicine,
 
14(4),
 
625-632.
 
234
 

=== PAGE 236 ===

 
Loop
 
Diuretics
 
Name
 
:
 
 
Unit
 
:
 
 
Pharmacological
 
Group
 
Loop
 
Diuretics
 
:
 
 
Furosemide
 
Bumetanide
 
 
 
 
Indications
 
and
 
Dosage
 
Indications:
 
Signs
 
and
 
symptoms
 
of
 
congestion
 
1.
 
Furosemide:
 
 
Initial
 
daily
 
dose:
 
20-40mg
 
od/bd
 
Usual
 
daily
 
dose:
 
20-40mg
 
od/bd
 
 
2.
 
Bumetanide
 
 
Initial
 
daily
 
dose:
 
0.5-1mg
 
od/bd
 
Usual
 
daily
 
dose:
 
0.5-1mg
 
od/bd
 
 
To
 
counsel
 
based
 
on
 
specific
 
medication’ s
 
indication
 
and
 
dosage
 
as
 
prescribed
 
by
 
the
 
doctor
 
 
 
 
Method
 
of
 
Administration*
 
1.
 
May
 
administer
 
with
 
or
 
without
 
food.
 
2.
 
Preferably
 
to
 
take
 
in
 
day
 
time
 
to
 
avoid
 
frequent
 
urination
 
at
 
sleep
 
time.
 
 
Do
 
not
 
stop
 
taking
 
your
 
medication
 
unless
 
advised
 
to
 
do
 
so
 
by
 
your
 
prescriber
 
 
 
 
Self
 
Dosage
 
Adjustment
 
(in
 
selected
 
patient)
 
1.
 
If
 
there
 
is
 
a
 
consistent
 
increase
 
in
 
weight
 
of
 
>
 
2kg
 
in
 
3
 
days,
 
selected
 
patients
 
can
 
be
 
taught
 
to
 
self-adjust
 
the
 
dose
 
of
 
furosemide.
 
(eg.
 
additional
 
dose
 
of
 
furosemide
 
20-40mg/day
 
/
 
bumetanide
 
0.5-1mg/day)
 
2.
 
Once dry weight is achieved, change furosemide dose 
to
 
baseline.
 
3.
 
If
 
there
 
is
 
no
 
response
 
to
 
the
 
increased
 
furosemide
 
dose
 
after
 
3
 
days
 
(or
 
earlier
 
if
 
condition
 
deteriorates),
 
seek
 
medical
 
attention
 
immediately .
 
4.
 
Dose
 
may
 
need
 
to
 
be
 
decreased
 
if
 
there
 
is
 
fluid
 
loss
 
(e.g.
 
due
 
to
 
diarrhoea/vomiting,
 
excessive
 
sweating).
 
 
 
 
Special
 
Considerations
 
Pregnancy
 
 
 
 
1.
 
Heart
 
failure
 
in
 
pregnancy
 
is
 
associated
 
with
 
adverse
 
maternal
 
and
 
fetal
 
outcomes.
 
Furosemide
 
may
 
be
 
used
 
for
 
symptoms
 
management
 
in
 
pregnant
 
patients
 
with
 
HF
 
 
2.
 
Closely
 
monitor
 
volume
 
status
 
and
 
adjust
 
dose
 
to
 
minimize
 
risk
 
of
 
placenta
 
hypoperfusion
 
 
 
 
 
Breastfeeding
 
 
 
 
1.
 
Furosemide
 
is
 
present
 
in
 
breast
 
milk.
 
2.
 
Large
 
doses
 
of
 
loop
 
diuretics
 
have
 
the
 
potential
 
to
 
decrease
 
milk
 
volume
 
and
 
suppress
 
lactation;
 
When
 
used
 
for
 
the
 
treatment
 
of
 
heart
 
failure,
 
furosemide
 
may
 
be
 
considered
 
with
 
close
 
neonatal
 
monitoring
 
(AHA/ACC/HFSA
 
[Heidenreich
 
2022]).
 
 
 
 
Elderly
 
 
 
 
1.
 
Refer
 
to
 
adult
 
dosing.
 
Consider
 
lower
 
initial
 
doses
 
and
 
titrate
 
to
 
response.
 
2.
 
STOPP/ST ART
 
Criteria:
 
Increase
 
risk
 
of
 
falls,
 
urinary
 
incontinence,
 
acute
 
 
 
 
235
 

=== PAGE 237 ===

 
kidney
 
injury ,
 
electrolyte
 
imbalances.
 
Should
 
not
 
be
 
used
 
as
 
first-line
 
agent
 
Paediatric
 
 
 
 
Consider
 
lower
 
initial
 
doses
 
and
 
titrate
 
to
 
response.
 
 
 
 
Renal
 
impairment
 
 
 
 
1.
 
eGFR
 
≥30
 
mL/minute/1.73
 
m2:
 
No
 
dosage
 
adjustment
 
necessary .
 
2.
 
eGFR
 
<30
 
mL/minute/1.73
 
m2:
 
Higher
 
doses
 
may
 
be
 
required
 
to
 
achieve
 
desired
 
diuretic
 
response
 
due
 
to
 
decreased
 
secretion
 
into
 
the
 
tubular
 
fluid.
 
3.
 
ESRF-
 
Anuric
 
patients:
 
There
 
is
 
no
 
expected
 
clinical
 
benefit;
 
use
 
not
 
recommended.
 
 
 
 
Liver
 
impairment
 
 
 
 
Diminished
 
natriuretic
 
effect
 
with
 
increased
 
sensitivity
 
to
 
hypokalemia
 
and
 
volume
 
depletion
 
in
 
cirrhosis.
 
Monitor
 
effects,
 
particularly
 
with
 
high
 
doses.
 
 
 
 
Side
 
Effects
 
and
 
their
 
Management*
 
1.
 
Asymptomatic
 
low
 
blood
 
pressure
 
a.
 
Dose
 
may
 
be
 
reduced
 
if
 
there
 
are
 
no
 
symptoms
 
or
 
signs
 
of
 
congestion.
 
2.
 
Symptomatic
 
hypotension
 
a.
 
Dizziness/light-headedness;
 
reduce
 
dose
 
if
 
no
 
signs/symptoms
 
of
 
congestion.
 
b.
 
Review
 
medications
 
and
 
reconsider
 
the
 
need
 
for
 
nitrates,
 
CCBs
 
and
 
other
 
vasodilators.
 
3.
 
Hypokalaemia/hypomagnesaemia
 
a.
 
Increase
 
an
 
ACE-I/ARB
 
dose
 
b.
 
Add
 
an
 
MRA,
 
K+
 
supplements;
 
magnesium
 
supplements
 
4.
 
Hyponatraemia
 
(<135
 
mmol/L)
 
 
a.
 
If
 
volume
 
depleted:
 
●
 
Stop
 
thiazide
 
●
 
Reduce
 
dose/stop
 
loop
 
diuretics
 
if
 
possible
 
b.
 
If
 
volume
 
overloaded:
 
(seek
 
specialist
 
advice-
 
patient
 
might
 
need
 
IV
 
diuretic)
 
●
 
Fluid
 
restriction
 
●
 
Consider
 
increasing
 
dose
 
of
 
loop
 
diuretic
 
●
 
Consider
 
AVP
 
antagonist
 
(e.g.
 
tolvaptan
 
if
 
available)
 
5.
 
Hypovolaemia
 
/
 
dehydration
 
 
a.
 
Assess
 
volume
 
status;
 
consider
 
a
 
diuretic
 
dosage
 
reduction
 
6.
 
Hyperuricaemia
 
/
 
gout
 
 
a.
 
For
 
gouty
 
flares
 
use
 
colchicine
 
for
 
pain
 
relief.
 
b.
 
Avoid
 
NSAIDs.
 
c.
 
Consider
 
allopurinol
 
prophylaxis
 
(not
 
initiated
 
during
 
acute
 
exacerbation)
 
7.
 
Insuf ficient
 
diuretic
 
response/diuretic
 
resistance
 
a.
 
Check
 
adherence
 
and
 
fluid/salt
 
intake.
 
b.
 
Increase
 
dose
 
of
 
diuretic
 
/
 
consider
 
switching
 
from
 
furosemide
 
to
 
bumetanide
 
 
c.
 
Add
 
an
 
MRA/increase
 
dose
 
of
 
an
 
MRA.
 
d.
 
Combine
 
loop
 
diuretic
 
and
 
thiazide/metolazone.
 
e.
 
Administer
 
loop
 
diuretic
 
twice
 
(or
 
more
 
times)
 
daily
 
or
 
on
 
empty
 
stomach
 
8.
 
Worsening
 
of
 
renal
 
function
 
a.
 
Check
 
for
 
hypovolaemia/dehydration.
 
b.
 
If
 
using
 
concomitant
 
loop
 
and
 
thiazide
 
 
 
 
236
 

=== PAGE 238 ===

 
diuretic,
 
stop
 
thiazide
 
diuretic.
 
c.
 
Avoid
 
nephrotoxic
 
agents,
 
e.g.
 
NSAIDs,
 
trimethoprim.
 
d.
 
Withhold
 
an
 
MRA.
 
e.
 
Consider
 
reducing
 
a
 
dose
 
of
 
ACE-I/ARB.
 
Storage*
 
1.
 
Store
 
at
 
room
 
temperature
 
protected
 
from
 
light.
 
Store
 
in
 
a
 
dry
 
place.
 
2.
 
Keep
 
all
 
drugs
 
in
 
a
 
safe
 
place.
 
Keep
 
all
 
drugs
 
out
 
of
 
the
 
reach
 
of
 
children.
 
3.
 
Throw
 
away
 
unused
 
or
 
expired
 
drugs.
 
 
 
 
Others
 
 
Monitoring
 
Parameters
 
a.
 
Renal function
 
b.
 
Fluid status
 
- Fluid input and output ]
 
c.
 
Serum electrolyte
 
- Sodium, potassium,
 
magnesium
 
d.
 
Blood pressure
 
e.
 
Body
 
weight
 
 
Drug-drug
 
Interactions
 
Nonsteroidal
 
Anti-Inflammatory
 
Agents:
 
May
 
diminish
 
the
 
therapeutic
 
effect
 
of
 
Loop
 
Diuretics.
 
Loop
 
Diuretics
 
may
 
enhance
 
the
 
nephrotoxic
 
effect
 
of
 
Nonsteroidal
 
Anti-Inflammatory
 
Agents.
 
 
 
 
Before
 
ending
 
this
 
peer
 
review
 
session,
 
the
 
reviewee
 
should
 
be
 
informed
 
of
 
the
 
step(s)
 
that
 
he/
 
she
 
missed
 
out
 
in
 
order
 
to
 
ensure
 
all
 
the
 
counselling
 
points
 
are
 
being
 
covered.
 
 
Remarks:
 
 
 
 
Reviewed
 
by:
 
Name
 
&
 
Signature
                                                                   
Date:
 
 
 
 
*Mandatory
 
for
 
validation
 
/
 
peer
 
review
 
References:
 
 
1.
 
Lexicomp.
 
(2023).
 
In
 
Lexicomp
 
Online.
 
Wolters
 
Kluwer .
 
https://www .lexicomp.com/
  
 
2.
 
Malaysian
 
Clinical
 
Practice
 
Guidelines:
 
Management
 
of
 
Heart
 
Failure
 
2023
 
(5
th
 
edition).
 
 
3.
 
South
 
London
 
Cardiovascular
 
Disease
 
Medicines
 
Working
 
Group
 
on
 
behalf
 
of
 
the
 
SEL
 
Integrated
 
Medicines
 
Optimisation
 
Committee,
 
South
 
East
 
London
 
guidance
 
on
 
the
 
pharmacological
 
management
 
of
 
Heart
 
Failure
 
in
 
adults,
 
Last
 
reviewed
 
and
 
approved:
 
October
 
2023,
 
Available
 
at:
 
https://www .slcn.nhs.uk/cardiac-odn/workstreams/heart-failure/hf-prescribing-guidance/
 
4.
 
RxFiles.
 
Heart
 
Failure:
 
Diuretic
 
Use
 
and
 
Sliding
 
Scale
 
Guidance.
 
RxFiles
 
Academic
 
Detailing
 
Program.
 
Available
 
at:
 
https://www .rxfiles.ca/rxfiles/uploads/documents/hf-furosemideslidingscale.pdf.
 
 
5.
 
McDonagh
 
T.A.,
 
Metra
 
M.,
 
Adamo
 
M.,
 
et
 
al.
 
"2021
 
ESC
 
Guidelines
 
for
 
the
 
diagnosis
 
and
 
treatment
 
of
 
acute
 
and
 
chronic
 
heart
 
failure:
 
Developed
 
by
 
the
 
Task
 
Force
 
for
 
the
 
diagnosis
 
and
 
treatment
 
of
 
acute
 
and
 
chronic
 
heart
 
failure
 
of
 
the
 
European
 
Society
 
of
 
Cardiology
 
(ESC)
 
With
 
the
 
special
 
contribution
 
of
 
the
 
Heart
 
Failure
 
Association
 
(HFA)
 
of
 
the
 
ESC".
 
Eur
 
Heart
 
J
 
2021;42:36:
 
3599-3726
 
6.
 
Chang,
 
C.
 
T.,
 
Chan,
 
H.
 
K.,
 
Cheah,
 
W.
 
K.,
 
Tan,
 
M.
 
P.,
 
Ch’ng,
 
A.
 
S.
 
H.,
 
Thiam,
 
C.
 
N.,
 
...
 
&
 
Lee,
 
S.
 
W.
 
H.
 
(2023).
 
Development
 
of
 
a
 
Malaysian
 
potentially
 
inappropriate
 
prescribing
 
screening
 
tool
 
in
 
older
 
adults
 
(MALPIP):
 
a
 
Delphi
 
study .
 
Journal
 
of
 
Pharmaceutical
 
Policy
 
and
 
Practice,
 
16(1),
 
122.
 
 
 
 
 
 
 
237
 

=== PAGE 239 ===

 
Lopinavir/Ritonavir
 
Name
 
:
 
 
Unit
 
:
 
 
●
 
Please
 
tick
 
(
✔
)
 
Yes
 
for
 
correct
 
instruction.
 
●
 
Please
 
tick
 
(
✔
)
 
No
 
for
 
incorrect
 
instruction.
 
Yes
 
No
 
Remarks
 
Pharmacological
 
Group
 
Antiretroviral:
 
Protease
 
Inhibitor
 
(PI)
 
 
 
 
Indications
 
and
 
Dosage
 
Second
 
line
 
treatment
 
of
 
HIV-1
 
infected
 
patients,
 
in
 
combination
 
with
 
other
 
antiretroviral
 
medicinal
 
products.
 
 
a.
 
Adults:
 
 
Therapy-naive
 
patients:
 
400/100mg
 
BD
 
or
 
800/200mg
 
once
 
daily
 
(with
 
no
 
prior
 
PI
 
used)
 
Therapy-experience
 
patients:
 
400/100mg
 
BD.
 
 
b.
 
Children
 
(>
 
6
 
months):
 
Oral
 
tablet:
 
 
15-25kg
 
or
 
>
 
0.6
 
-<0.9m2:
 
200mg/50mg
 
BD
 
25-35kg
 
or
 
>
 
0.9
 
-<1.4m2:
 
300mg/50mg
 
BD
 
>35kg
 
or
 
>
 
1.4m2:
 
400mg/100mg
 
BD
 
Oral
 
solution
 
(based
 
on
 
LPV
 
component):
 
7-14kg:
 
12mg/kg
 
BD
 
15-40kg:
 
10mg/kg
 
BD
 
>
 
40kg:
 
400mg
 
BD
 
 
c.
 
Infants
 
(14
 
days
 
-
 
6
 
months)
 
300mg/75mg
 
LPV/r
  
per
 
m2
 
BD
 
or
 
16mg/4mg
 
LPV/r
 
per
 
kg
 
BD
 
 
 
 
Method
 
of
 
Administration*
 
Lopinavir/Ritonavir
 
solution:
 
To
 
be
 
taken
 
with
 
food.
 
Lopinavir/Ritonavir
 
tablets:
 
May
 
be
 
taken
 
with
 
or
 
without
 
food.
 
The
 
tablets
 
should
 
be
 
swallowed
 
whole
 
and
 
not
 
chewed,
 
crushed
 
or
 
broken.
 
 
Use
 
of
 
Oral
 
solution
 
with
 
feeding
 
tube:
 
Lopinavir/Ritonavir
 
oral
 
solution
 
can
 
be
 
administered
 
via
 
feeding
 
tube.
 
 
Missed
 
dose
 
management
 
 
 
1.
 
Patients
 
should
 
take
 
Lopinavir/Ritonavir
  
as
 
soon
 
as
 
they
 
remember
 
it.
  
However ,
 
if
 
it
 
is
 
almost
 
time
 
for
 
the
 
next
 
dose,
 
the
 
patient
 
should
 
skip
 
the
 
missed
 
dose
 
and
 
simply
 
resume
 
the
 
normal
 
dosing
 
schedule.
 
 
Do
 
not
 
stop
 
taking
 
your
 
medication
 
unless
 
advised
 
to
 
do
 
so
 
by
 
your
 
prescriber
 
 
 
 
Special
 
Considerations
 
Pregnancy
 
 
 
 
Available
 
human
 
data
 
suggest
 
Lopinavir/Ritonavir
 
does
 
not
 
increase
 
the
 
risk
 
of
 
overall
  
major
 
defects
 
compared
 
to
 
the
 
background
 
rate.
 
Lopinavir/Ritonavir
 
can
 
be
 
used
 
during
 
pregnancy
 
if
 
clinically
 
indicated.
 
 
 
 
Breastfeeding
 
 
 
 
Lopinavir/Ritonavir
 
are
 
present
 
in
 
breast
 
milk.
 
Because
 
of
 
both
 
the
 
potential
 
for
 
HIV
 
transmission
 
and
 
the
 
potential
 
for
 
serious
 
adverse
 
reactions
 
in
 
nursing
 
infants,
 
mothers
 
should
 
be
 
instructed
 
not
 
to
 
breastfeed
 
if
 
they
 
are
 
receiving
 
Lopinavir/Ritonavir .
 
 
 
 
238
 

=== PAGE 240 ===

 
Elderly
 
 
 
 
Limited
 
data
 
is
 
available
 
for
 
patients
 
aged
 
more
 
than
 
65
 
years
 
old.
 
In
 
general,
 
appropriate
 
caution
 
should
 
be
 
exercised
 
in
 
the
 
administration
 
and
 
monitoring
 
of
 
Lopinavir/Ritonavir
 
in
 
elderly
 
which
 
may
 
include
 
hepatic,
 
renal
 
and
 
cardiac
 
function.
 
 
 
 
Paediatric
 
 
 
 
1.
 
The
 
safety
 
and
 
efficacy
 
of
 
Lopinavir/Ritonavir
 
in
 
premature
 
neonates
 
below
 
the
 
age
 
of
 
14
 
days
 
have
 
not
 
been
 
established.
 
 
2.
 
Reserve
 
when
 
benefits
 
outweigh
 
risks
 
and
 
no
 
alternatives
 
are
 
available.
 
 
 
 
Fasting
 
 
 
 
To
 
discuss
 
with
 
ID
 
Consultant
 
as
 
it
 
would
 
be
 
based
 
on
 
the
 
patient's
 
latest
 
viral
 
load
 
status.
 
 
 
 
Others
  
 
 
 
 
1.
 
Hepatic
 
impairment:
 
 
No
 
data
 
are
 
available
 
in
 
patients
 
with
 
severe
 
hepatic
 
impairment
 
(Child-Pugh
 
Grade
 
C).
 
Use
 
with
 
caution
 
in
 
these
 
patients.
 
2.
 
Renal
 
Impairment:
 
Lopinavir
 
pharmacokinetics
 
have
 
not
 
been
 
studied
 
in
 
patients
 
with
 
renal
 
insuf ficiency .
 
However ,
 
since
 
renal
 
clearance
 
of
 
lopinavir
 
is
 
negligible,
 
a
 
decrease
 
in
 
total
 
body
 
clearance
 
is
 
not
 
expected
 
in
 
patients
 
with
 
renal
 
insuf ficiency
 
 
 
 
Side
 
Effects
 
and
 
their
 
Management*
 
1.
 
Commonly
 
reported
 
adverse
 
reactions
 
to
 
Lopinavir/Ritonavir
 
included
 
diarrhea,
 
nausea,
 
vomiting,
 
hypertriglyceridemia
 
and
 
hypercholesterolemia.
 
2.
 
Diarrhea,
 
nausea
 
and
 
vomiting
 
may
 
occur
 
at
 
the
 
beginning
 
of
 
the
 
treatment.
 
 
 
 
Storage*
 
1.
 
Lopinavir/Ritonavir
 
solution:
 
(2-8
℃
)
 
until
 
dispensed.
 
Avoid
 
exposure
 
to
 
excessive
 
heat.
 
Refrigeration
 
is
 
not
 
required
 
if
 
used
 
within
 
2
 
months
 
and
 
stored
 
below
 
25
℃
.
 
2.
 
Lopinavir/Ritonavir
 
tablets:
 
store
 
tablets
 
at
 
or
 
below
 
30
℃
.
 
 
 
 
Others
 
Beware
 
of
 
Lopinavir/ritonavir-drug
 
interactions.
 
Kindly
 
refer
 
to
 
Liverpool
 
HIV
 
Interactions
 
website
 
for
 
further
 
information.
 
 
1.
 
Lopinavir/Ritonavir
 
is
 
an
 
inhibitor
 
of
 
the
 
P450
 
isoform
 
CYP3A.
 
Co-administration
 
of
 
Lopinavir/Ritonavir
 
and
 
drugs
 
primarily
 
metabolized
 
by
 
CYP3A
  
may
 
result
 
in
 
increased
 
plasma
 
concentrations
 
of
 
the
 
other
 
drugs
 
(e.g.
 
HMG
 
CoA
 
reductase,
 
dihydropyridine
 
calcium
 
channel
 
blockers,
 
immunosuppressant
 
etc)
 
2.
 
Overdoses
 
with
 
Lopinavir/Ritonavir
 
have
 
been
 
reported
 
in
 
association
 
with
 
complete
 
AV
 
block,
 
cardiomyopathy ,
 
lactic
 
acidosis
 
and
 
acute
 
renal
 
failure.
 
Treatment
 
of
 
overdose
 
should
 
consist
 
of
 
general
 
supportive
 
measures
 
including
 
monitoring
 
of
 
vital
 
signs
 
and
 
clinical
 
status
 
of
 
patients.
 
 
 
 
239
 

=== PAGE 241 ===

 
Before
 
ending
 
this
 
peer
 
review
 
session,
 
the
 
reviewee
 
should
 
be
 
informed
 
of
 
the
 
step(s)
 
that
 
he/
 
she
 
missed
 
out
 
in
 
order
 
to
 
ensure
 
all
 
the
 
counselling
 
points
 
are
 
being
 
covered.
 
 
Remarks:
 
 
 
 
 
Reviewed
 
by:
 
Name
 
&
 
Signature
                                                                   
Date:
 
 
 
 
 
*Mandatory
 
for
 
validation
 
/
 
peer
 
review
 
References:
 
 
1.
 
Wolter
 
Kluwer
 
(2024).
 
UpToDate
 
-
 
Lopinavir/Ritonavir .
 
UpToDate,Inc.
 
2.
 
Ministry
 
of
 
Health
 
Malaysia
 
(2022).
 
Malaysian
 
Consensus
 
Guidelines
 
on
 
Antiretroviral
 
Therapy .
 
 
3.
 
Kaletra
 
Product
 
Insert.
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
240
 

=== PAGE 242 ===

 
Methadone
 
Name
 
:
 
 
Unit
 
:
 
 
●
 
Please
 
tick
 
(
✔
)
 
Yes
 
for
 
correct
 
instruction.
 
●
 
Please
 
tick
 
(
✔
)
 
No
 
for
 
incorrect
 
instruction.
 
Yes
 
No
 
Remarks
 
Pharmacological
 
Group
 
Full
 
opioid
 
agonist
 
1.
 
Synthetic
 
opioid
 
that
 
acts
 
as
 
a
 
full
 
agonist
 
at
 
the
 
μ-
opioid
 
receptor
 
and
 
other
 
opioid
 
receptors.
 
2.
 
These
 
μ-
opioid
 
receptors
 
are
 
located
 
in
 
different
 
parts
 
of
 
the
 
central
 
nervous
 
system
 
(CNS),
 
such
 
as
 
the
 
brainstem,
 
locus
 
coeruleus,
 
periaqueductal
 
gray
 
matter ,
 
and
 
various
 
parts
 
of
 
the
 
gastrointestinal
 
tract.
 
3.
 
These
 
receptors
 
are
 
crucial
 
in
 
modulating
 
various
 
neurochemical
 
activities
 
linked
 
to
 
analgesia,
 
euphoria,
 
and
 
sedation.
 
4.
 
It
 
induces
 
receptor
 
internalization
 
and
 
recycling,
 
contributing
 
to
 
reduced
 
opioid
 
tolerance
 
in
 
patients.
 
5.
 
It
 
occupies
 
and
 
activates
 
these
 
opioid
 
receptors,
 
it
 
does
 
so
 
more
 
slowly
 
than
 
other
 
opioids
 
in
 
an
 
opioid-dependent
 
person.
 
6.
 
Treatment
 
doses
 
do
 
not
 
produce
 
euphoria.
 
 
Brief
 
pharmacokinetic
 
of
 
Methadone
 
1.
 
Onset:
 
30
 
minutes
 
2.
 
Peak
 
effects:
 
~
 
3
 
hours
 
3.
 
Half-life:
 
24-36
 
hours
 
4.
 
Time
 
to
 
reach
 
steady
 
state:
 
3-10
 
days
 
 
5.
 
Absorption
 
(PO):
 
30
 
minutes
 
 
6.
 
Metabolized
 
in
 
the
 
liver
 
by
 
the
 
cytochrome
 
P450
 
system
 
through
 
N-demethylation
 
and
 
cyclization.
 
Susceptible
 
to
 
interactions
 
with
 
other
 
drugs
 
by
 
speeding
 
up
 
or
 
slowing
 
down
 
its
 
breakdown
 
 
 
 
Indications
 
and
 
Dosage
 
 
Detoxification
 
treatment
 
or
 
maintenance
 
treatment
 
of
 
narcotic
 
addiction.
 
 
 
Dosage
 
 
Initial
 
10-20mg
 
per
 
day,
 
increasing
 
by
 
10
 
-
 
20mg
 
per
 
day
 
until
 
there
 
are
 
no
 
signs
 
of
 
withdrawal
 
or
 
intoxication.
 
Usual
 
therapeutic
 
dose
 
40
 
-
 
60mg
 
per
 
day
 
 
Therapeutic
 
dose
 
in
 
opioid
 
dependence
 
is
 
determined
 
by
 
methadone
 
ability
 
to
 
prevent
 
cravings,
 
prevent
 
withdrawal
 
symptoms,
 
and
 
prevent
 
relapse
 
without
 
inducing
 
euphoria
 
or
 
sedation.
 
 
Induction
 
Dosage
 
Initial:
 
10
 
-
 
20mg
 
per
 
day
 
 
Maximum
 
induction
 
dose:
 
40mg
 
per
 
day
 
Reevaluation
 
is
 
advised
 
within
 
2
 
to
 
4
 
hours,
 
once
 
peak
 
levels
 
have
 
been
 
attained.
 
The
 
timing
 
of
 
reassessment
 
should
 
not
 
impede
 
the
 
initiation
 
of
 
methadone
 
Supplementary
 
dose
 
of
 
5mg
 
can
 
be
 
given
 
on
 
the
 
same
 
day
 
after
 
induction
 
dose
 
(not
 
counted
 
as
 
total
 
therapeutic
 
dose)
 
 
 
Titration
 
Dosage:
 
Increase
 
5
 
-
 
10mg
 
every
 
3
 
days
 
Maximum
 
increment:
 
20mg
 
per
 
week
 
 
Maintenance
 
Dosage
 
Usual
 
maintenance
 
dose:
 
40
 
-
 
60mg
 
per
 
day
 
 
But
 
some
 
patient
 
may
 
require
 
higher
 
doses
 
(80
 
-
 
100mg
 
per
 
day)
 
 
 
 
 
241
 

=== PAGE 243 ===

 
In
 
certain
 
cases,
 
dosages
 
exceeding
 
120mg
 
per
 
day
 
may
 
be
 
cautiously
 
considered,
 
especially
 
for
 
patients
 
misusing
 
highly
 
potent
 
opioids
 
such
 
as
 
fentanyl
 
and
 
other
 
synthetic
 
opioids
 
 
Due
 
to
 
methadone's
 
extended
 
half-life,
 
caution
 
is
 
essential
 
to
 
prevent
 
rapid
 
dose
 
escalation
 
within
 
the
 
initial
 
1
 
to
 
3
 
weeks
 
of
 
therapy .
 
Patients
 
should
 
be
 
informed
 
that
 
experiencing
 
discomfort
 
is
 
expected
 
during
 
the
 
initial
 
days
 
of
 
methadone
 
titration.
 
 
Detoxification:
 
 
In
 
general,
 
methadone
 
treatment
 
is
 
a
 
long-term
 
treatment,
 
similar
 
to
 
other
 
chronic
 
conditions.
 
However ,
 
for
 
patients
 
who
 
wish
 
to
 
discontinue
 
treatment,
 
they
 
should
 
be
 
referred
 
to
 
a
 
doctor
 
for
 
appropriate
 
assessment
 
and
 
intervention.
 
 
i.
 
The
 
reduction
 
of
 
the
 
methadone
 
dose
 
should
 
be
 
discussed
 
with
 
the
 
patient.
 
It
 
is
 
advisable
 
for
 
the
 
patient
 
to
 
gradually
 
reduce
 
the
 
dose
 
over
 
a
 
long
 
period
 
until
 
they
 
feel
 
comfortable
 
with
 
the
 
tapering
 
regimen
 
to
 
ensure
 
that
 
the
 
withdrawal
 
process
 
can
 
be
 
safely
 
managed.
 
 
ii.
 
It
 
is
 
recommended
 
to
 
reduce
 
the
 
methadone
 
dose
 
by
 
10
 
mg
 
per
 
week
 
until
 
reaching
 
40
 
mg
 
per
 
day,
 
and
 
then
 
by
 
5
 
mg
 
per
 
week
 
thereafter ,
 
and
 
should
 
only
 
be
 
done
 
once
 
a
 
week.
 
 
Contraindication
 
 
Methadone
 
is
 
contraindicated
 
in
 
individuals
 
with:
 
●
 
Severe
 
respiratory
 
depression
 
or
 
asthma.
 
Methadone
 
can
 
further
 
depress
 
breathing,
 
increasing
 
the
 
risk
 
of
 
respiratory
 
arrest
 
or
 
death
 
●
 
Recent
 
use
 
of
 
MAO
 
inhibitors
 
(e.g.,
 
Selegiline)
 
within
 
the
 
last
 
14
 
days.
 
Combining
 
methadone
 
with
 
MAOIs
 
can
 
cause
 
serious,
 
potentially
 
fatal
 
interactions,
 
such
 
as
 
serotonin
 
syndrome
 
●
 
Paralytic
 
ileus
 
due
 
to
 
the
 
risk
 
of
 
intestinal
 
obstruction
 
and
 
gastrointestinal
 
(GI)
 
complications
 
or
 
severe
 
liver
 
disease
 
(e.g.,
 
cirrhosis
 
or
 
liver
 
failure)
 
due
 
to
 
the
 
risk
 
of
 
increased
 
methadone
 
levels
 
and
 
toxicity .
 
●
 
Severe
 
CNS
 
depression,
 
including
 
head
 
injuries
 
or
 
coma.
 
●
 
Significant
 
hypersensitivity
 
to
 
methadone.
 
 
It
 
is
 
essential
 
that
 
methadone
 
use
 
be
 
carefully
 
monitored
 
especially
 
for
 
individuals
 
with
 
any
 
of
 
the
 
above
 
conditions,
 
to
 
avoid
 
serious
 
side
 
effects,
 
including
 
overdose,
 
respiratory
 
depression,
 
and
 
death.
 
 
Method
 
of
 
Administration*
 
Once
 
daily
 
(OD)
 
dispensing
 
in
 
low-concentration
 
liquid
 
form
 
via
 
Direct-Observation
 
Therapy
 
(DOT)
 
and
 
Take
 
Away
 
(TA)
 
doses
 
per
 
orally
 
(PO)
 
 
Direct-Observation
 
Therapy
 
(DOT)
 
1.
 
Methadone
 
has
 
to
 
be
 
diluted
 
until
 
30ml
 
or
 
more
 
and
 
must
 
be
 
swallowed
 
completely .
 
 
2.
 
Appropriate
 
measures
 
must
 
be
 
in
 
place
 
to
 
ensure
 
methadone
 
is
 
swallowed
 
completely
 
and
 
reduce
 
any
 
risk
 
of
 
diversion
 
such
 
as
 
by
 
a.
 
Directly
 
observe
 
the
 
patient
 
while
 
they
 
take
 
their
 
dose
 
of
 
methadone
 
b.
 
Drink
 
the
 
remaining
 
methadone
 
dose
 
by
 
rinsing
 
the
 
container
 
 
c.
 
Encourage
 
patient
 
to
 
speak
 
after
 
swallowing
 
methadone
 
 
 
 
 
 
242
 

=== PAGE 244 ===

 
Takeaway
 
(TA)
 
dose
 
1.
 
Methadone
 
dose
 
should
 
be
 
diluted
 
as
 
follows
 
or
 
as
 
according
 
to
 
latest
 
guideline:
 
a.
 
For
 
a
 
methadone
 
dose
 
≤
 
25
 
mg,
 
dilute
 
to
 
30
 
ml.
 
b.
 
For
 
a
 
methadone
 
dose
 
>
 
25
 
mg,
 
dilute
 
to
 
50
 
ml
 
or
 
more.
 
2.
 
Hand
 
over
 
TA
 
doses
 
to
 
the
 
patient.
 
In
 
situations
 
where
 
the
 
patient
 
is
 
accompanied
 
by
 
a
 
guardian,
 
it
 
is
 
recommended
 
that
 
TA
 
doses
 
be
 
handed
 
over
 
to
 
the
 
guardian.
 
 
Ideally
 
to
 
be
 
taken
 
in
 
the
 
morning
 
and
 
after
 
meal
 
 
In
 
specific
 
cases,
 
total
 
daily
 
dose
 
can
 
be
 
divided
 
into
 
BD
 
dose.
 
 
Dosing
 
interval
 
for
 
BD
 
dose
 
is
 
not
 
restricted
 
to
 
12
 
hours
 
interval
 
 
Takeaway
 
and
 
divided
 
doses
 
should
 
be
 
supplied
 
in
 
Unit
 
of
 
Dose
 
(UoD)
 
in
 
a
 
separate
 
labelled
 
container
 
 
Missed
 
dose
 
management
 
Take
  
full
 
dose
 
immediately
 
as
 
soon
 
as
 
patient
 
remember
 
within
 
the
 
same
 
day
 
 
●
 
1-2
 
days
 
missed
 
dose:
 
Maintain
 
same
 
dose
 
●
 
3
 
days
 
missed
 
dose:
 
Half
 
of
 
total
 
dose
 
and
 
discuss
 
with
 
prescriber
 
●
 
4
 
days
 
missed
 
dose:
 
Discuss
 
with
 
prescriber
 
before
 
dispensing
 
●
 
5
 
days
 
and
 
more
 
missed
 
dose:
 
Reinitiation
 
with
 
induction
 
dose
 
 
Do
 
not
 
inject
 
methadone
 
dose
 
 
 
Do
 
not
 
stop
 
taking
 
your
 
medication
 
unless
 
advised
 
to
 
do
 
so
 
by
 
your
 
prescriber
 
Special
 
Considerations
 
Pregnancy
 
 
 
 
1.
 
Maintenance
 
treatment
 
should
 
be
 
continued
 
in
 
pregnant
 
women
 
with
 
opioid
 
dependence
 
2.
 
Patient
 
may
 
require
 
higher
 
dose
 
during
 
pregnancy
 
3.
 
FDA
 
Category:
 
C
 
 
 
 
 
Breastfeeding
 
 
 
 
1.
 
Methadone
 
can
 
be
 
excreted
 
through
 
human
 
milk
 
 
2.
 
Therefore,
 
patient
 
is
 
advised
 
to
 
breastfeed
 
their
 
infant
 
to
 
prevent
 
Neonatal
 
Abstinence
 
Syndrome
 
(NAS)
 
3.
 
Abrupt
 
weaning
 
of
 
breastfed
 
infants
 
of
 
women
 
on
 
methadone
 
might
 
result
 
in
 
precipitation
 
of
 
or
 
an
 
increase
 
in
 
infant
 
withdrawal
 
symptoms,
 
and
 
gradual
 
weaning
 
is
 
advised
 
4.
 
Methadone
 
patient
 
with
 
HIV
 
is
 
not
 
advised
 
to
 
breastfeed
 
and
 
infant
 
to
 
be
 
monitored
 
for
 
Neonatal
 
Abstinence
 
Syndrome
 
(NAS)
 
 
 
 
Elderly
 
 
 
 
 
If
 
methadone
 
is
 
deemed
 
necessary
 
for
 
opioid
 
dependence
 
management,
 
it
 
should
 
be
 
done
 
under
 
strict
 
medical
 
supervision,
 
with
 
dose
 
adjustments
 
based
 
on
 
the
 
individual’ s
 
age,
 
renal
 
function,
 
hepatic
 
function,
 
and
 
concomitant
 
medications
 
(Refer
 
Beers
 
Criteria)
 
 
Beers
 
Criteria:
 
 
 
 
243
 

=== PAGE 245 ===

 
a.
 
Avoid
 
in
 
patients
 
with
 
or
 
at
 
high
 
risk
 
for
 
delirium,
 
as
 
may
 
induce
 
or
 
worsen
 
delirium.
 
b.
 
Avoid
 
in
 
patients
 
with
 
a
 
history
 
of
 
fractures
 
or
 
falls
 
(excludes
 
pain
 
management
 
for
 
severe
 
acute
 
pain)
 
as
 
ataxia,
 
syncope,
 
impaired
 
psycho-motor
 
function
 
or
 
additional
 
falls
 
may
 
occur .
 
c.
 
Avoid
 
concomitant
 
use
 
of
 
3
 
or
 
more
 
CNS
 
active
 
agents
 
in
 
any
 
combination
 
due
 
to
 
increased
 
risk
 
of
 
falls
 
Paediatric
 
 
 
 
1.
 
Safety
 
and
 
efficacy
 
of
 
Methadone
 
in
 
paediatric
 
patients
 
under
 
18
 
years
 
old
 
have
 
not
 
been
 
established
 
in
 
d
etoxification
 
or
 
maintenance
 
treatment
 
of
 
narcotic
 
addiction.
 
 
 
 
 
Fasting
 
 
 
 
1.
 
Patient
 
is
 
advised
 
to
 
drink
 
during
 
pre-dawn
 
meal
 
(sahur)
 
 
 
 
 
Others
 
 
 
 
 
Hepatic
 
Impairment
 
 
Close
 
dose
 
monitoring
 
required
 
for
 
patient
 
with
 
hepatic
 
impairment
 
 
Vomited
 
dose
 
 
1.
 
If
 
a
 
patient
 
vomits
 
the
 
given
 
dose:
 
●
 
Less
 
than
 
15
 
minutes
 
after
 
taking
 
the
 
dose:
 
replace
 
the
 
full
 
dose
 
●
 
Between
 
15
 
minutes
 
to
 
30
 
minutes
 
after
 
taking
 
the
 
dose:
 
replace
 
50%
 
of
 
the
 
dose
 
●
 
If
 
vomiting
 
occurs
 
more
 
than
 
30
 
minutes
 
after
 
taking
 
the
 
dose:
 
no
 
replacement
 
dose
 
 
 
 
 
Side
 
Effects
 
and
 
their
 
Management*
 
Drowsiness
 
1.
 
Cause:
 
overdose,
 
concomitant
 
substance
 
use
 
(benzodiazepine,
 
alcohol,
 
CNS
 
depressants)
 
 
2.
 
Plan:
 
 
a.
 
Inform
 
your
 
doctor
 
or
 
pharmacist.
 
b.
 
Avoid
 
driving
 
a
 
vehicle
 
or
 
operating
 
machinery
 
for
 
at
 
least
 
the
 
first
 
two
 
weeks
 
 
Nausea,
 
vomiting
 
and
 
loss
 
of
 
appetite
 
1.
 
Cause:
  
methadone
 
syrup
 
2.
 
Plan:
 
Avoid
 
taking
 
on
 
an
 
empty
 
stomach
 
 
Craving
 
towards
 
heroin
 
1.
 
Cause:
 
insuf ficient
 
dose
 
2.
 
Plan:
 
Inform
 
your
 
doctor
 
or
 
pharmacist
 
 
Increase
 
in
 
body
 
weight
 
 
1.
 
Cause:
 
water
 
retention
 
in
 
body
 
2.
 
Plan:
 
 
○
 
Inform
 
your
 
doctor
 
or
 
pharmacist
 
for
 
dose
 
review
 
 
○
 
Healthy
 
lifestyle
 
&
 
diet
 
adjustment
 
 
 
Constipation
 
1.
 
Cause:
 
methadone
 
syrup,
 
unhealthy
 
diet
 
&
 
lifestyle
 
 
2.
 
Plan:
 
 
○
 
Inform
 
your
 
doctor
 
or
 
pharmacist
 
for
 
dose
 
 
 
 
244
 

=== PAGE 246 ===

 
review
 
 
○
 
Healthy
 
lifestyle
 
&
 
diet
 
adjustment
 
○
 
Medication
 
for
 
constipation
 
 
 
Insomnia
 
 
1.
 
Cause:
 
underdose
 
or
 
overdose,
 
time
 
of
 
methadone
 
consumption,
 
concomitant
 
substance
 
use
 
(stimulants)
 
2.
 
Plan:
 
 
○
 
Adjust
 
methadone
 
dose
 
and
 
time
 
of
 
methadone
 
consumption
 
 
○
 
Sleep
 
hygiene
 
○
 
Identify
 
&
 
advise
 
on
 
concomitant
 
substance
 
use
 
 
 
Dental
 
issues
 
1.
 
Cause:
 
methadone
 
syrup
 
reduces
 
saliva
 
production,
 
inappropriate
 
dental
 
care
 
2.
 
Plan:
 
increase
 
awareness
 
of
 
oral
 
hygiene
 
 
 
Decrease
 
in
 
libido
 
&
 
sexual
 
function
 
 
1.
 
Cause:
 
high
 
methadone
 
dose,
 
psychological
 
&
 
personal
 
issues
 
2.
 
Plan:
 
 
○
 
Discuss
 
with
 
doctor
 
or
 
pharmacist
 
for
 
dose
 
review
 
 
○
 
Seek
 
advice
 
from
 
counselor
 
 
 
Lethargy
 
1.
 
Cause:
 
environmental
 
factor ,
 
overdose
 
 
2.
 
Plan:
 
 
○
 
Discuss
 
with
 
doctor
 
or
 
pharmacist
 
 
○
 
Enough
 
rest
 
 
 
Excess
 
perspiration
 
 
1.
 
Cause:
 
overdose
 
2.
 
Plan:
 
 
○
 
Wear
 
clothing
 
that
 
is
 
not
 
too
 
thick
 
○
 
Discuss
 
with
 
doctor
 
or
 
pharmacist
 
 
 
Bruised
 
and
 
itchy
 
skin
 
 
1.
 
Cause:
 
methadone
 
syrup
 
2.
 
Plan:
 
Inform
 
your
 
doctor
 
or
 
pharmacist
 
 
Tachycardia
 
/
 
Bradycardia
 
1.
 
Cause:
 
overdose
 
2.
 
Plan:
 
Seek
 
medical
 
treatment
 
 
Breathing
 
difficulties
 
1.
 
Cause:
 
overdose
 
2.
 
Plan:
 
Seek
 
medical
 
treatment
 
Storage*
 
Methadone
 
syrup
 
that
 
is
 
taken
 
home
 
must
 
be
 
stored:
 
1.
 
In
 
a
 
safe
 
place
 
(in
 
a
 
high,
 
locked
 
cabinet
 
or
 
drawer)
 
and
 
out
 
of
 
reach
 
of
 
children.
 
2.
 
At
 
room
 
temperature
 
(in
 
a
 
dry
 
place
 
and
 
not
 
hot),
 
and
 
not
 
in
 
the
 
refrigerator .
 
3.
 
Do
 
not
 
store
 
with
 
other
 
food
 
or
 
medications
 
4.
 
Avoid
 
exposure
 
to
 
sunlight
 
5.
 
Use
 
a
 
sling
 
bag
 
or
 
pouch
 
to
 
store
 
the
 
newly
 
obtained
 
takeaway
 
doses
 
temporarily
 
6.
 
Do
 
not
 
transfer
 
takeaway
 
doses
  
into
 
unlabelled
 
containers
 
as
 
it
 
could
 
cause
 
confusion
 
 
 
 
 
245
 

=== PAGE 247 ===

 
Others
 
Drug-drug
 
interaction
 
 
●
 
Alcohol
:
 
Alcohol
 
increases
 
the
 
effect
 
of
 
Methadone.
 
It
 
is
 
advised
 
to
 
avoid
 
alcohol
 
consumption
 
●
 
Antiepileptics
 
 
○
 
Phenytoin:
 
decrease
 
the
 
effect
 
of
 
Methadone.
 
To
 
overcome
 
this,
 
Methadone
 
dose
 
may
 
need
 
to
 
be
 
increased
 
or
 
divided.
 
○
 
Carbamazepine:
 
decrease
 
the
 
effect
 
of
 
methadone
 
●
 
Antifungal
 
(e.g.
 
Fluconazole):
 
QT
 
prolongation
 
●
 
Antipsychotic
 
-
 
Typical
 
○
 
Haloperidol:
 
QT
 
prolongation
 
○
 
Chlorpromazine:
 
QT
 
prolongation
 
●
 
Antipsychotic
 
-
 
Atypical
 
 
○
 
Aripiprazole:
 
CNS
 
depressant
 
○
 
Amisulpride:
 
QT
 
prolongation
 
○
 
Clozapine:
 
QT
 
prolongation
 
○
 
Olanzapine:
 
CNS
 
depressant
 
○
 
Paliperidone:
 
QT
 
prolongation
 
○
 
Risperidone:
 
QT
 
prolongation
 
○
 
Quetiapine:
 
QT
 
prolongation
 
 
●
 
Antituberculosis
 
○
 
Isoniazid:
 
Increase
 
plasma
 
level
 
of
 
methadone
 
○
 
Rifampicin:
 
Decreases
 
the
 
effect
 
of
 
Methadone
 
●
 
Benzodiazepines
:
 
Benzodiazepines
 
increase
 
the
 
effect
 
of
 
Methadone.
 
Use
 
of
 
benzodiazepines
 
should
 
be
 
limited.
 
●
 
Ciprofloxacin
:
 
Ciprofloxacin
 
increases
 
the
 
effect
 
of
 
Methadone.
 
Methadone
 
dose
 
may
 
need
 
to
 
be
 
reduced.
 
●
 
Highly
 
Active
 
Antiretroviral
 
Therapy
 
(HAAR T):
 
○
 
Efavirenz:
 
Efavirenz
 
decreases
 
the
 
effect
 
of
 
Methadone.
 
Methadone
 
dose
 
may
 
need
 
to
 
be
 
increased
 
or
 
divided.
 
○
 
Zidovudine:
 
Zidovudine
 
has
 
no
 
significant
 
effect
 
on
 
Methadone,
 
but
 
it
 
may
 
increase
 
zidovudine
 
levels.
 
The
 
Zidovudine
 
dose
 
may
 
need
 
to
 
be
 
reduced.
 
●
 
Nicotine
:
 
Nicotine
 
decreases
 
the
 
effect
 
of
 
Methadone.
 
It
 
is
 
advised
 
to
 
encourage
 
the
 
patient
 
to
 
stop
 
smoking.
 
●
 
Neuropathic
 
agent
 
 
○
 
Gabapentin:
 
CNS
 
depressant
 
○
 
Pregabalin:
 
CNS
 
depressant
 
●
 
Opiod
 
○
 
Buprenorphine:
 
QT
 
prolongation
 
○
 
Codein:
 
CNS
 
depressant
 
○
 
Morphine:
 
CNS
 
depressant
 
●
 
Selective
 
Norepinephrine
 
Reuptake
 
Inhibitor
 
(SNRI)
 
○
 
Duloxetine:
 
Increase
 
plasma
 
level
 
of
 
methadone
 
○
 
Venlafaxine:
 
CNS
 
depressant
 
●
 
Selective
 
Serotonin
 
Reuptake
 
Inhibitor
 
Sertraline
 
(SSRI)
 
○
 
Escitalopram:
 
QT
 
prolongation
 
○
 
Fluoxetine:
 
QT
 
prolongation
 
and
 
increases
 
the
 
effect
 
of
 
Methadone.
 
It
 
is
 
recommended
 
to
 
switch
 
to
 
another
 
SSRI
 
○
 
Fluvoxamine:
 
Increases
 
the
 
effect
 
of
 
Methadone.
 
It
 
is
 
recommended
 
to
 
switch
 
to
 
another
 
SSRI.
 
○
 
Sertraline:
 
QT
 
prolongation
 
●
 
Tricyclic
 
Antidepressants
 
(e.g.
 
Amitriptyline):
 
Increase
 
the
 
effect
 
of
 
Methadone.
 
●
 
Urine
 
acidifiers
 
(e.g.,
 
Ascorbic
 
Acid):
 
Urine
 
acidifiers
 
decrease
 
the
 
effect
 
of
 
Methadone.
 
 
●
 
Urine
 
alkalinizers
 
(e.g.,
 
Sodium
 
Bicarbonate):
 
Urine
 
 
 
 
246
 

=== PAGE 248 ===

 
alkalinizers
 
increase
 
the
 
effect
 
of
 
Methadone.
 
 
Do
 
not
 
take
 
over-the-counter
 
(OTC)
 
medications
 
for
 
cough,
 
cold,
 
or
 
pain
 
relief
 
during
 
methadone
 
treatment
 
without
 
consulting
 
a
 
doctor
 
first.
 
These
 
medications
 
may
 
contain
 
alcohol
 
or
 
narcotic
 
substances
 
that
 
could
 
harm
 
condition
 
or
 
affect
 
urine
 
drug
 
test
 
results
 
 
Drug-food
 
Interaction
 
 
Grapefruit
:
 
Increased
 
serum
 
concentration
 
 
St
 
John’ s
 
Wort
:
 
Decreased
 
serum
 
plasma
 
concentration
 
with
 
 
Overdose
 
Overdose
 
can
 
occur
 
when
 
more
 
than
 
one
 
drug
 
(or
 
a
 
combination
 
of
 
drugs)
 
is
 
taken
 
excessively
 
into
 
the
 
body
 
and
 
can
 
be
 
fatal.
 
 
Symptoms
 
of
 
overdose
 
include:
 
1.
 
Pinpoint
 
pupils
 
2.
 
Nausea
 
3.
 
Dizziness
 
4.
 
Excessive
 
sweating
 
5.
 
Sleepiness
 
(nodding
 
off)
 
6.
 
Slurred
 
speech
 
7.
 
Unsteady
 
gait,
 
 
8.
 
Snoring
 
9.
 
Low
 
blood
 
pressure
 
10.
 
Slow
 
pulse
 
(bradycardia)
 
11.
 
Shallow
 
breathing
 
(hypoventilation)
 
12.
 
Frothing
 
at
 
the
 
mouth
 
13.
 
Coma
 
Types
 
of
 
Substances/Drugs
 
involved:
 
●
 
Depressant
 
Drugs
 
(reduce
 
nervous
 
system
 
activity):
 
1.
 
Heroin
 
2.
 
Morphine
 
3.
 
Methadone
 
4.
 
Sleeping
 
pills
 
5.
 
Benzodiazepines
 
(e.g.,
 
diazepam),
 
alcohol
 
Depressant
 
drugs
 
work
 
by
 
reducing
 
nervous
 
system
 
activity
 
to
 
dangerous
 
levels,
 
which
 
can
 
cause
 
the
 
patient
 
to
 
stop
 
breathing.
 
●
 
Stimulant
 
Drugs
 
(accelerate
 
nervous
 
system
 
activity):
 
1.
 
Amphetamines
 
2.
 
Ecstasy
 
3.
 
Caffeine
 
4.
 
Nicotine
 
Stimulant
 
drugs
 
work
 
by
 
accelerating
 
body
 
activity
 
and
 
can
 
cause
 
increased
 
blood
 
pressure,
 
increased
 
heart
 
rate,
 
and
 
raised
 
body
 
temperature.
 
Factors
 
that
 
influence
 
the
 
effects
 
of
 
drugs
 
on
 
an
 
individual:
 
1.
 
Tolerance
 
to
 
the
 
drug:
 
for
 
example,
 
how
 
sensitive
 
a
 
person’ s
 
body
 
is
 
to
 
the
 
drug
 
and
 
how
 
frequently
 
the
 
drug
 
is
 
used.
 
2.
 
Quantity
 
of
 
the
 
drug
 
taken
 
3.
 
Mixing
 
with
 
other
 
drugs,
 
such
 
as
 
any
 
medication
 
that
 
may
 
have
 
been
 
taken
 
and
 
is
 
still
 
present
 
in
 
the
 
system.
 
4.
 
Method
 
of
 
taking
 
the
 
drug,
 
such
 
as
 
injecting,
 
swallowing,
 
 
 
 
247
 

=== PAGE 249 ===

 
or
 
inhaling.
 
Injecting
 
Methadone
 
can
 
pose
 
serious
 
health
 
risks.
 
It
 
can
 
increase
 
the
 
risk
 
of
 
overdose
 
and
 
can
 
cause
 
blood
 
clots,
 
narrowing
 
of
 
blood
 
vessels,
 
and
 
other
 
complications.
 
Toxicity
 
management:
 
IV
 
Naloxone
 
0.4-2mg
 
should
 
be
 
administered
 
every
 
2-3
 
minutes,
 
depending
 
on
 
the
 
patient's
 
needs
 
Special
 
Monitoring
 
Parameter:
 
1.
 
Urine
 
drug
 
screening
 
test
 
2.
 
Liver
 
function
 
test
 
3.
 
Electrocardiogram
 
 
4.
 
CNS
 
status
 
5.
 
Respiratory
 
status
 
 
 
 
 
Withdrawal
 
Symptoms
 
 
Three
 
or
 
more
 
of
 
the
 
following
 
effects
 
may
 
occur
 
within
 
minutes
 
or
 
days
 
after
 
stopping
 
or
 
reducing
 
the
 
dose/usage
 
of
 
opioids
 
that
 
have
 
been
 
taken
 
for
 
several
 
weeks
 
or
 
more.
 
If
 
someone
 
experiences
 
an
 
overdose
 
with
 
heroin,
 
Methadone,
 
or
 
other
 
opioids,
 
IV
 
Naloxone
 
0.4-2mg
 
every
 
2-3
 
minutes
 
should
 
be
 
administered
 
depending
 
on
 
the
 
patient’ s
 
needs.
 
Some
 
withdrawal
 
symptoms
 
include:
 
1.
 
Dysphoria
 
2.
 
Nausea
 
and
 
vomiting
 
3.
 
Muscle
 
aches
 
4.
 
Runny
 
nose
 
and
 
watery
 
eyes
 
5.
 
Pupillary
 
dilation
 
(enlarged
 
pupils)
 
6.
 
Diarrhea
 
7.
 
Excessive
 
yawning
 
8.
 
Fever
 
9.
 
Insomnia
 
 
 
 
Self-care
 
for
 
patients
 
 
1.
 
Do
 
not
 
give
 
methadone
 
syrup
 
to
 
others
 
as
 
it
 
is
 
very
 
dangerous
 
and
 
can
 
cause
 
accidental
 
drug
 
overdose.
 
2.
 
 
Do
 
not
 
inject
 
methadone
 
syrup
 
as
 
it
 
can
 
cause
 
dangerous
 
complications.
 
3.
 
Please
 
visit
 
your
 
dentist
 
at
 
least
 
twice
 
a
 
year
 
for
 
a
 
dental
 
check-up.
 
4.
 
Drink
 
at
 
least
 
2
 
liters
 
of
 
water
 
a
 
day
 
(about
 
8
 
glasses).
 
5.
 
Engage
 
in
 
regular
 
exercise.
 
6.
 
Eat
 
a
 
balanced
 
diet.
 
7.
 
Maintain
 
personal
 
hygiene.
 
8.
 
Engage
 
in
 
religious
 
activities
 
to
 
find
 
inner
 
peace.
 
 
 
 
248
 

=== PAGE 250 ===

 
Before
 
ending
 
this
 
peer
 
review
 
session,
 
the
 
reviewee
 
should
 
be
 
informed
 
of
 
the
 
step(s)
 
that
 
he/
 
she
 
missed
 
out
 
in
 
order
 
to
 
ensure
 
all
 
the
 
counselling
 
points
 
are
 
being
 
covered.
 
 
Remarks:
 
 
 
 
 
Reviewed
 
by:
 
Name
 
&
 
Signature
                                                                   
Date:
 
 
 
 
 
*Mandatory
 
for
 
validation
 
/
 
peer
 
review
 
 
References:
 
 
1.
 
American
 
Society
 
of
 
Addiction
 
Medicine.
 
(2020).
 
The
 
ASAM
 
National
 
Practice
 
Guideline
 
for
 
the
 
Treatment
 
of
 
Opioid
 
Use
 
Disorder:
 
2020
 
Focused
 
Update.
 
Journal
 
of
 
Addiction
 
Medicine,
 
14(2S
 
Suppl
 
1),
 
1-91.
 
https://doi.org/10.1097/ADM.0000000000000660
 
2.
 
American
 
Geriatrics
 
Society
 
Beers
 
Criteria®
 
Update
 
Expert
 
Panel.
 
(2023).
 
American
 
Geriatrics
 
Society
 
2023
 
updated
 
AGS
 
Beers
 
Criteria®
 
for
 
potentially
 
inappropriate
 
medication
 
use
 
in
 
older
 
adults.
 
Journal
 
of
 
the
 
American
 
Geriatrics
 
Society ,
 
71
(7),
 
2052–2081.
 
https://doi.org/10.1 111/jgs.17777
 
3.
 
Benmebarek,
 
M.,
 
Devaud,
 
C.,
 
Gex-Fabry ,
 
M.,
 
Powell,
 
K.,
 
Brogli,
 
C.,
 
Baumann,
 
P.,
 
Gravier ,
 
B.,
 
Eap,
 
C.B.
 
Effects
 
of
 
grapefruit
 
juice
 
on
 
the
 
pharmacokinetics
 
of
 
the
 
enantiomers
 
of
 
methadone.Clin
 
Pharmacol
 
Ther.
 
2004
 
Jul;76(1):55-63.
 
doi:
 
10.1016/j.clpt.2004.03.007.
 
PMID:
 
15229464.
 
4.
 
Garis
 
Panduan
 
Pendispensan
 
Methadone,
 
2010
 
5.
 
Hudak,
 
M.
 
L.,
 
Tan,
 
R.
 
C.,
 
Committee
 
on
 
Drugs,
 
&
 
Committee
 
on
 
Fetus
 
and
 
Newborn.
 
(2012).
 
Neonatal
 
drug
 
withdrawal.
 
Pediatrics,
 
129
(2),
 
e540–e560.
 
https://doi.org/10.1542/peds.201 1-3212
 
6.
 
Polisi
 
dan
 
Prosedur
 
Operasi
 
Piawai
 
Program
 
Rawatan
 
Methadone,
 
May
 
2016
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
249
 

=== PAGE 251 ===

 
Methoxy
 
Polyethylene-glycol
 
Epoetin
 
Beta
 
Name
 
:
 
 
Unit
 
:
 
 
●
 
Please
 
tick
 
(
✔
)
 
Yes
 
for
 
correct
 
instruction.
 
●
 
Please
 
tick
 
(
✔
)
 
No
 
for
 
incorrect
 
instruction.
 
Yes
 
No
 
Remarks
 
Pharmacological
 
Group
 
Other
 
antianemic
 
preparations
 
methoxy
 
polyethylene
 
glycol-epoetin
 
beta
 
 
 
 
 
Indications
 
and
 
Dosage
 
1.
 
Treatment
 
of
 
anaemia
 
associated
 
with
 
chronic
 
kidney
 
failure.Patients
 
who
 
require
 
higher
 
doses
 
of
 
erythropoietin
 
if
 
it
 
is
 
more
 
cost
 
saving
 
to
 
use
 
a
 
long-acting
 
agent
 
instead
 
of
 
short-acting
 
agents.
 
a.CKD
 
ON
 
dialysis:
 
 
IV/SC:
 
0.6
 
mcg/kg
 
once
 
every
 
2
 
weeks
 
b.CKD
 
NOT
 
on
 
dialysis:
 
SC:
  
0.6
 
mcg/kg
 
once
 
every
 
2
 
weeks
 
or
 
1.2
 
mcg/kg
 
once
 
monthly
 
 
Dosing
 
is
 
according
 
to
 
product
 
insert
 
 
To
 
counsel
 
based
 
on
 
specific
 
medication’ s
 
indication
 
and
 
dosage
 
as
 
prescribed
 
by
 
the
 
doctor
 
 
 
 
Method
 
of
 
Administration*
 
Route
 
of
 
Administration:
 
Intravenous
 
(IV)
 
or
 
Subcutaneous
 
(SC)
 
 
Site
 
of
 
administration
 
for
 
SC:
 
Lower
 
part
 
of
 
abdomen,
 
thigh
 
or
 
arm
 
 
Injection
 
technique
 
for
 
SC
 
(for
 
self-administered):
 
1.
 
Take
 
one
 
syringe
 
out
 
of
 
the
 
package
 
and
 
check
 
that
 
the
 
solution
 
is
 
clear ,
 
colourless
 
and
 
free
 
from
 
visible
 
particles
.
 
2.
 
Allow
 
the
 
syringe
 
to
 
reach
 
room
 
temperature.
 
3.
 
Wash
 
your
 
hands.
 
4.
 
Holding
 
the
 
syringe
 
by
 
the
 
middle
 
of
 
the
 
body
 
without
 
touching
 
the
 
release
 
clip
 
to
 
avoid
 
premature
 
release
 
of
 
the
 
safety
 
device.
 
5.
 
Remove
 
the
 
rubber
 
tip
 
cap
 
from
 
the
 
syringe
 
(bend
 
and
 
pull).
 
6.
 
Break
 
the
 
seal
 
of
 
the
 
needle,
 
using
 
a
 
twisting
 
motion,
 
and
 
remove
 
the
 
needle
 
cap.
 
Do
 
not
 
remove
 
the
 
needle
 
shield
 
that
 
protects
 
the
 
needle.
 
 
7.
 
Attach
 
the
 
needle
 
to
 
the
 
syringe
 
by
 
pushing
 
it
 
firmly
 
on
 
the
 
syringe
 
by
 
twisting
 
it.
 
Pull
 
off
 
the
 
needle
 
shield
 
and
 
throw
 
it
 
away .
 
 
8.
 
Hold
 
the
 
syringe
 
with
 
the
 
needle
 
pointing
 
up
 
and
 
tap
 
the
 
syringe
 
gently
 
to
 
bring
 
any
 
bubble
 
to
 
the
 
top.
 
Push
 
the
 
plunger
 
up
 
slowly
 
to
 
remove
 
the
 
air.
 
 
9.
 
Clean
 
the
 
skin
 
at
 
the
 
site
 
of
 
injection
 
using
 
an
 
alcohol
 
swab.
 
10.
 
Pinch
 
a
 
fold
 
of
 
loose
 
skin
 
at
 
the
 
clean
 
injection
 
site.
 
11.
 
Fully
 
insert
 
the
 
needle
 
90
0
 
 
angle
 
into
 
the
 
skin
 
in
 
a
 
quick,
 
‘’dart-like’ ’
 
motion.
 
Once
 
the
 
neddle
 
is
 
inserted,
 
release
 
the
 
pinch.
 
12.
 
Slowly
 
push
 
the
 
plunger
 
until
 
all
 
the
 
medicine
 
is
 
injected.
 
The
 
plunger
 
rod
 
should
 
be
 
fully
 
pushed
 
down
 
until
 
hear
 
a
 
click
 
indicating
 
the
 
activation
 
of
 
the
 
needle
 
guard.
 
Do
 
not
 
release
 
the
 
plunger
 
before
 
the
 
end
 
of
 
injection.
 
 
13.
 
Take
 
the
 
needle
 
out
 
of
 
the
 
skin
 
without
 
releasing
 
the
 
plunger .
 
 
 
 
250
 

=== PAGE 252 ===

 
14.
 
Once
 
the
 
needle
 
is
 
fully
 
out,
 
release
 
the
 
plunger
 
to
 
activate
 
the
 
needle
 
guard.
 
15.
 
Dispose
 
the
 
empty
 
syringe
 
in
 
a
 
special
 
waste
 
container .
 
16.
 
Tear
 
off
 
the
 
medication
 
label
 
on
 
the
 
syringe
 
and
 
stick
 
into
 
the
 
booklet/diary
 
(e.g.,
 
CAPD
 
book)
 
after
 
the
 
injection
 
for
 
the
 
administration
 
record,
 
if
 
available.
 
 
Consideration:
 
1.
 
Blood
 
pressure
 
(BP)
 
cutof f
 
for
 
administering
 
Erythropoietin
 
Stimulating
 
Agent
 
(ESA)
 
is
 
individualised.
 
Generally ,
 
ESA
 
is
 
not
 
given
 
if
 
BP
 
exceeds
 
160/100
 
mmHg.
 
Patients
 
need
 
to
 
be
 
informed
 
about
 
their
 
specific
 
BP
 
cutof f
 
whether
 
to
 
continue
 
or
 
hold
 
ESA
 
at
 
home.
 
2.
 
The
 
site
 
of
 
SC
 
injection
 
should
 
be
 
rotated
 
if
 
necessary .
 
 
Missed
 
dose
 
management:
 
The
 
missed
 
dose
 
should
 
be
 
administered
 
as
 
soon
 
as
 
possible
 
and
 
administration
 
of
 
MIRCERA
 
is
 
to
 
be
 
restarted
 
at
 
the
 
prescribed
 
dosing
 
frequency ..
 
 
Do
 
not
 
stop
 
taking
 
your
 
medication
 
unless
 
advised
 
to
 
do
 
so
 
by
 
your
 
prescriber
 
Special
 
Considerations
 
 
Pregnancy
 
 
 
 
No
 
adequate
 
data
 
on
 
the
 
use
 
of
 
MIRCERA
 
in
 
pregnant
 
women
 
 
 
 
Breastfeeding
 
 
 
 
Unknown
 
 
 
 
 
Elderly
 
 
 
 
Dose
 
selection
 
for
 
an
 
elderly
 
patient
 
should
 
be
 
cautious,
 
usually
 
starting
 
at
 
the
 
low
 
end
 
of
 
the
 
dosing
 
range
 
 
 
 
Paediatric
 
 
 
 
MIRCERA
 
can
 
be
 
used
 
in
 
children
 
from
 
3
 
months
 
to
 
17
 
years
 
old
 
if
 
the
 
patient's
 
hemoglobin
 
is
 
already
 
stabilized
 
on
 
either
 
epoetin
 
or
 
darbepoetin.
 
 
 
 
Fasting
 
 
 
 
Administer
 
MIRCERA
 
as
 
usual
 
 
 
 
Others
 
 
 
 
 
No
 
dosage
 
adjustment
 
was
 
provided
 
in
 
the
 
manufacturer ’s
 
labelling.
 
 
 
 
Side
 
Effects
 
and
 
their
 
Management*
 
Common
 
side
 
effects,
 
generally
 
not
 
serious:
 
Headache,
 
increased
 
blood
 
pressure,
 
irritation
 
or
 
pain
 
at
 
the
 
injection
 
site.
 
 
Note:
 
●
 
To
 
advise
 
patients
 
on
 
the
 
importance
 
of
 
compliance
 
with
 
antihypertensive
 
medications
 
and
 
dietary
 
restrictions
 
for
 
BP
 
control.
 
●
 
If
 
side
 
effects
 
persist,
 
please
 
consult
 
a
 
healthcare
 
professional
 
 
Uncommon/rare:
 
 
 
 
251
 

=== PAGE 253 ===

 
Pure
 
red
 
cell
 
aplasia
 
(PRCA).
 
Storage*
 
1.
 
Transport
 
of
 
ESA
 
is
 
only
 
allowed
 
in
 
cool
 
box
 
with
 
ice
 
packs.
 
2.
 
Preferably
 
to
 
return
 
home
 
immediately
 
after
 
getting
 
ESA
 
from
 
the
 
pharmacy
 
to
 
facilitate
 
fast
 
storage.
 
3.
 
ESA
 
is
 
very
 
sensitive
 
to
 
light
 
and
 
temperature.
 
4.
 
Protect
 
ESA
 
from
 
light
 
5.
 
Store
 
ESA
 
in
 
the
 
refrigerator ,
 
do
 
not
 
freeze.
 
Keep
 
at
 
2-8°C.
 
 
6.
 
Avoid
 
fridge
 
doors,
 
and
 
vegetable
 
compartments.
 
Ensure
 
there
 
is
 
proper
 
air
 
circulation
 
around
 
your
 
ESA.
 
7.
 
If
 
you're
 
travelling,
 
try
 
to
 
keep
 
your
 
medication
 
in
 
a
 
cooler
 
with
 
ice
 
packs,
 
and
 
avoid
 
storing
 
it
 
in
 
any
 
place
 
where
 
it
 
might
 
get
 
too
 
hot,
 
like
 
in
 
a
 
car.
 
 
Do
 
not
 
take
 
out
 
the
 
ESA
 
from
 
the
 
fridge
 
unless
 
it
 
is
 
time
 
for
 
use.
 
If
 
the
 
ESA
 
is
 
accidentally
 
left
 
outside
 
the
 
fridge,
 
it
 
should
 
be
 
used
 
as
 
soon
 
as
 
possible
 
to
 
prevent
 
damage.
 
Below
 
is
 
the
 
expiry
 
period
 
following
 
a
 
break
 
in
 
the
 
cold
 
chain:
 
 
Product
 
Expiry
 
period
 
after
 
break
 
of
 
cold
 
chain
 
Mircera
 
30
 
Days
 
 
 
Handling
 
of
 
disposal:
 
●
 
Needles
 
and
 
syringes
 
should
 
never
 
be
 
reused.
  
 
●
 
Place
 
all
 
used
 
needles
 
and
 
syringes
 
into
 
a
 
sharps
 
container
 
(puncture-proof
 
disposable
 
container).
 
●
 
Keep
 
the
 
sharp
 
container
 
out
 
of
 
the
 
reach
 
of
 
children.
  
 
●
 
Avoid
 
disposing
 
of
 
used
 
sharps
 
containers
 
in
 
household
 
waste.
 
●
 
Dispose
 
of
 
full
 
sharps
 
containers
 
according
 
to
 
local
 
regulations
 
or
 
at
 
designated
 
facilities.
 
 
 
 
Others
 
Precautions:
 
1.
 
Hypertension.
 
2.
 
Cardiovascular
 
disease
 
including
 
recent
 
myocardia
 
infarction
 
(MI)
 
and
 
venous
 
thromboembolism
 
3.
 
Malignant
 
disease
 
4.
 
Patients
 
with
 
epilepsy ,
 
history
 
of
 
seizures,
 
or
 
medical
 
conditions
 
associated
 
with
 
a
 
predisposition
 
to
 
seizure
 
activity
 
such
 
as
 
CNS
 
infections
 
and
 
brain
 
metastases.
 
 
Monitoring
 
parameters:
 
1.
 
Blood
 
pressure
 
particularly
 
at
 
the
 
start
 
of
 
therapy
 
2.
 
Monitor
 
haemoglobin
 
at
 
least
 
monthly
 
during
 
the
 
initiation
 
phase.
 
 
3.
 
Monitor
 
iron
 
status
 
at
 
least
 
every
 
3
 
months
 
during
 
ESA
 
therapy .
 
 
Contraindications
 
:
 
1.
 
Known
 
hypersensitivity
 
to
 
the
 
active
 
substance
 
or
 
to
 
any
 
of
 
the
 
excipients
 
2.
 
Uncontrolled
 
hypertension.
 
3.
 
Pure
 
red
 
cell
 
aplasia
 
(PRCA)
 
that
 
begins
 
after
 
treatment
 
with
 
other
 
erythropoietin
 
stimulating
 
agents
 
(ESAs).
 
 
 
 
 
 
252
 

=== PAGE 254 ===

 
Before
 
ending
 
this
 
peer
 
review
 
session,
 
the
 
reviewee
 
should
 
be
 
informed
 
of
 
the
 
step(s)
 
that
 
he/
 
she
 
missed
 
out
 
in
 
order
 
to
 
ensure
 
all
 
the
 
counselling
 
points
 
are
 
being
 
covered.
 
 
Remarks:
 
 
 
 
 
Reviewed
 
by:
 
Name
 
&
 
Signature
                                                                   
Date:
 
 
 
 
 
*Mandatory
 
for
 
validation
 
/
 
peer
 
review
 
References:
 
 
1.
 
Formulari
 
Ubat
 
KKM.
 
(2025,
 
January
 
1).
 
Accessed
 
on
 
January
 
1,
 
2025.
 
 
2.
 
Kidney
 
Disease:
 
Improving
 
Global
 
Outcomes
 
(KDIGO)
 
Anemia
 
Work
 
Group.
 
(2012).
 
KDIGO
 
clinical
 
practice
 
guideline
 
for
 
anemia
 
in
 
chronic
 
kidney
 
disease.
 
Kidney
 
International
 
Supplements,
 
2(4),
 
279–335.
 
3.
 
Roche
 
(2024).
 
Product
 
information
 
leaflet:
 
Mircera®
.
 
Retrieved
 
from
 
Quest
 
3+
 
Product
 
Search
 
on
 
January
 
1,
 
2025.
 
4.
 
Bahagian
 
Perkhidmatan
 
Farmasi,
 
Kementerian
 
Kesihatan
 
Malaysia.
 
(2016).
 
Garis
 
panduan
 
pemantauan
 
keselamatan
 
produk
 
erythropoietin
 
stimulating
 
agents
 
(ESAs)
 
dan
 
pelaporan
 
kesan
 
advers
 
pure
 
red
 
cell
 
aplasia
 
(PRCA).
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
253
 

=== PAGE 255 ===

 
Methylphenidate
 
 
 
Unit
 
:
 
 
●
 
Please
 
tick
 
(
✔
)
 
Yes
 
for
 
correct
 
instruction.
 
●
 
Please
 
tick
 
(
✔
)
 
No
 
for
 
incorrect
 
instruction.
 
Yes
 
No
 
Remarks
 
Pharmacological
 
Group
 
Centrally
 
acting
 
sympathomimetics
 
 
 
 
 
Indications
 
and
 
Dosage
 
Indication:
 
Attention
 
deficit
 
hyperactivity
 
disorder
 
(ADHD)
 
Dosage:
 
1.
 
Immediate-release
 
Tablet
 
(Ritalin
):
 
Children
 
&
 
adolescent
 
≥
 
6
 
years
 
old
 
Initially
 
5
 
mg
 
OD
 
or
 
BD
 
with
 
5
 
or
 
10
 
mg
 
gradual
 
increments
 
weekly .
 
Max:
 
60
 
mg
 
daily.
 
2.
 
Modified-release
 
Capsule
 
(Ritalin
 
LA
):
 
Adult
 
Initially
 
20
 
mg
 
od.
 
Max:
 
80
 
mg
 
daily.
 
Treatment
 
in
 
adults
 
should
 
only
 
use
 
Ritalin
 
LA
 
formulation.
 
3.
 
Extended-release
 
Tablet
 
(Concerta)
:
 
Patient
 
new
 
to
 
methylphenidate
:
 
Children
 
&
 
adolescents
 
18
 
mg
 
OD
 
 
Adult
 
18
 
or
 
36
 
mg
 
OD
 
 
Patients
 
currently
 
using
 
methylphenidate
 
18-72
 
mg
 
OD
 
depending
 
on
 
previous
 
methylphenidate
 
daily
 
dose.
 
May
 
be
 
adjusted
 
in
 
18
 
mg
 
increments
 
at
 
weekly
 
intervals.
 
Max:
 
54
 
mg
 
daily
 
(Children)
 
and
 
72
 
mg
 
daily
 
(Adolescent)
 
 
Or
 
To
 
counsel
 
based
 
on
 
specific
 
medication’ s
 
indication
 
and
 
dosage
 
as
 
prescribed
 
by
 
the
 
doctor
 
 
 
 
Method
 
of
 
Administration*
 
1.
 
Immediate-release
 
Tablet
 
(Ritalin)
:
 
 
a.
 
May
 
be
 
taken
 
with
 
or
 
without
 
food.
 
The
 
rate
 
of
 
absorption
 
is
 
faster
 
when
 
taken
 
with
 
food.
 
Take
 
consistently
 
either
 
always
 
with
 
or
 
always
 
without
 
food.
 
 
b.
 
If
 
given
 
twice
 
daily,
 
doses
 
should
 
be
 
taken
 
at
 
breakfast
 
and
 
lunch
 
(second
 
dose
 
should
 
not
 
be
 
later
 
than
 
6pm)
 
c.
 
Only
 
immediate
 
release
 
formulation
 
can
 
be
 
crushed
 
or
 
chewed.
 
2.
 
Modified-release
 
Capsule
 
(Ritalin
 
LA)
:
 
May
 
be
 
swallowed
 
whole.
 
Alternatively ,
 
carefully
 
open
 
capsule
 
&
 
sprinkle
 
contents
 
over
 
room
 
temperature
 
soft
 
food
 
(e.g.
 
applesauce).
 
Swallow
 
mixture
 
immediately
 
without
 
chewing.
 
Do
 
not
 
store
 
for
 
future
 
use.
 
3.
 
Extended-release
 
Tablet
 
(Concerta)
:
 
May
 
be
 
taken
 
with
 
or
 
without
 
food.
 
Swallow
 
whole,
 
do
 
not
 
divide,
 
chew
 
or
 
crush.
 
Contain
 
non-absorbable
 
tablet
 
shells,
 
which
 
will
 
be
 
eliminated
 
from
 
the
 
body .
 
Empty
 
tablets
 
may
 
appear
 
in
 
the
 
stool
 
normally .
 
Do
 
not
 
stop
 
taking
 
your
 
medication
 
unless
 
advised
 
to
 
do
 
so
 
by
 
your
 
prescriber
 
`
 
 
 
Special
 
Considerations
 
Pregnancy
 
 
 
 
1.
 
Should
 
not
 
be
 
given
 
to
 
pregnant
 
women
 
unless
 
the
 
potential
 
benefit
 
outweighs
 
the
 
risk
 
to
 
the
 
fetus.
 
2.
 
For
 
ADHD
 
patients,
 
MPH
 
should
 
generally
 
be
 
discontinued
 
before
 
anticipated
 
pregnancies.
 
 
 
 
254
 

=== PAGE 256 ===

 
3.
 
Inform
 
your
 
prescriber
 
if
 
you
 
are
 
planning
 
for
 
pregnancy
 
or
 
become
 
pregnant
 
while
 
taking
 
this
 
medication.
 
Breastfeeding
 
 
 
 
1.
 
Detected
 
in
 
human
 
milk
 
and
 
the
 
breastfed
 
infant
 
may
 
experience
 
irritability ,
 
agitation
 
and
 
crying.
 
It
 
is
 
recommended
 
to
 
avoid
 
breastfeeding.
 
2.
 
Can
 
decrease
 
breast
 
milk
 
production.
 
 
 
 
Elderly
 
 
 
 
MALPIP:
 
1.
 
May
 
increase
 
risk
 
of
 
cardiovascular
 
events.
 
2.
 
Use
 
of
 
methylphenidate
 
in
 
patients
 
over
 
65
 
years
 
old
 
has
 
not
 
been
 
studied
 
in
 
controlled
 
trials.
 
Should
 
not
 
be
 
used
 
in
 
patients
 
over
 
65
 
years
 
old.
 
 
 
 
Paediatric
 
 
 
 
The
 
safety
 
and
 
efficacy
 
of
 
Methylphenidate
 
in
 
pediatric
 
patients
 
younger
 
than
 
6
 
years
 
of
 
age
 
have
 
not
 
been
 
established.
  
 
 
 
 
Fasting
 
 
 
 
Administer
 
during
 
Sahur
 
or
 
after
 
Iftar.
 
 
To
 
refer
 
to
 
the
 
latest
 
advisory
 
by
 
religious
 
authority
 
 
 
 
Renal
 
impairment
 
 
 
 
No
 
data
 
available.
 
 
 
 
Hepatic
 
Impairment
 
 
 
 
No
 
data
 
available
 
 
 
 
Side
 
Effects
 
and
 
their
 
Management*
 
1.
 
Decreased
 
Appetite
 
a.
 
Largest
 
cases
 
reported
 
during
 
lunch
 
time.
 
Instruct
 
patients
 
to
 
eat
 
a
 
nutritious,
 
high
 
calorie
 
breakfast
 
and
 
dinner .
 
b.
 
May
 
require
 
switching
 
to
 
another
 
formulation
 
or
 
non-stimulant,
 
talk
 
to
 
your
 
prescriber .
 
2.
 
Insomnia
 
a.
 
When
 
given
 
twice
 
daily,
 
the
 
second
 
dose
 
should
 
be
 
taken
 
preferably
 
at
 
lunch
 
or
 
no
 
later
 
than
 
6pm
 
b.
 
May
 
require
 
switching
 
to
 
another
 
formulation
 
or
 
non-stimulant,
 
talk
 
to
 
your
 
prescriber .
 
3.
 
Gastrointestinal
 
Distress
 
a.
 
Take
 
doses
 
with
 
food.
 
b.
 
May
 
require
 
switching
 
to
 
another
 
formulation
 
or
 
non-stimulant,
 
talk
 
to
 
your
 
prescriber .
 
4.
 
Irritability
 
a.
 
May
 
require
 
switching
 
to
 
another
 
formulation
 
or
 
non-stimulant,
 
talk
 
to
 
your
 
prescriber
 
5.
 
Headache
 
a.
 
Taking
 
doses
 
with
 
food
 
might
 
help.
 
Taking
 
analgesics
 
may
 
help
 
b.
 
May
 
require
 
the
 
dose
 
to
 
be
 
divided,
 
decreased,
 
or
 
changed
 
to
 
another
 
stimulant
 
or
 
non-stimulant
 
talk
 
to
 
your
 
prescriber
 
6.
 
Other
 
potentially
 
common
  
side
 
effects
 
a.
 
Nasopharyngitis,
 
dry
 
mouth,
 
nervousness,
 
 
 
 
 
 
255
 

=== PAGE 257 ===

 
dizziness,
 
anxiety ,
 
restlessness,
 
increased
 
blood
 
pressure,
 
irregular
 
heart
 
beats,
 
rash,
 
itchiness,
 
blurred
 
vision,
 
growth
 
suppression
 
Storage*
 
1.
 
Store
 
at
 
a
 
temperature
 
below
 
30°C..
 
 
2.
 
Keep
 
out
 
of
 
the
 
reach
 
of
 
children.
 
3.
 
Store
 
in
 
the
 
original
 
package
 
in
 
order
 
to
 
protect
 
from
 
moisture.
 
(Ritalin)
 
4.
 
Keep
 
the
 
container
 
tightly
 
closed.
 
(Ritalin
 
LA
 
&
 
Concerta)
 
 
 
 
Others
 
Drug
 
Interactions
 
1.
 
Not
 
to
 
be
 
used
 
with
 
MAOIs.
 
 
2.
 
Possible
 
increased
 
blood
 
pressure
 
with
 
vasopressor
 
agents.
 
3.
 
Decreased
 
effectiveness
 
of
 
antihypertensives.
 
4.
 
Increased
 
risk
 
of
 
sudden
 
blood
 
pressure
 
&
 
heart
 
rate
 
with
 
halogenated
 
anesthetics.
 
 
5.
 
Serotonin
 
syndrome
 
with
 
serotonergic
 
drugs.
 
6.
 
Pharmacodynamic
 
interaction
 
with
 
antipsychotics.
 
 
7.
 
Inhibited
 
metabolism
 
of
 
coumarin
 
anticoagulants,
 
anticonvulsants
 
(e.g.
 
phenobarbitone,
 
phenytoin,
 
primidone)
 
and
 
some
 
antidepressants
 
(TCAs,
 
SSRIs).
 
8.
 
Use
 
with
 
other
 
psychostimulants
 
can
 
have
 
addictive
 
effects
 
(e.g.
 
increase
 
BP,
 
HR).
 
9.
 
Antacids,
 
PPIs
 
and
 
H2
 
receptor
 
antagonists
 
can
 
affect
 
the
 
absorption
 
of
 
methylphenidate,
 
particularly
 
LA
 
formulation.
 
Food
 
Interactions
 
1.
 
Alcohol
 
may
 
exacerbate
 
adverse
 
CNS
 
effects
 
of
 
MPH.
 
Patient
 
Education
 
1.
 
When
 
taken
 
appropriately ,
 
the
 
risk
 
of
 
misusing
 
stimulants
 
is
 
low.
 
Untreated
 
ADHD
 
increases
 
the
 
risk
 
of
 
substance
 
misuse
 
compared
 
with
 
treated
 
ADHD
 
children.
 
 
 
 
Before
 
ending
 
this
 
peer
 
review
 
session,
 
the
 
reviewee
 
should
 
be
 
informed
 
of
 
the
 
step(s)
 
that
 
he/
 
she
 
missed
 
out
 
in
 
order
 
to
 
ensure
 
all
 
the
 
counselling
 
points
 
are
 
being
 
covered.
 
 
Remarks:
 
 
 
Reviewed
 
by:
                                                                                                   
Date:
 
 
 
*Mandatory
 
for
 
validation/peer
 
review
 
 
References
 
:
 
 
1.
 
Novartis
 
(2023).
 
Product
 
Information
 
Leaflet:
 
Ritalin.
 
Retrieved
 
from
 
https://www .novartis.com/sg-en/sites/novartis_sg/files/Ritalin-Oct2023.SIN-app291223-pdf.pdf
 
 
2.
 
Johnson
 
&
 
Johnson
 
Sdn
 
Bhd,
 
Malaysia
 
(2024).
 
Product
 
Information
 
Leaflet:
 
Concerta.
 
Retrieved
 
from
 
Quest
 
3+
 
Search
 
on
 
January
 
21,
 
2025
 
3.
 
Pharmaceutical
 
Services
 
Programme,
 
Ministry
 
of
 
Health
 
Malaysia.
 
(2025).
 
Formulari
 
Ubat
 
KKM
 
(FUKKM).
 
Retrieved
 
from
 
https://pharmacy .moh.gov .my/ms/apps/fukkm
 
4.
 
UpToDate,
 
Inc.
 
(2024).
 
Methylphenidate:
 
Drug
 
information
 
(Version
 
3.68.3)
 
[Mobile
 
application].
 
UpToDate,
 
Inc.
 
5.
 
Stahl,
 
S.
 
M.
 
(2017).
 
Stahl’ s
 
Essential
 
Psychopharmacology
 
Prescriber ’s
 
Guide.
 
In
 
Australian
 
Prescriber
 
(6th
 
ed.,
 
Issue
 
1).
 
Cambridge
 
University
 
Press.
 
https://doi.org/10.18773/austprescr .2016.001
 
6.
 
Krishnasamy
 
A.
 
et.
 
al.
 
Medication
 
Counseling
 
for
 
Pharmacists.
 
(First
 
Edition
 
2021).
 
Perak
 
State
 
Health
 
Department,
 
Pharmaceutical
 
Services
 
Division.
 
7.
 
Taylor ,
 
D.,
 
Barnes,
 
T.
 
R.
 
E.,
 
&
 
Young,
 
A.
 
H.
 
(2021).
 
The
 
Maudsley
 
prescribing
 
guidelines
 
in
 
psychiatry
 
(14th
 
ed.).
 
Wiley-Blackwell.
 
 
256
 

=== PAGE 258 ===

 
8.
 
Chang,
 
C.
 
T.,
 
Chan,
 
H.
 
K.,
 
Cheah,
 
W.
 
K.,
 
Tan,
 
M.
 
P.,
 
Ch’ng,
 
A.
 
S.
 
H.,
 
Thiam,
 
C.
 
N.,
 
...
 
&
 
Lee,
 
S.
 
W.
 
H.
 
(2023).
 
Development
 
of
 
a
 
Malaysian
 
potentially
 
inappropriate
 
prescribing
 
screening
 
tool
 
in
 
older
 
adults
 
(MALPIP):
 
a
 
Delphi
 
study .
 
Journal
 
of
 
Pharmaceutical
 
Policy
 
and
 
Practice,
 
16(1),
 
122
 
Miconazole,
 
Topical
 
Name
 
:
 
 
Unit
 
:
 
 
●
 
Please
 
tick
 
(
✔
)
 
Yes
 
for
 
correct
 
instruction.
 
●
 
Please
 
tick
 
(
✔
)
 
No
 
for
 
incorrect
 
instruction.
 
Yes
 
No
 
Remarks
 
Pharmacological
 
Group
 
Antifungals
 
for
 
dermatological
 
use.
 
 
 
 
Indications
 
and
 
Dosage
 
Miconazole
 
cream
 
used
 
for
 
the
 
treatment
 
of
 
fungal
 
skin
 
infections,
 
including:
 
1.
 
Cutaneous
 
candidiasis:
 
2.
 
Tinea
 
infections
 
a.
 
Tinea
 
pedis
 
(athlete's
 
foot)
 
b.
 
Tinea
 
capitis
 
(scalp
 
ringworm)
 
c.
 
Tinea
 
corporis
 
(ringworm
 
of
 
the
 
body)
 
d.
 
Other
 
dermatophyte
 
infections
 
caused
 
by
 
Trichophyton
 
and
 
Epidermophyton
 
species.
 
 
Apply
 
a
 
thin
 
layer
 
of
 
cream
 
to
 
the
 
affected
 
area
 
twice
 
daily.
 
Treatment
 
usually
 
lasts
 
2
 
to
 
6
 
weeks,
 
depending
 
on
 
the
 
localization
 
and
 
severity
 
of
 
the
 
infection.
 
 
 
 
Method
 
of
 
Administration*
 
1.
 
Clean
 
and
 
dry
 
the
 
affected
 
area
 
before
 
applying
 
the
 
cream.
 
2.
 
Apply
 
a
 
thin
 
layer
 
to
 
the
 
affected
 
skin
 
and
 
surrounding
 
area.
 
3.
 
Gently
 
rub
 
the
 
cream
 
into
 
the
 
skin
 
until
 
absorbed.
 
 
Do
 
not
 
stop
 
using
 
your
 
medication
 
unless
 
advised
 
to
 
do
 
so
 
by
 
your
 
prescriber
 
 
 
 
Special
 
Considerations
 
Pregnancy
 
 
 
 
Since
 
topical
 
and
 
vaginal
 
miconazole
 
are
 
not
 
well
 
absorbed,
 
they
 
are
 
unlikely
 
to
 
increase
 
risks
 
to
 
a
 
pregnancy .
 
Most
 
studies
 
have
 
shown
 
that
 
miconazole
 
at
 
low
 
doses
 
(<400
 
mg/day)
 
does
 
not
 
increase
 
the
 
chance
 
of
 
birth
 
defects.
 
 
 
 
Breastfeeding
 
 
 
 
It
 
is
 
not
 
known
 
if
 
miconazole
 
is
 
present
 
in
 
breast
 
milk.
 
Use
 
with
 
caution.
 
 
 
 
 
Elderly
 
 
 
 
Patients
 
who
 
use
 
topical
 
oils,
 
creams,
 
and
 
ointments
 
have
 
potential
 
fall
 
risk
 
.Patients
 
may
 
be
 
advised
 
to
 
wear
 
nonslip
 
socks
 
if
 
applying
 
topical
 
medications
 
to
 
feet.
 
Patients
 
should
 
be
 
advised
 
to
 
apply
 
cream
 
while
 
seated
 
or
 
standing
 
on
 
non-slip
 
surfaces.
 
 
 
 
Paediatric
 
 
 
 
The
 
safety
 
and
 
efficacy
 
of
 
Miconazole
 
cream
 
2%
  
in
 
paediatric
 
patients
 
age
 
below
 
2
 
have
 
not
 
been
 
established.
 
 
 
 
257
 

=== PAGE 259 ===

 
Fasting
 
 
 
 
1.
 
Cream
 
is
 
permissible
 
to be
 
used
 
during
 fasting.
 
2.
 
While
 
it
 
may
 
absorb
 
into
 
the
 
skin
 
to
 
treat
 
the
 
infection,
 
this
 
does
 
not
 
reach
 
systemically
 
in
 
a
 
way
 
that
 
would
 
invalidate
 
fasting.
 
To
 
refer
 
to
 
the
 
latest
 
advisory
 
by
 
religious
 
authority .
 
 
 
 
Others
  
 
 
 
 
N/A
 
 
 
 
Side
 
Effects
 
and
 
their
 
Management*
 
Allergic
 
contact
 
dermatitis,
 
burning
 
sensation
 
of
 
skin
 
and
 
maceration
 
of
 
skin.
 
Discontinue
 
if
 
sensitivity
 
or
 
irritation
 
occurs
 
 
 
 
 
Storage*
 
Store
 
between
 
20
 
-
 
25
 
℃
.
 
Protect
 
from
 
light.
 
 
 
 
 
Others
 
1.
 
Cleanse
 
and
 
thoroughly
 
dry
 
the
 
affected
 
area
 
before
 
application.
 
2.
 
Apply
 
a
 
thin
 
layer
 
of
 
the
 
cream
 
to
 
the
 
affected
 
area
 
and
 
extend
 
2-3
 
cm
 
beyond
 
the
 
edge
 
of
 
the
 
lesion.
 
3.
 
Rub
 
the
 
cream
 
well
 
into
 
the
 
skin
 
until
 
it
 
has
 
been
 
completely
 
absorbed.
 
4.
 
For
 
Tinea
 
pedis
 
(athlete's
 
foot),
 
pay
 
special
 
attention
 
to
 
the
 
spaces
 
between
 
the
 
toes.
 
5.
 
Wash
 
hands
 
after
 
applying
 
the
 
cream
 
to
 
avoid
 
spreading
 
the
 
infection.
 
6.
 
Continue
 
treatment
 
for
 
up
 
to
 
1-2
 
weeks
 
after
 
the
 
lesion
 
has
 
disappeared
 
to
 
ensure
 
complete
 
eradication
 
of
 
the
 
infection.
 
 
 
 
 
Before
 
ending
 
this
 
peer
 
review
 
session,
 
the
 
reviewee
 
should
 
be
 
informed
 
of
 
the
 
step(s)
 
that
 
he/
 
she
 
missed
 
out
 
in
 
order
 
to
 
ensure
 
all
 
the
 
counselling
 
points
 
are
 
being
 
covered.
 
 
Remarks:
 
 
 
 
 
Reviewed
 
by:
 
Name
 
&
 
Signature
                                                                   
Date:
 
 
 
 
 
*Mandatory
 
for
 
validation
 
/
 
peer
 
review
 
References:
 
 
1.
 
Miconazole
 
(topical)
 
(2024)
 
UpToDate
 
[Drug
 
information]
 
Retrieved
 
November
 
1,
 
2024,
 
from
 
https://www .uptodate.com
 
2.
 
MIMS
 
Malaysia.
 
(n.d.)
 
Miconazole.
 
MIMS
 
Pte
 
Ltd.
 
Retrieved
 
November
 
1,
 
2024,
 
from
 
https://www .mims.com/malaysia/drug/info/miconazole?mtype=generic
 
3.
 
MotherT oBaby
 
|
 
Fact
 
Sheets
 
[Internet].
 
Brentwood
 
(TN):
 
Organization
 
of
 
Teratology
 
Information
 
Specialists
 
(OTIS);
 
1994-.
 
Miconazole.
 
2023
 
Oct.
 
Available
 
from:
 
https://www .ncbi.nlm.nih.gov/books/NBK605073/
 
4.
 
Price
 
KN,
 
Grinnell
 
M,
 
Butler
 
D,
 
Shah
 
A.
 
Art
 
of
 
prevention:
 
Practical
 
tips
 
for
 
improving
 
adherence
 
to
 
treatments
 
for
 
older
 
patients
 
in
 
dermatology .
 
Int
 
J
 
Womens
 
Dermatol.
 
2021
 
Mar
 
18;7(4):478-481.
 
 
  
 
 
 
 
 
258
 

=== PAGE 260 ===

 
Minocycline
 
Name
 
:
 
 
Unit
 
:
 
 
●
 
Please
 
tick
 
(
✔
)
 
Yes
 
for
 
correct
 
instruction.
 
●
 
Please
 
tick
 
(
✔
)
 
No
 
for
 
incorrect
 
instruction.
 
Yes
 
No
 
Remarks
 
Pharmacological
 
Group
 
Tetracycline
 
 
 
 
Indications
 
and
 
Dosage
 
Second-line
 
leprosy
 
treatment/drug-resistant
 
leprosy
 
Dosage:
 
100mg
 
daily
 
for
 
6-18
 
months
 
(in
 
combination
 
with
 
other
 
anti-leprosy
 
agents)
 
 
 
 
Method
 
of
 
Administration*
 
Oral
 
:
 
 
1.
 
Take
 
at
 
the
 
same
 
time
 
each
 
day.
 
2.
 
To
 
be
 
taken
 
with
 
or
 
without
 
food.
 
 
3.
 
Pellet-filled
 
capsule
 
should
 
be
 
taken
 
on
 
an
 
empty
 
stomach
 
4.
 
May
 
be
 
taken
 
with
 
food
 
to
 
reduce
 
GI
 
discomfort.
 
5.
 
Swallow
 
whole.
 
Take
 
with
 
a
 
full
 
glass
 
of
 
water
 
or
 
a
 
small
 
amount
 
of
 
food.
 
This
 
is
 
to
 
avoid
 
oesophageal
 
irritation
 
and
 
ulceration.
 
6.
 
Food
 
and/or
 
milk
 
products
 
may
 
decrease
 
the
 
rate
 
and
 
extent
 
of
 
oral
 
absorption.
 
7.
 
Avoid
 
products
 
containing
 
iron,
 
aluminium,
 
calcium
 
or
 
magnesium
 
at
 
least
 
2
 
hours
 
before/after
 
administration.
 
8.
 
Avoid
 
alcohol
 
 
Missed
 
dose
 
:
 
 
1.
 
Take
 
a
 
missed
 
dose
 
as
 
soon
 
as
 
remembered,
 
however ,
 
if
 
near
 
to
 
the
 
next
 
dose,
 
skip
 
the
 
dose
 
and
 
continue
 
with
 
the
 
usual
 
dosing
 
time.
 
Do
 
not
 
double
 
the
 
dose
 
or
 
take
 
extra
 
doses.
 
 
Do
 
not
 
stop
 
taking
 
your
 
medication
 
unless
 
advised
 
to
 
do
 
so
 
by
 
your
 
prescriber
 
 
 
 
Special
 
Considerations
 
Pregnancy
 
 
 
 
1.
 
US
 
FDA
 
category
 
D
 
(PO)
 
2.
 
Minocycline
 
crosses
 
the
 
placenta,
 
and
 
may
 
cause
 
fetal
 
harm
 
following
 
maternal
 
use
 
during
 
pregnancy .
 
3.
 
Causes
 
permanent
 
tooth
 
staining
 
in
 
the
 
fetus
 
and
 
is
 
more
 
likely
 
to
 
occur
 
following
 
long-term
 
exposure
 
or
 
repeated
 
exposure.
 
 
 
 
Breastfeeding
 
 
 
 
1.
 
Minocycline
 
is
 
present
 
in
 
breastmilk
 
2.
 
Tetracyclines
 
have
 
generally
 
been
 
avoided
 
in
 
breastfeeding
 
patients
 
due
 
to
 
theoretical
 
concerns
 
that
 
they
 
may
 
cause
 
problems
 
in
 
bone
 
and
 
tooth
 
development.
 
 
3.
 
In
 
general,
 
antibiotics
 
that
 
are
 
present
 
in
 
breast
 
milk
 
may
 
cause
 
modification
 
of
 
bowel
 
flora,
 
therefore,
 
should
 
monitor
 
infants
 
for
 
GI
 
disturbances.
 
 
4.
 
Long-term
 
use
 
is
 
not
 
recommended
 
in
 
breastfeeding
 
patients.
 
5.
 
Use
 
alternatives
 
if
 
possible.
 
 
 
 
Elderly
 
 
 
 
259
 

=== PAGE 261 ===

 
1.
 
Recommended
 
to
 
start
 
with
 
the
 
lowest
 
effective
 
dose
 
2.
 
Generally ,
 
it
 
is
 
safe
 
to
 
give
 
the
 
normal
 
recommended
 
dosage
 
in
 
elderly ,
 
however
 
need
 
to
 
be
 
done
 
cautiously ,
 
taking
 
into
 
consideration
 
the
 
declining
 
in
 
hepatic
 
and
 
renal
 
function
 
as
 
well
 
as
 
the
 
use
 
of
 
other
 
medications.
 
 
 
 
Paediatric
 
 
 
 
1.
 
Contraindicated
 
for
 
patients
 
under
 
12
 
years
 
old.
 
 
2.
 
Safety
 
and
 
effectiveness
 
for
 
those
 
below
 
12
 
years
 
old
 
have
 
not
 
been
 
established
 
3.
 
Contraindicated
 
in
 
neonates
 
and
 
those
 
below
 
8
 
years
 
old
 
due
 
to
 
teeth
 
staining
 
and
 
potentially
 
suppresses
 
bone
 
growth
 
 
 
 
Fasting
 
 
 
 
N/A
 
To
 
refer
 
to
 
the
 
latest
 
advisory
 
by
 
religious
 
authority
 
 
 
 
Others
  
 
Renal
 
impairment
 
1.
 
No
 
dosage
 
adjustment
 
 
Hepatic
 
impairment
 
 
1.
 
Hepatotoxicity
 
has
 
been
 
reported.
 
Use
 
with
 
caution.
 
 
 
 
Side
 
Effects
 
and
 
their
 
Management*
 
1.
 
Headache
 
2.
 
Nausea
 
and
 
vomiting
 
3.
 
Stomach
 
pain
 
4.
 
Indigestion
 
5.
 
Difficulty
 
swallowing
 
6.
 
Joint
 
pain
 
and
 
stiffness
 
7.
 
Swollen
 
tongue
 
8.
 
Nail
 
discolouration
 
 
Minocycline
 
can
 
cause
 
abnormal
 
blood
 
test
 
results.
 
 
 
 
Storage*
 
1.
 
Keep
 
in
 
original
 
packaging
 
2.
 
Store
 
below
 
30°C
 
 
 
 
Others
 
Precautions
 
:
 
 
1.
 
Use
 
in
 
patients
 
below
 
8
 
years
 
old
 
may
 
cause
 
permanent
 
tooth
 
staining.
 
2.
 
Enamel
 
hypoplasia
 
in
 
renal
 
failure
 
has
 
been
 
reported
 
3.
 
Super
 
infection
 
4.
 
Avoid
 
prolonged
 
exposure
 
to
 
sunlight
 
or
 
UV
 
lamps.
 
Apply
 
sunscreen
 
and
 
wear
 
loose
 
fitting
 
clothes
 
when
 
going
 
outdoors
 
 
Monitoring
 
Parameters
 
:
 
 
1.
 
Perform
 
culture
 
and
 
susceptibility
 
test
 
before
 
treatment
 
initiation.
 
 
2.
 
In
 
prolonged
 
therapy ,
 
monitor
 
LFTs,
 
renal
 
function
 
and
 
BUN
 
3.
 
Serum
 
Mg
 
in
 
renal
 
impairment
 
patients
 
4.
 
Monitor
 
antinuclear
 
antibody
 
(ANA)
 
and
 
CBC
 
if
 
symptomatic
 
for
 
autoimmune
 
disorder .
 
5.
 
Perform
 
ophthalmologic
 
evaluation
 
if
 
visual
 
disturbances
 
occur .
 
 
6.
 
In
 
patients
 
with
 
idiopathic
 
intrac=ranial
 
hypertension,
 
monitor
 
intracranial
 
pressure
 
until
 
stabilisation.
 
 
 
 
Significant
 
drug-drug
 
/
 
drug-food
 
interactions
 
(if
 
applicable)
 
:
 
 
1.
 
Food
 
and
 
milk
 
products
 
including
 
iron-containing
 
 
 
 
260
 

=== PAGE 262 ===

 
preparations
,
 
may
 
interfere
 
with
 
drug
 
absorption
 
2.
 
May
 
potentiate
 
effects
 
of
 
anticoagulants
.
 
Reduce
 
plasma
 
prothrombin
 
activity
 
by
 
inhibiting
 
the
 
production
 
of
 
Vitamin
 
K.
 
3.
 
Colestyramine,
 
colestipol,
 
quinapril,
 
antacids
 
or
 
drugs
 
containing
 
Al,
 
Ca,
 
or
 
MG,
 
ulcer-healing
 
agents
 
(e.g.
 
sucralfate,
 
bismuth
 
salts),
 
oral
 
iron
 
preparations
 
may
 
impaired
 
absorption.
 
4.
 
Diuretics
 
may
 
aggravate
 
nephrotoxicity
 
5.
 
With
 
penicillin
,
 
may
 
interfere
 
with
 
bactericidal
 
action
 
6.
 
Decrease
 
the
 
efficacy
 
of
 
oral
 
contraceptives
.
 
7.
 
Sodium
 
bicarbonate
 
may
 
inhibit
 
tetracyclines
 
in
 
the
 
digestive
 
tract
 
by
 
increasing
 
the
 
pH.
 
8.
 
Increased
 
risk
 
of
 
ergotism
 
with
 
ergotamine
 
and
 
ergometrine
.
 
9.
 
Reduce
 
therapeutic
 
effect
 
of
 
t
yphoid
 
vaccine
.
 
10.
 
Concurrent
 
use
 
with
 
methoxyflurane
 
may
 
lead
 
to
 
renal
 
toxicity .
 
11.
 
Increase
 
risk
 
of
 
benign
 
intracranial
 
hypertension
 
with
 
isotretinoin
 
or
 
other
 
systemic
 
retinoids
.
 
Before
 
ending
 
this
 
peer
 
review
 
session,
 
the
 
reviewee
 
should
 
be
 
informed
 
of
 
the
 
step(s)
 
that
 
he/
 
she
 
missed
 
out
 
in
 
order
 
to
 
ensure
 
all
 
the
 
counselling
 
points
 
are
 
being
 
covered.
 
 
Remarks:
 
 
 
 
 
Reviewed
 
by:
 
Name
 
&
 
Signature
                                                                   
Date:
 
 
 
 
 
*Mandatory
 
for
 
validation
 
/
 
peer
 
review
 
References:
 
 
1.
 
Nomika
 
(Minocycline)
 
Prescribing
 
Info.
 
(n.d.).
 
MIMS.
 
Retrieved
 
March
 
27,
 
2025,
 
from
 
https://www .mims.com/indonesia/drug/info/nomika?type=full
 
2.
 
Minocycline
 
General
 
Medicine
 
Info.
 
(n.d.).
 
MIMS.
 
Retrieved
 
March
 
27,
 
2025,
 
from
 
https://www .mims.com/malaysia/drug/info/minocycline?mtype=generic
 
3.
 
Cooreman/Leprosy ,
 
E.
 
A.
 
(Ed.).
 
(2018).
 
Guidelines
 
for
 
the
 
Diagnosis,
 
Treatment
 
and
 
Prevention
 
of
 
Leprosy .
 
World
 
Health
 
Organization.
 
https://iris.who.int/bitstream/handle/10665/274127/9789290226383-eng.pdf
 
4.
 
AA-Minocycline
 
Capsule
 
Consumer
 
Medication
 
Information
 
Leaflet
 
(RiMUP).
 
(2024,
 
March
 
20).
 
BPFK
 
(Quest3plus).
 
Retrieved
 
March
 
27,
 
2025,
 
from
 
https://quest3plus.bpfk.gov .my/front-end/attachment/681/pharma/222557/V_87192_20240320_105022_
D4.pdf
 
5.
 
Minocycline
 
Hydrochloride
 
Extended-Release
 
Capsules.
 
(2020,
 
July).
 
JG
 
Pharma
 
Inc.
 
Retrieved
 
March
 
27,
 
2025,
 
from
 
https://www .jgpharmainc.com/assets/pdf/minocycline-hydrochloride.pdf
 
6.
 
Minocin
 
(minocycline
 
hydrochloride)
 
pellet-filled
 
capsules
 
Labeling
 
Information.
 
(2008,
 
May).
 
FDA
 
Drug
 
Database.
 
Retrieved
 
March
 
27,
 
2025,
 
from
 
https://www .accessdata.fda.gov/drugsatfda_docs/label/2008/050649s022lbl.pdf
 
7.
 
Minomycin.
 
(2009,
 
September).
 
New
 
Zealand
 
Data
 
Sheet.
 
Retrieved
 
March
 
27,
 
2025,
 
from
 
https://www .medsafe.govt.nz/profs/datasheet/m/Minomycincap.pdf
 
8.
 
Carney
 
S,
 
Butcher
 
RA,
 
Dawborn
 
JK,
 
Pattison
 
G.
 
Minocycline
 
excretion
 
and
 
distribution
 
in
 
relation
 
to
 
renal
 
function
 
in
 
man.
 
Clin
 
Exp
 
Pharmacol
 
Physiol.
 
1974;1(4):299-308.
 
doi:10.1 111/j.1440-1681.1974.tb00552.x
 
9.
 
Minocycline
 
(systemic):
 
Patient
 
Drug
 
Information.
 
(2024,
 
November
 
14).
 
UpToDate.
 
 
 
 
 
261
 

=== PAGE 263 ===

 
Mirtazapine
 
Name
 
:
 
 
Unit
 
:
 
 
●
 
Please
 
tick
 
(
✔
)
 
Yes
 
for
 
correct
 
instruction.
 
●
 
Please
 
tick
 
(
✔
)
 
No
 
for
 
incorrect
 
instruction.
 
Yes
 
No
 
Remar
ks
 
Pharmacological
 
Group
 
Noradrenaline
 
and
 
Specific
 
Serotonergic
 
Agent
 
(NaSSA)
 
 
 
 
 
 
Indications
 
and
 
Dosage
 
1.
 
Major
 
Depressive
 
Disorder
 
a.
 
Initial
 
15
 
mg
 
daily
 
at
 
bedtime,
 
increase
 
based
 
on
 
response
 
and
 
tolerability
 
to
 
max
 
45mg
 
daily
 
as
 
single
 
dose
 
at
 
bedtime
 
or
 
in
 
2
 
divided
 
dose
 
Or
 
 
 
To
 
counsel
 
based
 
on
 
specific
 
medication’ s
 
indication
 
and
 
dosage
 
as
 
prescribed
 
by
 
the
 
doctor
 
 
 
 
Method
 
of
 
Administration*
 
1.
 
Orodispersible
 
Tablet:
 
a.
 
In
 
order
 
to
 
prevent
 
crushing
 
the
 
tablet,
 
do
 
not
 
push
 
against
 
the
 
tablet
 
pocket.
 
b.
 
Each
 
strip
 
contains
 
six
 
tablet
 
pockets,
 
which
 
are
 
separated
 
by
 
perforations.
 
Tear
 
off
 
one
 
tablet
 
pocket
 
along
 
the
 
dotted
 
lines.
 
c.
 
Carefully
 
peel
 
off
 
the
 
lidding
 
foil,
 
starting
 
in
 
the
 
corner
 
indicated
 
by
 
the
 
arrow .
 
 
d.
 
The
 
tablet
 
should
 
be
 
taken
 
out
 
of
 
the
 
strip
 
with
 
dry
 
hands
 
and
 
should
 
be
 
placed
 
on
 
the
 
tongue.
 
The
 
tablet
 
will
 
rapidly
 
disintegrate
 
and
 
can
 
be
 
swallowed
 
without
 
water .
 
 
2.
 
Tablet:
 
Swallow
 
the
 
tablets
 
with
 
some
 
fluid
 
 
Do
 
not
 
stop
 
taking
 
your
 
medication
 
unless
 
advised
 
to
 
do
 
so
 
by
 
your
 
prescriber
 
 
 
 
Special
 
Considerations
 
Pregnancy
 
 
 
 
1.
 
Risk
 
of
 
treatment
 
to
 
the
 
child
 
must
 
be
 
weighed
 
against
 
the
 
risk
 
of
 
no
 
treatment
 
to
 
the
 
mother
 
and
 
child.
 
Inform
 
your
 
doctor
 
if
 
you
 
are
 
planning
 
for
 
pregnancy
 
or
 
become
 
pregnant
 
while
 
taking
 
this
 
medication.
 
 
 
 
Breastfeeding
 
 
 
 
1.
 
Some
 
of
 
this
 
drug
 
is
 
found
 
in
 
mother ’s
 
breast
 
milk.
 
2.
 
Consult
 
your
 
prescriber
 
if
 
your
 
child
 
becomes
 
irritable
 
or
 
sedated.
 
Breastfeeding
 
or
 
drugs
 
may
 
need
 
to
 
be
 
discontinued.
 
 
 
 
Elderly
 
 
 
 
Use
 
with
 
caution
 
and
 
dose
 
conservatively
 
by
 
starting
 
at
 
the
 
low
 
end
 
of
 
range
 
 
To
 
be
 
aware
 
of
 
hypersomnolence
 
(sleepiness)
 
adverse
 
effects
 
especially
  
during
 
the
 
initiation
 
period.
 
To
 
advise
 
on
 
fall
 
precautions.
 
Mirtazapine
 
is
 
also
 
associated
 
with
 
increased
 
appetite
 
&
 
weight
 
gain.
 
Suggest
 
for
 
routine
 
monitoring.
 
Beers
 
Criteria:
 
1)
 
May
 
exacerbate
 
or
 
cause
 
SIADH
 
or
 
hyponatremia;
 
monitor
 
sodium
 
level
 
closely
 
when
 
starting
 
or
 
changing
 
dosages
 
in
 
older
 
adults.
 
 
 
 
262
 

=== PAGE 264 ===

 
Pediatrics
 
 
 
 
Safety
 
and
 
efficacy
 
in
 
pediatrics
 
patients
 
have
 
not
 
been
 
established.
 
Should
 
not
 
be
 
used
 
in
 
children
 
under
 
the
 
age
 
of
 
18
 
years.
 
If
 
based
 
on
 
clinical
 
need,
 
a
 
decision
 
to
 
treat
 
is
 
nevertheless
 
taken,
 
should
 
carefully
 
monitor
 
suicidal
 
symptoms.
 
 
 
 
Fasting
 
 
 
 
Administer
 
during
 
Sahur
 
or
 
after
 
Iftar.
 
 
To
 
refer
 
to
 
the
 
latest
 
advisory
 
by
 
religious
 
authority
 
 
 
 
Hepatic
 
Impairment
 
 
 
 
Moderate
 
to
 
severe:
 
A
 
decrease
 
in
 
dosage
 
may
 
be
 
necessary .
 
 
 
 
Renal
 
impairment
 
 
 
 
egfr
 
>
 
30ml/min
 
:
 
No
 
dosage
 
adjustment
 
necessary
 
 
egfr
 
<
 
30ml/min
 
:
 
Initial
 
7.5mg
 
to
 
15mg
 
OD,
 
titrate
 
dosage
 
carefully
 
 
 
 
Side
 
Effects
 
and
 
their
 
Management*
 
1.
 
Endocrine
 
metabolic:
 
weight
 
gain,
 
increased
 
appetite.
 
a.
 
advise
 
on
 
nutritional
 
counselling
 
(avoid
 
low-volume,
 
high-calorie
 
foods)
 
and
 
emphasize
 
need
 
for
 
physical
 
exercise.
 
 
2.
 
Anticholinergic:
 
 
a.
 
Constipation
 
can
 
be
 
managed
 
by
 
physical
 
activity ,
 
fluid
 
and
 
fibre
 
intake
 
or
 
laxatives
 
b.
 
Dry
 
mouth
 
 
3.
 
Neurologic
 
a.
 
Headache,
 
dizziness,
 
fatigue.
 
May
 
require
 
dosage
 
adjustment.
 
Inform
 
prescriber
 
at
 
next
 
appointment
 
b.
 
Sedation:
 
Avoid
 
activity
 
requiring
 
mental
 
alertness
 
or
 
coordination.
 
Do
 
not
 
drink
 
alcohol
 
during
 
treatment
 
with
 
this
 
medicine
 
as
 
it
 
might
 
increase
 
the
 
sedative
 
effect.
 
Do
 
not
 
drive
 
or
 
work
 
with
 
tools
 
or
 
machinery
 
if
 
affected.
 
Inform
 
prescriber
 
at
 
next
 
appointment.
 
 
Most
 
side
 
effects
 
are
 
immediate
 
but
 
often
 
go
 
away
 
with
 
time. 
 
It
 
may
 
take
 
a
 
few
 
weeks
 
before
 
you
 
feel
 
any
 
improvement.
 
Therefore,
 
do
 
not
 
change
 
the
 
dose
 
of
 
the
 
medicine
 
or
 
stop
 
taking
 
the
 
medicine
 
without
 
consulting
 
your
 
doctor
 
first. 
 
Instruct
 
patient
 
to
 
immediately
 
report
 
worsening
 
depression,
 
suicidal
 
ideation,
 
especially
 
at
 
initiation
 
of
 
therapy
 
(children
 
and
 
adolescents
 
are
 
at
 
higher
 
risk
 
for
 
these
 
effects
 
during
 
the
 
first
 
few
 
months
 
of
 
therapy). 
 
 
 
 
Storage*
 
Store
 
below
 
30’C.
 
Avoid
 
light
 
&
 
moisture.
 
 
 
 
Other
 
1.
 
Significant
 
Pharmacodynamic
 
Interactions
 
a.
 
Risk
 
of
 
life-threatening
 
Serotonin
 
syndrome
 
when
 
SSRIs
 
co-prescribed
 
with
 
serotonergic
 
drugs.
 
(e.g.
 
tramadol,
 
ondansetron,
 
sumatriptan,
 
MAOI)
 
 
Signs
 
and
 
Symptoms:
 
i.
 
Mild:
 
Insomnia,
 
anxiety ,
 
nausea,
 
diarrhea,
 
hypertension,
 
tachycardia,
 
hyper-reflexia
 
 
 
 
263
 

=== PAGE 265 ===

 
ii.
 
Moderate:Agitation,
 
myoclonus,
 
tremor ,
 
mydriasis,
 
flushing,
 
diaphoresis,
 
low
 
fever
 
(<38.5°C)
 
iii.
 
Severe:
 
Severe
 
hyperthermia,
 
confusion,rigidity ,
 
respiratory
 
failure,
 
coma,
 
death
 
Management:
 
Seek
 
immediate
 
medical
 
attention
 
if
 
you
 
experience
 
any
 
of
 
the
 
symptoms
 
mentioned
 
above.
 
b.
 
Increase
 
risk
 
of
 
upper
 
GI
 
bleeding
 
if
 
SSRIs
 
are
 
used
 
together
 
with
 
Aspirin
 
and
 
NSAID
 
due
 
to
 
inhibition
 
of
 
platelet
 
aggregation.
 
Watch
 
out
 
for
 
black
 
or
 
tarry
 
stools,
 
easily
 
bleeding
 
gums
 
or
 
spontaneous
 
bruises
 
c.
 
Risk
 
of
 
hyponatremia
 
especially
 
if
 
SSRIs
 
are
 
used
 
with
 
drugs
 
such
 
as
 
diuretics.
 
 
2.
 
Discontinuation
 
Syndrome
 
a.
 
SSRIs
 
should
 
not
 
be
 
stopped
 
abruptly
 
as
 
this
 
may
 
cause
 
discontinuation/
 
withdrawal
 
symptoms.
 
The
 
symptoms
 
are
 
usually
 
mild
 
and
 
selflimiting
 
(e.g.
 
include
 
flu-like
 
symptoms,
 
insomnia,
 
nausea,
 
imbalance,
 
sensory
 
disturbances
 
and
 
hyperarousal),
 
but
 
can
 
occasionally
 
be
 
severe
 
and
 
prolonged.
 
b.
 
The
 
patients
 
must
 
inform
 
prescribers
 
if
 
they
 
wish
 
to
 
change
 
or
 
stop
 
medications
 
Before
 
ending
 
this
 
peer
 
review
 
session,
 
the
 
reviewee
 
should
 
be
 
informed
 
of
 
the
 
step(s)
 
that
 
he/
 
she
 
missed
 
out
 
in
 
order
 
to
 
ensure
 
all
 
the
 
counselling
 
points
 
are
 
being
 
covered.
 
 
Remarks:
 
 
 
 
 
Reviewed
 
by:
 
Name
 
&
 
Signature
                                                                   
Date:
 
 
 
 
 
*Mandatory
 
for
 
validation
 
/
 
peer
 
review
 
References
 
:
 
 
1.
 
Mirtazapine
 
(2025).
 
Micromedex
 
(electronic
 
version).
 
Retrieved
 
January
 
20,
 
2025
 
from
 
http://www .micromedexsolutions.com/
 
2.
 
Organon
 
(2021).
 
Remeron
 
Solutab
 
package
 
insert.
 
Retrieved
 
from
 
Quest
 
3+
 
search
 
on
 
January
 
20,
 
2025.
 
3.
 
Pharmaceutical
 
Services
 
Programme,
 
Ministry
 
of
 
Health
 
Malaysia.
 
(2025).
 
Formulari
 
Ubat
 
KKM
 
(FUKKM).
 
Retrieved
 
from
 
https://pharmacy .moh.gov .my/ms/apps/fukkm
 
4.
 
Visvalingam
 
U,
 
et.
 
al.
 
CPG
 
Management
 
of
 
Major
 
Depressive
 
Disorder
 
(2019).
 
Accessed
 
on
 
January
 
20,
 
2025.
 
Available
 
from:
 
CPG
 
Management
 
of
 
Major
 
Depressive
 
Disorder
 
(Second
 
Edition).pdf
 
5.
 
Krishnasamy
 
A.
 
et.
 
al.
 
Medication
 
Counseling
 
for
 
Pharmacists.
 
(First
 
Edition
 
2021).
 
Perak
 
State
 
Health
 
Department,
 
Pharmaceutical
 
Services
 
Division.
 
6.
 
Taylor ,
 
D.,
 
Barnes,
 
T.
 
R.
 
E.,
 
&
 
Young,
 
A.
 
H.
 
(2021).
 
The
 
Maudsley
 
prescribing
 
guidelines
 
in
 
psychiatry
 
(14th
 
ed.).
 
Wiley-Blackwell.
 
 
7.
 
2023
 
American
 
Geriatrics
 
Society
 
Beers
 
Criteria®
 
Update
 
Expert
 
Panel.
 
(2023).
 
American
 
Geriatrics
 
Society
 
2023
 
updated
 
AGS
 
Beers
 
Criteria®
 
for
 
potentially
 
inappropriate
 
medication
 
use
 
in
 
older
 
adults.
 
Journal
 
of
 
the
 
American
 
Geriatrics
 
Society ,
 
71(7),
 
2052-2081
 
8.
 
Silverman,
 
J.
 
J.,
 
Galanter ,
 
M.,
 
Jackson-T riche,
 
M.,
 
Jacobs,
 
D.
 
G.,
 
Lomax,
 
J.
 
W.,
 
Riba,
 
M.
 
B.,
 
...
 
&
 
Yager,
 
J.
 
(2015).
 
The
 
American
 
Psychiatric
 
Association
 
practice
 
guidelines
 
for
 
the
 
psychiatric
 
evaluation
 
of
 
adults.
 
American
 
Journal
 
of
 
Psychiatry ,
 
172(8),
 
798-802.
 
264
 

=== PAGE 266 ===

 
Moxifloxacin
  
 
Name
 
:
 
 
Unit
 
:
 
 
Please
 
tick
 
(
✔
)
 
Yes
 
for
 
correct
 
instruction.
 
Please
 
tick
 
(
✔
)
 
No
 
for
 
incorrect
 
instruction.
 
Yes
 
No
 
Remarks
 
Pharmacological
 
Group
 
Fluoroquinolone
 
 
 
 
Indications
 
and
 
Dosage
 
1.
 
Second-line
 
treatment
 
for
 
leprosy
  
(Moxifloxacin
 
may
 
replace
 
Ofloxacin)
 
2.
 
Drug-resistant
 
leprosy
 
 
 
Adult
 
:
 
400mg
 
once
 
daily
 
(in
 
combination
 
with
 
other
    
anti-leprosy
 
drugs)
 
 
 
 
 
Method
 
of
 
Administration*
 
Food:
 
Administered
 
with
 
or
 
without
 
food
 
 
 
 
RT
 
administration:
 
Absorption
 
was
 
not
 
significantly
 
affected
 
by
 
concurrent
 
enteral
 
nutrition;
 
however ,
 
it
 
may
 
be
 
advisable
 
to
 
hold
 
enteral
 
nutrition
 
for
 
up
 
to
 
2
 
hours
 
before
 
and
 
after
 
administration
 
to
 
ensure
 
optimal
 
absorption
 
 
Missed
 
dose:
 
Take
 
as
 
soon
 
as
 
remembered
 
if
 
more
 
than
 
8
 
hours
 
before
 
the
 
next
 
scheduled
 
dose.
 
Skip
 
the
 
missed
 
dose
 
if
 
less
 
than
 
8
 
hours
 
remain
 
before
 
the
 
next
 
dose
 
 
 
Do
 
not
 
stop
 
taking
 
your
 
medication
 
unless
 
advised
 
to
 
do
 
so
 
by
 
your
 
prescriber
 
 
 
 
Special
 
Considerations
 
Pregnancy
 
 
 
 
Avoid
 
unless
 
benefits
 
outweigh
 
risks
 
 
 
 
Breastfeeding
 
 
 
 
Limited
 
data
 
available--
 
use
 
with
 
caution
 
 
 
 
Elderly
 
 
 
 
Increased
 
risk
 
of
 
adverse
 
effects—use
 
with
 
caution
 
 
 
 
Paediatric
 
 
 
 
Limited
 
data
 
 
 
 
 
Fasting:
 
 
 
 
 
NA
 
 
 
 
Others
:
 
1.
 
Renal
 
impairment:
 
No
 
dose
 
adjustment
 
needed
 
2.
 
Liver
 
Impairment:
 
No
 
dose
 
adjustment
 
needed
 
 
 
 
Side
 
Effects
 
and
 
their
 
Management*
 
Common
 
Side
 
Effects
 
Gastrointestinal:
 
Abdominal
 
cramps,
 
abdominal
 
pain,
 
nausea,
 
vomiting,
 
diarrhoea
 
 
 
 
265
 

=== PAGE 267 ===

 
Neurological:
 
Headache,
 
dizziness,
 
insomnia
 
 
Serious
 
but
 
Rare
 
Side
 
Effects
 
Tendinopathy
 
and
 
tendon
 
rupture
 
Peripheral
 
neuropathy
 
QTc
 
prolongation
 
 
Storage*
 
Store
 
in
 
a
 
cool,
 
dry
 
place,
 
away
 
from
 
sunlight
 
 
 
 
Others
 
Precautions:
 
1.
 
QT
 
prolongation
 
risk
 
:
 
avoid
 
in
 
patients
 
with
 
cardiac
 
arrhythmias
 
or
 
those
 
on
 
QT-prolonging
 
drugs
 
2.
 
May
 
cause
 
photosensitivity:
 
use
 
sunscreen
 
and
 
wear
 
protective
 
clothing
 
3.
 
May
 
trigger
 
seizures:
 
caution
 
in
 
epilepsy
 
or
 
seizure-prone
 
patients
 
4.
 
Avoid
 
in
 
patients
 
with
 
myasthenia
 
gravis:
 
may
 
worsen
 
symptoms
 
5.
 
Tendon
 
pain
 
or
 
swelling:
 
stop
 
medication
 
and
 
see
 
your
 
doctor
 
immediately
 
 
Significant
 
drug-drug
 
/
 
drug-food
 
interactions:
 
1.
 
Avoid
 
taking
 
with
 
milk,
 
calcium,
 
iron
 
supplements,
 
or
 
antacids
 
as
 
these
 
reduce
 
absorption.
 
Administer
 
at
 
least
 
4
 
hours
 
before
 
or
 
8
 
hours
 
after
 
these
 
products.
 
 
2.
 
Avoid
 
alcohol
 
as
 
it
 
may
 
worsen
 
dizziness
 
or
 
other
 
CNS
 
side
 
effects
 
3.
 
Avoid
 
driving
 
or
 
operating
 
machinery
 
if
 
feeling
 
dizzy
 
or
 
light-headed
 
 
 
 
Before
 
ending
 
this
 
peer
 
review
 
session,
 
the
 
reviewee
 
should
 
be
 
informed
 
of
 
the
 
step(s)
 
that
 
he/
 
she
 
missed
 
out
 
in
 
order
 
to
 
ensure
 
all
 
the
 
counselling
 
points
 
are
 
being
 
covered.
 
 
Remarks:
 
 
 
 
 
Reviewed
 
by:
 
Name
 
&
 
Signature
                                                                   
Date:
 
 
 
 
 
*Mandatory
 
for
 
validation
 
/
 
peer
 
review
 
References:
 
 
1.
 
World
 
Health
 
Organization.
 
Guidelines
 
for
 
the
 
diagnosis,
 
treatment
 
and
 
prevention
 
of
 
leprosy .
 
2018
 
2.
 
TB
 
Drug
 
Monographs.
 
Moxifloxacin.
 
https://www .tbdrugmonographs.co.uk/moxifloxacin.html
 
3.
 
WHO
 
Expert
 
Committee
 
on
 
Leprosy .
 
WHO
 
Expert
 
Committee
 
on
 
Leprosy:
 
Eighth
 
Report.
 
World
 
Health
 
Organization.
 
2010
 
4.
 
Critical
 
Care
 
Pharmacy
 
Handbook.
 
Pharmaceutical
 
Services
 
Programme.
 
Second
 
edition.
 
2020
 
5.
 
Manual
 
Pe
ngurusan
 
Kusta
 
Edisi
 
Ke-3.
 
MOH.
 
2023
 
6.
 
Protocol
 
on
 
Drug
 
Administration
 
Via
 
Enteral
 
Feeding
 
Tubes.
 
First
 
edition.
 
MOH.
 
2022
 
7.
 
UpToDate
 
Inc.
 
 
 
 
 
 
 
266
 

=== PAGE 268 ===

 
Mupirocin,
 
Topical
 
 
 
Name
 
:
 
 
Unit
 
:
 
 
●
 
Please
 
tick
 
(
✔
)
 
Yes
 
for
 
correct
 
instruction.
 
●
 
Please
 
tick
 
(
✔
)
 
No
 
for
 
incorrect
 
instruction.
 
Yes
 
No
 
Remarks
 
Pharmacological
 
Group
 
Antibiotics
 
for
 
dermatological
 
use
 
 
 
 
Indications
 
and
 
Dosage
 
Bacterial
 
skin
 
infection,e.g.
 
impetigo,
 
folliculitis
 
and
 
furunculosis:
 
 
Apply
 
2-3
 
times
 
daily
 
for
 
5
 
days.
 
The
 
duration
 
may
 
be
 
extended
 
up
 
to
 
10
 
days,
 
depending
 
on
 
the
 
clinical
 
response.
 
 
 
 
Method
 
of
 
Administration*
 
Topical
 
Application:
 
 
Apply
 
a
 
small
 
amount
 
of
 
mupirocin
 
ointment
 
to
 
the
 
affected
 
area,
 
ensuring
 
it
 
is
 
fully
 
covered.
 
If
 
desired,
 
the
 
treated
 
area
 
may
 
be
 
covered
 
with
 
a
 
dressing,
 
though
 
this
 
is
 
optional
 
unless
 
specifically
 
advised
 
by
 
a
 
healthcare
 
provider .
 
 
Completion
 
of
 
Treatment:
 
 
Continue
 
using
 
the
 
medication
 
for
 
the
 
full
 
prescribed
 
duration,
 
even
 
if
 
symptoms
 
improve
 
before
 
completing
 
the
 
treatment.
 
Do
 
not
 
discontinue
 
the
 
ointment
 
unless
 
instructed
 
by
 
a
 
healthcare
 
provider .
 
This
 
ensures
 
the
 
infection
 
is
 
fully
 
treated
 
and
 
helps
 
prevent
 
resistance.
 
 
 
 
Special
 
Considerations
 
Pregnancy
 
 
 
 
There
 
is
 
no
 
evidence
 
of
 
harm
 
to
 
the
 
fetus,
 
as
 
there
 
is
 
no
 
clinical
 
data
 
on
 
its
 
use
 
during
 
pregnancy .
 
Mupirocin
 
should
 
be
 
used
 
during
 
pregnancy
 
only
 
if
 
the
 
potential
 
benefits
 
outweigh
 
the
 
possible
 
risks.
 
 
 
 
Breastfeeding
 
 
 
 
1.
 
Compatible
 
with
 
breastfeeding
 
2.
 
If
 
applied
 
to
 
the
 
breast
 
or
 
nipple
 
area,
 
it
 
is
 
advisable
 
to
 
cleanse
 
the
 
area
 
thoroughly
 
before
 
breastfeeding
 
to
 
prevent
 
any
 
contact
 
with
 
the
 
infant.
 
 
 
 
Elderly
 
 
 
 
 
1.
 
No
 
restriction
 
of
 
use.
 
2.
 
Patients
 
who
 
use
 
topical
 
oils,
 
creams,
 
and
 
ointments
 
have
 
potential
 
fall
 
risk
 
.Patients
 
may
 
be
 
advised
 
to
 
wear
 
nonslip
 
socks
 
if
 
applying
 
topical
 
medications
 
to
 
feet.
 
Patients
 
should
 
be
 
advised
 
to
 
apply
 
cream
 
while
 
seated
 
or
 
standing
 
on
 
non-slip
 
surfaces.
 
 
 
 
Paediatric
 
 
 
 
1.
 
Application
 
as
 
per
 
adult
 
patients.
 
 
 
 
Others
 
 
 
 
 
1.
 
Do
 
not
 
use
 
polyethylene
 
glycol-based
 
ointments
 
in
 
conditions
 
where
 
absorption
 
of
 
large
 
quantities
 
of
 
polyethylene
 
glycol
 
is
 
possible
 
(e.g.
 
extensive
 
burn
 
or
 
 
 
 
267
 

=== PAGE 269 ===

 
open
 
wounds),
 
especially
 
in
 
the
 
presence
 
of
 
moderate
 
to
 
severe
 
renal
 
impairment.
 
Side
 
Effects
 
and
 
their
 
Management*
 
Burning
 
localized
 
to
 
the
 
area
 
of
 
application
 
is
 
usually
 
transient
 
and
 
resolves
 
with
 
continued
 
use.
 
However ,
 
if
 
the
 
burning
 
persists,
 
discontinue
 
use.
 
The
 
patient
 
should
 
be
 
treated
 
supportively ,
 
with
 
appropriate
 
monitoring
 
as
 
needed.
 
 
 
 
Storage*
 
1.
 
Store
 
in
 
a
 
dry
 
place
 
at
 
a
 
temperature
 
below
 
30°C.
 
2.
 
Protect
 
from
 
light.
 
3.
 
Do
 
not
 
freeze.
 
 
 
 
Others
 
Sensitization
 
or
 
severe
 
irritation:
 
If
 
a
 
sensitization
 
reaction
 
or
 
severe
 
local
 
irritation
 
occurs
 
at
 
the
 
application
 
site,
 
discontinue
 
treatment
 
immediately .
 
Wash
 
the
 
affected
 
area
 
thoroughly
 
to
 
remove
 
the
 
ointment.
 
Prolonged
 
use:
 
As
 
with
 
other
 
antibacterial
 
products,
 
prolonged
 
use
 
of
 
mupirocin
 
ointment
 
may
 
lead
 
to
 
the
 
overgrowth
 
of
 
non-susceptible
 
organisms,
 
including
 
fungi.
 
If
 
this
 
occurs,
 
appropriate
 
treatment
 
should
 
be
 
initiated.
 
Drug
 
interactions:
 
No
 
significant
 
drug
 
interactions
 
have
 
been
 
identified
 
with
 
mupirocin
 
ointment,
 
as
 
it
 
is
 
minimally
 
absorbed
 
through
 
the
 
skin.
 
 
 
 
Before
 
ending
 
this
 
peer
 
review
 
session,
 
the
 
reviewee
 
should
 
be
 
informed
 
of
 
the
 
step(s)
 
that
 
he/
 
she
 
missed
 
out
 
in
 
order
 
to
 
ensure
 
all
 
the
 
counselling
 
points
 
are
 
being
 
covered.
 
 
Remarks:
 
 
 
 
 
Reviewed
 
by:
 
Name
 
&
 
Signature
                                                                   
Date:
 
 
 
 
 
*Mandatory
 
for
 
validation
 
/
 
peer
 
review
 
 
References:
 
 
1.
 
Bethesda
 
(2006).
 
Drugs
 
and
 
Lactation
 
Database
 
(LactMed®)
 
[Internet].
 
National
 
Institute
 
of
 
Child
 
Health
 
and
 
Human
 
Development.
  
Retrieved
 
January
 
21,
 
2025,
 
from
 
https://www .ncbi.nlm.nih.gov/books/NBK501922/
 
2.
 
Cern,
 
A.,
 
et
 
al.
 
(2021).
 
Therapeutic
 
Potential
 
of
 
Injectable
 
Nano-Mupirocin
 
Liposomes
 
for
 
Infections
 
Involving
 
Multidrug-Resistant
 
Bacteria. Pharmaceutics
 
 
3.
 
Kusum
 
Healthcare
 
(2020).
 
Bactopic
 
[Package
 
insert]
 
4.
 
Shivanna,
 
V.
 
&
 
Dasegowda,
 
V.
 
(2023).
 
Comparison
 
of
 
disk
 
diffusion
 
and
 
agar
 
dilution
 
method
 
for
 
the
 
detection
 
of
 
mupirocin
 
resistance
 
in
 
staphylococcal
 
isolates
 
from
 
skin
 
and
 
soft
 
tissue
 
infections. J
 
Lab
 
Physicians. 
 
5.
 
Swiss
 
Garnier
 
Life
 
Sciences
 
(2023).
 
Pirobact
 
[Package
 
insert]
 
6.
 
Price
 
KN,
 
Grinnell
 
M,
 
Butler
 
D,
 
Shah
 
A.
 
Art
 
of
 
prevention:
 
Practical
 
tips
 
for
 
improving
 
adherence
 
to
 
treatments
 
for
 
older
 
patients
 
in
 
dermatology .
 
Int
 
J
 
Womens
 
Dermatol.
 
2021
 
Mar
 
18;7(4):478-481.
 
 
 
 
 
 
268
 

=== PAGE 270 ===

 
Mycophenolate
 
Mofetil/Mycophenolate
 
Sodium
 
Name
 
:
 
 
Unit
 
:
 
 
●
 
Please
 
tick
 
(
✔
)
 
Yes
 
for
 
correct
 
instruction.
 
●
 
Please
 
tick
 
(
✔
)
 
No
 
for
 
incorrect
 
instruction.
 
Yes
 
No
 
Remarks
 
Pharmacological
 
Group
 
Selective
 
immunosuppressants
 
mycophenolic
 
acid
 
 
 
 
Indications
 
and
 
Dosage
 
1.
 
Prophylaxis
 
of
 
acute
 
organ
 
rejection
 
in
 
patients
 
receiving
 
allogeneic
 
kidney ,
 
cardiac
 
and
 
hepatic
 
transplant
 
2.
 
Used
 
with
 
steroids
 
for
 
induction
 
and
 
maintenance
 
of
 
severe
 
lupus
 
nephritis
 
 
Available
 
in
 
two
 
formulations:
 
i)
 
Mycophenolate
 
mofetil
 
(MMF)
 
-
 
Cellcept
 
®,
 
Mycofit
 
®
 
-
 
Available
 
in
 
250
 
mg
 
capsule
 
and
 
500
 
mg
 
tablet
 
ii)
 
Mycophenolate
 
sodium
 
(MPS)
 
-
 
Myfortic
 
®
 
-
 
Available
 
in
 
180
 
mg
 
tablet
 
and
 
360
 
mg
 
tablet
 
 
 
Equimolar
 
dose
 
in
 
terms
 
of
 
mycophenolic
 
acid:
 
i)
 
MMF
 
250
 
mg
 
=
 
MPS
 
180
 
mg
 
ii)
 
MMF
 
500
 
mg
 
=
 
MPS
 
360
 
mg
 
 
●
 
Both
 
are
 
NOT
 
interchangeable.
                                    
:
 
(WARNING:
 
These
 
two
 
formulations
 
are
 
at
 
risk
 
of
 
medication
 
errors)
 
 
 
*Dose
 
will
 
be
 
adjusted
 
based
 
on
 
indication,
 
kidney
 
function
 
&
 
immune
 
response.
 
 
To
 
counsel
 
based
 
on
 
specific
 
medication’ s
 
indication
 
and
 
dosage
 
as
 
prescribed
 
by
 
the
 
doctor
 
  
 
 
Method
 
of
 
Administration*
 
1.
 
To
 
be
 
swallowed
 
whole
 
twice
 
daily,
 
12
 
hours
 
apart.
 
 
2.
 
It
 
may
 
be
 
taken
 
before
 
a
 
meal
 
to
 
improve
 
absorption.
 
If
 
a
 
patient
 
experiences
 
gastrointestinal
 
adverse
 
effects,
 
may
 
take
 
it
 
after
 
a
 
meal
 
to
 
reduce
 
the
 
incidence
 
of
 
adverse
 
effects.
 
Be
 
consistent
 
on
 
either
 
taking
 
it
 
before
 
or
 
after
 
a
 
meal.
 
3.
 
Do
 
not
 
cut/
 
crush/
 
open/
 
chew
 
the
 
capsule
 
or
 
tablet.
 
Missed
 
dose
 
management:
 
1.
 
If
 
dose
 
is
 
missed,
 
patients
 
should
 
take
 
it
 
as
 
soon
 
as
 
possible
 
within
 
six
 
hours
 
after
 
regular
 
dose.
 
2.
 
If
 
it
 
is
 
more
 
than
 
6
 
hours,
 
skip
 
the
 
missed
 
dose
 
and
 
return
 
to
 
normal
 
dosing
 
schedule.
 
 
3.
 
Do
 
not
 
double
 
a
 
dose
 
under
 
any
 
circumstances.
 
 
Do
 
not
 
stop
 
taking
 
your
 
medication
 
unless
 
advised
 
to
 
do
 
so
 
by
 
your
 
prescriber
 
 
 
 
Special
 
Considerations
 
Pregnancy
 
 
 
 
1.
 
Contraindicated
 
in
 
pregnancy .
 
Use
 
appropriate
 
contraception.
 
Pregnancy
 
needs
 
to
 
be
 
pre-planned
 
and
 
switched
 
to
 
an
 
alternative
 
agent
 
before,
 
during
 
pregnancy
 
and
 
breastfeeding.
 
2.
 
Contraception
 
should
 
be
 
practised
 
before
 
initiation
 
of
 
mycophenolate,
 
during
 
the
 
therapy
 
and
 
6
 
weeks
 
after
 
discontinuation
 
of
 
the
 
medication.
 
3.
 
For
 
male
 
patients
 
who
 
are
 
taking
 
mycophenolate
 
and
 
 
 
 
269
 

=== PAGE 271 ===

 
are
 
still
 
sexually
 
active,
 
their
 
partner
 
should
 
also
 
use
 
an
 
effective
 
contraceptive
 
method.
 
Breastfeeding
 
 
 
 
Mycophenolate
 
may
 
be
 
excreted
 
into
 
breast
 
milk
 
and
 
thus,
 
breastfeeding
 
is
 
not
 
recommended
 
while
 
the
 
patient
 
is
 
taking
 
mycophenolate.
 
 
 
 
Elderly
 
 
 
 
Elderly
 
patients
 
may
 
be
 
at
 
an
 
increased
 
risk
 
of
 
adverse
 
events
 
such
 
as
 
infections,
 
possibly
 
gastrointestinal
 
haemorrhage
 
and
 
pulmonary
 
oedema.
 
 
 
 
Paediatric
 
 
 
 
Paediatric
 
patients
 
have
 
the
 
same
 
adverse
 
effect
 
profile
 
as
 
adult
 
patients.
 
Apply
 
the
 
same
 
counselling
 
points
 
as
 
adult
 
patients.
 
 
 
 
Fasting
 
 
 
 
1.
 
If
 
fasting
 
is
 
permissible,
 
take
 
mycophenolate
 
during
 
Sahur
 
(the
 
meal
 
before
 
dawn)
 
and
 
Iftar
 
(the
 
meal
 
after
 
sunset).
 
2.
 
It’s
 
important
 
to
 
stay
 
hydrated
 
throughout
 
the
 
night.
 
If
 
you
 
miss
 
a
 
dose
 
during
 
Sahur ,
 
you
 
must
 
break
 
your
 
fast
 
that
 
day
 
to
 
take
 
the
 
missed
 
dose.
 
 
 
 
Others
  
 
 
 
 
1.
 
Teratogenic
 
effect.
 
Capsules
 
should
 
not
 
be
 
opened,
 
and
 
tablets
 
should
 
not
 
be
 
crushed.
 
2.
 
Avoid
 
inhalation
 
or
 
contact
 
of
 
the
 
skin
 
or
 
mucous
 
membranes
 
with
 
the
 
powder
 
in
 
the
 
capsules.
 
Wash
 
thoroughly
 
with
 
soap
 
and
 
water ,
 
rinse
 
eyes
 
with
 
plain
 
water
 
if
 
such
 
contact
 
occurs.
 
 
 
 
Side
 
Effects
 
and
 
their
 
Management*
 
1.
 
Gastrointestinal
 
-
 
heartburn,
 
nausea,
 
vomiting,
 
diarrhoea
 
 
-
 
May
 
take
 
the
 
dose
 
after
 
a
 
meal
 
-
 
May
 
discuss
 
with
 
the
 
prescriber
 
to
 
split
 
the
 
dosing
 
into
 
TDS
 
or
 
QID
 
to
 
minimise
 
the
 
adverse
 
effect.
 
For
 
example,
 
Mycophenolate
 
mofetil
 
500
 
mg
 
TDS
 
instead
 
of
 
750
 
mg
 
BD
 
-
 
May
 
discuss
 
with
 
the
 
prescriber
 
to
 
switch
 
to
 
a
 
different
 
strength
 
or
 
different
 
formulation.
 
For
 
example,
 
switch
 
from
 
MMF
 
to
 
MPS,
 
or
 
replace
 
every
 
500
 
mg
 
MMF
 
tablet
 
with
 
two
 
250
 
mg
 
MMF
 
capsule
 
 
-
 
Notify
 
the
 
prescriber
 
if
 
symptoms
 
persist
 
2.
 
Cytopenias,
 
including
 
anaemia,
 
leukopaenia
 
and
 
thrombocytopaenia
 
 
-
 
Monitor
 
blood
 
counts
 
-
 
Take
 
note
 
of
 
signs
 
and
 
symptoms
 
of
 
infections
 
(such
 
as
 
fever ,
  
cough,
 
sore
 
throat,
 
pain
 
or
 
difficulty
 
in
 
passing
 
urine)
 
-
 
Take
 
note
 
of
 
signs
 
and
 
symptoms
 
of
 
bleeding
 
(such
 
as
 
bruising,
 
tarry
 
stools,
 
blood
 
in
 
vomitus
 
or
 
blood
 
in
 
urine)
 
-
 
Seek
 
treatment
 
immediately
 
when
 
signs
 
and
 
symptoms
 
occur
 
3.
 
Increase
 
risk
 
of
 
infections
 
-
 
Practise
 
frequent
 
hand-washing
 
-
 
Avoid
 
close
 
contact
 
with
 
sick
 
people
 
who
 
have
 
 
 
 
270
 

=== PAGE 272 ===

 
active
 
infections
 
-
 
Seek
 
treatment
 
immediately
 
when
 
signs
 
and
 
symptoms
 
occur
 
4.
 
Increase
 
risk
 
of
 
malignancies,
 
especially
 
lymphoma
 
and
 
skin
 
cancer
 
-
  
Use
 
sunscreen
 
with
 
a
 
high
 
protection
 
factor
 
and
 
wear
 
protective
 
clothing
 
that
 
covers
 
the
 
head,
 
neck,
 
arms
 
and
 
legs
 
when
 
being
 
outdoors.
 
Storage*
 
1.
 
Store
 
at
 
room
 
temperature.
 
Protect
 
from
 
moisture.
 
Store
 
in
 
the
 
original
 
package.
 
2.
 
Mycophenolate
 
capsules
 
or
 
tablets
 
should
 
remain
 
in
 
the
 
blister
 
when
 
kept
 
in
 
the
 
pillbox.
 
3.
 
Mycophenolate
 
capsules
 
or
 
tablets
 
should
 
be
 
taken
 
immediately
 
after
 
being
 
removed
 
from
 
the
 
blister
 
pack.
 
 
 
 
Others
 
1.
 
Do
 
not
 
switch
 
to
 
another
 
brand
 
of
 
mycophenolate
 
without
 
informing
 
the
 
prescriber .
 
2.
 
Avoid
 
live-attenuated
 
vaccination.
 
3.
 
Drug-drug
 
interactions:
 
i)
 
Antacid
 
or
 
proton-pump
 
inhibitor-
  
May
 
decrease
 
mycophenolate
 
level.
 
Try
 
to
 
leave
 
a
 
2
 
hours
 
gap
 
between
 
mycophenolate
 
and
 
antacid
 
or
 
proton-pump
 
inhibitor .
 
ii)
 
Sevelamer
 
–
 
May
 
decrease
 
mycophenolate
 
level.
 
Try
 
to
 
leave
 
a
 
1
 
to
 
3
 
hours
 
gap
 
between
 
mycophenolate
 
and
 
sevelamer .
 
 
 
 
Before
 
ending
 
this
 
peer
 
review
 
session,
 
the
 
reviewee
 
should
 
be
 
informed
 
of
 
the
 
step(s)
 
that
 
he/
 
she
 
missed
 
out
 
in
 
order
 
to
 
ensure
 
all
 
the
 
counselling
 
points
 
are
 
being
 
covered.
 
 
Remarks:
 
 
 
 
Reviewed
 
by:
 
Name
 
&
 
Signature
                                                                   
Date:
 
 
 
 
*Mandatory
 
for
 
validation
 
/
 
peer
 
review
 
References:
 
 
1.
 
Formulari
 
Ubat
 
KKM.
 
(2025,
 
January
 
1).
 
Accessed
 
on
 
January
 
1,
 
2025.
 
2.
 
Roche,
 
Ltd,
 
Basel,
 
Switzerland
 
(2023).
 
Product
 
information
 
leaflet:
 
Cellcept.
 
Retrieved
 
from
 
Quest
 
3+
 
Product
 
Search
 
on
 
January
 
1,
 
2025
 
3.
 
INTAS
 
Pharmaceuticals.,
 
Ltd
 
(2024).
 
Product
 
information
 
leaflet:
 
Mycofit.
 
Retrieved
 
from
 
Quest
 
3+
 
Product
 
Search
 
on
 
January
 
1,
 
2025.
 
4.
 
Novartis
 
Pharma
 
AG,
 
Basel,
 
Switzerland
 
(2021).
 
Product
 
information
 
leaflet:
 
Myfortic.
 
Retrieved
 
from
 
Quest
 
3+
 
Product
 
Search
 
on
 
January
 
1,
 
2025.
 
 
5.
 
BC
 
Transplant
 
–
 
Provincial
 
Health
 
Services
 
Authority .
 
(2021,
 
May).
 
Medication
 
guidelines
 
for
 
solid
 
organ
 
transplant
 
(Version
 
2)
 
6.
 
Rovin,
 
B.
 
H.,
 
Ayoub,
 
I.
 
M.,
 
Chan,
 
T.
 
M.,
 
Liu,
 
Z.
 
H.,
 
Mejía-V ilet,
 
J.
 
M.,
 
&
 
Floege,
 
J.
 
(2024).
 
KDIGO
 
2024
 
Clinical
 
Practice
 
Guideline
 
for
 
the
 
management
 
of
 
LUPUS
 
NEPHRITIS. Kidney
 
International, 105(1),
 
S1-S69.
 
7.
 
Boobes,
 
Y.,
 
Afandi,
 
B.O.,
 
Alkindi,
 
F.,
 
Tarakji,
 
A.R.,
 
Al
 
Ghamdi,
 
S.M.,
 
Alrukhaimi,
 
M.,
 
Hassanein,
 
M.,
 
Alsahow ,
 
A.,
 
Said,
 
R.,
 
Alsaid,
 
J.,
 
Alsuwaida,
 
A.,
 
Al
 
Obaidli,
 
A.A.,
 
Alketbi,
 
L.B.,
 
Boubes,
 
K.Y.,
 
Attallah,
 
N.,
 
Al
 
Salmi,
 
I.,
 
Abdelhamid,
 
Y.M.,
 
Bashir ,
 
N.,
 
Aburahma,
 
R.M.,
 
Hassan,
 
M.H.,
 
&
 
Al-Hakim,
 
M.R.
 
(2024).
 
Consensus
 
recommendations
 
on
 
fasting
 
during
 
Ramadan
 
for
 
patients
 
with
 
kidney
 
disease:
 
review
 
of
 
available
 
evidence
 
and
 
a
 
call
 
for
 
action
 
(RaK
 
Initiative).
 
BMC
 
Nephrology ,
 
25.
 
 
 
 
 
271
 

=== PAGE 273 ===

 
Neomycin,
 
Topical
 
Name
 
:
 
 
Unit
 
:
 
 
●
 
Please
 
tick
 
(
✔
)
 
Yes
 
for
 
correct
 
instruction.
 
●
 
Please
 
tick
 
(
✔
)
 
No
 
for
 
incorrect
 
instruction.
 
Yes
 
No
 
Remarks
 
Pharmacological
 
Group
 
Antibiotic,
 
Topical
 
 
 
 
Indications
 
and
 
Dosage
 
Neomycin
 
is
 
indicated
 
for
 
the
 
treatment
 
of
 
skin
 
infection
 
caused
 
by
 
susceptible
 
organisms:
 
 
Apply
 
sparingly
 
to
 
the
 
affected
 
area
 
up
 
to
 
3
 
times
 
daily
 
(for
 
short
 
term
 
use,
 
1-2
 
weeks).
 
 
 
 
Method
 
of
 
Administration*
 
1.
 
Clean
 
the
 
affected
 
area
 
thoroughly
 
with
 
soap
 
and
 
water
 
before
 
applying
 
the
 
cream.
 
Dry
 
the
 
area
 
completely
 
with
 
a
 
clean
 
towel
 
or
 
cloth.
 
2.
 
Apply
 
a
 
thin
 
layer
 
of
 
the
 
cream
 
to
 
the
 
affected
 
area,
 
gently
 
massaging
 
it
 
in
 
to
 
ensure
 
even
 
coverage.
 
3.
 
If
 
desired,
 
you
 
can
 
cover
 
the
 
treated
 
area
 
with
 
a
 
sterile
 
gauze
 
dressing
 
after
 
application,
 
but
 
this
 
is
 
not
 
required
 
unless
 
a
 
healthcare
 
provider
 
recommends
 
it.
 
 
Do
 
not
 
stop
 
taking
 
your
 
medication
 
unless
 
advised
 
to
 
do
 
so
 
by
 
your
 
prescriber
 
 
 
 
Special
 
Considerations
 
Pregnancy
 
 
 
 
Safety
 
for
 
use
 
in
 
pregnancy
 
has
 
not
 
been
 
established.
 
(Pregnancy
 
Category:
 
C)
 
 
 
 
Breastfeeding
 
 
 
 
Safety
 
for
 
use
 
in
 
breastfeeding
 
has
 
not
 
been
 
established.
 
 
 
 
Elderly
 
 
 
 
Patients
 
who
 
use
 
topical
 
oils,
 
creams,
 
and
 
ointments
 
have
 
potential
 
fall
 
risk
 
.Patients
 
may
 
be
 
advised
 
to
 
wear
 
nonslip
 
socks
 
if
 
applying
 
topical
 
medications
 
to
 
feet.
 
Patients
 
should
 
be
 
advised
 
to
 
apply
 
cream
 
while
 
seated
 
or
 
standing
 
on
 
non-slip
 
surfaces.
 
 
 
 
Paediatric
 
 
 
 
There
 
is
 
limited
 
data
 
specifically
 
regarding
 
the
 
use
 
of
 
topical
 
neomycin
 
in
 
pediatric
 
populations.
 
Therefore,
 
there
 
is
 
no
 
specific
 
information
 
available
 
comparing
 
the
 
safety
 
and
 
efficacy
 
of
 
neomycin
 
cream
 
in
 
children.
 
 
 
 
 
Fasting
 
 
 
 
Not
 
applicable
 
 
 
 
 
Others
 
 
 
 
 
N/A
 
 
 
 
Side
 
Effects
 
and
 
their
 
Management*
 
Hypersensitivity
 
Reactions:
 
-
 
Common
 
reactions
 
(often
 
delayed)
 
include
 
burning,
 
redness,
 
or
 
irritation
 
at
 
the
 
application
 
site.
 
These
 
are
 
 
 
 
272
 

=== PAGE 274 ===

 
typically
 
mild
 
and
 
resolve
 
after
 
discontinuing
 
use.
 
Serious
 
Side
 
Effects
 
(Rarely
 
Reported):
 
-
 
Balance
 
or
 
hearing
 
problems
 
(especially
 
with
 
prolonged
 
or
 
widespread
 
use,
 
as
 
neomycin
 
can
 
be
 
systemically
 
absorbed
 
in
 
certain
 
cases).
 
-
 
Folliculitis:
 
Small
 
red
 
bumps
 
or
 
pustules
 
may
 
appear
 
on
 
the
 
skin.
 
Storage*
 
Store
 
at
 
or
 
below
 
30
o
C.
 
Protect
 
from
 
freezing.
 
 
 
 
Others
 
1.
 
Contraindication
 
in
 
patients
 
with
 
hypersensitivity
 
to
 
neomycin
 
or
 
other
 
aminoglycosides.
 
2.
 
Do
 
not
 
apply
 
to
 
deep
 
or
 
punctured
 
wounds,
 
serious
 
burns,
 
or
 
raw
 
areas
 
unless
 
specifically
 
directed
 
by
 
a
 
physician
 
3.
 
Avoid
 
contact
 
with
 
the
 
eyes
 
or
 
the
 
inside
 
of
 
the
 
moutj.
 
If
 
the
 
medication
 
comes
 
into
 
contact
 
with
 
these
 
areas,
 
wipe
 
it
 
off
 
immediately
 
and
 
rinse
 
thoroughly
 
with
 
water .
 
 
 
 
Before
 
ending
 
this
 
peer
 
review
 
session,
 
the
 
reviewee
 
should
 
be
 
informed
 
of
 
the
 
step(s)
 
that
 
he/
 
she
 
missed
 
out
 
in
 
order
 
to
 
ensure
 
all
 
the
 
counselling
 
points
 
are
 
being
 
covered.
 
 
Remarks:
 
 
 
 
 
Reviewed
 
by:
 
Name
 
&
 
Signature
                                                                   
Date:
 
 
 
 
 
*Mandatory
 
for
 
validation
 
/
 
peer
 
review
 
 
References:
 
 
1.
 
Formulari
 
Ubat
 
KKM
 
(2025).
 
Ministry
 
of
 
Health
 
Malaysia.
 
Retrieved
 
January
 
20,
 
2025
 
from
 
 
https://pharmacy .moh.gov .my/ms/apps/fukkm?generic=neomycin&category=&indications=
 
2.
 
Hovid
 
BHD
 
(2023).
 
Neomycin
 
cream
 
0.5%
 
[product
 
Insert]
 
3.
 
Price
 
KN,
 
Grinnell
 
M,
 
Butler
 
D,
 
Shah
 
A.
 
Art
 
of
 
prevention:
 
Practical
 
tips
 
for
 
improving
 
adherence
 
to
 
treatments
 
for
 
older
 
patients
 
in
 
dermatology .
 
Int
 
J
 
Womens
 
Dermatol.
 
2021
 
Mar
 
18;7(4):478-481.
 
 
 
 
 
 
 
 
 
 
 
 
 
 
273
 

=== PAGE 275 ===

 
Nevirapine
 
 
Name
 
:
 
 
Unit
 
:
 
 
●
 
Please
 
tick
 
(
✔
)
 
Yes
 
for
 
correct
 
instruction.
 
●
 
Please
 
tick
 
(
✔
)
 
No
 
for
 
incorrect
 
instruction.
 
Yes
 
No
 
Remarks
 
Pharmacological
 
Group
 
Non-Nucleoside
 
Reverse
 
Transcriptase
 
Inhibitors
 
(NNR TIs)
 
 
 
 
Indications
 
and
 
Dosage
 
Treatment
 
for
 
HIV-1
 
infections
 
in
 
combination
 
with
 
Nucleoside
 
Reverse
 
Transcriptase
 
Inhibitors
 
(NRTIs)
 
1.
 
Adults:
 
 
a.
 
200mg
 
OD
 
for
 
the
 
first
 
14
 
days
 
upon
 
initiation,
 
followed
 
by
 
200mg
 
BD
 
if
 
no
 
rash
 
or
 
hepatitis.
 
b.
 
If
 
a
 
patient
 
experiences
 
non-severe
 
rash
 
(without
 
constitutional
 
symptoms)
 
during
 
the
 
14-day
 
lead-in
 
period
 
with
 
200mg/day ,
 
do
 
not
 
increase
 
to
 
200mg
 
BD
 
until
 
rash
 
has
 
resolved.
 
If
 
rash
 
continues
 
beyond
 
28
 
days
 
on
 
the
 
200mg/day
 
dose,
 
use
 
an
 
alternative
 
regimen.
 
b.
 
Re-introduce
 
with
 
lead-in
 
dose
 
for
 
14
 
days
 
if
 
treatment
 
is
 
interrupted
 
for
 
>7
 
days.
 
 
2.
 
Paediatrics:
 
a.
 
Infants
 
and
 
children
 
<8
 
years:
 
200mg/m
2
/dose
 
OD
 
(max:
 
200mg/dose)
 
the
 
first
 
14
 
days
 
upon
 
initiation,
 
followed
 
by
 
200mg/m
2
/dose
 
BD
 
(max:
 
200mg/dose)
 
if
 
no
 
rash.
 
b.
 
Children
 
≥
8
 
years:
 
120-150mg/m
2
/dose
 
OD
 
(max:
 
200mg/dose)
 
the
 
first
 
14
 
days
 
upon
 
initiation,
 
followed
 
by
 
120-150mg/m
2
/dose
 
BD
 
(max:
 
200mg/dose)
 
if
 
no
 
rash.
 
c.
 
Adolescents:
 
200mg
 
OD
 
for
 
the
 
first
 
14
 
days
 
upon
 
initiation,
 
followed
 
by
 
200mg
 
BD
 
if
 
no
 
rash.
 
c.
 
If
 
a
 
patient
 
experiences
 
non-severe
 
rash
 
(without
 
constitutional
 
symptoms)
 
during
 
the
 
14-day
 
lead-in
 
period,
 
do
 
not
 
increase
 
the
 
dose
 
until
 
the
 
rash
 
has
 
resolved.
 
If
 
rash
 
continues
 
beyond
 
28
 
days,
 
use
 
an
 
alternative
 
regimen.
 
d.
 
If
 
nevirapine
 
is
 
interrupted
 
≤
 
14
 
days
 
(infants/children)
 
or
 
≤
 
7
 
days
 
(adolescents),
 
restart
 
at
 
the
 
full
 
dose.
  
Re-introduce
 
with
 
lead-in
 
dose
 
for
 
14
 
days
 
if
 
treatment
 
is
 
interrupted
 
for
 
>7
 
days.
 
 
 
 
 
Method
 
of
 
Administration*
 
1.
 
May
 
be
 
taken
 
with
 
or
 
without
 
food.
 
2.
 
For
 
oral
 
suspensions,
 
shake
 
the
 
suspension
 
gently
 
prior
 
to
 
administration,
 
the
 
use
 
of
 
oral
 
dosing
 
syringe
 
is
 
recommended.
 
 
Missed
 
dose
 
management
 
 
1.
 
To
 
take
 
medication
 
consistently
 
at
 
the
 
same
 
time
 
everyday .
 
Any
 
missed
 
dose
 
to
 
be
 
taken
 
as
 
soon
 
as
 
possible.
 
2.
 
However
 
if
 
the
 
gap
 
is
 
more
 
than
 
6
 
hours,
 
to
 
skip
 
and
 
continue
 
with
 
a
 
regular
 
dosing
 
schedule.
 
Do
 
not
 
double
 
the
 
dose
 
on
 
the
 
next
 
administration
 
time.
 
 
Do
 
not
 
stop
 
taking
 
your
 
medication
 
unless
 
advised
 
to
 
do
 
so
 
by
 
your
 
prescriber .
 
 
 
 
Special
 
Pregnancy
 
 
 
 
274
 

=== PAGE 276 ===

 
Considerations
 
1.
 
Nevirapine
 
is
 
not
 
recommended
 
in
 
female
 
patients
 
who
 
are
 
trying
 
to
 
conceive.
 
 
2.
 
Nevirapine
 
has
 
a
 
high
 
level
 
of
 
transfer
 
across
 
the
 
human
 
placenta.
 
3.
 
Nevirapine
 
is
 
not
 
recommended
 
as
 
an
 
initial
 
NNR TI
 
for
 
use
 
in
 
treatment
 
of
 
naïve
 
pregnant
 
patients
 
because
 
of
 
the
 
potential
 
adverse
 
events.
 
 
4.
 
Patients
 
who
 
become
 
pregnant
 
while
 
on
 
nevirapine
 
may
 
continue
 
if
 
viral
 
load
 
suppressive
 
is
 
achieved
 
and
 
the
 
regimen
 
is
 
well
 
tolerated.
 
 
 
 
 
Breastfeeding
 
 
 
 
1.
 
Nevirapine
 
is
 
present
 
in
 
breast
 
milk.
 
2.
 
Mothers
 
living
 
with
 
HIV
 
are
 
not
 
recommended
 
to
 
breastfeed
 
their
 
infants
 
to
 
avoid
 
risk
 
of
 
transmission
 
to
 
the
 
baby .
 
Because
 
of
 
the
 
potential
 
for
 
HIV
 
transmission
 
in
 
breastfed
 
infants,
 
advise
 
women
 
not
 
to
 
breastfeed.
 
 
 
 
Elderly
 
 
 
 
None
 
specifically
 
to
 
Nevirapine
 
 
 
 
Paediatric
 
 
 
 
1.
 
May
 
use
 
the
 
oral
 
suspension
 
or
 
tablet
 
formulation.
 
 
2.
 
CD4
 
>15%:
 
3-fold
 
increased
 
risk
 
of
 
rash
 
and
 
hepatotoxicity
 
during
 
initiation.
 
 
 
 
Fasting
 
 
 
 
1.
 
To
 
be
 
discussed
 
with
 
infectious
 
disease
 
consultant
 
 
 
 
Others
  
 
 
 
 
1.
 
Contraindicated
 
in
 
moderate
 
or
 
severe
 
hepatic
 
impairment
 
(Child-Pugh
 
B
 
or
 
C).
 
 
2.
 
No
 
renal
 
dose
 
adjustment
 
needed
 
for
 
any
 
degree
 
of
 
impairment.
 
An
 
additional
 
dose
 
of
 
nevirapine
 
should
 
be
 
given
 
following
 
dialysis.
 
 
 
 
 
Side
 
Effects
 
and
 
their
 
Management*
 
1.
 
Rash,
 
including
 
Stevens-Johnson
 
syndrome
 
-
 
Patients
 
must
 
be
 
monitored
 
intensively
 
during
 
the
 
18
 
weeks
 
of
 
therapy
 
to
 
detect
 
any
 
potentially
 
life-threatening
 
event.
 
2.
 
Hepatotoxicity
 
-
 
Patients
 
must
 
be
 
monitored
 
intensively
 
during
 
the
 
18
 
weeks
 
of
 
therapy
 
to
 
detect
 
any
 
potentially
 
life-threatening
 
hepatotoxicity .
 
-
 
Do
 
not
 
restart
 
nevirapine
 
following
 
clinical
 
hepatitis,
 
transaminitis
 
combined
 
with
 
rash
 
or
 
other
 
systemic
 
symptoms
 
3.
 
Abdominal
 
pain,
 
diarrhoea
 
 
 
 
Storage*
 
Store
 
at
 
room
 
temperature.
 
 
 
 
Others
 
1.
 
Nevirapine
 
is
 
a
 
substrate
 
and
 
inducer
 
of
 
cytochrome
 
P450
 
(CYP)
 
3A4
 
and
 
CYP2B6.
 
To
 
check
 
for
 
any
 
potential
 
drug
 
interactions.
 
2.
 
Nevirapine
 
should
 
not
 
be
 
initiated
 
in
 
antiretroviral
 
naïve
 
patients
 
with
 
elevated
 
CD4
 
counts
 
i.e.
 
females
 
with
 
CD4>250cells/mm;
 
males
 
with
 
CD4>400cells/mm3
 
 
 
 
275
 

=== PAGE 277 ===

 
Before
 
ending
 
this
 
peer
 
review
 
session,
 
the
 
reviewee
 
should
 
be
 
informed
 
of
 
the
 
step(s)
 
that
 
he/
 
she
 
missed
 
out
 
in
 
order
 
to
 
ensure
 
all
 
the
 
counselling
 
points
 
are
 
being
 
covered.
 
 
Remarks:
 
 
 
 
 
Reviewed
 
by:
 
Name
 
&
 
Signature
                                                                   
Date:
 
 
 
 
 
*Mandatory
 
for
 
validation
 
/
 
peer
 
review
 
References:
 
 
1.
 
Nevirapine.
 
(n.d.).
 
Formulari
 
Ubat
 
Kementerian
 
Kesihatan
 
Malaysia
 
(FUKKM).
 
Retrieved
 
November
 
2024.
 
2.
 
Panel
 
on
 
Antiretroviral
 
Guidelines
 
for
 
Adults
 
and
 
Adolescents.
 
(n.d.).
 
Guidelines
 
for
 
the
 
Use
 
of
 
Antiretroviral
 
Agents
 
in
 
Adults
 
and
 
Adolescents
 
with
 
HIV.
 
Department
 
of
 
Health
 
and
 
Human
 
Services.
 
Retrieved
 
from
 
https://clinicalinfo.hiv .gov/en/guidelines/adult-and-adolescent-arv .
 
3.
 
Malaysian
 
Society
 
for
 
HIV
 
Medicine.
 
(2022).
 
Malaysian
 
Consensus
 
Guidelines
 
on
 
Antiretroviral
 
Therapy
 
2022
 
4.
 
Nevirapine.
 
(n.d.).
 
In
 
UpToDate.
 
Retrieved
 
January
 
21,
 
2025.
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
276
 

=== PAGE 278 ===

 
Nifedipine
 
 
Name
 
:
 
 
Unit
 
:
 
 
●
 
Please
 
tick
 
(
✔
)
 
Yes
 
for
 
correct
 
instruction.
 
●
 
Please
 
tick
 
(
✔
)
 
No
 
for
 
incorrect
 
instruction.
 
Yes
 
No
 
Remarks
 
Pharmacological
 
Group
 
Nifedipine
 
 
 
 
Indications
 
and
 
Dosage
 
1.
 
Hypertension
 
a.
 
10mg
 
TDS.
 
Maximum
 
60mg/day
 
2.
 
Antianginal
 
a.
 
10mg
 
TDS.
 
Maximum
 
60mg/day
 
 
To
 
counsel
 
based
 
on
 
specific
 
medication’ s
 
indication
 
and
 
dosage
 
as
 
prescribed
 
by
 
the
 
doctor
 
 
 
 
Method
 
of
 
Administration*
 
1.
 
Should
 
be
 
taken
 
swallowed
 
with
 
water ,before
 
or
 
after
 
meal
 
2.
 
Avoid
 
taking
 
with
 
grapefruit
 
juice.
 
 
Do
 
not
 
stop
 
taking
 
your
 
medication
 
unless
 
advised
 
to
 
do
 
so
 
by
 
your
 
prescriber
 
 
 
 
Special
 
Considerations
 
Pregnancy
 
 
 
 
Human
 
Data
 
Suggest
 
Low
 
Risk
 
in
 
pregnancy
 
 
 
 
Breastfeeding
 
 
 
 
Nifedipine
 
is
 
excreted
 
into
 
breast
 
milk
.
 
Classified
 
as
 
compatible
 
with
 
breastfeeding
 
 
 
 
Elderly
 
 
 
 
1.
 
Initial
 
treatment
 
with
 
lower
 
daily
 
dose
 
should
 
be
 
considered.
 
2.
 
Beers
 
Criteria:
 
Avoid
 
use,
 
potential
 
for
 
hypotension;
 
risk
 
of
 
precipitating
 
myocardial
 
ischemia.
 
 
 
 
Paediatric
 
 
 
 
Limited
 
data.
 
 
 
 
 
Fasting
 
 
 
 
To
 
refer
 
to
 
the
 
latest
 
advisory
 
by
 
religious
 
authority
 
 
 
 
Others
 
 
 
 
1.
 
Renal
 
impairment:
 
No
 
dosage
 
adjustment.
 
Not
 
removed
 
by
 
hemo-
 
or
 
peritoneal
 
dialysis;
 
supplemental
 
dose
 
is
 
not
 
necessary
 
2.
 
Liver
 
impairment:
 
No
 
dosage
 
adjustment.
 
Use
 
with
 
caution
 
as
 
clearance
 
of
 
Nifedipine
 
is
 
reduced
 
in
 
cirrhotic
 
patients.
 
A
 
dose
 
reduction
 
may
 
be
 
necessary .
 
 
 
 
 
Side
 
Effects
 
and
 
their
 
Management*
 
1.
 
Significant: Peripheral
 
oedema,
 
deterioration
 
of
 
heart
 
failure;
 
symptomatic
 
hypotension
 
with
 
or
 
without
 
syncope
 
(conventional
 
form).
 
Rarely ,
 
exacerbation
 
of
 
 
 
 
 
277
 

=== PAGE 279 ===

 
angina
 
and/or
 
acute
 
MI
 
(during
 
treatment
 
initiation
 
or
 
dose
 
increase
 
2.
 
Cardiac
 
disorders: Palpitations
 
3.
 
Gastrointestinal
 
disorders: Constipation,
 
abdominal
 
pain,
 
dyspepsia,
 
diarrhoea,
 
flatulence,
 
dry
 
mouth,
 
nausea,
 
heartburn.
 
4.
 
Musculoskeletal
 
and
 
connective
 
tissue
 
disorders: Muscle
 
cramps
 
5.
 
Nervous
 
system
 
disorders: Headache,
 
dizziness,
 
tremor .
 
6.
 
Psychiatric
 
disorders: Nervousness,
 
mood
 
changes.
 
7.
 
Respiratory ,
 
thoracic
 
and
 
mediastinal
 
disorders: Nasal
 
congestion,
 
cough,
 
wheezing,
 
sore
 
throat,
 
dyspnoea.
 
8.
 
Skin
 
and
 
subcutaneous
 
tissue
 
disorders: Dermatitis,
 
rash,
 
pruritus,
 
urticaria,
 
diaphoresis.
 
9.
 
Vascular
 
disorders: V asodilation,
 
flushing.
 
Storage*
 
1.
 
Room
 
temperature.
 
Do
 
not
 
store
 
above
 
30
0
C
 
 
 
 
Others
 
1.
 
Enzyme
 
inhibitor
 
of
 
cytochrome
 
P450
 
has
 
been
 
shown
 
to
 
cause
 
increase
 
in
 
Nifedipine
 
plasma
 
concentrations
 
such
 
as:
 
-
 
Erythromycin
 
-
 
Ritonavir
 
-
 
Ketoconazole
 
-
 
Fluoxetine
 
-
 
Valproic
 
Acid
 
2.
 
Enzyme
 
inducer
 
of
 
cytochrome
 
P450
 
may
 
cause
 
decrease
 
in
 
Nifedipine
 
plasma
 
concentrations
 
such
 
as:
 
-
 
Phenytoin
 
-
 
Carbamazepine
 
-
 
Rifampicin
 
-
 
Barbiturates
 
 
 
 
Before
 
ending
 
this
 
peer
 
review
 
session,
 
the
 
reviewee
 
should
 
be
 
informed
 
of
 
the
 
step(s)
 
that
 
he/
 
she
 
missed
 
out
 
in
 
order
 
to
 
ensure
 
all
 
the
 
counselling
 
points
 
are
 
being
 
covered.
 
 
Remarks:
 
 
 
 
 
Reviewed
 
by:
 
Name
 
&
 
Signature
                                                                   
Date:
 
 
 
 
 
*Mandatory
 
for
 
validation
 
/
 
peer
 
review
 
References:
 
 
1.
 
Product
 
Information
 
Leaflet.
 
FENAMON
 
10mg
 
tablets
 
(MEDOCHEMIE)
 
2.
 
Briggs
 
G
 
et
 
al
 
(2022).
 
Drugs
 
in
 
Pregnancy
 
and
 
Lactation
 
12
th
 
Edition
 
3.
 
Nifedipine
  
(2024).
 
MIMS
 
(online)
 
4.
 
2023
 
American
 
Geriatrics
 
Society
 
Beers
 
Criteria®
 
Update
 
Expert
 
Panel.
 
(2023).
 
American
 
Geriatrics
 
Society
 
2023
 
updated
 
AGS
 
Beers
 
Criteria®
 
for
 
potentially
 
inappropriate
 
medication
 
use
 
in
 
older
 
adults.
 
Journal
 
of
 
the
 
American
 
Geriatrics
 
Society ,
 
71(7),
 
2052-2081
.
 
 
 
 
 
 
 
 
 
 
278
 

=== PAGE 280 ===

 
Non-steroidal
 
Anti-inflammatory
 
Drugs
 
(NSAIDs)
 
/
 
COX-2
 
Inhibitors
 
Name
 
:
 
 
Unit
 
:
 
 
●
 
Please
 
tick
 
(
✔
)
 
Yes
 
for
 
correct
 
instruction.
 
●
 
Please
 
tick
 
(
✔
)
 
No
 
for
 
incorrect
 
instruction.
 
Yes
 
No
 
Remarks
 
Pharmacological
 
Group
 
Antiinflammatory
 
and
 
antirheumatic
 
products,
 
non-steroids
 
 
 
 
Indications
 
and
 
Dosage
 
Indication
 
 
1.
 
Pain
 
and
 
inflammation
 
in
 
rheumatic
 
disease
 
 
Dosage
 
1.
 
Celecoxib:
 
200
 
-
 
400
 
mg
 
daily
 
in
 
1-2
 
divided
 
doses
 
2.
 
Diclofenac:
 
Initial
 
dose
 
of
 
150
 
mg
 
daily.
 
Mild
 
or
 
long
 
term:
 
75
 
-
 
150
 
mg
 
daily
 
in
 
2
 
to
 
3
 
divided
 
doses
 
after
 
food.
 
3.
 
Etoricoxib:
 
60
 
-
 
120
 
mg
 
once
 
daily
 
4.
 
Ibuprofen:
 
200
 
-
 
400
 
mg
 
3
 
times
 
daily
 
after
 
food,
 
maximum
 
3.2
 
g
 
daily
 
5.
 
Mefenamic
 
acid:
 
250
 
-
 
500
 
mg
 
3
 
times
 
daily
 
after
 
meals.
 
6.
 
Meloxicam:
 
initially
 
7.5
 
mg
 
daily.
 
May
 
be
 
increased
 
to
 
15
 
mg
 
daily
 
7.
 
Naproxen:
 
500
 
mg
 
initially
 
then
 
250
 
mg
 
every
 
6
 
-
 
8
 
hour
 
as
 
required
 
 
 
To
 
counsel
 
based
 
on
 
specific
 
medication’ s
 
indication
 
and
 
dosage
 
as
 
prescribed
 
by
 
the
 
doctor
 
 
 
 
Method
 
of
 
Administration*
 
Immediate
 
release:
 
1.
 
Administer
 
IR
 
formulations
 
with
 
food
 
or
 
milk
 
to
 
avoid
 
gastric
 
distress.
 
2.
 
RT
 
administration:
 
IR
 
formulations
 
can
 
be
 
crushed
 
(e.g.:
 
Ibuprofen)
 
or
 
capsules
 
(e.g.:
 
Celecoxib)
 
can
 
be
 
opened
 
and
 
mixed
 
with
 
water
 
for
 
RT
 
administration.
 
 
Extended
 
release:
 
1.
 
Do
 
not
 
break,
 
crush
 
or
 
chew
 
delayed-release
 
or
 
ER
 
tablets.
 
Should
 
swallow
 
the
 
tablet
 
whole
 
with
 
food
 
or
 
milk
 
to
 
avoid
 
gastric
 
distress.
 
2.
 
In
 
the
 
event
 
RT
 
administration
 
is
 
required:
 
Place
 
the
 
tablet
 
in
 
10
 
mL
 
of
 
water ,
 
where
 
it
 
quickly
 
breaks
 
into
 
fine
 
granules
 
that
 
can
 
be
 
easily
 
mixed
 
and
 
flushed
 
through
 
a
 
RT.
 
3.
 
E.g.:
 
Etoricoxib
 
and
 
Meloxicam
 
 
Please
 
refer
 
to
 
the
 
specific
 
brand
 
guidelines
 
for
 
feasibility
 
and
 
instructions
 
for
 
RT
 
administration.
 
 
Do
 
not
 
stop
 
taking
 
your
 
medication
 
unless
 
advised
 
to
 
do
 
so
 
by
 
your
 
prescriber
 
 
 
 
Special
 
Considerations
 
Pregnancy
 
 
 
 
1.
 
NSAIDs
 
can
 
cross
 
the
 
placenta
 
and
 
may
 
increase
 
the
 
risk
 
of
 
miscarriage
 
if
 
used
 
around
 
the
 
time
 
of
 
conception.
 
2.
 
Avoid
 
NSAIDs
 
during
 
pregnancy
 
unless
 
absolutely
 
necessary .
 
They
 
should
 
not
 
be
 
used
 
in
 
the
 
third
 
 
 
 
279
 

=== PAGE 281 ===

 
trimester .
 
Breastfeeding
 
 
 
 
1.
 
The
 
use
 
of
 
NSAIDs
 
during
 
breastfeeding
 
is
 
generally
 
considered
 
safe
 
as
 
they
 
typically
 
pass
 
into
 
breast
 
milk
 
in
 
very
 
small
 
amounts.
 
 
 
 
Elderly
 
 
 
 
1.
 
Beers
 
criteria:
 
a.
 
Avoid
 
combining
 
NSAIDs
 
with
 
steroids,
 
blood
 
thinners,
 
or
 
medications
 
that
 
prevent
 
clots
 
unless
 
absolutely
 
necessary .
 
If
 
needed,
 
a
 
stomach-protecting
 
medicine
 
should
 
also
 
be
 
used.
 
b.
 
Potential
 
to
 
promote
 
fluid
 
retention
 
and
 
lead
 
to
 
heart
 
failure
 
exacerbation
 
2.
 
Always
 
start
 
with
 
the
 
lowest
 
possible
 
dose.
 
 
 
 
Paediatric
 
 
 
 
To
 
improve
 
NSAID
 
safety
 
in
 
the
 
paediatric
 
population,
 
therapy
 
should
 
be
 
initiated
 
with
 
the
 
lowest
 
age-appropriate
 
or
 
weight-based
 
dose.
 
Duration
 
of
 
treatment
 
and
 
drug
 
doses
 
used
 
should
 
be
 
regularly
 
evaluated
 
and
 
maximum
 
dose
 
limits
 
and
 
other
 
recommendations
 
by
 
the
 
manufacturer
 
or
 
expert
 
committees
 
should
 
be
 
followed.
 
 
 
 
Side
 
Effects
 
and
 
their
 
Management*
 
1)
 
Gastrointestinal
 
(Stomach)
 
Effects:
 
Management:
 
Take
 
NSAIDs
 
with
 
food
 
or
 
antacids
 
to
 
reduce
 
stomach
 
irritation.
 
If
 
you're
 
at
 
higher
 
risk
 
(e.g.,
 
elderly
 
or
 
history
 
of
 
ulcers),
 
a
 
stomach-protecting
 
medicine
 
like
 
a
 
proton
 
pump
 
inhibitor
 
may
 
help.
 
 
2)
 
Cardiovascular
 
Effects:
 
Management:
 
Before
 
starting
 
NSAIDs,
 
your
 
doctor
 
will
 
check
 
for
 
heart-related
 
risks.
 
If
 
you
 
have
 
heart
 
disease
 
or
 
high
 
blood
 
pressure,
 
other
 
pain
 
relievers
 
like
 
acetaminophen
 
might
 
be
 
safer .
 
 
3)
 
Kidney
 
Effects:
 
Management:
 
Avoid
 
NSAIDs
 
if
 
you
 
have
 
severe
 
kidney
 
problems
 
(e.g.,
 
CrCl
 
≤
 
30
 
ml/min).
 
Stay
 
well-hydrated,
 
use
 
the
 
lowest
 
dose
 
for
 
the
 
shortest
 
time,
 
and
 
your
 
doctor
 
may
 
monitor
 
kidney
 
function
 
if
 
you're
 
using
 
NSAIDs
 
long-term.
 
 
4)
 
NSAID-Exacerbated
 
Respiratory
 
Disease:
 
Management:
 
Use
 
with
 
caution
 
in
 
patient
 
with
 
pre-existing
 
asthma
 
 
 
 
Storage*
 
1.
 
Store
 
the
 
medication
 
at
 
room
 
temperature
 
in
 
a
 
safe
 
location,
 
away
 
from
 
direct
 
sunlight
 
and
 
humidity .
 
 
2.
 
Keep
 
the
 
medication
 
out
 
of
 
children’ s
 
reach.
 
 
 
 
Others
 
1.
 
Chronic
 
non-cancer
 
pain:
 
Do
 
not
 
use
 
NSAIDs
 
/
 
COX-2
 
inhibitors
 
longer
 
than
 
1-2
 
weeks.
 
You
 
may
 
use
 
them
 
for
 
a
 
few
 
days
 
to
 
get
 
control
 
of
 
a
 
flare
 
up
 
of
 
chronic
 
pain,
 
but
 
they
 
should
 
never
 
be
 
given
 
for
 
long
 
term
 
as
 
the
 
patient
 
will
 
have
 
a
 
risk
 
of
 
developing
 
renal
 
failure
 
and
 
higher
 
risk
 
of
 
cardiovascular
 
events.
 
 
 
 
280
 

=== PAGE 282 ===

 
Before
 
ending
 
this
 
peer
 
review
 
session,
 
the
 
reviewee
 
should
 
be
 
informed
 
of
 
the
 
step(s)
 
that
 
he/
 
she
 
missed
 
out
 
in
 
order
 
to
 
ensure
 
all
 
the
 
counselling
 
points
 
are
 
being
 
covered.
 
 
Remarks:
 
 
 
 
 
Reviewed
 
by:
 
Name
 
&
 
Signature
                                                                   
Date:
 
 
 
 
 
*Mandatory
 
for
 
validation
 
/
 
peer
 
review
 
References:
 
 
1.
 
American
 
Geriatrics
 
Society
 
2023
 
updated
 
AGS
 
Beers
 
Criteria®
 
for
 
potentially
 
inappropriate
 
medication
 
use
 
in
 
older
 
adults.
 
(2023).
 
Journal
 
of
 
the
 
American
 
Geriatrics
 
Society ,
 
71(7),
 
2052–2081.
 
https://doi.org/10.1 111/jgs.18372
 
2.
 
Formulari
 
Ubat
 
KKM
 
(n.d.).
 
Ministry
 
of
 
Health
 
Malaysia.
 
Retrieved
 
December
 
20,
 
2024,
 
from
 
https://pharmacy .moh.gov .my/ms/apps/fukkm
 
3.
 
Pain
 
Management
 
Handbook
 
(Third
 
Edition)
 
(2022).
 
Ministry
 
of
 
Health
 
Malaysia
 
4.
 
Celecoxib
 
(2024).
 
UpToDate.
 
Retrieved
 
December
 
20,
 
2024
 
from
 
https://www .uptodate.com
 
5.
 
Diclofenac
 
(Systemic)
 
(2024).
 
UpToDate.
  
Retrieved
 
December
 
20,
 
2024
 
from
 
https://www .uptodate.com
 
6.
 
Mefenamic
 
Acid
 
(2024).
 
UpToDate.
  
Retrieved
 
December
 
20,
 
2024
 
from
 
https://www .uptodate.com
 
7.
 
Meloxicam
 
(2024).
 
UpToDate.
 
Retrieved
 
December
 
20,
 
2024
 
from
 
https://www .uptodate.com
 
8.
 
White,
 
R.
 
&
 
Bradnam,
 
V.
 
(2015).
 
Handbook
 
of
 
Drug
 
Administration
 
via
 
Enteral
 
Feeding
 
Tubes
 
(Third
 
Edition).
 
Pharmaceutical
 
Press.
 
 
9.
 
Ziesenitz,
 
V.
 
C.,
 
Welzel,
 
T.,
 
van
 
Dyk,
 
M.,
 
Saur,
 
P.,
 
Gorenflo,
 
M.,
 
&
 
van
 
den
 
Anker ,
 
J.
 
N.
 
(2022).
 
Efficacy
 
and
 
safety
 
of
 
NSAIDs
 
in
 
infants:
 
a
 
comprehensive
 
review
 
of
 
the
 
literature
 
of
 
the
 
past
 
20
 
years.
 
Pediatric
 
Drugs,
 
24(6),
 
603-655.
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
281
 

=== PAGE 283 ===

 
Nystatin,
 
Topical
 
Name
 
:
 
 
Unit
 
:
 
 
●
 
Please
 
tick
 
(
✔
)
 
Yes
 
for
 
correct
 
instruction.
 
●
 
Please
 
tick
 
(
✔
)
 
No
 
for
 
incorrect
 
instruction.
 
Yes
 
No
 
Remarks
 
Pharmacological
 
Group
 
Antifungal
 
for
 
dermatological
 
use.
 
 
 
 
Indications
 
and
 
Dosage
 
1.
 
Adult
 
Fungal
 
infections
 
(cutaneous
 
and
 
mucocutaneous)
 
caused
 
by
 
Candida
 
albicans
:
 
Apply
 
to
 
the
 
affected
 
areas
 
twice
 
daily
 
or
 
as
 
indicated
 
until
 
healing
 
is
 
complete.
 
2.
 
Paediatric
 
Diaper
 
dermatitis,
 
Mucocutaneous
 
candida
 
infection:
 
Apply
 
2
 
to
 
4
 
times
 
daily
 
to
 
the
 
affected
 
area.
 
 
 
 
Method
 
of
 
Administration*
 
1.
 
Wash
 
and
 
dry
 
your
 
hands:
 
Before
 
application,
 
cleanse
 
your
 
hands
 
thoroughly
 
with
 
soap
 
and
 
water
 
and
 
dry
 
them
 
completely .
 
2.
 
Prepare
 
the
 
affected
 
area:
 
Gently
 
clean
 
and
 
dry
 
the
 
skin
 
where
 
the
 
cream
 
will
 
be
   
applied.
 
Ensure
 
the
 
area
 
is
 
free
 
of
 
dirt
 
or
 
residue.
 
3.
 
Check
 
the
 
cream
 
label:
 
Verify
 
the
 
cream's
 
label
 
to
 
confirm
 
you
 
are
 
using
 
nystatin
 
cream
 
as
 
prescribed.
 
4.
 
Apply
 
the
 
cream:
 
-
 
Remove
 
the
 
cap
 
and
 
squeeze
 
a
 
small
 
amount
 
of
 
cream
 
onto
 
your
 
fingertip.
 
-
 
Apply
 
a
 
thin
 
layer
 
of
 
the
 
cream
 
to
 
the
 
affected
 
area,
 
ensuring
 
complete
 
coverage.
 
-
 
For
 
areas
 
with
 
hair,
 
apply
 
the
 
cream
 
gently
 
in
 
the
 
direction
 
of
 
hair
 
growth
 
to
 
reduce
 
irritation
 
and
 
ensure
 
even
 
application.
 
5.
 
Avoid
 
contamination:
 
Do
 
not
 
touch
 
the
 
tube's
 
tip
 
to
 
the
 
skin
 
or
 
any
 
other
 
surface
 
to
 
prevent
 
contamination.
 
6.
 
Post-application
 
hygiene:
 
Wash
 
your
 
hands
 
again
 
with
 
soap
 
and
 
water
 
to
 
remove
 
any
 
residual
 
cream
 
unless
 
the
 
treated
 
area
 
is
 
on
 
your
 
hands.
 
7.
 
Follow
 
prescribed
 
duration:
 
-
 
Continue
 
using
 
the
 
cream
 
for
 
the
 
full
 
duration
 
prescribed
 
by
 
your
 
healthcare
 
provider ,
 
even
 
if
 
symptoms
 
improve
 
early .
 
-
 
Do
 
not
 
skip
 
doses
 
or
 
stop
 
the
 
treatment
 
prematurely
 
to
 
ensure
 
the
 
infection
 
is
 
fully
 
treated.
 
Additional
 
Notes:
 
●
 
Avoid
 
contact
 
with
 
eyes,
 
mouth
 
or
 
other
 
mucous
 
membranes
 
unless
 
directed
 
by
 
a
 
healthcare
 
provider .
 
●
 
Inform
 
your
 
healthcare
 
provider
 
if
 
irritation
 
or
 
worsening
 
of
 
symptoms
 
occurs
 
during
 
use.
 
 
 
 
Special
 
Considerations
 
Pregnancy
 
:
 
 
 
 
 
1.
 
Animal
 
reproduction
 
studies
 
have
 
not
 
been
 
conducted.
 
 
2.
 
Nystatin
 
topical
 
preparations
 
should
 
be
 
prescribed
 
for
 
a
 
pregnant
 
woman
 
only
 
if
 
the
 
potential
 
benefit
 
to
 
the
 
mother
 
outweighs
 
the
 
potential
 
risk
 
to
 
the
 
fetus.
 
 
 
 
282
 

=== PAGE 284 ===

 
Breastfeeding
 
 
 
 
It
 
is
 
not
 
known
 
if
 
nystatin
 
is
 
excreted
 
in
 
breast
 
milk;.
 
The
 
manufacturer
 
recommends
 
that
 
caution
 
be
 
exercised
 
when
 
administering
 
nystatin
 
to
 
nursing
 
women.
 
 
 
 
Elderly
 
 
 
 
Patients
 
who
 
use
 
topical
 
oils,
 
creams,
 
and
 
ointments
 
have
 
potential
 
fall
 
risk
 
.Patients
 
may
 
be
 
advised
 
to
 
wear
 
nonslip
 
socks
 
if
 
applying
 
topical
 
medications
 
to
 
feet.
 
Patients
 
should
 
be
 
advised
 
to
 
apply
 
cream
 
while
 
seated
 
or
 
standing
 
on
 
non-slip
 
surfaces.
 
 
 
 
Paediatric
 
 
 
 
Dosage
 
recommendations
 
may
 
vary
 
among
 
individual
  
products.
 
To
 
refer
 
to
 
individual
 
products.
 
 
 
 
Fasting
 
 
 
 
1.
 
Cream
 
is
 
permissible
 
to be
 
used
 
during
 fasting.
 
2.
 
While
 
it
 
may
 
absorb
 
into
 
the
 
skin
 
to
 
treat
 
the
 
infection,
 
this
 
does
 
not
 
reach
 
systemically
 
in
 
a
 
way
 
that
 
would
 
invalidate
 
fasting.
 
 
To
 
refer
 
to
 
the
 
latest
 
advisory
 
by
 
religious
 
authority
 
 
 
 
Side
 
Effects
 
and
 
their
 
Management*
 
If
 
irritation
 
or
 
sensitisation
 
develops,
 
treatment
 
should
 
be
 
discontinued
 
and
 
appropriate
 
measures
 
taken
 
as
 
indicated.
 
 
 
 
Storage*
 
1.
 
Keep
 
the
 
container
 
tightly
 
closed
 
in
 
a
 
dry
 
place.
 
2.
 
Store
 
below
 
30
°
 
C.
 
or
 
at
 
20-
 
25
°
 
C.
 
3.
 
Protect
 
from
 
light
 
and
 
avoid
 
freezing.
 
 
 
 
Others
 
1.
 
For
 
topical
 
external
 
use
 
only;
 
not
 
for
 
systemic,
 
oral,
 
intravaginal
 
or
 
ophthalmic
 
use.
 
2.
 
Since
 
nystatin
 
is
 
not
 
absorbed
 
systemically
 
when
 
applied
 
to
 
intact
 
skin
 
or
 
mucous
 
membranes,
 
the
 
likelihood
 
of
 
drug
 
interactions
 
or
 
incompatibilities
 
is
 
minimal.
 
 
 
 
Before
 
ending
 
this
 
peer
 
review
 
session,
 
the
 
reviewee
 
should
 
be
 
informed
 
of
 
the
 
step(s)
 
that
 
he/
 
she
 
missed
 
out
 
in
 
order
 
to
 
ensure
 
all
 
the
 
counselling
 
points
 
are
 
being
 
covered.
 
 
Remarks:
 
 
 
Reviewed
 
by:
 
Name
 
&
 
Signature
                                                                   
Date:
 
 
 
*Mandatory
 
for
 
validation
 
/
 
peer
 
review
 
References:
 
 
1.
 
Idaman
 
Pharma
 
Manufacturing
 
Sdn
 
Bhd
 
(n.d.)
 
Candistatin
 
Cream
 
100,000
 
U/g.
 
Retrieved
 
November
 
10,
 
2024,
 
from
 
https://www .npra.gov .my
 
 
2.
 
Upsher-Smith
 
Laboratories
 
LLC
 
(2024).
 
Nyamyc
 
(nystatin)
 
[prescribing
 
information].
 
3.
 
Torrent
 
Pharmaa
 
Inc
 
(2021).
 
Nystatin
 
cream
 
USP
 
[prescribing
 
information].
 
 
4.
 
Macleods
 
Pharma
 
USA
 
Inc
 
(2021).
 
Nystatin
 
ointment
 
USP
 
[prescribing
 
information].
 
 
5.
 
MIMS
 
Malaysia
 
(2025,
 
January
 
21).
 
Nystatin.
 
Retrieved
 
from
 
https://www .mims.com/malaysia/drug/info/nystatin?mtype=generic
.
 
6.
 
Price
 
KN,
 
Grinnell
 
M,
 
Butler
 
D,
 
Shah
 
A.
 
Art
 
of
 
prevention:
 
Practical
 
tips
 
for
 
improving
 
adherence
 
to
 
treatments
 
for
 
older
 
patients
 
in
 
dermatology .
 
Int
 
J
 
Womens
 
Dermatol.
 
2021
 
Mar
 
18;7(4):478-481.
 
283
 

=== PAGE 285 ===

 
Nystatin
 
Oral
 
Suspension
 
Name
 
:
 
 
 
Unit
 
:
 
 
●
 
Please
 
tick
 
(
✔
)
 
Yes
 
for
 
correct
 
instruction.
 
●
 
Please
 
tick
 
(
✔
)
 
No
 
for
 
incorrect
 
instruction.
 
Yes
 
No
 
Remarks
 
Pharmacological
 
Group
 
Polyenes
 
Antifungal
 
 
 
 
Indications
 
and
 
Dosage
 
Nystatin
 
100,000units/ml
 
Suspension
 
 
Prevention
 
and
 
treatment
 
of
 
candidiasis
 
of
 
the
 
skin
 
and
 
mucous
 
membranes,
 
protection
 
against
 
candidas
 
overgrowth
 
during
 
antimicrobial
 
/corticosteroid
 
therapy
 
and
 
as
 
selective
 
decontamination
 
regimens
 
(Dosage
 
as
 
per
 
prescribed)
 
 
 
 
Method
 
of
 
Administration*
 
1.
 
Shake
 
the
 
bottle
 
well
 
before
 
use,
 
then
 
draw
 
up
 
the
 
correct
 
amount
 
into
 
the
 
measuring
 
dropper
 
provided.
 
2.
 
The
 
suspension
 
should
 
be
 
swished
 
throughout
 
or
 
be
 
retained
 
in
 
the
 
mouth
 
for
 
as
 
long
 
as
 
possible(several
 
minutes)
 
before
 
swallowing.
 
 
3.
 
Individuals
 
should
 
avoid
 
taking
 
food
 
or
 
drink
 
earlier
 
than
 
one
 
hour
 
after
 
a
 
dose.
 
In
 
infants
 
and
 
young
 
children,
 
apply
 
one
 
half
 
of
 
a
 
dose
 
in
 
each
 
side
 
of
 
the
 
mouth.
 
4.
 
The
 
dosage
 
should
 
be
 
continued
 
for
 
48
 
hours
 
after
 
lesions
 
have
 
resolved.
 
 
Missed
 
dose
 
management
 
Take
 
the
 
missed
 
dose
 
as
 
soon
 
as
 
you
 
remember .
 
If
 
it
 
is
 
almost
 
time
 
for
 
your
 
next
 
dose,
 
wait
 
until
 
then
 
to
 
take
 
the
 
medicine
 
and
 
skip
 
the
 
missed
 
dose.
 
Do
 
not
 
take
 
a
 
double
 
dose
 
to
 
make
 
up
 
for
 
the
 
missed
 
dose.
 
 
 
 
 
Do
 
not
 
stop
 
taking
 
your
 
medication
 
unless
 
advised
 
to
 
do
 
so
 
by
 
your
 
prescriber
 
 
 
 
Special
 
Considerations
 
Pregnancy
 
 
 
 
N/A
 
 
 
 
Breastfeeding
 
 
 
 
Nystatin
 
is
 
poorly
 
absorbed
 
after
 
oral
 
administration,
 
if
 
at
 
all,
 
serum
 
and
 
milk
 
levels
 
would
 
not
 
occur .
 
 
 
 
Elderly
 
 
 
 
None
 
specifically
 
to
 
Nystatin
 
 
 
 
Paediatric
 
 
 
 
Some
 
dosage
 
forms
 
may
 
contain
 
propylene
 
glycol.
 
In
 
neonate
 
receiving
 
propylene
 
glycol
 
>
 
3000mg/day
 
via
 
orally ,
 
intravenously
 
or
 
topically
 
have
 
been
 
associated
 
with
 
toxicities
 
e.g.
 
seizures,renal
 
failure
 
and
 
central
 
nervous
 
system
 
depression
 
 
 
 
Fasting
 
 
 
 
To
 
refer
 
to
 
the
 
latest
 
advisory
 
by
 
religious
 
authority
 
 
 
 
284
 

=== PAGE 286 ===

 
Others
 
 
 
 
NA
 
 
 
 
Side
 
Effects
 
and
 
their
 
Management*
 
1.
 
Nausea
 
 
2.
 
Vomiting
 
3.
 
Diarrhoea
 
4.
 
Mouth
 
irritation
 
or
 
sensitivity
 
 
 
Management:
 
1.
 
Drink
 
plenty
 
of
 
water
 
to
 
avoid
 
dehydration
 
2.
 
Stop
 
using
 
medication
 
if
 
you
 
experience
 
any
 
irritation
 
or
 
sensitivity
 
and
 
seek
 
medical
 
assistance.
 
 
 
 
Storage*
 
1.
 
Store
 
below
 
30°C
 
in
 
a
 
well-closed
 
container .
 
 
2.
 
Do
 
not
 
freeze
 
and
 
protect
 
from
 
light.
 
 
3.
 
Refer
 
product
 
insert
 
 
 
 
Others
 
Not
 
intended
 
to
 
treat
 
systemic
 
mycoses.
 
If
 
hypersensitivity
 
develops,
 
discontinue
 
use
 
 
 
 
 
Before
 
ending
 
this
 
peer
 
review
 
session,
 
the
 
reviewee
 
should
 
be
 
informed
 
of
 
the
 
step(s)
 
that
 
he/
 
she
 
missed
 
out
 
in
 
order
 
to
 
ensure
 
all
 
the
 
counselling
 
points
 
are
 
being
 
covered.
 
 
Remarks:
 
 
 
 
 
Reviewed
 
by:
 
Name
 
&
 
Signature
                                                                   
Date:
 
 
 
 
 
*Mandatory
 
for
 
validation/
 
peer
 
review
 
 
References:
 
 
1.
 
Sterling,
 
A.,
 
M
 
Zand,
 
Jonathan.
 
:
 
Nystatin
 
(oral)
 
Drug
 
information.
 
UpToDate.
 
(2024)
 
UpToDate
 
(Version
 
3.68.3)
 
[Mobile
 
App]
 
Mobile
 
Clinical
 
Decision
 
Support
 
App
 
|
 
UpToDate
 
|
 
Wolters
 
Kluwer
 
2.
 
Formulari
 
Ubat
 
KKM
 
(FUKKM).
 
(2024).
 
(Version
 
241030.001).
 
Retrieved
 
from
 
https://i.pharmacy .gov.my/fukkm
 
3.
 
Frishauf,
 
Peter .
 
Nystatin.
 
Medscape.
 
(2024)
 
Medscape
 
(Version
 
12.2.1)
 
[Mobile
 
App]
 
Point-of-Care
 
Medical
 
Reference
 
App
 
For
 
Doctors
 
|
 
Medscape
 
4.
 
Merative,
 
L.P.
 
Nystatin.
 
Micromedex.
 
(2024)
 
Micromedex
 
(Version
 
4.6.0)
 
[Mobile
 
App]
 
https://play .google.com/store/apps/details?id=com.truven.druginfonative.customer
 
5.
 
T.O
 
Chemicals.
 
(2020).
 
TYST ATIN
 
ORAL
 
SUSPENSION®.
 
Retrieved
 
from
 
https://quest3plus.bpfk.gov .my/front-end/attachment/706/pharma/224630/V_38496_20201 123_104322_
D4.pdf
 
6.
 
Briggs,
 
G.
 
G.,
 
Towers,
 
G.
 
V.,
 
&
 
Forinash,
 
A.
 
B.
 
(2022).
 
Drugs
 
in
 
Pregnancy
 
and
 
Lactation
 
(12th
 
ed.).
 
Wolters
 
Kluwer .
 
 
 
 
 
 
 
 
 
285
 

=== PAGE 287 ===

 
Ofloxacin
 
 
 
Name
 
:
 
 
Unit
 
:
 
 
Please
 
tick
 
(
✔
)
 
Yes
 
for
 
correct
 
instruction.
 
Please
 
tick
 
(
✔
)
 
No
 
for
 
incorrect
 
instruction.
 
Yes
 
No
 
Remarks
 
Pharmacological
 
Group
 
Fluoroquinolone
 
 
 
 
Indications
 
and
 
Dosage
 
1.
 
Second-line
 
treatment
 
for
 
leprosy
  
 
2.
 
Drug-resistant
 
leprosy
 
 
      
Adult
 
:
 
400mg
 
once
 
daily
 
(in
 
combination
 
with
 
other
 
anti-leprosy
 
drugs)
 
 
 
 
Method
 
of
 
Administration*
 
Food:
 
Administered
 
with
 
or
 
without
 
food
 
 
RT
 
administration:
 
Significant
 
interaction
 
when
 
mixed
 
directly
 
with
 
the
 
enteral
 
formula.
 
Should
 
not
 
be
 
given
 
within
 
2
 
hours
 
before
 
or
 
4
 
hours
 
after
 
enteral
 
formulas
 
 
Missed
 
dose:
 
Take
 
the
 
missed
 
dose
 
as
 
soon
 
as
 
possible
 
 
Do
 
not
 
stop
 
taking
 
your
 
medication
 
unless
 
advised
 
to
 
do
 
so
 
by
 
your
 
prescriber
 
 
 
 
 
Special
 
Considerations
 
Pregnancy
 
 
 
 
Avoid
 
unless
 
benefits
 
outweigh
 
risks
 
 
 
 
Breastfeeding
 
 
 
 
Avoid
 
 
 
 
Elderly
 
 
 
 
Adverse
 
effects
 
may
 
be
 
increased
 
in
 
older
 
patients
 
 
 
 
Paediatric:
 
 
 
 
Use
 
with
 
caution
 
–
 
risk
 
of
 
arthropathy
 
 
 
 
Fasting
 
 
 
 
NA
 
 
 
 
Others
:
 
1.
 
Renal
 
impairment
 
 
CrCl
 
≥20
 
mL/min:
 
No
 
dose
 
adjustment
 
required
 
at
 
doses
 
used
 
in
 
leprosy
 
 
 
2.
 
Liver
 
Impairment:
 
No
 
dose
 
adjustment
 
required
 
at
 
doses
 
used
 
for
 
leprosy
 
 
 
 
Side
 
Effects
 
and
 
their
 
Management*
 
Common
 
Side
 
Effects
 
Gastrointestinal:
 
Abdominal
 
cramps,
 
abdominal
 
pain,
 
nausea,
 
vomiting,
 
diarrhoea
 
 
 
 
286
 

=== PAGE 288 ===

 
Neurological:
 
Headache,
 
dizziness,
 
insomnia
 
 
Serious
 
but
 
Rare
 
Side
 
Effects
 
Tendinopathy
 
and
 
tendon
 
rupture
 
Peripheral
 
neuropathy
 
QTc
 
prolongation
 
 
Storage*
 
Store
 
in
 
a
 
cool,
 
dry
 
place,
 
away
 
from
 
sunlight
 
 
 
 
Others
 
Precautions:
 
1.
 
QT
 
prolongation
 
risk
 
:
 
avoid
 
in
 
patients
 
with
 
cardiac
 
arrhythmias
 
or
 
those
 
on
 
QT-prolonging
 
drugs
 
2.
 
May
 
cause
 
photosensitivity:
 
use
 
sunscreen
 
and
 
wear
 
protective
 
clothing
 
3.
 
May
 
trigger
 
seizures:
 
caution
 
in
 
epilepsy
 
or
 
seizure-prone
 
patients
 
4.
 
Avoid
 
in
 
patients
 
with
 
myasthenia
 
gravis:
 
may
 
worsen
 
symptoms
 
5.
 
Tendon
 
pain
 
or
 
swelling:
 
stop
 
medication
 
and
 
see
 
your
 
doctor
 
immediately
 
 
Significant
 
drug-drug
 
/
 
drug-food
 
interactions:
 
1.
 
Avoid
 
taking
 
with
 
milk,
 
calcium,
 
iron
 
supplements,
 
or
 
antacids
 
as
 
these
 
reduce
 
absorption.
 
Separate
 
doses
 
by
 
at
 
least
 
2
 
hours
 
before
 
or
 
after
 
these
 
substances
 
2.
 
Avoid
 
alcohol
 
as
 
it
 
may
 
worsen
 
dizziness
 
or
 
other
 
CNS
 
side
 
effects
 
3.
 
Avoid
 
driving
 
or
 
operating
 
machinery
 
if
 
feeling
 
dizzy
 
or
 
light-headed
 
 
 
 
Before
 
ending
 
this
 
peer
 
review
 
session,
 
the
 
reviewee
 
should
 
be
 
informed
 
of
 
the
 
step(s)
 
that
 
he/
 
she
 
missed
 
out
 
in
 
order
 
to
 
ensure
 
all
 
the
 
counselling
 
points
 
are
 
being
 
covered.
 
 
Remarks:
 
 
 
 
 
Reviewed
 
by:
 
Name
 
&
 
Signature
                                                                   
Date:
 
 
 
 
 
*Mandatory
 
for
 
validation/
 
peer
 
review
 
 
References:
 
 
1.
 
World
 
Health
 
Organization.
 
Guidelines
 
for
 
the
 
diagnosis,
 
treatment
 
and
 
prevention
 
of
 
leprosy .
 
2018
 
2.
 
World
 
Health
 
Organization.
 
WHO
 
model
 
prescribing
 
information:
 
drugs
 
used
 
in
 
leprosy .
 
In
 
WHO
 
model
 
prescribing
 
information:
 
drugs
 
used
 
in
 
leprosy
 
1998
 
3.
 
TB
 
Drug
 
Monographs.
 
Ofloxacin.
 
https://www .tbdrugmonographs.co.uk/ofloxacin.html
 
4.
 
WHO
 
Expert
 
Committee
 
on
 
Leprosy .
 
WHO
 
Expert
 
Committee
 
on
 
Leprosy:
 
Eighth
 
Report.
 
World
 
Health
 
Organization.
 
2010
 
5.
 
Critical
 
Care
 
Pharmacy
 
Handbook.
 
Pharmaceutical
 
Services
 
Programme.
 
Second
 
edition.
 
2020
 
6.
 
Manual
 
Pengurusan
 
Kusta
 
Edisi
 
Ke-3.
 
MOH.
 
2023
 
7.
 
Protocol
 
on
 
Drug
 
Administration
 
Via
 
Enteral
 
Feeding
 
Tubes.
 
First
 
edition.
 
MOH.
 
2022
 
8.
 
UpToDate
 
Inc.
 
 
 
 
 
287
 

=== PAGE 289 ===

 
Opioids,
 
Short
 
Acting
 
Strong
 
Name
 
:
 
 
Unit
 
:
 
 
●
 
Please
 
tick
 
(
✔
)
 
Yes
 
for
 
correct
 
instruction.
 
●
 
Please
 
tick
 
(
✔
)
 
No
 
for
 
incorrect
 
instruction.
 
Yes
 
No
 
Remarks
 
Pharmacological
 
Group
 
Opioid
 
Analgesic
 
Available
 
preparations:
 
1.
 
Aqueous
 
Morphine
 
10mg/5ml
 
 
2.
 
Oxycodone
 
HCL
 
1mg/ml
 
Oral
 
Solution
 
3.
 
Oxycodone
 
HCL
 
5mg
 
and
 
10mg
 
Immediate
 
Release
 
Capsules
 
 
 
 
Indications
 
and
 
Dosage
 
1.
 
Aqueous
 
morphine:
 
For
 
use
 
in
 
management
 
of
 
moderate
 
to
 
severe
 
pain
 
especially
 
that
 
associated
 
with
 
neoplastic
 
disease
 
Dose
:
 
5-20mg
 
or
 
more
 
regularly
 
every
 
4
 
hours
 
in
 
terminal
 
pain.
 
 
2.
 
Oxycodone
 
HCl
 
1mg/ml
 
Oral
 
Solution:
 
 
As
 
a
 
second-line
 
drug
 
in
 
the
 
management
 
of
 
responsive,
 
moderate
 
to
 
severe
 
pain
 
in
 
patients
 
who;
 
a.
 
Have
 
difficulty
 
swallowing
 
b.
 
Require
 
low
 
dose
 
oxycodone
 
(<5mg)
 
Dose:
 
Initial
 
dose
 
for
 
opioid
 
naïve
 
patients
 
or
 
patients
 
presenting
 
with
 
severe
 
pain
 
uncontrolled
 
by
 
weak
 
opioids
 
is
 
5mg,
 
4-6
 
hourly .
 
The
 
dose
 
should
 
be
 
carefully
 
titrated,
 
as
 
frequently
 
as
 
once
 
a
 
day,
 
to
 
achieve
 
pain
 
relief.
 
 
      
 
       
3.
 
Oxycodone
 
HCl
 
5mg
 
and
 
10
 
mg
 
Immediate
 
Release
       
           
Capsules
 
a.
 
As
 
a
 
second
 
line
 
drug
 
in
 
the
 
management
 
of
 
opioid
 
responsive,
 
moderate
 
to
 
severe
 
chronic
 
cancer
 
pain
 
 
b.
 
As
 
a
 
step-down
 
analgesic
 
drug
 
in
 
post-operative
 
procedures
 
Dose:
 
Initially
 
5
 
mg
 
every
 
4
 
to
 
6
 
hours,
 
increased
 
if
 
necessary ,
 
according
 
to
 
severity
 
of
 
pain
 
 
To
 
counsel
 
based
 
on
 
specific
 
medication’ s
 
indication
 
and
 
dosage
 
as
 
prescribed
 
by
 
the
 
doctor
 
 
 
 
Method
 
of
 
Administration*
 
How
 
to
 
take
 
immediate
 
release
 
solution
 
1.
 
Take
 
exactly
 
as
 
instructed
 
2.
 
Aqueous
 
morphine
 
solution/
 
Syrup
 
Oxycodone
 
Immediate
 
Release
 
is
 
usually
 
taken
 
every
 
4
 
-
 
6
 
hours. 
 
3.
 
Take
 
the
 
solution
 
by
 
mouth.
 
Use
 
a
 
plastic
 
syringe
 
to
 
measure
 
your
 
dose.
 
4.
 
Your
 
doctor
 
may
 
instruct
 
you
 
to
 
take
 
additional
 
doses
 
for
 
breakthrough
 
pain
 
–
 
as
 
often
 
as
 
every
 
hour.
 
5.
 
Record
 
the
 
number
 
of
 
additional
 
doses
 
you
 
have
 
taken
 
and
 
inform
 
your
 
doctor
 
at
 
the
 
next
 
visit.
 
6.
 
DO
 
NOT
 
exceed
 
the
 
dose
 
prescribed
 
by
 
your
 
doctor .
 
7.
 
If
 
you
 
find
 
that
 
you
 
are
 
still
 
in
 
pain
 
whilst
 
taking
 
this
 
drug,
 
discuss
 
this
 
with
 
your
 
doctor .
 
 
How
 
to
 
take
 
Oxycodone
 
Immediate
 
Release
 
Capsules
 
1.
 
Take
 
exactly
 
as
 
instructed
 
2.
 
DO
 
NOT
 
break,
 
crush
 
or
 
chew
 
them.
 
3.
 
Swallow
 
your
 
capsule
 
whole
 
with
 
a
 
glass
 
of
 
water .
 
 
 
 
288
 

=== PAGE 290 ===

 
4.
 
OxyNORM
 
capsules
 
are
 
usually
 
taken
 
every
 
4
 
-
 
6
 
hours.
 
5.
 
OxyNORM
 
capsules
 
may
 
also
 
be
 
prescribed
 
as
 
“when
 
needed”
 
medication
 
for
 
breakthrough
 
pain.
 
(Breakthrough
 
pain
 
occurs
 
despite
 
regular
 
painkillers)
 
·
 
Always
 
take
 
the
 
capsules
 
exactly
 
as
 
instructed.
 
6.
 
Record
 
the
 
number
 
of
 
additional
 
doses
 
you
 
have
 
taken
 
and
 
inform
 
your
 
doctor
 
at
 
the
 
next
 
visit.
 
7.
 
DO
 
NOT
 
exceed
 
the
 
dose
 
prescribed
 
by
 
your
 
doctor .
 
8.
 
If
 
you
 
find
 
that
 
you
 
are
 
still
 
in
 
pain
 
whilst
 
taking
 
this
 
drug,
 
discuss
 
this
 
with
 
your
 
doctor .
 
 
Missed
 
dose
 
management
 
1.
 
If
 
you
 
forget
 
a
 
dose,
 
take
 
it
 
as
 
soon
 
as
 
you
 
remember
 
it
 
and
 
take
 
your
 
next
 
dose
 
at
 
the
 
usual
 
time.
 
2.
 
DO
 
NOT
 
take
 
a
 
double
 
dose
 
to
 
make
 
up
 
for
 
a
 
forgotten
 
dose
 
 
Do
 
not
 
stop
 
taking
 
your
 
medication
 
unless
 
advised
 
to
 
do
 
so
 
by
 
your
 
prescriber
 
Special
 
Considerations
 
Pregnancy
 
&
 
Breastfeeding
 
 
 
 
1.
 
Opioid
 
crosses
 
the
 
placenta
 
and
 
can
 
be
 
detected
 
in
 
breast
 
milk
 
too.
 
2.
 
Use
 
during
 
pregnancy
 
and
 
breastfeeding
 
needs
 
to
 
be
 
carefully
 
considered
 
and
 
there
 
is
 
a
 
need
 
to
 
balance
 
pain
 
management
 
and
 
the
 
risk
 
of
 
neonatal
 
opioid
 
withdrawal
 
symptoms.
 
 
 
 
Elderly
 
 
 
 
1.
 
Increased
 
sensitivity
 
to
 
weak
 
opioids
  
in
 
elderly
 
patients
 
can
 
result
 
in
 
excessive
 
sedation,
 
dizziness,
 
confusion,
 
and
 
an
 
elevated
 
risk
 
of
 
delirium
 
and
 
lead
 
to
 
falls.
 
2.
 
Use
 
with
 
caution
 
in
 
the
 
elderly ,
 
debilitated
 
or
 
cachectic
 
patients
 
have
 
an
 
increased
 
risk
 
for
 
respiratory
 
depression.
 
3.
 
Use
 
in
 
elderly
 
patients
 
carry
 
risks
 
of
  
constipation
 
that
 
lead
 
to
  
delirium
 
and
 
increased
 
risk
 
of
 
falls.
 
4.
 
Avoid
 
in
 
patients
 
with
 
a
 
history
 
of
 
fractures
 
or
 
falls,
 
it
 
may
 
contribute
 
to
 
additional
 
fall.
 
 
 
 
Paediatric
 
 
 
 
1.
 
Although
 
opioids
 
are
 
highly
 
effective
 
in
 
treating
 
pain,
 
their
 
use
 
frequently
 
results
 
in
 
various
 
side
 
effects
 
including
 
nausea
 
and
 
vomiting,
 
pruritus,
 
constipation,
 
sedation
 
as
 
well
 
as
 
potentially
 
fatal
 
respiratory
 
depression
 
in
 
children.
 
 
 
 
Abuse
 
/
 
Misuse
 
/
 
Diversion
 
 
 
 
1.
 
Use
 
with
 
caution
 
in
 
patients
 
with
 
a
 
history
 
of
 
substance
 
use
 
disorder ,
 
as
 
the
 
potential
 
for
 
drug
 
dependency
 
exists.
 
 
 
 
Side
 
Effects
 
and
 
their
 
Management*
 
1.
 
Opioid-induced
 
constipation
 
a.
 
A
 
common
 
side
 
effect
 
b.
 
Tolerance
 
does
 
not
 
develop,
 
hence
 
laxatives
 
must
 
be
 
taken
 
regularly 
 
c.
 
Use
 
combination
 
of
 
stimulant
 
(e.g.
 
bisacodyl)
 
+
 
softener
 
(e.g.
 
lactulose)
 
d.
 
Increase
 
fluid
 
and
 
dietary
 
fibre
 
intake,
 
 
 
 
289
 

=== PAGE 291 ===

 
maintain
 
good
 
physical
 
activity ,
 
and
 
try
 
to
 
establish
 
a
 
toilet
 
routine
 
 
2.
 
Opioid-induced
 
sedation
 
/
 
impaired
 
alertness
 
a.
 
May
 
occur
 
upon
 
initiation
 
of
 
opioids
 
b.
 
Avoid
 
driving
 
and
 
other
 
activities
 
that
 
require
 
mental
 
alertness
 
until
 
it
 
is
 
clear
 
how
 
morphine/
 
Oxycodone
 
affects
 
the
 
patient
 
c.
 
Tolerance
 
develops
 
after
 
5
 
-
 
10
 
days
 
 
3.
 
Opioid-induced
 
neurotoxicity
 
(delirium,
 
confusion)
 
a.
 
May
 
occur ,
 
but
 
usually
 
transient
 
b.
 
May
 
consider
 
use
 
of
 
haloperidol
 
for
 
delirium
 
 
4.
 
Opioid-induced
 
nausea
 
and
 
vomiting
 
a.
 
May
 
occur
 
upon
 
initiation
 
of
 
opioids
 
b.
 
Tolerance
 
develops
 
5
 
-
 
10
 
days
 
after
 
starting
 
c.
 
May
 
use
 
antiemetics
 
(e.g.
 
metoclopramide,
 
haloperidol
 
or
 
prochlorperazine)
 
d.
 
Be
 
consistent
 
when
 
taking
 
morphine
 
with
 
or
 
without
 
meals
 
 
5.
 
Opioid-induced
 
dry
 
mouth 
 
a.
 
Sip
 
water
 
often,
 
let
 
small
 
ice
 
chips
 
melt
 
in
 
your
 
mouth
 
b.
 
Minimise
 
intake
 
of
 
caffeinated
 
drinks,
 
such
 
as
 
coffee,
 
tea,
 
and
 
some
 
sodas
 
as
 
well
 
as
 
use
 
of
 
tobacco
 
and
 
alcohol
 
c.
 
Chew
 
sugarless
 
gum
 
or
 
suck
 
on
 
sugarless
 
hard
 
candy
 
to
 
stimulate
 
saliva
 
flow
 
Storage*
 
1.
 
Medication
 
may
 
be
 
kept
 
at
 
room
 
temperature,
 
in
 
a
 
safe
 
place
 
and
 
out
 
of
 
direct
 
sunlight,
 
and
 
humidity .
 
2.
 
Ensure
 
medication
 
is
 
out
 
of
 
the
 
reach
 
of
 
children
 
and
 
pets.
 
 
 
 
Others
 
1.
 
Respiratory
 
depression
 
is
 
rare
 
but
 
may
 
occur
 
if
 
morphine
 
is
 
used
 
incorrectly
 
and
 
can
 
be
 
fatal. 
 
2.
 
Do
 
not
 
take
 
more
 
than
 
what
 
has
 
been
 
prescribed.
 
3.
 
Concurrent
 
use
 
of
 
other
 
central
 
nervous
 
system
 
(CNS)
 
depressants,
 
such
 
as
 
benzodiazepines,
 
barbiturates,
 
sedatives,
 
hypnotics,
 
or
 
alcohol,
 
can
 
potentiate
 
the
 
sedative
 
and
 
respiratory
 
depressant
 
effects
 
of
 
morphine,
 
increasing
 
the
 
risk
 
of
 
profound
 
sedation,
 
respiratory
 
depression,
 
coma,
 
or
 
death.
 
4.
 
Medication
 
should
 
be
 
tapered
 
gradually
 
when
 
discontinuing
 
therapy
 
to
 
minimize
 
withdrawal
 
effects..
 
 
 
 
 
Before
 
ending
 
this
 
peer
 
review
 
session,
 
the
 
reviewee
 
should
 
be
 
informed
 
of
 
the
 
step(s)
 
that
 
he/
 
she
 
missed
 
out
 
in
 
order
 
to
 
ensure
 
all
 
the
 
counselling
 
points
 
are
 
being
 
covered.
 
 
Remarks:
 
 
 
 
 
Reviewed
 
by:
 
Name
 
&
 
Signature
                                                                   
Date:
 
 
 
 
 
*Mandatory
 
for
 
validation
 
/
 
peer
 
review
 
 
290
 

=== PAGE 292 ===

 
References:
 
 
1.
 
2023
 
American
 
Geriatrics
 
Society
 
Beers
 
Criteria®
 
Update
 
Expert
 
Panel.
 
(2023).
 
American
 
Geriatrics
 
Society
 
2023
 
updated
 
AGS
 
Beers
 
Criteria®
 
for
 
potentially
 
inappropriate
 
medication
 
use
 
in
 
older
 
adults.
 
Journal
 
of
 
the
 
American
 
Geriatrics
 
Society
,
 
71
(7),
 
2052-2081
.
 
2.
 
Clinical
 
Practice
 
Guidelines
 
Management
 
of
 
Cancer
 
Pain
 
(Second
 
Edition)
 
(2023)
 
Ministry
 
of
 
Health
 
Malaysia.
 
3.
 
Morphine
 
Sulphate.
 
(2024).
 
Micromedex
 
(electronic
 
version).
 
Retrieved
 
October
 
23,
 
2024
 
from
 
http://www .micromedexsolutions.com/
 
4.
 
Oxycodone
 
Hydrochloride.
 
(2024).
 
Micromedex
 
(electronic
 
version).
 
Retrieved
 
October
 
23,
 
2024
 
from
 
http://www .micromedexsolutions.com/
 
291
 

=== PAGE 293 ===

 
Opioids,
 
Sustained-Release
 
Strong
 
 
Name
 
:
 
 
Unit
 
:
 
 
●
 
Please
 
tick
 
(
✔
)
 
Yes
 
for
 
correct
 
instruction.
 
●
 
Please
 
tick
 
(
✔
)
 
No
 
for
 
incorrect
 
instruction.
 
Yes
 
No
 
Remarks
 
Pharmacological
 
Group
 
Opioid
 
Analgesic
 
Preparations
 
available:
 
1.
 
Morphine
 
Sulphate
 
Prolonged
 
Release
 
Tablets
 
2.
 
Oxycodone
 
Hydrochloride
 
Controlled
 
Release
 
Tablets
 
 
 
 
Indications
 
and
 
Dosage
 
1.
 
Moderate
 
to
 
severe
 
cancer
 
pain
 
2.
 
Non-cancer
 
chronic
 
pain
 
refractory
 
to
 
adjuvant
 
analgesics
 
and
 
non-pharmacological
 
approaches
 
 
a.
 
Dose
 
requirement
 
is
 
established
 
using
 
short-acting
 
preparations
 
before
 
switching
 
to
 
long-acting
 
formulations.
 
b.
 
Dose
 
is
 
individualised
 
based
 
on
 
patient-specific
 
factors
 
and
 
severity
 
of
 
pain,
 
and
 
usually
 
given
 
in
 
12
 
hourly
 
intervals
 
(twice
 
a
 
day).
 
c.
 
Subsequently ,
 
dose
 
is
 
adjusted
 
according
 
to
 
patient
 
response,
 
taking
 
into
 
account
 
the
 
amount
 
of
 
rescue
 
medication
 
used,
 
pain
 
score,
 
functional
 
assessment
 
and
 
side
 
effects.
 
 
To
 
counsel
 
based
 
on
 
specific
 
medication’ s
 
indication
 
and
 
dosage
 
as
 
prescribed
 
by
 
the
 
doctor
 
 
 
 
Method
 
of
 
Administration*
 
1.
 
Tablets
 
must
 
be
 
swallowed
 
whole,
 
with
 
enough
 
water
 
to
 
ensure
 
complete
 
swallowing.
 
2.
 
Do
 
not
 
crush,
 
chew
 
or
 
dissolve
 
the
 
tablets
 
as
 
it
 
may
 
result
 
in
 
uncontrolled
 
delivery
 
of
 
drugs.
 
3.
 
Cannot
 
be
 
administered
 
through
 
a
 
feeding
 
tube.
 
4.
 
May
 
be
 
administered
 
with
 
food.
 
 
Missed
 
dose
 
management
 
1.
 
In
 
the
 
event
 
of
 
a
 
missed
 
dose,
 
take
 
it
 
as
 
soon
 
as
 
possible.
 
Omit
 
the
 
dose
 
if
 
more
 
than
 
6
 
hours
 
has
 
passed.
 
Never
 
double
 
a
 
dose
 
to
 
make
 
up
 
for
 
a
 
missed
 
dose.
 
 
Do
 
not
 
stop
 
taking
 
your
 
medication
 
unless
 
advised
 
to
 
do
 
so
 
by
 
your
 
prescriber
 
 
 
 
Special
 
Considerations
 
Pregnancy
 
&
 
Breastfeeding
 
 
 
 
1.
 
Opioid
 
crosses
 
the
 
placenta
 
and
 
can
 
be
 
detected
 
in
 
breast
 
milk
 
too.
 
2.
 
Use
 
during
 
pregnancy
 
and
 
breastfeeding
 
needs
 
to
 
be
 
carefully
 
considered
 
and
 
there
 
is
 
a
 
need
 
to
 
balance
 
pain
 
management
 
and
 
the
 
risk
 
of
 
neonatal
 
opioid
 
withdrawal
 
symptoms.
 
 
 
 
Elderly
 
 
 
 
 
1.
 
Increased
 
sensitivity
 
to
 
weak
 
opioids
  
in
 
elderly
 
patients
 
can
 
result
 
in
 
excessive
 
sedation,
 
dizziness,
 
confusion,
 
and
 
an
 
elevated
 
risk
 
of
 
delirium
 
and
 
lead
 
to
 
falls.
 
 
 
 
292
 

=== PAGE 294 ===

 
2.
 
Use
 
with
 
caution
 
in
 
the
 
elderly ,
 
debilitated
 
or
 
cachectic
 
patients
 
have
 
an
 
increased
 
risk
 
for
 
respiratory
 
depression.
 
3.
 
Use
 
in
 
elderly
 
patients
 
carry
 
risks
 
of
  
constipation
 
that
 
lead
 
to
  
delirium
 
and
 
increased
 
risk
 
of
 
falls.
 
4.
 
Avoid
 
in
 
patients
 
with
 
a
 
history
 
of
 
fractures
 
or
 
falls,
 
it
 
may
 
contribute
 
to
 
additional
 
fall.
 
5.
 
Avoid
 
use
 
in
 
patients
 
with
 
dysphagia.
 
Paediatric
 
 
 
 
1.
 
Although
 
opioids
 
are
 
highly
 
effective
 
in
 
treating
 
pain,
 
their
 
use
 
frequently
 
results
 
in
 
various
 
side
 
effects
 
including
 
nausea
 
and
 
vomiting,
 
pruritus,
 
constipation,
 
sedation
 
as
 
well
 
as
 
potentially
 
fatal
 
respiratory
 
depression
 
in
 
children.
 
 
 
 
Abuse
 
/
 
Misuse
 
/
 
Diversion
 
 
 
 
1.
 
Use
 
with
 
caution
 
in
 
patients
 
with
 
a
 
history
 
of
 
substance
 
use
 
disorder ,
 
as
 
the
 
potential
 
for
 
drug
 
dependency
 
exists.
 
 
 
 
Others
  
(
eg.
 
hepatic
 
impairment,
 
renal
 
impairment
 
which
 
will
 
be
 
relevant
 
to
 
the
 
patient)
 
 
 
 
1.
 
The
 
use
 
of
 
long-acting
 
formulations
 
is
 
not
 
advisable
 
if
 
a
 
patient
 
develops
 
renal
 
impairment
 
or
 
hepatic
 
impairment.
 
2.
 
Speak
 
to
 
your
 
doctor
 
about
 
using
 
a
 
more
 
appropriate
 
analgesic
 
to
 
manage
 
your
 
pain.
 
 
 
 
Side
 
Effects
 
and
 
their
 
Management*
 
1.
 
Opioid-induced
 
constipation
 
a.
 
A
 
common
 
side
 
effect
 
b.
 
Tolerance
 
does
 
not
 
develop,
 
hence
 
laxatives
 
must
 
be
 
taken
 
regularly 
 
c.
 
Use
 
combination
 
of
 
stimulant
 
(e.g.
 
bisacodyl)
 
+
 
softener
 
(e.g.
 
lactulose)
 
d.
 
Increase
 
fluid
 
and
 
dietary
 
fibre
 
intake,
 
maintain
 
good
 
physical
 
activity ,
 
and
 
try
 
to
 
establish
 
a
 
toilet
 
routine
 
 
2.
 
Opioid-induced
 
sedation
 
/
 
impaired
 
alertness
 
a.
 
May
 
occur
 
upon
 
initiation
 
of
 
opioids
 
b.
 
Avoid
 
driving
 
and
 
other
 
activities
 
that
 
require
 
mental
 
alertness
 
until
 
it
 
is
 
clear
 
how
 
morphine/
 
Oxycodone
 
affects
 
the
 
patient
 
c.
 
Tolerance
 
develops
 
after
 
5
 
-
 
10
 
days
 
 
3.
 
Opioid-induced
 
neurotoxicity
 
(delirium,
 
confusion)
 
a.
 
May
 
occur ,
 
but
 
usually
 
transient
 
b.
 
May
 
consider
 
use
 
of
 
haloperidol
 
for
 
delirium
 
 
4.
 
Opioid-induced
 
nausea
 
and
 
vomiting
 
a.
 
May
 
occur
 
upon
 
initiation
 
of
 
opioids
 
b.
 
Tolerance
 
develops
 
5
 
-
 
10
 
days
 
after
 
starting
 
c.
 
May
 
use
 
antiemetics
 
(e.g.
 
metoclopramide,
 
haloperidol
 
or
 
prochlorperazine)
 
d.
 
Be
 
consistent
 
when
 
taking
 
morphine
 
with
 
or
 
without
 
meals
 
e.
 
 
5.
 
Opioid-induced
 
dry
 
mouth 
 
a.
 
Sip
 
water
 
often,
 
let
 
small
 
ice
 
chips
 
melt
 
in
 
your
 
mouth
 
b.
 
Minimise
 
intake
 
of
 
caffeinated
 
drinks,
 
such
 
as
 
 
 
 
293
 

=== PAGE 295 ===

 
coffee,
 
tea,
 
and
 
some
 
sodas
 
as
 
well
 
as
 
use
 
of
 
tobacco
 
and
 
alcohol
 
c.
 
Chew
 
sugarless
 
gum
 
or
 
suck
 
on
 
sugarless
 
hard
 
candy
 
to
 
stimulate
 
saliva
 
flow.
 
 
Storage*
 
1.
 
Medication
 
may
 
be
 
kept
 
at
 
room
 
temperature,
 
in
 
a
 
safe
 
place
 
and
 
out
 
of
 
direct
 
sunlight,
 
and
 
humidity .
 
2.
 
Ensure
 
medication
 
is
 
out
 
of
 
the
 
reach
 
of
 
children
 
and
 
pets.
 
 
 
 
Others
 
1.
 
Respiratory
 
depression
 
is
 
rare
 
but
 
may
 
occur
 
if
 
morphine
 
is
 
used
 
incorrectly ,
 
and
 
can
 
be
 
fatal.
 
 
2.
 
Do
 
not
 
take
 
more
 
than
 
what
 
has
 
been
 
prescribed.
 
3.
 
Concurrent
 
use
 
of
 
other
 
central
 
nervous
 
system
 
(CNS)
 
depressants,
 
such
 
as
 
benzodiazepines,
 
barbiturates,
 
sedatives,
 
hypnotics,
 
or
 
alcohol,
 
can
 
potentiate
 
the
 
sedative
 
and
 
respiratory
 
depressant
 
effects
 
of
 
morphine,
 
increasing
 
the
 
risk
 
of
 
profound
 
sedation,
 
respiratory
 
depression,
 
coma,
 
or
 
death.
 
4.
 
Medication
 
should
 
be
 
tapered
 
gradually
 
when
 
discontinuing
 
therapy
 
to
 
minimize
 
withdrawal
 
effects.
 
 
 
 
 
Before
 
ending
 
this
 
peer
 
review
 
session,
 
the
 
reviewee
 
should
 
be
 
informed
 
of
 
the
 
step(s)
 
that
 
he/
 
she
 
missed
 
out
 
in
 
order
 
to
 
ensure
 
all
 
the
 
counselling
 
points
 
are
 
being
 
covered.
 
 
Remarks:
 
 
 
 
 
Reviewed
 
by:
 
Name
 
&
 
Signature
                                                                   
Date:
 
 
 
 
 
*Mandatory
 
for
 
validation
 
/
 
peer
 
review
 
 
References:
 
 
1.
 
2023
 
American
 
Geriatrics
 
Society
 
Beers
 
Criteria®
 
Update
 
Expert
 
Panel.
 
(2023).
 
American
 
Geriatrics
 
Society
 
2023
 
updated
 
AGS
 
Beers
 
Criteria®
 
for
 
potentially
 
inappropriate
 
medication
 
use
 
in
 
older
 
adults.
 
Journal
 
of
 
the
 
American
 
Geriatrics
 
Society ,
 
71(7),
 
2052-2081
.
 
2.
 
Clinical
 
Practice
 
Guidelines
 
Management
 
of
 
Cancer
 
Pain
 
(Second
 
Edition)
 
(2023)
 
Ministry
 
of
 
Health
 
Malaysia.
 
3.
 
Morphine
 
Sulphate.
 
(2024).
 
Micromedex
 
(electronic
 
version).
 
Retrieved
 
October
 
23,
 
2024
 
from
 
http://www .micromedexsolutions.com/
 
4.
 
Oxycodone
 
Hydrochloride.
 
(2024).
 
Micromedex
 
(electronic
 
version).
 
Retrieved
 
October
 
23,
 
2024
 
from
 
http://www .micromedexsolutions.com/
 
294
 

=== PAGE 296 ===

 
Opioids,
 
Weak
 
Name
 
:
 
 
Unit
 
:
 
 
●
 
Please
 
tick
 
(
✔
)
 
Yes
 
for
 
correct
 
instruction.
 
●
 
Please
 
tick
 
(
✔
)
 
No
 
for
 
incorrect
 
instruction.
 
Yes
 
No
 
Remarks
 
Pharmacological
 
Group
 
Weak
 
opioid
 
Analgesic
 
Preparations
 
available:
 
1.
 
Tramadol
 
HCl
 
50mg
 
Tablet
 
2.
 
Dihydrocodeine
 
Tartrate
 
30mg
 
Tablet(DF1 18)
 
 
 
 
Indications
 
and
 
Dosage
 
1.
 
Tramadol:
 
Moderate
 
to
 
severe
 
acute
 
or
 
chronic
 
pain
 
 
a.
 
Dose:
 
50
 
–
 
100
 
mg
 
6
 
–
 
8-hourly
 
(Maximum
 
dose:
 
400
 
mg/day)
 
b.
 
Paediatric:
 
Over
 
12
 
years:
 
Maximum
 
dose
 
1
 
mg/kg
 
6-8h,
 
max
 
400
 
mg/day
 
c.
 
Renal
 
adjustment:
 
 
                             
CrCl
 
<30
 
ml/min
 
:
 
200
 
mg/day ,
 
BD
 
dosing
 
d.
 
Severe
 
hepatic
 
impairment:
 
 
       
50
 
mg
 
BD
 
 
2.
 
Dihydrocodeine:
 
For
 
the
 
control
 
of
 
moderate
 
to
 
severe
 
pain
 
a.
 
30
 
–
 
60
 
mg,
 
4-6
 
hourly
 
(Maximum
 
dose:
 
240
 
mg/day)
 
b.
 
Paediatric:
 
Over
 
4
 
years:
 
0.5-1mg/kg
 
(adult
 
15-60mg)
 
4-6h
 
c.
 
Renal/hepatic
 
adjustment:
 
To
 
avoid
 
or
 
reduce
 
dose
 
 
To
 
counsel
 
based
 
on
 
specific
 
medication’ s
 
indication
 
and
 
dosage
 
as
 
prescribed
 
by
 
the
 
doctor
 
 
 
 
Method
 
of
 
Administration*
 
1.
 
Tramadol
 
a.
 
May
 
be
 
taken
 
with
 
or
 
without
 
food.
 
b.
 
Capsules
 
can
 
be
 
opened
 
easily
 
and
 
the
 
contents
 
mix
 
easily
 
with
 
water
 
to
 
form
 
a
 
fine
 
suspension
 
that
 
flushes
 
easily
 
via
 
a
 
Ryle’ s
 
Tube
 
(RT).
 
 
2.
 
Dihydrocodeine
 
a.
 
Should
 
be
 
taken
 
with
 
food.
 
b.
 
Tablets
 
can
 
be
 
crushed.
 
 
Do
 
not
 
stop
 
taking
 
your
 
medication
 
unless
 
advised
 
to
 
do
 
so
 
by
 
your
 
prescriber
 
 
 
 
Special
 
Considerations
 
Pregnancy
 
 
 
 
1.
 
Tramadol
 
a.
 
Human
 
data
 
suggest
 
risk.
 
 
b.
 
Prolonged
 
use
 
of
 
opioid
 
analgesics
 
during
 
pregnancy
 
may
 
cause
 
neonatal
 
opioid
 
withdrawal
 
syndrome.
  
 
 
2.
 
Dihydrocodeine
 
Human
 
data
 
suggest
 
risk
 
in
 
third
 
trimester
 
 
 
 
Breastfeeding
 
 
 
 
1.
 
Tramadol
 
Limited
 
human
 
data.
 
Unlikely
 
to
 
cause
 
harm
 
in
 
healthy
 
 
 
 
295
 

=== PAGE 297 ===

 
term
 
infants
 
 
2.
 
Dihydrocodeine
 
No
 
human
 
data.
 
Probably
 
compatible
 
Elderly
 
 
 
 
1.
 
Increased
 
sensitivity
 
to
 
weak
 
opioids
  
in
 
elderly
 
patients
 
can
 
result
 
in
 
excessive
 
sedation,
 
dizziness,
 
confusion,
 
and
 
an
 
elevated
 
risk
 
of
 
delirium
 
and
 
lead
 
to
 
falls.
 
2.
 
Use
 
in
 
elderly
 
patients
 
carry
 
risks
 
of
  
constipation
 
that
 
lead
 
to
  
delirium
 
and
 
increased
 
risk
 
of
 
falls.
 
 
 
 
 
Paediatric
 
 
 
 
1.
 
Although
 
opioids
 
are
 
highly
 
effective
 
in
 
treating
 
pain,
 
their
 
use
 
frequently
 
results
 
in
 
various
 
side
 
effects
 
including
 
nausea
 
and
 
vomiting,
 
pruritus,
 
constipation,
 
sedation
 
as
 
well
 
as
 
potentially
 
fatal
 
respiratory
 
depression
 
in
 
children.
 
 
 
 
Others
  
 
 
 
 
1.
 
Tramadol
 
a.
 
Risk
 
of
 
seizures
 
in
 
patients
 
with
 
a
 
history
 
of
 
seizures
 
and
 
with
 
high
 
doses.
 
b.
 
Use
 
with
 
caution
 
in
 
patients
 
taking
 
drugs
 
which
 
decrease
 
seizure
 
threshold
 
eg:
 
tricyclic
 
antidepressants
 
(TCAs),
 
selective
 
serotonin
 
reuptake
 
inhibitors
 
(SSRI)
 
&
 
serotonin
 
noradrenalin
 
reuptake
 
inhibitors
 
(SNRI).
 
c.
 
Avoid
 
concomitant
 
use
 
with
 
or
 
within
 
14
 
days
 
following
 
MAO
 
inhibitor
 
therapy .
 
 
2.
 
Dihydrocodeine
 
Cautions
 
and
 
contraindications:
 
 
a.
 
May
 
cause
 
the
 
release
 
of
 
histamine
 
thus
 
should
 
not
 
be
 
administered
 
during
 
an
 
asthmatic
 
attack.
 
b.
 
Respiratory
 
depression,
 
acute
 
alcoholism,
 
paralytic
 
ileus,
 
raised
 
intracranial
 
pressure
 
 
 
 
 
Side
 
Effects
 
and
 
their
 
Management*
 
1.
 
Opioid-induced
 
constipation
 
a.
 
A
 
common
 
side
 
effect
 
b.
 
Tolerance
 
does
 
not
 
develop,
 
hence
 
laxatives
 
must
 
be
 
taken
 
regularly 
 
c.
 
Use
 
combination
 
of
 
stimulant
 
(e.g.
 
bisacodyl)
 
+
 
softener
 
(e.g.
 
lactulose)
 
d.
 
Increase
 
fluid
 
and
 
dietary
 
fibre
 
intake,
 
maintain
 
good
 
physical
 
activity ,
 
and
 
try
 
to
 
establish
 
a
 
toilet
 
routine
 
 
2.
 
Opioid-induced
 
sedation
 
/
 
impaired
 
alertness
 
a.
 
May
 
occur
 
upon
 
initiation
 
of
 
opioids
 
b.
 
Avoid
 
driving
 
and
 
other
 
activities
 
that
 
require
 
mental
 
alertness
 
until
 
it
 
is
 
clear
 
how
 
morphine/
 
Oxycodone
 
affects
 
the
 
patient
 
c.
 
Tolerance
 
develops
 
after
 
5
 
-
 
10
 
days
 
 
3.
 
Opioid-induced
 
neurotoxicity
 
(delirium,
 
confusion)
 
a.
 
May
 
occur ,
 
but
 
usually
 
transient
 
b.
 
May
 
consider
 
use
 
of
 
haloperidol
 
for
 
delirium
 
 
 
 
 
296
 

=== PAGE 298 ===

 
4.
 
Opioid-induced
 
nausea
 
and
 
vomiting
 
a.
 
May
 
occur
 
upon
 
initiation
 
of
 
opioids
 
b.
 
Tolerance
 
develops
 
5
 
-
 
10
 
days
 
after
 
starting
 
c.
 
May
 
use
 
antiemetics
 
(e.g.
 
metoclopramide,
 
haloperidol
 
or
 
prochlorperazine)
 
d.
 
Be
 
consistent
 
when
 
taking
 
morphine
 
with
 
or
 
without
 
meals
 
 
5.
 
Opioid-induced
 
dry
 
mouth 
 
a.
 
Sip
 
water
 
often,
 
let
 
small
 
ice
 
chips
 
melt
 
in
 
your
 
mouth
 
b.
 
Minimise
 
intake
 
of
 
caffeinated
 
drinks,
 
such
 
as
 
coffee,
 
tea,
 
and
 
some
 
sodas
 
as
 
well
 
as
 
use
 
of
 
tobacco
 
and
 
alcohol
 
c.
 
Chew
 
sugarless
 
gum
 
or
 
suck
 
on
 
sugarless
 
hard
 
candy
 
to
 
stimulate
 
saliva
 
flow.
 
Storage*
 
1.
 
Medication
 
may
 
be
 
kept
 
at
 
room
 
temperature,
 
in
 
a
 
safe
 
place
 
and
 
out
 
of
 
direct
 
sunlight,
 
and
 
humidity .
 
2.
 
Ensure
 
medication
 
is
 
out
 
of
 
the
 
reach
 
of
 
children
 
and
 
pets.
 
 
 
 
Before
 
ending
 
this
 
peer
 
review
 
session,
 
the
 
reviewee
 
should
 
be
 
informed
 
of
 
the
 
step(s)
 
that
 
he/
 
she
 
missed
 
out
 
in
 
order
 
to
 
ensure
 
all
 
the
 
counselling
 
points
 
are
 
being
 
covered.
 
 
Remarks:
 
 
 
 
 
Reviewed
 
by:
 
Name
 
&
 
Signature
                                                                   
Date:
 
 
 
 
 
*Mandatory
 
for
 
validation
 
/
 
peer
 
review
 
 
 
References:
 
 
1.
 
2023
 
American
 
Geriatrics
 
Society
 
Beers
 
Criteria®
 
Update
 
Expert
 
Panel.
 
(2023).
 
American
 
Geriatrics
 
Society
 
2023
 
updated
 
AGS
 
Beers
 
Criteria®
 
for
 
potentially
 
inappropriate
 
medication
 
use
 
in
 
older
 
adults.
 
Journal
 
of
 
the
 
American
 
Geriatrics
 
Society ,
 
71(7),
 
2052-2081.
 
2.
 
Briggs,
 
G.
 
G.,
 
Freeman,
 
R.
 
K.,
 
Towers,
 
C.
 
V.,
 
&
 
Forinash,
 
A.
 
B.
 
(2017).
 
Drugs
 
in
 
pregnancy
 
and
 
lactation:
 
a
 
reference
 
guide
 
to
 
fetal
 
and
 
neonatal
 
risk.
 
Eleventh
 
edition.
 
Philadelphia,
 
PA,
 
Wolters
 
Kluwer .
 
3.
 
MIMS
 
Malaysia.
 
(n.d.).
 
Tramadol.
 
In
 
MIMS
 
online.
 
Retrieved
 
October
 
10,
 
2024,
 
from
 
https://www .mims.com/malaysia
 
4.
 
MIMS
 
Malaysia.
 
(n.d.).
 
Dihydrocodeine.
 
In
 
MIMS
 
online.
 
Retrieved
 
October
 
10,
 
2024,
 
from
 
https://www .mims.com/malaysia
 
 
5.
 
Ministry
 
of
 
Health
 
Malaysia
 
(2018). Pain
 
as
 
The
 
5
 
th
 
Vital
 
Sign
 
Guideline:
 
3
 
rd
 
Edition.
 
[online]
 
Available
 
at:
 
https://www .moh.gov .my/moh/resources/Penerbitan/Program%20Bebas%20Kesakitan/Garis%20Pandu
an/2_in_1_P5VS_Guide
 
 
6.
 
Tramadol
 
(2024).
 
UpToDate
 
Inc.
 
[Drug
 
information].
 
Lexi-Drugs,
 
UpToDate
 
Lexidrug.
 
Retrieved
 
October
 
10,
 
2024,
 
from
 
http://online.lexi.com
 
 
297
 

=== PAGE 299 ===

 
Paracetamol
 
 
Name
 
:
 
 
Unit
 
:
 
 
●
 
Please
 
tick
 
(
✔
)
 
Yes
 
for
 
correct
 
instruction.
 
●
 
Please
 
tick
 
(
✔
)
 
No
 
for
 
incorrect
 
instruction.
 
Yes
 
No
 
Remarks
 
Pharmacological
 
Group
 
Non-opioid
 
analgesic
 
 
 
 
Indications
 
and
 
Dosage
 
Indication
 
1.
 
Relief
 
of
 
fever
 
2.
 
Relief
 
of
 
pain
 
 
Dosage
 
1.
 
Adults
 
and
 
children
 
above
 
12
 
years:
 
500mg
 
-
 
1g
 
every
 
4
 
-
 
6
 
hours.
 
Maximum
 
4g
 
daily.
 
2.
 
Children:
 
a.
 
0
 
-
 
3
 
months:
 
15mg/kg
 
6
 
–
 
8H
 
(Max:
 
60mg/kg/day;
 
if
 
preterm
 
28-32
 
CGA,
 
max
 
30mg/kg/day)
 
 
b.
 
>
 
3months
 
-12
 
years:
 
15mg/kg
 
4-6H
 
(Max:
 
75mg/kg/day
 
or
 
4
 
grams/day)
 
 
 
To
 
counsel
 
based
 
on
 
specific
 
medication’ s
 
indication
 
and
 
dosage
 
as
 
prescribed
 
by
 
the
 
doctor
 
 
 
 
Method
 
of
 
Administration*
 
1.
 
May
 
be
 
taken
 
with
 
or
 
without
 
food.
 
2.
 
Missed
 
dose
 
management:
 
Take
 
the
 
missed
 
dose
 
as
 
soon
 
as
 
you
 
remember .
 
If
 
it
 
is
 
almost
 
time
 
for
 
your
 
next
 
dose,
 
wait
 
until
 
then
 
to
 
take
 
the
 
medicine
 
and
 
skip
 
the
 
missed
 
dose.
 
Do
 
not
 
take
 
a
 
double
 
dose
 
to
 
make
 
up
 
for
 
the
 
missed
 
dose.
 
 
Do
 
not
 
stop
 
taking
 
your
 
medication
 
unless
 
advised
 
to
 
do
 
so
 
by
 
your
 
prescriber
 
 
 
 
Special
 
Considerations
 
Pregnancy
 
 
 
 
1.
 
Pregnancy
 
category:
 
B
 
2.
 
Paracetamol
 
crosses
 
the
 
placenta
 
but
 
the
 
drug
 
has
 
been
 
used
 
widely
 
as
 
an
 
analgesic
 
in
 
pregnancy
 
and
 
no
 
adverse
 
fetal
 
effects
 
have
 
been
 
recorded.
 
 
 
 
Breastfeeding
 
 
 
 
1.
 
Compatible
 
with
 
breast
 
feeding.
 
 
 
 
Elderly
 
 
 
 
1.
 
Use
 
the
 
lowest
 
effective
 
dose
 
for
 
the
 
shortest
 
duration
 
(example
 
≤
 
3gm/
 
day).
 
2.
 
Caution
 
for
 
long
 
term
 
use
 
in
 
elderly;
 
deranged
 
liver
 
enzyme.
 
 
 
 
Paediatric
 
 
 
 
298
 

=== PAGE 300 ===

 
1.
 
There
 
are
 
different
 
types
 
of
 
paracetamol,
 
including
 
two
 
strengths
 
of
 
oral
 
syrup.
 
Care
 
must
 
be
 
taken
 
to
 
avoid
 
accidental
 
overdose.
 
 
 
 
Others
 
 
 
 
 
1.
 
Should
 
be
 
given
 
with
 
care
 
to
 
patients
 
with
 
impaired
 
kidney
 
or
 
liver
 
function
 
2.
 
Contraindicated
 
in
 
patients
 
with
 
severe
 
hepatic
 
impairment
 
or
 
active
 
liver
 
disease
 
 
 
 
Side
 
Effects
 
and
 
their
 
Management*
 
1.
 
Cutaneous
 
hypersensitivity
 
reaction
 
including
 
skin
 
rashes,
 
angioedema,
 
Stevens
 
Johnson
 
Syndrome
 
2.
 
Risk
 
of
 
hepatotoxicity
 
 
 
 
Storage*
 
1.
 
Store
 
in
 
a
 
dry
 
place,
 
below
 
30
℃
 
 
 
 
Others
 
1.
 
Be
 
careful
 
when
 
using
 
other
 
products
 
that
 
contain
 
paracetamol
 
at
 
the
 
same
 
time.
 
2.
 
Caution
 
in
 
alcoholism
 
 
 
 
Before
 
ending
 
this
 
peer
 
review
 
session,
 
the
 
reviewee
 
should
 
be
 
informed
 
of
 
the
 
step(s)
 
that
 
he/
 
she
 
missed
 
out
 
in
 
order
 
to
 
ensure
 
all
 
the
 
counselling
 
points
 
are
 
being
 
covered.
 
 
Remarks:
 
 
 
 
 
Reviewed
 
by:
 
Name
 
&
 
Signature
                                                                   
Date:
 
 
 
 
 
*Mandatory
 
for
 
validation
 
/
 
peer
 
review
 
 
References:
 
 
1.
 
Briggs,
 
G.
 
G.,
 
Freeman,
 
R.
 
K.,
 
Towers,
 
C.
 
V.,
 
&
 
Forinash,
 
A.
 
B.
 
(2017).
 
Drugs
 
in
 
pregnancy
 
and
 
lactation:
 
a
 
reference
 
guide
 
to
 
fetal
 
and
 
neonatal
 
risk.
 
Eleventh
 
edition.
 
Philadelphia,
 
PA,
 
Wolters
 
Kluwer .
 
2.
 
CCM
 
Pharmaceutical
 
(2021).
 
Uphamol
 
tablet
 
500mg
 
product
 
Information.
 
3.
 
MIMS
 
Malaysia.
 
(n.d.).
 
Paracetamol.
 
In
 
MIMS
 
online.
 
Retrieved
 
October
 
10,
 
2024,
 
from
 
https://www .mims.com/malaysia
 
4.
 
Ministry
 
of
 
Health
 
Malaysia
 
(2018).
 
Pain
 
as
 
The
 
5
 
th
 
Vital
 
Sign
 
Guideline:
 
3rd
 
Edition.
 
[online]
 
Available
 
at:
 
https://www .moh.gov .my/moh/resources/Penerbitan/Program%20Bebas%20Kesakitan/Garis%20Pandu
an/2_in_1_P5VS_Guide
 
 
5.
 
Ministry
 
of
 
Health
 
Malaysia
 
(2023).
 
Paediatric
 
Pain
 
Management
 
Guidelines.
 
Retrieved
 
January
 
20,
 
2025
 
from
 
https://www .moh.gov .my/moh/resources/Penerbitan/Program%20Bebas%20Kesakitan/Garis%20Pandu
an/PAEDIA TRIC_P AIN_MANAGEMENT_GUIDELINE_-_2023.pdf
 
6.
 
Paracetamol
 
(2024).
 
UpToDate
 
[Drug
 
information].
 
Lexi-Drugs,
 
UpToDate
 
Lexidrug.
 
Retrieved
 
October
 
10,
 
2024,from
 
http://online.lexi.com
 
7.
 
Reid,
 
O.,
 
Ngo,
 
J.,
 
Lalic,
 
S.,
 
Su,
 
E.,
 
&
 
Elliott,
 
R.
 
A.
 
(2022).
 
Paracetamol
 
dosing
 
in
 
hospital
 
and
 
on
 
discharge
 
for
 
older
 
people
 
who
 
are
 
frail
 
or
 
have
 
low
 
body
 
weight.
 
British
 
Journal
 
of
 
Clinical
 
Pharmacology ,
 
88(10),
 
4565-4572.
 
 
299
 

=== PAGE 301 ===

 
Permethrin,
 
Lotion
 
Name
 
:
 
 
Unit
 
:
 
 
●
 
Please
 
tick
 
(
✔
)
 
Yes
 
for
 
correct
 
instruction.
 
●
 
Please
 
tick
 
(
✔
)
 
No
 
for
 
incorrect
 
instruction.
 
Yes
 
No
 
Remarks
 
Pharmacological
 
Group
 
Scabicides;
 
Topical
 
insecticide
 
 
 
 
Indications
 
and
 
Dosage
 
1.
 
Permethrin
 
1%
 
Lotion
 
 
For
 
topical
 
treatment
 
of
 
head
 
lice
 
 
2.
 
Permethrin
 
5%
 
Lotion
 
 
Treatment
 
of
 
scabies
 
 
To
 
counsel
 
based
 
on
 
specific
 
medication’ s
 
indication
 
and
 
dosage
 
as
 
prescribed
 
by
 
the
 
doctor
 
 
 
 
Method
 
of
 
Administration*
 
Permethrin
 
1%
 
Lotion
 
 
(
Treatment
 
of
 
head
 
lice)
 
 
1.
 
Before
 
application,
 
wash
 
hair
 
with
 
a
 
mild
 
regular
 
shampoo
 
and
 
towel
 
dry.
 
 
2.
 
Apply
 
sufficient
 
amounts
 
to
 
completely
 
saturate
 
the
 
hair
 
and
 
scalp
 
(especially
 
behind
 
the
 
ear
 
and
 
nape
 
of
 
the
 
neck).
 
3.
 
Leave
 
on
 
the
 
hair
 
for
 
10
 
minutes
 
then
 
rise
 
thoroughly
 
with
 
water .
 
4.
 
Remove
 
nits
 
with
 
fine-toothed
 
comb
 
as
 
necessary .
 
5.
 
May
 
repeat
 
treatment
 
7
 
-
 
1
 
days
 
after
 
initial
 
application
 
if
 
live
 
lice
 
or
 
nits
 
are
 
found.
 
 
Permethrin
 
5%
 
Lotion
  
(
Treatment
 
of
 
scabies)
 
 
1.
 
Applied
 
from
 
the
 
jawline
 
downwards,
 
and
 
left
 
overnight
 
for
 
8–14
 
hours.
 
Reapplication
 
is
 
needed
 
if
 
hands
 
are
 
washed
 
during
 
the
 
treatment
 
period.
 
Infants,
 
the
 
elderly ,
 
and
 
the
 
immunosuppressed
 
should
 
also
 
treat
 
the
 
face
 
and
 
scalp.
 
2.
 
Application
 
should
 
include
 
under
 
the
 
nails
 
and
 
between
 
the
 
toes.
 
3.
 
Treatment
 
should
 
be
 
repeated
 
after
 
7–10
 
days.
 
 
Missed
 
dose
 
management
:
 
If
 
a
 
dose
 
is
 
missed,
 
use
 
it
 
as
 
soon
 
as
 
possible.
 
If
 
it
 
is
 
almost
 
time
 
for
 
the
 
next
 
dose,
 
use
 
only
 
that
 
dose.
 
Do
 
not
 
use
 
double
 
or
 
extra
 
doses.
 
 
Do
 
not
 
stop
 
your
 
medication
 
unless
 
advised
 
to
 
do
 
so
 
by
 
your
 
prescriber
 
 
 
 
Special
 
Considerations
 
Pregnancy
 
 
 
 
1.
 
Safe
 
for
 
pregnant
 
women.
 
 
 
 
Breastfeeding
 
 
 
 
1.
 
Safe
 
for
 
breastfeeding
 
women.
 
 
 
 
Elderly
 
 
 
 
None
 
specifically
 
to
 
the
 
product
 
 
 
 
 
300
 

=== PAGE 302 ===

 
Paediatric
 
 
 
 
1.
 
Not
 
recommended
 
for
 
infants
 
less
 
than
 
2
 
months
 
of
 
age.
 
 
 
 
Fasting
 
 
 
 
N/A
 
 
 
 
Others
  
 
 
 
 
N/A
 
 
 
 
Side
 
Effects
 
and
 
their
 
Management*
 
Itching
 
&
 
burning/stinging
 
sensation
 
on
 
application.
 
 
 
 
Storage*
 
1.
 
Store
 
at
 
room
 
temperature
 
below
 
25C.
 
2.
 
Protect
 
from
 
light.
 
3.
 
Discard
 
any
 
unused
 
medicine
 
after
 
the
 
expired
 
date.
 
 
 
 
Others
 
1.
 
Patients
 
with
 
scabies
 
and
 
their
 
close
 
physical
 
contacts,
 
even
 
without
 
symptoms,
 
should
 
receive
 
treatment
 
at
 
the
 
same
 
time.
 
 
2.
 
Avoid
 
contact
 
with
 
eyes
 
or
 
mucous
 
membranes
 
or
 
the
 
area
 
around
 
the
 
mouth.
 
3.
 
In
 
infants,
 
hands
 
covered
 
with
 
mittens
 
will
 
prevent
 
removal
 
and
 
ingestion
 
of
 
the
 
treatment
 
product.
 
4.
 
If
 
the
 
treatment
 
is
 
applied
 
by
 
someone
 
without
 
scabies,
 
this
 
person
 
should
 
wear
 
medical
 
gloves
 
during
 
application.
 
5.
 
After
 
completion
 
of
 
treatment,
 
patients
 
should
 
use
 
fresh,
 
clean
 
bedding
 
and
 
clothing.
 
 
6.
 
Itching
 
and
 
rash
 
may
 
continue
 
for
 
up
 
to
 
4
 
weeks
 
after
 
treatment,
 
but
 
this
 
is
 
usually
 
a
 
temporary
 
reaction.
 
7.
 
Wash
 
all
 
toys
 
in
 
very
 
hot
 
soapy
 
water
 
for
 
5-10min
 
or
 
seal
 
in
 
an
 
airtight
 
plastic
 
bag
 
for
 
2
 
weeks.
 
This
 
is
 
especially
 
important
 
for
 
stuffed
 
toys
 
used
 
on
 
the
 
bed.
 
 
 
 
 
Before
 
ending
 
this
 
peer
 
review
 
session,
 
the
 
reviewee
 
should
 
be
 
informed
 
of
 
the
 
step(s)
 
that
 
he/
 
she
 
missed
 
out
 
in
 
order
 
to
 
ensure
 
all
 
the
 
counselling
 
points
 
are
 
being
 
covered.
 
 
Remarks:
 
 
 
 
 
Reviewed
 
by:
 
Name
 
&
 
Signature
                                                                   
Date:
 
 
 
 
 
*Mandatory
 
for
 
validation
 
/
 
peer
 
review
 
References:
 
 
1.
 
MIMS
 
Malaysia
 
(2025).
 
Permethrin.
 
Retrieved
 
from:
 
https://www .mims.com/malaysia/drug/info/permethrin?mtype=generic
.
 
Accessed
 
on
 
January
 
21,
 
2025.
 
2.
 
Vasanwala
 
et
 
al.
 
(2019).
 
Management
 
of
 
Scabies.
 
Singapore
 
Medical
 
Journal.
 
Retrieved
 
from:
  
http://www .smj.org.sg/sites/default/files/SMJ-60-281.pdf
 
3.
 
DermNet®.
 
Retrieved
 
from:
 
https://dermnetnz.org/topics/scabies
.
 
Accessed
 
on
 
January
 
21,
 
2025.
 
4.
 
Formulari
 
Ubat
 
KKM
 
(2025).
 
Accessed
 
on
 
January
 
1,
 
2025.
 
5.
 
Ministry
 
of
 
Health
 
Malaysia
 
(2015).
 
Guideline
 
for
 
Management
 
of
 
Scabies
 
in
 
Adults
 
and
 
Children.
 
 
301
 

=== PAGE 303 ===

 
 
Podophyllum
 
Paint
 
Name
 
:
 
 
Unit
 
:
 
 
●
 
Please
 
tick
 
(
✔
)
 
Yes
 
for
 
correct
 
instruction.
 
●
 
Please
 
tick
 
(
✔
)
 
No
 
for
 
incorrect
 
instruction.
 
Yes
 
No
 
Remarks
 
Pharmacological
 
Group
 
Keratolytic
 
Agent
 
 
 
 
Indications
 
and
 
Dosage
 
Indication:
 
External
 
genital
 
warts
 
              
 
Dosage:
 
Apply
 
2-3
 
drops
 
carefully
 
to
 
lesion
 
after
 
protecting
 
the
 
surrounding
 
area
 
with
 
white
 
soft
 
paraf fin.
 
Wash
 
off
 
after
 
6
 
hours
 
or
 
if
 
you
 
feel
 
a
 
burning
 
sensation.
 
Repeat
 
2-3
 
times
 
weekly
 
or
 
once
 
weekly .
 
 
 
 
 
Method
 
of
 
Administration*
 
1.
 
Use
 
a
 
toothpick
 
or
 
a
 
cotton-tipped
 
or
 
given
 
applicator
 
to
 
apply
 
this
 
medicine.
 
Apply
 
1
 
drop
 
at
 
a
 
time,
 
allowing
 
time
 
for
 
drying
 
between
 
drops,
 
until
 
the
 
affected
 
area
 
is
 
covered.
 
2.
 
After
 
podophyllum
 
is
 
applied,
 
allow
 
it
 
to
 
remain
 
in
 
the
 
affected
 
area
 
for
 
1
 
to
 
6
 
hours
 
as
 
directed
 
by
 
your
 
doctor .
 
Then,
 
remove
 
the
 
medicine
 
by
 
thoroughly
 
washing
 
the
 
affected
 
area
 
with
 
soap
 
and
 
water .
 
If
 
this
 
medicine
 
contains
 
tincture
 
of
 
benzoin,
 
it
 
may
 
be
 
removed
 
more
 
easily
 
by
 
swabbing
 
the
 
affected
 
area
 
with
 
rubbing
 
alcohol.
 
However ,
 
this
 
may
 
be
 
more
 
irritating
 
than
 
washing
 
with
 
soap
 
and
 
water .
 
3.
 
Immediately
 
after
 
applying
 
this
 
medicine,
 
wash
 
your
 
hands
 
to
 
remove
 
any
 
medicine
 
that
 
may
 
be
 
on
 
them.
 
 
Missed
 
dose
 
management:
 
If
 
you
 
miss
 
a
 
dose
 
of
 
this
 
medicine,
 
take
 
it
 
as
 
soon
 
as
 
possible.
 
However ,
 
if
 
it
 
is
 
almost
 
time
 
for
 
your
 
next
 
dose,
 
skip
 
the
 
missed
 
dose
 
and
 
go
 
back
 
to
 
your
 
regular
 
dosing
 
schedule.
 
 
Do
 
not
 
double
 
doses.
 
 
Do
 
not
 
stop
 
taking
 
your
 
medication
 
unless
 
advised
 
to
 
do
 
so
 
by
 
your
 
prescriber
 
 
 
 
Special
 
Considerations
 
Pregnancy
 
 
 
 
Contraindicated
 
 
 
 
Breastfeeding
 
 
 
 
1.
 
Use
 
in
 
breastfeeding
 
patients
 
is
 
contraindicated
 
by
 
the
 
manufacturer .
 
2.
 
Avoid
 
use
 
during
 
breastfeeding.
 
 
 
 
Elderly
 
 
 
 
None
 
specifically
 
to
 
Podophyllum
 
 
 
 
 
Paediatric
 
 
 
 
The
 
safety
 
and
 
efficacy
 
in
 
paediatric
 
patients
 
have
 
not
 
been
 
established.
 
 
 
 
302
 

=== PAGE 304 ===

 
Fasting
 
 
 
 
To
 
refer
 
to
 
the
 
latest
 
advisory
 
by
 
religious
 
authority
 
 
 
 
Others
 
 
 
 
Not
 
applicable
 
 
 
 
Side
 
Effects
 
and
 
their
 
Management*
 
Local
 
skin
 
irritation
 
 
Special
 
care
 
must
 
be
 
taken
 
to
 
ensure
 
application
 
is
 
restricted
 
to
 
the
 
wart
 
itself.
 
 
 
 
Storage*
 
Room
 
Temperature
 
 
 
 
Others
 
 
1.
 
Avoid
 
normal
 
(unaf fected)
 
skin
 
and
 
open
 
wound
 
2.
 
Do
 
not
 
use
 
it
 
if
 
wart
 
or
 
surrounding
 
tissue
 
is
 
inflamed
 
or
 
irritated.
 
 
3.
 
Do
 
not
 
use
 
on
 
bleeding
 
warts,
 
moles,
 
birthmarks,
 
or
 
unusual
 
warts
 
with
 
hair
 
growing
 
from
 
them.
 
4.
 
Do
 
not
 
treat
 
large
 
areas
 
or
 
many
 
warts
 
at
 
one
 
time.
 
 
 
 
 
Before
 
ending
 
this
 
peer
 
review
 
session,
 
the
 
reviewee
 
should
 
be
 
informed
 
of
 
the
 
step(s)
 
that
 
he/
 
she
 
missed
 
out
 
in
 
order
 
to
 
ensure
 
all
 
the
 
counselling
 
points
 
are
 
being
 
covered.
 
 
Remarks:
 
 
 
 
 
Reviewed
 
by:
 
Name
 
&
 
Signature
                                                                   
Date:
 
 
 
 
 
*Mandatory
 
for
 
validation/
 
peer
 
review
 
 
References:
 
 
1.
 
Stephanie
 
Abel,
 
PharmD,
 
BCPS
 
et
 
al
 
(2025),
 
Podophyllum
 
resin
 
(Podophyllin
 
resin):
 
Drug
 
information.
 
Retrieved
 
from
 
https://www .uptodate.com/contents/podophyllum-resin-podophyllin-resin-drug-information?search=podo 
phyllum&source=panel_search_result&selectedT itle=1%7E15&usage_type=panel&kp_tab=drug_genera 
l&display_rank=1
 
2.
 
Product
 
Information
 
Leaflet,
 
Podophyllum
 
Resin.
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
303
 

=== PAGE 305 ===

 
Ranolazine
 
 
Name
 
:
 
 
Unit
 
:
 
 
●
 
Please
 
tick
 
(
✔
)
 
Yes
 
for
 
correct
 
instruction.
 
●
 
Please
 
tick
 
(
✔
)
 
No
 
for
 
incorrect
 
instruction.
 
Yes
 
No
 
Remarks
 
Pharmacological
 
Group
 
Antianginal
 
drug
 
–
 
as
 
adjunct
 
therapy
 
 
 
MOA:
 
inhibition
 
of
 
the
 
late
 
sodium
 
current
 
in
 
heart
 
cells.
 
 
 
 
Indications
 
and
 
Dosage
 
1.
 
Add-on
 
therapy
 
for
 
the
 
symptomatic
 
treatment
 
of
 
patients
 
with
 
stable
 
angina
 
pectoris
 
who
 
are
 
inadequately
 
controlled
 
or
 
intolerant
 
to
 
first-line
 
antianginal
 
therapies
 
(such
 
as
 
beta-blockers
 
and/or
 
calcium
 
antagonists)
 
a.
 
Initial
 
375mg
 
bd,
 
titrate
 
to
 
500mg
 
bd
 
after
 
2-4
 
weeks;
 
may
 
further
 
titrate
 
to
 
maximum
 
750mg
 
bd
 
according
 
to
 
patient’ s
 
response
 
b.
 
Down-titration
 
to
 
375mg
 
or
 
500mg
 
bd
 
or
 
even
 
discontinued
 
may
 
be
 
required
 
if
 
patient
 
experiences
 
treatment-related
 
adverse
 
events.
 
 
 
 
 
Method
 
of
 
Administration*
 
Should
 
be
 
swallowed
 
whole
 
and
 
not
 
crushed,
 
broken,
 
or
 
chewed.
 
They
 
may
 
be
 
taken
 
with
 
or
 
without
 
food.
 
 
If
 
you
 
forget
 
to
 
take
 
a
 
dose,
 
take
 
it
 
as
 
soon
 
as
 
you
 
remember
 
unless
 
it
 
is
 
nearly
 
time
 
(less
 
than
 
6
 
hours)
 
to
 
take
 
your
 
next
 
dose.
 
Do
 
not
 
take
 
a
 
double
 
dose
 
to
 
make
 
up
 
for
 
a
 
forgotten
 
dose.
 
 
Do
 
not
 
stop
 
taking
 
your
 
medication
 
unless
 
advised
 
to
 
do
 
so
 
by
 
your
 
prescriber
 
 
 
 
Special
 
Considerations
 
Pregnancy
 
 
 
 
Limited
 
data.
 
Should
 
not
 
be
 
used
 
during
 
pregnancy
 
unless
 
clearly
 
necessary .
 
 
 
 
Breastfeeding
 
 
 
 
Should
 
not
 
be
 
used
 
during
 
breast-feeding.
 
 
 
 
Elderly
 
 
 
 
Use
 
with
 
caution
 
in
 
patients
 
≥75
 
years
 
of
 
age,
 
they
 
may
 
experience
 
more
  
adverse
 
events
 
and
 
drug
 
discontinuation
 
due
 
to
 
adverse
 
events
 
 
 
 
 
Paediatric
 
 
 
 
No
 
data
 
available.
 
 
 
 
Fasting
 
 
 
 
Not
 
applicable.
 
 
 
 
Others
 
 
 
 
 
Contraindicated
 
in
 
concomitant
 
administration
 
of
 
potent
 
CYP3A4
 
inhibitors;
 
crcl
 
<30
 
ml/min;
 
moderate
 
or
 
severe
 
hepatic
 
 
 
 
304
 

=== PAGE 306 ===

 
impairment;
 
concomitant
 
administration
 
of
 
Class
 
Ia
 
(e.g.
 
quinidine)
 
or
 
Class
 
III
 
(e.g.
 
dofetilide,
 
sotalol)
 
antiarrhythmics
 
other
 
than
 
amiodarone.
 
Side
 
Effects
 
and
 
their
 
Management*
 
Side
 
effects
 
usually
 
develop
 
within
 
the
 
first
 
2
 
weeks
 
of
 
treatment.
 
1.
 
Nervous
 
system
 
disorders:
 
dizziness,
 
headache.
 
2.
 
Gastrointestinal
 
disorders:
 
constipation,
 
vomiting,
 
nausea.
 
3.
 
General
 
fatigue
 
and
 
weakness
 
(asthenia)
 
 
 
 
Storage*
 
This
 
medicinal
 
product
 
does
 
not
 
require
 
any
 
special
 
storage
 
conditions.
 
Store
 
below
 
30°C.
 
 
 
 
Others
 
1.
 
Avoid
 
grapefruit
 
juice.
 
2.
 
Caution
 
should
 
be
 
exercised
 
when
 
prescribing
 
or
 
uptitrating
 
ranolazine
 
to
 
patients
 
in
 
whom
 
an
 
increased
 
exposure
 
is
 
expected:
 
●
 
Concomitant
 
administration
 
of
 
moderate
 
CYP3A4
 
inhibitors
 
 
●
 
Concomitant
 
administration
 
of
 
P-gp
 
inhibitors
 
●
 
Mild
 
hepatic
 
impairment
 
 
●
 
Mild
 
to
 
moderate
 
renal
 
impairment
 
(crcl
 
30–80ml/min)
 
 
●
 
Elderly
 
●
 
Patients
 
with
 
low
 
weight
 
(≤
 
60
 
kg)
 
 
●
 
Patients
 
with
 
moderate
 
to
 
severe
 
CHF
 
(NYHA
 
Class
 
III–IV)
 
 
 
 
 
Before
 
ending
 
this
 
peer
 
review
 
session,
 
the
 
reviewee
 
should
 
be
 
informed
 
of
 
the
 
step(s)
 
that
 
he/
 
she
 
missed
 
out
 
in
 
order
 
to
 
ensure
 
all
 
the
 
counselling
 
points
 
are
 
being
 
covered.
 
 
Remarks:
 
 
 
 
 
Reviewed
 
by:
 
Name
 
&
 
Signature
                                                                   
Date:
 
 
 
 
 
*Mandatory
 
for
 
validation
 
/
 
peer
 
review
 
References:
 
 
1.
 
Product
 
Information
 
Leaflet.
 
(2020).
 
Ranexa®.
 
Menarini.
 
 
2.
 
Consumer
 
Medication
 
Information
 
Leaflet
 
(RiMUP).
 
(2020).
 
RANEXA
 
Prolonged
 
Release
 
Tablets.
 
A.
 
Menarini
 
Singapore
 
Pte
 
Ltd.
 
3.
 
Rich,
 
M.
 
W.,
 
Crager ,
 
M.,
 
&
 
McKay ,
 
C.
 
R.
 
(2007).
 
Safety
 
and
 
efficacy
 
of
 
extended
‐
release
 
ranolazine
 
in
 
patients
 
aged
 
70
 
years
 
or
 
older
 
with
 
chronic
 
stable
 
angina
 
pectoris.
 
The
 
American
 
Journal
 
of
 
Geriatric
 
Cardiology ,
 
16(4),
 
216-221.
 
 
 
 
 
 
 
305
 

=== PAGE 307 ===

 
Renin-angiotensin
 
aldosterone
 
system
 
inhibitor
 
(RAASi)
 
Name
 
:
 
 
Unit
 
:
 
 
Please
 
tick
 
(
✔
)
 
Yes
 
for
 
correct
 
instruction.
 
Please
 
tick
 
(
✔
)
 
No
 
for
 
incorrect
 
instruction.
 
Yes
 
No
 
Remarks
 
Pharmacological
 
Group
 
Angiotensin-Converting
 
Enzyme
 
Inhibitors
 
(ACE-I)
 
Angiotension
 
Receptor
 
Blocker
 
(ARB)
 
Anigiotensin
 
Receptor
 
Blocker
 
Neprisylin
 
Inhinitor
 
(ARNI)
 
 
 
 
Indications
 
and
 
Dosage
 
Hypertension
 
 
Drug
 
Initial
 
dose
 
Maksimum
 
dose
 
                     
ACE-I
 
Captopril
 
25mg
 
bd
 
50g
 
tds
 
Enalapril
 
2.5mg
 
od
 
20g
 
bd
 
Lisinopril
 
5mg
 
od
 
80mg
 
od
 
Perindopril
 
erbumine
 
2mg
 
od
 
8mg
 
od
 
Ramipril
 
2.5mg
 
od
 
8mg
 
od
 
                    
ARB
 
Candesartan
 
8mg
 
od
 
16mg
 
od
 
Losartan
 
50mg
 
od
 
100mg
 
od
 
Valsartan
 
80mg
 
od
 
160mg
 
od
 
 
Heart
 
Failure
 
 
Drug
 
Initial
 
dose
 
Maksimum
 
dose
 
                    
ACE-I
 
Captopril
 
6.25mg
 
bd
 
50mg
 
tds
 
Enalapril
 
2.5mg
 
od
 
10-20mg
 
bd
 
Lisinopril
 
2.5-5.mg
 
od
 
20-40mg
 
od
 
Perindopril
 
erbumine
 
2mg
 
od
 
8-16mg
 
od
 
Ramipril
 
2.5mg
 
od
 
10mg
 
od
 
                   
ARB
 
Candesartan
 
4-8mg
 
od
 
32mg
 
od
 
Losartan
 
25-50mg
 
od
 
50-150mg
 
od
 
Valsartan
 
40mg
 
od
 
160mg
 
bd
 
                    
ARNI
 
Sacubutril/
 
Valsartan
 
100mg
 
bd
 
200mg
 
bd
 
 
Stable
 
Coronary
 
Artery
 
Disease
 
 
Drug
 
Initial
 
dose
 
Maximum
 
dose
 
                      
ACE-I
 
Captopril
 
6.25mg
 
bd/tds
 
25-50mg
 
tds
 
Enalapril
 
2.5-5mg
 
od
 
20g
 
bd
 
Lisinopril
 
 
 
Perindopril
 
erbumine
 
2mg
 
8mg
 
od
 
Ramipril
 
2.5mg
 
od
 
10mg
 
od
 
                      
ARB
 
Candesartan
 
4mg
 
od
 
32mg
 
od
 
Losartan
 
25-50mg
 
od
 
100mg
 
od
 
Valsartan
 
40mg
 
od
 
160mg
 
bd
 
 
To
 
counsel
 
based
 
on
 
specific
 
medication’ s
 
indication
 
and
 
dosage
 
as
 
prescribed
 
by
 
the
 
doctor
 
 
 
 
 
 
 
306
 

=== PAGE 308 ===

 
Method
 
of
 
Administration*
 
 
Drug
 
Before
 
Food
 
After
 
Food
 
Compatible
  
with
 
RT
 
administration
 
Consideration
 
on
 
fluid
 
restriction
 
ACE-I
 
☑
 
 
 
☑
 
 
 
ARB
 
☑
 
☑
 
☑
 
 
 
ARNI
 
☑
 
☑
 
☑
 
 
 
 
Missed
 
dose
 
management:
 
 
Single
 
daily
 
dosing
 
regime:
 
missed
 
dose
 
taken
 
upto
 
until
 
12
 
h
 
after
 
the
 
scheduled
 
dosing
 
 
Twice
 
daily
 
dosing
 
regime:
 
missed
 
dose
 
taken
 
up
 
until
 
6
 
h
    
after
 
the
 
scheduled
 
intake
 
 
 
Do
 
not
 
stop
 
taking
 
your
 
medication
 
unless
 
advised
 
to
 
do
 
so
 
by
 
your
 
prescriber
 
 
 
 
Special
 
Considerations
 
Pregnancy
 
 
 
 
Contraindicated
 
 
 
 
Breastfeeding
 
 
 
 
Contraindicated
 
 
 
 
Elderly
 
 
 
 
1.
 
To
 
start
 
with
 
lower
 
dose
 
and
 
safely
 
titrate
 
to
 
tolerated
 
dose.
 
Hypotensive
 
effects
 
are
 
unpredictable
 
in
 
elderly .
 
 
Beers
 
Criteria:
 
Avoid
 
routinely
 
using
 
2
 
or
 
more
 
RAS
 
inhibitors,
 
or
 
a
 
RAS
 
inhibitor
 
and
 
potassium
 
sparing
 
diuretic,
 
concurrently
 
in
 
those
 
with
 
chronic
 
kidney
 
disease
 
Stage
 
3a
 
or
 
higher
 
due
 
to
 
an
  
increased
 
risk
 
of
 
hyperkalemia.
 
 
 
 
Paediatric
 
 
 
 
Dose
 
calculated
 
based
 
on
 
body
 
weight
 
 
 
 
Fasting
 
 
 
 
To
 
refer
 
to
 
the
 
latest
 
advisory
 
by
 
religious
 
authority
 
 
 
 
Others
  
 
 
 
 
Renal
 
impairment:
 
consider
 
starting
 
at
 
low
 
dose,
 
monitor
 
renal
 
function
 
and
 
potassium
 
level
 
closely
 
 
 
 
Side
 
Effects
 
and
 
their
 
Management*
 
1.
 
Dizziness,symptomatic
 
hypotension,
 
hyperkalaemia
 
(To
 
seek
 
medical
 
attention
 
immediately)
 
2.
 
For
 
ACE-I
 
induced
 
cough:
 
consider
 
replacement
 
with
 
ARB
 
3.
 
Angioedema:
 
switching
 
among
 
RAASi
 
is
 
not
 
recommended
 
 
 
 
Storage*
 
To
 
store
 
at
 
room
 
temperature
 
 
 
 
Others
 
ACE-i
 
need
 
to
 
be
 
stopped
 
at
 
least
 
36
 
hours
 
prior
 
to
 
the
 
initiation
 
of
 
ARNI
 
 
 
 
307
 

=== PAGE 309 ===

 
Before
 
ending
 
this
 
peer
 
review
 
session,
 
the
 
reviewee
 
should
 
be
 
informed
 
of
 
the
 
step(s)
 
that
 
he/
 
she
 
missed
 
out
 
in
 
order
 
to
 
ensure
 
all
 
the
 
counselling
 
points
 
are
 
being
 
covered.
 
 
Remarks:
 
 
 
 
 
Reviewed
 
by:
 
Name
 
&
 
Signature
                                                                   
Date:
 
 
 
 
 
*Mandatory
 
for
 
validation
 
/
 
peer
 
review
 
References:
 
 
1.
 
Malaysian
 
Clinical
 
Practice
 
Guidelines:
 
Management
 
of
 
Heart
 
Failure
 
2023
 
(5
th
 
Edition)
 
2.
 
Malaysian
 
Clinical
 
Practice
 
Guidelines
 
Management
 
of
 
Hypertension
 
2018
 
(3
rd
 
Edition)
 
3.
 
2023
 
American
 
Geriatrics
 
Society
 
Beers
 
Criteria®
 
Update
 
Expert
 
Panel.
 
(2023).
 
American
 
Geriatrics
 
Society
 
2023
 
updated
 
AGS
 
Beers
 
Criteria®
 
for
 
potentially
 
inappropriate
 
medication
 
use
 
in
 
older
 
adults.
 
Journal
 
of
 
the
 
American
 
Geriatrics
 
Society ,
 
71(7),
 
2052-2081.
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
308
 

=== PAGE 310 ===

 
Ribavirin
 
Name
 
:
 
 
Unit
 
:
 
 
●
 
Please
 
tick
 
(
✔
)
 
Yes
 
for
 
correct
 
instruction.
 
●
 
Please
 
tick
 
(
✔
)
 
No
 
for
 
incorrect
 
instruction.
 
Yes
 
No
 
Remarks
 
Pharmacological
 
Group
 
Purine
 
nucleoside
 
analogue
 
 
 
 
 
Indications
 
and
 
Dosage
 
For
 
the
 
treatment
 
of
 
chronic
 
hepatitis
 
C
 
-
 
Use
 
as
 
part
 
of
 
an
 
appropriate
 
combination
 
regimen.
 
 
●
 
<75
 
kg:
 
1
 
g/day
 
in
 
2
 
divided
 
doses
 
●
 
≥75
 
kg:
 
1.2
 
g/day
 
in
 
2
 
divided
 
doses
 
●
 
Dosage
 
is
 
individualized
 
and
 
titrated
 
in
 
accordance
 
with
 
the
 
baseline
 
characteristics
 
of
 
the
 
disease
 
and
 
patient’ s
 
liver
 
status
 
 
Or
 
To
 
counsel
 
based
 
on
 
specific
 
medication’ s
 
indication
 
and
 
dosage
 
as
 
prescribed
 
by
 
the
 
doctor
 
 
 
 
Method
 
of
 
Administration*
 
1.
 
To
 
be
 
taken
 
orally
 
with
 
food
 
to
 
improve
 
absorption
 
 
2.
 
Must
 
be
 
taken
 
at
 
the
 
same
 
time
 
everyday .
 
3.
 
Capsules
 
should
 
not
 
be
 
opened,
 
crushed,
 
or
 
broken.
 
4.
 
Patients
 
must
 
complete
 
the
 
prescribed
 
treatment
 
regimen.
 
This
 
is
 
to
 
ensure
 
treatment
 
effectiveness
 
and
 
prevent
 
resistance.
 
5.
 
DO
 
NOT
 
RUN
 
OUT
 
OF
 
MEDICA TION
.
 
Refill
 
the
 
prescription
 
before
 
it
 
finishes.
 
 
Missed
 
dose
 
management:
 
1.
 
If
 
you
 
miss
 
a
 
dose
 
and
 
it
 
is
 
less
 
than
 
6
 
hours
 
past
 
your
 
usual
 
time,
 
take
 
the
 
missed
 
dose
 
as
 
soon
 
as
 
possible.
 
2.
 
If
 
more
 
than
 
6
 
hours
 
have
 
passed
 
since
 
your
 
usual
 
dose,
 
skip
 
the
 
missed
 
dose
 
and
 
take
 
the
 
next
 
dose
 
at
 
the
 
usual
 
time.
 
3.
 
DO
 
NOT
 
take
 
double
 
doses
 
to
 
make
 
up
 
for
 
the
 
missed
 
dose.
 
 
Do
 
not
 
stop
 
taking
 
your
 
medication
 
unless
 
advised
 
to
 
do
 
so
 
by
 
your
 
prescriber
 
 
 
 
Special
 
Considerations
 
Pregnancy
 
 
 
 
1.
 
Contraindicated
 
in
 
pregnancy
 
 
2.
 
Contraindicated
 
in
 
male
 
patients
 
whose
 
partners
 
are
 
pregnant
 
 
 
 
 
Breastfeeding
 
 
 
 
It
 
is
 
not
 
known
 
whether
 
ribavirin
 
is
 
excreted
 
in
 
human
 
milk.
 
Because
 
of
 
the
 
potential
 
for
 
adverse
 
reactions
 
in
 
nursing
 
infants,
 
a
 
decision
 
should
 
be
 
made
 
either
 
to
 
discontinue
 
nursing
 
or
 
not
 
to
 
initiate
 
therapy .
 
 
 
 
Elderly
 
 
 
 
Use
 
with
 
caution
 
in
 
the
 
elderly;
 
may
 
be
 
more
 
susceptible
 
to
 
adverse
 
effects
 
such
 
as
 
anemia.
 
Monitor
 
renal
 
function
 
closely .
 
 
 
 
 
Paediatric
 
 
 
 
309
 

=== PAGE 311 ===

 
Not
 
recommended
 
for
 
paediatric
 
patients
 
less
 
than
 
3
 
years
 
old
 
 
 
 
Fasting
 
 
 
 
To
 
take
 
twice
 
daily
 
during
 
Sahur
 
and
 
Iftar
.
 
 
 
 
Renal
 
Impairment
 
 
 
 
The
 
dosage
 
of
 
ribavirin
 
may
 
be
 
adjusted
 
based
 
on
 
the
 
patient's
 
kidney
 
function.
 
1.
 
CrCl
 
≥
 
50mL/min:
 
No
 
dosage
 
adjustments
 
necessary
 
2.
 
CrCl
 
30-50mL/min:
 
Alternate
 
200mg
 
and
 
400mg
 
every
 
other
 
day
 
3.
 
CrCl
 
<
 
30mL/min:
 
200mg
 
once
 
daily
 
4.
 
Hemodialysis:
 
200mg
 
once
 
daily
 
 
 
 
Hepatic
 
Impairment
 
 
 
 
1.
 
Low
 
initial
 
dosage
 
(600
 
mg/day)
 
with
 
titration
 
as
 
tolerated
 
is
 
recommended
 
in
 
patients
 
with
 
Child-Pugh
 
Class
 
C.
 
2.
 
During
 
treatment
 
of
 
Hepatitis
 
C:
 
 
○
 
Asymptomatic
 
increases
 
in
 
ALT
 
<10-fold:
 
Closely
 
monitor
 
with
 
repeat
 
testing
 
every
 
2
 
weeks.
 
If
 
persistent
 
elevation,
 
consider
  
stopping
 
therapy
 
○
 
Symptomatic
 
(weakness,
 
nausea,
 
vomiting,
 
jaundice)
 
increases
 
in
 
ALT
 
<10-fold
 
from
 
baseline
 
OR
 
significantly
 
increased
 
bilirubin,
 
alkaline
 
phosphatase,
 
or
 
INR:
 
Discontinue
 
DAA
 
○
 
≥10-fold
 
increase
 
in
 
ALT
 
from
 
baseline:
 
Discontinue
 
DAA
 
 
 
 
 
Side
 
Effects
 
and
 
their
 
Management*
 
1.
 
Hemolytic
 
anemia:
 
Usually
 
occurs
 
within
 
1
 
to
 
2
 
weeks
 
after
 
starting
 
therapy .
 
a.
 
Hematologic
 
tests
 
should
 
be
 
performed
 
prior
 
to
 
starting
 
therapy
 
and
 
at
 
treatment
 
weeks
 
2
 
and
 
4.
 
2.
 
Birth
 
defects
 
-
 
advise
 
on
 
contraception
 
3.
 
Insomnia
 
-
 
to
 
take
 
higher
 
doses
 
in
 
morning
 
4.
 
Fatigue,
 
nausea,
 
rash,
 
dry
 
skin
 
and
 
itch
 
5.
 
If
 
patients
 
experience
 
any
 
aller gic
 
reaction
 
(
e.g.
 
rashes,
 
breathlessness,
 
swollen
 
eyes),
 
they
 
should
 
stop
 
the
 
medication
 
immediately
 
and
 
seek
 
immediate
 
medical
 
assistance.
 
 
 
 
Storage*
 
1.
 
Store
 
below
 
30
ᣞ
C.
 
2.
 
Keep
 
medication
 
in
 
its
 
original
 
container ,
 
tightly
 
sealed
 
to
 
protect
 
from
 
moisture
 
and
 
light.
 
 
3.
 
Keep
 
out
 
of
 
reach
 
and
 
sight
 
of
 
children.
 
 
 
 
Others
 
Drug-drug/
 
Drug-food
 
Interactions:
 
1.
 
Patients
 
should
 
report
 
all
 
prescribed
 
medications,
 
over-the-counter
 
medications,
 
traditional
 
medicines
 
or
 
drinks,
 
and
 
health
 
supplements,
 
both
 
before
 
starting
 
therapy
 
and
 
during
 
treatment.
 
 
2.
 
They
 
must
 
stop
 
taking
 
any
 
traditional
 
or
 
herbal
 
medications,
 
health
 
supplements,
 
or
 
health
 
drinks
 
during
 
treatment
 
and
 
should
 
consult
 
prescribers
 
before
 
starting
 
any
 
new
 
medications.
 
 
Precautions:
 
1.
 
Advise
 
female
 
patients
 
to
 
use
 
effective
 
form
 
of
 
contraception
 
during
 
treatment
 
and
 
for
 
9
 
months
 
 
 
 
310
 

=== PAGE 312 ===

 
post-therapy
 
2.
 
As
 
for
 
male
 
patients
 
with
 
female
 
partners,
 
effective
 
forms
 
of
 
contraception
 
should
 
be
 
used
 
during
 
treatment
 
and
 
for
 
6
 
months
 
post-therapy .
 
Before
 
ending
 
this
 
peer
 
review
 
session,
 
the
 
reviewee
 
should
 
be
 
informed
 
of
 
the
 
step(s)
 
that
 
he/
 
she
 
missed
 
out
 
in
 
order
 
to
 
ensure
 
all
 
the
 
counselling
 
points
 
are
 
being
 
covered.
 
 
Remarks:
 
 
 
 
 
Reviewed
 
by:
 
Name
 
&
 
Signature
                                                                   
Date:
 
 
 
 
 
*Mandatory
 
for
 
validation
 
/
 
peer
 
review
 
References:
 
 
1.
 
Formulari
 
Ubat
 
KKM.
 
(2025,
 
January
 
1).
 
Accessed
 
on
 
January
 
20,
 
2025.
 
2.
 
American
 
Association
 
of
 
the
 
Study
 
of
 
Liver
 
Diseases/
 
Infectious
 
Diseases
 
Society
 
of
 
America
 
(AASLD/IDSA).
 
Recommendations
 
for
 
testing,
 
managing,
 
and
 
treating
 
hepatitis
 
C.
 
www .hcvguidelines.org.
 
Accessed
 
on
 
January
 
20,
 
2025.
 
 
3.
 
Ribavirin.
 
(2024).
 
MimsGateway .
 
Retrieved
 
January
 
21,
 
2025,
 
from
 
https://online1.mimsgateway .com.my/
 
4.
 
F.
 
Hoffmann-La
 
Roche
 
Ltd.
 
(2015).
 
Product
 
information
 
leaflet:
 
Copegus.
 
Retrieved
 
January
 
21,
 
2025,
 
from
 
https://assets.roche.com/f/170883/x/a0bd86b4d0/copegus-pi-jul-2015.pdf
 
5.
 
Uptodate
 
2024
 
Medical
 
Apps
 
Application.
 
Wolters
 
Kluwer .
 
Accessed
 
on
 
January
 
22,
 
2025.
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
311
 

=== PAGE 313 ===

 
Rifampicin
 
 
Name
 
:
 
 
Unit
 
:
 
 
●
 
Please
 
tick
 
(
✔
)
 
Yes
 
for
 
correct
 
instruction.
 
●
 
Please
 
tick
 
(
✔
)
 
No
 
for
 
incorrect
 
instruction.
 
Yes
 
No
 
Remarks
 
Pharmacological
 
Group
 
Rifamycin
 
antibiotic
 
 
 
 
Indications
 
and
 
Dosage
 
1.
 
First-line
 
treatment
 
for
 
leprosy
 
(Paucibacillary
 
&
 
Multibacillary)
 
(to
 
be
 
used
 
in
 
combination
 
with
 
other
 
anti-leprosy
 
agents)
 
a.
 
Adult:
 
600mg
 
once
 
a
 
month
 
b.
 
Children:
 
i)
 
10-14
 
years
 
old
 
:
 
450mg
 
once
 
a
 
month
 
ii)
 
<10
 
years
 
old
 
or
 
<40kg:
 
10mg/kg
 
once
 
a
 
month
 
 
2.
 
Contact
 
chemoprophylaxis
 
(to
 
be
 
administered
 
as
 
single
 
dose
 
only)
 
a.
 
Adult
 
(age
 
15
 
years
 
and
 
above):
 
600mg
 
b.
 
Children:
 
i)
 
10-14
 
years
 
old:
 
450mg
 
ii)
 
6-9
 
years
 
old
 
(body
 
weight
 
≥20kg):
 
300mg
 
iii)
 
≥2
 
years
 
old
 
(body
 
weight
 
<20kg)):
 
10-15mg/kg
 
  
 
 
 
 
Method
 
of
 
Administration*
 
Food
 
To
 
be
 
taken
 
preferably
 
before
 
food.
 
However ,
 
this
 
can
 
be
 
disregarded
 
if
 
Direct
 
Observation
 
Therapy
 
(DOT)
 
is
 
being
 
performed.
 
 
 
RT
 
administration
 
Capsule
 
can
 
be
 
opened,
 
its
 
content
 
mixed
 
with
 
water
 
and
 
administered
 
through
 
Ryles
 
Tube
 
 
Missed
 
dose
 
Take
 
as
 
soon
 
as
 
remembered,
 
skip
 
if
 
near
 
next
 
dose;
 
do
 
not
 
double
 
dose
 
 
Do
 
not
 
stop
 
taking
 
your
 
medication
 
unless
 
advised
 
to
 
do
 
so
 
by
 
your
 
prescriber
 
 
 
 
Special
 
Considerations
 
Pregnancy
 
 
 
 
Safe
 
in
 
pregnancy
 
 
 
 
Breastfeeding
 
 
 
 
Safe
 
to
 
be
 
used
 
in
 
breastfeeding
 
 
 
 
Elderly
 
 
 
 
NA
 
 
 
 
Paediatric
 
 
 
 
Extemporaneous
 
preparations
 
with
 
different
 
concentrations
 
can
 
be
 
compounded:
 
●
 
Rifampicin
 
syrup
 
10mg/ml
 
●
 
Rifampicin
 
suspension
 
25mg/ml
 
●
 
Rifampicin
 
suspension
 
50mg/ml
 
 
 
 
312
 

=== PAGE 314 ===

 
Fasting
 
 
 
 
NA
 
 
 
 
Others
 
 
1.
 
Use
 
in
 
renal
 
disease:
 
 
Can
 
be
 
used
 
without
 
dose
 
adjustment
 
 
2.
 
Use
 
in
 
hepatic
 
disease:
 
Use
 
with
 
caution.
 
Consider
 
discontinuation
 
if
 
hepatic
 
function
 
worsens.
 
 
 
 
Side
 
Effects
 
and
 
their
 
Management*
 
1.
 
Orange
 
discolouration
 
of
 
body
 
fluids
 
(e.g.
 
urine,
 
saliva,
 
tears,
 
sweat)
 
2.
 
Rash
 
and
 
pruritus
 
3.
 
GI
 
upset
 
(nausea,
 
vomiting)
 
4.
 
Flu-like
 
symptoms
 
 
5.
 
Hepatotoxicity
 
(jaundice
 
and
 
hepatitis)
 
 
A
dvise
 
patients
 
to
 
inform
 
their
 
healthcare
 
providers
 
if
 
they
 
experience
 
any
 
side
 
effects.
 
 
 
 
Storage*
 
1.
 
Capsules
 
should
 
be
 
kept
 
at
 
room
 
temperature
 
2.
 
10mg/ml
 
syrup
 
should
 
be
 
refrigerated
 
and
 
protected
 
from
 
light;
 
stable
 
for
 
28
 
days
  
(Extemp
 
formulation
 
2015)
 
3.
 
25mg/ml
 
and
 
50mg/ml
 
oral
 
suspensions
 
can
 
be
 
stored
 
at
 
room
 
temperature
 
and
 
protected
 
from
 
light;
 
stable
 
for
 
90
 
days
 
(X-Temp
 
Oral
 
Suspension
 
Master
 
Formulation
 
Sheets)
 
 
 
 
Others
 
Monitor
 
liver
 
function
 
closely
 
if
 
given
 
with
 
other
 
potential
 
hepatotoxic
 
medications
 
 
 
 
Before
 
ending
 
this
 
peer
 
review
 
session,
 
the
 
reviewee
 
should
 
be
 
informed
 
of
 
the
 
step(s)
 
that
 
he/
 
she
 
missed
 
out
 
in
 
order
 
to
 
ensure
 
all
 
the
 
counselling
 
points
 
are
 
being
 
covered.
 
 
Remarks:
 
 
 
 
 
Reviewed
 
by:
 
Name
 
&
 
Signature
                                                                   
Date:
 
 
 
 
 
*Mandatory
 
for
 
validation
 
/
 
peer
 
review
 
References:
 
 
1.
 
Manual
 
Pengurusan
 
Kusta
 
Kebangsaan,
 
Edisi
 
3.
 
(2023).
 
Kementerian
 
Kesihatan
 
Malaysia.
 
2.
 
Extemporaneous
 
Formulation.
 
(2015).
 
Kementerian
 
Kesihatan
 
Malaysia.
 
3.
 
Senarai
 
Ubat
 
Galenikal
 
dan
 
Ekstemporaneous
 
(GAEX)
 
Dalam
 
PhIS,
 
updated
 
on
 
5
 
Dec
 
2024
 
4.
 
X-Temp
 
Oral
 
Suspension
 
Master
 
Formulation
 
Sheets.
 
(2023).
 
Pharm-D.
 
5.
 
Rifampin
 
(rifampicin):
 
Drug
 
information.
 
UpToDate
 
Inc.
 
Accessed
 
March
 
2025.
 
 
 
313
 

=== PAGE 315 ===

 
Rilpivirine
 
 
Name
 
:
 
 
Unit
 
:
 
 
●
 
Please
 
tick
 
(
✔
)
 
Yes
 
for
 
correct
 
instruction.
 
●
 
Please
 
tick
 
(
✔
)
 
No
 
for
 
incorrect
 
instruction.
 
Yes
 
No
 
Remarks
 
Pharmacological
 
Group
 
Non-nucleoside
 
reverse
 
transcriptase
 
inhibitors
 
(NNR TIs)
 
 
 
 
Indications
 
and
 
Dosage
 
Children
 
and
 
adolescent
 
(aged
 
>12
 
years
 
and
 
weighing
 
>35
 
kg)
 
and
 
adult
 
dose
 
:
 
 
 
1.
 
Indicated
 
with
 
other
 
antiretroviral
 
agents
 
for
 
the
 
treatment
 
of
 
human
 
immunodeficiency
 
virus
 
type
 
1
 
(H1V -1)
 
infection
 
in
 
antiretroviral
 
treatment-naive
 
adult
 
patients
 
with
 
a
 
viral
 
load
 
is
 
less
 
than
 
100,000
 
copies/mL.
 
 
a.
 
The
 
recommended
 
dose
 
is
 
25
 
mg
 
once
 
daily
 
taken
 
with
 
meals.
 
 
2.
 
Indicated
 
in
 
combination
 
with
 
cabotegravir
 
as
 
a
 
complete
 
regimen
 
for
 
short-term
 
treatment
 
of
 
human
 
immunodeficiency
 
virus
 
type
 
1
 
(HIV-1)
 
infection
 
in
 
adults
 
who
 
are
 
virologically
 
suppressed
 
(HIV-1
 
RNA
 
<50
 
copies/mL)
 
on
 
a
 
stable
 
antiretroviral
 
therapy
 
(ART)
 
regimen
 
with
 
no
 
history
 
of
 
treatment
 
failure
 
and
 
with
 
no
 
known
 
or
 
suspected
 
resistance
 
to
 
either
 
cabotegravir
 
or
 
rilpivirine.
 
a.
 
The
 
recommended
 
dose
 
is
 
25
 
mg
 
once
 
daily
 
taken
 
with
 
meals.
 
 
 
 
Method
 
of
 
Administration*
 
Must
 
administer
 
a
 
meal
 
of
 
at
 
least
 
500
 
calories
 
on
 
a
 
regular
 
schedule
 
(a
 
protein
 
drink
 
alone
 
does
 
not
 
constitute
 
a
 
meal)
 
once
 
a
 
day.
 
 
Antacids
 
should
 
be
 
administered
 
either
 
at
 
least
 
2
 
hours
 
before
 
or
 
at
 
least
 
4
 
hours
 
after
 
Rilpivirine.
 
 
Enteral
 
feeding/enteral
 
tube:
 
Swallow
 
tablet
 
whole
 
with
 
water ,
 
cannot
 
crush.
 
Tablets
 
for
 
oral
 
suspension
 
are
 
available
 
for
 
dispersing
 
in
 
water
 
for
 
administration.
 
 
If
 
the
 
patient
  
missed
 
a
 
dose,
 
the
 
patient
 
should
 
take
 
the
 
missed
 
dose
 
as
 
soon
 
as
 
possible
 
with
 
a
 
meal.
 
Howe ver,if
 
it
 
has
 
been
 
more
 
than
 
12
 
hours
 
since
 
the
 
last
 
dose,
 
skip
 
the
 
missed
 
dose
 
and
 
continue
 
the
 
regular
 
dosing
 
schedule.
 
Do
 
not
 
take
 
a
 
double
 
dose
 
to
 
mak e
 
up
 
for
 
a
 
missed
 
one.
 
 
Do
 
not
 
stop
 
taking
 
your
 
medication
 
unless
 
advised
 
to
 
do
 
so
 
by
 
your
 
prescriber
 
 
 
 
Special
 
Considerations
 
Pregnancy
 
 
 
 
1.
 
Available
 
data
 
from
 
the
 
Antiretroviral
 
Pregnancy
 
Registry
 
(APR)
 
show
 
no
 
difference
 
in
 
the
 
overall
 
risk
 
of
 
birth
 
defects
 
for
 
rilpivirine
 
compared
 
with
 
the
 
background
 
rate
 
for
 
major
 
birth
 
defects
 
of
 
2.7%
 
in
 
the
 
Metropolitan
 
Atlanta
 
Congenital
 
Defects
 
Program
 
(MACDP)
 
reference
 
population.
 
2.
 
In
 
animal
 
reproduction
 
studies,
 
no
 
adverse
 
developmental
 
outcomes
 
were
 
observed
 
when
 
drug
 
was
 
administered
 
orally
 
at
 
exposure
 
up
 
to
 
15
 
(rats)
 
and
 
 
 
 
314
 

=== PAGE 316 ===

 
70
 
(rabbits)
 
times
 
exposure
 
in
 
humans
 
at
 
recommended
 
dose
 
of
 
25
 
mg
 
once
 
daily.
 
Breastfeeding
 
 
 
 
It
 
is
 
not
 
known
 
whether
 
Rilpivirine
 
is
 
secreted
 
in
 
human
 
milk.
 
Because
 
of
 
both
 
the
 
potential
 
for
 
HIV
 
transmission
 
and
 
the
 
potential
 
for
 
adverse
 
effect
 
events
 
in
 
nursing
 
infants,
 
mothers
 
should
 
be
 
obstructed
 
not
 
to
 
breastfeed
 
if
 
they
 
are
 
receiving
 
Rilpivirine.
 
 
 
 
Elderly
 
 
 
 
None
 
specifically
 
to
 
Rilpivirine.
 
 
 
 
Paediatric
 
 
 
 
Rilpivirine
 
should
 
not
 
be
 
administered
 
to
 
children
 
less
 
than
 
12
 
years
 
of
 
age
 
and
 
those
 
who
 
weigh
 
less
 
than
 
25
 
kg.
 
 
 
 
 
Fasting
 
 
 
 
Advice
 
for
 
nighttime
 
dose
 
taking.
 
 
 
 
Others
  
 
 
 
 
1.
 
Mild
 
to
 
moderate
 
renal
 
impairment:
 
No
 
dose
 
adjustment
 
required.
 
2.
 
Severe
 
renal
 
impairment
 
or
 
ESRD:
 
Used
 
with
 
caution
 
and
 
with
 
increased
 
monitoring
 
for
 
adverse
 
effects,
 
plasma
 
concentrations
 
may
 
be
 
increased
 
because
 
of
 
altered
 
drug
 
absorption,
 
distribution
 
and
 
metabolism
 
secondary
 
to
 
renal
 
impairment.
 
3.
 
Severe
 
hepatic
 
impairment
 
(Child-Pugh
 
Class
 
C):
 
Has
 
not
 
been
 
studied.
 
 
 
 
Side
 
Effects
 
and
 
their
 
Management*
 
1.
 
Common
 
side
 
effects
 
are
 
rash
 
along
 
with
 
fever ,
 
swelling
 
of
 
the
 
face,
 
lips,
 
mouth,
 
tongue
 
or
 
throat,
 
blisters,
 
trouble
 
breathing
 
or
 
swallowing,
 
mouth
 
sores,
 
redness
 
or
 
swelling
 
of
 
the
 
eyes
 
(conjunctivitis),
 
pain
 
on
 
the
 
right
 
side
 
of
 
the
 
stomach
 
(abdominal)
 
area,
 
or
 
dark
 
colored
 
urine.
 
2.
 
Severe
 
skin
 
and
 
hypersensitivity
 
reactions
 
reported
 
with
 
rilpivirine-containing
 
regimens,
 
immediately
 
discontinue
 
treatment
 
if
 
hypersensitivity
 
or
 
rash
 
develop
 
and
 
closely
 
monitor
 
clinical
 
status,
 
including
 
hepatic
 
serum
 
biochemistries.
 
3.
 
May
 
increase
 
risk
 
for
 
depressive
 
disorders
 
if
 
coadministration
 
with
 
other
 
NNR TIs.
 
Avoid
 
use
 
with
 
other
 
NNR TIs.
 
 
 
 
Storage*
 
Store
 
it
 
at
 
room
 
temperature
 
and
 
away
 
from
 
light,
 
excess
 
heat
 
and
 
moisture.
 
 
 
 
Others
 
1.
 
Coadministration
 
with
 
drug
 
(eg,
 
CYP
 
inducers
 
like
 
phenobarbital,
 
dexamethasone,
 
oxcarbazepine,
 
phenytoin,
 
or
 
carbamazepine)
 
where
 
significant
 
decreases
 
in
 
rilpivirine
 
plasma
 
concentrations
 
may
 
occur ,
 
which
 
may
 
result
 
in
 
loss
 
of
 
virologic
 
response
 
and
 
possible
 
resistance
 
and
 
drug-resistance
 
to
 
other
 
NNR TIs.
 
2.
 
Contraindicated
 
with
 
drugs
 
that
 
increase
 
gastric
 
pH
 
(eg,
 
esomeprazole,
 
rabeprazole)
 
that
 
may
 
decrease
 
rilpivirine
 
absorption
 
and
 
result
 
in
 
decreased
 
rilpivirine
 
plasma
 
concentrations.
 
Antacids
 
should
 
be
 
 
 
 
315
 

=== PAGE 317 ===

 
administered
 
either
 
at
 
least
 
2
 
hours
 
before
 
or
 
at
 
least
 
4
 
hours
 
after
 
Rilpivirine.
 
3.
 
More
 
rilpivirine
 
treated
 
individuals
 
with
 
HIV-1
 
RNA
 
>100,000
 
copies/mL
 
at
 
the
 
start
 
of
 
therapy
 
experienced
 
virological
 
failure
 
compared
 
to
 
those
 
with
 
<100,000
 
copies/mL.
 
Before
 
ending
 
this
 
peer
 
review
 
session,
 
the
 
reviewee
 
should
 
be
 
informed
 
of
 
the
 
step(s)
 
that
 
he/
 
she
 
missed
 
out
 
in
 
order
 
to
 
ensure
 
all
 
the
 
counselling
 
points
 
are
 
being
 
covered.
 
 
Remarks:
 
 
 
 
 
Reviewed
 
by:
 
Name
 
&
 
Signature
                                                                   
Date:
 
 
 
 
 
*Mandatory
 
for
 
validation
 
/
 
peer
 
review
 
References:
 
 
1.
 
Janssen
 
Pharmaceuticals
 
Inc
 
(2023).
 
EDURANT
 
25MG
 
TABLET
 
(Consumer
 
Medication
 
Information
 
Leaflet
 
 
2.
 
Wolter
 
Kluwer
 
(2024)
 
.
 
UpToDate
 
-
 
Rilpivirine.
 
UpToDate,Inc.
 
3.
 
Panel
 
on
 
Antiretroviral
 
Therapy
 
and
 
Medical
 
Management
 
of
 
Children
 
Living
 
with
 
HIV
 
(2024).
 
Guidelines
 
for
 
the
 
Use
 
of
 
Antiretroviral
 
Agents
 
in
 
Pediatric
 
HIV
 
Infection.
 
Department
 
of
 
Health
 
and
 
Human
 
Services.
 
2024.
 
Available
 
at
 
https://clinicalinfo.hiv .gov/en/guidelines/pediatric-arv
.
 
Accessed
 
December
 
2,
 
2024.
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
316
 

=== PAGE 318 ===

 
Rivaroxaban
 
Name
 
:
 
 
Unit
 
:
 
 
●
 
Please
 
tick
 
(
✔
)
 
Yes
 
for
 
correct
 
instruction
 
or
 
sequence.
 
●
 
Please
 
tick
 
(
✔
)
 
No
 
for
 
incorrect
 
instruction
 
or
 
sequence.
 
Yes
 
No
 
Remarks
 
Pharmacological
 
Group
 
Factor
 
Xa
 
inhibitors
 
 
 
 
Indications
 
and
 
dosage
 
1.
 
Prophylaxis
 
of
 
postoperative
 
venous
 
thromboembolism
 
 
Dosage:
 
10
 
mg
 
once
 
daily.
 
Dose
 
starts
 
6-10
 
hours
 
after
 
surgery .
 
Treatment
 
duration:
 
2
 
weeks
 
(major
 
knee
 
surgery);
 
5
 
weeks
 
(major
 
hip
 
surgery).
 
 
2.
 
Prophylaxis
 
of
 
stroke
 
and
 
systemic
 
embolism
 
in
 
adult
 
patients
 
with
 
non-valvular
 
atrial
 
fibrillation
 
(AF)
 
with
 
one
 
or
 
more
 
risk
 
factors,
 
such
 
as
 
congestive
 
heart
 
failure,
 
hypertension,
 
age≥75
 
yrs,
 
diabetes
 
mellitus,
 
prior
 
stroke
 
or
 
transient
 
ischaemic
 
attack.
 
 
 
Dosage:
 
20
 
mg
 
OD
 
(CrCl≥50
 
mL/min)
 
or
 
15
 
mg
 
OD
 
(CrCl
 
15-49
 
mL/min)
 
 
3.
 
Deep
 
vein
 
thrombosis,
 
Pulmonary
 
embolism
 
 
Dosage:
 
Treatment:
 
Initially ,
 
15
 
mg
 
twice
 
daily
 
for
 
3
 
weeks.
 
Maintenance:
 
20
 
mg
 
once
 
daily.
 
Prevention
 
of
 
recurrence:
 
10
 
mg
 
once
 
daily,
 
following
 
completion
 
of
 
at
 
least
 
6
 
months
 
of
 
anticoagulant
 
therapy .
 
May
 
consider
 
20
 
mg
 
daily
 
in
 
patients
 
at
 
high
 
risk
 
of
 
recurrence.
 
 
4.
 
Prevention
 
of
 
atherothrombotic
 
events
 
 
Dosage:
 
In
 
cases
 
following
 
an
 
acute
 
coronary
 
syndrome:
 
2.5
 
mg
 
twice
 
daily
 
in
 
combination
 
with
 
aspirin
 
alone,
 
or
 
aspirin
 
plus
 
clopidogrel
 
or
 
ticlopidine.
 
 
 
 
 
Method
 
of
 
Administration*
 
1.
 
Must
 
be
 
taken
 
at
 
the
 
dose
 
prescribed
 
 
2.
 
Swallow
 
the
 
tablet
 
whole
 
with
 
water
 
 
3.
 
MUST
 
be
 
taken
 
with
 
food
 
to
 
maximise
 
absorption
 
4.
 
Aim
 
to
 
take
 
at
 
the
 
same
 
time
 
each
 
day
 
 
5.
 
Do
 
not
 
stop
 
taking
 
your
 
medication
 
unless
 
advised
 
to
 
do
 
so
 
by
 
your
 
prescriber
 
6.
 
If
 
a
 
dose
 
is
 
missed,
 
take
 
it
 
as
 
soon
 
as
 
possible
 
(do
 
not
 
double
 
the
 
dose)
 
Once
 
daily
 
dosing:
 
take
 
within
 
12
 
hours
 
of
 
missed
 
dose,
 
if
 
more
 
than
 
12
 
hours,
 
omit
 
the
 
dose
 
and
 
then
 
continue
 
at
 
the
 
usual
 
time.
 
Twice
 
daily
 
dosing:
 
take
 
within
 
6
 
hours
 
of
 
missed
 
dose,
 
if
 
more
 
than
 
6
 
hours,
 
omit
 
the
 
dose
 
and
 
then
 
continue
 
at
 
the
 
usual
 
time.
 
 
 
 
Special
 
Considerations
 
Pregnancy
 
 
 
 
Use
 
Rivaroxaban
 
with
 
caution
 
in
 
pregnant
 
women
 
due
 
to
 
the
 
potential
 
for
 
obstetric
 
haemorrhage
 
and/or
 
emergent
 
delivery .
  
Promptly
 
evaluate
 
signs
 
and
 
symptoms
 
of
 
blood
 
loss.
  
 
 
 
 
317
 

=== PAGE 319 ===

 
Breastfeeding
 
 
 
 
Discontinue
 
drug
 
or
 
discontinue
 
nursing
 
 
 
 
Elderly
 
 
 
 
Beers
 
Citeria:
 
1.
 
 
At
 
doses
 
used
 
for
 
long-term
 
treatment
 
of
 
VTE
 
or
 
nonvalvular
 
atrial
 
fibrillation,
 
rivaroxaban
 
appears
 
to
 
have
 
higher
 
risk
 
of
 
major
 
bleeding
 
and
 
GI
 
bleeding
 
in
 
older
 
adults
 
than
 
other
 
DOACs,
 
particularly
 
apixaban
 
2.
 
Rivaroxaban
 
may
 
be
 
reasonable
 
in
 
special
 
situations,
 
for
 
example
 
when
 
once-daily
 
dosing
 
is
 
necessary
 
to
 
facilitate
 
medication
 
adherence.
 
 
**
 
alternative
 
patient
 
on
 
enteral
 
tube
 
feeding
 
 
 
 
Paediatric
 
 
 
 
Rivaroxaban
 
was
 
not
 
studied
 
and
 
therefore
 
dosing
 
cannot
 
be
 
reliably
 
determined
 
or
 
recommended
 
in
 
children
 
less
 
than
 
6
 
months
 
who
 
were
 
less
 
than
 
37
 
weeks
 
of
 
gestation
 
at
 
birth,
 
had
 
less
 
than
 
10
 
days
 
of
 
oral
 
feeding,
 
or
 
had
 
a
 
body
 
weight
 
of
 
less
 
than
 
2.6
 
kg.
 
 
 
 
Others
 
 
 
 
1.
 
Renal
 
impairment:
 
To
 
avoid
 
usage
 
when
 
CrCl
 
≤50
 
mL/min
 
2.
 
Moderate
 
to
 
severe
 
hepatic
 
impairment
 
(Child-Pugh
 
class
 
B
 
and
 
C):
 
Contraindicated.
 
 
 
 
Side
 
Effects
 
and
 
their
 
Management*
 
1.
 
The
 
most
 
concerning
 
side
 
effect
 
is
 
the
 
bleeding,
 
which
 
is
 
the
 
result
 
of
 
the
 
blood
 
being
 
too
 
thin.
 
●
 
Bruising
 
 
●
 
Nosebleeds
  
 
●
 
Bleeding
 
gums
 
(careful
 
when
 
brushing
 
teeth
 
–
 
use
 
soft
 
toothbrush)
  
 
●
 
Pink
 
or
 
brown
 
urine
 
 
●
 
Red
 
or
 
black
 
stools
  
 
●
 
Vomiting
 
blood
 
or
 
material
 
that
 
looks
 
like
 
coffee
 
grounds
 
 
2.
 
Allergic
 
reactions
 
●
 
Itching
 
or
 
hives
  
 
●
 
Swelling
 
in
 
face,
 
hands,
 
mouth,
 
or
 
throat
 
●
 
Difficulty
 
breathing
 
or
 
chest
 
tightness
  
 
●
 
Skin
 
rash
 
 
 
 
Storage*
 
1.
 
Store
 
at
 
room
 
temperature
 
between
 
15°C
 
to
 
30°C
 
 
 
 
Others
 
1.
 
Avoid
 
activities
 
that
 
may
 
cause
 
bleeding/bruising
 
(acupuncture,
 
massage,
 
cupping/‘bekam’,
 
aggressive
 
sports).
 
 
2.
 
Monitoring
 
of
 
creatinine
 
clearance
 
should
 
be
 
done
 
at
 
least
  
 
○
 
Once
 
or
 
twice
 
a
 
year
 
for
 
patients
 
who
 
had
 
CrCl
 
≥
 
50ml/min
  
 
○
 
Every
 
6
 
months
 
for
 
patients
 
who
 
had
 
CrCl
 
≤
 
50ml/min
 
3.
 
Drug-drug
 
interactions
 
:
 
 
○
 
Interactions
 
below
 
lead
 
to
 
an
 
increased
 
bleeding
 
risk
 
–
 
patients
 
should
 
be
 
monitored
 
closely
 
for
 
signs
 
of
 
bleeding
 
and
 
anaemia.
  
 
■
 
Concomitant
 
use
 
of
 
systemic
 
azole
 
 
 
 
318
 

=== PAGE 320 ===

 
antimycotics
 
e.g.
 
ketoconazole,
 
itraconazole,
 
voriconazole,
 
posaconazole
 
 
■
 
HIV
 
protease
 
inhibitors
 
 
■
 
Other
 
anticoagulants
  
 
■
 
NSAIDs
 
(e.g.
 
ibuprofen,
 
naproxen,
 
diclofenac
 
and
 
platelet
 
aggregation
 
inhibitors(e.g.
 
aspirin,
 
clopidogrel)
 
○
 
Interactions
 
below
 
lead
 
to
 
a
 
decrease
 
in
 
anticoagulant
 
concentration
 
therefore
 
treatment
 
may
 
be
 
suboptimal
 
■
 
Concomitant
 
use
 
strong
 
CYP3A4
 
inducers
 
e.g.
 
phenytoin,
 
carbamazepine,
 
phenobarbital
 
4.
 
Drug-food
 
interaction
 
:
 
 
○
 
Decreased
 
serum
 
concentration
 
with
 
St.
 
John’ s
 
wort
 
Before
 
ending
 
this
 
peer
 
review
 
session,
 
the
 
reviewee
 
should
 
be
 
informed
 
of
 
the
 
step(s)
 
that
 
he/
 
she
 
missed
 
out
 
in
 
order
 
to
 
ensure
 
all
 
the
 
counselling
 
points
 
are
 
being
 
covered.
 
 
Remarks:
 
 
 
 
 
Reviewed
 
by:
 
Name
 
&
 
Signature
                                                                   
Date:
 
 
 
 
 
*Mandatory
 
for
 
validation
 
/
 
peer
 
review
 
References:
 
1.
 
MIMS
 
Malaysia.
 
(2024).
 
Rivaroxaban
 
In
 
MIMS
 
Online.
 
Retrieved
 
26
 
November ,
 
2024,
 
from
 
https://www .mims.com/malaysia/drug/info/rivaroxaban?mtype=generic
 
2.
 
Xarelto
 
Product
 
Leaflet
 
3.
 
Anticoagulation
 
MTAC
 
(AC-MT AC)
 
Protocol
 
2nd
 
Edition
 
4.
 
2023
 
American
 
Geriatrics
 
Society
 
Beers
 
Criteria®
 
Update
 
Expert
 
Panel.
 
(2023).
 
American
 
Geriatrics
 
Society
 
2023
 
updated
 
AGS
 
Beers
 
Criteria®
 
for
 
potentially
 
inappropriate
 
medication
 
use
 
in
 
older
 
adults.
 
Journal
 
of
 
the
 
American
 
Geriatrics
 
Society ,
 
71(7),
 
2052-2081.
 
 
 
 
 
 
 
 
 
 
 
 
 
 
319
 

=== PAGE 321 ===

 
Salicylic
 
Acid,
 
Topical
 
Name
 
:
 
 
Unit
 
:
 
 
●
 
Please
 
tick
 
(
✔
)
 
Yes
 
for
 
correct
 
instruction.
 
●
 
Please
 
tick
 
(
✔
)
 
No
 
for
 
incorrect
 
instruction.
 
Yes
 
No
 
Remarks
 
Pharmacological
 
Group
 
Keratolytic
 
Agent
 
 
 
 
Indications
 
and
 
Dosage
 
Salicylic
 
Acid
 
2-10%
 
Cream/Ointment
 
1.
 
Indication:
 
Seborrhoeic
 
dermatitis,
 
scalp,
 
psoriasis
 
&
 
hyerkeratotic
 
skin
 
disorders.Dosage:Apply
 
sparingly
 
to
 
the
 
affected
 
area
 
2-3
 
times
 
daily
 
 
Salicylic
 
Acid
 
20%
 
Ointment
 
2.
 
Indication:
 
Plantar
 
warts.
 
Dosage:
 
Apply
 
daily.May
 
need
 
to
 
continue
 
up
 
to
 
3
 
months
 
 
 
 
Method
 
of
 
Administration*
 
Salicylic
 
Acid
 
2-10%
 
Cream/Ointment
 
NA
 
 
Salicylic
 
Acid
 
20%
 
Ointment:
 
a)
 
Before
 
using
 
Salicylic
 
Acid
 
20%
 
ointment,
 
moisten
 
or
 
soak
 
the
 
wart
 
in
 
warm
 
water
 
for
 
but
 
5
 
minutes
 
to
 
help
 
soften
 
the
 
treatment
 
area.
 
b)
 
Dry
 
thoroughly .
 
c)
 
Use
 
the
 
emery
 
board
 
to
 
remove
 
the
 
top
 
dead
 
skin
 
layer
 
of
 
the
 
skin.
 
d)
 
Protect
 
surrounding
 
healthy
 
skin
 
(eg
 
white
 
soft
 
paraf fin
 
or
 
specifically
 
designated
 
plaster).
 
e)
 
Apply
 
the
 
ointment
 
onto
 
the
 
affected
 
area.
 
 
 
 
Special
 
Considerations
 
Pregnancy
 
 
 
 
1.
 
Should
 
be
 
only
 
used
 
only
 
if
 
potential
 
benefit
 
outweighs
 
the
 
potential
 
risk
 
to
 
the
 
fetus.
 
2.
 
It
 
should
 
not
 
be
 
used
 
extensively
 
in
 
large
 
amounts
 
or
 
prolonged
 
periods
 
in
 
pregnant
 
women.
 
 
 
 
Breastfeeding
 
 
 
 
1.
 
Should
 
be
 
used
 
cautiously
 
in
 
nursing
 
mothers.
 
If
 
used
 
by
 
nursing
 
mothers,
 
should
 
not
 
be
 
used
 
on
 
the
 
chest
 
area
 
to
 
avoid
 
accidental
 
contamination
 
of
 
the
 
child.
 
 
 
 
Elderly
 
 
 
 
1.
 
Used
 
cautiously
 
in
 
elderly .
 
 
 
 
Paediatric
 
 
 
 
1.
 
Avoid
 
prolonged
 
use
 
over
 
large
 
areas;
 
may
 
result
 
in
 
salicylism.
 
2.
 
Limit
 
application
 
area
 
in
 
children
 
<12
 
years
 
of
 
age.
 
3.
 
Use
 
caution
 
in
 
children
 
with
 
varicella
 
or
 
influenza.
 
 
 
 
Fasting
 
 
 
 
To
 
refer
 
to
 
the
 
latest
 
advisory
 
by
 
religious
 
authority
 
 
 
 
320
 

=== PAGE 322 ===

 
Others
 
 
 
 
 
NA
 
 
 
 
Side
 
Effects
 
and
 
their
 
Management*
 
Side
 
Effects:
 
1.
 
Contact
 
dermatitis
 
or
 
skin
 
irritation;
 
flushing,
 
unusually
 
warm
 
skin,
 
burning
 
sensation,
 
pruritus
 
and
 
stinging
 
of
 
skin.
 
2.
 
Skin
 
ulceration
 
3.
 
Excessive
 
drying
 
and
 
peeling
 
of
 
skin
 
 
Management:
 
1.
 
Do
 
not
 
use
 
large
 
amounts
 
or
 
longer
 
than
 
directed.
 
2.
 
If
 
irritation
 
or
 
sensitisation
 
develops,
 
seek
 
medical
 
advice.
 
 
 
 
Storage*
 
1.
 
Keep
 
the
 
tube
 
tightly
 
closed.
 
2.
 
Store
 
below
 
30C.
 
3.
 
Protect
 
from
 
heat,
 
moisture
 
and
 
light.
 
 
 
 
Others
 
 
1.
 
Apply
 
carefully
 
onto
 
warts
 
(affected
 
area)
 
and
 
not
 
the
 
surroundings.
 
2.
 
Avoid
 
using
 
an
 
open
 
wound
 
or
 
broken
 
area.
 
3.
 
Prolonged
 
use
 
or
 
application
 
to
 
large
 
areas
 
(risk
 
for
 
salicylism).
 
4.
 
Concurrent
 
drug
 
therapy
 
issues:
 
a)
 
Do
 
not
 
combine
 
use
 
of
 
topical
 
salicylic
 
acid
 
with
 
use
 
of
 
other
 
salicylates
 
or
 
drugs
 
that
 
can
 
increase
 
salicylate
 
serum
 
concentrations;
 
systemic
 
absorption
 
following
 
topical
 
use
 
may
 
occur
 
and
 
lead
 
to
 
toxicity .
 
 
 
 
 
Before
 
ending
 
this
 
peer
 
review
 
session,
 
the
 
reviewee
 
should
 
be
 
informed
 
of
 
the
 
step(s)
 
that
 
he/
 
she
 
missed
 
out
 
in
 
order
 
to
 
ensure
 
all
 
the
 
counselling
 
points
 
are
 
being
 
covered.
 
 
Remarks:
 
 
 
 
 
Reviewed
 
by:
 
Name
 
&
 
Signature
                                                                   
Date:
 
 
 
 
 
*Mandatory
 
for
 
validation
 
/
 
peer
 
review
 
 
References:
 
 
1.
 
Formulari
 
Ubat
 
KKM
 
(FUKKM).
 
(2024).
 
(Version
 
241030.001).
 
Retrieved
 
from
 
https://i.pharmacy .gov.my/fukkm/1260
,
 
https://i.pharmacy .gov.my/fukkm/1261
,
 
https://i.pharmacy .gov.my/fukkm/1262
 
2.
 
Menter ,
 
A.
 
(2009),
 
Salicylic
 
acid:
 
Drug
 
information.
 
UpToDate.
 
Retrieved
 
from
 
https://www .uptodate.com/contents/topical-salicylic-acid-drug-information?search=salicylic%20acid&sou 
rce=panel_search_result&selectedT itle=1%7E72&usage_type=panel&kp_tab=drug_general&display_ra 
nk=1#F219767
 
 
 
 
 
 
 
321
 

=== PAGE 323 ===

 
Selective
 
Norepinephrine
 
Reuptake
 
Inhibitor
 
(SNRI)
 
Name
 
:
 
 
Unit
 
:
 
 
●
 
Please
 
tick
 
(
✔
)
 
Yes
 
for
 
correct
 
instruction.
 
●
 
Please
 
tick
 
(
✔
)
 
No
 
for
 
incorrect
 
instruction.
 
Yes
 
No
 
Remarks
 
Pharmacological
 
Group
 
Serotonin
 
Norepinephrine
 
Reuptake
 
Inhibitor
 
(SNRI)
 
Duloxetine
 
 
Venlafaxine
 
Desvenlafaxine
 
 
 
 
Indications
 
and
 
Dosage
 
 
1.
 
Duloxetine:
 
 
a.
 
Major
 
Depressive
 
Disorder ,
 
Diabetic
 
peripheral
 
neuropathic
 
pain
:
Initial:
 
60
 
mg
 
once
 
daily
 
up
 
to
 
a
 
maximum
 
dose
 
of
 
120mg/day
 
(in
 
divided
 
doses)
 
b.
 
Generalised
 
Anxiety
 
Disorder
 
Initial:
 
30
 
mg
 
once
 
daily
 
up
 
to
 
a
 
usual
 
recommended
 
dose
 
of
 
60
 
mg/day
 
 
2.
 
Venlafaxine:
 
a.
 
Major
 
Depressive
 
Disorder ,
 
Generalised
 
Anxiety
 
Disorder ,
 
Social
 
Anxiety
 
Disorder:
 
Initial:75mg
 
OD,
 
may
 
g
radually
 
increase
 
based
 
on
 
response
 
and
 
tolerability
 
to
 
a
 
maximum
 
225
 
mg/day
 
(severe
 
depression,
 
max:
 
375mg/day)
 
b.
 
Panic
 
Disorder:
 
Initial:
 
37.5mg/day ,
 
may
 
g
radually
 
increase
 
based
 
on
 
response
 
and
 
tolerability
 
to
 
a
 
maximum
 
225mg/day
 
 
3.
 
Desvenlafaxine:
 
a.
 
Major
 
Depressive
 
Disorder
 
Recommended:
 
50mg
 
once
 
daily.
 
The
 
maximum
 
dose
 
should
 
not
 
exceed
 
200
 
mg/day .
 
 
Or
 
 
 
To
 
counsel
 
based
 
on
 
specific
 
medication’ s
 
indication
 
and
 
dosage
 
as
 
prescribed
 
by
 
the
 
doctor
 
 
 
 
Method
 
of
 
Administration*
 
1.
 
Duloxetine
 
Delayed
 
Release
 
Capsule:
 
 
Must
 
be
 
swallowed
 
whole
 
with
 
fluid
 
and
 
not
 
divided,
 
crushed,
 
chewed.
 
Can
 
be
 
taken
 
with
 
or
 
without
 
food
 
 
2.
 
Venlafaxine
 
Extended-Release
 
Capsule:
 
It
 
is
 
recommended
 
that
 
venlafaxine
 
extended-release
 
capsules
 
can
 
be
 
taken
 
with
 
food.
 
Capsule
 
must
 
be
 
swallowed
 
whole
 
with
 
fluid
 
and
 
not
 
divided,
 
crushed,
 
chewed
 
or
 
dissolved
 
or
 
it
 
may
 
be
 
administered
 
by
 
carefully
 
opening
 
the
 
capsule
 
and
 
sprinkling
 
the
 
entire
 
contents
 
on
 
a
 
spoonful
 
of
 
applesauce.
 
This
 
drug/food
 
mixture
 
should
 
be
 
swallowed
 
immediately
 
without
 
chewing
 
and
 
followed
 
with
 
a
 
glass
 
of
 
water
 
to
 
ensure
 
complete
 
swallowing
 
of
 
the
 
pellets.
 
 
3.
 
Desvenlafaxine
 
Extended-Release
 
Capsule:
 
Must
 
be
 
swallowed
 
whole
 
with
 
fluid
 
and
 
not
 
divided,
 
crushed,
 
chewed.
 
Can
 
be
 
taken
 
with
 
or
 
without
 
food
 
 
Do
 
not
 
stop
 
taking
 
your
 
medication
 
unless
 
advised
 
to
 
do
 
so
 
by
 
your
 
prescriber
 
 
 
 
Special
 
Considerations
 
Pregnancy
 
 
 
 
Risk
 
of
 
treatment
 
to
 
the
 
child
 
must
 
be
 
weighed
 
against
 
the
 
risk
 
 
 
 
322
 

=== PAGE 324 ===

 
of
 
no
 
treatment
 
to
 
the
 
mother
 
and
 
child.
 
Inform
 
your
 
doctor
 
if
 
you
 
are
 
planning
 
for
 
pregnancy
 
or
 
become
 
pregnant
 
while
 
taking
 
antidepressants.
 
Breastfeeding
 
 
 
 
In
 
general,
 
a
 
relative
 
infant
 
dose
 
(RID)
 
below
 
10%
 
of
 
the
 
average
 
maternal
 
level
 
of
 
an
 
antidepressant
 
is
 
considered
 
safe.
 
 
Reported
 
RID
 
 
1.
 
Duloxetine:
 
0.14
 
-
 
0.82%
 
2.
 
Venlafaxine:
 
3.20
 
-
 
8.10%
 
Only
 
administer
 
Desvenlafaxine
 
to
 
breastfeeding
 
women
 
if
 
the
 
expected
 
benefits
 
outweigh
 
any
 
possible
 
risk
 
 
 
 
Elderly
 
 
 
 
Beers
 
Criteria:
 
1)
 
SNRI
 
may
 
exacerbate
 
or
 
cause
 
SIADH
 
or
 
hyponatremia;
 
monitor
 
sodium
 
level
 
closely
 
when
 
starting
 
or
 
changing
 
dosages
 
in
 
older
 
adults.
 
2)
 
Avoid
 
SNRI
 
in
 
patients
 
with
 
a
 
history
 
of
 
fall
 
or
 
fracture;
 
unless
 
safer
 
alternatives
 
are
 
not
 
available.
 
SNRI
 
may
 
increase
 
fall
 
risk.
 
3)
 
Avoid
 
concomitant
 
use
 
of
 
3
 
or
 
more
 
CNS-active
 
agents
 
4)
 
Duloxetine:
 
Avoid
 
in
 
elderly
 
with
 
CrCl
 
less
 
than
 
30ml/min
 
due
 
to
 
increased
 
GI
 
adverse
 
effect.
 
STOPP/Start
 
Criteria:
 
1)
 
Avoid
 
Serotonin/noradrenaline
 
reuptake
 
inhibitors
 
(SNRI’ s
 
e.g.,
 
venlafaxine,
 
duloxetine)
 
and
 
severe
 
hypertension
 
i.e.,
 
systolic
 
blood
 
pressure
 
>
 
180
 
mmHg
 
+/-
 
diastolic
 
blood
 
pressure
 
>
 
105
 
mmHg
 
(likely
 
to
 
make
 
hypertension
 
worse).
 
 
 
 
Pediatrics
 
 
 
 
Safety
 
and
 
efficacy
 
in
 
pediatrics
 
patients
 
have
 
not
 
been
 
established.
 
 
 
 
Fasting
 
 
 
 
Administer
 
during
 
Sahur
 
or
 
after
 
Iftar.
 
 
To
 
refer
 
to
 
the
 
latest
 
advisory
 
by
 
religious
 
authority
 
 
 
 
Renal
 
Impairment
 
 
 
 
Duloxetine:
 
 
eGFR
 
>
 
30ml/min
 
:
 
there
 
is
 
no
 
dosage
 
adjustment
 
eGFR
 
30mL/min
 
or
 
less:
 
avoid
 
use
 
 
Venlafaxine
:
 
eGFR
 
30
 
–
 
89
 
mL/min:
 
decrease
 
total
 
daily
 
dose
 
by
 
25%
 
t0
 
50%
 
eGFR
 
30mL/min
 
or
 
less:
 
reduce
 
total
 
daily
 
dose
 
by
  
50%
 
or
 
more
 
 
 
Desvenlafaxine:
 
eGFR
 
30mL/min
 
or
 
less:
 
25mg
 
daily
 
 
 
 
323
 

=== PAGE 325 ===

 
Hepatic
 
Impairment
 
 
 
 
Duloxetine
:
 
Avoid
 
use
 
 
Venlafaxine
:
 
Decrease
 
total
 
daily
 
dose
 
by
 
50%
 
 
Desvenlafaxine
:
 
No
 
adjustment
 
 
 
 
Side
 
Effects
 
and
 
their
 
Management*
 
1.
 
Hypertension:
 
Check
 
blood
 
pressure
 
before
 
initiating
 
the
 
treatment
 
and
 
regularly
 
monitor
 
during
 
treatment.
 
(more
 
common
 
with
 
venlafaxine
 
&
 
desvenlafaxine)
 
2.
 
Anticholinergic:
 
 
a.
 
Blurred
 
vision(more
 
common
 
with
 
desvenlafaxine
 
&
 
venlafaxine),
 
constipation,
 
urinary
 
retention
 
and
 
dry
 
mouth
 
b.
 
Constipation
 
can
 
be
 
managed
 
by
 
physical
 
activity ,
 
fluid
 
and
 
fibre
 
intake
 
or
 
laxatives.
 
 
3.
 
Neurologic
 
a.
 
Anxiety:
 
Contact
 
your
 
prescriber
 
if
 
intolerable
 
b.
 
Headache,
 
dizziness,
 
fatigue,
 
weakness,
 
insomnia,
 
agitation,
 
nervousness,
 
restlessness.
 
May
 
require
 
dosage
 
adjustment.
 
Inform
 
prescriber
 
at
 
next
 
appointment
 
c.
 
Sedation:
 
Avoid
 
activity
 
requiring
 
mental
 
alertness
 
or
 
coordination.
 
Do
 
not
 
drink
 
alcohol
 
during
 
treatment
 
with
 
this
 
medicine
 
as
 
it
 
might
 
increase
 
the
 
sedative
 
effect.
 
Do
 
not
 
drive
 
or
 
work
 
with
 
tools
 
or
 
machinery
 
if
 
affected.
 
Inform
 
prescriber
 
at
 
next
 
appointment.
 
 
4.
 
Gastrointestinal:
 
a.
 
Nausea
 
&
 
vomiting:
 
consider
 
taking
 
doses
 
with
 
food
 
 
b.
 
Heartburn,
 
anorexia(more
 
common
 
with
 
desvenlafaxine
 
&
 
venlafaxine),
 
diarrhea,
 
abdominal
 
discomfort
 
such
 
as
 
gastric
 
or
 
bloatedness
 
c.
 
Weight
 
Gain:
 
advise
 
on
 
nutritional
 
counselling
 
(avoid
 
low-volume,
 
high-calorie
 
foods)
 
and
 
emphasize
 
need
 
for
 
physical
 
exercise.
 
 
5.
 
Sexual
 
Dysfunction:
 
Decrease
 
libido,
 
delayed
 
ejaculation,
 
anorganism
 
and
 
erectile
 
dysfunction
 
 
a.
 
Inform
 
prescriber
 
at
 
next
 
appointment
 
 
6.
 
Hyponatremia
 
and
 
SIADH:
 
Rare
 
but
 
potentially
 
fatal
 
side
 
effects
 
a.
 
Signs
 
and
 
Symptoms:
 
headache,
 
difficulty
 
concentrating,
 
memory
 
changes,
 
confusion,
 
weakness
 
and
 
unsteadiness
 
on
 
your
 
feet.
 
In
 
severe
 
or
 
more
 
sudden
 
cases,
 
symptoms
 
can
 
include:
 
hallucinations
 
(seeing
 
or
 
hearing
 
things
 
that
 
are
 
not
 
real),
 
fainting,
 
seizures
 
and
 
coma
 
b.
 
Contact
 
your
 
prescriber
 
and
 
restrict
 
water
 
intake
 
 
7.
 
Sweating
 
(more
 
common
 
with
 
desvenlafaxine
 
&
 
venlafaxine)
 
 
8.
 
Liver
 
failure
 
with
 
or
 
without
 
jaundice
 
 
Most
 
side
 
effects
 
are
 
immediate
 
but
 
often
 
go
 
away
 
with
 
time. 
 
 
 
 
324
 

=== PAGE 326 ===

 
It
 
may
 
take
 
a
 
few
 
weeks
 
before
 
you
 
feel
 
any
 
improvement.
 
Therefore,
 
do
 
not
 
change
 
the
 
dose
 
of
 
the
 
medicine
 
or
 
stop
 
taking
 
the
 
medicine
 
without
 
consulting
 
your
 
doctor
 
first. 
 
Instruct
 
patient
 
to
 
immediately
 
report
 
worsening
 
depression,
 
suicidal
 
ideation,
 
especially
 
at
 
initiation
 
of
 
therapy
 
(children
 
and
 
adolescents
 
are
 
at
 
higher
 
risk
 
for
 
these
 
effects
 
during
 
the
 
first
 
few
 
months
 
of
 
therapy). 
 
Storage*
 
Store
 
below
 
30’c.
 
Protect
 
from
 
light
 
and
 
moisture.
 
 
 
 
Others
 
1.
 
Significant
 
Pharmacodynamic
 
Interactions
 
a.
 
Risk
 
of
 
life-threatening
 
Serotonin
 
syndrome
 
when
 
SSRIs
 
co-prescribed
 
with
 
serotonergic
 
drugs.
 
(e.g.
 
tramadol,
 
ondansetron,
 
sumatriptan,
 
MAOI)
 
 
Signs
 
and
 
Symptoms
 
i.
 
Mild:
 
Insomnia,
 
anxiety ,
 
nausea,
 
diarrhea,
 
hypertension,
 
tachycardia,
 
hyper-reflexia
 
ii.
 
Moderate:Agitation,
 
myoclonus,
 
tremor ,
 
mydriasis,
 
flushing,
 
diaphoresis,
 
low
 
fever
 
(<38.5°C)
 
iii.
 
Severe:
 
Severe
 
hyperthermia,
 
confusion,rigidity ,
 
respiratory
 
failure,
 
coma,
 
death
 
Management:
 
Seek
 
immediate
 
medical
 
attention
 
if
 
you
 
experience
 
any
 
of
 
the
 
symptoms
 
mentioned
 
above.
 
b.
 
Increase
 
risk
 
of
 
upper
 
GI
 
bleeding
 
if
 
SSRIs
 
are
 
used
 
together
 
with
 
Aspirin
 
and
 
NSAID
 
due
 
to
 
inhibition
 
of
 
platelet
 
aggregation.
 
Watch
 
out
 
for
 
black
 
or
 
tarry
 
stools,
 
easily
 
bleeding
 
gums
 
or
 
spontaneous
 
bruises
 
c.
 
Risk
 
of
 
hyponatremia
 
especially
 
if
 
SSRIs
 
are
 
used
 
with
 
drugs
 
such
 
as
 
diuretics.
 
2.
 
Discontinuation
 
Syndrome
 
a.
 
SSRIs
 
should
 
not
 
be
 
stopped
 
abruptly
 
as
 
this
 
may
 
cause
 
discontinuation/
 
withdrawal
 
symptoms.
 
The
 
symptoms
 
are
 
usually
 
mild
 
and
 
selflimiting
 
(e.g.
 
include
 
flu-like
 
symptoms,
 
insomnia,
 
nausea,
 
imbalance,
 
sensory
 
disturbances
 
and
 
hyperarousal),
 
but
 
can
 
occasionally
 
be
 
severe
 
and
 
prolonged.
 
b.
 
The
 
patients
 
must
 
inform
 
prescribers
 
if
 
they
 
wish
 
to
 
change
 
or
 
stop
 
medications
 
 
 
 
Before
 
ending
 
this
 
peer
 
review
 
session,
 
the
 
reviewee
 
should
 
be
 
informed
 
of
 
the
 
step(s)
 
that
 
he/
 
she
 
missed
 
out
 
in
 
order
 
to
 
ensure
 
all
 
the
 
counselling
 
points
 
are
 
being
 
covered.
 
 
Remarks:
 
 
 
 
Reviewed
 
by:
 
Name
 
&
 
Signature
                                                                   
Date:
 
 
 
 
*Mandatory
 
for
 
validation
 
/
 
peer
 
review
 
 
 
325
 

=== PAGE 327 ===

 
References
 
:
 
 
1.
 
Duloxetine
 
(2025).
 
Micromedex
 
(electronic
 
version).
 
Retrieved
 
January
 
20,
 
2025
 
from
 
http://www .micromedexsolutions.com/
 
2.
 
Venlafaxine
 
(2025).
 
Micromedex
 
(electronic
 
version).
 
Retrieved
 
January
 
20,
 
2025
 
from
 
http://www .micromedexsolutions.com/
 
3.
 
Desvenlafaxine
 
(2025).
 
Micromedex
 
(electronic
 
version).
 
Retrieved
 
January
 
20,
 
2025
 
from
 
http://www .micromedexsolutions.com/
 
4.
 
Eli
 
Lilly
 
and
 
Company .
 
(2025).
 
Cymbalta®
 
(duloxetine
 
hydrochloride)
 
capsules
 
prescribing
 
information.
 
Retrieved
 
from
 
https://pi.lilly .com/us/cymbalta-pi.pdf
  
 
5.
 
Viatris
 
Specialty
 
LLC.
 
(2023).
 
Effexor®
 
XR
 
(venlafaxine
 
hydrochloride)
 
capsules,
 
extended-release
 
prescribing
 
information.
 
Retrieved
 
from
 
https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=c848a5d8-ba94-4c84-80e3-0bf35fb8e3
2e&type=display
 
 
6.
 
Wyeth
 
Pharmaceuticals
 
LLC.
 
Pfizer
 
Inc.
 
(2022).
 
Pristiq
 
extended-release-desvenlafaxine
 
succinate
 
tablet,
 
extended
 
release
 
prescribing
 
information.
 
Retrieved
 
from
 
https://labeling.pfizer .com/showlabeling.aspx?id=497
  
 
7.
 
Pharmaceutical
 
Services
 
Programme,
 
Ministry
 
of
 
Health
 
Malaysia.
 
(2025).
 
Formulari
 
Ubat
 
KKM
 
(FUKKM).
 
Retrieved
 
from
 
https://pharmacy .moh.gov .my/ms/apps/fukkm
 
8.
 
Visvalingam
 
U,
 
et.
 
al.
 
CPG
 
Management
 
of
 
Major
 
Depressive
 
Disorder
 
(2019).
 
Accessed
 
on
 
January
 
20,
 
2025.
 
Available
 
from:
 
CPG
 
Management
 
of
 
Major
 
Depressive
 
Disorder
 
(Second
 
Edition).pdf
 
9.
 
Krishnasamy
 
A.
 
et.
 
al.
 
Medication
 
Counseling
 
for
 
Pharmacists.
 
(First
 
Edition
 
2021).
 
Perak
 
State
 
Health
 
Department,
 
Pharmaceutical
 
Services
 
Division.
 
10.
 
Taylor ,
 
D.,
 
Barnes,
 
T.
 
R.
 
E.,
 
&
 
Young,
 
A.
 
H.
 
(2021).
 
The
 
Maudsley
 
prescribing
 
guidelines
 
in
 
psychiatry
 
(14th
 
ed.).
 
Wiley-Blackwell.
 
 
11.
 
College
 
of
 
Psychiatric
 
and
 
Neurologic
 
Pharmacist
 
2022-2023
 
Psychiatric
 
Pharmacotherapy
 
Review
 
12.
 
2023
 
American
 
Geriatrics
 
Society
 
Beers
 
Criteria®
 
Update
 
Expert
 
Panel.
 
(2023).
 
American
 
Geriatrics
 
Society
 
2023
 
updated
 
AGS
 
Beers
 
Criteria®
 
for
 
potentially
 
inappropriate
 
medication
 
use
 
in
 
older
 
adults.
 
Journal
 
of
 
the
 
American
 
Geriatrics
 
Society ,
 
71(7),
 
2052-2081
 
13.
 
O’Mahony ,
 
D.,
 
Cherubini,
 
A.,
 
Guiteras,
 
A.
 
R.,
 
Denkinger ,
 
M.,
 
Beuscart,
 
J.
 
B.,
 
Onder ,
 
G.,
 
...
 
&
 
Curtin,
 
D.
 
(2023).
 
STOPP/ST ART
 
criteria
 
for
 
potentially
 
inappropriate
 
prescribing
 
in
 
older
 
people:
 
version
 
3.
 
European
 
geriatric
 
medicine,
 
14(4),
 
625-632.
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
326
 

=== PAGE 328 ===

 
Selective
 
Serotonin
 
Reuptake
 
Inhibitors
 
(SSRIs)
 
/
 
Multimodal
 
Serotonin
 
Modulator
 
Name
 
:
 
 
Unit
 
:
 
 
●
 
Please
 
tick
 
(
✔
)
 
Yes
 
for
 
correct
 
instruction.
 
●
 
Please
 
tick
 
(
✔
)
 
No
 
for
 
incorrect
 
instruction.
 
Yes
 
No
 
Remarks
 
Pharmacological
 
Group
 
Selective
 
Serotonin
 
Reuptake
 
Inhibitors
 
(SSRIs)
 
Fluoxetine
 
 
 
 
 
 
Sertraline
 
 
 
 
 
Fluvoxamine
 
 
 
Escitalopram
 
 
Multimodal
 
serotonin
 
modulator
 
Vortioxetine
 
 
 
 
Indications
 
and
 
Dosage
 
1.
 
Escitalopram
 
:
 
a.
 
Major
 
depression,
 
Social
 
anxiety
 
disorder
 
(social
 
phobia),
 
Obsessive-compulsive
 
disorder
 
(OCD),
  
Generalised
 
Anxiety
 
Disorder
 
(GAD):
 
Adult
 
Initial
 
10mg/day ,
 
may
 
gradually
 
increase
 
based
 
on
 
response
 
and
 
tolerability
 
to
 
a
 
maximum
 
dose
 
of
 
20mg/day
 
b.
 
Treatment
 
of
 
panic
 
disorder
 
with
 
or
 
without
 
Agoraphobia:
 
Adult
 
Initial:
 
5mg/day ,
 
may
 
gradually
 
increase
 
based
 
on
 
response
 
and
 
tolerability
 
to
 
a
 
maximum
 
dose
 
of
 
20mg/day
 
 
2.
 
Fluvoxamine
 
a.
 
Depression:
 
Adult
 
Initial:
 
50
 
-
 
100
 
mg
 
daily
 
in
 
the
 
evening,
 
increased
 
if
 
necessary
 
to
 
300
 
mg
 
daily
 
 
b.
 
Obsessive
 
Compulsive
 
Disorder:
 
Adult:
 
50mg
 
per
 
day
 
for
 
3
 
–
 
4
 
days,
 
increase
 
gradually
 
up
 
to
 
a
 
maximum
 
of
 
300
 
mg/day
 
c.
 
Doses
 
over
 
150
 
mg
 
should
 
be
 
given
 
in
 
2
 
-3
 
divided
 
doses
 
 
3.
 
Fluoxetine
 
a.
 
Depression,
 
Obsessive-compulsive
 
disorder:
 
Adult
 
Initial
 
20mg/day
 
may
 
gradually
 
increase
 
based
 
on
 
response
 
and
 
tolerability
 
to
 
a
 
maximum
 
dose
 
of
 
80
 
mg/day
 
 
4.
 
Sertraline
 
a.
 
Major
 
depression,
 
obsessive-compulsive
 
disorder
 
(OCD)
 
Initial
 
50mg/day
 
may
 
gradually
 
increase
 
based
 
on
 
response
 
and
 
tolerability
 
to
 
a
 
maximum
 
dose
 
of
 
200mg/day
 
b.
 
Panic
 
disorder ,
 
Social
 
anxiety
 
disorder
 
(social
 
phobia),
 
Post-traumatic
 
stress
 
disorder
 
Initial
 
25mg/day
 
then
 
after
 
one
 
week,
 
the
 
dose
 
should
 
be
 
increased
 
to
 
50
 
mg/day .
 
Thereafter ,
  
may
 
gradually
 
increase
 
based
 
on
 
response
 
and
 
tolerability
 
to
 
a
 
maximum
 
dose
 
of
 
200mg/day
 
 
5.
 
Vortioxetine
 
a.
 
Major
 
depression
 
 
 
 
327
 

=== PAGE 329 ===

 
Adult
 
Initial:10mg/day
 
may
 
gradually
 
increase
 
based
 
on
 
response
 
and
 
tolerability
 
to
 
a
 
maximum
 
dose
 
of
 
20mg/day
 
Or
 
 
 
To
 
counsel
 
based
 
on
 
specific
 
medication’ s
 
indication
 
and
 
dosage
 
as
 
prescribed
 
by
 
the
 
doctor .
 
Method
 
of
 
Administration*
 
General
 
Instructions
:
 
1.
 
Must
 
be
 
swallowed
 
whole
 
with
 
water ,
 
and
 
must
 
not
 
be
 
chewed
 
or
 
crushed.
 
 
Specific
 
Instructions
:
 
 
1.
 
Fluoxetine
 
should
 
be
 
taken
 
in
 
the
 
morning
 
due
 
to
 
its
 
activating
 
properties.
 
2.
 
Fluvoxamine
 
is
 
preferably
 
taken
 
in
 
the
 
evening
 
as
 
it
 
tends
 
to
 
be
 
sedative.
 
Doses
 
>
 
150
 
mg
 
to
 
be
 
taken
 
at
 
divided
 
dose
 
with
 
higher
 
dose
 
taken
 
at
 
evening.
 
3.
 
Sertraline
 
and
 
Escitalopram,
 
generally
 
not
 
sedating,
  
can
 
be
 
taken
 
once
 
daily
 
either
 
morning
 
or
 
night.
 
 
Do
 
not
 
stop
 
taking
 
your
 
medication
 
unless
 
advised
 
to
 
do
 
so
 
by
 
your
 
prescriber
 
 
 
 
Special
 
Considerations
 
Pregnancy
 
 
 
 
Most
 
SSRIs
 
including
 
Escitalopram,
 
Fluoxetine,
 
Fluvoxamine
 
and
 
Sertraline
 
(except
 
for
 
Paroxetine
 
Category
 
D)
 
are
 
classified
 
as
 
Category
 
C
 
by
 
FDA
 
Pregnancy
 
Risk
 
Category .
 
 
Risk
 
of
 
treatment
 
to
 
the
 
child
 
must
 
be
 
weighed
 
against
 
the
 
risk
 
of
 
no
 
treatment
 
to
 
the
 
mother
 
and
 
child.
 
Inform
 
your
 
doctor
 
if
 
you
 
are
 
planning
 
for
 
pregnancy
 
or
 
become
 
pregnant
 
while
 
taking
 
antidepressants.
 
 
 
 
Breastfeeding
 
 
 
 
In
 
general,
 
a
 
relative
 
infant
 
dose
 
(RID)
 
below
 
10%
 
of
 
the
 
average
 
maternal
 
level
 
of
 
an
 
antidepressant
 
is
 
considered
 
safe.
 
 
Reported
 
RID
 
 
1.
 
 
Escitalopram:
 
4.50
 
-
 
6.40%
 
2.
 
 
Fluoxetine:
 
2.40
 
-
 
6.80%
 
 
3.
 
 
Fluvoxamine:
 
0.20
 
-
 
0.62%
 
 
4.
 
 
Sertraline:
 
0.50
 
-
 
3.70%
 
 
 
 
Elderly
 
 
 
 
Dosing
 
in
 
elderly:
 
1.
 
Escitalopram:
 
Starting
 
dose
 
5
 
mg/day .
 
Maximum
 
10
 
mg/day .
 
Risk
 
of
 
dose
 
related
 
increase
 
in
 
QTc
 
prolongation.
 
2.
 
Fluoxetine:
 
Lower
 
initial
 
dose
 
and/or
 
longer
 
dosing
 
interval
 
recommended.
 
3.
 
Sertraline:
 
No
 
dose
 
adjustment
 
required.
 
 
Beers
 
Criteria:
 
1)
 
SSRI
 
may
 
exacerbate
 
or
 
cause
 
SIADH
 
or
 
hyponatremia;
 
monitor
 
sodium
 
level
 
closely
 
when
 
starting
 
or
 
changing
 
dosages
 
in
 
older
 
adults.
 
2)
 
Avoid
 
SSRI
 
in
 
patients
 
with
 
a
 
history
 
of
 
fall
 
or
 
fracture;
 
unless
 
safer
 
alternatives
 
are
 
not
 
available.
 
Avoid
 
concomitant
 
use
 
of
 
3
 
or
 
more
 
CNS-active
 
agents
 
as
 
may
 
increase
 
risk
 
of
 
fall.
 
1
 
 
328
 

=== PAGE 330 ===

 
3)
 
Avoid
 
SSRI
 
if
 
used
 
together
 
with
 
warfarin.
 
SSRI
 
may
 
increase
 
the
 
risk
 
of
 
bleeding.
 
Caution
  
if
 
used
 
together
 
with
 
other
 
class
 
of
 
drugs
 
that
 
may
 
induce
 
bleeding
 
(e.g.
 
NSAIDS,
 
antiplatelet)
 
STOPP/Start
 
Criteria:
 
1)
 
Selective
 
serotonin
 
reuptake
 
inhibitors
 
(SSRIs)
 
in
 
combination
 
with
 
Vitamin
 
K
 
antagonist,
 
direct
 
thrombin
 
inhibitor
 
or
 
factor
 
Xa
 
inhibitor
 
with
 
a
 
previous
 
history
 
of
 
major
 
haemorrhage
 
(increased
 
risk
 
of
 
bleeding
 
due
 
to
 
antiplatelet
 
effects
 
of
 
SSRIs).
 
 
2)
 
Selective
 
serotonin
 
re-uptake
 
inhibitors
 
(SSRI’ s)
 
with
 
current
 
or
 
recent
 
significant
 
hyponatraemia
 
i.e.,
 
serum
 
Na+
 
<
 
130
 
mmol/l
 
(risk
 
of
 
exacerbating
 
or
 
precipitating
 
hyponatraemia).
 
3)
 
Selective
 
serotonin
 
re-uptake
 
inhibitors
 
(SSRI’ s)
 
with
 
current
 
or
 
recent
 
significant
 
bleeding
 
(risk
 
of
 
exacerbation
 
or
 
recurrence
 
of
 
bleeding
 
due
 
to
 
antiplatelet
 
effects
 
of
 
SSRI’ s).
 
Paediatric
 
 
 
 
1)
 
The
 
safety
 
and
 
efficacy
 
of
 
Fluoxetine
 
younger
 
than
 
6
 
years
 
of
 
age
 
have
 
not
 
been
 
established.
 
2)
 
The
 
safety
 
and
 
efficacy
 
of
 
Fluvoxamine
   
in
 
pediatric
 
patients
 
younger
 
than
 
8
 
years
 
of
 
age
 
have
 
not
 
been
 
established
 
except
 
for
 
the
 
treatment
 
of
 
OCD.
 
3)
 
The
 
safety
 
and
 
efficacy
 
of
 
Sertraline
   
in
 
pediatric
 
patients
 
younger
 
than
 
6
 
years
 
of
 
age
 
have
 
not
 
been
 
established
 
except
 
for
 
the
 
treatment
 
of
 
OCD.
 
4)
 
The
 
safety
 
and
 
efficacy
 
of
 
Vortioxetine
 
in
 
pediatric
 
patients
 
have
 
not
 
been
 
established.
 
 
 
 
Fasting
 
 
 
 
Administer
 
during
 
Sahur
 
or
 
after
 
Iftar.
 
 
To
 
refer
 
to
 
the
 
latest
 
advisory
 
by
 
religious
 
authority
 
 
 
 
Renal
 
Impairment
 
 
 
 
 
1.
 
Dose
 
adjustments
 
may
 
be
 
required
 
in
 
pre-existing
 
or
 
newly
 
developed
 
renal
 
or
 
hepatic
 
impairment.
 
Please
 
contact
 
your
 
prescriber .
 
 
2.
 
Escitalopram,
 
Fluvoxamine,
 
Vortioxetine:
 
No
 
dosing
 
adjustment
 
required.
 
3.
 
Fluoxetine:
 
Max
 
daily
 
dose
 
20
 
mg
 
(ESRD)
 
4.
 
Sertraline:
 
Starting
 
dose
 
25
 
mg.
 
Maximum
 
150
 
mg/day
 
(ESRD)
 
 
 
 
Hepatic
 
Impairment
 
 
 
 
 
1.
 
Dose
 
adjustments
 
may
 
be
 
required
 
in
 
pre-existing
 
or
 
newly
 
developed
 
renal
 
or
 
hepatic
 
impairment.
 
Please
 
contact
 
your
 
prescriber .
  
 
2.
 
Escitalopram:
 
Maximum
 
recommended
 
dose
 
10
 
mg/day
 
3.
 
Fluoxetine:
 
Liver
  
impairment
 
can
 
affect
 
the
 
elimination
 
of
 
fluoxetine.
 
 
4.
 
Fluvoxamine:
 
It
 
may
 
be
 
appropriate
 
to
 
modify
 
the
 
initial
 
dose
 
and
 
the
 
subsequent
 
dose
 
titration
 
for
 
these
 
patient
 
groups.
  
 
5.
 
Sertraline:
 
Use
 
in
  
moderate
 
(Child-Pugh
 
score
 
7
 
to
 
10)
 
 
 
 
329
 

=== PAGE 331 ===

 
or
 
severe
 
hepatic
 
impairment
 
(Child-Pugh
 
score
 
10-15)
 
is
 
not
 
recommended.
 
6.
 
Vortioxetine:
 
No
 
dosing
 
adjustment
 
required.
 
Side
 
Effects
 
and
 
their
 
Management*
 
1.
 
Neurologic
 
a.
 
Anxiety:
 
Contact
 
your
 
prescriber
 
if
 
intolerable
 
b.
 
Headache,
 
dizziness,
 
fatigue,
 
weakness,
 
insomnia
 
(more
 
common
 
with
 
fluoxetine),
 
agitation,
 
nervousness,
 
restlessness.
 
May
 
require
 
dosage
 
adjustment.
 
Inform
 
prescriber
 
at
 
next
 
appointment
 
c.
 
Sedation:
 
Avoid
 
activity
 
requiring
 
mental
 
alertness
 
or
 
coordination.
 
Do
 
not
 
drink
 
alcohol
 
during
 
treatment
 
with
 
this
 
medicine
 
as
 
it
 
might
 
increase
 
the
 
sedative
 
effect.
 
Do
 
not
 
drive
 
or
 
work
 
with
 
tools
 
or
 
machinery
 
if
 
affected.
 
Inform
 
prescriber
 
at
 
next
 
appointment.
 
 
2.
 
Gastrointestinal:
 
a.
 
Nausea
 
&
 
vomiting:
 
consider
 
taking
 
doses
 
with
 
food
 
(more
 
common
 
with
 
Sertaline)
 
b.
 
Heartburn,
 
anorexia,
 
diarrhea,
 
abdominal
 
discomfort
 
such
 
as
 
gastric
 
or
 
bloatedness
 
c.
 
Weight
 
Gain:
 
advise
 
on
 
nutritional
 
counselling
 
(avoid
 
low-volume,
 
high-calorie
 
foods)
 
and
 
emphasize
 
need
 
for
 
physical
 
exercise.
 
 
3.
 
Sexual
 
Dysfunction:
 
Decrease
 
libido,
 
delayed
 
ejaculation,
 
anorgasmia
 
and
 
erectile
 
dysfunction
 
 
a.
 
Inform
 
prescriber
 
at
 
next
 
appointment
 
 
4.
 
Anticholinergic:
 
 
a.
 
Constipation
 
can
 
be
 
managed
 
by
 
physical
 
activity ,
 
fluid
 
and
 
fibre
 
intake
 
or
 
laxatives.
 
 
5.
 
Hyponatremia
 
and
 
SIADH:
 
Rare
 
but
 
potentially
 
fatal
 
side
 
effects
 
a.
 
Signs
 
and
 
Symptoms:
 
headache,
 
difficulty
 
concentrating,
 
memory
 
changes,
 
confusion,
 
weakness
 
and
 
unsteadiness
 
on
 
your
 
feet.
 
In
 
severe
 
or
 
more
 
sudden
 
cases,
 
symptoms
 
can
 
include:
 
hallucinations
 
(seeing
 
or
 
hearing
 
things
 
that
 
are
 
not
 
real),
 
fainting,
 
seizures
 
and
 
coma
 
b.
 
Contact
 
your
 
prescriber
 
and
 
restrict
 
water
 
intake
 
 
6.
 
QTc
 
Prolongation
 
a.
 
Escitalopram
 
associated
 
with
 
higher
 
risk
 
of
 
QTc
 
prolongation
 
(dose
 
related)
 
 
7.
 
Hyperhidrosis:
 
abnormally
 
excessive
 
sweating
 
that’s
 
not
 
necessarily
 
related
 
to
 
heat
 
or
 
exercise
 
(common
 
in
 
Vortioxetine)
 
a.
 
Inform
 
your
 
prescriber
 
at
 
next
 
appointment
 
 
Most
 
side
 
effects
 
are
 
immediate
 
but
 
often
 
go
 
away
 
with
 
time. 
 
It
 
may
 
take
 
a
 
few
 
weeks
 
before
 
you
 
feel
 
any
 
improvement.
 
Therefore,
 
do
 
not
 
change
 
the
 
dose
 
of
 
the
 
medicine
 
or
 
stop
 
taking
 
the
 
medicine
 
without
 
consulting
 
your
 
doctor
 
first. 
 
Instruct
 
patient
 
to
 
immediately
 
report
 
worsening
 
depression,
 
suicidal
 
ideation,
 
especially
 
at
 
initiation
 
of
 
therapy
 
(children
 
and
 
 
 
 
330
 

=== PAGE 332 ===

 
adolescents
 
are
 
at
 
higher
 
risk
 
for
 
these
 
effects
 
during
 
the
 
first
 
few
 
months
 
of
 
therapy). 
 
Storage*
 
Store
 
at
 
a
 
temperature
 
below
 
30°C.
 
 
 
 
Others
 
1.
 
Possible
 
Drug
 
Interactions
 
a.
 
Cytochrome
 
P450
 
Interaction
 
with
 
SSRIs
 
 
Isoform
 
Drugs
 
Degree
 
of
 
Inhibition
 
Clinical
 
Relevance
 
1A2
 
Fluvoxamine
 
Potent
 
Avoid
 
or
 
use
 
caution
 
with
 
Clozapine,
 
Warfarin
 
and
 
Methylxanthines.
 
2C19
 
Fluoxetine
 
Fluvoxamine
 
Moderate
 
Caution
 
with
 
concomitant
 
warfarin
 
due
 
to
 
increased
 
risk
 
of
 
bleeding.
 
Use
 
with
 
caution
 
with
 
medication
 
metabolised
 
by
 
CYP2C19
 
(e.g
 
Diazepam,
 
Phenytoin).
 
 
2D6
 
Fluoxetine
 
 
 
 
 
Escitalopram
 
Sertraline
 
Potent
 
 
 
 
 
Weak-Moderate
 
Weak-Moderate
 
(>
 
150
 
mg/day)
 
Avoid
 
or
 
use
 
with
 
caution
 
with
 
medications
 
solely
 
metabolised
 
by
 
CYP2D6
 
(e.g
 
Metoprolol).
 
 
Avoid
 
coadministration
 
of
 
potent
 
CYP2D6
 
inhibitors
 
with
 
Tamoxifen
 
or
 
use
 
cautiously
 
as
 
the
 
efficacy
 
of
 
Tamoxifen
 
may
 
be
 
reduced.
 
3A4
 
Fluvoxamine
 
Weak-Moderate
 
Avoid
 
or
 
use
 
with
 
caution
 
with
 
medication
 
metabolised
 
by
 
CYP3A4
 
(e.g
 
Simvastatin,
 
other
 
HMG-CoA
 
reductase
 
inhibitors).
 
2.
 
Significant
 
Pharmacodynamic
 
Interactions
 
a.
 
Risk
 
of
 
life-threatening
 
Serotonin
 
syndrome
 
when
 
SSRIs
 
co-prescribed
 
with
 
serotonergic
 
drugs.
 
(e.g.
 
tramadol,
 
ondansetron,
 
sumatriptan,
 
MAOI)
 
 
Signs
 
and
 
Symptoms
 
i.
 
Mild:
 
Insomnia,
 
anxiety ,
 
nausea,
 
diarrhea,
 
hypertension,
 
tachycardia,
 
hyper-reflexia
 
ii.
 
Moderate:Agitation,
 
myoclonus,
 
tremor ,
 
mydriasis,
 
flushing,
 
diaphoresis,
 
low
 
fever
 
(<38.5°C)
 
iii.
 
Severe:
 
Severe
 
hyperthermia,
 
confusion,rigidity ,
 
respiratory
 
failure,
 
coma,
 
death
 
Management:
 
Seek
 
immediate
 
medical
 
attention
 
if
 
you
 
experience
 
any
 
of
 
the
 
symptoms
 
mentioned
 
above.
 
b.
 
Increase
 
risk
 
of
 
upper
 
GI
 
bleeding
 
if
 
SSRIs
 
are
 
used
 
together
 
with
 
Aspirin
 
and
 
NSAID
 
due
 
to
 
inhibition
 
of
 
platelet
 
aggregation.
 
Watch
 
out
 
for
 
black
 
or
 
tarry
 
stools,
 
easily
 
bleeding
 
gums
 
or
 
spontaneous
 
bruises
 
c.
 
Risk
 
of
 
hyponatremia
 
especially
 
if
 
SSRIs
 
are
 
used
 
with
 
drugs
 
such
 
as
 
diuretics.
 
 
3.
 
Discontinuation
 
Syndrome
 
a.
 
SSRIs
 
should
 
not
 
be
 
stopped
 
abruptly
 
as
 
this
 
may
 
cause
 
discontinuation/
 
withdrawal
 
symptoms.
 
The
 
symptoms
 
are
 
usually
 
mild
 
and
 
selflimiting
 
(e.g.
 
include
 
flu-like
 
 
 
 
 
331
 

=== PAGE 333 ===

 
symptoms,
 
insomnia,
 
nausea,
 
imbalance,
 
sensory
 
disturbances
 
and
 
hyperarousal),
 
but
 
can
 
occasionally
 
be
 
severe
 
and
 
prolonged.
 
b.
 
The
 
patients
 
must
 
inform
 
prescribers
 
if
 
they
 
wish
 
to
 
change
 
or
 
stop
 
medications
 
Before
 
ending
 
this
 
peer
 
review
 
session,
 
the
 
reviewee
 
should
 
be
 
informed
 
of
 
the
 
step(s)
 
that
 
he/
 
she
 
missed
 
out
 
in
 
order
 
to
 
ensure
 
all
 
the
 
counselling
 
points
 
are
 
being
 
covered.
 
 
Remarks:
 
 
 
 
 
Reviewed
 
by:
 
Name
 
&
 
Signature
                                                                   
Date:
 
 
 
 
 
*Mandatory
 
for
 
validation
 
/
 
peer
 
review
 
References
 
:
 
 
1.
 
Pfizer
 
(2024).
 
Package
 
Insert:
 
Zoloft®
 
Tablet.
 
Retrieved
 
from
 
Quest
 
3+
 
Search
 
on
 
January
 
20,
 
2025.
 
2.
 
H.
 
Lundbeck
 
A/S
 
(2025).
 
Physician
 
Information
 
Leaflet:
 
Lexapro®
 
Tablet.
 
Retrieved
 
from
 
Quest
 
3+
 
Search
 
on
 
January
 
20,
 
2025.
 
3.
 
Mylan
 
Laboratories
 
SAS
 
(2022).
 
Package
 
Insert:
 
Luvox®
 
Tablet.
 
Retrieved
 
from
 
Quest
 
3+
 
Search
 
on
 
January
 
20,
 
2025.
 
4.
 
Patheon
 
France
 
(2021).
 
Package
 
Insert:
 
Prozac®
 
Tablet.
 
Retrieved
 
from
 
Quest
 
3+
 
Search
 
on
 
January
 
20,
 
2025.
 
5.
 
Lundbeck
 
(2024).
 
Product
 
Information
 
Leaflet:
 
Vortioxetine.
 
Retrieved
 
from
 
Quest
 
3+
 
Search
 
on
 
January
 
20,
 
2025
 
6.
 
Stahl,
 
S.
 
M.
 
(2017).
 
Stahl’ s
 
Essential
 
Psychopharmacology
 
Prescriber ’s
 
Guide.
 
In
 
Australian
 
Prescriber
 
(6th
 
ed.,
 
Issue
 
1).
 
Cambridge
 
university
 
ress.
 
https://doi.org/10.18773/austprescr .2016.001
 
 
7.
 
Pharmaceutical
 
Services
 
Programme,
 
Ministry
 
of
 
Health
 
Malaysia.
 
(2025).
 
Formulari
 
Ubat
 
KKM
 
(FUKKM).
 
Retrieved
 
from
 
https://pharmacy .moh.gov .my/ms/apps/fukkm
 
8.
 
Visvalingam
 
U,
 
et.
 
al.
 
CPG
 
Management
 
of
 
Major
 
Depressive
 
Disorder
 
(2019).
 
Accessed
 
on
 
January
 
20,
 
2025.
 
Available
 
from:
 
CPG
 
Management
 
of
 
Major
 
Depressive
 
Disorder
 
(Second
 
Edition).pdf
 
9.
 
Krishnasamy
 
A.
 
et.
 
al.
 
Medication
 
Counseling
 
for
 
Pharmacists.
 
(First
 
Edition
 
2021).
 
Perak
 
State
 
Health
 
Department,
 
Pharmaceutical
 
Services
 
Division.
 
10.
 
Taylor ,
 
D.,
 
Barnes,
 
T.
 
R.
 
E.,
 
&
 
Young,
 
A.
 
H.
 
(2021).
 
The
 
Maudsley
 
prescribing
 
guidelines
 
in
 
psychiatry
 
(14th
 
ed.).
 
Wiley-Blackwell.
 
 
11.
 
College
 
of
 
Psychiatric
 
and
 
Neurologic
 
Pharmacist
 
2022-2023
 
Psychiatric
 
Pharmacotherapy
 
Review
 
12.
 
2023
 
American
 
Geriatrics
 
Society
 
Beers
 
Criteria®
 
Update
 
Expert
 
Panel.
 
(2023).
 
American
 
Geriatrics
 
Society
 
2023
 
updated
 
AGS
 
Beers
 
Criteria®
 
for
 
potentially
 
inappropriate
 
medication
 
use
 
in
 
older
 
adults.
 
Journal
 
of
 
the
 
American
 
Geriatrics
 
Society ,
 
71(7),
 
2052-2081
 
 
 
 
 
 
 
 
 
 
 
 
 
332
 

=== PAGE 334 ===

 
Sevelamer
 
Name
 
:
 
 
Unit
 
:
 
 
●
 
Please
 
tick
 
(
✔
)
 
Yes
 
for
 
correct
 
instruction.
 
●
 
Please
 
tick
 
(
✔
)
 
No
 
for
 
incorrect
 
instruction.
 
Yes
 
No
 
Remarks
 
Pharmacological
 
Group
 
Drugs
 
for
 
treatment
 
of
 
hyperkalemia
 
and
 
hyperphosphatemia
 
Sevelamer
 
 
 
 
 
Indications
 
and
 
Dosage
 
Control
 
of
 
hyperphosphataemia
 
in
 
adult
 
patients
 
receiving
 
haemodialysis
 
and
 
peritoneal
 
dialysis.
 
a.
 
Starting
 
dose
 
is
 
one
 
or
 
two
 
800mg
 
tablets
 
three
 
times
 
per
 
day
 
with
 
meals.Adjust
 
by
 
one
 
tablet
 
per
 
meal
 
in
 
two
 
weeks
 
interval
 
as
 
needed
 
to
 
obtain
 
serum
 
phosphorus
 
target
 
(1.13
 
to
 
1.78mmol/L).
 
 
To
 
counsel
 
based
 
on
 
specific
 
medication’ s
 
indication
 
and
 
dosage
 
as
 
prescribed
 
by
 
the
 
doctor
 
 
 
 
Method
 
of
 
Administration*
 
To
 
swallow
 
whole
 
WITH
 
meals.
 
DO
 
NOT
 
crush,
 
chew
 
or
 
break.
 
 
Missed
 
dose
 
management:
 
If
 
a
 
dose
 
is
 
missed,
 
it
 
should
 
be
 
skipped.
 
Do
 
not
 
double
 
the
 
dose.
 
 
 
Do
 
not
 
stop
 
taking
 
your
 
medication
 
unless
 
advised
 
to
 
do
 
so
 
by
 
your
 
prescriber
 
 
 
 
Special
 
Considerations
 
Pregnancy
 
 
 
 
Sevelamer
 
is
 
not
 
absorbed
 
systemically ,
 
therefore
 
fetal
 
risk
 
is
 
minimal.
 
But
 
may
 
reduce
 
maternal
 
absorption
 
of
 
folic
 
acid
 
and
 
fat
 
soluble
 
vitamins.
  
 
 
 
 
Breastfeeding
 
 
 
 
Sevelamer
 
is
 
not
 
absorbed
 
systemically
 
therefore
 
it
 
is
 
not
 
expected
 
to
 
cause
 
exposure
 
to
 
a
 
breastfeeding
 
infant.
   
 
 
 
 
Elderly
 
 
 
 
1.
 
Dose
 
selection
 
for
 
elderly
 
patients
 
should
 
be
 
cautious,
 
usually
 
starting
 
at
 
the
 
lower
 
end
 
of
 
the
 
dosing
 
range.
 
2.
 
Swallowing
 
difficulties
 
(dysphagia):
 
May
 
benefit
 
from
 
alternative
 
formulations.
 
 
 
 
Paediatric
 
 
 
 
Not
 
recommended
 
to
 
be
 
used
 
in
 
children
 
that
 
are
 
below
 
6
 
years
 
of
 
age,
 
have
 
a
 
BSA
 
below
 
0.75
 
m2
 
,
 
or
 
that
 
have
 
mild
 
hyperphosphatemia.
 
 
 
 
 
Fasting
 
 
 
 
1.
 
Adjust
 
the
 
timing
 
of
 
administration
 
according
 
to
 
the
 
fasting
 
schedule
 
during
 
Ramadhan;
 
to
 
take
 
during
 
Sahur
 
and
 
Iftar.
 
2.
 
If
 
more
 
than
 
two
 
doses
 
have
 
been
 
prescribed,
 
consult
 
with
 
your
 
healthcare
 
provider
 
to
 
adjust
 
your
 
phosphate
 
binder
 
administration.
  
 
 
 
 
Others
  
 
 
 
 
333
 

=== PAGE 335 ===

 
No
 
dosage
 
adjustment
 
provided
 
in
 
the
 
manufacturer ’s
 
labelling
 
 
 
 
Side
 
Effects
 
and
 
their
 
Management*
 
Serious
 
adverse
 
events:
 
Cases
 
of
 
dysphagia
 
and
 
esophageal
 
tablet
 
retention
 
have
 
been
 
reported
 
in
 
association
 
with
 
use
 
of
 
the
 
tablet
 
formulation
 
of
 
Sevelamer ,
 
some
 
requiring
 
hospitalization
 
and
 
intervention.
 
Cases
 
of
 
bowel
 
obstruction
 
and
 
perforation
 
have
 
also
 
been
 
reported
 
with
 
Sevelamer
 
use.
 
Constipation
 
may
 
be
 
a
 
preceding
 
symptom.
 
 
 
 
Others:
 
Endocrine
 
&
 
metabolic:
 
Metabolic
 
acidosis
 
Gastrointestinal:
 
Abdominal
 
pain,
 
constipation,
 
flatulence,
 
peritonitis
 
Dermatologic:
 
Pruritus,
 
skin
 
rash
 
 
 
 
Storage*
 
1.
 
Store
 
at
 
room
 
temperature.
 
2.
 
Store
 
in
 
a
 
dry
 
place
 
and
 
protect
 
from
 
moisture.
 
3.
 
Keep
 
out
 
of
 
reach
 
of
 
children.
 
 
 
 
Others
 
Precautions:
 
 
1.
 
Use
 
with
 
caution
 
in
 
patients
 
with
 
GI
 
motility
 
disorder
 
Contraindications:
 
1.
 
 
Patients
 
with
 
hypophosphatemia,
 
patients
 
with
 
GI
 
disorders
 
including
 
dysphagia,
 
swallowing
 
disorders,
 
severe
 
GI
 
motility
 
disorders
 
(including
 
severe
 
constipation)
 
or
 
major
 
gastrointestinal
 
surgery ,
 
patients
 
hypersensitive
 
to
 
sevelamer
 
or
 
one
 
of
 
the
 
other
 
ingredients
 
in
 
the
 
product.
 
 
Drug-
 
drug
 
interactions:
 
1.
 
Ciprofloxacin:
 
Decrease
 
bioavailability
 
of
 
ciprofloxacin
 
by
 
~50%
 
when
 
taken
 
simultaneously .
 
Take
 
ciprofloxacin
 
at
 
least
 
2
 
hours
 
before
 
or
 
6
 
hours
 
after
 
sevelamer .
 
2.
 
Immunosuppressants:
 
Reduce
 
concentrations
 
of
 
cyclosporin,
 
mycophenolate
 
mofetil
 
and
 
tacrolimus.
 
These
 
drugs
 
should
 
be
 
taken
 
at
 
least
 
1
 
hour
 
before
 
or
 
3
 
hours
 
after
 
sevelamer .
 
3.
 
Levothyroxine:
 
May
 
increase
 
thyroid
 
stimulating
 
hormone
 
(TSH)
 
levels
 
when
 
taken
 
together
 
with
 
levothyroxine.
 
Separate
 
administration
 
of
 
sevelamer
 
and
 
levothyroxine
 
by
 
at
 
least
 
4
 
hours.
 
 
 
 
Before
 
ending
 
this
 
peer
 
review
 
session,
 
the
 
reviewee
 
should
 
be
 
informed
 
of
 
the
 
step(s)
 
that
 
he/
 
she
 
missed
 
out
 
in
 
order
 
to
 
ensure
 
all
 
the
 
counselling
 
points
 
are
 
being
 
covered.
 
 
Remarks:
 
 
 
 
Reviewed
 
by:
 
Name
 
&
 
Signature
                                                                   
Date:
 
 
 
 
*Mandatory
 
for
 
validation
 
/
 
peer
 
review
 
References:
 
 
1.
 
Formulari
 
Ubat
 
KKM.
 
(2025,
 
January
 
1).
 
Accessed
 
on
 
January
 
1,
 
2025.
 
2.
 
Sanofi-aventis
 
Canada
 
Inc.
 
(2023).
 
Renvela
 
(sevelamer
 
carbonate)
 
product
 
monograph.
 
Sanofi-aventis
 
Canada
 
Inc.
 
3.
 
MIMS.
 
(2025).
 
Sevelamer .
 
MIMS.
 
Retrieved
 
January
 
20,
 
2025,
 
from
 
https://www .mims.com/malaysia/drug/info/sevelamer
 
334
 

=== PAGE 336 ===

 
Sodium-Glucose
 
Cotransporter
 
2
 
(SGLT2)
 
Inhibitor
 
(SGLT2-i)
 
Name
 
:
 
 
Unit
 
:
 
 
●
 
Please
 
tick
 
(
✔
)
 
Yes
 
for
 
correct
 
instruction.
 
●
 
Please
 
tick
 
(
✔
)
 
No
 
for
 
incorrect
 
instruction.
 
Yes
 
No
 
Remarks
 
Pharmacological
 
Group
 
Antidiabetic
 
agent,
 
Sodium-Glucose
 
Cotransporter
 
2
 
(SGL T2)
 
Inhibitor
 
 
 
 
Indications
 
and
 
Dosage
 
1.
 
Add-on
 
combination
 
therapy
 
in
 
combination
 
with
 
other
 
glucose-lowering
 
medicinal
 
products
 
including
 
insulin,
 
to
 
improve
 
glycaemic
 
control
 
in
 
adult
 
patients
 
with
 
type
 
2
 
diabetes
 
mellitus
 
when
 
these,
 
together
 
with
 
diet
 
and
 
exercise,
 
do
 
not
 
provide
 
adequate
 
glycaemic
 
control.
 
 
Dapagliflozin:
 
10mg
 
once
 
daily
 
 
Empagliflozin:
 
10mg
 
once
 
daily
 
(starting
 
dose),
 
 
25mg
 
once
 
daily
 
(maximum
 
dose)
 
 
2.
 
To
 
reduce
 
the
 
risk
 
of
 
hospitalization
 
for
 
heart
 
failure
 
in
 
adults
 
with
 
type
 
2
 
diabetes
 
mellitus
 
and
 
established
 
cardiovascular
 
disease
 
(CVD).
 
 
Dapagliflozin:
 
10mg
 
once
 
daily
 
 
Empagliflozin:
 
10mg
 
once
 
daily
 
(starting
 
dose),
 
25mg
 
once
 
daily
 
(maximum
 
dose)
 
 
3.
 
To
 
reduce
 
the
 
risk
 
of
 
cardiovascular
 
death
 
and
 
hospitalization
 
for
 
heart
 
failure
 
in
 
adults
 
with
 
heart
 
failure
 
(NYHA
 
class
 
ll
 
-
 
lV)
 
with
 
reduced
 
ejection
 
fraction.
 
 
Dapagliflozin:
 
10mg
 
once
 
daily
 
 
Empagliflozin:
 
10mg
 
once
 
daily
 
 
4.
 
For
 
cardiorenal
 
protection
 
in
 
adult
 
patients
 
with
 
chronic
 
kidney
 
disease,
 
with
 
or
 
without
 
Type
 
2
 
Diabetes
 
Mellitus,
 
with
 
eGFR≥25mL/min/1.73m2
 
and
 
urine
 
albumin
 
creatinine
 
ratio
 
(UACR)
 
≥200-5,000mg/m2
 
(or
 
the
 
equivalent
 
in
 
uPRC/u-dipstick)
 
receiving
 
stable
 
treatment
 
with
 
ACEi
 
or
 
ARB
 
(unless
 
they
 
are
 
contraindicated
 
or
 
not
 
tolerated).
 
 
Dapagliflozin:
 
10mg
 
once
 
daily
 
 
 
 
 
Method
 
of
 
Administration*
 
Administration
 
1.
 
Swallow
 
the
 
tablet
 
whole
 
with
 
water .
 
2.
 
Do
 
not
 
chew ,
 
crush
 
or
 
split
 
the
 
tablet
 
(no
 
data
 
available
 
on
 
enteral
 
feeding).
 
3.
 
Take
 
the
 
tablet
 
with
 
or
 
without
 
food.
 
4.
 
Take
 
it
 
once
 
a
 
day,
 
in
 
the
 
morning.
 
Missed
 
dose
 
management:
 
1.
 
Take
 
a
 
missed
 
dose
 
as
 
soon
 
as
 
you
 
remember
 
it.
 
2.
 
If
 
it
 
is
 
close
 
to
 
the
 
time
 
for
 
your
 
next
 
dose
 
(<12
 
hours
 
until
 
the
 
next
 
dose),
 
skip
 
the
 
missed
 
dose
 
and
 
take
 
the
 
next
 
dose
 
at
 
the
 
usual
 
time.
 
3.
 
Do
 
not
 
take
 
a
 
double
 
dose
 
to
 
make
 
up
 
for
 
a
 
forgotten
 
dose.
 
 
Do
 
not
 
stop
 
taking
 
your
 
medication
 
unless
 
advised
 
to
 
do
 
so
 
by
 
your
 
prescriber
 
 
 
 
Special
 
Pregnancy
 
 
 
 
335
 

=== PAGE 337 ===

 
Consideration
 
1.
 
Pregnancy
 
Category:
 
C
 
(should
 
be
 
avoided
 
especially
 
during
 
2
nd
 
or
 
3
rd
 
trimester
 
of
 
pregnancy)
 
2.
 
To
 
discontinue
 
medications
 
once
 
pregnancy
 
is
 
detected
 
as
 
a
 
precautionary
 
measure.
 
Animal
 
studies
 
have
 
shown
 
adverse
 
effects
 
on
 
postnatal
 
development.
 
 
 
 
Breastfeeding
 
 
 
 
Should
 
not
 
be
 
used
 
while
 
breastfeeding
 
due
 
to
 
insuf ficient
 
data
 
on
 
the
 
excretion
 
of
 
SGLT2-i
 
into
 
human
 
breast
 
milk.
 
 
 
 
Elderly
 
 
 
 
MALPIP
 
1.
 
Higher
 
incidence
 
of
 
volume
 
depletion-related
 
adverse
 
reactions
 
(hypotension.,
 
acute
 
kidney
 
injury).
 
To
 
assess
 
volume
 
status
 
and
 
blood
 
pressure
 
before
 
initiating
 
treatment.
 
 
 
Beers
 
Criteria
 
1.
 
Use
 
with
 
caution.
 
Monitor
 
patient
 
for
 
urogenital
 
infection
 
and
 
ketoacidosis
 
(increased
 
risk
 
of
 
urogenital
 
infections
 
and
 
euglycaemic
 
diabetic
 
ketoacidosis
 
in
 
elderly).
 
 
 
 
Paediatric
 
 
 
 
1.
 
Empagliflozin
 
can
 
be
 
used
 
in
 
children
 
aged
 
10
 
years
 
and
 
older
 
for
 
the
 
treatment
 
of
 
type
 
2
 
diabetes.
 
No
 
data
 
are
 
available
 
in
 
children
 
below
 
10
 
years
 
of
 
age.
 
Not
 
recommended
 
for
 
children
 
and
 
adolescents
 
under
 
18
 
years
 
of
 
age
 
for
 
the
 
treatment
 
of
 
heart
 
failure
 
or
 
for
 
the
 
treatment
 
of
 
chronic
 
kidney
 
disease,
 
because
 
it
 
has
 
not
 
been
 
studied
 
in
 
these
 
patients.
 
 
2.
 
Dapagliflozin
 
is
 
not
 
to
 
be
 
used
 
in
 
children
 
and
 
adolescents
 
under
 
18
 
years
 
of
 
age.
 
 
 
 
 
Fasting
 
 
 
 
1.
 
No
 
dosage
 
adjustment
 
is
 
needed
 
during
 
fasting
 
2.
 
Advisable
 
to
 
be
 
taken
 
after
 
iftar.
 
3.
 
Ensure
 
good
 
hydration
 
is
 
maintained
 
 
To
 
refer
 
to
 
the
 
latest
 
advisory
 
by
 
religious
 
authority
 
 
 
 
Others
  
 
 
 
 
1.
 
Liver
 
impairment
 
a.
 
No
 
dosage
 
adjustment
 
is
 
required.
 
b.
 
Severe:
 
no
 
data
 
(Dapagliflozin)
 
2.
 
Renal
 
impairment
 
a.
 
More
 
likely
 
to
 
experience
 
hypotension.
 
b.
 
Higher
 
risk
 
for
 
acute
 
kidney
 
injury .
 
c.
 
Increased
 
risk
 
of
 
urinary
 
tract
 
infection.
 
d.
 
Contraindicated
 
use
 
in
 
ESRF
 
and
 
dialysis
 
patients.
 
3.
 
SGLT2
 
-inhibitor
 
should
 
not
 
be
 
used
 
in
 
Type
 
1
 
Diabetes
 
Mellitus.
 
4.
 
Use
 
with
 
caution
 
in
 
patients
 
who
 
may
 
be
 
at
 
higher
 
risk
 
of
 
DKA
 
(i.e
 
very
 
low
 
carbohydrate
 
diet,
 
patients
 
with
 
conditions
 
that
 
restricted
 
food
 
intake,
 
severe
 
dehydration,
 
or
 
conditions
 
that
 
increased
 
insulin
 
requirements
 
due
 
to
 
acute
 
medical
 
illness,
 
surgery
 
or
 
alcohol
 
abuse).
 
If
 
DKA
 
is
 
suspected,
 
discontinue
 
use
 
of
 
SGLT2
 
-inhibitor
 
 
 
 
336
 

=== PAGE 338 ===

 
Side
 
Effects
 
and
 
their
 
Management*
 
1.
 
Polyuria,
 
dehydration
 
and
 
hypotension
 
-
 
The
 
degree
 
of
 
polyuria
 
is
 
typically
 
higher
 
in
 
people
 
with
 
more
 
marked
 
hyperglycaemia.
 
-
 
Management:
 
a.
 
Maintain
 
adequate
 
hydration
 
(mindful
 
of
 
any
 
fluid
 
restrictions
 
required
 
for
 
renal
 
disease
 
or
 
heart
 
failure)
 
b.
 
For
 
elderly
 
patients
 
or
 
those
 
on
 
other
 
antihypertensives,
 
blood
 
pressure
 
should
 
be
 
reassessed
 
one
 
to
 
two
 
weeks
 
after
 
SGLT2
 
inhibitor
 
commencement
 
2.
 
Urinary
 
tract
 
infections
 
-
 
Mostly
 
mild
 
to
 
moderate
 
-
 
Occurs
 
more
 
frequently
 
in
 
female
 
patients
 
-
 
Symptoms
 
:
 
a.
 
Burning
 
or
 
pain
 
during
 
urination
 
b.
 
Frequent
 
urination
 
c.
 
Strong-smelling
 
urine
 
d.
 
Fever ,
 
nausea
 
&
 
vomiting
 
-
 
General
 
advice
 
to
 
reduce
 
the
 
likelihood
 
of
 
urinary
 
tract
 
infections:
 
a.
 
Maintain
 
good
 
genital
 
hygiene.
 
b.
 
Wash
 
genital
 
area
 
from
 
front
 
to
 
back
 
and
 
wipe
 
genital
 
organs
 
with
 
clean
 
clothes
 
c.
 
Do
 
not
 
hold
 
urine.
 
3.
 
Genital
 
mycotic
 
infections
 
-
 
Mostly
 
mild
 
to
 
moderate
 
-
 
Symptoms:
 
a.
 
Swelling
 
in
 
the
 
genital
 
area
 
b.
 
Pain/
 
itchiness
 
in
 
the
 
genital
 
area
 
c.
 
Foul-smelling
 
vaginal
 
or
 
penile
 
discharge
 
-
 
General
 
advice
 
to
 
reduce
 
the
 
likelihood
 
of
 
genital
 
infections:
 
a.
 
Clean
 
the
 
private
 
part
 
thoroughly
 
following
 
urination,
 
defecation
 
or
 
sexual
 
intercourse.
 
 
b.
 
Wash
 
the
 
genital
 
area
 
from
 
front
 
to
 
back
 
and
 
wipe
 
genital
 
organs
 
with
 
clean
 
clothes.
 
c.
 
Change
 
sanitary
 
pads
 
or
 
adult
 
diapers
 
frequently .
 
d.
 
Seek
 
medical
 
attention
 
if
 
there
 
are
 
symptoms
 
of
 
urogenital
 
infection
 
4.
 
Diabetic
 
ketoacidosis
 
(DKA)
 
/
 
Euglycemic
 
ketoacidosis
 
-
 
This
 
can
 
occur
 
due
 
to
 
dehydration
 
-
 
Signs
 
and
 
symptoms:
 
a.
 
Unusual
 
fatigue
 
b.
 
Nausea,
 
vomit
 
c.
 
Frequent
 
urination
 
d.
 
Fruity
 
smelling
 
breath
 
e.
 
Shortness
 
of
 
breath
 
-
 
General
 
advice:
 
a.
 
Temporarily
 
stop
 
taking
 
SGLT2-i
  
when
 
unwell
 
(vomit/diarrhoea/fever)
 
or
 
when
 
unable
 
to
 
eat/drink
 
as
 
usual.
 
Resume
 
taking
 
SGLT2-i
 
once
 
able
 
to
 
eat/drink
 
as
 
usual.
 
b.
 
Interruption
 
of
 
treatment
 
should
 
be
 
considered
 
in
 
patients
 
who
 
are
 
hospitalized
 
for
 
major
 
surgical
 
procedures,
 
serious
 
infections
 
or
 
acute
 
serious
 
medical
 
illness.
 
c.
 
Drink
 
plenty
 
of
 
fluid
 
to
 
avoid
 
dehydration.
 
 
 
 
Storage*
 
Store
 
at
 
room
 
temperature
 
(<30ºC)
 
in
 
a
 
dry
 
place.
 
 
 
 
Others
 
1.
 
Use
 
with
 
caution
 
in
 
patients
 
with
 
an
 
elevated
 
risk
 
of
 
volume
 
depletion
 
i.e
 
marked
 
hyperglycaemia,
 
impaired
 
renal
 
function,
 
elderly
 
patients
 
and
 
concomitant
 
use
 
of
 
 
 
 
337
 

=== PAGE 339 ===

 
volume-depleting
 
medications
 
(e.g.
 
diuretics,
 
ACE-inhibitors)
 
as
 
risk
 
of
 
dehydration
 
and
 
hypotension
 
may
 
increase.
 
2.
 
Risk
 
of
 
hypoglycaemia
 
in
 
patients
 
taking
 
concurrent
 
insulin
 
or
 
insulin
 
secretagogues.
 
3.
 
Concomitant
 
use
 
of
 
an
 
SGLT2
 
inhibitor
 
with
 
lithium
 
may
 
decrease
 
serum
 
lithium
 
concentrations.
 
Monitor
 
serum
 
lithium
 
concentration
 
more
 
frequently
 
during
 
SGLT2
 
inhibitor
 
initiation
 
and
 
dosage
 
changes.
 
4.
 
The
 
tablets
 
contain
 
lactose.
 
Patients
 
with
 
rare
 
hereditary
 
problems
 
of
 
galactose
 
intolerance,
 
Lapp
 
lactase
 
deficiency
 
or
 
glucose-galactose
 
malabsorption
 
should
 
not
 
take
 
the
 
medications.
 
5.
 
Patients
 
on
 
SGLT2
 
inhibitors
 
will
 
test
 
positive
 
for
 
glucose
 
in
 
their
 
urine.
 
 
6.
 
Patients
 
who
 
present
 
with
 
pain
 
or
 
tenderness,
 
erythema,
 
or
 
swelling
 
in
 
the
 
genital
 
or
 
perineal
 
area,
 
with
 
or
 
without
 
fever
 
or
 
malaise,
 
should
 
be
 
evaluated
 
for
 
necrotizing
 
fasciitis.
 
If
 
suspected,
 
SGLT2
 
inhibitor
 
should
 
be
 
discontinued
 
and
 
prompt
 
treatment
 
should
 
be
 
instituted
 
Before
 
ending
 
this
 
peer
 
review
 
session,
 
the
 
reviewee
 
should
 
be
 
informed
 
of
 
the
 
step(s)
 
that
 
he/
 
she
 
missed
 
out
 
in
 
order
 
to
 
ensure
 
all
 
the
 
counselling
 
points
 
are
 
being
 
covered.
 
 
Remarks:
 
 
 
 
Reviewed
 
by:
 
Name
 
&
 
Signature
                                                                   
Date:
 
 
 
*Mandatory
 
for
 
validation
 
/
 
peer
 
review
 
References:
 
 
1.
 
American
 
Diabetes
 
Association
 
(ADA).
 
(2023).
 
Standards
 
of
 
care
 
in
 
diabetes–2023.
 
Diabetes
 
Care.
 
https://diabetesjournals.org/care/issue/46/Supplement_1.
 
2.
 
Astra
 
Zeneca.
 
(2024).
 
Forxiga:
 
EPAR-
 
product
 
information.
 
Retrieved
 
from
 
https://www .ema.europa.eu/en/documents/product-information/forxiga-epar-product-information_en.pdf
 
 
3.
 
Boehringer
 
Ingelheim
 
Pharmaceuticals.
 
(2023).
 
Jardiance
 
(Empagliflozin)
 
tablet
 
prescribing
 
information.
 
Retrieved
 
from
 
https://content.boehringer-ingelheim.com/DAM/7d9c41 1c-ec33-4f82-886f-af1e01 1f35bb/jardiance-us-pi.
pdf
 
 
4.
 
DeSantis
 
A.
 
(2024).
 
Sodium-glucose
 
cotransporter
 
2
 
inhibitors
 
for
 
the
 
treatment
 
of
 
hyperglycemia
 
in
 
type
 
2
 
diabetes
 
mellitus.
 
Post
 
TW,
 
ed.
 
UpToDate.
 
Waltham,
 
MA:
 
UpToDate
 
Inc.
 
http://www .uptodate.com.
 
5.
 
Lunati,
 
M.
 
E.,
 
Cimino,
 
V.,
 
Gandolfi,
 
A.,
 
Trevisan,
 
M.,
 
Montefusco,
 
L.,
 
Pastore,
 
I.,
 
...
 
&
 
Fiorina,
 
P.
 
(2022).
 
SGLT2-inhibitors
 
are
 
effective
 
and
 
safe
 
in
 
the
 
elderly:
 
The
 
SOLD
 
study .
 
Pharmacological
 
Research,
 
183,
 
106396.
 
6.
 
Ministry
 
of
 
Health
 
Malaysia.
 
(2020).
 
Clinical
 
practice
 
guidelines
 
on
 
the
 
management
 
of
 
Type
 
2
 
Diabetes
 
Mellitus
 
(6th
 
edition).
 
7.
 
Ministry
 
of
 
Health
 
Malaysia.
 
(2024).
 
Formulari
 
Ubat
 
Kementerian
 
Kesihatan
 
Malaysia.
 
 
8.
 
Zinman
 
B,
 
Wanner
 
C,
 
Lachin
 
JM,
 
et
 
al.
 
(2015).
 
Empagliflozin,
 
cardiovascular
 
outcomes,
 
and
 
mortality
 
in
 
type
 
2
 
diabetes.
 
The
 
New
 
England
 
Journal
 
of
 
Medicine,
 
373,
 
2117-2128.
  
doi:10.1056/NEJMoa1504720
 
[PubMed
 
26378978]
 
9.
 
Zala
 
A.,
 
Maple-Brown
 
L.J.,
 
Shaw
 
J.E.
 
&
  
Hare
 
M.J.L.
 
(2021).
 
Current
 
evidence
 
and
 
practical
 
guidance
 
for
 
the
 
use
 
of
 
sodium–glucose
 
co-transporter-2
 
inhibitors
 
in
 
type
 
2
 
diabetes.
 
Australian
 
Journal
 
of
 
General
 
Practice.
 
50(4).
  
https://www1.racgp.org.au/ajgp/2021/april/use-of-sodium-glucose-co-transporter-2-inhibitors
 
 
 
 
338
 

=== PAGE 340 ===

 
Sodium
 
Valproate
 
 
Name
 
:
 
 
Unit
 
:
 
 
●
 
Please
 
tick
 
(
✔
)
 
Yes
 
for
 
correct
 
instruction.
 
●
 
Please
 
tick
 
(
✔
)
 
No
 
for
 
incorrect
 
instruction.
 
Yes
 
No
 
Remarks
 
Pharmacological
 
Group
 
Mood
 
Stabiliser
 
 
 
 
 
Indications
 
and
 
Dosage
 
1.
 
Treatment
 
and
 
prevention
 
of
 
mania
 
associated
 
with
 
bipolar
 
disorders
 
a.
 
Initial
 
dose:
 
Fixed
 
dose
 
method:
  
500
 
-
 
1000mg/day
 
in
 
divided
 
doses.
 
 
Loading
 
dose
 
method
 
20mg-30mg/kg
 
in
 
divided
 
doses
 
 
(Therapeutic
 
range
 
in
 
mania
 
50
 
-125
 
mg/L)
 
b.
 
Usual
 
maintenance
 
dose
 
range:
 
1g/day
 
-
 
2.5g/day
 
(suggested
 
max;
 
3g/day;
 
Therapeutic
 
range
 
50
 
-100
 
mg/L)
 
2.
 
Epilepsy
 
 
a.
 
Initially
 
15mg/kg
 
then
 
increased
 
by
 
5-10
 
mg/kg
 
at
 
weekly
 
intervals
 
until
 
seizures
 
are
 
controlled.
 
Max
 
60
 
mg/kg
 
daily
 
administered
 
in
 
divided
 
doses
 
if
 
total
 
daily
 
dose
 
exceeds
 
250
 
mg
 
 
 
 
 
Method
 
of
 
Administration*
 
1.
 
Sodium
 
valproate
 
enteric
 
coated
 
200mg
 
and
 
and
 
Epilim
 
Chrono
 
Controlled
 
Release
 
500mg
 
a.
 
Tablets
 
should
 
be
 
swallowed
 
whole.Do
 
not
 
crush
 
or
 
chew
 
the
 
tablets.
 
 
b.
 
Tablets
 
are
 
hygroscopic.
 
The
 
tablet
 
should
 
not
 
be
 
removed
 
from
 
the
 
foil
 
or
 
container
 
until
 
immediately
 
before
 
they
 
are
 
taken.
 
c.
 
Epilim
 
EC
 
tablet
 
should
 
be
 
taken
 
in
 
divided
 
doses.
 
d.
 
Epilim
 
Chrono
 
can
 
be
 
taken
 
once
 
or
 
twice
 
daily
 
2.
 
Missed
 
dose
 
management:
 
If
 
you
 
forget
 
to
 
take
 
a
 
dose,
 
take
 
it
 
as
 
soon
 
as
 
you
 
remember .
 
Do
 
not
 
take
 
two
 
doses
 
at
 
once.
 
 
Do
 
not
 
stop
 
taking
 
your
 
medication
 
unless
 
advised
 
to
 
do
 
so
 
by
 
your
 
prescriber
 
 
 
 
Special
 
Considerations
 
Pregnancy
 
 
 
 
1.
 
Valproate
 
can
 
be
 
harmful
 
to
 
unborn
 
children
 
when
 
taken
 
by
 
a
 
woman
 
during
 
pregnancy .
 
2.
 
Men
 
and
 
women
 
taking
 
Valproate
 
should
 
practise
 
effective
 
contraception
 
methods.
 
3.
 
Talk
 
to
 
your
 
doctor
 
immediately
 
if
 
you
 
plan
 
to
 
have
 
a
 
baby
 
or
 
become
 
pregnant
 
while
 
taking
 
this
 
medication.
 
 
4.
 
Patient
 
card
 
for
 
sodium
 
valproate
 
may
 
be
 
issued
 
to
 
patient
 
as
 
educational
 
material
 
 
 
 
Breastfeeding
 
 
 
 
1.
 
Valproate
 
is
 
present
 
in
 
breast
 
milk
 
&
 
is
 
considered
 
compatible
 
with
 
breastfeeding.
 
However ,
 
the
 
potential
 
benefits
 
of
 
breastfeeding
 
should
 
be
 
weighed
 
against
 
the
 
potential
 
risk
 
of
 
adverse
 
effects
 
occurring
 
in
 
the
 
 
 
 
339
 

=== PAGE 341 ===

 
infant.
 
2.
 
If
 
medication
 
is
 
continued,
 
infants
 
exposed
 
to
 
valproate
 
via
 
breast
 
milk
 
should
 
be
 
monitored
 
for
 
sign
 
of
 
liver
 
damage,
 
including
 
jaundice
 
and
 
unusual
 
bruising
 
or
 
bleeding
 
Elderly
 
 
 
 
1.
 
Start
 
at
 
a
 
reduced
 
dose
 
and
 
titrate
 
slowly .
 
2.
 
Lower
 
initial
 
and
 
maintenance
 
doses
 
(eg,
 
administration
 
50%-60%
 
of
 
usual
 
doses)
 
are
 
recommended
 
due
 
to
 
decreased
 
elimination
 
and
 
increased
 
incidences
 
of
 
somnolence
 
in
 
elderly
 
3.
 
Monitor
 
closely
 
for
 
adverse
 
events
 
(sedation,
 
dehydration,
 
decreased
 
nutritional
 
intake)
 
4.
 
Use
 
is
 
associated
 
with
 
fall
 
risk.
 
To
 
advise
 
on
 
fall
 
precautions.
 
 
Beers
 
criteria:
 
1.
 
Avoid
 
use
 
in
 
elderly
  
with
 
history
 
of
 
falls
 
or
 
fractures
 
(
 
unless
 
used
 
for
 
seizure
 
or
 
mood
 
disorders)
 
and
 
unless
 
safer
 
alternatives
 
are
 
not
 
available,
 
syncope
 
,
 
impaired
 
psychomotor
 
function,
 
or
 
ataxia
 
may
 
occur
 
2.
 
Avoid
 
concomitant
 
use
 
of
 
3
 
or
 
more
 
CNS
 
active
 
agents
 
in
 
any
 
combination
 
due
 
to
 
increased
 
risk
 
of
 
falls.
 
 
 
 
Paediatric
 
 
 
 
1.
 
The
 
safety
 
and
 
efficacy
 
of
 
Sodium
 
Valproate
 
for
 
the
 
treatment
 
of
 
manic
 
episodes
 
in
 
bipolar
 
disorder
 
has
 
not
 
been
 
established
 
in
 
patients
 
aged
 
less
 
than
 
18
 
years
 
(product
 
leaflet).
 
 
 
 
Fasting
 
 
 
 
Administer
 
during
 
Sahur
 
or
 
after
 
Iftar.
 
 
To
 
refer
 
to
 
the
 
latest
 
advisory
 
by
 
religious
 
authority
 
 
 
 
Renal
 
Impairment
 
 
 
 
 
1.
 
CrCl
 
>10ml/min:
 
No
 
dosage
 
adjustment
 
2.
 
CrCl
 
<10ml/min:
 
No
 
specific
 
dosage
 
adjustment
 
necessary .
 
Free
 
valproate
 
clearance
 
reduces
 
to
 
~
 
30%.
 
Closely
 
monitor
 
clinical
 
response
 
and
 
tolerability
 
in
 
addition
 
to
 
TDM
 
level
 
when
 
appropriate
 
 
 
 
Hepatic
 
Impairment
 
 
 
 
 
1.
 
Child-T urcotte-Pugh
 
class
 
A:
 
Lowest
 
dose
 
possible,
 
gradually
 
adjust
 
dose
 
to
 
reach
 
desired
 
clinical
 
effect.
 
2.
 
Child-T urcotte-Pugh
 
class
 
B
 
&
 
C:
 
Contraindicated
 
 
 
 
Side
 
Effects
 
and
 
their
 
Management*
 
1.
 
Weight
 
gain:
 
Advise
 
on
 
nutritional
 
counselling
 
(avoid
 
low-volume,
 
high-calorie
 
foods)
 
and
 
emphasize
 
need
 
for
 
physical
 
exercise.
 
2.
 
Gastrointestinal
 
a.
 
Nausea,
 
vomiting,
 
gingival
 
hyperplasia,
 
stomatitis,
 
upper
 
abdominal
 
pain
 
upper ,
 
diarrhoea
 
frequently
 
occur
 
in
 
some
 
patients
 
at
 
the
 
start
 
of
 
treatment,
 
but
 
they
 
usually
 
disappear
 
after
 
a
 
few
 
days
 
without
 
discontinuing
 
the
 
treatment
 
b.
 
Taking
 
with
 
or
 
after
 
food
 
may
 
minimise
 
the
 
GI
 
upset
 
 
 
 
340
 

=== PAGE 342 ===

 
3.
 
Hepato-biliary
 
disorders
 
 
a.
 
Liver
 
injury ,
 
severe
 
liver
 
damage,
 
including
 
hepatic
 
failure
 
sometimes
 
resulting
 
in
 
death,
 
has
 
been
 
reported.
 
b.
 
Symptoms
 
may
 
include
 
but
 
are
 
not
 
limited
 
to
 
jaundice,
 
abdominal
 
pain,
 
lethargy .
 
Immediately
 
contact
 
your
 
prescriber .
 
4.
 
Nervous
 
system
 
disorders
 
a.
 
Tremor ,
 
somnolence,
 
sedation
 
and
 
dizziness
 
b.
 
Occurs
 
early
 
in
 
treatment
 
and
 
is
 
usually
 
transient,
 
wears
 
off
 
over
 
time
 
c.
 
May
 
require
 
dosage
 
adjustment.
 
Inform
 
your
 
prescriber
 
at
 
next
 
appointment
 
5.
 
Blood
 
and
 
lymphatic
 
disorders
 
a.
 
Anaemia
 
and
 
thrombocytopenia:
 
Spontaneous
 
bruising
 
or
 
bleeding,
 
blood
 
in
 
stools
 
or
 
black
 
tarry
 
stools.
 
Immediately
 
contact
 
your
 
prescriber .
 
 
Storage*
 
Store
 
at
 
a
 
temperature
 
below
 
30°C,
 
protect
 
from
 
light
 
and
 
moisture.
 
 
 
 
 
Others
 
1.
 
Contraception
 
a.
 
Concomitants
 
of
 
oestrogen-containing
 
products,
 
including
 
oestrogen-containing
 
hormonal
 
contraceptives,
 
may
 
potentially
 
result
 
in
 
decreased
 
valproate
 
efficacy .
 
2.
 
Drug-drug
 
interaction
 
 
Advise
 
patients
 
always
 
let
 
healthcare
 
providers
 
know
 
about
 
all
 
the
 
medications
 
they
 
are
 
taking,
 
including
 
over-the-counter
 
drugs
 
and
 
supplements
 
a.
 
Valproate
 
may
 
potentiate
 
the
 
effect
 
of
 
other
 
psychotropics
 
such
 
as
 
neuroleptics,
 
MAO
 
inhibitors,
 
antidepressants
 
and
 
benzodiazepines;
 
therefore,
 
clinical
 
monitoring
 
is
 
advised
 
and
 
dosage
 
should
 
be
 
adjusted
 
when
 
appropriate
 
b.
 
Clinical
 
toxicity
 
has
 
been
 
reported
 
when
 
valproate
 
was
 
co-administered
 
with
 
carbamazepine
 
as
 
valproate
 
may
 
potentiate
 
toxic
 
effect
 
of
 
carbamazepine
 
c.
 
Epilim
 
reduces
 
the
 
metabolism
 
of
 
lamotrigine
 
and
 
increases
 
the
 
lamotrigine
 
mean
 
half-life
 
by
 
nearly
 
two-fold.
 
This
 
interaction
 
may
 
lead
 
to
 
increased
 
lamotrigine
 
toxicity ,
 
in
 
particular
 
serious
 
skin
 
rashes
 
d.
 
Valproic
 
acid
 
may
 
decrease
 
the
 
olanzapine
 
plasma
 
concentration
 
e.
 
Carbapenem
 
antibiotics
 
such
 
as
 
imipenem,
 
panipenem
 
and
 
meropenem:
 
Decreases
 
in
 
blood
 
levels
 
of
 
valproic
 
acid
 
 
f.
 
Rifampicin
 
may
 
decrease
 
the
 
valproic
 
acid
 
blood
 
levels
 
resulting
 
in
 
a
 
lack
 
of
 
therapeutic
 
effect
 
3.
 
Blood
 
levels
 
can
 
be
 
drawn
 
to
 
make
 
sure
 
that
 
the
 
drug
 
levels
 
are
 
in
 
the
 
right
 
range
 
to
 
get
 
the
 
most
 
benefit
 
with
 
the
 
least
 
side
 
effects.
 
Encourage
 
patients
 
to
 
learn
 
their
 
own
 
blood
 
levels.
 
4.
 
Monitoring
 
parameters:
 
 
a.
 
Serum
 
level
 
of
 
valproate
 
b.
 
 
Liver
 
function
 
test
 
c.
 
Blood
 
count
 
with
 
platelets
 
 
 
 
341
 

=== PAGE 343 ===

 
Before
 
ending
 
this
 
peer
 
review
 
session,
 
the
 
reviewee
 
should
 
be
 
informed
 
of
 
the
 
step(s)
 
that
 
he/
 
she
 
missed
 
out
 
in
 
order
 
to
 
ensure
 
all
 
the
 
counselling
 
points
 
are
 
being
 
covered.
 
 
Remarks:
 
 
 
 
 
Reviewed
 
by:
 
Name
 
&
 
Signature
                                                                   
Date:
 
 
 
 
 
*Mandatory
 
for
 
validation
 
/
 
peer
 
review
 
References:
 
 
1.
 
Formulari
 
Ubat
 
KKM.
 
(2025,
 
January
 
1).
 
Accessed
 
on
 
January
 
20,
 
2025.
 
2.
 
UpToDate,
 
Inc.
 
(2025).
 
Valproate(V alproic
 
Acid):
 
Drug
 
information
 
(Version
 
3.68.3)
 
[Mobile
 
application].
 
UpToDate,
 
Inc.
 
3.
 
Sanofi-A ventis
 
(Malaysia)
 
Sdn.
 
Bhd
 
(2024)
 
Product
 
information
 
leaflet:
 
Epilim.
 
Retrieved
 
from
 
Quest
 
3+
 
Search
 
on
 
January
 
1,
 
2025.
 
4.
 
Sanofi-A ventis
 
(2024).
 
Product
 
Information
 
Leaflet:
 
Epilim
 
EC
 
and
 
Epilim
 
Chrono.
 
Retrieved
 
from
 
Quest
 
3+
 
Search
 
on
 
January
 
20,
 
2025
 
5.
 
Alimuddin
 
AS.
 
et.
 
al.
 
CPG
 
Management
 
of
 
Bipolar
 
Disorder
 
(Second
 
Edition,
 
2024).
 
Accessed
 
on
 
January
 
21,
 
2025.
 
Available
 
from:
 
acadmed.org.my/CPGdl/CPG
 
Management
 
of
 
Bipolar
 
Disorder
 
(2nd
 
Edition).pdf
 
6.
 
Stahl,
 
S.
 
M.
 
(2017).
 
Stahl’ s
 
Essential
 
Psychopharmacology
 
Prescriber ’s
 
Guide.
 
In
 
Australian
 
Prescriber
 
(6th
 
ed.,
 
Issue
 
1).
 
Cambridge
 
university
 
press.
 
https://doi.org/10.18773/austprescr .2016.001
 
 
7.
 
Krishnasamy
 
A.
 
et.
 
al.
 
Medication
 
Counseling
 
for
 
Pharmacists.
 
(First
 
Edition
 
2021).
 
Perak
 
State
 
Health
 
Department,
 
Pharmaceutical
 
Services
 
Division.
 
8.
 
Taylor ,
 
D.,
 
Barnes,
 
T.
 
R.
 
E.,
 
&
 
Young,
 
A.
 
H.
 
(2021).
 
The
 
Maudsley
 
prescribing
 
guidelines
 
in
 
psychiatry
 
(14th
 
ed.).
 
Wiley-Blackwell.
 
 
9.
 
2023
 
American
 
Geriatrics
 
Society
 
Beers
 
Criteria®
 
Update
 
Expert
 
Panel.
 
(2023).
 
American
 
Geriatrics
 
Society
 
2023
 
updated
 
AGS
 
Beers
 
Criteria®
 
for
 
potentially
 
inappropriate
 
medication
 
use
 
in
 
older
 
adults.
 
Journal
 
of
 
the
 
American
 
Geriatrics
 
Society ,
 
71(7),
 
2052-2081.
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
342
 

=== PAGE 344 ===

 
Spironolactone
 
Name
 
:
 
 
Unit
 
:
 
 
●
 
Please
 
tick
 
(
✔
)
 
Yes
 
for
 
correct
 
instruction
 
or
 
sequence.
 
●
 
Please
 
tick
 
(
✔
)
 
No
 
for
 
incorrect
 
instruction
 
or
 
sequence.
 
Yes
 
No
 
Remarks
 
Pharmacological
 
Group
 
Antagonists
 
of
 
Mineralocorticoid
 
Receptors:
 
 
Potassium-sparing
 
Diuretic;
 
Aldosterone
 
antagonist
 
 
 
 
Indications
 
and
 
Dosage
 
Key
 
Monitoring
 
Before
 
Starting
 
Therapy
 
1.
 
Serum
 
Potassium
:
 
<5
 
mmol/L
 
2.
 
eGFR
:
 
>30
 
mL/min/1.73
 
m²
 
 
If
 
Issues
 
Arise:
 
Hyperkalemia
 
or
 
Kidney
 
Function
 
Decline
:
 
●
 
Reduce
 
dose
 
or
 
switch
 
to
 
every-other-day
 
dosing.
 
●
 
Discontinue
 
if
 
serum
 
potassium
 
>5.5
 
mmol/L
 
despite
 
adjustments.
 
●
 
Investigate
 
other
 
causes
 
before
 
stopping
 
permanently
 
 
Hypertension
 
●
 
25-100mg/day
 
(once
 
daily
 
or
 
split
 
into
 
two
 
doses)
 
●
 
Doses
 
greater
 
than
 
100mg/day
 
do
 
not
 
provide
 
additional
 
reduction
 
in
 
blood
 
pressure
 
 
Heart
 
Failure
 
with
 
Preserved
 
Ejection
 
Fraction
 
(HFpEF)
 
Dosing:
 
●
 
Initial:
 
12.5
 
mg
 
once
 
daily
 
●
 
Adjustments:
 
Double
 
dose
 
every
 
2–4
 
weeks
 
if
 
stable,
 
up
 
to
 
50
 
mg/day
 
Conservative
 
Approach:
 
●
 
Start
 
or
 
increase
 
dose
 
only
 
if
 
potassium
 
≤4.7
 
mmol/L
 
 
Heart
 
Failure
 
with
 
Reduced
 
Ejection
 
Fraction
 
(HFrEF)
 
Dosing:
 
●
 
Tablet:
 
12.5–25
 
mg
 
once
 
daily.
 
Max:
 
50
 
mg/day
 
(can
 
divide
 
into
 
1–2
 
doses)
 
 
Titration:
 
●
 
Increase
 
dose
 
every
 
4
 
weeks
 
if
 
stable
 
 
Post-Myocardial
 
Infarction
 
(MI)
 
with
 
Reduced
 
Ejection
 
Fraction
 
(Off-label)
 
Dosing:
 
●
 
Tablet:
 
12.5–25
 
mg
 
once
 
daily.
 
Max:
 
50
 
mg/day
 
 
Note:
 
Regularly
 
monitor
 
serum
 
potassium
 
and
 
kidney
 
function
 
during
 
treatment.
 
 
 
 
 
Method
 
of
 
Administration*
 
Tablet:
 
Take
 
with
 
or
 
without
 
food,
 
but
 
stay
 
consistent
 
with
 
how
 
you
 
take
 
it.
 
 
 
 
Special
 
Considerations
 
Pregnancy
 
.
 
 
 
Spironolactone
 
crosses
 
the
 
placenta
 
and
 
may
 
cause
 
feminization
 
of
 
a
 
male
 
fetus.
 
High
 
doses
 
later
 
in
 
pregnancy
 
may
 
restrict
 
fetal
 
growth.
 
 
Chronic
 
hypertension
 
during
 
pregnancy
 
increases
 
risks
 
for
 
both
 
mother
 
and
 
baby ,
 
including
 
birth
 
defects,
 
low
 
birth
 
weight,
 
and
 
delivery
 
complications.
 
Spironolactone
 
is
 
not
 
recommended
 
for
 
 
 
 
343
 

=== PAGE 345 ===

 
treating
 
hypertension
 
or
 
heart
 
failure
 
in
 
pregnancy .
 
 
Patients
 
with
 
primary
 
aldosteronism
 
(PA)
 
should
 
stop
 
spironolactone
 
before
 
conception
 
or
 
during
 
the
 
first
 
trimester .
 
Alternative
 
treatments
 
are
 
recommended
 
if
 
PA
 
remains
 
uncontrolled.
 
 
Potassium-sparing
 
diuretics
 
like
 
spironolactone
 
have
 
been
 
used
 
in
 
rare
 
cases
 
to
 
treat
 
conditions
 
like
 
Gitelman
 
syndrome
 
during
 
pregnancy
 
Breastfeeding
 
 
 
 
Spironolactone’ s
 
active
 
metabolite,
 
canrenone,
 
is
 
present
 
in
 
breast
 
milk
 
but
 
at
 
very
 
low
 
levels
 
(~0.2%
 
of
 
the
 
maternal
 
dose).
 
 
Spironolactone
 
is
 
generally
 
considered
 
safe
 
for
 
breastfeeding.
 
However ,
 
the
 
decision
 
should
 
weigh
 
the
 
benefits
 
of
 
breastfeeding
 
against
 
potential
 
infant
 
exposure
 
and
 
the
 
mother ’s
 
need
 
for
 
treatment.
 
 
 
 
Elderly
 
 
 
 
STOPP/ST ART
 
Criteria:
 
 
1.
 
Avoid
 
spironolactone
 
if
 
eGFR
 
<
 
30
 
ml/min/1.73m2
 
(risk
 
of
 
dangerous
 
hyperkalaemia).
 
2.
 
Avoid
 
spironolactone
 
with
 
concurrent
 
potassium
 
conserving
 
drugs
 
(e.g.,
 
ACEI’ s,
 
ARB’ s,
 
amiloride,
 
triamterene)
 
without
 
monitoring
 
of
 
serum
 
potassium
 
(risk
 
of
 
dangerous
 
hyperkalaemia
 
i.e.,
 
>
 
6.0
 
mmol/l
 
–
 
serum
 
K
 
should
 
be
 
monitored
 
regularly ,
 
i.e.,
 
at
 
least
 
every
 
6
 
months)
 
 
 
 
Paediatric
 
 
 
 
Paediatric
 
dosing
 
is
 
based
 
on
 
experience
 
with
 
tablets
 
and
 
extemporaneously
 
compounded
 
suspension.
 
 
 
 
Fasting
 
 
 
 
NA
 
 
 
 
Others
 
 
 
 
Kidney
 
Impairment
 
(Adults)
 
General
 
Guidance:
 
●
 
Use
 
with
 
caution
 
and
 
monitor
 
potassium
 
closely .
 
●
 
Consider
 
low-potassium
 
diets
 
or
 
other
 
interventions
 
(e.g.,
 
loop
 
diuretics,
 
sodium
 
bicarbonate)
 
to
 
manage
 
risks.
 
Heart
 
Failure:
 
●
 
eGFR
 
>50
 
mL/min:
 
No
 
dosage
 
adjustment
 
needed.
 
●
 
eGFR
 
30–50
 
mL/min:
 
Start
 
with
 
12.5
 
mg
 
daily
 
or
 
every
 
other
 
day.
 
Increase
 
gradually
 
up
 
to
 
25
 
mg/day
 
if
 
potassium
 
remains
 
<5
 
mEq/L.
 
●
 
eGFR
 
<30
 
mL/min:
 
Not
 
recommended.
 
Liver
 
Impairment
 
(Adults)
 
General
 
Guidance:
 
●
 
No
 
dosage
 
adjustment
 
needed
 
for
 
liver
 
cirrhosis
 
(Child-T urcotte-Pugh
 
Class
 
A
 
to
 
C),
 
but
 
monitor
 
closely
 
due
 
to
 
slower
 
drug
 
elimination
 
in
 
liver
 
impairment.
 
●
 
Careful
 
dose
 
titration
 
is
 
necessary ,
 
especially
 
in
 
patients
 
with
 
ascites
 
and
 
cirrhosis,
 
as
 
aldosterone
 
levels
 
may
 
be
 
elevated.
 
 
 
 
344
 

=== PAGE 346 ===

 
Side
 
Effects
 
and
 
their
 
Management*
 
Adverse
 
Reactions
 
to
 
Spironolactone:
 
Key
 
Considerations
 
 
1.
 
Gynecomastia
 
(Breast
 
Enlargement)
 
a.
 
Description:
 
May
 
affect
 
one
 
or
 
both
 
breasts,
 
usually
 
reversible
 
upon
 
stopping
 
the
 
medication.
 
b.
 
Mechanism:
 
Related
 
to
 
decreased
 
androgen
 
activity
 
and
 
increased
 
estrogen
 
effects.
 
c.
 
Onset:
 
Delayed;
 
occurs
 
after
 
1–12+
 
months
 
of
 
therapy .
 
d.
 
Risk
 
Factors:
 
e.
 
Higher
 
doses
 
(≥150
 
mg/day)
 
f.
 
Longer
 
treatment
 
duration
 
g.
 
Alternative:
 
Consider
 
switching
 
to
 
eplerenone
 
(lower
 
risk
 
of
 
gynecomastia).
 
 
2.
 
Hyperkalemia
 
(High
 
Potassium
 
Levels)
 
a.
 
Description:
 
Can
 
lead
 
to
 
serious
 
complications,
 
including
 
hospitalization
 
or
 
death.
 
b.
 
Mechanism:
 
Inhibits
 
aldosterone,
 
reducing
 
potassium
 
excretion.
 
c.
 
Onset:
 
Intermediate;
 
typically
 
within
 
4
 
weeks
 
of
 
starting
 
or
 
adjusting
 
the
 
dose.
 
d.
 
Risk
 
Factors:
 
e.
 
Kidney
 
impairment
 
f.
 
Older
 
age
 
g.
 
Excessive
 
potassium
 
intake
 
(supplements,
 
salt
 
substitutes)
 
h.
 
Concurrent
 
use
 
of
 
medications
 
that
 
increase
 
potassium
 
(e.g.,
 
ACE
 
inhibitors,
 
ARBs,
 
NSAIDs)
 
i.
 
Heart
 
failure,
 
especially
 
with
 
diabetes
 
or
 
higher
 
baseline
 
potassium
 
levels
 
 
 
 
Storage*
 
1.
 
Store
 
below
 
30
o
c.
 
Keep
 
away
 
from
 
children.
 
 
2.
 
Protect
 
from
 
moisture
 
and
 
light
 
 
 
 
Others
 
1.
 
Interactions
 
Increasing
 
Risk
 
of
 
Hyperkalemia
 
–
 
Avoid
 
Combination
:
 
Potassium
 
salts,
 
other
 
potassium-sparing
 
diuretics
 
(e.g.,
 
eplerenone),
 
Tacrolimus
 
and
 
Cyclosporine,Drospirenone-containing
 
products,
 
Drospirenone-containing
 
products.
 
 
2.
 
Interactions
 
Requiring
 
Therapy
 
Monitoring
:
 
ACE
 
Inhibitors/ARBs,
 
NSAIDs
 
(e.g.,
 
ibuprofen),
 
Digoxin
 
and
 
other
 
cardiac
 
glycosides,
 
Lithium,
 
CYP3A4/CYP2C8
 
Substrates,
 
Trimethoprim,
 
Ciprofloxacin
 
 
3.
 
Interactions
 
Enhancing
 
Hypotensive
 
Effects
 
–
 
Use
 
Caution
:
 
Antihypertensive
 
agents
 
(e.g.,
 
ACE
 
inhibitors,
 
ARBs,
 
beta-blockers),
 
Alpha-blockers
 
(e.g.,
 
prazosin,
 
terazosin),
 
Phosphodiesterase-5
 
inhibitors
 
(e.g.,
 
sildenafil),
 
Opioids
 
and
 
barbiturates
 
 
4.
 
Interactions
 
That
 
May
 
Reduce
 
Therapeutic
 
Effect
 
of
 
Spironolactone
:
 
Aspirin
 
and
 
NSAIDs,Amphetamines
 
and
 
methylphenidate,
 
Fludrocortisone
 
5.
 
Food
 
increases
 
spironolactone’ s
 
bioavailability
 
by
 
90-95%,
 
enhancing
 
its
 
absorption
 
 
 
 
345
 

=== PAGE 347 ===

 
Before
 
ending
 
this
 
peer
 
review
 
session,
 
the
 
reviewee
 
should
 
be
 
informed
 
of
 
the
 
step(s)
 
that
 
he/
 
she
 
missed
 
out
 
in
 
order
 
to
 
ensure
 
all
 
the
 
counselling
 
points
 
are
 
being
 
covered.
 
 
Remarks:
 
 
 
 
 
Reviewed
 
by:
 
Name
 
&
 
Signature
                                                                   
Date:
 
 
 
 
 
*Mandatory
 
for
 
validation
 
/
 
peer
 
review
 
References:
 
 
1.
 
Formulari
 
Ubat
 
KKM.
 
(2025).
 
Accessed
 
on
 
January
 
20,
 
2025.
 
2.
 
Lexi-Comp,
 
I.
 
and
 
Lexicomp
 
(2013).
 
Drug
 
Information
 
Handbook:
 
A
 
Comprehensive
 
Resource
 
for
 
All
 
Clinicians
 
and
 
Healthcare
 
Professionals,
 
Lexi-Comp.
 
3.
 
 
UpToDate.
 
(2024)
 
UpToDate
 
(Version
 
3.70.4)
 
[Mobile
 
App]
 
Mobile
 
Clinical
 
Decision
 
Support
 
App
 
|
 
UpToDate
 
|
  
 
4.
 
O’Mahony ,
 
D.,
 
Cherubini,
 
A.,
 
Guiteras,
 
A.R.,
 
Denkinger ,
 
M.,
 
Beuscart,
 
J.B.,
 
Onder ,
 
G.,
 
et
 
al.
 
(2023).
 
STOPP/ST ART
 
criteria
 
for
 
potentially
 
inappropriate
 
prescribing
 
in
 
older
 
people:
 
version
 
3.
 
European
 
Geriatric
 
Medicine,
 
14(4),
 
625–632.
 
5.
 
Whelton,
 
P.K.,
 
Carey ,
 
R.M.,
 
Aronow ,
 
W.S.,
 
et
 
al.
 
(2018).
 
2017
 
ACC/AHA/AAP A/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA
 
guideline
 
for
 
the
 
prevention,
 
detection,
 
evaluation,
 
and
 
management
 
of
 
high
 
blood
 
pressure
 
in
 
adults:
 
a
 
report
 
of
 
the
 
American
 
College
 
of
 
Cardiology/American
 
Heart
 
Association
 
Task
 
Force
 
on
 
Clinical
 
Practice
 
Guidelines.
 
Hypertension,
 
71(6),
 
e13-e1 15.
 
doi:10.1 161/HYP .0000000000000065.
 
[PubMed
 
29133356]
 
6.
 
Brook
 
RD,
 
Townsend
 
RR.
 
Treatment
 
of
 
resistant
 
hypertension.
 
Post
 
TW,
 
ed.
 
UpToDate.
 
Waltham,
 
MA:
 
UpToDate
 
Inc.
 
http://www .uptodate.com.
 
Accessed
 
December
 
8,
 
2020.
 
7.
 
Mann
 
JFE,
 
Flack
 
JM.
 
Choice
 
of
 
drug
 
therapy
 
in
 
primary
 
(essential)
 
hypertension.
 
Post
 
TW,
 
ed.
 
UpToDate.
 
Waltham,
 
MA:
 
UpToDate
 
Inc.
 
http://www .uptodate.com.
 
Accessed
 
March
 
7,
 
2023
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
346
 

=== PAGE 348 ===

 
Statin
 
 
Name
 
:
 
 
Unit
 
:
 
 
●
 
Please
 
tick
 
(
✔
)
 
Yes
 
for
 
correct
 
instruction.
 
●
 
Please
 
tick
 
(
✔
)
 
No
 
for
 
incorrect
 
instruction.
 
Yes
 
No
 
Remarks
 
Pharmacological
 
Group
 
Antihyperlipidemic
 
(HMG
 
–
 
COA
 
reductase
 
inhibitor
 
)
 
 
 
 
 
Indications
 
and
 
Dosage
 
●
 
Simvastatin
 
Indication:
 
1.
 
Hypercholesterolaemia
 
2.
 
Prevention
 
of
 
cardiovascular
 
disease
 
Dosage:
 
10
 
-
 
40
 
mg
 
once
 
daily.
 
Maximum:
 
80
 
mg
 
daily
 
 
●
 
Atorvastatin
 
Indication:
 
1.
 
Hypercholesterolaemia
 
2.
 
Prevention
 
of
 
cardiovascular
 
disease
 
Dosage:
 
10
 
mg
 
once
 
daily.
 
Maximum:
 
80
 
mg
 
daily
 
 
●
 
Pravastatin
 
Indication:
 
Hypercholesterolaemia
 
and
 
coronary
 
heart
 
disease
 
intolerant
 
or
 
not
 
responsive
 
to
 
other
 
forms
 
of
 
therapy .
 
In
 
health
 
clinics,
 
Pravastatin
 
is
 
restricted
 
to
 
HIV
 
patients
 
on
 
HAAR T.
 
Dosage:
 
10
 
-
 
20
 
mg
 
once
 
daily.
 
Maximum:
 
40
 
mg
 
daily.
 
 
●
 
Rosuvastatin:
 
 
Indication:
 
Dyslipidaemia
 
not
 
responsive
 
to
 
atorvastatin
 
40mg
 
or
 
equivalent
 
doses
 
of
 
other
 
statins
 
Dosage:
 
Initially
 
5-10
 
mg
 
once
 
daily
 
(5mg
 
in
 
patients
 
with
 
pre-disposing
 
factors
 
to
 
myopathy),
 
increased
 
if
 
necessary
 
at
 
intervals
 
of
 
at
 
least
 
4
 
weeks
 
to
 
20
 
mg
 
once
 
daily,
 
increased
 
after
 
further
 
4
 
weeks
 
to
 
40
 
mg
 
daily
 
ONLY
 
in
 
severe
 
hypercholesterolemia
 
with
 
high
 
cardiovascular
 
risk.
 
 
Or
 
 
To
 
counsel
 
based
 
on
 
specific
 
medication’ s
 
indication
 
and
 
dosage
 
as
 
prescribed
 
by
 
the
 
doctor
 
 
 
 
Method
 
of
 
Administration*
 
1.
 
Simvastatin:
 
Take
 
in
 
the
 
evening.
 
2.
 
Atorvastatin:
 
Any
 
time
 
of
 
the
 
day
 
with
 
or
 
without
 
food.
 
3.
 
Pravastatin:
 
 
a.
 
Any
 
time
 
of
 
the
 
day
 
with
 
or
 
without
 
food
 
 
b.
 
To
 
take
 
at
 
least
 
1
 
hour
 
before
 
or
 
4
 
hours
 
after
 
bile
 
acid
 
sequestrant.
 
4.
 
Rosuvastatin:
 
a.
 
Any
 
time
 
of
 
the
 
day
 
with
 
or
 
without
 
food
 
b.
 
Administer
 
at
 
least
 
2
 
hours
 
before
 
antacid
 
containing
 
both
 
aluminium
 
and
 
magnesium
 
 
Do
 
not
 
stop
 
taking
 
your
 
medication
 
unless
 
advised
 
to
 
do
 
so
 
by
 
your
 
prescriber .
 
 
 
 
Special
 
Considerations
 
Pregnancy
 
 
 
 
Avoid,
 
can
 
cause
 
fetal
 
harm
 
 
 
 
347
 

=== PAGE 349 ===

 
Breastfeeding
 
 
 
 
Avoid
 
breastfeeding.
 
 
 
 
Elderly
 
 
 
 
STOPP/ST ART
 
Criteria:
 
Avoid
 
using
 
statins
 
for
 
primary
 
cardiovascular
 
prevention
 
in
 
persons
 
aged
 
≥
 
85
 
and
 
established
 
frailty
 
with
 
expected
 
life
 
expectancy
 
likely
 
less
 
than
 
3
 
years
 
(lack
 
of
 
evidence
 
of
 
efficacy).
 
 
 
 
Paediatric
 
 
 
 
Safety
 
and
 
effectiveness
  
in
 
children
 
below
 
10
 
years
 
old
 
have
 
not
 
been
 
established
 
except
 
for
 
Rosuvastatin
 
can
 
be
 
used
 
in
 
children
 
7
 
years
 
and
 
above
 
as
 
well
 
as
 
Pravastatin
 
in
 
children
 
8
 
years
 
and
 
above.
 
 
 
 
Fasting
 
 
 
 
To
 
refer
 
to
 
the
 
latest
 
advisory
 
by
 
religious
 
authority
 
 
 
 
Renal
 
impairment
 
 
 
 
1.
 
Simvastatin
 
a.
 
Mild
 
to
 
moderate
 
:
 
No
 
dose
 
adjustment
 
b.
 
Severe
 
(CrCl
 
<
 
30ml/min),
 
dosage
 
above
 
10mg/day
 
should
 
be
 
carefully
 
considered
 
c.
 
 
2.
 
Atorvastatin:
 
No
 
dosage
 
adjustment
 
 
a.
 
 
3.
 
Pravastatin:
 
No
 
dosage
 
adjustment
 
 
4.
 
Rosuvastatin
 
 
-
 
Mild
 
to
 
moderate:
 
No
 
dosage
 
adjustment
 
-
 
Severe
 
(CrCl
 
<
 
30ml/min)
 
5-10mg
 
OD
 
 
 
 
Hepatic
 
impairment
 
 
 
 
 
Dosing
 
in
 
hepatic
 
impairment
 
differs
 
according
 
to
 
statin
 
type.
 
 
 
 
Side
 
Effects
 
and
 
their
 
Management*
 
1.
 
Elevated
 
serum
 
transaminases
 
and
 
hepatoxicity
 
a.
 
Patients
 
who
 
developed
 
elevated
 
transaminase
 
levels
 
should
 
be
 
monitored
 
until
 
abnormality
 
resolves.
 
b.
 
Withdrawal
 
of
 
treatment
 
is
 
recommended
 
if
 
there
 
is
 
persistent
 
increase
 
in
 
serum
 
transaminases
 
more
 
than
 
3
 
times
 
upper
 
limit
 
of
 
normal.
 
 
2.
 
Muscle-
 
related
 
effect
 
(myalgia,
 
myopathy ,
 
rhabdomyolysis)
 
 
a.
 
Patient
 
should
 
be
 
advised
 
of
 
myopathy
 
risk,
 
and
 
rhabdomyolysis
 
and
 
to
 
report
 
any
 
unexplained
 
muscle
 
pain,
 
tenderness,
 
or
 
weakness
 
 
b.
 
Discontinued
 
immediately
 
in
 
patients
 
with
 
rhabdomyolysis
 
 
3.
 
Gastrointestinal
 
(constipation,
 
nausea,
 
dyspepsia,
 
diarrhea)
 
 
 
 
Storage*
 
Store
 
at
 
room
 
temperature
 
 
 
 
348
 

=== PAGE 350 ===

 
Others
 
1.
 
Avoid
 
grapefruit
 
juice.
 
2.
 
Use
 
of
 
gemfibrozil
 
should
 
be
 
avoided
 
in
 
combination
 
with
 
pravastatin
 
or
 
simvastatin.
 
 
3.
 
Patients
 
on
 
higher
 
doses
 
of
 
atorvastatin
 
may
 
be
 
at
 
increased
 
risk
 
of
 
digoxin
 
toxicity;
 
close
 
monitoring
 
of
 
digoxin
 
toxicity
 
is
 
recommended.
 
4.
 
Strong
 
CYP3A4
 
inhibitors
 
are
 
contraindicated
 
with
 
use
 
of
 
simvastatin.
 
 
 
 
Before
 
ending
 
this
 
peer
 
review
 
session,
 
the
 
reviewee
 
should
 
be
 
informed
 
of
 
the
 
step(s)
 
that
 
he/
 
she
 
missed
 
out
 
in
 
order
 
to
 
ensure
 
all
 
the
 
counselling
 
points
 
are
 
being
 
covered.
 
 
Remarks:
 
 
 
 
 
Reviewed
 
by:
 
Name
 
&
 
Signature
                                                                   
Date:
 
 
 
 
 
*Mandatory
 
for
 
validation
 
/
 
peer
 
review
 
References:
 
 
1.
 
Formulari
 
Ubat
 
KKM.
 
(2025,
 
January
 
1).
 
Accessed
 
on
 
January
 
21,
 
2025.
 
2.
 
Ranbaxy
 
(Malaysia)
 
Sdn.
 
Bhd.
 
(2020).
 
Product
 
information
 
leaflet:
 
SIMVOR.
 
Retrieved
 
from
 
Quest
 
3+
 
Product
 
Search
 
on
 
January
 
21,
 
2025.
 
3.
 
Ranbaxy
 
(Malaysia)
 
Sdn.
 
Bhd.
 
(2024).
 
Product
 
information
 
leaflet:
 
STORVAS.
 
Retrieved
 
from
 
Quest
 
3+
 
Product
 
Search
 
on
 
January
 
21,
 
2025.
 
4.
 
Hovid
 
Bhd
 
(2024).
 
Product
 
information
 
leaflet:
 
Rosuvid.
 
Retrieved
 
from
 
Quest
 
3+
 
Product
 
Search
 
on
 
January
 
21,
 
2025.
 
5.
 
Intas
 
Pharm
 
Ltd
 
(2022).
 
Product
 
information
 
leaflet:
 
PRAVATAS.
 
Retrieved
 
from
 
Quest
 
3+
 
Product
 
Search
 
on
 
January
 
21,
 
2025.
 
6.
 
Wiggins,
 
B.
 
S.,
 
Saseen,
 
J.
 
J.,
 
Page,
 
R.
 
L.,
 
Reed,
 
B.
 
N.,
 
Sneed,
 
K.,
 
Kostis,
 
J.
 
B.,
 
...
 
&
 
Morris,
 
P.
 
B.
 
(2016).
 
Recommendations
 
for
 
management
 
of
 
clinically
 
significant
 
drug-drug
 
interactions
 
with
 
statins
 
and
 
select
 
agents
 
used
 
in
 
patients
 
with
 
cardiovascular
 
disease:
 
a
 
scientific
 
statement
 
from
 
the
 
American
 
Heart
 
Association.
 
Circulation,
 
134(21),
 
e468-e495.
 
7.
 
O’Mahony ,
 
D.,
 
Cherubini,
 
A.,
 
Guiteras,
 
A.
 
R.,
 
Denkinger ,
 
M.,
 
Beuscart,
 
J.
 
B.,
 
Onder ,
 
G.,
 
...
 
&
 
Curtin,
 
D.
 
(2023).
 
STOPP/ST ART
 
criteria
 
for
 
potentially
 
inappropriate
 
prescribing
 
in
 
older
 
people:
 
version
 
3.
 
European
 
geriatric
 
medicine,
 
14(4),
 
625-632.
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
349
 

=== PAGE 351 ===

 
Sulphur
 
in
 
calamine/
 
petrolatum
 
 
 
350
 
Name
 
:
 
 
Unit
 
:
 
 
●
 
Please
 
tick
 
(
✔
)
 
Yes
 
for
 
correct
 
instruction.
 
●
 
Please
 
tick
 
(
✔
)
 
No
 
for
 
incorrect
 
instruction.
 
Yes
 
No
 
Remarks
 
Pharmacological
 
Group
 
Parasiticidal
 
 
 
 
Indications
 
and
 
Dosage
 
1.
 
1st
 
line
 
treatment
 
of
 
scabies
 
for
 
infants
 
<2months
 
old
 
2.
 
2nd
 
line
 
treatment
 
of
 
scabies
 
for
 
infants
 
<2yo
 
and
 
pregnant
 
woman
 
 
To
 
counsel
 
based
 
on
 
specific
 
medication’ s
 
indication
 
and
 
dosage
 
as
 
prescribed
 
by
 
the
 
doctor
 
 
 
 
Method
 
of
 
Administration*
 
1.
 
Rinse
 
off
 
after
 
24
 
hours
 
and
 
then
 
reapply
 
every
 
day
 
for
 
the
 
next
 
3
 
days
 
(with
 
a
 
bath
 
taken
 
in
 
between
 
each
 
application).
 
2.
 
Treat
 
the
 
whole
 
body
 
including
 
the
 
face
 
(avoid
 
eyes
 
and
 
mouth).
 
 
 
Missed
 
dose
 
management
:
 
If
 
a
 
dose
 
is
 
missed,
 
use
 
it
 
as
 
soon
 
as
 
possible.
 
If
 
it
 
is
 
almost
 
time
 
for
 
the
 
next
 
dose,
 
use
 
only
 
that
 
dose.
 
Do
 
not
 
use
 
double
 
or
 
extra
 
doses.
 
 
Do
 
not
 
stop
 
your
 
medication
 
unless
 
advised
 
to
 
do
 
so
 
by
 
your
 
prescriber
 
 
 
 
Special
 
Considerations
 
Pregnancy
 
 
 
 
Safe
 
for
 
pregnant
 
women.
 
 
 
 
Breastfeeding
 
 
 
 
Safe
 
for
 
breastfeeding
 
women.
 
 
 
 
Elderly
 
 
 
 
None
 
specifically
 
to
 
the
 
product.
 
 
 
 
Paediatric
 
 
 
 
Safe
 
for
 
infants.
 
 
 
 
Fasting
 
 
 
 
N/A
 
 
 
 
Others
  
 
 
 
 
N/A
 
 
 
 
Side
 
Effects
 
and
 
their
 
Management*
 
Skin
 
Irritation.
 
 
 
 
Storage*
 
1.
 
Store
 
at
 
room
 
temperature
 
below
 
25C.
 
2.
 
Discard
 
any
 
unused
 
medicine
 
after
 
the
 
expired
 
date.
 
 
 
 

=== PAGE 352 ===

 
*Mandatory
 
for
 
validation
 
/
 
peer
 
review
 
 
References:
 
 
1.
 
Vasanwala,
 
F.
 
F.,
 
Ong,
 
C.
 
Y.,
 
Aw,
 
C.
 
W.
 
D.,
 
&
 
How,
 
C.
 
H.
 
(2019).
 
Management
 
of
 
scabies.
 
Singapore
 
medical
 
journal,
 
60(6),
 
281.
 
 
2.
 
Ismail,
 
H.I.H.M.,
 
Ibrahim,
 
H.M.,
 
Ng,
 
H.P.,
 
Kesihatan,
 
M.K.
 
and
 
Thomas,
 
T.
 
(2019)
 
Paediatric
 
Protocols
 
for
 
Malaysian
 
Hospitals.
 
4th
 
Edition,
 
Ministry
 
of
 
Health,
 
Putrajaya.
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
351
 
Others
 
1.
 
Patients
 
with
 
scabies
 
and
 
their
 
close
 
physical
 
contacts,
 
even
 
without
 
symptoms,
 
should
 
receive
 
treatment
 
at
 
the
 
same
 
time.
 
 
2.
 
Wash
 
clothing
 
and
 
bedding
 
in
 
hot
 
water
 
or
 
by
 
dry
 
cleaning.
 
Clothing
 
that
 
cannot
 
be
 
washed
 
may
 
be
 
stored
 
in
 
a
 
sealed
 
plastic
 
bag
 
for
 
three
 
days.
 
3.
 
If
 
the
 
treatment
 
is
 
applied
 
by
 
someone
 
without
 
scabies,
 
this
 
person
 
should
 
wear
 
medical
 
gloves
 
during
 
application.
 
4.
 
After
 
completion
 
of
 
treatment,
 
patients
 
should
 
use
 
fresh,
 
clean
 
bedding
 
and
 
clothing.
 
 
5.
 
To
 
prevent
 
re-infestation,
 
put
 
freshly
 
washed
 
or
 
dry-cleaned
 
clothing
 
and
 
change
 
bedding.
 
 
 
 
Before
 
ending
 
this
 
peer
 
review
 
session,
 
the
 
reviewee
 
should
 
be
 
informed
 
of
 
the
 
step(s)
 
that
 
he/
 
she
 
missed
 
out
 
in
 
order
 
to
 
ensure
 
all
 
the
 
counselling
 
points
 
are
 
being
 
covered.
 
 
Remarks:
 
 
 
 
 
Reviewed
 
by:
 
Name
 
&
 
Signature
                                                                   
Date:
 
 
 
 
 

=== PAGE 353 ===

 
Tacrolimus
 
Name
 
:
 
 
Unit
 
:
 
 
●
 
Please
 
tick
 
(
✔
)
 
Yes
 
for
 
correct
 
instruction.
 
●
 
Please
 
tick
 
(
✔
)
 
No
 
for
 
incorrect
 
instruction.
 
Yes
 
No
 
Remarks
 
Pharmacological
 
Group
 
Calcineurin
 
inhibitors
 
 
 
 
 
Indications
 
and
 
Dosage
 
1.
 
Primary
 
immunosuppression
 
in
 
liver
 
and
 
kidney
 
allograft
 
recipients
 
2.
 
Liver
 
and
 
kidney
 
allograft
 
rejection
 
resistant
 
to
 
conventional
 
immunosuppressive
 
agents.
 
 
Available
 
in
 
two
 
formulations:
 
i)
 
Tacrolimus
 
immediate
 
release
 
(IR)
 
-
 
Prograf
 
®
 
ii)
 
Tacrolimus
 
prolonged
 
release
 
(PR)
 
-
 
Advagraf
 
®
 
●
 
Both
 
are
 
in
 
capsule
 
form
 
available
 
in
 
three
 
strength:
 
 
 
0.5mg,
 
1mg
 
and
 
5mg
 
●
 
 
Both
 
are
 
NOT
 
interchangeable.
                                    
:
 
(WARNING:
 
These
 
two
 
formulations
 
are
 
at
 
risk
 
of
 
medication
 
errors)
 
 
      
Dose
 
is
 
adjusted
 
based
 
on
 
therapeutic
 
drug
 
monitoring.
 
 
 
To
 
counsel
 
based
 
on
 
specific
 
medication’ s
 
indication
 
and
 
dosage
 
as
 
prescribed
 
by
 
the
 
doctor
 
 
 
 
 
Method
 
of
 
Administration*
 
1.
 
Tacrolimus
 
IR:
 
To
 
be
 
swallowed
 
whole
 
twice
 
daily,
 
12
 
hours
 
apart.
 
 
2.
 
Tacrolimus
 
PR:
 
To
 
be
 
swallowed
 
whole
 
once
 
daily
 
in
 
the
 
morning.
 
3.
 
Both
 
must
 
be
 
taken
 
at
 
the
 
same
 
time
 
every
 
day
 
on
 
an empty
 
stomach
 
(1
 
hour
 
before
 
or
 
2
 
hours
 
after
 
a
 
meal)
 
for
 
the best
 
absorption.
 
 
4.
 
Do
 
not
 
chew ,
 
crush
 
or
 
open
 
the
 
capsule.
 
5.
 
Capsules
 
should
 
be
 
taken
 
immediately
 
following
 
removal
 
from
 
the
 
blister .
 
 
6.
 
To
 
ensure
 
the
 
accuracy
 
of
 
tacrolimus
 
levels,
 
it
 
is
 
important
 
to
 
take
 
the
 
tacrolimus
 
after
 
the
 
blood
 
is
 
drawn
 
for
 
therapeutic
 
drug
 
monitoring.
 
 
Missed
 
dose
 
management:
 
1.
 
If
 
an
 
immediate
 
release
 
tacrolimus
 
dose
 
is
 
missed,
 
patients
 
should
 
take
 
it
 
as
 
soon
 
as
 
possible,
 
ideally
 
within
 
four
 
hours.
 
 
2.
 
If
 
a prolonged-release
 
tacrolimus
 
dose
 
is
 
missed,
 
the patient
 
should
 
take
 
it
 
as
 
soon
 
as
 
possible
 
within
 
14-15
 
hours.
 
3.
 
Do
 
not
 
double
 
a
 
dose
 
under
 
any
 
circumstances
 
 
Do
 
not
 
stop
 
taking
 
your
 
medication
 
unless
 
advised
 
to
 
do
 
so
 
by
 
your
 
prescriber
 
 
 
 
 
 
Special
 
Considerations
 
Pregnancy
 
 
 
 
1.
 
Tacrolimus
 
can
 
cross
 
the
 
placenta,
 
causing
 
risks
 
to
 
infants,
 
including
 
prematurity ,
 
birth
 
defects,
 
low
 
birth
 
weight,
 
and
 
fetal
 
distress.It
 
may
 
still
 
be
 
used
 
in
 
pregnant
 
women
 
if
 
there
 
are
 
no
 
safer
 
options
 
available
 
and
 
if
 
the
 
benefits
 
outweigh
 
the
 
potential
 
risks
 
to
 
the
 
fetus.
 
2.
 
To
 
inform
 
specialist
 
if
 
you
 
want
 
to
 
get
 
pregnant
 
/
 
 
 
 
352
 

=== PAGE 354 ===

 
pregnant
 
 
Breastfeeding
 
 
 
 
Excreted
 
into
 
breast
 
milk,
 
and
 
breastfeeding
 
is
 
not
 
recommended.
 
 
 
 
Elderly
 
 
 
 
Dose
 
selection
 
for
 
an
 
elderly
 
patient
 
should
 
be
 
cautious,
 
usually
 
starting
 
at
 
the
 
low
 
end
 
of
 
the
 
dosing
 
range.
 
 
 
 
Paediatric
 
 
 
 
Younger
 
children
 
generally
 
require
 
higher
 
maintenance
 
doses
 
on
 
a
 
mg/kg
 
basis
 
than
 
older
 
children,
 
adolescents,
 
or
 
adults.
 
 
 
 
Fasting
 
 
 
 
1.
 
Transplant
 
patients
 
should
 
consult
 
with
 
transplant
 
specialists
 
to
 
assess
 
their
 
conditions
 
and
 
determine
 
whether
 
fasting
 
is
 
safe
 
for
 
them.
 
2.
 
If
 
fasting
 
is
 
permissible,tacrolimus
 
can
 
be
 
taken
 
on
 
an
 
empty
 
stomach
 
during
 
Sahur
 
and
 
Iftar.
 
It's
 
important
 
to
 
stay
 
hydrated
 
throughout
 
the
 
night.
 
If
 
you
 
miss
 
a
 
dose
 
during
 
Sahur ,
 
you
 
must
 
break
 
your
 
fast
 
that
 
day
 
to
 
take
 
the
 
missed
 
dose.
 
 
 
 
Others
  
 
 
 
 
Severe
 
liver
 
impairment
 
(Child-Pugh
 
class
 
C):
 
Lower
 
 
initial
 
doses
 
may
 
be
 
required
 
(due
 
to
 
reduced
 
clearance
 
and
 
increased
 
half-life).
 
 
 
 
Side
 
Effects
 
and
 
their
 
Management*
 
1.
 
Mild
 
tremor
 
is
 
common.
 
2.
 
Increased
 
risk
 
of
 
infection.
 
Seek
 
healthcare
 
advice
 
if
 
have
 
any
 
symptoms
 
of
 
infections
 
such
 
as
 
fever ,
 
chills,
 
or flu-like
 
symptoms.
 
 
3.
 
Metabolic
 
abnormalities:
 
diabetes
 
mellitus,
 
hyperlipidaemia,
 
hyperkalaemia,
 
hypomagnesemia
 
4.
 
Hypertension
 
5.
 
Nephrotoxicity
 
6.
 
Increased
 
risk
 
of
 
squamous
 
cell
 
skin
 
cancer ,
 
therefore
 
exposure
 
to
 
sunlight
 
and
 
UV
 
light
 
should
 
be
 
limited
 
by
 
wearing
 
clothing
 
and
 
using
 
a
 
broad-spectrum
 
with
 
a
 
sun
 
protection
 
factor
 
(SPF)
 
of
 
30
 
or
 
higher
 
are
 
recommended
 
when
 
performing
 
outdoor
 
activities.
 
 
 
 
Storage*
 
1.
 
Store
 
at
 
room
 
temperature.
 
 
2.
 
Prograf
 
®
 
:
 
After
 
opening
 
the
 
outer
 
aluminium
 
wrapper
 
containing
 
the
 
blisters
 
inside
 
the
 
box,
 
the
 
capsules
 
remain
 
stable
 
for
 
3
 
months.
 
3.
 
Advagraf
 
®
:After
 
opening
 
the
 
outer
 
aluminium
 
wrapper
 
containing
 
the
 
blisters
 
inside
 
the
 
box,
 
the
 
capsules
 
remain
 
stable
 
for
 
1
 
year.
 
4.
 
The
 
capsules
 
should
 
remain
 
in
 
the
 
blister
 
when
 
kept
 
in
 
the
 
pillbox.
 
 
 
 
 
Others
 
1.
 
Avoid
 
live
 
and
 
live-attenuated
 
vaccination.
 
 
2.
 
Inhibitors
 
or
 
inducers
 
of
 
CYP3A4
 
should
 
only
 
be
 
co-administered
 
with
 
tacrolimus
 
after
 
consulting
 
a
 
transplant
 
specialist,
 
due
 
to
 
the
 
potential
 
for
 
drug
 
interactions
 
resulting
 
in
 
rejection
 
or
 
toxicity .
 
 
3.
 
Concomitant
 
use
 
with
 
strong
 
CYP3A4
 
inhibitors
 
such
 
as
 
ritonavir ,
 
ketoconazole,
 
itraconazole,
 
voriconazole,
 
 
 
 
353
 

=== PAGE 355 ===

 
clarithromycin
 
may
 
increase
 
tacrolimus
 
level
 
and
 
the
 
risk
 
of
 
serious
 
adverse
 
reactions
 
(e.g.
 
nephrotoxicity ,
 
neurotoxicity ,
 
QT
 
prolongation).
 
Dose
 
adjustment
 
needs
 
to
 
be
 
based
 
upon
 
the
 
individual
 
situation
 
upon
 
treatment
 
initiation
 
and
 
discontinuation
 
by
 
the
 
transplant
 
specialist.
 
 
4.
 
Concomitant
 
use
 
with
 
strong
 
CYP3A4
 
inducers
 
such
 
as
 
rifampicin,
 
phenytoin,
 
carbamazepine
 
may
 
decrease
 
tacrolimus
 
level,
 
potentially
 
increasing
 
the
 
risk
 
of
 
rejection.
 
Dose
 
adjustment
 
needs
 
to
 
be
 
based
 
upon
 
the
 
individual
 
situation
 
upon
 
treatment
 
initiation
 
and
 
discontinuation
 
by
 
the
 
transplant
 
specialist.
 
 
5.
 
Avoid
 
the
 
fruit
 
and
 
juice
 
of
 
grapefruit,
 
pomelo
 
and
 
pomegranate
 
as
 
it
 
may
 
increase
 
the
 
tacrolimus
 
level.
 
Before
 
ending
 
this
 
peer
 
review
 
session,
 
the
 
reviewee
 
should
 
be
 
informed
 
of
 
the
 
step(s)
 
that
 
he/
 
she
 
missed
 
out
 
in
 
order
 
to
 
ensure
 
all
 
the
 
counselling
 
points
 
are
 
being
 
covered.
 
 
Remarks:
 
 
 
 
 
 
Reviewed
 
by:
 
Name
 
&
 
Signature
                                                                   
Date:
 
 
 
 
 
*Mandatory
 
for
 
validation
 
/
 
peer
 
review
 
References:
 
 
1.
 
Formulari
 
Ubat
 
KKM.
 
(2025,
 
January
 
1).
 
Accessed
 
on
 
January
 
1,
 
2025.
 
2.
 
Astellas
 
Ireland
 
Co.,
 
Ltd
 
(2024).
 
Product
 
information
 
leaflet:
 
Prograf.
 
Retrieved
 
from
 
Quest
 
3+
 
Product
 
Search
 
on
 
January
 
1,
 
2025.
 
3.
 
Astellas
 
Ireland
 
Co.,
 
Ltd
 
(2022).
 
Product
 
information
 
leaflet:
 
Advagraf.
 
Retrieved
 
from
 
Quest
 
3+
 
Product
 
Search
 
on
 
January
 
1,
 
2025.
 
4.
 
UpToDate.
 
(2024).
 
Pharmacology
 
of
 
calcineurin
 
inhibitors:
 
Dose
 
and
 
administratio
n
.
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
354
 

=== PAGE 356 ===

 
Tar,
 
Topical
 
Name
 
:
 
 
Unit
 
:
 
 
●
 
Please
 
tick
 
(
✔
)
 
Yes
 
for
 
correct
 
instruction.
 
●
 
Please
 
tick
 
(
✔
)
 
No
 
for
 
incorrect
 
instruction.
 
Yes
 
No
 
Remarks
 
Pharmacological
 
Group
 
Antipsoriatics
 
for
 
topical
 
use
 
 
 
 
Indications
 
and
 
Dosage
 
 
1.
 
Eczema
 
and
 
Psoriasis
 
2.
 
Seborrheic
 
Dermatitis
 
Dosage:
 
Apply
 
sparingly
 
to
 
the
 
affected
 
area
 
as
 
required
 
or
 
as
 
directed
 
by
 
your
 
pharmacist
 
or
 
doctor .
 
 
 
 
Method
 
of
 
Administration*
 
1.
 
Coal
 
tar
 
and
 
salicylic
 
acid
 
shampoo
 
(Sebitar
 
shampoo)
 
a.
 
Use
 
it
 
2-3
 
times
 
a
 
week.
 
b.
 
Wet
 
hair,
 
apply
 
to
 
the
 
affected
 
area
 
&
 
massage
 
well.
 
 
c.
 
Apply
 
for
 
5
 
minutes
 
then
 
wash
 
off.
 
d.
 
Do
 
not
 
scratch
 
the
 
scalp
 
as
 
it
 
will
 
worsen
 
the
 
psoriasis.
 
2.
 
Liquor
 
Picis
 
Carbonis
 
3%
 
or
 
6%
 
in
 
Ung
 
Emulsificans
 
a.
 
Start
 
with
 
coal
 
tar
 
in
 
vaseline
 
1%
 
and
 
slowly
 
titrate
 
to
 
higher
 
strength
 
if
 
needed.
 
b.
 
Test
 
dose:
 
To
 
apply
 
onto
 
the
 
affected
 
area
 
(small
 
amount).
 
If
 
a
 
patient
 
experienced
 
irritation
 
with
 
LPC,
 
please
 
ask
 
the
 
patient
 
to
 
see
 
a
 
doctor
 
immediately .
 
c.
 
Usually
 
apply
 
at
 
night
 
due
 
to
 
the
 
unpleasant
 
smell.
 
3.
 
Coal
 
tar
 
solution
 
20%
 
a.
 
1
 
cap
 
(15
 
ml)
 
added
 
to
 
10L
 
of
 
water
 
in
 
a
 
pail.
 
b.
 
Soak
 
diluted
 
solution
 
for
 
20
 
minutes.
 
c.
 
Do
 
not
 
rinse
 
again
 
with
 
tap
 
water .
 
4.
 
Ung
 
Cocois
 
Co
 
a.
 
Separate
 
hair-Part
 
your
 
hair
 
to
 
expose
 
the
 
scalp
 
for
 
easy
 
application.
 
b.
 
Apply
 
directly
 
to
 
scalp
 
areas
 
where
 
raised
 
plaques
 
are
 
noticeable.
 
c.
 
Preferably
 
to
 
be
 
applied
 
at
 
night.
 
d.
 
Use
 
a
 
towel
 
or
 
shower
 
cap
 
to
 
wrap
 
the
 
scalp.
 
e.
 
Cover
 
the
 
pillow
 
with
 
a
 
towel
 
to
 
prevent
 
stains.
 
f.
 
Shampoo
 
off
 
the
 
next
 
morning.
 
g.
 
Apply
 
on
 
the
 
scalp,
 
wash
 
off
 
after
 
1
 
hour
 
(for
 
Cera
 
scalp
 
only)
 
Do
 
not
 
stop
 
taking
 
your
 
medication
 
unless
 
advised
 
to
 
do
 
so
 
by
 
your
 
prescriber
 
 
 
 
Special
 
Considerations
 
Pregnancy
 
 
 
 
1.
 
Short-term
 
use
 
of
 
topical
 
coal
 
tar
 
is
 
probably
 
safe
 
in
 
the
 
second
 
and
 
third
 
trimester
 
of
 
pregnancy .
 
2.
 
As
 
a
 
precaution,
 
coal
 
tar
 
is
 
often
 
avoided
 
in
 
the
 
first
 
trimester
 
of
 
pregnancy .
 
 
 
 
Breastfeeding
 
 
 
 
Do
 
not
 
apply
 
to
 
the
 
breast
 
and
 
areas
 
of
 
skin
 
that
 
the
 
infant
 
may
 
come
 
in
 
contact
 
with
 
or
 
suck
 
on.
 
Extreme
 
care
 
should
 
be
 
taken
 
to
 
avoid
 
contact
 
with
 
the
 
mother's
 
skin
 
during
 
treatment
 
or
 
a
 
safer
 
alternative
 
should
 
be
 
chosen.
 
 
 
 
355
 

=== PAGE 357 ===

 
Elderly
 
 
 
 
NA
 
 
 
 
Paediatric
 
 
 
 
1.
 
Safety
 
and
 
efficacy
 
of
 
tar
 
preparations
 
are
 
established
 
in
 
pediatric
 
patients.
 
Follow
 
the
 
specific
 
instructed
 
duration
 
and
 
need
 
for
 
different
 
potencies.
 
2.
 
Safety
 
and
 
efficacy
 
of
 
topical
 
salicylic
 
acid
 
preparations
  
in
 
pediatric
 
patients
 
below
 
the
 
age
 
of
 
2
 
years
 
have
 
not
 
been
 
established.
 
 
 
 
Fasting
 
 
 
 
To
 
refer
 
to
 
the
 
latest
 
advisory
 
by
 
religious
 
authority
 
 
 
 
Others
  
 
 
 
 
NA
 
 
 
 
Side
 
Effects
 
and
 
their
 
Management*
 
1.
 
May
 
cause
 
staining,
 
skin
 
irritation,
 
photosensitivity
 
or
 
folliculitis.
 
2.
 
Avoid
 
applying
 
to
 
open
 
wounds.
 
 
 
 
Storage*
 
1.
 
Keep
 
the
 
jar
 
tightly
 
closed.
 
 
2.
 
Store
 
below
 
30°C
 
 
3.
 
Protect
 
from
 
heat,
 
moisture,
 
and
 
light.
 
 
4.
 
Do
 
not
 
freeze.
 
 
5.
 
Keep
 
out
 
of
 
reach
 
of
 
children.
 
 
 
 
 
Others
 
1.
 
For
 
topical
 
use
 
only.
 
2.
 
Avoid
 
contact
 
with
 
eyes.
 
3.
 
Avoid
 
inflamed
 
or
 
broken
 
skin.
 
4.
 
Do
 
not
 
apply
 
on
 
body-folds,
 
genital
 
or
 
rectal
 
areas.
 
5.
 
Avoid
 
exposure
 
to
 
sunlight
 
for
 
at
 
least
 
24
 
hours.
 
6.
 
Keep
 
away
 
from
 
fire/flame
 
(coal
 
tar
 
is
 
flammable).
 
 
 
 
Before
 
ending
 
this
 
peer
 
review
 
session,
 
the
 
reviewee
 
should
 
be
 
informed
 
of
 
the
 
step(s)
 
that
 
he/
 
she
 
missed
 
out
 
in
 
order
 
to
 
ensure
 
all
 
the
 
counselling
 
points
 
are
 
being
 
covered.
 
 
Remarks:
 
 
 
Reviewed
 
by:
 
Name
 
&
 
Signature
                                                                   
Date:
 
 
 
*Mandatory
 
for
 
validation
 
/
 
peer
 
review
 
References:
 
 
1.
 
Ego
 
Pharm
 
PTY
 
LTD.
 
(2018).
 
Product
 
information
 
leaflet:
 
Sebitar
 
Scalp
 
cleansing
 
treatment
.
 
Retrieved
 
from
 
Quest
 
3+
 
Product
 
Search
 
on
 
January
 
20,
 
2025.
 
2.
 
Coal
 
Tar
 
20%
 
Solution.
 
(2024).
 
MimsGateway .
 
Retrieved
 
January
 
20,
 
2025,
 
from
 
https://online1.mimsgateway .com.my/
 
 
3.
 
Sebitar .
 
(2024).
 
MimsGateway .
 
Retrieved
 
January
 
20,
 
2025,
 
from
 
https://online1.mimsgateway .com.my/
 
 
4.
 
Weatherhead,
 
S.,
 
Robson,
 
S.
 
C.,
 
&
 
Reynolds,
 
N.
 
J.
 
(2007).
 
Management
 
of
 
psoriasis
 
in
 
pregnancy .
 
BMJ
 
(Clinical
 
research
 
ed.),
 
334(7605),
 
1218–1220.
 
https://doi.org/10.1 136/bmj.39202.518484.80
 
 
5.
 
Belinchón,
 
I.,
 
Velasco,
 
M.,
 
Ara-Martín,
 
M.,
 
Armesto
 
Alonso,
 
S.,
 
Baniandrés
 
Rodríguez,
 
O.,
 
Ferrándiz
 
Pulido,
 
L.,
 
García-Bustinduy ,
 
M.,
 
Martínez-López,
 
J.
 
A.,
 
Martínez
 
Sánchez,
 
N.,
 
Pérez
 
Ferriols,
 
A.,
 
Pérez
 
Pascual,
 
E.,
 
Rivera
 
Díaz,
 
R.,
 
Ruiz-V illaverde,
 
R.,
 
Taberner
 
Ferrer ,
 
R.,
 
Vicente
 
Villa,
 
A.,
 
&
 
Carrascosa,
 
J.
 
M.
 
(2021).
 
Management
 
of
 
Psoriasis
 
During
 
Preconception,
 
Pregnancy ,
 
Postpartum,
 
and
 
Breastfeeding:
 
A
 
Consensus
 
Statement.
 
Consenso
 
sobre
 
las
 
actuaciones
 
a
 
seguir
 
durante
 
la
 
edad
 
fértil,
 
el
 
embarazo,
 
el
 
posparto
 
y
 
la
 
lactancia
 
en
 
pacientes
 
con
 
psoriasis.
 
Actas
 
dermo-sifiliograficas,
 
112(3),
 
225–241.
 
https://doi.org/10.1016/j.ad.2020.10.002
 
356
 

=== PAGE 358 ===

 
Tenofovir
 
Alafenamide
 
Name
 
:
 
 
Unit
 
:
 
 
●
 
Please
 
tick
 
(
✔
)
 
Yes
 
for
 
correct
 
instruction.
 
●
 
Please
 
tick
 
(
✔
)
 
No
 
for
 
incorrect
 
instruction.
 
Yes
 
No
 
Remarks
 
Pharmacological
 
Group
 
Antiretroviral:
 
Reverse
 
Transcriptase
 
Inhibitor ,
 
Nucleotide
 
(NRTI)
 
 
 
 
Indications
 
and
 
Dosage
 
1.
 
Indicated
 
for
 
the
 
treatment
 
of
 
Chronic
 
Hepatitis
 
B
 
in
 
adults
 
and
 
adolescents
 
(aged
 
12
 
years
 
and
 
older
 
with
 
body
 
weight
 
at
 
least
 
35kg).
 
 
       
a.
 
One
 
tablet
 
once
 
daily
 
To
 
counsel
 
based
 
on
 
specific
 
medication’ s
 
indication
 
and
 
dosage
 
as
 
prescribed
 
by
 
the
 
doctor
 
 
 
 
Method
 
of
 
Administration*
 
1.
 
May
 
be
 
administered
 
orally
 
with
 
food.
 
2.
 
If
 
a
 
patient
 
vomits
 
within
 
1
 
hour
 
of
 
taking
 
Tenofovir
 
Alafenamide,
 
the
 
patient
 
should
 
take
 
another
 
tablet.
 
Missed
 
dose
 
management
 
 
1.
 
Patients
 
should
 
take
 
Tenofovir
 
Alafenamide
 
as
 
soon
 
as
 
possible,
 
provided
 
that
 
less
 
than
 
18
 
hours
 
have
 
passed
 
from
 
the
 
time
 
it
 
is
 
usually
 
taken.
 
 
2.
 
If
 
more
 
than
 
18
 
hours
 
have
 
passed,
 
the
 
patient
 
should
 
not
 
take
 
the
 
missed
 
dose
 
and
 
simply
 
resumes
 
the
 
normal
 
dosing
 
schedule.
 
Do
 
not
 
stop
 
taking
 
your
 
medication
 
unless
 
advised
 
to
 
do
 
so
 
by
 
your
 
prescriber
 
 
 
 
Special
 
Considerations
 
Pregnancy
 
 
 
 
1.
 
There
 
is
 
no
 
or
 
limited
 
data
 
from
 
use
 
of
 
Tenofovir
 
Alafenamide
 
in
 
pregnant
 
women.
 
However ,
 
a
 
large
 
amount
 
of
 
data
 
on
 
pregnant
 
women
 
indicates
 
no
 
malformative
 
nor
 
fetal/neonatal
 
toxicity
 
associated
 
with
 
the
 
use
 
of
 
Tenofovir
 
disoproxil
 
fumarate.
 
 
2.
 
The
 
use
 
of
 
Tenofovir
 
Alafenamide
 
may
 
be
 
considered
 
during
 
pregnancy ,
 
if
 
necessary .
 
 
 
 
Breastfeeding
 
 
 
 
Tenofovir
 
Alafenamide
 
is
 
present
 
in
 
breast
 
milk
 
following
 
administration
 
of
 
Tenofovir
 
Alafenamide.Risk
 
to
 
the
 
breastfed
 
child
 
cannot
 
be
 
excluded;
 
therefore,
 
Tenofovir
 
Alafenamide
 
should
 
not
 
be
 
used
 
during
 
breastfeeding.
 
 
 
 
Elderly
 
 
 
 
No
 
dose
 
adjustment
 
is
 
required.
 
 
 
 
Paediatric
 
 
 
 
No
 
safety
 
and
 
efficacy
 
data
 
available
 
in
 
children
 
younger
 
than
 
12
 
years
 
of
 
age
 
or
 
weighing
 
<
 
35
 
kg.
 
 
 
 
Fasting
 
 
 
 
To
 
be
 
discussed
 
with
 
infectious
 
disease
 
consultant
 
 
 
 
Others
 
 
 
 
 
357
 

=== PAGE 359 ===

 
1.
 
Renal
 
adjustment:
 
No
 
dose
 
adjustment
 
of
 
Tenofovir
 
Alafenamide
 
is
 
required
 
in
 
adults
 
or
 
adolescents
 
with
 
estimated
 
creatinine
 
clearance
 
(CrCl)
 
>
 
15mL/min
 
or
 
in
 
patients
 
with
 
CrCl
 
<
 
15mL/min
 
who
 
are
 
receiving
 
hemodialysis
 
(Tenofovir
 
Alafenamide
 
should
 
be
 
administered
 
after
 
completion
 
of
 
hemodialysis
 
treatment).
 
The
 
use
 
of
 
Tenofovir
 
Alafenamide
 
is
 
not
 
recommended
 
in
 
patients
 
with
 
CrCl
 
<
 
15mL/min
 
who
 
are
 
not
 
receiving
 
hemodialysis.
 
2.
 
Hepatic
 
impairment:
 
 
Mild
 
impairment
 
(Child-Pugh
 
A):
 
No
 
dose
 
adjustment
 
of
 
Tenofovir
 
Alafenamide
 
is
 
required.
 
Decompensated
 
cirrhosis
 
(Child-Pugh
 
B
 
or
 
C):
 
Use
 
is
 
not
 
recommended.
 
 
 
 
Side
 
Effects
 
and
 
their
 
Management*
 
The
 
most
 
frequently
 
reported
 
adverse
 
reactions
 
were
 
headache,
 
nausea
 
and
 
fatigue.
 
 
 
 
Storage*
 
Store
 
in
 
a
 
dry
 
place
 
below
 
30
 
C.
 
Store
 
in
 
the
 
original
 
container .
 
 
 
 
Others
 
1.
 
Co-administration
 
medicinal
 
products
 
that
 
are
 
P-gp
 
inducers
 
(e.g.,
 
rifampicin,
 
rifabutin,
 
carbamazepine,
 
phenobarbital
 
or
 
St.
 
John’ s
 
wort)
 
and
 
Inhibitors
 
(e.g.
 
itraconazole
 
and
 
ketoconazole)
 
may
 
affect
 
plasma
 
concentrations
 
of
 
Tenofovir
 
Alafenamide.
 
2.
 
For
 
patients
 
with
 
Hepatitis
 
B
 
and
 
HIV
 
co-infection,
 
HIV
 
antibody
 
testing
 
should
 
be
 
offered
 
to
 
all
 
HIV-infected
 
patients
 
whose
 
HIV
 
status
 
is
 
unknown
 
before
 
initiating
 
therapy
 
with
 
Tenofovir
 
Alafenamide.
 
3.
 
Exacerbation
 
of
 
hepatitis
 
flares
 
while
 
on
 
treatment
 
are
 
relatively
 
common
 
and
 
characterized
 
by
 
transient
 
increases
 
in
 
serum
 
alanine
 
aminotransferase
 
(ALT).
 
Abrupt
 
discontinuation
 
of
 
the
 
antiviral
 
is
 
not
 
recommended.Patients
 
with
 
cirrhosis
 
may
 
be
 
at
 
a
 
higher
 
risk
 
for
 
hepatic
 
decompensation
 
therefore
 
should
 
be
 
monitored
 
closely
 
during
 
therapy .
 
4.
 
Flares
 
after
 
treatment
 
discontinuation
 
has
 
been
 
reported
 
and
 
usually
 
associated
 
with
 
rising
 
of
 
HBV
 
DNA
 
levels
 
in
 
plasma.
 
Majority
 
are
 
self-limited
 
but
 
severe
 
exacerbations;
 
including
 
fatal
 
outcomes,
 
may
 
occur
 
after
 
the
 
discontinuation
 
of
 
treatment
 
for
 
hepatitis
 
B.
 
Therefore
 
hepatic
 
function
 
should
 
be
 
monitored
 
for
 
at
 
least
 
6
 
months
 
after
 
treatment
 
discontinuation.
 
 
 
 
Before
 
ending
 
this
 
peer
 
review
 
session,
 
the
 
reviewee
 
should
 
be
 
informed
 
of
 
the
 
step(s)
 
that
 
he/
 
she
 
missed
 
out
 
in
 
order
 
to
 
ensure
 
all
 
the
 
counselling
 
points
 
are
 
being
 
covered.
 
 
Remarks:
 
 
 
 
Reviewed
 
by:
 
Name
 
&
 
Signature
                                                                   
Date:
 
 
 
*Mandatory
 
for
 
validation
 
/
 
peer
 
review
 
References:
 
 
1.
 
MyTaff
 
25mg
 
Tenofovir
 
Alafenamide
 
Tablet.
 
(n.d.).
 
Product
 
insert.
 
2.
 
Tenofovir
 
Alafenamide.
 
(n.d.).
 
In
 
UpToDate.
 
Retrieved
 
October
 
28,
 
2024
 
3.
 
Panel
 
on
 
Antiretroviral
 
Guidelines
 
for
 
Adults
 
and
 
Adolescents.
 
(n.d.).
 
Guidelines
 
for
 
the
 
use
 
of
 
antiretroviral
 
agents
 
in
 
adults
 
and
 
adolescents
 
with
 
HIV.
 
Department
 
of
 
Health
 
and
 
Human
 
Services.
 
Retrieved
 
January
 
20,
 
2025,
 
from
 
https://clinicalinfo.hiv .gov/en/guidelines/adult-and-adolescent-arv
 
358
 

=== PAGE 360 ===

 
Tenofovir
 
Disoproxil
 
Fumarate
 
(TDF)
 
Name
 
:
 
 
Unit
 
:
 
 
●
 
Please
 
tick
 
(
✔
)
 
Yes
 
for
 
correct
 
instruction.
 
●
 
Please
 
tick
 
(
✔
)
 
No
 
for
 
incorrect
 
instruction.
 
Yes
 
No
 
Remarks
 
Pharmacological
 
Group
 
Nucleotide
 
reverse
 
transcriptase
 
inhibitors
 
 
 
 
 
Indications
 
and
 
Dosage
 
1.
 
Use
 
as
 
first
 
line
 
monotherapy
 
for
 
chronic
 
hepatitis
 
B
 
or
 
as
 
a
 
rescue
 
therapy
 
for
 
patients
 
with
 
drug
 
resistance
 
hepatitis
 
B
 
virus
 
(according
 
to
 
resistant
 
profile
 
or
 
treatment
 
guidelines).
 
Dosage:
 
300mg
 
once
 
daily
 
 
2.
 
Treatment
 
of
 
HIV-1
 
infected
 
adults
 
in
 
combination
 
with
 
other
 
antiretroviral
 
agents.
 
Dosage:
 
300mg
 
once
 
daily
 
plus
 
other
 
antiretrovirals
 
 
3.
 
For
 
antenatal
 
patients
 
only
 
with
 
chronic
 
Hepatitis
 
B
 
with
 
HBeAg
 
reactive
 
or
 
HBV
 
DNA
 
more
 
than
 
200,000
 
or
 
deranged
 
LFT.
 
 
Dosage:
 
300mg
 
once
 
daily
 
from
 
28
 
weeks
 
of
 
gestation
 
and
 
continue
 
till
 
4
 
weeks
 
postpartum
 
Or
 
 
To
 
counsel
 
based
 
on
 
specific
 
medication’ s
 
indication
 
and
 
dosage
 
as
 
prescribed
 
by
 
the
 
doctor
 
 
 
 
Method
 
of
 
Administration*
 
1.
 
Can
 
be
 
taken
 
orally
 
with
 
or
 
without
 
food.
 
 
2.
 
Must
 
be
 
taken
 
at
 
the
 
same
 
time
 
every
 
day
 
as
 
instructed
 
for
 
it
 
to
 
be
 
effective.
 
3.
 
Continue
 
taking
 
this
 
medicine
 
as
 
prescribed,
 
even
 
if
 
you
 
feel
 
better .
 
This
 
medication
 
does
 
not
 
cure
 
hepatitis
 
B;
 
it
 
helps
 
to
 
suppress
 
the
 
virus
 
and
 
prevent
 
relapse.
 
4.
 
For
 
patients
 
with
 
swallowing
 
difficulties,
 
the
 
tablet
 
can
 
be
 
crushed
 
and
 
dispersed
 
in
 
water .
 
 
5.
 
DO
 
NOT
 
RUN
 
OUT
 
OF
 
MEDICA TION
.
 
Reﬁll
 
the
 
prescription
 
befor e
 
it
 
ﬁnishes.
 
 
Missed
 
dose
 
management
 
1.
 
If
 
you
 
miss
 
a
 
dose
 
and
 
it
 
is
 
less
 
than
 
12
 
hours
 
past
 
your
 
usual
 
time,
 
take
 
the
 
missed
 
dose
 
as
 
soon
 
as
 
possible,
 
then
 
take
 
the
 
next
 
dose
 
at
 
the
 
usual
 
time.
 
2.
 
If
 
more
 
than
 
12
 
hours
 
have
 
passed
 
since
 
your
 
missed
 
dose,
 
skip
 
the
 
missed
 
dose
 
and
 
take
 
your
 
next
 
dose
 
at
 
the
 
usual
 
time.
 
3.
 
DO
 
NOT
 
take
 
double
 
doses
 
to
 
make
 
up
 
for
 
the
 
missed
 
dose.
 
 
Do
 
not
 
stop
 
taking
 
your
 
medication
 
unless
 
advised
 
to
 
do
 
so
 
by
 
your
 
prescriber
 
 
 
 
Special
 
Considerations
 
Pregnancy
 
 
 
 
1.
 
Preferred
 
choice
 
due
 
to
 
a
 
better
 
resistance
 
profile
 
and
 
more
 
extensive
 
safety
 
data.
 
2.
 
Available
 
data
 
suggests
 
that
 
it
 
does
 
not
 
increase
 
risk
 
of
 
major
 
birth
 
defects
 
in
 
first
 
trimester
 
pregnancy
 
and
 
no
 
adverse
 
pregnancy
 
related
 
outcomes
 
during
 
third
 
trimester .
 
3.
 
Preferred
 
antiviral
 
for
 
hepatitis
 
B
 
e
 
antigen-positive
 
mothers
 
or
 
viral
 
load
 
>200,000
 
IU/ml
 
(antiviral
 
prophylaxis)
 
 
 
 
359
 

=== PAGE 361 ===

 
Breastfeeding
 
 
 
 
1.
 
Breastfeeding
 
is
 
not
 
contraindicated.
 
 
2.
 
It
 
is
 
unknown
 
if
 
TDF
 
affects
 
lactation
 
or
 
has
 
effects
 
on
 
breastfed
 
children.
 
 
 
 
 
Elderly
 
 
 
 
Decreased
 
bone
 
mineral
 
density ,
 
effects
 
on
 
long-term
 
bone
 
health
 
and
 
future
 
fracture
 
risk.
 
Consider
 
monitoring
 
bone
 
density
 
in
 
patients
 
with
 
history
 
of
 
pathologic
 
fractures
 
or
 
with
 
other
 
risk
 
factors
 
for
 
bone
 
loss
 
or
 
osteoporosis.
 
 
 
 
 
Paediatric
 
 
 
 
For
 
children
 
≥
 
2
 
years
 
weighing
 
≥10kg
 
 
 
 
Fasting
 
 
 
 
To
 
take
 
once
 
daily
 
during
 
Sahur
 
or
 
Iftar
.
 
 
 
 
Renal
 
impairment
  
 
 
 
 
1.
 
CrCl
 
>
 
50
 
mL/min:
 
No
 
dosage
 
adjustment
 
required
 
2.
 
CrCl
 
30
 
-
 
49
 
mL/min:
 
300mg
 
every
 
48
 
hours
 
3.
 
CrCL
 
10
 
-
 
29
 
mL/min:
 
300mg
 
every
 
72
 
-
 
96
 
hours
 
4.
 
CrCl
 
<10
 
mL/min:
 
Has
 
not
 
been
 
studied.
 
If
 
alternative
 
therapy
 
is
 
not
 
available,
 
may
 
consider
 
300mg
 
every
 
7
 
days.
 
5.
 
Hemodialysis:
 
300mg
 
every
 
7
 
days.
 
When
 
a
 
scheduled
 
dose
 
falls
 
on
 
hemodialysis
 
day,
 
TDF
 
should
 
be
 
taken
 
after
 
hemodialysis.
 
 
 
 
 
Side
 
Effects
 
and
 
their
 
Management*
 
1.
 
Side
 
effects
 
may
 
include
 
rash,
 
diarrhea,
 
nausea,
 
dizziness,
 
headache,
 
fatigue
 
and
 
fever .
 
2.
 
Advise
 
patients
 
to
 
report
 
symptoms
 
of
 
lactic
 
acidosis
 
(nausea,
 
vomiting,
 
abdominal
 
pain,
 
tachypnea)
 
and
 
liver
 
problems
 
(dark
 
urine,
 
light-coloured
 
stools,
 
or
 
yellow
 
skin
 
or
 
eyes).
 
3.
 
Advise
 
patients
 
to
 
report
 
any
 
bone
 
problems
 
such
 
as
 
bone
 
pain.
 
Take
 
calcium
 
and
 
vitamin
 
D
 
as
 
instructed
 
by
 
prescribers.
 
 
 
 
 
Storage*
 
1.
 
Store
 
below
 
30
°
C.
 
 
2.
 
Keep
 
medication
 
in
 
its
 
original
 
container ,
 
tightly
 
sealed
 
to
 
protect
 
from
 
moisture
 
and
 
light.
 
 
3.
 
Keep
 
out
 
of
 
reach
 
and
 
sight
 
of
 
children.
 
 
 
 
Others
 
1.
 
Advise
 
patients
 
against
 
sudden
 
discontinuation
 
of
 
TDF
 
due
 
to
 
potential
 
exacerbation
 
of
 
hepatitis
 
B.
 
 
2.
 
Advise
 
patients
 
to
 
practise
 
safe
 
sex
 
and
 
ensure
 
to
 
take
 
proper
 
precautions
 
to
 
avoid
 
transmission.
 
This
 
drug
 
does
 
not
 
prevent
 
disease
 
transmission.
 
 
Vomiting
 
management
 
1.
 
If
 
vomiting
 
occurs
 
within
 
1
 
hour
 
of
 
dosing,
 
an
 
additional
 
tablet
 
should
 
be
 
taken.
 
 
2.
 
If
 
vomiting
 
occurs
 
more
 
than
 
1
 
hour
 
after
 
dosing,
 
no
 
additional
 
dose
 
is
 
needed.
 
 
 
 
360
 

=== PAGE 362 ===

 
Before
 
ending
 
this
 
peer
 
review
 
session,
 
the
 
reviewee
 
should
 
be
 
informed
 
of
 
the
 
step(s)
 
that
 
he/
 
she
 
missed
 
out
 
in
 
order
 
to
 
ensure
 
all
 
the
 
counselling
 
points
 
are
 
being
 
covered.
 
 
Remarks:
 
 
 
 
 
Reviewed
 
by:
 
Name
 
&
 
Signature
                                                                   
Date:
 
 
 
 
*Mandatory
 
for
 
validation
 
/
 
peer
 
review
 
References:
 
 
1.
 
Formulari
 
Ubat
 
KKM.
 
(2025,
 
January
 
1).
 
Accessed
 
on
 
January
 
20,
 
2025.
 
2.
 
Tenofovir
 
disoproxil
 
fumarate.
 
(2024).
 
MimsGateway .
 
Retrieved
 
January
 
20,
 
2025,
 
from
 
https://online1.mimsgateway .com.my/
 
3.
 
Hetero
 
Labs
 
Limited.
 
(2015).
 
Product
 
information
 
leaflet:
 
TENOF .
 
Retrieved
 
from
 
Quest
 
3+
 
Product
 
Search
 
on
 
January
 
20,
 
2025.
 
4.
 
Terrault,
 
N.
 
A.,
 
Lok,
 
A.
 
S.
 
F.,
 
McMahon,
 
B.
 
J.,
 
Chang,
 
K.
 
M.,
 
Hwang,
 
J.
 
P.,
 
Jonas,
 
M.
 
M.,
 
Brown,
 
R.
 
S.,
 
Jr,
 
Bzowej,
 
N.
 
H.,
 
&
 
Wong,
 
J.
 
B.
 
(2018).
 
Update
 
on
 
prevention,
 
diagnosis,
 
and
 
treatment
 
of
 
chronic
 
hepatitis
 
B:
 
AASLD
 
2018
 
hepatitis
 
B
 
guidance.
 
Hepatology
 
(Baltimore,
 
Md.),
 
67(4),
 
1560–1599.
 
https://doi.org/10.1002/hep.29800
 
5.
 
European
 
Association
 
for
 
the
 
Study
 
of
 
the
 
Liver .
 
(2017).
 
EASL
 
2017
 
Clinical
 
Practice
 
Guidelines
 
on
 
the
 
management
 
of
 
hepatitis
 
B
 
virus
 
infection.
 
Journal
 
of
 
Hepatology ,
 
67(2),
 
370–398.
 
https://doi.org/10.1016/j.jhep.2017.03.021
 
6.
 
Swanepoel,
 
C.
 
R.,
 
Atta,
 
M.
 
G.,
 
D'Agati,
 
V.
 
D.,
 
Estrella,
 
M.
 
M.,
 
Fogo,
 
A.
 
B.,
 
Naicker ,
 
S.,
 
Post,
 
F.
 
A.,
 
Wearne,
 
N.,
 
Winkler ,
 
C.
 
A.,
 
Cheung,
 
M.,
 
Wheeler ,
 
D.
 
C.,
 
Winkelmayer ,
 
W.
 
C.,
 
Wyatt,
 
C.
 
M.,
 
&
 
Conference
 
Participants
 
(2018).
 
Kidney
 
disease
 
in
 
the
 
setting
 
of
 
HIV
 
infection:
 
conclusions
 
from
 
a
 
Kidney
 
Disease:
 
Improving
 
Global
 
Outcomes
 
(KDIGO)
 
Controversies
 
Conference.
 
Kidney
 
international,
 
93(3),
 
545–559.
 
https://doi.org/10.1016/j.kint.2017.1 1.007
 
7.
 
Uptodate
 
2024
 
Medical
 
Apps
 
Application.
 
Wolters
 
Kluwer .
 
Accessed
 
on
 
January
 
22,
 
2025.
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
361
 

=== PAGE 363 ===

 
Tenofovir
 
Disoproxil
 
Fumarate
 
/
 
Emtricitabine
 
Name
 
:
 
 
Unit
 
:
 
 
●
 
Please
 
tick
 
(
✔
)
 
Yes
 
for
 
correct
 
instruction.
 
●
 
Please
 
tick
 
(
✔
)
 
No
 
for
 
incorrect
 
instruction.
 
Yes
 
No
 
Remarks
 
Pharmacological
 
Group
 
Antiretroviral
 
-
 
Nucleotide/nucleoside
 
reverse
 
transcriptase
 
inhibitors
 
(NRTIs)
 
 
 
Indications
 
and
 
Dosage
 
1.
 
HIV-1
 
Treatment
 
(in
 
combination
 
with
 
other
 
antiretroviral
 
agents)
 
a.
 
One
 
tablet
 
orally
 
once
 
daily
 
 
2.
 
In
 
combination
 
with
 
safer
 
sex
 
practices
 
for
 
pre-exposure
 
prophylaxis
 
(PrEP)
 
to
 
reduce
 
the
 
risk
 
of
 
HIV-1
 
infection
 
in
 
adults
 
at
 
increased
 
risk.
  
 
a.
 
Daily
 
PrEP:
 
One
 
tablet
 
orally
 
once
 
daily
 
b.
 
Event
 
driven
 
PrEP
 
(only
 
for
 
cisgender
 
men,
 
trans
 
and
 
gender
 
diverse
 
people
 
assigned
 
male
 
at
 
birth
 
who
 
are
 
not
 
taking
 
exogenous
 
estradiol-based
 
hormones)
 
:
 
2
 
loading
 
tablets
 
2-24
 
hours
 
before
 
sex,
 
followed
 
by
 
1
 
tablet
 
24
 
hours
 
later
 
and
 
1
 
tablet
 
48
 
hours
 
later.
 
 
 
 
Method
 
of
 
Administration
 
1.
 
It
 
can
 
be
 
taken
 
with
 
or
 
without
 
food.
 
 
Missed
 
dose
 
management
 
 
1.
 
For
 
HIV-1
 
treatment
 
and
 
daily
 
PrEP ,
 
to
 
take
 
as
 
soon
 
as
 
remember ,
 
however
 
if
 
gap
 
is
 
more
 
than
 
12
 
hours,
 
to
 
skip
 
and
 
continue
 
with
 
regular
 
dosing
 
schedule
 
 
2.
 
Event
 
driven
 
PrEP:
 
to
 
contact
 
prescriber
 
as
 
post
 
exposure
 
prophylaxis
 
(PEP)
  
may
 
be
 
needed
 
 
Do
 
not
 
stop
 
taking
 
your
 
medication
 
unless
 
advised
 
to
 
do
 
so
 
by
 
your
 
prescriber
 
 
 
 
Special
 
Considerations
 
Pregnancy
 
 
 
 
Safe
 
to
 
be
 
used
 
in
 
pregnancy .
 
 
 
 
Breastfeeding
 
 
 
 
1.
 
Excreted
 
in
 
breast
 
milk,
 
insuf ficient
 
information
 
in
 
newborn/infants.
 
 
2.
 
It
 
is
 
recommended
 
that
 
HIV
 
infected
 
women
 
do
 
not
 
breastfeed
 
their
 
infants
 
under
 
any
 
circumstances
 
to
 
avoid
 
transmission
 
to
 
the
 
infant.
 
 
 
 
 
Elderly
 
 
 
 
Use
 
in
 
caution
 
in
 
elderly
 
as
 
they
 
are
 
more
 
likely
 
to
 
have
 
decreased
 
renal
 
function.
 
 
 
 
Paediatric
 
 
 
 
Not
 
recommended
 
to
 
be
 
used
 
for
 
the
 
paediatric
 
population
 
below
 
35kg.
 
 
 
 
 
Renal
 
impairment
 
 
 
 
362
 

=== PAGE 364 ===

 
1.
   
Monitoring
 
of
 
renal
 
function
 
required.
 
2.
   
Dosage
 
adjustment
 
required
 
for
 
CrCl
 
below
 
50ml/min:
 
a.
 
30-49
 
ml/min:
 
1
 
tab
 
EOD
 
b.
 
<30
 
ml/min
 
:
 
not
 
recommended
 
 
 
 
 
Side
 
Effects
 
and
 
their
 
Management
 
1.
 
Renal
 
toxicity:
 
Monitor
 
kidney
 
function;
 
dose
 
adjustments
 
may
 
be
 
needed.
 
Prevention:
 
drink
 
at
 
least
 
1.5–2
 
litres
 
of
 
non-caf feinated
 
fluid
 
per
 
day
 
(preferably
 
water
 
&
 
no
 
requirement
 
of
 
fluid
 
restriction).
 
2.
 
Bone
 
Density
 
Loss
:
 
Consider
 
calcium
 
and
 
vitamin
 
D
 
supplementation
 
and
 
regular
 
bone
 
health
 
monitoring.
 
3.
 
Others
 
(headache,
 
nausea,
 
diarrhoea,
 
or
 
abdominal
 
pain)
:
 
may
 
require
 
symptomatic
 
treatment.
 
 
 
 
Storage
 
1.
 
Do
 
not
 
store
 
above
 
30°C.
 
 
2.
 
Protect
 
from
 
light.
 
 
 
 
Others
 
1.
 
To
 
watch
 
out
 
for
 
hepatic
 
flares
 
when
 
discontinued
 
in
 
patients
 
with
 
HBV
 
co-infection.
 
2.
 
Avoid
 
protein
 
supplements.
 
3.
 
Avoid
 
in
 
patients
 
with
 
chronic
 
kidney
 
disease
 
and
 
progressively
 
declining
 
renal
 
function.
 
 
 
 
Before
 
ending
 
this
 
peer
 
review
 
session,
 
the
 
reviewee
 
should
 
be
 
informed
 
of
 
the
 
step(s)
 
that
 
he/
 
she
 
missed
 
out
 
in
 
order
 
to
 
ensure
 
all
 
the
 
counselling
 
points
 
are
 
being
 
covered.
 
 
Remarks:
 
 
 
 
 
Reviewed
 
by:
 
Name
 
&
 
Signature
                                                                   
Date:
 
 
 
 
 
*Mandatory
 
for
 
validation
 
/
 
peer
 
review
 
References:
 
 
1.
 
Malaysian
 
Consensus
 
Guideline
 
on
 
Antiretroviral
 
Therapy .
 
(2022).
 
Malaysian
 
Consensus
 
Guideline
 
on
 
Antiretroviral
 
Therapy .
 
2.
 
Ricovir-EM
 
200mg/300mg
 
Tablet.
 
(n.d.).
 
Product
 
insert.
 
3.
 
Panel
 
on
 
Antiretroviral
 
Therapy
 
and
 
Medical
 
Management
 
of
 
Children
 
Living
 
with
 
HIV.
 
(2024).
 
Guidelines
 
for
 
the
 
use
 
of
 
antiretroviral
 
agents
 
in
 
pediatric
 
HIV
 
infection.
 
Department
 
of
 
Health
 
and
 
Human
 
Services.
 
Retrieved
 
October
 
28,
 
2024,
 
from
 
https://clinicalinfo.hiv .gov/en/guidelines/pediatric-arv
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
363
 

=== PAGE 365 ===

 
Ticagrelor
 
 
Name
 
:
 
 
Unit
 
:
 
 
●
 
Please
 
tick
 
(
✔
)
 
Yes
 
for
 
correct
 
instruction.
 
●
 
Please
 
tick
 
(
✔
)
 
No
 
for
 
incorrect
 
instruction.
 
Yes
 
No
 
Remarks
 
Pharmacological
 
Group
 
Antiplatelet-Non
 
thienopyridine
 
P2Y12
 
Antagonist
 
 
 
 
Indications
 
and
 
Dosage
 
Co-administration
 
with
 
aspirin
 
(ASA),
 
for
 
the
 
prevention
 
of
 
atherothrombotic
 
events:
 
 
1.
 
Second
 
line
 
treatment
 
for
 
patients
 
readmitted
 
to
 
hospital
 
with
 
recurrent
 
atherothrombotic
 
event
 
failing
 
treatment
 
with
 
clopidogrel.
 
2.
 
STEMI
 
patients
 
going
 
for
 
invasive
 
PCI
 
3.
 
NSTEMI/UA
 
patients
 
with
 
intermediate
 
to
 
high
 
risk
 
TIMI
 
score.
 
4.
 
Other
 
complicated
 
ACS
 
cases
 
treated
 
either
 
medically
 
or
 
invasively
 
via
 
PCI
 
or
 
CABG(risk
 
of
 
Stent
 
thrombosis,3VD
 
etc.)
 
 
Dosage
 
:
 
Initially ,
 
180mg
 
as
 
a
 
single
 
dose
 
followed
 
by
 
90mg
 
bd
 
with
 
maintenance
 
dose
 
of
 
ASA
 
75-150mg
 
daily.
 
 
 
 
Method
 
of
 
Administration*
 
1.
 
Take
  
with
 
or
 
without
 
food.
 
2.
 
Tablet
 
can
 
be
 
crushed
 
and
 
mixed
 
with
 
half
 
a
 
glass
 
of
 
water
 
and
 
drank
 
immediately .
 
3.
 
Can
 
be
 
administered
 
via
 
a
 
nasogastric
 
tube.It
 
is
 
important
 
to
 
flush
 
the
 
nasogastric
 
tube
 
through
 
with
 
water
 
after
 
administration
 
of
 
the
 
mixture.
 
 
Missed
 
dose
 
management
:
 
If
 
you
 
forget
 
or
 
miss
 
a
 
dose,
 
skip
 
the
 
missed
 
dose
 
and
 
take
 
your
 
next
 
dose
 
at
 
the
 
usual
 
time.
 
Do
 
not
 
take
 
two
 
doses
 
at
 
once
 
to
 
make
 
up
 
for
 
the
 
missed
 
dose.
 
 
Do
 
not
 
stop
 
taking
 
your
 
medication
 
unless
 
advised
 
to
 
do
 
so
 
by
 
your
 
prescriber
 
 
 
 
Special
 
Considerations
 
Pregnancy
 
 
 
 
There
 
is
 
no
 
or
 
limited
 
amount
 
of
 
data
 
from
 
the
 
use
 
of
 
ticagrelor
 
in
 
pregnant
 
women.Studies
 
in
 
animals
 
have
 
shown
 
reproductive
 
toxicity .Therefore
 
it
 
is
 
not
 
recommended
 
during
 
pregnancy .
 
 
 
 
Breastfeeding
 
 
 
 
Available
 
pharmacodynamic/toxicological
 
data
 
in
 
animals
 
have
 
shown
 
excretion
 
of
 
ticagrelor
 
and
 
its
 
active
 
metabolites
 
in
 
milk.A
 
risk
 
to
 
newborns/infants
 
cannot
 
be
 
excluded.
 
Drugs
 
should
 
be
 
given
 
only
 
if
 
the
 
potential
 
benefit
 
justifies
 
the
 
potential
 
risk
 
to
 
the
 
newborn/infants.
 
 
 
 
Elderly
 
 
 
 
Beers
 
Criteria:
 
1.
 
Use
 
with
 
caution,
 
particularly
 
in
 
adults
 
75
 
years
 
old
 
and
 
older .
 
Increase
 
the
 
risk
 
of
 
major
 
bleeding
 
in
 
older
 
adults
 
compared
 
with
 
Clopidogrel,
 
especially
 
among
 
those
 
75
 
years
 
old
 
and
 
older .
 
However ,
 
this
 
risk
 
may
 
be
 
offset
 
by
 
cardiovascular
 
benefits
 
in
 
select
 
patients.
 
 
 
 
364
 

=== PAGE 366 ===

 
Paediatric
 
 
 
 
The
 
safety
 
and
 
efficacy
 
of
 
ticagrelor
 
in
 
children
 
below
 
the
 
age
 
of
 
18
 
in
 
the
 
approved
 
adult
 
indication
 
has
 
not
 
been
 
established.
 
 
 
 
Fasting
 
 
 
 
To
 
refer
 
to
 
the
 
latest
 
advisory
 
by
 
religious
 
authority
 
 
 
 
Others
  
 
 
 
 
1.
 
No
 
dosage
 
adjustment
 
is
 
necessary
 
for
 
patients
 
with
 
renal
 
impairment.
 
2.
 
Contraindicated
 
in
 
patients
 
with
 
severe
 
renal
 
impairments.There
 
is
 
limited
 
experience
 
with
 
ticagrelor
   
in
 
patients
 
with
 
moderate
 
hepatic
 
impairment
 
therefore
 
caution
 
is
 
advised.
 
 
 
 
Side
 
Effects
 
and
 
their
 
Management*
 
1.
 
 
Most
 
common:
  
bleeding
 
and
 
dyspnoea.
 
2.
 
Dizziness
 
and
 
confusion
 
have
 
been
 
reported.Therefore,
 
patients
 
who
 
experience
 
these
 
symptoms
 
should
 
be
 
cautious
 
while
 
driving
 
or
 
using
 
machines.
 
3.
 
Hyperuricemia.
 
 
 
 
Storage*
 
Do
 
not
 
store
 
above
 
30ºC
 
 
 
 
Others
 
1.
 
If
 
a
 
patient
 
is
 
to
 
undergo
 
elective
 
surgery ,ticagrelor
 
should
 
be
 
discontinued
 
5
 
days
 
prior
 
to
 
surgery .
 
2.
 
Ticagrelor
 
should
 
be
 
used
 
with
 
caution
 
in
 
patients
 
with
 
a
 
history
 
of
 
asthma
 
and/or
 
COPD.
 
3.
 
Caution
 
is
 
advised
 
in
 
patients
 
with
 
history
 
of
 
hyperuricaemia
 
or
 
gouty
 
arthritis.
 
4.
 
Ticagrelor
 
is
 
primarily
 
a
 
CYP3A4
 
substrate
 
and
 
a
 
mild
 
inhibitor
 
of
 
CYP3A4.Co-administration
 
with
 
strong
 
CYP3A4
 
inhibitors
 
such
 
as
 
Ketoconazole,Clarithromycin,Ritonavir ,Atazanavir
 
will
 
increase
 
Ticagrelor
 
plasma
 
level.
 
 
 
 
Before
 
ending
 
this
 
peer
 
review
 
session,
 
the
 
reviewee
 
should
 
be
 
informed
 
of
 
the
 
step(s)
 
that
 
he/
 
she
 
missed
 
out
 
in
 
order
 
to
 
ensure
 
all
 
the
 
counselling
 
points
 
are
 
being
 
covered.
 
 
Remarks:
 
 
 
Reviewed
 
by:
 
Name
 
&
 
Signature
                                                                   
Date:
 
 
 
*Mandatory
 
for
 
validation
 
/
 
peer
 
review
 
References:
 
 
1.
 
Astra
 
Zeneca,
 
Ticagrelor
 
(Brilinta)
 
Product
 
Leaflet.Revised:
 
June
 
2022
 
2.
 
MIMS
 
Gateway
 
Online.Release
 
version:
 
October
 
2024
 
3.
 
Formulari
 
Ubat
 
KKM.
 
(2025,
 
January
 
1).
 
Accessed
 
on
 
January
 
21,
 
2025.
 
4.
 
2023
 
American
 
Geriatrics
 
Society
 
Beers
 
Criteria®
 
Update
 
Expert
 
Panel.
 
(2023).
 
American
 
Geriatrics
 
Society
 
2023
 
updated
 
AGS
 
Beers
 
Criteria®
 
for
 
potentially
 
inappropriate
 
medication
 
use
 
in
 
older
 
adults.
 
Journal
 
of
 
the
 
American
 
Geriatrics
 
Society ,
 
71(7),
 
2052-2081.
 
 
 
365
 

=== PAGE 367 ===

 
Ticlopidine
 
 
Name
 
:
 
 
Unit
 
:
 
 
●
 
Please
 
tick
 
(
✔
)
 
Yes
 
for
 
correct
 
instruction.
 
●
 
Please
 
tick
 
(
✔
)
 
No
 
for
 
incorrect
 
instruction.
 
Yes
 
No
 
Remarks
 
Pharmacological
 
Group
 
Antiplatelet.
 
 
 
 
 
Indications
 
and
 
Dosage
 
1.
 
Prevention
 
of
 
thrombotic
 
stroke
 
for
 
patients
 
who
 
are
 
sensitive
 
/intolerant
 
to
 
Acetylsalicylic
 
Acid
 
2.
 
Maintenance
 
of
 
coronary
 
bypass
 
surgery
 
or
 
angioplasty
 
3.
 
Maintenance
 
of
 
patency
 
of
 
access
 
in
 
patients
 
on
 
chronic
 
Dose
 
:
 
Ticlopidine
 
250mg
 
twice
 
daily
 
 
 
 
Method
 
of
 
Administration*
 
To
 
be
 
taken
 
with
 
food.
 
Do
 
not
 
stop
 
taking
 
your
 
medication
 
unless
 
advised
 
to
 
do
 
so
 
by
 
your
 
prescriber
 
 
 
 
Special
 
Considerations
 
Pregnancy
 
 
 
 
There
 
are
 
no
 
controlled
 
studies
 
in
 
pregnancy .
 
Animal
 
reproduction
 
studies
 
have
 
not
 
shown
 
teratogenic
 
effects.
 
 
 
 
 
Breastfeeding
 
 
 
 
It
 
is
 
not
 
known
 
if
 
ticlopidine
 
is
 
excreted
 
in
 
breast
 
milk.
 
Due
 
to
 
the
 
potential
 
for
 
serious
 
adverse
 
reactions
 
in
 
the
 
nursing
 
infant,
 
a
 
decision
 
should
 
be
 
made
 
whether
 
to
 
discontinue
 
nursing
 
or
 
to
 
discontinue
 
the
 
drug,
 
taking
 
into
 
account
 
the
 
importance
 
of
 
treatment
 
to
 
the
 
mother .
 
 
 
 
 
Elderly
 
 
 
 
STOPP/ST ART
 
Criteria:
 
1.
 
Avoid
 
ticlopidine
 
in
 
any
 
circumstances
 
(clopidogrel
 
and
 
prasugrel
 
have
 
similar
 
efficacy ,
 
stronger
 
evidence
 
and
 
fewer
 
side-ef fects).
 
 
 
 
Paediatric
 
 
 
 
No
 
data
 
on
 
paediatric
 
use.
 
 
 
 
 
Fasting
 
 
 
 
To
 
refer
 
to
 
the
 
latest
 
advisory
 
by
 
religious
 
authority
 
 
 
 
Others
  
 
 
 
 
1.
 
Renal
 
impairment
 
 
-
 
Dose
 
adjustment
 
not
 
necessary
 
2.
 
Liver
 
impairment
 
-
 
Use
 
with
 
caution.
 
Contraindicated
 
in
 
severe
 
liver
 
impairment
 
 
 
 
366
 

=== PAGE 368 ===

 
Side
 
Effects
 
and
 
their
 
Management*
 
Seek
 
medical
 
attention
 
if
 
you
 
have
 
signs/symptoms
 
as
 
below
 
after
 
initiation
 
:
 
1.
 
Fever ,
 
chills,
 
sore
 
throat
 
or
 
other
 
sign
 
of
 
infection
 
2.
 
Bruising,
 
purpura
 
3.
 
Prolonged/
 
abnormal
 
bleeding,
 
dark
 
stool
 
4.
 
Yellow
 
eyes/skin,
 
dark
 
urine,
 
light
 
coloured
 
stool
 
5.
 
Fatigue,
 
shortness
 
of
 
breath
 
6.
 
Rash
 
 
 
 
Storage*
 
Keep
 
out
 
of
 
reach
 
of
 
children,
 
Store
 
in
 
dry
 
places
 
below
 
30
o
C.
 
Protect
 
from
 
light.
 
 
 
 
 
Others
 
Special
 
Precautions
 
1.
 
Consider
 
discontinuation
 
of
 
therapy
 
10-14
 
days
 
prior
 
to
 
elective
 
surgery
 
if
 
antiplatelet
 
effect
 
is
 
not
 
desirable.
 
2.
 
Used
 
with
 
caution
 
in
 
individuals
 
who
 
are
 
at
 
increased
 
risk
 
of
 
bleeding,
 
individuals
 
with
 
impaired
 
liver
 
function
 
and
 
should
 
be
 
discontinued
 
if
 
inflammation
 
of
 
the
 
liver
 
or
 
yellowing
 
of
 
skin
 
develops.
 
Monitoring
 
1.
 
Due
 
to
 
heightened
 
risk
 
of
 
hematological
 
complications,
 
patients
 
should
 
have
 
their
 
white
 
blood
 
cell
 
count,
 
differential
 
and
 
platelet
 
count
 
monitored
 
at
 
baseline
 
prior
 
to,
 
biweekly
 
after
 
initiation
 
until
 
the
 
end
 
of
 
3
rd
 
month
 
therapy .
 
2.
 
Discontinuation
 
is
 
recommended
 
should
 
neutropenia/
 
thrombocytopenia
 
occur .
 
Monitoring
 
should
 
still
 
be
 
performed
 
2
 
weeks
 
after
 
discontinuation.
 
 
3.
 
Perform
 
liver
 
function
 
test
 
for
 
the
 
first
 
4
 
months
 
if
 
liver
 
impairment
 
is
 
suspected.
 
 
Drug-drug
 
interaction
 
1.
 
Increased
 
risk
 
of
 
bleeding
 
with
 
anticoagulants,
 
other
 
antiplatelet
 
agents
 
(e.g.
 
aspirin),
 
thrombolytic
 
agents,
 
SSRIs,
 
pentoxifylline,
 
NSAIDs.
 
 
2.
 
Increased
 
serum
 
concentration
 
of
 
carbamazepine
,
 
phenytoin
,
 
theophylline
,
 
ketamine
.
 
 
3.
 
Decreased
 
serum
 
concentration
 
with
 
antacids.
 
Reduced
 
clearance
 
with
 
cimetidine.
 
4.
 
Decreased
 
serum
 
concentration
 
of
 
digoxin
 
and
 
ciclosporin
.
 
 
5.
 
May
 
increase
 
the
 
plasma
 
half-life
 
of
 
CYP450
 
substrates
 
(e.g.
 
phenazone).
 
Drug-food
 
interaction
 
1.
 
May
 
increase
 
bioavailability
 
with
 
food
 
 
 
 
Before
 
ending
 
this
 
peer
 
review
 
session,
 
the
 
reviewee
 
should
 
be
 
informed
 
of
 
the
 
step(s)
 
that
 
he/
 
she
 
missed
 
out
 
in
 
order
 
to
 
ensure
 
all
 
the
 
counselling
 
points
 
are
 
being
 
covered.
 
Remarks:
 
 
Reviewed
 
by:
 
Name
 
&
 
Signature
                                                                   
Date:
 
*Mandatory
 
for
 
validation
 
/
 
peer
 
review
 
References:
 
 
1.
 
Shah,
 
J.,
 
Teitelbaum,
 
P.,
 
Molony ,
 
B.,
 
Gabuzda,
 
T.,
 
&
 
Massey ,
 
I.
 
(1991).
 
Single
 
and
 
multiple
 
dose
 
pharmacokinetics
 
of
 
ticlopidine
 
in
 
young
 
and
 
elderly
 
subjects. British
 
journal
 
of
 
clinical
 
pharmacology , 32(6),
 
761–764.
 
2.
 
Ticlopidine.
 
(2024).
 
MimsGateway .
 
Retrieved
 
January
 
20,
 
2025,
 
from
 
https://online1.mimsgateway .com.my/
 
3.
 
Dynapharm
 
(M)
 
sdn.
 
Bhd.
 
(2020).
 
Product
 
information
 
leaflet:
 
Dyna
 
ticlopidine
 
tablet
 
250mg.
 
Retrieved
 
from
 
Quest
 
3+
 
Product
 
Search
 
on
 
January
 
21,
 
2025.
 
4.
 
O’Mahony ,
 
D.,
 
Cherubini,
 
A.,
 
Guiteras,
 
A.
 
R.,
 
Denkinger ,
 
M.,
 
Beuscart,
 
J.
 
B.,
 
Onder ,
 
G.,
 
...
 
&
 
Curtin,
 
D.
 
(2023).
 
STOPP/ST ART
 
criteria
 
for
 
potentially
 
inappropriate
 
prescribing
 
in
 
older
 
people:
 
version
 
3.
 
European
 
geriatric
 
medicine,
 
14(4),
 
625-632.
 
 
367
 

=== PAGE 369 ===

 
Tretinoin,
 
Topical
 
Name
 
:
 
 
Unit
 
:
 
 
●
 
Please
 
tick
 
(
✔
)
 
Yes
 
for
 
correct
 
instruction.
 
●
 
Please
 
tick
 
(
✔
)
 
No
 
for
 
incorrect
 
instruction.
 
Yes
 
No
 
Remarks
 
Pharmacological
 
Group
 
Acne
 
product;
 
Vitamin
 
A
 
derivative
 
 
 
 
 
Indications
 
and
 
Dosage
 
1.
 
Treatment
 
of
 
Acne
 
Vulgaris
 
and
 
recalcitrant
 
cases
 
of
 
acne
 
in
 
which
 
comedones,papules
 
and
 
pustules
 
predominate.
 
 
Apply
 
once
 
daily
 
to
 
the
 
affected
 
area
 
at
 
bedtime.
 
 
 
 
Method
 
of
 
Administration*
 
1.
 
Wash
 
face
 
with
 
a
 
gentle,
 
non-medicated
 
cleanser
 
and
 
allow
 
the
 
face
 
to
 
dry
 
thoroughly .
 
 
2.
 
Apply
 
a
 
thin
 
layer
 
to
 
the
 
entire
 
face
 
or
 
other
 
affected
 
area
 
at
 
night.
 
 
3.
 
Wash
 
well
 
in
 
the
 
morning.
 
 
 
Do
 
not
 
stop
 
taking
 
your
 
medication
 
unless
 
advised
 
to
 
do
 
so
 
by
 
your
 
prescriber
 
 
 
 
Special
 
Considerations
 
Pregnancy
 
 
 
 
1.
 
Tretinoin
 
cream/gel
 
is
 
contraindicated
 
during
 
pregnancy
 
and
 
in
 
women
 
planning
 
to
 
become
 
pregnant.
 
2.
 
Pregnancy
 
should
 
be
 
avoided
 
during
 
treatment
 
and
 
for
 
at
 
least
 
4
 
weeks
 
after
 
discontinuing
 
the
 
use
 
of
 
tretinoin
.
 
 
 
 
Breastfeeding
 
 
 
 
1.
 
Contraindicated
 
to
 
be
 
used
 
during
 
breastfeeding.
 
 
 
 
Elderly
 
 
 
 
1.
 
No
 
elderly-specific
 
problems
 
have
 
been
 
documented
 
to
 
date.
 
 
 
 
Paediatric
 
 
 
 
1.
 
The
 
safety
 
and
 
efficacy
 
of
 
topical
 
Tretinoin
 
for
 
selected
 
conditions,
 
in
 
paediatric
 
patients
 
below
 
9
 
years
 
old
 
have
 
not
 
been
 
established.
 
Precautions
 
do
 
apply .
 
 
 
 
Fasting
 
 
 
 
1.
 
To
 
refer
 
to
 
the
 
latest
 
advisory
 
by
 
religious
 
authority
 
 
 
 
 
 
Side
 
Effects
 
and
 
their
 
Management*
 
1.
 
Erythema
 
2.
 
Scaling
 
3.
 
Dryness
 
4.
 
Pruritus
 
5.
 
Burning
 
sensation
 
 
6.
 
Photosensitivity
 
7.
 
Skin
 
peeling
 
 
 
 
 
368
 

=== PAGE 370 ===

 
Storage*
 
1.
 
Keep
 
the
 
container
 
tightly
 
closed.
 
2.
 
Store
 
at
 
room
 
temperature.
 
3.
 
Protect
 
from
 
light,
 
heat
 
and
 
moisture.
 
4.
 
Keep
 
medicine
 
out
 
of
 
reach
 
of
 
children.
 
 
 
 
Others
 
1.
 
After
 
applying
 
the
 
medication,
 
a
 
mild
 
sensation
 
of
 
warmth,
 
slight
 
redness,
 
and
 
a
 
burning
 
feeling
 
may
 
occur .
 
2.
 
Some
 
redness
 
and
 
skin
 
peeling
 
may
 
occur
 
in
 
the
 
days
 
following
 
application
 
but
 
should
 
subside
 
with
 
time.
 
3.
 
Protect
 
the
 
face
 
from
 
direct
 
sunlight.
 
Wear
 
sunscreen.
 
4.
 
Excessive
 
sun
 
exposure,
 
including
 
sunlamps,
 
should
 
be
 
avoided
 
while
 
using
 
the
 
preparation.
 
5.
 
Particular
 
caution
 
is
 
needed
 
when
 
using
 
products
 
containing
 
sulfur ,
 
resorcinol,
 
or
 
salicylic
 
acid,
 
as
 
they
 
may
 
cause
 
peeling
 
or
 
irritation
 
when
 
combined
 
with
 
tretinoin
.
 
6.
 
Prolonged
 
or
 
repeated
 
use
 
may
 
lead
 
to
 
hypersensitivity .
 
Excessive
 
application
 
should
 
be
 
avoided.
 
If
 
hypersensitivity
 
symptoms
 
occur ,
 
discontinue
 
use
 
and
 
consult
 
your
 
physician.
 
7.
 
Do
 
not
 
use
 
the
 
cream
 
if
 
the
 
skin
 
is
 
weeping
 
or
 
severely
 
inflamed.
 
8.
 
Avoid
 
contact
 
with
 
the
 
eyes,
 
mouth,
 
and
 
other
 
mucous
 
membranes.
 
9.
 
For
 
external
 
use
 
only.
 
10.
 
Dispose
 
of
 
any
 
remaining
 
product
 
in
 
the
 
tube
 
after
 
completing
 
your
 
course
 
of
 
treatment
 
or
 
once
 
the
 
product
 
has
 
expired.
 
 
 
 
Before
 
ending
 
this
 
peer
 
review
 
session,
 
the
 
reviewee
 
should
 
be
 
informed
 
of
 
the
 
step(s)
 
that
 
he/
 
she
 
missed
 
out
 
in
 
order
 
to
 
ensure
 
all
 
the
 
counselling
 
points
 
are
 
being
 
covered.
 
 
Remarks:
 
 
 
 
 
Reviewed
 
by:
 
Name
 
&
 
Signature
                                                                   
Date:
 
 
 
 
 
*Mandatory
 
for
 
validation
 
/
 
peer
 
review
 
References
 
:
 
 
1.
 
Formulari
 
Ubat
 
Kementerian
 
Kesihatan
 
Malaysia
 
Bil
 
2/2024.
 
2.
 
Y.S.P
 
Industries
 
(M)
 
SDN
 
BHD.(
 
March
 
2022).
 
Tretinon
 
Cream
 
0.05%
 
 
Product
 
Leaflet.
 
 
  
 
 
 
 
 
 
 
 
 
 
369
 

=== PAGE 371 ===

 
Trihexyphenidyl
 
(benzhexol)
 
Name
 
:
 
 
Unit
 
:
 
 
Please
 
tick
 
(
✔
)
 
Yes
 
for
 
correct
 
instruction.
 
Please
 
tick
 
(
✔
)
 
No
 
for
 
incorrect
 
instruction.
 
Yes
 
No
 
Remarks
 
Pharmacological
 
Group
 
Antimuscarinic
 
agents
 
 
 
 
Indications
 
and
 
Dosage
 
1.
 
Symptomatic
 
treatment
 
of
 
paralysis
 
agitans
 
and
 
of
 
parkinsonism,
 
arteriosclerotic,
 
idiopathic,
 
or
 
post-encephalitic
 
origin,
 
spasmodic
 
torticollis,
 
facial
 
spasms
 
and
 
other
 
dyskinesia:
 
 
Initially
 
1-2
 
mg
 
daily.
 
May
 
gradually
 
increase
 
to
 
6-10mg
 
daily
 
according
 
to
 
response.
 
2.
 
Alleviate
 
extrapyramidal
 
syndrome
 
induced
 
by
 
phenothiazine
 
derivatives
 
or
 
reserpine:
 
 
From
 
5-15
 
mg
 
daily
 
in
 
3-4
 
divided
 
doses
 
 
Or
 
To
 
counsel
 
based
 
on
 
specific
 
medication’ s
 
indication
 
and
 
dosage
 
as
 
prescribed
 
by
 
the
 
doctor
 
 
 
 
Method
 
of
 
Administration*
 
1.
 
May
 
be
 
taken
 
with
 
or
 
without
 
food.
 
2.
 
Take
 
before
 
meals
 
if
 
dry
 
mouth
 
occurs,
 
after
 
meals
 
if
 
drooling/
 
nausea
 
occurs.
 
 
3.
 
Take
 
at
 
the
 
same
 
time
 
each
 
day.
 
 
4.
 
Missed
 
dose:
 
take
 
as
 
soon
 
as
 
you
 
remember .
 
If
 
it
 
is
 
close
 
to
 
the
 
time
 
for
 
your
 
next
 
dose,
 
skip
 
the
 
missed
 
dose
 
and
 
go
 
back
 
to
 
your
 
normal
 
time.
 
Do
 
not
 
take
 
2
 
doses
 
at
 
the
 
same
 
time
 
or
 
extra
 
doses.
 
 
Do
 
not
 
stop
 
taking
 
your
 
medication
 
unless
 
advised
 
to
 
do
 
so
 
by
 
your
 
prescriber
 
 
 
 
Special
 
Considerations
 
Pregnancy
 
 
 
 
Benzhexol
 
should
 
not
 
be
 
used
 
during
 
pregnancy
 
unless
 
clearly
 
necessary .
 
Inform
 
your
 
prescriber
 
if
 
you
 
are
 
planning
 
for
 
pregnancy
 
or
 
become
 
pregnant
 
while
 
taking
 
this
 
medication.
 
 
 
 
Breastfeeding
 
 
 
 
 
Benzhexol
 
should
 
not
 
be
 
used
 
during
 
breastfeeding.
 
 
 
 
Elderly
 
 
 
 
Beer
 
Criteria
 
:
 
 
Avoid.
 
Strong
 
anticholinergic
 
activity .
 
Not
 
recommended
 
for
 
prevention
 
or
 
treatment
 
of
 
extrapyramidal
 
symptoms
 
due
 
to
 
antipsychotics;
 
more
 
effective
 
agents
 
available
 
for
 
treatment
 
of
 
Parkinson
 
disease.
 
 
 
 
Paediatric
 
 
 
 
Safety
 
and
 
efficacy
 
in
 
paediatric
 
patients
 
have
 
not
 
been
 
established.
 
 
 
 
 
Fasting
 
 
 
 
370
 

=== PAGE 372 ===

 
Administer
 
during
 
Sahur
 
or
 
after
 
Iftar.
 
 
 
To
 
refer
 
to
 
the
 
latest
 
advisory
 
by
 
religious
 
authority
 
 
 
 
Renal
 
Impairment
 
 
 
 
 
Use
 
with
 
caution
 
 
 
 
Hepatic
 
Impairment
 
 
 
 
 
Use
 
with
 
caution
 
 
 
 
Side
 
Effects
 
and
 
their
 
Management*
 
1.
 
Anticholinergic
 
a.
 
Blurred
 
vision,
 
constipation,
 
urinary
 
retention
 
and
 
dry
 
mouth
 
b.
 
Constipation
 
can
 
be
 
managed
 
by
 
physical
 
activity ,
 
fluid
 
and
 
fibre
 
intake
 
or
 
laxatives.
 
 
c.
 
Increased
 
ocular
 
pressure:
 
Change
 
in
 
eyesight,
 
eye
 
pain,
 
or
 
severe
 
eye
 
irritation.
 
Immediately
 
contact
 
your
 
prescriber
 
2.
 
Cardiovascular
 
a.
 
May
 
cause
 
rapid,
 
slow
 
or
 
irregular
 
heart
 
beats
 
3.
 
Neurologic
 
a.
 
Memory
 
problems
 
or
 
loss,
 
confusion,
 
hallucination
 
(seeing
 
or
 
hearing
 
things
 
that
 
is
 
not
 
there),
 
agitation,
 
change
 
in
 
behavior ,
 
dizziness,
 
nervousness
 
4.
 
Other
 
potentially
 
concerning
 
side
 
effects
 
a.
 
GI
 
s/e
 
such
 
as
 
nausea
 
&
 
vomiting
 
b.
 
Unexplained
 
fever
 
or
 
not
 
sweating
 
during
 
activities
 
or
 
in
 
warm
 
temperatures
 
c.
 
Sensitivity
 
to
 
light
 
 
 
 
Storage*
 
Store
 
at
 
a
 
temperature
 
below
 
30°C.
 
 
 
 
Other
 
Used
 
with
 
caution
 
in
 
patients
 
with
 
arteriosclerosis,
 
history
 
of
 
drug
 
idiosyncrasy ,
 
CV
 
disease,
 
glaucoma,
 
GI
 
obstruction,
 
prostatic
 
hyperplasia
 
and
 
/or
 
urinary
 
stricture.
 
Not
 
intended
 
for
 
treatment
 
of
 
tardive
 
dyskinesia
 
 
 
 
Before
 
ending
 
this
 
peer
 
review
 
session,
 
the
 
reviewee
 
should
 
be
 
informed
 
of
 
the
 
step(s)
 
that
 
he/
 
she
 
missed
 
out
 
in
 
order
 
to
 
ensure
 
all
 
the
 
counselling
 
points
 
are
 
being
 
covered.
 
Remarks:
 
 
Reviewed
 
by:
 
Name
 
&
 
Signature
                                                                   
Date:
 
*Mandatory
 
for
 
validation/peer
 
review
 
References
 
:
 
 
1.
 
Pharmaniaga
 
(2024).
 
Product
 
Information
 
Leaflet:
 
Benzhexol.
 
Retrieved
 
from
 
Quest
 
3+
 
Search
 
on
 
January
 
21,
 
2025
 
2.
 
UpToDate,
 
Inc.
 
(2024).
 
Trihexyphenidyl:
 
Drug
 
information
 
(Version
 
3.68.3)
 
[Mobile
 
application].
 
UpToDate,
 
Inc.
 
3.
 
Formulari
 
Ubat
 
KKM.
 
(2025,
 
January
 
1).
 
Accessed
 
on
 
January
 
20,
 
2025.
 
4.
 
Stahl,
 
S.
 
M.
 
(2017).
 
Stahl’ s
 
Essential
 
Psychopharmacology
 
Prescriber ’s
 
Guide.
 
In
 
Australian
 
Prescriber
 
(6th
 
ed.,
 
Issue
 
1).
 
Cambridge
 
university
 
press.
 
https://doi.org/10.18773/austprescr .2016.001
 
 
5.
 
2023
 
American
 
Geriatrics
 
Society
 
Beers
 
Criteria®
 
Update
 
Expert
 
Panel.
 
(2023).
 
American
 
Geriatrics
 
Society
 
2023
 
updated
 
AGS
 
Beers
 
Criteria®
 
for
 
potentially
 
inappropriate
 
medication
 
use
 
in
 
older
 
adults.
 
Journal
 
of
 
the
 
American
 
Geriatrics
 
Society ,
 
71(7),
 
2052-2081.
 
371
 

=== PAGE 373 ===

 
Trimetazidine/Trimetazidine
 
Modified
 
Release
 
(MR)
 
 
Name
 
:
 
 
Unit
 
:
 
 
●
 
Please
 
tick
 
(
✔
)
 
Yes
 
for
 
correct
 
instruction.
 
●
 
Please
 
tick
 
(
✔
)
 
No
 
for
 
incorrect
 
instruction.
 
Yes
 
No
 
Remarks
 
Pharmacological
 
Group
 
Antianginal
 
drug,
 
MOA:
 
3-Ketoacyl
 
CoA
 
thiolase
 
[KAT]
 
inhibitor
 
 
 
 
Indications
 
and
 
Dosage
 
Prophylactic
 
treatment
 
of
  
episodes
 
of
 
angina
 
pectoris
 
 
1.
 
Trimetazidine
 
20mg
 
tds
 
20mg
 
3
 
times
 
daily
 
 
2.
 
Trimetazidine
 
MR
 
35mg
 
bd
 
35mg
 
twice
 
daily
 
in
 
the
 
morning
 
and
 
evening
 
with
 
meals
 
 
 
 
 
Method
 
of
 
Administration*
 
1.
 
To
 
be
 
taken
 
with
 
food.
 
2.
 
For
 
MR
 
preparation,
 
swallow
 
whole.
 
Do
 
not
 
split,
 
crush.
 
 
Do
 
not
 
stop
 
taking
 
your
 
medication
 
unless
 
advised
 
to
 
do
 
so
 
by
 
your
 
prescriber
 
 
 
 
Special
 
Considerations
 
Pregnancy
 
 
 
 
1.
 
No
 
data
 
available.
 
Avoid
 
use
 
during
 
pregnancy .
 
 
 
 
Breastfeeding
 
 
 
 
1.
 
Not
 
recommended.
 
 
 
 
 
Elderly
 
 
 
 
Product
 
Leaflet:
 
 
Elderly
 
patients
 
may
 
have
 
increased
 
trimetazidine
 
exposure
 
due
 
to
 
age-related
 
decrease
 
in
 
renal
 
function.
 
Dose
 
titration
 
in
 
elderly
 
patients
 
should
 
be
 
exercised
 
with
 
caution.
 
 
 
 
 
Paediatric
 
 
 
 
1.
 
No
 
data
 
available.
 
 
 
 
Fasting
 
 
 
 
1.
 
To
 
refer
 
to
 
the
 
latest
 
advisory
 
by
 
religious
 
authority
 
 
 
 
 
Others
  
(
eg.
 
hepatic
 
impairment,
 
renal
 
impairment
 
which
 
will
 
be
 
relevant
 
to
 
the
 
patient)
 
 
 
 
Renal
 
impairment
 
 
1.
 
CrCl<
 
30ml/min:
 
contraindicated
 
2.
 
CrCl
 
30-60
 
ml/min:
 
Require
 
dose
 
adjustment
 
to
 
Trimetazidine
 
20mg
 
bd
 
OR
 
Trimetazidine
 
MR
 
35mg
 
om
 
 
 
 
Side
 
Effects
 
and
 
1.
 
New-onset
 
or
 
worsening
 
of
 
parkinsonian
 
symptoms
 
 
 
 
372
 

=== PAGE 374 ===

 
their
 
Management*
 
(e.g.
 
akinesia,
 
hypertonia,
 
tremor).
 
Close
 
monitoring
 
in
 
elderly
 
and
 
patients
 
with
 
renal
 
impairment.
 
 
2.
 
Drowsiness
 
and
 
dizziness.
 
If
 
affected,
 
do
 
not
 
drive
 
or
 
operate
 
machinery .
 
 
3.
 
May
 
cause
 
headache;
 
gastrointestinal
 
disorders
 
ie
 
abdominal
 
pain,
 
diarrhea,
 
dyspepsia,
 
nausea,
 
vomiting;
 
rash,
 
pruritus,
 
urticarial;
 
asthenia.
 
 
Storage*
 
1.
 
Store
 
below
 
30
o
C.
 
Keep
 
out
 
reach
 
of
 
children.
 
 
 
 
Others
 
NA
 
 
 
 
Before
 
ending
 
this
 
peer
 
review
 
session,
 
the
 
reviewee
 
should
 
be
 
informed
 
of
 
the
 
step(s)
 
that
 
he/
 
she
 
missed
 
out
 
in
 
order
 
to
 
ensure
 
all
 
the
 
counselling
 
points
 
are
 
being
 
covered.
 
 
Remarks:
 
 
 
 
 
Reviewed
 
by:
 
Name
 
&
 
Signature
                                                                   
Date:
 
 
 
 
 
*Mandatory
 
for
 
validation
 
/
 
peer
 
review
 
References:
 
 
1.
 
Trimetazidine
.
 
(2024).
 
MimsGateway .
 
Retrieved
 
January
 
21,
 
2025,
 
from
 
https://online1.mimsgateway .com.my/
 
 
2.
 
Medreich
 
Limited
 
(Unit
 
3).
 
(2022).
 
Product
 
information
 
leaflet:
 
Trime
 
MR
 
(Trimetazidine
 
Dihydrochloride
 
MR
 
Tablets
 
35mg.
 
Retrieved
 
from
 
Quest
 
3+
 
Product
 
Search
 
on
 
January
 
21,
 
2025.
 
3.
 
Duopharm(M)
 
Sdn
 
Bhd.
 
(2015).
 
Product
 
Information
 
leaflet:
 
Metazine.
 
Retrieved
 
January
 
21,
 
2025.
 
from
 
file:///C:/Users/asetbpf05/Downloads/Metazine%20T ablet%20(T rimetazidine)%20Duopharma%20(M)%2
0Sdn.%20Bhd.%2021Apr2015%20BM.pdf
 
 
 
 
 
 
 
 
 
 
 
 
 
373
 

=== PAGE 375 ===

 
Verapamil
 
 
Name
 
:
 
 
Unit
 
:
 
 
●
 
Please
 
tick
 
(
✔
)
 
Yes
 
for
 
correct
 
instruction.
 
●
 
Please
 
tick
 
(
✔
)
 
No
 
for
 
incorrect
 
instruction.
 
Yes
 
No
 
Remarks
 
Pharmacological
 
Group
 
Antianginal;
 
Calcium
 
Channel
 
Blocker ,
 
Nondihydropyridine
 
Antihypertensive;
 
antiarrhythmic
 
agent
 
 
 
 
Indications
 
and
 
Dosage
 
1.
 
Supraventricular
 
arrhythmias
 
(SVT)
 
prophylaxis
:
 
120mg
 
-480mg
 
in
 
2-3
  
divided
 
dose
 
 
 
2.
 
Angina:
 
80mg-120mg
 
3
 
times
 
daily
 
 
3.
 
Hypertension:
 
Initially
 
240mg
 
daily
 
in
 
2-3
 
divided
 
dose
 
Maximum
 
:
 
480mg
 
daily
 
 
4.
 
Supraventricular
 
tachycardia:
 
Initially
 
5-10
 
mg
 
via
 
slow
 
iv
 
over
 
at
 
least
 
2
 
minutes.The
 
dose
 
can
 
be
 
repeated
 
10mg
 
30
 
minutes
 
after
 
the
 
first
 
dose
 
if
 
the
 
initial
 
response
 
is
 
not
 
adequate.
 
 
 
 
Method
 
of
 
Administration*
 
1.
 
Should
 
be
 
taken
 
with
 
food
 
2.
 
Should
 
not
 
be
 
taken
 
with
 
grapefruit
 
juice
 
 
Do
 
not
 
stop
 
taking
 
your
 
medication
 
unless
 
advised
 
to
 
do
 
so
 
by
 
your
 
prescriber
 
 
 
 
Special
 
Considerations
 
Pregnancy
 
 
 
 
 
1.
 
Limited
 
data.
 
Drugs
 
should
 
be
 
given
 
only
 
if
 
the
 
potential
 
benefit
 
justifies
 
the
 
potential
 
risk
 
to
 
the
 
foetus.
 
 
 
 
Breastfeeding
 
 
 
 
1.
 
Limited
 
Human
 
Data—Probably
 
Compatible
 
 
 
 
Elderly
 
 
 
 
STOPP/ST ART
 
Criteria:
 
1.
 
Avoid
 
Verapamil
 
with
 
NYHA
 
Class
 
III
 
or
 
IV
 
heart
 
failure
 
(may
 
worsen
 
heart
 
failure
 
with
 
reduced
 
ejection
 
fraction
 
i.e.,
 
HFREF).
 
2.
 
Avoid
 
beta-blocker
 
in
 
combination
 
with
 
verapamil
 
(risk
 
of
 
heart
 
block).
 
3.
 
Avoid
 
verapamil
 
with
 
bradycardia
 
(<
 
50/min),
 
type
 
II
 
heart
 
block
 
or
 
complete
 
heart
 
block
 
(risk
 
of
 
complete
 
heart
 
block,
 
asystole)
 
4.
 
Avoid
 
apixaban,
 
dabigatran,
 
edoxaban,
 
rivaroxaban
 
and
 
P-glycoprotein
 
(P-gp)
 
drug
 
efflux
 
pump
 
inhibitors
 
and
 
verapamil
 
(increased
 
risk
 
of
 
bleeding)
 
5.
 
Avoid
 
acetylcholinesterase
 
inhibitors
 
with
 
concurrent
 
treatment
 
with
 
verapamil
 
(risk
 
of
 
cardiac
 
conduction
 
failure,
 
syncope
 
and
 
injury).
 
6.
 
Avoid
 
verapamil
 
with
 
chronic
 
constipation
 
where
 
non-constipating
 
alternatives
 
are
 
available
 
(risk
 
of
 
exacerbation
 
of
 
constipation).
 
 
 
 
Paediatric
 
 
 
 
374
 

=== PAGE 376 ===

 
1.
 
Antihypertensive
 
  
≤2
 
yr
 20
 
mg
 
2-3
 
times
 
daily; 
>2
 
yr
 40-120
 
mg
 
2-3
 
times
 
daily,
 
depending
 
on
 
age
 
and
 
response.
 
 
2.
 
Supraventricular
 
arrhythmias
:
 
a.
 
ORAL:
 
 
≤2
 
yr 
20
 
mg
 
2-3
 
times
 
daily
 
 
>2
 
yr
 40-120
 
mg
 
2-3
 
times
 
daily,
 
 
depending
 
on
 
age
 
and
 
response.
 
b.
 
IV:
 
 
≤1
 
years
 0.1-0.2
 
mg/kg
 
 
1-15
 
years
 0.1-0.3
 
mg/kg
 
(Max:
 
5
 
mg).
 
 
All
 
doses
 
to
 
be
 
given
 
over
 
at
 
least
 
2
 
minutes,
 
repeat
 
after
 
30
 
min
 
if
 
needed.
 
 
 
 
Fasting
 
 
 
 
1.
 
To
 
refer
 
to
 
the
 
latest
 
advisory
 
by
 
religious
 
authority
 
 
 
 
Others
  
(
eg.
 
hepatic
 
impairment,
 
renal
 
impairment
 
which
 
will
 
be
 
relevant
 
to
 
the
 
patient)
 
 
 
 
1.
 
Renal
 
impairment:
 
 
No
 
dosage
 
adjustment.
 
Not
 
removed
 
by
 
hemo-
 
or
 
peritoneal
 
dialysis;
 
supplemental
 
dose
 
is
 
not
 
necessary
 
2.
 
Liver
 
impairment:
 
Oral:
 
In
 
cirrhosis,
 
reduce
 
dose
 
to
 
20%
 
of
 
normal
 
and
 
monitor
 
ECG.
 
IV:
  
In
 
cirrhosis,
 
reduce
 
dose
 
to
 
50%
 
of
 
normal
 
and
 
monitor
 
ECG.
 
 
 
 
Side
 
Effects
 
and
 
their
 
Management*
 
-
 
Common
 
side
 
effect
 
:
 
 
AV
 
block,
 
bradycardia,
 
worsening
 
heart
 
failure,
 
transient
 
asystole,
 
hypotension,
 
dizziness,
 
flushing,
 
fatigue,
 
headache,
 
dyspnoea,
 
peripheral
 
oedema,
 
constipation,
 
nausea,
 
abnormal
 
liver
 
function,
 
skin
 
reactions,
 
gingival
 
hyperplasia,
 
extrapyramidal
 
symptoms.
 
 
-
 
Rarely ,
 
gynaecomastia.
 
 
-
 
Potentially
 
Fatal:
 H
epatotoxicity .
 
 
 
 
 
Storage*
 
1.
 
Store
 
below
 
30
0
C,
 
protect
 
from
 
light.
 
 
 
 
Others
 
Precautions
 
1.
 
Use
 
with
 
caution
 
in
 
patients
 
in
 
acute
 
stage
 
of
 
myocardial
 
infarction,
 
hepatic
 
impairment,
 
bradycardia
 
or
 
1
st
 
degree
 
AV
 
block,
 
attenuated
 
neuromuscular
 
transmission.
 
Monitoring
 
parameters
 
1.
 
Blood
 
pressure,
 
ECG,
 
heart
 
rate,
 
liver
 
function
 
test
 
(ALT)
 
Significant
 
drug-drug
 
interactions
 
1.
 
Ivabradine:
 
Concomitant
 
use
 
is
 
contraindicated
 
due
 
to
 
additional
 
heart
 
lowering
 
effect
 
of
 
verapamil
 
to
 
Ivabradine
 
2.
 
Beta
 
blockers
 
&
 
antiarrhythmic
 
agent:
 
May
 
lead
 
to
 
additive
 
cardiovascular
 
effects
 
such
 
as
 
AV
 
block,bradycardia,hypotension,heart
 
failure.
 
3.
 
Lithium:
 
Concomitant
 
use
 
may
 
enhanced
 
neurotoxicity
 
4.
 
Atorvastatin
 
:
 
May
 
increase
 
risk
 
of
 
myopathy
 
and
 
rhabdomyolysis
 
 
 
 
 
375
 

=== PAGE 377 ===

 
Before
 
ending
 
this
 
peer
 
review
 
session,
 
the
 
reviewee
 
should
 
be
 
informed
 
of
 
the
 
step(s)
 
that
 
he/
 
she
 
missed
 
out
 
in
 
order
 
to
 
ensure
 
all
 
the
 
counselling
 
points
 
are
 
being
 
covered.
 
 
Remarks:
 
 
 
 
 
Reviewed
 
by:
 
Name
 
&
 
Signature
                                                                   
Date:
 
 
 
 
 
*Mandatory
 
for
 
validation
 
/
 
peer
 
review
 
References:
 
 
1.
 
MEDOCHEMIE
 
LTD.
 
(2021).
 
Product
 
Information
 
Leaflet:
 
Akilen.
 
Retrieved
 
January
 
21,
 
2025.
 
from
 
https://medicinesauthority .gov.mt/file.ashx?f=3585B7F7E76D20642D14A8183D5BF1F8BCC2EA01CAD
BD15C
 
 
2.
 
Verapamil
.
 
(2024).
 
MimsGateway .
 
Retrieved
 
January
 
21,
 
2025,
 
from
 
https://online1.mimsgateway .com.my/
 
 
3.
 
Somogyi,
 
A.,
 
Albrecht,
 
M.,
 
Kliems,
 
G.,
 
Schäfer ,
 
K.,
 
&
 
Eichelbaum,
 
M.
 
(1981).
 
Pharmacokinetics,
 
bioavailability
 
and
 
ECG
 
response
 
of
 
verapamil
 
in
 
patients
 
with
 
liver
 
cirrhosis.
 
British
 
journal
 
of
 
clinical
 
pharmacology ,
 
12(1),
 
51–60.
 
https://doi.org/10.1 111/j.1365-2125.1981.tb01854.x
 
4.
 
O’Mahony ,
 
D.,
 
Cherubini,
 
A.,
 
Guiteras,
 
A.
 
R.,
 
Denkinger ,
 
M.,
 
Beuscart,
 
J.
 
B.,
 
Onder ,
 
G.,
 
...
 
&
 
Curtin,
 
D.
 
(2023).
 
STOPP/ST ART
 
criteria
 
for
 
potentially
 
inappropriate
 
prescribing
 
in
 
older
 
people:
 
version
 
3.
 
European
 
geriatric
 
medicine,
 
14(4),
 
625-632
.
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
376
 

=== PAGE 378 ===

 
Vitamin
 
D
 
Analogues
 
Name
 
:
 
 
Unit
 
:
 
 
●
 
Please
 
tick
 
(
✔
)
 
Yes
 
for
 
correct
 
instruction.
 
●
 
Please
 
tick
 
(
✔
)
 
No
 
for
 
incorrect
 
instruction.
 
Yes
 
No
 
Remarks
 
Pharmacological
 
Group
 
Antipsoriatics
 
for
 
topical
 
use;
 
Vitamin
 
D
 
Analogues
 
 
 
 
Indications
 
and
 
Dosage
 
Indication:
 
 
1.
 
Psoriasis
 
vulgaris
 
2.
 
Resistant
 
plaque
 
psoriasis
 
 
 
Calcipotriol
 
50mcg/g
 
Ointment:
 
ADUL T:
 
Apply
 
to
 
the
 
affected
 
skin
 
lesions
 
twice
 
daily.
 
Maintenance
 
therapy
 
may
 
be
 
achieved
 
with
 
less
 
frequent
 
application.
 
The
 
weekly
 
dose
 
should
 
not
 
exceed
 
100g.
 
 
 
CHILD
 
over
 
6
 
years:
 
apply
 
twice
 
daily.
 
6-12
 
years
 
maximum
 
50gm
 
weekly ,
 
over
 
12
 
years
 
maximum
 
75gm
 
weekly
 
 
The
 
dosing
 
is
 
individualized
 
according
 
to
 
product
 
insert
 
/
 
protocol.
 
 
Calcipotriol
 
Hydrate
 
50
 
mcg/g
 
&
 
Betamethasone
 
Dipropionate
 
0.5
 
mg/g
 
Ointment:
 
Apply
 
once
 
daily
 
up
 
to
 
4
 
weeks
 
with
 
maximum
 
weekly
 
dose
 
of
 
100g
 
and
 
maximum
 
treatment
 
area
 
30%
 
of
 
body
 
surface.
 
 
Calcipotriol
 
Monohydrate
 
50
 
mcg/g
 
&
 
Betamethasone
 
Dipropionate
 
0.5
 
mg/g
 
Gel:
 
Should
 
be
 
applied
 
to
 
affected
 
areas
 
once
 
daily.
 
The
 
recommended
 
treatment
 
period
 
is
 
4
 
weeks
 
for
 
scalp
 
areas
 
and
 
8
 
weeks
 
for
 
non-scalp
 
areas.
 
The
 
body
 
surface
 
area
 
treated
 
with
 
calcipotriol
 
containing
 
products
 
should
 
not
 
exceed
 
30%
 
and
 
maximum
 
dose
 
should
 
not
 
exceed
 
15g
 
or
 
100g/
 
week.
 
 
Calcipotriol
 
Monohydrate
 
50mcg/g
 
&
 
Betamethasone
 
Dipropionate
 
0.5mg/g
 
Cutaneous
 
Foam:
 
Apply
 
once
 
daily
 
up
 
to
 
4
 
weeks
 
with
 
maximum
 
daily
 
dose
 
of
 
15g
 
and
 
maximum
 
treatment
 
area
 
30%
 
of
 
body
 
surface.
 
 
Or
 
 
 
To
 
counsel
 
based
 
on
 
specific
 
medication’ s
 
indication
 
and
 
dosage
 
as
 
prescribed
 
by
 
the
 
doctor
 
 
 
 
Method
 
of
 
Administration*
 
Calcipotriol
 
ointment:
 
•
 
Should
 
be
 
applied
 
to
 
the
 
affected
 
area.
 
•
 
Use
 
as
 
directed
 
by
 
your
 
doctor
 
or
 
pharmacist
 
 
Calcipotriol
 
+
 
Betamethasone
 
Ointment:
 
•
 
Should
 
be
 
applied
 
to
 
the
 
affected
 
area.
 
In
 
order
 
to
 
achieve
 
optimal
 
effect,
 
it
 
is
 
not
 
recommended
 
to
 
take
 
a
 
shower
 
or
 
bath
 
immediately
 
after
 
application.
 
Once
 
daily
 
application
 
(usually
 
at
 
night)
 
 
Calcipotriol
 
+
 
Betamethasone
 
Gel:
 
1.
 
Use
 
only
 
for
 
scalp
 
psoriasis
 
and
 
do
 
not
 
use
 
it
 
on
 
skin
 
which
 
does
 
not
 
have
 
psoriasis.
 
2.
 
Washing
 
your
 
hair
 
before
 
application
 
of
 
Xamiol
 
is
 
not
 
necessary .
 
 
 
 
377
 

=== PAGE 379 ===

 
3.
 
Shake
 
the
 
bottle
 
before
 
use
 
and
 
remove
 
the
 
cap.
 
4.
 
Before
 
applying
 
Xamiol
 
to
 
the
 
scalp,
 
comb
 
the
 
hair
 
to
 
remove
 
any
 
loose
 
scales.
 
Apply
 
Xamiol
 
to
 
the
 
affected
 
area
 
with
 
your
 
fingertips,
 
and
 
rub
 
it
 
in
 
gently .
 
5.
 
Do
 
not
 
bandage,
 
tightly
 
cover
 
or
 
wrap
 
the
 
treated
 
skin
 
area.
 
6.
 
Wash
 
your
 
hands
 
well
 
after
 
using
 
Xamiol.
 
This
 
will
 
avoid
 
accidentally
 
spreading
 
the
 
gel
 
to
 
other
 
parts
 
of
 
your
 
body
 
(especially
 
the
 
face,
 
mouth
 
and
 
eyes).
 
7.
 
In
 
order
 
to
 
achieve
 
optimal
 
effect,
 
it
 
is
 
recommended
 
that
 
the
 
hair
 
is
 
not
 
washed
 
immediately
 
after
 
application
 
of
 
Xamiol.
 
Let
 
Xamiol
 
remain
 
on
 
the
 
scalp
 
during
 
the
 
night
 
or
 
during
 
the
 
day.
 
8.
 
Apply
 
a
 
mild
 
shampoo
 
to
 
the
 
dry
 
hair,
 
especially
 
to
 
those
 
areas
 
where
 
the
 
gel
 
was
 
applied.
 
9.
 
Leave
 
the
 
shampoo
 
on
 
the
 
scalp
 
for
 
a
 
couple
 
of
 
minutes
 
before
 
washing.
 
10.
 
Then
 
wash
 
your
 
hair
 
as
 
usual.
  
 
 
Calcipotriol
 
+
 
Betamethasone
 
cutaneous
 
foam:
 
•
 
Should
 
be
 
applied
 
to
 
dry
 
skin
 
on
 
the
 
affected
 
areas
 
of
 
the
 
body .
 
 
 
 
For
 
body
 
psoriasis:
 
 
1.
 
The
 
can
 
should
 
be
 
shaken
 
for
 
a
 
few
 
seconds
 
before
 
use.
 
 
2.
 
Apply
 
the
 
foam
 
by
 
holding
 
the
 
can
 
at
 
least
 
3
 
cm
 
from
 
the
 
skin
 
and
 
spray
 
directly
 
onto
 
each
 
affected
 
area.
 
 
3.
 
The
 
foam
 
can
 
be
 
sprayed
 
holding
 
the
 
can
 
in
 
any
 
orientation
 
except
 
horizontally .
 
 
4.
 
It
 
should
 
be
 
sprayed
 
directly
 
onto
 
each
 
affected
 
skin
 
area
 
and
 
rubbed
 
in
 
gently .
 
 
5.
 
After
 
applying
 
the
 
foam,
 
put
 
the
 
cap
 
back
 
on
 
the
 
can
 
to
 
prevent
 
accidental
 
spraying
 
when
 
not
 
in
 
use.
 
 
6.
 
Wash
 
your
 
hands
 
well
 
after
 
using
 
(unless
 
you
 
are
 
using
 
the
 
foam
 
to
 
treat
 
your
 
hands).
 
This
 
will
 
avoid
 
accidentally
 
spreading
 
the
 
foam
 
to
 
other
 
parts
 
of
 
your
 
body
 
(especially
 
the
 
face,
 
mouth
 
and
 
eyes).
 
7.
 
In
 
order
 
to
 
achieve
 
optimal
 
effect,
 
it
 
is
 
recommended
 
that
 
the
 
body
 
is
 
not
 
washed
 
immediately
 
after
 
application.
 
Let
 
the
 
foam
 
remain
 
on
 
the
 
skin
 
during
 
the
 
night
 
or
 
during
 
the
 
day.
 
8.
 
The
 
treated
 
area
 
does
 
not
 
need
 
to
 
be
 
covered.
 
You
 
may
 
wear
 
your
 
usual
 
clothes
 
however
 
avoid
 
contact
 
with
 
fabric
 
that
 
is
 
easily
 
stained
 
by
 
grease
 
(e.g.silk).
 
 
 
For
 
scalp
 
psoriasis:
 
 
1.
 
Comb
 
the
 
hair
 
to
 
remove
 
any
 
loose
 
scales.
 
 
2.
 
Shake
 
the
 
can
 
for
 
a
 
few
 
seconds
 
before
 
use.
 
 
3.
 
Hold
 
the
 
can
 
at
 
least
 
3
 
cm
 
away .
 
Spray
 
directly
 
into
 
the
 
palm
 
of
 
your
 
hand.
 
The
 
foam
 
can
 
be
 
sprayed
 
holding
 
the
 
can
 
in
 
any
 
orientation
 
except
 
horizontally .
 
4.
 
Scoop
 
the
 
foam
 
onto
 
your
 
finger
 
and
 
apply
 
it
 
directly
 
to
 
the
 
affected
 
areas.
 
Minimize
 
applying
 
into
 
the
 
hair
 
to
 
make
 
it
 
easier
 
to
 
wash
 
it
 
out.
 
Gently
 
rub
 
the
 
foam
 
into
 
the
 
scalp.
 
After
 
applying
 
the
 
foam,
 
put
 
the
 
cap
 
on
 
the
 
can
 
to
 
prevent
 
accidental
 
spraying
 
when
 
not
 
in
 
use.
 
5.
 
Wash
 
your
 
hands
 
well
 
after
 
using
 
Enstilar
 
(unless
 
you
 
are
 
using
 
the
 
foam
 
to
 
treat
 
your
 
hands).
 
This
 
will
 
avoid
 
accidentally
 
spreading
 
the
 
foam
 
to
 
other
 
parts
 
of
 
your
 
body
 
(especially
 
the
 
face,
 
mouth
 
and
 
eyes).
 
 
6.
 
In
 
order
 
to
 
achieve
 
optimal
 
effect,
 
it
 
is
 
recommended
 
that
 
the
 
hair
 
is
 
not
 
washed
 
immediately
 
after
 
378
 

=== PAGE 380 ===

 
application.
 
Let
 
the
 
foam
 
remain
 
on
 
the
 
scalp
 
during
 
the
 
night
 
or
 
during
 
the
 
day.
 
7.
 
Apply
 
a
 
mild,
 
non-medicated
 
shampoo
 
to
 
the
 
dry
 
hair,
 
focusing
 
on
 
the
 
areas
 
where
 
the
 
foam
 
was
 
applied.
 
It
 
is
 
easier
 
to
 
remove
 
Enstilar
 
when
 
shampoo
 
is
 
applied
 
to
 
dry
 
hair
 
as
 
water
 
dilutes
 
the
 
cleansing
 
effect
 
of
 
the
 
shampoo.
 
 
8.
 
Massage
 
the
 
shampoo
 
into
 
the
 
dry
 
hair/scalp.
 
Leave
 
the
 
shampoo
 
on
 
the
 
scalp
 
for
 
a
 
couple
 
of
 
minutes
 
before
 
washing.
 
 
9.
 
Rinse
 
thoroughly
 
with
 
water .
 
 
10.
 
Repeat
 
normal
 
shampooing
 
if
 
necessary .
 
 
Do
 
not
 
stop
 
taking
 
your
 
medication
 
unless
 
advised
 
to
 
do
 
so
 
by
 
your
 
prescriber
 
Special
 
Considerations
 
Pregnancy
 
 
 
 
1.
 
Limited
 
data
 
on
 
humans.
 
2.
 
Studies
 
with
 
animals
 
show
 
higher
 
incidence
 
of
 
skeletal
 
abnormalities.
 
3.
 
Systemic
 
absorption
 
may
 
occur
 
with
 
topical
 
vitamin
 
D
 
analogues.
 
Although
 
the
 
recommended
 
topical
 
dosage
 
is
 
considered
 
safe,
 
caution
 
is
 
required
.
 
 
 
 
 
Breastfeeding
 
 
 
 
1.
 
Calcipotriol
 
is
 
excreted
 
into
 
milk,
 
but
 
there
 
is
 
no
 
available
 
data
 
on
 
Calcipotriol.
 
Use
 
with
 
caution.
 
 
2.
 
If
 
applied
 
to
 
the
 
breasts,
 
stop
 
breastfeeding.
 
 
 
 
Elderly
 
 
 
 
1.
 
Use
 
with
 
caution
 
in
 
elderly
 
patients.
 
Severity
 
of
 
skin-related
 
adverse
 
reactions
 
may
 
be
 
increased
 
compared
 
to
 
younger
 
adults.
 
 
 
 
 
Paediatric
 
 
 
 
1)
 
Safety
 
and
 
efficacy
 
of
 
topical
 
Vitamin
 
D
 
analogues
 
preparations
 
in
 
pediatric
 
patients
 
below
 
the
 
age
 
of
   
6
 
years
 
have
 
not
 
been
 
established.
 
 
2)
 
Safety
 
and
 
efficacy
 
with
 
a
 
combination
 
of
 
topical
 
steroids
 
are
 
established
 
in
 
pediatric
 
patients.
 
 
Follow
 
the
 
specific
 
instructed
 
duration,
 
use
 
different
 
potencies
 
on
 
different
 
areas,
 
avoid
 
sensitive
 
areas
 
and
 
occlusion
 
unless
 
directed,
 
and
 
monitor
 
for
 
side
 
effects
 
such
 
as
 
skin
 
atrophy
 
or
 
systemic
 
absorption
 
 
 
 
Fasting
 
 
 
 
NA
 
 
 
 
Others
  
(
eg.
 
hepatic
 
impairment,
 
renal
 
impairment
 
which
 
will
 
be
 
relevant
 
to
 
the
 
patient)
 
 
 
 
1.
 
 
 
 
 
Side
 
Effects
 
and
 
their
 
Management
 
Itching,
 
rash,
 
thinning
 
of
 
the
 
skin,
 
skin
 
burning
 
 
 
 
379
 

=== PAGE 381 ===

 
Storage*
 
Keep
 
the
 
jar
 
tightly
 
closed.
 
Store
 
below
 
30°C
 
and
 
protect
 
from
 
heat,
 
moisture,
 
and
 
light.
 
Do
 
not
 
freeze.
 
Keep
 
out
 
of
 
reach
 
of
 
children.
 
 
 
Calcipotriol
 
+
 
Betamethasone
 
cutaneous
 
foam:
 
1.
 
Do
 
not
 
store
 
above
 
25°C.
 
2.
 
Extremely
 
flammable
 
aerosol.
 
 
3.
 
Pressurised
 
container:
 
May
 
burst
 
if
 
heated.
 
Protect
 
from
 
sunlight.
 
Do
 
not
 
expose
 
to
 
temperatures
 
exceeding
 
50°C.
 
 
4.
 
Do
 
not
 
pierce
 
or
 
burn,
 
even
 
after
 
use.
 
 
5.
 
Do
 
not
 
spray
 
on
 
an
 
open
 
flame
 
or
 
other
 
ignition
 
source.
 
Keep
 
away
 
from
 
sparks,
 
open
 
flames
 
and
 
other
 
ignition
 
sources.
 
No
 
smoking
 
near
 
the
 
can.
 
 
 
 
 
Others
 
1.
 
Do
 
not
 
use
 
more
 
than
 
the
 
recommended
 
dose
 
because
 
of
 
the
 
risk
 
of
 
hypercalcaemia.
 
2.
 
Avoid
 
contact
 
w/
 
face,
 
mouth
 
&
 
eyes.
 
3.
 
Avoid
 
excessive
 
exposure
 
to
 
sunlight.
 
4.
 
Avoid
 
concurrent
 
treatment
 
w/
 
other
 
steroids.
 
5.
 
Avoid
 
in
 
erythrodermic
 
and
 
generalised
 
pustular
 
psoriasis.
 
 
 
 
Before
 
ending
 
this
 
peer
 
review
 
session,
 
the
 
reviewee
 
should
 
be
 
informed
 
of
 
the
 
step(s)
 
that
 
he/
 
she
 
missed
 
out
 
in
 
order
 
to
 
ensure
 
all
 
the
 
counselling
 
points
 
are
 
being
 
covered.
 
 
Remarks:
 
 
 
 
 
Reviewed
 
by:
 
Name
 
&
 
Signature
                                                                   
Date:
 
 
 
 
 
 
*Mandatory
 
for
 
validation
 
/
 
peer
 
review
 
References:
 
 
1.
 
LEO
 
Laboratotories
 
Ltd.
 
(2021).Product
 
information
 
leaflet:
 
Enstilar®
 
.
 
Retrieved
 
from
 
Quest
 
3+
 
Product
 
Search
 
on
 
January
 
20,
 
2025.
 
2.
 
GENUONE
 
Sciences
 
Inc.
 
(2022).Product
 
information
 
leaflet:
 
CALCIBET
 
Ointment
.
 
Retrieved
 
from
 
Quest
 
3+
 
Product
 
Search
 
on
 
January
 
20,
 
2025.
 
3.
 
LEO
 
Laboratotories
 
Ltd.
 
(2019).Product
 
information
 
leaflet:
 
Xamiol®.
 
Retrieved
 
from
 
Product
 
Search
 
on
 
January
 
20,
 
2025.
 
4.
 
D
aivobet
 
oint.
 
(2025).
 
MimsGateway .
 
Retrie ved
 
January
 
20,
 
2025,
 
from
 
https://online1.mimsgateway .com.my/
 
 
5.
 
Enstilar
 
foam.
 
(2025).
 
MimsGateway .
 
Retrieved
 
January
 
20,
 
2025,
 
from
 
https://online1.mimsgateway .com.my/
 
 
6.
 
Butler ,
 
D.
 
C.,
 
Heller ,
 
M.
 
M.,
 
&
 
Murase,
 
J.
 
E.
 
(2014).
 
Safety
 
of
 
dermatologic
 
medications
 
in
 
pregnancy
 
and
 
lactation:
 
Part
 
II.
 
Lactation.
 
Journal
 
of
 
the
 
American
 
Academy
 
of
 
Dermatology ,
 
70(3),
 
417-e1.
 
7.
 
Maul,
 
J.
 
T.,
 
Anzengruber ,
 
F.,
 
Conrad,
 
C.,
 
Cozzio,
 
A.,
 
Häusermann,
 
P.,
 
Jalili,
 
A.,
 
...
 
&
 
Navarini,
 
A.
 
A.
 
(2021).
 
Topical
 
treatment
 
of
 
psoriasis
 
vulgaris:
 
the
 
Swiss
 
treatment
 
pathway .
 
Dermatology ,
 
237(2),
 
166-178.
 
8.
 
Ferreira,
 
C.,
 
Azevedo,
 
A.,
 
Nogueira,
 
M.,
 
&
 
Torres,
 
T.
 
(2020).
 
Management
 
of
 
psoriasis
 
in
 
pregnancy
 
-
 
a
 
review
 
of
 
the
 
evidence
 
to
 
date.
 
Drugs
 
in
 
context,
 
9,
 
2019-1 1-6.
 
https://doi.org/10.7573/dic.2019-1 1-6
 
 
 
380
 

=== PAGE 382 ===

 
Warfarin
 
Name
 
:
 
 
Unit
 
:
 
 
●
 
Please
 
tick
 
(
✔
)
 
Yes
 
for
 
correct
 
instruction.
 
●
 
Please
 
tick
 
(
✔
)
 
No
 
for
 
incorrect
 
instruction.
 
Yes
 
No
 
Remarks
 
Pharmacological
 
Group
 
Anticoagulant,
 
Vitamin
 
K
 
antagonist
 
 
 
 
 
Indications
 
and
 
Dosage
 
Treatment
 
and
 
prophylaxis
 
of
 
thromboembolic
 
disorders
 
1.
 
Initially
 
2-5mg
 
per
 
day.
 
2.
 
Maintenance
 
dose
 
2-10mg
 
daily
 
according
 
to
 
the
 
INR.
 
 
3.
 
Dosing
 
is
 
individualised
 
based
 
on
 
the
 
patient's
 
INR
 
and
 
according
 
to
 
product
 
insert/
 
protocol/
 
guideline.
 
 
 
 
Method
 
of
 
Administration*
 
1.
 
To
 
be
 
taken
 
with
 
or
 
without
 
food,
 
at
 
the
 
same
 
time
 
each
 
day.
 
Missed
 
dose
 
management
 
:
 
 
2.
 
If
 
you
 
miss
 
a
 
dose
 
(within
 
8
 
hours
 
of
 
usual
 
time),
 
take
 
it
 
as
 
soon
 
as
 
you
 
remember .
 
 
3.
 
If
 
it
 
is
 
almost
 
time
 
for
 
your
 
next
 
dose,
 
wait
 
until
 
then
 
to
 
take
 
the
 
medicine
 
and
 
skip
 
the
 
missed
 
dose.
 
 
4.
 
Do
 
not
 
take
 
a
 
double
 
dose.
 
 
Do
 
not
 
stop
 
taking
 
your
 
medication
 
unless
 
advised
 
to
 
do
 
so
 
by
 
your
 
prescriber .
 
 
 
 
Special
 
Considerations
 
Pregnancy
 
 
 
 
1.
 
Warfarin
 
crosses
 
the
 
placenta.
 
It
 
increases
 
the
 
risk
 
of
 
adverse
 
fetal
 
outcomes.
1
 
2.
 
Discuss
 
with
 
your
 
doctor
 
if
 
you
 
are
 
planning
 
for
 
a
 
pregnancy/
 
have
 
become
 
pregnant
 
while
 
taking
 
warfarin.
 
 
 
 
 
Breastfeeding
 
 
 
 
Warfarin
 
does
 
not
 
enter
 
human
 
milk
 
and
 
is
 
compatible
 
with
 
breastfeeding.
 
 
 
 
 
Elderly
 
 
 
 
Beers
 
Criteria:
 
 
Avoid
 
starting
 
warfarin
 
as
 
initial
 
therapy
 
for
 
the
 
treatment
 
of
 
nonvalvular
 
atrial
 
fibrillation
 
or
 
VTE
 
unless
 
alternative
 
options
 
(i.e.,
 
DOACs)
 
are
 
contraindicated
 
or
 
there
 
are
 
substantial
 
barriers
 
to
 
their
 
use.
 
Rationale:
 
Compared
 
with
 
DOACs,
 
warfarin
 
has
 
higher
 
risks
 
of
 
major
 
bleeding
 
(particularly
 
intracranial
 
bleeding)
 
and
 
similar
 
or
 
lower
 
effectiveness
 
for
 
the
 
treatment
 
of
 
nonvalvular
 
atrial
 
fibrillation
 
and
 
VTE.
 
Patients
 
more
 
than
 
60
 
years
 
of
 
age
 
tend
 
to
 
require
 
lower
 
dosage
 
to
 
produce
 
a
 
therapeutic
 
level
 
of
 
anticoagulation.
 
(
 
Due
 
to
 
changes
 
in
 
warfarin
 
metabolism)
 
 
 
 
Paediatric
 
 
 
 
Initiation
 
and
 
follow
 
up
 
is
 
carried
 
out
 
by
 
pediatricians.
 
Monitor
 
to
 
ensure
 
INR
 
is
 
in
 
therapeutic
 
range.
 
 
 
 
 
381
 

=== PAGE 383 ===

 
Fasting
 
 
 
 
To
 
be
 
taken
 
after
 
breaking
 
fast.
 
 
To
 
refer
 
to
 
the
 
latest
 
advisory
 
by
 
religious
 
authority
 
 
 
 
Others
 
 
 
 
 
Renal
 
impairment/
 
Hepatic
 
impairment
 
●
 
Patients
 
may
 
have
 
a
 
higher
 
risk
 
of
 
bleeding
 
and
 
enhanced
 
response
 
to
 
warfarin.
 
Monitor
 
to
 
avoid
 
over-anticoagulation.
2,
 
3
 
 
 
 
 
Side
 
Effects
 
and
 
their
 
Management*
 
1.
 
Educate
 
patients
 
on
 
symptoms
 
of
 
bleeding
 
such
 
as
 
bruises
 
of
 
unknown
 
cause,
 
blood
 
in
 
urine/dark-coloured
 
urine,
 
black
 
stools,
 
gum
 
bleeding
 
or
 
heavy
 
menstrual
 
bleeding.
 
 
2.
 
Seek
 
urgent
 
medical
 
attention
 
if
 
you
 
experience
 
symptoms
 
as
 
above.
 
 
 
 
 
Storage*
 
1.
 
Store
 
below
 
30
o
c.
 
Keep
 
away
 
from
 
children.
 
 
2.
 
Protect
 
from
 
moisture
 
and
 
light
 
 
 
 
Others
 
Precautions
 
 
1.
 
To
 
inform
 
healthcare
 
professionals
 
(dentist,
 
surgeon,
 
doctor ,
 
pharmacist)
 
if
 
you
 
are
 
planning
 
for
 
tooth
 
extraction,
 
or
 
when
 
getting
 
consultation
 
for
 
medication,
 
supplement
 
or
 
herbal
 
remedies.
 
2.
 
Avoid
 
hazardous
 
activities
 
that
 
could
 
result
 
in
 
serious
 
lacerations
 
or
 
blunt
 
trauma.
 
 
Monitoring
 
1.
 
INR
 
(International
 
normalised
 
ratio)
 
measures
 
how
 
long
 
it
 
takes
 
for
 
your
 
blood
 
to
 
clot.
 
2.
 
Target
 
therapeutic
 
range
 
is
 
individualized
 
based
 
on
 
the
 
condition
 
which
 
you
 
are
 
being
 
treated
 
for.
 
3.
 
Dose
 
of
 
warfarin
 
will
 
be
 
adjusted
 
based
 
on
 
INR.
 
 
4.
 
It
 
is
 
crucial
 
to
 
adhere
 
to
 
the
 
scheduled
 
blood
 
test
 
and
 
counselling
 
appointment
 
to
 
ensure
 
that
 
target
 
INR
 
is
 
achieved.
 
Bring
 
along
 
an
 
anticoagulant
 
booklet
 
and
 
all
 
medications
 
during
 
the
 
doctor/pharmacist
 
appointment.
 
 
Drug-drug
 
Interaction
 
 
Consult
 
doctor/
 
pharmacist
 
before
 
starting,
 
stopping
 
or
 
changing
 
dose
 
of
 
any
 
medications/
 
supplements/
 
vitamins,
 
regardless
 
of
 
whether
 
it
 
is
 
a
 
prescription
 
or
 
over-the-counter
 
medication
 
including
 
traditional
 
medicines/
 
herbal
 
remedies.
 
 
 
*Please
 
refer
 
to
 
the
 
Warfarin
 
Interaction
 
Handbook
4
 
for
 
more
 
information.
 
 
 
 
Drug-food
 
interaction
 
1.
 
Follow
 
a
 
healthy ,
 
well-balanced
 
and
 
consistent
 
diet.
 
1.
 
Foods
 
high
 
in
 
vitamin
 
K
 
(such
 
as
 
liver,
 
green
 
leafy
 
vegetables)
 
can
 
inhibit
 
warfarin
 
effect.
 
 
2.
 
However ,
 
it
 
is
 
not
 
necessary
 
to
 
completely
 
avoid
 
them.
 
Have
 
consistent
 
intake
 
of
 
vegetables/
 
food
 
with
 
high
 
content
 
of
 
high
 
vitamin
 
K.
 
3.
 
Avoid
 
drastic
 
change
 
in
 
diet
 
to
 
minimize
 
fluctuations
 
in
 
INR.
  
 
4.
 
*
 
Please
 
refer
 
to
 
the
 
Warfarin
 
Interaction
 
Handbook
4
 
for
 
more
 
information.
 
Lifestyle
 
 
382
 

=== PAGE 384 ===

 
Alcohol
 
consumption,
 
smoking
 
and
 
stress
 
affect
 
warfarin
 
therapy .
 
Advice
 
to
 
only
 
consume
 
small
 
quantity
 
of
 
alcohol,
 
stop
 
smoking
 
and
 
manage
 
stress
 
well.
 
 
Avoid
 
hazardous
 
activities
 
that
 
could
 
result
 
in
 
serious
 
lacerations
 
or
 
blunt
 
trauma.
 
Strengths/
 
colour
 
of
 
warfarin
 
tablets
 
 
●
 
1
 
mg
 
-
 
Apo-W arfarin
 
(pink),
 
Maforan
 
(white)
 
●
 
2
 
mg
 
-
 
Apo-W arfarin
 
(lavender),
 
Maforan
 
(orange)
 
●
 
3
 
mg
 
-
 
Orfarin
 
(blue),
 
Maforan
 
(dark
 
blue)
 
●
 
5
 
mg
 
-
 
Apo-W arfarin
 
(peach),
 
Maforan
 
(pink)
 
Remind
 
the
 
patient
 
to
 
double
 
check
 
if
 
a
 
new
 
brand
 
is
 
dispensed.
 
Advice
 
not
 
to
 
remember
 
the
 
colour ,
 
remember
 
the
 
dose
 
prescribed
 
instead.
 
Before
 
ending
 
this
 
peer
 
review
 
session,
 
the
 
reviewee
 
should
 
be
 
informed
 
of
 
the
 
step(s)
 
that
 
he/
 
she
 
missed
 
out
 
in
 
order
 
to
 
ensure
 
all
 
the
 
counselling
 
points
 
are
 
being
 
covered.
 
 
Remarks:
 
 
 
Reviewed
 
by:
 
Name
 
&
 
Signature
                                                                   
Date:
 
 
*Mandatory
 
for
 
validation
 
/
 
peer
 
review
 
References:
 
 
1.
 
Otto,
 
C.
 
M.,
 
Nishimura,
 
R.
 
A.,
 
Bonow ,
 
R.
 
O.,
 
Carabello,
 
B.
 
A.,
 
Erwin,
 
J.
 
P.,
 
3rd,
 
Gentile,
 
F.,
 
Jneid,
 
H.,
 
Krieger ,
 
E.
 
V.,
 
Mack,
 
M.,
 
McLeod,
 
C.,
 
O'Gara,
 
P.
 
T.,
 
Rigolin,
 
V.
 
H.,
 
Sundt,
 
T.
 
M.,
 
3rd,
 
Thompson,
 
A.,
 
&
 
Toly,
 
C.
 
(2021).
 
2020
 
ACC/AHA
 
Guideline
 
for
 
the
 
Management
 
of
 
Patients
 
With
 
Valvular
 
Heart
 
Disease:
 
Executive
 
Summary:
 
A
 
Report
 
of
 
the
 
American
 
College
 
of
 
Cardiology/American
 
Heart
 
Association
 
Joint
 
Committee
 
on
 
Clinical
 
Practice
 
Guidelines.
 
Circulation,
 
143(5),
 
e35–e71.
 
https://doi.org/10.1 161/CIR.0000000000000932
 
 
2.
 
Sakaan,
 
S.
 
A.,
 
Hudson,
 
J.
 
Q.,
 
Oliphant,
 
C.
 
S.,
 
Tolley,
 
E.
 
A.,
 
Cummings,
 
C.,
 
Alabdan,
 
N.
 
A.,
 
&
 
Self,
 
T.
 
H.
 
(2014).
 
Evaluation
 
of
 
warfarin
 
dose
 
requirements
 
in
 
patients
 
with
 
chronic
 
kidney
 
disease
 
and
 
end-stage
 
renal
 
disease. Pharmacotherapy , 34(7),
 
695–702.
 
https://doi.org/10.1002/phar .1445
 
 
3.
 
Nakazawa,
 
T.,
 
Yamazaki,
 
S.,
 
Uchida,
 
M.,
 
Suzuki,
 
T.,
 
Nakamura,
 
T.,
 
Ohtsuka,
 
M.,
 
&
 
Ishii,
 
I.
 
(2023).
 
Relationship
 
between
 
elevated
 
bilirubin
 
levels
 
and
 
enhanced
 
warfarin
 
effects
 
during
 
biliary
 
obstruction. European
 
journal
 
of
 
clinical
 
pharmacology , 79(3),
 
437–443.
 
https://doi.org/10.1007/s00228-023-03459-7
 
 
4.
 
Clinical
 
Pharmacy
 
Working
 
Committee
 
(Cardiology
 
Subspecialty),
 
Pharmaceutical
 
Services
 
Division
 
M
 
of
 
H.
   
Warfarin
 
Interaction
 
Handbook.
 
5.
 
Apotex
 
Inc.
 
(2022).
 
Product
 
information
 
leaflet:
 
Apo
 
Warfarin
 
2mg
 
tablet.
 
Retrieved
 
from
 
Quest
 
3+
 
Search
 
on
 
January
 
21,
 
2025.
 
6.
 
2023
 
American
 
Geriatrics
 
Society
 
Beers
 
Criteria®
 
Update
 
Expert
 
Panel.
 
(2023).
 
American
 
Geriatrics
 
Society
 
2023
 
updated
 
AGS
 
Beers
 
Criteria®
 
for
 
potentially
 
inappropriate
 
medication
 
use
 
in
 
older
 
adults.
 
Journal
 
of
 
the
 
American
 
Geriatrics
 
Society ,
 
71(7),
 
2052-2081.
 
 
 
 
 
 
 
 
 
 
 
 
 
 
383
 

=== PAGE 385 ===

 
Zidovudine
 
/
 
Lamivudine
 
 
Name
 
:
 
 
 
●
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
1.
 
 
 
 
 
 
 
 
 
1.
 
 
 
 
 
 
 
 
 
1.
 
 
 
 
 
 
 
 
 
1.
 
 
 
 
 
 
 
 
 
1.
 
 
 
 
 
 
 
 
 
 
 
1.
 
 
 
 
 
 
1.
 
 
 
 
 
 
*Mandatory
 
for
 
validation
 
/
 
peer
 
review
 
References:
 
 
1.
 
Malaysian
 
Society
 
for
 
HIV
 
Medicine.
 
(2022).
 
Malaysian
 
consensus
 
guidelines
 
on
 
antiretroviral
 
therapy .
 
Ministry
 
of
 
Health
 
Malaysia.
 
2.
 
MIMS
 
Gateway .
 
(n.d.).
 
Lamivudine
 
+
 
zidovudine.
 
Retrieved
 
from
 
https://online1.mimsgateway .com.my/
 
3.
 
The
 
Sanford
 
Guide.
 
(2024,
 
October
 
16).
 
Combivir:
 
Lamivudine
 
+
 
zidovudine
 
–
 
Usage
 
and
 
dosing.
 
The
 
Sanford
 
Guide
 
to
 
HIV/AIDS
 
Therapy .
 
384
 

=== PAGE 386 ===

 
4.
 
ZOVILAM.
 
(n.d.).
 
Product
 
insert.
 
 
 
 
 
385
 

=== PAGE 387 ===

CONTENTS
 
 
(PART
 
B
 
:
 
DEVICES/PREP ARA TIONS/OTHERS)
 
 
Accuhaler
................................................................................................................................
1
 
Breezhaler
...............................................................................................................................
4
 
Bowel
 
Cleansing
....................................................................................................................
7
 
Combined
 
Oral
 
Contraceptive
 
Pills
 
(COCP)
......................................................................
11
 
Ear
 
Drops
..............................................................................................................................
17
 
Ellipta
....................................................................................................................................
19
 
Emergency
 
Contraception
..................................................................................................
22
 
Emollient/
 
Moisturisers
........................................................................................................
24
 
Eye
 
Drops
.............................................................................................................................
26
 
Eye
 
Ointment
........................................................................................................................
30
 
Menopausal
 
Hormone
 
Therapy
...........................................................................................
33
 
Nasal
 
Douche/Irrigation
.......................................................................................................
37
 
Nasal
 
Drops
..........................................................................................................................
39
 
Nasal
 
Spray
...........................................................................................................................
42
 
Oral
 
Ovulation
 
Induction
 
Drugs
..........................................................................................
45
 
Pressurised
 
Metered-dose
 
Inhaler
 
(pMDI)
.........................................................................
47
 
Progestogen-Only
 
Pills
 
(POP)
.............................................................................................
51
 
Respimat
 
(Re-usable)
..........................................................................................................
54
 
Suppositories
 
/
 
Enema
........................................................................................................
58
 
Throat
 
Spray
.........................................................................................................................
61
 
Turbuhaler
.............................................................................................................................
63
 
Vaginal
 
Preparation/Pessary
...............................................................................................
67
 
Valved
 
Holding
 
Chamber
 
(VHC)
 
with
 
Facemask
...............................................................
71
 
Multiple
 
Breath
 
or
 
Tidal
 
Breathing
 
Method
..................................................................
71
 
Valved
 
Holding
 
Chamber
 
(VHC)
 
with
 
Mouthpiece
.............................................................
74
 
Single
 
Breath
 
Method
....................................................................................................
74
 
Valved
 
Holding
 
Chamber
 
(VHC)
 
with
 
Mouthpiece
.............................................................
78
 
Multiple
 
Breath
 
or
 
Tidal
 
Breathing
 
Method
..................................................................
78
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 

=== PAGE 388 ===

 
Accuhaler
 
Name
 
:
 
 
Unit
 
:
 
 
●
 
Please
 
tick
 
(
✔
)
 
Yes
 
for
 
correct
 
instruction.
 
●
 
Please
 
tick
 
(
✔
)
 
No
 
for
 
incorrect
 
instruction.
 
Yes
 
No
 
Remarks
 
Type
 
of
 
Device
 
Dry
 
powder
 
inhaler
 
(DPI)
 
 
 
 
Indications
 
and
 
Dosage
 
The
 
indication
 
and
 
dosage
 
depend
 
on
 
the
 
drug
 
content.
 
 
 
 
Method
 
of
 
Administration*
 
DEVICE
 
PREP ARA TION
 
 
Before
 
Every
 
Use
 
 
 
Make
 
sure:
  
 
 
 
 
The
 
Accuhaler
 
has
 
not
 
expired.
 
 
 
 
 
The
 
Accuhaler
 
is
 
not
 
empty .
 
 
 
 
 
Check
 
inside
 
the
 
mouthpiece
 
of
 
the
 
Accuhaler
 
and
 
ensure
 
it
 
is
 
free
 
from
 
foreign
 
objects.
 
 
 
 
 
DEVICE
 
INHALA TION
 
TECHNIQUES
 
 
Prepare
 
 
Step
 
1
 
●
 
Hold
 
the
 
outer
 
case
 
in
 
one
 
hand
 
and
 
place
 
the
 
thumb
 
of
 
the
 
other
 
hand
 
on
 
the
 
thumb
 
grip
 
of
 
Accuhaler
 
to
 
slide
 
open
 
the
 
cover
 
until
 
a
 
“click”
 
sound
 
is
 
heard.
 
●
 
Hold
 
the
 
Accuhaler
 
horizontally;
 
slide
 
the
 
lever
 
away
 
as
 
far
 
as
 
it
 
will
 
go
 
until
 
another
 
“click”
 
sound
 
is
 
heard.
 
The
 
dose
 
is
 
loaded.
 
 
Note:
 
Do
 
not
 
tip
 
the
 
Accuhaler
 
upside
 
down
 
or
 
shake
 
the
 
device
 
after
 
dose
 
loading.
 
 
 
 
Exhale
 
 
Step
 
2
 
●
 
Sit
 
upright
 
or
 
stand
 
in
 
an
 
erect
 
position.
 
●
 
Breathe
 
out
 
(exhale)
 
slowly
 
and
 
fully,
 
away
 
from
 
the
 
Accuhaler .
 
 
 
 
Chin
 
&
 
mouth
 
 
Step
 
3
 
●
 
Slightly
 
tilt
 
the
 
chin
 
up.
 
●
 
Place
 
the
 
inhaler
 
mouthpiece
 
gently
 
between
 
the
 
teeth.
 
Ensure
 
a
 
tight
 
seal
 
of
 
the
 
lips
 
around
 
the
 
mouthpiece.
 
Do
 
not
 
bite
 
the
 
mouthpiece.
 
 
 
Notes:
 
Do
 
not
 
block
 
the
 
opening
 
of
 
the
 
mouthpiece
 
with
 
the
 
tongue
 
or
 
teeth.
 
The
 
tongue
 
should
 
be
 
lowered
 
under
 
the
 
mouthpiece.
 
 
 
 
Inhale
 
 
Step
 
4
 
Breathe
 
in
 
forcefully
 
and
 
deeply
 
through
 
the
 
mouth.
 
 
 
 
Hold
 
breath
 
 
Step
 
5
 
Remove
 
the
 
Accuhaler
 
from
 
the
 
mouth,
 
and
 
with
 
the
 
lips
 
closed,
 
hold
 
the
 
breath
 
for
 
5-10
 
seconds
 
or
 
as
 
long
 
as
 
comfortable.
 
 
 
 
Exhale
 
 
Step
 
6
 
 
 
 
1
 

=== PAGE 389 ===

 
Breathe
 
out
 
(exhale)
 
gently ,
 
away
 
from
 
the
 
Accuhaler .
 
Close
 
&
 
Rinse
 
Step
 
7
 
•
 
Close
 
the
 
device
 
by
 
sliding
 
the
 
thumb
 
grip
 
back
 
to
 
the
 
original
 
position
 
until
 
a
 
“click”
 
sound
 
is
 
heard.
 
 
•
 
Rinse
 
and
 
gargle
 
the
 
mouth
 
with
 
water
 
and
 
spit
 
it
 
out
 
(for
 
a
 
steroid-containing
 
inhaler).
 
 
 
 
Missed
 
dose
 
management
 
:
 
 
If
 
a
 
maintenance
 
dose
 
is
 
missed,
 
take
 
it
 
as
 
soon
 
as
 
possible
 
and
 
then
 
resume
 
the
 
regular
 
schedule.
 
However ,
 
if
 
it
 
is
 
almost
 
time
 
for
 
the
 
next
 
dose,
 
skip
 
the
 
missed
 
dose.
 
Never
 
take
 
a
 
double
 
dose
 
to
 
make
 
up
 
for
 
a
 
missed
 
maintenance
 
dose.
 
Do
 
not
 
stop
 
taking
 
your
 
medication
 
unless
 
advised
 
to
 
do
 
so
 
by
 
your
 
prescriber .
 
 
 
 
Special
 
Considerations
 
Pregnancy
 
 
 
 
NA
 
 
 
 
Breastfeeding
 
 
 
 
NA
 
 
 
 
Elderly
 
 
 
 
Consider
 
patient-related
 
factors
 
such
 
as
 
inspiratory
 
effort
,
 
manual
 
dexterity ,
 
hand
 
strength,
 
tremors,
 
vision,
 
comorbidities,
 
respiratory
 
muscle
 
strength,
 
cognition
 
and
 
others.
 
 
 
 
Paediatric
 
 
 
 
Some
 
DPIs
 
may
 
be
 
appropriate
 
for
 
older
 
children.
 
Refer
 
guidelines,
 
for
 
example
 
Global
 
Initiative
 
for
 
Asthma
 
 
 
 
Fasting
 
 
 
 
To
 
refer
 
to
 
the
 
latest
 
advisory
 
by
 
religious
 
authority
 
 
 
 
Others
  
 
 
 
 
NA
 
 
 
 
Side
 
Effects
 
and
 
their
 
Management*
 
For
 
corticosteroid-containing
 
inhalers,
 
gargle
 
the
 
mouth
 
with
 
water
 
and
 
spit
 
it
 
out.
 
 
 
 
 
Storage*
 
Refer
 
to
 
product
 
inserts
 
for
 
complete
 
information.
 
In
 
general:
 
•
 
Store
 
the
 
device
 
in
 
a
 
clean,
 
cool,
 
and
 
dry
 
place
 
at
 
appropriate
 
temperatures.
 
•
 
Avoid
 
extreme
 
temperatures
 
and
 
humidity
 
(e.g.,
 
do
 
not
 
store
 
it
 
in
 
cars
 
or
 
bathrooms).
 
•
 
Keep
 
it
 
safely
 
out
 
of
 
the
 
reach
 
of
 
children.
 
 
 
 
Others
 
Cleaning*
 
 
 
 
Wipe
 
the
 
outside
 
of
 
the
 
mouthpiece
 
at
 
least
 
once
 
a
 
week
 
with
 
dry
 
tissue
 
or
 
cloth.
 
Do
 
not
 
use
 
water
 
or
 
liquids.
 
 
 
 
Dose
 
checking
 
●
 
Contains
 
a
 
dose
 
counter .
 
 
●
 
On
 
the
 
last
 
five
 
(5)
 
doses,
 
the
 
numbers
 
on
 
the
 
dose
 
counter
 
will
 
appear
 
in
 
red.
 
 
 
 
2
 

=== PAGE 390 ===

 
When
 
the
 
counter
 
shows
 
0,
 
Accuhaler
 
is
 
empty
 
and
 
should
 
be
 
disposed
 
of.
 
Expiry
 
date
 
 
Follow
 
the
 
expiry
 
date
 
on
 
the
 
product.
 
 
 
 
 
Before
 
ending
 
this
 
peer
 
review
 
session,
 
the
 
reviewee
 
should
 
be
 
informed
 
of
 
the
 
step(s)
 
that
 
he/
 
she
 
missed
 
out
 
in
 
order
 
to
 
ensure
 
all
 
the
 
counselling
 
points
 
are
 
being
 
covered.
 
 
Remarks:
 
 
 
 
 
Reviewed
 
by:
 
Name
 
&
 
Signature
                                                                   
Date:
 
 
 
 
 
*Mandatory
 
for
 
validation
 
/
 
peer
 
review
 
 
References:
 
 
1.
 
Usmani
 
OS.
 
(2019
 
Mar).
 
Choosing
 
the
 
right
 
inhaler
 
for
 
your
 
asthma
 
or
 
COPD
 
patient.
 
Therapeutics
 
and
 
clinical
 
risk
 
management.
 
14:461-72.
 
2.
 
Ohar
 
JA,
 
Ferguson
 
GT,
 
Mahler
 
DA,
 
Drummond
 
MB,
 
Dhand
 
R,
 
Pleasants
 
RA,
 
Anzueto
 
A,
 
Halpin
 
DM,
 
Price
 
DB,
 
Drescher
 
GS,
 
Hoy
 
HM.
 
(2022
 
Jan).
 
Measuring 
 
peak
 
inspiratory
 
flow
 
in
 
patients
 
with
 
chronic
 
obstructive
 
pulmonary
 
disease.
 
International
 
journal
 
of
 
chronic
 
obstructive
 
pulmonary
 
disease.
  
6:79-92.
 
3.
 
The
 
Electronic
 
Medicine
 
Compendium
 
(eMC)
 
(Available
 
at 
http://www .medicines.org.uk/emc/
).
 
Accessed
 
on
 
October
 
15,
 
2024.
 
4.
 
Asthma
 
UK.
 
How
 
to
 
use
 
your
 
inhaler
 
(Available
 
at 
https://www .asthmaandlung.org.uk/living-with/inhaler-videos
).
 
Accessed
 
on
 
October
 
15,
 
2024.
 
5.
 
Mohammad
 
Y.
 
(2019
 
Oct).
 
How
 
to
 
manage
 
asthma
 
during
 
Ramadan?
 
97(10):
 
1073-1076.
 
PMID:
 
3169193
 
6.
 
Global
 
Initiative
 
for
 
Asthma.
 
Global
 
Strategy
 
for
 
Asthma
 
Management
 
and
 
Prevention,
 
2024.
 
Updated
 
May
 
2024.
 
Available
 
from:
 
www .ginasthma.org.
 
Accessed
 
on
 
January
 
20,
 
2025.
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
3
 

=== PAGE 391 ===

 
Breezhaler
 
 
Name
 
:
 
 
Unit
 
:
 
 
●
 
Please
 
tick
 
(
✔
)
 
Yes
 
for
 
correct
 
instruction.
 
●
 
Please
 
tick
 
(
✔
)
 
No
 
for
 
incorrect
 
instruction.
 
Yes
 
No
 
Remarks
 
Type
 
of
 
Device
 
Dry
 
powder
 
inhaler
 
(DPI)
 
 
 
 
Indications
 
and
 
Dosage
 
The
 
indication
 
and
 
dosage
 
depend
 
on
 
the
 
drug
 
content.
 
 
 
 
Method
 
of
 
Administration*
 
DEVICE
 
PREP ARA TION
 
 
 
 
 
 
Before
 
Every
 
Use
 
 
 
Make
 
sure:
  
 
 
 
 
The
 
Breezhaler
 
capsule
 
is
 
not
 
expired.
 
 
 
 
 
The
 
patient
 
has
 
the
 
capsules.
 
 
 
 
 
Check
 
inside
 
the
 
mouthpiece
 
of
 
the
 
Breezhaler
 
and
 
ensure
 
it
 
is
 
free
 
from
 
foreign
 
objects.
 
 
 
 
 
DEVICE
 
INHALA TION
 
TECHNIQUES
 
 
Prepare
 
 
Step
 
1
 
 
●
 
Pull
 
off
 
the
 
cap
 
and
 
tilt
 
the
 
mouthpiece
 
to
 
open
 
the
 
inhaler .
 
 
●
 
Ensure
 
the
 
hands
 
are
 
dry
 
and
 
clean.
 
Remove
 
one
 
capsule
 
from
 
the
 
blister
 
pack.
  
 
●
 
Insert
 
the
 
capsule
 
into
 
the
 
chamber
 
in
 
the
 
middle
 
of
 
the
 
Breezhaler
 
and
 
close
 
the
 
mouthpiece
 
until
 
a
 
“click”
 
sound
 
is
 
heard.
 
 
●
 
Hold
 
the
 
inhaler
 
upright
 
and
 
pierce
 
the
 
capsule
 
by
 
firmly
 
pressing
 
both
 
side
 
buttons
 
at
 
the
 
same
 
time.
 
Pierce
 
the
 
capsule
 
only
 
ONCE.
 
 
●
 
Release
 
the
 
side
 
buttons
 
of
 
the
 
Breezhaler .
 
 
 
Notes:
 
Do
 
not
 
tip
 
the
 
Breezhaler
 
upside
 
down
 
or
 
shake
 
the
 
device
 
after
 
dose
 
loading.
 
Do
 
not
 
block
 
the
 
air
 
vents.
 
 
 
 
 
Exhale
 
 
Step
 
2
 
 
●
 
Sit
 
upright
 
or
 
stand
 
in
 
an
 
erect
 
position.
 
 
●
 
Breathe
 
out
 
(exhale)
 
slowly
 
and
 
fully,
 
away
 
from
 
the
 
Breezhaler .
 
 
 
 
 
Chin
 
&
 
mouth
 
 
Step
 
3
 
 
●
 
Slightly
 
tilt
 
the
 
chin
 
up.
 
 
●
 
Place
 
the
 
inhaler
 
mouthpiece
 
gently
 
between
 
the
 
teeth.
 
Ensure
 
a
 
tight
 
seal
 
of
 
the
 
lips
 
around
 
the
 
mouthpiece.
 
Do
 
not
 
bite
 
the
 
mouthpiece.
 
 
 
 
Notes:
 
Do
 
not
 
block
 
the
 
opening
 
of
 
the
 
mouthpiece
 
with
 
the
 
tongue
 
or
 
teeth.
 
The
 
tongue
 
should
 
be
 
lowered
 
under
 
the
 
mouthpiece.
 
 
 
 
 
 
Inhale
 
 
Step
 
4
 
 
 
 
 
4
 

=== PAGE 392 ===

 
Breathe
 
in
 
forcefully
 
and
 
deeply
 
through
 
the
 
mouth.
 
A
 
whirring
 
sound
 
is
 
heard
 
during
 
inhalation.
 
 
 
 
Notes
:
 
If
 
the
 
whirring
 
sound
 
is
 
not
 
heard,
 
the
 
capsule
 
may
 
be
 
stuck
 
in
 
the
 
capsule
 
chamber .
 
Loosen
 
the
 
capsule
 
by
 
gently
 
tapping
 
the
 
base
 
of
 
the
 
inhaler
 
and
 
start
 
from
 
step
 
2
 
again.
 
Hold
 
breath
 
 
Step
 
5
 
 
Remove
 
the
 
Breezhaler
 
from
 
the
 
mouth,
 
and
 
with
 
the
 
lips
 
closed,
 
hold
 
the
 
breath
 
for
 
5-10
 
seconds
 
or
 
as
 
long
 
as
 
comfortable.
 
 
 
 
 
Exhale
 
 
Step
 
6
 
 
Breathe
 
out
 
(exhale)
 
gently ,
 
away
 
from
 
the
 
Breezhaler .
 
 
 
 
 
Repeat
 
 
 
 
Step
 
7
 
 
Open
 
the
 
mouthpiece
 
and
 
inspect
 
for
 
any
 
remaining
 
powder
 
left
 
in
 
the
 
capsule.
 
If
 
there
 
is
 
so,
 
close
 
the
 
mouthpiece
 
and
 
repeat
 
steps
 
2
 
to
 
6
 
(
do
 
not
 
pierce
 
the
 
capsule
 
again).
 
 
Note
:
 
A
 
good
 
practice
 
based
 
on
 
expert
 
opinion
 
is
 
to
 
perform
 
two
 
separate
 
inhalations
 
from
 
a
 
single
 
capsule.
 
 
 
 
 
Close
 
&
 
Rinse
 
Step
 
8
 
 
•
 
Remove
 
the
 
empty
 
capsule
 
and
 
dispose
 
appropriately .
 
 
•
 
Replace
 
the
 
mouthpiece
 
with
 
the
 
cap
 
after
 
use.
 
•
 
Rinse
 
and
 
gargle
 
the
 
mouth
 
with
 
water
 
and
 
spit
 
it
 
out
 
(for
 
a
 
steroid-containing
 
inhaler).
 
 
 
 
 
Missed
 
dose
 
management
 
:
 
 
If
 
a
 
maintenance
 
dose
 
is
 
missed,
 
take
 
it
 
as
 
soon
 
as
 
possible
 
and
 
then
 
resume
 
the
 
regular
 
schedule.
 
However ,
 
if
 
it
 
is
 
almost
 
time
 
for
 
the
 
next
 
dose,
 
skip
 
the
 
missed
 
dose.
 
Never
 
take
 
a
 
double
 
dose
 
to
 
make
 
up
 
for
 
a
 
missed
 
maintenance
 
dose.
 
Do
 
not
 
stop
 
taking
 
your
 
medication
 
unless
 
advised
 
to
 
do
 
so
 
by
 
your
 
prescriber .
 
 
 
 
Special
 
Considerations
 
Pregnancy
 
 
 
 
NA
 
 
 
 
Breastfeeding
 
 
 
 
NA
 
 
 
 
Elderly
 
 
 
 
Consider
 
patient-related
 
factors
 
such
 
as
 
inspiratory
 
effort
,
 
manual
 
dexterity ,
 
hand
 
strength,
 
tremors,
 
vision,
 
comorbidities,
 
respiratory
 
muscle
 
strength,
 
cognition
 
and
 
others.
 
 
 
 
Paediatric
 
 
 
 
Some
 
DPIs
 
may
 
be
 
appropriate
 
for
 
older
 
children.
 
Refer
 
guidelines,
 
for
 
example
 
Global
 
Initiative
 
for
 
Asthma
 
 
 
 
5
 

=== PAGE 393 ===

 
Fasting
 
 
 
 
To
 
refer
 
to
 
the
 
latest
 
advisory
 
by
 
religious
 
authority .
 
 
 
 
Others
 
 
 
 
 
NA
 
 
 
 
Side
 
Effects
 
and
 
their
 
Management*
 
For
 
corticosteroid-containing
 
inhalers,
 
gargle
 
the
 
mouth
 
with
 
water
 
and
 
spit
 
it
 
out.
 
 
 
 
 
Storage*
 
Refer
 
to
 
product
 
inserts
 
for
 
complete
 
information.
 
In
 
general:
 
●
 
Store
 
the
 
device
 
in
 
a
 
clean,
 
cool,
 
and
 
dry
 
place
 
at
 
appropriate
 
temperatures.
 
●
 
Avoid
 
extreme
 
temperatures
 
and
 
humidity
 
(e.g.,
 
do
 
not
 
store
 
it
 
in
 
cars
 
or
 
bathrooms).
 
●
 
Breezhaler
 
capsules
 
must
 
always
 
be
 
stored
 
in
 
the
 
blister
 
card
 
and
 
only
 
removed
 
immediately
 
before
 
use.
 
 
●
 
Keep
 
it
 
safely
 
out
 
of
 
the
 
reach
 
of
 
children.
 
 
 
 
Others
 
Cleaning*
 
 
 
 
Wipe
 
the
 
outside
 
of
 
the
 
mouthpiece
 
at
 
least
 
once
 
a
 
week
 
with
 
dry
 
tissue
 
or
 
cloth.
 
Do
 
not
 
use
 
water
 
or
 
liquids.
 
 
 
 
 
Expiry
 
date
 
 
Follow
 
the
 
expiry
 
date
 
on
 
the
 
product.
 
 
 
 
 
Additional
 
notes
 
 
●
 
Do
 
not
 
swallow
 
the
 
capsule.
 
 
●
 
Do
 
not
 
use
 
the
 
Breezhaler
 
capsules
 
with
 
any
 
other
 
inhaler .
 
 
●
 
Never
 
place
 
the
 
capsule
 
into
 
the
 
mouthpiece
 
of
 
the
 
inhaler .
 
 
●
 
Do
 
not
 
press
 
the
 
side
 
buttons
 
more
 
than
 
once.
 
 
●
 
Do
 
not
 
press
 
the
 
side
 
buttons
 
while
 
inhaling
 
through
 
the
 
mouthpiece.
 
 
 
 
Before
 
ending
 
this
 
peer
 
review
 
session,
 
the
 
reviewee
 
should
 
be
 
informed
 
of
 
the
 
step(s)
 
that
 
he/
 
she
 
missed
 
out
 
in
 
order
 
to
 
ensure
 
all
 
the
 
counselling
 
points
 
are
 
being
 
covered.
 
 
Remarks:
 
 
 
 
Reviewed
 
by:
 
Name
 
&
 
Signature
                                                                   
Date:
 
 
 
 
*Mandatory
 
for
 
validation
 
/
 
peer
 
review
 
 
References:
 
 
1.
 
Usmani
 
OS.
 
(2019
 
Mar).
 
Choosing
 
the
 
right
 
inhaler
 
for
 
your
 
asthma
 
or
 
COPD
 
patient.
 
Therapeutics
 
and
 
clinical
 
risk
 
management.
 
14:461-72.
 
2.
 
Ohar
 
JA,
 
Ferguson
 
GT,
 
Mahler
 
DA,
 
Drummond
 
MB,
 
Dhand
 
R,
 
Pleasants
 
RA,
 
Anzueto
 
A,
 
Halpin
 
DM,
 
Price
 
DB,
 
Drescher
 
GS,
 
Hoy
 
HM.
 
(2022
 
Jan).
 
Measuring 
 
peak
 
inspiratory
 
flow
 
in
 
patients
 
with
 
chronic
 
obstructive
 
pulmonary
 
disease.
 
International
 
journal
 
of
 
chronic
 
obstructive
 
pulmonary
 
disease.
  
6:79-92.
 
3.
 
The
 
Electronic
 
Medicine
 
Compendium
 
(eMC)
 
(Available
 
at 
http://www .medicines.org.uk/emc/
).
 
Accessed
 
on
 
October
 
15,
 
2024.
 
4.
 
Asthma
 
UK.
 
How
 
to
 
use
 
your
 
inhaler
 
(Available
 
at 
https://www .asthmaandlung.org.uk/living-with/inhaler-videos
).
 
Accessed
 
on
 
October
 
15,
 
2024.
 
5.
 
Mohammad
 
Y.
 
(2019
 
Oct).
 
How
 
to
 
manage
 
asthma
 
during
 
Ramadan?
 
97(10):
 
1073-1076.
 
PMID:
 
31691934
 
6.
 
Global
 
Initiative
 
for
 
Asthma.
 
Global
 
Strategy
 
for
 
Asthma
 
Management
 
and
 
Prevention,
 
2024.
 
Updated
 
May
 
2024.
 
Available
 
from:
 
www .ginasthma.org.
 
Accessed
 
on
 
January
 
20,
 
2025.
 
 
 
6
 

=== PAGE 394 ===

 
Bowel
 
Cleansing
 
 
Name
 
:
 
 
Unit
 
:
 
 
●
 
Please
 
tick
 
(
✔
)
 
Yes
 
for
 
correct
 
instruction.
 
●
 
Please
 
tick
 
(
✔
)
 
No
 
for
 
incorrect
 
instruction.
 
Yes
 
No
 
Remarks
 
Pharmacological
 
Group
 
Laxatives
 
and
 
bowel
 
preparation
 
agents:
 
 
1.
 
Polyethylene
 
Glycol/Macrogol
 
4000
 
Powder
 
 
2.
 
Sodium
 
picosulfate,
 
magnesium
 
oxide
 
&
 
citric
 
acid
 
powder
 
3.
 
Monobasic
 
Sodium
 
Phosphate
 
48%,
 
Dibasic
 
Sodium
 
Phosphate
 
18%
 
4.
 
Sodium
 
Biphosphate
 
16%,
 
Sodium
 
Phosphate
 
6%
 
Rectal
 
Solution
 
 
 
 
Indications
 
and
 
Dosage
 
This
 
medicine
 
is
 
used
 
as
 
part
 
of
 
a
 
bowel
 
cleansing
 
procedure
 
before
 
x-ray
 
examination,
 
endoscopy ,
 
colonoscopy ,
 
radiological
 
examination
 
or
 
colonic
 
surgery .
 
It
 
works
 
by
 
producing
 
bowel
 
motions.
 
It
 
usually
 
works
 
within
 
30
 
minutes,
 
however ,
 
it
 
may
 
take
 
as
 
long
 
as
 
6
 
hours
 
to
 
produce
 
the
 
effect.
 
Expect
 
frequent
 
liquid
 
stools.
 
The
 
patient
 
needs
 
to
 
stay
 
close
 
to
 
a
 
toilet
 
until
 
the
 
cleansing
 
effect
 
is
 
complete.
 
 
Refer
 
method
 
of
 
administration
 
for
 
dosage
 
of
 
each
 
agent.
 
 
 
To
 
counsel
 
based
 
on
 
specific
 
medication’ s
 
indication
 
and
 
dosage
 
as
 
prescribed
 
by
 
the
 
doctor
 
 
 
 
Method
 
of
 
Administration*
 
Polyethylene
 
Glycol/Macrogol
 
4000
 
Powder
 
 
1.
 
Dilute
 
1
 
sachet
 
(3
 
in
 
total)
 
with
 
1
 
L
 
of
 
water
 
(3
 
L
 
in
 
total)
 
at
 
the
 
recommended
 
timing
 
by
 
the
 
physician.
 
Volume
 
adjustment
 
is
 
not
 
needed
 
for
 
fluid
 
restriction
 
patients.
 
2.
 
To
 
improve
 
the
 
flavour ,
 
the
 
solution
 
may
 
be
 
chilled
 
or
 
lemon
 
juice
 
added.
 
3.
 
Dosing
 
time:
 
a.
 
Early
 
morning
 
procedure:
 
First
 
dose
 
taken
 
at
 
4
 
pm,
 
second
 
dose
 
at
 
6
 
pm,
 
and
 
third
 
dose
 
at
 
8
 
pm,
 
one
 
day
 
before
 
the
 
procedure.
 
b.
 
Afternoon
 
(or
 
later)
 
procedure:
 
First
 
dose
 
taken
 
at
 
6
 
pm,
 
second
 
dose
 
at
 
8
 
pm,
 
one
 
day
 
before
 
procedure
 
and
 
third
 
dose
 
at
 
6
 
am
 
on
 
the
 
day
 
of
 
procedure.
 
 
Sodium
 
picosulfate,
 
magnesium
 
oxide
 
&
 
citric
 
acid
 
powder
 
1.
 
Fill
 
a
 
mug
 
with
 
150ml
 
of
 
cold
 
water .
 
Empty
 
contents
 
of
 
1
 
sachet
 
in
 
the
 
mug.
 
Stir
 
until
 
completely
 
dissolved.
 
2.
 
Following
 
each
 
dose,
 
advise
 
the
 
patient
 
to
 
drink
 
1.5L
 
to
 
2L
 
of
 
a
 
variety
 
of
 
clear
 
fluids
 
over
 
4
 
hours.
 
3.
 
No
 
fluid
 
should
 
be
 
taken
 
at
 
least
 
2
 
hours
 
before
 
the
 
procedure.
 
4.
 
Dosing
 
time:
 
a.
 
Early
 
morning
 
procedure:
 
First
 
dose
 
taken
 
at
 
5pm
 
and
 
second
 
dose
 
at
 
9pm,
 
one
 
day
 
before
 
the
 
procedure.
 
b.
 
Afternoon
 
(or
 
later)
 
procedure:
 
First
 
dose
 
taken
 
at
 
7
 
pm,
 
one
 
day
 
before
 
procedure
 
and
 
second
 
dose
 
at
 
6
 
am
 
on
 
the
 
day
 
of
 
procedure.
 
 
Monobasic
 
Sodium
 
Phosphate
 
48%,
 
Dibasic
 
Sodium
 
Phosphate
 
18%
 
1.
 
Adult:
 
45
 
mL
 
solution
 
diluted
 
in
 
half
 
glass
 
cold
 
water
 
(~120
 
mL
 
of
 
cold
 
water)
 
for
 
2
 
doses.
 
This
 
should
 
be
 
drunk
 
over
 
½
 
hour
 
followed
 
by
 
at
 
least
 
4
 
–
 
6
 
glasses
 
of
 
 
 
 
7
 

=== PAGE 395 ===

 
plain
 
water
 
thereafter .
 
Drink
 
a
 
glass
 
of
 
clear
 
liquid
 
before
 
taking
 
this
 
preparation
 
to
 
prevent
 
vomiting.
 
 
2.
 
Dosing
 
time:
 
 
a.
 
For
 
morning
 
appointment:
 
First
 
dose
 
is
 
given
 
at
 
7
 
am
 
then
 
2nd
 
dose
 
at
 
7
 
pm
 
on
 
the
 
day
 
before
 
the
 
procedure.
 
b.
 
For
 
afternoon
 
appointment:
 
First
 
dose
 
is
 
given
 
at
 
7
 
pm
 
on
 
the
 
day
 
before
 
the
 
procedure
 
then
 
2nd
 
dose
 
at
 
7
 
am
 
on
 
the
 
day
 
of
 
the
 
procedure.
 
Timing
 
recommendations
 
may
 
vary.
 
 
Sodium
 
Biphosphate
 
16%,
 
Sodium
 
Phosphate
 
6%
 
Rectal
 
Solution
 
(Enema)
 
1.
 
Lie
 
on
 
your
 
left
 
side
 
with
 
both
 
knees
 
bent
 
and
 
your
 
arm
 
are
 
rest
 
in
 
front
 
of
 
you.
 
2.
 
Remove
 
protective
 
shield
 
from
 
the
 
enema
 
tip
 
while
 
holding
 
the
 
bottle
 
upright.
 
3.
 
Gently
 
insert
 
enema
 
tip
 
into
 
rectum
 
with
 
the
 
tip
 
pointing
 
towards
 
the
 
navel.
 
4.
 
Do
 
not
 
force
 
enema
 
into
 
the
 
rectum
 
as
 
this
 
may
 
cause
 
injury .
 
5.
 
Squeeze
 
the
 
bottle
 
until
 
nearly
 
all
 
liquid
 
is
 
expelled.
 
It
 
is
 
not
 
necessary
 
to
 
empty
 
the
 
bottle
 
completely
 
as
 
it
 
has
 
more
 
than
 
the
 
amount
 
needed.
 
6.
 
Remove
 
enema
 
from
 
rectum.
 
Maintain
 
position
 
until
 
the
 
urge
 
to
 
evacuate
 
is
 
strong
 
(Usually
 
2-5
 
minutes).
 
7.
 
Dosing
 
regimen:
 
Using
 
more
 
than
 
1
 
enema
 
within
 
24
 
hours
 
can
 
be
 
harmful.
 
8.
 
The
 
enema
 
should
 
be
 
inserted
 
2
 
hours
 
before
 
the
 
procedure.
 
9.
 
Patients
 
with
 
stoma
 
bag:
 
50ml
 
to
 
be
 
inserted
 
into
 
stoma
 
bag,
 
another
 
50ml
 
to
 
be
 
inserted
 
through
 
anal.
 
 
7
 
days
 
before
 
procedure:
 
1.
 
Stop
 
taking
 
iron
 
preparation.
 
2.
 
Persons
 
taking
 
antiplatelet
 
agents,
  
e.g.
 
aspirin,
 
ticlopidine,
 
should
 
discontinue
 
them
 
upon
 
a
 
prior
 
consultation
 
with
 
the
 
prescribing
 
physician.
 
3.
 
Persons
 
taking
 
anticoagulants,
 
e.g.
 
Warfarin,
 
should
 
consult
 
their
 
attending
 
physician.
 
It
 
should
 
be
 
withheld
 
3
 
–
 
5
 
days
 
prior
 
to
 
the
 
procedure
 
and
 
restarted
 
within
 
24
 
hours.
 
 
4.
 
Continuation
 
or
 
re-initiation
 
of
 
anticoagulation
 
should
 
be
 
adjusted
 
according
 
to
 
the
 
stability
 
of
 
the
 
patient
 
and
 
estimated
 
risks
 
surrounding
 
the
 
specific
 
intervention/
 
procedure
 
performed.
 
 
Dietary
 
and
 
medication
 
consideration:
 
●
 
2
 
days
 
before
 
procedure:
 
 
1.
 
Eat
 
a
 
low
 
residue
 
and
 
low
 
fiber
 
diet.
 
Avoid
 
fruits
 
and
 
vegetables,
 
particularly
 
those
 
with
 
fine
 
seeds,
 
red
 
meat,
 
high
 
fibre
 
breads
 
or
 
high
 
fibre
 
cereals.
 
 
●
 
1
 
day
 
before
 
procedure
 
1.
 
Milk
 
or
 
milk
 
products,
 
red/purple-coloured
 
drink
 
or
 
meal,
 
alcohol
 
and
 
carbonated
 
drink
 
should
 
not
 
be
 
taken.
 
a.
 
No
 
solid
 
food
 
after
 
lunch.
 
b.
 
Drink
 
plenty
 
of
 
clear
 
water
 
before
 
midnight.
 
 
 
●
 
On
 
the
 
day
 
of
 
procedure
 
1.
 
Continue
 
taking
 
other
 
medications
 
as
 
advised
 
by
 
the
 
doctor
 
a.
 
Check
 
on
 
the
 
patient's
 
medication
 
list
 
that
 
to
 
be
 
continued,
 
stopped
 
or
 
day
 
for
 
reinitiating.
 
8
 

=== PAGE 396 ===

 
●
 
Clear
 
fluid
 
list
 
1.
 
Water,
 
tea
 
or
 
coffee
 
(no
 
milk
 
or
 
non
 
dairy
 
creamer),
 
sweeteners
 
are
 
acceptable.
 
2.
 
Carbonated
 
or
 
non-carbonated
 
soft
 
drinks
 
(not
 
red-
 
or
 
purple-coloured).
 
3.
 
Fruit
 
flavoured
 
cordial
 
(not
 
red-
 
or
 
purple-coloured).
 
4.
 
Strained
 
fruit
 
juices
 
without
 
pulp.
 
5.
 
Do
 
not
 
drink
 
any
 
alcoholic
 
beverages.
 
6.
 
Clear
 
soups.
 
7.
 
Strained
 
low-sodium
 
chicken
 
or
 
beef
 
soup
 
without
 
solid
 
material.
 
 
Do
 
not
 
stop
 
taking
 
your
 
medications
 
unless
 
advised
 
to
 
do
 
so
 
by
 
your
 
prescriber
 
Special
 
Considerations
 
Pregnancy
 
 
 
 
1.
 
Monobasic
 
Sodium
 
Phosphate
 
48%,
 
Dibasic
 
Sodium
 
Phosphate
 
18%
:
 
It
 
cannot
 
be
 
used
 
during
 
pregnancy ,
 
unless
 
its
 
use
 
is
 
completely
 
necessar y
 
and
 
under
 
medical
 
monit oring.
 
2.
 
Polyethylene
 
Glycol/Macrogol
 
4000
 
Powder
:
 
Limited
 
data
 
is
 
available.
 
Should
 
only
 
be
 
used
 
when
 
necessar y.
 
3.
 
Sodium
 
Biphosphate
 
16%,
 
Sodium
 
Phosphate
 
6%
 
Rectal
 
Solution:
 
Pregnancy
 
category
 
C
 
 
 
 
Breastfeeding
 
 
 
 
1.
 
Monobasic
 
Sodium
 
Phosphate
 
48%,
 
Dibasic
 
Sodium
 
Phosphate
 
18%
:
 
It
 
is
 
not
 
known
 
whether
 
it
 
enters
 
nursing
 
milk.
 
Do
 
not
 
breastf eed
 
from
 
the
 
ﬁrst
 
dose
 
to
 
24
 
hours
 
after
 
the
 
last
 
dose.
 
 
2.
 
Polyethylene
 
Glycol/Macrogol
 
4000
 
Powder
:
 
Limited
 
data
 
is
 
available.
 
Should
 
only
 
be
 
used
 
when
 
necessar y.
 
 
 
 
Elderly
 
 
 
 
1.
 
Sodium
 
Biphosphate
 
16%,
 
Sodium
 
Phosphate
 
6%
 
Rectal
 
Solution:
 
Risk
 
of
 
electrolyte
 
disturbances
 
(especially
 
in
 
patients
 
with
 
kidney
 
disease
 
or
 
those
 
taking
 
diuretics).
 
Generally
 
not
 
recommended
 
in
 
frail
 
elderly
 
patients.
 
2.
 
Polyethylene
 
Glycol/Macrogol
 
4000
 
Powder:
 
Requires
 
significant
 
fluid
 
intake,
 
which
 
may
 
be
 
challenging
 
for
 
elderly
 
patients
 
with
 
heart
  
or
 
kidney
 
disease.
 
Option
 
:
  
split-dose
 
regimen
 
(half
 
the
 
dose
 
the
 
evening
 
before,
 
and
 
half
 
on
 
the
 
morning
 
of
 
the
 
procedure)
 
 
 
 
Paediatric
 
 
 
 
1.
 
Polyethylene
 
Glycol/Macrogol
 
4000
 
Powder:
 
contra-indicated
 
(subjected
 
to
 
brand)
 
2.
 
Sodium
 
Biphosphate
 
16%,
 
Sodium
 
Phosphate
 
6%
 
Rectal
 
Solution:
 
caution
 
in
 
children
 
aged
 
2-11
 
3.
 
Monobasic
 
Sodium
 
Phosphate
 
48%,
 
Dibasic
 
Sodium
 
Phosphate
 
18%:
 
no
 
approved
 
indication
 
for
 
paediatric
 
 
 
 
Fasting
 
 
 
 
1.
 
To
 
refer
 
to
 
the
 
latest
 
advisory
 
by
 
religious
 
authority
 
 
 
 
Others
 
 
 
 
 
1.
 
Sodium
 
Biphosphate
 
16%,
 
Sodium
 
Phosphate
 
6%
 
 
 
 
9
 

=== PAGE 397 ===

 
Rectal
 
Solution:
 
Use
 
in
 
caution
 
in
 
patients
 
with
 
severe
 
renal
 
impairment
 
(creatinine
 
clearance
 
<30mL/min)
 
2.
 
May
 
cause
 
fluid
 
and
 
electrolyte
 
disturbances
 
due
 
to
 
dehydration
 
3.
 
Use
 
cautiously
 
in
 
people
 
with
 
cardiac
 
insuﬃciency
 
and
 
those
 
treated
 
with
 
diuretics,
 
who
 
may
 
be
 
at
 
higher
 
risk
 
of
 
ﬂuid
 
and
 
electr olyte
 
imbalances.
 
4.
 
Polyethylene
 
Glycol/Macrogol
 
4000
 
Powder
 
can
 
be
 
used
 
in
 
people
 
with
 
ﬂuid
 
restriction
 
(eg.
 
renal
 
failur e,
 
hear t
 
failur e)
 
with
 
the
 
same
 
method
 
of
 
dilution.
 
Side
 
Effects
 
and
 
their
 
Management*
 
1.
 
Frequent
 
bowel
 
movement
 
within
 
1
 
–
 
2
 
hours,
 
stay
 
within
 
easy
 
reach
 
to
 
the
 
toilet.
 
2.
 
Some
 
people
 
may
 
encounter
 
nausea,
 
vomiting
 
and
 
bloating.
 
3.
 
It
 
is
 
advisable
 
to
 
bring
 
a
 
responsible
 
adult
 
to
 
accompany
 
the
 
patient
 
before
 
and
 
after
 
the
 
procedure.
 
 
 
 
Storage*
 
Store
 
in
 
a
 
cool
 
dry
 
place.
 
 
 
 
Others
 
1.
 
Do
 
not
 
take
 
an
 
extra
 
dose
 
unless
 
directed
 
by
 
a
 
health
 
professional.
 
2.
 
Monobasic
 
Sodium
 
Phosphate
 
48%,
 
Dibasic
 
Sodium
 
Phosphate
 
18%
:
 
Concomitant
 
use
 
with
 
other
 
prepar ations
 
based
 
on
 
sodium
 
phosphate
 
is
 
not
 
permitted.
 
 
3.
 
Polyethylene
 
Glycol/Macrogol
 
4000
 
Powder
:
 
Avoid
 
intak e
 
of
 
oral
 
treatments
 
befor e
 
and
 
after
 
laxativ es
 
ingestion
 
until
 
medical
 
examination
 
is
 
completed.
 
For
 
drugs
 
with
 
narrow
 
therapeutic
 
range
 
or
 
shor t
 
half-lif e
 
(eg.
 
digo xin,
 
antiepileptics,
 
coumarins,
 
immunosuppr essants),
 
eﬃcacy
 
might
 
be
 
affected.
 
 
 
 
Before
 
ending
 
this
 
peer
 
review
 
session,
 
the
 
reviewee
 
should
 
be
 
informed
 
of
 
the
 
step(s)
 
that
 
he/
 
she
 
missed
 
out
 
in
 
order
 
to
 
ensure
 
all
 
the
 
counselling
 
points
 
are
 
being
 
covered.
 
 
Remarks:
 
 
 
 
 
Reviewed
 
by:
 
Name
 
&
 
Signature
                                                                   
Date:
 
 
 
 
 
*
 
Mandatory
 
for
 
peer
 
review/validation
 
 
References:
 
 
1.
 
MIMS
 
Hong
 
Kong.
 
(2025).
 
Phosphosoda.
 
MIMS
 
Online.
 
https://www .mims.com/hongkong/drug/info/phosphosoda
 
2.
 
MIMS
 
Malaysia.
 
(2025).
 
Fortrans.
 
MIMS
 
Online.
 
https://www .mims.com/malaysia/drug/info/fortrans
 
3.
 
MIMS
 
Singapore.
 
(2025).
 
Fleet
 
Enema.
 
MIMS
 
Online.
 
https://www .mims.com/singapore/drug/info/fleet-enema
 
4.
 
Saltzman,
 
J.
 
R.,
 
Cash,
 
B.
 
D.,
 
Pasha,
 
S.
 
F.,
 
Early ,
 
D.
 
S.,
 
Muthusamy ,
 
V.
 
R.,
 
Khashab,
 
M.
 
A.,
 
...
 
&
 
Acosta,
 
R.
 
D.
 
(2015).
 
Bowel
 
preparation
 
before
 
colonoscopy .
 
Gastrointestinal
 
endoscopy ,
 
81(4),
 
781-794.
 
 
 
 
 
 
 
 
10
 

=== PAGE 398 ===

 
Combined
 
Oral
 
Contraceptive
 
Pills
 
(COCP)
 
Name
 
:
 
 
Unit
 
:
 
 
●
 
Please
 
tick
 
(
✔
)
 
Yes
 
for
 
correct
 
instruction.
 
●
 
Please
 
tick
 
(
✔
)
 
No
 
for
 
incorrect
 
instruction.
 
Yes
 
No
 
Remarks
 
Pharmacological
 
Group
 
Hormonal
 
Contraception
 
:
 
 
1.
 
Ethinyl
 
Estradiol
 
30
 
mcg
 
and
 
Levonorgestrel
 
150
 
mcg
 
(Rigevidon)
 
2.
 
Ethinyl
 
Estradiol
 
30
 
mcg
 
and
 
Desogestrel
 
150
 
mcg
 
(Marvelon)
 
3.
 
Ethinyl
 
Estradiol
 
20
 
mcg
 
and
 
Desogestrel
 
150
 
mcg
 
(Mercilon)
 
4.
 
Ethinyl
 
Estradiol
 
20
 
mcg
 
and
 
Levonorgestrel
 
100
 
mcg
 
(Loette)
 
5.
 
Ethinyl
 
Estradiol
 
20
 
mcg
 
and
 
Drospirenone
 
3mg
  
(Yaz)
 
6.
 
Ethinyl
 
Estradiol
 
35
 
mcg
 
and
 
Cyproterone
 
2mg
 
(Dianne
 
35)
 
 
 
 
 
Indications
 
and
 
Dosage
 
Indication
 
(1-3)
 
Oral
 
Contraception,
 
Abnormal
 
Uterine
 
Bleeding
 
(PCOS,
 
Fibroid,
 
Endometriosis)
 
 
Dosage
 
:
 
1
 
tablet
 
daily
 
as
 
prescribed
 
by
 
the
 
doctor .
 
Duration
 
to
 
be
 
taken
 
will
 
depend
 
on
 
desire
 
of
 
withdrawal
 
bleed.
 
Cyclical
 
(21/7
 
or
 
24/4)
 
vs
 
Extended
 
(84/7)
 
vs
 
Continuous.
 
 
 
Subsequent
 
courses
 
of
 
COCP
 
can
 
be
 
repeated
 
as
 
per
 
doctor ’s
 
instructions.
 
 
Indication
 
(4-6)
 
Oral
 
Contraception,
 
Abnormal
 
Uterine
 
Bleeding
 
(PCOS,
 
Fibroid,
 
Endometriosis).
 
Used
 
especially
 
in
 
patients
 
with
 
PCOS
 
androgen
 
features
 
 
 
 
Dosage
 
:
 
1
 
tablet
 
daily
 
as
 
prescribed
 
by
 
the
 
doctor .
 
Duration
 
to
 
be
 
taken
 
will
 
depend
 
on
 
desire
 
of
 
withdrawal
 
bleed.
 
Cyclical
 
(21/7
 
or
 
24/4)
 
vs
 
Extended
 
(84/7)
 
vs
 
Continuous.
 
 
 
Subsequent
 
courses
 
of
 
COCP
 
can
 
be
 
repeated
 
as
 
per
 
doctor ’s
 
instructions.
 
 
To
 
counsel
 
based
 
on
 
specific
 
medication’ s
 
indication
 
and
 
dosage
 
as
 
prescribed
 
by
 
the
 
doctor
 
 
 
 
Method
 
of
 
Administration*
 
For
 
Contraception:
 
 
Need
 
to
 
be
 
taken
 
immediately
 
or
 
at
 
least
 
within
 
(including)
 
D5
 
of
 
menstrual
 
cycle.
 
If
 
it
 
exceeds
 
D5
 
of
 
the
 
menstrual
 
cycle,
 
an
 
additional
 
contraception
 
method
 
is
 
needed
 
for
 
7
 
days.
 
 
For
 
Other
 
Indication:
 
 
Can
 
be
 
taken
 
anytime
 
once
 
prescribed
 
by
 
the
 
doctor .
 
 
Must
 
be
 
taken
 
at
 
the
 
same
 
time
 
every
 
day
 
before
 
or
 
after
 
a
 
meal.
 
If
 
prone
 
to
 
nausea,
 
can
 
be
 
taken
 
after
 
meal
 
 
 
It
 
is
 
important
 
to
 
take
 
the
 
pills
 
as
 
directed
 
because
 
missing
 
pills
 
or
 
taking
 
them
 
not
 
on
 
time
 
make
 
them
 
less
 
effective.
 
 
Do
 
not
 
stop
 
taking
 
your
 
medication
 
unless
 
advised
 
to
 
do
 
so
 
by
 
your
 
prescriber
 
 
 
 
11
 

=== PAGE 399 ===

 
Missed
 
Pills
 
Cyclical
 
COCP
 
(21/7)
 
Management
 
 
1
 
tablet
 
daily
 
for
 
21
 
consecutive
 
days,
 
followed
 
by
 
a
 
7-days
 
tablet
 
(hormone)
 
free
 
interval
 
Hormone-Free
 
Interval
 
(HFI)
 
is
 
considered
 
to
 
start
 
24
 
hours
 
after
 
the
 
last
 
pill
 
is
 
taken.
 
 
 
INCORRECT
 
USE
 
OF
 
COCP
 
RECOMMENDA TION
 
 
LATE
 
REST ARTING
 
AFTER
 
HFI
 
≥
 
9
 
days
 
since
 
last
 
active
 
pill
 
was
 
taken
  
 
●
 
Take
 
the
 
most
 
recent
 
missed
 
pill
 
as
 
soon
 
as
 
possible
  
 
●
 
Continue
 
the
 
remaining
 
pills
 
at
 
the
 
usual
 
time
  
 
●
 
Condoms
 
should
 
be
 
used
 
or
 
sex
 
avoided
 
until
 
pills
 
have
 
been
 
taken
 
for
 
7
 
consecutive
 
days
 
 
●
 
Consider
 
follow
 
up
 
pregnancy
 
test
 
 
●
 
Consider
 
EC
 
if
 
UPSI
 
has
 
taken
 
place
 
during
 
or
 
after
 
the
 
HFI
  
 
 
1
 
MISSED
 
PILL
 
(48
 
TO
 
<72
 
HOURS
 
SINCE
 
LAST
 
PILL
 
IN
 
CURRENT
 
PACK
 
WAS
 
TAKEN)
 
Week
 
1
 
 
1
 
pill
 
missed
 
after
 
HFI
 
 
 
(The
 
first
 
pill
 
after
 
the
 
HFI
 
must
 
have
 
been
 
taken
 
correctly;
 
if
 
not,
 
follow
 
recommendation
 
for
 
late
 
restarting)
  
 
●
 
Take
 
the
 
missed
 
pill
 
as
 
soon
 
as
 
possible
 
●
 
Continue
 
the
 
remaining
 
pills
 
at
 
the
 
usual
 
time
  
 
●
 
No
 
additional
 
contraceptive
 
precaution
 
required*
  
 
●
 
EC
 
not
 
required*
 
 
*
 
If
 
the
 
pack
 
is
 
used
 
correctly
 
earlier
 
in
 
week
 
1
 
and
 
the
 
7
 
days
 
prior
 
to
 
the
 
HFI.
 
If
 
in
 
doubt,
 
consider
 
additional
 
contraceptive
 
precaution/
 
EC
 
Week
 
2
 
or
 
Week
 
3
 
 
(or
 
subsequent
 
consecutive
 
weeks
 
of
 
continuous
 
pill-taking)
 
 
1
 
pill
 
missed
 
after
 
HFI
 
 
●
 
Take
 
the
 
missed
 
pill
 
as
 
soon
 
as
 
possible
 
●
 
Continue
 
the
 
remaining
 
pills
 
at
 
the
 
usual
 
time
 
 
●
 
No
 
additional
 
contraceptive
 
precaution
 
required**
  
 
●
 
 
EC
 
not
 
required**
 
 
**
 
If
 
the
 
pack
 
is
 
used
 
correctly
 
in
 
the
 
previous
 
7
 
days.
 
If
 
in
 
doubt,
 
consider
 
additional
 
contraceptive
 
precaution/
 
EC
 
2
 
OR
 
MORE
 
MISSED
 
PILLS
 
(≥72
 
HOURS
 
SINCE
 
LAST
 
PILL
 
IN
 
CURRENT
 
PACK
 
WAS
 
TAKEN)
 
Week
 
1
 
 
2-7
 
pills
 
missed
 
after
 
HFI
  
 
 
(The
 
first
 
pill
 
after
 
the
 
HFI
 
must
 
have
 
been
 
taken
 
correctly;
 
if
 
not,
 
follow
 
recommendation
 
for
 
●
 
Take
 
the
 
most
 
recent
 
missed
 
pill
 
as
 
soon
 
as
 
possible
  
 
●
 
Continue
 
the
 
remaining
 
pills
 
at
 
the
 
usual
 
time
  
 
●
 
Condoms
 
should
 
be
 
used
 
or
 
sex
 
avoided
 
until
 
pills
 
have
 
been
 
taken
 
for
 
7
 
consecutive
 
days
 
●
 
Consider
 
follow
 
up
 
pregnancy
 
test
 
●
 
Consider
 
EC
 
if
 
UPSI
 
has
 
taken
 
 
 
 
12
 

=== PAGE 400 ===

 
late
 
restarting)
 
place
 
during
 
the
 
HFI
 
or
 
week
 
1
 
Week
 
2
 
or
 
Week
 
3
 
 
(or
 
subsequent
 
consecutive
 
weeks
 
of
 
continuous
 
pill-taking)
 
 
2-7
 
pills
 
missed
 
after
 
HFI
  
 
●
 
Take
 
the
 
most
 
recent
 
missed
 
pill
 
as
 
soon
 
as
 
possible
  
 
●
 
Continue
 
the
 
remaining
 
pills
 
at
 
the
 
usual
 
time
  
 
●
 
If
 
2
 
or
 
more
 
pills
 
missed
 
in
 
the
 
7
 
days
 
prior
 
to
 
a
 
scheduled
 
HFI,
 
omit
 
the
 
HFI
  
 
●
 
Condoms
 
should
 
be
 
used
 
or
 
sex
 
avoided
 
until
 
pills
 
have
 
been
 
taken
 
for
 
7
 
consecutive
 
days
 
●
 
EC
 
not
 
required**
 
 
 
**
 
If
 
the
 
pack
 
is
 
used
 
correctly
 
in
 
the
 
previous
 
7
 
days.
 
If
 
in
 
doubt,
 
consider
 
additional
 
contraceptive
 
precaution/
 
EC
 
>7
 
consecutive
 
pills
 
missed
 
in
 
any
 
week
 
of
 
pill
 
taking
 
●
 
Manage
 
as
 
new
 
start
 
contraception
  
 
●
 
Consider
 
immediate
 
pregnancy
 
test
  
 
●
 
Quick
 
start
 
new
 
COCP
 
packet
 
(or
 
consider
 
other
 
effective
 
contraception)
  
 
●
 
Condoms
 
should
 
be
 
used
 
or
 
sex
 
avoided
 
until
 
pills
 
have
 
been
 
taken
 
for
 
7
 
consecutive
 
days
 
●
 
Consider
 
follow
 
up
 
pregnancy
 
test
 
●
 
Consider
 
EC
 
 
Abbreviations:
 
COCP ,
 
combined
 
oral
 
contraception;
 
EC,
 
emergency
 
contraception;
 
HFI,
 
hormone-free
 
interval;
   
UPSI,
 
unprotected
 
sexual
 
intercourse
 
 
 
Note:
 
Always
 
read
 
the
 
product
 
information
 
leaflet
 
before
 
counsel
 
the
 
patient.
 
Information
 
may
 
differ
 
depending
 
on
 
the
 
product
 
Missed
 
Pills
 
Cyclical
 
COCP
 
(24/4)
 
Management
 
 
1
 
tablet
 
daily
 
for
 
24
 
consecutive
 
days,
 
followed
 
by
 
a
 
4-days
 
inactive
 
tablet
 
(hormone-
 
free
 
interval)
 
Missed
 
pill
 
management
 
refers
 
to
 
hormone-containing
 
tablets
 
 
INCORRECT
 
USE
 
OF
 
COCP
 
RECOMMENDA TION
 
 
<
 
12
 
Hours
 
Late
 
●
 
Take
 
the
 
most
 
recent
 
missed
 
pill
 
as
 
soon
 
as
 
possible
  
 
●
 
Continue
 
the
 
remaining
 
pills
 
at
 
the
 
usual
 
time
  
 
≥
 
12
 
Hours
 
Late
 
●
 
Take
 
the
 
most
 
recent
 
missed
 
pill
 
as
 
soon
 
as
 
possible
 
 
●
 
Continue
 
the
 
remaining
 
pills
 
at
 
the
 
usual
 
time
  
 
●
 
Do
 
not
 
miss
 
taking
 
the
 
tablets
 
for
 
longer
 
than
 
4
 
days
 
(or
 
up
 
to
 
7
 
days
 
for
 
optimum
 
contraception)
 
Day
 
1
 
to
 
Day
 
7
 
●
 
Take
 
the
 
most
 
recent
 
missed
 
pill
 
as
 
soon
 
as
 
possible
 
(this
 
may
 
mean
 
take
 
2
 
tablets
 
at
 
the
 
same
 
time)
 
 
 
 
13
 

=== PAGE 401 ===

 
●
 
Continue
 
the
 
remaining
 
pills
 
at
 
the
 
usual
 
time
 
 
●
 
Condoms
 
should
 
be
 
used
 
or
 
sex
 
avoided
 
until
 
pills
 
have
 
been
 
taken
 
for
 
7
 
consecutive
 
days
 
●
 
Consider
 
follow
 
up
 
pregnancy
 
test
 
if
 
UPSI
 
has
 
taken
 
place
 
in
 
the
 
preceding
 
7
 
days
 
Day
 
8
 
to
 
Day
 
14
 
●
 
Take
 
the
 
most
 
recent
 
missed
 
pill
 
as
 
soon
 
as
 
possible
 
(this
 
may
 
mean
 
take
 
2
 
tablets
 
at
 
the
 
same
 
time)
 
●
 
Continue
 
the
 
remaining
 
pills
 
at
 
the
 
usual
 
time
 
 
●
 
If
 
have
 
taken
 
the
 
tablets
 
correctly
 
in
 
the
 
7
 
days
 
before
 
the
 
1
st
 
missed
 
tablet,
 
no
 
extra
 
contraception
 
is
 
needed
 
●
 
If
 
the
 
tablets
 
are
 
not
 
taken
 
correctly
 
or
 
more
 
than
 
1
 
tablet
 
is
 
missed,
 
extra
 
contraception
 
is
 
advised
 
for
 
7
 
days
 
Day
 
15
 
to
 
Day
 
24
 
●
 
Take
 
the
 
most
 
recent
 
missed
 
pill
 
as
 
soon
 
as
 
possible
 
(this
 
may
 
mean
 
take
 
2
 
tablets
 
at
 
the
 
same
 
time)
 
●
 
Continue
 
the
 
remaining
 
pills
 
at
 
the
 
usual
 
time
 
●
 
Discard
 
the
 
4
 
inactive
 
tablet
 
and
 
start
 
the
 
next
 
pack
 
right
 
away
 
●
 
If
 
the
 
tablets
 
are
 
not
 
taken
 
correctly
 
or
 
more
 
than
 
1
 
tablet
 
is
 
missed,
 
extra
 
contraception
 
is
 
advised
 
for
 
7
 
days
 
 
Abbreviations:
 
COCP ,
 
combined
 
oral
 
contraception;
 
EC,
 
emergency
 
contraception;
 
HFI,
 
hormone-free
 
interval;
   
UPSI,
 
unprotected
 
sexual
 
intercourse
 
 
 
Note:
 
Always
 
read
 
the
 
product
 
information
 
leaflet
 
before
 
counsel
 
the
 
patient.
 
Information
 
may
 
differ
 
depending
 
on
 
the
 
product
 
Special
 
Considerations
 
Pregnancy
 
 
 
 
Contraindicated
 
 
 
 
Breastfeeding
 
 
 
 
Postpartum
 
breastfeeding
:
 
Start
 
after
 
6
 
months
 
Postpartum
 
but
 
not
 
breastfeeding
:
 
Start
 
after
 
Day
 
21
 
postpartum.
 
If
 
started
 
beyond
 
this,
 
additional
 
contraception
 
is
 
needed
 
for
 
7
 
days.
 
 
 
 
Elderly
 
 
 
 
Caution
 
in
 
women
 
who
 
are
 
above
 
60
 
years
 
old
 
due
 
to
 
stroke,
 
cardiovascular
 
and
 
VTE
 
risk
 
 
 
 
Paediatric
 
 
 
 
The
 
safety
 
and
 
efficacy
 
of
 
COCP
 
in
 
children
 
who
 
have
 
not
 
achieved
 
menarche
 
have
 
not
 
been
 
established.
 
 
 
 
Fasting
 
 
 
 
To
 
refer
 
to
 
the
 
latest
 
advisory
 
by
 
religious
 
authority
 
 
 
 
Others
  
 
 
 
 
Hepatic
 
Impairment
:
 
Contraindicated
 
 
 
 
14
 

=== PAGE 402 ===

 
Side
 
Effects
 
and
 
their
 
Management*
 
Nausea,
 
headaches,
 
breast
 
tenderness,
 
diarrhoea,
 
bloating
 
and
 
breakthrough
 
bleeding.
 
Continue
 
taking
 
the
 
pills
 
as
 
most
 
of
 
these
 
symptoms
 
will
 
improve
 
with
 
time.
 
 
If
 
any
 
of
 
the
 
following
 
symptoms
 
occur ,
 
the
 
drug
 
should
 
be
 
stopped
 
and
 
urgent
 
medical
 
advice
 
should
 
be
 
sought
 
after:
 
 
●
 
Severe
 
and
 
sudden
 
pain
 
in
 
the
 
chest
 
 
●
 
Breathlessness
 
 
●
 
Severe
 
headache
 
 
●
 
Abdominal
 
pain
 
 
●
 
Sudden
 
blurred
 
vision
 
or
 
loss
 
of
 
sight
 
 
●
 
Unexplained
 
tenderness
 
or
 
pain
 
and
 
swelling
 
in
 
one
 
leg
 
 
●
 
Weakness,
 
numbness
 
or
 
difficulty
 
speaking
 
 
●
 
Change
 
in
 
mood
 
or
 
depression
 
 
 
 
 
Storage*
 
Store
 
in
 
dry,
 
cool
 
places
 
at
 
room
 
temperature.
 
Direct
 
sunlight
 
and
 
extreme
 
temperatures
 
may
 
cause
 
them
 
to
 
break
 
down
 
and
 
become
 
less
 
effective
 
 
 
 
Others
 
COCP
 
increases
 
the
 
risk
 
of
 
VTE,
 
especially
 
during
 
the
 
first
 
year
 
of
 
initiation.
 
VTE
 
risk
 
is
 
dependent
 
on
 
progestogen
 
type
 
and
 
oestrogen
 
dose.
 
 
 
Caution
 
should
 
be
 
exercised
 
in
 
women
 
over
 
50
 
years
 
of
 
age
 
due
 
to
 
the
 
increased
 
risks
 
of
 
stroke,
 
cardiovascular
 
events
 
and
 
VTE.
 
 
Patients
 
who
 
have
 
had
 
bariatric
 
surgery
 
should
 
be
 
advised
 
that
 
the
 
effectiveness
 
of
 
COCP
 
could
 
be
 
reduced
 
 
Patients
 
should
 
be
 
informed
 
that
 
current
 
use
 
of
 
COCP
 
is
 
associated
 
with
 
an
 
increased
 
risk
 
of
 
myocardial
 
infarction
 
and
 
ischaemic
 
stroke
 
but
 
these
 
events
 
are
 
still
 
extremely
 
uncommon
 
in
 
COCP
 
users.
 
 
 
Patients
 
should
 
also
 
be
 
advised
 
that
 
current
 
use
 
of
 
COCP
 
is
 
associated
 
with
 
a
 
small
 
increased
 
risk
 
of
 
breast
 
cancer
 
which
 
reduces
 
with
 
time
 
after
 
stopping
 
COCP .
 
 
 
Patients
 
should
 
also
 
be
 
advised
 
that
 
current
 
use
 
of
 
COCP
 
for
 
more
 
than
 
5
 
years
 
is
 
associated
 
with
 
a
 
small
 
increased
 
risk
 
of
 
cervical
 
cancer;
 
risk
 
reduces
 
over
 
time
 
after
 
stopping
 
COCP
 
and
 
is
 
no
 
longer
 
increased
 
by
 
about
 
10
 
years
 
after
 
stopping.
 
 
 
Drug-drug
 
interactions
 
(Enzyme
 
Inducing
 
Drugs
 
-
 
May
 
reduce
 
the
 
effectiveness
 
of
 
COCP
 
up
 
to
 
28
 
days
 
after
 
stopping)
 
1.
 
Antibiotics
 
–
 
Rifampicin
 
2.
 
Antiretrovirals
 
–
 
Ritonavir ,
 
Nevirapine,
 
Darunavir ,
 
Efavirenz
 
3.
 
Anticonvulsants
 
–
 
Carbamazepine,
 
Phenytoin,
 
Lamotrigine,
 
Topiramate,
 
Rufinamide,
 
Oxcarbazepine
 
4.
 
Antifungals
 
–
 
Griseofulvin,
 
Fluconazole,
 
Ketoconazole
 
5.
 
St.
 
John’ s
 
Wort
 
 
Drug-food
 
interactions
 
(May
 
cause
 
symptoms
 
of
 
oestrogen
 
excess)
 
1.
 
Grapefruit
 
juice
 
 
 
 
15
 

=== PAGE 403 ===

 
Before
 
ending
 
this
 
peer
 
review
 
session,
 
the
 
reviewee
 
should
 
be
 
informed
 
of
 
the
 
step(s)
 
that
 
he/
 
she
 
missed
 
out
 
in
 
order
 
to
 
ensure
 
all
 
the
 
counselling
 
points
 
are
 
being
 
covered.
 
 
Remarks:
 
 
 
 
 
Reviewed
 
by:
 
Name
 
&
 
Signature
                                                                   
Date:
 
 
 
 
 
*
 
Mandatory
 
for
 
peer
 
review/validation
 
 
References:
 
1.
 
Formulari
 
Ubat
 
KKM
 
(FUKKM)
 
2.
 
MIMS
 
Malaysia
 
3.
 
Faculty
 
of
 
Sexual
 
&
 
Reproductive
 
Healthcare
 
(FSRH)
 
Guidance
 
2018:
 
Drug
 
Interactions
 
with
 
Hormonal
 
Contraception
 
4.
 
Faculty
 
of
 
Sexual
 
&
 
Reproductive
 
Healthcare
 
(FSRH)
 
Guideline
 
2019:
 
Combined
 
Hormonal
 
Contraception
 
5.
 
Faculty
 
of
 
Sexual
 
&
 
Reproductive
 
Healthcare
 
(FSRH)
 
Guideline
 
2017:
 
Contraception
 
After
 
Pregnancy
 
6.
 
Faculty
 
of
 
Sexual
 
&
 
Reproductive
 
Healthcare
 
(FSRH)
 
CEU
 
Guidance
 
2021:
 
Recommended
 
Actions
 
after
 
Incorrect
 
Use
 
of
 
Combined
 
Hormonal
 
Contraception
  
 
7.
 
U.S.
 
Medical
 
Eligibility
 
Criteria
 
for
 
Contraceptive
 
Use
 
2024
 
(U.S.
 
MEC)
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
16
 

=== PAGE 404 ===

 
Ear
 
Drops
 
Name
 
:
 
 
Unit
 
:
 
 
●
 
Please
 
tick
 
(
✔
)
 
Yes
 
for
 
correct
 
instruction.
 
●
 
Please
 
tick
 
(
✔
)
 
No
 
for
 
incorrect
 
instruction.
 
Yes
 
No
 
Remarks
 
Pharmacological
 
Group
 
1.
 
Antiinfective
 
2.
 
Antiinflammatory
 
3.
 
Cerumenolytics
 
 
 
 
Indications
 
and
 
Dosage
 
To
 
counsel
 
based
 
on
 
specific
 
medication’ s
 
indication
 
and
 
dosage
 
as
 
prescribed
 
by
 
doctor
 
 
 
 
 
Method
 
of
 
Administration*
 
1.
 
Read
 
the
 
medication
 
label.
 
2.
 
Wash
 
hands
 
with
 
soap
 
and
 
water .
 
Dry
  
them
 
with
 
a
 
clean
 
towel
 
or
 
tissue.
 
3.
 
If
 
the
 
ear
 
drops
 
are
 
a
 
cloudy
 
suspension,
 
shake
 
the
 
bottle
 
well
 
for
 
10
 
seconds.
 
If
 
necessary ,
 
roll
 
the
 
bottle
 
between
 
the
 
palms
 
of
 
your
 
hands
 
to
 
help
 
warm
 
the
 
drops
 
to
 
near
 
body
 
temperature.
 
4.
 
Remove
 
the
 
dropper
 
cap
 
and
 
look
 
closely
 
at
 
the
 
tip
 
to
 
make
 
sure
 
it
 
is
 
not
 
cracked
 
or
 
chipped.
 
Do
 
not
 
touch
 
the
 
tip.
 
5.
 
Position
 
the
 
head
 
with
 
the
 
affected
 
ear
 
facing
 
upward.
 
Either
 
lie
 
on
 
your
 
side
 
or
 
tilt
 
the
 
affected
 
ear
 
up.
 
Pull
 
the
 
upper
 
ear
 
back
 
and
 
upward.
 
Look
 
for
 
the
 
ear
 
canal
 
to
 
open.
 
6.
 
Place
 
the
 
correct
 
number
 
of
 
drops
 
in
 
the
 
ear.
 
 
7.
 
Keep
 
the
 
ear
 
tilted
 
up
 
for
 
5-10
 
minutes
 
or
 
insert
 
a
 
soft
 
cotton
 
plug
 
in
 
the
 
ear
 
to
 
keep
 
the
 
solution
 
in
 
the
 
ear.
 
8.
 
Use
 
a
 
clean
 
tissue
 
to
 
absorb
 
and
 
wipe
 
away
 
any
 
drops
 
that
 
spill
 
out
 
of
 
the
 
ear.
 
9.
 
Repeat
 
steps
 
4
 
till
 
7
 
on
 
the
 
other
 
ear,
 
if
  
using
 
ear
 
drops
 
on
 
both
 
ears,.
 
10.
 
Replace
 
cap
 
on
 
the
 
bottle
 
and
 
screw
 
it
 
on
 
securely .
 
11.
 
Use
 
the
 
drops
 
as
 
directed
 
for
 
the
 
length
 
of
 
time
 
prescribed.
 
Missed
 
dose
 
management:
 
 
1.
 
Take
 
as
 
soon
 
as
 
you
 
remember
 
and
 
do
 
not
 
double
 
the
 
dose.
 
 
 
 
Special
 
Considerations
 
Pregnancy
 
 
 
 
1.
 
NOT
 
recommended
 
during
 
pregnancy
 
a.
 
Polymyxin
 
B
 
Sulphate
 
10,000U,
 
Neomycin
 
Sulphate
 
5mg
 
and
 
Hydrocortisone
 
10mg
 
Ear
 
Drops
 
2.
 
Used
 
only
 
if
 
the
 
benefit
 
outweighs
 
the
 
risk
 
a.
 
Ofloxacin
 
b.
 
Gentamicin
 
 
 
 
Breastfeeding
 
 
 
 
1.
 
NOT
 
recommended
 
during
 
breastfeeding
 
a.
 
Polymyxin
 
B
 
Sulphate
 
10,000U,
 
Neomycin
 
Sulphate
 
5mg
 
and
 
Hydrocortisone
 
10mg
 
Ear
 
Drops
 
b.
 
Ofloxacin
 
 
 
 
Paediatric
 
 
 
 
1.
 
Infant:
 
try
 
swaddling
 
them
 
to
 
keep
 
them
 
still.
 
 
2.
 
Toddlers:
 
may
 
need
 
to
 
be
 
cradled
 
with
 
their
 
arms
 
and
 
 
 
 
17
 

=== PAGE 405 ===

 
legs
 
fully
 
restrained.
 
3.
 
For
 
children
 
<3
 
year
 
old,
 
you
 
will
 
need
 
to
 
pull
 
the
 
edge
 
of
 
the
 
ear
 
downward
 
and
 
backward.
 
Look
 
for
 
the
 
ear
 
canal
 
to
 
open.
 
Fasting
 
 
 
 
Refer
 
to
 
the
 
latest
 
advisory
 
by
 
the
 
religious
 
authority
 
 
 
 
Side
 
Effects
 
and
 
their
 
Management*
 
1.
 
Irritation.
 
2.
 
Swelling.
 
3.
 
Skin
 
rash.
 
4.
 
Unpleasant
 
taste
 
in
 
your
 
mouth.
 
This
 
is
 
because
 
the
 
ear
 
canal
 
is
 
connected
 
to
 
the
 
throat
 
and
 
some
 
of
 
the
 
 
liquid
 
may
 
drain
 
into
 
your
 
mouth.
 
Contact
 
your
 
healthcare
 
provider
 
if
 
you
 
think
 
you
 
are
 
having
 
a
 
side
 
effect
 
of
 
a
 
medicine.
 
 
 
 
Storage*
 
1.
 
Keep
 
away
 
from
 
the
 
reach
 
of
 
children.
 
2.
 
Store
 
in
 
a
 
cool,
 
dry
 
place,
 
away
 
from
 
direct
 
heat
 
and
 
light.
 
3.
 
For
 
ear
 
drops
 
requiring
 
storage
 
inside
 
the
 
fridge,
 
do
 
not
 
store
 
at
 
the
 
door
 
side
 
and
 
inside
 
the
 
freezer .
 
4.
 
Discard
 
if
 
there
 
is
 
any
 
preparation
 
left
 
in
 
the
 
container
 
after
 
you
 
have
 
finished
 
your
 
course
 
of
 
treatment.
 
 
5.
 
Ear
 
drops
 
should
 
not
 
be
 
used
 
if
 
the
 
bottle
 
has
 
been
 
open
 
for
 
longer
 
than
 
prescribed
 
duration.
 
 
 
 
Others
 
1.
 
Do
 
not
 
allow
 
the
 
dropper
 
tip
 
to
 
touch
 
your
 
ears,
 
fingers
 
or
 
any
 
other
 
surface.
 
2.
 
Do
 
not
 
poke
 
inside
 
your
 
ear
 
with
 
a
 
cotton
 
bud
 
as
 
this
 
can
 
cause
 
a
 
perforated
 
eardrum.
 
3.
 
Do
 
not
 
share
 
ear
 
drops
 
with
 
anyone
 
else.
 
4.
 
If
 
you
 
have
 
a
 
ruptured
 
eardrum,
 
do
 
not
 
use
 
drops
 
unless
 
your
 
healthcare
 
provider
 
says
 
to.
 
It
 
can
 
allow
 
potentially
 
damaging
 
chemicals
 
into
 
the
 
middle
 
ear.
 
 
5.
 
After
 
you
 
have
 
completed
 
the
 
course
 
of
 
treatment,
 
throw
 
away
 
any
 
leftover
 
drops.
 
6.
 
If
 
unopened
 
drops
 
have
 
expired,
 
discard
 
them
 
at
 
once.
 
 
 
 
Before
 
ending
 
this
 
peer
 
review
 
session,
 
the
 
reviewee
 
should
 
be
 
informed
 
of
 
the
 
step(s)
 
that
 
he/
 
she
 
missed
 
out
 
in
 
order
 
to
 
ensure
 
all
 
the
 
counselling
 
points
 
are
 
being
 
covered.
 
 
Remarks:
 
 
Reviewed
 
by:
 
Name
 
&
 
Signature
                                                                   
Date:
 
 
*Mandatory
 
for
 
peer
 
review/validation
 
 
References:
 
1.
 
Ministry
 
of
 
Health
 
Malaysia.
 
FUKKM
 
list.
 
Retrieved
 
September
 
12,
 
2024,
 
from
 
https://i.pharmacy .gov.my/fukkm
 
2.
 
American
 
Academy
 
of
 
Paediatrician
 
(2024).
 
Medication
 
administration
 
in
 
early
 
education
 
and
 
child
 
care
 
settings.
  
Retrieved
 
September
 
12,
 
2024,
 
from
 
https://wcmcahs.com/wp-content/uploads/2020/07/Medication_Administration.pd
 
3.
 
SingHealth.
 
(2024).
 
Ear
 
Drops
 
-
 
Dosage
 
and
 
How
 
to
 
Use.
 
Retrieved
 
September
 
12,
 
2024,
 
from
 
 
https://www .singhealth.com.sg/patient-care/medicine/ear-drops
 
4.
 
Drugs.com.
 
(2024).
 
Clotrimazole
 
topical
 
Pregnancy
 
and
 
Breastfeeding
 
Warnings.
 
Retrieved
 
September
 
12,
 
2024,
 
from
 
https://www .drugs.com/pregnancy/clotrimazole-topical.html
 
5.
 
Ildong
 
Pharm.
 
(2016).
 
Effexin
 
Otic
 
Solution
 
(Ofloxacin
 
Ear
 
drops)Ear
 
Drop
 
Package
 
insert.
 
Retrieved
 
from
 
https://www .pharmacompass.com/chemistry-chemical-name/ef fexin
 
6.
 
Glenmark.
 
(2022).
 
Candid
 
Ear
 
drops(
 
Clotrimazole)/
 
Ear
 
Drop
 
Package
 
insert.
 
Retrieved
 
from
 
https://www .1mg.com/drugs/candid-ear-drop-175798?srsltid=AfmBOoqsnHbmn3cl2gzdvRRCkDW4-JtB- 
BU_WtGfN8ZgbqqT2t6rlUf3&wpsrc=Google+Organic+Search
 
 
18
 

=== PAGE 406 ===

 
Ellipta
 
Name
 
:
 
 
Unit
 
:
 
 
●
 
Please
 
tick
 
(
✔
)
 
Yes
 
for
 
correct
 
instruction.
 
●
 
Please
 
tick
 
(
✔
)
 
No
 
for
 
incorrect
 
instruction.
 
Yes
 
No
 
Remarks
 
Type
 
of
 
Device
 
Dry
 
powder
 
inhaler
 
(DPI)
 
 
 
 
Indications
 
and
 
Dosage
 
The
 
indication
 
and
 
dosage
 
depend
 
on
 
the
 
drug
 
content.
 
 
 
 
Method
 
of
 
Administration*
 
DEVICE
 
PREP ARA TION
 
 
 
Before
 
Every
 
Use
 
 
 
Make
 
sure:
  
 
 
 
 
The
 
Ellipta
 
has
 
not
 
expired.
 
 
 
 
 
The
 
Ellipta
 
is
 
not
 
empty .
 
 
 
 
 
Check
 
inside
 
the
 
mouthpiece
 
of
 
the
 
Ellipta
 
and
 
ensure
 
it
 
is
 
free
 
from
 
foreign
 
objects.
 
 
 
 
 
DEVICE
 
INHALA TION
 
TECHNIQUES
 
 
Prepare
 
 
Step
 
1
 
●
 
Hold
 
the
 
inhaler
 
upright
 
with
 
the
 
cover
 
on
 
the
 
top.
 
●
 
Slide
 
the
 
cover
 
down
 
until
 
a
 
“click”
 
sound
 
is
 
heard.
 
The
 
dose
 
is
 
loaded.
 
The
 
dose
 
counter
 
counts
 
down
 
by
 
1
 
to
 
confirm.
 
 
Note:
 
Do
 
not
 
tip
 
the
 
Ellipta
 
upside
 
down
 
or
 
shake
 
the
 
device
 
after
 
dose
 
loading.
 
Do
 
not
 
block
 
the
 
air
 
vents.
 
 
 
 
 
Exhale
 
 
Step
 
2
 
●
 
Sit
 
upright
 
or
 
stand
 
in
 
an
 
erect
 
position.
 
●
 
Breathe
 
out
 
(exhale)
 
slowly
 
and
 
fully,
 
away
 
from
 
the
 
Ellipta.
 
 
 
 
Chin
 
&
 
mouth
 
 
Step
 
3
 
●
 
Slightly
 
tilt
 
the
 
chin
 
up.
 
●
 
Place
 
the
 
inhaler
 
mouthpiece
 
gently
 
between
 
the
 
teeth.
 
Ensure
 
a
 
tight
 
seal
 
of
 
the
 
lips
 
around
 
the
 
mouthpiece.
 
Do
 
not
 
bite
 
the
 
mouthpiece.
 
 
 
Notes:
 
Do
 
not
 
block
 
the
 
opening
 
of
 
the
 
mouthpiece
 
with
 
the
 
tongue
 
or
 
teeth.
 
The
 
tongue
 
should
 
be
 
lowered
 
under
 
the
 
mouthpiece.
 
 
 
 
Inhale
 
 
Step
 
4
 
Breathe
 
in
 
forcefully
 
and
 
deeply
 
through
 
the
 
mouth.
 
 
 
 
Hold
 
breath
 
 
Step
 
5
 
Remove
 
the
 
Ellipta
 
from
 
the
 
mouth,
 
and
 
with
 
the
 
lips
 
closed,
 
hold
 
the
 
breath
 
for
 
5-10
 
seconds
 
or
 
as
 
long
 
as
 
comfortable.
 
 
 
 
Exhale
 
 
Step
 
6
 
Breathe
 
out
 
(exhale)
 
gently ,
 
away
 
from
 
the
 
Ellipta.
 
 
 
 
19
 

=== PAGE 407 ===

 
Close
 
&
 
Rinse
 
Step
 
7
 
•
 
Slide
 
the
 
cover
 
upwards
 
as
 
far
 
as
 
it
 
will
 
go
 
to
 
cover
 
the
 
mouthpiece.
 
•
 
Rinse
 
and
 
gargle
 
the
 
mouth
 
with
 
water
 
and
 
spit
 
it
 
out
 
(for
 
a
 
steroid-containing
 
inhaler).
 
 
 
 
Missed
 
dose
 
management
 
:
 
 
If
 
a
 
maintenance
 
dose
 
is
 
missed,
 
take
 
it
 
as
 
soon
 
as
 
possible
 
and
 
then
 
resume
 
the
 
regular
 
schedule.
 
However ,
 
if
 
it
 
is
 
almost
 
time
 
for
 
the
 
next
 
dose,
 
skip
 
the
 
missed
 
dose.
 
Never
 
take
 
a
 
double
 
dose
 
to
 
make
 
up
 
for
 
a
 
missed
 
maintenance
 
dose.
 
Do
 
not
 
stop
 
taking
 
your
 
medication
 
unless
 
advised
 
to
 
do
 
so
 
by
 
your
 
prescriber .
 
 
 
 
Special
 
Considerations
 
Pregnancy
 
 
 
 
NA
 
 
 
 
Breastfeeding
 
 
 
 
NA
 
 
 
 
Elderly
 
 
 
 
Consider
 
patient-related
 
factors
 
such
 
as
 
inspiratory
 
effort
,
 
manual
 
dexterity ,
 
hand
 
strength,
 
tremors,
 
vision,
 
comorbidities,
 
respiratory
 
muscle
 
strength,
 
cognition
 
and
 
others.
 
 
 
 
Paediatric
 
 
 
 
Some
 
DPIs
 
may
 
be
 
appropriate
 
for
 
older
 
children.
 
Refer
 
guidelines,
 
for
 
example
 
Global
 
Initiative
 
for
 
Asthma
 
 
 
 
Fasting
 
 
 
 
To
 
refer
 
to
 
the
 
latest
 
advisory
 
by
 
religious
 
authority
 
 
 
 
Others
  
 
 
 
 
NA
 
 
 
 
Side
 
Effects
 
and
 
their
 
Management*
 
For
 
corticosteroid-containing
 
inhalers,
 
gargle
 
the
 
mouth
 
with
 
water
 
and
 
spit
 
it
 
out.
 
 
 
 
 
Storage*
 
Refer
 
to
 
product
 
inserts
 
for
 
complete
 
information.
 
In
 
general:
 
•
 
Store
 
the
 
device
 
in
 
a
 
clean,
 
cool,
 
and
 
dry
 
place
 
at
 
appropriate
 
temperatures.
 
•
 
Avoid
 
extreme
 
temperatures
 
and
 
humidity
 
(e.g.,
 
do
 
not
 
store
 
it
 
in
 
cars
 
or
 
bathrooms).
 
•
 
Ellipta
 
is
 
packed
 
in
 
a
 
tray
 
(with
 
a
 
desiccant
 
sachet).
 
Don’t
 
open
 
the
 
tray
 
until
 
ready
 
to
 
start
 
using
 
the
 
new
 
inhaler .
 
•
 
 
Keep
 
it
 
safely
 
out
 
of
 
the
 
reach
 
of
 
children.
 
 
 
 
Others
 
Cleaning*
 
 
 
Wipe
 
the
 
mouthpiece
 
with
 
a
 
dry
 
cloth
 
or
 
tissue
 
once
 
a
 
week
 
(after
 
dose
 
inhalation,
 
before
 
sliding
 
back
 
the
 
cover).
 
Do
 
not
 
use
 
water
 
or
 
liquids.
 
 
 
 
Expiry
 
date
 
 
Follow
 
the
 
expiry
 
date
 
on
 
the
 
product.
 
Ellipta’ s
 
in-use
 
shelf-life
 
is
 
6
 
weeks.
 
 
 
 
20
 

=== PAGE 408 ===

 
Dose
 
checking
 
●
 
Contains
 
dose
 
counter
 
●
 
Half
 
of
 
the
 
dose
 
counter
 
shows
 
red
 
once
 
the
 
inhaler
 
has
 
fewer
 
than
 
10
 
doses.
 
 
●
 
After
 
the
 
last
 
dose
 
is
 
loaded,
 
the
 
dose
 
will
 
display
 
the
 
number
 
0.
 
Once
 
this
 
dose
 
is
 
inhaled,
 
the
 
inhaler
 
is
 
now
 
empty .
 
 
●
 
Further
 
opening
 
of
 
the
 
cover
 
will
 
change
 
the
 
dose
 
counter
 
display
 
to
 
be
 
completely
 
red.
 
 
 
 
 
 
Additional
 
notes
 
Do
 
not
 
slide
 
open
 
the
 
cover
 
when
 
not
 
taking
 
the
 
dose
 
as
 
it
 
may
 
cause
 
a
 
waste
 
of
 
medication
 
 
 
 
 
Before
 
ending
 
this
 
peer
 
review
 
session,
 
the
 
reviewee
 
should
 
be
 
informed
 
of
 
the
 
step(s)
 
that
 
he/
 
she
 
missed
 
out
 
in
 
order
 
to
 
ensure
 
all
 
the
 
counselling
 
points
 
are
 
being
 
covered.
 
 
Remarks:
 
 
 
 
 
Reviewed
 
by:
 
Name
 
&
 
Signature
                                                                   
Date:
 
 
 
 
 
*Mandatory
 
for
 
validation
 
/
 
peer
 
review
 
 
References:
 
 
1.
 
Usmani
 
OS.
 
(2019
 
Mar).
 
Choosing
 
the
 
right
 
inhaler
 
for
 
your
 
asthma
 
or
 
COPD
 
patient.
 
Therapeutics
 
and
 
clinical
 
risk
 
management.
 
14:461-72.
 
2.
 
Ohar
 
JA,
 
Ferguson
 
GT,
 
Mahler
 
DA,
 
Drummond
 
MB,
 
Dhand
 
R,
 
Pleasants
 
RA,
 
Anzueto
 
A,
 
Halpin
 
DM,
 
Price
 
DB,
 
Drescher
 
GS,
 
Hoy
 
HM.
 
(2022
 
Jan).
 
Measuring 
 
peak
 
inspiratory
 
flow
 
in
 
patients
 
with
 
chronic
 
obstructive
 
pulmonary
 
disease.
 
International
 
journal
 
of
 
chronic
 
obstructive
 
pulmonary
 
disease.
  
6:79-92.
 
3.
 
The
 
Electronic
 
Medicine
 
Compendium
 
(eMC)
 
(Available
 
at 
http://www .medicines.org.uk/emc/
).
 
Accessed
 
on
 
October
 
15,
 
2024.
 
4.
 
Asthma
 
UK.
 
How
 
to
 
use
 
your
 
inhaler
 
(Available
 
at 
https://www .asthmaandlung.org.uk/living-with/inhaler-videos
).
 
Accessed
 
on
 
October
 
15,
 
2024.
 
5.
 
Mohammad
 
Y.
 
(2019
 
Oct).
 
How
 
to
 
manage
 
asthma
 
during
 
Ramadan?
 
97(10):
 
1073-1076.
 
PMID:
 
31691934
 
6.
 
Global
 
Initiative
 
for
 
Asthma.
 
Global
 
Strategy
 
for
 
Asthma
 
Management
 
and
 
Prevention,
 
2024.
 
Updated
 
May
 
2024.
 
Available
 
from:
 
www .ginasthma.org.
 
Accessed
 
on
 
January
 
20,
 
2025
.
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
21
 

=== PAGE 409 ===

 
Emergency
 
Contraception
 
Name
 
:
 
 
Unit
 
:
 
 
●
 
Please
 
tick
 
(
✔
)
 
Yes
 
for
 
correct
 
instruction.
 
●
 
Please
 
tick
 
(
✔
)
 
No
 
for
 
incorrect
 
instruction.
 
Yes
 
No
 
Remarks
 
Pharmacological
 
Group
 
Progestogens
 
/
 
Progestogens
 
and
 
estrogens
 
in
 
combination
 
 
 
1.
 
Levonorgestrel
 
1.5mg
 
(Escapelle)
 
Yuzpe
 
Method
 
2.
 
Ethinyl
 
Estradiol
 
30
 
mcg
 
and
 
Levonorgestrel
 
150
 
mcg
 
(Rigevidon)
 
3.
 
Ethinyl
 
Estradiol
 
20
 
mcg
 
and
 
Levonorgestrel
 
100
 
mcg
 
(Loette)
 
 
 
 
Indications
 
and
 
Dosage
 
Indication
 
 
Prevent
 
pregnancy following sexual
 
intercourse
 
 
Dosage
 
:
 
Single
 
dose
 
immediately
 
(Escapelle)
 
 
Dosage
 
for
 
Yuzpe
 
Method*
 
:
 
 
 
Rigevidon
 
4
 
tablets
 
immediately .
 
Repeat
 
12
 
hours
 
later
 
 
 
            
Loette
 
5
 
tablets
 
immediately .
 
Repeat
 
12
 
hours
 
later
 
 
 
*Refer
 
Others
 
Section
 
 
 
 
Method
 
of
 
Administration*
 
Need
 
to
 
be
 
taken
 
as
 
soon
 
as
 
possible
 
within
 
72
 
hours
 
of
 
unprotected
 
sex.
 
 
Note:
 
Always
 
read
 
the
 
product
 
information
 
leaflet
 
before
 
counsel
 
the
 
patient.
 
Information
 
may
 
differ
 
depending
 
on
 
the
 
product
 
 
Do
 
not
 
stop
 
taking
 
your
 
medication
 
unless
 
advised
 
to
 
do
 
so
 
by
 
your
 
prescriber
 
 
 
 
Special
 
Considerations
 
Pregnancy
 
 
 
 
NA
 
 
 
 
Breastfeeding
 
 
 
 
Safe
 
to
 
be
 
taken
 
 
 
 
Elderly
 
 
 
 
Contraindicated
 
in
 
post-menopausal
 
women
 
 
 
 
Paediatric
 
 
 
 
The
 
safety
 
and
 
efficacy
 
of
 
these
 
medications
 
in
 
children
 
who
 
have
 
not
 
achieved
 
menarche.
 
 
 
 
 
Fasting
 
 
 
 
To
 
refer
 
to
 
the
 
latest
 
advisory
 
by
 
religious
 
authority
 
 
 
 
Others
  
 
 
 
 
22
 

=== PAGE 410 ===

 
NA
 
 
 
 
Side
 
Effects
 
and
 
their
 
Management*
 
1.
 
Nausea,
 
abdominal
 
pain,
 
headache,
 
dizziness,
 
breast
 
tenderness,
 
vomiting,
 
diarrhoea,
 
irregular
 
bleeding
 
and
 
spotting.
 
These
 
symptoms
 
will
 
usually
 
pass
 
within
 
24
 
hours
 
2.
 
Pills
 
can
 
be
 
taken
 
with
 
water
 
or
 
milk
 
to
 
curb
 
nausea
 
3.
 
If
 
the
 
pills
 
are
 
vomited
 
within
 
2
 
hours
 
of
 
taking
 
the
 
dose,
 
repeat
 
the
 
dose
 
again
 
 
 
 
 
Storage
 
1.
 
Store
 
below
 
30
o
C.
 
 
2.
 
Protect
 
from
 
light
 
and
 
moisture.
 
 
 
 
Others
 
*
 
Yuzpe
 
Method
 
-
 
each
 
dose
 
containing
 
100
 
mcg
 
of
 
Ethinyl
 
Estradiol
 
and
 
0.5mg
 
of
 
Levonorgestrel
 
(less
 
effective
 
method
 
as
 
compared
 
to
 
T.
 
Levonorgestrel
 
1.5
 
mg)
 
 
Emergency
 
Contraception
 
will
 
not
 
cause
 
harm
 
to
 
the
 
fetus
 
if
 
it
 
fails
 
to
 
prevent
 
pregnancy
 
 
Taking
 
extra
 
pills
 
does
 
not
 
increase
 
effectiveness
 
but
 
induces
 
side
 
effects
 
 
Expect
 
delay
 
of
 
menses
 
>
 
1
 
week
 
 
Start
 
regular
 
contraception
 
as
 
soon
 
as
 
possible
 
 
Drug-drug
 
interactions
 
(may
 
reduce
 
the
 
effectiveness
 
of
 
Emergency
 
Contraception)
 
1.
 
Antibiotics
 
–
 
Rifampicin
 
2.
 
Antivirals
 
–
 
Ritonavir ,
 
Nevirapine,
 
Darunavir ,
 
Efavirenz
 
3.
 
Anticonvulsants
 
–
 
Carbamazepine,
 
Phenytoin,
 
Lamotrigine,
 
Topiramate,
 
Rufinamide,
 
Oxcarbazepine
 
4.
 
Antifungals
 
–
 
Griseofulvin,
 
Fluconazole,
 
Ketoconazole
 
5.
 
St.
 
John’ s
 
Wort
 
 
 
 
Before
 
ending
 
this
 
peer
 
review
 
session,
 
the
 
reviewee
 
should
 
be
 
informed
 
of
 
the
 
step(s)
 
that
 
he/
 
she
 
missed
 
out
 
in
 
order
 
to
 
ensure
 
all
 
the
 
counselling
 
points
 
are
 
being
 
covered.
 
 
Remarks:
 
 
 
 
 
Reviewed
 
by:
 
Name
 
&
 
Signature
                                                                   
Date:
 
 
 
 
 
*Mandatory
 
for
 
peer
 
review/validation
 
 
Reference:
 
1.
 
Formulari
 
Ubat
 
KKM
 
(FUKKM)
 
2.
 
MIMS
 
Malaysia
 
3.
 
Faculty
 
of
 
Sexual
 
&
 
Reproductive
 
Healthcare
 
(FSRH)
 
Guideline
 
2023:
 
Emergency
 
Contraception
 
4.
 
U.S.
 
Medical
 
Eligibility
 
Criteria
 
for
 
Contraceptive
 
Use
 
2024
 
(U.S.
 
MEC)
 
5.
 
The
 
American
 
College
 
of
 
Obstetricians
 
and
 
Gynecologists
 
(ACOG)
 
Practice
 
Bulletin
 
No.
 
152:
 
Emergency
 
Contraception.
 
Obstet
 
Gynecol.
 
2015
 
Sep;126(3):e1-e1 1.
 
 
 
 
 
 
23
 

=== PAGE 411 ===

 
Emollient/
 
Moisturisers
 
Name
 
:
 
 
Unit
 
:
 
 
●
 
Please
 
tick
 
(
✔
)
 
Yes
 
for
 
correct
 
instruction.
 
●
 
Please
 
tick
 
(
✔
)
 
No
 
for
 
incorrect
 
instruction.
 
Yes
 
No
 
Remarks
 
Pharmacological
 
Group
 
Emollients
 
&
 
Protectives
 
 
 
Emollient:
 
Fill
 
in
 
cracks
 
and
 
lines
 
by
 
repairing
 
the
 
skin
 
barrier ,
 
helps
 
smooth
 
and
 
soften
 
skin
 
 
Humectant:
 
Attract
 
and
 
hold
 
water
 
in
 
the
 
top
 
layer
 
of
 
skin.
 
It
 
increases
 
water
 
holding
 
capacity
 
of
 
stratum
 
corneum
 
1.
 
Urea
 
cream
 
10%
 
2.
 
Glycerin
 
25%
 
-
 
50%
 
in
 
Aqueous
 
cream
 
 
 
Occlusive:
 
Repels
 
water ,
 
also
 
form
 
a
 
protective
 
barrier
 
to
 
trap
 
the
 
moisture
 
in
 
the
 
skin
 
1.
 
Aqueous
 
cream
 
2.
 
Emulsifying
 
ointment
 
 
3.
 
White
 
soft
 
paraf fin
 
+
 
liquid
 
paraf fin
 
 
4.
 
White/
 
Yellow
 
soft
 
paraf fin
 
 
 
 
 
Indications
 
and
 
Dosage
 
1.
 
As
 
an
 
emollient
 
for
 
the
 
symptomatic
 
relief
 
of
 
dry
 
skin
 
conditions
 
and
 
as
 
soap-substitute
 
for
 
skin-bathing
 
2.
 
Dosage:
 
Apply
 
sparingly
 
to
 
the
 
affected
 
area
 
as
 
required
 
or
 
as
 
directed
 
by
 
your
 
pharmacist
 
or
 
doctor .
 
3.
 
Moisturisers
 
come
 
in
 
a
 
range
 
of
 
formulations
 
such
 
as
 
lotion,
 
cream,
 
ointment
 
and
 
usage
 
depends
 
on
 
their
 
own
 
preference.
 
Generally ,
 
moderately
 
dry
 
to
 
very
 
dry
 
skin
 
responds
 
best
 
to
 
an
 
ointment
 
and
 
mildly
 
dry
 
skin
 
responds
 
best
 
to
 
creams
 
or
 
lotions.
 
 
 
 
Method
 
of
 
Administration*
 
As
 
an
 
emollient:
 
●
 
Best
 
apply
 
after
 
taking
 
a
 
bath
 
or
 
showering
 
when
 
the
 
skin
 
is
 
moist,
 
while
 
water
 
is
 
still
 
trapped
 
in
 
the
 
skin
 
for
 
extra
 
hydration.
 
●
 
To
 
apply
 
emollients
 
liberally
 
(at
 
least
 
2-4
 
times
 
a
 
day).
 
●
 
To
 
apply
 
by
 
smoothing
 
into
 
the
 
skin
 
gently
 
in
 
the
 
same
 
direction
 
of
 
hair
 
grows
 
to
 
avoid
 
folliculitis
 
As
 
a
 
soap
 
substitute:
 
●
 
To
 
use
 
when
 
washing,
 
put
 
a
 
half
 
to
 
one
 
teaspoonful
 
in
 
the
 
palm
 
of
 
your
 
hand
 
and
 
mix
 
with
 
a
 
small
 
amount
 
of
 
warm
 
water .
 
This
 
can
 
then
 
be
 
applied
 
to
 
wet
 
skin
 
and
 
rinse
 
off
 
with
 
water .
 
●
 
If
 
having
 
a
 
bath
 
or
 
shower ,
 
emollients
 
can
 
be
 
rubbed
 
‘neat’
 
directly
 
into
 
the
 
skin
 
and
 
then
 
rinsed
 
off
 
with
 
water .
 
●
 
Please
 
be
 
careful,
 
as
 
it
 
may
 
cause
 
the
 
floor
 
to
 
be
 
slippery
 
and
 
increase
 
risk
 
of
 
patient
 
fall.
 
Using
 
emollients
 
with
 
other
 
skin
 
treatments:
 
●
 
If
 
you’re
 
using
 
a
 
steroid
 
cream
 
or
 
another
 
treatment
 
for
 
your
 
skin
 
condition,
 
wait
 
20
 
to
 
30
 
minutes
 
between
 
using
 
an
 
emollient
 
and
 
using
 
the
 
other
 
treatment.
 
 
To
 
counsel
 
based
 
on
 
specific
 
medication’ s
 
indication
 
and
 
dosage
 
as
 
prescribed
 
by
 
the
 
doctor
 
Do
 
not
 
stop
 
taking
 
your
 
medication
 
unless
 
advised
 
to
 
do
 
so
 
by
 
your
 
prescriber
 
 
 
 
Special
 
Considerations
 
Pregnancy
 
 
 
 
The
 
safety
 
of
 
emollients
 
during
 
pregnancy
 
has
 
not
 
been
 
 
 
 
24
 

=== PAGE 412 ===

 
established
 
but
 
is
 
not
 
considered
 
to
 
constitute
 
a
 
hazard
 
during
 
these
 
periods.
 
Breastfeeding
 
 
 
 
The
 
safety
 
of
 
emollients
 
during
 
lactation
 
has
 
not
 
been
 
established
 
but
 
is
 
not
 
considered
 
to
 
constitute
 
a
 
hazard
 
during
 
these
 
periods.
 
 
 
 
Elderly
 
 
 
 
NA
 
 
 
 
Paediatric
 
 
 
 
Safety
 
and
 
efficacy
 
of
 
emollients
 
for
 
pediatric
 
patients
 
are
 
established
 
as
 
per
 
the
 
indications
 
stated.
 
 
 
 
 
Fasting
 
 
 
 
To
 
refer
 
to
 
the
 
latest
 
advisory
 
by
 
religious
 
authority
 
 
 
 
Others
 
 
 
 
 
NA
 
 
 
 
Side
 
Effects
 
and
 
their
 
Management*
 
Emollients
 
can
 
sometimes
 
cause
 
a
 
skin
 
reaction,
 
such
 
as:
 
 
1.
 
An
 
overheating,
 
burning
 
sensation
 
or
 
stinging
 
that
 
does
 
not
 
settle
 
after
 
a
 
few
 
days
 
of
 
treatment
 
–
 
usually
 
caused
 
by
 
a
 
reaction
 
to
 
a
 
certain
 
ingredient
 
in
 
the
 
emollient
 
2.
 
Blocked
 
or
 
inflamed
 
hair
 
follicles
 
(folliculitis)
 
that
 
may
 
cause
 
boils
 
3.
 
Rashes
 
on
 
the
 
face
 
that
 
can
 
aggravate
 
acne
 
 
 
 
Storage*
 
Keep
 
the
 
jar
 
tightly
 
closed.
 
Store
 
below
 
30°C
 
and
 
protect
 
from
 
heat,
 
moisture,
 
and
 
light.
 
Do
 
not
 
freeze.
 
Keep
 
out
 
of
 
reach
 
of
 
children.
 
 
 
 
 
Others
 
●
 
Never
 
rub
 
up
 
and
 
down
 
vigorously ,
 
as
 
this
 
could
 
trigger
 
itchiness,
 
block
 
hair
 
follicles
 
and
 
create
 
more
 
heat
 
in
 
the
 
skin.
 
●
 
It
 
is
 
recommended
 
to
 
use
 
a
 
spoon
 
or
 
spatula
 
to
 
scoop
 
out
 
ointments
 
from
 
tubs
 
to
 
avoid
 
contamination
 
 
 
 
Before
 
ending
 
this
 
peer
 
review
 
session,
 
the
 
reviewee
 
should
 
be
 
informed
 
of
 
the
 
step(s)
 
that
 
he/
 
she
 
missed
 
out
 
in
 
order
 
to
 
ensure
 
all
 
the
 
counselling
 
points
 
are
 
being
 
covered.
 
 
Remarks:
 
 
 
Reviewed
 
by:
 
Name
 
&
 
Signature
                                                                   
Date:
 
 
 
*Mandatory
 
for
 
validation
 
/
 
peer
 
review
 
References
 
:
 
 
1.
 
Dynapharm
 
(M)
 
sdn.
 
Bhd.
 
(2024).
 
Product
 
information
 
leaflet:
 
Dyna
 
Aqueous
 
cream.
 
Retrieved
 
from
 
Quest
 
3+
 
Product
 
Search
 
on
 
January
 
21,
 
2025.
 
2.
 
National
 
Health
 
Service.
 
(2023).
 
Emollients.
 
NHS.
 
Retrieved
 
January
 
21,
 
2025,
 
from
 
https://www .nhs.uk/conditions/emollients/
 
 
3.
 
National
 
Health
 
Service.
 
(2020).
 
Using
 
emollients
 
(moisturiser)
 
as
 
soap
 
substitutes.
 
NHS.
 
Retrieved
 
January
 
21,
 
2025,
 
from
 
https://nhsdorset.nhs.uk/Downloads/aboutus/medicines-management/NHS%20Dorset%20Site/Patient%
20information%20leaflet%20-%20Using%20emollients%20as%20soap%20substitutes.pdf
 
 
25
 

=== PAGE 413 ===

 
Eye
 
Drops
 
Name
 
:
 
 
Unit
 
:
 
 
●
 
Please
 
tick
 
(
✔
)
 
Yes
 
for
 
correct
 
instruction.
 
●
 
Please
 
tick
 
(
✔
)
 
No
 
for
 
incorrect
 
instruction.
 
Yes
 
No
 
Remarks
 
Pharmacological
 
Group
 
1.
 
Anticholinergic
 
(e.g.
 
Atropine
 
Sulphate
 
1%
 
Eye
 
Drops,
 
Homatropine
 
2%
 
Eye
 
Drops)
 
2.
 
Antiglaucoma
 
(e.g.
 
Bimatoprost
 
0.01%
 
ophthalmic
 
solution,
 
Brimonidine
 
Tartrate
 
0.15%
 
Ophthalmic
 
solution,
 
Dorzolamide
 
HCl
 
2%
 
Ophthalmic
 
Solution)
 
3.
 
Antihistamine
 
(e.g.
 
Sodium
 
Cromoglycate
 
2%
 
Eye
 
Drops)
 
4.
 
Antiinfective
 
(e.g.
 
Chloramphenicol
 
0.5%
 
Eye
 
Drops,
 
Ciprofloxacin
 
HCl
 
0.3%
 
Ophthalmic
 
Solution,
 
Gentamicin
 
0.3%
 
Eye
 
Drops)
 
5.
 
Antiinflammatory
 
(e.g.
 
Dexamethasone
 
Sodium
 
Phosphate
 
0.1%
 
Eye
 
Drops,
 
Prednisolone
 
Acetate
 
1%
 
ophthalmic
 
suspension,
 
Fluorometholone
 
0.1%
 
Ophthalmic
 
Suspension)
 
6.
 
Antimuscarinic
 
(e.g.
 
Cyclopentolate
 
1%
 
Eye
 
Drops,
 
Pilocarpine
 
1%
 
&
 
2%
 
Eye
 
Drops)
 
7.
 
Lubricating/
 
Moisturizing
 
agent
 
(e.g.
 
Sodium
 
Chloride
 
0.9%
 
Eye
 
Drops,
 
Artificial
 
tears/eye
 
lubricant
 
ophthalmic
 
solution)
 
8.
 
Mydriatic
 
agent
 
(e.g.
 
Phenylephrine
 
HCI
 
2.5%
 
Eye
 
Drops)
 
 
 
 
Indications
 
and
 
Dosage
 
Counsel
 
patients
 
based
 
on
 
indication
 
and
 
dosage
 
as
 
prescribed.
 
 
 
 
 
Method
 
of
 
Administration*
 
1.
 
Read
 
the
 
medication
 
label.
 
2.
 
Wash
  
hands
 
with
 
soap
 
and
 
water .
 
Dry
 
them
 
with
 
a
 
clean
 
towel
 
or
 
tissue.
 
3.
 
Remove
 
contact
 
lenses
 
if
 
wearing
 
them.
 
 
4.
 
Wash
 
hands
 
with
 
soap
 
and
 
water
 
again.
 
Dry
 
them
 
with
 
a
 
clean
 
towel
 
or
 
tissue.
 
5.
 
Warm
 
the
 
bottle
 
by
 
rolling
 
between
 
palms
 
if
 
the
 
eye
 
drop
 
is
 
stored
 
in
 
the
 
refrigerator .
 
6.
 
Gently
 
agitate
 
the
 
bottle
 
before
 
use
 
to
 
make
 
sure
 
the
 
drug
 
is
 
properly
 
mixed.
 
7.
 
Unscrew
 
the
 
cap
 
of
 
the
 
bottle.
 
Look
 
closely
 
at
 
the
 
tip
 
to
 
make
 
sure
 
it’s
 
not
 
cracked
 
or
 
damaged.
 
DO
 
NOT
 
TOUCH
 
THE
 
TIP
.
 
8.
 
Lie
 
down
 
or
 
tilt
 
the
 
head
 
back
 
and
 
look
 
up
 
at
 
the
 
ceiling,
 
keeping
 
the
 
eyes
 
wide
 
open.
 
9.
 
Place
 
one
 
or
 
two
 
fingers
 
on
 
the
 
face
 
and
 
gently
 
pull
 
the
 
lower
 
eyelid
 
down
 
with
 
the
 
finger
 
to
 
form
 
a
 
pocket.
 
10.
 
Hold
 
the
 
eye
 
drop
 
bottle
 
at
 
least
 
1–
 
2
 
cm
 
above
 
the
 
eye
 
with
 
the
 
other
 
hand.
 
Be
 
careful
 
not
 
to
 
let
 
the
 
dropper
 
touch
 
any
 
surface
 
to
 
avoid
 
contamination.
 
11.
 
Squeeze/
 
drop
 
the
 
correct
 
number
 
of
 
drops
 
inside
 
the
 
lower
 
eyelid.
 
12.
 
Close
 
the
 
eyes
 
slowly
 
for
 
approximately
 
1
 
minute
 
to
 
allow
 
the
 
medication
 
to
 
be
 
absorbed.
 
13.
 
To
 
keep
 
as
 
much
 
of
 
the
 
drop
 
on
 
the
 
eye
 
as
 
possible,
 
gently
 
press
 
a
 
finger
 
against
 
the
 
inside
 
corner
 
of
 
each
 
eye
 
next
 
to
 
the
 
nose.
 
14.
 
Straighten
 
the
 
head
 
and
 
use
 
a
 
clean
 
tissue
 
to
 
wipe
 
away
 
any
 
drops
 
that
 
spilled
 
out.
 
15.
 
Repeat
 
steps
 
8
 
till
 
14
 
on
 
the
 
other
 
eye
 
if
 
need
 
to
 
instill
 
eye
 
drop
 
in
 
both
 
eyes.
 
16.
 
Replace
 
cap
 
on
 
the
 
bottle
 
and
 
screw
 
it
 
on
 
securely .
 
 
 
 
26
 

=== PAGE 414 ===

 
17.
 
If
 
more
 
than
 
one
 
eye
 
drop
 
at
 
a
 
time
 
is
 
prescribed,
 
wait
 
about
 
5
 
minutes
 
before
 
using
 
the
 
next
 
eye
 
drop.
 
Repeat
 
steps
 
5
 
till
 
14.
 
18.
 
Order
 
of
 
using
 
different
 
types
 
of
 
eye
 
drops
 
is
 
as
 
below:
 
 
I.
 
aqueous
 
based
 
eye
 
drops
 
e.g.
 
artificial
 
tears
 
II.
 
suspension
 
based
 
eye
 
drop
 
e.g.
 
antibiotic
 
eye
 
drops
 
III.
 
ointment
 
based
 
eye
 
preparation
 
19.
 
If
 
using
 
both
 
eye
 
drops
 
and
 
eye
 
ointment,
 
put
 
the
 
eye
 
drop
 
in
 
at
 
least
 
10
 
minutes
 
before
 
the
 
ointment.
 
Special
 
Considerations
 
Pregnancy
 
 
 
 
1.
 
Sodium
 
Cromoglycate
 
eye
 
drop,
 
use
 
not
 
recommended
 
during
 
first
 
3
 
months
 
of
 
pregnancy
 
2.
 
Use
 
only
 
if
 
the
 
benefit
 
outweighs
 
the
 
risk
 
:
 
 
●
 
Atropine
 
/
 
●
 
Cyclopentolate
 
/
 
●
 
Fluorometholone
 
/
 
●
 
Gentamicin
 
/
 
●
 
Homatropine
 
/
 
●
 
Latanoprost
 
/
 
●
 
Phenylephrine
 
 
●
 
Pilocarpine
 
/
 
●
 
Tafluprost
 
&
 
Timolol
 
/
 
●
 
Travoprost
 
&
 
Timolol
 
 
●
 
Tropicamide
 
/
 
 
 
 
Breastfeeding
 
 
 
 
1.
 
Long-term
 
use
 
might
 
reduce
 
milk
 
production
 
or
 
milk
 
letdown.
 
Observe
 
the
 
infant
 
for
 
signs
 
of
 
decreased
 
lactation
 
(e.g.,
 
insatiety ,
 
poor
 
weight
 
gain)
 
:
 
atropine,
 
cyclopentolate,
 
tropicamide
 
2.
 
Monitor
 
the
 
infant
 
for
 
signs
 
of
 
cholinergic
 
excess
 
(diarrhea,
 
lacrimation,
 
and
 
excessive
 
salivation
 
or
 
urination)
 
:
 
pilocarpine
 
3.
 
Potential
 
for
 
serious
 
adverse
 
effects
 
in
 
nursing
 
infants.
 
Decision
 
should
 
be
 
made
 
whether
 
to
 
discontinue
 
nursing
 
or
 
to
 
discontinue
 
drug,
 
taking
 
into
 
account
 
the
 
importance
 
of
 
the
 
drug
 
to
 
the
 
mother
 
:
 
fluorometholone
 
eye
 
drop
 
 
 
 
Elderly
 
 
 
 
1.
 
No
 
overall
 
differences
 
in
 
safety
 
or
 
effectiveness
 
have
 
not
 
been
 
observed
 
between
 
elderly
 
and
 
younger
 
patients.
 
 
 
 
Paediatric
 
 
 
 
1.
 
Precaution:
 
safety
 
and
 
efficacy
 
of
 
most
 
eye
 
drops
 
have
 
not
 
been
 
demonstrated
 
in
 
children
 
of
 
the
 
age
 
group
 
2
 
years
 
and
 
below .
 
2.
 
Sodium
 
Cromoglycate
 
eye
 
drop
 
use
 
recommended
 
for
 
children
 
above
 
4
 
years
 
old
 
onwards.
 
 
 
 
Fasting
 
 
 
 
Refer
 
to
 
the
 
latest
 
advisory
 
by
 
the
 
religious
 
authority
 
 
 
 
Others
 
 
 
 
 
27
 

=== PAGE 415 ===

 
1.
 
Contact
 
lenses
 
should
 
not
 
be
 
worn
 
for
 
the
 
first
 
20
 
minutes
 
following
 
the
 
instillation
 
of
 
the
 
drops.
 
In
 
certain
 
cases,
 
you
 
may
 
need
 
to
 
stop
 
using
 
your
 
contact
 
lenses
 
2.
 
To
 
minimise
 
the
 
absorption
 
of
 
any
 
drug
 
into
 
the
 
blood
 
stream
 
you
 
can
 
apply
 
naso-lachrymal
 
occlusion
 
(pressing
 
over
 
the
 
tear
 
duct
 
to
 
close
 
it
 
off)
 
as
 
you
 
use
 
the
 
drops.
 
3.
 
 
To
 
avoid
 
in
 
G6PD
 
Deficiency
 
(definite
 
risk
 
of
 
haemolysis)
 
●
 
Chloramphenicol
 
●
 
Brinzolamide
 
●
 
Dorzolamide
 
●
 
Ciprofloxacin
 
●
 
Levofloxacin
 
●
 
Ofloxacin
 
 
 
 
Side
 
Effects
 
and
 
their
 
Management*
 
1.
 
Eye
 
burning,
 
irritation,
 
stinging
 
or
 
itching
 
 
It
 
should
 
go
 
after
 
a
 
few
 
minutes
 
as
 
your
 
eyes
 
get
 
used
 
to
 
the
 
medicines.
 
If
 
symptoms
 
continue,
 
stop
 
using
 
the
 
eye
 
drop
 
and
 
inform
 
the
 
doctor .
 
2.
 
Eye
 
redness
 
3.
 
Blurry/
 
changes
 
in
 
vision
 
If
 
vision
 
does
 
not
 
go
 
back
 
to
 
normal
 
after
 
a
 
few
 
minutes
 
or
 
slowly
 
gets
 
worse,
 
stop
 
using
 
the
 
eye
 
drop
 
and
 
inform
 
the
 
doctor .
 
4.
 
Unpleasant
 
taste
 
in
 
the
 
mouth
 
Rinse
 
your
 
mouth
 
with
 
water
 
or
 
have
 
a
 
drink
 
of
 
water .
 
 
Contact
 
your
 
healthcare
 
provider
 
if
 
you
 
think
 
you
 
are
 
having
 
a
 
side
 
effect
 
of
 
a
 
medicine.
 
 
 
 
Storage*
 
1.
 
Keep
 
away
 
from
 
reach
 
of
 
children
 
2.
 
Store
 
in
 
a
 
cool,
 
dry
 
place,
 
away
 
from
 
direct
 
heat
 
and
 
light.
 
3.
 
Some
 
eye
 
drops,
 
such
 
as
 
chloramphenicol,
 
must
 
be
 
stored
 
in
 
a
 
refrigerator
 
before
 
and
 
after
 
opening
 
while
 
others
 
are
 
stored
 
in
 
the
 
refrigerator
 
after
 
opening
 
only
 
-
 
it
 
is
 
important
 
to
 
read
 
the
 
instructions
 
carefully .
 
4.
 
For
 
eye
 
drops
 
requiring
 
storage
 
inside
 
the
 
fridge,
 
do
 
not
 
store
 
at
 
the
 
door
 
side
 
and
 
inside
 
the
 
freezer
 
5.
 
Eye
 
drops
 
should
 
not
 
be
 
used
 
if
 
the
 
bottle
 
has
 
been
 
open
 
for
 
longer
 
than
 
prescribed
 
duration
 
or
 
after
 
4
 
weeks.
 
6.
 
Discard
 
if
 
there
 
is
 
any
 
preparation
 
left
 
in
 
the
 
container
 
after
 
you
 
have
 
finished
 
your
 
course
 
of
 
treatment.
 
 
 
 
 
Others
 
1.
 
Do
 
not
 
allow
 
the
 
dropper
 
tip
 
to
 
touch
 
your
 
eyes,
 
fingers
 
or
 
any
 
other
 
surface.
 
2.
 
Do
 
not
 
share
 
eye
 
drops
 
with
 
anyone
 
else.
 
3.
 
If
 
unopened
 
drops
 
have
 
expired,
 
discard
 
them
 
at
 
once.
 
4.
 
Missed
 
dose:
 
take
 
as
 
soon
 
as
 
you
 
remember
 
and
 
DO
 
NOT
 
DOUBLE
 
the
 
dose.
 
 
 
 
Before
 
ending
 
this
 
peer
 
review
 
session,
 
the
 
reviewee
 
should
 
be
 
informed
 
of
 
the
 
step(s)
 
that
 
he/
 
she
 
missed
 
out
 
in
 
order
 
to
 
ensure
 
all
 
the
 
counselling
 
points
 
are
 
being
 
covered.
 
Remarks:
 
 
 
 
Reviewed
 
by:
 
Name
 
&
 
Signature
                                                                   
Date:
 
 
 
 
*
 
Mandatory
 
for
 
peer
 
review/validation
 
28
 

=== PAGE 416 ===

 
References:
 
 
1.
 
Alcon.
 
(2021).
 
Alcon
 
Atropine
 
Sulfate
 
1%
 
Eye
 
Drop
 
Eye
 
Drop
 
package
 
insert.
 
Retrieved
 
from
 
https://www .myalcon.com/professional/cataract-surgery/procedural-eye-drops/#isoptoatropine
 
2.
 
Alcon.
 
(2022).
 
Mydriacyl
 
1.0%
 
Sterile
 
Ophthalmic
 
Solution
 
(
 
Tropicamide)
 
Eye
 
Drop
 
package
 
insert.
 
Retrieved
 
from
 
https://www .myalcon.com/professional/cataract-surgery/procedural-eye-drops/#mydriacyl
 
 
3.
 
Allergan.
 
(2020).
 
FML
 
(Fluorometholone
 
0.1%)
 
Eye
 
Drop
 
package
 
insert.
 
Retrieved
 
from
 
https://allergan-web-cdn-prod.azureedge.net/allergan/allergannewzealand/media/allergannewzealand/pr
oducts/fml-cmi.pdf
 
4.
 
Drugs.com
 
(2024).
 
Retrieved
 
September
 
12,
 
2024,
 
from
 
https://www .drugs.com/pregnancy/homatropine-ophthalmic.html
 
5.
 
Drugs.com
 
(2024).
 
Retrieved
 
September
 
12,
 
2024,
 
from
 
https://www .drugs.com/pregnancy/phenylephrine-ophthalmic.html
 
6.
 
FDC
 
Limited.
 
(2020).
 
Bactigen
 
Eye
 
Drops
 
0.3%
 
(Gentamicin
 
Sulphate)
 
Eye
 
Drop
 
package
 
insert.
 
Retrieved
 
from
 
https://www .medicines.org.uk/emc/files/pil.4218.pdf
 
7.
 
Gwenhure
 
T
 
and
 
NT
 
contributors.(2014,
 
26
 
September).
 
How
 
to
 
administer
 
eye
 
drops
 
and
 
ointments.
 
Nursing
 
Times,
 
110(40),
 
16-18.
 
Retrieved
 
from
 
https://www .nursingtimes.net/archive/how-to-administer-eye-drops-and-ointments-26-09-2014/
 
8.
 
Gudgel
 
D.T.
 
(2023,
 
May
 
5).
 
How
 
to
 
put
 
in
 
eye
 
drops.
 
American
 
Academy
 
of
 
Ophthalmology .
 
Retrieved
 
from
 
https://www .aao.org/eye-health/treatments/how-to-put-in-eye-drops
 
 
9.
 
Jones
 
W.
 
(2019,
 
Sept).
 
(2024).
 
Eye
 
Infection
 
and
 
Breastfeeding.
 
The
 
Breastfeeding
 
Network.
 
Retrieved
 
September
 
12,
 
2024,
 
from
 
https://www .breastfeedingnetwork.org.uk/factsheet/eye-infection/
 
10.
 
MIMS.
 
(2006).
 
MIMS
 
Summary
 
table:
 
Drugs
 
to
 
avoid
 
in
 
G6PD
 
deficiency .
 
 
11.
 
MIMS
 
(2024).
 
Tapcom-S
 
full
 
prescribing
 
information.
 
Retrieved
 
September
 
12,
 
2024,
 
from
 
https://www .mims.com/singapore/drug/info/tapcom-s?type=full#:~:text=T afluprost%3A%20There%20are 
%20no%20adequate,animals%20have%20shown%20reproductive%20toxicity
.
 
12.
 
Ministry
 
of
 
Health
 
Malaysia.
 
Formulari
 
Ubat
 
Kementerian
 
Kesihatan
 
Malaysia.
 
Retrieved
 
September
 
12,
 
2024,
 
from
 
https://i.pharmacy .gov.my/fukkm
 
13.
 
New
 
Zealand
 
Data
 
Sheet.
 
Cyclopentolate
 
1%
 
Eye
 
Drops
 
(2024).
 
Retrieved
 
September
 
12,
 
2024,
 
from
 
https://www .medsafe.govt.nz/profs/datasheet/c/Cyclogyleyedrop.pdf
 
14.
 
News
 
Medical
 
Life
 
Science
 
(2024).
 
Retrieved
 
September
 
12,
 
2024,
 
from
 
https://www .news-medical.net/drugs/T ravatan.aspx
 
15.
 
Novartis.
 
(2022).
 
Isopto
 
Crpine
 
2%
 
sterile
 
Opthalmic
 
solution
 
(Pilocarpine
 
Hydrochloride)
 
Eye
 
Drop
 
package
 
insert.
 
Retrieved
 
from
 
https://www .novartis.com/us-en/sites/novartis_us/files/isopto_carpine.pdf
 
16.
 
Pfizer .
 
(2022).
 
Xalatan
 
(Latanoprost)
 
Eye
 
Drop
 
package
 
insert.
 
Retrieved
 
from
 
https://labeling.pfizer .com/ShowLabeling.aspx?id=613
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
29
 

=== PAGE 417 ===

 
Eye
 
Ointment
 
Name
 
:
 
 
Unit
 
:
 
 
●
 
Please
 
tick
 
(
✔
)
 
Yes
 
for
 
correct
 
instruction.
 
●
 
Please
 
tick
 
(
✔
)
 
No
 
for
 
incorrect
 
instruction.
 
Yes
 
No
 
Remarks
 
Pharmacological
 
Group
 
1.
 
Antiinfectives
 
2.
 
Antiinflammatory
 
 
 
 
Indications
 
and
 
Dosage
 
To
 
counsel
 
based
 
on
 
specific
 
medication’ s
 
indication
 
and
 
dosage
 
as
 
prescribed
 
by
 
doctor
 
 
 
 
 
Method
 
of
 
Administration*
 
1.
 
Read
 
the
 
medication
 
label.
 
2.
 
Wash
 
hands
 
with
 
soap
 
and
 
water .
 
Dry
 
them
 
with
 
a
 
clean
 
towel
 
or
 
tissue.
 
3.
 
Remove
 
contact
 
lenses
 
if
 
wearing
 
them.
 
4.
 
Wash
 
hands
 
with
 
soap
 
and
 
water
 
again.
 
Dry
 
them
 
with
 
a
 
clean
 
towel
 
or
 
tissue.
 
 
5.
 
Unscrew
 
the
 
cap
 
from
 
tube
 
and
 
hold
 
the
 
tube
 
as
 
if
 
holding
 
a
 
pen
 
6.
 
Tilt
 
the
 
head
 
slightly
 
backwards
 
and
 
look
 
up,
 
keeping
 
the
 
eyes
 
wide
 
open.
 
7.
 
Using
 
the
 
one/two
 
fingers
 
of
 
the
 
free
 
hand,
 
gently
 
pull
 
down
 
the
 
lower
 
eyelid
 
to
 
form
 
a
 
pocket
.
 
8.
 
Squeeze
 
the
 
tube
 
to
 
apply
 
about
 
0.5
 
–
 
1
 
cm
 
of
 
ointment
 
inside
 
the
 
pocket
 
of
 
the
 
lower
 
eyelid.
 
Avoid
 
touching
 
the
 
eye
 
with
 
the
 
tube.
 
9.
 
Remove
 
the
 
fingers
 
from
 
the
 
face
 
then
 
close
 
the
 
eyes
 
gently
 
for
 
1
 
to
 
2
 
minutes
 
to
 
allow
 
medication
 
to
 
absorb.
 
The
 
vision
 
can
 
become
 
blurry
 
for
 
a
 
few
 
minutes
 
as
 
the
 
medication
 
is
 
quite
 
viscous.
 
You
 
should
 
remain
 
comfortably
 
seated
 
until
 
vision
 
is
 
cleared.
 
10.
 
Use
 
a
 
clean
 
tissue
 
to
 
wipe
 
away
 
any
 
excess
 
ointment.
 
Do
 
not
 
dab
 
at
 
the
 
eye
 
directly .
 
11.
 
Repeat
 
steps
 
6
 
till
 
10
 
on
 
the
 
other
 
eye
 
if
 
using
 
both
 
eyes
 
.
 
12.
 
Replace
 
the
 
cap
 
of
 
the
 
tube
 
and
 
screw
 
it
 
on
 
securely .
 
13.
 
If
 
more
 
than
 
one
 
eye
 
ointment
 
is
 
prescribed
  
at
 
a
 
time,
 
wait
 
about
 
5
 
minutes
 
before
 
using
 
the
 
next
 
eye
 
ointment.
 
Repeat
 
steps
 
5
 
till
 
12.
 
14.
 
If
 
using
 
both
 
eye
 
drops
 
and
 
eye
 
ointment,
 
put
 
the
 
eye
 
drop
 
in
 
at
 
least
 
10
 
minutes
 
before
 
the
 
ointment.
 
 
Missed
 
dose
 
management:
 
 
1.
 
Take
 
as
 
soon
 
as
 
you
 
remember
 
and
 
do
 
not
 
double
 
the
 
dose.
 
 
 
 
Special
 
Considerations
 
Pregnancy
 
 
 
 
1.
 
Most
 
eye
 
ointments
 
are
 
safe
 
during
 
pregnancy
 
 
2.
 
NOT
 
recommended
 
during
 
pregnancy
 
a.
 
Dexamathasone
 
and
 
Neomycin
 
Sulphate
 
and
 
Polymyxin
 
B
 
Eye
 
Ointment
 
3.
 
Used
 
only
 
if
 
the
 
benefit
 
outweighs
 
the
 
risk
 
a.
 
Gentamicin
 
0.3%
 
Eye
 
Ointment
 
b.
 
Oxytetracycline
 
with
 
Polymyxin
 
B
 
Sulphate
 
Eye
 
Ointment
 
 
 
 
Breastfeeding
 
 
 
 
1.
 
Maternal
 
use
 
of
 
most
 
eye
 
ointment
 
presents
 
little
 
or
 
no
 
 
 
 
30
 

=== PAGE 418 ===

 
risk
 
for
 
the
 
nursing
 
infant.
 
2.
 
Used
 
only
 
if
 
the
 
benefit
 
outweighs
 
the
 
risk
 
for
 
Dexamathasone
 
and
 
Neomycin
 
Sulphate
 
and
 
Polymyxin
 
B
 
Eye
 
Ointment
 
Elderly
 
 
 
 
1.
 
No
 
elderly-specific
 
problems
 
have
 
been
 
documented
 
to
 
date
 
with
 
most
 
eye
 
ointments.
 
 
 
 
Paediatric
 
 
 
 
1.
 
No
 
pediatrics-specific
 
problems
 
have
 
been
 
documented
 
to
 
date
 
with
 
most
 
eye
 
ointments.
 
 
 
 
Fasting
 
 
 
 
1.
 
Refer
 
to
 
the
 
latest
 
advisory
 
by
 
the
 
religious
 
authority
 
 
 
 
Others
  
 
 
 
 
1.
 
Chloramphenicol:
 
to
 
avoid
 
in
 
G6PD
 
Deficiency
 
(definite
 
risk
 
of
 
haemolysis)
 
 
 
 
Side
 
Effects
 
and
 
their
 
Management*
 
1.
 
Eye
 
burning,
 
irritation,
 
stinging
 
or
 
itching:
 
It
 
should
 
go
 
after
 
a
 
few
 
minutes
 
as
 
your
 
eyes
 
gets
 
used
 
to
 
the
 
medicines.
 
If
 
symptoms
 
continue,
 
stop
 
using
 
the
 
eye
 
drop
 
and
 
inform
 
the
 
doctor .
 
2.
 
Eye
 
redness
 
3.
 
Blurry/
 
changes
 
in
 
vision:
 
If
 
vision
 
does
 
not
 
go
 
back
 
to
 
normal
 
after
 
a
 
few
 
minutes
 
or
 
slowly
 
gets
 
worse,
 
stop
 
using
 
the
 
eye
 
drop
 
and
 
inform
 
the
 
doctor .
 
 
Contact
 
your
 
healthcare
 
provider
 
if
 
you
 
think
 
you
 
are
 
having
 
a
 
side
 
effect
 
of
 
a
 
medicine.
 
 
 
 
Storage*
 
1.
 
Keep
 
out
 
of
 
the
 
reach
 
of
 
children.
 
2.
 
Store
 
in
 
a
 
cool,
 
dry
 
place,
 
away
 
from
 
direct
 
heat
 
and
 
light.
 
3.
 
For
 
eye
 
ointment
 
requiring
 
storage
 
inside
 
the
 
fridge,
 
do
 
not
 
store
 
at
 
the
 
door
 
side
 
and
 
inside
 
the
 
freezer
 
4.
 
Discard
 
if
 
there
 
is
 
any
 
preparation
 
left
 
in
 
the
 
container
 
after
 
you
 
have
 
finished
 
your
 
course
 
of
 
treatment.
 
 
Eye
 
ointment
 
should
 
not
 
be
 
used
 
if
 
the
 
tube
 
has
 
been
 
open
 
for
 
longer
 
than
 
prescribed
 
duration
 
or
 
after
 
4
 
weeks.
 
 
 
 
Others
 
1.
 
To
 
prevent
 
the
 
spread
 
of
 
infection,
 
apply
 
ointment
 
directly
 
from
 
the
 
tube.
 
Avoid
 
using
 
fingers
 
to
 
place
 
ointment
 
on
 
your
 
eyelid
 
 
2.
 
Contact
 
lenses
 
should
 
not
 
be
 
worn
 
for
 
the
 
first
 
20
 
minutes
 
following
 
the
 
instillation
 
of
 
eye
 
ointment.
 
In
 
certain
 
cases,
 
you
 
may
 
need
 
to
 
stop
 
using
 
your
 
contact
 
lenses.
 
3.
 
If
 
you
 
are
 
prescribed
 
eye
 
drop
 
and
 
eye
 
ointment
 
together ,
 
use
 
eye
 
drop
 
first
 
 
 
 
31
 

=== PAGE 419 ===

 
Before
 
ending
 
this
 
peer
 
review
 
session,
 
the
 
reviewee
 
should
 
be
 
informed
 
of
 
the
 
step(s)
 
that
 
he/
 
she
 
missed
 
out
 
in
 
order
 
to
 
ensure
 
all
 
the
 
counselling
 
points
 
are
 
being
 
covered.
 
 
Remarks:
 
 
 
 
 
Reviewed
 
by:
 
Name
 
&
 
Signature
                                                                   
Date:
 
 
 
 
 
*Mandatory
 
for
 
peer
 
review/validation
 
 
References:
 
1.
 
Ministry
 
of
 
Health
 
Malaysia.
 
FUKKM
 
list
.
 
Retrieved
 
September
 
12,
 
2024,
 
from
 
https://i.pharmacy .gov.my/fukkm
 
2.
 
Garis
 
Panduan
 
Kaunseling
 
Edisi
 
Ke-3
 
2019.
 
Retrieved
 
September
 
12,
 
2024,
 
from
 
https://pharmacy .moh.gov .my/sites/default/files/document-upload/garis-panduan-kaunseling-ubat-ubatan 
-edisi-ketiga_0.pdf
 
 
3.
 
Ministry
 
of
 
Health
 
Malaysia.
 
FUKKM
 
list
.
 
Retrieved
 
September
 
12,
 
2024,
 
from
 
https://i.pharmacy .gov.my/fukkm
 
4.
 
MIMS
 
(2024).
 
Dexamethasone+neomycin+Polymycin
 
B.
 
Retrieved
 
September
 
12,
 
2024,
 
from
 
 
https://www .mims.com/malaysia/drug/info/dexamethasone%20+%20neomycin%20+%20polymyxin%20 
b?mtype=generic
 
5.
 
WebMD
 
(2024).
 
Ophthalmic
 
Ointment
 
-
 
Uses,
 
Side
 
Effects,
 
and
 
More.
 
Retrieved
 
September
 
12,
 
2024,
 
from
 
https://www .webmd.com/drugs/2/drug-60509/ophthalmic-ophthalmic-eye/details
 
6.
 
NHS
 
(2024).
 
Pregnancy ,
 
breastfeeding
 
and
 
fertility
 
while
 
taking
 
or
 
using
 
aciclovir .
 
Retrieved
 
September
 
12,
 
2024,
 
from
 
https://www .nhs.uk/medicines/aciclovir/pregnancy-breastfeeding-and-fertility-while-taking-or-using-aciclo 
vir/#:~:text=Aciclovir%20and%20pregnancy ,for%20you%20and%20your%20baby .Accessed
 
7.
 
British
 
Columbia
 
HealthLink
 
BC.
 
(2024).
 
Retrieved
 
September
 
12,
 
2024,
 
from
 
https://www .healthlinkbc.ca/health-topics/eye-problems-using-eyedrops-and-eye-ointment
 
8.
 
Novartis.
 
(2018).
 
Maxidex
 
ophthalmic
 
suspension
 
(Dexamethasone)
 
Eye
 
Ointment
 
package
 
insert.
 
Retrieved
 
from
 
https://www .novartis.com/us-en/sites/novartis_us/files/maxidex.pdf
 
9.
 
SM
 
Pharmaceuticals.
 
(2022).
 
Chlorop
 
Eye
 
ointment
 
1%
 
Eye
 
Ointment
 
package
 
insert.
 
Retrieved
 
from
 
https://www .mims.com/malaysia/drug/info/chlorop-eye-ointment?type=full
 
10.
 
Novartis.
 
(2021).
 
Maxitrol
 
sterile
 
ophthalmic
 
ointment
 
(Dexamethasone,Neomycin&
 
Polymyxin
 
B)
 
Eye
 
Ointment
 
package
 
insert.
 
Retrieved
 
from
 
https://www .novartis.com/sg-en/sites/novartis_sg/files/Maxitrol-Jan2018.SINv3-app221222-pdf.pdf
 
11.
 
Alcon.
 
(2021).
 
Duratears
 
Lubricating
 
Eye
 
Ointment
 
Eye
 
Ointment
 
package
 
insert.
 
Retrieved
 
from
 
https://www .nps.org.au/assets/medicines/e94e6624-d671-4832-b992-a53300f f7a5b.pdf
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
32
 

=== PAGE 420 ===

 
Menopausal
 
Hormone
 
Therapy
 
Name
 
:
 
 
Unit
 
:
 
 
●
 
Please
 
tick
 
(
✔
)
 
Yes
 
for
 
correct
 
instruction.
 
●
 
Please
 
tick
 
(
✔
)
 
No
 
for
 
incorrect
 
instruction.
 
Yes
 
No
 
Remarks
 
Pharmacological
 
Group
 
Estrogen;
 
Progestin;
 
Progestogen;
 
Selective
 
estrogen
 
receptor
 
modulator
 
(SERM)
 
:
 
 
 
1.
 
Estradiol
 
1mg
 
&
 
Estradiol
 
1mg
 
with
 
Dydrogesterone
 
10mg
 
 
2.
 
Estradiol
 
1mg
 
 
3.
 
Estradiol
 
Valerate
 
2mg
 
and
 
Norgestrel
 
500mcg
 
with
 
Estradiol
 
Valerate
 
2mg
 
4.
 
Lactobacillus
 
Acidophilus
 
100million
 
viable
 
cells
 
&
 
Estriol
 
0.03mg
 
vaginal
 
tablet
 
5.
 
Tibolone
 
2.5mg
 
6.
 
Conjugated
 
estogens
 
0.3mg
 
7.
 
Conjugated
 
estrogens
 
0.625mg
 
 
8.
 
Conjugated
 
estrogens
 
0.625mg/g
 
Cream
 
 
 
 
Indications
 
and
 
Dosage
 
1.
 
Indication
:
 
 
a.
 
Hormone
 
Replacement
 
Therapy
 
(HRT)
 
for
 
for
 
women
 
with
 
disorders
 
due
 
to
 
natural
 
or
 
surgically
 
induced
 
menopause
 
with
 
intact
 
uterus
 
Dosage
:
 
 
1
 
tablet
 
daily
 
without
 
pill-free
 
days,
 
starting
 
with
 
Estradiol
 
1mg
 
for
 
first
 
14
 
days,
 
followed
 
by
 
Estradiol
 
1mg
 
with
 
Dydrogesterone
 
10mg
 
 
 
2.
 
Indication
:
 
 
a.
 
Hormone
 
Replacement
 
Therapy
 
(HRT)
 
for
 
treatment
 
of
 
signs
 
and
 
symptoms
 
of
 
estrogen
 
deficiency
 
due
 
to
 
natural
 
menopause
 
or
 
total
 
hysterectomy
 
(TAHBSO)
 
 
b.
 
Prevention
 
of
 
postmenopausal
 
osteoporosis
 
 
Dosage
:
 
 
1
 
tablet
 
daily
 
continuously .
 
Titrate
 
dose
 
to
 
minimum
 
effective
 
dose
 
necessary
 
to
 
control
 
symptoms
 
 
 
3.
 
Indication
:
 
 
a.
 
 
Hormone
 
Replacement
 
Therapy
 
(HRT)
 
for
 
treatment
 
of
 
signs
 
and
 
symptoms
 
of
 
estrogen
 
deficiency
 
due
 
to
 
natural
 
menopause
 
or
 
hypogonadism,
 
TAHBSO
 
or
 
primary
 
ovarian
 
failure
 
in
 
women
 
with
 
intact
 
uterus
 
b.
 
Prevention
 
of
 
postmenopausal
 
osteoporosis
 
 
c.
 
Control
 
of
 
irregular
 
menstrual
 
cycle
 
d.
 
Treatment
 
of
 
primary
 
or
 
secondary
 
amenorrhea
 
 
Dosage
:
 
 
1
 
white
 
tablet
 
daily
 
for
 
11
 
days
 
followed
 
by
 
1
 
light
 
brown
 
tablet
 
for
 
10
 
days
 
then
  
stop
 
for
 
7
 
days
 
(tablet
 
free
 
interval
 
before
 
starting
 
new
 
pack).
 
 
 
4.
 
Indication
:
 
 
a.
 
Atrophic
 
vaginitis
 
due
 
to
 
estrogen
 
deficiency
 
during
 
menopause
 
and
 
post-menopause,
 
or
 
as
 
co-medication
 
to
 
systemic
 
hormone
 
replacement
 
therapy
 
b.
 
Restoration
 
of
 
the
 
Lactobacillus
 
flora
 
after
 
local
 
and/or
 
systemic
 
treatment
 
with
 
anti-infective
 
agents
 
or
 
chemotherapeutic
 
agents
 
 
 
 
 
33
 

=== PAGE 421 ===

 
Dosage
:
 
 
a.
 
Atropic
 
vaginitis
 
daily
 
for
 
6-12
 
days
 
followed
 
by
 
a
 
maintenance
 
dose
 
of
 
1
 
vaginal
 
tablet
 
for
 
1-2
 
days
 
per
 
week
 
 
b.
 
Restoration
 
therapy:
 
1-2
 
vagital
 
tableets
 
daily
 
for
 
6-12
 
days
 
 
 
5.
 
Indication
:
 
 
a.
 
Treatments
 
of
 
complaints
 
resulting
 
from
 
the
 
natural
 
or
 
surgical
 
menopause
 
&
 
in
 
cases
 
at
 
high
 
risk
 
for
 
breast
  
carcinomas
 
where
 
general
 
hormone
 
replacement
 
therapy
 
is
 
contraindicated
 
b.
 
Prevention
 
of
 
osteoporosis
 
in
 
postmenopausal
 
women
 
at
 
high
 
risk
 
of
 
future
 
fractures
 
who
 
are
 
intolerant
 
of,
 
or
 
contraindicated
 
for,
 
other
 
medicinal
 
products
 
approved
 
for
 
the
 
prevention
 
of
 
osteoporosis
 
Dosage
:
 
2.5mg
 
daily
 
 
 
 
6.
 
Indication:
 
a.
 
Prevention
 
of
 
management
 
of
 
osteoporosis
 
associated
 
with
 
estrogen
 
deficiency
 
b.
 
Female
 
hypoestrogenism
 
c.
 
Moderate
 
to
 
severe
 
vasomotor
 
symptoms
 
associated
 
with
 
estrogen
 
deficiency
 
d.
 
Atrophic
 
vaginiti
 
and
 
atrophic
 
urethritis
 
Dosage:
 
 
a.
 
0.3
 
-
 
0.625mg
 
daily
 
b.
 
0.3
 
-
 
1.25mg
 
daily
 
for
 
3
 
weeks,
 
then
 
off
 
for
 
1
 
week
 
c.
 
0.3
 
-
 
1.25mg
 
daily
 
 
d.
 
0.3
 
-
 
1.25mg
 
daily
 
 
7.
 
Indication:
 
a.
 
Prevention
 
of
 
management
 
of
 
osteoporosis
 
associated
 
with
 
estrogen
 
deficiency
 
b.
 
Female
 
hypoestrogenism
 
c.
 
Moderate
 
to
 
severe
 
vasomotor
 
symptoms
 
associated
 
with
 
estrogen
 
deficiency
 
d.
 
Atrophic
 
vaginiti
 
and
 
atrophic
 
urethritis
 
Dosage:
 
 
a.
 
0.3
 
-
 
0.625mg
 
daily
 
b.
 
0.3
 
-
 
1.25mg
 
daily
 
for
 
3
 
weeks,
 
then
 
off
 
for
 
1
 
week
 
c.
 
0.3
 
-
 
1.25mg
 
daily
 
 
d.
 
0.3
 
-
 
1.25mg
 
daily
 
 
8.
 
Indication:
 
Treatment
 
of
 
atrophic
 
vaginitis,
 
dyspareunia
 
and
 
kraurosis
 
vulvae
 
Dosage:
 
 
a.
 
Atrophic
 
vaginitis
 
and
 
Kraurosis
 
Vulvae:
 
Cyclical
 
regimen:
 
Intravaginal
 
0.5g
 
daily
 
for
 
21
 
days
 
then
 
off
 
for
 
7
 
days
 
.
 
Dose
 
range
 
between
 
0.5g
 
-
 
2g
 
daily
 
between
 
individual
 
response
 
b.
 
Dyspareunia:
 
Intravaginal
 
 
i.
 
0.5g
 
twice
 
weekly
 
continuously
 
or
 
cyclically
 
for
 
21
 
days
 
and
 
7
 
days
 
off
 
treatment.
 
 
Method
 
of
 
Administration*
 
1.
 
To
 
be
 
taken
 
daily
 
at
 
the
 
same
 
time
 
with
 
or
 
without
 
food.
 
 
2.
 
Preferably
 
to
 
take
 
with
 
oily
 
food
 
for
 
better
 
absorption
 
 
3.
 
Take
 
will
 
full
 
glass
 
of
 
water
 
 
 
 
34
 

=== PAGE 422 ===

 
4.
 
Hormone
 
medications
 
should
 
not
 
be
 
crushed
 
and
 
not
 
suitable
 
for
 
Ryle’ s
 
Tube
 
administration
 
 
5.
 
For
 
pessary
 
preparations,
 
kindly
 
refer
 
to
 
the
 
pessary
 
administration
 
method.
 
 
 
Do
 
not
 
stop
 
taking
 
your
 
medication
 
unless
 
advised
 
to
 
do
 
so
 
by
 
your
 
prescriber
 
Special
 
Consideration
 
1.
 
Contraindicated
 
in
 
patients
 
with
 
a.
 
liver
 
diseases
 
 
b.
 
history
 
of
 
estrogen
 
hormone
 
receptor
 
sensitive
 
malignancies
 
including
 
breast
 
cancer ,
 
ovarian
 
cancer ,
 
and
 
endometrial
 
cancers.
 
 
c.
 
coronary
 
arterial
 
disease.
 
 
d.
 
history
 
of
 
thromboembolism
 
or
 
thrombophlebitis
 
 
 
 
Elderly
 
 
 
 
Beers
 
Criteria:
 
Estrogens
 
with
 
or
 
without
 
progestins
 
(includes
 
natural
 
and
 
synthetic
 
estrogen
 
preparations).
 
 
Do
 
not
 
initiate
 
systemic
 
estrogen
 
(e.g.,
 
oral
 
tablets
 
or
 
transdermal
 
patch).
 
Consider
 
deprescribing
 
among
 
older
 
women
 
already
 
using
 
this
 
medication.
 
Vaginal
 
cream
 
or
 
vaginal
 
tablets:
 
acceptable
 
to
 
use
 
low-dose
 
intravaginal
 
estrogen
 
for
 
management
 
of
 
dyspareunia,
 
recurrent
 
lower
 
urinary
 
tract
 
infections,
 
and
 
other
 
vaginal
 
symptoms.
 
 
Evidence
 
of
 
carcinogenic
 
potential
 
(breast
 
and
 
endometrium);
 
lack
 
of
 
cardioprotective
 
effect
 
and
 
cognitive
 
protection
 
in
 
older
 
women.
 
For
 
women
 
who
 
start
 
HRT
 
at
 
age
 
60
 
and
 
older ,
 
the
 
risks
 
of
 
HRT
 
are
 
greater
 
than
 
the
 
benefits,
 
as
 
HRT
 
is
 
linked
 
to
 
a
 
higher
 
risk
 
of
 
heart
 
disease,
 
stroke,
 
blood
 
clots,
 
and
 
dementia
.
 
Evidence
 
indicates
 
that
 
vaginal
 
estrogens
 
for
 
the
 
treatment
 
of
 
vaginal
 
dryness
 
are
 
safe
 
and
 
effective;
 
women
 
with
 
a
 
history
 
of
 
breast
 
cancer
 
who
 
do
 
not
 
respond
 
to
 
nonhormonal
 
therapies
 
are
 
advised
 
to
 
discuss
 
the
 
risks
 
and
 
benefits
 
of
 
low-dose
 
vaginal
 
estrogen
 
(e.g.,
 
dosages
 
of
 
estradiol
 
<25
 
mcg
 
twice
 
weekly)
 
with
 
their
 
healthcare
 
provider .
 
 
 
 
Adverse
 
Effects
 
and
 
their
  
Management*
 
1.
 
Headache
 
or
 
abdominal
 
pain
 
a.
 
mild
 
NSAIDS
 
or
 
Paracetamol
 
may
 
help
 
to
 
reduce
 
symptoms.
 
 
b.
 
Take
 
regular
 
rest
 
c.
 
If
 
symptoms
 
worsen,
 
kindly
 
go
 
to
 
the
 
clinic
 
for
 
treatment.
 
2.
 
Unexpected
 
vaginal
 
bleeding
 
 
a.
 
Spotting
 
is
 
common
 
especially
 
within
 
the
 
first
 
few
 
months
 
of
 
starting
 
HRT
 
however
 
if
 
frequent
 
to
 
stop
 
medications
 
and
 
seek
 
prescriber ’s
 
opinion.
 
 
3.
 
Vaginal
  
or
 
urinary
 
tract
 
discomfort
 
itchiness
 
or
 
infection
 
a.
 
Common
 
while
 
using
 
pessaries,
 
advice
 
for
 
proper
 
toilet
 
hygiene
 
 
b.
 
If
 
prolonged
 
discomfort
 
to
 
seek
 
doctor ’s
 
opinion
 
 
4.
 
Shortness
 
of
 
breath
 
a.
 
Seek
 
medical
 
assistance
 
5.
 
Swelling/
 
water
 
retention
 
a.
 
Seek
 
medical
 
assistance
 
 
 
 
Storage*
 
1.
 
To
 
store
 
at
 
room
 
temperature
 
in
 
a
 
cool
 
dry
 
place
 
and
 
avoid
 
direct
 
heat
 
or
 
light.
 
 
 
 
Others
 
VTE
 
risk
 
increases
 
with
 
high
 
ethinyl
 
estradiol
 
dose,
 
special
 
 
 
 
35
 

=== PAGE 423 ===

 
precaution
 
should
 
be
 
taken
 
when
 
prescribing
 
patient
 
to
 
reduce
 
risk
 
Before
 
ending
 
this
 
peer
 
review
 
session,
 
the
 
reviewee
 
should
 
be
 
informed
 
of
 
the
 
step(s)
 
that
 
he/
 
she
 
missed
 
out
 
in
 
order
 
to
 
ensure
 
all
 
the
 
counselling
 
points
 
are
 
being
 
covered.
 
 
Remarks:
 
 
 
 
 
Reviewed
 
by:
 
Name
 
&
 
Signature
                                                                   
Date:
 
 
 
 
 
*Mandatory
 
for
 
peer
 
review/V alidation
 
 
References:
 
 
1.
 
https://www .nhs.uk/medicines/hormone-replacement-therapy-hrt/vaginal-oestrogen/side-ef fects-of-vagin 
al-oestrogen/
 
2.
 
https://www .drugs.com/drug-interactions/estradiol.html
 
3.
 
2023
 
American
 
Geriatrics
 
Society
 
Beers
 
Criteria®
 
Update
 
Expert
 
Panel.
 
(2023).
 
American
 
Geriatrics
 
Society
 
2023
 
updated
 
AGS
 
Beers
 
Criteria®
 
for
 
potentially
 
inappropriate
 
medication
 
use
 
in
 
older
 
adults.
 
Journal
 
of
 
the
 
American
 
Geriatrics
 
Society ,
 
71(7),
 
2052-2081.
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
36
 

=== PAGE 424 ===

 
 
 
Nasal
 
Douche/Irrigation
 
Name
 
:
 
 
 
Unit
 
:
 
 
●
 
Please
 
tick
 
(
✔
)
 
Yes
 
for
 
correct
 
instruction.
 
●
 
Please
 
tick
 
(
✔
)
 
No
 
for
 
incorrect
 
instruction.
 
Yes
 
No
 
Remarks
 
Pharmacological
 
Group
 
Alkaline
 
nasal
 
douche
 
 
 
 
 
Indications
 
and
 
Dosage
 
1.
 
To
 
remove
 
nasal
 
plug
 
(Dosage
 
as
 
per
 
prescribed)
 
 
 
 
Method
 
of
 
Administration*
 
1.
 
Douche
 
solution
 
is
 
prepared
 
by
 
adding
 
warm
 
water
 
if
 
undiluted
 
product
 
or
 
pre-mixed
 
preparation
 
is
 
given.
 
 
2.
 
Wash
 
hands
 
thoroughly
 
with
 
soap
 
and
 
water .
 
3.
 
Lean
 
over
 
a
 
sink
 
at
 
a
 
45-degree
 
angle,
 
tilting
 
your
 
head
 
so
 
one
 
nostril
 
is
 
pointed
 
toward
 
the
 
sink.
 
4.
 
Place
 
the
 
tip
 
of
 
the
 
device
 
at
 
your
 
nostril
 
opening
 
and
 
gently
 
squeeze
 
or
 
pour
 
the
 
solution
 
into
 
your
 
nose.
 
(Remember
 
to
 
breathe
 
through
 
your
 
mouth
 
or
 
hold
 
your
 
breath
 
while
 
performing
 
the
 
irrigation.)
 
The
 
solution
 
should
 
come
 
out
 
of
 
your
 
other
 
nostril.
 
5.
 
Blow
 
your
 
nose
 
to
 
clear
 
out
 
any
 
remaining
 
solution.
 
 
6.
 
Repeat
 
the
 
procedure
 
with
 
the
 
other
 
nostril.
 
 
 
 
Missed
 
dose
 
management
 
If
 
you
 
forget
 
to
 
take
 
a
 
dose,
 
take
 
it
 
as
 
soon
 
as
 
you
 
remember .
 
However ,
 
if
 
it
 
is
 
almost
 
time
 
to
 
take
 
the
 
next
 
dose,
 
wait
 
until
 
then.
 
Do
 
not
 
take
 
a
 
double
 
dose
 
to
 
make
 
up
 
for
 
a
 
forgotten
 
dose.
 
 
 
 
Special
 
Considerations
 
Pregnancy
 
 
 
 
N/A
 
 
 
 
Breastfeeding
 
 
 
 
N/A
 
 
 
 
Elderly
 
 
 
 
None
 
specifically
 
to
 
alkaline
 
nasal
 
douche
 
 
 
 
Paediatric
 
 
 
 
Nasal
 
douching
 
can
 
be
 
performed
 
by
 
parents/caregivers
 
for
 
their
 
children.
 
 
 
 
Fasting
 
 
 
 
Refer
 
to
 
latest
 
advisory
 
by
 
religious
 
authority
 
 
 
 
Others
  
 
 
 
 
Epistaxis,
 
not
 
to
 
be
 
used
 
in
 
cranial
 
surgery
 
or
 
trans
 
nasal
 
neurosurgical
 
procedure.
 
 
 
 
Side
 
Effects
 
and
 
their
 
Management*
 
1.
 
Stinging
 
of
 
the
 
nasal
 
passage
 
wall
 
may
 
be
 
experienced.
 
However ,
 
this
 
may
 
be
 
improved
 
by
 
further
 
diluting
 
down
 
the
 
douche
 
solution
 
with
 
water .
 
 
 
 
37
 

=== PAGE 425 ===

 
Storage*
 
1.
 
Store
 
the
 
medicine
 
in
 
a
 
dry
 
place
 
at
 
room
 
temperature,
 
away
 
from
 
heat
 
and
 
direct
 
light.
 
 
 
 
Others
 
1.
 
If
 
a
 
patien
t
 
is
 
using
 
intranasal
 
medication,
 
this
 
should
 
be
 
used
 
after
 
nasal
 
irrigation.
 
This
 
is
 
because
 
the
 
medication
 
will
 
have
 
better
 
distribution
 
and
 
efficacy .
 
2.
 
Avoid
 
breathing
 
through
 
the
 
nose
 
while
 
performing
 
irrigation,
 
as
 
this
 
can
 
introduce
 
water
 
into
 
the
 
ear
 
canal
 
potentially
 
leading
 
to
 
infection.
 
3.
 
A
 
burning
 
sensation
 
in
 
the
 
nasal
 
cavity
 
may
 
occur
 
particularly
 
if
 
a
 
non-buf fered
 
hyper
 
or
 
hypotonic
 
irrigation
 
solution
 
is
 
used.
 
Most
 
patients
 
seem
 
to
 
adapt
 
to
 
this.
 
 
Please
 
refer
 
product
 
insert
 
 
 
 
Before
 
ending
 
this
 
peer
 
review
 
session,
 
the
 
reviewee
 
should
 
be
 
informed
 
of
 
the
 
step(s)
 
that
 
he/
 
she
 
missed
 
out
 
in
 
order
 
to
 
ensure
 
all
 
the
 
counselling
 
points
 
are
 
being
 
covered.
 
 
Remarks:
 
 
 
 
 
Reviewed
 
by:
 
Name
 
&
 
Signature
                                                                   
Date:
 
 
 
 
 
*Mandatory
 
for
 
validation
 
/
 
peer
 
review
 
 
References:
 
1.
 
Formulari
 
Ubat
 
KKM
 
(FUKKM).
 
(Version
 
241030.001)
  
Retrieved
 
from
 
https://i.pharmacy .gov.my/fukkm
 
2.
 
Principi
 
N,
 
Esposito
 
S.(2017).
 
Nasal
 
Irrigation:
 
An
 
Imprecisely
 
Defined
 
Medical
 
Procedure.
 
IJERPH
,
 
14(5):516.
 
doi:
 
10.3390/ijerph14050516
 
3.
 
University
 
Hospitals
 
Sussex.
 
(2024).
 
Nasal
 
Douche.
 
Retrieved
 
from
 
https://www .uhsussex.nhs.uk/wp-content/uploads/2022/08/Nasal-douche.pdf
 
4.
 
National
 
University
 
Hospital.
 
(n.d.).
 
Nasal
 
Wash/Douche.
 
Retrieved
 
from
 
https://www .nuh.com.sg/docs/nuhlibraries/content-document/care-at-nuh/specialties/pharmacy/pharmac 
y-patient-education/nasal-wash-douche---sodium-bicarbonate---sodium-chloride-(2007).pdf
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
38
 

=== PAGE 426 ===

 
Nasal
 
Drops
 
39
 
Name
 
:
 
 
Unit
 
:
 
 
●
 
Please
 
tick
 
(
✔
)
 
Yes
 
for
 
correct
 
instruction.
 
●
 
Please
 
tick
 
(
✔
)
 
No
 
for
 
incorrect
 
instruction.
 
Yes
 
No
 
Remarks
 
Pharmacological
 
Group
 
Decongestant
 
 
1.
 
Oxymetazoline
 
HCL
 
0.01%
 
Nasal
 
Drops
 
2.
 
Oxymetazoline
 
HCL
 
0.025%
 
(Paediatric)
 
Nasal
 
Drops
 
3.
 
Oxymetazoline
 
HCL
 
0.05%
 
(Adult)
 
Nasal
 
Drops
 
 
 
 
Indications
 
and
 
Dosage
 
Counsel
 
patients
 
based
 
on
 
the
 
medication
 
and
 
indications
 
as
 
prescribed.
 
 
 
 
Method
 
of
 
Administration*
 
PRIMING
 
1.
 
Prime
 
the
 
nasal
 
drops
 
before
 
using
 
it
 
for
 
the
 
first
 
time.
 
Check
 
the
  
dropper
 
tip
 
to
 
make
 
sure
 
that
 
it
 
is
 
not
 
chipped
 
or
 
cracked.
 
 
2.
 
Squeeze
 
the
 
bottle
 
until
 
a
 
few
 
drops
 
appear
 
from
 
the
 
dropper
 
tip.
 
 
 
 
ADMINISTRA TION
 
1.
 
Blow
 
your
 
nose
 
gently .
 
2.
 
Wash
 
hands
 
thoroughly
 
with
 
soap
 
and
 
water .
 
3.
 
Shake
 
well
 
before
 
use.
 
Remove
 
cap
 
of
 
the
 
bottle
 
(for
 
bottles
 
with
 
integrated
 
dropper ,
 
draw
  
some
 
liquid
 
into
 
the
 
dropper)
 
4.
 
Tilt
 
your
 
head
 
as
 
far
 
as
 
possible
 
or
 
lie
 
down
 
on
 
your
 
back
 
on
 
a
 
flat
  
surface
 
and
 
hang
 
your
 
head
 
over
 
the
 
edge.
 
5.
 
Hold
 
the
 
bottle
 
or
 
dropper
 
above
 
your
 
nostrils
 
and
 
gently
 
squeeze
 
the
  
correct
 
number
 
of
 
drops
 
into
 
the
 
nostrils.
 
Breath
 
normally
 
through
 
your
 
mouth
 
while
 
putting
 
the
 
drops
 
into
 
your
 
nostril.(Do
 
not
 
touch
 
the
 
nose
 
with
  
the
 
tip
 
of
 
the
 
bottle
 
or
 
dropper)
 
6.
 
Keep
 
your
 
head
 
tilted
 
back
 
for
  
two
 
minutes
 
to
 
allow
 
the
 
drops
 
to
  
drain
 
into
 
the
 
back
 
of
 
the
 
nose.
 
7.
 
Repeat
 
steps
 
5
 
till
 
6
 
for
 
the
 
other
 
nostril
 
8.
 
Wipe
 
dropper
 
tip
 
with
 
dry
 
cloth
 
9.
 
Replace
 
cap
 
on
 
bottle
 
right
 
away
 
 
ADMINISTRA TION
 
(PAEDIA TRIC)
 
1.
 
Wipe
 
your
 
child’ s
 
nose
 
and
 
ask
 
them
 
to
 
blow
 
it
 
if
 
needed.
 
 
2.
 
Wash
 
your
 
hands
 
thoroughly
 
with
 
soap
 
and
 
water .
 
3.
 
Shake
 
well
 
before
 
use.
 
Remove
 
cap
 
of
 
the
 
bottle
 
(for
 
bottles
 
with
 
integrated
 
dropper ,
 
draw
  
some
 
liquid
 
into
 
the
 
dropper)
 
4.
 
Get
 
your
 
child
 
into
 
any
 
of
 
these
 
positions
 
to
 
give
 
the
 
nasal
 
drops:
 
:
 
a.
 
Tilt
 
your
 
child’ s
 
head
 
back
 
 
b.
 
Lay
 
your
 
child
 
flat
 
on
 
their
 
back
 
 
c.
 
Ask
 
someone
 
to
 
hold
 
your
 
child
 
in
 
a
 
safe
 
position
 
as
 
above
 
d.
 
Wrap
 
your
 
baby
 
or
 
young
 
child
 
in
 
a
 
light
 
blanket
 
or
 
sheet
 
to
 
keep
 
their
 
arms
 
still.
 
5.
 
Keep
 
your
 
child
 
in
 
the
 
position
 
for
 
two
 
minutes
 
to
 
allow
 
the
 
drops
 
to
 
drain
 
into
 
the
 
back
 
of
 
the
 
nose.
 
6.
 
Repeat
 
step
 
3
 
till
 
5
 
for
 
the
 
other
 
nostril
 
7.
 
Wipe
 
dropper
 
tip
 
with
 
dry
 
cloth
 
8.
 
Replace
 
cap
 
on
 
bottle
 
right
 
away
 
 
 
 
 

=== PAGE 427 ===

 
40
 
MISSED
 
DOSE
 
If
 
you
 
forget
 
to
 
take
 
a
 
dose,
 
take
 
it
 
as
 
soon
 
as
 
you
 
remember .
 
However ,
 
if
 
it
 
is
 
almost
 
time
 
to
 
take
 
the
 
next
 
dose,
 
wait
 
until
 
then.
 
Do
 
not
 
take
 
a
 
double
 
dose
 
to
 
make
 
up
 
for
 
a
 
forgotten
 
dose.
 
 
Do
 
not
 
stop
 
taking
 
your
 
medication
 
unless
 
advised
 
to
 
do
 
so
 
by
 
your
 
prescriber
 
 
 
 
Special
 
Considerations
 
Pregnancy
 
 
 
 
1.
 
Fetal
 
risk
 
cannot
 
be
 
ruled
 
out
 
(oxymetazoline)
 
 
 
 
Breastfeeding
 
 
 
 
1.
 
Infant
 
risk
 
cannot
 
be
 
ruled
 
out
 
(oxymetazoline)
 
2.
 
Nasal
 
Oxymetazoline
 
has
 
minimal
 
systemic
 
absorption.
 
 
 
 
Elderly
 
 
 
 
 
1.
 
Caution
 
in
 
patients
 
with
 
hypertension,
 
cardiac
 
disease,metabolic
 
disorder .
 
2.
 
Caution
 
in
 
patients
 
with
 
narrow-angle
 
glaucoma.
 
3.
 
Has
 
anticholinergic
 
effects.
 
To
 
use
 
short
 
term.
 
 
 
 
Paediatric
 
 
 
 
Oxymetazoline
 
HCL
 
0.01%
 
Nasal
 
Drops
 
1.
 
Effect
 
set
 
in
 
approximately
 
20minutes
 
 
2.
 
Effect
 
last
 
around
 
6
 
to
 
8
 
hours
 
 
3.
 
Should
 
not
 
be
 
used
 
for
 
more
 
than
 
consecutive
 
10
 
days
 
without
 
medical
 
supervision.
 
A
 
treatment-free
 
period
 
should
 
precede
 
any
 
repeated
 
use
 
 
Oxymetazoline
 
HCL
 
0.025%
 
(Paediatric)
 
Nasal
 
Drops
 
1.
 
Effect
 
set
 
in
 
within
 
few
 
minutes
 
 
2.
 
Effect
 
last
 
around
 
12
 
hours
 
 
3.
 
Should
 
not
 
be
 
used
 
for
 
children
 
under
 
1
 
year
 
old
 
4.
 
Should
 
not
 
be
 
used
 
for
 
more
 
than
 
consecutive
 
10
 
days
 
without
 
medical
 
supervision.
 
A
 
treatment-free
 
period
 
should
 
precede
 
any
 
repeated
 
use
 
 
 
 
Fasting
 
 
 
 
Refer
 
to
 
the
 
latest
 
advisory
 
by
 
religious
 
authority .
 
 
 
 
Others
  
 
 
 
 
NA
 
 
 
 
Side
 
Effects
 
and
 
their
 
Management*
 
1.
 
Dryness
 
or
 
irritation
 
of
 
nose/throat
 
 
2.
 
Nose
 
bleeds
 
 
 
Management:
 
1.
 
Rinse
 
your
 
mouth
 
with
 
water
 
or
 
drink
 
water .
 
2.
 
Refer
 
to
 
the
 
doctor .
 
 
 
 
Storage*
 
1.
 
Store
 
in
 
a
 
cool,
 
dry
 
and
 
dark
 
place.
 
 
2.
 
Keep
 
away
 
from
 
the
 
reach
 
of
 
children.
 
 
 
 
 
Others
 
1.
 
Some
 
nasal
 
drops
 
can
 
give
 
unpleasant
 
taste
 
as
 
they
 
drain
 
into
 
the
 
back
 
of
 
the
 
throat.
 
Drink
 
water
 
or
 
other
 
liquid
 
to
 
clear
 
the
 
taste.
 
 
2.
 
Do
 
not
 
use
 
your
 
nasal
 
drops
 
more
 
often
 
or
 
for
 
longer
 
 
 
 

=== PAGE 428 ===

 
*Mandatory
 
for
 
peer
 
review/validation
 
 
 
References:
 
1.
 
Formulari
 
Ubat
 
KKM
 
(FUKKM).
 
(2024)
 
2.
 
Sterling,
 
A.,
 
M
 
Zand,
 
Jonathan.
 
Oxymetazoline
 
(nasal):
 
Drug
 
Information.
 
UpToDate.
 
(2024)
 
UpToDate
 
(Version
 
3.68.3)
 
[Mobile
 
App]
 
Mobile
 
Clinical
 
Decision
 
Support
 
App
 
|
 
UpToDate
 
|
 
Wolters
 
Kluwer
 
3.
 
Merative,
 
L.P.
 
Oxymetazoline
 
Hydrochloride.
 
Micromedex.
 
(2024)
 
Micromedex
 
(Version
 
4.6.0)
 
[Mobile
 
App]
 
https://play .google.com/store/apps/details?id=com.truven.druginfonative.customer
 
4.
 
Frishauf,
 
Peter .
 
Oxymetazoline
 
intranasal.
 
Medscape.
 
(2024)
 
Medscape
 
(Version
 
12.2.1)
 
[Mobile
 
App]
 
Point-of-Care
 
Medical
 
Reference
 
App
 
For
 
Doctors
 
|
 
Medscape
 
5.
 
Briggs,
 
G.
 
G.,
 
Towers,
 
G.
 
V.,
 
&
 
Forinash,
 
A.
 
B.
 
(2022).
 
Drugs
 
in
 
Pregnancy
 
and
 
Lactation
 
(12th
 
ed.).
 
Wolters
 
Kluwer .
 
6.
 
ENTUK(2022).
 
How
 
to
 
Use
 
Nasal
 
Drops.
 
https://www .entuk.org/patients/conditions/77/how_to_use_nasal_drops/
 
7.
 
Product
 
leaflet
 
Iliadin
@
 
0.01%
 
Decongestant
 
Nasal
 
Drops
 
(2025,
 
January
 
20).
 
Retrieved
 
from
 
https://quest3plus.bpfk.gov .my/front-end/attachment/34/pharma/224963/V_46790_20201 106_1 13432_D3.p 
df
 
8.
 
Product
 
leaflet
 
Iliadin
@
 
0.025%
 
Decongestant
 
Nasal
 
Drops
 
(2025,
 
January
 
20).
 
Retrieved
 
from
 
https://quest3plus.bpfk.gov .my/front-end/attachment/34/pharma/212386/V_92220_20241004_144920_D3.p 
df
 
9.
 
Great
 
Ormond
 
Street
 
Hospital
 
For
 
Children.
 
How
 
to
 
give
 
your
 
child
 
nose
 
ointment,
 
drops
 
or
 
sprays
 
(2025,
 
January
 
20)..
 
Retrieved
 
from:
 
https://www .gosh.nhs.uk/conditions-and-treatments/medicines-information/how-give-your-child-nose-ointme 
nt-drops-or-spray/
 
10.
 
Oxymetazoline
 
(Xylocon
 
Nasal)
 
Drops
 
0.05%,0.025%
 
Product
 
information.
 
 
 
 
 
 
 
 
 
 
 
 
41
 
than
 
you
 
have
 
been
 
told.
 
Some
 
nasal
 
drops
 
must
 
only
 
be
 
used
 
for
 
a
 
short
 
period
 
of
 
time
 
and
 
will
 
become
 
ineffective
 
if
 
it
 
is
 
used
 
for
 
too
 
long.
 
For
 
example:
 
Decongestant
 
nasal
 
drop.
 
3.
 
Not
 
to
 
be
 
used
 
longer
 
than
 
7
 
days.
 
Longer
 
use
 
may
 
damage
 
mucosal
 
epithelium
 
with
 
inhibition
 
of
 
ciliary
 
activity .
 
4.
 
Throw
 
leftover
 
nasal
 
drops
 
when
 
you
 
have
 
finished
 
the
 
course
 
of
 
treatment.
 
5.
 
Drug
 
interaction
 
with
 
Monoamine
 
Oxidase
 
Inhibitor .
 
 
Note
 
:
 
Please
 
refer
 
to
 
the
 
product
 
insert.
 
Before
 
ending
 
this
 
peer
 
review
 
session,
 
the
 
reviewee
 
should
 
be
 
informed
 
of
 
the
 
step(s)
 
that
 
he/
 
she
 
missed
 
out
 
in
 
order
 
to
 
ensure
 
all
 
the
 
counselling
 
points
 
are
 
being
 
covered.
 
 
Remarks:
 
 
 
 
 
Reviewed
 
by:
 
Name
 
&
 
Signature
                                                                   
Date:
 
 
 
 
 

=== PAGE 429 ===

 
Nasal
 
Spray
 
Name
 
:
 
 
 
Unit
 
:
 
 
●
 
Please
 
tick
 
(
✔
)
 
Yes
 
for
 
correct
 
instruction.
 
●
 
Please
 
tick
 
(
✔
)
 
No
 
for
 
incorrect
 
instruction.
 
Yes
 
No
 
Remarks
 
Pharmacological
 
Group
 
1.
 
Steroid
 
nasal
 
spray
 
2.
 
Antihistamine
 
steroid
 
combination
 
nasal
 
spray
 
3.
 
Decongestant
 
nasal
 
spray
 
4.
 
Vasopressin
 
5.
 
Local
 
Anaesthetic
 
 
 
 
Indications
 
and
 
Dosage
 
To
 
counsel
 
based
 
on
 
specific
 
medication’ s
 
indication
 
and
 
dosage
 
as
 
prescribed
 
by
 
doctor
 
 
 
 
 
Method
 
of
 
Administration*
 
PRIMING
 
 
1.
 
Prime
 
the
 
nasal
 
spray
 
before
 
using
 
a
 
nasal
 
spray
 
for
 
the
 
first
 
time.
 
 
2.
 
Shake
 
well
 
and
 
remove
 
the
 
cap.
 
3.
 
Pump
 
the
 
bottle
 
until
 
a
 
uniform
 
mist
 
appears.
 
 
Refer
 
to
 
the
 
respective
 
product
 
leaflet
 
for
 
the
 
number
 
of
 
sprays
 
to
 
be
 
released
 
before
 
the
 
nasal
 
spray
 
is
 
ready
 
for
 
use.
 
 
 
 
 
ADMINISTRA TION
 
1.
 
If
 
possible,
 
blow
 
your
 
nose
 
gently
 
before
 
spraying
 
(if
 
blocked).
 
 
2.
 
Wash
 
your
 
hands
 
thoroughly
 
with
 
soap
 
and
 
water .
 
3.
 
Shake
 
nasal
 
spray
 
gently .
 
(Shake
 
the
 
nasal
 
spray
 
vigorously
 
for
 
preparation
 
with
 
thick
 
suspension
 
i.e.
 
Avamys).
 
4.
 
Remove
 
cap.
  
 
5.
 
Hold
 
nasal
 
spray
 
upright,
 
thumb
 
beneath
 
bottle
 
and
 
fingers
 
on
 
either
 
side
 
of
 
the
 
nozzle.
 
(Press
 
the
 
button
 
firmly
 
all
 
the
 
way
 
in
 
with
 
your
 
thumb
 
for
 
Avamys
 
and
 
use
 
two
 
hands
 
if
 
you
 
experience
 
any
 
difficulty
 
pressing
 
with
 
one).
 
6.
 
Close
 
one
 
nostril
 
with
 
your
 
finger .
 
Tilt
 
your/patient
 
head
 
forward
 
slightly
 
and,
 
keeping
 
the
 
bottle
 
upright,
 
carefully
 
insert
 
the
 
nozzle
 
into
 
the
 
other
 
nostril.
 
7.
 
Point
 
the
 
nozzle
 
away
 
from
 
the
 
centre
 
ridge
 
of
 
your/patient
 
nose
 
(septum),
 
towards
 
the
 
outside
 
corner
 
of
 
your
 
eye
 
on
 
the
 
same
 
side.
 
 
8.
 
Breathe
 
in
 
gently
 
through
 
your
 
nose
 
and
 
press
 
the
 
applicator/pump
 
firmly .
 
9.
 
Remove
 
the
 
nozzle
 
from
 
the
 
nostril
 
and
 
breathe
 
out
 
gently
 
through
 
the
 
mouth.
  
 
10.
 
If
 
the
 
patient
 
requires
 
more
 
than
 
1
 
spray
 
in
 
each
 
nostril,
 
repeat
 
steps
 
5
 
till
 
8.
  
 
11.
 
Repeat
 
steps
 
5
 
till
 
8
 
for
 
the
 
other
 
nostril.
 
12.
 
Wipe
 
the
 
nasal
 
applicator
 
with
 
a
 
clean
 
and
 
dry
 
tissue
 
and
 
replace
 
the
 
plastic
 
cap.
 
ADMINISTRA TION
 
(PAEDIA TRIC)
 
1.
 
Wipe
 
your
 
child’ s
 
nose
 
and
 
ask
 
them
 
to
 
blow
 
it
 
if
 
needed.
 
 
2.
 
Wash
 
your
 
hands
 
thoroughly
 
with
 
soap
 
and
 
water .
 
3.
 
Shake
 
nasal
 
spray
 
gently
 
or
 
according
 
to
 
the
 
instructions
 
for
 
a
 
particular
 
product.
 
4.
 
Remove
 
cap.
 
5.
 
Hold
 
nasal
 
spray
 
upright,
 
thumb
 
beneath
 
bottle
 
and
 
fingers
 
on
 
either
 
side
 
of
 
the
 
nozzle.
 
 
6.
 
Get
 
your
 
child
 
into
 
any
 
of
 
these
 
positions
 
to
 
give
 
the
 
nasal
 
sprays:
 
 
a.
 
Tilt
 
your
 
child’ s
 
head
 
back
 
 
 
 
 
42
 

=== PAGE 430 ===

 
b.
 
Lay
 
your
 
child
 
flat
 
on
 
their
 
back
 
 
c.
 
Ask
 
someone
 
to
 
hold
 
your
 
child
 
in
 
a
 
safe
 
position
 
as
 
above
 
d.
 
Wrap
 
your
 
baby
 
or
 
young
 
child
 
in
 
a
 
light
 
blanket
 
or
 
sheet
 
to
 
keep
 
their
 
arms
 
still
 
7.
 
Close
 
one
 
nostril
 
of
 
your
 
child
 
with
 
your
 
finger
 
and
  
keep
 
the
 
bottle
 
upright,
 
carefully
 
insert
 
the
 
nozzle
 
into
 
the
 
other
 
nostril.
 
8.
 
Point
 
the
 
nozzle
 
away
 
from
 
the
 
centre
 
ridge
 
of
 
your
 
patient
 
nose
 
(septum),
 
towards
 
the
 
outside
 
corner
 
of
 
your
 
eye
 
on
 
the
 
same
 
side.
 
 
9.
 
Ask
 
your
 
child
 
to
 
breathe
 
through
 
the
 
mouth
 
and
 
press
 
the
 
applicator/pump
 
firmly .
 
10.
 
Remove
 
the
 
nozzle
 
from
 
the
 
nostril.
 
11.
 
Keep
 
your
 
child
 
in
 
the
 
position
 
for
 
two
 
minutes
 
to
 
allow
 
the
 
medication
 
to
 
spread
 
through
 
the
 
nose.
 
12.
 
If
 
your
 
child
 
requires
 
more
 
than
 
1
 
spray
 
in
 
each
 
nostril,
 
repeat
 
step
 
3
 
till
 
11.
 
13.
 
Repeat
 
step
 
3
 
till
 
11
 
for
 
the
 
other
 
nostril.
 
14.
 
Wipe
 
the
 
nozzle
 
with
 
dry
 
cloth.
 
15.
 
Replace
 
cap
 
on
 
bottle
 
right
 
away .
 
Missed
 
dose
 
management:
 
 
If
 
you
 
forget
 
to
 
take
 
a
 
dose,
 
take
 
it
 
as
 
soon
 
as
 
you
 
remember .
 
However ,
 
if
 
it
 
is
 
almost
 
time
 
to
 
take
 
the
 
next
 
dose,
 
wait
 
until
 
then.
 
Do
 
not
 
take
 
a
 
double
 
dose
 
to
 
make
 
up
 
for
 
a
 
forgotten
 
dose.
 
Do
 
not
 
stop
 
taking
 
your
 
medication
 
unless
 
advised
 
to
 
do
 
so
 
by
 
your
 
prescriber
 
Special
 
Considerations
 
Pregnancy
 
 
 
 
1.
 
Fluticasone,
 
Mometasone,
 
Oxymetazoline:
 
Should
 
be
 
used
 
in
 
pregnancy
 
only
 
if
 
the
 
benefits
 
to
 
the
 
mother
 
outweigh
 
the
 
potential
 
risks
 
to
 
the
 
mother
 
or
 
fetus.
 
2.
 
Desmopressin:
 
Fetal
 
risk
 
can
 
not
 
be
 
ruled
 
out.
 
 
 
 
Breastfeeding
 
 
 
 
1.
 
Infant
 
risk
 
cannot
 
be
 
ruled
 
out.
 
 
2.
 
Lignocaine
 
HCL
 
5%
 
and
 
Phenylephrine
 
5%
 
present
 
in
 
milk
 
but
 
too
 
small
 
amounts
 
to
 
be
 
harmful.
 
 
 
 
Elderly
 
 
 
 
Steroid
 
nasal
 
spray
 
1.
 
Consider
 
initiating
 
at
 
the
 
low
 
end
 
of
 
the
 
dosing
 
range.
 
 
 
 
 
Paediatric
 
 
 
 
Paediatric
 
age
 
limit
 
for
 
specific
 
drug,
 
please
 
refer
 
to
 
medication
 
product
 
insert.
 
 
 
 
Fasting
 
 
 
 
Refer
 
to
 
the
 
latest
 
advisory
 
by
 
religious
 
authority .
 
 
 
 
Others
  
 
 
 
 
Decongestant
 
nasal
 
spray:
 
1.
 
Use
 
for
 
no
 
longer
 
than
 
7
 
days,
 
to
 
avoid
 
rebound
 
congestion
 
(please
 
refer
 
to
 
product
 
insert).
 
 
Desmopressin
 
100mcg/ml
 
1.
 
Renal
 
impairment:
 
contraindicated
 
CrCl<50
 
ml/min
 
 
 
 
Side
 
Effects
 
and
 
1.
 
Dryness
 
or
 
irritation
 
of
 
nose
 
and
 
throat
 
 
 
 
 
43
 

=== PAGE 431 ===

 
their
 
Management*
 
2.
 
Blood-tinged
 
mucus
 
or
 
phlegm
 
 
3.
 
Nose
 
bleeds
 
 
Management:
 
1.
 
Rinse
 
mouth
 
with
 
water
 
or
 
drink
 
water
 
2.
 
Refer
 
to
 
a
 
doctor .
 
Storage*
 
1.
 
Keep
 
away
 
from
 
sunlight
 
or
 
heat
 
and
 
moisture
 
 
2.
 
Keep
 
away
 
from
 
reach
 
of
 
children
 
 
3.
 
Store
 
between
 
20-25°C
 
(refer
 
product
 
insert)
 
 
 
 
Others
 
1.
 
Patients
 
may
 
find
 
it
 
easier
 
if
 
they
 
hold
 
the
 
nasal
 
spray
 
in
 
the
 
hand
 
opposite
 
of
 
the
 
nostril
 
they
 
intend
 
to
 
spray ,
 
i.e.
 
left
 
hand
 
with
 
right
 
nostril
 
and
 
vice
 
versa.
 
2.
 
Drug
 
interactions
 
between
 
Desmopressin
 
100mcg/ml
 
with
 
corticosteroids
 
and
 
loop
 
diuretics
 
3.
 
Drug
 
interactions
 
between
 
Oxymetazoline
 
and
 
Monoamine
 
Oxidase
 
Inhibitors
 
and
 
tricyclic
 
antidepressants.
 
4.
 
Food
 
/drink
 
should
 
not
 
be
 
ingested
 
within
 
2
 
hours
 
of
 
local
 
anaesthetic
 
use.
 
 
Please
 
refer
 
to
 
the
 
product
 
insert.
 
 
 
 
Before
 
ending
 
this
 
peer
 
review
 
session,
 
the
 
reviewee
 
should
 
be
 
informed
 
of
 
the
 
step(s)
 
that
 
he/
 
she
 
missed
 
out
 
in
 
order
 
to
 
ensure
 
all
 
the
 
counselling
 
points
 
are
 
being
 
covered.
 
 
Remarks:
 
 
 
Reviewed
 
by:
 
Name
 
&
 
Signature
                                                                   
Date:
 
 
 
*Mandatory
 
for
 
peer
 
review/V alidation
 
References:
 
1.
 
Sterling,
 
A.,
 
M
 
Zand,
 
Jonathan.
 
Budesonide
 
(nasal):
 
Drug
 
Information.
 
UpToDate.
 
(2024)
 
UpToDate
 
(
Version
 
3.68.3)
 
[Mobile
 
App]
 
Mobile
 
Clinical
 
Decision
 
Support
 
App
 
|
 
UpToDate
 
|
 
Wolters
 
Kluwer
 
2.
 
Sterling,
 
A.,
 
M
 
Zand,
 
Jonathan.
 
Fluticasone
 
(nasal)
 
:
 
Drug
 
Information.
 
UpToDate.
 
(2024)
 
UpToDate
 
(
Version
 
3.68.3)
 
[Mobile
 
App]
 
Mobile
 
Clinical
 
Decision
 
Support
 
App
 
|
 
UpToDate
 
|
 
Wolters
 
Kluwer
 
3.
 
Sterling,
 
A.,
 
M
 
Zand,
 
Jonathan.
 
Oxymetazoline
 
(nasal):
 
Drug
 
Information.
 
UpToDate.
 
(2024)
 
UpToDate
 
(
Version
 
3.68.3)
 
[Mobile
 
App]
 
Mobile
 
Clinical
 
Decision
 
Support
 
App
 
|
 
UpToDate
 
|
 
Wolters
 
Kluwer
 
4.
 
Sterling,
 
A.,
 
M
 
Zand,
 
Jonathan.
 
Desmopressin:
 
Drug
 
Information.
 
UpToDate.
 
(2024)
 
UpToDate
 
(
Version
 
3.68.3)
 
[Mobile
 
App]
 
Mobile
 
Clinical
 
Decision
 
Support
 
App
 
|
 
UpToDate
 
|
 
Wolters
 
Kluwer
 
5.
 
Formulari
 
Ubat
 
KKM
 
(FUKKM).
 
(Version
 
241030.001
)
 
Retrieved
 
from
 
https://i.pharmacy .gov.my/fukkm
 
6.
 
Frishauf,
 
Peter .
 
Budesonide
 
intranasal.
 
Medscape.
 
(2024)
 
Medscape
 
(Version
 
12.2.1)
 
[Mobile
 
App]
 
Point-of-Care
 
Medical
 
Reference
 
App
 
For
 
Doctors
 
|
 
Medscape
 
7.
 
Frishauf,
 
Peter .
 
Fluticasone
 
intranasal.
 
Medscape.
 
(2024)
 
Medscape
 
(Version
 
12.2.1)
 
[Mobile
 
App]
 
Point-of-Care
 
Medical
 
Reference
 
App
 
For
 
Doctors
 
|
 
Medscape
 
8.
 
Frishauf,
 
Peter .
 
Oxymetazoline
 
intranasal.
 
Medscape.
 
(2024)
 
Medscape
 
(Version
 
12.2.1)
 
[Mobile
 
App]
 
Point-of-Care
 
Medical
 
Reference
 
App
 
For
 
Doctors
 
|
 
Medscape
 
9.
 
Frishauf,
 
Peter .
 
Desmopressin.
 
Medscape.
 
(2024)
 
Medscape
 
(Version
 
12.2.1)
 
[Mobile
 
App]
 
Point-of-Care
 
Medical
 
Reference
 
App
 
For
 
Doctors
 
|
 
Medscape
 
10.
 
Merative,
 
L.P.
 
Oxymetazoline
 
Hydrochloride.
 
Micromedex.
 
(2024)
 
Micromedex
 
(Version
 
4.6.0)
 
[Mobile
 
App]
 
https://play .google.com/store/apps/details?id=com.truven.druginfonative.customer
 
11.
 
Merative,
 
L.P.
 
Fluticasone
 
Furoate.
 
Micromedex.
 
(2024)
 
Micromedex
 
(Version
 
4.6.0)
 
[Mobile
 
App]
 
https://play .google.com/store/apps/details?id=com.truven.druginfonative.customer
 
12.
 
Merative,
 
L.P.
 
Budesonide.
 
Micromedex.
 
(2024)
 
Micromedex
 
(Version
 
4.6.0)
 
[Mobile
 
App]
 
https://play .google.com/store/apps/details?id=com.truven.druginfonative.customer
 
13.
 
Merative,
 
L.P.
 
Desmopressin
 
Acetate.
 
Micromedex.
 
(2024)
 
Micromedex
 
(Version
 
4.6.0)
 
[Mobile
 
App]
 
https://play .google.com/store/apps/details?id=com.truven.druginfonative.customer
 
14.
 
National
 
Health
 
Service
 
(2023).
 
Side
 
effects
 
of
 
fluticasone
 
nasal
 
spray
 
and
 
drops
.
 
Retrieved
 
from
 
15.
 
https://www .nhs.uk/medicines/fluticasone-nasal-spray-and-drops/side-ef fects-of-fluticasone-nasal-spray- 
and-drops/
 
16.
 
GlaxoSmithKline
 
Inc.
 
(2021).
 
AVAMYS
.
 
Retrieved
 
from
 
https://ca.gsk.com/media/6133/avamys.pdf
 
17.
 
NHS
 
Foundation
 
Trust
 
(2024).
 
How
 
to
 
Apply
 
Your
 
Child’ s
 
Nasal
 
Spray .
 
Retrieved
 
from
 
https://www .alderhey .nhs.uk/conditions/patient-information-leaflets/how-to-apply-your-childs-nasal-spray 
/#:~:text=Ask%20your%20child%20to%20lie,or%20her%20head%20tilted%20back.&text=Ask%20your
%20child%20to%20breathe,of%20the%20bottle%20after%20using
.
 
44
 

=== PAGE 432 ===

 
Oral
 
Ovulation
 
Induction
 
Drugs
 
Name
 
:
 
 
Unit
 
:
 
 
●
 
Please
 
tick
 
(
✔
)
 
Yes
 
for
 
correct
 
instruction.
 
●
 
Please
 
tick
 
(
✔
)
 
No
 
for
 
incorrect
 
instruction.
 
Yes
 
No
 
Remarks
 
Pharmacological
 
Group
 
1.
 
Letrozole
 
2.5mg
 
Tablet
 
(Aromatase
 
Inhibitors)
 
2.
 
Clomiphene
 
Citrate
 
50mg
 
Tablet
 
(Selective
 
Oestrogen
 
Receptor
 
Modulator
 
(SERM))
 
 
 
 
Indications
 
and
 
Dosage
 
1.
 
Used
 
to
 
induce
 
ovulation
 
and
 
increase
 
the
 
chances
 
of
 
pregnancy
 
in
 
women
 
who
 
do
 
not
 
ovulate
 
regularly
 
or
 
at
 
all,
 
particularly
 
those
 
with
 
PCOS.
 
 
Dosage:
 
 
Lestrozole:
 
2.5mg
 
from
 
D2-
 
D7
 
of
 
menstrual
 
cycle
 
continuously
 
 
Clomiphene:
 
50mg
 
on
 
D5-D25
 
of
 
menstruation
 
 
2.
 
Letrozole:
 
H
ormonal
 
therapy
 
in
 
breast
 
cancer
 
in
 
postmenopausal
 
women
 
if
 
failed
 
/contraindicated
 
to
 
tamoxifen
 
 
 
 
Method
 
of
 
Administration*
 
1.
 
Medication
 
should
 
be
 
taken
 
whole
 
with
 
a
 
full
 
glass
 
of
 
water
 
and
 
with
 
meals
 
2.
 
Medication
 
should
 
be
 
taken
 
at
 
the
 
same
 
time
 
daily
 
for
 
five
 
consecutive
  
days.
 
 
3.
 
Medication
 
should
 
not
 
be
 
crushed
 
and
 
should
 
not
 
be
 
administered
 
via
 
Ryle’ s
 
Tube
 
 
4.
 
If
 
missed
 
dose,
 
 
a.
 
within
 
12H
 
of
 
expecting
 
dosing
 
time:
 
:
 
take
 
medication
 
as
 
remembered
 
and
 
to
 
continue
 
same
 
schedule
 
the
 
next
 
day
 
b.
 
after
 
12H
 
of
 
expected
 
dosing
 
time:
 
to
 
omit
 
the
 
dose
 
and
 
continue
 
taking
 
the
 
next
 
following
 
dose.
 
Do
 
not
 
double
 
the
 
dose.
 
 
5.
 
Do
 
not
 
stop
 
taking
 
your
 
medication
 
unless
 
advised
 
to
 
do
 
so
 
by
 
your
 
prescriber
 
 
 
 
Special
 
Considerations
 
Pregnancy
 
 
 
 
Contraindicated
 
in
 
Pregnancy
 
 
 
 
Breastfeeding
 
 
 
 
Contraindicated
 
in
 
Breastfeeding
 
 
 
 
Elderly
 
 
 
 
No
 
dose
 
adjustment
 
1
 
 
Paediatric
 
 
 
 
No
 
dose
 
adjustments
 
required
 
 
 
 
 
Fasting
 
 
 
 
Medication
 
can
 
be
 
taken
 
during
 
non-fasting
 
period,
 
kindly
 
ensure
 
to
 
take
 
medication
 
at
 
the
 
same
 
time
 
 
 
 
Others
  
 
 
 
 
1.
 
Renal
 
and
 
mild
 
liver
 
impairment:
 
No
 
dose
 
adjustment
 
is
 
necessary
 
 
 
 
45
 

=== PAGE 433 ===

 
2.
 
Patients
 
with
 
cirrhosis
 
or
 
severe
 
hepatic
 
dysfunction:
 
 
Lestrozole
:
 
2.5mg
 
EOD
 
for
 
5
 
days
 
(not
 
to
 
complete
 
whole
 
cycle)
 
Clomiphene
:
 
contraindicated
 
 
Side
 
Effects
 
and
 
their
 
Management*
 
1.
 
GI
 
disturbance
 
(gastritis,
 
nausea
 
vomiting,
 
heartburn
 
loss
 
of
 
appetite
 
)
 
-
 
to
 
take
 
medication
 
with
 
meals
 
2.
 
Hot
 
flushes,
 
headache,
 
insomnia
 
 
-
 
suggest
 
to
 
take
 
medication
 
early
 
morning
 
with
 
full
 
glass
 
of
 
water
 
and
  
to
 
wear
 
thin
 
clothes,
 
 
3.
 
Muscle
 
pain,
 
mild
 
headache
 
 
-
 
mild
  
NSAIDS
 
like
 
paracetamol
 
and
 
ibuprofen
 
may
 
help
 
to
 
reduce
 
pain
 
and
 
muscle
 
aches
 
-
 
avoid
 
driving
 
while
 
taking
 
on
 
medication.
 
Others
 
(advise
 
to
 
stop
 
taking
 
the
 
medications
 
and
 
to
 
go
 
to
 
the
 
hospital
 
immediately):
 
 
-
 
blurred
 
vision
 
-
 
visual
 
spots
 
or
 
flashes
 
-
 
double
 
vision
 
-
 
stomach
 
or
 
lower
 
stomach
 
pain
 
-
 
stomach
 
swelling
 
-
 
weight
 
gain
 
-
 
shortness
 
of
 
breath
 
 
 
 
Storage*
 
1.
 
Store
 
in
 
a
 
cool
 
dry
 
place
 
away
 
from
 
direct
 
heat,
 
moisture
 
and
 
sunlight.
 
(below
 
30
℃
)
 
 
 
 
 
Others
 
1.
 
Keep
 
out
 
of
 
the
 
reach
 
of
 
childr en.
 
2.
 
Clomiphene
 
should
 
not
 
be
 
used
 
more
 
than
 
6
 
cycles
 
to
 
avoid
 
risk
 
of
 
ovarian
 
cancer
 
3.
 
Preferably
 
to
 
take
 
with
 
high
 
lipid
 
food
 
for
 
faster
 
absorption
 
 
 
 
Before
 
ending
 
this
 
peer
 
review
 
session,
 
the
 
reviewee
 
should
 
be
 
informed
 
of
 
the
 
step(s)
 
that
 
he/
 
she
 
missed
 
out
 
in
 
order
 
to
 
ensure
 
all
 
the
 
counselling
 
points
 
are
 
being
 
covered.
 
 
Remarks:
 
 
 
Reviewed
 
by:
 
Name
 
&
 
Signature
                                                                   
Date:
 
 
 
*
 
Mandatory
 
for
 
peer
 
review/validation
 
 
 
References:
 
1.
 
Clomiphene.
  
AHFS
 
Patient
 
Medication
 
Information
 
[Internet].
 
Bethesda
 
(MD):
 
American
 
Society
 
of
 
Health-System
 
Pharmacists,
 
Inc.;
 
c2019.
 
Clomiphene;
 
[revised
 
2017
 
May
 
15
  
Available
 
from:
 
https://medlineplus.gov/druginfo/meds/a682704.html
 
2.
 
Lestrozole.
 
AHFS
 
Patient
 
Medication
 
Information
 
[Internet].
 
Bethesda
 
(MD):
 
American
 
Society
 
of
 
Health-System
 
Pharmacists,
 
Inc.;
 
c2019.
 
Lestrozole
 
[revised
 
2018
 
Jan
 
15
  
Available
 
from:
 
https://medlineplus.gov/druginfo/meds/a698004.html
 
 
3.
 
Letrozole
 
oral
 
route.
 
MayoClinic
 
https://www .mayoclinic.org/drugs-supplements/letrozole-oral-route/description/drg-20067579
 
 
4.
 
Letrozole:
 
Uses,
 
Dosage,
 
Side
 
Effects
 
and
 
More.
 
MIMS
 
(https://www .mims.com/malaysia/drug/info/clomifene?mtype=generic)
 
5.
 
Clomiphene:
 
 
Uses,
 
Dosage,
 
Side
 
Effects
 
and
 
More.
 
MIMS
 
https://www .mims.com/malaysia/drug/info/clomifene?mtype=generic
 
 
 
 
 
 
46
 

=== PAGE 434 ===

 
Pressurised
 
Metered-dose
 
Inhaler
 
(pMDI)
 
Name
 
:
 
 
Unit
 
:
 
 
●
 
Please
 
tick
 
(
✔
)
 
Yes
 
for
 
correct
 
instruction.
 
●
 
Please
 
tick
 
(
✔
)
 
No
 
for
 
incorrect
 
instruction.
 
Yes
 
No
 
Remarks
 
Type
 
of
 
Device
 
Pressurised
 
metered-dose
 
inhaler
 
(pMDI)
 
 
 
 
Indications
 
and
 
Dosage
 
The
 
indication
 
and
 
dosage
 
depend
 
on
 
the
 
drug
 
content
 
 
 
 
Method
 
of
 
Administration*
 
DEVICE
 
PREP ARA TION
 
 
 
Before
 
Every
 
Use
 
 
 
Make
 
sure:
  
 
 
 
 
The
 
pMDI
 
has
 
not
 
expired
 
 
 
 
 
The
 
pMDI
 
is
 
not
 
empty
 
 
 
 
Check
 
inside
 
the
 
mouthpiece
 
of
 
the
 
pMDI
 
and
 
ensure
 
it
 
is
 
free
 
from
 
foreign
 
objects.
 
 
 
 
 
Priming
 
 
Conditions
 
in
 
which
 
priming
 
is
 
required:
  
 
●
 
Before
 
using
 
pMDI
 
for
 
the
 
first
 
time.
 
 
●
 
If
 
pMDI
 
has
 
not
 
been
 
used
 
for
 
a
 
specific
 
period.
 
 
 
 
 
Priming
 
steps:
  
 
●
 
Remove
 
the
 
cap
 
and
 
hold
 
the
 
inhaler
 
in
 
an
 
upright
 
position.
 
 
●
 
Shake
 
the
 
pMDI
 
well.
 
 
●
 
Press
 
down
 
the
 
canister
 
to
 
release
 
1
 
spray
 
into
 
the
 
air.
 
 
●
 
Repeat
 
the
 
above
 
steps
 
if
 
needed.
 
 
Notes:
 
The
 
number
 
of
 
puffs,
 
non-use
 
period,
 
and
 
the
 
need
 
for
 
shaking
 
differ
 
from
 
product
 
to
 
product.
 
Refer
 
to
 
product
 
inserts
 
for
 
specific
 
instructions
.
 
 
 
 
DEVICE
 
INHALA TION
 
TECHNIQUES
 
 
Prepare
 
 
Step
 
1
 
 
Remove
 
the
 
cap
 
and
 
hold
 
the
 
pMDI
 
in
 
an
 
upright
 
position.
 
 
Shake
 
the
 
pMDI
 
well
 
(suspensions).
 
 
 
Notes:
 
Shaking
 
is
 
not
 
required
 
for
 
solution-based
 
pMDIs.
 
Refer
 
to
 
product
 
inserts.
 
 
 
 
 
 
Exhale
 
 
Step
 
2
 
 
•
 
Sit
 
upright
 
or
 
stand
 
in
 
an
 
erect
 
position.
 
 
•
 
Breathe
 
out
 
(exhale)
 
slowly
 
and
 
fully,
 
away
 
from
 
the
 
pMDI.
 
 
 
 
Chin
 
&
 
mouth
 
 
Step
 
3
 
 
•
 
Slightly
 
tilt
 
the
 
chin
 
up.
 
 
•
 
Place
 
the
 
inhaler
 
mouthpiece
 
gently
 
between
 
the
 
teeth.
 
Ensure
 
a
 
tight
 
seal
 
of
 
the
 
lips
 
around
 
the
 
mouthpiece.
 
Do
 
not
 
bite
 
the
 
mouthpiece.
 
 
 
 
Notes:
 
Do
 
not
 
block
 
the
 
opening
 
of
 
the
 
mouthpiece
 
with
 
the
 
tongue
 
or
 
teeth.
 
The
 
 
 
 
47
 

=== PAGE 435 ===

 
tongue
 
should
 
be
 
lowered
 
under
 
the
 
mouthpiece.
 
 
Inhale
 
 
Step
 
4
 
 
Inhale
 
slowly
 
and
 
deeply
 
through
 
the
 
mouth
,
 
pressing
 
the
 
canister
 
down
 
ONCE
 
at
 
the
 
start
 
of
 
inhalation.
 
 
Continue
 
breathing
 
in
 
slowly
 
and
 
deeply
 
for
 
4-5
 
seconds.
 
 
 
 
Note:
 
Do
 
not
 
actuate
 
the
 
canister
 
before
 
starting
 
the
 
inhalation
 
 
 
 
 
 
Hold
 
breath
 
 
Step
 
5
 
 
Remove
 
the
 
pMDI
 
from
 
the
 
mouth
 
and
 
with
 
the
 
lips
 
closed,
 
hold
 
the
 
breath
 
for
 
5-10
 
seconds
 
or
 
as
 
long
 
as
 
comfortable.
 
 
 
 
Exhale
 
 
Step
 
6
 
 
Breathe
 
out
 
(exhale)
 
gently ,
 
away
 
from
 
the
 
pMDI.
 
 
 
 
Repeat
 
 
 
 
Step
 
7
 
 
Wait
 
about
 
30
 
seconds
 
to
 
1
 
minute.
 
Repeat
 
steps
 
1
 
to
 
6
 
if
 
another
 
dose
 
is
 
needed.
 
 
 
 
 
Close
 
&
 
Rinse
 
Step
 
8
 
 
●
 
Replace
 
the
 
cap.
 
 
●
 
Rinse
 
and
 
gargle
 
the
 
mouth
 
with
 
water
 
and
 
spit
 
it
 
out
 
(for
 
steroid-containing
 
inhalers).
 
 
 
 
 
 
Missed
 
dose
 
management
 
:
 
 
If
 
a
 
maintenance
 
dose
 
is
 
missed,
 
take
 
it
 
as
 
soon
 
as
 
possible
 
and
 
then
 
resume
 
the
 
regular
 
schedule.
 
However ,
 
if
 
it
 
is
 
almost
 
time
 
for
 
the
 
next
 
dose,
 
skip
 
the
 
missed
 
dose.
 
Never
 
take
 
a
 
double
 
dose
 
to
 
make
 
up
 
for
 
a
 
missed
 
maintenance
 
dose.
 
Do
 
not
 
stop
 
taking
 
your
 
medication
 
unless
 
advised
 
to
 
do
 
so
 
by
 
your
 
prescriber .
 
 
 
 
Special
 
Considerations
 
Pregnancy
 
 
 
 
NA
 
 
 
 
Breastfeeding
 
 
 
 
NA
 
 
 
 
Elderly
 
 
 
 
1.
 
Consider
 
spacers
 
or
 
valved
 
holding
 
chambers
 
 
2.
 
Consider
 
patient-related
 
factors
 
such
 
as
 
manual
 
dexterity ,
 
hand
 
strength,
 
tremors,
 
vision,
 
comorbidities,
 
respiratory
 
muscle
 
strength,
 
cognition
 
and
 
others.
  
 
 
 
 
Paediatric
 
 
 
 
Choose
 
age-appropriate
 
spacers/
 
valved
 
holding
 
chambers
 
 
 
 
 
Fasting
 
 
 
 
To
 
refer
 
to
 
the
 
latest
 
advisory
 
by
 
religious
 
authority
 
 
 
 
48
 

=== PAGE 436 ===

 
Others
  
 
 
 
 
NA
 
 
 
 
Side
 
Effects
 
and
 
their
 
Management*
 
For
 
corticosteroid-containing
 
inhalers,
 
gargle
 
the
 
mouth
 
with
 
water
 
and
 
spit
 
it
 
out.
 
 
 
 
 
Storage*
 
Refer
 
to
 
product
 
inserts
 
for
 
complete
 
information.
 
In
 
general:
 
●
 
Store
 
the
 
device
 
in
 
a
 
clean,
 
cool,
 
and
 
dry
 
place
 
at
 
appropriate
 
temperatures.
 
●
 
Avoid
 
extreme
 
temperatures
 
and
 
humidity
 
(e.g.,
 
do
 
not
 
store
 
it
 
in
 
cars
 
or
 
bathrooms).
 
●
 
Keep
 
it
 
safely
 
out
 
of
 
the
 
reach
 
of
 
children.
 
 
 
 
Others
 
Cleaning*
 
 
 
Clean
 
the
 
pMDI
 
at
 
least
 
once
 
a
 
week
 
or
 
whenever
 
necessary .
 
 
Cleaning
 
steps
 
in
 
general
 
(for
 
specific
 
details
 
refer
 
to
 
product
 
inserts):
 
 
●
 
Remove
 
the
 
cap
 
and
 
the
 
canister
 
from
 
the
 
plastic
 
casing.
 
 
●
 
Rinse
 
the
 
plastic
 
casing
 
and
 
cap
 
under
 
running
 
water
 
until
 
no
 
medication
 
buildup
 
or
 
dirt
 
is
 
visible.
 
Do
 
not
 
put
 
the
 
metal
 
canister
 
in
 
water .
 
 
●
 
Shake
 
off
 
to
 
remove
 
excess
 
water .
 
 
●
 
Allow
 
it
 
to
 
air
 
dry
 
thoroughly
 
inside
 
and
 
outside.
 
 
●
 
Replace
 
the
 
canister
 
inside
 
the
 
plastic
 
casing
 
and
 
recap
 
the
 
mouthpiece.
 
 
 
 
Notes
:
 
For
 
some
 
pMDIs,
 
the
 
canister
 
cannot
 
be
 
removed
 
from
 
the
 
plastic
 
casing
 
and
 
cannot
 
be
 
cleaned
 
with
 
water .
 
Refer
 
to
 
product
 
inserts
 
for
 
specific
 
instructions.
 
 
 
 
 
 
Dose
 
checking
 
 
Check
 
pMDI
 
for
 
remaining
 
doses:
 
 
●
 
Check
 
the
 
dose
 
counter
 
(if
 
the
 
pMDI
 
has
 
one).
 
●
 
For
 
pMDI
 
without
 
a
 
dose
 
counter ,
 
mark
 
the
 
date
 
of
 
opening
 
on
 
the
 
new
 
pMDI
 
and
 
keep
 
track
 
of
 
the
 
doses
 
used.
 
Record
 
the
 
doses
 
used
 
on
 
a
 
daily
 
log.
 
 
 
 
Expiry
 
date
 
 
Follow
 
the
 
expiry
 
date
 
on
 
the
 
product.
 
 
 
 
Notes:
 
Some
 
pMDIs
 
have
 
in-use
 
shelf
 
life.
 
Refer
 
to
 
product
 
inserts
 
for
 
specific
 
instructions.
 
 
 
 
 
 
Before
 
ending
 
this
 
peer
 
review
 
session,
 
the
 
reviewee
 
should
 
be
 
informed
 
of
 
the
 
step(s)
 
that
 
he/
 
she
 
missed
 
out
 
in
 
order
 
to
 
ensure
 
all
 
the
 
counselling
 
points
 
are
 
being
 
covered.
 
 
Remarks:
 
 
 
 
Reviewed
 
by:
 
Name
 
&
 
Signature
                                                                   
Date:
 
 
 
 
 
*Mandatory
 
for
 
validation
 
/
 
peer
 
review
 
 
49
 

=== PAGE 437 ===

 
References:
 
 
1.
 
Usmani
 
OS.
 
(2019
 
Mar).
 
Choosing
 
the
 
right
 
inhaler
 
for
 
your
 
asthma
 
or
 
COPD
 
patient.
 
Therapeutics
 
and
 
clinical
 
risk
 
management.
 
14:461-72.
 
2.
 
Ohar
 
JA,
 
Ferguson
 
GT,
 
Mahler
 
DA,
 
Drummond
 
MB,
 
Dhand
 
R,
 
Pleasants
 
RA,
 
Anzueto
 
A,
 
Halpin
 
DM,
 
Price
 
DB,
 
Drescher
 
GS,
 
Hoy
 
HM.
 
(2022
 
Jan).
 
Measuring 
 
peak
 
inspiratory
 
flow
 
in
 
patients
 
with
 
chronic
 
obstructive
 
pulmonary
 
disease.
 
International
 
journal
 
of
 
chronic
 
obstructive
 
pulmonary
 
disease.
  
6:79-92.
 
3.
 
The
 
Electronic
 
Medicine
 
Compendium
 
(eMC)
 
(Available
 
at 
http://www .medicines.org.uk/emc/
).
 
Accessed
 
on
 
October
 
15,
 
2024.
 
4.
 
Asthma
 
UK.
 
How
 
to
 
use
 
your
 
inhaler
 
(Available
 
at 
https://www .asthmaandlung.org.uk/living-with/inhaler-videos
).
 
Accessed
 
on
 
October
 
15,
 
2024.
 
5.
 
Mohammad
 
Y.
 
(2019
 
Oct).
 
How
 
to
 
manage
 
asthma
 
during
 
Ramadan?
 
97(10):
 
1073-1076.
 
PMID:
 
31691934
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
50
 

=== PAGE 438 ===

 
Progestogen-Only
 
Pills
 
(POP)
 
Name
 
:
 
 
Unit
 
:
 
 
●
 
Please
 
tick
 
(
✔
)
 
Yes
 
for
 
correct
 
instruction.
 
●
 
Please
 
tick
 
(
✔
)
 
No
 
for
 
incorrect
 
instruction.
 
Yes
 
No
 
Remarks
 
Pharmacological
 
Group
 
Progestogen
 
:
 
 
1.
 
Norethisterone
 
0.35mg
 
Tablet
 
(Noriday)
 
2.
 
Desogestrel
 
0.075mg
 
Tablet
 
(Cerazette)
 
3.
 
Medroxyprogesterone
 
5mg
 
Tablet
 
(Provera)
 
 
 
 
Indications
 
and
 
Dosage
 
I
ndication
 
(1-2)
 
Oral
 
Contraception
 
 
Dosage
 
:
 
1
 
tablet
 
daily
 
as
 
prescribed
 
by
 
the
 
doctor .
 
Duration
 
to
 
be
 
taken
 
will
 
depend
 
on
 
desire
 
of
 
withdrawal
 
bleed
 
(Cyclical
 
vs
 
Continuous).
 
 
 
Subsequent
 
courses
 
of
 
POP
 
can
 
be
 
repeated
 
as
 
per
 
doctor ’s
 
instructions.
 
 
Indication
 
(3)
 
Abnormal
 
Uterine
 
Bleeding
 
Secondary
 
Amenorrhea
 
 
  
Dosage
 
:
 
5
 
to
 
10
 
mg
 
daily
 
for
 
5-10
 
days
 
started
 
anytime
 
during
 
cycle
 
or
 
on
 
day
 
16-21
 
of
 
menstrual
 
cycle
 
as
 
prescribed
 
by
 
the
 
doctor .
 
Duration
 
to
 
be
 
taken
 
will
 
depend
 
on
 
desire
 
of
 
withdrawal
 
bleed
 
(Cyclical
 
vs
 
Continuous).
 
 
 
Subsequent
 
courses
 
of
 
POP
 
can
 
be
 
repeated
 
as
 
per
 
doctor ’s
 
instructions.
 
 
To
 
counsel
 
based
 
on
 
specific
 
medication’ s
 
indication
 
and
 
dosage
 
as
 
prescribed
 
by
 
the
 
doctor
 
 
 
 
Method
 
of
 
Administration*
 
Must
 
be
 
taken
 
at
 
the
 
same
 
time
 
every
 
day
 
after
 
meal
 
 
For
 
Contraception:
 
 
Need
 
to
 
be
 
taken
 
immediately
 
or
 
at
 
least
 
within
 
D5
 
of
 
the
 
menstrual
 
cycle.
 
If
 
it
 
exceeds
 
D5
 
of
 
the
 
menstrual
 
cycle,
 
an
 
additional
 
contraception
 
method
 
is
 
needed
 
for
 
7
 
days.
 
 
It
 
is
 
important
 
to
 
take
 
the
 
pills
 
as
 
directed
 
because
 
missing
 
pills
 
or
 
taking
 
them
 
not
 
on
 
time
 
make
 
them
 
less
 
effective.
 
 
Do
 
not
 
stop
 
taking
 
your
 
medication
 
unless
 
advised
 
to
 
do
 
so
 
by
 
your
 
prescriber
 
 
Missed
 
dose
 
management
 
 
Norethisterone
 
0.35mg
 
Tablet
 
 
consider
 
missed
 
dose
 
if
 
>
 
3
 
hours
 
later
 
than
 
the
 
usual
 
dose
 
timing
 
 
Desogestrel
 
0.075mg
 
Tablet
 
 
consider
 
missed
 
dose
 
if
 
>
 
12
 
hours
 
later
 
than
 
the
 
usual
 
dose
 
timing
 
 
If
 
you
 
missed
 
the
 
dose,
 
take
 
one
 
pill
 
as
 
soon
 
as
 
you
 
remember .
 
Take
 
the
 
next
 
pill
 
at
 
the
 
usual
 
time.
 
This
 
may
 
mean
 
taking
 
2
 
pills
 
in
 
one
 
day.
 
This
 
is
 
not
 
harmful
 
 
 
 
51
 

=== PAGE 439 ===

 
 
Additional
 
method
 
of
 
contraception
 
(condoms
 
or
 
abstinence)
 
is
 
advised
 
for
 
the
 
next
 
2
 
days
 
(48
 
hours
 
after
 
the
 
POP
 
has
 
been
 
taken).
 
 
Medroxyprogesterone
 
5mg
 
Tablet
 
 
Take
 
it
 
as
 
soon
 
as
 
remembered
 
within
 
12
 
hours
 
of
 
the
 
missed
 
dose.
 
If
 
it
 
is
 
more
 
than
 
12
 
hours
 
since
 
your
 
missed
 
dose,
 
skip
 
the
 
missed
 
dose
 
and
 
go
 
back
 
to
 
the
 
usual
 
dosing
 
times.
 
 
Note:
 
Always
 
read
 
the
 
product
 
information
 
leaflet
 
before
 
counsel
 
the
 
patient.
 
Information
 
may
 
differ
 
depending
 
on
 
the
 
product
 
 
Special
 
Considerations
 
Pregnancy
 
 
 
 
Contraindicated
 
 
 
 
Breastfeeding
 
 
 
 
Postpartum
 
breastfeeding
:
 
Start
 
after
 
6
 
weeks
 
 
Postpartum
 
but
 
not
 
breastfeeding
:
 
Start
 
within
 
Day
 
21
 
postpartum.
 
If
 
exceeded,
 
additional
  
contraception
 
methods
 
are
 
needed.
 
 
 
 
Elderly
 
 
 
 
Caution
 
in
 
women
 
who
 
are
 
above
 
60
 
years
 
old
 
due
 
to
 
stroke,
 
cardiovascular
 
and
 
VTE
 
risk
 
 
 
 
Paediatric
 
 
 
 
1.
 
The
 
safety
 
and
 
efficacy
 
of
 
Norethisterone
 
and
 
Desogestrel
 
in
 
children
 
who
 
have
 
not
 
achieved
 
menarche
 
have
 
not
 
been
 
established.
 
2.
 
The
 
safety
 
and
 
efficacy
 
of
 
Medroxyprogesterone
  
in
 
paediatric
 
patients
 
below
 
age
 
18
 
have
 
not
 
been
 
established
.
 
 
 
 
Fasting
 
 
To
 
refer
 
to
 
the
 
latest
 
advisory
 
by
 
religious
 
authority
 
 
 
 
Others
 
 
 
 
Hepatic
 
Impairment:
 
Contraindicated
 
 
 
 
Side
 
Effects
 
and
 
their
 
Management*
 
Nausea,
 
headaches,
 
breast
 
tenderness,
 
diarrhoea,
 
bloating
 
and
 
breakthrough
 
bleeding.
 
Continue
 
taking
 
the
 
pills
 
as
 
most
 
of
 
these
 
symptoms
 
will
 
improve
 
with
 
time.
 
 
If
 
any
 
of
 
the
 
following
 
symptoms
 
occur ,
 
the
 
drug
 
should
 
be
 
stopped
 
and
 
urgent
 
medical
 
advice
 
should
 
be
 
sought
 
after:
 
 
●
 
Severe
 
and
 
sudden
 
pain
 
in
 
the
 
chest
 
 
●
 
Breathlessness
 
 
●
 
Severe
 
headache
 
 
●
 
Abdominal
 
pain
 
 
●
 
Sudden
 
blurred
 
vision
 
or
 
loss
 
of
 
sight
 
 
●
 
Unexplained
 
tenderness
 
or
 
pain
 
and
 
swelling
 
in
 
one
 
leg
 
 
●
 
Weakness,
 
numbness
 
or
 
difficulty
 
speaking
 
 
●
 
Change
 
in
 
mood
 
or
 
depression
 
 
 
a
 
 
52
 

=== PAGE 440 ===

 
Storage*
 
Store
 
in
 
dry,
 
cool
 
places
 
at
 
room
 
temperature.
 
Direct
 
sunlight
 
and
 
extreme
 
temperatures
 
may
 
cause
 
them
 
to
 
break
 
down
 
and
 
become
 
less
 
effective
 
 
 
 
Others
 
POP
 
may
 
increase
 
the
 
risk
 
of
 
VTE
 
especially
 
with
 
the
 
3rd
 
and
 
4th
 
generation
 
progestin
 
(such
 
as
 
desogestrel
 
and
 
drospirenone)
 
 
Caution
 
should
 
be
 
exercised
 
in
 
women
 
over
 
55
 
years
 
of
 
age
 
due
 
to
 
the
 
increased
 
risks
 
of
 
stroke,
 
cardiovascular
 
events
 
and
 
VTE
 
 
Drug-drug
 
interactions
 
 
(Enzyme
 
Inducing
 
Drugs
 
-
 
May
 
reduce
 
the
 
effectiveness
 
of
 
POP)
 
1.
 
Antibiotics
 
–
 
Rifampicin
 
2.
 
Antiretrovirals
 
–
 
Ritonavir ,
 
Nevirapine,
 
Darunavir ,
 
Efavirenz
 
3.
 
Anticonvulsants
 
–
 
Carbamazepine,
 
Phenytoin,
 
Lamotrigine,
 
Topiramate,
 
Rufinamide,
 
Oxcarbazepine
 
4.
 
Antifungals
 
–
 
Griseofulvin,
 
Fluconazole,
 
Ketoconazole
 
5.
 
St.
 
John’ s
 
Wort
 
 
Drug-food
 
interactions
 
 
(May
 
cause
 
symptoms
 
of
 
progestogen
 
excess)
 
Grapefruit
 
juice
 
 
 
 
Before
 
ending
 
this
 
peer
 
review
 
session,
 
the
 
reviewee
 
should
 
be
 
informed
 
of
 
the
 
step(s)
 
that
 
he/
 
she
 
missed
 
out
 
in
 
order
 
to
 
ensure
 
all
 
the
 
counselling
 
points
 
are
 
being
 
covered.
 
 
Remarks:
 
 
 
 
 
Reviewed
 
by:
 
Name
 
&
 
Signature
                                                                   
Date:
 
 
 
 
 
*Mandatory
 
for
 
validation
 
/
 
peer
 
review
 
 
References:
 
1.
 
Faculty
 
of
 
Sexual
 
&
 
Reproductive
 
Healthcare
 
(FSRH)
 
Guidance
 
2018:
 
Drug
 
Interactions
 
with
 
Hormonal
 
Contraception
 
2.
 
Faculty
 
of
 
Sexual
 
&
 
Reproductive
 
Healthcare
 
(FSRH)
 
Guidance
 
2022:
 
Progesterone-only
 
Pills
 
3.
 
Faculty
 
of
 
Sexual
 
&
 
Reproductive
 
Healthcare
 
(FSRH)
 
Guideline
 
2017:
 
Contraception
 
After
 
Pregnancy
 
4.
 
Formulari
 
Ubat
 
KKM
 
(FUKKM).
 
(Version
 
241030.001
)
  
Retrieved
 
from
 
https://i.pharmacy .gov.my/fukkm
 
5.
 
MIMS
 
Malaysia
 
6.
 
U.S.
 
Medical
 
Eligibility
 
Criteria
 
for
 
Contraceptive
 
Use
 
2024
 
(U.S.
 
MEC)
 
7.
 
Product
 
leaflet
 
PROVERA
@
 
medroxyprogesterone
 
acetate
 
tablets
 
(2025,
 
January
 
20).
 
Retrieved
 
from:
https://quest3plus.bpfk.gov .my/front-end/attachment/286/pharma/21 1009/V_15150_20180214 
_074028_D3.pd
f
 
 
 
 
 
 
 
 
 
 
 
53
 

=== PAGE 441 ===

 
Respimat
 
(Re-usable)
 
Name
 
:
 
Unit
 
:
 
 
●
 
Please
 
tick
 
(
✔
)
 
Yes
 
for
 
correct
 
instruction.
 
●
 
Please
 
tick
 
(
✔
)
 
No
 
for
 
incorrect
 
instruction.
 
Yes
 
No
 
Remarks
 
 
Type
 
of
 
Device
 
Soft
 
Mist
 
Inhaler
 
 
 
 
 
 
 
Indications
 
and
 
Dosage
 
The
 
indication
 
and
 
dosage
 
depend
 
on
 
the
 
drug
 
content.
 
 
 
 
Method
 
of
 
Administration*
 
DEVICE
 
PREP ARA TION
 
●
 
Respimat
 
Re-usable
 
is
 
available
 
in
 
two
 
different
 
packaging:
 
 
a)
 
Device
 
Pack
 
consist
 
of
 
one
 
device
 
and
 
a
 
cartridge
 
b)
 
Refill
 
Pack
 
consists
 
of
 
a
 
cartridge
 
only.
 
 
●
 
The
 
Respimat
 
device
 
is
 
designed
 
for
 
use
 
with
 
up
 
to
 
6
 
cartridges.
 
 
 
 
Before
 
Every
 
Use
 
 
 
Make
 
sure:
  
 
 
 
 
 
 
The
 
Respimat
 
has
 
not
 
expired
 
 
 
 
 
 
 
 
The
 
Respimat
 
is
 
not
 
empty
 
 
 
 
 
 
 
 
Check
 
inside
 
the
 
mouthpiece
 
of
 
the
 
Respimat
 
and
 
ensure
 
it
 
is
 
free
 
from
 
foreign
 
objects.
 
 
 
 
 
 
 
 
Assemble
 
With
 
the
 
cap
 
closed,
 
press
 
the
 
safety
 
catch
 
and
 
pull
 
off
 
the
 
clear
 
base.
 
 
 
 
 
 
 
 
Take
 
the
 
cartridge
 
out
 
of
 
the
 
box.
 
Push
 
the
 
narrow
 
end
 
of
 
the
 
cartridge
 
into
 
the
 
Respimat
 
until
 
it
 
clicks
 
into
 
place.
  
 
 
 
Note:
 
The
 
cartridge
 
should
 
be
 
pushed
 
gently
 
against
 
a
 
firm
 
surface.
 
 
 
 
 
 
 
 
Mark
 
the
 
checkbox
 
on
 
the
 
inhaler ’s
 
label
 
to
 
track
 
the
 
number
 
of
 
cartridges.
 
 
 
 
 
 
 
 
Replace
 
the
 
clear
 
base
 
into
 
place
 
until
 
it
 
clicks.
 
 
 
 
 
 
 
 
 
54
 

=== PAGE 442 ===

 
Priming
 
Conditions
 
in
 
which
 
priming
 
is
 
required:
  
 
●
 
Before
 
using
 
Respimat
 
for
 
the
 
first
 
time.
 
●
 
If
 
Respimat
 
has
 
not
 
been
 
used
 
for
 
a
 
specific
 
period.
 
1)
 
Hold
 
the
 
Respimat
 
upright
 
with
 
the
 
cap
 
closed.
 
2)
 
Turn
 
the
 
clear
 
base
 
in
 
the
 
direction
 
of
 
the
 
black
 
    
arrows
 
on
 
the
 
label
 
until
 
it
 
“
clicks
”
 
(half
 
a
 
turn).
 
3)
 
Open
 
the
 
cap
 
until
 
it
 
snaps
 
fully
 
open.
 
4)
 
Point
 
the
 
Respimat
 
towards
 
the
 
ground.
 
Press
 
the
 
dose
 
release
 
button.
 
Close
 
the
 
cap.
 
5)
 
Perform
 
steps
 
1-4
 
until
 
a
 
cloud
 
is
 
visible.
 
After
 
a
 
cloud
 
is
 
visible,
 
repeat
 
steps
 
1-4,
 
three
 
(3)
 
more
 
times
 
to
 
ensure
 
the
 
inhaler
 
is
 
prepared
 
for
 
use.
 
6)
 
Hold
 
the
 
Respimat
 
upright
 
with
 
the
 
cap
 
closed.
 
 
 
Notes:
 
If
 
Respimat
 
has
 
not
 
been
 
used
 
for
 
more
 
than
 
7
 
days
,
 
release
 
ONE
 
(1)
 
puff
 
towards
 
the
 
ground.
 
If
 
Respimat
 
has
 
not
 
been
 
used
 
for
 
more
 
than
 
21
 
days
,
 
repeat
 
step
 
5.
 
 
 
 
 
 
 
 
DEVICE
 
INHALA TION
 
TECHNIQUES
 
 
 
Prepare
 
Step
 
1
 
●
 
Hold
 
the
 
Respimat
 
upright
 
with
 
the
 
cap
 
closed.
 
●
 
Turn
 
the
 
clear
 
base
 
in
 
the
 
direction
 
of
 
the
 
black
 
arrows
 
     
 
on
 
the
 
label
 
until
 
it
 
“
clicks
”
 
(half
 
a
 
        
turn).
 
The
 
dose
 
is
 
loaded.
 
●
 
Open
 
the
 
cap
 
until
 
it
 
snaps
 
fully
 
open.
 
 
 
 
 
 
 
 
Exhale
 
Step
 
2
 
●
 
Sit
 
upright
 
or
 
stand
 
in
 
an
 
erect
 
position.
 
●
 
Breathe
 
out
 
(exhale)
 
slowly
 
and
 
fully,
 
away
 
from
 
the
 
Respimat.
 
 
 
 
 
 
 
 
Chin
 
&
 
mouth
 
Step
 
3
 
 
●
 
Slightly
 
tilt
 
the
 
chin
 
up.
 
●
 
Place
 
the
 
inhaler
 
mouthpiece
 
gently
 
between
 
the
 
teeth.
 
Ensure
 
a
 
tight
 
seal
 
of
 
the
 
lips
 
around
 
the
 
mouthpiece.
 
Do
 
not
 
bite
 
the
 
mouthpiece.
 
 
 
 
Notes:
 
Do
 
not
 
block
 
the
 
opening
 
of
 
the
 
mouthpiece
 
with
 
the
 
tongue
 
or
 
teeth.
 
The
 
tongue
 
should
 
be
 
lowered
 
under
 
the
 
mouthpiece
.
 
Do
 
not
 
block
 
the
 
air
 
vents.
 
 
 
 
 
 
 
 
Inhale
 
Step
 
4
 
●
 
Inhale
 
slowly
 
and
 
deeply
 
through
 
the
 
mouth,
 
pressing
 
the
 
“dose
 
release
 
button”
 
at
 
the
 
start
 
of
 
inhalation.
 
 
●
 
Continue
 
breathing
 
in
 
slowly
 
and
 
deeply
 
for
 
4-5
 
seconds.
 
 
 
 
 
 
 
 
55
 


=== PAGE 443 ===

 
Hold
 
breath
 
Step
 
5
 
 
Remove
 
the
 
Respimat
 
from
 
the
 
mouth,
 
and
 
with
 
the
 
lips
 
closed
 
hold
 
the
 
breath
 
for
 
5-10
 
seconds
 
or
 
as
 
long
 
as
 
comfortable.
 
 
 
 
 
 
 
 
Exhale
 
Step
 
6
 
Breathe
 
out
 
(exhale)
 
gently ,
 
away
 
from
 
the
 
Respimat.
 
 
 
 
 
 
 
 
Repeat
 
 
 
 
Step
 
7
 
 
Repeat
 
steps
 
1
 
to
 
6
 
for
 
the
 
second
 
dose.
 
 
 
 
 
 
 
 
Close
 
Step
 
8
 
Close
 
the
 
cap
 
of
 
the
 
Respimat.
 
 
 
 
 
 
 
 
Missed
 
dose
 
management
 
:
 
 
If
 
a
 
maintenance
 
dose
 
is
 
missed,
 
take
 
it
 
as
 
soon
 
as
 
possible
 
and
 
then
 
resume
 
the
 
regular
 
schedule.
 
However ,
 
if
 
it
 
is
 
almost
 
time
 
for
 
the
 
next
 
dose,
 
skip
 
the
 
missed
 
dose.
 
Never
 
take
 
a
 
double
 
dose
 
to
 
make
 
up
 
for
 
a
 
missed
 
maintenance
 
dose.
 
Do
 
not
 
stop
 
taking
 
your
 
medication
 
unless
 
advised
 
to
 
do
 
so
 
by
 
your
 
prescriber .
 
 
 
 
 
 
 
 
Special
 
Considerations
 
Pregnancy
 
 
 
 
 
 
 
 
NA
 
 
 
 
Breastfeeding
 
 
 
 
 
 
 
 
NA
 
 
 
 
Elderly
 
 
 
 
 
 
 
 
1.
 
Consider
 
patient-related
 
factors
 
such
 
as
 
manual
 
dexterity ,
 
hand
 
strength
,
 
tremors,
 
vision,
 
comorbidities,
 
respiratory
 
muscle
 
strength,
 
cognition
 
and
 
others.
 
 
 
 
Paediatric
 
 
 
 
 
Can
 
be
 
used
 
with
 
VHC
 
(Aerochamber
 
Plus
 
Flow-V u)
 
 
 
 
 
 
 
 
Fasting
 
 
 
 
 
 
 
 
To
 
refer
 
to
 
the
 
latest
 
advisory
 
by
 
religious
 
authority
 
 
 
 
Others
  
 
 
 
 
 
 
 
 
NA
 
 
 
 
Side
 
Effects
 
and
 
their
 
Management*
 
Depend
 
on
 
the
 
drug
 
contents
 
 
 
 
Others
 
Cleaning*
 
 
 
Clean
 
the
 
Respimat
 
mouthpiece
 
including
 
the
 
metal
 
part
 
inside
 
the
 
mouthpiece
 
with
 
a
 
damp
 
cloth
 
or
 
tissue,
 
at
 
least
 
once
 
a
 
week.
  
 
 
 
Note:
 
Poor
 
hygiene
 
may
 
cause
 
brown
 
discolouration
 
on
 
the
 
metal
 
part
 
and
 
mouthpiece
  
 
 
 
 
 
 
 
56
 

=== PAGE 444 ===

 
Dose
 
checking
 
●
 
Contains
 
a
 
dose
 
indicator .
 
●
 
When
 
the
 
dose
 
indicator
 
window
 
shows
 
a
 
yellow
 
colour ,
 
there
 
are
 
approximately
 
10
 
puffs
 
of
 
medication
 
left.
  
 
●
 
When
 
the
 
dose
 
indicator
 
window
 
shows
 
a
 
white
 
arrow
 
on
 
a
 
red
 
background,
 
the
 
cartridge
 
is
 
empty .
 
 
 
 
 
 
 
Replacing
 
Respimat
 
Cartridge
 
●
 
Once
 
the
 
cartridge
 
is
 
empty ,
 
turn
 
the
 
clear
 
base
 
to
 
loosen
 
it.
 
The
 
inhaler
 
is
 
now
 
in
 
a
 
locked
 
position.
 
 
●
 
Pull
 
off
 
the
 
cartridge
 
from
 
the
 
inhaler .
 
●
 
 
Insert
 
a
 
new
 
cartridge
 
(continue
 
with
 
‘Assemble’
 
and
 
‘Priming’
 
steps).
 
 
 
 
 
 
 
Expiry
 
date
 
●
 
Follow
 
the
 
expiry
 
date
 
on
 
the
 
product.
 
●
 
The
 
cartridge
 
has
 
an
 
in-use
 
shelf
 
life
 
of
 
3
 
months.
 
 
 
 
 
 
 
Before
 
ending
 
this
 
peer
 
review
 
session,
 
the
 
reviewee
 
should
 
be
 
informed
 
of
 
the
 
step(s)
 
that
 
he/
 
she
 
missed
 
out
 
in
 
order
 
to
 
ensure
 
all
 
the
 
counselling
 
points
 
are
 
being
 
covered.
 
 
Remarks:
 
  
 
 
 
Reviewed
 
by:
 
Name
 
&
 
Signature
                                                                   
Date:
 
 
*Mandatory
 
for
 
validation
 
/
 
peer
 
review
 
 
References:
 
1.
 
Usmani
 
OS.
 
(2019
 
Mar).
 
Choosing
 
the
 
right
 
inhaler
 
for
 
your
 
asthma
 
or
 
COPD
 
patient.
 
Therapeutics
 
and
 
clinical
 
risk
 
management.
 
14:461-72.
 
2.
 
Ohar
 
JA,
 
Ferguson
 
GT,
 
Mahler
 
DA,
 
Drummond
 
MB,
 
Dhand
 
R,
 
Pleasants
 
RA,
 
Anzueto
 
A,
 
Halpin
 
DM,
 
Price
 
DB,
 
Drescher
 
GS,
 
Hoy
 
HM.
 
(2022
 
Jan).
 
Measuring
  
peak
 
inspiratory
 
flow
 
in
 
patients
 
with
 
chronic
 
obstructive
 
pulmonary
 
disease.
 
International
 
journal
 
of
 
chronic
 
obstructive
 
pulmonary
 
disease.
  
6:79-92.
 
3.
 
The
 
Electronic
 
Medicine
 
Compendium
 
(eMC)
 
(Available
 
at
 
http://www .medicines.org.uk/emc/
).
 
Accessed
 
on
 
October
 
15,
 
2024.
 
4.
 
Asthma
 
UK.
 
How
 
to
 
use
 
your
 
inhaler
 
(Available
 
at
 
https://www .asthmaandlung.org.uk/living-with/inhaler-videos
).
 
Accessed
 
on
 
October
 
15,
 
2024.
 
5.
 
Mohammad
 
Y.
 
(2019
 
Oct).
 
How
 
to
 
manage
 
asthma
 
during
 
Ramadan?
 
97(10):
 
1073-1076.
 
PMID:
 
31691934
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
57
 

=== PAGE 445 ===

 
Suppositories
 
/
 
Enema
 
Name
 
:
 
 
Unit
 
:
 
 
●
 
Please
 
tick
 
(
✔
)
 
Yes
 
for
 
correct
 
instruction.
 
●
 
Please
 
tick
 
(
✔
)
 
No
 
for
 
incorrect
 
instruction.
 
Yes
 
No
 
Remarks
 
Pharmacological
 
Group
 
1.
 
Laxative
 
a.
 
Bisacodyl
 
suppository
 
(5mg,
 
10mg)
 
b.
 
Glycerin
 
25%
 
and
 
Sodium
 
Chloride
 
15%
 
Enema
 
2.
 
NSAIDS
 
a.
 
Diclofenac
 
suppository
 
(12.5mg,
 
25mg,
 
50mg)
 
3.
 
Antipyretic
 
a.
 
Paracetamol
 
suppository
 
(125mg,
 
250mg)
 
4.
 
Opioid
 
a.
 
Morphine
 
sulphate
 
suppository
 
(10mg,
 
20mg,
 
30mg)
 
5.
 
Antiinflammatory
 
a.
 
Lignocaine
 
(Lidocaine),
 
Aluminium
 
Acetate,
 
Zinc
 
Oxide
 
and
 
Hydrocortisone
 
Suppository
 
b.
 
Mesalazine
 
1g
 
suppository
 
c.
 
Mesalazine
 
1g/100ml
 
enema
 
d.
 
Mesalazine
 
6.67%
 
w/w
 
Enema
 
e.
 
Zinc
 
oxide,
 
benzyl
 
benzoate
 
and
 
balsam
 
peru
 
suppository
 
 
 
 
Indications
 
and
 
Dosage
 
Counsel
 
patients
 
based
 
on
 
indication
 
and
 
dosage
 
as
 
prescribed.
 
 
 
 
Method
 
of
 
Administration*
 
A.
 
SUPPOSIT ORY
 
1.
 
A
 
visit
 
to
 
the
 
toilet
 
is
 
recommended
 
before
 
inserting
 
a
 
suppository .
 
 
2.
 
Wash
 
hands
 
with
 
soap
 
and
 
water
 
and
 
dry
 
it.
 
3.
 
Take
 
out
 
the
 
suppositories
 
from
 
its
 
storage
 
place.
 
(Refer
 
to
 
product
 
insert
 
for
 
specific
 
storage
 
condition)
 
4.
 
Remove
 
the
 
wrapper .
 
5.
 
Do
 
not
 
cut
 
the
 
suppositories
 
unless
 
instructed
 
otherwise.
 
If
 
you
 
need
 
to
 
cut
 
it
 
in
 
half,
 
cut
 
it
 
length
 
wise
 
with
 
a
 
clean
 
single
 
edge
 
razor
 
blade.
 
6.
 
Lubricate
 
the
 
tip
 
of
 
the
 
suppositories
 
with
 
water .
 
7.
 
Lie
 
down
 
on
 
the
 
side
 
with
 
the
 
upper
 
leg
 
bent
 
forward
 
toward
 
the
 
stomach
 
while
 
your
 
lower
 
leg
 
straightens
 
out.
 
8.
 
Insert
 
the
 
suppository ,
 
pointed
 
end
 
first
 
with
 
the
 
finger
 
about
 
1
 
inch
 
(adult)
 
and
 
1/2
 
inch
 
(infant)
 
depth.
 
9.
 
Straighten
 
both
 
legs
 
together
 
and
 
hold
 
buttocks
 
together
 
for
 
about
 
a
 
few
 
seconds.
 
10.
 
Remain
 
lying
 
down
 
for
 
about
 
15
 
to
 
20
 
minutes
 
to
 
ensure
 
the
 
suppository
 
is
 
fully
 
absorbed.
 
11.
 
Discard
 
the
 
wrapper
 
and
 
wash
 
your
 
hands
 
thoroughly .
 
 
 
B.
 
ENEMA
 
1.
 
The
 
best
 
results
 
are
 
achieved
 
if
 
the
 
bowel
 
is
 
emptied
 
before
 
administration
 
of
 
enemas.
 
 
2.
 
Preparation:
 
i.
 
Shake
 
the
 
bottle
 
for
 
30
 
seconds.
 
ii.
 
Remove
 
the
 
protective
 
cap
 
of
 
the
 
applicator .
 
iii.
 
The
 
bottle
 
should
 
be
 
held
 
at
 
the
 
top
 
and
 
the
 
bottom.
 
 
3.
 
The
 
patient
 
should
 
lie
 
down
 
on
 
his/her
 
left
 
side
 
with
 
his/her
 
left
 
leg
 
stretched
 
out
 
and
 
right
 
leg
 
bent.
 
This
 
makes
 
it
 
easier
 
for
 
the
 
rectal
 
suspension
 
to
 
be
 
administered
 
and
 
for
 
the
 
enema
 
to
 
be
 
effective
 
4.
 
Administration
 
of
 
the
 
rectal
 
suspension:
 
 
 
 
58
 

=== PAGE 446 ===

 
i.
 
The
 
tip
 
of
 
the
 
applicator
 
should
 
be
 
inserted
 
deep
 
into
 
the
 
rectum.
 
ii.
 
The
 
bottle
 
should
 
be
 
tipped
 
downwards
 
slightly
 
and
 
then
 
squeezed
 
slowly .
 
Maintain
 
sufficient
 
steady
 
hand
 
pressure
 
while
 
dispersing
 
the
 
bottle
 
content
 
iii.
 
Once
 
the
 
bottle
 
is
 
empty ,
 
the
 
applicator
 
tip
 
should
 
be
 
slowly
 
withdrawn
 
from
 
the
 
rectum.
 
iv.
 
The
 
patient
 
should
 
remain
 
lying
 
down
 
in
 
this
 
position
 
for
 
at
 
least
 
30
 
minutes
 
to
 
allow
 
the
 
contents
 
of
 
the
 
enema
 
to
 
spread
 
throughout
 
the
 
rectum.
 
v.
 
If
 
possible,
 
the
 
rectal
 
suspension
 
should
 
be
 
allowed
 
to
 
exert
 
its
 
effects
 
all
 
night.
 
 
Do
 
not
 
stop
 
taking
 
your
 
medication
 
unless
 
advised
 
to
 
do
 
so
 
by
 
your
 
prescriber
 
Special
 
Considerations
 
Pregnancy
 
 
 
 
Refer
 
to
 
individual
 
product
 
information.
 
 
 
 
 
Breastfeeding
 
 
 
 
Refer
 
to
 
individual
 
product
 
information.
 
 
 
 
 
Elderly
 
 
 
 
Refer
 
to
 
individual
 
product
 
information.
 
 
 
 
 
Paediatric
 
 
 
 
Refer
 
to
 
individual
 
product
 
information.
 
 
 
 
 
Fasting
 
 
 
 
Administration
 
of
 
suppository
 
or
 
enema
 
during
 
fasting
 
is
 
deemed
 
to
 
invalidate
 
the
 
fasting.
 
 
 
 
 
Others
  
 
 
 
 
For
 
rectal
 
use
 
only.
 
 
 
 
Side
 
Effects
 
and
 
their
 
Management*
 
1.
 
In
 
general,
 
administration
 
of
 
a
 
suppository
 
or
 
enema
 
may
 
lead
 
to
 
painful
 
sensations
 
and
 
local
 
irritation,
 
especially
 
in
 
patients
 
with
 
anal
 
fissures,
 
stomach
 
or
 
bowel
 
disorders
 
including
 
ulcerative
 
proctitis
 
or
 
Crohn’ s
 
disease.
 
 
2.
 
Suppositories
 
or
 
enemas
 
should
 
be
 
used
 
under
 
medical
 
advice
 
or
 
as
 
directed
 
by
 
a
 
physician.
 
3.
 
Refer
 
to
 
individual
 
product
 
information
 
for
 
specific
 
side
 
effects
 
for
 
each
 
medication.
 
 
 
 
Storage*
 
Store
 
suppositories
 
and
 
enemas
 
in
 
a
 
cool,
 
dry
 
place
 
and
 
away
 
from
 
direct
 
heat
 
and
 
light.
 
Generally ,
 
there
 
is
 
no
 
need
 
to
 
store
 
in
 
the
 
refrigerator
 
unless
 
stated
 
on
 
drug
 
labels.
 
Store
 
the
 
medications
 
out
 
of
 
reach
 
of
 
children
 
to
 
avoid
 
accidental
 
ingestion.
 
 
 
 
Others
 
1.
 
Do
 
not
 
take
 
the
 
suppository
 
or
 
enemas
 
if
 
allergic
 
to
 
any
 
component
 
in
 
the
 
medication.
 
2.
 
Avoid
 
concurrent
 
use
 
of
 
NSAIDS
 
or
 
COX-2
 
(cyclo-oxgenase-2)
 
inhibitor
 
with
 
diclofenac
 
suppositories
 
(eg
 
Ibuprofen,
 
Aspirin)
 
 
 
 
59
 

=== PAGE 447 ===

 
3.
 
Refer
 
to
 
individual
 
product
 
information
 
for
 
contraindications
 
and
 
drug-drug
 
interactions.
 
 
Before
 
ending
 
this
 
peer
 
review
 
session,
 
the
 
reviewee
 
should
 
be
 
informed
 
of
 
the
 
step(s)
 
that
 
he/
 
she
 
missed
 
out
 
in
 
order
 
to
 
ensure
 
all
 
the
 
counselling
 
points
 
are
 
being
 
covered.
 
 
Remarks:
 
 
 
 
 
Reviewed
 
by:
 
Name
 
&
 
Signature
                                                                   
Date:
 
 
 
 
 
*
 
Mandatory
 
for
 
peer
 
review/validation
 
 
 
References:
 
 
1.
 
Aspen.
 
(2023).
 
Xyloproct
 
suppositories
 
package
 
insert.
 
Retrieved
 
from
 
https://quest3plus.bpfk.gov .my/front-end/attachment/54379/pharma/210194/V_90804_20240627_18021 
4_D3.pdf
 
 
2.
 
DCH
 
Auriga.
 
(2024).
 
Salofalk
 
(Mesalazine)
 
enemas
 
package
 
insert.
 
Retrieved
 
from
 
https://quest3plus.bpfk.gov .my/front-end/attachment/4556/pharma/218371/V_91600_20240327_152537 
_D3.pdf
 
 
3.
 
Ferring.
 
(2023).
 
Pentasa
 
(Mesalazine)
 
enemas
 
package
 
insert.
 
Retrieved
 
from
 
https://quest3plus.bpfk.gov .my/front-end/attachment/34793/pharma/218361/V_84760_2023101 1_13505 
4_D3.pdf
 
 
4.
 
Ferring.
 
(2023).
 
Pentasa
 
(Mesalazine)
 
suppositories
 
package
 
insert.
 
Retrieved
 
from
 
https://quest3plus.bpfk.gov .my/front-end/attachment/34793/pharma/220525/V_85559_2023101 1_15561 
8_D3.pdf
 
 
5.
 
Jabatan
 
Kemajuan
 
Islam
 
Malaysia.
 
(2009).
 
Panduan
 
Berpuasa
 
Bagi
 
Pesakit.
 
http://e-smaf.islam.gov .my/e-smaf/assets/files/old-site/garis_panduan_berpuasa_bagi_pesakit.pdf
 
 
6.
 
Komedic
 
Sdn
 
Bhd.
 
(2022).
 
Arfen
 
(Paracetamol)
 
suppositories
 
package
 
insert.
 
Retrieved
 
from
 
https://quest3plus.bpfk.gov .my/front-end/attachment/24338/pharma/231556/V_61431_20220215_1 1432 
3_D3.pdf
 
 
7.
 
Ministry
 
of
 
Health
 
Malaysia.
 
(2024).
 
Formulari
 
Ubat
 
Kementerian
 
Kesihatan
 
Malaysia.
 
Retrieved
 
from
 
https://pharmacy .moh.gov .my/ms/apps/fukkm?generic=&category=&indications=
 
 
8.
 
Novartis.
 
(2022).
 
Voltaren
 
(Diclofenac)
 
suppositories
 
package
 
insert.
 
Retrieved
 
from
 
https://quest3plus.bpfk.gov .my/front-end/attachment/17050/pharma/210104/V_81 160_20230612_17345 
7_D3.pdf
 
 
9.
 
Sanofi.
 
(2023).
 
Dulcolac
 
(bisacodyl)
 
suppositories
 
package
 
insert.
 
Retrieved
 
from
 
https://quest3plus.bpfk.gov .my/front-end/attachment/66/pharma/62383/V_90125_20240217_164128_D3 
.pdf
 
10.
 
Y.S.P
 
Industries.
 
(2018).
 
Anucare
 
suppositories
 
package
 
insert.
 
Retrieved
 
from
 
https://quest3plus.bpfk.gov .my/front-end/attachment/68/pharma/233696/V_85337_20231006_101514_D 
3.pdf
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
60
 

=== PAGE 448 ===

 
Throat
 
Spray
 
Name
 
:
  
 
 
Unit
 
:
 
 
●
 
Please
 
tick
 
(
✔
)
 
Yes
 
for
 
correct
 
instruction.
 
●
 
Please
 
tick
 
(
✔
)
 
No
 
for
 
incorrect
 
instruction.
 
Yes
 
No
 
Remarks
 
Pharmacological
 
Group
 
Non-steroidal
 
anti-inflammatory
 
drug
 
(NSAID)
 
:
 
 
Benzydamine
 
HCl
 
 
 
 
 
Indications
 
and
 
Dosage
 
Temporary
 
relief
 
of
 
painful
 
conditions
 
of
 
the
 
mouth
 
and
 
throat
 
including
 
tonsillitis,
 
sore
 
throat,
 
radiation
 
mucositis,
 
aphthous
 
ulcers,
 
pharyngitis,
 
swelling,
 
redness,
 
inflammatory
 
conditions,
 
post-orosurgical
 
and
 
periodontal
 
procedures.
 
(For
 
paediatric
 
and
 
otorhinolaringology
 
use.
 
Restrict
 
to
 
patients
 
who
 
are
 
not
 
able
 
to
 
gargle)
 
 
Adults
 
and
 
children
 
over
 
12
 
years
 
2-4
 
sprays
 
(1-2
 
mg)
 
directly
 
onto
 
the
 
sore/inflamed
 
area
 
and
 
swallow
 
gently .
 
Repeat
 
every
 
1½
 
to
 
3
 
hours
 
as
 
necessary .
 
 
Children
 
(6-12
 
years)
 
2
 
sprays
 
(1
 
mg)
 
directly
 
onto
 
the
 
sore/inflamed
 
area
 
and
 
swallow
 
gently .
 
Repeat
 
every
 
1½
 
to
 
3
 
hours
 
as
 
necessary .
 
 
Children
 
under
 
6
 
years
 
Not
 
recommended.
 
 
 
Uninterrupted
 
treatment
 
should
 
not
 
exceed
 
7
 
days,
 
unless
 
under
 
medical
 
supervision.
 
 
 
 
Method
 
of
 
Administration*
 
1.
 
Hold
 
the
 
bottle
 
in
 
an
 
upright
 
position.
 
2.
 
You
 
need
 
to
 
prime
 
the
 
spray
 
the
 
first
 
time
 
you
 
use
 
it
 
(max.
 
5
 
sprays).
 
Point
 
the
 
spray-tube
 
away
 
from
 
your
 
face.
 
Press
 
down
 
firmly
 
until
 
a
 
fine
 
spray
 
appears
 
from
 
the
 
end
 
of
 
the
 
spray-tube.
 
3.
 
Point
 
the
 
spray-tube
 
at
 
the
 
affected
 
area
 
and
 
press
 
down.
 
One
 
press
 
releases
 
one
 
actuation.
 
4.
 
After
 
spraying
 
the
 
desired
 
number
 
of
 
actuations,
 
wipe
 
the
 
end
 
of
 
the
 
spray-tube
 
with
 
a
 
tissue.
 
This
 
prevents
 
the
 
spray-tube
 
becoming
 
blocked.
 
 
 
Precaution
 
:
 
 
1.
 
Do
 
not
 
push
 
anything
 
into
 
the
 
end
 
of
 
the
 
spray-tube
 
if
 
it
 
becomes
 
blocked.
 
Return
 
the
 
spray
 
to
 
the
 
pharmacist.
 
2.
 
If
 
any
 
spray
 
gets
 
in
 
your
 
eyes,
 
wash
 
them
 
immediately
 
with
 
cold
 
water .
 
 
 
 
MISSED
 
DOSE
 
If
 
you
 
forget
 
to
 
use
 
the
 
medication,
 
take
 
the
 
next
 
dose
 
as
 
soon
 
as
 
you
 
remember .
 
 
Do
 
not
 
take
 
a
 
double
 
dose
 
to
 
make
 
up
 
for
 
a
 
dose
 
you
 
have
 
missed.
 
 
Do
 
not
 
stop
 
taking
 
your
 
medication
 
unless
 
advised
 
to
 
do
 
so
 
by
 
your
 
prescriber
 
 
 
 
Special
 
Considerations
 
Pregnancy
 
 
 
 
The
 
safety
 
of
 
benzydamine
 
hydrochloride
 
has
 
not
 
been
 
established
 
in
 
pregnant
 
patients.
 
 
 
 
61
 

=== PAGE 449 ===

 
Breastfeeding
 
 
 
 
It
 
is
 
unknown
 
if
 
benzydamine
 
via
 
throat
 
spray
  
is
 
excreted
 
in
 
breast
 
milk.
 
 
 
 
Elderly
 
 
 
 
None
 
specifically
 
to
 
Benzydamine
 
 
 
 
Paediatric
 
 
 
 
Not
 
recommended
 
for
 
children
 
below
 
6
 
years
 
old.
 
 
 
 
 
Fasting
 
 
 
 
To
 
refer
 
to
 
the
 
latest
 
advisory
 
by
 
religious
 
authority .
 
 
 
 
Others
  
 
 
 
 
NA
 
 
 
 
Side
 
Effects
 
and
 
their
 
Management*
 
1.
 
Oral
 
numbness,
 
burning
 
or
 
stinging,
 
dryness
 
or
 
thirst,
 
tingling,
 
warm
 
feeling
 
in
 
mouth,
 
altered
 
sense
 
of
 
taste.
 
 
 
Seek
 
immediate
 
medical
 
assistance
 
if:
 
1.
 
Severe
 
allergic
 
reaction
 
(anaphylaxis)
 
seen
 
as
 
swelling
 
of
 
throat
 
and
 
mouth,
 
difficulty
 
in
 
swallowing
 
or
 
speaking,
 
alterations
 
in
 
heart
 
rate,
 
severe
 
asthma,
 
collapse,
 
and
 
unconsciousness.
 
 
 
 
Storage*
 
1.
 
Do
 
not
 
store
 
above
 
30°C.
 
Do
 
not
 
refrigerate.
 
Protect
 
from
 
light.
 
After
 
opening,
 
refer
 
to
 
the
 
respective
 
product
 
leaflet
 
for
 
shelf
 
life.
 
 
 
 
Others
 
Wipe
 
the
 
nozzle
 
with
 
a
 
clean
 
towel
 
after
 
application
 
to
 
prevent
 
blockage.
 
 
 
 
Before
 
ending
 
this
 
peer
 
review
 
session,
 
the
 
reviewee
 
should
 
be
 
informed
 
of
 
the
 
step(s)
 
that
 
he/
 
she
 
missed
 
out
 
in
 
order
 
to
 
ensure
 
all
 
the
 
counselling
 
points
 
are
 
being
 
covered.
 
 
Remarks:
 
 
 
 
 
Reviewed
 
by:
 
Name
 
&
 
Signature
                                                                   
Date:
 
 
 
 
 
 
*
 
Mandatory
 
for
 
peer
 
review/validation
 
 
 
References:
 
1.
 
3M
 
Pharmaceuticals
 
Pty
 
Ltd
 
(2005),
 
Difflam
 
Forte
 
Anti-Inflammatory
 
Throat
 
Spray
 
Product
 
Infromation.
 
Retrieved
 
from
 
https://www1.ndmctsgh.edu.tw/pharm/pic/medinsert/005DIF04E.pdf
 
2.
 
Formulari
 
Ubat
 
KKM
 
(FUKKM).
 
(2024).
 
(Version
 
241030.001).
 
Retrieved
 
from
 
https://i.pharmacy .gov.my/fukkm/1359
 
3.
 
iNova
 
Pharmaceuticals
 
(Singapore)
 
Pte
 
Ltd
 
(2025),
 
Consumer
 
Medication
 
Information
 
Leaflet:
 
Difflam
 
Forte
 
Anti-Inflammatory
 
Throat
 
Spray
 
0.3%
 
w/v.
 
Retrieved
 
from
 
https://quest3plus.bpfk.gov .my/front-end/attachment/10182/pharma/227368/V_93556_20250103_16271 
6_D4.pdf
 
4.
 
Unimed
 
Sdn
 
Bhd
 
(2022),
 
Zipelor
 
forte,
 
oromucosal
 
spray:
 
Patient
 
information
 
Leaflet.
  
Retrieved
 
from
 
https://quest3plus.bpfk.gov .my/front-end/attachment/624/pharma/537767/V_72040_20220929_223653_ 
D3.pdf
 
62
 

=== PAGE 450 ===

 
Turbuhaler
 
 
Name
 
:
 
 
Unit
 
:
 
 
●
 
Please
 
tick
 
(
✔
)
 
Yes
 
for
 
correct
 
instruction.
 
●
 
Please
 
tick
 
(
✔
)
 
No
 
for
 
incorrect
 
instruction.
 
Yes
 
No
 
Remarks
 
Type
 
of
 
Device
 
Dry
 
powder
 
inhaler
 
(DPI)
 
 
 
 
Indications
 
and
 
Dosage
 
The
 
indication
 
and
 
dosage
 
depend
 
on
 
the
 
drug
 
content.
 
 
 
 
Method
 
of
 
Administration*
 
DEVICE
 
PREP ARA TION
 
 
 
Before
 
Every
 
Use
 
 
 
Make
 
sure:
  
 
 
 
 
The
 
Turbuhaler
 
has
 
not
 
expired
 
 
 
 
 
The
 
Turbuhaler
 
is
 
not
 
empty .
 
 
 
 
 
Check
 
inside
 
the
 
mouthpiece
 
of
 
the
 
Turbuhaler
 
and
 
ensure
 
it
 
is
 
free
 
from
 
foreign
 
objects.
 
 
 
 
 
Priming
 
 
Conditions
 
in
 
which
 
priming
 
is
 
required:
  
 
Before
 
using
 
the
 
Turbuhaler
 
for
 
the
 
first
 
time.
 
 
 
 
 
Priming
 
steps
 
(single
 
occasion
 
only
 
with
 
the
 
newly
 
opened
 
device):
  
 
●
 
Unscrew
 
the
 
cover
 
of
 
the
 
Turbuhaler
 
and
 
lift
 
it
 
off.
 
 
●
 
Hold
 
the
 
Turbuhaler
 
upright
 
with
 
the
 
base
 
grip
 
at
 
the
 
bottom.
 
 
●
 
Turn
 
the
 
base
 
grip
 
as
 
far
 
as
 
it
 
will
 
go
 
in
 
one
 
direction
 
and
 
then
 
turn
 
it
 
back
 
as
 
far
 
as
 
it
 
will
 
go
 
in
 
the
 
other
 
direction.
 
A
 
"click"
 
sound
 
will
 
be
 
heard
 
(it
 
does
 
not
 
matter
 
which
 
way
 
it
 
is
 
turned
 
first)
 
●
 
Repeat
 
this
 
step
 
one
 
more
 
time
 
to
 
complete
 
priming.
 
 
 
 
 
DEVICE
 
INHALA TION
 
TECHNIQUES
 
 
Prepare
 
 
Step
 
1
 
 
●
 
Unscrew
 
the
 
cover
 
of
 
the
 
Turbuhaler
 
and
 
lift
 
it
 
off.
 
 
●
 
Hold
 
the
 
Turbuhaler
 
upright
 
with
 
the
 
base
 
grip
 
at
 
the
 
bottom.
 
 
●
 
To
 
load
 
the
 
Turbuhaler
 
with
 
a
 
dose,
 
turn
 
the
 
base
 
grip
 
as
 
far
 
as
 
it
 
will
 
go
 
in
 
one
 
direction.
 
Then
 
turn
 
it
 
back
 
again
 
as
 
far
 
as
 
it
 
will
 
go
 
in
 
the
 
opposite
 
direction
 
until
 
a
 
“click”
 
sound
 
is
 
heard
 
(it
 
does
 
not
 
matter
 
which
 
way
 
it
 
is
 
turned
 
first)
 
 
Notes:
 
Do
 
not
 
tip
 
the
 
Turbuhaler
 
upside
 
down
 
or
 
shake
 
the
 
device
 
after
 
dose
 
loading.
 
Do
 
not
 
hold
 
the
 
mouthpiece
 
when
 
turning
 
the
 
grip.
 
Do
 
not
 
block
 
the
 
air
 
vents.
 
 
 
 
 
 
 
Exhale
 
 
Step
 
2
 
 
•
 
Sit
 
upright
 
or
 
stand
 
in
 
an
 
erect
 
position.
 
 
 
 
 
63
 

=== PAGE 451 ===

 
•
 
Breathe
 
out
 
(exhale)
 
slowly
 
and
 
fully,
 
away
 
from
 
the
 
Turbuhaler .
 
Chin
 
&
 
mouth
 
 
Step
 
3
 
 
•
 
Slightly
 
tilt
 
the
 
chin
 
up.
 
 
•
 
Place
 
the
 
inhaler
 
mouthpiece
 
gently
 
between
 
the
 
teeth.
 
Ensure
 
a
 
tight
 
seal
 
of
 
the
 
lips
 
around
 
the
 
mouthpiece.
 
Do
 
not
 
bite
 
the
 
mouthpiece.
 
 
 
 
Notes:
 
Do
 
not
 
block
 
the
 
opening
 
of
 
the
 
mouthpiece
 
with
 
the
 
tongue
 
or
 
teeth.
 
The
 
tongue
 
should
 
be
 
lowered
 
under
 
the
 
mouthpiece.
 
 
 
 
 
Inhale
 
 
Step
 
4
 
 
Breathe
 
in
 
forcefully
 
and
 
deeply
 
through
 
the
 
mouth.
 
 
 
 
 
Hold
 
breath
 
 
Step
 
5
 
 
Remove
 
the
 
Turbuhaler
 
from
 
the
 
mouth,
 
and
 
with
 
the
 
lips
 
closed,
 
hold
 
the
 
breath
 
for
 
5-10
 
seconds
 
or
 
as
 
long
 
as
 
comfortable.
 
 
 
 
 
Exhale
 
 
Step
 
6
 
 
Breathe
 
out
 
(exhale)
 
gently ,
 
away
 
from
 
the
 
Turbuhaler .
 
 
 
 
 
Repeat
 
 
 
 
Step
 
7
 
 
Repeat
 
steps
 
1
 
to
 
6
 
if
 
another
 
dose
 
is
 
needed.
 
 
 
 
 
Close
 
&
 
Rinse
 
Step
 
8
 
 
•
 
Replace
 
the
 
cover
 
tightly
 
after
 
use.
 
 
•
 
Rinse
 
and
 
gargle
 
the
 
mouth
 
with
 
water
 
and
 
spit
 
it
 
out
 
(for
 
a
 
steroid-containing
 
inhaler).
 
 
 
 
 
Missed
 
dose
 
management
 
:
 
 
If
 
a
 
maintenance
 
dose
 
is
 
missed,
 
take
 
it
 
as
 
soon
 
as
 
possible
 
and
 
then
 
resume
 
the
 
regular
 
schedule.
 
However ,
 
if
 
it
 
is
 
almost
 
time
 
for
 
the
 
next
 
dose,
 
skip
 
the
 
missed
 
dose.
 
Never
 
take
 
a
 
double
 
dose
 
to
 
make
 
up
 
for
 
a
 
missed
 
maintenance
 
dose.
 
Do
 
not
 
stop
 
taking
 
your
 
medication
 
unless
 
advised
 
to
 
do
 
so
 
by
 
your
 
prescriber .
 
 
 
 
Special
 
Considerations
 
Pregnancy
 
 
 
 
NA
 
 
 
 
Breastfeeding
 
 
 
 
NA
 
 
 
 
Elderly
 
 
 
 
Consider
 
patient-related
 
factors
 
such
 
as
 
inspiratory
 
effort
,
 
manual
 
dexterity ,
 
hand
 
strength,
 
tremors,
 
vision,
 
comorbidities,
 
respiratory
 
muscle
 
strength,
 
cognition
 
and
 
others.
 
 
 
 
Paediatric
 
 
 
 
Some
 
DPIs
 
may
 
be
 
appropriate
 
for
 
older
 
children.
 
Refer
 
guidelines,
 
for
 
example
 
Global
 
Initiative
 
for
 
Asthma
 
 
 
 
64
 

=== PAGE 452 ===

 
Fasting
 
 
 
 
To
 
refer
 
to
 
the
 
latest
 
advisory
 
by
 
religious
 
authority .
 
 
 
 
Others
  
(
eg.
 
hepatic
 
impairment,
 
renal
 
impairment
 
which
 
will
 
be
 
relevant
 
to
 
the
 
patient)
 
 
 
 
NA
  
 
 
 
 
Side
 
Effects
 
and
 
their
 
Management*
 
For
 
corticosteroid-containing
 
inhalers,
 
gargle
 
the
 
mouth
 
with
 
water
 
and
 
spit
 
it
 
out.
  
 
 
 
 
Storage*
 
Refer
 
to
 
product
 
inserts
 
for
 
complete
 
information.
 
In
 
general:
 
•
 
Store
 
the
 
device
 
in
 
a
 
clean,
 
cool,
 
and
 
dry
 
place
 
at
 
appropriate
 
temperatures.
 
•
 
Avoid
 
extreme
 
temperatures
 
and
 
humidity
 
(e.g.,
 
do
 
not
 
store
 
it
 
in
 
cars
 
or
 
bathrooms).
 
•
 
Keep
 
it
 
safely
 
out
 
of
 
the
 
reach
 
of
 
children.
 
 
 
 
Others
 
Cleaning*
 
 
 
 
Wipe
 
the
 
outside
 
of
 
the
 
mouthpiece
 
at
 
least
 
once
 
a
 
week
 
with
 
dry
 
tissue
 
or
 
cloth.
 
Do
 
not
 
use
 
water
 
or
 
liquids.
  
 
 
 
 
Dose
 
checking
  
 
●
 
Contains
 
a
 
dose
 
indicator .
 
 
●
 
The
 
dose
 
indicator
 
is
 
marked
 
in
  
intervals
 
of
 
10
 
doses
 
for
 
Symbicort
 
120-dose
 
inhalers
 
and
 
15
 
doses
 
for
 
Symbicort
 
30-dose
 
inhalers.
 
 
●
 
When
 
a
 
red
 
mark
 
is
 
first
 
seen
 
at
 
the
 
edge
 
of
 
the
 
indicator
 
window ,
 
there
 
are
 
approximately
 
20
 
doses
 
left
 
for
 
Symbicort
 
120-dose
 
inhalers
 
and
 
15
 
doses
 
for
 
Symbicort
 
30-dose
 
inhalers.
 
For
 
the
 
last
 
10
 
doses,
 
the
 
background
 
of
 
the
 
dose
 
indicator
 
is
 
red.
  
No
 
more
 
medicine
 
is
 
left
 
when
 
the
 
“0”
 
on
 
the
 
red
 
background
 
has
 
reached
 
the
 
middle
 
of
 
the
 
window .
 
 
 
 
Notes:
 
The
 
grip
 
will
 
still
 
twist
 
and
 
“click”
 
even
 
when
 
the
 
Turbuhaler
 
is
 
empty .
  
The
 
sound
 
upon
 
shaking
 
the
 
Turbuhaler
 
is
 
produced
 
by
 
a
 
drying
 
agent,
 
not
 
the
 
medication.
 
 
 
 
 
Expiry
 
date
 
 
Follow
 
the
 
expiry
 
date
 
on
 
the
 
product.
 
 
 
 
 
 
Before
 
ending
 
this
 
peer
 
review
 
session,
 
the
 
reviewee
 
should
 
be
 
informed
 
of
 
the
 
step(s)
 
that
 
he/
 
she
 
missed
 
out
 
in
 
order
 
to
 
ensure
 
all
 
the
 
counselling
 
points
 
are
 
being
 
covered.
 
 
Remarks:
 
 
 
 
 
Reviewed
 
by:
 
Name
 
&
 
Signature
                                                                   
Date:
 
 
 
 
 
*Mandatory
 
for
 
validation
 
/
 
peer
 
review
 
 
 
 
65
 

=== PAGE 453 ===

 
References:
 
 
1.
 
Usmani
 
OS.
 
(2019
 
Mar).
 
Choosing
 
the
 
right
 
inhaler
 
for
 
your
 
asthma
 
or
 
COPD
 
patient.
 
Therapeutics
 
and
 
clinical
 
risk
 
management.
 
14:461-72.
 
2.
 
Ohar
 
JA,
 
Ferguson
 
GT,
 
Mahler
 
DA,
 
Drummond
 
MB,
 
Dhand
 
R,
 
Pleasants
 
RA,
 
Anzueto
 
A,
 
Halpin
 
DM,
 
Price
 
DB,
 
Drescher
 
GS,
 
Hoy
 
HM.
 
(2022
 
Jan).
 
Measuring 
 
peak
 
inspiratory
 
flow
 
in
 
patients
 
with
 
chronic
 
obstructive
 
pulmonary
 
disease.
 
International
 
journal
 
of
 
chronic
 
obstructive
 
pulmonary
 
disease.
  
6:79-92.
 
3.
 
The
 
Electronic
 
Medicine
 
Compendium
 
(eMC)
 
(Available
 
at 
http://www .medicines.org.uk/emc/
).
 
Accessed
 
on
 
October
 
15,
 
2024.
 
4.
 
Asthma
 
UK.
 
How
 
to
 
use
 
your
 
inhaler
 
(Available
 
at 
https://www .asthmaandlung.org.uk/living-with/inhaler-videos
).
 
Accessed
 
on
 
October
 
15,
 
2024.
 
5.
 
Mohammad
 
Y.
 
(2019
 
Oct).
 
How
 
to
 
manage
 
asthma
 
during
 
Ramadan?
 
97(10):
 
1073-1076.
 
PMID:
 
31691934
 
6.
 
Global
 
Initiative
 
for
 
Asthma.
 
Global
 
Strategy
 
for
 
Asthma
 
Management
 
and
 
Prevention,
 
2024.
 
Updated
 
May
 
2024.
 
Available
 
from:
 
www .ginasthma.org.
 
Accessed
 
on
 
January
 
20,
 
2025.
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
66
 

=== PAGE 454 ===

 
Vaginal
 
Preparation/Pessary
 
Name
 
:
 
 
Unit
 
:
 
 
●
 
Please
 
tick
 
(
✔
)
 
Yes
 
for
 
correct
 
instruction.
 
●
 
Please
 
tick
 
(
✔
)
 
No
 
for
 
incorrect
 
instruction.
 
Yes
 
No
 
Remarks
 
Pharmacological
 
Group
 
Antifungal
 
 
a.
 
Clotrimazole
 
500mg
 
vaginal
 
tablet
 
Progestin
 
 
a.
 
Progesterone
 
100mg
 
capsule
 
 
b.
 
Progesterone
 
8%
 
Vaginal
 
Gel
 
Estrogens
 
a.
 
Conjugated
 
Estrogen
 
0.625mg/g
 
cream
 
 
 
 
 
Indications
 
and
 
Dosage
 
Counsel
 
based
 
on
 
indication
 
and
 
dosage
 
as
 
prescribed
 
by
 
the
 
doctor .
 
 
 
 
Method
 
of
 
Administration*
 
1.
 
Read
 
the
 
product
 
insert
 
before
 
counselling.
 
Each
 
product
 
will
 
have
 
specific
 
instructions
 
for
 
use.
 
2.
 
The
 
recommended
 
time
 
of
 
administration
 
is
 
just
 
before
 
your
 
bedtime.
 
3.
 
Wash
 
hands
 
with
 
soap
 
and
 
water ,
 
rinse
 
and
 
dry
 
it.
 
4.
 
Prepare
 
pessary
 
for
 
application:
 
a.
 
Tablet:
 
 
i.
 
Remove
 
the
 
foil
 
or
 
plastic
 
wrapping
 
from
 
the
 
pessary .
 
 
ii.
 
Place
 
the
 
blunt
 
end
 
of
 
the
 
pessary
 
into
 
the
 
open
 
end
 
of
 
the
 
applicator
 
(if
 
you
 
have
 
been
 
supplied
 
with
 
one)
 
iii.
 
During
 
pregnancy
 
the
 
applicator
 
should
 
NOT
 
normally
 
be
 
used.
 
b.
 
Vaginal
 
Cream:
 
 
i.
 
Firmly
 
attach
 
the
 
applicator
 
to
 
the
 
opening
 
of
 
the
 
tube.
 
ii.
 
Squeeze
 
the
 
cream
 
into
 
the
 
applicator
 
until
 
it
 
reaches
 
the
 
level
 
of
 
the
 
indicator
 
of
 
your
 
dose.
 
iii.
 
Twist
 
and
 
remove
 
the
 
applicator .
 
5.
 
Lie
 
on
 
your
 
back
 
with
 
your
 
knees
 
bent
 
and
 
legs
 
apart.
 
6.
 
Using
 
the
 
applicator
 
gently
 
put
 
the
 
pessary
 
into
 
the
 
vagina
 
as
 
far
 
as
 
it
 
will
 
comfortably
 
go.
 
If
 
there
 
is
 
no
 
applicator
 
available,
 
see
 
point
 
13.
 
7.
 
Holding
 
the
 
outer
 
part
 
of
 
the
 
applicator
 
push
 
the
 
plunger
 
in
 
to
 
release
 
the
 
pessary
 
from
 
the
 
applicator .
 
8.
 
Remove
 
the
 
applicator
 
from
 
the
 
vagina.
 
9.
 
Remain
 
lying
 
down
 
for
 
about
 
15
 
-
 
30
 
minutes
 
to
 
ensure
 
the
 
medication
 
is
 
fully
 
absorbed.
 
10.
 
Wash
 
your
 
hands
 
thoroughly .
 
 
11.
 
If
 
the
 
applicator
 
is
 
to
 
be
 
used
 
again,
 
clean
 
it
 
in
 
warm
 
soapy
 
water ,
 
then
 
dry
 
and
 
keep
 
it
 
in
 
a
 
clean
 
place.
 
12.
 
If
 
you
 
encounter
 
any
 
remaining
 
medication
 
that
 
is
 
not
 
absorbed
 
on
 
the
 
next
 
coming
 
morning,
 
do
 
not
 
reinsert
 
the
 
remaining
 
medication
 
and
 
wash
 
your
 
vagina
 
area.
 
You
 
may
 
use
 
a
 
sanitary
 
pad
 
/
 
panty
 
liner
 
to
 
prevent
 
staining.
 
13.
 
To
 
insert
 
without
 
using
 
the
 
plastic
 
applicator:
 
Holding
 
the
 
pessary
 
between
 
your
 
thumb
 
and
 
first
 
two
 
fingers,
 
gently
 
put
 
the
 
pessary ,
 
narrow
 
end
 
first,
 
as
 
high
 
into
 
the
 
vagina
 
as
 
is
 
comfortable.
 
Then
 
wash
 
your
 
hands.
 
 
Missed
 
dose
 
management:
 
 
1.
 
Use
 
or
 
insert
 
the
 
missed
 
dose
 
once
 
remembered.
 
2.
 
If
 
it
 
is
 
almost
 
time
 
for
 
the
 
next
 
dose,
 
skip
 
the
 
missed
 
dose
 
and
 
continue
 
the
 
regular
 
dosing
 
schedule.
 
Do
 
not
 
 
 
 
67
 

=== PAGE 455 ===

 
use
 
a
 
double
 
dose.
 
 
Do
 
not
 
stop
 
taking
 
your
 
medication
 
unless
 
advised
 
to
 
do
 
so
 
by
 
your
 
prescriber .
 
 
Special
 
Considerations
 
Pregnancy
 
 
 
 
1.
 
Clotrimazole
 
vaginal
 
tablet:
 
Pregnancy
 
Category
 
B
 
2.
 
Progesterone
 
capsule:
 
Pregnancy
 
Category
 
B
 
3.
 
Conjugated
 
Estrogen
 
cream:
 
 
-
 
contraindicated
 
in
 
known
 
or
 
suspected
 
pregnancy .
 
-
 
If
 
pregnancy
 
occurs
 
during
 
treatment,
 
treatment
 
should
 
be
 
withdrawn
 
immediately .
 
 
 
 
 
Breastfeeding
 
 
 
 
1.
 
Clotrimazole
 
Vaginal
 
Tablet:
 
use
 
with
 
precautions.
 
2.
 
Progesterone
 
Vaginal
 
Capsule:
 
can
 
pass
 
into
 
breast
 
milk
 
and
 
may
 
harm
 
a
 
nursing
 
baby
 
3.
 
Conjugated
 
Estrogens
 
Cream
 
and
 
Progesterone
 
Gel
 
;
 
not
 
to
 
be
 
used
 
in
 
lactation.
 
 
 
 
Elderly
 
 
 
 
1.
 
Vaginal
 
Atrophy
 
and
 
Fragility:
 
Postmenopausal
 
women
 
often
 
have
 
atrophic
 
vaginal
 
tissues
 
due
 
to
 
decreased
 
estrogen
 
levels,
 
increasing
 
the
 
risk
 
of
 
irritation,
 
ulceration,
 
or
 
bleeding
 
from
 
pessary
 
use
 
2.
 
Cognitive
 
and
 
Physical
 
Limitations:
 
Elderly
 
patients
 
may
 
have
 
difficulty
 
with
 
self-care
 
due
 
to
 
physical
 
disabilities,
 
arthritis,
 
or
 
cognitive
 
impairments
 
3.
 
Conjugated
 
Estrogens
 
Cream
 
;
 
not
 
to
 
be
 
used
 
in
 
elderly
 
more
 
than
 
65
 
years
 
old.
 
4.
 
Beers
 
Criteria:
 
 
Vaginal
 
cream:
 
acceptable
 
to
 
use
 
low-dose
 
intravaginal
 
estrogen
 
for
 
the
 
management
 
of
 
dyspareunia,
 
recurrent
 
lower
 
urinary
 
tract
 
infections,
 
and
 
other
 
vaginal
 
symptoms.
 
 
 
 
Paediatric
 
 
 
 
1.
 
Clotrimazole
 
Vaginal
 
Tablet:
 
use
 
with
 
precautions
 
in
 
children
 
<
 
16
 
years
 
old
 
(refer
 
to
 
individual
 
product
 
leaflet)
 
2.
 
Conjugated
 
Estrogens
 
Cream
 
and
 
Progesterone
 
Gel
 
;
 
not
 
to
 
be
 
used
 
in
 
children
 
who
 
have
 
not
 
achieved
 
menarche
 
 
 
 
Fasting
 
 
 
 
1.
 
Administration
 
of
 
suppository
 
or
 
enema
 
during
 
fasting
 
is
 
deemed
 
to
 
invalidate
 
the
 
fasting.
 
 
 
 
 
Others
 
 
 
 
1.
 
Clotrimazole
 
Vaginal
 
Tablet:
 
Use
 
with
 
cautions
 
in
 
patients
 
with
 
hepatic
 
impairment,
 
patients
 
who
 
have
 
had
 
>2
 
infections
 
of
 
candidal
 
vaginitis
 
for
 
the
 
past
 
6
 
months,
 
history
 
of
 
STD
 
or
 
exposure
 
to
 
partner
 
with
 
STD,
 
irregular
 
or
 
abnormal
 
bleeding,
 
vaginal
 
ulcers,
 
diarrhoea,
 
dysuria
 
or
 
lower
 
abdominal
 
pain,
 
fever
 
or
 
chills.
 
 
2.
 
Progesterone
 
Vaginal
 
Capsule:
 
Contraindicated
 
in
 
history
 
of
 
stroke
 
or
 
blood
 
clot,
 
circulation
 
problems,
 
 
 
 
68
 

=== PAGE 456 ===

 
liver
 
disease
,
 
breast
 
or
 
uterine
 
cancer
,
 
abnormal
 
vaginal
 
bleeding,
 
or
 
recently
 
had
 
a
 
tubal
 
pregnancy
 
or
 
an
 
incomplete
 
abortion.
 
3.
 
Conjugated
 
Estrogens
 
Cream
 
:
 
contraindicated
 
in
 
active
 
or
 
chronic
 
liver
 
dysfunction
 
or
 
disease
 
Side
 
Effects
 
and
 
their
 
Management*
 
1.
 
Vaginal
 
skin
 
irritation
 
or
 
burning,
 
Itching
 
or
 
discomfort
 
2.
 
Drowsiness
 
or
 
dizziness
 
3.
 
Breast
 
tenderness
 
or
 
swelling
 
4.
 
Headache
 
and
 
nausea
 
 
 
Other
 
specific
 
side
 
effects
 
refer
 
to
 
individual
 
active
 
ingredients.
 
 
 
 
 
Storage*
 
1.
 
Store
 
at
 
below
 
25°C.
 
2.
 
Store
 
in
 
a
 
place
 
that
 
is
 
not
 
exposed
 
to
 
light.
 
 
 
 
Others
 
1.
 
Some
 
pessaries
 
may
 
contain
 
ingredients
 
that
 
can
 
damage
 
latex
 
condoms.
 
Use
 
an
 
alternative
 
method
 
of
 
contraception
 
(or
 
do
 
not
 
have
 
sex)
 
for
 
at
 
least
 
five
 
days
 
after
 
using
 
pessary .
 
2.
 
Do
 
not
 
use
 
tampons,
 
intravaginal
 
douches,
 
spermicides
 
or
 
other
 
vaginal
 
products
 
while
 
using
 
this
 
product.
 
3.
 
Do
 
not
 
use
 
pessary
 
during
 
menstruation.
 
4.
 
Conjugated
 
Estrogens
 
Cream
 
;
 
Reduced
 
plasma
 
conc
 
w/
 
CYP3A4
 
inducers
 
eg,
 
St.
 
John's
 
wort
 
prep,
 
phenobarb,
 
phenytoin
,
 
carbamazepine
,
 
rifampicin
,
 
dexamethasone.
 
Increased
 
plasma
 
conc
 
w/
 
CYP3A4
 
inhibitors
 
eg,
 
cimetidine,
 
erythromycin
,
 
clarithromycin,
 
ketoconazole
,
 
itraconazole
,
 
ritonavir
,
 
grapefruit
 
juice.
 
 
 
 
Before
 
ending
 
this
 
peer
 
review
 
session,
 
the
 
reviewee
 
should
 
be
 
informed
 
of
 
the
 
step(s)
 
that
 
he/
 
she
 
missed
 
out
 
in
 
order
 
to
 
ensure
 
all
 
the
 
counselling
 
points
 
are
 
being
 
covered.
 
 
Remarks:
 
 
 
 
 
Reviewed
 
by:
 
Name
 
&
 
Signature
                                                                   
Date:
 
 
 
 
 
*
 
Mandatory
 
for
 
peer
 
review/validation
 
 
 
References:
 
 
1.
 
Bø,
 
K.,
 
Anglès-Acedo,
 
S.,
 
Batra,
 
A.,
 
Brækken,
 
I.
 
H.,
 
Chan,
 
Y.
 
L.,
 
Jorge,
 
C.
 
H.,
 
Kruger ,
 
J.,
 
Yadav ,
 
M.,
 
&
 
Dumoulin,
 
C.
 
(2022).
 
International
 
urogynecology
 
consultation
 
chapter
 
3
 
committee
 
2;
 
conservative
 
treatment
 
of
 
patient
 
with
 
pelvic
 
organ
 
prolapse:
 
Pelvic
 
floor
 
muscle
 
training.
 
International
 
urogynecology
 
journal,
 
33(10),
 
2633–2667.
 
https://doi.org/10.1007/s00192-022-05324-0
 
2.
 
Cyndea
 
Pharma
 
S.L.
 
(2024).
 
Utrogestan
 
capsule
 
100mg
 
package
 
insert.
 
Retrieved
 
from
 
https://quest3plus.bpfk.gov .my/front-end/attachment/1209/pharma/22221 1/V_85121_20240513_145822 
_D3.pdf
 
3.
 
Jabatan
 
Kemajuan
 
Islam
 
Malaysia.
 
(2009).
 
Panduan
 
Berpuasa
 
Bagi
 
Pesakit.
 
http://e-smaf.islam.gov .my/e-smaf/assets/files/old-site/garis_panduan_berpuasa_bagi_pesakit.pdf
 
 
4.
 
Medicines
 
Resource
 
Centre.
 
(2022).
 
Patient
 
advice
 
sheet:
 
How
 
to
 
use
 
your
 
pessaries.
 
Buckinghamshire
 
Healthcare.
 
Retrieved
 
from
 
https://www .buckshealthcare.nhs.uk/pifs/how-to-use-your-pessaries/
 
 
5.
 
Mims
 
Gateway .
 
Clotrimazole
 
500mg
 
Vaginal
 
Tablet.
 
Retrieved
 
September
 
12,
 
2024,
 
from
 
https://online1.mimsgateway .com.my/
 
6.
 
Ministry
 
of
 
Health
 
Malaysia.
 
(2024).
 
Formulari
 
Ubat
 
Kementerian
 
Kesihatan
 
Malaysia.
 
Retrieved
 
from
 
https://pharmacy .moh.gov .my/ms/apps/fukkm?generic=&category=&indications=
 
 
7.
 
Multum
 
C.(2023,
 
July
 
31).
 
Progesterone
 
Vaginal.
 
Retrieved
 
from
 
https://www .drugs.com/mtm/progesterone-vaginal.html
 
69
 

=== PAGE 457 ===

 
8.
 
Pfizer .
 
(2021).
 
Premarin®
 
(conjugated
 
estrogens)
 
Vaginal
 
Cream
 
package
 
insert.
 
Retrieved
 
from
 
https://quest3plus.bpfk.gov .my/front-end/attachment/286/pharma/210169/V_56530_20210726_185759_ 
D3.pdf
 
9.
 
Synervv
 
Sdn
 
Bhd.
 
(2021).
 
Candigo
 
(clotrimazole)
 
pessary
 
500mg
 
package
 
insert.
 
Retrieved
 
from
 
https://quest3plus.bpfk.gov .my/front-end/attachment/39206/pharma/512970/V_54600_20210525_12044 
4_D3.pdf
 
 
10.
 
Stewart
 
M.(2023,
 
October
 
16).
 
Clotrimazole
 
for
 
vaginal
 
thrush.
 
Retrieved
 
from
 
https://patient.info/medicine/clotrimazole-for-vaginal-thrush-canesten
 
11.
 
The
 
American
 
Society
 
of
 
Health-System
 
Pharmacists.
 
(2023,
 
March
 
15).
  
Progesterone
 
Vaginal.
 
Retrieved
 
from
 
https://medlineplus.gov/druginfo/meds/a623013.html
 
12.
 
Wong
 
C.
 
(2024,
 
December
 
3).
 
What
 
to
 
Eat
 
When
 
You
 
Have
 
Candidiasis.
 
Retrieved
 
from
 
https://www .verywellhealth.com/candida-diet-foods-to-avoid-89881#toc-foods-to-avoid-on-the-candida-di 
et
 
 
13.
 
Premarin
 
Vaginal
 
Cream,
 
MIMS
 
online.
 
https://www .mims.com/malaysia/drug/info/premarin-vaginal-cream/dosage?selectedT ab=overdosage
 
14.
 
Oestrogen
 
Vaginal
 
Cream,
 
Formulari
 
Ubat
 
Kementerian
 
Kesihatan
 
Malaysia;
 
https://pharmacy .moh.gov .my/ms/apps/fukkm?generic=estrogen&category=&indications=
 
15.
 
Vaginal
 
Oestrogen,
 
NHS
 
UK
 
websiteview-source:https://www .nhs.uk/medicines/hormone-replacement-therapy-hrt/vaginal-oestrogen/
 
16.
 
Estradiol
 
Topical,
 
MedlinePlus
 
Online;
 
https://medlineplus.gov/druginfo/meds/a605041.html
 
17.
 
2023
 
American
 
Geriatrics
 
Society
 
Beers
 
Criteria®
 
Update
 
Expert
 
Panel.
 
(2023).
 
American
 
Geriatrics
 
Society
 
2023
 
updated
 
AGS
 
Beers
 
Criteria®
 
for
 
potentially
 
inappropriate
 
medication
 
use
 
in
 
older
 
adults.
 
Journal
 
of
 
the
 
American
 
Geriatrics
 
Society ,
 
71(7),
 
2052-2081.
 
18.
 
Premarin
 
(Conjugated
 
Oestrogen)
 
side
 
effects,
 
Premarin
 
website
 
https://www .premarinvaginalcream.com/side-ef fects
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
70
 

=== PAGE 458 ===

 
Valved
 
Holding
 
Chamber
 
(VHC)
 
with
 
Facemask
 
Multiple
 
Breath
 
or
 
Tidal
 
Breathing
 
Method
 
 
Name
 
:
 
 
Unit
 
:
 
 
●
 
Please
 
tick
 
(
✔
)
 
Yes
 
for
 
correct
 
instruction.
 
●
 
Please
 
tick
 
(
✔
)
 
No
 
for
 
incorrect
 
instruction.
 
Yes
 
No
 
Remarks
 
Type
 
of
 
Device
 
Valved
 
holding
 
chamber
 
(VHC)
 
with
 
facemask
 
(Multiple
 
Breath
 
or
 
Tidal
 
Breathing
 
Method)
 
 
 
 
Indications
 
and
 
Dosage
 
A
 
medical
 
device
 
used
 
with
 
a
 
pMDI
 
 
 
 
Method
 
of
 
Administration*
 
Before
 
Every
 
Use
 
Make
 
sure:
  
 
 
 
 
The
 
pMDI
 
has
 
not
 
expired
 
 
 
 
 
The
 
pMDI
 
is
 
not
 
empty
 
 
 
 
The
 
VHC
 
structure
 
is
 
intact
 
(e.g.,
 
there
 
is
 
no
 
crack),
 
and
 
the
 
valve
 
is
 
working
 
properly
 
(e.g.,
 
it
 
is
 
not
 
stuck
 
or
 
brittle).
 
 
 
 
Check
 
inside
 
the
 
pMDI
 
mouthpiece
 
and
 
VHC,
 
ensure
 
it
 
is
 
free
 
from
 
foreign
 
objects.
 
 
 
 
Priming
 
Conditions
 
in
 
which
 
priming
 
is
 
required:
 
 
●
 
Before
 
using
 
pMDI
 
for
 
the
 
first
 
time.
 
●
 
If
 
pMDI
 
has
 
not
 
been
 
used
 
for
 
a
 
specific
 
period.
 
 
 
 
Priming
 
steps:
  
 
●
 
Remove
 
the
 
cap
 
and
 
hold
 
the
 
inhaler
 
in
 
an
 
upright
 
position.
 
●
 
Shake
 
the
 
pMDI
 
well.
 
 
●
 
Press
 
down
 
the
 
canister
 
to
 
release
 
1
 
spray
 
into
 
the
 
air.
 
●
 
Repeat
 
the
 
above
 
steps
 
if
 
needed.
 
 
 
Notes
:
 
The
 
number
 
of
 
puffs,
 
non-use
 
period,
 
and
 
the
 
need
 
for
 
shaking
 
differ
 
from
 
product
 
to
 
product.
 
Refer
 
to
 
product
 
inserts
 
for
 
specific
 
instructions.
 
 
 
 
 
DEVICE
 
INHALA TION
 
TECHNIQUES
 
Prepare
 
Step
 
1
 
 
●
 
Remove
 
the
 
cap
 
and
 
hold
 
the
 
pMDI
 
in
 
an
 
upright
 
position.
 
 
●
 
Shake
 
the
 
pMDI
 
well
 
(suspensions).
 
 
●
 
Insert
 
pMDI
 
upright
 
into
 
the
 
back
 
of
 
the
 
VHC.
 
 
 
 
Notes
:
 
Shaking
 
is
 
not
 
required
 
for
 
solution-based
 
pMDIs.
 
Refer
 
to
 
product
 
inserts.
 
 
 
 
Exhale
 
Step
 
2
 
 
●
 
Sit
 
upright
 
or
 
stand
 
in
 
an
 
erect
 
position.
 
 
●
 
Breathe
 
out
 
(exhale)
 
slowly
 
and
 
fully
 
 
 
 
Chin
 
&
 
mouth
 
Step
 
3
 
 
 
 
 
71
 

=== PAGE 459 ===

 
●
 
Slightly
 
tilt
 
the
 
chin
 
up.
 
 
●
 
Apply
 
VHC
 
facemask
 
to
 
face
 
and
 
ensure
 
an
 
effective
 
seal
 
over
 
mouth
 
and
 
nose
.
 
Inhale
 
Step
 
4
 
 
●
 
Inhale
 
slowly
 
and
 
deeply
 
through
 
the
 
mouth,
 
pressing
 
the
 
canister
 
down
 
ONCE
 
at
 
the
 
start
 
of
 
inhalation
.
 
 
●
 
Inhale
 
and
 
exhale
 
slowly
 
5
 
times
 
through
 
the
 
mouth.
 
Remove
 
the
 
VHC
 
from
 
the
 
mouth.
 
 
Note
:
 
Some
 
HCPs
 
may
 
recommend
 
the
 
“Single
 
Breath
 
Method”,
 
however ,
 
this
 
is
 
not
 
common
 
 
 
 
Repeat
 
Step
 
5
 
Wait
 
about
 
30
 
seconds
 
to
 
1
 
minute,
 
repeat
 
steps
 
1
 
to
 
4
 
if
 
another
 
dose
 
is
 
needed.
 
 
 
 
Close
 
&
 
Rinse
 
Step
 
6
 
 
●
 
Remove
 
the
 
pMDI
 
from
 
the
 
VHC.
 
 
●
 
Recap
 
the
 
mouthpiece
 
of
 
pMDI.
  
 
●
 
Wash
 
the
 
face
 
area
 
in
 
contact
 
with
 
the
 
facemask;
 
rinse
 
and
 
gargle
 
the
 
mouth
 
with
 
water
 
and
 
spit
 
it
 
out
 
(for
 
a
 
steroid-containing
 
inhaler).
 
 
 
 
Missed
 
dose
 
management
 
:
 
 
If
 
a
 
maintenance
 
dose
 
is
 
missed,
 
take
 
it
 
as
 
soon
 
as
 
possible
 
and
 
then
 
resume
 
the
 
regular
 
schedule.
 
However ,
 
if
 
it
 
is
 
almost
 
time
 
for
 
the
 
next
 
dose,
 
skip
 
the
 
missed
 
dose.
 
Never
 
take
 
a
 
double
 
dose
 
to
 
make
 
up
 
for
 
a
 
missed
 
maintenance
 
dose.
 
Do
 
not
 
stop
 
taking
 
your
 
medication
 
unless
 
advised
 
to
 
do
 
so
 
by
 
your
 
prescriber .
 
 
 
 
Special
 
Considerations
 
Pregnancy
 
 
 
 
NA
 
 
 
 
Breastfeeding
 
 
 
 
NA
 
 
 
 
Elderly
 
 
 
 
1.
 
Consider
 
VHCs
 
among
 
pMDI
 
users
 
2.
 
Consider
 
patient-related
 
factors
 
such
 
as
 
manual
 
dexterity ,
 
hand
 
strength,
 
tremors,
 
vision,
 
comorbidities,
 
respiratory
 
muscle
 
strength,
 
cognition
 
and
 
others.
 
 
 
 
Paediatric
 
 
 
 
Choose
 
age-appropriate
 
valved
 
holding
 
chambers
 
 
 
 
Fasting
 
 
 
 
To
 
refer
 
to
 
the
 
latest
 
advisory
 
by
 
religious
 
authority
 
 
 
 
Others
  
 
 
 
 
NA
 
 
 
 
72
 

=== PAGE 460 ===

 
Side
 
Effects
 
and
 
their
 
Management*
 
For
 
corticosteroid-containing
 
inhalers,
 
gargle
 
mouth
 
with
 
water
 
and
 
spit
 
it
 
out;
 
wash
 
the
 
face
 
area
 
in
 
contact
 
with
 
the
 
facemask
 
 
 
 
Storage*
 
Refer
 
to
 
product
 
inserts
 
for
 
complete
 
information.
 
In
 
general:
 
•
 
Store
 
the
 
device
 
in
 
a
 
clean,
 
cool,
 
and
 
dry
 
place
 
at
 
              
appropriate
 
temperatures.
 
•
 
Avoid
 
extreme
 
temperatures
 
and
 
humidity
 
(e.g.,
 
do
 
not
 
              
store
 
it
 
in
 
cars
 
or
 
bathrooms).
 
•
 
Keep
 
it
 
safely
 
out
 
of
 
the
 
reach
 
of
 
children.
 
 
 
 
Others
 
Cleaning*
 
Clean
 
spacer
 
and
 
pMDI
 
at
 
least
 
once
 
a
 
week.
 
Cleaning
 
instructions
 
vary
 
between
 
products.
 
Refer
 
to
 
the
 
product
 
insert
 
for
 
specific
 
instructions.
 
 
 
 
Dose
 
checking
  
 
Check
 
pMDI
 
for
 
remaining
 
doses:
 
 
●
 
Check
 
the
 
dose
 
counter
 
(if
 
the
 
pMDI
 
has
 
one).
 
●
 
For
 
pMDI
 
without
 
a
 
dose
 
counter ,
 
mark
 
the
 
date
 
of
 
opening
 
on
 
the
 
new
 
pMDI
 
and
 
keep
 
track
 
of
 
the
 
doses
 
used.
 
Record
 
the
 
doses
 
used
 
on
 
a
 
daily
 
log.
 
 
 
 
Expiry
 
date
 
●
 
Replace
 
the
 
VHC
 
according
 
to
 
the
 
manufacturer ’s
 
recommendations
 
or
 
sooner
 
if
 
damaged.
 
 
●
 
Follow
 
the
 
expiry
 
date
 
on
 
the
 
pMDIs
 
 
Notes
:
 
Some
 
pMDIs
 
have
 
in-use
 
shelf
 
life.
 
Refer
 
to
 
product
 
inserts
 
for
 
specific
 
instructions.
  
 
 
 
 
Additional
 
notes
 
Some
 
VHCs
 
are
 
equipped
 
with
 
alert
 
whistles
 
intended
 
to
 
indicate
 
fast
 
inhalation.
 
Instruct
 
the
 
patient
 
to
 
slow
 
breathing
 
if
 
a
 
whistling
 
sound
 
is
 
heard.
 
 
 
 
Before
 
ending
 
this
 
peer
 
review
 
session,
 
the
 
reviewee
 
should
 
be
 
informed
 
of
 
the
 
step(s)
 
that
 
he/
 
she
 
missed
 
out
 
in
 
order
 
to
 
ensure
 
all
 
the
 
counselling
 
points
 
are
 
being
 
covered.
 
 
Remarks:
 
 
 
 
Reviewed
 
by:
 
Name
 
&
 
Signature
                                                                   
Date:
 
 
 
 
 
*Mandatory
 
for
 
validation
 
/
 
peer
 
review
 
 
References:
 
 
1.
 
Usmani
 
OS.
 
(2019
 
Mar).
 
Choosing
 
the
 
right
 
inhaler
 
for
 
your
 
asthma
 
or
 
COPD
 
patient.
 
Therapeutics
 
and
 
clinical
 
risk
 
management.
 
14:461-72.
 
2.
 
Ohar
 
JA,
 
Ferguson
 
GT,
 
Mahler
 
DA,
 
Drummond
 
MB,
 
Dhand
 
R,
 
Pleasants
 
RA,
 
Anzueto
 
A,
 
Halpin
 
DM,
 
Price
 
DB,
 
Drescher
 
GS,
 
Hoy
 
HM.
 
(2022
 
Jan).
 
Measuring 
 
peak
 
inspiratory
 
flow
 
in
 
patients
 
with
 
chronic
 
obstructive
 
pulmonary
 
disease.
 
International
 
journal
 
of
 
chronic
 
obstructive
 
pulmonary
 
disease.
  
6:79-92.
 
3.
 
The
 
Electronic
 
Medicine
 
Compendium
 
(eMC)
 
(Available
 
at 
http://www .medicines.org.uk/emc/
).
 
Accessed
 
on
 
October
 
15,
 
2024.
 
4.
 
Asthma
 
UK.
 
How
 
to
 
use
 
your
 
inhaler
 
(Available
 
at 
https://www .asthmaandlung.org.uk/living-with/inhaler-videos
).
 
Accessed
 
on
 
October
 
15,
 
2024.
 
5.
 
Mohammad
 
Y.
 
(2019
 
Oct).
 
How
 
to
 
manage
 
asthma
 
during
 
Ramadan?
 
97(10):
 
1073-1076.
 
PMID:
 
3169193
 
73
 

=== PAGE 461 ===

 
Valved
 
Holding
 
Chamber
 
(VHC)
 
with
 
Mouthpiece
 
Single
 
Breath
 
Method
 
 
Name
 
:
 
 
Unit
 
:
 
 
●
 
Please
 
tick
 
(
✔
)
 
Yes
 
for
 
correct
 
instruction.
 
●
 
Please
 
tick
 
(
✔
)
 
No
 
for
 
incorrect
 
instruction.
 
Yes
 
No
 
Remarks
 
Type
 
of
 
Device
 
Valved
 
holding
 
chamber
 
(VHC)
 
with
 
mouthpiece
 
(Single
 
Breath
 
Method)
 
 
 
 
Indications
 
and
 
Dosage
 
A
 
medical
 
device
 
used
 
with
 
a
 
pMDI
 
 
 
 
Method
 
of
 
Administration*
 
Before
 
Every
 
Use
 
Make
 
sure:
  
 
 
 
 
The
 
pMDI
 
has
 
not
 
expired
 
 
 
 
 
The
 
pMDI
 
is
 
not
 
empty
 
 
 
 
The
 
VHC
 
structure
 
is
 
intact
 
(e.g.,
 
there
 
is
 
no
 
crack),
 
and
 
the
 
valve
 
is
 
working
 
properly
 
(e.g.,
 
it
 
is
 
not
 
stuck
 
or
 
brittle).
 
 
 
 
Check
 
inside
 
the
 
pMDI
 
mouthpiece
 
and
 
VHC,
 
and
 
ensure
 
it
 
is
 
free
 
from
 
foreign
 
objects.
 
 
 
 
 
Priming
 
Conditions
 
in
 
which
 
priming
 
is
 
required:
 
●
 
Before
 
using
 
pMDI
 
for
 
the
 
first
 
time.
 
●
 
If
 
pMDI
 
has
 
not
 
been
 
used
 
for
 
a
 
specific
 
period.
 
 
 
 
Priming
 
steps:
  
 
●
 
Remove
 
the
 
cap
 
and
 
hold
 
the
 
inhaler
 
in
 
an
 
upright
 
position.
 
 
●
 
Shake
 
the
 
pMDI
 
well.
 
 
●
 
Press
 
down
 
the
 
canister
 
to
 
release
 
1
 
spray
 
into
 
the
 
air.
 
●
 
Repeat
 
the
 
above
 
steps
 
if
 
needed.
 
 
 
Notes
:
 
The
 
number
 
of
 
puffs,
 
non-use
 
period,
 
and
 
the
 
need
 
for
 
shaking
 
differ
 
from
 
product
 
to
 
product.
 
Refer
 
to
 
product
 
inserts
 
for
 
specific
 
instructions.
 
 
 
 
DEVICE
 
INHALA TION
 
TECHNIQUES
 
Prepare
 
Step
 
1
 
 
●
 
Remove
 
the
 
cap
 
and
 
hold
 
the
 
pMDI
 
in
 
an
 
upright
 
position.
 
●
 
Shake
 
 
the
 
 
pMDI
 
 
well
 
 
        
(suspensions).
 
 
●
 
Insert
 
pMDI
 
upright
 
into
 
the
 
back
 
of
 
the
 
VHC.
 
If
 
the
 
VHC
 
has
 
a
 
mouthpiece
 
cap,
 
remove
 
it.
  
 
 
 
Notes
:
 
Shaking
 
is
 
not
 
required
 
for
 
solution-based
 
pMDIs.
 
Refer
 
to
 
product
 
inserts.
 
 
 
 
Exhale
 
Step
 
2
 
 
●
 
Sit
 
upright
 
or
 
stand
 
in
 
an
 
erect
 
position.
 
 
●
 
Breathe
 
out
 
(exhale)
 
slowly
 
and
 
fully,
 
 
 
 
74
 

=== PAGE 462 ===

 
away
 
from
 
the
 
VHC.
 
 
Chin
 
&
 
mouth
 
Step
 
3
 
 
●
 
Slightly
 
tilt
 
the
 
chin
 
up.
 
●
 
Place
 
the
 
VHC
 
mouthpiece
 
gently
 
between
 
the
 
teeth.
 
Ensure
 
a
 
tight
 
seal
 
of
 
the
 
lips
 
around
 
the
 
mouthpiece.
 
Do
 
not
 
bite
 
the
 
mouthpiece.
  
 
 
Notes
:
 
Do
 
not
 
block
 
the
 
opening
 
of
 
the
 
mouthpiece
 
with
 
the
 
tongue
 
or
 
teeth.
 
The
 
tongue
 
should
 
be
 
lowered
 
under
 
the
 
mouthpiece.
 
 
 
 
Inhale
 
Step
 
4
 
 
●
 
Inhale
 
slowly
 
and
 
deeply
 
through
 
the
 
mouth,
 
pressing
 
the
 
canister
 
down
 
ONCE
 
at
 
the
 
start
 
of
 
inhalation.
 
●
 
Continue
 
breathing
 
in
 
slowly
 
and
 
deeply
 
for
 
4-5
 
seconds.
 
 
 
 
Hold
 
Breath
 
Step
 
5
 
Remove
 
the
 
VHC
 
from
 
the
 
mouth
 
and
 
with
 
the
 
lips
 
closed,
 
hold
 
the
 
breath
 
for
 
5-10
 
seconds
 
or
 
as
 
long
 
as
 
comfortable.
 
 
 
 
Exhale
 
Step
 
6
 
 
Breathe
 
out
 
(exhale)
 
gently
 
away
 
from
 
the
 
VHC.
 
 
 
 
Repeat
 
Step
 
7
 
 
Wait
 
about
 
30
 
seconds
 
to
 
1
 
minute,
 
repeat
 
steps
 
1
 
to
 
6
 
if
 
another
 
dose
 
is
 
needed.
 
 
 
 
Close
 
&
 
Rinse
 
Step
 
8
 
●
 
Remove
 
the
 
pMDI
 
from
 
the
 
VHC.
 
 
●
 
Recap
 
the
 
mouthpiece
 
of
 
pMDI
 
and
 
VHC
 
(if
 
the
 
VHC
 
has
 
a
 
cap)
 
●
 
Rinse
 
and
 
gargle
 
the
 
mouth
 
with
 
water
 
and
 
spit
 
it
 
out
 
(for
 
a
 
steroid-containing
 
inhaler).
 
 
 
 
Missed
 
dose
 
management
 
:
 
 
If
 
a
 
maintenance
 
dose
 
is
 
missed,
 
take
 
it
 
as
 
soon
 
as
 
possible
 
and
 
then
 
resume
 
the
 
regular
 
schedule.
 
However ,
 
if
 
it
 
is
 
almost
 
time
 
for
 
the
 
next
 
dose,
 
skip
 
the
 
missed
 
dose.
 
Never
 
take
 
a
 
double
 
dose
 
to
 
make
 
up
 
for
 
a
 
missed
 
maintenance
 
dose.
 
Do
 
not
 
stop
 
taking
 
your
 
medication
 
unless
 
advised
 
to
 
do
 
so
 
by
 
your
 
prescriber .
 
 
 
 
Special
 
Considerations
 
Pregnancy
 
 
 
 
1.
 
NA
 
 
 
 
Breastfeeding
 
 
 
 
1.
 
NA
 
 
 
 
Elderly
 
 
 
 
1.
 
Consider
 
VHCs
 
among
 
pMDI
 
users
 
2.
 
Consider
 
patient-related
 
factors
 
such
 
as
 
manual
 
 
 
 
75
 

=== PAGE 463 ===

 
dexterity ,
 
hand
 
strength,
 
tremors,
 
vision,
 
comorbidities,
 
respiratory
 
muscle
 
strength,
 
cognition
 
and
 
others.
  
 
 
Paediatric
 
 
 
 
Choose
 
age-appropriate
 
valved
 
holding
 
chambers
 
 
 
 
Fasting
 
 
 
 
To
 
refer
 
to
 
the
 
latest
 
advisory
 
by
 
religious
 
authority .
 
 
 
 
Others
  
 
 
 
 
NA
 
 
 
 
Side
 
Effects
 
and
 
their
 
Management*
 
For
 
corticosteroid-containing
 
inhalers,
 
gargle
 
the
 
mouth
 
with
 
water
 
and
 
spit
 
it
 
out.
 
 
 
 
 
Storage*
 
Refer
 
to
 
product
 
inserts
 
for
 
complete
 
information.
 
In
 
general:
 
•
 
Store
 
the
 
device
 
in
 
a
 
clean,
 
cool,
 
and
 
dry
 
place
 
at
 
appropriate
 
temperatures.
 
•
 
Avoid
 
extreme
 
temperatures
 
and
 
humidity
 
(e.g.,
 
do
 
not
 
store
 
it
 
in
 
cars
 
or
 
bathrooms).
 
•
 
Keep
 
it
 
safely
 
out
 
of
 
the
 
reach
 
of
 
children.
 
 
 
 
Others
 
Cleaning*
 
●
 
Clean
 
VHC
 
and
 
pMDI
 
at
 
least
 
once
 
a
 
week.
 
Cleaning
 
instructions
 
vary
 
between
 
products.
 
●
 
Refer
 
to
 
the
 
product
 
insert
 
for
 
specific
 
instructions.
  
 
 
 
 
Dose
 
checking
  
 
Check
 
pMDI
 
for
 
remaining
 
doses:
 
 
●
 
Check
 
the
 
dose
 
counter
 
(if
 
the
 
pMDI
 
has
 
one).
 
●
 
For
 
pMDI
 
without
 
a
 
dose
 
counter ,
 
mark
 
the
 
date
 
of
 
opening
 
on
 
the
 
new
 
pMDI
 
and
 
keep
 
track
 
of
 
the
 
doses
 
used.
 
Record
 
the
 
doses
 
used
 
on
 
a
 
daily
 
log.
 
 
 
 
Expiry
 
date
 
●
 
Replace
 
the
 
VHC
 
according
 
to
 
the
 
manufacturer ’s
 
recommendations
 
or
 
sooner
 
if
 
damaged.
 
 
●
 
Follow
 
the
 
expiry
 
date
 
on
 
the
 
pMDIs.
 
 
Notes
:
 
Some
 
pMDIs
 
have
 
in-use
 
shelf
 
life.
 
 
Refer
 
to
 
product
 
inserts
 
for
 
specific
 
instructions.
  
 
 
 
 
Additional
 
notes
 
Some
 
VHCs
 
are
 
equipped
 
with
 
alert
 
whistles
 
intended
 
to
 
indicate
 
fast
 
inhalation.
 
Instruct
 
the
 
patient
 
to
 
slow
 
the
 
breathing
 
if
 
a
 
whistling
 
sound
 
is
 
heard.
 
 
 
 
76
 

=== PAGE 464 ===

 
Before
 
ending
 
this
 
peer
 
review
 
session,
 
the
 
reviewee
 
should
 
be
 
informed
 
of
 
the
 
step(s)
 
that
 
he/
 
she
 
missed
 
out
 
in
 
order
 
to
 
ensure
 
all
 
the
 
counselling
 
points
 
are
 
being
 
covered.
 
 
Remarks:
 
 
 
 
 
Reviewed
 
by:
 
Name
 
&
 
Signature
                                                                   
Date:
 
 
 
 
 
*Mandatory
 
for
 
validation
 
/
 
peer
 
review
 
 
References:
 
 
1.
 
Usmani
 
OS.
 
(2019
 
Mar).
 
Choosing
 
the
 
right
 
inhaler
 
for
 
your
 
asthma
 
or
 
COPD
 
patient.
 
Therapeutics
 
and
 
clinical
 
risk
 
management.
 
14:461-72.
 
2.
 
Ohar
 
JA,
 
Ferguson
 
GT,
 
Mahler
 
DA,
 
Drummond
 
MB,
 
Dhand
 
R,
 
Pleasants
 
RA,
 
Anzueto
 
A,
 
Halpin
 
DM,
 
Price
 
DB,
 
Drescher
 
GS,
 
Hoy
 
HM.
 
(2022
 
Jan).
 
Measuring 
 
peak
 
inspiratory
 
flow
 
in
 
patients
 
with
 
chronic
 
obstructive
 
pulmonary
 
disease.
 
International
 
journal
 
of
 
chronic
 
obstructive
 
pulmonary
 
disease.
  
6:79-92.
 
3.
 
The
 
Electronic
 
Medicine
 
Compendium
 
(eMC)
 
(Available
 
at 
http://www .medicines.org.uk/emc/
).
 
Accessed
 
on
 
October
 
15,
 
2024.
 
4.
 
Asthma
 
UK.
 
How
 
to
 
use
 
your
 
inhaler
 
(Available
 
at 
https://www .asthmaandlung.org.uk/living-with/inhaler-videos
).
 
Accessed
 
on
 
October
 
15,
 
2024.
 
5.
 
Mohammad
 
Y.
 
(2019
 
Oct).
 
How
 
to
 
manage
 
asthma
 
during
 
Ramadan?
 
97(10):
 
1073-1076.
 
PMID:
 
31691934
 
 
 
 
77
 

=== PAGE 465 ===

 
Valved
 
Holding
 
Chamber
 
(VHC)
 
with
 
Mouthpiece
 
Multiple
 
Breath
 
or
 
Tidal
 
Breathing
 
Method
 
 
Name
 
:
 
 
Unit
 
:
 
 
●
 
Please
 
tick
 
(
✔
)
 
Yes
 
for
 
correct
 
instruction.
 
●
 
Please
 
tick
 
(
✔
)
 
No
 
for
 
incorrect
 
instruction.
 
Yes
 
No
 
Remarks
 
Type
 
of
 
Device
 
Valved
 
Holding
 
Chamber
 
(VHC)
 
with
 
mouthpiece.
 
(Multiple
 
Breath
 
or
 
Tidal
 
Breathing
 
Method)
 
 
 
 
Indications
 
and
 
Dosage
 
A
 
medical
 
device
 
used
 
with
 
a
 
pMDI
 
 
 
 
Method
 
of
 
Administration*
 
Before
 
Every
 
Use
 
Make
 
sure:
  
 
 
 
 
The
 
pMDI
 
has
 
not
 
expired
 
 
 
 
 
The
 
pMDI
 
is
 
not
 
empty
 
 
 
 
The
 
VHC
 
structure
 
is
 
intact
 
(e.g.,
 
there
 
is
 
no
 
crack),
 
and
 
the
 
valve
 
is
 
working
 
properly
 
(e.g.,
 
it
 
is
 
not
 
stuck
 
or
 
brittle).
 
 
 
 
 
Check
 
inside
 
the
 
pMDI
 
mouthpiece
 
and
 
VHC,
 
ensure
 
it
 
is
 
free
 
from
 
foreign
 
objects.
 
 
 
 
 
Priming
 
Conditions
 
in
 
which
 
priming
 
is
 
required:
  
 
●
 
Before
 
using
 
pMDI
 
for
 
the
 
first
 
time.
 
 
●
 
If
 
pMDI
 
has
 
not
 
been
 
used
 
for
 
a
 
specific
 
period.
 
 
 
 
Priming
 
steps:
  
 
 
●
 
Remove
 
the
 
cap
 
and
 
hold
 
the
 
inhaler
 
in
 
an
 
upright
 
position.
 
●
 
Shake
 
the
 
pMDI
 
well.
 
 
●
 
Press
 
down
 
the
 
canister
 
to
 
release
 
1
 
spray
 
into
 
the
 
air.
 
 
●
 
Repeat
 
the
 
above
 
steps
 
if
 
needed.
 
 
 
Notes
:
 
The
 
number
 
of
 
puffs,
 
non-use
 
period,
 
and
 
the
 
need
 
for
 
shaking
 
differ
 
from
 
product
 
to
 
product.
 
Refer
 
to
 
product
 
inserts
 
for
 
specific
 
instructions.
 
 
 
 
DEVICE
 
INHALA TION
 
TECHNIQUES
 
Prepare
 
Step
 
1
 
 
●
 
Remove
 
the
 
cap
 
and
 
hold
 
the
 
pMDI
 
in
 
an
 
upright
 
position.
 
 
●
 
Shake
 
 
the
 
 
pMDI
 
 
well
 
 
(suspensions).
 
 
●
 
Insert
 
pMDI
 
upright
 
into
 
the
 
back
 
of
 
the
 
VHC.
 
If
 
the
 
VHC
 
has
 
a
 
mouthpiece
 
cap,
 
remove
 
it.
  
 
 
 
Notes
:
 
Shaking
 
is
 
not
 
required
 
for
 
solution-based
 
pMDIs.
 
Refer
 
to
 
product
 
inserts.
 
 
 
 
Exhale
 
Step
 
2
 
 
●
 
Sit
 
upright
 
or
 
stand
 
in
 
an
 
erect
 
position
 
●
 
Breathe
 
out
 
(exhale)
 
slowly
 
and
 
fully
 
 
 
 
78
 

=== PAGE 466 ===

 
Chin
 
&
 
mouth
 
Step
 
3
 
 
●
 
Slightly
 
tilt
 
the
 
chin
 
up.
 
 
●
 
Place
 
the
 
VHC
 
mouthpiece
 
gently
 
between
 
the
 
teeth.
 
Ensure
 
a
 
tight
 
seal
 
of
 
the
 
lips
 
around
 
the
 
mouthpiece.
 
Do
 
not
 
bite
 
the
 
mouthpiece.
  
 
 
Notes
:
 
Do
 
not
 
block
 
the
 
opening
 
of
 
the
 
mouthpiece
 
with
 
the
 
tongue
 
or
 
teeth.
 
The
 
tongue
 
should
 
be
 
lowered
 
under
 
the
 
mouthpiece
.
 
 
 
 
Inhale
 
Step
 
4
 
 
●
 
Inhale
 
slowly
 
and
 
deeply
 
through
 
the
 
mouth,
 
pressing
 
the
 
canister
 
down
 
ONCE
 
at
 
the
 
start
 
of
 
inhalation
.
 
 
●
 
Inhale
 
and
 
exhale
 
slowly
 
5
 
times
 
through
 
the
 
mouth.
 
Remove
 
the
 
VHC
 
from
 
the
 
mouth.
 
 
 
 
Repeat
 
Step
 
5
 
Wait
 
about
 
30
 
seconds
 
to
 
1
 
minute,
 
repeat
 
steps
 
1
 
to
 
4
 
if
 
another
 
dose
 
is
 
needed.
 
 
 
 
Close
 
&
 
Rinse
 
Step
 
6
 
●
 
Remove
 
the
 
pMDI
 
from
 
the
 
VHC.
 
 
●
 
Recap
 
the
 
mouthpiece
 
of
 
pMDI
 
and
 
VHC
 
(if
 
the
 
VHC
 
has
 
a
 
cap)
 
●
 
Rinse
 
and
 
gargle
 
the
 
mouth
 
with
 
water
 
and
 
spit
 
it
 
out
 
(for
 
a
 
steroid-containing
 
inhaler).
 
 
 
 
Missed
 
dose
 
management
 
:
 
 
If
 
a
 
maintenance
 
dose
 
is
 
missed,
 
take
 
it
 
as
 
soon
 
as
 
possible
 
and
 
then
 
resume
 
the
 
regular
 
schedule.
 
However ,
 
if
 
it
 
is
 
almost
 
time
 
for
 
the
 
next
 
dose,
 
skip
 
the
 
missed
 
dose.
 
Never
 
take
 
a
 
double
 
dose
 
to
 
make
 
up
 
for
 
a
 
missed
 
maintenance
 
dose.
 
Do
 
not
 
stop
 
taking
 
your
 
medication
 
unless
 
advised
 
to
 
do
 
so
 
by
 
your
 
prescriber
 
 
 
 
Special
 
Considerations
 
Pregnancy
 
 
 
 
NA
 
 
 
 
Breastfeeding
 
 
 
 
NA
 
 
 
 
Elderly
 
 
 
 
       
1.
 
Consider
 
VHCs
 
among
 
pMDI
 
users
 
       
2.
 
Consider
 
patient-related
 
factors
 
such
 
as
 
manual
 
              
dexterity ,
 
hand
 
strength,
 
tremors,
 
vision,
 
comorbidities,
 
              
respiratory
 
muscle
 
strength,
 
cognition
 
and
 
others.
  
 
 
 
 
Paediatric
 
 
 
 
Choose
 
age-appropriate
 
valved
 
holding
 
chambers
 
 
 
 
Fasting
 
 
 
 
To
 
refer
 
to
 
the
 
latest
 
advisory
 
by
 
religious
 
authority
 
 
 
 
Others:
 
 
 
 
79
 

=== PAGE 467 ===

 
NA
 
 
 
 
Side
 
Effects
 
and
 
their
 
Management*
 
For
 
corticosteroid-containing
 
inhalers,
 
gargle
 
the
 
mouth
 
with
 
water
 
and
 
spit
 
it
 
out.
 
 
 
 
 
Storage*
 
Refer
 
to
 
product
 
inserts
 
for
 
complete
 
information.
 
In
 
general:
 
•
 
Store
 
the
 
device
 
in
 
a
 
clean,
 
cool,
 
and
 
dry
 
place
 
at
 
appropriate
 
temperatures.
 
•
 
Avoid
 
extreme
 
temperatures
 
and
 
humidity
 
(e.g.,
 
do
 
not
 
store
 
it
 
in
 
cars
 
or
 
bathrooms).
 
•
 
Keep
 
it
 
safely
 
out
 
of
 
the
 
reach
 
of
 
children.
 
 
 
 
Others
 
Cleaning*
 
Clean
 
VHC
 
and
 
pMDI
 
at
 
least
 
once
 
a
 
week.
 
Cleaning
 
instructions
 
vary
 
between
 
products.
 
Refer
 
to
 
the
 
product
 
insert
 
for
 
specific
 
instructions.
 
  
 
 
 
 
Dose
 
checking
  
 
Check
 
pMDI
 
for
 
remaining
 
doses:
 
 
●
 
Check
 
the
 
dose
 
counter
 
(if
 
the
 
pMDI
 
has
 
one).
 
●
 
For
 
pMDI
 
without
 
a
 
dose
 
counter ,
 
mark
 
the
 
date
 
of
 
opening
 
on
 
the
 
new
 
pMDI
 
and
 
keep
 
track
 
of
 
the
 
doses
 
used.
 
Record
 
the
 
doses
 
used
 
on
 
a
 
daily
 
log.
 
 
 
 
Additional
 
notes
 
Some
 
VHCs
 
are
 
equipped
 
with
 
alert
 
whistles
 
intended
 
to
 
indicate
 
fast
 
inhalation.
 
Instruct
 
the
 
patient
 
to
 
slow
 
the
 
breathing
 
if
 
a
 
whistling
 
sound
 
is
 
heard.
 
 
 
 
Before
 
ending
 
this
 
peer
 
review
 
session,
 
the
 
reviewee
 
should
 
be
 
informed
 
of
 
the
 
step(s)
 
that
 
he/
 
she
 
missed
 
out
 
in
 
order
 
to
 
ensure
 
all
 
the
 
counselling
 
points
 
are
 
being
 
covered.
 
 
Remarks:
 
 
 
 
 
Reviewed
 
by:
 
Name
 
&
 
Signature
                                                                   
Date:
 
 
 
 
 
*Mandatory
 
for
 
validation
 
/
 
peer
 
review
 
 
References:
 
 
1.
 
Usmani
 
OS.
 
(2019
 
Mar).
 
Choosing
 
the
 
right
 
inhaler
 
for
 
your
 
asthma
 
or
 
COPD
 
patient.
 
Therapeutics
 
and
 
clinical
 
risk
 
management.
 
14:461-72.
 
2.
 
Ohar
 
JA,
 
Ferguson
 
GT,
 
Mahler
 
DA,
 
Drummond
 
MB,
 
Dhand
 
R,
 
Pleasants
 
RA,
 
Anzueto
 
A,
 
Halpin
 
DM,
 
Price
 
DB,
 
Drescher
 
GS,
 
Hoy
 
HM.
 
(2022
 
Jan).
 
Measuring 
 
peak
 
inspiratory
 
flow
 
in
 
patients
 
with
 
chronic
 
obstructive
 
pulmonary
 
disease.
 
International
 
journal
 
of
 
chronic
 
obstructive
 
pulmonary
 
disease.
  
6:79-92.
 
3.
 
The
 
Electronic
 
Medicine
 
Compendium
 
(eMC)
 
(Available
 
at 
http://www .medicines.org.uk/emc/
).
 
Accessed
 
on
 
October
 
15,
 
2024.
 
4.
 
Asthma
 
UK.
 
How
 
to
 
use
 
your
 
inhaler
 
(Available
 
at 
https://www .asthmaandlung.org.uk/living-with/inhaler-videos
).
 
Accessed
 
on
 
October
 
15,
 
2024.
 
5.
 
Mohammad
 
Y.
 
(2019
 
Oct).
 
How
 
to
 
manage
 
asthma
 
during
 
Ramadan?
 
97(10):
 
1073-1076.
 
PMID:
 
31691934
 
 
 
80
 

